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Summary
Research has been conducted in the general area of the bioorganic chemistry of 
antitumor antibiotics. Included in this submission are studies that identify and 
solve contemporary problems in the biosynthesis of antibiotics, the structures of 
drug-DNA complexes, the molecular mechanisms for DNA sequence recognition, 
the design and structures of novel DNA-DNA crosslinkers, and the application of 
small molecular probes in the study of transcriptional control. Collectively, these 
studies have required the use of a wide breadth of methods, including radioactive 
and stable isotope techniques, high-field NMR, molecular modeling, DNA 
sequencing and construction techniques, and various other techniques borrowed 
from biophysical and synthetic organic chemistry and molecular biology. Using 
these techniques, the biosynthetic origin of three structurally different classes of 
-antibiotics has been determined (section I), including the novel conversion of L- 
tyrosine to the C2 - and C3 -proline units of the pyrrolo(l,4)benzodiazepines 
antibiotics. The three-dimensional structures of four classes of unique drug-DNA  
complexes (sections II, IV, VI, and VIII) have been elucidated, including the 
u n p recedented  structures of the covalent DNA adducts of the 
pyrrolo(l,4)benzodiazepines, (+)-CC-1065, and the pluramycins and a unique self- 
assembly of a 2:2 Mg2+ to drug complex on duplex DNA. New principles for the 
molecular recognition of DNA by DNA-interactive drugs have been identified, 
which involve achieving sequence selectivity at the covalent alkylation step by 
interactions involving catalytic activation and conformation flexibility of DNA  
(sections II and IV). Based upon an understanding of how these drugs structurally 
modify DNA, specific protein-DNA complexes, such as those involving Spl and 
TBP, have been shown to be possible receptors for these drugs. This work has 
provided new approaches and opportunities in anticancer drug development and 
has important implications in molecular recognition and the control of gene 
expression.
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Biosynthesis of Anthramycin. Determination of the Labeling 
Pattern  by the Use of Radioactive and Stable 
Isotope Techniques
Laurence H. Hurley,*1* Milton Zmijewski,1* and Ching-Jer Chang,b
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Abstract: The building blocks for anthram ycin, an antilumor antibiotic produced by a strain of S trep to m yces  refuineus. have 
been shown to be L-tryptophan, probably via 3-hydroxyanthranilic acid, L-tyrosine which loses two o f its arom atic carbons, 
and L-melhioninc which contributes two methyl groups. W hile one of the two methyl groups is transferred intact, the other 
loses all o f its hydrogens and becom es the carbonyl o f an amide group. A mechanism involving extradiol cleavage o f Dopa is 
proposed on the basis of double labeling and stable isotope experiments. A general schem e for the biosynthetic origin of the 
C 3-proline m oieties o f anthramycin. lincomycin A. and sibiromycin and the Cj-proline m oieties o f tom aym ycin and lincomy- 
cin 11 is proposed
Anthramycin (la )  is an antitumor antibiotic produced by 
S trep tom yces refuineus var th erm oto leran s.2 The structure 
and stereochemistry o f anthramycin have been elucidated3-4 
and the total synthesis o f anthramycin has been reported.5 
Anthramycin has been shown to possess antitumor,6 antibi­
otic,6 am cbicida!,6 and chem osterilant properties.7 All the 
biological properties of the antitumor agent can be attrib­
uted to the effect o f anthramycin on nucleic acid biosynthe­
sis. Anthramycin appears to act by virtue of its ability to 
bind to DN A  and therefore interfere with the function of 
D N A .8-10 Anthramycin causes inhibition of D N A  and 
R N A  synthesis in both bacterial and mammalian cells. 
However, the synthesis o f R N A  is most powerfully af­
fected.' 1
The biosynthetic origin of the non-4-m ethyl-3-hydroxy- 
anthranilic acid part of anthramycin was of prime interest 
in this investigation. A similarly structured element can be 
founJ in tomaym ycin ( l l ) , 12 sibiromycin (111),13 and the 
lincomycin group of antibiotics (IV a .b ).14 (Sec Chart I.) 
This structural similarity might suggest a common biogene- 
tic origin for all of these antibiotics. The biogenetic origin 
of the propylproline group of lincomycin A has been shown 
to be tyrosine and two one-carbon units via m ethionine.15 In 
this case the /V-mcthyl and terminal methyl groups were 
those derived from methionine. In the case of tomaymycin, 
we have established that this antibiotic is derived in an 
analogous way to anthram ycin.16
In this paper we wish to report on the determination of 
the biogenetic origin of anthramycin. Som e of these results 
have been communicated in preliminary form .17
Results
Biosynthetic experiments were carried out with shake 
cultures of the anthramycin-producing S. refuineus strain 
N R R L  3143 grown in a complex medium. The amount of 
anthramycin produced at the time o f harvest was about 80 
p g/m l, as determined by a spectroscopic m ethod.18 The an­
tibiotic was isolated from the culture medium by extraction 
with butanol and further purified if necessary by counter­
current distribution.
The time course of anthramycin production was followed 
by measuring spectroscopically the amount of anthramycin 
produced and the incorporation o f radioactive methionine 
into the antibiotic at different times during the culture peri­
od. As shown in Figure 1, maximum production of an­
thramycin occurred at 15 hr and maximum incorporation of 
methionine into anthramycin occurred when the precursor 
was added at 12 hr.
The efficiency of incorporation of potential radioactive 
precursors into anthramycin was evaluated as follows. The 
thin-layer chromatograms of the methanol solubilized ex­
tracts were scanned for radioactivity and the areas under 
the peaks were integrated to obtain the percentage of the 
radioactivity of the extract residing in anthramycin. From 
this value and from the total radioactivity of the methanol 
extract, the total radioactivity incorporated into anthramy­
cin was calculated, w<hich was related to the total radioac­
tivity of the precursor fed to give the percentage incorpora­
tion. This latter figure was also obtained independently by 
recrystallizing to constant specific activity those samples of
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Figure I. Time course of the production of anthramycin and incorpora­
tion of l.-(M e-l4C)mcthionine into anthramycin by S', refuineus. At 
the times indicated the cultures were incubated with 2.2 X I07 dpm of 
L-[M e-l4C)methioninc for a period of 3 hr: 0 — 0 , ^g/m l of anthramy­
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CHiCHnCHa (lincomycin A) 
CH2CH3 (lincomycin B)
anthramycin which appeared to be appreciably labeled 
from fed compounds.
Using these conditions a number o f possible precursors 
were fed to refuineus cultures and the incorporations 
given in Table I were obtained. It is apparent that the aro­
matic ring of tryptophan but not its side chain, L-tyrosine, 
L-Dopa, and the methyl group of L-mcthionine are utilized 
efficiently for anthramycin synthesis. A number of other 
compounds were fed to the organism (Table 1, experiments 
1, 2, 4, 5, 7, and 8) but were not detectably incorporated.
The role o f tryptophan, methionine, and tyrosine as an- 
thramycin precursors was substantiated by degradation of 
the labeled sam ples of the antibiotic. As outlined in Schem e 











tcCH,-NH2 +  CO,
(M H A A ) which was extracted from the reaction mixture 
and crystallized. The purity o f  M H A A  was checked by 
TLC. After dilution with carrier material it was degraded 
further by Kuhn Roth oxidation,19 and the resulting acetic 
acid was subjected to Schmidt degradation.20 The data ob­
tained are presented in Table II. The results o f these degra­
dations show that whereas all the radioactivity from trypto­
phan was found in M H A A , only 42% of that from m ethio­
nine and none of that from the tyrosine were found in this 
compound. Subsequent degradation of the M H AA  labeled 
from methionine showed that all the radioactivity in 
M H A A  was located in the methyl group. The origin o f the 
M H AA from tryptophan and m ethionine is analogous to 
that in actinomycin biosynthesis21-22 and probably involved 
a diversion of the weli-known m etabolic pathway leading to
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1 11-I4C] Acetic acid 3.2 2.80 X 107 5.8 a < 0.1
[4-14C]-6-AminolevuLinic acid 0.7 2.14 X 107 7.3 a < 0.1
L-( 1-‘4C j Dihydroxypbenylalanine 0.1 3.2 X 10* 35.6 62.5 22.1
4 D-[ 1-I4C] Glucose 0.1 4.46 X 10* 2.3 a <0.3
<; D-16-MC| Glucose 0.1 7.37 X 10* 3.7 a < 0.2
6 L-[Me-l4CJ Methionine 0.3 7.8 X 106 26.6 62.0 16.4
7 L-(U-,4C] Phenylalanine 0.1 2.2 X 107 2.3 a < 0.1
8 L-(U-,4C JProline 1.0 1.7 X 1 0 7 0.8 a < 0.1
<} Dl.-17a-l4C] Tryptophan 13.4 2.2 X 107 42.8 31.8 13.7
HI L-[G-3H j Tryptophan 10.0 5.7 X 107 7.6 14.4 1.1
11 L-(Aia-3-i4CJ Tryptophan 14.9 5.24 X I06 15.2 a <0.3
12 L-(U-!4C jTyrosinc 0.1 2.2 X 107 13.2 85.5 1 1.7
13 L-( 1-|4C j Tyrosine 5.7 2.06 X 1 0 ’ 20.0 51.8 10.4
a .'clow limit o f  detection.
II (tomaymycin)
NH.,
Ia, R =  H (anthramycin) 
b, R -C H , (AME)
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Table IL Degradation of Anthramycin
% radioactivity o f anthramycin 
recovered in
Precursor MHAAa CH,COOH CH,NI1S CO,
L-( 7a~,4C) Tryptophan 104 NE* NE* NE*
L-1 U*MC] Tyrosine 0.3 NE* NE* NE*
L-[Me-,4C] Methionine 42.4 42.2 40 .8  0.1
0 MHAA = 4-methyl-3-hydroxyanthrunilic acid. * NE, not 
examined.
Table III. Cocrystallization o f  AMEa from Feeding Experiments 
with L-| 1 -l4C,3- or 5-3H | Tyrosine and l.- |U -14C,3- or 5 -3I1) - 
Tvros ne with Unlabclcd AME
Fi-
AMEa nal






o f  
tyro­
sine 1st 2nd 3rd tion*
1 L - j l- ,4C,3- or 5-3H) Tyrosine 9.17 4.74 4 .68  4.68 51
2 L-( 1-I4C,3- or 5 -3H] Tyrosine 3.73 1.85 1.81 1.82 49
3 L-IU-,4C,3- or 5-*H]Tyrosine 8.96 6.08 6 .02  5 .73  64
4 L-(U-I4C,3- or 5 -3H |Tyrosine 10.1 6.84 6 .92  6.86 68
a Anthramycin methyl ether. *Tritium retention = ( 3H /14C of 
product)/! 3H /,4C of substrate) X 100%.
the formation of 3-hydroxyanthranilic acid from L-trypto-
phan.23
By analogy with the known biosynthesis o f the propylpro- 
line moiety of lincomycin A 15 the building blocks for an­
thramycin were proposed as shown in Schem e II.
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In this scheme the M H AA  moiety would be derived from 
tryptophan via 3-hydroxyanthranilic acid and the methyl 
group of methionine. In addition, 7 of the 8 carbons of the 
acrylamide prolific moiety would be derived from L-tyro- 
sine, the eighth being a further C -l unit from methionine. 
In order to determine how many carbon atoms o f L-tyrosinc 
were actually incorporated into anthramycin, we compared 
the incorporation of l [U -14C] tyrosine with that of L -[ l-  
4C]tyrosinc using L-|3- or 5-JH ]iyrosine as a reference 
label. The data obtained are presented in Table i l l .  The 
o4 6.S% retention of tritium is indicative of a transfer of 7 
of the 9 carbon atoms of tyrosine to the acrylam ide prolific



















Anthramycin 100 1.41 48
Acetic acid4* 44 2.90 99 2.98
Values ealed from 56 0.24 8 0.25
above data for 
the acrylamide 
prolinc moiety
a Derived from Kuhn Roth oxidation o f anthramycin.
moiety of anthramycin. Incorporation of 6, 7, or 8 carbons 
of tyrosine into anthramycin would be represented by tri­
tium retentions of 75, 64, and 56%, respectively.24 By anal­
ogy with the biosynthesis of the propylprolinc group of lin­
comycin A from tyrosine and methionine, the am ide carbon 
of the acrylamide side chain should be that which is derived 
from methionine. If this were true, then a feeding experi­
ment with doubly labeled {M e-l4C ,M e-3H 3]methionine 
should show transfer o f a one carbon unit to the acrylam ide 
proline group with complete loss o f tritium. The data from 
this experiment (Table IV) substantiate our postulation but 
do not supply unequivocal proof of this. The data also arc 
indicative of a transfer of an intact methyl group to the 3- 
hydroxyanthranilic acid group.
During the conversion of tyrosine to anthramycin, ring 
cleavage of the aromatic ring must take place. Two types of 
ring cleavage arc possible, either intradiol (ortho) or extra- 
diol (m cta) cleavage. These two alternative pathways arc 
shown in Scheme III. It is possible to differentiate between
Scheme III. Alternative Pathways for the Conversion o f  
( 1-I4C,3- or 5-3H)T yrosine into the “ Acrylamide Proline”
Group o f Anthramycin Involving either Ortho or Meta Cleavage
<‘H)H




0 0  H
m thram ycin
0 0  H
OH) HOC 
HOOC OO H
these types of ring cleavage because “ m cta” cleavage will 
lead to retention of half of the tritium from (3- or 5-3H]ty- 
rosinc in anthramycin, whereas “ortho” cleavage will lead 
to complete loss of tritium during the conversion of tyrosine 
to anthramycin. The results in Table 111 (experim ents 1 and 
2) arc in agreement with a “ m cta” cleavage pathway and 
rule out the alternative “ortho” cleavage.
One ambiguity exists, in that a mechanism  involving an
Journal of ifit’ Amcricun Chemical S ocie ty  j  97:15  /  Jul y  25. 1975
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Table V. Dilution of L-Tyrosinc in Anthramycin, Obtained by 
heeding Varying Am ounts o f  the Amino Acid to the S. 
refuineus
Table VI. Enrichments o f Carbons in AME from Feeding 
Experiments with L-(Mc-,3C] Methionine and L-[ 1 -' 3CJ Tyrosine










o f tyrosine, 
dp m/p mol
Antliramycin 




2 7 6 .0
3 .98  X 1 0 5 
1.33 X 10 s
7 .97  x  104





5 .2 3  X 104 
2.91 X 104 






“ Specific activity o f  L-tyrosine/specific activity o f  anthramycin.
NIH  shift with 100% retention of tritium, followed by 
“ortho” cleavage, could conceivably lead to the sam e result, 
that is, retention of 50% of the label in anthramycin. This is 
illustrated in Schem e IV. It is possible to differentiate be­
tween these pathways (A and B in Schem e IV) providing
Scheme IV. A lternatec Mechanisms Leading to the Retention  
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one can determine the position cl the isotopicaliy labeled 
hydrogen in anthramycin. Pathway A leads to isotopicaliy 
labeled hydrogen at position 13 whereas pathway B results 
in t h e  label at position 12. In ordci to differentiate between 
these two pathways we prepared i.-[3 ,5 -2H]tyrosinc which 
was f e d  to the anthramycin producing organism under con­
ditions for least dilution of the label (see Table V). The an­






L-|M c-IJC j- L -|1-j3C |-  
Mctluonine Tyrosine
1 34.7 t 1.2 1.2
2 121.1 s 1.0 1.3
3 135.1 d 1.1 0.8
5 163.4 s 1.1 0.9
5a 114.5 s 1.4 0.7
6 123.7 d 1.3 0.8
7 1 19.0 d 1.2 0.9
8 127.5 s 1.2 1.5
9 141.7 s 0.7 0.6
9a 135.1 s 1.1 0.8
1 1 86.7 d 1.1 27.5
1 la 59.1 d 1.1 0.9
12 120.2 d 1.2 0.9
13 134.1 d 1.3 1.0
i 4 167.7 s 3.6 0.7
15 17.1 q 7.1 0.8
16 54.2 q 1.0 1.0
“ Numbering for AMF is shown in Chart 1 (lb). ^Chemical shifts 
arc given relative to I MS. c This multiplicity arises from one-bond 
l3C proton coupling. Calculated by measuring peak heights in the 
spectrum o f  enriched AME relative to the height o f the m ethoxy  
group o f  AME, then dividing these relative heights by the relative 
heights o f  the same peaks (calculated in the same way) in the 
natural abundance spectrum.
countercurrent distribution and recrystallized twice from 
methanol to produce anthramycin methyl ether (A M E, lb). 
The mass spectrum o f A M E  showed only species of Do, Dj, 
and D 2 molecules in the ratio o f 53.2, 46.0, and 0.9. This 
therefore confirmed our result with the double labeled tyro­
sine in which we had shown that only one of the two tritium  
atoms from [3- or 5-3H ]tyrosine was retained. The 1H 
N M R  on the sam e sam ple shows clearly a reduction of ap­
proximately 0.5 H for the doublet due to substitution of 
deuterium for the proton at position 13 of A M E  (Figure 
2).25 This therefore is in accord with pathway A and rules 
out the mechanism involving an N IH  shift.
Subsequent experiments to confirm the labeling pattern 
of methionine and tyrosine in the acrylam ide prolinc moiety 
of anthramycin were carried out using carbon-13 N M R . 
The carbon N M R  assignm ents for A M E  are shown in 
Table VI. Assignm ents for carbon atoms 1, 11, 11a, 15, and 
16 w'crc made on the basis o f m ultiplicity and specific 
neighboring groups.26 Resonance signals for quaternary ar­
omatic carbons were assigned on the basis o f chem ical shift 
calculations o f model com pounds such as methyl anthrani- 
latc27 and the shielding constants o f the methyl and hydrox­
yl substituents o f other arom atic com pounds.28 Since all 
these calculated values differ by at least 5 ppm, none of 
these assignments arc in doubt. The remaining quaternary 
carbon signal which occurs at 121.2 ppm can therefore be 
assigned to C-2 of A M E . On the basis o f the calculated  
values for the methyl ester o f M H A A  and other model 
compounds of unsaturated carboxylic com pounds,29-30 the 
123.7-ppm signal can be designated to C-6 o f AM E. The 
two pairs of signals at 1 19.0 and 120.2 ppm and 134.1 and 
135.1 ppm cannot be so readily distinguished by simple 
chemical shift theory. However, based on the known proton
OH
CH , U - N H ,
l.wjl ' p w f i
1 in,>'L 6 
1*4.1 0 0 / 'H,
calculated  va lu es
Hurley. S m ijew sk i . Chang  /  Biosynthesis of Anthram ycin
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Figure 2. ’H NM R spectra of nonisotopically labeled AM E (A) and 
AM E isotopicaliy labeled from L-[3,5-2H]tyrosine (B) in [6- 
*H]DM SO (60 M Hz), (a) The numbering for lb is shown in Chart I.
spectral analysis of the nonisotopically labeled A M E ,4 in 
conjunction with samples o f A M E  biosynthetically specifi­
cally enriched with deuterium at C -12 31 and C - l3, we have 
been able to unambiguously differentiate C-7 from C-12 
and C-3 from C - l3 in the l3C N M R  spectra. The assign­
ment of C-3 and C - l3 to the Signals at 135.1 and 134.1 
ppm, respectively, is substantiated by the large difference in 
one-bond l3C -*H  coupling constants [ 'y e n  = 194 H z (C -3) 
and 157.6 H z (C -13 )] .32'34 In order to differentiate be­
tween the two amide carbonyls which give rise to signals at
163.4 and 167.7 ppm, we used tom aym ycin (11) as a model 
compound. This antibiotic lacks the terminal am ide carbon­
yl group found in A M E and consequently only one signal at
165.5 ppm is found in the 160-170-ppm  range. This signal 
can therefore be assigned to C-5 o f tomaym ycin. A small 
upficld shift o f the carbonyl carbon resonance from an un­
conjugated to a conjugated am ide can be anticipated . 35 
Thus the 163.4-ppm signal in the 13C N M R  of A M E  can be 
assigned to C-5, and furthermore the remaining signal at 
167.7 ppm must be that due to C - l4 .36
The (M c-13C)m ethionine (90% 13C ) was fed to 12 flasks 
of the anthramycin producing S. refuineus  just prior to an­
thramycin production. After 9 hr the anthramycin was pu­
rified by countercurrent distribution, 30 mg of unlabeled 
A M E  added to the 7 mg of enriched anthramycin and re­
crystallized from m ethanol.37 Analysis o f the 13C N M R  
spectra of A M E (Table VI) showed that [M e-13C ]m ethion­
ine enriched the aromatic methyl group and the terminal 
am ide carbonyl o f the antibiotic. The enrichment of the 
am ide carbonyl at C-14 of A M E  from [M c-l3C]m cthioninc 
confirm s that the biogenetic origin o f the acrylamide pro­
line moiety o f anthramycin is the sam e as that o f the pro- 
pylproline moiety of lincomycin A .15
t - ( l - 13C]tyrosine (95% 13C) prepared by the method of 
Loll h e ld 38 was fed to 5  re fu in e u s  as described for the spe- 
citically deuteratcd tyrosine m olecules. Isolation and re- 
crystallization ol anthramycin in the usual manner gave a 
sam ple of antibiotic in which the 1 C N M R  spectra only 
showed enrichment of ihe expected C - l l  o f anthramycin
(Table VI). This result in conjunction with that of the spe­
cific incorporation of L -[3,5-2H] tyrosine into anthramycin 
firmly establishes the manner in which tyrosine is incorpo­
rated into anthramycin.
Discussion
The results o f this study firmly establish the origin of the 
carbon skeleton of anthramycin from tryptophan, tyrosine, 
and methionine. The manner in which these three amino 
acids are incorporated into anthramycin is as shown in 
Schem e 11. The incorporation of tryptophan, labeled in the 
aromatic ring, exclusively in the M H AA  moiety o f  an­
thramycin is probably analogous to the biosynthesis of 
M H AA  in actinomycin biosynthesis .21,22
This report provides the second exam ple o f  an antibiotic 
containing a C 3-proIine moiety which is derived from tyro­
sine (7C ) and m ethionine (1C ), the first report being the 
propylproline moiety of lincomycin A (IV a ) . 15 In both cases 
comparison of the incorporation o f L -[U -I4C ]tyrosinc with
l . - [ l - 14C]tyrosinc leads to the conclusion that tyrosine con­
tributes seven o f its nine carbons to the Cj-prolinc moiety. 
Also, in both cases the terminal carbon atom of the C 3 side 
chain is derived from methionine. However, anthramycin  
differs from lincomycin A in that the terminal carbon atom  
is an amide carbonyl, whereas in lincomycin A it is a methyl 
group. To our knowledge this is the first exam ple of an 
amide carbonyl biogenetically derived from the .S-mcthyl 
group of m ethionine, although it has been previously re­
ported that the carboxyl group in leucensom ycin39 and the 
carbomethoxylcarbonyl carbon in streptovaricin D40 arc 
biogentically derived from the methyl group o f propionate. 
Tomaymycin (II) and lincomycin B (IV b) arc antibiotics 
containing proline moieties with 2 -carbon side chains at­
tached at equivalent positions to the 3-carbon side chains of 
anthramycin and lincomycin A. The biogenetic origin of the 
C 2-prolinc unit o f lincomycin B has been previously shown 
to be tyrosine ( 6 C) and the terminal methyl group from me­
thionine. We have recently show n 16 that the entire C 2-pro- 
line moiety o f tomaymycin is derived from tyrosine, without 
an additional C -l unit from m ethionine. Our results from 
double labeling experim ents using [1 -14C,3- or 5-3H ]lyros- 
ine with both anthramycin and tomaym ycin are in accord 
with an extradiol ring cleavage reaction. Sim ilar experi­
ments carried out at Upjohn on lincom ycin A are also in ac­
cord with extradiol cleavage of the arom atic ring .41 It is 
therefore tempting to predict that extradiol cleavage of
5,6-dihydroxycyclo-Dopa and 6,7-dihydroxycyclo-Dopa  
would lead to lincomycin B and sibiromycin, respectively. 
Schem e V represents an attempt to generalize the biogenel- 
ic origin of C 2- and C 3-proline m oieties of antibiotics, which 
arc known or expected to be derived from tyrosine.
The intermediates in the pathway to anthramycin are as 
yet largely unresolved. The most urgent question is whether 
tyrosine or Dopa condenses with the anthranilic acid moiety 
before or after conversion to the CVproline moiety. Prelimi­
nary results based on the incorporation of double labeled 
methionine and tyrosine into an interm ediate in anthramy­
cin biosynthesis suggest that tyrosine condensed with 
M H AA  prior to subsequent m odification. Further evidence 
for the existence of this type of compound can be found in 
the known structure of the fungal m etabolite cyclopenin 
(V ) . 42 (Sec Chart II.)
Experimental Section
Fermentations. .S', refuineus  var thernuUoieruns N R R I. 3143 
was maintained on slants containing (gram s per liter) N -Z  Amine 
B (5 ), yeast extract (2 ). soytonc (2 ). soluble starch ( I ). D-mannito! 
(5 ). and F c S 0 4 • 71 DO (0 .0 1 5 ). and agar ( 15) adjusted to p ll 7 in
PPM
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Scheme V. Proposed General Scheme for the Biogenetic Origin o f C.2- and C3-Prolinc Moieties o f Antibiotics Derived from L-Tyrosine










distilled water. To prepare seed cultures spores were transferred 
aseptically to 500-ml baffled, erlcnm eycr flasks containing 50 ml 
of a medium consisting o f (grams per liter) peptonized milk ( 20), 
dried yeast (3), and cornstarch (10) adjusted to pH 7 in distilled  
water. The seed cultures were incubated for 24 hr at 47° in a New  
Brunswick Model G -25 gyrotory shaker. Sam ples (2 ml) o f the 
seed culture were used to inoculate 500-ml baffled erlcnmeyer 
flasks containing 50 ml o f the same medium and these were incu­
bated with shaking as before. After 12 hr the radioactive precur­
sors dissolved in I ml o f  water were added to the cultures and these 
were incubated for another 3 hr. Where stable isotope experiments 
were carried out, the precursors (138 n M )  were added at 6 and 12 
hr and the cultures harvested at 15 hr.
Chromatography. Thin-layer chromatography on 5 X 20 cm prc- 
coatcd silica gel F-254 (M erck) was used throughout this study. 
Visualization o f anthramycin occurred spontaneously if the plates 
were exposed to air for a few hours, w hen a brownish yellow color­
ation formed. The chromatography system consisted o f hcxane-2- 
propanol-ethanol (6:3:1): anthramycin R f 0 .25, M H A A  R f  0.80. 
The development time was about 2.5 hr.
Radioactive!)’ Labeled Compounds. ( I-l4C] A cetic acid and L- 
[ 1- u C]lyrosine were purchased from New England Nuclear, (4- 
l4CJ-6-aminolevulinic acid, D-[ 1- u C)glucosc, D-(6- l4C]glucosc, 
!.-(M e-14C]m cthioninc, l.-( l - l4C]dihvdroxyphcnylalanine, L-[G- 
3Hjtryptophan, L -[U -l4C]lyrosinc, l .- [U - | 4C]prolinc, and L-[U- 
l4C]phenylalaninc from A m ersham /Scarlc, and Dl - [7 a -l4C]tryp- 
tophan and L- [ A la-3-14C] try ptoplian from ICN.
Stable Isotope Labeled Compounds. L -(M e-IJC ]M cthioninc and 
K* ’CN were purchased from Merck (Canada); L-| I -1-’C)tyrosine  
was synthesized by the method of Loftficld .38 L -(3 ,5-2H]Tyrosine 
was prepared by rcfluxing unlabeled L-tyrosinc in 5N 2HC1 for I 
hr. After lyophilizing o ff the 2HCI the exchangeable deuterium  
was removed by repeated freeze drying, first from dilute HCI and 
then from water. Com plete exchange of the (3 -5 )  hydrogens was 
confirmed by mass spectrometry and 1H N M R .
Nonlabeled Compounds. 4-M ethvl-3-hydroxyanthranilic acid 
was a gift from Dr. U. Horncmann, Purdue University, and Dr. D. 
Perlman of Wisconsin University Anthramycin methyl ether was 
a kind gift of Dr. Julius Berger of the H oflm ann-La Roche Com ­
pany.
Isotope Analysis. All radioactivity m easurements were carried 
out on a Packard Model 3375 liquid scintillation counter. A solu­
tion (15 ml) containing 6 g of PPO and 1.2 g o f M ejPO PO P and 
500 ml o f !  riton-X in 1 I. o f toluene w is used as the scintillator so­
lution. Sam ples were counted to at least 2% statistical error and
COOH — -  III and IVa
COOH — - la
H — ► IVb
( / V l l
counting efficiencies were determined using an external standard­
ization technique. Radioactivity on chrom atogram s was detected  
using a Packard Model 7 2 0 1 radiochrom atogram  scanner.
General Techniques. Hi N M R  and ,3C  N M R  spectra were re­
corded on Varian A -60 and Jeol PPT -100 N M R  spectrom eters, re­
spectively. The N M R  spectra in deuteriodim cthyl sulfoxide ( (6- 
2H )M c2SO ) were obtained in I0 ( 13C N M R ) and 5 mm ('H  
N M R ) spinning tubes. Tetram cthylsilane (MC4S 1) was used as in­
ternal reference for ('H  N M R ) spectra. Integration of signals in 
the proton N M R  was obtained by averaging five successive scans. 
The l3C resonance of [6-2H )M e2SO  served as internal reference 
for ,3C N M R  spectra and conversion to the M c4Si scale involved 
the following correction: 6(M e4S i) =  5[6-2H ]M c2S O  +  39.6 ppm. 
The instrument employed was a Jeol P F T -I00  spectrom eter oper­
ating at 23.5 kG, interfaced with a Jeol EC-100 Fourier transform  
computer with 20K memory. The spectra were recorded at am bi­
ent temperature using a deuterium  lock. All proton lines were 
decoupled by a broad-band (2 .5  kH z) irradiation from an incoher­
ent 99.99-M Hz. source. The chem ical shifts were measured for 
5000-H z sweep width. The proton-coupled l3C spectrum  was ob­
tained using gated, noise decoupling in order to achieve greater 
sensitivity. The typical pulse width was 13 //sec, and the repetition 
time between pulses was 3.0 sec. Uv spectra were recorded on a 
Cary and mass spectra on a Hitachi R M U -7. For quantitative iso­
tope analysis, several slow scans o f the ion region were recorded at 
12 mV. A M E  was assayed spectrophotom ctrically as described by 
Stefanovich .18
Calculation of Isotope Composition from M ass Spectral Data.
The actual isotope com position o f deuterium labeled compounds 
was calculated from the intensity o f the ion at 296, and its satel­
lites of the labeled compound and the corresponding unlabeled 
compound, using Bicmann’s formula43 for the correction for natu­
ral isotope abundances. Anthram ycin methyl ether (m olecular 
weight 329) was used for the mass spectral analysis. This com ­
pound loses methanol (M — 32) and one more mass unit to give 
rise to a high mass ion of 296. Leimgrubcr ct a l.4 report only an ion 
at 297 (M — 32) but in our hands we always recorded a high mass 
of 296 for unlabclcd compounds.
Isolation o f Anthramycin from Cultures and Determination of 
Percentage Incorporation o f Precursors. Al the end of the ferm en­
tation period the combined beer and mycelium were extracted with 
two 50-ml portions of water-saturated butanol. The phases were 
separated by centrifugation and concentrated under vacuum at 
below 36° by distilling off the butanol with water. The residue was 
redissolved in methanol up to about 5 ml to produce the methyl 
ether of anthramycin. A 11 aliquot o f this solution, usually 0.1 ml, 
was counted to determine the total radioactivity in this phase. A n ­
other aliquot equivalent to 10,000 dpm was chromatographed on a 
5 X 20 cm TLC plate in the chrom atography system  together with 
reference spots o f authentic anthram ycin methyl ether. The plate 
was then scanned for radioactivity and the anthram ycin zone was 
located by inspection under ordinary light after a few hours. To de­
termine the percentage of the radioactivity of the neutral fraction 
residing in anthramycin, ihe area under the recorder tracing from 
the radiochromatogram scanner was integrated by cutting out and 
weighing the paper. This percentage figure multiplied by the total
Hurley. Smiji'wski. C hat ig' /  liiasytuhvsi.s of''Anthramycin
r  • Am
radioactivity o f the methanol extract gives the total radioactivity 
incorporated into anthramycin, which was divided by the total ra­
dioactivity fed and multiplied by 100 to give the percentage incor­
poration. If no radioactivity was detected at the position of an­
thramycin. it was assumed on the basis o f the limits o f detection by 
the scanner that less than 104 dpm l4C or 5 X 104 dpm 3H had 
been incorporated and these figures were used to calculate upper 
limits of the percentage of incorporation. Since all attem pts to 
elute anthramycin methyl ether from the plates without causing 
extensive breakdown failed, we were unable to rechromatograph in 
alternative solvents to confirm the radiochemical purity. There­
fore, those samples of anthramycin shown to be significantly la­
beled from added precursors were cocrystallized with carrier AM I: 
to constant specific activity to substantiate the combined counting 
and scanning result. The radioactive \M E  sam ples were diluted 
with exactly 25 mg o f cold carrier material and rccrystallizcd, 
firstly from m ethanol-H ^O, then a ccto n e-f^ O , and finally mctha- 
n ol-H jO  again. After each crystallization about 2 -3  mg o f AM E  
was weighed out accurately and used to measure the specific radio­
activity. The recovery in each crystallization was about 70%. The 
radiochemical purity o f the A M E  obtained this way was checked  
by TLC.
Purification of Anthramycin Labeled with Stable Isotopes from 
Culture Broths. The concentrated butanol extracts o f the culture 
media were taken to dryness and subjected to countercurrent dis­
tribution in a solvent system  consisting of ch loroform -2-propanol- 
cthanol-watcr (3:1:1:5), 99 transfers; K  =  0 .69 for anthramycin 
methyl ether .4 The anthramycin was located in the collection tubes 
by uv absorption at 335 nm. Those tubes containing anthramycin 
were pooled, concentrated under reduced pressure, and crystallized  
twice from m ethanol-IH O .
Degradation of Anthramycin. A known amount o f  radiochemi- 
cally pure AM E and an amount o f nonlabelcd carrier A M E  to 
make a total weight o f 50 mg were placed in a round-bottomed  
flask equipped with a gas inlet and a reflux condenser. Five m illili­
ters o f 5 A' HC1 was added to the flask and the reaction mixture 
was rcfluxcd for 2 hr in a sand bath. At the end o f  the reaction the 
acid solution was diluted to 25 ml with water and extracted with 
three 25-ml portions o f ethyl acetate. This extract was dried over 
sodium sulfate, taken to dryness, and redissolved in about 2 ml of 
methanol; a few drops o f water were added and the solution was a l­
lowed to stand overnight. The brownish crystals which formed 
were weighed out accurately and redissolved in methanol and an 
aliquot was counted for radioactivity. A further aliquot was chro­
matographed to determine radiochemical purity. The M H A A  ob­
tained in the degradation of AM E labeled from L -[M e-,4C]m eth- 
ioninc was mixed with a known amount o f synthetic M H A A  to 
give a total weight o f 50 mg and subjected to Kuhn Roth oxida­
tion .19 The acetic acid obtained from the Kuhn Roth oxidation on 
M H A A  labeled from L -[M e-,4C]m clhionine was further degraded 
by the Schmidt procedure.20
AM E  labeled from l.-[M e-l4C ,M c-JH j]m ethioninc was added 
to a known amount o f nonlabelcd carrier material to make a total 
of 50 mg and subjected to Kuhn Roth oxidation.
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Pyrrolo[l,4]benzodiazepine Antibiotics. Biosynthesis of the 
Antitum or Antibiotic 11-Demethyltomaymycin and Its 
Biologically Inactive Metabolite Oxotomaymycin 
by Streptom yces achromogenes^
Laurence H. Hurley,* Chandrachuranand Gairola, and Nobel V. Das
a b s t r a c t : 11-Demethyltomaymycin, an antitumor antibiotic 
produced by Streptom yces achromogenes, and its biologically 
inactive metabolite oxotomaymycin are biosynthesized from 
L-tyrosine, DL-tryptophan, and L-methionine. The anthranilate 
part of 11-demethyltomaym ycin is derived from tryptophan 
probably via the kynurenine pathway. The predominant loss 
of tritium from DL-[5-3H]tryptophan, during its conversion 
to 11-demethyltomaymycin and oxotomaymycin is interpreted 
to mean by N IH  shift rules, that the main pathway to the 5- 
methoxy-4-hydroxy anthranilate moiety is through hydrox- 
ylation at C-8 prior to hydroxylation at C - l.  The methoxy 
carbon is derived from the S-m ethyl group of methionine by 
transfer of an intact methyl group. The ethylideneproline 
moiety of 11-demethyltomaymycin is biosynthesized from 
tyrosine, without a 1 -carbon unit from methionine. The results 
of biosynthetic feeding experiments with L -[1-14C, 3- or 5- 
3H] tyrosine are consistent with a “meta” or extradiol cleavage
of 6,7-dihydroxycyclodopa as has also been demonstrated  
previously for anthramycin and lincomycin A. An experiment 
in which l - [ 1 - 14C, A la-2,3-3H]tyrosine was fed showed that 
both of the 0  hydrogens of this amino acid are retained in 
11-demethyltomaymycin. It has been demonstrated in cultures 
and washed cell preparations that 1 1 -demethyltomaym ycin  
is enzymatically converted to oxotomaymycin by an intracel­
lular constitutive enzyme. Conversion of oxotom aym ycin to 
1 1 -demethyltomaymycin by these same preparations could not 
be demonstrated. The enzym atic activity associated with the 
conversion of 1 1 -demethyltomaymycin to oxotomaym ycin is 
not limited to the 1 1 -demethyltomaymycin production phase, 
since trophophase cells and even cells from 1 1 -dem ethylto­
maymycin nonproducing cultures of S. achrom ogenes  were 
equally active in converting 1 1 -demethyltomaym ycin to oxo­
tomaymycin.
11-_L /em ethyltom aym ycin (D M T ) 1 is one o f three pyr- 
rolo[l ,4 ]benzodiazepine antitumor antibiotics isolated from 
culture filtrates of actinomycetes. The other antibiotics within 
this class are anthramycin and sibiromycin. The structures of 
these compounds and the DM T related compound oxoto­
maymycin (O T) are shown in Schem e I. D M T was originally 
isolated from the culture filtrates o f S trep tom yces achrom o­
genes by Professor K. Arima and co-workers at the University 
of Tokyo and the Fujisawa Pharmaceutical Company (Arima 
et al., 1972). The structures of D M T and the closely related 
compound, OT, which is also produced by cultures of S. 
achromogenes, were established by Kariyone et al. (1971). 
D M T and its methylated product tomaymycin have been 
shown to possess antiviral activity against Escherichia coli T | 
and T 3 phages, antibacterial activity against gram-positive
f Contribution from the Division of Medicinal Chemistry and Phar­
macognosy, College of Pharmacy, University of Kentucky, Lexington, 
Kentucky 40506. Received January 22, 1976. This work was partially 
supported by National Institutes of Health Research Grant CA 17047 
and American Cancer Society Institutional Grant IN -106.
1 Abbreviations used are: DMT, 11-demethyltomaymycin; OT, oxo­
tomaymycin; DMAA, methyl-4,5-dimethoxyanthranilate; TLC, thin-layer 
chromatography; PPO, 2,5-diphenyloxazole; POPOP, 1,4-bis[2-(5- 
phenyloxazoly!)] benzene.
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bacteria (Arima et al., 1972), and cytotoxic activity towards 
Leukemia L 1210 cells (Nishioka et al., 1972). All o f the bio­
logical properties of these pyrrolo[l,4]benzodiazepine anti­
biotics can be attributed to the effects of these compounds on 
nucleic acid biosynthesis. DM T and tomaymycin appear to act 
by virtue of their ability to bind to D N A  and thereby interfere 
with the function of D N A  (Nishioka et al., 1972).
As part of a continuing effort to discover more about the 
biosynthesis o f these pyrrolo[ 1,4] benzodiazepine antibiotics, 
we are currently studying in our laboratory the biosynthesis 
of anthramycin, DM T, OT, and sibiromycin. Our work on 
anthramycin (Hurley et al., 1975b) and preliminary data on 
DM T (Hurley et al., 1975a) have already appeared. For both 
of these antibiotics and sibiromycin (Hurley et al., unpublished 
data) we have shown that the anthranilate moiety of these 
antibiotics is derived from tryptophan probably via the kynu­
renine pathway. Our studies on anthramycin (H urley et al., 
1975b) show conclusively that the acrylamide proline moiety 
of this antibiotic is derived from tyrosine (7 carbons) and 
methionine (1 carbon) to give rise to the demonstrated labeling 
pattern shown in Schem e II. Dopa, or more likely its conden­
sation product with the anthranilate part o f the molecule, is 
considered to be the intermediate that undergoes “ m eta” or 
extradiol cleavage.
B I O S Y N T H E S I S  O F  1 l - D E M E T H Y L T O M A Y M Y C I N
SCHEME I: Comparison o f  the Structures o f  
DMT and Related Compounds.
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This report described the results of radioactive tracer studies 
using both single- and double-labeling techniques and the 
subsequent degradations of the purified crystalline radiolabeled 
DM T. These results are interpreted in terms of possible 
biogenetic pathways. The biogenetic relationship between 
DM T and OT is also described.
SCHEME II: Established Labeling Pattern o f  Tyrosine and 
Methionine in Anthramycin.
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Ferm entations. S . achromogenes var. tom aym yceticu s  
ATCC 21353 was maintained on Bennett’s agar slants. Fre­
quent transfer was required in order to maintain a viable an­
tibiotic-producing strain. To prepare seed cultures mycelial 
fragments were transferred aseptically to 500-m l erlenmeyer 
flasks containing 100 ml of a medium consisting o f (g/1.) 
phytone BBL-lot 305 6 1 7 (5 ), yeast extract BBL-lot 
A 6D A T J(5), glucose Baker-lot 38515(10), Bacto-casitone
Difco-lot 588134( 1), and N aC l(5) adjusted to pH 7. The seed 
cultures were incubated for 48 h at 29 °C in a N ew Brunswick 
Model G-25 gyrotary shaker at 250 rpm. Sam ples (5 ml) of 
the seed culture were used to inoculate 500-ml erlenmeyer 
flasks containing 100 ml of a medium consisting of (g/1.) 
Bacto-lactose Difco-lot 608376(30), polypepto BBL-lot 
G8DDT1( 10), beef extract BBL-lot B 7D D H U ( 10), yeast ex­
tract BBL-lot AG DATJ(IO ), N aC l(2 .5), K H 2P 0 4(15), 
N a 2H P0 4 (4 ), adjusted to pH 6.2, if necessary, in distilled 
water. After 72 h, the radioactive precursors, usually dissolved 
in 0.5 ml o f distilled water, were added to the cultures and in­
cubated for a further 12 h. For short-term experiments aliquots 
of 5 ml of the culture medium were removed at appropriate 
times. Washed cell preparations were prepared by collecting 
the mycelium by Filtration, washing twice with saline, and once 
with 0.2 M phosphate buffer (pH 7.1). The washed cells were 
finally suspended in the same buffer so as to attain a four- 
times-concentrated cell suspension. This concentrated sus­
pension (100 or 25 ml) was then transferred to 500- or 250-ml 
erlenmeyer flasks that were incubated for usually 6 or 12 h 
under the same conditions as described for routine growth of 
the S. achromogenes.
Chrom atography. Thin-layer chromatography on either 5 
X 20 cm precoated silica gel F-254 (Merck) or 20 X 20 cm on 
preparative thick-layer plates (0.5 mm) was used throughout 
this study. Visualization of D M T and OT on TLC plates was 
carried out by observing the developed plates under short uv 
light with authentic reference materials. Chromatography 
system A consisted of ethyl acetate. DMT /?/0.32, OT R /  0.46. 
Chromatography system B consisted of hexane, 2-propanol, 
ethanol 6:3:1. D M T R/  0.65. Chromatography system C 
consisted of benzene, ethyl acetate 9:1, D M A A  Rj 0.37.
R adioactively Labeled Compound. L-[1-14C] Tyrosine and 
L-[3,5-3H]tyrosine were purchased from New England N u ­
clear, DL-5-hydroxy[G-3H]tryptophan, L-[A la-2,3-3H]tyro- 
sine, L -[U -14C]tyrosine, L -[M e-14C]m ethionine, L-[1-I4C]- 
dihydroxyphenylalanine, and L-[M e-3H 3]methionine were 
from Amersham Searle, D L -[l-14C]tyrosine and DL-[7a- 
l4C]tryptophan were from I.C .N ., and DL-[5-3H]tryptophan 
was from Research Products International. [11 -I4C ]D M T  
(1.04 yuCi/Mmol) and [1 l - 14C ]O T  (1.2 ^Ci/Mmol) were pre­
pared biosynthetically by adding 50 AtCi of d l - [ 1 - ,4C]tyrosine 
to a 72-h S. achrom ogenes culture. After a 12-h incubation 
period, the D M T and OT were removed from the culture by 
repeated extractions with ethyl acetate and purified by pre­
parative TLC in system A. Radiochem ical purity was deter­
mined in solvent system B. The [1 1-14C ]D M T  was converted 
to [1 l - l4C]tom aym ycin by heating in methanol for 2 -3  min 
and then recrystallized with carrier tomaymycin. This proce­
dure showed the antibiotic to be >95%  radiochemically 
pure.
N onlabeled Compounds. Tomaymycin and OT were a kind 
gift from Dr. Kohsaka of Fujisawa Pharmaceuticals. Other 
chemicals were obtained from commercial sources.
Isotope Analysis. Radioactivity measurements were carried 
out on a Packard Model 2425 liquid scintillation counter. A 
solution (15 ml) containing 6 g of PPO, 1.2 g of M e2POPOP, 
and 500 ml of Triton-X in 1 1. o f toluene was used as the scin­
tillator solution, except for radioactivity determinations of 
D M T -D N A  complexes. In this latter case the buffer solution 
containing the D M T -D N A  complex (0.5 ml) was treated with 
0.5 ml of 1 N  HC1 for 30 min at 70 °C before adding 10 ml of 
Aquasol. Samples were counted to 1% standard deviation and 
counting efficiencies were determined using an external 
standardization technique. Where double-label samples were
B I O C H E M I S T R Y ,  V O L .  1 5 ,  N O .  1 7 ,  1 9 7 6  3761
H U R L E Y ,  G A I R O L A ,  A N D  D A S
counted, appropriate adjustments were made for spillover of 
carbon-14 into the tritium channel. Radioactivity on chro­
matograms was detected using a Packard Model 7201 radi­
ochromatograph scanner.
General Techniques
{a) Determination o f  M ycelia l Dry Weight. Cultures were 
filtered on a Buchner funnel by suction on tared Whatman No. 
1 paper (7 cm ) disks. After washing with cold distilled water, 
the filter paper and mycelium were dried at 80 °C  to constant 
weight.
(b ) Q uantita tive D eterm ination o f  D M T. The concentra­
tion of D M T in the culture broth was determined by m ea­
surement o f the absorbance at 320 nm after purifying the an­
tibiotic by preparative TLC. Since the recovery of DM T from 
different plates, as determined by radioactivity measurement, 
varied between 65 and 80%, an adjustment for the percent 
recovery from each isolation was made. This latter figure was 
determined by following the amount of recovered radioactive 
D M T through to the end of the isolation procedure.
(c) U ptake o f  D M T  into Cells. 4.5 X 104 dpm of DM T  
(1.09 n C \/p m o \)  was added to 20 ml of a washed cell prepa­
ration, and 0.2-ml aliquots were taken at various time intervals 
up to 6 h. The washed cell suspension was prepared from a 74-h 
culture as described under fermentations. The samples were 
filtered through a 0.45-nm Millipore filter. The mycelium and 
filter were washed twice with about 2-ml of cold saline solution. 
The filter and washed m ycelium  were transferred to a scintil­
lation vial, 0.5 ml of 1 N  HC1 was added, and the contents were 
heated at 80 °C  for 30 min, cooled, and 1 ml of ethyl acetate 
was added to dissolve the filter. After incubating at room 
temperature for 30 min ten m illiliters o f Aquasol was added 
and the sample was counted for radioactivity.
(d ) O ther A n aly tica l M ethods. Ultraviolet spectra were 
obtained on a Cary 15. Mass spectral studies were carried out 
on a Hitachi RM U-7. M elting points were obtained with a 
Thom as-H oover apparatus and were uncorrected.
Isolation  o f  D M T  and O T  fro m  C ultures and D eterm ina­
tion o f  Percent Incorporation o f  Precursors. At the end of the 
fermentation period the combined beer and mycelium were 
extracted with three 100-ml portions o f ethyl acetate. The 
organic phases were combined, dried over anhydrous sodium  
sulfate, and then concentrated under vacuum at below 36 °C  
using a rotary evaporator. The residue was redissolved in 
methanol up to about 3 ml to convert the DM T to tomaymycin. 
An aliquot of this solution, usually 10 pi, was counted to de­
termine the total radioactivity in this phase. Another aliquot 
equivalent to 20 000 dpm was chromatographed on a 5 X 20 
cm TLC plate in chromatography system  A together with 
reference tomaymycin and OT. The plate was then scanned 
for radioactivity and the tomaymycin and OT zones were lo­
cated by inspection under short uv light. To determine the 
percentage of radioactivity of the ethyl acetate extract residing 
in tomaymycin and OT, the area under the recorder tracing 
from the radiochromatogram scanner was integrated by cut­
ting out and weighing the paper. These percentage figures 
multiplied by the total radioactivity of ethyl acetate extract 
gave the total radioactivity incorporated into tomaymycin and 
OT, which was divided by the total radioactivity fed and 
multiplied by 100 to give percentage incorporation. If no ra­
dioactivity was detected at the position o f tomaymycin or OT, 
it was assumed on the b£fsis o f the limits o f detection by the 
scanner that less than 2 X 103 dpm l4C or 2 X 104 dpm 3H had 
been incorporated and these figures were used to calculate 
upper limits of the percentage o f incorporation. Tomaymycin
and OT samples that were radioactively labeled were then 
isolated by preparative TLC and the zones corresponding to 
these compounds eluted with methanol. Aliquots o f these 
isolated components were rechromatographed on precoated 
glass plates in the same system to ensure degradation had not 
taken place, before they were subjected to further purification 
procedures. Those samples of D M T shown to be significantly 
labeled from added precursors were further purified by co­
crystallization with carrier antibiotic to constant specific ac­
tivity to substantiate the combined counting and scanning 
result (see below).
Further Purification o f  D M T  Isolation  fro m  C ulture  
F iltrates
Samples o f tomaymycin isolated by preparative TLC were 
further purified by either recrystallization or covalent com- 
plexation with D N A  and in some cases by both procedures.
(a ) R ecrysta lliza tion . Tomaymycin was recrystallized to 
constant specific activity by adding exactly 25 mg of cold 
carrier material and recrystallizing repeatedly from metha- 
n o l-H 20 . After each crystallization, about 2 -3  mg of to­
maymycin was weighed out accurately and used to measure 
the specific radioactivity. The recovery in each crystallization 
was about 70%.
(b ) Covalent C om plexation  with D N A. Tom aym ycin  
dissolved in methanol was transferred to a test tube and the 
methanol was removed by evaporation over a stream of ni­
trogen. One milliliter o f SSC  (sodium chloride 0.015 M, so­
dium citrate 0.0015 M ) was added to the residue, mixed, and 
allowed to stand for 1 h. This procedure reconverts tom aym ­
ycin to DM T. To the DM T dissolved in SCC, 1 ml o f a 1.0 mM  
calf thymus D N A  (Sigm a Chemical Co.) solution was added 
and allowed to incubate at room temperature for 3 -4  h. The 
final concentration o f the antibiotic was generally about 0.4  
mM , which represents an excess o f antibiotic. The noncov- 
alently DN A-bound material (unreacted D M T and other 
impurities) was removed from the incubation mixture by di­
alysis against 50 volumes o f SSC  buffer, changed twice over 
a 48-h period. An aliquot, usually 0.5 ml, o f the purified 
D M T -D N A  complex from the dialysis bag was counted to 
determine tritium to carbon-14 ratio. A similar experiment in 
which the biologically inactive OT (this compound does not 
react with D N A  to form a covalent complex) was carried 
through this procedure resulted in an almost negligible amount 
of DNA-bound radioactive material (<0.1% ). This was in 
contrast to the reaction with D M T in which about 40-50%  of 
the activity remains bound to the complex. The less than 100% 
reaction of D M T with D N A  is due to the excess o f D M T  
present for maximum binding to D N A .
D egradation o f  Tom aym ycin. A known amount o f radi- 
ochem ically pure tomaymycin and an amount of nonlabeled 
carrier tomaymycin to make a total o f 50 mg were dissolved 
in about 5 ml of methanol. A freshly prepared solution of di- 
azomethane in ether was added and allowed to stand overnight 
to form the 8-methoxy-8-deoxytom aym ycin (Schem e III). 
Excess diazom ethane was removed by evaporation at room 
temperature under vacuum and the volume was reduced to 
about 1 ml. Four milliliters o f 6 N  N aO H  was added to this 
solution and the mixture was stirred at room temperature for 
1 h. At the end of the reaction, the alkaline reaction mixture 
was acidified to pH 2 with concentrated HC1 and extracted  
three times with 10 ml of ethyl acetate to remove the 4,5- 
dimethoxyanthranilate. The anthranilate derivative was re­
moved from the organic phase by extraction three times with 
about 5 ml o f 10% sodium carbonate solution. The sodium
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f i g u r e  1: Time-course production of DMT and incorporation of L- 
[me/A>7-,4C]methionine into DMT and OT by S. achromogenes. At the 
times indicated flasks were harvested and L-[methyl- l4C]methionine was 
added 12 h prior to harvesting. ( • — • )  m g /100-ml dry weight of myce­
lium; ( ■ — ■ ) M g / m l  of DMT; (x--x) % incorporation in DMT; (O- -O) 
% incorporation into OT.




to m a y m y c in
KUHN ROTH
CH3+COOH




| c h 2 n 2
c h 30 \ ^ / N H 2
XXCHsCr^^COOCHa
m ethyl-4,5 -dimethoxyanthranilate 
(DMAA)
carbonate phases were combined, acidified to pH 2 with 2 N  
HC1, and the anthranilate finally extracted into ethyl acetate. 
This organic phase was dried over sodium sulfate, concentrated 
under vacuum, and redissolved in about 2 ml of ether. Excess 
diazom ethane in ether was added and allowed to stand for a 
few minutes at room temperature to form the methyl ester of 
4,5-dim ethoxyanthranilate. The reaction mixture was taken 
to dryness by evaporation at 35 °C  under vacuum and redis­
solved in a small amount of ethyl acetate. Since the D M A A  
could not be induced to crystallize at this state, preparative 
TLC was carried out in system C. The D M A A  zone was lo­
cated by inspection under short uv light, and eluted from the 
silica gel with methanol. After removing the solvent, the yel­
lowish residue was redissolved in hot benzene and allowed to 
crystallize at room temperature. The crystals that formed were 
collected and an aliquot was weighed out accurately and 
counted for radioactivity. A further aliquot was chrom ato­
graphed and scanned to determine radiochemical purity. The 
melting point of the D M A A  (1 3 3 -1 3 4  °C ) was in close 
agreement to the literature value (133 °C ) (Heidelberger and 
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FIGURE 2: Short-term time-course incorporation of D L -|l-l4C]tyrosine 
into DMT and OT by an 80-h culture of S. achromogenes. 2.14 X 107 dpm 
of tyrosine was added to 95 ml of medium and 5-ml aliquots were taken 
at the times indicated.
expected (mol wt =  211).
Carbon atoms 12 and 13 of tomaymycin were solated from 
the antibiotic by K uhn-Roth oxidation. A known amount of 
radiochemically pure tomaymycin was added to an amount of 
carrier tomaymycin to make a total o f 50 mg anc subjected to 
Kuhn-Roth oxidation (Simon and Floss, 1967).
Results
The biosynthetic experiments were carried out with shake 
cultures of the D M T and OT producing S', achromogenes 
ATCC 21353 grown in a complex medium. DM T and OT were 
isolated from the culture medium by repeated extractions with 
ethyl acetate. Purification was carried out by preparative TLC 
and in the case of D M T followed by recrystallization or co­
valent complexation with D N A .
Representative data on mycelial growth and production of 
D M T and OT are shown in Figure 1. Onset o f  DMT produc­
tion and also OT biosynthesis, as judged by incorporation of 
precursors, takes place between 72 and 84 h. Typically, like 
most other microbial secondary metabolites, production of  
D M T and OT is delayed until almost the end cf the growth 
phase. The maximum production of DM T occurred at 84 h and 
titers reached about 40 /ug/ml- The optimum time for incor­
poration of labeled precursors into these compounds occurred 
when the precursor was added at 72 h. The shcrt-term time 
course incorporation of L - [ l- l4C]tyrosine into DMT and OT 
is shown in Figure 2. M aximum incorporation of this amino 
acid into D M T occurred between 12 and 16 h ard into OT at 
24 h. Partially for convenience and also because D M T was of  
prime interest in this investigation, cultures were harvested 12 
h after addition of the labeled precursors to '2-h-old cul­
tures.
In order to establish the precursors of DM T and OT, various 
carbon-14 and tritium labeled compounds were fed to the S. 
achrom ogenes under optimum conditions for incorporation 
into DM T and OT. The choice of possible precursors was based 
upon our previous studies on anthramycin in which we had 
demonstrated that tyrosine, dopa, tryptophan, and methionine
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t a b l e  l: Incorporation of Labeled Substrates into D M T  and OT.
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DM T OT D M T  OT
l-[ l - 14C]Dihydroxyphenylalanine 0.1 3.59 X 107 8.3 83.9 16.1 6.9  1.4
5-H ydroxy-DL-[G -3H] tryptophan 0.1 2.21 X 108 0.4 a a < 0.01 < 0.01
L-[methyl-  l4C] M ethionine 0.2 4.45 X 106 23.4 76 24 17.8 5.6
L-[7a-l4C]Tryptophan 1.3 9.29 X 106 11.6 54 25 6.3 2.8
D L -[l-l4C]Tyrosine 0.3 2.14 X 107 17.4 47 32 8.1 5.6
L-[ 1 - l4C] Tyrosine 0.5 8.66 X 107 11.9 85 10 10.1 1.2
L -[U -l4C]Tyrosine 0.01 1.82 X 10* 10.7 70 30 7.6 3.1
a Below limit o f  detection.
contributed to the antibiotic molecule (Hurley et al, 1975b). 
As anticipated, these amino acids were all well incorporated 
into DM T and OT (Table I).
The role o f methionine, tryptophan, and tyrosine as D M T  
precursors was substantiated by degradation o f the biosyn- 
thetically labeled samples o f the antibiotic. Prior to chemical 
degradation as outlined in Schem e III, D M T was converted 
to tomaymycin by recrystallization from methanol, and then 
methylated with diazomethane to produce 8-methoxy-8- 
deoxytomaymycin. Alkaline hydrolysis o f this compound with 
6 N NaO H  produced the 4,5-dimethoxyanthranilate that was 
converted to its methyl ester (D M A A ) after extraction from 
the reaction mixture with ether. The radiochemical purity of 
D M A A  was checked by TLC. Carbon atoms 12 and 13 of 
DM T were isolated from tomaymycin by K uhn-Roth oxida­
tion (Sim on and Floss, 1967). The data obtained from these 
degradations are shown in Table II. These results show that 
whereas L-[CH 3- 14C]methionine and DL-[7a-14C]tryptophan 
label D M A A  exclusively, virtually none of the activity from 
L -[U -l4C]tyrosine was found in this degradation product. 
Kuhn-Roth oxidation on tomaymycin shows that, whereas all 
the radioactivity in DM T labeled from l- [3 -  or 5-3H]tyrosine 
resides at carbon atom 13 of the antibiotic, the acetic acid 
representing C-12 and -13 of DM T from the sample labeled 
from L-[CH3- 14C]methionine is almost devoid of radioactivity. 
Kuhn-Roth oxidation on a sample of tomaymycin labeled from 
l - [ U - I4C] tyrosine shows that 30% of the activity resides with 
the acetic acid. The theoretical figure should be about 29% (i.e., 
two of the seven carbons of the ethylideneproline moiety iso­
lated as acetic acid).
Based on the known biosynthesis o f anthramycin and re­
ported work on the biosynthesis of the ethyl- and propylproline 
moieties o f lincomycins A and B, respectively (W itz et al., 
1971; Argoudelis et al., 1973) the three alternative pathways 
shown in Schem e IV for the biosynthesis o f the “ethylidene 
proline” grouping of D M T can be postulated. Pathways “a” 
and “ b” each require that 5,6-dihydroxycyclodopa be the 
substrate that undergoes ring cleavage.2 However, these 
pathways differ in that b involves ortho cleavage and gives rise 
directly to a seven-carbon unit, whereas a involves meta 
cleavage and would require an extra carbon from the C -l pool
2 It is equally likely that the anthranilate condensation product with 
dopa or cyclodopa is the real substrate that undergoes ring cleavage; 
however, for convenience sake we will consider the uncondensed cyclodopa 
as the example for our argument, while maintaining an open mind as to 
the true identity for this intermediate.
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t a b l e  II: Degradation of Tomaymycin.
% Radioactivity o f  Tomaymycin 
Recovered in
Precursor D M A A c h 3-c o o h
L-[methyl-  l4C] M ethionine 107 2
L -[U -l4C]Tyrosine 10 30
L-[3- or 5-3H]Tyrosine N E “ 102
DL-[7a-l4C]Tryptophan 108 N E a
a N E , not examined.
t a b l e  i l l :  Incorporation of Double-Labeled Precursors into DM T  
and OT by S. achrom ogenes.
% Retention o f 3H
Expt Precursor D M T  OT
1 l - [ 1 - I4C, 3- or 5-3H]Tyrosine 50 ,a 49,* 44 <• _
2 l - [ U - 14C, 3- or 5-3H]Tyrosine 6 4 ,a 62* -
3 l - [ 1 - I4C, A la -2, -3-3H]Tyrosine 4 9 ,°  5 1 ' 48°
4 l - [ U - 14C, A la -2 , -3-3H]Tyrosine 6 3 ,°  62,* 6 3 ' 64°
5 DL-[7a-l4C, 5-3H]Tryptophan 17,“ 16,* 14' 17°
6 L-[m eth y l-  l4C, m eth yl-^ H i]-  
Methionine
96 ,°  8 7 ' 9 1 “
a Purification by preparative TLC. * Recrystallization to constant 
specific activity. '  Complexation with D N A  and dialysis against two 
changes o f buffer.
to produce a total o f seven carbons. Pathway “a” would be 
analogous to that suggested for lincomycin B biosynthesis 
(W itz et al., 1971). The third possibility, pathway “c” utilizes
6,7-dihydoxycyclodopa as the substrate for ring cleavage, and 
would be analogous to the anthramycin and lincomycin A 
biosynthetic pathways, except that an extra carbon from me­
thionine would not be required for D M T biosynthesis. D if­
ferentiation o f pathways b and c from a can be made on the 
basis o f the origin of the terminal carbon o f the ethylidene­
proline moiety of DM T and the number of carbon atoms ty­
rosine contributes to DM T. Furthermore, it is possible to dif­
ferentiate between pathways b and c on the basis o f the com ­
plete loss or 50% retention of tritium from L - [3- or 5-3H ]ty- 
rosine in DMT. In the case of pathway “c” meta cleavage leads
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to retention of half o f the tritium from l - [3- or 5-3H]tyrosine 
in DM T, whereas in pathway b ortho cleavage will lead to 
com plete loss o f tritium during the conversion of tyrosine to 
DM T. The appropriate experiments were carried out to de­
termine the correct pathway.
The results demonstrate that pathway a can be eliminated 
on the basis o f both chemical degradation of tomaymycin and 
the number of carbon atoms from tyrosine that appear in DM T  
and OT. First, the results in Table II on the chemical degra­
dation o f  tomaymycin, biosynthetically labeled from L- 
[M e-l4C]m ethionine, show that virtually all o f the radioac­
tivity was located in the D M A A  moiety, presumably in the 
methoxy group, while the acetic acid derived from carbon 
atoms 12 and 13 was almost devoid of radioactivity. Second, 
our results show that tyrosine contributes seven of its nine 
carbon atoms to DM T, again clearly not in accord with path­
way a which demands only six carbons in D M T should arise 
from tyrosine. In order to determine how many carbon atoms 
o f L-tyrosine were actually incorporated into D M T and OT, 
we compared the incorporation of l- [U -I4C]tyrosine with that 
of L - [ l- l4C]tyrosine using L-[A la-2,3-3H]tyrosine and L -[3- 
or 5-3H ]tyrosine as reference labels. The data (experiments 
1, 2, 3, and 4) obtained are presented in Table III. The 62-64%  
retention o f tritium is indicative of a transfer of seven of the 
nine carbon atoms of tyrosine to the ethylideneproline moiety 
of D M T and OT. Incorporation of six or seven carbons of ty­
rosine into D M T  and OT would be represented by tritium re­
tentions of 75 and 64%, respectively.3
Elimination of pathway b as a viable alternative is based 
upon the results o f the double-labeling experiment with l -  
[1-I4C, 3- or 5-3H]tyrosine in which almost exactly half o f the 
tritium was retained in DM T, a result which is not compatible 
with this pathway (Table III). Pathway c is in agreement with 
the retention o f seven of the nine carbon atoms of tyrosine in 
DM T and OT and should also lead to acetic acid, derived from 
Kuhn-Roth oxidation of tomaymycin, biosynthetically labeled 
from l- [ 3- or 5-3H]tyrosine, which has the same specific ac­
tivity as the antibiotic. This was found in practice (Table II). 
Taken together these results lead to the inescapable conclusion
3 Taking into account the 50% loss of tritium from L -[/f/a-2,3-3H] 
tyrosine during its conversion to DMT and OT then retentions of 7 or 6 
carbons of L-tyrosine in DMT or OT will be % X xh X 100 =  64.3%, % X
X 100 =  75%. respectively.
that only pathway c is compatible with these results and 
pathway a and b cannot be operative. This, therefore, estab­
lished that the ring cleavage of cyclodopa occurs extradiol 
(meta), as is also the case with anthramycin, lincomycin A, and 
probably sibiromycin.
Chemical degradation of DM T labeled from D L -[7a-  
,4C] tryptophan revealed that all of the activity from this amino 
acid resides with the D M A A  moiety. The origin o f the 5- 
methoxy-4-hydroxyanthranilic acid from tryptophan probably 
involved a diversion of the well-known metabolic pathway 
leading to the formation of anthranilic acid from L-tryptophan 
(Greenberg, 1969). The double-labeling experiment with L- 
[M e-l4C, M e-3H 3]methionine and subsequent degradation 
indicates that the methyl group is transferred intact, barring 
an unexpected tritium isotope effect. (Chem ical degradation 
of tomaymycin biosynthetically labeled from L-[m ethyl- 14C, 
m eth y l-^ H i]methionine gave D M A A  which had an 88% tri­
tium retention.) Our results are compatible with the proposed 
building blocks shown in Schem e V.












In an effort to learn more about the structures of the possible 
intermediates in DM T biosynthesis before we embarked upon 
lengthy synthetic procedures designed to ultimately test the 
intermediacy of these compounds in DM T biosynthesis, we
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carried out a number of double-labeling experiments with ty­
rosine and tryptophan.
The existence of the fungal m etabolites cyclopenin (M o­
hammed, 1963) and cyclic dipeptides, such as gliotoxin 
(Brannon et al., 1971) and brevianamide A (Baidas et al.,
1974) (Schem e VI), led us to suspect that a cyclopenin-like
SCHEME VI: Structure o f Cyclopenin, G liotoxin, 
and Brevianamide A.
compound might be an intermediate in DM T, OT, anthram­
ycin, and sibiromycin biosynthesis. An epoxide similar in 
structure to cyclopenin could be looked upon as the reactive 
interm ediate that undergoes cyclization to form cycloan- 
thranilylcyclodopa (Scheme VII). If such an epoxide (Scheme
SCHEME VII: Postulated Mechanism for the Formation o f the 
Pyrrolo Ring o f DMT.
—  — >► DMT
VII) is an intermediate on the biosynthetic pathway to DM T, 
then the a-hydrogen and one of the two (3 hydrogens of tyrosine 
must be lost during conversion of this amino acid to DM T. In 
order to test this hypothesis, L -[l- l4C,Ala-2,3-3H]tyrosine was 
added to a culture of S. achrom ogenes and the DM T was 
isolated in radiochemically pure form. This sample o f DM T  
showed a tritium retention of 50% (Table III). The relative 
distribution of tritium between the a  hydrogen and the two 13 
hydrogens in L-[Ala-2,3-3H]tyrosine has recently been pub­
lished (Kirby et al., 1975). Results o f the study show that as 
expected 50% of the total activity resides in the a  carbon and 
the remaining 50% of activity is distributed unequally between 
the p r o -R  (8.5%) and p ro -S  (41.5%) hydrogens at the /3 car­
bon.4 Therefore, our 50% retention of tritium in DM T and OT
4 The relative distribution of radioactivity between carbon atoms 2 and
3 was also checked by us on our sample of L-[/l/fl-2,3-3H]tyrosine using
the racemization procedure described by Kirby et al. (1975). Approxi­
mately 50% of the activity was lost during this procedure.
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is most likely related to the loss of just the a  hydrogen o f  ty­
rosine.5 Therefore, our conclusion from this experiment is that 
the epoxide shown in Scheme VII is not a feasible intermediate 
in D M T biosynthesis.
Since DM T and OT are hydroxylated in the aromatic ring, 
it was of interest to determine whether these hydroxylation 
reactions involved an intramolecular migration o f aromatic 
ring substituents (the N IH  shift). Such migrations have been 
demonstrated in a variety of biological systems including plant, 
animal, and bacterial tissues (D aly et al., 1972). The wealth 
of knowledge on the N IH  shift has led to the formulation of  
a number of basic rules concerning the migration or loss o f the 
hydrogen atom from the carbon atom at which hydroxylation 
has occurred and, consequently, the order in which substituents 
are inserted into the aromatic ring (Daly et al., 1972).
The possible pathways for conversion o f DL-[5-3Hltrypto- 
phan into D M T are as shown in Schem e VIII. Selective m i­
gration of displaced tritium to C-6 during hydroxylation at C-7 
but prior to hydroxylation at C-8 would result in 85% or greater 
retention o f  tritium in DM T (pathway a). Nonselective m i­
gration of tritium to C-6 and -8, during hydroxylation at C-7 
but again prior to hydroxylation at C-8 would result in about 
42-47%  retention in DM T (pathway c). Hydroxylation at C-8 
prior to hydroxylation at C-7 would result in com plete loss o f  
tritium during the conversion of DL-[5-3H]tryptophan to D M T  
(pathway b). The experimentally determined retention of 16% 
(Table III) can be explained in two ways. First, it is suggested 
that b is the major pathway, with a or c being minor alternate 
pathways, or second, that a modification o f pathway c is op­
erative such that an 84% migration to C-8 and a 16% migration 
to C-6 occurs during the first hydroxylation reaction. The 
d l - [ 5-3H]tryptophan used in this experiment was prepared 
by catalytic dehalogenation of 5-bromo-DL-tryptophan with 
tritium gas (Research Products International). This procedure 
has been demonstrated to produce tryptophan with greater 
than 90% of the tritium in the 5 position (Renson et al., 1966), 
and, therefore, our retention cannot adequately be explained 
by nonspecific labeling. Finally, the possibility that 5-hy- 
droxytryptophan is an intermediate on the pathway to D M T  
has been excluded, since this substrate, fed in labeled form (see 
Table I) with tritium predominately in the aromatic ring, was 
not detectably incorporated (i.e., less than 0.1%).
The next step in our study of the biosynthesis o f D M T  and 
OT was to determine the biogenetic relationship between these 
two compounds. Upon feeding in parallel flasks D M T and OT  
(both substrates were prepared in radiolabeled form in a pre­
vious biosynthetic experiment in which DL-[1-14C] tyrosine had 
been fed) to 72-h cultures o f S. achromogenes, the results 
shown in Table IV were obtained. This data reveals that, while 
DM T was converted into OT, the reverse does not occur. It is 
also interesting to note that while virtual complete recovery 
of radioactivity from the flask-fed OT was found both at 24 
and 48 h, in contrast, after addition of D M T only about two- 
thirds of the total radioactivity could be recovered. The ex­
planation for this observation is probably that, while some of  
the biologically active DM T becomes bound to the S', achro-
5 The incorporation of D L -[l-l4C,37?5-3H)-tyrosine and the two ste- 
reospecifically labeled substrates, D L -[l-l4C ,(3S)3-3H]tyrosine, DL- 
[ l - 14C ,(3/?)3-3H]tyrosine, together with the equivalent deuterated sub­
strates in DMT, anthramycin and sibiromycin will be the subject of an­
other publication (L. Hurley, N. Das, and R. Parry, manuscript in prep­
aration). However, our results with these radioactively labeled substrates 
into DMT do show complete retention of tritium in this antibiotic sub­
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mogenes D N A  and therefore becomes unavailable for reex­
traction into ethyl acetate, the biologically inactive OT does 
not bind to D N A  and is completely available for reextraction  
into ethyl acetate.
The bioconversion or inactivation of D M T through its 
conversion into OT was further examined in washed cell 
preparations. The kinetics of conversion of D M T to OT in a 
72-h-washed cell preparation is shown in Figure 3. In this ex­
periment, D M T biosynthetically radiolabeled from D L -[1 -  
14C]tyrosine was added to a 100-ml concentrated washed cell 
preparation. Aliquots o f 5 ml were taken at appropriate times 
and worked up in the usual manner to determine the amount 
of conversion o f DM T to OT. Uptake o f D M T from the me­
dium into the cells was also measured and found to occur ini­
tially in a linear manner, then leveling out by about 60 min at 
which time 42.6% of the added [1 1-I4C ]D M T  had been taken 
up from the medium. Control experiments in which a boiled 
washed cell preparation or buffer was used did not show ap­
preciable conversion of DM T to OT (Table V). An incubation 
with broth from which the mycelium has been removed by 
filtration did show a small amount of conversion of D M T into 
OT, but this was probably due to traces of cells which had 
passed through the filter.
The ability of different aged mycelium to carry out this 
conversion was also tested. W ashed cell preparation from the 
trophophase (44 and 60 h) and idiophase (78 and 102 h) of 
equal density were prepared, radiolabeled D M T was added, 
and the preparations were incubated for 12 h. The results in
t a b l e  iv: Conversion of DM T to OT by S. achrom ogenes 
Culture.
% of Added Total 
Act. Recovered in





Tim e (h) DM T OT
into Ethyl 
acetate
OT 24 0 98 2
OT 48 0 92 8
DM T 24 34 30 36
DM T 48 24 36 40
0
Figure 4 show that comparable conversion of D M T into OT  
and D M T recovery are found at 44, 60, and 78 h, thus indi­
cating that this enzym atic activity is not restricted to the idi­
ophase. The markedly lower conversion of DM T to OT at 102 
h is probably due to a larger competitive D N A  binding reac­
tion, which occurs due to release of D N A  into the medium after 
lysis o f the cells and possibly enzym e inactivation in these 
advanced cultures.
Discussion
By a combination of feeding experiments with specifically  
labeled amino acids and chemical degradation of the resulting 
biosynthetically labeled DM T molecues, the building blocks 
for D M T have been established as tryptophan, tyrosine, and 
methionine. The manner in which these amino acids are in­










FIGURE 3: Time-course conversion of [1 1-I4C]DM  into OT by a 78-h 
washed cell preparation. 1.05 X 105 dpm of DTM was added to 100 ml 
of the washed cell preparation and 20-ml aliquots were taken at the times 
indicated.
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Age o f  W ash ed  c e l l  p r e p a r a t i o n  (HR)
f i g u r e  4: Conversion of DMT into OT by different aged washed cell 
suspensions of 5 . achromogenes. At the times indicated DMT (5.25 X 104 
dpm /25 ml of suspension) was added to the washed cell preparation and 
incubated for 12 h. (□ )  Recovered DMT; (□ )  OT produced.
The incorporation o f tryptophan, labeled in the aromatic 
ring, exclusively in the M H AA  m oiety of D M T and presum­
ably OT is analogous to the biosynthesis o f anthramycin, al­
though the arom atic substitution pattern differs in each anti­
biotic. The predominant loss of tritium from DL-[5-3H]tryp- 
tophan during its conversion to D M T and OT is interpreted 
to mean either that the major pathway for D M T biosynthesis 
requires hydroxylation at C-8 prior to hydroxylation at C-7, 
or that only partially selective migration of tritium occurs 
during the first hydroxylation at C-7. In sibiromycin a 91% 
retention o f tritium from d l- [ 5 - 3H]tryptophan is found 
(Hurley et al., 1976), indicating that in this case migration of 
tritium from C-7 occurs either selectively to C-6 in a substrate 
where C-6 and -8 are unsubstituted or that hydroxylation at 
C-7 occurs after methylation at C-8. In any event, this latter 
exam ple does indicate that N IH  shifts do occur in actinomy-1 
cetes and, therefore, our interpretation of data leading to the 
prediction of the order in which the hydroxylation reactions 
take place in D M T and OT is not unreasonable. This report 
apparently provides the first example of an antibiotic con­
taining a C 2-proline moiety in which the carbon skeleton is 
derived in its entirety from tyrosine. Argoudelis et al. (1973) 
have reported that the C 2-proline m oiety of lincomycin B is 
derived from tyrosine (6 carbons) and methionine (1 carbon). 
On the other hand, our results do fall in line with anthramycin, 
lincomycin A, and sibiromycin6 in that “meta cleavage” of
6,7-dihydroxycyclodopa is implicated. In this respect, the 
proposed “meta cleavage” of 5,6-dihydroxycyclodopa to give 
rise ultimately to the C2-proline moiety of lincomycin B seems 
unlikely considering the generality o f the pathway to the other 
antibiotics.7 Additional evidence that the “meta cleavage” 
pathway is operative in the biosynthesis o f these antibiotics is 
that we are able to isolate from the acid phases o f all our pyr-
6 Our preliminary results on sibiromycin indicate that some retention 
of tritium from L-[1-14C,3- or 5-3H]tyrosine occurs in sibiromycin com­
patible with a “meta cleavage” pathway.
7 After this manuscript was submitted for publication Rolls et al. (1976)
reported experiments using stable isotopes demonstrating that the C2-
proline unit of lincomycin B is derived in an analogous fashion to the
C2-proline unit of DMT. This, therefore, refutes the previous finding by
Argoudelis et al. (1973) and confirms the generality of the “meta cleavage”
pathway to these antibiotics.
t a b l e  v :  Conversion of DM T to  O T by 78-h W ashed Cell 
Preparation and Various Controls. D M T  (6 .0  X 104 dpm) W as
Added to 25 ml o f the Incubation System.
Incubation Incubation DM T OT
Conditions Tim e (h) Recovered (%) Converted (%)
Washed cells 6 6.7 22.3
W ashed cells 12 5.8 27.0
Boiled cells0 6 50.0 3.05
Boiled cells 12 26.3 1.37
Broth6 6 64.4 7.14
Broth 12 63.4 6.97
Buffer0 6 93.0 < 0.1
Buffer 12 95.0 < 0.1
0 A 25-ml suspension o f the washed cells was heated in a water bath 
at 100 °C  for 30 min. b The broth was obtained by filtering the culture 
under sterile conditions through W hatman N o. 1 filter paper to re­
move m ycelium . c Phosphate buffer, 0.02 M, pH 7.1.
rolo[ 1,4]benzodiazepine antibiotics-producing strains a very 
unstable compound that has all the characteristics o f a typical 
a-hydroxym uconic semialdehyde, which results from meta 
cleavage of a o-diphenol.
The results o f our feeding experiment with l - [ 1 - ,4C, A la-  
2,3-3H]tyrosine indicate that the a  hydrogen of tyrosine is lost 
prior to conversion into DM T and OT, while both /3-hydrogens 
are retained in these compounds. In an experiment with L- 
[1-14C, A la - 2,33H] tyrosine in which pool and protein tyrosine 
were examined, it was found that a tritium loss in excess of 50% 
was found in both cases. This indicates that the loss o f the a  
hydrogen o f tyrosine in DM T and OT may not necessarily be 
directly related to the biosynthesis o f these compounds. While 
it is highly likely that the two /3 hydrogens are located at C -l 
of D M T , this conclusion should be treated with some caution  
at this time in the absence of stable isotope (deuterium labeled) 
experiments or exhaustive chem ical degradation studies. 
Further studies in our laboratory utilizing specifically deu- 
terated m olecules are in progress to substantiate this result. 
The biogenetic relationship between D M T and OT was par­
ticularly interesting, since OT is biologically inactive and its 
production from DM T might represent a means to protect the 
cells against intracellular antibiotic that fails to be excreted  
or D M T retaken up by the cells. Our studies show that the 
conversion of D M T to OT is due to an intracellular enzym e 
that is active during both trophophase and idiophase. It was 
also found that cultures of S. achromogenes that have lost their 
ability to produce DM T were capable of converting the anti­
biotic to OT. This is suggestive that the D M T m etabolizing  
enzyme is constitutive. The enzym e that inactivates chlor­
amphenicol, chloramphenicol hydrase (M alik and Vining 
1971), has similar characteristics in that the enzym e is also 
found in chloramphenicol nonproducing cultures, and is in­
tracellular.
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Pyrrolo[ l,4]benzodiazepine Antibiotics. Biosynthesis of the 
Antitum or Antibiotic Sibiromycin by Streptosporangium  sibiricum f
Laurence H. Hurley,* William L. Lasswell, Ravinder K. Malhotra, and Nobel V. Das
a b s t r a c t : T h e  b io sy n th e sis  o f  th e  a n titu m o r  a n tib io t ic  s i­
b iro m y cin  b y  S trep tosporan giu m  sib iricum  req u ires the  
con stru ctio n  o f  four units: the am in o  su gar from  g lu cose; the  
anth ran ila te  ring from  DL-tryptophan probably via kynurenine; 
th e  a r o m a tic  m eth y l group  from  m eth ion in e; th e  propylidene
S ib ir o m y c in , an antitumor antibiotic produced by S trep ­
tosporangium  sibiricum  (Gause et al., 1969; Brazhnikov et 
al., 1972; Mesentev et al., 1974), is one of the pyrrolo- 
[1,4] benzodiazepine antibiotics. The other antibiotics in this 
group are anthramycin (Leimgruber et al., 1965), 11-de­
m ethyltom aymycin (Kariyone et al., 1971), and the neo- 
thramycins A and B (M iyam oto et al., 1977).1 The potent 
biological properties o f sibiromycin (Brazhnikova et al., 1970; 
Shorin & Rossolima, 1970) are attributed to the fact that this 
antibiotic, like anthramycin and tomaymycin, binds covalently 
to D N A  and thereby inhibits its template activity (Hurley et 
al., 1977a). A review on the comparative aspects, including 
the mode o f  action, o f anthramycin, tomaymycin, and sibi­
romycin has recently been published (Hurley, 1977).
These antibiotics are biogenetically related (Hurley et al., 
1975, 1976a; Hurley, 1977); in each case the anthranilate 
moiety of these antibiotics is derived from tryptophan probably 
via the kynurenine pathway (Hurley et al., 1976b; Hurley & 
Gairola, 1979). For anthramycin (Hurley et al., 1975) the 
acrylamide proline moiety is derived from tyrosine (seven 
carbons) and m ethionine (one carbon) (see labeling pattern 
shown in Schem e I). The ethylidene proline moiety of to­
maymycin is derived similarly with one less carbon atom from 
methionine (Schem e I). The present results firmly establish 
the labeling pattern of tyrosine, methionine, and tryptophan 
in sibiromycin. A preliminary account of this work has ap­
peared (H urley et al., 1977b).
Experimental Procedures 
All experimental details of this paper are given under 
supplementary material (see paragraph at the end of this paper 
regarding supplementary material).
Results and Discussion 
The biosynthetic experiments were carried out by using the 
sibiromycin producing organism S'. sibiricum  ATTC 29053 
which was grown in shake culture on a complex media. 
Sibirom ycin production follows the common trophophase- 
idiophase relationship, starting at about 24 h after inoculation 
of the flask and maximizing at 100 Mg/mL at 54 h.2 
M axim um  incorporation of precursors into sibiromycin oc­
curred when the radiotagged molecules were added at 44 h 
and harvested between 1 and 6 h later. Further incubation 
after this time resulted in a marked reduction in the incor­
poration into sibiromycin.2
4 From the Division of Medicinal Chemistry and Pharmacognosy, College 
of Pharmacy, University of Kentucy, Lexington, Kentucky 40506. 
Received September 7, 1978. This work was supported by a grant from 
the National Institutes of Health, Research Grant CA 17047.
proline from L-tyrosine with the loss of two aromatic carbons 
and addition of a C -l from methionine. Retention o f tritium  
from dl- [5-3H]tryptophan in sibiromycin suggests an N IH  
shift during hydroxylation of an intermediate.
Sibiromycin was harvested from the culture broth by using 
the procedure described by Gause et al. (1969). This method 
requires the extraction of the combined media and mycelium  
using a methylene dichloride-oleic acid mixture, followed by 
reextraction of the organic phase with a citric acid buffer at 
pH 4. After adjustment of the pH of the aqueous phase to 
7.8, the sibiromycin is Finally partitioned into chloroform. This 
procedure yields a product which is predominantly sibiromycin.
The efficiency of incorporation of potential precursors into 
sibiromycin was evaluated as described before for anthramycin 
and tomaymycin (Hurley et al., 1975, 1976a). The validity 
of these figures was checked for all substrates showing sig­
nificant incorporation into sibiromycin by conversion of the 
amorphous sibiromycin to anhydrosibiromycin which was 
recrystallized from 1-butanol to constant specific activity  
(results not shown). The incorporation of expected precursors 
of sibiromycin into this antibiotic by S. sib iricum  are sum ­
marized in Table I. As expected, based upon our previous 
biosynthetic studies on anthramycin and tom aym ycin, the 
methyl group of methionine, L-Dopa, L-tyrosine, and the 
aromatic ring of tryptophan were all efficiently incorporated  
into sibiromycin. D-[6-14C]G lucose was also incorporated 
presumably into the sibirosaminide moiety of sibiromycin.
On the basis of our previously reported biosynthetic studies 
on anthramycin and tomaymycin, the anticipated labeling 
pattern for L -[l-13C]tyrosine, L-[m ethyl-n C ]methionine, and 
DL-[5-3H]tryptophan in the aglycon moiety o f  sibiromycin  
should be as shown in Schem e II. This schem e predicts the 
following points. (1) L-Tyrosine should exclusively label the 
PPA3 moiety of sibiromycin, and, furthermore, the only carbon 
atom enriched with carbon-13 in sibiromycin from a bio­
synthetic experiment with l - [1 - 13C]tyrosine should be carbon 
atom 11. (2) L -[m ethyl-l4C ] M ethionine will label both the 
anthranilic acid as well as the PPA moiety of sibiromycin. The 
methyl groups transferred should reside exclusively at either 
carbon atoms 14 or 15 of the aglycon unit o f sibiromycin and
1 It has recently been reported (Miyamoto et al., 1978) that the proline 
unit of the neothramycins is derived from an intact L-proline molecule 
rather than tyrosine.
2 Time course production of sibiromycin and incorporation of L-[l- 
14C]tyrosine into sibiromycin as well as the short-term time course in­
corporation of L -[l-uC]tyrosine, L-[mer/iy/-14C]nnethionine, and DL- 
[7a-14C]tryptophan into sibiromycin are given in Supplementary Material 
(see paragraph at end of this paper regarding supplementary material).
3 Abbreviations used: AS, anhydrosibiromycin; AS-one, anhydrosi- 
biromycinone; DAS-one, 7,9-diacetylanhydrosibiromycinone; DMAS-one, 
7,9-dimethoxyanhydrosibiromycinone; DM AA, 3,5-dim ethoxy-4- 
methylanthranilate; PPA, propylproline aldehyde; TLC, thin-layer 
chromatography; PPO, 2,5-diphenyloxazole; POPOP, l,4-b is[2-(5- 
phenyloxazolyl)] benzene.
[Reprinted from Biochem istry, (1979) 18, 4225.]
Copyright © 1979 hy the American Chemical Society and reprinted by permission of the copyright owner.
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Scheme I: Established Labeling Pattern o f  Tyrosine and Methionine in Anthramycin and Tomaymycin
OH







_  ^  CONH,O ' - —  2





T o m a y m y c i n
Scheme II: Proposed Labeling Pattern o f  L -[ l- l4C]Tyrosine, L-[mer/zv/-l3C | Methionine, and DL-[5-3H] Tryptophan in Sibiromycin 
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1 D-[6-14C]glucose 0.4 3.08 X 107 2.06 X 106 32 2.1
2 L-[ l - l4C]dihydroxyphenylalanine 0.01 5.0 X 106 1.12 X 106 82 18.4
3 L- \m e th y l-l*C] m ethionine 3.2 6.2 X 107 1.52 X 107 100 24.5
4 DL-[7a-14C] tryptophan 7.1 1.17 X 107 2.13 X 106 42 7.7
5 DL-[ l - 14C]tyrosine 0.2 7.93 X 106 1.52 X 106 80 15.3
6 L-[U-14C]tyrosine 0.03 6.70 X 106 6.54 X 10s 67 6.5
7 L-[ l - 14C] tyrosine 0.05 7.5 X 106 2.61 X 106 80 27.9
furthermore should be transferred intact, i.e., as a C H 3 unit. 
(3) DL-Tryptophan will be found solely in the anthranilate 
moiety of sibiromycin. Assuming that the tritium at position 
5 of tryptophan undergoes an N IH  shift (Daly et al., 1972)
upon hydroxylation of some intermediate between tryptophan 
and sibiromycin, then this tritium atom will be retained in the 
antibiotic and should now reside at carbon atom 6 of sibi­
romycin. A series of experiments utilizing both radioactive
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Table II: Enrichments o f  Carbons in DAS-one from Feeding 











11.17 q 14 3.1 0.8
18.49 q 15 3.0 0.8
20.72 q 17, 19 1.0 1.0
120.76 d na° 1.0 1.0
121.16 s na 1.5 0.8
121.75 d na 0.8 0.7
122.54 d na 1.0 1.0
123.52 d na 0.8 0.9
128.58 d na 0.8 0.8
128.89 s na 0.7 0.8
131.60 s na 0.7 0.9
137.32 s na 0.8 0.9
146.79 d 11 0.9 3.9
148.32 s 7 or 9 0.8 0.8
149.20 s 7 or 9 0.9 0.9
160.53 s 5 0.7 0.8
168.66 s 16 or 18 1.0 0.6
169.00 s 18 or 16 1.1 0.9
a Chemical shifts are given relative to Me4Si. b This multipli­
city arises from one-bond 13C proton coupling. 0 Numbering for 
DAS-one is shown in Scheme III. d Calculated by measuring 
peak heights in the spectrum o f  enriched DAS-one relative to the 
height o f  the acetyl m ethyl groups o f  DAS-one and then dividing 
these relative heights by the relative heights o f  the same peak 
(calculated in the same way) in the natural abundance spectrum.
0 na, not assigned.
and stable isotope techniques were carried out to test these 
predictions.
Chemical degradation of biosynthetically labeled species of 
sibiromycin was carried out by modification of a procedure 
described by Mesentsev et al. (1974) which is shown in Scheme
III. Sibiromycin was chemically degraded through AS and 
A S-one to D M A S-one, which was then recrystallized and 
further checked for radiochemical purity by TLC. The in­
termediates AS and A S-one were not evaluated for specific 
incorporation of precursors due to lack of sufficient carrier 
material. DM AS-one was degraded by alkaline conditions to 
yield the anthranilate fragment as DM AA and the remaining 
part o f  the molecule as PPA. PPA was isolated and re­
crystallized to determine the relative contribution of tryptophan 
to this moiety. The D M A A  isolated from the biosynthetic 
experiment with DL-[7a-14C,5-3H]tryptophan was diluted with 
cold authentic D M A A  and recrystallized to a constant 3H / I4C 
ratio.
The partial carbon N M R  assignments for DAS-one are 
shown in Table II. Assignments for carbon atoms 5, 7, 9, 
11, 14, 15, 16, 17, 18, and 19 were straightforward and made 
on the basis of multiplicity and specific neighboring groups 
(Stothers, 1972). The remaining carbon resonance signal 
assignments were not made due to both the complexity of the 
problem and also the fact that these atoms were neither 
expected nor found in practice to be enriched with carbon-13.
S pecific  Precursor R o le  o f  Tyrosine in S ibirom ycin . L- 
[ l - 13C]Tyrosine (95% 13C) was added to 30 flasks of S. s i­
biricum  just prior to the onset of antibiotic production (see 
Table III). After 24 h the sibiromycin was extracted from 
the culture and chemically converted to DAS-one (see Scheme 
III). Comparison of the l3C N M R  spectrum of the biosyn­
thetically enriched species with the spectrum of the noniso­
topically labeled species clearly showed that only carbon atom 
11 of DAS-one was enriched in the isotopicaliy labeled species 
(see Table II). This result therefore demonstrates that tyrosine
Table III: Conditions and Results o f  Stable Isotope Feeding 
Experiments with Deuteratcd and Carbon-13 Enriched Substrates
feeding sibiro­ isotopic
condi­ mycin DAS-one anal, o f
precursor feda tions01 yieldb yield DAS-one0
L-[ 1-13C]- 1 70 mg 5 mg D0 = 95.1%
tyrosine D, =4.9%
(95% 13C) Dj = 0 .0%
L-[mer/iv/-13C |- 5 40 mg° 7 mg D0 = 95.4%
methionine D, = 4.6%
(90% , 3C) 
h -[m eth yl-2H3\-
D2 = 0 .0%
15 60 mg 8 mg D0 = 79.9%
methionine D, =2.1%
(95% 2 H) Dj = 0 .0%
D 3 = 12.0% 
D6 = 8.1%
a Precursors were added at about 32 h o f  growth, and the sibiro­
mycin was harvested 24 h later. b This value was based upon 
measurement o f  absorption at 310 nm (E = 21 800) o f  the sibiro­
mycin dissolved and diluted out in methanol. c D0, D ,, D 2, D 3, 
and D 6 represent the parent ions at m /e  366, 367, 368, 369, and 
372, respectively. d Number o f milligrams added per flask to 30 
flasks. Each 500-mL baffled flask contained 100 mL o f  media.
0 Because o f  the low yield o f  sibiromycin, 70 mg of unlabeled 
sibiromycin was added before chemical conversion to DAS-one.
Table IV: Rccrystallization o f  DAS-one Produced from Feeding 
Experiments with L-[1-14C,2- or 6-3H|Tyrosine, L -[U -I4C,2- or 
6-3H]Tyrosine, and L -[m ethyl-'*C ,m ethyl-3 H3]Methionine
!H /,4C
ratio
DAS-one 3 H /14C 
ratio o f  recrystn % final
expt precursor cursor first second third tention0
1 L-[ 1-14C,2- or 6.50 2.24 2.31 2.20 34.6
2
6-3HJtyrosine 




14C, m ethyl-3 H3]- 
methionine
2.58 2.65 2.43 2.70 100.5
a Tritium retention = (3H /14C o f product)/(3H /‘4C o f precursor)
X 100.
is incorporated into the aglycon moiety of sibiromycin in an 
analogous manner to that previously demonstrated for an­
thramycin and tomaymycin.
In order to determine how many carbon atoms of L-tyrosine 
were actually incorporated into sibiromycin, we compared the 
incorporation of L-[U -l4C]tyrosine with that of l - [ 1 - 14C ] -  
tyrosine using l - [2 -  or 6-3H]tyrosine as a reference label. The 
data (experiments 1 and 2 )  obtained are presented in Table
IV. The 45.1% retention of tritium in DAS-one (experiment 
2, Table IV) is indicative of a transfer of seven of the nine 
carbon atoms of tyrosine to the DAS-one. Incorporation of 
six or seven or eight carbon atoms of tyrosine into DA S-one  
would be represented by tritium retentions of 38.9, 44.9, and 
51.9%, respectively.4
Specific Precursor Role o f  Methionine in the Aglycon Part 
o f  S ibirom ycin . The specific carbon atoms of DM A A  and 
PPA that are labeled from methionine were determined by 
carbon N M R . L-[m ethyl-]3C ] Methionine (90% l3C) was fed 
to 30 flasks of S. sibiricum  as described for the l - [ 1 - I3C]- 
tyrosine experiment, and DAS-one was prepared from the 
isolated sibiromycin (see Table III). Analysis of the 13C N M R
4 Taking into account the 34.6% retention of tritium from L-[2- or 
6-3H]tyrosine during its conversion to DAS-one, then the retention of 6, 
7, or 8 carbon atoms of L-tyrosine in DAS-one will be 9 /6  X 34.6 = 51.9, 
9 /7  x  34.6 = 44.9, and 9 /8  X 34.6 = 38.9, respectively.
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Scheme III: Chemical Degradation o f  Sibiromycin [after Mesentsev et aL (1974)]
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spectrum o f D A S-one (Table II) showed that [m ethyl- 
13C]m ethionine enriched the aromatic methyl group and the 
terminal propylidene methyl group of DAS-one. The C-l pool 
origin of the terminal propylidene methyl group of sibiromycin 
is in line with both our previous studies on anthramycin 
(Hurley et al., 1975) and tomaymycin (Hurley et al., 1976a) 
and those of the Upjohn group on lincomycins A and B (Witz 
et al., 1971; Rolls et al., 1976) and suggests that the C2- and 
C 3-proline units are derived from a common intermediate in 
which divergence takes place at the point at which either a 
proton or a methyl group is transferred to the branch point 
compound (Hurley et al., 1979).
In order to verify that both methionine-derived methyl 
groups in DAS-one were transferred as intact methyl units, 
we carried out feeding experiments with L -[m ethyl-l*C,- 
m ethyl-^H i]methionine and L-tm et/iy/^H^methionine. The 
100% retention of tritium (Table IV) in DAS-one is in accord 
with this assumption; however, to avoid any ambiguity due 
to an isotope effect, we conducted an experiment with deu- 
terated methionine in which the D A S-one was analyzed by 
mass spectrometry. In this experiment, in addition to the 
nondeuterated species, two other predominant ions occurred 
corresponding to D 3 and D6 (see Table III). This confirms 
that both methyl groups are transferred intact to the aglycon 
m oiety of sibiromycin.
Specific Precursor Role o f  Tryptophan in Sibiromycin. The 
results in Table V show that DL-[7a-l4C]tryptophan labeled 
alm ost exclusively the D M A A  moiety of sibiromycin. This 
unit o f sibiromycin is derived from tryptophan via the ky- 
nurenine pathway (Hurley & Gairola, 1979), and the origin 
of this moiety is therefore analogous to that of variously 
substituted anthranilates found in anthramycin (Hurley et al.,
1975), tomaymycin (Hurley et al., 1976a), and actinomycin 
D (Herbert, 1974; Salzmann et al., 1969).
The availability of dl-[5-3H]tryptophan has allowed us to 
conveniently determine whether an N IH  shift of the tritium 
originally located at the 5 position of tryptophan occurred 
during its conversion to sibiromycin. This experiment was
Table V: Feeding Experiment with L-[7a-14C,5-3H|Tryptophan




3H /I4C tritium 
ratio retention (%)
[7a-'4C,5-3H l- 12.7 100
tryptophana
sibiromycin^ 100c 10.7 84.3
DMAS-one 89.0 9.63 76.0
DMAA
first crystn 86.3 12.0 94.5
second crystn 87.5 11.7 92.3
PPA 0.0
a DL-(7a-14C]Tryptophan (1.40 X 10 7 dpm; sp act. 3.5 mCi/ 
mmol) and DL-j5-3H| tryptophan (1 .78  X 108 dpm ;sp act. 1 Ci/ 
mmol) were fed to 24 100-mL cultures o f  S. sibiricum. b The 
sibiromycin isolated from this experiment (68.5 mg) had a specific 
activity o f 9 .10 X 103 dpm/^M. 0 Based upon carbon-14.
carried out using d l - [7a-l4C]tryptophan as a reference label 
and chemical degradation of the sibiromycin to D M AA. The 
tritium retention in D M A A  (93%) (Table V) is a direct 
measure of the magnitude of the N IH  shift, and since there 
is only one aromatic proton in D M A A , the tritium is pre­
sumably located exclusively at this position. An indication 
of the step at which hydroxylation of the aromatic ring occurs, 
resulting in an N IH  shift, can be assessed from the following 
facts. In a feeding experiment with [ l - 14C]-4-m ethyl-3- 
hydroxyanthranilic acid (Hurley & Gairola, 1979), we found 
a 14.1% incorporation into sibiromycin. An almost complete 
retention of tritium from DL-[5-3H]tryptophan takes place in 
sibiromycin at C-6. The empirical rule that enzym atic hy­
droxylation para to a highly activating group such as - N H 2 
results in virtually complete loss of isotopic hydrogen from the 
product (Daly et al., 1972) leads us to suspect that the hy­
droxylation may take place on a compound possessing a less 
activating para substituent such as an amide.
In summary, this study clearly demonstrates that the 
biogenetic building blocks for the aglycon moiety of sibiro-
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mycin are tyrosine, tryptophan, and methionine. The de­
termined biosynthetic labeling pattern o f these three amino 
acids in the aglycon moiety of sibiromycin is shown in Scheme
II. The paper immediately following this one supplies more 
information on the conversion of tyrosine to the C 2- and 
C 3-proline units of the pyrrolof 1,4] benzodiazepine antibiotics 
(H urley et al., 1979). Our continuing studies are directed 
toward determining more about the biosynthetic pathways to 
these unique antibiotics and also their function, if  any, to the 
producer organisms.
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Pyrrolo[l,4]benzodiazepine Antibiotics. Biosynthetic Conversion of 
Tyrosine to the C 2- and C 3-Proline Moieties of Anthramycin, 
Tomaymycin, and Sibiromycin+
Laurence H. Hurley,* W illiam L. Lasswell, John M. Ostrander, and Ronald Parry (in Part)
a b s t r a c t : This paper describes biosynthetic labeling ex­
periments on the conversion of tyrosine to the C 2- and C 3- 
proline units o f  anthramycin, tomaymycin, and sibiromycin. 
The biosynthetic fate o f all of the aromatic and side-chain  
hydrogens has been determined in each antibiotic by using dual 
tagged ( 3H / ,4C) and 2H-labeled tyrosine molecules. In ad­
dition, experiments using [l5N]tyrosine and the tritiated d  and 
L isomers of tyrosine have shed some light on the biochemical 
reactions which take place at the a  position of tyrosine. On 
the basis o f results of all these experiments, a biosynthetic
./A n th ram ycin , sibiromycin, and tom aym ycin1 are struc­
turally and biosynthetically related antitumor antibiotics 
produced by various actinomycetes (Scheme I). The potent 
biological properties o f these antibiotics, which we named as 
a group the “pyrroIo[ 1,4]benzodiazepine antibiotics”, can be 
attributed to the effects of these compounds on nucleic acid 
biosynthesis (Hurley et al., 1977; Horwitz & Grollman, 1968; 
Gause & Dudnik, 1972; Nishioka et al., 1972).
Biosynthetic studies establishing the biosynthetic building 
blocks for anthramycin (Hurley et al., 1975), tomaymycin  
(H urley et al., 1976), and sibiromycin (Hurley et al., 1979) 
have been published. These studies have demonstrated that 
the biosynthetic origins of the anthranilate and C 2- or C 3- 
proline units o f these antibiotics are closely related as shown 
in Schem e I. The anthranilate moieties o f these antibiotics 
are derived from tryptophan via the kynurenine pathway 
(H urley & Gairola, 1979). Each antibiotic differs in the 
arom atic substitution pattern, insertion of the substituents 
appearing to occur at the kynurenate stage. The C2- and 
C 3-proline units o f these antibiotics are derived from cata­
bolism o f tyrosine. In the case of the C 3-proline units of 
anthramycin and sibiromycin, the additional carbon absent 
in the C 2-proline unit o f tomaymycin is derived from me­
thionine. The labeling patterns illustrated in Schem e I for 
anthram ycin, sibiromycin, and tom aym ycin have been 
demonstrated by radioactive and stable isotope techniques 
(H urley et al., 1975, 1976, 1979).
One of the prime objectives of our biosynthetic studies on 
these antibiotics is to establish a general pathway for the 
unusual biosynthetic conversion o f tyrosine through Dopa to 
the C 2- and C3-proline moieties of these antibiotics. Spe­
cifically, we would like to determine at which intermediate 
the common pathway diverges to give rise to either the C 2- 
or C 3-proline unit and which subsequent modifications can be 
thought o f as being cosmetic in character.
t From the Division of Medicinal Chemistry and Pharmacognosy, College 
of Pharmacy, University of Kentucky, Lexington, Kentucky 40506, and 
the Department of Chemistry, Brandeis University, Waltham, Massa­
chusetts 02154. Received September 7, 1978. This work was supported 
by a grant to L.H.H. from the National Institutes of Health, Research 
Grant CA 17047.
scheme has been proposed to rationalize the apparent in­
consistencies which occur between the results for the three 
antibiotics. This scheme proposes that a common main 
pathway involving proximal extradiol cleavage of Dopa and 
condensation to form the pyrrolo ring leads ultimately to a C-7 
branch point compound. Parallel pathways from this central 
branch point compound lead by well-known biochemical 
transformations to the C2- and C3-proline units of anthramycin, 
tomaymycin, and sibiromycin. The reactions in these parallel 
pathways are suggested to be “cosmetic or after events” .
This paper describes the results of double-labeling exper­
iments (3H and 14C) using various specifically labeled tyrosine 
molecules and also experiments utilizing 2H- and 15N-labeled  
substrates. These results, which have been obtained with all 
three antibiotics, are interpreted in terms o f possible inter­
mediates in the biosynthetic pathways to the C2- and C3-proline 
units. A preliminary account of some of this work has ap­
peared (Lasswell et al., 1978).
Experimental Procedures
All experimental details o f this paper are given under 
supplementary material (see paragraph at the end of paper 
regarding supplementary material).
Results and Discussion
The optimum conditions for biosynthetic incorporation of 
tyrosine into anthramycin (Hurley et al., 1975), sibiromycin 
(Hurley et al., 1979), and tomaymycin (Hurley et al., 1976) 
have been described previously. Final tritium to carbon-14 
ratios in anthramycin and tomaymycin were determined after 
recrystallization with cold carrier material (Hurley et al., 1975,
1976). Sibiromycin was converted to DAS-one (for structure 
see preceding paper) before recrystallization to a constant 
tritium to carbon-14 ratio (Hurley et al., 1979). Where 
exchangeable tritium was likely to be present in tyrosine 
samples, this was evaluated by either repeated addition and 
removal of water or recrystallization to a constant tritium to 
carbon-14 ratio. Anthramycin was chem ically converted to 
DAA in certain cases (Hurley et al., unpublished experiments).
OH
DAA
1 Abbreviations used: AME, anthramycin 11-methyl ether; TME, 
tomaymycin 11-methyl ether; Dopa, 3,4-dihydroxyphenylalanine; cy- 
clo-Dopa, 6,7-dihydroxycyclophenylalanine; DAS-one, 7,9-diacetylan- 
hydrosibiromycinone; DAA, 1,1 la-didehydroanhydroanthramycin; 
F3AcOH, trifluoroacetic acid; PPA, propylproline aldehyde.
[Reprinted from Biochem istry, (1979) 18, 4230.)
Copyright © 1979 by the American Chemical Society and reprinted by permission of the copyright owner.
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Scheme I: Structures o f  Anthramycin, Tom aym ycin, and Sibiromycin and Their Demonstrated Biosynthetic Labeling Patterns from 

























S ib iro m y c in
Sibiromycin was converted to PPA for mass spectral analysis 
of 15N  labeling (for structure see the preceding paper).
The double-labeled biosynthetic experiments were designed 
to answer specific questions. Each question will be considered 
in turn and the results rationalized in a suggested biosynthetic 
scheme leading to these antibiotics.
W hat routes via arom atic ring cleavage and cyclization to  
fo rm  the five-m em bered  ring are possib le? During the 
conversion of tyrosine through Dopa to the C 2- and C3-proline 
moieties of the pyrrolo[ 1,4] benzodiazepine antibiotics, cleavage 
of the aromatic ring must take place. This in turn will be 
followed by condensation with the 2 or 6 position of tyrosine 
to form the pyrrolo ring. The alternative pathways for ring 
cleavage and condensation are shown in Schem e II. Bio­
synthetic pathways leading to structures of the type 1, 111, or 
V in Scheme II would necessarily require elimination of both 
tritium atoms from l - [ 3 -  or 5-3H]tyrosine, whereas pathways 
leading to II, IV, or VI only require loss of one of the two 
tritium atoms from this substrate. The results in Table I 
(experiments 1-3) exclude pathways leading to I, III, or V 
as possible alternatives in the cases of anthramycin and to­
maymycin. However, the almost complete loss o f tritium from 
DAS-one would be in agreement with any of the pathways in 
Schem e II.2 The position of the retained tritium from l - [ 3 -  
or 5-3H]tyrosine in anthramycin (Hurley et al., 1975) and 
tomaymycin (Hurley et al., 1976) was as expected at C-13 
of these antibiotics. In view of the fact that the meta cleavage 
pathway is implicated not only for anthramycin and to­
maymycin but also in the case of the lincomycin antibiotics 
(Rolls et al., 1976), which contain similar C3- and C2-proline 
units to the pyrrolo[l,4]benzodiazepine antibiotics, we suspect 
that the almost complete loss of tritium from l - [3- or 5- 
3H]tyrosine in sibiromycin is due to a later biosynthetic 
transformation. A plausible hypothesis for this loss, peculiar 
to sibiromycin, is presented later.
Does ring cleavage o f  the arom atic ring take place before 
or after cyclization to fo rm  the five-m em bered ring? Just as
2 We had previously reported a tritium retention of 17% in sibiromycin 
from an experiment with L-[1-I4C,3- or 5-3H]tyrosine (Hurley, 1977). 
This result is correct; however, upon conversion of sibiromycin to DAS-one, 
further loss of tritium occurs such that only a 3.9% tritium retention is 
found in DAS-one.
l - [ 3 -  or 5-3H]tyrosine can be used to differentiate between 
alternative methods for ring cleavage of Dopa, species of l - [ 2 -  
or 6-3H]tyrosine can be utilized to shed some information on 
the stage at which cyclization to form the five-membered ring 
of anthramycin, tomaymycin, and sibiromycin takes place. 
The intermediacy of cyclo-Dopa would require the loss o f at 
least 50% of the tritium from l - [ 2 -  or 6-3H]tyrosine in these 
antibiotics, whereas a pathway in which ring cleavage occurs 
prior to formation of the five-membered ring would not require 
loss of either of the tritium atoms from l - [ 2 -  or 6-3H]tyrosine 
in these antibiotics. The results in Table I (experiments 5-7) 
show considerable variations in retention of tritium from one 
antibiotic to another. The 78% retention of tritium in to­
maymycin would appear to rule out cyclo-Dopa as a plausible 
intermediate in this case. However, the 52 and 33% retentions 
in the cases of anthramycin and DAS-one are in agreement 
with either pathway.
Information on the labeling pattern of these species of 
tyrosine in anthramycin and sibiromycin was obtained by 
feeding the corresponding deuterated tyrosine molecules. l - [ 2 -  
or 6-2H 2]Tyrosine (97% 2H 2) was fed to anthramycin-pro- 
ducing cultures (20 m g/flask) and sibiromycin-producing 
cultures (20 mg/flask) by using conditions described previously 
(Hurley et al., 1975, 1979). The anthramycin isolated was 
crystallized as A M E and subjected to mass spectra and 'H 
N M R  analysis. Mass spectral analysis of A M E  showed only 
species of D 0 and D, in the ratio of 48.15 to 51.85 (Table II), 
confirming that one deuterium atom was lost during the 
conversion of l - [ 2 -  and 6-2H 2]tyrosine to anthramycin. The 
'H N M R  analysis of the same sample showed a clear reduction 
of the doublet due to substitution of deuterium for the proton 
at C-12 of A M E (Figure 1 A ,B). Significantly, no reduction 
in the intensity of the proton signal at C-3 was found. The 
sibiromycin isolated from a feeding experiment in which 20 
m g/flask of the deuterated tyrosine was added was converted 
to DAS-one (Hurley et al., 1979). Mass spectral analysis on 
this sample showed only species o f D0 and D! in the ratio of
72.5 to 27.5 (Table II). The 'H N M R  analysis revealed that 
the remaining deuterium  atom was located at C -12 of 
DAS-one (Figure 1C,D), as was also the case for A M E .
These results, considered together with the experiment 
utilizing l - [ 2 -  or 6-3H]tyrosine, lead to the conclusion that the
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Table I: Results o f  Co crystallization o f  AME, TME, DAS-one, and DAA from Feeding Experiments with Various Double-Labeled 
Tyrosine Molecules
3I./14^ f  3H /14C ratio o f crystallizationH /’ C ratio o f  ___ '______________ 1___________  final tritium
pt no. species o f  tyrosine product tyrosine first second third retention ('
1 L -[l'-14C,3- or 5-3H] AME 9.17 4.74 4.68 4.68 51
2 L -[l'-14C,3- or 5-3H] TME 6.45 3.25 3.16 3.07 48.9
3 L-[ l ' - l4C,3- or 5-3H] DAS-one 8.91 0.32 0.26 0.47 3.9
4 L -[1’-I4C,3- or 5-3H] DAA 11.20 (5 .79)° 5.53 5.69 b 98.4
5 L-[ l ' - 14C,2- or 6-3H] AME 8.16 4.31 4.31 4.25 52.6
6 L -[l'- l4C,2- or 6-3H] TME 8.75 7.22 6.83 6.82 78.0
7 L-[ l ' -14C,2- or 6-3H] DAS-one 8.33 2.77 2.74 2.65 32.7
8 L-[ l ' - 14C,2- or 6-3H] DAA 18.38 (8.86)° 8.05 8.45 b 95.4
9 DL-[ l ' - 14C,3'-7?S-(3'-3H)] AME 3.19 2.97 3.06 3.06 95.0
10 DL-[ l ' - 14C,3'-7?5-(3'-3H)] TME 3.18 3.18 3.31 b 102.0
11 D L -[l'-14C,3'-/?5-(3'-3H)] DAS-one 4.87 2.84 3.00 3.07 61.0
12 DL-[ l ' - 14C,3'-7?5-(3'-3H) J DAA 12.70 (9 .97)a 4.76 4.92 5.44 54.5
13 D L -[l'-14C,3'-/?-(3'-3H)] AME 11.04 10.81 9.03 9.12 87.4
14 d l - [ 1 ' - 14C,3'-7?-(3'-3H)] TME 4.86 4.29 4.49 b 90.3
15 DL-[ l ' - 14C,3'-/2-(3'-3H)] DAS-one 9.70 9.68 9.37 9.40 97.8
16 DL-[ l ' - l 4C,3'-7?-(3'-3H)] DAA 11.04 (9 .12)° 6.51 5.10 4.63 50.6
17 DL-[ l ' - l4C,3'-5-(3'-3H)] AME 9.85 10.03 8.12 7.81 80.9
18 DL-[ l ' - 14C,3'-S-(3'-3H)] TME 3.94 3.59 3.75 b 92.4
19 DL-[ l ' - 14C,3'-5-(3'-3H)] DAS-one 6.92 2.29 2.36 b 33.7
20 DL-[ r - 14C,3'-5-(3'-3H)] DAA 9.85 (7 .81)° 4.04 3.48 3.43 44.2
21 L-[1'-14C, Ala-2', 3'-3H] AME 3.30 1.64 1.64 b 49.7
22 L -[l'-I4C,Ala-2',3'-3H] TME 3.30 1.47 1.69 b 47.9
23 L-[1'-I4C,Ala-2',3'-3H] DAS-one 9.12 1.71 1.62 b 19.3
24 D L -[l'-l4C ],L -[2-or 6-3H] AME 18.04 16.77 18.57 17.70 100.5C
25 D L -[l'-14C ],D -[2- or 6-3H] AME 11.86 0.75 0.84 0.54 5 .8C
26 D L -[l'-14C],L-[2- or 6-3H] DAS-one 5.82 2.89 2.92 3.34 5 3 .8C
27 D L -[l'-14C ],D -[2- or 6-3H] DAS-one 6.17 0.55 0.63 0.48 9.0C
a Final 3H /I4C ratio o f  AME after two crystallizations and before conversion to DAA. b Insufficient material for a third recrystallization. 
c Taking into account the retention o f  only approximately 50 and 32.7% o f  the tritium during the conversion o f L-[ l '-14C,2- or 6-3H]tyrosine 
to anthramycin and DAS-one, respectively (experiments 5 and 7, Table I), the experiments with D L -[1'-14C] and L-[2-or 6-3H] and DL-[1'- 
14C] and D-[2- or 6-3H ]tyrosine have relative retentions o f  (100.5 X 100)/52 .6  = 191.1% and 5.8 X 100/52.6  = 11.0% (for AME) and 53.8 X 
100/32.7 = 165% and 9.0 X 100/32.7  = 27.5% (for DAS-one), i.e., the L isomer is incorporated at least 17 and 6 times more efficiently than 
the D isomer o f  tyrosine in AME and sibiromycin, respectively.6
Table II: Conditions and Results o f  Radioactive and Stable Isotope Feeding Experiments with 14C-, 2H-, and ,SN-Labeled Tyrosine 
Molecules Using S trep tom yces refuineus and Streptosporangium  sibiricum
species o f  tyrosine fed feeding conditions
isotopic analysis o f  products
mass spec- sp act. 
troscopya (%) (MCi/mmol)
calcd enrichments (%)
based upon based upon 
mass spec- 14C dilution 
troscopy values*
L-[2- and 6-2H2] (97% 2H2) 20 mg/flask added to 20 50-mL 
cultures at 6 h and harvested at 14 h
AMEb 
D0 = 48.1 
D, = 5 1 .9  
D2 = 0.0
na^ 51.9 (2 H) na
L-[2- and 6-2H2] (97% 2H2) 20 mg/flask added to 20 100-mL 
cultures at 34 h and harvested at 54 h
DAS-onec 
D0 = 72.5 
D, = 27.5 
D2 = 0.0
na 27.5 (2H) na
L-[3’,3'-2 H2 ] (98% 2H2) 10 mg/flask added to 20 flasks at 32 h 
and harvested at 40  h
DAS-onec 
D0 = 89.2 
D, = 10.8 
D2 = 0 .0
na 10.8 na
DL-[1-14C,3- and 5-2H2, lsN] 
(sp act. 10.50 MCi/mmol; 
>95% 2H2; 99% , 5N)
18 mg/flask added to 20 50-mL  
cultures at 6 h and harvested at 15 h
DAAd
D0 = 72.0  
D, = 2 1 .8  
D ,, 5N , = 6.2 
D2,5N, or 
D ,15N 2 = 0 .0
3.30 28.0 (2H) 
6.2 (15N)
31.5
L-[1-,4C,, 5N] (sp act. 19.11 
MCi/mmol; 99% I5N)
10 mg/flask added to 20 100-mL 
cultures at 32 h and harvested at 46 h
PPAe 
D0 = 91.6  
D, = 8.4 
D2 = 0 .0
5.47 8.4 ( I5N) 28.7
a Corrected for natural isotopic abundances after Biemann (1962). b D0, D ,, and D2 represent parent ions at m /e  296, 297, and 298. 
c D0, D , , and D 2 represent parent ions at m /e  366, 367, and 368. d D0, D ,, D21 sN , ,  and D 215N, or D ^ N ,  represent parent ions at m /e  295, 
296, 297, and 298. c D0, D , , and D 2 represent parent ions at m /e  135, 136, and 137.  ̂na, not applicable. * Dilution = (specific activity o f  
tyrosine)/(specific activity o f  product).
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Scheme II: Alternative Pathways for the Conversion of l - [3 -  or 5-3H]Tyrosine into the C2- and C3-Proline Moieties o f  Anthramycin,








































67% loss o f tritium in DAS-one is due to complete loss of the 
tritium that will reside at C-6 of Dopa and a partial loss of 
tritium (17%) that ultim ately labeled C-12 of DAS-one.
Stable isotope analysis of tomaymycin samples labeled from 
l - [ 2 -  and 6-2H ]tyrosine is lacking, due to the low antibiot­
ic-producing ability o f the available culture. Our double­
labeling experiment with l - [ 1 ' - 14C , 2 -  or 6-3H]tyrosine in which 
we found a retention of 78% of tritium is, however, only 
com patible with a pathway involving ring cleavage of Dopa 
prior to formation of a five-membered ring.
What is the biosynthetic fa te  o f  the side-chain hydrogens 
o f  tyrosine in anthram ycin , tom aym ycin , and sibirom ycin? 
On the basis o f our previous biosynthetic results with the 
pyrrolo[ 1,4]benzodiazepine antibiotics, the 2! and 3' side-chain 
hydrogens of tyrosine should reside at carbon atoms 1 and 1 la  
of these antibiotics, respectively (see Schem e 1).
Conclusive evidence for the biosynthetic origin of C -l of 
anthramycin as C-3' o f tyrosine was obtained, when it was 
found that species of A M E  biosynthetically labeled from 
d l - [ l ' - 14C ,3'-./?S'-(3/-3H )]tyrosine and the two stereospecif- 
ically labeled substrates lose approximately 50% of their 
radioactivity (experiments 12, 16, and 20, Table I) when they 
were converted to DA A  by using F3A cO H  (Hurley et al., 
unpublished experim ents). Control experiments in which 
l - [ 1 ' - 14C , 2 -  or 6-3H]tyrosine and l - [ 1 ' - 14C , 3 -  or 5-3H]tyrosine 
were administered to the anthramycin-producing culture and 
these samples were subsequently chemically converted to DAA
showed, as expected, no further loss of tritium during chemical 
conversion of AM E to DAA (experiments 4 and 8, Table I).
Inspection of the appropriate carbon atoms in tyrosine (side 
chain) and the three antibiotics (carbon atoms 11a and 1) 
reveals that, whereas in anthramycin and tomaym ycin the 
oxidation state of the corresponding carbon atoms are similar, 
in sibiromycin an additional double bond exists. Furthermore, 
the stereochemistry at C-2' of tyrosine is the same as that at 
C -l la  of anthramycin and tomaymycin. These facts would 
therefore suggest that, whereas in anthramycin and tom ay­
mycin all three side-chain hydrogens might be retained, in 
sibiromycin the 2'-hydrogen and one of the two diastereotopic 
3'-hydrogens must be lost. Double-labeled species of tyrosine 
labeled with tritium either at the 3'-carbon [D L -fl'-^C ^'- 
R S -(3'-3H )], d l - [ 1 ' - I4C , 3 , - / ? - ( 3 ' - 3H ) ] ,  and d l - [ 1 ' - 14C , 3 ' -  
5,-(3 '-3H )]] or at both the 2'- and 3'-carbons [ l - [ 1 ' - 14C , -  
Ala-2',3'-3H]] were fed to all three antibiotic-producing strains, 
the antibiotics were isolated, and the tritium to carbon-14 ratios 
were used to determine the fate of these hydrogens in an­
thramycin, tomaymycin, and sibiromycin.
The results of feeding experiments with tyrosine nonster- 
eospecifically labeled at C-3' and the two largely stereospe- 
cifically labeled tyrosine molecules [ d l - [ 3 ' - 5 - ( 3 ' - 3H ) ]  and 
d l - [ 3 ' - / ? - ( 3 ' - 3H ) ] ]  with the anthramycin- and tomaym y- 
cin-producing cultures (Table I, experiments 9, 13, and 17 and 
10, 14, and 18) as expected failed to show any significant loss 
of tritium. Therefore, any intermediate requiring loss of either
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f i g u r e  1 :  'H N M R  spectra of nonisotopically labeled A M E  (A ), A M E  labeled from l - [ 2 -  and 6-2H 2]tyrosine (B) in [mef/rp/-2H 6]M e2SO , 
and nonisotopically labeled DAS-one (C) and DA S-one labeled from l - [ 2 -  and 6-2H 2]tyrosine (D ) in C 2HC13.
one of these diastereotopic hydrogens can be eliminated from 
consideration. The equivalent experiments utilizing the same 
specifically labeled substrates but with the sibiromycin-pro- 
ducing organism showed that appreciable loss o f tritium  
occurred from the D L -[r-14C,3'-/?S’-(3 '-3H )]- and d l - [ 1 ' -  
14C,3'-5'-(3/-3H)] tyrosine in DAS-one (Table I, experiments 
11 and 1 9 ) .  Very little loss occurred from d l - [ 1 ' - ,4C , 3 ' -  
/?-(3'-3H )]tyrosine (Table I, experiment 15), in accord with 
the stereospecific loss o f the 3'-(5’)-hydrogen from tyrosine. 
The predominant loss o f the 3'-(S’)-hydrogen from tyrosine 
is analogous to that found in secrurinine, mycelianamide, 
cryptoschiculine A and the ammonium-lyase reaction (Parry, 
1 9 7 8 ) .  The loss of one of the two diastereotopic 3/-hydrogens 
from tyrosine during its conversion to sibiromycin is further 
substantiated by an experiment in which l - [3',3/-2H 2]tyrosine 
was fed to a culture of S treptosporangium  sibiricum . The 
isolated DAS-one showed only species of D0 and D, in the ratio 
of 8 9 . 2  to 10 .8  (Table II). Our results with DAS-one isolated 
from feeding experiments with DL-[r-l4C,3'-/?S'-(3'-3H )]- and 
D L-[r-14C,3'-5'-(3'-3H)]tyrosine (Table I, experiments 11 and 
19) show tritium retentions (61 and 34%, respectively) which 
are higher than that theoretically expected (3 '-R S, 50%; and
3'-S, 15%).3 The excess tritium retentions for both of these 
species were reproducible from one experiment to another. As 
yet no firm basis for this excess tritium retention is known; 
however, it is possible that some competing reaction, unrelated 
to sibiromycin biosynthesis, could be selectively enriching the 
3'-iS,-(3 '-3H) species of tyrosine relative to the 3'-/?-(3'-3H) 
species and ( l ' - l4C) species o f tyrosine. Such an explanation 
has been suggested by Johns et al. ( 1 9 7 5 )  to explain the 
unexpected results found in gliotoxin after feeding d l - [ 3 ' , -  
3'-2H 2] phenylalanine to the fungus Trichoderm a viride. In 
this case it was found that gliotoxin derived from [3',3'- 
2H2]phenylalanine is mainly monodeuteriated but also contains 
some dideuterio species. Hydrogen loss is not therefore ob­
ligatory in gliotoxin biosynthesis, but some competing reaction 
selectively removes the 3'-profl-deuterium atom with retention 
of configuration.
The fate of the hydrogen at C-2' o f tyrosine in the three 
antibiotics was determined by using l - [ 1 ' - 14C , A la-2'- or 
3'-3H]tyrosine since the tritium labeling pattern in this amino
3 Each of the stereospecifically labeled species is only about 85% 
stereochemically pure (Parry, 1975).
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acid is known (Kirby et al., 1975). First, the tritium is 
distributed equally between position 2' and 3' o f tyrosine. 
Second, the tritium at C-3' o f tyrosine is predominantly in the 
p ro -S  position (41.5 ±  0.5%) relative to 8.5 ±  0.5% in the 
p ro -R  position. Since we had demonstrated using the C-3' 
labeled species o f tyrosine that complete retention of this 
tritium is found in anthramycin and tomaymycin, then any 
loss o f tritium in these antibiotics from feeding experiments 
using L -[Ala-2'- or -3'-3H]tyrosine would necessarily have to 
be from the C-2' position. The results in Table I (experiments
21 and 22) show an approximate 50% retention of tritium in 
both anthramycin and tomaymycin; following that complete 
loss of the tritium from C-2' o f tyrosine occurs during its 
conversion o f  these antibiotics.
The result of the feeding experiment with L -[l'-14C,Ala-2'- 
or -3'-3H ]tyrosine with the sibiromycin-producing organism 
revealed a retention of 19.3% of tritium in DAS-one (Table 
I, experiment 23). This is again larger than the expected 8.5% 
based upon the relative distribution of tritium in this species 
of tyrosine. However, this agrees with our finding in ex­
periments 11 and 19 shown in Table I. As expected, the result 
with l - [Ala-2'- or -3'-3H]tyrosine predicts the loss of the 
3'-(/?)-hydrogen and the 2'-hydrogen of tyrosine.
Is the nitrogen o f  tyrosine retained in anthram ycin and 
sibirom ycin? The complete loss of the 2'-hydrogen of tyrosine 
in the pyrrolo[ 1,4]benzodiazepine antibiotics could be asso­
ciated with a rapidly equilibrating transaminase washing out 
the tritium from this position. In order to test this, we fed d l -  
or L-[15N ]tyrosine to the anthramycin- and sibiromycin- 
producing cultures together with d l - or l - [ 1 ' - 14C ]  tyrosine to 
act as an internal reference label to measure the dilution of 
tyrosine in these antibiotics. In the case of the anthramycin 
experiment, as an additional measure of the in tact incorpo­
ration of the amino group with the carbon skeleton of tyrosine, 
a species containing deuterium  ( d l - [ 1 ' - 14C , 3 -  or 5- 
2H 2,15N ]tyrosine labeled intramolecularly with 15N was 
prepared.4 The results of experiments using the anthramycin 
and sibiromycin experiment are shown in Table II. The ,4C 
data indicated theoretical enrichments of 31.5 and 28.7% for 
15N  in anthramycin and sibiromycin provided  the l5/V was 
com plete ly  retained. The deuterium data in the case of 
anthramycin, measured as D A A , its chemical degradation 
product, showed an enrichment of 28.0%, i.e., in good 
agreement with the carbon-14 calculated theoretical en­
richment. The mass spectral data on the 15N  in DAA and 
PAA, however, showed only 6.2 and 8.4% enrichments,5 i.e.,
22 and 29% of the comparative enrichments calculated from 
14C or 2H data. These experiments therefore reveal that only 
a partial retention of 15N  is found in either case and therefore 
argue strongly against transamination being entirely re­
sponsible for the complete loss o f the 2'-hydrogen of tyrosine 
in anthramycin.
Is L- or D-tyrosine the precursor o f  the C2- and C y proline 
units o f  anthram ycin  and sib irom ycin ? An alternative ex­
planation for the complete loss o f the 2'-hydrogen of tyrosine 
could be a rapid racemization in which l - or D-tyrosine would 
serve equally well as precursors for these antibiotics. Ex­
periments using l - [ 2 -  or 6-3H]tyrosine and d - [ 2 -  or 6-3H]-
4 This would not be useful with the sibiromycin experiment since both 
of these deuterium atoms are lost during biosynthesis of this antibiotic 
(see Results and Discussion).
5 It could be argued that the l5N could be equilibrating with the nitrogen 
pool and subsequently could be transferred back to the same or other 
tyrosine molecules. However, the complete absence of the D ,I5N 2 species 
of DAA (Table II) makes this possibility much less likely than the partial 
retention of ,5N from tyrosine in anthramycin.
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tyrosine, with DL-[l'-14C]tyrosine as a reference la>el, have 
been utilized to answer this question. The results (experiments 
2 4 -2 7 ,6 Table I) show that in both cases exam iied (an­
thramycin and sibiromycin) L-tyrosine serves almost e;clusively 
as the precursor of these antibiotics, thus eliminating race­
mization as a means to explain the complete loss cf the 2'- 
hydrogen of tyrosine in these cases. It appears, therefore, that 
the complete loss of the 2'-hydrogen, at least in the case of 
anthramycin and sibiromycin, is due to reaction in the 
biosynthetic pathway unrelated to either transamiration or 
racemization of tyrosine.
Formulation o f  Parallel Biosynthetic Pathw ays to the C2- 
and C yP rolin e Units o f  the Anthram ycin, Tom cym ycin, 
S ibirom ycin , and Lincomycin A ntibiotics. The overall ob­
jective of this detailed examination of the conversion of tyrosine 
into the C2- and C3-proline units of anthramycin, tomcymycin, 
and sibiromycin was to consolidate the biosynthetic information 
into a biosynthetic scheme that would accommodate some if 
not all of these apparent inconsistencies. The biosynthetic 
pathway shown in Schem e III was proposed, based ipon the 
following assumptions. (1) Proximal extradiol cleavage of 
Dopa is involved as the common ring cleavage reaction. 
Neither the distal extradiol cleavage nor the ortho cleavage 
(pathways b and c in Scheme II) can be completely eliminated 
from consideration at this time; however, these were considered 
to be less likely than the proximal extradiol cleavage.7 (2) 
Cyclo-Dopa is unlikely to be a common intermediate in the 
pathway. (3) Divergence of the pathways occurs at the step 
at which addition of either a C H 3+ group or a H + to a x>mmon 
C 2-proline unit takes place. (4) Formation of the ethylidene 
methyl group of tomaymycin and the conjugated acrylamide 
side chain of anthramycin and the unsaturation in the side 
chain and pyrrolo ring of sibiromycin are cosmetic after events 
which occur subsequent to the main pathway.
The important features of the main and branch pathways 
leading to the C 2- and C 3-proline units of the pyrrolo[l,4]- 
benzodiazepine antibiotics and the lincomycins shown in 
Scheme III are as follows. (I) Following 2,3-extradiol cleavage 
of the aromatic ring of Dopa, a condensation reaction to form 
a Sch iff base between the a-am ino group and the aldehydic 
group takes place. (II) The conjugated enol (I) then undergoes 
enolization to yield the a-keto acid (II) which itself then loses 
two carbon atoms (carbon atoms 4 and 5 of Dopa) in a 
stepwise manner to form the diene (III). (I ll)  The diene (III) 
is considered to be the branch point compound for which a 
1,4 addition of H -X  results in divergent pathways dependent 
upon the nature of X +. If X + is H +, then the pathway leads 
to the C2-proline moieties o f tomaymycin and lincomycin B, 
whereas if X + is S +-C H 3, then the pathway leads to the 
C 3-proline moieties o f anthramycin, sibiromycin, and linco­
mycin A. (IV) Subsequent modification of the first inter­
mediates past the branch point leads to the propylproline unit
6 The company supplier of d-[2- or 6-3H]tyrosine reports that the optical 
purity was about 97%, and therefore our results reported here are 
conservative estimates of the much more efficient utilization of L- than 
D-tyrosine.
7 Our rationale for this conclusion was based upon the following 
observations, (a) When substituted catechol derivatives are used as 
substrates for metapyrocatechase, they are cleaved exclusively at this 
proximal site by the action of this enzyme (Nozaki et al.. 1970); (b) 
mechanistically, the formation of a Schiff base (I in Scheme V) and its 
subsequent conversion to the diene (III in Scheme V) are attractive; (c) 
the presence of a similar yellow compound derived from tyosine in the 
acid extract of the broths of all three antibiotic fermentations with spectral 
properties similar to products of extradiol ring fission of aromatic 
compounds is supportive evidence for a pathway involvng a meta­
pyrocatechase (Hurley, unpublished experiments).
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Scheme 111: Proposed Parallel Biosynthetic Pathways for the Conversion o f  Tyrosine into the C2- and C,-Proline Moieties o f  Anthramycin, 
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of lincomycin A (IV —*• V I), the acrylamideproline unit of 
anthramycin (IV -*• IX ), the propylideneproline unit o f si­
biromycin (IV -*■ X III), and the ethylproline unit of linco­
mycin B (V —*• X IV ). The ethylideneproline unit o f to­
maymycin is formed directly from the branch point compound 
(III —*• V). W here m odifications are required, these would 
be considered as “cosm etic or after events” which occur 
subsequent to the main pathway. The cosmetic modifications 
leading to the lincomycins are straightforward and do not 
require further comment. For the branch pathways leading 
to the C 3-proline units o f anthramycin and sibiromycin, hy­
droxylation at the allylic carbon8 in a stereospecific manner 
leads to VII. This compound can then undergo a 1,4-conjugate 
elimination of phosphoric acid in two analogous but different 
ways (VII —► VIII and VII —► X ).9 These reactions would
8 Allylic hydroxylations carried out by microorganisms have been 
previously demonstrated (LeMahieu et al., 1970; Tabenkin et al., 1969; 
Robertson et al., 1978).
9 Although stereochemical details for these compounds are as yet lacking, 
a similar postulated mechanism in which a 1,4-conjugate trans elimination 
involving a two-stage X-group mechanism (Cornforth, 1968) can be found 
in the chorismate synthetase reaction (Floss et al., 1972; Hill & Newkome, 
1969) and might be a model for our suggested examples.
result in the stereospecific loss of hydrogen that was originally 
at C-2 or -6 of tyrosine (anthramycin pathway) or the 3'-S  
position of tyrosine (sibiromycin pathway). The conversion 
of VIII to IX requires oxidation and amination to produce the 
acrylamideproline moiety of anthramycin. In the case of the 
sibiromycin branch, X undergoes an allylic rearrangement to 
produce XI which is then hydroxylated at the allylic carbon 
thereby eliminating in a stereospecific manner the hydrogen 
that was originally located at C-3 or -5 of tyrosine. The 
product of this reaction, XII, is then able to undergo a second 
stereospecific 1,4-conjugate elimination of phosphoric acid 
which leads to loss of the hydrogen originally located at C-2 
or C-6 of tyrosine and concomitantly the formation of the 
desired propylidene side chain o f sibiromycin.
A consideration of the details in Scheme III allows us to 
explain the apparent inconsistencies between results from 
different antibiotic fermentations.
For example, the 1,4-conjugate elimination reactions (VII 
—*■ VIII and XII -*> X III) peculiar to the anthramycin and 
sibiromycin pathways explain the loss of the tritium originally 
located at C-6 of Dopa, which is at least partially retained in 
tomaymycin.
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Furthermore, the com plete loss of tritium from l- [3- or
5-3H]tyrosine peculiar to the sibiromycin biosynthesis is linked 
indirectly to the introduction of the extra degree of unsatu­
ration found solely in sibiromycin (1 la-1 bond), which requires 
an additional postulated allylic hydroxylation at C - l3 (XI -»  
X II).
Although the proposed biosynthetic pathway shown in 
Schem e III is probably not the only one capable of explaining 
our results, we feel its development and existence is an im­
portant step in our program to establish a general biosynthetic 
pathway to these interesting antibiotics.
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Biosynthesis of the Lincomycins. 1. Studies Using Stable 
Isotopes on the Biosynthesis of the Propyl- and Ethyl-L-hygric 
Acid M oieties of Lincomycins A and B
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Abstract: The biosynthesis of the propyl-L-hygric acid and ethyl-L-hygric acid moieties of lincomycins A and B has been examined 
by using deuterated and carbon-13 labeled precursors in combination with carbon-13 NMR and mass spectral analysis. The 
results, using specifically deuterated tyrosine, DOPA, and methionine, demonstrate that tyrosine is converted via DOPA to 
an intermediate that undergoes aromatic ring cleavage most probably via a 2,3-extradiol cleavage reaction. An experiment 
using D-(13C6)glucose in combination with analysis of the 13C -13C spin-coupling patterns in lincomycin A and propyl-L-hygric 
acid permits the determination of those carbon atoms that remain together during the biosynthesis of lincomycin A. Glucose 
is converted via glycolysis and the hexose monophosphate shunt to phosphoenolpyruvate and erythrose 4-phosphate, respectively, 
which are in turn converted via the shikimic acid pathway to tyrosine and hence into DOPA. The subsequent reactions after 
DOPA are consistent with the 2,3-extradiol cleavage pathway and an addition of a C-l unit from methionine to give rise to 
the terminal methyl group of the propyl side chain. These results are now consistent with those obtained for the C2- and C3-proline 
moieties found in anthramycin, tomaymycin, and sibiromycin that are also biosynthetically derived from tyrosine.
The antibiotic-producing strain Streptom yces lincolnensis 
produces two closely related antibiotics, lincomycins A and B 
(Figure 1). While both antibiotics carry an identical unusual 
sugar moiety, namely, a-methylthiolincosaminide (M TL), they 
differ in the amino acid moiety; lincomycin A having a propyl- 
L-hygric acid (PHA) moiety (C3-proline) while lincomycin B has 
an ethyl-L-hygric acid (EH A) moiety (C2-proline). Earlier 
biosynthetic studies on the lincomycins published by scientists at 
The Upjohn Co. in the 1960s and early 1970s1'3 provided the first 
biosynthetic example of a C2- or C3-proline unit formed from 
L-tyrosine. However, some inconsistencies emerged between this 
work and subsequent work on the origin of the biosynthetically 
similar C2- and C3-proline units found in the pyrrolo[l,4]- 
benzodiazepine antibiotics, anthramycin,4 tomaymycin,5 and si­
biromycin.6 In recent reviews7,8 one of us had postulated a 
common biosynthetic pathway arising from tyrosine leading to 
a common branch-point compound, which can be converted by 
similar mechanisms to either a C2-proline unit (lincomycin B, 
tomaymycin) or a C3-proline unit (lincomycin A, anthramycin 
and sibiromycin). The results of experiments described in this 
article provide firm evidence that discriminates between the earlier 
postulate1 and the more recent unified postulated7,8 that encom­
passes all known representatives of the C2- and C3-proline type 
of biosynthetic unit. The accompanying paper9 provides the first 
insight into how the MTL unit of the lincomycins is assembled 
from glucose. Some of the results described in this paper were 
previously presented as an abstract.10
Results and Discussion
The alternative postulates for the biosynthetic pathways leading 
from tyrosine to the C2 and C3-proline units of the lincomycins 
are shown in Figures 2 and 3. Whereas the original Upjohn 
postulate proposed two different types of ring cleavage reaction 
(2,3-extradiol cleavage of cyclo-DOPA or 3,4-intradiol cleavage 
of cyclo-DOPA) leading to intermediates each requiring the ad­
dition of a C-l unit from methionine, the later revised postulate3 
and the unified postulate for C2- and C3-proline units in the 
lincomycins and the pyrrolo[l,4]benzodiazepines requires a single 
type of ring cleavage (2,3-extradiol cleavage of DOPA) and the 
addition of a C-l unit only in the case of the C3-proline unit. 
Experiments were designed to discriminate between these alter­
7 University of Texas.
*The Upjohn Co.
native pathways using both specifically deuterated tyrosine and 
DOPA molecules in combination with 13C N M R , and using 
deuterated methionine in combination with mass spectral analysis. 
The second portion of this paper describes the results of an ex­
periment using D-(13C6)glucose in combination with analysis of 
13C - 13C coupling patterns in PHA, to trace the path of glucose 
carbons through the shikimic acid pathway to tyrosine and Finally 
into lincomycin A.
B io sy n th etic  E xperim ents w ith L -(3 ',5 '-2H 2)T yrosin e , L- 
( I ' .S '^ '^ H ^ D O P A , and L-(6-2H 3)M ethion ine. An examination 
of the biosynthetic fate of the aromatic protons of DOPA in 
lincomycins A and B, when followed through the cyc/o-DOPA  
(Figure 2) and 2,3-extradiol DOPA cleavage pathways (Figure
3) reveals a number of distinct differences. While the Ha proton 
is lost via the cyclodopa pathway in PHA and EHA, it may be 
retained via the 2,3-extradiol DOPA cleavage pathway in the 
propyl or ethyl side chains of lincomycins A and B, respectively. 
A similar analysis of the H b protons for both pathways reveals 
a retention of just one of these protons via the cyclo-DOPA 
pathway, while there is retention of both protons via the 2,3-ex­
tradiol DOPA cleavage pathway. While one of these Hb protons 
is found at the same position of PHA and EHA irrespective of 
the type of ring-cleavage pathway, the second H b proton retained 
only in the 2,3-extradiol DOPA cleavage pathway is found at the
(1) Witz, D. F.; Hessler, E. J.; Miller, T. L. Biochemistry 1971, 10, 
1128-1133.
(2) Argoudelis, A. D.; Eble, T. E.; Fox, J. A.; Masan, D. J.; Biochemistry 
1969, 8, 3408-3411.
(3) Rolls, J. P.; Ruff, B. D.; Haak, W. J.; Hessler, E. J. “Abstracts of the 
76th Annual Meeting of the American Society for Microbiology”; American 
Society for Microbiology: Atlantic City, NJ, 1976; No. O 27.
(4) Hurley, L. H.; Zmijewski, M.; Chang, C.-J. J. Am. Chem. Soc. 1975, 
97, 4372-4378.
(5) Hurley, L. H.; Gairola, C.; Das, N. Biochemistry 1976, 15, 3760-3769.
(6) Hurley, L. H.; Lasswell, W. L.; Malhotra, R. K.; Das, N. V. Bio­
chemistry 1979, 18, 4225-4229.
(7) Hurley, L. H. Acc. Chem. Res. 1980, 13, 263-269.
(8) Hurley, L.H.; Speedie, M. K. In “Antibiotics IV. Biosynthesis"; Cor­
coran, J. W., Ed.; Springer-Verlag: Berlin and Heidelberg, 1981; pp 262-294.
(9) Brahme, N.; Gonzalez, J.; Rolls, J.; Hessler, E.; Miszak, S.; Hurley, 
L. J. Am. Chem. Soc., following paper in this issue.
(10) Brahme, N. M.; Gonzalez, J. E.; Mizsak, S.; Hurley, L. H. “Abstracts
of Papers, 186th Annual Meeting of the American Chemical Society,
Washington, DC, 1983; American Chemical Society: Washington, DC, 1983;
BIOL 60.
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Figure 1. Structures o f the lincomycins A and B and the products of 
alkaline hydrolysis.
5'-position of both PHA and EHA.
Biosynthetic feeding experiments with L-(3',5'-2H2)tyrosine and 
L-(2',5',6'-2H 3)DOPA and l3C NM R analysis of the resulting 
PHA and EHA moieties in lincomycins A and B clearly dis­
criminate between the pathways shown in Figures 2 and 3. 
Comparison of the broad-band proton-decoupled natural-abun- 
dance spectra of lincomycins A and B (Figure 4A and 5A) with 
those samples obtained from feeding experiments with l-(3',5'- 
2H 2)tyrosine (Figure 4B and 5B) shows both a reduction in the 
13C NM R resonance signal for the /3-carbons of PHA and EHA  
( 'H - 13C species) and an appearance of an isotopically shifted 
triplet (2H -13C coupled species) at approximately the same 
chemical shift. This same deuterated species of PHA and EHA  
is found in the sample of lincomycins A and B obtained from 
feeding experiments with l-(2 /,5/,6'-2H3)DOPA presumably arising 
from the deuterated Ha atom of DOPA (see Figure 4C and 5C). 
Additional partially deuterated carbon atoms are also clearly 
detectable at the 5'- and a-positions of lincomycins A and B. 
(Interestingly, the 4'-carbon resonance signal in lincomycins A 
and B appears reduced in intensity in both samples labeled from 
l-(2',5',6'-2H 3)DOPA presumably broadened due to an isotope 
effect brought about by the cumulative presence of deuterium 
atoms at the 5', a, and /3-positions.) Taken together, these results 
clearly rule out the cyclo-DOPA pathway (Figure 2) and are in 
accord with 2,3-extradiol DOPA cleavage pathway (Figure 3).
An additional important discriminating difference between the 
pathways proposed in Figures 2 and 3 is the contribution of the
Table I. Mass Spectral Analysis of Lincomycins A and B Isolated 
from an Experiment in Which L-(6-2H3)Methioninefl Was Fed to 5. 
lincolnensis0
rel % of 2H , and
2H6 species*
antibiotic 2h 3 2h 6
lincomycin A 17.7 82.3
lincomycin B 95.4 4.6
“90% Atom enriched added at a level of 0.5 g per flask at 96 h. 
*Tri- and hexadeuterated species were estimated from the ions of m /z  
158 and 177, respectively. Biemann’s formula12 was used to calculate 
the excess isotopic abundances.
C -l unit from methionine to the PHA and EHA moieties of 
lincomycins A and B, respectively. While both moieties carry a 
N C H 3 unit derived from the C-l pool via methionine,2 the cy- 
c/o-DOPA pathway requires an additional methyl group at the 
a- or /3-positions of lincomycins A and B, respectively. In contrast, 
the 2,3-extradiol DOPA cleavage pathway only requires an ad­
ditional methyl group at the y  position of lincomycin A. Mass 
spectra analysis (Table I) of PHA and EHA from an experiment 
in which L-(6-2H 3)methionine was fed to S. lincolnensis demon­
strates that only in the case of PHA is there found both an N- 
and C-methyl unit derived from the deuterated methionine; while 
only one methyl unit is present in EHA. Therefore, it can be 
concluded that the 2,3-extradiol DOPA cleavage pathway is op­
erative in the lincomycin biosynthetic pathway.
B iosynthetic E xperim ents U sin g  D -(13C 6)G lucose. As a con­
sequence of experiments using specifically carbon-13 labeled 
glucose, glycerol, and pyruvate designed to provide biosynthetic 
information on the origin of MTL, it was deduced that the shikimic 
acid pathway could be implicated in the origin of PHA in lin­
comycin A .3 This was expected in view of the demonstrated 
intermediacy of tyrosine in PHA biosynthesis. Primarily as means 
to provide new insight into the biosynthetic origin of MTL, but 
also to follow the path of carbon from glucose through the shikimic 
acid pathway to tyrosine, we have now analyzed samples of lin­
comycin A biosynthetically labeled from D-(13C6)glucose. A 
fermentation medium was used in which glucose was the sole 
carbon source during the antibiotic-producing phase and the
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Figure 2. Proposed parallel biosynthetic pathways leading to PHA and EHA via 2,3-extradiol cleavage of cyclo-DOPA and 3,4-intradiol cleavage of 
cyc/o-DOPA.
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Figure 3. Proposed parallel biosynthetic pathways leading to PHA and EHA via 2,3-extradiol cleavage of DOPA .7,8 A referee has suggested an alternative 
and attractive mechanism for the addition of X + (SAM  or H) in which alkylation (protonation) of an enamine followed by decarboxylation to quench 
the immonium ion is proposed. We thank this referee for this suggestion.
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Figure 4. Partial 13C N M R spectra (10-65 ppm region) of natural 
abundance lincomycin A (A), samples of lincomycin A obtained from 
feeding experiments with l-(3 ', 5'-2H 2)tyrosine (97% 2H 2) added at a 
level of 0.5 g per flask at 72 h (B), and l-(2',5',6'-2H 3)DOPA (79% 2H 3) 
added at a level of 0.5 g per flask at 96 h (C).
contiguously carbon-13 labeled glucose was diluted one to nine 
with unlabeled glucose. The resulting carbon-13 enriched lin­
comycin A was purified and hydrolyzed to MTL and PHA (Figure
1). Analysis of the MTL spectrum from this experiment is given 
in the accompanying paper,9 while the PHA results are presented
4 , 2 ’
S- CH






Figure 5. Partial 13C NM R spectra (10-95 ppm region) of natural 
abundance lincomycin B (A), samples of lincomycin B obtained from 
feeding experiments with L-(3',5'-2H 2)tyrosine with an expanded region 
around (8-carbon showing detail (B), and l-(2',5',6'-2H2)DOPA (C). 
Feeding conditions as stated in legend for Figure 4.
in this manuscript. The analysis of 13C -I3C spin coupling patterns 
in the biosynthetic product was used to deduce pathways through 
which the carbon atoms remain connected during conversion of 
the contiguously labeled glucose to the final product. Dilution 
of the carbon-13 labeled substrate with unlabeled material is 
necessary so that those carbon atoms that remain connected can 
be discerned through their I3C - 13C coupling pattern from those
HO OC
H 0 0 C
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F ig u re  o . summary ot tne proposed oiosyntnetic patnway leading trom 
glucose to the PHA unit of lincomycin A. Thickened solid bands indicate 
intact carbon units derived from PEP, whereas the cross-hatched bands 
correspond to intact carbons units derived from E4P.
which are separated and reconnected again at a later step. Thus, 
neighboring carbons derived from glucose as an intact unit retain 
13C -13C coupling; while those separated and rejoined have a 90% 
probability of losing their coupling. Such an approach to solving 
biosynthetic problems using contiguously labeled substrates has 
been described before.11 (For a more elaborate discussion of the 
derivation of the coupling patterns possible from D-(13C6)glucose 
see the following paper in this issue.)
An outline of the biosynthetic route from glucose to the PHA  
moiety of lincomycin A is shown in Figure 6. Glucose is converted 
via glycolysis and the hexose monophosphate shunt to phos- 
phoenolpyruvate (PEP) and erythrose 4-phosphate (E-4-P), re­
spectively. One molecule of each of these primary metabolites 
is then channeled through the shikimic acid pathway to chorismic 
acid, now containing a second PEP molecule. The chorismic acid 
is converted via prephenic acid to tyrosine and hence into a sec­
ondary metabolic pathway via DOPA to give rise Finally to PHA
(11) Rinehart, K. L., Jr.; Potgieter, M.; Wright, D. A. J. Am. Chem. Soc. 
1982, 104, 2649-2652. Gould, S. J.; Cane, D. E. J. Am. Chem. Soc. 1982, 
104, 343-346. Gagnaire, D. Y.; Taravel, F. R. Eur. J. Biochem. 1980, 103, 
133-143.
(12) Biemann, K. “Mass Spectrometry Organic Chemical Affiliate”; 
McGraw-Hill: New York, 1962; pp 224-227.
Table II. Summary of Information from l3C NM R Spectrum of 




shift," ppm multiplicity* Jc~o  Hz
carbonyl 171.8 s +  d 2co,2' = 57.0
2' 68.4 s +  dd Jr ,y =  32.5 
J  2-,co = 57.2
3' 34.0 s +  d J y y  =  32.4
4' 36.2 s +  d +  d y4-5- =  34.0 
JVja = 35.4
5' 61.3 s +  d Jy, 4' = 33.6
N C H 3 40.7 s
a 33.8 s +  d +  d JaV = 35.6 
Jafi = 34.0
6 20.3 s +  d J$.a =  33.9
7 13.1 s
"Chemical shifts of the singlets are listed. Assignments are made by 
comparison with the reported spectrum.13 All chemical shifts are given 
in parts per million relative to tetramethylsilane (M e4Si). 1,4-Dioxane 
was used as the internal standard, the shifts were converted to Me4Si 
by the relationship 5c (C H 3)4Si = 5(l,4-dioxane) +  67.4 ppm. 
* Multiplicity and coupling constants are obtained from the spectra 
shown in Figures 7 (A and B); s =  singlet, d = doublet, dd =  doublet 
of doublet.
in lincomycin A. Those carbons remaining connected are indicated 
by thick solid lines or cross-hatched lines. The dissymmetric 
rotamers of l-DOPA  should be expected to give rise to equal 
amounts of PHA' and PHA" (Figure 6).
The analysis of the biosynthetic pathway shown in Figure 6 
demonstrates which neighboring carbons originally derived from 
glucose may be incorporated as intact carbon units in the product. 
For example, a three-carbon unit derived via PEP could be in­
corporated intact into the carbonyl carbons and 2' and 3'-carbon 
atoms of PHA. PEP may also contribute an intact two-carbon 
unit to either carbon atoms 4' -a  of PHA' or 5'-4' of PHA". 
Lastly, a two-carbon unit derived from E-4-P could be incorporated 
into carbon atoms a - /3 of PHA.
In order to resolve a number of overlapping carbon resonance 
signals in the sample of lincomycin A, which was derived from 
a feeding experiment with D-(13C6)glucose, the antibiotic was 
hydrolyzed to PHA and MTL (Figure 1). Analysis of the l3C - l3C 
spin coupling pattern in PHA and a portion of the lincomycin A 
spectrum is presented in this article, while the MTL analysis is 
found in the accompanying paper.9 Owing to the complexity of 
the coupling pattern, the spectra are presented as expanded regions 
of the pertinent carbon atoms which were assigned on the basis 
of chemical shift, specific proton decoupling, and ’H -13C coupling 
patterns.13 These results are presented in Figure 7 and Table 
II.
Carbon atom 2' occurs either as a singlet (18%) or a doublet 
of doublets (82%) coupled simultaneously to both the carbonyl 
and 3'-carbon atoms. Little if any species of a doublet that would 
be coupled with either carbonyl carbon or 3', but not both, is 
present. This eliminates the significant contribution of two-carbons 
units that might arise from cycling of pyruvate through the TCA 
cycle.
The carbon signals 5-4 '-a-/3  show the 13C - 13C spin coupling 
characteristics of three two-carbon units. Carbons 5' and 0  show 
resonance signals for a singlet (54% and 53% for 5' and /?, re­
spectively) and doublet (46% and 47% for 5' and /3, respectively) 
due to coupling with carbon atoms 4' and a, respectively. The 
internal carbons 4' and a, show a resonance signal for a singlet 
(17% and 22% for 4' and a, respectively) and also show two 
doublets due to coupling between each other (39%) and with 5' 
(43%) and /3 (44%), respectively.
The results obtained in this investigation using both deuterated 
amino acids and carbon-13 enriched glucose clearly support the 
previously proposed unified biosynthetic pathway7 leading from
(13) Mizsak, S.; Slomp, G.; Neszmelyi, A.; Gero, S. D.; Lukacz, G. Tet­
rahedron Lett. 1977, 721-724.
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Figure 7. Partial ,3C N M R spectra of pertinent expanded regions (20-70 ppm) of PHA (A) and the expanded region (35-38 ppm) of lincomycin (B) 
obtained from feeding D-(13C6)glucose (98.1% enrichment) to S.lincolnensis at a level of 0.3 g per flask at 0 h. Spectral parameters: Varian XL-200, 
spectral width 11 062 Hz, number of transients 462 000, data points 16K, pulse width 5 fis, acquisition time 0.74 s.
tyrosine via DOPA and involving a 2,3-extradiol cleavage pathway 
to produce a common precursor of the C2- and C3-proline units 
found in the lincomycin and pyrrolo[ 1,4]benzodiazepine antibiotics. 
The difference between the pathways leading to C2- or C3-proline 
units is the addition of an C -l unit from methionine to the C3- 
proline derived units.
Experimental Section
General Techniques. 13C N M R  spectra were recorded on a Varian 
CFT-20, X L -100, or XL-200 FT-NM R spectrometer. The NM R  
spectra were run in D20 .
Mass spectral analysis was performed on a Varian MAT CH7 mass 
spectrometer and the relative enrichments of deuterium calculated using 
Biemann’s formula.12
Fermentations. A high-producing strain derived from the original soil 
isolate of S. lincolnensis var. lincolnensis, denominated NR RL2936 in 
the culture collection, was maintained in Hickey-Tresner medium at 
liquid nitrogen temperature. The culture was grown in chloramphenicol 
agar slants proceeding inoculation into seeds. The three seed media (in 
grams/liter) used in these experiments (the three sets of numbers in 
parentheses refer to the three different seed media. The first set were 
used in the DOPA experiment, the second set for the tyrosine and me­
thionine experiments, and the third set for the glucose experiment) con­
sisted of Cerelose, Clinton Corn Processing Co. (5.0, 20.0, or 10.0), 
Hi-Starch, Illinois Cereal Mills, Inc. (20.0, 0, or 0), Yeastolac, A.F. 
Staley Man. Co. (10.0, 10.0, and 0.0), yeast extract, Difco Lab (0, 0, or
10.0), and N -Z  Amine B, Sheffield Co. (5.0, 5.0 and 5.0). The fer­
mentation media consisted of (grams/liter) D-glucose (30.0), Z n S 0 4- 
2H 20  (0.001), F eS 04-7H20  (0.001), M g S 04 (1.0), NaCl (0.5), sodium 
citrate dihydrate (3.0), (N H 4)2N 0 3 (1.6), and K2H P 04-3H20  (3.3). The 
seed media were adjusted to pH 7.0 with sodium hydroxide prior to 
inoculation. Five hundred milliliter Erlenmeyer flasks were filled with 
100 mL of seed or fermentation media. Typically, the culture was in­
cubated for 2 days in one of these seed media at 28 °C while agitated 
at 250 rpm in a rotary shaker prior to inoculation of the fermentation 
at a 50-fold dilution ratio. The fermentations were usually harvested 
after 6 days of incubation in a rotary shaker at 28 °C and the lincomy- 
cin(s) isolated.
Stable Isotope Labeled Substrates. All the stable isotope compounds 
were purchased from M SD Isotopes, Canada with the exception of the 
dideuteriotyrosine and 2H3-l-D O PA , which were prepared as described 
before.4
Isolation of Lincomycin. Contents o f the 500-mL fermentation flask 
were filtered through Whatman no. 1 to remove the cells. The filtrate 
(approximately 100 mL) was then filtered through another filter unit (0.2 
Mm) to remove finer particles, and the pH of the filtrate was adjusted to 
5.0. A cation-exchange column of 10-mL bed volume was prepared as 
below. The cation-exchange resin (Bio-Rad AG 50W-X4, 200-400 mesh 
size, hydrogen form) was successively washed with distilled water, 0.5% 
N H 3 in H20 ,  and again with distilled water until the washings were 
neutral. The resin was slurried with distilled water and then poured into 
a column. The column was washed with 100 mL of 10% aqueous NaCl 
solution, 100 mL of 1% aqueous H 2S 0 4, and finally by distilled H20  until
the pH of the eluant was neutral. The fermentation filtrate was gravity 
fed on the top of this column and about 20 fractions of 5 mL each were 
collected. These fractions were examined on TLC (silica gel, CHC13-  
M eO H -N H 4OH, 61:35:4 v /v ) to ensure lincomycin was not passing 
through the column. Lincomycin was then eluted using 0.5% N H 3 in 
H20 ,  and about 20 fractions of 5 mL each were collected. Usually, 
lincomycin was eluted immediately after the pH of the eluant turned 
basic. Fractions were examined on TLC, and those fractions containing 
lincomycin were combined and extracted with 6 X 10 mL of CH2C12. 
The pooled CH 2C12 extract was washed with 20 mL of saturated brine 
solution, dried over anhydrous N a 2S 0 4, and then evaporated to dryness. 
After the powder was taken up in 5 mL of distilled H20 ,  the solution was 
lyophilized to obtain lincomycin as a white powder (15-20  mg).
Separation of Lincomycins A and B. Typically, the separation was 
carried out as described below. The crude lincomycin (4.2 g) obtained 
from 14 L of whole beer inoculated with L-(3',5'-2H 2)tyrosine and as­
saying ca. 4.5% lincomycin B 4- 95.5% lincomycin A (by GC) was sep­
arated by Craig countercurrent distribution.
The solvent/solvent system used was methylene chloride/1% aqueous 
sodium chloride in 200 X 100 mL tubes with 50 mL of each phase. A 
total of 190 transfers was carried out; Lincomycin A was located in tubes 
70-100, and Lincomycin B was located in tubes 160-185 and was de­
termined by TLC as follows: 2.5-mL CH 2C12 fraction was evaporated 
to dryness, 0.1 mL of ethyl acetate added, and 10 mL spotted on TLC 
(0.25-mm silica gel G plates; 20 X  20 cm); the developing solvent was 
75:25:10 methyl ethyl ketone/acetone/water, and the detection was done 
by I2 vapor).
Fractions 160-185 were combined, and the phases were separated. 
The CH2C12 phase was concentrated to dryness and the water was con­
centrated to a small volume (20 g). The water phase was extracted with 
4 X  200 mL of CH 2C12 after addition of 8 g of potassium carbonate. The 
total CH2C12 extracts (including the Craig extract) were combined and 
concentrated to a foam. The foam was dissolved in 0.20 mL of water, 
0.25 mL of acetone, and 0.05 mL of concentrated hydrochloric acid. 
Acetone (3.0 mL) was added dropwise at 40 °C to the solution, and after 
cooling first to room temperature and then to 0 °C, crystals of lincomycin 
B hydrochloride salt were formed. These were collected by filtration to 
give 152 mg  after washing with 2 X  0.5 mL of 95:5 acetone/water and 
drying under vacuum.
Base Hydrolysis of Lincomycin from D-(l3C6)Glucose. Typically the 
hydrolysis was performed as described below. Lincomycin (20 mg, 0.049 
mmol) was dissolved in 1.5 mL of distilled HzO and the solution was 
heated in an oil bath at 90 °C for 5 min under N 2, 0.3 mL of 50% 
aqueous NaO H  was then added to this solution and heated at 95-100  
°C under N 2 for an additional 5 h. The temperature was then raised to 
110 °C and heating continued for a total of 22 h. A TLC (silica gel, 
CHCl3-M eO H -N H 4OH, 61:35:4 v /v) showed that all the lincomycin 
was hydrolyzed.
Isolation of PHA from the Lincomycin Hydrolysate. Following the 
isolation of MTL (see the next article in this issue), the anion-exchange 
column was washed with distilled H20  until the eluant pH was about 6.0. 
The column was then eluted with 0.1 N HC1, and 35 fractions of 2 mL 
each were collected. Those fractions containing PHA (no. 19-22) were 
identified by TLC (silica gel, CHCl3-M eO H -N H 4OH, 61:35:4 v/v) and
7878
were combined and lyophilized to obtain PHA-HC1 as a slightly grayish 
powder (9 mg, 88% yield) .14
Acknowledgment. This research was supported by a University 
Industry Cooperative National Science Foundation grant 
(PCM -7923087) to L.H.H. and J.E.G. We acknowledge the
(14) Huber, J. E., personal communication.
technical assistance of Brenda Ruff, Willard Haak, and Ron 
VanZanten and helpful discussions with Al Garcia, Joel Huber, 
Tom Miller, Bill Maxon, and Tom Pyke.
Registry No. DOPA, 59-92-7; PHA, 13380-36-4; EHA, 92695-07-3; 
MTL, 14810-93-6; lincomycin A, 154-21-2; lincomycin B, 2520-24-3; 
tyrosine, 60-18-4; glucose, 50-99-7; methionine, 63-68-3; glycerol, 56- 
81-5; pyruvic acid, 127-17-3.
R eprinted from the Journal of the A m erican C hem ical Society, 1984, 106, 7878 
Copyright © 1984 by the Am erican Chem ical Society and reprinted by perm ission of the copyright ow ner.
Biosynthesis of the Lincomycins. 2. Studies Using Stable 
Isotopes on the Biosynthesis of M ethylthiolincosam inide 
M oiety of Lincomycin A
Nanda M . Brahm e/ Jose E. Gonzalez,** Steve M izsa k / Jim R. R o lls / Ed J. H essler/ and 
Laurence H. Hurley *+
Contribution from  Fermentation Research and Development, The Upjohn Company,
Kalamazoo, Michigan 49001, and The Drug Dynamic Institute, College o f  Pharmacy, University 
o f  Texas at Austin, Austin, Texas 78712. Received M ay 14, 1984
Abstract: Lincomycin is an antibiotic produced by Streptomyces lincolnensis and consists of a unique aminooctose moiety, 
a-methylthiolincosaminide (MTL), attached via an amide linkage to a propylhygric acid unit. The biosynthesis of the MTL 
moiety of lincomycin has been investigated by using both specifically carbon-13 labeled substrates and uniformly carbon-13 
labeled D-glucose. In the latter case 13C -13C spin coupling patterns in lincomycin and MTL were used to determine those 
carbon atoms from glucose that remained intact during their conversion to the antibiotic. By combination of the biosynthetic 
information obtained from the 13C -I3C spin coupling patterns with that from those carbon atoms in MTL which were enriched 
from carbon-13 specifically labeled molecules, conclusions can be drawn about likely pathways and intermediates between 
glucose and MTL. The Cg-carbon skeleton of MTL is assembled through condensation of a pentose unit (C5) and a C3 unit. 
The C5 unit can be assembled in two ways. Either it is derived from glucose via the hexose monophosphate shunt (HMPS) 
as an intact unit or it is assembled from condensation of a C3 unit (glyceraldehyde 3-phosphate) with a C2-unit donor such 
as sedoheptulose 7-phosphate (SH7P) via a transketolase reaction. The C3 unit, which combines with the C5 unit, is likely 
contributed from a suitable donor molecule such as SH7P via a transaldolase reaction. Dependent upon the origin of the C3-unit 
donor, this unit may consist either of an intact C3 unit or a C2 unit combined with a Q  unit. The octase produced from condensation 
of a C5 unit and a C3 unit can then be converted by unexceptional means to MTL.
Lincomycin (1) is a clinically important antibiotic produced 
by Streptomyces lincolnensis (Figure 1). Structurally, lincomycin 
is an aminooctose glycoside. The aglycone moiety, propylhygric 
acid, is biosynthetically derived from tyrosine most probably via 
2,3-extradiol ring cleavage of DOPA, while methionine contributes 
the two additional C -l units.1 The aminooctose moiety, a-me- 
thylthiolincosaminide (2) (M TL), is a structurally unique com­
pound, which has previously defied efforts to elucidate its bios­
ynthetic origin.2 Recently, a totally synthetic route to lincosamine 
(3) has been published.3 The commercial importance of linco­
mycin has prompted an attempt to improve this fermentation 
through genetic approaches. However, these efforts have so far 
been hampered by insufficient information on the biosynthetic 
pathway and intermediates that lead from glucose to MTL. The 
availability of D-(I3C6)glucose and the ability to analyze complex 
13C -13C spin coupling patterns prompted us to attempt to use this 
substrate as a means to gain insight into how this C8 unit was 
assembled from glucose. The existence of a fermentation medium 
in which glucose could be used as a sole carbon source was also 
important, so that sufficient enrichment could be achieved to 
observe the complex coupling patterns. While this work was in 
progress, the power of this method has been illustrated in studies 
using d-(13C6)glucose in combination with analysis of 13C -13C spin 
coupling patterns in the antibiotics pactamycin,4 streptonigrin,5 
geldanamycin,6 and naphridinomycin.7 The results described in
+ University of Texas.
*The Upjohn Co.
this manuscript have been presented in preliminary form.8
R esu lts and D iscussion
The strategy behind our approach to elucidating the manner 
in which d- ( i3C6)glucose might provide the precursors of the C8 
unit in lincomycin was to first determine the patterns of con­
nectivity of units derived from glucose in MTL. Since glucose 
served as the sole carbon source during the antibiotic production 
phase, the D-(13C6)glucose was diluted 1 in 10 with nonisotopically 
labeled glucose prior to addition to the fermentation medium. 
After isolation of the antibiotic from the fermentation broth, either 
the parent antibiotic or MTL, obtained by alkaline hydrolysis of
(1) Brahme, N. M.; Gonzalez, J. E.; Rolls, J. P.; Hurley, L. H. J. Am. 
Chem. Soc., preceeding paper in this issue.
(2) The results of biosynthetic experiments on the MTL moiety using 
specifically carbon-13 labeled substrates have been presented as an abstract 
(Rolls, J. P.; Ruff, B. D.; Haak, W. J.; Hessler, E. J. “Abstracts of the 76th 
Annual Meeting of the American Society for Microbiology"; American So­
ciety for Microbiology: Atlantic City, NJ, 1976; No. O 27), but these did 
not provide insight into likely biosynthetic precursors of this moiety in lin­
comycin.
(3) Larson, E. R.; Danishefsky, S. J. Am. Chem. Soc. 1983, 105, 
6715-6716.
(4) Rinehart, K. L., Jr.; Potgieter, M.; Delaware, D. L.; Seto, H.; J. Am. 
Chem. Soc. 1981, 103, 2099-2102.
(5) Gould, S. J.; Cane, D. E. J. am. Chem. Soc. 1982, 104, 343-346.
(6) Rinehart, K. L., Jr.; Potgieter, M.; Wright, D. A. J. Am. Chem. Soc. 
1982, 104, 2649-2652.
(7) Zmijewski, M. J., Jr. Tetrahedron Lett. 1982, 1775-1776.
(8) Brahme, N. M.; Gonzalez, J. E.; Mizsak, S.; Hurley, L. H. “Abstracts 
of Papers”, 136th Annual Meeting 1983; American Chemical Society: 
Washington, DC, 1983; BIOL 60.
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Figure 1. Structures of lincomycin, MTL, and lincosamine.
lincomycin, was subjected to 13C NM R analysis. Those carbon 
atoms remaining connected through the biosynthetic process are 
readily detected by their coupling patterns. For example, an intact 
C3 unit should be recognizable by three sets of signals. The two 
external carbon atoms should each show a doublet around the 
noncoupled singlet resonance signal. The central carbon resonance 
should show a doublet of doublets (or a triplet when the coupling 
constants are identical) on each side of the noncoupled singlet 
resonance signal. Similarly, a four- or five-carbon unit will consist 
of exterior carbon atoms showing a doublet around a singlet and 
interior carbons showing a doublet of doublets around a singlet. 
More complex patterns will result from situations where a con­
stituent C3, C4, or C5 unit can in some cases be derived from 
smaller units. Identification of the largest fragm ents that could 
be incorporated into the C8 unit was of utmost importance, since 
this presumably would provide information on the most direct 
pathway to form the aminooctose moiety of lincomycin. Smaller 
subunits of these larger fragments would presumably arise via more 
circuitous pathways.
Presuming that we were able to identify the carbon atom size 
of the constituent fragments from the experiment with D- 
( 13C6)glucose, we would still lack evidence on the identity, ori­
entation within C„ units, and origin of the precursors. Conse­
quently, we also designed experiments with carbon-13 specifically 
enriched glucose and C3 units. Although the results from these 
later experiments alone would be unlikely to yield definitive in­
formation on the probable identity of precursors of the C8 unit, 
when used in combination with the 13C - 13C spin coupling data 
from the D-(13C6)glucose experiment they should provide firmer 
conclusions.
Analysis of the MTL and Lincomycin Carbon-13 NMR Spin 
Coupling Patterns from an Experiment with D-(I3C6)Glucose. 
D-(13C6)Glucose (98% enriched) diluted 1 in 10 with nonisotop­
ically labeled glucose was fed to flasks of 5 . lincolnensis producing 
lincomycin. Following isolation of the 13C-enriched lincomycin 
from the fermentation broth, its ,3C NM R was recorded. This 
sample was then hydrolyzed to MTL, and a second 13C N M R  
was obtained. l3C N M R  analysis and the spectra are presented 
in Figure 2A,C. The carbon-13 NM R assignments for MTL were 
made primarily on the basis of the previously assigned spectra 
of lincomycin A9 and by using specific 13C -'H  decoupling for each 
carbon. Also included in Table I is the multiplicity observed for 
l3C -13C spin coupling patterns and the coupling constants. While 
the multiplicity of carbon atoms 1-6 and 8 could be clearly ob­
served in the 13C N M R  spectra of MTL (see Figure 2A,B). 
However, since the complexity for carbon atom 7 was considerably
(9) Mizsak, S.; Slomp, G.; Neszmelyu, A.; Gero, S. D.; Lukacs, G. Tet­
rahedron Lett. 1977, 721-724.
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Figure 2. l3C NM R spectrum of MTL derived from an experiment with 
D-(13C6)glucose (A). 13C NM R spectrum of expanded regions of carbon 
atoms 2-5  and 7 for MTL (B). 13C NM R spectrum of expanded region 
of carbon atom 7 in lincomycin (C).
Table I. I3C N M R J of MTL from an Experiment in Which 








contributn, % •7cc> Hz
1 87.97 9C d, 68 
s, 32
j \  .2 =  40.3
2 67.77 9 dd, 32 
d, 34
•7i,2.3 =  40.1 
•72,1/3 -  40.8
3 70.37 'H - 13C decoupling d, 31 
s, 69
•73.2/4 =  40.3
4 68.34 9 d, 46
s, 54
*74,5/3 =  40.0
5 71.30 ‘H - 13C decoupling dd, 16 
d, 38 
s, 16
•74,5,6 =  40.0 
•75, 3/6 = 39.6
6 53.60 9 dd, 19 
d, 47 
s, 34
•75,6,7 = 41.6 
•76, 7/5 = 39.3
7 67.09 9 dd, 66 
d, 17 
s, 17
*76,7,8 = 39.5 
*77,8/6 — 39.0
8 14.21 9 d, 80 
s, 20
•7s. 7 = 38.7
SC H 3 12.98 9 s, 100
"See ref 1. 4 All chemical shifts are given in parts per million rela­
tive to tetramethylsilane (M e4Si). 1,4-Dioxane was used as the inter­
nal standard, the shifts were converted to Me4Si by the relationship 
Sc (C H 3)4Si =  5(p-dioxane) +  67.4 ppm. c From ref 9. ds = singlet, d 
= doublet, dd = doublet of doublets (see text).
reduced in the lincomycin spectrum, this spectrum was used for 
the analysis of this resonance signal (Figure 2C).
The multiplicity observed in Figure 2A -C  and tabulated in 
Table I show that carbon atoms 1, 3, 4, and 8 each shows a doublet
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Table II. Enrichments of Carbon-13 Resonance Signals of Lincomycin from Experiments with Various Carbon-13 Enriched Substrates, Relative 
to Nonisotopically Labeled Lincomycin Run under Similar Conditions
enrichment carbon atom enriched and enrichment factor*
precursor fed° of precursor 1 2 3 4 5 6 7 8 SCHj
D -(l-13C)glucose 90.7 3.16 1.23 1.45 1.63 1.34 1.31 1.32 1.57 1.55
D-(6-13C)glucose 91.9 1.32 1.18 1.22 1.16 1.07 1.24 1.14 3.00 1.88
( l - 13C)pyruvate 90.0 0.99 0.86 0.93 0.95 0.94 1.32 0.90 0.96 0.96
(2-13C)glycerol 90.0 0.94 1.12 0.97 1.00 1.04 0.87 3.08 1.01 1.84
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“Ulucose was ted at U h at a level ot U.3 g/tlask. Pyruvate was ted at 12 h at a level ot 0.3 g/tlask, while gly  
g/flask. * Defined as the ratio of signal intensity in the 13C-enriched lincomycin to that in unenriched lincomycin.
(d) as well as a singlet (s). The absence of a doublet of doublets 
(dd) for these signals indicates that these carbon atoms are at 
external positions of an intact C„ (n >  2) units; i.e., a C3 unit is 
evident between carbon atoms 1, and 3 and a C5 unit is evident 
between carbon atoms 4 and 8. Conversely, carbon atoms 2 and 
5-7 show a “dd” in addition to a “d” and a “s” signal. Therefore, 
each of these must be internal carbons within carbon atom units 
at least three carbons in length.
An analysis of the relative percentages of each of the constituent 
signals within the multiplet, i.e., percentage of s, d, and dd species, 
provides further information on the contributions of the smaller 
subunits found within the previously identified C3 and C5 units.
For carbon atoms 1-3, the percentage of dd for C-2 (32%) is a 
direct measure of the relative amount of C3 vs. C2 and C, species, 
which, together, make up the total amount of carbon species 
present in these carbon atoms of the antibiotic. Furthermore, since 
the d at C-3 (31%) occurs at almost the same percentage as the 
dd at C-2 (32%), then the d at C-2 (34%) must be due solely to 
coupling with C -l. In accord with this conclusion, the d at C-l 
(68%) is almost equal to the addition of the d (34%) and dd (32%) 
at C-2. Therefore, the carbon atoms between C -l and C-3 are 
derived from a C3 unit (32%), a C2 unit (C -l and C-2) (34%), 
and C, units due to carbon atoms derived from both carbon-13 
in the natural abundance D-glucose and randomized label from 
D-(I3C6)glucose.
Analysis of carbon atoms 4-8  leads to conclusions on how this 
unit may be derived. The dd signals for carbon atoms 5-7 provide 
compelling evidence for a C5 unit. While the dd for C-5 (16%) 
and C-6 (19%) carry approximately equal percentage values, the 
dd for C-7 (66%) occurs at a much higher value. On the basis 
of these data alone, we can conclude that a C5 unit contributes 
at about a level of 16-19% to this set of carbons. The percentage 
of dd for C-7 in excess of that needed for the C5 unit (66 -  16 
= 50%) must be due to a C3 unit comprised of C-6, C-7, and C-8.
This is supported by ds at C-6 (47%) and C-8 (80%). The excess 
d percentage at C-8 (80 -  (50 +  16) = 14%) is then due to a C2 
unit (C-7, C-8), also evidenced by a doublet at C-7 (17%). Since 
the d and dd at C-7 can be completely accounted for through the 
C3 unit (C-6, C-7, and C-8) and the C2 unit (C-7 and C-8), 
evidence for a C2 unit between C-6 and C-7 is lacking. The d 
at C-4 (46%) is more than fully accounted for by contributions 
to the C5 unit (16-19%) and a C2 unit (C-4 and C-5) (38%).
Contributions of Cj units to carbon atoms between C-4 and C-8 
vary from a high of about 50% (C-4 and C-5) to a low of about 
20% (C-7 and C-8) and arise due to randomized label from 
d - ( 13C 6) glucose and from carbon-13 in natural abundance d- 
glucose. A diagrammatic representation of the relative contri­
butions of C)-C5 units to the MTL moiety of lincomycin is shown 
in Figure 3.
Carbon-13 Enrichments in MTL Resulting from Feeding Ex­
periments with Specifically Labeled Substrates and Identification 
of Probable Precursors of MTL. The 13C -13C spin coupling data 
in the MTL isolated from an experiment in which D-(13C6)glucose 
had been added to the fermentation broth had provided conclusive 
data on the pattern of carbon units incorporated into this C8 sugar.
However, evidence on the identity or orientation of probable 
precursors that constitute these C2, C3, or C5 units was lacking.
To provide biosynthetic information, which would identify likely 
candidates for the constituent subunits of this aminooctose, ex­
periments with specifically enriched carbon-13 labeled substrates
Figure 4. Stepwise condensation of subunits that lead to the oculose 
precursor of MTL. The relative contributions of each signal have an 
error factor of ±10% o f  the calculated value. This results from the 
concentration dependency of the chemical shift values of resonance sig­
nals that are in close proximity. These concentration dependent changes 
cause errors in signal heights which consequently affect the calculated 
values of relative contributions of various pathways to the octose.
were conducted. Carbon atoms in MTL found to be enriched with 
carbon-13 relative to the corresponding atoms in a nonisotopically 
enriched sample of MTL are shown in Table II.
The aminooctose (C8 unit) can be formed from condensation 
of a C5 unit (carbon atoms 4-8) and a C3 unit (carbon atoms 1-3). 
Furthermore, the C5 unit can be either supplied intact or from 
condensation of a C3 unit (carbon atoms 6-8) and a C2 unit 
(carbon atoms 4-5). Finally, the two C3 units (carbon atoms 1-3 
and carbon atoms 6-8) may each be contributed as an intact C3 
unit or by condensation of a C2 unit (carbon atoms 1-2 and carbon 
atoms 7-8) with a C3 unit (carbon 3 and carbon 6, respectively). 
This is shown dramatically in Figure 4. Significantly, the ratios 
of the relative percentages of the C2 units to the C, units, which 
comprise the two C3 units, is quite different for the C3 unit found 
in carbon atoms (1-3  (ratio 1:1) to the C3 unit found in carbon 
atoms 6 -8  ratio 1:2). This suggests that these two C3 units are 
derived from different precursors.
Several lines of evidence point toward glyceraldehyde 3- 
phosphate (G-3-P) being the source of the C3 unit comprising 
carbon atoms 6-8 . First, ( l - I3C)pyruvate, (2-l3C)glycerol, and 
( l ,3 - 13C2)glycerol all enrich one or more of the carbon atoms 
between C-6 and C-8 (see Table II). The specific enrichment of
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Figure 5. Alternative pathways from D-(13C6)glucose leading to the formation of carbon atoms 4-8  in MTL. Bold lines represent intact carbon atom 
units retaining 13C - I3C spin coupling.
C-6 of MTL from ( l - l3C)pyruvate is in accord with the expected 
conversion of pyruvate to G-3-P. Similarly, specific enrichments 
of C-7 of MTL from (2-13C)glycerol and C-6 and C-8 of MTL 
from ( l ,3 - l3C2)glycerol are also as expected. Second, while D- 
(6-l3C)glucose significantly enriches C-8 of MTL, D-(l-13C)glucose 
enriches this carbon of MTL to a much lower extent. Glucose 
is converted by glycolysis to the trioses, G-3-P and dihydroxy- 
acetone phosphate, which, because they are interconvertible by 
triose isomerase, equilibrate the label between C-l and C-6 of 
glucose. Therefore, if glycolysis was the sole source of G-3-P 
incorporated into this C3 unit, we would expect equivalent en­
richments at C-8 of MTL from d-(1-i3C)- and D(6-13C)glucose, 
which is clearly not the case. To explain the greater enrichment 
of C-8 by D-(6-I3C)glucose, we suggest that the hexose mono­
phosphate shunt (HMPS) also contributes significantly to the pool 
of G-3-P which may serve as a precursor of carbon atoms 6-8  
in MTL. Unlike glycolysis, the HMPS does not equilibrate C-l 
of glucose with C-6 and can generate G-3-P exclusively from 
C-4-C-6 of glucose via the transketolase reaction. Since this series 
of reactions involving the HMPS provides G-3-P in which C-3 
is enriched from C-6 of glucose, this would help explain the greater 
enrichment of C-8 of MTL from D-(6-13C)glucose rather than 
from D -(l-13C)glucose (Figure 5, pathway a). Another factor 
contributing to the observed enrichment pattern is the derivation 
of a MTL precursor pentose from glucose by the HMPS-mediated 
elimination of carbon 1 of glucose.
As shown in Figure 3, the C3 unit comprising carbon atoms
6-8 in MTL can also be derived through a minor pathway in which 
a C2 unit (C-7 and C-8) and a Q  unit are constituents. A 
combination of steps in the HMPS and glycolysis can explain this 
pattern of subunits for the C3 unit. The HM PS can generate 
D-fructose 6-phosphate (F-6-P) in which carbon atoms 1 and 2 
are retained as a C2 unit. F-6-P can then enter into glycolysis 
to produce C-3-P in which carbon atoms 2 and 3 remain intact 
and become the C2 unit comprising carbon atoms 7 and 8 of MTL 
(see Figure 5, pathway b).
The information on the probable origin of the C3-unit com­
prising carbon atoms 6-8 in MTL provides a starting point to track 
down the probable origin of the C5 unit comprising carbon atoms 
4-8  of MTL. This C5 unit can either be derived directly or be 
formed by condensation of a C3 unit (carbon atoms 6 -8 ) and a 
C2 unit (carbon atoms 4-5). The HMPS produces three pentoses 
(D-xylulose 5-phosphate (X-5-P), D-ribose 5-phosphate, and d -  
ribulose 5-phosphate), each of which can be formed as intact C5 
units derived from glucose prior to incorporation into MTL (see 
Figure 5, pathway c). Furthermore, molecules of X-5-P can also 
be generated in which carbon atoms C -l and C-2 exist as a C2 
unit and carbon atoms C-3-C-5 exist as a C3 unit, derived from 
G-3-P. Additional support that a molecule such as X-5-P can 
provide carbon atoms 4-8 of MTL is that the expected orientation 
of G-3-P in X-5-P is such that C-6 of glucose should enrich C-3 
of G-3-P and subsequently C-8 of MTL, which is found in practice. 
The remaining carbon atoms (1 and 2) in X-5-P molecules, which 
are not derived from G-3-P, are transferred by a transketolase 
reaction from sedoheptulose 7-phosphate (SH7P). This C 2 unit 
donated from SH7P is originally derived from carbon atoms 1 
and 2 of F-6-P, which are in turn derived from carbon atoms 1 
and 2 of glucose. Consequently, carbon 4 of MTL should be more 
significantly labeled from glucose labeled in the 1 rather than in 
the 6 position, which also is found in practice (see Figure 5, 
pathway d).
The remaining C3 unit comprising carbon atoms 1-3 of MTL 
is not labeled from pyruvate or glycerol but is more heavily en­
riched at the C -l position from D -(l-13C)glucose than from d -  
(6-13C)glucose, which is opposite to the observed enrichment 
pattern at C-8 of MTL. In addition to an intact C3 unit, the 
carbon atoms comprising C -l-C -3  of MLT may also be con­
tributed as a C2 unit (C-l and C-2 of MTL) and a C, unit (C-3 
of MTL). We therefore searched for a C3-donor molecule that 
would fulfill all these requirements. SH7P meets all the criteria. 
A transaldolase reaction can transfer a C3 unit (C -l-C -3 of SH7P 
to a pentose, such as X-5-P, to produce the octulose of Cs unit
7 8 8 2  J. Am. Chem. Soc., Vol. 106, No. 25, 1984 Brahme et al.
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Figure 6. Alternative pathways from D-(13C6)glucose leading to forma­
tion of carbon atoms 1-3 in MTL. Bold lines represent intact carbon 
atom unit retaining 13C - 13C spin coupling.
precursor of MTL. SH7P may be formed either by a transaldolase 
reaction, which involves transfer of a C3 unit from an intact C6 
unit (F-6-P) to D-erythrose 4-phosphate, or by a transketolase 
reaction which involves transfer of C2 unit from an intact C5 
(X-5-P) to R-5-P (Figure 6, pathways a and b). In order that 
an intact C3 unit can be transformed from F-6-P, the F-6-P must 
be generated via the glycolytic pathway rather than the HMPS. 
If equal amounts of carbon traveled through these alternative 
pathways, then the SH7P formed would consist of equal amounts 
of three-carbon atom donor molecules, containing either an intact 
C3 unit (Figure 6, pathway a) or a C2 unit and a Q  unit (Figure 
6, pathway b). This would lead to the 13C - 13C spin coupling 
pattern shown in MTL. Furthermore, the enrichment in C -l of 
MTL from D -(l-13C)glucose can also be rationalized by assuming 
transaldolase formation of the three-carbon atom donor molecule 
(SH7P) from F-6-P and E-4-P. Providing the F-6-P utilized in 
this reaction is generated through the glycolytic pathway, then 
C-l of SH7P is derived from C-l of glucose. Transfer of the C3 
unit from SH7P to the C5 unit to form the C8 unit would result 
in the established enrichment of C -l of MTL from d- ( 1-13C)- 
glucose.
Conclusions
Using a combination of results, obtained from analysis of 
13C -13C spin coupling patterns in MTL and lincomycin derived 
from a biosynthetic experiment with D-(13C6)glucose, and the 
specific carbon-13 enrichments in MTL produced from specifically 
labeled substrates, we have been able to predict the probable 
biosynthetic intermediates and pathways, leading to a C8 unit that 
can be converted into MTL by unexceptional reactions. The 
intermediates and pathways involved up to the production of an 
octulose are those associated with the HMPS and glycolysis.
In addition to the importance of these results in providing the 
first real evidence of how MTL is biosynthetically produced, this 
study further illustrates how powerful a tool 13C -13C spin coupling 
patterns can be in solving complex biosynthetic problems. It is 
doubtful that more traditional approaches to solving biosynthetic 
problems, such as those using radioactive or even single-labeled 
stable isotope precursors, would have revealed much useful in­
formation. The ambiguities produced as a result of alternative 
pathways leading to the same subunits would almost certainly have 
prevented any firm conclusions from being made.
The results presented in this paper and the previous one in this 
issue1 provide considerable insight into the conversion of glucose 
to a C„ unit and a C2-proline unit. Whereas the pathway leading 
to PHA is common also to the C3-proline units found in an­
thramycin and sibiromycin,10 the C8 unit of MTL appears so far 
to be unique to the lincomycin antibiotics. The terminal steps 
involved in the conversion of the C8 unit to MTL and the con­
version of the C2-proline unit to PHA are still unclear. Conversion 
of the octulose to MTL would presumably involve isomerization
(10) Hurley, L. H. Acc. Chem. Res. 1980, 13, 263-269.
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Figure 7. Proposed biosynthetic pathway leading to lincomycin A.
of the octulose to an octose, dephosphorylation and reduction of 
C-8, thiomethylation of C -l, and transamination of a suitable 
6-ketooctose. The final steps to produce lincomycin involve 
condensation of MTL with propylproline and methylation of the 
adduct (unpublished results). This is shown in Figure 7.
Future studies will involve experiments to implicate more di­
rectly intermediates in the biosynthetic pathway to MTL. Efforts 
are already under way to apply the equally powerful techniques 
of microbial genetics to solve some of these problems.
Experimental Section
Fermentation and Isolation of Lincomycin. The fermentation condi­
tions and procedures for isolation of lincomycin were as described pre­
viously.1 The conditions for specific feeding experiments are listed in 
Table II.
NMR Experiments. 13C NM R experiments were performed on a 
Varian XL-200 FT-NM R spectrometer as described in the previous 
paper.1
Isolation of MTL. Following the base hydrolysis of lincomycin (see 
previous paper1) MTL was isolated as follows. A mini anion-exchange 
resin column was prepared from 1 g of Bio-Rad AG 1X2, CL form, 
200-400 mesh. It was washed with 1 N NaOH until free of chloride and 
then equilibrated with 0.01 N  NaOH. The reaction solution was loaded 
on the column, and the column was eluted with 0.01 N  NaOH. Twelve 
fractions of 1 mL each were collected and examined on TLC (silica gel, 
M eO H -C H C l3- N H 4OH, 35:61:4 v /v). Fractions having MTL were 
combined and the pH was adjusted to 6.0.
Another column was prepared using 20.0 g of ion-retardation resin 
(Bio Rad AG11A8 50-100 mesh) and was thoroughly washed with 
distilled water until free of chloride. The combined MTL fractions (pH
6.0) were passed through this column and eluted with H20 .  Twenty 
fractions of 4 mL each were collected and examined on TLC. The 
fractions having MTL were combined and lyophilized to obtain MTL as 
a white powder (9-11 mg).
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The biosynthesis of the antitumor antibiotic, CC-1065, has been investigated by radioac­
tive isotope techniques, in combination with chemical degradation of CC-1065. Tyrosine, 
dopa, serine and methionine (S-CHs group) have been shown to be precursors of CC-1065.
Tyrosine is proposed to be a precursor of all three benzodipyrrole subunits, while dopa is only 
apparently incorporated into subunits B and C. Serine is postulated to contribute three 2C 
units, with loss of C-l, to all three subunits of CC-1065. The S-CH3 group of methionine 
probably contributes four C-l units to CC-1065 of which one is incorporated with considera­
ble loss of tritium, most probably into the cyclopropane ring of subunit A.
CC-106515 is a potent antitumor antibiotic produced by Streptom yces zelensis1,2,35 which interacts 
with double stranded D N A 4,35. M echanism o f  action studies suggest CC-1065 forms a covalent ad- 
duct in which the drug is bound in the minor groove o f  D N A . Although CC-1065 is highly active 
against a variety o f  mouse tum ors25 its potential as a clinical agent has yet to  be proven.
M aterials and Methods
Fermentations
S. zelensis D ietz and Li sp. m. was maintained on Hickney Tresner agar at 4°C. In a typical 
fermentation, spores were inoculated into 100 ml o f  seed medium [Bacto-tryptone (D ifco) 5.0, Bacto- 
yeast extract (D ifco) 3.0, dextrin 1.0, M g S 0 4*7H20  1.0, F e S 0 4 -7H 20  0.02, M nCl2 0.002, CoC12-7H 20  
0.02, Z n S 0 4 7H 20  0.01 (grams/liter) distilled H zO to 1 liter], contained in a 500-ml Erlenmeyer flask 
and incubated for 48 hours at 28°C at 250 r.p.m. on a rotary incubator shaker. For production 5 ml 
o f  the 48 hours seed culture was transferred to 100 ml o f  a fermentation medium [Dextrose 3.0, dextrin
10.0, cornmeal 10.0, torula yeast 4.0, CaCOs 5.0, M g S 0 4-7H 20  1.0, N a  citrate 2.5, fish meal 10.0, KC1
2.0, N a2H P 0 4 2.0 (grams/liter) distilled H 20  to 1 liter] which is incubated for up to 90 hours, under the 
same conditions as the seed flask. Production starts at about 66 hours reaching a maximum o f  between 
2 ~ 4  ^g/m l at 90 hours.
Radioactive precursors were added at 66 hours and the incubation continued for 24 hours before 
harvesting.
Radioactively Labelled Compounds
L-[l'-14C]Dopa, L-[3'-14C]dopa, L-[3-14C]serine, L-[Ala-2 or 3-sH]dopa, L-[14C H 8]methionine, 
L-[U-C14]threonine and L-[3-3H]serine were purchased from  Amersham. l-[C3H 3]Methionine, l -  
[U -14C]serine, L-[U-14C]tyrosine, L-[l/-14C]tyrosine, l-[2- or 6-3H]tyrosine, l-[3- or 5-3H]tyrosine, l -  
[8-14C]dopamine and [2-14C]acetate were purchased from N ew  England Nuclear and DL-[7a-14C]trypto- 
phan from International Chemical and Nuclear.
* To whom inquires should be addressed.
** Present address: Department of Applied Microbiology, The Hebrew University-Hadassah Medical 
School, Jerusalem, Israel.
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Nonlabelled Compounds
CC-1065 (U-56,314, lot N o . 15168-DGM -33.17) was obtained from  D r. D a v id  M a r t i n  at the 
Upjohn Company and dissolved in 5% D M F  in water prior to use. The methylpyrrole com pound  
(4-methylpyrrole-2,3-dicarboxylic acid) used in the K uhn-Roth oxidation was obtained from  Dr. 
K o s t e n b a u d e r  at the University o f  Kentucky.
Isotope Analysis
Radioactivity measurements were carried out on Packard M odel 2425 liquid scintillation counter. 
Radioactive samples were added to 8 ml o f  Aquasure and counted to  at least 2 % statistical error and 
counting efficiencies were determined using an external standardization method. Radioactivity on  
chromatograms was detected using a Packard M odel 7201 radiochromatogram scanner.
Chromatography
Thin-layer chromatography on 5 x  20 cm  precoated Silica gel 60 F-254 was used throughout this 
study. Visualization o f  CC-1065 was by short U V  light in which CC-1065 produced a blue fluorescence. 
Chromatography systems consisted o f  methylethylketone - acetone - water, 8 0 :17 : 3; CC-1065 R f  0.66  
(TLC-1) and chloroform - methanol - ammonium hydroxide, 80: 20: 0 .5; CC-1065 R f 0.56 (TLC-2).
Sephadex G-100 colum n chromatography on the C C-1065-D N A  adduct was carried out in 5 ml 
syringes (about 1 ~  2 ml o f  Sephadex) and eluted with water. A lthough adduct formation with D N A  
and then Sephadex chromatography will eliminate non-D N A  reactive compounds, other CC-1065 
degradation products still containing the D N A  alkylating m oiety will not be removed. C C -1065-DN A  
adduct were prepared by incubation o f  the isolated CC-1065 dissolved in 450 /A o f  0.1 SSC, with an excess 
o f  calf thymus D N A  (62 fj,g in 50 (A o f  0.1 SSC) at 4°C overnight. 1 ml fractions were collected and  
200 /A used for liquid scintillation counting in 8 ml o f  Aquasure and the remaining 800 /A used for 
O .D . measurements at 260 nm (D N A ) and 363 nm (CC-1065). The C C -1065-DN A  eluted in frac­
tions 2 ~ 4  and fraction 3 was used for radioactivity determinations.
Isolation o f  CC-1065 from Cultures and Determination o f  Percentage Incorporation o f Precursors
A t the end o f  the incubation period after adjusting the pH  o f  the broth to 10 with concentrated 
N H 4OH, the whole fermentation broth is extracted twice with 200 ml o f  methylene chloride. The 
organic layers are pooled, dried over anhydrous sodium sulfate and taken to dryness on a rotary eva­
porator at 40°C. The residue is redissolved in acetone (about 3 ml) and 10 /A taken for radioactivity 
determination. A n aliquot equivalent to  about 2 x  104 dpm (14C) or 2 x  10® dpm (8H) is spotted on a 
TLC plate alongside reference CC-1065 and developed in TLC-1. The CC-1065 is located on the de­
veloped plate by exposure to  U V  light. The plate was then scanned for radioactivity using a radiochro­
mogram scanner and the percentage incorporation determined from  the combined radioactivity and  
scanning results as previously described85. Those samples found to be significantly labelled in TLC-1 
were further purified by scraping off the band corresponding to CC-1065 rechromatographing in TLC-2 
and Sephadex G-100 system to check for radiochemical purity.
Degradation o f  CC-1065 by K uhn-Roth Oxidation
Radiochemically pure samples o f  CC-1065 labelled from methionine and serine were degraded by 
Kuhn-Roth oxidation75. D ue to the unavailability o f  significant amounts o f  carrier CC-1065, a 
methylpyrrol com pound was used as a carrier material (100 mg) since it carries an equivalent C -C H 8 
group in a pyrrole ring. The acetic acid obtained from the K uhn-Roth oxidation was isolated and 
counted for radioactivity.
Results
Determination o f  the Biosynthetic Precursors for CC-1065
CC-1065 consists o f  three very similar benzodipyrrole subunits (A, B, and C in Fig. 1) o f  which 
B and C are identical and subunit A  is distinguished by having an extra carbon atom  incorporated into  
a cyclopropane ring and also containing an indole quinone in place o f a dihydroxyindole moiety. 
Based upon biosynthetic considerations it seemed m ost likely that the indole ring o f  tryptophan or cycli-
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Table 1. Incorporation o f  labelled substrates in CC-1065 by S. zelensis.
Experim ent N o . Substrate fed Radioactivity  fed (juCi)
% Incorporation  
into CC-1065
1 L-[14C H 3]M ethionine 10 0 .5
2 L-[U-14C]Tyrosine 20 0 .5
3 L-[l'-14C]Tyrosine 10 0 .8
4 L-[l'-14C]Dopa 10 0 .3
5 L-[U-14C]Serine 10 0 .3
6 L-[U-14C]Threonine 10 < 0 .0 3
7 DL-[7a-14C]Tryptophan 10 < 0.01
8 DL-[8-14C]Dopam ine 10 < 0.01
9 L-[G-sH]Tyramine 50 < 0.1
10 [2-14C]Acetate 10 < 0.01
zation o f  tyrosine or dopa would give rise to two o f the three rings in each o f the benzodipyrrole sub­
units. Assuming this to be the case, then the remaining C2- N  unit in subunits B and C and C3- N  unit 
in subunit A  could reasonably be derived from serine (B and C), serine and a C -l unit (A) or threonine 
(A).
The results o f radioisotope tracer experiments are shown in Table 1 and demonstrate that o f the 
suspected precursors fed, only tyrosine, dopa, serine and methionine were detectable incorporated 
into CC-1065. Scarcity o f  cold carrier material precluded recrystallization to constant specific activity, 
however, the isolated biosynthetically labelled CC-1065 was shown to be radiochemically pure by both 
chromatography in two TLC systems and then binding to D N A  which was then purified by Sephadex 
chromatography. The relative low levels o f incorporation (i.e. 0.3 ~  0.8%) o f precursors into CC- 
1065 is most likely due to dilution by the relatively large amounts o f amino acids (approximately 20 
mg o f  each per 100 ml o f media) contained in the fish meal which was found to be essential for anti­
biotic production. The incorporation o f  tyrosine,
dopa, serine and methionine into CC-1065 leaves 
open several options how these precursors could 
be incorporated into subunits A or B and C. A  
series o f  double-isotope (8H /14C) experiments 
and chemical degradation o f biosynthetically 
labelled CC-1065 molecules were designed and 
performed to answer these questions.
Fig. 1. Structure o f CC-1065.
Fig. 2. Possible m odes o f  incorporation o f  tyrosine 
into subunit A  (pathways a and d) and subunits B 
and C (pathways b and c) showing metabolic fate 
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Incorporation o f  Tyrosine into CC-1065 
The possible modes in which tyrosine can be incorporated into the A  or B and C subunits o f  CC- 
1065 are shown in Fig. 2. O f these alternatives only pathway “c” leading to subunits B and C results 
in retention o f  the carboxyl carbon o f  tyrosine. Parallel feeding experiments in which tyrosine doubly  
labelled with carbon-14 either at C -l' or uniformly labelled and carrying tritium in the side chain as a 
reference label were carried out, and the CC-1065 isolated and purified by successive chromatography 
and D N A  binding. The results (experiments 1 and 2 in Table 2) demonstrate that while l-[1'-14C]- 
tyrosine is incorporated into CC-1065, the L-[U-14C]tyrosine is one third more efficiently incorporated  
into the antibiotic than the carboxyl labelled tyrosine. These results eliminate pathway “b” as an al­
ternative and are in accord with both B and C subunits being derived by pathway “c ”. While these 
double labelling experiments do not distinguish between pathways “ a” and “ d” in Fig. 2, they are in 
accord with the incorporation o f  tyrosine with loss o f  the carboxyl carbon in the case o f  subunit A .
D ual labelled feeding experiments with both l - [ 3-  or 5-8H] and l - [ 2-  or 6-sH]tyrosine and l-[U-14C]- 
tyrosine as a reference label were carried out to shed som e light on the fate o f  the aromatic hydrogens 
in CC-1065. Since the six membered rings o f  subunits B and C are fully substituted, com plete loss o f  
tritium from both tyrosine species was expected. However, in the case o f  subunit A  the operation o f  
pathway “a” might allow a 16% retention o f  tritium from l - [3-  or 5-sH] tyrosine barring other chemical 
or enzymatic events which might eliminate this aromatic proton. The results shown in Table 2 (experi­
ments 3 and 4) indicate a virtual complete loss o f  tritium from all aromatic positions o f tyrosine during 
conversion into subunits A , B and C. In fact, the 98 ~  99 % loss o f  tritium from  these substrates is 
further proof that our purification o f  CC-1065 using thin-layer and Sephadex chromatography leads 
to radiochemically pure material. W hile the virtual complete loss o f  tritium from l - [2-  or 6-*H]tyrosine 
was expected and is in accord with all four pathways in Fig. 2, the com plete loss o f  tritium from  l - [ 3-  
or 5-3H]tyrosine does not necessarily distinguish between pathways “ a” and “d” in Fig. 2. I f  pathway 
“a” is indeed operative the loss o f  tritium from  l - [3-  or 5-8H]tyrosine w ould be attributed to som e event 
directly or indirectly associated with the biosynthetic pathway to subunit A .
Incorporation o f  D opa into CC-1065 
The incorporation o f  dopa into CC-1065 (see Table 1) could be explained by its sole incorpora-







3H/14C ratio of CC-1065 Final tritium6 
retention (%)TLC-1 TLC-2 Sephadex
1 l-[1'-14C, Ala-2',3'-8H]tyrosine 9.92 5.05 — 4.76 47.9
2 l-[U-14C, Ala-2', 3'-3H]tyrosine 9.06 3.21 4.50 2.95 32.6
3 l-[1'-14C, Ala-2',3'-8H]dopa 9.26 2.48 2.80 2.59 28.0
4 l-[3'-14C, Ala-2',3'-8H]dopa 10.30 4.12 2.83 3.03 29.4
5 l-[U-14C, 2- or 6-8H]Tyrosine 8.25 0.11 — 0.01 0.1
6 l-[U-14C, 3- or 5-8H]Tyrosine 9.63 0.12 — 0.06 0.6
7 l-[3-14C, 3-8H]Serine 8.90 5.70 — 5.70 64.0
8 dl-[1-14C], L-[3-8H]Serine 7.01 454.0 — — (98.5)b
9 L-[14C3H3]Methionine 7.80 6 .0 — 5.38 69.0
a Tritium retention=(8H/14C ratio of CC-1065 after Sephadex chromatography/8H /14C ratio of precursor) 
xlOO.
b Relative loss of carbon-14 with respect to tritium based upon TLC-1.
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Fig. 3.  Possible mode of incorporation of dopa into subunits B  and C, showing metabolic fate of the V 
and 3 '  carbon atoms of dopa.
OH
tion into subunits B and C (see Fig. 3), which would rationalize the hydroxylation pattern in the six mem- 
bered rings. If tyrosine, but not dopa, is a precursor o f  subunit A this would strongly support path­
way “ a” in Fig. 2, since the quinone oxygen would be in the correct position relative to the phenolic hy­
droxy o f  tyrosine. Incorporation via pathway “d” would require a dopa intermediate and then loss o f 
the tyrosine phenolic hydroxyl group. To distinguish between these possibilities dopa labelled either 
in the V  or 3' position was fed in parallel experiments with a common tritium reference label [[L-Ala-2'- 
or 3-sH]dopa]. The results (experiments 5 and 6) in Table 2 demonstrate that both carbon-14 labels 
are incorporated to almost the same extent. This result is consistent with dopa not being incorporated 
into subunit A. Consequently pathway “a” in which tyrosine but not dopa is an intermediate is 
supported by these experiments.
The retention o f  between 28 and 30% of tritium from L-[Ala-2' or 3'-sH]dopa in CC-1065 may 
have some significance in terms o f  the stereospecificity o f elimination o f  one o f the hydrogen atoms 
originally at 3' o f dopa (and by inference tyrosine). The C-3' carbon o f dopa should be located 
exclusively at C -l7 and C-30 o f  subunit B and C respectively o f CC-1065, both o f which are methine 
carbons. Since C-2' o f  tyrosine is predicted to label C -l6 and C-29 o f  CC-1065, which is a quaternary 
carbon in both cases the tritium must be lost from this position. The tritium labelling pattern in the 
side chain o f phenylalanine and tyrosine prepared in a similar manner to the dopa used in this ex­
periment has been shown by K i r b y 8> to be as follows: First, the tritium is distributed equally between 
positions 2' and 3' o f the side chain. Second, the tritium at C-3' o f the side chain is predominantly 
in the pro-51 position (41.5±0.5% ) relative to 8 .5± 0 .5%  in the pro-/? position. The 28~30%  reten­
tion o f  tritium is in between that expected for loss o f  the pro-5 hydrogen (8.5 % retention) or the pro-/? 
hydrogen (41.5% retention). However, previous investigations9,110 have also revealed excess tritium 
and deuterium retentions in sibiromycin and gliotoxin respectively. By analogy with sibiromycin (19 % 
retention o f tritium) we would predict the stereospecific loss o f  the 3'-(/?) hydrogen o f  dopa during 
its conversion o f  subunits B and C, however, until experiments with stereospecific labelled substrates 
and chemical degradation are carried out, this conclusion should only be very tentatively offered.
Incorporation o f  Serine into CC-1065
Based upon the results o f  double-labelling experiments with tyrosine and dopa we can predict 
that serine should label CC-1065 as shown in Fig. 4. In this figure we proposed C-2 and 3 serine give 
rise to C-2 and 3 o f subunit A  and C-24 and 25 plus C-37 and 38 of subunits B and C respectively. A  
number o f  single, and double labelling experiments using serine in conjunction with chemical degrada­
tion o f CC-1065 were designed and executed to test this postulate.
Fig. 4 predicts that while the tritium at C-3 o f  serine should be retained at C-24 and C-37 o f sub­
units B and C o f CC-1065 respectively, the tritium should be lost in subunit A  and furthermore C-l
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Fig. 4. Postulated labelling pattern o f  serine in CC-1065 and origin o f  the acetic acid derived from Kuhn- 
Roth oxidation o f CC-1065.
o f serine should not be incorporated into CC-1065. The results (experiments 7 and 8) in Table 2 de­
monstrate that as expected one third o f the tritium is lost from L-[3-8H]serine and C-l o f serine is neg­
ligibly incorporated into CC-1065. A  sample o f CC-1065 biosynthetically labelled from l-[U-14C]- 
serine and degraded by Kuhn-Roth oxidation to remove C-3 and 3' as acetic acid showed 91 % of the 
calculated amount o f carbon-14 in the acetic acid. (Table 3). These results taken together provide 
strong evidence that serine contributes three 2C units to CC-1065, as shown in Fig. 4.
Incorporation o f Methionine into CC-1065
Our previously described results with tyrosine, dopa and serine account for all the carbon atoms 
o f CC-1065, except the C-methyl group in subunit A (C-3') the cyclopropane carbon in subunit B (C-10), 
the two O-methyl groups in subunits B and C (C-20' and C-33') and the terminal amide carbonyl (C-40). 
The C- and O-methyl groups seemed likely to be derived from the 5’-methyl group o f methionine, while 
the extra cyclopropane carbon by analogy with cyclopropane fatty acidsn) seemed likely also to be 
derived from the C -l pool. Experiments using double labelled L-[14CsH 3]methionine and chemical 
degradation o f  CC-1065 biosynthetically labelled from L-[14CH 3]methionine were designed to investi­
gate this postulate.
The results o f double labelling experiments using L-[14C3H 3]methionine (experiment 9) in Table 
2 indicate an 69% retention o f tritium in CC-1065. The less than 100% retention o f tritium in CC- 
1065 is in accord with an additional C-l unit, other than the three intact methyl groups found in sub­
units A (C-3'), B (C-20') and C (C-33'), which is incorporated with significant loss o f  tritium. Assum­
ing that the C -l units contribute equally to each of 
the 4carbons in CC-1065 derived from methionine,
Table 3. K uhn-R oth oxidation o f  CC-1065 biosyn­





L-[14CH 3]M ethionine 100 2 2 .5  (25)a
L-[U-14C]Serine 100 1 5 .2 (1 6 .7 ) b
a Figure in parenthesis is the theoretical expected  
assuming L-[14C H 3]methionine contributes 4  
C -l units equally to CC-1065. 
b Figure in parenthesis is the theoretical expected  
assuming L-[U-14C]serine contributes 3 C-2
units equally to CC-1065. M e th io n in e
Fig. 5. Precursors o f  CC-1065 and their postulated  
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then transfer o f  the C -l unit to the cyclopropane ring with 0, 1 or 2 associated hydrogens w ould give 
rise to  theoretical tritium retentions o f  75, 83 and 92% respectively, [e.g. (3 x C H 8) + ( l  x C H x)-i-1 2 =  
83.3 %]. Therefore the tritium retention o f  69% is suggestive o f  a transfer o f  a  C -l unit to the cyclo­
propane ring without any associated hydrogen. This latter result should, however, be treated with 
some caution since not only is this dependant upon the assumption that methionine labels each C -l 
unit equally but that isotope effects are not operating during this transfer.
K uhn-R oth oxidation o f  CC-1065 (see Fig. 4), biosynthetically labelled from L-[u C H 8]methionine 
yielded acetic acid possessing 22.5 % o f  the total radioactivity o f  CC-1065. This is in reasonable agree­
ment o f  the calculated 25 % that w ould be expected if  methionine contributed four C -l units all o f  which  
approximately equally labelled the CC-1065.
Discussion
The results o f  this study demonstrate that tyrosine, dopa, serine and methionine (C -l units) are 
biosynthetic precursors o f  CC-1065. Our double-labelling experiments with these precursors provide 
a reasonable basis for the postulated biosynthetic labelling pattern o f  these amino acids in CC-1065 
which is shown in Fig. 5. This study also provides an example o f  how  thoughtful experimental design 
can reveal much useful information on probably biosynthetic labelling patterns in a secondary meta­
bolite, where stable isotope techniques have proven to be difficult to apply.
CC-1065 is produced in relatively low  amounts (2 ~  4 mg/liter) in a complex media containing 
large amounts o f  amino acids in a fish meal extract. Experiments using radioactively labelled tyrosine 
and methionine reveal at best, dilution values o f in excess o f 500 which rules out the possibility o f  stable- 
isotope experiments. Persistent efforts to  develop a synthetic or semisynthetic media w hich will support 
production o f  more than trace amounts o f  CC-1065 have also so far failed. Likewise w e have been 
unsuccessful in developing a washed cell suspension that will support antibiotic production, although  
possibly a resting cell system in which amino acids were limited but antibiotic synthetases were already 
form ed prior to  cell collection might be successful. Therefore, more definitive experiments with stable 
isotopes w ill have to await the isolation o f  CC-1065 producing strains with improved properties or 
fermentation conditions.
Acknowledgments
This work was supported by the U.S. Public Health Service (Research grant CA-30349), and a grant from the 
Welch Foundation. The authors acknowledge the suggestions and contributions of Drs. M a r t i n  and H a n k a  
(Upjohn Co.) for their assistance in producing and handling CC-1065 and for samples of CC-1065 and S. 
zelensis.
References
1) H a n k a ,  L. J.; A. D ie tz ,  S. A. G e rp h e id e , S. L. K u e n t z e l  &  D . G . M a r t i n :  C C 1065 (NSC-298223), 
a new antitumor antibiotic. J. Antibiotics 31: 1211 ~  1217, 1978
2) M a r t i n ,  D. G .; C. B ile s , S. A. G e rp h e id e , L. J. H a n k a ,  W. C. K r u e g e r ,  J. P. M c G o v e rn ,  S. A. M iz sa k , 
G. L. N e i l ,  J. C. S t e w a r t  & J. V isse r  : CC-1065 (NSC-298223), a potent new antitumor agent. Improved 
production and isolation, characterization and antitumor activity. J. Antibiotics 34: 1119~ 1125, 1981
3) M a r t i n ,  D . G.; C. G. C h id e s te r ,  D . J. D u c h a m p  & S. A. M iz s a k :  Structure of CC-1065 (NSC-298223), 
a new antitumor antibiotic. J. Antibiotics 33: 902 ~  903, 1980
4) Li, L. H.; D . H. S w e n so n , S. L. F. S c h p o k , S. L. K u e n t z e l ,  B. D a y t o n  & W. C. K r u e g e r :  CC-1065 
(NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA . Cancer Res. 
42: 999 ~  1004, 1982
5) S w en so n , D . H .; L. H. Li, L. H. H u r l e y ,  J. S. R okem , G. L. P e t z o l d ,  B. D. D a y to n ,  T. L. W a l la c e ,  
A. H. L in  & W. C. K r u e g e r :  Mechanism of interaction of CC-1065 (NSC 298223) with D NA . Cancer 
Res. 42: 2821 ~  2828, 1982
390 THE JOURNAL OF ANTIBIOTICS APR. 1983J j
6) H u r l e y ,  L. H.; M. Z m u e w sk i & C.-J. C h a n g :  Biosynthesis of anthramycin. Determination of the 
labelling pattern by the use of radioactive and stable isotope techniques. J. Am. Chem. Soc. 97: 4372 ~  
4378, 1975
7) Sim on, H. & H. G. F lo s s :  Bestimmung der Isotopenverteilung in Markierten Verbindungen. Springer- 
Verlag, West Berlin and Heidleberg, 12, 1965
8) K ir b y ,  G. W.; S. N a r a y a n a s w a m i  & P. S. R a o :  On the preparation of L-[2,3-8H2]phenylalanine and L- 
[2,3-8H2]tyrosine. J. Chem. Soc. Perkin Trans 1 1975: 645 ~  647, 1975
9) H u r l e y ,  L. H .; W. L L a s s w e l l ,  J. M. O s t r a n d e r  &  R  P a r r y :  Pyrrolo (1,4) benzodiazepine antibiotics. 
Biosynthetic conversion of tyrosine to the Q - and C8-proline moieties of anthramycin, tomaymycin and 
sibiromycin. Biochemistry 18: 4230 ~  4237, 1979
10) B u ’l o c k ,  J. D .; A. P. R y le s ,  N. J o h n s  & G. W. K ir b y :  A stereospecific exchange reaction at the /3-CH2 
of phenylalanine, competing with gliotoxin biosynthesis. J. Chem. Soc., Chem. Comm. 1972: 100~ 101, 
1972
11) Buist, P. H. & D . B. M a c le a n :  The biosynthesis of cyclopropane fatty acids. II. Mechanistic studies 
using methionine labelled with one, two or three deuterium atoms in the methyl group. Can. J. Chem. 60: 
371~ 378,1982
B iosynthesis of A ntib iotics D erived from  
Catabolism  of Tyrosine
D. Review
Acc. Chem. Res. 1980, 13, 263-269 263
Elucidation and Formulation of Novel Biosynthetic Pathways 
Leading to the Pyrrolo[l,4]benzodiazepine Antibiotics 
Anthramycin, Tomaymycin, and Sibiromycin
L a u r e n c e  H . H u r l e y
Division of M edicinal C hem istry and Pharmacognosy, College of Pharmacy, U niversity of K entucky, Lexington, K entucky 40506
Received December 17, 1979
“When you have eliminated the impossible, what- 
I ever remains, however improbable, must be the 
I truth.”
j Sir Arthur Conan Doyle (1859-1930)
Antibiotics often occur in groups of closely related 
compounds, presumably because they are derived via 
^imilar biosynthetic pathways, but late biosynthetic 
tvents give rise to a multiplicity of products. The later 
biosynthetic events may be termed “cosmetic after 
pvents” and could well result from the presence of en­
zymes which have low specificities and perhaps other 
primary functions in the antibiotic producing cells, 
plthough definitive information on this point is lacking. 
Jin some cases the multiplicity of products may be found 
jwithin the same organism, for example, the tetracy­
clines,1 neomycins,2 and bleomycins.3 In other cases, 
while only single antibiotics within one group appear 
to be produced, biosynthetic analogues are produced 
by other organisms. This is the case with the “C-7 unit” 
,found in mitomycin C,4 validamycin A,3 kinamycin C,6 
.rifamycin S,' and geldanamycin.8
We have determined the biosynthetic precursors and 
Ijtheir labeling patterns in the pyrrolo[ 1,4) benzodiazepine 
(antibiotics anthramycin (I), tomaymycin (II), and si- 
jbiromycin (III). The results show that they have 
(biosynthetic analogies in the antibiotics actinomycin D 
I and lincomycins A (Va) and B (Vb). Tryptophan is the 
jcommon biosynthetic precursor of the anthranilate 
jinoieties of actinomycin D and the pyrrolo[l,4]benzo- 
jdiazepine antibiotics, while tyrosine is the common 
j precursor of the C2 and C3 proline units of the linco- 
• mycins and the pyrrolo[l,4]benzodiazepine antibiotics. 
; Intriguingly, whereas in the case of the pyrrolo[l,4]- 
(benzodiazepine group only a C2 or C3 proline unit is 
produced, in the case of the lincomycins both C2 and 
IC3 proline units are produced side by side in this fer- 
I mentation.
j It is the main purpose of this Account to illustrate 
jhow we have elucidated and then consolidated the 
I biosynthetic information from our studies on the mem­
bers of the pyrrolo[l,4]benzodiazepine with that pre­
viously determined on actinomycin D and the linco­
mycins.
The biosynthetic labeling patterns of precursors in 
| the pyrrolo[l,4]benzodiazepine antibiotics were deter-
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mined using state-of-the-art techniques such as and 
l3C NMR in combination with 2H, 13C, and 15N spe­
cifically labeled compounds. This biosynthetic infor­
mation, together with the relative retentions of various 
tritium atoms from precursors of the various antibiotics, 
has allowed us to formulate logical biosynthetic grids 
leading from tryptophan and tyrosine to the anthra­
nilate and C2 or C3 proline units of the various anti­
biotics.
The pyrrolo[l,4]benzodiazepine antibiotics are of 
considerable interest to us not only because of their 
unique biosynthetic origin but also because they are 
very potent antitumor agents with a unique mechanism 
of action.9 Anthramycin and related drugs form a labile 
covalent adduct with DNA10-13 which results in inhib­
ition of nucleic acid synthesis14,15 and, at least in the 
case of anthramycin, excision repair of DNA,16 recom- 
binogenic effects in yeast,17 and sister chromatid ex­
change in skin fibroblasts.18 We have recently proposed 
structures for the anthramycin,19 tomaymycin, sibiro­
mycin, and neothramycin A (IVa) and B (IVb)20 ad-
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Figure 1. Structure of anthram ycin (I), tom aym ycin  (II), s ib i­
romycin (III), neothramycins A (IVa) and B (IVb), and lincomycin 
A (Va) and B (Vb).
ducts with D N A  in  w h i c h  t h e s e  d r u g s  b i n d  c o v a l e n t l y  
gh N -2 o f  g u a n i n e  a n d  l i e  s n u g l y  h i d d e n  in  t h e  
narrow groove o f  D N A .
Speculation a n d  C o n f i r m a t i o n  o f  t h e  
Biosynthetic P r e c u r s o r s
The s tr u ctu r es  o f  t h e  p y r r o l o [  1 , 4 ] b e n z o d i a z e p i n e  
antibiotics are s h o w n  in  F i g u r e  1. M y  i n t e r e s t  in  t h e  
biosynthesis o f  t h e s e  s t r u c t u r a l l y  u n i q u e  g r o u p s  o f  
[compounds arose  p r im a r i ly  f r o m  t h e  u n u s u a l  C 2 a n d  C 3 
proline units o f  a n t h r a m y c i n ,  t o m a y m y c i n ,  a n d  s i b i r o ­
mycin (see F ig u re  1) ,  s i n c e  i t  s e e m e d  h i g h l y  l i k e l y  t h a t  
the anthranilate m o ie t ie s  w e r e  d e r i v e d  f r o m  t r y p t o p h a n  
viathekynurenine p a t h w a y .21 P e n  a n d  p a p e r  c h e m ­
istry led to a n u m b e r  o f  a t t r a c t i v e  b u t  l a t e r  p r o v e n  
erroneous id eas. F o r  e x a m p l e ,  p r o l i n e  p l u s  a  C 3 u n i t ,  
or two con d en sed  m o l e c u l e s  o f  5 - a m i n o l e v u l i n i c  a c i d ,  
ad reaso n ab le  f o r  t h e  a c r y l a m i d e  p r o l i n e  u n i t  o f  
inthramycin, or, i f  a l l  e l s e  f a i l e d ,  a n  a c e t a t e / p r o p i o n a t e  
combination s e e m e d  a  p l a u s i b l e  o p t i o n .  U p o n  t h e  
[entle suggestion o f  a  c o l l e a g u e  a t  P u r d u e  w e  c h e c k e d  
apaper p u b lish ed  b y  W i t z  a n d  c o - w o r k e r s  o n  t h e  b i o ­
(21) Herbert, R. B. Tetrahedron L e tt. 1971, 4525. Salzmann, L.;
ieissback, H.; Katz, E. Arch. Biochem. Biophys. 1969, 30, 5 3 6 . Perlman,
POtani, S.; Perlman, K. L.; Walker, J. E. J. A n tib io t. 1973, 26, 289.
s y n t h e s i s  o f  t h e  l i n c o m y c i n s 22 w h i c h  p r o v i d e d  evidence ^  
t h a t  t y r o s i n e ,  o f  a l l  t h i n g s ,  w a s  a  l i k e l y  p r e c u r s o r  of the 
“ C 2 a n d  C 3 p r o l i n e ” u n i t s  o f  t h e s e  a n t i b i o t i c s .  I w a s  
b o t h  r e l i e v e d  a n d  a l s o  q u i t e  e l a t e d  w h e n  w e  demon- : 
s t r a t e d  v e r y  s h o r t l y  a f t e r w a r d s  t h a t  t y r o s i n e  w a s  indeed 
a  v e r y  e f f i c i e n t  p r e c u r s o r .23 T h i s  f i n d i n g  w a s  exciting ? 
t o  m e  b e c a u s e  n o w  I h a d  t h e  i n t r i g u i n g  p r o b l e m  of 
e l u c i d a t i n g  h o w  t y r o s i n e  w a s  c o n v e r t e d  t o  t h e  quite 
s t r u c t u r a l l y  v a r i e d  C 2 a n d  C 3 p r o l i n e  u n i t s  o f  anthra­
m y c i n ,  t o m a y m y c i n ,  a n d  t h e  r e c e n t l y  r e p o r t e d  sibiro­
m y c i n .  T h e  n e o t h r a m y c i n s  ( I V a  a n d  I V b )  w e r e  not 
r e p o r t e d  u n t i l  1976, w h i c h  w a s  p e r h a p s  f o r t u n a t e  for 
u s ,  s i n c e  r e c e n t l y  M i y a m o t o 24 h a s  s h o w n  t h e  “proline” 
u n i t  o f  t h e s e  a n t i b i o t i c s  i s  d e r i v e d  in  a n  u n e x c e p t i o n a l  
w a y  f r o m  L - p r o l i n e  a n d  t h i s  m i g h t  w e l l  h a v e  discour­
a g e d  u s  f r o m  i n i t i a t i n g  t h i s  w o r k .
O u r  d e m o n s t r a t i o n  t h a t  t y r o s i n e  a n d  D o p a  were 
b i o s y n t h e t i c  p r e c u r s o r s  o f  a n t h r a m y c i n  w a s  f o l lo w e d  by 
e x p e r i m e n t s  in  w h i c h  w e  a r e  a b l e  t o  s h o w  t h a t  trypto­
p h a n  r a d i o l a b e l e d  in  t h e  a r o m a t i c  r in g  a n d  m e t h i o n i n e  
r a d i o l a b e l e d  in  t h e  S - m e t h y l  g r o u p  w e r e  a l s o  very ef­
f i c i e n t l y  i n c o r p o r a t e d .  O u r  e x p e r i m e n t s  w i t h  t h e  a n -  
t h r a m y c i n - p r o d u c i n g  s t r a i n  w e r e  g r e a t l y  f a c i l i t a t e d  
b e c a u s e  t h e  p r o d u c in g  o r g a n i s m  g r o w s  a t  47 ° C  a n d  the 
c o m p l e t e  f e r m e n t a t i o n  t a k e s  o n l y  a b o u t  12 h. A bio­
s y n t h e t i c  s c h e m e  f o r  t h e  c o n v e r s i o n  o f  t y r o s i n e ,  tryp­
t o p h a n ,  a n d  m e t h i o n i n e  i n t o  t h e  p y r r o l o [  1,4]benzo­
d i a z e p i n e  a n t i b i o t i c s  i s  s h o w n  in  F i g u r e  2 .
T h e  s t r a t e g y  w h i c h  f o l l o w s  in  t h i s  A c c o u n t  p r o v id e d  
u s  w i t h  a n s w e r s  o n  t h e  f o l l o w i n g :  ( 1) h o w  t r y p t o p h a n  
i s  b i o s y n t h e t i c a l l y  c o n v e r t e d  t o  t h e  a n t h r a n i l i c  a c id  
m o i e t i e s  o f  t h e  p y r r o l o [ l , 4 ] b e n z o d i a z e p i n e s  a n d  t h e  
p r o b a b l e  o r d e r  o f  i n s e r t i o n  o f  s u b s t i t u e n t s  i n t o  t h e  
a r o m a t i c  r in g ;  (2) h o w  t h e  c a r b o n  s k e l e t o n  o f  t y r o s i n e  
b e c o m e s  a  C 2 o r  C 3 p r o l i n e  u n i t ;  a n d  ( 3 )  h o w  t h e  d i v ­
e r s i t y  in  C 2 a n d  C 3 p r o l i n e  m o i e t i e s  m i g h t  b e  e x p la in e d  
b a s e d  u p o n  a  r a t i o n a l  “ b i o s y n t h e t i c  g r i d ”.25 I  u s e  t h e  
t e r m  “ b i o s y n t h e t i c  g r i d ” t o  d e s c r i b e  a  m a i n  a r t e r ia l  
p a t h w a y  l e a d i n g  f r o m  t y r o s i n e  t o  a  k e y  b r a n c h  p o i n t  
c o m p o u n d ,  f r o m  w h i c h  t h e n  f o l l o w ,  i n  s o m e  c a s e s ,  
p a r a l l e l  b u t  d i v e r g e n t  p a t h w a y s  t o  t h e  C 2 p r o l i n e  u n i t  
o f  l i n c o m y c i n  B  a n d  t o m a y m y c i n  a n d  t o  t h e  C 3 p r o l in e  
u n i t s  o f  l i n c o m y c i n  A .  a n t h r a m y c i n ,  a n d  s ib ir o m y c i n .
T ryp top han  as th e P recu rso r  o f th e  
A n th ra n ila te  U n its  o f A n th ram ycin ,
T om aym ycin , and S ib irom ycin
T h e  o c c u r r e n c e  o f  4 - m e t h y l - 3 - h y d r o x y a n t h r a n i l i c  acid 
u n i t s  i n  a c t i n o m y c i n  D  a n d  a n t h r a m y c i n  l e d  us to 
s u s p e c t  t h a t  t h e y  w e r e  d e r i v e d  v i a  s i m i l a r  pathways 
f r o m  t r y p t o p h a n ,  t h e  e s t a b l i s h e d  p r e c u r s o r  of t h i s  unit 
in  a c t i n o m y c i n  D .21 F e e d i n g  e x p e r i m e n t s  w i t h  DL-[7a- 
14C ] t r y p t o p h a n  a n d  [ m e f / i y / - 14C ] m e t h i o n i n e  followed 
b y  c h e m i c a l  d e g r a d a t i o n  o f  t h e  b i o s y n t h e t i c a l l y  labeled 
a n t h r a m y c i n  p r o v i d e d  p r o o f  t h a t  t h e  r a d i o a c t i v i t y  from 
t h e  t r y p t o p h a n  w a s  f o u n d  e x c l u s i v e l y  in  t h e  anthra-
(22) Witz, D. F.; Hessler, E. J.; Miller, T. L. Biochemistry 1971, JO, 
1128.
(23) Hurley, L. H.; Zmijewski, M.; Chang, C.-J. J. Am. Chem. Soc. 
1975, 97, 4372.
(24) Miyamoto, M.; Sawa, T.; Kondo, S.; Takeuchi, T.; U m e z a w a ,  H- 
J. Ferment. Technol. 1978, 56, 329. , . n
(25) The term “biosynthetic grid” is adapted from “metabolic grid 
which was originally proposed by Bu’Lock26 to describe intersecting set5 
of parallel transformations and the existence of one set of e n z y m i c  re­
actions occurring analogously with different substrates.
(26) Bu’Lock, J. D. In "The Biosynthesis of Natural P r o d u c t s  , 
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figure 2. Biosynthetic conversion of tryptophan, tyrosine, a n d  m e th io n in e  in to  th e  p y r r o lo [ l ,4 ]b e n z o d ia z e p in e  a n t ib io t ic s .
n i la t e  u n i t  w h i l e  t h e  l a b e l  f r o m  m e t h i o n i n e  w a s  f o u n d  
in th e  a r o m a t i c  m e t h y l  g r o u p  a n d  a l s o  in  t h e  a c r y la m id e
proline m o ie ty .23 S i m i l a r  e x p e r i m e n t s  u s i n g  DL-[7a- 
i4C ] tryptophan w i t h  t h e  t o m a y m y c i n , 2,a s i b i r o m y c i n ,2715 
and n eo th ram ycin s A  a n d  B 24 p r o d u c i n g  o r g a n i s m s  
showed an a logou s r e s u l t s .
T h e  m a n n e r  in  w h i c h  t r y p t o p h a n  i s  i n c o r p o r a t e d  i n t o  
th e  a n t h r a n i l a t e  r i n g  o f  a n t h r a m y c i n  w a s  d e t e r m i n e d  
b y  lo c a t io n  o f  t h e  lo N  a t o m  f r o m  L - ( / n d o / e - 15N ) t r y p t o -  
p h a n  in  t h e  a n t h r a m y c i n  m o l e c u l e .  T h e  i n d o l e  n i t r o g e n  
o f  t r v p t o p h a n  w a s  f o u n d  t o  r e s i d e  e x c l u s i v e l y  a t  N -10 
o f  a n t h r a m y c i n  b y  o b s e r v a t i o n  o f  t h e  c l e a r  c o u p l i n g  o f  
a I3C - e n r i c h e d  c a r b o n  a t  C - l  1 o f  a n t h r a m y c i n  w i t h  t h e  
a d j a c e n t  15N  a t o m  in  t h e  13C  N M R  s p e c t r a  o f  t h e  d u a l  
la b e l ( 15N  a n d  13C ) e n r i c h e d  a n t i b i o t i c .28 S i n c e  t r i t i u m  
fr o m  D L - [ 5- !H ] t r y p t o p h a n  i s  c o m p l e t e l y  r e t a i n e d  in  
a n t h r a m y c in ,  t h i s  l e a d s  t o  t h e  u n a m b i g u o u s  l a b e l i n g  
p a t t e r n  o f  t r y p t o p h a n  s h o w n  in  F i g u r e  2 .29
T h e  a v a i l a b i l i t y  o f  D L - [ 5 -3H ] t r y p t o p h a n  a n d  a  
k n o w le d g e  o f  N I H  s h i f t  r u l e s 30 h a v e  a l l o w e d  u s  t o  
p r e d ic t  t h e  o r d e r  in  w h i c h  s u b s t i t u e n t s  a r e  i n t r o d u c e d  
in to  t h e  a r o m a t i c  r in g  o f  t o m a y m y c i n  a n d  s i b i r o m y c i n  
b y  d e t e r m i n a t i o n  o f  t r i t i u m  r e t e n t i o n s  in  e a c h  o f  t h e s e  
a n t i b i o t i c s .29 I n  t h e  c a s e  o f  t o m a y m y c i n  a  v e r y  l o w  
r e t e n t io n  o f  t r i t i u m  s u g g e s t s  t h a t  t h e  b i o s y n t h e t i c  
p a t h w a y  i n v o l v e s  h y d r o x y l a t i o n  a t  C -8 p r i o r  t o  h y -  
d r o x y la t io n  a t  C - 7  s i n c e ,  a c c o r d i n g  t o  N I H  s h i f t  r u l e s ,30 
h y d r o x y la t io n  o r t h o  t o  a n  e x i s t i n g  h y d r o x y l  g r o u p  l e a d s  
to  lo s s  o f  t r i t i u m .  H o w e v e r ,  i n  t h e  c a s e  o f  s i b i r o m y c i n  
th e  a l m o s t  c o m p l e t e  r e t e n t i o n  o f  t r i t i u m  ( 9 3 % )  f r o m  
DL -[7 a -14C ;5 -3H ] t r y p t o p h a n  d e m o n s t r a t e s  t h a t  a n  N I H  
s h if t  o c c u r s  a n d  t h a t  t h i s  h y d r o x y l a t i o n  t a k e s  p l a c e  o n  
a c o m p o u n d  p o s s e s s i n g  a  l e s s  a c t i v a t e d  p a r a  s u b s t i t u e n t  
s u c h  a s  a n  a m i d e .  O t h e r  r e s u l t s  f r o m  c o m p e t i t i o n  e x ­
p e r i m e n t s  b e t w e e n  u n l a b e l e d  k y n u r e n i n e  d e r i v a t i v e s  
artd  c a r b o n - 1 4  l a b e l e d  t r y p t o p h a n  i n d i c a t e  t h a t  9 -  
h y d r o x y l a t i o n  a n d  8- m e t h y l a t i o n  p r e c e d e  t h i s  N I H  
s h i f t ,31'
027) (a) Hurley, L. H.; Gairola, C.; Das, N. Biochemistry 1976, 15, 3760. 
b) Hurley, L. H.; Lasswell, VV. L.; Malhotra, R. K.; Das, N. V. Ibid. 1979,
18- 4225.
(28) Ostrander, J. M.; Hurley, L. H.; Wright, J. L. C. Submitted for
Publicat ion.
(29) Hurlev, L. H.; Gairola, C.; Das, N.; Zmijewski, M. Tetrahedron 
Lett- 1976, 1419.
(>'0) Daly, ,J. W.; Jerina, D. M.; Witkop, B. Experientia  1972, 28, 1129.
(° 1) Hurley, L. H.; Gairola, C. Antimierob. Ag. Chemother. 1979, 15,
E s t a b l i s h m e n t  o f  t h e  P r e c u r s o r s  a n d  T h e i r  
B i o s y n t h e t i c  L a b e l i n g  P a t t e r n  i n  t h e  C 2 a n d  C 3 
P r o l i n e  U n i t s  o f  A n t h r a m y c i n ,  T o m a y m y c i n ,  
a n d  S i b i r o m y c i n
B y  fa r  t h e  m o s t  i n t r i g u i n g  a s p e c t  o f  o u r  b i o s y n t h e t i c  
w o r k  w a s  e l u c i d a t i o n  o f  t h e  m a n n e r  i n  w h i c h  t y r o s i n e  
i s  c o n v e r t e d  t o  t h e  C 2 a n d  C 3 p r o l i n e  u n i t s  o f  a n t h r a ­
m y c i n ,  t o m a y m y c i n ,  a n d  s i b i r o m y c i n .  C o n c e i v a b l y ,  
p a r a l l e l  p a t h w a y s  l e a d i n g  t o  t h e  C 2 p r o l i n e  ( C 7) o r  C 3 
p r o l i n e  ( C 8) u n i t s  c o u l d  a r i s e  e i t h e r  f r o m  a  c o m m o n  
r i n g - c l e a v a g e  p r o d u c t ,  w i t h  ( C 8) o r  w i t h o u t  ( C 7) a  
u n i t ,  o r  r in g  c l e a v a g e  p r o d u c t s  d i f f e r i n g  b y  o n e  c a r b o n  
b u t  e a c h  r e c e i v i n g  a  s i m i l a r  Cb u n i t  f r o m  m e t h i o n i n e .  
T h e  e a r l i e r  w o r k  b y  t h e  U p j o h n  g r o u p  o n  t h e  l i n c o ­
m y c i n s  s u g g e s t e d  t h e  l a t t e r  s e q u e n c e ;22 h o w e v e r ,  o u r  
s u b s e q u e n t  r e s u l t s  o n  a n t h r a m y c i n ,23 t o m a y m y c i n ,273 
a n d  s i b i r o m y c i n 276 a n d  t h e n  l a t e r  e x p e r i m e n t s  b y  t h e  
U p j o h n  g r o u p 32 r e f u t e d  t h i s  in  f a v o r  o f  t h e  f o r m e r  h y ­
p o t h e s i s  i n v o l v i n g  o n l y  a  c o m m o n  r i n g - c l e a v a g e  r e a c ­
t i o n ,  w i t h  o r  w i t h o u t  a n  a d d i t i o n a l  Cb u n i t .
C r i t i c a l  a n d  d e f i n i t i v e  e x p e r i m e n t s  u t i l i z i n g  v a r i o u s l y  
l a b e l e d  t y r o s i n e  a n d  m e t h i o n i n e  m o l e c u l e s  w e r e  c a r r i e d  
o u t  t o  d e t e r m i n e  ( 1) h o w  m a n y  c a r b o n  a t o m s  w e r e  
d e r i v e d  f r o m  t y r o s i n e ,  ( 2) w h e t h e r  m e t h i o n i n e  l a b e l e d  
t h e  C 2 o r  C 3 p r o l i n e  u n i t s ,  a n d  ( 3 )  t h e  p r e c i s e  l a b e l i n g  
p a t t e r n s  o f  t y r o s i n e  a n d  m e t h i o n i n e  i n  t h e s e  u n i t s .  
T y r o s i n e  c o n t r i b u t e d  e x a c t l y  s e v e n  c a r b o n  a t o m s  t o  
e a c h  a n t i b i o t i c  m o l e c u l e ,  s i n c e  L - [ U - 14C ] t y r o s i n e  w a s  
i n c o r p o r a t e d  o n l y  :/ 9 a s  e f f i c i e n t l y  a s  L - [ l - 14C ] t y r o -  
s i n e .23,27 T h e  t e r m i n a l  c a r b o n  a t o m s  ( C - 1 4 )  o f  a n t h r a ­
m y c i n  a n d  s i b i r o m y c i n  a r e  d e r i v e d  f r o m  t h e  Cb p o o l  v i a  
m e t h i o n i n e ,  w h e r e a s  t h e  e t h y l i d e n e  m e t h y l  g r o u p  o f  
t o m a y m y c i n  i s  d e r i v e d  f r o m  c a r b o n  a t o m  3  o r  5  o f  t h e  
a r o m a t i c  r i n g  o f  t y r o s i n e .  T h e s e  f i n d i n g s  w e r e  b a s e d  
u p o n  a  13C  N M R  e x a m i n a t i o n  o f  L -[m e th y l-13C ]- 
m e t h i o n i n e - e n r i c h e d  a n t h r a m y c i n 23 a n d  s i b i r o m y c i n 2'6 
a n d  c h e m i c a l  d e g r a d a t i o n  ( K u h n - R o t h  o x i d a t i o n )33 o f
l - [ 3 -  o r  5 - 3H ] t y r o s i n e - l a b e l e d  t o m a y m y c i n .2'3 I t  r e ­
m a i n e d  t o  p i n p o i n t  t h e  e x a c t  l o c a t i o n  o f  t h e  s i d e - c h a i n  
c a r b o n s  a n d  h y d r o g e n s  o f  t y r o s i n e  a n d  t h e  o t h e r  a r o ­
m a t i c  h y d r o g e n s  in  e a c h  o f  t h e  a n t i b i o t i c s .  T h i s  w e  d i d
(32) Rolls, J. P.; Ruff, B. D.; Haak, W. J.; Hessler, E. J. Abst. 76th 
Annu. Meet. A.S.M., 027 (1976).
(33) Simon, H.; Floss, H. G. "Bestimmung der Isotopenverteilung in 
inarkierten Verbindungen”; Springer-Verlag: West Berlin and Heidel­
berg, 1967; p 12.
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F ig u re  3. Biosynthetic labeling p a ttern  o f ty r o s in e  in  th e  C2 an d  
C, proline u n its  o f  anthramycin (I), to m a y m y c in  (II), a n d  s ib i-  
romycin (III).
b v  c h e m i c a l l y  d e g r a d i n g  s a m p l e s  o f  a n t h r a m y c i n  l a ­
b e le d  f r o m  L - [ ( 3 ' - R S ) - 3 ' - 3H ] t y r o s i n e 34 o r  b y  13C  N M R  
or *H N M R  e x a m i n a t i o n  o f  a n t h r a m y c i n  b i o s y n t h e t i ­
c a lly  l a b e l e d  f r o m  L - [ 1 ' - 13C ] t y r o s i n e 23 ( 13C  N M R ) ,  l - [3 -  
a n d  5-2H 2] t y r o s i n e 23 C H  N M R ) ,  a n d  L - [ 2 -  a n d  6 - 2H 2]-  
ty r o s in e 35 ( LH  N M R ) .  I n  m a n y  c a s e s  t h i s  w a s  r e p e a t e d  
for s a m p l e s  o f  s i b i r o m y c i n 27b a n d  t o m a y m y c i n .273 A  
s u m m a r y  o f  t h e  p r o v e n  b i o s y n t h e t i c  l a b e l i n g  p a t t e r n s  
is s h o w n  in  F i g u r e  3 .
A t t h i s  p o i n t  i n  o u r  b i o s y n t h e t i c  w o r k  w e  w e r e  c o g ­
n iz a n t o f  h o w  t h e  c a r b o n  a t o m s  o f  t y r o s i n e  p r o v i d e d  t h e  
Co a n d  C 3 p r o l i n e  s k e l e t o n s  o f  t h e  p y r r o l o [ l , ^ b e n z o ­
d ia z e p in e  a n t i b i o t i c s ,  b u t  w e  h a d  l i t t l e  u n d e r s t a n d i n g  
o f  t h e  s e q u e n c e  o f  b i o s y n t h e t i c  r e a c t i o n s  a n d  t h e r e f o r e  
th e  i d e n t i t y  o f  t h e  i n t e r m e d i a t e s .  T h i s  o b j e c t i v e  w a s  
t h e r e f o r e  o u r  n e x t  s t e p .
R e l a t i v e  R e t e n t i o n s  o f  A r o m a t i c  a n d  
S i d e - C h a i n  H y d r o g e n s  f r o m  T y r o s i n e  i n  t h e  C 2 
a n d  C 3 P r o l i n e  U n i t s  o f  A n t h r a m y c i n ,  
T o m a y m y c i n ,  a n d  S i b i r o m y c i n
D u r in g  c o n v e r s i o n  o f  t y r o s i n e  t o  t h e  C 2 a n d  C 3 p r o l i n e  
u n it s  o f  t h e  p y r r o l o [  1 , 4 ] b e n z o d i a z e p i n e  a n t i b i o t i c s ,  a  
n u m b e r  o f  b i o s y n t h e t i c  e v e n t s  m u s t  t a k e  p l a c e ,  i n ­
c lu d in g  a r o m a t i c  r i n g  c l e a v a g e ,  c v c l i z a t i o n  t o  f o r m  t h e  
p v r r o lo  r in g ,  l o s s  o f  t w o  a r o m a t i c  c a r b o n s ,  a n d ,  i n  t h e  
case  o f  s ib ir o m y c i n ,  l o s s  o f  o n e  o f  t h e  t w o  d i a s t e r e o t o p i c  
0 ’h y d r o g e n s  a n d  t h e  2 ' - h y d r o g e n  o f  t y r o s i n e .  T h e  
a v a i la b i l i t y  o f  s p e c i f i c a l l y  t r i t i a t e d  t y r o s i n e  m o l e c u l e s ,  
to g e th e r  w i t h  t h e i r  v i g o r o u s l y  e s t a b l i s h e d  b i o s y n t h e t i c  
a b e lin g  p a t t e r n s  i n  e a c h  o f  t h e  a n t i b i o t i c s ,  h a s  a l l o w e d  
t0 i n t e r p r e t  t h e  r e l a t i v e  t r i t i u m  r e t e n t i o n s  i n  t e r m s  
0 P o s s ib le  b i o s y n t h e t i c  i n t e r m e d i a t e s  b e t w e e n  t y r o s i n e  
, t h e  f i n a l  b i o s y n t h e t i c  p r o d u c t s .  I n  g e n e r a l ,  t h i s  
a h ° w e d  u s  t o  e l i m i n a t e  m a n y  a l t e r n a t i v e s  
r are  i n c o m p a t i b l e  w i t h  t h e  d a t a  w h i l e  l e a v i n g  o p e n  
\ y ^ vv ° P t i o n s  w h i c h  m u s t  t h e n  b e  c h o s e n  b e t w e e n .  
h a v ^ V ^ 0*06 b e t w e e n  v a r i o u s  o p t i o n s  s t i l l  e x i s t s ,  w e  
rea<.0 o s e n  I h e  o p t i o n  t h a t  i s  m o s t  m e c h a n i s t i c a l l y  
° n a b le  w h i le  b e a r i n g  in  m i n d  t h a t  t h e r e  i s  p r o b a b l y
■̂ mith ^  ’ Malhotra, R. V.; Ostrander, J. M.; M clnnes, A. G.;
*35) Hi,T’ , ter> 3- A.; Wright, J. L. C. Submitted for publication, 
tv 107a r,oy’ ^ ; Lasawell, W. L.; Ostrander, .J.; Parry, R. Riochem- y  J7“. 18, 4230.
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F ig u re  4. Alternative pathways for ring cleavage and cyclization 
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a  m a i n  a r t e r i a l  p a t h w a y  l e a d i n g  t h r o u g h  a  k e y  
b r a n c h - p o i n t  i n t e r m e d i a t e  t o  p a r a l l e l  b i o s y n t h e t i c  
p a t h w a y s  t o  t h e  C 2 a n d  C 3 p r o l i n e  u n i t s  o f  p y r r o l o -  
[ l , 4 ] b e n z o d i a z e p i n e  a n d  t h e  l i n c o m y c i n  a n t i b i o t i c s .
I m p l i c a t i o n s  o f  t h e  R e l a t i v e  R e t e n t i o n  o f  
T r i t i u m ,  f r o m  l - [ 3 -  o r  5 - 3H ] T y r o s i n e  i n  t h e  
P y r r o l o [ l , 4 ] b e n z o d i a z e p i n e  A n t i b i o t i c s ,  f o r  t h e  
T y p e  o f  A r o m a t i c  R i n g  C l e a v a g e  R e a c t i o n
D u r i n g  c o n v e r s i o n  o f  L - [3 -  o r  5 - 3H ] t y r o s i n e  t o  t h e  C 2 
a n d  C 3 p r o l i n e  u n i t s ,  a t lea s t  5 0 %  o f  t h e  t r i t i u m  m u s t  
b e  l o s t  d u r i n g  t h e  t y r o s i n e  h y d r o x y l a s e  r e a c t i o n  ( s e e  
F i g u r e  4 ) .  H o w e v e r ,  t h e  s u b s e q u e n t  l o s s  o r  r e t e n t i o n  
o f  t h e  r e m a i n i n g  5 0 %  o f  t h e  t r i t i u m  w i l l  d e p e n d  u p o n  
b o t h  t h e  t y p e  o f  a r o m a t i c  r in g  c l e a v a g e  a n d  c y c l i z a t i o n  
r e a c t i o n s  a n d  t h e  s u b s e q u e n t  “ c o s m e t i c  a f t e r  e v e n t s ”  
o c c u r r i n g  a t  t h e  c a r b o n  a t o m  c a r r y i n g  t h e  t r i t i u m  a t o m .
D o p a  c a n  u n d e r g o  t h r e e  t y p e s  o f  r i n g  c l e a v a g e  ( a ,  b ,  
a n d  c  i n  F i g u r e  4 ) ,  a n d  e a c h  o f  t h e s e  p r o d u c t s  c a n  t h e n  
c y c l i z e  i n  t w o  p o s s i b l e  w a y s  ( a i ,  a 2; b l7 b 2; C i, c 2; F i g u r e  
4 ) ,  p r o v i d i n g  a  t o t a l  o f  s i x  a l t e r n a t i v e  p a t h w a y s .  T h r e e  
o f  t h e s e  s i x  p a t h w a y s  ( a 2, b 2, a n d  c 2) w o u l d  n e c e s s i t a t e  
c o m p le te  loss  o f  t r i t i u m  f r o m  l - [ 3 -  o r  5 - 3H ] t y r o s i n e  i n  
t h e  f i n a l  a n t i b i o t i c s ,  a n d  s i n c e  i n  t h e  c a s e s  o f  a n t h r a ­
m y c i n 23 a n d  t o m a y m y c i n 273 a  5 0 %  r e t e n t i o n  o f  t r i t i u m  
i s  f o u n d ,  t h e s e  a l t e r n a t i v e s  c a n  b e  e l i m i n a t e d ,  a t  l e a s t  
f o r  t h e s e  t w o  a n t i b i o t i c s .  F i g u r e  4  i l l u s t r a t e s  o n ly  t h e  
v i a b l e  a l t e r n a t i v e s  ( a ! ,  b 1( a n d  c ^  w h i c h  f o l l o w  p r o x i m a l  
e x t r a d i o l  c l e a v a g e  ( a ) ,  i n t r a d i o l  c l e a v a g e  ( b ) ,  a n d  d i s t a l  
e x t r a d i o l  c l e a v a g e  ( c ) ,  r e s p e c t i v e l y .  T h e  c h o i c e  o f  t h e  
m o s t  l i k e l y  o f  t h e s e  t h r e e  r e m a i n i n g  v i a b l e  p a t h w a y s ^  
s h o w n  i n  F i g u r e  4  i s  b a s e d  u p o n  t h e  o c c u r r e n c e  i n  t h e  
f e r m e n t a t i o n  b r o t h s  o f  a l l  t h r e e  a n t i b i o t i c  p r o d u c i n g ]
V ol- l 3 ’ 1 9 8 0
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p v u re  5- Cyclodopa (XII) as an interm ediate in the biosynthesis 
f the  p y rro lo [l,4 ]b en zod iazep in e  an tib iotics.
g r a i n s  of a  b r i g h t  y e l l o w  a c i d i c  c o m p o u n d  w h i c h  h a s  
s p e c tr a l  c h a r a c t e r i s t i c s  o f  t h e  a l d e h y d o  o x o  a c i d  V I .  
T h is  a l d e h y d o  o x o  a c i d  h a s  b e e n  s y n t h e s i z e d  r e c e n t l y 36 
an d  h a s  been f o u n d  t o  c y c l i z e  t o  a  d i h y d r o p y r r o l e  d e ­
r iv a t iv e 36 (IX  in F i g u r e  4) a n d  m u s c a f l a v i n ,  a  f u n g a l  
p ig m e n t .3 '
We th e re fo re  s t r o n g l y  s u s p e c t  t h a t  a  p r o x i m a l  e x ­
tr a d io l cleavage o f  D o p a  f o l l o w e d  b y  s p o n t a n e o u s  r in g  
closure to form  t h e  S c h i f f  b a s e  ( I X  in  F i g u r e  4 )  i s  t h e  
common p a th w a y  t o  t h e s e  a n t i b i o t i c s .  Q u i t e  u n e x ­
pectedly we fo u n d  t h a t  s i b i r o m y c i n  l o s e s  v i r t u a l l y  a l l  
o f  the t r i t i u m  f r o m  L - [3 -  o r  5 - :!H ] t y r o s i n e ; 27b h o w e v e r ,  
we believe th is  i s  d u e  t o  a  l a t e r  “ c o s m e t i c  a f t e r  e v e n t ” 
which is l i n k e d  i n d i r e c t l y  t o  t h e  e x t r a  d e g r e e  o f  u n s a ­
tu r a t io n  f o u n d  o n l y  i n  t h e  p y r r o l o  r i n g  s i b i r o m y c i n .
R e t e n t i o n  o f  L - [ 2 -  o r  6- 3H ] T y r o s i n e  i n  
A n t h r a m y c i n ,  T o m a y m y c i n ,  a n d  S i b i r o m y c i n  
a n d  t h e  T i m i n g  o f  t h e  C y c l i z a t i o n  R e a c t i o n
The in te rm ediacy  o f  c y c l o d o p a  ( X I I )  r e q u i r e s  t h a t  a t  
least 50% o f  t r i t i u m  s h o u l d  b e  l o s t  f r o m  L - [ 2 -  o r  6 - 
:,H]tyrosine d u r i n g  i t s  c o n v e r s i o n  t o  t h e  p y r r o l o [ l , 4 ] -  
benzodiazepine a n t i b i o t i c s  ( s e e  F i g u r e  5 ) .  O u r  r e s u l t s  
show th a t  in  t h e  c a s e  o f  t o m a y m y c i n  ( 7 8 %  r e t e n t i o n  
tritium)273 c y c l o d o p a  c a n n o t  b e  a  v i a b l e  i n t e r m e d i a t e ,  
and therefore  r i n g  c l e a v a g e  t a k e s  p l a c e  p r io r  t o  f o r ­
mation of the f i v e - m e m b e r e d  r in g .  T h e  5 0 %  a n d  3 2 .7 %  
retentions o f  t r i t i u m  in  a n t h r a m y c i n 23 a n d  s i b i r o m y ­
c i n . - r e s p e c t i v e l y ,  w o u l d  a p p e a r  t o  l e a v e  o p e n  t h i s  
possibility. H o w e v e r ,  i n  a c c o r d  w i t h  t h e  c o n c e p t  t h a t  
there is a c o m m o n  m a i n  p a t h w a y  e n d i n g  i n  a  b r a n c h ­
point c o m p o u n d  w h i c h  i t s e l f  l e a d s  t o  e i t h e r  t h e  C 2 o r  
C3 proline m o i e t i e s  o f  t h e s e  a n t i b i o t i c s  b y  “ c o s m e t i c  
after events” , w e  f e e l  t h a t  t h e  l o s s  o f  g r e a t e r  t h a n  5 0 %  
(4 the t r i t iu m  i n  t h e s e  e x p e r i m e n t s ,  u s i n g  L - [ 2 -  o r  6 - 
Hjtyrosine, i s  m o s t  l i k e l y  d u e  t o  a  l a t e r  b i o s y n t h e t i c  
event ra th e r  t h a n  t h e  i n t e r m e d i a c y  o f  c y c l o d o p a .
R e t e n t i o n s  o f  t h e  S i d e - C h a i n  H y d r o g e n s  o f  
f y r o s i n e  i n  A n t h r a m y c i n ,  T o m a y m y c i n ,  a n d
S i b i r o m y c i n
E x a m in a t io n  o f  t h e  s i d e - c h a i n  c a r b o n s  o f  t y r o s i n e  a n d  
th eir  b i o s y n t h e t i c  f a t e  in  t h e  p y r r o l o [ l , 4 ] b e n z o d i a z e p i n e  
dn t i b i o t i c s  r e v e a l s  t h a t ,  w h e r e a s  in  a n t h r a m y c i n  a n d  
, ° m a y m y c i n  r e t e n t i o n  a t  c a r b o n  a t o m s  11a  a n d  1 o f  
o th  C -2' a n d  C - 3 '  h y d r o g e n s  o f  t y r o s i n e  i s  p o s s i b l e ,  in  
c a s e  o f  s i b i r o m y c i n  t h e  2 ' - h y d r o g e n  a n d  o n e  o f  t h e  
u °  d i a s t e r e o t o p i c  3 ' - h y d r o g e n s  m u s t  b e  l o s t  ( s e e  F ig u r e  
■ U s i n g  a  c o m b i n a t i o n  o f  d o u b l e - l a b e l e d  t y r o s i n e  
| n ° l e c u l e s ,  i n c l u d i n g  t h e  t w o  s t e r e o s p e c i f i c a l l y  C - 3 '  
Jh a t e d  s p e c i e s ,  w e  h a v e  s h o w n  t h a t ,  w h i l e  in  a n t h r a -  
U ( in  a n d  t o m a y m y c i n  r e t e n t i o n  o f  b o t h  C - 3 '  h y d r o -
146) Professor W. Ste^lich, private communication. 
lor- i’3 Von Ardenne, R.; Dopp, H.; Musso, H.; Steglich, W. Z. Natur-
sch■ C, Biosci. 1971, 29, 637.
g e n s  o c c u r s ,  i n  s i b i r o m y c i n  t h e r e  i s  a  p r e d o m i n a n t  
s t e r e o s p e c i f i c  l o s s  o f  t h e  3 ' ( S ) - h y d r o g e n  o f  t y r o s i n e .35
T h e  f a t e  o f  t h e  h y d r o g e n  a t  C - 2' o f  t y r o s i n e  i n  t h e  
t h r e e  a n t i b i o t i c s  w a s  d e t e r m i n e d  b y  u s i n g  l - [ 1 ' - 14C;- 
A l a - 2 ' -  o r  3 ' - 3H ] t y r o s i n e ,  s i n c e  t h e  t r i t i u m  l a b e l i n g  
p a t t e r n  in  t h e  a m i n o  a c i d  i s  k n o w n ,38 a n d  w e  h a d  a l ­
r e a d y  e s t a b l i s h e d  t h e  f a t e  o f  t h e  C - 3 '  h y d r o g e n s  o f  
t y r o s i n e .  S i n c e  t h e  s t e r e o c h e m i s t r y  a t  C - 2' o f  t y r o s i n e  
i s  t h e  s a m e  a s  t h a t  a t  C - l  l a  o f  a n t h r a m y c i n  a n d  t o ­
m a y m y c i n ,  w e  w e r e  s o m e w h a t  s u r p r i s e d  t o  f i n d  c o m ­
p l e t e  l o s s  o f  t h e  C - 2' h y d r o g e n  i n  b o t h  o f  t h e s e  a n t i ­
b i o t i c s  a s  w e l l  a s  i n  s i b i r o m y c i n .30 T h e  p o s s i b i l i t y  t h a t  
e i t h e r  r a c e m i z a t i o n  o r  a  t r a n s a m i n a s e  w a s  r e s p o n s i b l e  
f o r  t h i s  c o m p l e t e  l o s s  o f  t r i t i u m  a t  C - 2' o f  t y r o s i n e  w a s  
e x p l o r e d  in  c o m p e t i t i o n  e x p e r i m e n t s  b e t w e e n  L- a n d  
D - t y r o s i n e  a n d  e x p e r i m e n t s  w i t h  D L - [ 1 ' - 14C ; 3 -  a n d  
5 - 2H 2;15N ] t y r o s i n e ,  r e s p e c t i v e l y .  L - T y r o s i n e  w a s  f o u n d  
t o  b e  t h e  s p e c i f i c  p r e c u r s o r  o f  a l l  t h e  p y r r o l o [ 1 . 4 ] -  
b e n z o d i a z e p i n e  a n t i b i o t i c s  u s i n g  L - [2 -  o r  6- 3H ] t y r o s i n e  
a n d  d - [ 2 -  o r  6- 3H ] t y r o s i n e ,  w i t h  D L - [ l ' - 14C ] t y r o s i n e  a s  
a  r e f e r e n c e  l a b e l  i n  e x p e r i m e n t s  s i m i l a r  t o  t h a t  o r i g i ­
n a l l y  p r o p o s e d  b y  L e i s t n e r  e t  a l .39 t o  d i s t i n g u i s h  b e ­
t w e e n  d i f f e r e n t  i s o m e r  s p e c i f i c  u t i l i z a t i o n .  A l t h o u g h  
o n l y  a  p a r t i a l  r e t e n t i o n  o f  15N  f r o m  d l - [ 1oN ] t y r o s i n e  w a s  
f o u n d  i n  a n t h r a m y c i n  ( 2 2 % )  a n d  s i b i r o m y c i n  {2 9 % )  
c o m p a r e d  t o  t h e  d e u t e r i u m  o r  14C  r e t e n t i o n ,  t h i s  i s  
u n l i k e l y  t o  b e  e n t i r e l y  r e s p o n s i b l e  fo r  t h e  c o m p l e t e  l o s s  
o f  t h e  2' - h y d r o g e n  o f  t y r o s i n e  i n  a n t h r a m y c i n .30 T h e  
r e a s o n  f o r  t h e  c o m p l e t e  l o s s  o f  t h e  C - 2 '  h y d r o g e n  o f  
t y r o s i n e  i n  a n t h r a m y c i n  a n d  s i b i r o m y c i n  i s  t h e r e f o r e  
a t  t h i s  t i m e  u n k n o w n .
F o r m u l a t i o n  o f  t h e  B i o s y n t h e t i c  G r i d  f r o m  
T y r o s i n e  t o  t h e  C2 a n d  C3 P r o l i n e  U n i t s  o f  t h e  
P y r r o l o [ l , 4 ] b e n z o d i a z e p i n e  a n d  L i n c o m y c i n  
A n t i b i o t i c s
O n  t h e  b a s i s  o f  a  d e t a i l e d  e x a m i n a t i o n  o f  t h e  c o n ­
v e r s i o n  o f  t y r o s i n e  t o  t h e  C 2 a n d  C 3 p r o l i n e  u n i t s  o f  t h e  
p y r r o l o [ l , 4 ] b e n z o d i a z e p i n e  a n t i b i o t i c ,  a  b i o s y n t h e t i c  
g r i d  h a s  b e e n  p r o p o s e d .35 T h i s  g r i d ,  c o n s i s t i n g  o f  a  
c o m m o n  m a i n  p a t h w a y  l e a d i n g  t o  a  b r a n c h - p o i n t  c o m ­
p o u n d ,  t h e n  d i v e r g e s  i n t o  f i v e  b r a n c h e s ,  e a c h  l e a d i n g  
u l t i m a t e l y  t o  o n e  o f  t h e  C 2 a n d  C 3 p r o l i n e  u n i t s  o f  t h e  
p y r r o l o [ l , 4 ] b e n z o d i a z e p i n e  o r  l i n c o m y c i n  a n t i b i o t i c s .  
N o t  o n l y  d o e s  t h i s  p r o p o s e d  g r id  a c c o m m o d a t e  a l l  o u r  • 
d a t a ,  b u t  i t  a l s o  e x p l a i n s  s o m e  o f  t h e  a p p a r e n t  i n c o n ­
s i s t e n c i e s  w h i c h  a p p e a r  b e t w e e n  e x p e r i m e n t s  u s i n g  t h e  
s a m e  i s o t o p i c a l l y  l a b e l e d  p r e c u r s o r  a n d  t h e  d i f f e r e n t  
a n t i b i o t i c s .
T h i s  p a t h w a y  i s  s h o w n  in  F i g u r e  6 a n d  i s  b a s e d  u p o n  
t h e  f o l l o w i n g  a s s u m p t i o n s :  ( 1) p r o x i m a l  e x t r a d i o l
c l e a v a g e  o f  D o p a  i s  i n v o l v e d  a s  t h e  c o m m o n  r i n g -  
c l e a v a g e  r e a c t i o n ;  ( 2) c y c l o d o p a  i s  u n l i k e l y  t o  b e  a  
c o m m o n  i n t e r m e d i a t e  in  t h e  p a t h w a y ;  ( 3 )  d i v e r g e n c e  
o f  t h e  p a t h w a y s  o c c u r s  a t  t h e  s t e p  a t  w h i c h  a d d i t i o n  
o f  e i t h e r  a  C H 3+ g r o u p  o r  a  H + t o  a  c o m m o n  C 2 p r o l i n e  
u n i t  t a k e s  p l a c e ;  a n d  ( 4 )  f o r m a t i o n  o f  t h e  e t h y l i d e n e  
m e t h y l  g r o u p  o f  t o m a y m y c i n  a n d  t h e  c o n j u g a t e d  
a c r y l a m i d e  s i d e  c h a i n  o f  a n t h r a m y c i n  a n d  t h e  u n s a t u ­
r a t i o n  i n  t h e  s i d e  c h a i n  a n d  p y r r o l o  r in g  o f  s i b i r o m y c i n  
a r e  c o s m e t i c  a f t e r  e v e n t s  w h i c h  o c c u r  s u b s e q u e n t  t o  t h e  
m a i n  p a t h w a y .
(38) Kirby, G. W.; Narayanaswam i, S.; Rao, P. S. J. Chem . Soc., 
P erkin  Trans. 1, 1975, 645.
(39) Leistner, E.; Gupta, R. N.; Spenser, I. D. J. Am . Chem. Soc. 1973, 
95, 4040.
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'Sure 6. Proposed biosynthetic grid for the conversion of tyrosine into the C2 and C3 proline units of anthramycin (I), tomaymycin^ 
| h), sibiromycin (III), and lincomycins A (Va) and B (Vb).
f h e  i m p o r t a n t  f e a t u r e s  o f  t h e  m a i n  a n d  b r a n c h  
P a th w a y s  l e a d i n g  t o  t h e  C 2 a n d  C 3 p r o l i n e  u n i t s  o f  t h e  
Pyrr o l o [ l , 4 ] b e n z o d i a Ze p i n e  a n t i b i o t i c s  a n d  t h e  l i n c o -  
^ • c i n s  s h o w n  i n  F i g u r e  6 a r e  a s  f o l l o w s :  ( 1 )  F o l l o w i n g  
^ - e x t r a d i o l  c l e a v a g e  o f  t h e  a r o m a t i c  r i n g  o f  D o p a ,  a  
c° h d e n s a t io n  r e a c t i o n  t o  f o r m  a  S c h i f f  b a s e  b e t w e e n  t h e  
f a m i n e  g r o u p  a n d  t h e  a l d e h y d i c  g r o u p  t a k e s  p l a c e .  (2) 
e c o n j u g a t e d  e n o l  X I I I  t h e n  u n d e r g o e s  t a u t o m e r i -  
f a tl0 n  t o  y i e l d  t h e  o - k e t o  a c i d  X I V  w h i c h  i t s e l f  t h e n  
° Ses tw o  c a r b o n  a t o m s  ( c a r b o n  a t o m s  4  a n d  5  o f  D o p a )
in  a  s t e p w i s e  m a n n e r  t o  f o r m  t h e  d i e n e  X V .  ( 3 )  Diene 
X V  i s  c o n s i d e r e d  t o  b e  t h e  b r a n c h - p o i n t  c o m p o u n d  fo r  
w h i c h  a  1,4 a d d i t i o n  o f  H - X  r e s u l t s  i n  d i v e r g e n t  path* 
w a y s  d e p e n d e n t  u p o n  t h e  n a t u r e  o f  X + . If X + is H \  
t h e n  t h e  p a t h w a y  l e a d s  t o  t h e  C 2 p r o l i n e  m o i e t i e s  of 
t o m a y m y c i n  a n d  l i n c o m y c i n  B ,  w h e r e a s  i f  X + i s  S +C H 3. 
t h e n  t h e  p a t h w a y  l e a d s  t o  t h e  C 3 p r o l i n e  m o i e t i e s  of * 
a n t h r a m y c i n ,  s i b i r o m y c i n ,  a n d  l i n c o m y c i n  A . ( 4 )  Sub- , 
s e q u e n t  m o d i f i c a t i o n  o f  t h e  f i r s t  i n t e r m e d i a t e s  p a s t  th e ,,  
b r a n c h  p o i n t  l e a d s  t o  t h e  p r o p y l p r o l i n e  u n i t  of linco-
Biosyn the tic Path ways
. \  ( X V I  —-  V a ) ,  t h e  a c r y l a m i d o p r o l i n e  u n i t  o f  
piV1'1'1 n v c in  ( X V I  —*• I ) ,  t h e  p r o p y l i d e n e p r o l i n e  u n i t  
iull tr-..()rn y c i n  ( X V I  —  I I I ) ,  a n d  t h e  e t h y l p r o l i n e  u n i t  
‘̂ ' ’c o in y 0111 B  ( X V I I  —* V b ) .  T h e  e t h y l i d e n e p r o l i n e  
(’I I111 ()f  t o m a y m y c i n  i s  f o r m e d  d i r e c t l y  f r o m  t h e  
u'1'1 .p o i n t  c o m p o u n d  X V .  W h e r e  m o d i f i c a t i o n s  a r e  
l,r:imrea . t h e s e  w o u l d  b e  c o n s i d e r e d  a s  “ c o s m e t i c  a f t e r  
r1̂ 11 •• w h i c h  o c c u r  s u b s e q u e n t  t o  t h e  m a i n  p a t h w a y .  
f«ellc 0 s m e t i c  m o d i f i c a t i o n s  l e a d i n g  t o  t h e  l i n c o m y c i n s  
s t r a ig h t f o r w a r d  a n d  d o  n o t  r e q u i r e  f u r t h e r  c o m -  
^  F o r  t h e  b r a n c h  p a t h w a y s  l e a d i n g  t o  t h e  C 3 
,1K'|jn e  u n i t s  o f  a n t h r a m y c i n  a n d  s i b i r o m y c i n ,  h y -  
? “ a v ia t io n  a t  t h e  a l l y l i c  c a r b o n  i n  a  s t e r e o s p e c i f i c  
•inner leads t o  X I X .  T h i s  c o m p o u n d  c a n  t h e n  u n -  
:J\ cr0 a 1,4- c o n j u g a t e  e l i m i n a t i o n  o f  p h o s p h o r i c  a c id  in  
vn analogous b u t  d i f f e r e n t  w a y s  ( X I X  —  X X  a n d  X I X  
X X ID - T h ese  r e a c t i o n s  w o u l d  r e s u l t  i n  t h e  s t e r e o -  
- -jeVific loss of h y d r o g e n  t h a t  w a s  o r i g i n a l l y  a t  C -2 o r  
1  of tyrosine ( a n t h r a m y c i n  p a t h w a y )  o r  t h e  3 ' - S  p o s -  
hion of tyrosine ( s i b i r o m y c i n  p a t h w a y ) .  T h e  c o n v e r s i o n  
j yX  to X X I  r e q u i r e s  o x i d a t i o n  a n d  a n i m a t i o n  t o  
produce t h e  a c r y l a m i d o p r o l i n e  m o i e t y  o f  a n t h r a m y c i n .  
n the c a s e  of t h e  s i b i r o m y c i n  b r a n c h ,  X X I I  u n d e r g o e s  
U1 allylic r e a r r a n g e m e n t  t o  p r o d u c e  X X I I I  w h i c h  i s  
then hydroxylated a t  t h e  a l l y l i c  c a r b o n ,  t h e r e b y  e l i m ­
inating in a s t e r e o s p e c i f i c  m a n n e r  t h e  h y d r o g e n  t h a t  
ivas originally l o c a t e d  a t  C - 3  o r  - 5  o f  t y r o s i n e .  T h e  
product of t h i s  r e a c t i o n ,  X X I V ,  i s  t h e n  a b l e  t o  u n d e r g o  
i second s t e r e o s p e c i f i c  1 , 4 - c o n j u g a t e  e l i m i n a t i o n  o f  
jhosphoric acid  w h i c h  l e a d s  t o  l o s s  o f  t h e  h y d r o g e n  
)riginally located  a t  C -2 o r  C -6 o f  t y r o s i n e  a n d  c o n -  
tomitantly t h e  f o r m a t i o n  o f  t h e  d e s i r e d  p r o p y l i d e n e  
tide c h a in  of s i b i r o m y c i n .
A consideration o f  t h e  d e t a i l s  in  F i g u r e  6 a l l o w s  u s  
o explain the a p p a r e n t  i n c o n s i s t e n c i e s  b e t w e e n  r e s u l t s  
rcm different a n t i b i o t i c  f e r m e n t a t i o n s .
For example, t h e  1 ,4 - c o n j u g a t e  e l i m i n a t i o n  r e a c t i o n s  
XIX —  X X  a n d  X X I V  —* X X V )  p e c u l i a r  t o  t h e  a n -  
hramycin and  s i b i r o m y c i n  p a t h w a y s  e x p l a i n  t h e  l o s s  
f  the tritium  o r i g i n a l l y  l o c a t e d  a t  C -6 o f  D o p a ,  w h i c h  
5 at least p a r t i a l l y  r e t a i n e d  i n  t o m a y m y c i n .  
Furthermore, t h e  c o m p l e t e  l o s s  o f  t r i t i u m  f r o m  l - [ 3 -  
r T 3H]tyrosine p e c u l ia r ’ t o  t h e  s i b i r o m y c i n  b i o s y n t h e s i s
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i s  l i n k e d  i n d i r e c t l y  t o  t h e  i n t r o d u c t i o n  o f  t h e  e x t r a  
d e g r e e  o f  u n s a t u r a t i o n  f o u n d  s o l e l y  i n  s i b i r o m y c i n  
(1 l a —1 b o n d ) ,  w h i c h  r e q u i r e s  a n  a d d i t i o n a l  p o s t u l a t e d  
a l l y l i c  h y d r o x y l a t i o n  a t  C - 1 3  ( X X I I I  —► X X I V ) .
A l t h o u g h  t h e  p r o p o s e d  b i o s y n t h e t i c  p a t h w a y  s h o w n  
i n  F i g u r e  6 i s  p r o b a b l y  n o t  t h e  o n l y  o n e  c a p a b l e  o f  
e x p l a i n i n g  o u r  r e s u l t s ,  w e  f e e l  i t s  d e v e l o p m e n t  a n d  
e x i s t e n c e  i s  a n  i m p o r t a n t  s t e p  in  o u r  p r o g r a m  t o  e s ­
t a b l i s h  a  g e n e r a l  b i o s y n t h e t i c  p a t h w a y  t o  t h e s e  i n t e r ­
e s t i n g  a n t i b i o t i c s .
S u m m a r y  a n d  F u t u r e  D i r e c t i o n s  f o r  R e s e a r c h
T h e  b i o s y n t h e t i c  w o r k  s o  f a r  c o m p l e t e d  h a s  a l l o w e d  
u s  t o  e l u c i d a t e  t h e  b u i l d i n g  p r e c u r s o r s  a n d  t h e i r  l a b e l e d  
p a t t e r n s  in  a n t h r a m y c i n ,  t o m a y m y c i n ,  a n d  s i b i r o m y c i n .  
A  r a t i o n a l  b i o s y n t h e t i c  g r id  l e a d i n g  f r o m  t y r o s i n e  t o  t h e  
C 2 a n d  C 3 p r o l i n e  u n i t s  o f  t h e  p y r r o l o [ l , 4 ] b e n z o -  
d i a z e p i n e  a n d  l i n c o m y c i n  a n t i b i o t i c s  t h a t  a c c o u n t s  f o r  
s o m e  u n e x p e c t e d  r e s u l t s  h a s  b e e n  p r o p o s e d .  T h e  n e x t  
l o g i c a l  s t e p  i n  o u r  b i o s y n t h e t i c  p r o j e c t  i s  t o  t e s t  t h e  
a c c u r a c y  o f  t h i s  g r i d  b y  s y n t h e s i s  o f  t h e  a p p r o p r i a t e  
p o s t u l a t e d  i n t e r m e d i a t e s  i n  l a b e l e d  f o r m .  S u c h  s t u d i e s  
a r e  i n  p r o g r e s s .  P r o j e c t s  a r e  a l s o  u n d e r  w a y  t o  e x a m i n e  
h o w  t h e  p r o d u c i n g  o r g a n i s m s  a v o i d  t h e  t o x i c i t y  o f  t h e s e  
p o t e n t  c y t o t o x i c  a g e n t s  a n d  a l s o  d e t e r m i n e  t h e  b i o l o g ­
i c a l  f u n c t i o n  o f  a n y  o f  t h e s e  a n t i b i o t i c s  i n  t h e  p r o d u c i n g  
c e l l s .  I n t r i g u i n g l y  t h e  m e c h a n i s m  o f  a c t i o n  o f  a n t h r a ­
m y c i n  a n d  r e l a t e d  d r u g s  a p p e a r s  t o  b e  a t  l e a s t  a s  u n i q u e  
a s  t h e i r  b i o s y n t h e t i c  o r ig in .  T h e  c h a r a c t e r i z a t i o n  o f  t h e  
p r e c i s e  m a n n e r  i n  w h i c h  t h e s e  d r u g s  r e a c t  w i t h  D N A  
c o u l d  l e a d  t o  s i g n i f i c a n t  d e v e l o p m e n t s  i n  t h e  d e s i g n  o f  
n e w  a n t i t u m o r  a g e n t s  b e l o n g i n g  t o  t h i s  c l a s s  o f  a g e n t s .
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Proposed structure of 
the anthramycin-DNA adduct
Laurence H . Hurley & Ruby Petrusek
College of Pharmacy, University of Kentucky, Lexington,
Kentucky 40506
Anthramycin, an antitumour antibiotic produced by Strep­
tomyces refuineus \  belongs to the pyrrolo(l,4)benzodiazepine 
antibiotic group2. Antibiotics within this group are potent 
inhibitors of nucleic acid synthesis because of their ability to 
form a labile covalent adduct with DNA2-6. The reaction of 
anthramycin with DNA is unusual in that the rate of adduct 
formation is slow2 4,s, shows an absolute specificity for deoxy- 
guanosine in a double-stranded template4, and is only stable as 
long as the secondary structure of DNA is retained6. Experi­
ments using confluent non-dividing human cell lines have 
demonstrated that while repair-proficient cells are able to 
remove up to 84% of the adduct within 72 h, xeroderma pig­
mentosum cells in complementation group A were only able to 
remove 49% during the same incubation period10. We propose 
here a Corey, Pauling and Koltun (CPK) molecular model for 
the anthramycin-DNA adduct in which anthramycin is attached 
through the 2-amino group of guanine and lies hidden in the 
narrow groove. Experimental data supporting this model are 
provided. The model is based on information about the probable 
covalent binding sites on anthramycin and guanine together with 
the known crystal structure of anthramyin7.
Structure activity relationships for anthramycin and related 
compounds provide compelling evidence that the carbinolamine 
is the reactive group on anthramycin24'514. X-ray diffraction 
studies on crystals of anthramycin show that the molecule is 
twisted 40 to 50° from one end to the other along the long axis 
and thus might fit into one of the grooves of D N A 7. From studies
O
Fig. 1 Structure (a) and CPK space filling model (b ) of the 
anthram ycin-DNA adduct in which anthramycin is attached 
through C -l 1 to the N-2 group of guanine.
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Fig. 2 Time course hydrolysis of calf thymus DN A  during diges­
tion with Si nuclease in the presence of increasing amounts of 
bound anthramycin. Assays were carried out essentially as 
described by V ogt15. Calf thymus DN A  in 0.1 M SSC was diluted 
into reaction buffer to produce a final concentration of 0.03M  Na 
acetate pH 4.6, 0.025 M NaCI and 0.005 M Z n S 0 4. The reactions 
were carried out at 37 °C. Aliquots were removed at various times 
and transferred into 0.4 ml cold 10% perchloric acid. The samples 
were centrifuged (10,000g for 15 min) and the A 26o of the super­
natant was measured to determine the release of nucleotides by the 
enzyme. The anthramycin:nucleotide ratio was 0(A); 0.015 (■); 
0.037 ( • ) ;  0.063 (A); DN A  concentration 150(j.gm l \  enzyme 
concentration 2 x l 0 3 U m l 1. Heat denatured D N A  (□ ). At 
90 min unmodified calf thymus D N A  was added to an enzyme 
incubation containing drug-modified calf thymus D N A  (O). Inset, 
dependence of the nucleotides released per min against 
anthramycin: nucleotide ratio.
using synthetic polydeoxynucleotides, guanine is apparently the 
reactive base on D N A 4. Of the possible positions for alkylation 
by anthramycin, N-7, N-3, and C-8 have been eliminated 
because of: (1) the results of an alkylation assay using [8- 
3H]guanine-IabeIled DNA; (2) absence of strand breakage in 
vitro using SV40 DNA; and (3) the lack of increased suscep­
tibility to depurination of the anthramycin modified [8- 
3H]guanine-labelled D N A H. The unreactivity of polydlidC  
towards anthramycin, while polydG idC binds the drug at least 
as well as native D N A 4, strongly suggests that the N-2 position 
on guanine is directly involved in adduct formation. Model 
building using a CPK molecular model of DNA and anthramy­
cin in the published crystal conformation demonstrated quite 
dramatically that while 0 - 6  was inaccessible to adduct forma­
tion without bond cleavage or serious distortion of D N A, adduct 
formation through N-2 of guanine produced a remarkably snug 
fit. The anthramycin molecule which is attached through C -l 1 to 
N-2 of guanine by an aminal linkage fits within the narrow 
groove of DN A  (Fig. 1). The predictions which result from this 
model and the experimental data substantiating our model are 
presented below.
At saturation binding in D N A , where 25% of the bases are 
guanine and the drug molecule covers five base pairs, the 
maximum binding ratio would be 1:10. However, as the dis­
tribution of guanine residues is not uniform the frequency will be 
somewhat lower, and the experimentally determined ratio of 
1:12 . 8 (ref. 2) is probably close to the theoretical value.
Binding of anthramycin should not cause unwinding or 
lengthening of D N A  as the drug binds in a non-intercalative 
manner within the narrow groove. Viscosity and sedimentation 
measurements have shown that the DNA molecule is stiffened 
but not lengthened on anthramycin binding9. Experiments using 
SV40 D N A , predominantly in the supercoiled form, have shown 
no unwinding at an antibiotic to base ratio of 1:300.
Our model shows that the angle of the chromophore of 
anthramycin is inclined at 45° relative to the helix axis. This
compared very well with the reported value of 36° as determined 
by electric dichromism measurement9.
The drug is held to DNA by an animal linkage plus secondary 
stabilising forces, chiefly between the phenolic group at C-9 of 
anthramycin and the 2-keto group of cytosine in the same base 
pajr. As the animal linkage..is inherently unstable, conditions 
which remove the secondary stabilising interaction should lead 
to release of anthramycin from the adduct. The predictions are 
mimicked in practice as denaturation of the DNA by acid pH 
(ref. 5), heat and enzymatic degradation6, lead to rapid release 
of free drug from the DNA adduct.
In the proposed model, anthramycin fits into the narrow 
groove of DNA without distortion-or protrusion outside of the 
helix. To probe the modified DNA for distortion or protrusion 
of the adduct outside the helix, Si nuclease digestions and 
benzoylated napthalated DEAE (BND)-cellulose chromato­
graphy on the adducts were carried out. The results (Fig. 2, 
Table 1) show that S] nuclease was unable to reveal any regions
Table 1 Estimation of the single strandedness and protrusion of 
anthramycin molecule external to DNA found in the anthramycin-DNA 
adduct using BND-cellulose chromatography
% Adherence*
Anthramycin: D N A 3H-Anthramycin





Chromatography on BND-cellulose in which step elution using 
1 M NET (1.0 M NaCl-10' 4 M, EDTA-0.01 M Tris HC1, pH 7.5) elu- 
ate and a 50:50  1 M NET: formamide mixture can be used to estimate 
the double-stranded DNA (eluted with 1 M NET) against DNA  
containing single-stranded regions11 or protruding aromatic moieties1 
in a sample of DNA. To obtain DN A without single-stranded breaks or 
regions, calf thymus DNA (Sigma) was pre-chromatographed on BND- 
cellulose. The 1 M NET eluate (double-stranded DNA) was dialysed 
against 0.1 SSC, bound to varying concentrations of [15-3H]anthttimy  ̂
cin (4.0 p.Ci M-mol-1)5, and again dialysed against 0.1 SSC to remove any 
unbound antibiotic. Control DNA was also dialysed. The D N A - 
anthramycin adduct (140-220 p.g DNA) was then applied to BND- 
cellulose columns (1 ml column volume) and eluted successively with 
10 ml of 0.3 M NET (0.3 M NaCl-10-4 , EDTA-0.01 M Tris HC1, 
pH 7.5), 10 ml of 1.0 M NET and 10 ml of 50% formamide in 
1.0 M NET. 2.0 ml fractions were collected. Radioactivity was deter­
mined by adding 1.0-ml aliquots to 10 ml of Aquasol (NEN) and DNA  
by optical density measurement at 260 nm. Optical density measure­
ments of the formamide: 1.0 M NET fractions were corrected for back­
ground absorption using a control column without adding DNA.
* The % adherence represents the fraction of absorbance at 260 nm 
and the fraction of radioactivity eluted with 50% formamide in 
I M NET out of the total amounts eluted with 1 M NET and 50% 
formamide in 1 M NET.
t The larger values for the apparent percentage adherence found in 
the radioactivity determinations are most probably due to a small 
amount of release of drug from the DN A during manipulation before 
and during chromatography.
of distortion in the drug-modified DNA and, in fact, release of 
nucleotides was inhibited with increasing amounts of drug 
modification. The BND-cellulose chromatography results 
demonstrated lack of single strandedness of DNA induced by 
anthramycin as well as binding of anthramycin to the resin which 
would be anticipated if the drug protruded outside the DNA  
helix.
The orientation of anthramycin in the narrow groove allows 
interactions between the phenolic group at C-9 of anthramycin j 
and the 2-keto group of cytosine. Titration4 and CD measure-1 
ments9 have shown that in the adduct, the phenolic hydroxy | 
proton is no longer available for titration, which is in accord with 
our model in which hydrogen bonding between the phenolic 
group and the 2-keto of cytosine is possible. Our model also 
accounts for the tighter binding of sibiromycin to D N A  than 
anthramycin as the amino sugar attached at C-7 of sibiromycin 
binds externally to the deoxyribsose phosphate backbone of the 
helix.
As the anthramycin-DNA adduct is well concealed within the 
narrow groove of DNA it might be anticipated that excision 
repair would be a slow process due to the lack of distortion or 
protrusion which would normally lead to ready recognition of 
the drug-modified DNA. In practice the drug is only excised 
relatively slowly over a 48-h period in confluent normal non­
dividing human cells10.
This proposed model for the anthramycin-DNA adduct 
explains fully both the in vitro and in vivo data so far obtained. 
The proposed type of binding to DNA in which the drug 
molecule is attached by a labile covalent adduct and resides 
inside the narrow groove seems to be unique to the pyr- 
ro!o(l,4)benzodiazepine antibiotics and perhaps explains some 
of the unusual biological effects of this group of agents. Further 
experiments using stable isotopically labelled anthramycin and 
synthetic polydeoxynucleotides should vigorously establish the 
points of covalent linkage.
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pyrrolo[ l,4]benzodiazepine Antibiotics. Proposed Structures and 
Characteristics of the in Vitro Deoxyribonucleic Acid Adducts of 
Anthramycin, Tomaymycin, Sibiromycin, and Neothramycins A and B*
Ruby L. Petrusek, Gary L . Anderson, Tim  F. Garner, Q uinton L . Fannin, David J . Kaplan, Stephen G. Zimmer, 
and Laurence H . Hurley*
<
a b s t r a c t :  The pyrrolo[l,4]bejnzodiazepine antibiotics an­
thramycin, tom aym ycin, sibiromycin, and neothramycins A  
and B are potent antitumor agents that bind to D N A  in a 
uir-iue manner, resulting in some unusual biological conse- 
qi tees. This paper describes results on which the points of 
co dent linkage between the drugs (carbinolam ine carbon 
atom) and D N A  (N -2  o f guanine) are deduced, as well as 
C orey-Pauling-K oltun (CPK) models for the various drug- 
DNA adducts. Predictions based upon these CPK models have 
been tested, and the results are reported in this paper. These 
tested experimental predictions include (1) instability of the 
d rug-D N A  adducts to denaturation of D N A , (2) saturation
£  e pyrrolo[ 1,4] benzodiazepine antibiotics anthramycin, 
tomaymycin, sibiromycin, and neothramycins A  and B are 
potent antitumor agents produced by various actinom ycetes 
(Hurley, 1977). Examination of the structures of these agents 
(Figure 1) reveals that while all, except the neothram ycins,1 
have, in com m on the reactive carbinolam ine (N -10 , C -11) 
group, they differ in their aromatic substitution patterns, the 
degree of saturation in the pyrrolo ring, and the type of side 
chain at C-2. W ith the exception of sibiromycin, all other 
members of this group have an asymmetric carbon at C -l la , 
fv; :n provides the molecules with a 45° right-handed twist 
from the arom atic ring to the pyrrolo ring (M ostad et al.,
1978). The carbinolam ine group is highly reactive and with 
the exception of sibiromycin can be reversibly converted via 
the imine to the two C -l 1 isomers. In the case of sibiromycin, 
dehydration leads to the (1-1  la ) conjugated imine, which is 
less susceptible to nucleophilic attack due to its lower reactivity, 
j! Addition of the pyrrolo[ 1,4]benzodiazepine antibiotics to 
cultures of prokaryotic or eukaryotic organisms leads to potent 
inhibition of nucleic acid synthesis (H orw itz & Grollman, 
19 ; Kann & Kohn, 1972; M aruyama et al., 1978; Gause
& nudnik, 1971, 1972; Kohn, 1975; N ish ioka et al., 1972), 
which is alm ost certainly due to m odification of the D N A  
template by these agents (Kohn et al., 1974; Hurley et al., 
1977; Gause and Dudnik, 1971; M aruyam a et al., 1979). 
jause and co-workers have demonstrated that anthramycin 
tnd sibiromycin produce selective inhibition of H-strand  
•ynthesis in animal mitochondrial D N A  (Gause & Dolgilevich, 
•975; Gause et al., 1976). The reaction of anthramycin and 
elated drugs with D N A  appears to be unique to this group
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b in d in g  l im it s ,  ( 3 )  e f f e c t  o f  d r u g  b in d in g  o n  th e  s t r u c tu r e  o f  
D N A ,  ( 4 )  la c k  o f  u n w in d in g  a n d  in  v i t r o  s t r a n d  b r e a k a g e  o f  
c lo s e d -c ir c u la r  s u p e r c o ile d  s im ia n  v ir u s  4 0  ( S V - 4 0 )  D N A ,  (5 )  
s e n s it iv ity  o f  th e  s e c o n d a r y  s tr u c tu r e  o f  D N A  to  d r u g  b in d in g ,
( 6)  h y d r o d y n a m ic  p r o p e r t ie s  o f  th e  d r u g - D N A  a d d u c t s ,  ( 7 )  
h y d r o g e n  b o n d in g  o f  th e  9 -p h e n o lic  p r o to n  in  a n t h r a m y c in  to  
D N A ,  ( 8)  s t r u c t u r e - a c t iv i t y  r e la t io n s h ip s ,  a n d  ( 9 )  b io lo g ic a l  
c o n s e q u e n c e s  o f  D N A  d a m a g e ,  in c lu d in g  c u m u la t iv e  d a m a g e  
a n d  s lo w  e x c is io n  r e p a ir ,  d o u b le - s t r a n d  b r e a k s  in  D N A  in  
r e p a ir -p r o f ic ie n t  c e l ls ,  a n d  th e  s e le c t iv e  in h ib it io n  o f  H -s tr a n d  
D N A  s y n th e s is  in  m ito c h o n d r ia .  T h e  r e s u l t s  a r e  c o m p le t e ly  
in  a c c o r d  w ith  o u r  p o s tu la t e d  s p a c e - f i l l i n g  m o d e ls .
o f  a g e n ts  (H u r le y , 1 9 7 7 ; K o h n  e t  a l . ,  1 9 7 4 ;  H u r le y  &  P e tr u se k ,
1 9 7 9 ) .  F o r  th is  r e a s o n ,  w e  h a v e  b e e n  a c t iv e l y  in v e s t ig a t in g  
b o t h  th e  in  v i t r o  r e a c t io n  o f  th e  a n t h r a m y c in  w ith  D N A  a s  
w e ll  a s  th e  b io lo g ic a l  c o n s e q u e n c e s  o f  D N A  d a m a g e  in  h u m a n  
c e l l  l in e s ,  y e a s t ,  a n d  b a c te r ia l  c e l l s .  T h e  r e s u l t s  o f  th e  la t t e r  
s t u d ie s  s h o w  t h a t  a n t h r a m y c in  b in d s  to  c e l lu la r  D N A  a n d  
i n d u c e s  u n s c h e d u le d  D N A  s y n t h e s i s  in  e x c i s io n  r e p a ir  p r o ­
f i c i e n t  c e l ls  ( H u r le y  e t  a l . ,  1 9 7 9 a ) .  T h e  d r u g  u n d e r g o e s  e x ­
c is io n  r e m o v a l fr o m  c e l lu la r  D N A  in  e x c is io n -p r o f ic ie n t  c e l ls ,  
b u t  a t  a  s lo w  r a te  in  c o m p a r is o n  t o  o t h e r  D N A - r e a c t i v e  
c o m p o u n d s  s u c h  a s  A A A F 2 o r  B M B A .  In  th e  y e a s t  Sac- 
chromyces cerevisiae, a n t h r a m y c in  is  o n ly  w e a k ly  m u t a g e n ic  
b u t  is h ig h ly  r e c o m b in o g e n ic  ( H a n n a n  e t  a l . ,  1 9 7 8 ) .  M u ta n t s  
o f  S. cerevisiae d e f e c t iv e  in  e ith e r  e x c i s io n  r e p a ir  or  r e p a ir  o f  
d o u b le -s tr a n d  b r e a k s  a r e  u n u s u a lly  s e n s i t iv e  to  a n t h r a m y c in ,  
t o m a y m y c in ,  a n d  s ib ir o m y c in  ( H a n n a n  &  H u r le y ,  1 9 7 8 ) .
T h e  r e s u lt s  d e s c r ib e d  in  th is  p a p e r  p r o v id e  a  s t r o n g  b a s is  
fo r  o u r  p r o p o s e d  s tr u c tu r e s  fo r  t h e  D N A  a d d u c t s  o f  a n t h r a ­
m y c in ,  t o m a y m y c in ,  s ib ir o m y c in ,  a n d  t h e  n e o t h r a m y c in s .  
C o n s t r u c t io n  o f  C P K  s p a c e - f i l l in g  m o d e l s  fo r  t h e s e  v a r io u s  
d r u g  a d d u c ts  le a d s  to  a  n u m b e r  o f  p r e d ic t io n s ,  s o m e  o f  w h ic h  
w e  h a v e  t e s t e d  b y  u s in g  v a r io u s  b i o c h e m i c a l  t e c h n iq u e s  a n d  
o t h e r s  th e  r e s u lt s  o f  w h ic h  h a v e  a lr e a d y  a p p e a r e d  in  t h e  l i t ­
e r a tu r e .  In  a l l  c a s e s ,  th e  p r e d ic t io n s  a r e  m im ic k e d  p r e c is e ly  
in  th e  p r a c t ic e .  S o m e  o f  th e s e  r e s u l t s  h a v e  b e e n  p u b l is h e d
1 The neothramycins possess masked carbinolamines, since when they 
are dissolved in aqueous solution nucleophilic addition of water produces 
the N-10, C -l 1 carbinolamine.
2 Abbreviations used: AAAF, 2-(JV-acetoxyacetylamino)fiuorene; 
BM BA, 7-(bromomethyl)benz[a]anthracene; CPK, Corey-Pauling- 
Koltun molecular models; TLC, thin-layer chromatography; SSC, 0.15 
M NaCl and 0.015 M sodium citrate, pH 7.4; BND-cellulose, benzoyl- 
ated, naphthoylated DEAE-cellulose; M EM , minimal essential media;
FCS, fetal calf serum; 0.3 M NET, 0.3 M N aC l, 10r* M EDTA, and 
0.01 M Tris-HCl, pH 7.5; 1.0 M NET, 1.0 M N aC l, 10-4 M EDTA, and 
0.01 M Tris-HCl, pH 7.2; TEA, 150 mM Tris, 2 mM EDTA, 20 mM 
sodium acetate, and 18 mM NaCl, pH 8.1; SV-40 FI DN A, simian virus 
40 form I DNA; SV-40 FII DNA, simian virus 40 form II DNA; SV-40
F il l  DN A, simian virus 40 form III D N A ; Hepes, 7V-2-(hydroxy- 
ethyl)piperazine-yV'-2-ethanesulfonic acid.






C H 3 H N '
SIBIROMYCIN
R, R„
NEOTHRAMYCIN A :R ,  = H ; R„=OH
NEOTHRAMYCIN B= R ,= O H ; R ,= H
FIGURE 1: Structures of the pyrrolo[1,4]benzodiazepine antitumor 
antibiotics.
either in preliminary form (Hurley & Petrusek, 1979; Hurley 
et al., 1980) or as an abstract (Hurley et al., 1978).
Experimental Procedures
(A) Chemicals and Supplies. (1) Drugs, Enzymes, Nucleic 
Acids, and Chromatographic Materials. Anthramycin and 
sibiromycin were produced biosynthetically in this laboratory 
by previously published procedures (Hurley et al., 1975, 
1979c). Tomaymycin and neothramycins A and B were 
generously provided by Dr. Aoki (Fujisawa Pharmaceutical 
Co., Ltd.) and Dr. J. Douros (Drug Development Branch, 
National Cancer Instutute), respectively.
Sj nuclease and DNase I were purchased from Sigma 
Chemical Co. Cs2S 0 4 and CsCl were purchased from Kaw- 
ecki Berylico Industry and Sigma Chemical Co., respectively. 
iscoRI and SV-40 DNA were purchased from BRL, and the 
latter was greater than 90% SV-40 FI DNA. Calf thymus 
DNA and Clostridium perfringens DNA were purchased from 
Sigma Chemical Co. T-4 DNA was purchased from Miles 
Laboratories. Poly(dG)-poly(dC) and poly(dG-dC)*poly(dC- 
dG) were purchased from P-L Biochemicals.
SV-40 F ill D NA was prepared from SV-40 FI DNA. by 
incubation with iscoRI (10 units/100 fig of DNA) in a final 
solution of 500 fig/m L  DNA in 100 mM Tris and 10 mM 
MgCl2, pH 8.1. Digestions were allowed to proceed for 30 
min at 37 °C and then stopped by the addition of an excess 
amount of EDTA.
(2) Radiolabeled Material. [15-3H] Anthramycin and 
[15-3H] sibiromycin were prepared biosynthetically from L-
[methyl-3H ]methionine (N EN , 80 Ci/mmol) as describ 
previously (Hurley et al., 1975,1979c, respectively). Specif| 
activities (jiCi//miol) of anthramycin and sibiromycin we* 
based upon molar extinction coefficients of 36800 at 333 ri 
and 21 800 at 310 nm in aqueous solution at pH 7.2, resp 
tively.
[8-3H] Guanine-labeled DNA was prepared by biosynthetii 
labeling. A human fibroblast cell line (TC-98) was establish 
from an explant of a primary human skin fibroblast kary 
typically normal and was maintained in MEM with 10% F< 
and 20 mM Hepes buffer; 0.5 mCi of deoxy[8-3H] guanine (1 
Ci/mmol; Amersham Searle) was added to a 150-cm2 Falcol 
flask. After a 12-h incubation, the DN A  was extracted ani 
purified by a CsCl-gradient method. The final DNA had 
specific activity of 2.5 X 106 dpm/1.0 A ^  unit. The specificit' 
of labeling of the deoxy[8-3H]guanosine in DNA was deter­
mined by enzymatic degradation of the DNA to the constituent 
deoxynucleosides. These were separated on a LH-20 colu 
with H20  as an eluate (Martin & Garner, 1977). The raj 
dioactivity was found exclusively in the deoxyguanosini 
functions.
14C-Labeled SV-40 DNA was prepared by addition of 
/zCi/mL [methyl-uC ]thymidine (52 mCi/mmol; Amersham 
to SV-40-infected cells of green monkey kidney cells (CV-l’s£ 
in 60-mm plates. Thymidine was added at 20-h postinfectiol 
and allowed to incubate for 22 h prior to harvesting by usinj 
a Hirt supernatant procedure (Hirt, 1967) and subsequent! 
purified by velocity CsCl centrifugation. -
(2?) General Methods. Antibiotic to base ratios were de! 
termined by using a combined radioactivity (drug) and a 
sorption (nucleic acid) method (Hurley et al., 1977). Nucleii 
acid concentrations were calculated by assuming £ ,260ran =  641 
(calf thymus DNA), E260nm = 6225 (C. perfringens), E2l 
= 7300 (T-4 DNA), £ 254nm = 8400 [poly(dG-dC)-poly(d(g 
dC)], and 2s253imL= 7400 M-1 cm-1 [poly(dG)-poly(dC)]. I** 
certain cases where drug concentrations were high enoug 
these ratios were also calculated by the absorbance metb 
of Kohn & Spears (1970), and these values never varied fro: 
the combined radioactivity-absorption method by more thaj 
±5%.
Absorption spectra were recorded on a Beckman Model 2 
spectrophotometer. Radioactivity was determined by usinj 
a Packard 2425 liquid scintillation counter. Radiochemi 
purity of drugs was determined on a Packard Model 720 
radiochromatogram scanner (Hurley et al., 1975, 1979^
(7) Alkaline CsfS04 Gradient o f  [15-3H]Anthramyci 
Poly(dG )'Poly(dQ . The [ 15-3H] anthramycin-poly(d(j 
poly(dC) adduct was prepared by addition of 0.05 mL (0.1 | 
Mmol) of [15-3H] anthramycin (1.0 fiCi/fimol) to a 6-mL 
lution of poly(dG)-poly(dC) at 0.034 Mmol/mL in 0.1 M SSj 
The solution was dialyzed for 48 h against SSC, after bindii 
for 24 h at room temperature. An aliquot was removed, a; 
the OD at 253 nm and 3H radioactivity were measured 
final solution used for alkaline denaturation contained 0; 
Mmol of poly(dG)*poly(dC) and 0.015 Mmol of [15-3K  
anthramycin, giving an antibiotic to base ratio of 1:10 
kaline denaturation was carried out by slow addition of 1 
NaOH to a final pH of 12.5. Denaturation was monitor 
by UV absorption changes. The denatured antibiotic-pol; 
solution (4.4 mL) was mixed with solid Cs2S 0 4 (2.95 g) 
give a final density of 1.5. The solution was then cenirifug 
at 30000 rpm for 44 h at 20 °C in the SW 50.1 roi 
Ten-drop fractions were collected. The OD of each fracfij 
was measured, and 3H radioactivity (cpm) was determined 
addition of 150-mL aliquots of the fractions to 1 mL of 1
O f l  4 ]  B E N Z O D I A Z E P I N E  A N T I B I O T I C S
u r i  in 10 mL of Aquasol. Refractive indices of selected  
f ctions were read on a Zeiss refractometer.
. Assay fo r  D istillab le Tritium  fro m  A nthram ycin  and  
Nitrogen M u stard  T reated  [8-3H ]G uanine-Labeled D N A . 
TVs procedure was based largely upon the published method 
A c r i b e d  by Tomasz (1970a). The incubation mixture con- 
Aed of 3 *  10-3 ^mo1 [8-3H]guanine-labeled D N A  in 200 
of 5 mM Tris buffer (pH 7.4) plus 200 p L  o f a 1 p g /m L  
s o lu t io n  of either anthramycin or nitrogen mustard. The 
volume was made up to a total of 1 mL with 5 m M  Tris buffer 
(nH 7-4) an(* a^owec^t0 react overnight at room temperature. 
Any released tritium was collected by vacuum distillation at 
35-40 °C. Aquasol (10 mL) was added to the distillate (1 
mL) and the radioactivity determined by liquid scintillation  
counting.
(5) Electrophoresis and A nalysis o f  Anthram ycin  Binding  
to SV-40 FI and F i l l  D N A. Electrophoresis o f  SV -40 D N A  
was p e r f o r m e d  in 1% agarose gels (w /v ) m ade up in TEA  
buffer. Aliquots of 10 pL  each of glycerin and 0.1% bromo- 
phcnol blue were added to each sample im mediately prior to 
loading the gels. Electrophoresis was carried out at 1 m A /gel 
until the marker dye migrated approximately 7 cm. The buffer 
used for electrophoresis was the same as that used to make 
up the gels. After electrophoresis, the gels were removed and 
washed extensively in TEA buffer containing 1% ethidium  
bromide. The D NA bands were then located with a shortwave 
UV (254 nm) cutout, hydrolyzed in 1 mL o f 0.5 N  HC1, and 
counted in Aquasol (N E N ). As a correction for variance in 
sample size, !4C-labeled SV-40 D N A  was used in these ex­
periments. The samples were counted for dual label (3H / 14C) 
and corrected for spillover o f 14C into the 3H channel.
Results and Discussion 
{A) Formulation o f  C P K  M odels f o r  the P y rro lo [l,4 \-  
benzodiazepine A n tib io tic -D N A  A ddu cts. Since the an­
thramycin-DNA adduct is unstable to enzymatic denaturation 
of DNA (Hurley et al., 1979b), the usual approaches involving 
isolation of the nucleoside adducts to determination o f the 
structures of the pyrrolo[l,]benzodiazepine nucleoside adducts 
could not be taken.
Our approach reported in this paper was therefore to obtain 
indirect evidence for the sites o f  covalent linkage between  
anthramycin and D N A .
( /)  Determination o f  the A nthram ycin  R eactive Base in 
D.\A. Previously reported results on anthramycin (Kohn et 
al., 1974) and the neothramycins (M aruyam a et al., 1979) 
have shown that these antibiotics have a specificity for G -C  
base pairs. Alkaline denaturation o f D N A , to which an- 
thramyom. sibiromycin, or tomaymycin is bound, does not lead 
to loss 01 the drugs from the single-stranded D N A  (Kohn & 
Spears, 1970; Hurley et al., 1977). Therefore, in order to  
determine whether anthramycin is bound to guanine or cy­
tosine, we have denatured the anthramycin-modified homo- 
polymer poly(dG)*poly(dC) under alkaline conditions and 
separated the two strands on a cesium sulfate gradient (see 
'gure 2). The results show that the radioactively labeled  
anthramycin is bound exclusively to the poly(dG ) strand.
b ^ ^ atlon S ite  on Poly(dG ). Since we had shown that 
anthramycin binds exclusively to the poly(dG ) strand of the 
omopolymer poly(dG)*poly(dC), it now remained to pinpoint 
A oca| ‘on on guanine to which anthramycin was attached.
n alkylation assay designed by Tom asz (Tom asz, 1970b) 
as used to determine if alkylation at C-8 or N -7  o f guanine 
I curred upon reaction of anthramycin with D N A . The la- 
* nation of the C-8 proton upon 7-alkylation has been dem- 
s rated previously (Tomasz, 1970a). The results o f our
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f i g u r e  2: Alkaline cesium sulfate gradient on denatured [ 15-3H]- 
anthramycin-poly(dG)*poly(dC). Conditions for preparation of 
[15-3H]anthramycin-poiy(dG>poly(dC), alkaline denaturation, and 
gradient analysis are as described under Experimental Procedures. 
Literature density values (Szybalski & Szybalski, 1970a) for poly- 
(dG)-poly(dC), poly(dG), and poly(dC) are 1.46-1.49. 1.54, and 
1.4(M.42, respectively. The slightly higher density of the anthra- 
mycin-poly(dG) (1.59-1.61) than that of poly(dG) alone may be due 
to the anthramycin modification of the polymer. The small increase 
in cpm in fraction 11 (density = 1.48) coincides with the position of 
undenatured anthramycin-poly(dG)-poly(dC) (data not shown). 
OD260 ( • ) ;  cpm (▼); p (O).
Table I: Release o f Distillable Tritium from





[8-3H]guanine-labeled D N A b (untreated) 0.7
[8-3H]guanine-labeled D N A b + anthramycin0 0.2 *—
[8-3H]guanine-labeled DN A b + A^mustard c 11.4
a Based on an average o f  two experiments. b 5 X 104 dpm o f  a
7.6 pCi/pm ol (nucleotide) solution. c 200 pL o f  a 1 pg/m L solu­
tion.
experiments show that alkylation at either C-8 or N-7 can be 
eliminated from consideration, since insignificant amounts of 
distillable tritium above that found in control experiments were 
found upon in vitro reaction of an amount of anthramycin 
known to produce saturation binding (1:12.5 antibiotic to base 
ratio) with [8-3H]guanine-labeled DNA (Table I). A control 
experiment with nitrogen mustard, which is known to alkylate 
N-7 of guanine (Tomasz, 1970a), showed the expected release 
of distillable tritium (Table I).
Alkylation of N-3 of guanine can also be eliminated since 
anthramycin-modified DNA does not undergo depurination 
(Hurley et al., 1978; Lown & Joshua, 1979) by neutral 
heating, a process known to depurinate N-7 and N-3 alkylated 
guanine (Singer, 1975).
Of the remaining sites on guanine N-2 or 0 -6  is potentially 
accessible in the minor and major groove of DNA, respectively. 
Binding experiments with T-4 phage, which is 100% gluco- 
sylated in the major groove and blocks 0 -6  as a potential 
binding site, have allowed us to distinguish between these 
possibilities. The results (Table II) show that T-4 phage was 
able to bind anthramycin to a final antibiotic to base ratio of 
1:15.5 whereas Clostridium perfringens DNA, which has a 
similar G-C content, produced a binding ratio of 1:13.5.
We therefore can narrow the choice to just one site on 
guanine, i.e., N-2. Supporting evidence for this position for 
alkylation by guanine comes from the unreactivity of poly- 
(dl)-poly(dC), which differs from poly(dG)*poly(dC) in that
f ig u r e  4: CPK space-filling model o f  the (A) anthramycin-, (B) tomaymycin-, (C) sibiromycin-, (D) neothramycin A-, and (E) neothramj 
B-DNA adducts in which anthramycin is attached through C-l 1 to the N-2 group of guanine.
f i g u r e  3: Proposed structure and mechanism for formation of the 
anthramycin-deoxyguanosine adduct in DNA.
i t  la c k s  a  2 - a m in o  g r o u p  o f  g u a n in e  ( K o h n  e t  a l . ,  1 9 7 4 ) ,  th e  
fa c t  th a t  a c t in o m y c in  D , w h ic h  a lso  b in d s  in  th e  n arro w  g r o o v e ,  
p r e v e n ts  a n th r a m y c in  b in d in g  ( K o h n  e t  a l . ,  1 9 7 4 ) ,  a n d  C P K  
m o d e l b u ild in g  s tu d ie s  w h ic h  s h o w  a d d u c t  fo r m a tio n  th r o u g h  
0-6  o f  g u a n in e  is  im p o s s ib le .
( 5 )  D N A  Reactive Group on th e P y r r o lo [ l^ b e n z o ­
diazepine Antibiotics. T h e  o n ly  com m on  p o te n t ia l ly  r e a c t iv e  
g r o u p  o n  a n t h r a m y c in ,  t o m a y m y c in ,  s ib ir o m y c in ,  a n d  th e  
n e o t h r a m y c in s  A  a n d  B 1 is  th e  N - 1 0 ,  C - l l  c a r b in o la m in e .  
F u r th e r  c o n f ir m a to r y  e v id e n c e  th a t  t h e  c a r b in o la m in e  is  th e  
D N A  r e a c t iv e  m o ie ty  is th a t  o x id a t io n  to  th e  a m id e  ( H o r w it z  
e t  a l . ,  1 9 7 1 ;  K a r iy o n e  e t  a l . ,  1 9 7 1 ) ,  r e d u c t io n  to  th e  m e t h -  
y le n a m in e  ( L e im g r u b e r  e t  a l . ,  1 9 6 5 ) ,  o r  d e h y d r a t io n  to  th e  
im in e  in  th e  c a s e  o f  s ib ir o m y c in  ( M e s e n t s e v  e t  a l . ,  1 9 7 4 )  a l l  
le a d  to  lo s s  o f  b io lo g ic a l  a c t iv ity .  In  th e  la t te r  c a s e ,  th e  im in e  
is  c o n ju g a te d  in to  th e  p y r r o lo  r in g  a n d  is  th e r e fo r e  u n r e a c t iv e  
to  n u c le o p h i l ic  a t ta c k . T h e  fa c i le  c o n v e r s io n  o f  a n t h r a m y c in
11- m e t h y l  e th e r  to  th e  tw o  i s o m e r s  o f  a n t h r a m y c in  w h e n  
d is s o lv e d  in  w a te r  is  fu r th e r  e v id e n c e  fo r  th e  h ig h  r e a c t iv i t y  
o f  th is  g r o u p  to  n u c le o p h ilic  a t ta c k . W e  h a v e  su g g e s te d  e a r lie r  
( H u r le y  e t  a l . ,  1 9 7 7 )  t h a t  a n t h r a m y c in  u n d e r g o e s  a  n u c le o ­
p h ilic  a t ta c k  v ia  a  S N l e a  m e c h a n is m  fr o m  s o m e  r e a c tiv e  g r o u p  
( i .e . ,  2 -a m in o  g r o u p  o f  g u a n in e )  o n  D N A  (F ig u r e  3 ) .  L o w n  
h a s  c la im e d  th e  im in e  is th e  m o r e  l ik e ly  D N A  r e a c tiv e  s p e c ie s ,  
b a s e d  m a in ly  u p o n  th e  f a c t  t h a t  th e  N - 1 0  a c e ty l  d e r iv a t iv e  
is  u n r e a c t iv e  to w a rd  D N A  (L o w n  &  J o sh u a , 1 9 7 9 ) . H o w e v e r ,  
th is  is n o t  n e c e s s a r i ly  a v a lid  a r g u m e n t  s in c e  th e  N - 1 0  a c e t y l  
g r o u p  s t e r ic a l ly  p r e v e n ts  a c c e s s  o f  t h e  c a r b in o la m in e  t o  th e
Table II: Saturation Binding o f  [15-3H]Anthramycin to  Calf 
Thymus DNA, T-4 DNA, and Clostridium  perfringens D N A a
binding ratio c 
(m ol o f  drug/ 
% G-C mol o f  DNA) 







a Saturated [15-3H] anthramycin-DNA adducts were prepared by 
incubation o f  1 ^m ol o f  DNA with 4 /amol o f  [15-3H]anthramycin] 
(sp act. = 5 .22 X 10"* ^Ci/Mmol) in 0.1 M SSC (1 mL) for 2 h a t . 
room temperature and overnight at 4 °C. Unbound anthramycin] 
was extracted from anthram ycin-DNA com plex as described 
before (Hurley et al., 1977). bSee Szybalski & Szybalski (1970b? 
c Binding ratios were determined independently by an absorption] 
m ethod (Kohn & Spears, 1970) and a m ixed absorption-radio- 
activity determination (Hurley et aL, 1977), and these values 
differed by more than 4.8%. d 100% glucosylation (70% a- and 
30% 0-glucosyl groups on the hydroxym ethyl derivatives o f  
cytosine) in the major groove o f  DNA (Kornberg, 1962).
e x o c y c l ic  a m in o  g r o u p  o f  g u a n in e .
( 4 ) C P K  S pace-F illing M odels f o r  the D N A  A ddu cts1 
Anthramycin, Tomaymycin, Sibirom ycin, and Neothramycin 
A  and B. T h e  r e s u lt s  d e s c r ib e d  s o  f a r  a l lo w e d  u s  to  pred ic  
w ith  s o m e  a s s u r a n c e  th e  s t r u c tu r e  o f  th e  a n t h r a m y c in -d e o x  
y g u a n o s in e  a d d u c t  ( s e e  F ig u r e  3 ) .  X - r a y  d i f f r a c t io n  stu d ic  
o n  c r y s ta l o f  a n th r a m y c in  m e th y l  e th e r  s h o w  th a t  th e  m o le  
is  t w is t e d  4 0 - 5 0 °  fr o m  o n e  e n d  t o  t h e  o t h e r  a lo n g  th e  lor 
a x is ,  a n d  th is  m ig h t  f i t  in t o  o n e  o f  t h e  g r o o v e s  o f  D I  
( M o s t a d  e t  a l . ,  1 9 7 8 ) .  M o d e l  b u i ld in g  w ith  C P K  m o le c i  
m o d e ls  o f  D N A  a n d  a n t h r a m y c in  in  th e  p u b l is h e d  c r y s t  
c o n f o r m a t io n  d e m o n s t r a t e d  t h a t  a d d u c t  f o r m a t io n  th rou g  
N - 2  o f  g u a n in e  a n d  C - l l  o f  a n t h r a m y c in  p r o d u c e s  a  
m a r k a b ly  s n u g  f i t  (H u r le y  &  P e tr u s e k ,  1 9 7 9 ) .  In  th is  m e  
th e  a n t h r a m y c in  m o le c u le  is  a t t a c h e d  th r o u g h  C - l l  to  
o f  g u a n in e  b y  a n  a m in a l  l in k a g e  a n d  l ie s  a lo n g  t h e  narro
p Y R R O L O [  1 , 4 ]  B E N Z O D I A Z E P I N E  A N T I B I O T I C S
groove of D N A  (Figure 4A ). The model has been extended 
to include the tomaymycin, sibiromycin, and neothramycin 
A and B adducts (Figure 4B-E) (Hurley et al., 1980). In each 
of these CPK models, the drug Fits snugly within the narrow 
groove without distortion of the helix. The bulky amino sugar 
of sibiromycin is the only part o f any o f the antibiotics which 
e x t e n d s  outside the groove of D N A  (Figure 4C).
The CPK models predict hydrogen-bonding stabilization 
through both protons at N -10  and C-9 anthramycin and si­
biromycin. With the exception of sibiromycin, the N -10 proton 
of each of the antibiotics should be hydrogen bonded to the
2-keto group of thymine or cytosine or N - l  o f guanine or 
adenine in the adjacent base pair on the same strand to which 
the drug is covalently bound. The replacement of the common 
sp3 carbon atom at C -l la  in anthramycin, tomaymycin, and 
the neothramycins by an sp2 carbon atom in sibiromycin should 
affect the conformation of the seven-membered ring such that 
the N-10 proton hydrogen bonds to the 2-keto group in cy­
tosine in the same base pair to which the drug is covalently 
bound. The phenolic proton at C-9 o f anthramycin should be 
hydrogen bonded to the 2-keto group in cytosine in the same 
base pair to which the drug is covalently bound whereas the 
equivalent proton in sibiromycin should be hydrogen bonded 
to the 2-keto group of thymine or cytosine or N - l  o f guanine 
or adenine in the adjacent base pair on the same strand to 
which the drug is covalently bound. In the case of tomaymycin 
and the neothramycins, hydrogen-bond stabilization occurs 
through the N -10 proton in an analogous manner to that o f  
anthramycin. In sibiromycin, the am ino sugar may further 
stabilize the adduct by interaction with the deoxyribose 
phosphate backbone of D N A .
( B) Evidence Which Supports the Proposed Structures o f  
the Pyrrolo[l,4]benzodiazepine Antibiotic-D N A  Adducts. 
For substantiation of our proposed structures o f the various 
drug-DNA adducts, predictions made from the CPK models 
were tested experimentally. In all cases, the experimental data 
support our proposed CPK models for the pyrrolo[l,4j- 
benzodiazepine-DNA adducts.
( /)  Stability o f  the Drug-DNA Adducts. According to our 
models, the drugs are held to D N A  by an aminal linkage plus 
secondary hydrogen-bonding stabilizing forces as previously 
described. As the aminal linkage is only stable when the 
exocyclic amine cannot be protonated (i.e., alkaline conditions), 
then in the absence of the secondary stabilizing forces (hy­
drogen bonding), the drugs should be released from their D N A  
adducts. We have previously shown that the anthramycin-, 
tomaymycin-, and sibirom ycin-D N A  adducts are unstable 
under v Hic conditions in which denaturation of D N A  occurs 
(Hurley et al., 1977). However, the d ru g-D N A  adducts are 
reasonably stable at neutral and alkaline conditions, even at 
alkaline pHs at which denaturation occurs (Hurley et al.,
1977). Significantly, the stability under acidic conditions 
increases in the order tomaymycin, anthramycin, and sibiro­
mycin, which follows the order of increases in the A Tm values 
°* each of the DN A  adducts, a pattern which can be predicted 
®n the basis of the number of secondary hydrogen-bonding 
interactions in our CPK models o f the various drug-D N A  
adducts.
. Although the anthramycin- and sibirom ycin-DN A adducts 
very stable at neutral pH at temperatures below the 
 ̂ e l*ng point of their D N A  complexes, at temperatures in
cess of their melting points rapid loss o f  drug occurs from 
n̂e complexes (Hurley et al., 1979b; L. H. Hurley and R. L. 
unPubl'shed experiments). The tom aym ycin-DNA  
Uct is less stable to neutral conditions, presumably due to
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its lower inherent hydrogen-bonding stabilization, but again 
this adduct is unstable to temperatures above the melting point 
of the drug-DNA complex (L. H. Hurley and R. L. Petrusek, 
unpublished experiments). Finally, we have demonstrated that 
enzymatic denaturation of DNA with DNase and venom 
phosphodiesterase at 37 °C leads to release of intact anthra­
mycin (Hurley et al., 1979b).
Irrespective of whether acidic, thermal, or enzymatic con­
ditions lead to denaturation of DNA and loss of radiolabeled 
product from the 3H-labeled drug-DNA adducts, we have 
demonstrated by chromatography that the released material 
is unchanged antibiotic.
Whereas acid denaturation of DNA leads to complete re­
lease of anthramycin, tomaymycin, or sibiromycin from DNA, 
both heat and enzymatic degradation appear to lead to in­
complete release, based upon butanol extraction procedures. 
The apparent incomplete loss in the case of thermal or enzy­
matic denaturation (37 °C for 8 h) we feel is most likely due 
to the extreme chemical instability of free anthramycin. We 
cannot, however, completely rale out at this time a minor 
adduct between these drugs and guanine which is acid labile 
but stable to heat and enzymatic degradation in addition to 
the major adduct described in this paper.
(2) Sa tura tion  Binding o f  th e D ru g -D N A  A ddu cts. Ac­
cording to our CPK models, the binding of anthramycin and 
releated drugs to DNA covers three base pairs. With the 
assumption of a random distribution of guanine, occurring at 
a frequency of 21.5% in calf thymus DNA, then a statistical 
analysis of binding sites shows that a maximum of 69.3% of 
the bases will be covered by anthramycin; i.e., the maximum 
binding ratio will be about 1:9.6. In practice, at maximum 
binding the sibriomycin, anthramycin, and tomaymycin drug 
to base ratios are 1:8.8,1:12.9, and 1:18.2, respectively (Hurley 
et al., 1977). The sibiromycin/base ratio is almost exactly 
what we would predict, while the somewhat lower binding of 
anthramycin and tomaymycin may be due to the more critical 
conformational selectivity of these drugs toward DNA, com­
pared to sibiromycin.3
(3) Effect o f  Drug Binding on the S tructure o f  D N A . One 
of the most attractive features of our CPK models of the 
various drug-DNA adducts is that the covalent binding does 
not require any distortion of DNA, unlike DNA adducts with 
such compounds as AAAF, BMBA, and intercalating agents. 
Furthermore, with the exception of the amino sugar of sibi­
romycin, no protrusion of any of the drug molecules outside 
the helix is predicted. In order to probe the modified DNA 
for distortion, S[ nuclease digestions and benzoylated, na- 
phthoylated DEA£-cellulose (BND-cellulose) chromatography 
were carried out. The S! nuclease results (Hurley & Petrusek, 
1979; Hurley et al., 1980) on the anthramycin-, tomaymycin-, 
sibiromycin-, and neothramycin-DNA adducts show that this 
enzyme was unable to reveal any regions of distortion in the 
drug-modified DNA, and, in fact, release of nucleotides was 
inhibited with increasing amounts of drug modification. The 
BND-cellulose chromatography results with anthramycin 
(Hurley & Petrusek, 1979) and sibiromycin (L. H. Hurley 
and R. L. Petrusek, unpublished experiments) demonstrated 
lack of any single strandedness of DNA induced by these 
drugs. Although the amino sugar of sibiromycin protrudes 
outside the DNA helix according to our CPK models, this did
3 According to our CPK models, the 11a sp3 carbon atoms of an­
thramycin, tomaymycin, and neothramycins dictate a closer and snugger 
fit along the narrow groove of D N A  than the equivalent sp2 carbon in 
sibiromycin, and this may explain their somewhat lower reactivity toward 
D N A . '
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fig u r e  5: Time-course binding o f  anthramycin to calf thymus DNA, 
poly(dG)-poly(dC), and poly(dG-dC)-poly(dG-dC). [15-3H]- 
Anthramycin (sp act. = 2.63 ^ C i/M m o l) in the amount of 7.80 X 1(T2 
mM was added to 4.5 mL of a 5 X 10~5 M solution of DNA of synthetic 
polydeoxynucleotide in SSC buffer (pH 7.2) at 23 °C. Aliquots (0.2 
mL) of the reaction mixture were removed at various intervals, diluted 
into 0.8 mL of water, and rapidly extracted twice with 2 X 1 mL of 
water-saturated 1-butanol to remove unreacted antibiotic, and a 
0.5-mL aliquot was removed from the aqueous layer for radioactivity 
determination.
n o t  c a u s e  th e  s ib ir o m y c i n - D N A  a d d u c t  to  a d h e r e  to  th e  r es in .
(4) Unwinding and S tra n d  B reakage o f  SV -40 D N A  in 
Vitro. O u r  C P K  m o d e ls  p r e d ic t  n o  u n w in d in g  o r  s tr a n d  
b r e a k a g e  in  v itr o  o f  th e  d r u g - m o d if ie d  D N A .  C o v a le n t ly  
c lo se d  s u p e r h e lic a l D N A  s u c h  a s  S V - 4 0  F I  D N A  is  a  s e n s it iv e  
p r o b e  for  d e te c t io n  o f  s in g le -  a n d  d o u b le -s tr a n d  sc is s io n  a s  w e ll  
a s  a m e a n s  to  m o n it o r  u n w in d in g  o f  D N A .  A  s in g le - s t r a n d  
b r e a k  p e r m its  th e  D N A  s t r a n d s  t o  u n w in d , r e s u lt in g  in  th e  
r e la x e d  F I I  D N A .  I n tr o d u c t io n  o f  a n o th e r  b r e a k  a d j a c e n t  to  
th e  first, b u t on  th e  o p p o s ite  s tr a n d , g iv e s  th e  lin ea r  F i l l  D N A .
B in d in g  o f  a n t h r a m y c in  t o  S V - 4 0  D N A  u p  to  m a x im u m  
d r u g  to  b a s e  r a t io s  o f  1 :1 2 5  d id  n o t  p r o d u c e  a n y  in c r e a s e  in  
th e  p r o p o r tio n  o f  S V - 4 0  F I I  D N A  o r  S V - 4 0  F i l l  D N A  o v e r  
th e  u n tr e a te d  c o n tr o l  ( H u r le y  e t  a l . ,  1 9 7 8 ) .  T h e  a b s e n c e  o f  
in te r m e d ia te  b a n d s  b e t w e e n  S V - 4 0  F I  a n d  F I I  D N A  o n  th e  
g e l  e l im in a t e s  th e  p o s s ib i l i t y  th a t  a n t h r a m y c in  c a u s e s  h e l ix  
u n w in d in g  o f  D N A .  S im i la r  r e s u lt s  h a v e  b e e n  o b ta in e d  w ith  
s ib ir o m y c in  ( K o z m y a n  e t  a l . ,  1 9 7 8 ) .
( 5 )  Sensitivity o f  the Secondary Structure o f  DN A to Drug  
Binding. T h e  C P K  s p a c e - f i l l i n g  m o d e ls  o f  th e  v a r io u s  p y r -  
r o l o [ l , 4 ] l b e n z o d i a z e p i n e - D N A  a d d u c t s  s h o w  th a t  th e  d r u g s  
f i t  v e r y  s n u g ly  in to  th e  n a r r o w  g r o o v e  o f  D N A .  T h e  r ig h t -  
h a n d e d  tw is t  o f  a n t h r a m y c in ,  t o m a y m y c in ,  a n d  t h e  n e o -  
th r a m y c in  m o le c u le s  fo l lo w s  th e  c o n to u r  o f  th e  n a r r o w  g r o o v e  
s o  c lo s e ly  th a t  i t  a lm o s t  a p p e a r s  t h a t  th e  d r u g s  w e r e  t a i lo r -  
m a d e  to  a c c o m m o d a t e  s p e c i f ic a l ly  to  D N A  in  th e  B  fo r m  a s  
a  m o le c u la r  ta r g e t .  I t  is  t h e r e f o r e  a n t ic ip a t e d  th a t  th e  d r u g s  
w ill  sh o w  a h ig h  s p e c i f ic i t y  fo r  D N A  in  th e  c o r r e c t  c o n f i g u ­
r a t io n a l  fo r m  a n d  m ig h t  e v e n  h a v e  s e q u e n c e  p r e f e r e n c e s  i f  
th e s e  d i f f e r e n t  s e q u e n c e s  p r o d u c e d  lo c a l  r e g io n s  o f  s l ig h t ly  
c h a n g e d  s e c o n d a r y  s tr u c tu r e  in  D N A .  K o h n  a n d  c o -w o r k e r s  
h a d  sh o w n  e a r l ie r  th a t  a n t h r a m y c in  s h o w s  a  s t r ic t  s p e c i f ic i t y  
fo r  D N A  o r  d e o x y g u a n o s in e  in  a  d o u b le - s t r a n d e d  t e m p la t e  
(K o h n  e t  a l .,  1 9 7 4 ) .  W e  h a v e  e x t e n d e d  th e s e  r e s u lts  to  c o m ­
p a r e  th e  r e a c t iv ity  o f  p o ly ( d G ) * p o ly ( d C )  a n d  p o ly (d G -d C )*  
p o ly (d G -d C )  w ith  c a l f  t h y m u s  D N A  in  fo r m  B . T h e  r e s u lt s  
(F ig u r e  5 )  sh o w  th a t a n th r a m y c in  h a s  a  m u c h  h ig h e r  r e a c t iv ity  
to w a r d  p o ly ( d G ) * p o ly ( d C )  a n d  l in e a r  D N A  th a n  to w a r d
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p o ly ( d G - d C ) * p o ly ( d G - d C ) .  S i g n i f i c a n t l y ,  in  th e  c a s e  q 
p o ly (d G -d C )* p o ly (d G -d C ) , a f t e r  e x te n d e d  p e r io d s  o f  t im e  (2  
h ) ,  th e  f in a l  e x t e n t  o f  b in d in g  w a s  a lm o s t  e x a c t ly  o n e - h a l f  <j 
th a t  o f  t h e  h o m o c o p o ly m e r  o r  c a l f  t h y m u s  D N A  [ i .e . ,  an t]  
b i o t i c / b a s e  r a t io  1 :2 5  fo r  p o ly ( d G - d C ) * p o ly ( d G - d C )  v s . 1:L 
a n d  1 :1 2 .5  fo r  th e  h o m o c o p o ly m e r  a n d  c a l f  t h y m u s  D N A  
r e s p e c t i v e ly ] .  A n t h r a m y c in ,  t o m a y m y c in ,  a n d  t h e  neq  
th r a m y c in s  h a v e  tw o  p h a s e s  o f  r e a c t io n  w ith  D N A ,  a n  in itia  
f a s t  r e a c t io n  w h ic h  ta k e s  p la c e  o v e r  a  2 0 - 5 0 - m i n  p e r io d  foj 
lo w e d  b y  a  s lo w e r  s e c o n d  p h a se  w h ic h  ta k e s  u p  to  2 4  h  to  reacl 
sa tu r a tio n  b in d in g  u n d e r  th e  c o n d it io n s  d e s c r ib e d  in  th e  legem  
to  F ig u r e  5 . W e  f e e l  th is  m a y  v e r y  w e l l  r e p r e s e n t  b in d in g  $  
g u a n in e s  in  a t  le a s t  tw o  d i f f e r e n t  s e q u e n c e s .  In  th e  c a s e  o  
th e  fa s t  r e a c t io n ,  th is  m a y  b e  r e a c t io n  o f  a n t h r a m y c in  w it] 
a  G - G  s e q u e n c e ,  s u c h  a s  o c c u r s  in  p o ly ( d G ) * p o ly ( d C ) ,  w hic] 
p r o c e e d s  m u c h  m o r e  r a p id ly  th a n  w ith  th e  G -C  se q u e n c e  founi 
in  p o ly (d G -d C )* p o ly (d G -d C ) . T h e  s lo w  r e a c t io n  th e n  consis?  
o f  r e a c t io n  o f  a n t h r a m y c in  w ith  t h e  s e q u e n c e  G - X  ( X  ma; 
b e  C , A ,  o r  T ) .  S u p e r im p o s it io n  o f  t h e  f a s t  ( G - G  s e q u e n c |  
a n d  s lo w  ( G - x  s e q u e n c e )  r e a c t io n s  th e n  le a d s  t o  th e  d e c r e a s  
in  th e  e x p o n e n tia l r ea c tio n  fo u n d  in  n a t iv e  D N A .  T h e s e  result 
s u g g e s t  th a t  d i f f e r e n t  b a s e  s e q u e n c e s  o c c u r r in g  in  D N A  lea< 
to  s l ig h t ly  d if fe r e n t  r e g io n a l c o n f ig u r a t io n a l  fo r m s , w h ic h  cai 
b e  d is t in g u is h e d  b y  d r u g s  s u c h  a s  a n t h r a m y c in  w h ic h  f it  ver] 
s n u g ly  a lo n g  a  c o n to u r  o f  D N A .
X - r a y  d i f f r a c t io n  p a t te r n s  o n  f ib e r s  o f  p o ly (d G )* p o ly (d C ]  
( A r n o t t  &  S e is in g ,  1 9 7 4 )  a n d  p o ly (d G -d C )* p o ly (d G -d C ]  
( A r n o t t  e t  a l . ,  1 9 7 4 )  s h o w  t h a t  b o t h  s p e c i e s  h a v e  m o le cu la j  
s tr u c tu r e s  r a th e r  d if fe r e n t  fr o m  c la s s ic a l  D N A  fo r m s  a n d  als< 
fr o m  o n e  a n o th e r .  T h e  p o ly ( d G ) * p o ly ( d C )  h a s  a  p referen ce  
fo r  th e  A  c o n fo r m a tio n  (w h ic h  h a s  th e  C 3 - e n d o fu r a n o s e  ring] 
w h i le  th e  p o ly ( d G - d C ) * p o ly ( d G - d C )  p r o d u c e s  a  d iffra c tio n  
p a t te r n  c a l l e d  D - D N A ,  w ith  e ig h t  r e s id u e s  p e r  tu r n . M art 
r e c e n t  r e s u lt s  o n  p o l y ( d G - d C ) * p o ly ( d G - d C )  b y  X - r a y  dif­
f r a c t io n  o f  o r ie n ta t e d  f ib e r s  ( A r n o t t  e t  a l . ,  1 9 8 0 )  a n d  o n  the 
fr a g m e n t  d (C p G p C p G p C p G ) b y  X - r a y  d if fr a c t io n  o f  a  crystal 
( W a n g  e t  a l . ,  1 9 7 9 )  h a v e  s h o w n  t h a t  t h e s e  fo r m s  ex istjin  
le ft-h a n d e d  D N A  h e lic e s  ( Z - D N A ) .  In  v ie w  o f  th e se  m arkedlj 
d i f f e r e n t  m o le c u la r  s t r u c tu r e  fo r  p o ly ( d G ) * p o ly ( d C )  and 
p o ly ( d G - d C ) * p o ly ( d G - d C ) ,  i t  is  n o t  s u r p r is in g  t h a t  a n th ra­
m y c in  sh o w s  s ig n if ic a n t ly  d if fe r e n t  r e a c t io n  k in e t ic s  w ith  these 
tw o  fo r m s. S tu d ie s  w ith  o th e r  d r u g s  h a v e  o th e r  characteristics; 
fo r  e x a m p le ,  w h i le  m it o m y c in  C  b in d s  e q u a l ly  w e l l  to  poly* 
(d G )* p o ly (d C )  a n d  p o ly (d G -d C )* p o ly (d G -d C )  (L ip m a n  et a l,
1 9 7 8 ) ,  a c t in o m y c in  D  b in d s  a p p r e c ia b ly  b e tte r  to  D N A s  which 
c o n ta in  b o th  p u r in e s  a n d  p y r im id in e s  in  b o t h  s tr a n d s  (W eU f  
1 9 6 9 ;  W e l ls  &  L a r s o n , 1 9 7 0 ) .  T h e  f a c t  t h a t  th e r e  a r e  obvi­
o u s ly  s e q u e n c e  s p e c i f ic i t i e s  d u e  e i t h e r  to  d ir e c t  b a s e - d ™  
in te r a c t io n s  o r  to  th e  e f f e c t  o f  b a s e  s e q u e n c e  o n  th e  co n fig u ­
r a t io n  o f  D N A  m a y  b e  im p o r ta n t  in  u n d e r s t a n d in g  the 
m e c h a n is m  o f  a c t io n  o f  t h e s e  c o m p o u n d s .
D u r in g  th e  c o u r s e  o f  o u r  e x p e r im e n t s  w i t h  c lo se d -c ir cu E u  
s u p e r c o ile d  S V - 4 0  F I  D N A  to  e x a m in e  in t e r c a la t io n  as * 
p o ss ib le  m e c h a n is m  fo r  d r u g  b in d in g , w e  d isc o v e r e d  th e  S V #  
^ F I  D N A  h a d  a  m u c h  lo w e r  r e a c t iv i t y  t o w a r d  a n t h r a m y f  
th a n  S V - 4 0  F i l l  D N A  ( s e e  F ig u r e  6) .  S e v e r a l  e x p la n a t io  
fo r  t h e  lo w e r  r e a c t iv ity  o f  a n t h r a m y c in  t o  s u p e r c o i le d  D I  
v s . l in e a r  D N A  c a n  b e  p r o p o s e d . H o w e v e r ,  w e  w o u ld  lik ?  
s u g g e s t  t h a t  th e  to r s io n a l  s tr e s s  in  s u p e r c o i le d  D N A  w h i$  
c a n  in d u c e  h e lix  c o il  tr a n s it io n s  ( V in o g r a d  e t  a l . ,  1 9 6 8 ;  Burk5 
&  B a u e r , 1 9 8 0 ) ,  w h ic h  m o v e  u p  a n d  d o w n  th e  m a c r o m o le c u |e 
b e t w e e n  G - C - r i c h  a r e a s ,  m a y  r e d u c e  a n t h r a m y c in  b in d in g  
T h e  s lo w n e s s  o f  th e  r e a c t io n  o f  a n t h r a m y c in  w ith  D N A ]r e]-  
a t iv e  to  th e  h e l ix  c o i l  tr a n s it io n  o r , a l t e r n a t iv e ly ,  th e  m e l  
a n d  u n z ip p in g  o f  lo n g  le n g t h s  o f  D N A  m a y  r e s u l t  in
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f i g u r e  6: Time-course binding of [ 15-3H]anthramycin to SV-40 FI 
and Fill DNA. [ 15-3H] Anthramycin (sp act. = 86.6 mC\/nmo\) in 
the amount of 4.45 X 10"3 mM in 10 nL  or 0.6 X 10-3 /xM in 59 mL 
o f  methanol was added to 1.2 Mg in 287 mL (SV-40 FI DNA) or 1.2
in 1.2 mL (SV-40 F ill DNA) in 0.1 M SSC and 2 mM EDTA 
buffer, pH 8, at 23 °C. At various times, aliquots of the reaction 
mixtures were removed and extracted twice with twice the volume 
of HiO-saturated n-BuOH. Half of the aqueous phase was then 
e l e c t 'ophoresed and assayed for anthramycin binding as described 
unuc Experimental Procedures.
already bound anthramycin molecules and would explain our 
results. We cannot, however, exclude other possibilities such 
as changes in the rotation angle o f the D N A  helix (Upholt 
et al., 1971), distortion due to bending under torsional stress 
(Bauer & Vinograd, 1970), or even regions of Z -D N A  (Davies 
& Zimmerman, 1980) in supercoiled D N A .
(6) Physical Properties o f  the A n th ram ycin -D N A  Adduct. 
The physical properties o f  drug-m odified D N A  should be 
pred; "able from the CPK models o f  the pyrrolo[l,4]benzo- 
diazepm e-DNA adducts. According to our CPK models, 
saturation binding of the pyrrolo[ 1,4] benzodiazepine antibiotics 
to D N A  results in the formation of an “artificial third strand” 
within the narrow groove of D N A  m ade up of end-to-end 
antibiotic molecules. The most obvious effect o f this type of 
binding would be stiffening, without causing lengthening, o f  
the helix. Therefore, increases in the viscosity of high mo­
lecular weight D N A  at a relatively high degree o f binding 
would be anticipated. On the other hand, low molecular 
weig; l D N A , which already exists in short rodlike structures, 
will r.ct be expected to undergo viscosity increases upon an­
thramycin binding. These anticipated results are exactly 
mimicked in practice (G laubiger et al., 1974). These same 
authors did not report any significant changes in the sedi­
mentation of either low or high molecular weight D N A  upon 
binding of anthramycin, which they state argues against any 
lengthening effect of drug binding. This is also in accord with 
our proposed CPK model.
Direct measurements from our CPK  model show that the 
angle of the chromophore of anthramycin is inclined at 45-55°  
relatr-e to the helix axis. Electric dichroism  measurements 
reported by Glaubiger et al. (1974) indicate the chromophore 
is inclined less than 54.7° and at an angle o f approximately 
36° relative to the helix axis, which is in reasonable agreement 
with our model.
(7) Hydrogen Bonding o f  the 9-P henolic Proton o f  An­
thramycin. Examination o f the C PK  m odels o f the anthra- 
naycin-DNA adduct reveals that the phenolic group at C-9 
•s hydrogen bonded to the 2-keto group of cytosine in the same 
hase pair to which the drug is covalently attached. It would 
theref re be anticipated that this phenolic hydroxy proton 
wouic not be available for titration when the drug is bound 
to DN'A. In practice, pH titration curves for the anthramy- 
oin-D N A  adduct (Kohn et al., 1974) dem onstrate that the 
Phenolic proton is absent. Circular dichroism (C D ) mea- 
SUrements on anthramycin and its adduct with native and 
denatured DN A  reveal some pertinent results, related to the 
absence or presence of the phenolic hydroxy proton (Glaubiger
e t  a l .,  1 9 7 4 ) .  B y  c o m p a r iso n  o f  th e  C D  sp e c tr a  o f  a n th r a m y c in  
a t  p H  1 0 .3 ,  w h ic h  w o u ld  b e  n th e  d e p r o to n a te d  fo r m  (pA^a =  
8 . 7 ) ,  w i t h  t h o s e  o f  th e  D N A  a d d u c t ,  t h e s e  a u t h o r s  c o n c lu d e  
th a t  a n th r a m y c in  is in  th e  h ig h -p H  or  d e p r o to n a te d  fo r m  w h e n  
c o m p le x e d  to  D N A .  E q u a l ly  im p o r ta n t  is  t h a t  e x a m in a t io n  
o f  th e  p u b l is h e d  C D  s p e c tr a  o f  a n t h r a m y c in  b o u n d  to  d e n a ­
tu r e d  D N A  s h o w s  t h a t  in  th is  c a s e  th e  a n t h r a m y c in  a p p e a r s  
t o  h a v e  p a r t ia l ly  r e v e r te d  to  th e  p r o to n a te d  fo r m . T h is  a g a in  
i s  p r e c is e ly  w h a t  w o u ld  b e  p r e d ic te d  fr o m  o u r  C P K  m o d e ls ,  
s in c e  in  th e  d e n a t u r e d  fo r m  th e  d r u g  is  b o u n d  o n ly  t o  o n e  
s t r a n d  a n d  t h e  s e c o n d a r y  h y d r o g e n -b o n d in g  in t e r a c t io n  b e ­
t w e e n  th e  p h e n o l ic  h y d r o x y  p r o to n  a n d  t h e  2- k e t o  g r o u p  o n  
c y t o s i n e  o n  th e  o p p o s i t e  s t r a n d  w o u ld  b e  a b s e n t .
(8) Structure-Activity Relationships for Derivatives o f the 
Pyrrolo[l,4]benzodiazepine Antibiotics. A n  im p o r t a n t  c o n ­
s e q u e n c e  o f  o u r  C P K  m o d e l  is  th e  p r e d ic t io n  o f  s t r u c t u r e -  
a c t iv i t y  r e la t io n s h ip s  fo r  d e r iv a t iv e s  o f  t h e  p y r r o l o [ l , 4 ] -  
b e n z o d ia z e p in e  a n t ib io t ic s .  F o r t u n a te ly ,  a  n u m b e r  o f  d e r iv ­
a t iv e s  o f  a n t h r a m y c in ,  t o m a y m y c in ,  s ib ir o m y c in ,  a n d  th e  
n e o t h r a m y c in s  a r e  a v a i la b le ,  w h ic h  h a v e  b e e n  e v a lu a t e d  fo r  
t h e ir  a b i l i t y  t o  r e a c t  w i t h  D N A .  M o s t  i m p o r t a n t ly ,  t h e s e  
d e r iv a t iv e s  in  s o m e  c a s e s  b e a r  o n ly  m in o r  c h a n g e s  in  s tr u c tu r e  
( e .g . ,  i s o m e r ic  f o r m s )  b u t  s h o w  d r a s t ic  d i f f e r e n c e s  in  th e ir  
a b i l i ty  to  r e a c t  w ith  D N A .  T h e  e x p e r im e n ta l  r e s u lt s  r e p o r te d  
in  th is  s e c t io n  f i t  p r e c is e ly  a n d  w it h o u t  e x c e p t io n  in to  o u r  
p r o p o s e d  C P K  m o d e ls ,  s u p p ly in g  c o m p e ll in g  e v id e n c e  fo r  o u r  
p r o p o s e d  s t r u c t u r e s  fo r  t h e s e  D N A  a d d u c t s .
( 0  Substituents on the Aromatic Ring. A c c o r d in g  to  o u r  
p r o p o s e d  m o d e ls ,  s u b s t i tu e n t s  a t  C -9  p o in t  d ir e c t ly  in  to w a r d  
t h e  n a r r o w  g r o o v e  o f  D N A  w h e r e a s  s u b s t i tu e n t s  a t  C -6, C - 7 ,  
o r  C -8 p o in t  a w a y  f r o m  th e  g r o o v e  a n d  t h e r e f o r e  s h o u ld  n o t  
a f f e c t  d r u g  b in d in g .  In  p r a c t ic e ,  th e  b u lk y  a m in o  s u g a r  o f  
s ib ir o m y c in  a t  C -7  d o e s  n o t p r e v e n t b in d in g  to  D N A  a n d  m a y  
in  f a c t  s t a b i l i z e  t h e  a d d u c t  b y  h y d r o g e n  b o n d in g  t o  t h e  d e -  
o x y r ib o s e  p h o s p h a t e  b a c k b o n e  o f  D N A .  A c c o r d i n g  to  o u r  
C P K  m o d e l ,  th e  p h e n o l ic  g r o u p  a t  C - 9  o f  a n t h r a m y c in  a n d  
s ib ir o m y c in  is  s t e r i c a l ly  a l lo w e d  a n d  s h o u ld  in  f a c t  s t a b i l i z e  
t h e  a d d u c t  d u e  to  h y d r o g e n  b o n d in g . T h is  m a y  b e  o n e  o f  th e  
r e a so n s  w h y  th e  s ib ir o m y c in -  a n d  a n t h r a m y c in - D N A  a d d u c ts  
a r e  m o r e  s ta b le  th a n  th e  t o m a y m y c in -  or  n e o t h r a m y c i n - D N A  
a d d u c t ,  w h ic h  la c k s  a  p h e n o lic  g r o u p  a t  C - 9 .  T h e  9 - m e t h o x y  
d e r iv a t iv e s  o f  a n t h r a m y c in  a n d  s ib ir o m y c in  d o  n o t  r e a c t  w ith  
D N A  a n d  a r e  b i o lo g ic a l ly  u n r e a c t iv e  ( H o r w i t z  e t  a l . ,  1 9 7 1 ;  
S t e f a n o v ic ,  1 9 6 8 ;  K o z m y a n  e t  a l . ,  1 9 7 7 ) ,  w h ic h  is  p r e d ic ta b le  
fr o m  a  C P K  m o d e l  s in c e  th e  m e th o x y  g r o u p  a t  C - 9  is to o  la r g e  
to  b e  a c c o m m o d a t e d  w ith in  th e  n a r ro w  g r o o v e  o f  D N A  w ith  
c o n c o m i t a n t  b o n d  f o r m a t io n .
(//) Substituents on the Carbinolamine Group. T h e  C P K  
m o d e ls  sh o w  th a t  th e  c a r b in o la m in e  g r o u p  o f  a l l  th e  a n t ib io t ic s  
is  in  d ir e c t  c o n t a c t  w i th  th e  in s id e  o f  th e  n a r r o w  g r o o v e .  
T h e r e fo r e , a s  e x p e c te d , th e  A - a c e t y l  d e r iv a tiv e  o f  a n th r a m y c in  
d o e s  n o t  r e a c t  w i t h  D N A  ( L o w n  &  J o s h u a ,  1 9 7 9 ) .  A s  p r e ­
v io u s ly  d e sc r ib e d  in  th is  p a p e r , v a r ia t io n s  o n  th e  c a r b in o la m in e  
s t r u c t u r e ,  s u c h  a s  a n  a m id e ,  m e t h y le n a m in e ,  o r  im in e  in  t h e  
c a s e  o f  s ib ir o m y c in  a n d  l . l la - d id e h y d r o a n h y d r o a n t h r a m y c in  
(M a lh o t r a  e t  a l . ,  1 9 8 1 ) ,  a r e  u n r e a c t iv e  to w a r d  D N A  b e c a u s e  
th is  is  th e  a lk y la t io n  g r o u p  o n  th e  p y r r o lo [  1 ,4 ] b e n z o d ia z e p in e  
a n t ib io t ic s  (H u r le y , 1 9 7 7 ;  L o w n  &  J o sh u a , 1 9 7 9 ) .  1 1 - O A lk y l  
s u b s t itu e n ts  su c h  a s  in  th e  11- m e th o x y  o r  11-e th o x y  d e r iv a tiv e s  
o f  a n t h r a m y c in  w i l l  r e a c t  w ith  D N A ;  h o w e v e r ,  t h e s e  g r o u p s  
a r e  lo s t  e ith e r  d u r in g  th e  r e a c t io n  w ith  D N A  o r  p r io r  to  th is  
r e a c t io n  b y  h y d r o ly s i s  in  a q u e o u s  m e d ia .
(Hi) Stereochemistry at C- l l a  o f Anthramycin, Tomay­
mycin, and Neothramycins A and B. T h e  s t e r e o c h e m is t r y  a t  
C - l  l a  o f  th e s e  a n t ib io t ic s  d e te r m in e s  w h e th e r  th e  d r u g s  h a v e
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a right- or left-handed twist along the length of the molecules 
(Mostad et al., 1978). Since the correct configuration is 
required to follow the right-handed twist of DNA in the B 
form, then only those molecules having the lla -R  configu­
ration should, according to our model, react with DNA. As 
anticipated, the only naturally occurring forms of the pyrro- 
lo[ 1,4]benzodiazepine antibiotics to be isolated are the lla -R  
isomers.
(iv) Substituents on the Pyrrolo Ring. The pyrrolo ring has 
various degrees of unsaturation in tomaymycin and neo- 
thramycins (none), anthramycin (one), and sibiromycin (two). 
Where sp3 carbon atoms exist at C-2 or C-3, then the ster- 
oechemistry of the substituents becomes an important factor 
in determining whether the drugs will react with DNA. 
Substituents at C-2 and C-3 which point toward the inside of 
the groove can only be accommodated if they are small. On 
the other hand, substituents at C-2 and C-3 can be much 
larger, providing they project away from the narrow groove. 
Derivatives in which there are substituents other than hy­
drogens at C-l should not react with DNA; however, these 
are not available, and, therefore, speculations remain untested 
for these cases. However, in the case of C-3, an ideal series 
of compounds have been prepared and tested for reactivity 
toward DNA. These are the isomeric neothramycins A and 
B and their 3-methoxy and -butoxy derivatives which have 
been tested by Maruyama et al. (1979), using fluorescence 
enhancement meausurements, for their ability to bind the calf 
thymus DNA. Individual members of the three isomeric pairs 
show surprisingly different DNA binding abilities, such that 
while neothramycin A binds more strongly to DNA than do 
neothramycin B and its 3-methoxy and 3-butoxy derivatives, 
the 3-methoxy and 3-butoxy derivatives of neothramycin A  
do not bind to DNA. Reassuringly, this is precisely what 
would be predicted from the CPK models of the neothramycin 
A and B adducts, since only in the case of neothramycin A 
is hydrogen bonding between the 3-hydroxy proton and 0-1 ' 
of the deoxyribose phosphate backbone of DNA possible. This 
explains the stronger binding of neothramycin A relative to 
neothramycin B and its derivatives. Furthermore, steric 
hindrance due to methylation or butylation of neothramycin 
A at position 3 prevents only these derivatives of this isomer 
of neothramycin from binding to DNA.
The presence of an sp2 carbon atom at C-2 of anthramycin, 
tomaymycin, and sibiromycin projects substituents at this 
position directly along the narrow groove of DNA. Therefore, 
the ethylidene, propylidene, and acrylamide side chains of 
tomaymycin, sibiromycin, and anthramycin do not prevent 
drug binding to DNA, and it is possible that the amide protons 
may help stabilize the anthramycin-DNA adduct by hydrogen 
bonding to base pairs one or two removed from the point of 
covalent attachment. ■ ^
(9) Biological Consequences o f  DNA Damage by the 
Pyrrolo[l,4]benzodiazepine Antibiotics. The in vitro studies 
on anthramycin and related drugs reveal certain unique fea­
tures of the adducts which might be predicted to cause unusual 
biological consequences. For example, because the drugs are 
well hidden within the narrow groove, and do not cause de­
tectable distortion of DNA, then recognition of the drug lesion 
and also identification of the damaged strand may be difficult 
for excision-repair complexes. A second peculiarity of the 
adducts is their instability to denaturation at physiological pH, 
and the fact that upon denaturation the active drug is released. 
This may result in cumulative damage as the drug “walks the 
DNA” through cycles of excision removal and rebinding to 
DNA. A third potentially important feature of the reaction
P E T R U S E K  ET A ]
between anthramycin and related drugs with DNA is m 
selective ability to bind only to a double-stranded templal 
Therefore, reactions which take place on an already singn 
stranded template, such as the synthesis of the L strand! 
mitochondrial DNA (Robberson et al., 1972; Berk & Claytg 
1974), will not be inhibited by these drugs whereas thosel 
which a double-stranded template is required will be inhibffl 
by anthramycin. im
These properties can be used to rationalize a number! 
previously unexplained biological effects of anthramycin. 
relatively slow excision repair (Hurley et al., 1979) and hij 
potency can be attributed to a slow endonucleolytic recognitw 
and/or the ability of the drug to undergo cycles of binding a  
excision removal to and from DNA. The production of a  
cisioh repair dependent double-strand breaks in DNA in H 
man cells exposed to anthramycin (L. H. Hurley, unpublisw 
experiments) may be rationalized on the proposed inabifl 
of repair complexes to identify only one of the two strands! 
the duplex as carrying the anthramycin lesion. Consequent 
simultaneous repair occurring on opposite strands tow afi 
single anthramycin lesion may result in near-overlapping rera 
patches and double-strand breaks in DNA. Lastly, Gauseiu 
co-workers (1975, 1976) have shown that both anthramya 
and sibiromycin selectively inhibit H-strand synthesis in m 
tochondrial DNA from animal cells. The explanation for m 
is believed to be that the synthesis of the L strand, whS 
proceeds on a single-strand template, is relatively resistanfl 
drug action while the H-strand synthesis, which proceeds! 
a double-stranded template to which drug is bound, is sg 
cifically inhibited (Gause et al., 1976). j j
Conclusions "m
The most important conclusions from this paper are a  
following: (1) Circumstantial evidence suggests that the pom 
of covalent attachment between the pyrrolo[l,4]benzodiazep| 
antibiotics and DNA are C-l 1 on the drug molecules and M 
of guanine. (2) CPK models of these drug-DNA adducts 1« 
to predictions concerning the properties of the drug-modify 
DNA and biological consequences. Experimental results eitS 
described in this paper or already published in the literatu! 
support, without exception, these CPK models and thus pn 
vided strong evidence that our proposed structures are corrw
(3) The CPK models of the various drug-DNA adductsjy 
scribed in this paper have important implications in both desn 
of new synthetic pyrrolo [1,4] benzodiazepine antitumor agesa 
and chemical carcinogenesis. Present and future researcfl 
directed along both of these lines. -jj
Added in Proof M
We have recently confirmed the points of covalent addra 
formation reported in this paper. In these studies we utilis 
‘H NMR on anthramycin-dinucleotide adducts and l3C NM 
on carbon-13-enriched anthramycin-DNA adducts (OstrarM 
et al., 1981). M
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Abstract: Anthramycin is a member of the pyrrolo [1,4] benzodiazepine group of antitumor antibiotics. Previous studies have 
demonstrated that anthramycin binds covalently through N-2 of guanine within the minor groove of DNA, resulting in a relatively 
nondistortive DNA adduct. From the nuclear Overhauser effect spectroscopy (NOESY) proton NMR spectra of the an- 
thramycin-d(ATGCAT)2 adduct, we have obtained results that unambiguously assign the orientation of the drug molecule 
in the minor groove of DNA. Four sets of NOE cross-peaks between anthramycin protons and nucleotide protons on either 
the covalently or the noncovalently modified strands reveal that the drug is specifically oriented with the aromatic ring to 
the 3'-side of the covalently modified guanine. Unequivocal assignment of the geometry at the site of attachment of anthramycin 
to d(ATGCAT)2 cannot be made by /-correlated spectroscopy (COSY). However, when combined with the results of modeling 
with the molecular mechanics program a m b e r ,  an 115 stereochemistry at this site can be confidently predicted. 31P NMR 
studies show that two of the resonance signals in the anthramycin-d(ATGCAT)2 adduct have moved significantly downfield. 
Both downfield 3IP NMR signals have been assigned by nO isotopic labeling and 1H-31P two-dimensional /-correlation experiments 
and shown to correspond to the phosphates on the 5'-sides of the covalently modified deoxyguanine and the deoxycytosine 
on the opposite strand. Assignment of resonance signals of nonexchangeable base and sugar protons of the anthramycin- 
d(ATGCAT)2 has been made with two-dimensional Fourier transform NMR methods (COSY and NOESY). Conformational 
details about the sugar puckers, the glycosidic dihedral angles, and the effect of anthramycin bonding on secondary structure 
of the duplex have been obtained from the relative intensities of cross-peaks in the two-dimensional NMR spectra in aqueous 
solution. All of the sugars that are amenable to this analysis possess a conformation consistent with B-type DNA. Molecular 
mechanics calculations with a m b e r  are predictive of the orientation and stereochemistry of anthramycin bound to d(ATGCAT)2. 
The species having an 115 stereochemistry at the covalent bonding site and oriented with the aromatic ring of anthramycin 
to the 3'-side of the covalently modified guanine of anthramycin-d(ATGCAT)2 appears to be favored over the three other 
possible species. This is because of the greater intermolecular binding for this species rather than lower helix distortion energies. 
The molecular modeling is also in accord with the experimentally determined nondistortive nature of the anthramycin-d- 
(ATGCAT)2 adduct.
Anthramycin (Figure 1) is the lead member of the naturally 
,occurring pyrrolo[1,4]benzodiazepine (P[1,4]B) antitumor an­
tibiotics.1 This potent antitumor compound is produced by 
jStreptom yces refuineus,2 and its biosynthetic origin3 and total 
I synthesis4 have been reported. The cytotoxic and antitumor effects 
-of anthramycin and related compounds are believed to be due to 
j their selective interaction with DNA,5 which causes inhibition of 
j nucleic acid synthesis,6 and production of excision-dependent 
I single- and double-strand breaks in cellular DNA.7 Studies from 
i this laboratory8 and others5 have provided strong evidence that 
;C 11 of anthramycin reacts selectively with the N-2 of guanine 
I in duplex DNA to form an aminal linkage (Figure 2). Further 
evidence for the covalent linkage sites between anthramycin and 
DNA has been provided through 'H and 13C NMR experiments 
on 6-mer- and 140-mer-anthramycin-DNA adducts, respectively.9 
Proton NMR and fluorescence measurements on tomaymycin 
(Figure 1), another P[1,4]B antibiotic, suggest that the N10,C11 
imine is the DNA-reactive species10 (Figure 2). DNA footprinting 
studies and an exonuclease III stop assay have shown that an­
thramycin prefers to bond to 5'-PuGPu sequences, while 5'-PuGPy 
and 5'-PyGPu are of intermediate preference and 5'-PyGPy se­
quences are least favored.11,12 Molecular modeling studies on 
the anthramycin-DNA adduct have been carried out by three 
different groups.13-15 A combined NMR, fluorescence, and
* To whom correspondence should be addressed. 
7 University of Texas at Austin.
* University of Arizona.
molecular modeling study shows that tomaymycin bonds to d- 
(ATGCAT)2 in two orientations, each having opposite linkage
(1) For reviews on the P[1,4]B antitumor antibiotics, see the following. For 
pharmacological and toxicological aspects: Hurley, L. H. / .  Antibiot. 1977, 
30, 349. For mechanism of action studies: Hurley, L. H.; Needham-Van- 
Devanter, D. R. Acc. Chem. Res. 1986, 19,230. For synthesis and mechanism 
of action studies see: Remers, W. A. In The Chemistry o f  Antitumor An­
tibiotics; John Wiley & Sons: New York, 1988; Vol. 2, pp 28-92.
(2) Tendler, M. D.; Korman, S. Nature (London) 1963, 199, 501.
(3) Hurley, L. H. Acc. Chem. Res. 1980, 13, 263.
(4) Leimgruber, W.; Batcho, A. D.; Czajkowski, R. C. / .  Am. Chem. Soc. 
1968, 90, 5641.
(5) (a) Kohn, K. W.; Glaubiger, D.; Spears, C. L. Biochem. Biophys. Acta 
1974, 361, 288. (b) Hurley, L. H.; Gariola, C.; Zmijewski, M. Biochem. 
Biophys. Acta 1977, 475, 521.
(6) Kohn, K. W. Anthramycin. In Antibiotics III. Mechanism o f  Action 
o f  Antimicrobial and Antitumor Agents', Corcoran, J. W., Hahn, F. E., Eds.; 
Springer-Verlag: New York, 1975; pp 3-11.
(7) Petrusek, R. L. D.; Uhlenhopp, E. L.; Duteau, N.; Hurley, L. H. / .  
Biol. Chem. 1982, 257, 6207.
(8) Petrusek, R. L.; Anderson, G. L.; Gamer, T. F.; Fannin, Q. L.; Kaplan, 
D. J.; Zimmer, S. G.; Hurley, L. H. Biochemistry 1981, 20, 1111.
(9) Graves, D. E.; Pattaroni, C.; Balakrishnan, C.; Ostrander, J. M.; 
Hurley, L. H.; Krugh, T. R. / .  Biol. Chem. 1984, 259, 8202.
(10) Barkley, M.; Cheatham, S.; Thurston, D. E.; Hurley, L. H. Bio­
chemistry 1986, 103, 7629.
(11) Hertzberg, R. P.; Hecht, S. M.; Reynolds, V. L.; Molineaux, I. J.; 
Hurley, L. H. Biochemistry 1986, 25, 1249.
(12) Hurley, L. H.; Reck, T.; Thurston, D. E.; Holden, K. G.; Hertzberg, 
R. P.; Hoover, J. R. E.; Gallagher, G., Jr.; Faucette, L. F.; Mong, S. M.; 
Johnson, R. K. Chem. Res. Toxicol. 1988, 1, 258.
(13) Zakrzewska, K.; Pullman, B. J. Biomol. Struct. Dyn. 1986, 4, 127.







Figure 1. Structures of anthramycin and tomaymycin.
stereochemistries.16 More recently, tomaymycin has been shown 
to covalently bond through N-2 of guanine in the sequence 5'-CGA 
with an 115 stereochemistry and 3'-orientation of the aromatic 
ring relative to the covalently modified guanine.17 A previous 
one- and two-dimensional 'H NMR study on anthramycin-d- 
(ATGCAT)2 has appeared.18 This present study extends the 
previous one in several important respects. The orientation of 
anthramycin on d(ATGCAT)2, as tentatively defined in a previous 
study,18 is now confirmed. A combined two-dimensional NOESY 
and molecular modeling approach provides convincing evidence 
for the stereochemistry at the covalent linkage site. Conforma­
tional aspects of the drug-modified duplex are examined by 
two-dimensional 'H and 31P NMR spectroscopy. Molecular 
modeling with a m b e r  is used to provide additional insight into 
binding interactions that stabilize the species of anthramycin-d- 
(ATGCAT)2 found in solution. A preliminary account of this 
work has appeared.19
Results and Discussion
Although the positions of the covalent linkage sites between 
anthramycin and DNA have been accepted for some time,8 the 
stereochemistry of the aminal linkage at Cl 1 and orientation of 
the drug molecule in the minor groove have yet to be firmly 
established.18 In the earlier published work from this laboratory, 
Corey-Pauling-Koltum (CPK) models were used to predict the 
linkage geometry and orientation of anthramycin in the minor 
groove of DNA.8 In these studies, and in subsequent publications, 
an 115 stereochemistry at the covalent linkage site with the 
aromatic ring to the 3'-side of the covalently modified guanine 
(A in Figure 3) was assumed, but without definite experimental 
data. The orientation of the aromatic ring of anthramycin to the 
3'-side of the covalently modified guanine was seemingly confirmed 
in a more recent two-dimensional !H NMR study,18® but we are 
unable to reproduce the results of this particular experiment (see
(14) Remers, W. A.; Mabilia, M.; Hopfinger, A. J. J. Med. Chem. 1986, 
29, 2492.
(15) Rao, S. N.; Singh, U. C.; Kollman, P. A. J. Med. Chem. 1986, 29, 
2484.
(16) Cheatham, S.; Kook, A.; Hurley, L. H.; Barkley, M.; Remers, W. J. 
Med. Chem. 1988, 31, 583.
(17) Boyd, F. L.; Stewart, D.; Remers, W. A.; Barkley, M. D.; Hurley, L. 
H. Biochemistry 1990, 29, 2387.
(18) (a) Graves, D. E.; Stone, M. P.; Krugh, T. R. Biochemistry 1985, 24, 
7573. (b) In a more recent contribution that was submitted for publication 
while this manuscript was in review Krugh and co-workers have provided 
additional data that confirm their preliminary findings and there is agreement 
with the data presented here. Krugh, T. R.; Graves, D. E.; Stone, M. P. 
Biochemistry 1989, 28, 9988.
(19) Boyd, F. L.; Cheatham, S.; Hurley, L. H. Abstracts o f  Papers, 193rd
American Chemical Society Meeting, Denver, CO, 1987; American Chemical 
Society: Washington, DC, 1987; MEDI 049.
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later text). In addition, this study provided only limited infor­
mation on the effect of drug bonding on local DNA structure. 
Theoretical modeling studies have also been recently published13-14 
that address the important questions of the stereochemistry at the 
covalent linkage site in the self-complementary duplex d- 
(ATGCAT)2 and the effect of drug bonding on local DNA 
structure.
In view of the importance of these assignments for future work 
designed to determine the effect of variation of drug structure and 
sequence on P[1,4]B bonding to DNA, we have undertaken a 
combined molecular modeling and one- and two-dimensional31P 
and *H NMR analysis designed to remove these uncertainties. 
The combined modeling and NMR approach also permits the 
predictability of modeling with the molecular mechanics program 
a m b e r  to be evaluated for drug-DNA adduct systems. Although 
the 6-mer self-complementary duplex chosen for this study belongs 
to the 5'-PyGPy class, and is therefore not a favored sequence 
for P[1,4]B binding.11-12 the previous ’H NMR studies9,18 on this 
oligomer led us to use this self-complementary oligomer. In 
principle, there are the four possible anthramycin-d(ATGCAT)2 ' 
adduct species, as shown in Figure 3. Consequently, an additional 
complication might be the presence of more than one species of 
the anthramycin-duplex adduct, e.g., a mixture of species A and . 
B in Figure 3. In this respect, in a previous combined fluorescence, ’ 
'H NMR, and molecular modeling study on tomaymycin bound 
to d(ATGCAT)2, we have confirmed that this drug may bond with  ̂
either the 115 or 11/? linkage geometry and most likely, as species  ̂
equivalent to A and D shown in Figure 3.16 However, in the more > 
preferred bonding sequence 5'-CGA, contained in a self-corn-1 
plementary 12-mer, there is only one species of tomaymycin co-1 
valently bound (i.e., that having an 115 linkage stereochemistry j 
and 3'-orientation, equivalent to species A in Figure 3).17 f
Determination of the Number of Species of Anthramycin Bound I 
Covalently to d(ATGCAT)2 by 31P and ]H NMR. Anthramy-1 
cin-d(ATGCAT)2 adducts were prepared by adding excess drug ] 
to a d(ATGCAT) solution that was stirred for 4 days at 4 °C j 
before removal of excess anthramycin. The solution structure of» 
the anthramycin-d(ATGCAT)2 adduct was observed at 500 MHz j 
in sodium acetate and sodium phosphate buffered D20 , which was j 
degassed with argon at 23 °C.
The complexity of the anthramycin-d(ATGCAT)2 adduct 
relative to d(ATGCAT), which exists as an equilibrium between 
double- and single-stranded forms at 23 °C, was examined by both 
one-dimensional and two-dimensional *H and 31P NMR experi­
ments. In the oligomer d(ATGCAT) just five phosphorus signals 
are observed (Figure 4A). However, upon formation of the 
anthramycin-d(ATGCAT)2 adduct, twice the number of phos­
phorus signals are seen (Figure 4B). This is in accord with the 
loss of duplex symmetry due to formation of just one species of 
duplex adduct. Two of the ten phosphorus signals are moved 
significantly downfield upon adduct formation. These have been 
assigned to individual phosphates by two-dimensional 31P -1H 
/-correlation NMR experiments (see later text).
The two-dimensional COSY spectrum of the anthramycin-d- 
(ATGCAT)2 adduct is not shown in Figure 5. In comparison 
to d(ATGCAT) alone20 and the tomaymycin-d(ATGCAT)2 
adduct,16 the spectrum of the anthramycin-duplex adduct is of 
intermediate complexity. The assignments of the chemical shifts 
for the aromatic base protons and 1'-, 2'-, 2"- and 3'-deoxyribose 
protons for the d(ATGCAT) and the anthramycin-d(ATGCAT)2 
adduct, together with their chemical shifts changes upon adduct 
formation, are shown in Table IA,B. Likewise, the anthramycin 
and anthramycin-adduct proton assignments and chemical shift 
changes are shown in Table II. Twice the number of DNA proton 
resonance signals appear in the anthramycin-d(ATGCAT)2 ad­
duct in comparison to the duplex alone. Just as for the 31P NMR | 
spectra, this is in accord with the loss of duplex symmetry due j 
to formation of just one species of the anthramycin-d(ATGCAT)2 
adduct. Furthermore, only one set of anthramycin ’H resonances i 
appears in the spectrum of the anthramycin-d(ATGCAT)2 adduct
(20) Patel, D. J.; Tonelli, A. E. Biochemistry 1975, 14, 3990.
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Figure 2. Proposed mechanism for alkylation of DNA by the N10,C11 imine to form the P[l,4]B-N-2-guanine— DNA adduct.10
Table I
A Comparison of the Base Proton Chemical Shift Assignments (ppm) and Relaxation Times of Nonexchangeable Protons of d(ATGCAT)2









8 A 8 A
‘AH8 8.09 8.10 +0.01 'AH2 7.87 (4.72)' 7.98 (4.96)' +0.21 (0.24)
2TH6 7.29 7.36 +0.07 2TMe 1.46 1.45 -0.01
3GH8 7.86 7.87 +0.01 4CH5 5.37 5.43 +0.06
4CH6 7.32 7.39 +0.07 SAH2 7.81 (5.13)' 8.00 (5.25)' +0.19 (0.12)
5AH8 8.26 8.16 -0.10 6TMe 1.29 1.35 +0.06
6TH6 7.23 7.17 -0.06 7AH2 7.87 (4.72)' 7.96 (5.46)' +0.09 (0.26)
7AH6 8.09 8.21 +0.12 8TMe 1.46 1.41 -0.05
8TH6 7.29 7.26 -0.03 ,0CH5 5.37 5.57 +0.20
9GH8 7.86 7.88 +0.02 UAH2 7.81 (5.13)' 7.70 (3.38)' -0.11 (1.75)
10CH6 7.32 7.45 +0.13 ,2TMe 1.29 1.33 +0.04
"AH8 8.26 8.30 +0.04
l2TH6 7.23 7.16 -0.07
B. Comparison of the Deoxyribofuranose Proton Chemical Shift Assignments (ppm) of d(ATGCAT) and the Anthramycin-d(ATGCAT)2
Adduct
assignt
HI' H2' H2" H3'
6-mer Anth-6-mer A 8a 6-mer Anth-6-mer A5a 6-mer Anih-6-mer A 8a 6-mer Anth-6-mer A 8a
'A 6.14 6.25 +0.09 2.61* 2.65 +0.04 2.78 2.96 +0.18 4.85 4.88' +0.07
2T 5.71 5.54 -0.17 2.15C 2.31 +0.16 2.42 2.47/ +0.04 4.85 4.88' +0.03
3G 5.88 6.03 +0.15 2.61* 2.47^ -0.14 2.70rf 2.77 +0.07 4.97 4.96 -0.01
4C 5.68 5.78 +0.10 1.95 2.15* +0.20 2.35 2.47/ +0.12 4.85 4.88' +0.03
5A 6.26 6.12 -0.14 2.10d 2.47/ -0.23 2.86 2.83 -0.03 4.97* 4.76 -0.23
6T 6.08 6.16 +0.08 2.15C 2.15* 0.00 2.15' 2.15* 0.00 4.85 4.50 -0.35
7A 6.14 6.21 +0.07 2.61 2.65 +0.04 2.78 2.87 +0.09 4.85 4.88' +0.03
8T 5.71 5.68 -0.03 2.14 2.15* 0.01 2.42 2.47/ +0.03 4.85 4.88' +0.03
9G 5.88 5.61 -0.27 2.61 2.67 +0.06 2.70 2.47/ -0.23 4.97 4.95 -0.02
l0C 5.68 6.03 +0.35 1.95 2.04 +0.09 2.35 2.47/ +0.12 4.85 4.88' +0.02
"A 6.26 5.99 -0.27 2.70 2.65 -0.05 2.86 2.65 -0.21 4.97 4.79 -0.18
I2y 6.08 6.07 -0.01 2.15 2.15* 0.00 2.15 2.15* 0.00 4.85 4.55 -0.30
aA5 underlined are >±0.20. b8 2.65-2.57 !AH2' further downfield than 3GH2'. cOverlapping chemical shifts in the range 8 2.21-2.08—order 
downfield to upfield 6TH2", 6TH2', 2TH2'. d8 2.75-2.66 5AH2' further downfield than 3GH2". 'Overlapping chemical shifts in the range 8 
4.92-4.83—order downfield to upfield 8TH3', 4CH3', 2TH3', ’AH3', 7AH3', ,0CH3—confirmed by H 8/H6-H3' cross-peaks in two-dimensional 
NOESY and H2'-H3' cross-peaks in two-dimensional COSY. /Overlapping chemical shifts in the range 5 2.51-2.42—order downfield to upfield 
5A H 2 ,3GH2', 2TH2" «  4CH2// 8TH2" =  9GH2" =  10CH2". *Overlapping chemical shifts in the range 8 2.21-2.09—order downfield to upfield
6TH2", 6TH2', 4CH2', 8TH2', 12TH2", H2'. * Under HOD peak. '7 ,  values are given in seconds.
Table II. Comparison of the Proton Chemical Shift (ppm) Assignments in Anthramycin Alone and in the Anthramycin-d(ATGCAT)2 Adduct"
species* HI H3
A,7
H6 (Hz) H7 8-CHj
■/l 1,1 la
HI 1 (Hz) HI la H12
2,13
(Hz) H13
ANTH 3.12 7.24 7.81 (d)' 8.34 6.89 (d) 2.18 4.99 (d) 8.91 3.81 (dd)' 7.35 (d) 15.8 5.87 (d)
ANTH-d(ATGCAT)2 3.80 7.60 7.26 (d)' 8.23 6.90 (d) 2.41 6.03 4.45 7.62 (d) 23 6.25 (d)
adduct 3.50
A 8 +0.68
+0.38 +0.36 -0.55 +0.01 +0.23 +  1.04 +0.64 +0.27 +0.38
0 For numbering of anthramycin, see Figure 1. bChemical shifts are in 8 with TSP as an internal reference. 'Key: d = doublet, dd = doublet of 
doublets.
(see Figure 5 and Table II), in contrast to the two sets of to­
maymycin signals found in the spectrum of the tomaymycin-d- 
|(ATGCAT ) 2 adducts. 16 Last, the two-dimensional COSY 
.spectrum (Figure 5) shows two intense sets of cytosine H5-H6
cross-peaks and four sets of thymine H5-C6CH3 cross-peaks, 
confirming the loss of duplex symmetry with formation of a single 
species of the anthramycin-d(ATGCAT) 2 adduct. While these 
results are more complete than those previously reported,18® there
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is complete accord between these two reports.
Chemical Shift Changes of Nonexchangeable Protons Occurring 
on Bonding of Anthramycin to d(ATGCAT)2. A comparison of 
the chemical shifts of protons in d(ATGCAT) and anthramycin 
with the anthramycin-d(ATGCAT) 2 adduct is shown in Tables 
IA,B and II. Only minor changes in the base aromatic proton 
chemical shifts occur in the anthramycin-d(ATGCAT) 2 adduct. 
However, for the adenine H2 protons, the nA proton moves upfield 
by 0.11 ppm in contrast to the downfield shifts of 'A, 5A, and 7A 
protons. The proximity of "A H 2 to the acrylamide side chain 
of anthramycin is probably responsible for this effect. The most 
significant chemical shift changes for deoxyribose protons occurs 
for H I7 protons (9G, 10C, and "A), H2' protons (4C and 5A), and 
H2" protons (9G and "A). The majority of these protons are also 
in proximity to anthramycin, and these changes may be ration­
alized by (de)shielding effects. Downfield shifts of anthramycin 
protons resulting from bonding to d(ATGCAT ) 2 occur for HI a, 
H lb , H3, 8 -CH3, HI 1, HI la, H12, and H13, and these are 
particularly pronounced for HI 1 and HI la. The H6 proton of 
anthramycin shifts upfield.
Determination of the Orientation of the Anthramycin Molecule 
in the Minor Groove of d(ATGCAT)2 by Two-Dimensional 'H  
NMR. In principle, species A and B in Figure 3 can be differ­
entiated from species C and D if unambiguous through-space 
interproton connectivities between anthramycin and d(ATGCAT) 2 
protons can be identified. Examination of molecular models of 
species A-D of anthramycin-d(ATGCAT) 2 adducts shows that 
the H2 proton of adenine-11 ( n AH2) is in proximity to either the 
anthramycin side chain H13 proton in A and B or the aromatic 
8 -CH 3 protons in C and D of Figure 3, respectively. Therefore, 
identification of a NOE cross-peak between either anthramycin 
H13 or 8 -CH3 proton and the "A H 2 proton would distinguish 
between the pairs AB or CD. Figure 6  shows an expansion of part 
of the two-dimensional NOESY 'H NMR spectrum of the an- 
thramycin-d(ATGCAT) 2 adduct at a mixing time of 250 ms. A 
cross-peak (A) is evident between anthramycin H 13 and an ad­
enine H2 previously assigned as that due to "A . 16 A through-space 
connectivity (B in Figure 6 ) between the anthramycin protons at
H 2-H 3'
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H11
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Figure 5. Two-dimensional COSY *H NM R spectra of the anthramycin-d(ATGCAT)2 adduct. The chemical shift regions for the oligodeoxynucleotide 
aromatic and sugar protons are bracketed or correspond to the enclosed boxes for the H2', H2", and thymine methyl protons. Scalar coupling between 
anthramycin protons is indicated by the vertical and horizontal lines. An expanded spectrum of the H I' to H2' and H2" region is shown in Figure
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Figure 3. Schematic representations of the possible C l 1-enantiomeric 
N-2-guanine-d(ATGCAT)2 adducts: A, 115 aromatic ring to the 3'-side; 
B, 1 \R  aromatic ring to the 3'-side; C, 115 aromatic ring to the 5'-side; 
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Figure 4. One-dimensional 31P NM R spectra of the d(ATGCAT) (A) 
and the anthramycin-d(ATGCAT)2 adduct (B).
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Figure 7. One-dimensional N O E difference spectra obtained by irradi­
ation on the " A H 2 at 23 °C  (A ) and n A (N H )2T at 5 °C  (B) protons 
to confirm the N O E cross-peak observed in Figure 6 and the assignment 
of the " A H 2 proton, respectively.
examined the NOESY spectra in the regions corresponding to 
the expected positions for an NOE cross-peak between the an­
thramycin 8 -CH 3 protons and 5AH 2 proton. An appropriate 
cross-peak was not evident in our two-dimensional NOE exper­
iments, which would confirm these connectivities (unpublished 
results). In addition, irradiation on the 5AH2 proton did not show 
a NOE into the anthramycin 8 -CH3 protons (unpublished results). 
We were puzzled why we were unable to reproduce the cross-peak 
for the proton connectivities between 5A H 2 and anthramycin 
8 -CH3. Therefore, molecular modeling was used to determine 
the critical drug-nucleotide interproton distances in species A of 
Figure 3. Of these computed drug-nucleotide interproton distances
Characterization o f  Anthramycin-d(ATGCAT)2 Adduct
Figure 6. Expansion of part o f the two-dimensional N O E SY  'H N M R  
spectrum of the anthram ycin-d(A T G C A T )2 adduct at a mixing time of 
250 ms. The through-space interproton connectivities between anthra­
mycin H 13 and " A H 2 (A ), anthramycin H 12 and H 13 (B), anthramycin 
H6 and H7 (C ), and anthramycin H 11 and 4CH V (D ), and H5 and H6 
connectivities for 4C and l0C (E and F, respectively).
C 12 and C 13 was also evident. The corresponding scalar couplings 
between H 12 and H 13 were found in the COSY spectrum (Figure 
5). Confirmation of the NOE between the "A H 2 proton and the 
H13 proton of anthramycin observed in Figure 6  was obtained 
through a one-dimensional NOE difference experiment (Figure 
7A). The critical assignment of the "A H 2 proton was also 
confirmed by a one-dimensional NOE difference experiment 
(Figure 7B). The lower T\ relaxation time (3.38 s) of the nA H 2 
proton (Table IA) relative to other adenine H2 protons (4 .9 6 -5 .4 6  
s) in anthramycin-d(ATGCAT ) 2 is also in accord with its close 
proximity to an anthramycin proton. Significantly, examination 
of the NOESY spectrum in the region where a cross-peak between 
the anthramycin 8 -CH3 and nAH 2 would be expected did not show 
evidence of a through-space interproton drug-nucleotide con­
nectivity (unpublished results). Additional through-space inter­
proton connectivities between anthramycin protons at Cl a and 
C lb  and the "A H 2 proton were also identified (unpublished 
results). These interproton connectivities are only consistent with 
the 3'-oriented species (i.e., A and B in Figure 3).
In a previous two-dimensional 'H NMR study on the anthra- 
mycin-d(ATGCAT ) 2 adduct, an NOE cross-peak between the 
aromatic 8 -CH 3 protons of anthramycin and the 5AH 2 was ten­
tatively identified183 to support assignment of species A in Figure 
3 as the anthramycin-d(ATGCAT ) 2 adduct. Consequently, we
1------ 1------ 1------ 1------ 1------ 1 1 1 I 1 1 r
Figure 8. Stereodrawings o f  the an thram ycin -d(A T G C A T )2 (Figure 3A ) energy minimized by a m b e r .
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Table III. Energies (k ca l/m o l) o f Covalent Com plexes between Anthramycin and d (A T G C A T )2°
species total
intermolecular distortion* net
binding^steric elstat total drug D N A total
A (1 1 5 , 3') -3 9 1 .8 -3 3 .5 -2 6 .2 -5 9 .7 2.4 16.0 18.4 -4 1 .3
B (1 \R . 3') -3 7 2 .6 -2 5 .2 -1 9 .6 -4 4 .8 6.3 16.4 22.7 -22 .1
C (1 1 5 , 5') -3 8 5 .4 -2 9 .7 -2 1 .0 -5 0 .7 2.7 12.6 15.3 -3 5 .4
D (1 \R . 5') -3 8 5 .4 -3 2 .2 -1 8 .0 -5 0 .2 2.0 13.3 15.3 -3 4 .9
“ These energies are valid only for comparison within the table. They should not be compared with other drugs or other D N A  segm ents. *DruE 
distortion and helix distortion energies equal their values in the com plex less their values when m inimized alone (14.0 and -3 6 4 .4  kcal/m ol, re. 
spectively). f N et binding energy equals the total intermolecular binding minus the total distortion energy.
Table IV. Energies (k ca l/m ol) for the Interactions o f Anthramycin  
with Individual Residues o f d (A T G C A T )2“
species*
residue A B C D
3 S -3 .1
3 G -8 .2 -5 .9
3, 4 P -8 .7 -3 .3
4 C -5 .4 * -4 .1 *
5 S -3 .3
5 A -3 .3 -8 .6 * -8 .7 *
10 C -3 .3 -3 .2 -3 .2
11 s -3 .4
11 A -4 .2 -3 .5
12 S -3 .2 -3 .7
12 T -6 .7 * -6 .5 *
“Only energies > -3 .0  kcal/m ol are listed. *S stands for sugar. 
Asterisk identifies an interaction involving a hydrogen bond (see Table 
V). The hydrogen bond between H N 2B  of 9G and 09 o f anthram ycin  
in species A has an energy o f only -2 .7  kcal/m ol.
(6 .1-6.2 A  for 8 -CH3 to 5AH 2 and 2.4-2.5 A  for H I3 to nAH 2), 
only the anthramycin H13 to "A H 2 interproton distance would 
be expected to be close enough to allow observation of an NOE 
cross-peak.21 Therefore, the results reported here provide un­
equivocal evidence for the orientation of the anthramycin molecule 
in the minor groove of DNA.
Assignment of the Covalent Linkage Site Geometry in Anthra- 
mycin-d(ATGCAT)2 by 'H NMR. On the basis of the observed 
two-dimensional NOE through-space connectivity between the 
nAH 2 proton and the anthramycin H13 proton, only species A 
and B in Figure 3 are possible. These species differ in the ster­
eochemistry at the covalent linkage site (A, 11 S'; B, 11R). CPK 
model building studies,8 previous molecular modeling, 13-15 and 
the results of molecular modeling described later predict that the 
1 IS geometry at the covalent linkage site is that favored for 
bonding of anthramycin to DNA. In anthramycin 11-methyl 
ether, of the two possible diastereomers (115,1 la5  and 11 /?, 1 la5) 
only the 115,1 la 5  can give rise to a one-bond scalar coupling 
pattern, since the 11 R ,\  laS  diastereomer of anthramycin has a 
predicted 77.6° dihedral angle between the protons at Cl 1 and 
Cl la and consequently is shown to lack a significant observable 
coupling.4 The two-dimensional COSY spectrum of anthramy- 
cin-d(ATGCAT ) 2 shows a strong cross-peak between a proton 
at 6.03 ppm and a doublet at 4.45 ppm identified as the Cl 1 and 
Cl la protons of anthramycin, respectively (Figure 5). This 
seemingly provides confirmation that the geometry at the covalent 
linkage site is 115 as previously predicted, first by CPK models8 
and then by computational methods reported previously. 13-15 
However, upon energy minimization of the anthramycin-d- 
(ATGCAT ) 2 adducts with the 115 and 11R configurations (A 
and B in Figure 3) the HI 1 —C 11-C1 la -H l la dihedral angles 
are 172° (115) and 17.4° (11/?). Therefore, due to the apparent 
considerable flexibility in the drug molecule, the seven-membered 
ring may adopt a conformation that accommodates to the local 
constraints within the minor groove of DNA. Consequently, it 
is apparently more difficult to differentiate, by 'H NM R exam-
(21) Although under our experimental conditions we were unable to detect 
this NOE connectivity, the authors of ref 18a report they consistently show 
a weak, but observable, connectivity for 8-CH3 to *AH2 at 600-ms mixing time 
in the two-dimensional NO ESY and the one-dimensional NOE difference 
experiment: Krugh, T. R. Private communication.
ination of the scalar coupling between HI 1 and HI la, between 
the 115 and 11R configurations in anthramycin-d(ATGCAT), 
Therefore, while the two-dimensional NOE data of Figure 6 car 
narrow down the four possibilities in Figure 3 to either A orB. 
the COSY data alone cannot definitively differentiate betweer 
these remaining species.
Since the scalar coupling between protons at Cl 1 and Cl la 
did not provide a definitive answer for the stereochemistry at the 
covalent linkage site, alternative 1H NMR evidence was sought 
One possible solution would be to identify one or more through- 
space intermolecular proton-proton couplings that would onlym 
consistent with either species A (115, T-orientation) or specie 
B (11 /?, 3'-orientation). In addition to the previously described 
anthramycin H13 to UAH 2 interproton connectivity, three othei 
drug-nucleotide interproton connectivities were identified, i.e. 
anthramycin H 1 a and H 1 b to 11AH 2 (unpublished results) anc 
anthramycin H 11 t o 4CHT. Of these NOEs, the anthramycit 
H 11 to 4CH T is particularly strong (D in Figure 6 ) as c o m p a r e d  
to cross-peaks C, E, and F in Figure 6 . An analysis of the cal­
culated distances between each pair of protons for the energy- 
minimized species A and B reveals that the anthramycin inter- 
proton distances to "AH 2 are not useful in differentiating betweer 
these possibilities. However, the very strong NOE between HB 
of anthramycin and the 4CH V is more consistent with the 2 .88«  
distance for species A than the 3.60-A distance for species f
In addition to intermolecular proton distances that would po* 
tentially differentiate between species A and B in Figure 3, it also 
seemed possible that the different environments of the 115 or l l  
protons in species A and B might provide a further piece of in’ 
dependent evidence to support one species over the other. In facj  
in related studies17 with tomaymycin covalently bound to «  
(CICGAATTCICG) 2 it has been demonstrated that the 115,1 la- 
species having a 3'-orientation is associated with a large downfi^ 
shift (0.9 ppm) of the Cl 1 proton. An equivalent Cl 1 proton]1 
just one species of the tomaymycin-d(ATGCAT ) 2 adduct alff
6 . 4  6 . 2  6 . 0  5 . 8  5 . 6  5 . 4  P P M  4
Figure 9. Two-dimensional expansion of a region of the C O SY  spectrur 
that shows coupling o f the H I' protons into the H2' and H2" protons. 
The H2" protons are downfield o f the H2' protons.
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Figure 10. Expanded regions o f the two-dimensional N O E S Y  spectra that show the H I' connectivities to purine (H 8) or pyrimidine (H 6) protons on 
the covalermy (A ) and noncovalently (B) modified strands.
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figure It 1 xpanded regions o f  the two-dim ensional N O E S Y  spectra that show the through-space connectivities between H 2" and H 2' protons to 
purine (H s) or pyrimidine (H 6) protons on the covalently (A ) and noncovalently (B) modified strands.
4c *t ®t
shows th’s characteristic large downfield chemical shift. Since 
ln the anthramycin-d(ATGCAT) 2 duplex the anthramycin H 11 
undergoes a downfield shift of about the same magnitude (1.04 
PPm), th. provides further support that the species of anthramycin 
°und to d(ATGCAT ) 2 is the 1 IS, 3'-oriented adduct. 
P red ic tion  of the Preferred Bonding Orientation and Covalent 
•nkage stereochemistry of Anthramycin on d(ATGCAT)2 by 
oiecular Modeling. Anthramycin was covalently bound through 
dtAT at° m 10 exocyclic 2-amino group (N-2) of 3G in 
n ‘G l^T)2. Four different binding modes were modeled: the 
a. S nfigurations at Cl 1 of anthramycin, each with the drug 
. 1 10ned in the minor groove so that its aromatic ring was 
‘nUng loward the 3'- or the 5'-end of the covalently bound strand 
net h Following energy minimization in a m b e r ,  the
j lndmg energy for each species was calculated from its total 
drura?°*ecu*ar drug-DNA binding energy minus the helix and 
Hi ® ^.°rtion energies that resulted from the induced fit (Table 
Coy | erc was a c lear preference by 5.9 kcal/mol for the 
enl complex with 1 IS configuration and aromatic ring toward
the 3'-direction (Figure 8 ). This result agrees with the direction 
of groove binding found in an earlier study that used the unit- 
ed-atom model for anthramycin and d(ATGCAT ) 2 and had no 
specification of configuration at Cl 1. 14 The earlier model adopted 
the 1 IS configuration in the course of energy refinement. More 
significantly there is a 19.2 kcal/mol difference in net binding 
energies between species A and B of Figure 3. This clearly dif­
ferentiates between the two viable alternatives (A and B) remaining 
after determination of the orientation of anthramycin in the minor 
groove of d(ATGCAT ) 2 (see earlier text) in favor of species A, 
which has the 1 IS stereochemistry and the aromatic ring oriented 
to the 3'-side. So while no single experimental or theoretical result 
is definitive in differentiating between species A and B in Figure 
3, each piece of evidence (NOESY, chemical shift change of Cl 1, 
and molecular modeling) when considered together provides a level 
of high confidence in predicting species A as the species found 
in solution.
The explanation for the greater stability of the 1 IS, 3'-direction 
complex over the next two favored complexes lies not in lower helix
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Figure 12. Two-dimensional 'H - 31P ./-correlated N M R  spectrum o f the 
an thram ycin -d(A T G C A T )2 adduct.
distortion energy but in greater intermolecular binding, as shown 
in Table III. This intermolecular binding is divided into the 
interactions between anthramycin and individual residues of d- 
(ATGCAT) 2 in Table IV. Among these interactions, hydrogen 
bond formation is especially significant. Table V lists the hydrogen 
bonds in the four different complexes, and Table IV indicates how 
they affect the intermolecular binding energies. The IIS', 3'- 
direction complex has the most hydrogen bonds, three, althrough 
one of them has less than -3 .0  kcal/mol energy. There are two 
hydrogen bonds for the 11/?, 3'-direction complex, but it suffers 
from serious distortion, especially in the drug, and poor overall
Boyd et al
Table V. Hydrogen Bond Parameters for 
A nthram ycin -d (A T G C A T )2 Interactions0
species hyd rogen  a to m






A (115 , 3') H N 2B  (9G) 09 (A N T H ) 1.83 ~14U "
H N 10  (A N T H ) 02 (4C) 1.99 1330
H N 14A  (A N T H )4 02 ( ,2T) 1.88 149.0
B (11/?, 3') H N 10 (A N T H ) 02 (4C) 2.22 1164
H N 14A  (A N T H ) 02 ( 12T) 1.83 159.3
C (115 , 50 H N 14A  (A N T H ) N 3 (5A) 1.85 165.2
D (11/?, 50 H N 14A  (A N T H ) N 3 (5A) 1.88 168.5
°O nly bond lengths < 2 .5  A are listed. bAnthramycin = ANTf; 
H N 14A  is the upper hydrogen on the amide nitrogen as it appears 
Figure 1.
intermolecular binding. The other two complexes have only on 
hydrogen bond each. One of the main sources of helix d is to r ts  
energy in the four complexes is a loss of about 6 - 8  kcal/mol i 
the interactions between the covalently bound guanine a nd  it 
opposing cytosine (3G -I0C). There are no other significant change 
in these Watson-Crick base-pairing energies or in the stackin  
energies between bases. The remainder of the helix distortio; 
energies are distribution throughout the system so that there ar 
many small local distortions.
In a previous combined fluorescence, 'H NMR, and molecuk 
modeling study, 16 we have shown that there are two species c 
tomaymycin-d(ATGCAT) 2 adducts present in approximate! 
equal amounts. These differ in their linkage site geometries an 
are most likely equivalent to species A and D of Figure 3. Tt 
results reported here strongly imply that just species A is presen 
in anthramycin-d(ATGCAT)2. While an exact energy different: 
between two species such as A and D, which would predict tf 
presence of only one species rather than two, is not known, it 
reassuring to note that while there is an energy difference of 6 
kcal/m ol between species A and D for anthramycin- 
(ATGCAT)2, there is only a 4.0 kcal/mol difference betwec 
species A and D for tomaymycin-d(ATGCAT ) 2. 16 Further e 
amplcs will, however, be required before the predictability! 
molecular mechanics can be relied upon for these types of pr 
dictions.
Determination of the Effect of Anthramycin Bonding on Loc 
DNA Structure by Two-Dimensional 3IP and 'FI NMR. Previo1
studies on anthramycin-DNA adducts with enzymatic (Srn. 
clease) and chemical (BND-cellulose chromatography) prob
Figure 13. Stereodrawings o f the superimposed d (A T G C A T )2 in orange and anthram ycin -d(A T G C A T )2 in m agenta and yellow.
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ve s u g g e s te d  t h a t  d r u g  b o n d in g  c a u s e s  l i t t l e  d i s to r t io n  o f  lo c a l 
L lA  s t ru c tu re .8 A  m o re  re c e n t  h ig h - re s o lu t io n  g e l e le c tro p h o re s is  
jU(jy w ith  u se  o f  ( m e th id iu m - p r o p y l ) E D T A - F e ( I I )  a n d  m e th y le n e  
I, e to  d e t e r m in e  th e  s e q u e n c e  s p e c i f i c i ty  o f  a n t h r a m y c i n  a n d  
lated P [ 1 ,4 ]B s sh o w e d  t h a t  t h e r e  a r e  d r u g - in d u c e d  c h a n g e s  in  
nNA s t r u c tu r e  a n d / o r  d y n a m ic s  t h a t  c a n  b e  d e te c te d  w ith  th e s e  
agen ts."  In  vivo  s tu d ie s  in re p a i r -p r o f ic ie n t  a n d  -d e f ic ie n t h u m a n  
rb rob las t  ce ll l in e s  d e m o n s t r a t e  t h a t  t h e  e x c is io n  r e p a i r  s y s te m , 
slially a s s o c ia te d  w i th  b u lk y  a n d  d i s to r t iv e  D N A  a d d u c t s ,  r e c ­
c e s  a n d  re m o v e s  u p  to  5 0 %  o f  t h e  a n t h r a m y c i n - D N A  a d d u c ts  
during a  7 2 -h  p e r io d . P re v io u s  m o d e lin g  s tu d ie s  w ith  th e  m o le c u la r  
m echanics p ro g r a m  a m b e r 14,15 p r e d ic t  l i t t l e  c h a n g e  in  lo ca l D N A  
structure , w h ile  th e  s i r  p r o g r a m  p r e d ic t s  a  c h a n g e  to  a n  A - ty p e  
pMA s t r u c t u r e  w i th  a  n e g a t iv e  t i l t  o f  b a s e  p a i r s  a n d  o p e n in g  o f  
the m inor g ro o v e  o f  D N A . In  v iew  o f  th e s e  in c o n s is te n c ie s  b e tw e e n  
theoretical s t u d ie s 13-15 a n d  th e ,  p e r h a p s ,  s u r p r is in g  a b i l i t y  o f  t h e  
excision p a i r  s y s te m  in  h u m a n  c e l ls  t o  r e c o g n iz e  a  n o n d is to r t iv e  
and u n c h a rg e d  D N A  a d d u c t ,7 it w a s  i m p o r t a n t  to  d e te r m in e  h ow  
drug b o n d in g  a f f e c t s  lo c a l  D N A  s t r u c t u r e .
The th r e e - d im e n s io n a l  s t r u c t u r e  o f  d r u g - m o d i f i e d  o l ig o m e rs  
such as th e  a n t h r a m y c i n - d ( A T G C A T ) 2 d u p le x  is f ix e d  b y  th e  
sugar g e o m e try , th e  g ly c o s id ic  b o n d  r o ta t io n ,  a n d  th e  c o n fo rm a tio n  
of the s u g a r - p h o s p h a t e  b a c k b o n e .  T w o - d im e n s io n a l  'H  N M R  
techniques in c lu d in g  C O S Y  a n d  N O E S Y  e x p e r im e n ts  c a n  b e  u sed  
to distinguish b e tw e e n  th e  v a r io u s  fa m il ie s  o f  D N A  s t r u c tu r e  s u c h  
as A, B, a n d  Z . H o w e v e r , th is  s t r a t e g y  re q u ir e s  t h a t  a s s ig n m e n ts  
for a ro m a tic , H I ' ,  H 2 ',  H 2 " ,  H 3 ' ,  a n d  H 4 '  p r o to n s  b e  u n e q u iv ­
ocally m a d e  fo r  e a c h  n u c le o t id e .  W e  h a v e  u s e d  t h e  s t a n d a r d  
approaches fo r  th e s e  a s s ig n m e n ts ,  w h ic h  d e p e n d s  u p o n  s e q u e n tia l  
imino, a r o m a t ic ,  a n d  s u g a r  a s s i g n m e n t s  f o r  e a c h  in d iv id u a l  
base-sugar s e t .  Im in o  a n d  a r o m a t i c  p r o to n s  f o r  a n t h r a m y c i n -  
d (A T G C A T )2 a d d u c t  h a v e  b e e n  a s s ig n e d  p re v io u s ly  b y  m e l t in g  
experim ents a n d  o n e - d im e n s io n a l  N O E  d i f f e r e n c e  s p e c t r a . 182 
These a s s ig n m e n ts  w e re  c o n f i r m e d  in  th i s  s tu d y  ( u n p u b l i s h e d  
results). O n  th e  b a s is  o f  a n  u n e q u iv o c a l  a s s ig n m e n t  o f  th e  g u a n in e  
NH pro ton  a t  th e  c o v a le n t  l in k a g e  s i te  in  a  to m a y m y c i n - 1 2 - m e r  
duplex a d d u c t 17 a t  8 .9  p p m , w e  t e n t a t i v e l y  a s s ig n  t h e  b r o a d  
resonance a s  8 .4  p p m  ( F i g u r e  7 B )  in  p a r t  to  t h i s  s a m e  p r o to n .
A. E ffe c t o f  Anthramycin Bonding on Sugar Geometries in 
d(ATGCAT)2. T h e  v ic in a l c o u p lin g  c o n s ta n ts  a m o n g  s u g a r  p ro to n s  
vary as a fu n c tio n  o f  p s e u d o r o ta t io n  a n g le .22 W h ile  th e  c o u p lin g  
constants fo r H 2 ' to  H 3 '  a n d  H I '  to  H 2 "  a r e  re la t iv e ly  in se n s it iv e  
to sugar p u ck e r, th e  H I '  to  H 2 ',  H 3 '  to  H 4 ',  a n d  H 2 "  to  H 3 ' sh o w  
considerable v a r ia t io n .  B -T y p e  D N A  e x is t s  p r e d o m in a n t ly  in  a  
C2'-endo s u g a r  c o n f o r m a t io n ,  w h ic h  is  c h a r a c t e r i z e d  b y  a  l a r g e  
H i 'to  H 2 ' c o u p l in g  a n d  th e  a b s e n c e  o f  s ig n i f i c a n t  H 2 "  to  H 3 '  
and H 3 ' to  H 4 ' c o u p l in g s .  In  c o n t r a s t ,  a n  A - ty p e  D N A  c o n ­
formation la rg e ly  m a i n t a i n s  a  C 3 '- e n d o  c o n f o r m a t io n  c h a r a c ­
terized by a la rg e  H 2 "  to  H 3 '  a n d  H 3 '  to  H 4 '  c o u p lin g s  b u t  la c k s  
significant H I '  to  H 2 '  c o u p l in g .
The tw o -d im e n s io n a l C O S Y  e x p a n s io n  o f  t h e  re g io n  s h o w in g  
the H i '  to  H 2 "  a n d  H 2 '  a n d  t h e  H 3 '  t o  H 2 "  a n d  H 2 '  c o u p l in g s  
•s shown in F ig u re  9 . T h e  H 2 "  s ig n a ls  a r e  d o w n f ie ld  o f  t h e  H 2 '  
stgnals, e x c e p t in  th e  c a s e  o f  9G .23 F o r  a l l  o f  t h e  H 1 ' to  H 2 "
c hary, K. V. R.; Hosur, R. V.; Govil, G.; Zu-kun, T.; Miles, H. T. 
Snr *^7, 26, 1315. Altona, C.; Sundaralingam, M. J. Am. Chem.
(23? ’ m S -
intrant! | l *S- ®enerahy observed that H2' protons resonate upfield of their 
intranucl6011^ 6 ^ ” Protons an(* tbat the former are spatially closer to their 
tensities eoV ê Pur>ne H 8  or pyrimidine H 6  base protons. Cross-peak in- 
a °ne-dim ■ two‘d'mensional NOESY at a short mixing time (100 ms) and 
Was irrad'6” H°na* ^C>E difference experiment, in which the 9G H 8  proton 
that the »r u  a,nt* tbe 'ntranucleotide sugar protons were observed, indicate 
(2.70 ppm. -j/ 2  proton resonates upfield (2.47 ppm) of the 9G H2' proton 
Hi' i \ i ,  e IB). This is confirmed by cross-peak intensities between 
cl°&er to H r, ?nc* (unpublished results), where H I' is predicted to be 
C ty £  (2.3 A) than to H2' (3.0 A ): Van De Ven, F. J. M.; Hilbers,
'be SUg ’ • °iochem. 1988, 178, 1. Predictions from amber suggest that
anthramVciCOnH0rmation of 9(5 mi&ht ** O1'-exo in d(ATGCAT)2-  
ântly djffm aĉ uct- Distances derived from this modeling are not signifi- 
V ;,G Hr 2  from those predicted for C2'-endo sugars: 9G H8-H2', 2.3 
JJOE i n t e n s , ’ 3 63 ; 9(5 H1'“ H2'- 3 06 A; 9G Hl'-H2", 2.47 A. As such, 
exoaver les.a*one cannot discriminate between typical C2'-endo and 
(YUPhng | u®ar geometries. However, on the basis of the observed
lTabl«iB F ; i n : G H 1' and the downfield resonance designated as H2' 
gure 9), we conclude that the sugar geometry at 9G is C2'-endo.
a n d  H 2 ' c o u p lin g s , e x c e p t th o s e  a s s o c ia te d  w ith  9G , th e  c ro s s -p e a k s  
to  H 2 '  a r e  m o re  in te n s e  t h a n  t h e  c r o s s - p e a k s  to  H 2 " .  T h e  c o ­
in c id e n c e  o f  th e  H 2 "  a n d  H 2 '  r e s o n a n c e  s ig n a ls  fo r  5A  a n d  12T  
d o e s  n o t  p e r m i t  c o m p a r i s o n  o f  t h e i r  r e la t iv e  in te n s i t i e s .  T h e s e  
d a t a  a r e  c o n s is te n t w ith  a  C 2 '- e n d o  c o n fo rm a tio n  fo r th e  r e m a in d e r  
o f  th e  n u c le o tid e s .  W e a k  c r o s s - p e a k s  b e tw e e n  H 3 '  a n d  H 4 '  a n d  
H 2 "  to  H 3 '  ( u n p u b l i s h e d  r e s u l t s )  a r e  a l s o  in  a c c o r d  w i th  a  
C 2 '- e n d o  c o n fo rm a t io n  fo r  th e s e  s u g a r s .  T h e  re s u lts  o f  th e  C O S Y  
e x p e r im e n t s  i n d ic a te  t h a t  m o s t  o f  t h e  s u g a r s  in  th e  a n t h r a m y -  
c i n - d ( A T G C A T ) 2 a d d u c t  m a i n t a i n  t h e  C 2 '- e n d o  g e o m e t r y  a s ­
s o c ia te d  w i th  B - ty p e  D N A ,  w h ic h  is a ls o  fo u n d  in  d ( A T G C A T )  
a lo n e .
B. Effect of Anthramycin Bonding on Glycosidic Dihedral 
Angles in d(ATGCAT)2. T h e  r e la t iv e  in te n s i t ie s  o f  t h e  in t r a -  a n d  
in te rn u c le o t id e  c o n n e c t iv it ie s  b e tw e e n  H I '  a n d  H 6  o r  H 8  p ro to n s  
a n d  H 2 '  to  H 6  o r  H 8  p r o to n s  p ro v id e  i m p o r t a n t  in f o r m a t io n  o n  
th e  g ly c o s id ic  d ih e d ra l  a n g le  a n d  in d ir e c t  in fo rm a tio n  o n  th e  s u g a r  
p h o s p h a te  b a c k b o n e  g e o m e tr y .  F o r  e x a m p le ,  w h ile  B - ty p e  D N A  
sh o w s  s h o r te r  in t r a n u c le o t id e  H 2 '  to  H 6  o r  H 8  c o n n e c t iv it ie s  th a n  
3 ' to  5 ' in te rn u c le o t id e  H 2 ' to  H 6  o f  H 8  c o n n e c t iv it ie s ,  th e  re v e rs e  
is  t r u e  fo r  A - ty p e  D N A .
E x p a n d e d  re g io n s  o f  th e  tw o - d im e n s io n a l  N O E S Y  s p e c t r a  
s h o w in g  H 1' c o n n e c tiv it ie s  to  p u r in e  H 8  o r  p y r im id in e  H 6  p ro to n s  
a r e  s h o w n  in  F ig u r e  1 0 A ,B . O n  b o th  t h e  c o v a le n t ly  ( 'A  to  6T )  
a n d  th e  n o n c o v a le n t ly  ( 7A  to  12T )  m o d if ie d  s t r a n d s ,  c o m p le te  3 ' 
to  5 ' s e q u e n tia l  “ w a lk s ” b e tw e e n  t h e  in t e r n u c le o t id e  c o n n e c t iv i ty  
fo r  H 1 ' o f  6T  (o r  12T )  a n d  H 8  o f  5A  ( o r  " A )  to  th e  in t r a n u c le o t id e  
H I '  to  H 8  o f  *A ( o r  7A )  c a n  b e  m a d e .  O f  th e s e  c o n n e c t iv i t i e s  
o n ly  t h e  ,0C  i n t r a n u c le o t id e  c r o s s - p e a k  m a y  b e  s o m e w h a t  le s s  
in t e n s e  t h a n  th e  o t h e r  i n t r a n u c le o t id e  c r o s s - p e a k s .  T h i s  is  a ls o  
t r u e  o f  t h e  d ( A T G C A T ) .  N o  s i g n i f i c a n t  c h a n g e s  in  in te n s i t i e s  
o f  in t e r n u c le o t id e  c r o s s - p e a k s  a r e  o b s e r v e d .
B -T y p e  (C 2 '-e n d o )  a n d  A - ty p e  (C 3 '- e n d o )  D N A  c o n fo rm a tio n s  
c a n  b e  d i f f e r e n t i a t e d  b y  H 6  ( H 8 )  c o n n e c t iv i t i e s  to  H 2 '  p ro to n s .  
F o r  C 2 '- e n d o  s u g a r  p u c k e r  t h e  i n t r a n u c le o t id e  c o n n e c t iv i ty  
( H 8 / H 6  to  H 2 ')  is m o re  in te n s e  t h a n  to  t h e  5 ' n e ig h b o r in g  H 2 '.  
T h e  r e v e r s e  is t r u e  fo r  C 3 '- e n d o  o r  A - ty p e  h e l ic ie s .24 T h e  H 2 "  
a n d  H 2 '  t h r o u g h - s p a c e  c o n n e c t iv i t i e s  to  t h e  p u r in e  H 8 ’s a n d  
p y r im id in e  H 6 ’s a r e  s h o w n  in  F ig u r e  11 A ,B . In  th i s  p a r t i c u l a r  
e x p e r im e n t  th e  lo n g  m ix in g  t im e  (5 0 0  m s )  p e r m i t te d  u s  to  o b se rv e  
n o t  o n ly  c o n n e c t iv i t i e s  b e tw e e n  t h e  H 2 '  to  a r o m a t i c  p r o to n  v ia  
in t r a -  a n d  i n t e r n u c le o t id e  p a th w a y s  b u t  a l s o  H 2 "  c o n n e c t iv i t i e s  
to  t h e  a r o m a t i c  p r o to n s .  F o r  e x a m p le ,  a t  7 .2 5  p p m  w e  o b s e r v e  
f o u r  c o n n e c t iv i t i e s  fo r  t h e  H 6  p r o to n  o f  2T .  T h e s e  a r e  f r o m  
d o w n f ie ld  to  u p f ie ld ,  t h e  i n t e r n u c le o t id e  ’A H 2 "  to  2T H 6  A H 2 ' 
to  2T H 6  a n d  t h e  in t r a n u c le o t id e  2T H 2 "  to  2T H 6  a n d  2 T H 2 '  to  
2 T H 6  c o n n e c t iv i t i e s  f o r  th i s  p a i r  o f  n u c le o t id e s .  F o r  b o th  th e  
c o v a le n t ly  a n d  n o n c o v a le n t ly  m o d i f ie d  s t r a n d s  ( F i g u r e  1 2 A ,B )  
th e  p a t t e r n  o f  s t r o n g e r  in t r a -  v s in te r n u c le o t id e  c o n n e c t iv i t ie s  fo r  
th e  a r o m a t ic  to  H 2 '  a n d  H 2 "  p ro to n  p a i r s  h o ld s  a t  s h o r t e r  m ix in g  
t im e s .  T h is  c o n f ir m s  C 2 '- e n d o  o r  B - ty p e  c o n f o r m a t io n  f o r  b o th  
s t r a n d s .  In  s o m e  c a s e s  o v e r la p p in g  c r o s s - p e a k s  ( i .e . ,  3G  a n d  9G )  
d o  n o t  p e r m i t  c o m p a r i s o n .
C. Effect of Anthramycin Bonding on Phosphate Backbone 
Conformation. A  c o m p a r i s o n  o f  t h e  31P N M R  s p e c t r a  fo r  d -  
( A T G C A T )  a n d  th e  a n t h r a m y c i n - d ( A T G C A T ) 2 a d d u c t  ( F ig u r e
3 )  re v e a le d  a  s ig n if ic a n t  d o w n f ie ld  s h i f t  f o r  tw o  o f  t h e  31P  N M R  
s ig n a ls  in  th e  d u p le x  a d d u c t .  In  o r d e r  to  d e t e r m in e  th e  id e n t i ty  
o f  th e s e  d o w n f ie ld - s h if te d  p h o s p h a te s ,  d ( A T G C A T )  w a s  p re p a re d  
c o n t a in i n g  s p e c if ic a l ly  170 - l a b e l e d  p h o s p h a te s .  T h e  o b s e r v e d  
b r o a d e n i n g  o f  c e r t a i n  31P r e s o n a n c e s  in  s p e c t r a  o f  b o th  t h e  d -  
( A T G C A T )  a n d  th e  a n th ra m y c in  a d d u c t  is d u e  to  th e  q u a d r u p o la r  
n a t u r e  o f  a n  a t t a c h e d  170  n u c le u s .  T h i s  p e r m i t s  a s s ig n m e n t  o f  
31P  r e s o n a n c e s  to  p a i r s  o f  p h o s p h a te s  in  th e  a n t h r a m y c i n - d -  
( A T G C A T ) 2 a d d u c t .  In  th i s  w a y , t h e  tw o  d o w n f ie ld - s h if te d  31P  
r e s o n a n c e s  a t  + 0 .2 0  a n d  - 0 . 0 4  p p m  ( F i g u r e  3 )  o f  t h e  a n t h r a -  
m y c i n - d ( A T G C A T ) 2 a d d u c t  c a n  b e  a s s ig n e d  to  p h o s p h a te s  fo r  
T - G  a n d  G - C  ( 5 '  to  3 ')  s te p s ,  r e s p e c t iv e ly  ( u n p u b l i s h e d  r e s u l t s ) .  
B e c a u s e  t h e  a n t h r a m y c i n - i j ( A T G C A T ) 2 a d d u c t  p o s s e s s e s  n o n -  
s y m m e tr ic a l  b u t  s e l f - c o m p le m e n ta ry  s t r a n d s ,  c o r re s p o n d in g  u p fie ld
(24) Haasnoot, C. A. G.; Westerink, H. P.; van der Marel, G. A.; van
Boom, J. H. J. Biomol. Struct. Dyn. 1984, 2, 345.
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31P  r e s o n a n c e s  a t  - 0 .5 1  a n d  - 1 . 0 2  p p m  fo r  T - G  a n d  G - C  ( 5 '  to  
3 ')  s te p s  w e re  a ls o  id e n t i f ie d .  A  tw o - d im e n s io n a l  31P - 'H  / - c o r ­
r e la t io n  N M R  e x p e r i m e n t  ( F i g u r e  1 2 ), in  c o m b in a t io n  w i th  
p r e v io u s ly  a s s ig n e d  H 3 ' ,  H 4 ' ,  a n d  H 5 '  p r o to n s ,  a l lo w e d  a s s i g n ­
m e n ts  o f  th e  n O - b ro a d e n e d  31P  re s o n a n c e s  to  e i th e r  th e  c o v a le n t ly  
o r  n o n c o v a le n t ly  m o d i f ie d  s t r a n d s .  T h e  tw o  f u r th e r m o s t  d o w n ­
f i e ld - s h i f te d  31P  r e s o n a n c e s  w e re  t h u s  id e n t i f ie d  a s  th o s e  5 '-  to  
3 '- s te p s  b e tw e e n  2T - 3G  a n d  9G - I0C , o n  t h e  c o v a le n t ly  a n d  n o n ­
c o v a le n t ly  m o d if ie d  s t r a n d s ,  r e s p e c t iv e ly .
I t  is p e r h a p s  n o t  s u r p r i s i n g  t h a t  o n e  o f  th e  d o w n f ie ld - s h i f t e d  
31P  N M R  s ig n a ls  ( 2T - 3G )  is d i r e c t ly  a d j a c e n t  to  t h e  c o v a le n t  
m o d i f i c a t io n  s i te  o n  d ( A T G C A T ) 2. A  s im i l a r  o b s e r v a t io n  h a s  
b e e n  m a d e  fo r  th e  p h o s p h a te  b e tw e e n  5 '- ( C - G )  c o n ta in e d  in  th e  
s e q u e n c e  5 '- C G A - 3 ' u p o n  b o n d in g  o f  to m a y m y c in .17 In  th is  c a s e , 
e x a m in a t io n  o f  th e  !H  N M R  s p e c t r a  a l lo w e d  u s  to  a s s o c ia te  th is  
d o w n f ie ld  31P  r e s o n a n c e  to  a  p e r tu r b a t i o n  o f  b a c k b o n e  c o n f i r ­
m a t io n .  T h e  s e c o n d  d o w n f ie ld - s h i f t e d  31P  r e s o n a n c e  in  t h e  a n -  
t h r a m y c i n - d ( A T C G A T ) 2 a d d u c t  is b e tw e e n  th e  C  a n d  G  ( 5 ' - 3 ' )  
o n  t h e  n o n c o v a le n t ly  m o d i f ie d  s t r a n d .  T h i s  is d i r e c t ly  a d j a c e n t  
to  9G , w h ic h  s h o w s  t h e  u p f ie ld  s h i f t  o f  t h e  H 2 "  p r o to n .  In  th e  
b i s ( t o m a y m y c i n ) - 1 2 - m e r  a d d u c t  w h e re  th e  b o n d in g  s e q u e n c e  is 
5 '- C G A - 3 ',  a n  e q u iv a le n t  d o w n f ie ld - s h if te d  3IP  r e s o n a n c e  o n  th e  
n o n c o v a le n t ly  m o d i f ie d  s t r a n d  d o e s  n o t  o c c u r .  A n t h r a m y c i n  is 
b o u n d  in  a  le a s t  f a v o re d  s e q u e n c e  ( 5 ' - T G C = 5 '- P y G P y ) ,  a n d  
to m a y m y c in  is b o u n d  in  a  m o r e  f a v o re d  s e q u e n c e  ( 5 ' - C G A =  
5 '- P y G P u ) .  T h e  e x t r a  d o w n f ie ld - s h if te d  3IP  re s o n a n c e  in  5 '- T G C  
m a y  b e  th e  r e s u l t  o f  d e s h ie ld in g  b y  a n th r a m y c in .  A l t e r n a t iv e ly ,  
t h e  31P  s h i f t s  m a y  b e  a n  i n d ic a t io n  o f  p e r tu r b a t i o n  o f  D N A  
s t r u c t u r e ,  w h ic h  c o u ld  b e  r e q u i r e d  fo r  c o v a le n t  b o n d in g  o f  a n ­
th r a m y c in  to  th is  se q u e n c e . F u r th e r m o r e ,  th is  c o u ld  b e  th e  re a s o n  
t h a t  P y G P y  s e q u e n c e s  a r e  le s s  f a v o re d  b o n d in g  s e q u e n c e s  fo r  
P [  1,4] B s t h a n  P y G P u  s e q u e n c e s .11 T h is  id e a  is f u r th e r  s u p p o r te d  
b y  u n p u b l i s h e d  31P  N M R  s tu d ie s  o n  a n t h r a m y c i n  b o u n d  to  a n  
o l ig o m e r  c o n ta in in g  th e  c o v a le n t  b o n d in g  s e q u e n c e  5 ' - A G A - 3 ' .  
In  th i s  c a s e  d o w n f ie ld - s h i f t e d  31P  r e s o n a n c e  s ig n a ls  a r e  n o t  o b ­
se rv ed . S in c e  th is  o l ig o m e r  b e lo n g s  to  th e  m o s t fa v o re d  5 '- P u G P u  
se q u e n c e , 31P  N M R  m a y  b e  a  s e n s i t iv e  to o l to  e v a lu a te  b a c k b o n e  
d i s to r t io n  o f  D N A , a s  th is  r e la t e s  to  P [  1 ,4] B p r e f e r r e d  s e q u e n c e  
s e le c t iv i ty .25
Comparison of Experimental (N M R ) and Molecular Modeling 
Results. T h e r e  is g e n e r a l ly  e x c e l l e n t  a g r e e m e n t  b e tw e e n  th e  
e x p e r im e n ta l  ( N M R )  f in d in g s  r e p o r te d  h e r e  a n d  th e  p re d ic t io n s  
f r o m  th e  m o le c u la r  m e c h a n ic s  p r o g r a m  a m b e r .  F o r  e x a m p le ,  
th e  a m b e r  p re d ic t io n  o f  s p e c ie s  A  ( F ig u r e  3 ) a s  th e  s p e c ie s  fo u n d  
in  so lu tio n  is in  a c c o rd  w ith  th e  e x p e r im e n ta l  r e s u lts ,  a m b e r  a ls o  
is p r e d ic t iv e  o f  th e  r e la t iv e ly  n o n d is to r t iv e  n a t u r e  o f  t h e  a n t h r a -  
m y c in - d ( A T G C A T ) 2 ( F ig u re  13). M o le c u la r  m o d e lin g  o f  sp ec ie s  
A  ( F i g u r e  3 )  p r e d ic t s  a  n a r r o w e r  g ro o v e  w id th  fo r  t h e  d u p le x  
a d d u c t  t h a n  in  th e  d u p le x  a lo n e . In  t h e  s t r u c t u r e  o f  th i s  d u p le x ,  
b u i l t  in  a m b e r  f r o m  A r n o t t ’s B  D N A  g e o m e tr y  a n d  m in im iz e d ,  
t h e  d i s ta n c e s  b e tw e e n  A 5 - H 2  a n d  G 9 - H F  a n d  b e tw e e n  A l  1 -H 2  
a n d  G 3 - H 1'  a r e  b o th  4 .1 2  A . W h e n  th e  d r u g  is c o v a le n t ly  b o u n d  
a n d  th e  s t r u c tu r e  is r e m in im iz e d ,  th e  c o r r e s p o n d in g  d i s ta n c e s  a r e  
3 .8 5  a n d  3 .6 7  A , re s p e c t iv e ly . T h e s e  in d ic a te  a  s m a ll  b u t  d e f in i te  
n a r r o w in g  o f  th e  m in o r  g ro o v e . T h e  r e a s o n  fo r  th is  b e h a v io r ,  a t  
le a s t  a c c o r d in g  to  t h e  m o d e ls ,  is fo u n d  in  t h e  h y d r o g e n - b o n d in g  
p a t te r n  b e tw e e n  th e  d r u g  a n d  D N A . T h u s , a n th r a m y c in  is b o u n d  
c o v a le n t ly ,  r o u g h ly  a t  i t s  c e n t e r ,  to  o n e  s t r a n d  a n d  a t t r a c t e d  to  
th e  o p p o s i te  s t r a n d  b y  h y d r o g e n  b o n d s  f r o m  e a c h  o f  i t s  e n d s  
( H N 2 B  to  G 9  to  0 9  o f  a n t h r a m y c i n  a n d  H 1 8 A  o f  a n t h r a m y c i n  
to  0 2  o f  T 1 2 ) . T h e s e  i n t e r a c t io n s  p u l l  th e  tw o  s t r a n d s  t o g e t h e r  
in  th e  v ic in i ty  o f  t h e  d r u g .  W h i l e  a l l  t h e s e  p re v io u s  m o d e l in g  
s tu d ie s 13" 15 c o r re c t ly  p re d ic te d  sp e c ie s  A  ( F ig u re  3 ) a s  t h a t  sp e c ie s  
w h ic h  s h o u ld  b e  fa v o re d ,  w e  c o u ld  f in d  n o  e v id e n c e  fo r  th e  B - to  
A - ty p e  t r a n s i t i o n  p r e d ic t e d  b y  t h e  s i r  p r o g r a m .13
(25) Patel, D. J. Biochim. Biophys. Acta 1976, 442, 98. Wilson, D. W.; 
Jones, R. L. Nucleic Acids Res. 1982, 10, 1399. Marzilli, L. G.; Bannville, 
D. L.; Zon, G.; Wilson, D. W. J. Am. Chem. Soc. 1986, 108, 4188. Wilson,
D. W.; Jones, R. L. J. Am. Chem. Soc. 1986, 108, 7113. Gao, X.; Patel, D. 
J. Biochemistry 1988, 27, 1744. Gao, X.; Patel, D. J. Biochemistry 1989, 28, 
751.
Conclusions and D N A  Repair Implications
( 1 )  D e f in i t iv e  e v id e n c e  fo r  t h e  o r i e n t a t i o n  o f  a n th ra rn v  • 
b o n d in g  in  th e  m in o r  g ro o v e  o f  d ( A T G C A T ) 2 ( a r o m a t i c  ring 
th e  3 '-s id e  o f  3G )  h a s  b e e n  o b ta in e d  b y  tw o -d im e n s io n a l  *H 
s tu d ie s .
(2 )  C o m b in e d  'H  N M R  a n d  m o le c u la r  m o d e lin g  re su lts  proVd 
s tro n g  e v id e n c e  t h a t  in  s o lu tio n  a n th r a m y c i n - d ( A T G C A T ) 2ex: ; 
a s  s p e c ie s  A . A n  X - r a y  s t r u c t u r e  w o u ld  b e  r e q u ir e d  for 
e q u iv o c a l  d e t e r m in a t io n  o f  t h e  s t e r e o c h e m is t r y  a t  C l  1 jn " 
t h r a m y c i n - d ( A T G C A T ) 2.
(3 )  In  c o n t r a s t  to  t h e  t o m a y m y c i n - d ( A T G C A T ) 2 adduct* 
w h ic h  e x is t ,  m o s t  l ik e ly  a s  a  5 0 :5 0  m i x tu r e  o f  s p e c ie s  A and [i 
(F ig u re  3 ) , th e  a n t h r a m y c i n - d ( A T G C A T ) 2 a d d u c t  ex is ts , a t leas 
p r e d o m in a n t ly ,  a s  s p e c ie s  A .
(4 )  A n t h r a m y c i n  b o n d in g  to  d ( A T G C A T ) 2 c a u s e s  relative! 
m in o r  d i s to r t io n  o f  t h e  lo c a l  D N A  s t r u c t u r e  ( F i g u r e  13), 
m o s t  s ig n i f ic a n t  c h a n g e s  a r e  p r e d ic t e d  b y  31P  N M R  to  occur a' 
t h e  p h o s p h a te s  to  t h e  5 '- s id e  o f  t h e  c o v a le n t ly  m o d if ie d  deoxj 
g u a n in e  a n d  to  t h e  d e o x y c y to s in e  o n  t h e  n o n c o v a le n t ly  modifiec 
s t r a n d .  T h e  m in o r - g r o o v e  w id th  o f  d ( A T G C A T ) 2 is pred ic ts 
to  b e  n a r r o w e r  fo l lo w in g  c o v a le n t  m o d i f ic a t io n .
( 5 )  M o d e l in g  p r e d ic t io n s  f r o m  t h e  m o le c u la r  m e c h a n ic s  pro 
g r a m  a m b e r  a r e  l a r g e ly  c o n f i r m e d  b y  th e  !H  N M R  studies
(6 )  T h e  re c o g n itio n  a n d  r e p a ir  o f  n o n d is to r t iv e  c o v a le n t adduct 
b y  D N A  r e p a i r  e n z y m e s  is a  l a r g e ly  ig n o re d  p ro b le m . Huma^ 
f ib ro b la s t  ce lls  a r e  a b le  to  re c o g n iz e  a n d  ex c ise  an th ram ycin -D N A  
a d d u c ts ,7 b u t  th e s e  p r e s u m a b ly  r e p r e s e n t  a  p o p u la t io n  o f  adduct 
in  v a r io u s  s e q u e n c e s .  I t  w ill b e  im p o r t a n t  to  e v a lu a te  th e  abilit 
o f  D N A - r e p a i r  e n z y m e s  to  r e c o g n iz e  a n d  in c is e  a n th ra m y c in ' 
D N A  a d d u c t s  o f  d e f in e d  s t r u c t u r e  so  t h a t  t h e  r u le s  t h a t  govern 
r e c o g n i t io n  o f  m o d i f ie d  D N A  c a n  b e  e x te n d e d  to  nondistortive 
c o v a le n t  D N A  a d d u c t s .
Experimental Procedures
M aterials and Preparation. Anthram ycin 11-methyl ether (lb) was
obtained from Hofmann LaRoche. d(A T G C A T ) was prepared in house 
by solid-phase phosphite-triester synthesis26 and purified across Mach 
ery-N agel N ucleogen H PL C  colum ns with an increasing gradient of 
sodium chloride in phosphate buffer. 170 -L ab eled  oligomers were prc 
pared in identical fashion with the exception that 35% isotopically en 
riched [170 ]w ater  (M S D  Isotopes) was used in the mixture th a t oxidize 
on intermediate phosphite to a phosphate. The oligomers w ere desaltei 
across W aters A ssociates C !8 Sep-pak cartridges.
An intimate mixture o f la  and d(A T G C A T ) was prepared by adding 
3 mg of lb in 0.5 mL of H PL C  grade methanol to a 23 mM solutiono 
the oligomer in a 10 m M  N a H P 0 4-1 0 0  mM N aC l-0 .1  mM EDT' 
buffer adjusted to pH 6.85. The combined solutions were lyophilizedtc 
dryness in a Savant Spin Vac concentrator, and the pellet was redissolvec 
in 0.5 mL of Burdick & Jackson H PLC  grade H 20 .  The resulting 
solution was heated to 65 °C  in a water bath for 20 min and allowed! 
gradually cool to 4 °C . Excess la  and lb was removed by purificatior 
across C lg Sep-pek cartridges. The desalted purified anthramycin^ 
(A T G C A T ) 2 duplex adduct was dissolved in 0.6 mL of 10 mM NaO 
A c-100  mM N aC l-0 .1  m M  EDTA buffer that had been adjusted to pH
7.2 and lyophilized to dryness followed by lyophilization with 2 X 0.5 ml 
o f D 20 .
NMR Experimental Parameters. All ‘H and 31P spectra were collects
on the G N -500 N M R  spectrometer at the University of Texas at Austir 
Austin, T X , at 23 °C , unless otherwise indicated. The N M R  samp 
were prepared in 0.6 mL o f  D 20  and degassed with argon. Cheiffl® 
shifts are reported (ppm) with positive values downfield from an externa 
reference o f 1 m g/m L  T SP in D 20  for ]H and an external reference0 
85% H 3PO4 in D20  for 31P resonances.
One-dimensional spectra of the exchangeable imino protons andNW 
difference spectra were performed on the D20  sam ple and the 
sample that had been lyophilized and redissolved in 90% H 2O -l0% W ” 
Suppression of the H 20  signal was achieved with a 1 3 3 1 p u flE  
quence , 27 and the protons were irradiated, observed, and assigned m ■ 
15, 10, 5, and 0 °C  as before . 16 Tx experiments were performed utl 
the standard nonselective 18 0 ° - 7 ’-9 0 °  pulse sequence as befo re.14®
(26) Atkinson, T.; Smith, M. Solid Phase Synthesis of OligodeoxjW| 
nucleotides by the Phosphodiester Method. In Oligonucleotide S ynt^ k tli  
Practical Approach-, Gait, M. J., Ed.; TRL: Washington, DC, 19“
35-81.
(27) Hore, P. J. J. Magn. Reson. 1983, 55, 283.
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uClear scalar coupling was best determined with the standard two- 
"f’^sional COSY experiment with 2K complex points in t2, 1K points 
%tt h domain, and a recycle delay of > 2  s in addition to the acquisition 
1,1 , The two-dimensional phase-sensitive NOESY was acquired with 
data p°inls ‘n the h  dimension, IK data points in and a recycle 
I 0f >2 s in addition to the acquisition time.27,28 Mixing times of 
,-nand 500 ms were used that were stochastically varied to suppress 
s.peaks arising from scalar coupling. A  shifted sine bell multiplica- 
crapodization of 45% was applied in the t2 and /, domains. 'H-De- 
!l° pled 31P spectra were collected at 202.44 MHz, and 'H -31P correla- 
^ experiments were performed according to the procedure described 
I!vBa* et a1'29
\Jolecular Modeling Studies. The crystal structure of lb  was used as 
initial structure in this investigation. Partial atomic charges for 
' 'ihramycin with the methoxy group removed were provided by Rao et 
i5 gond length, bond angle, and dihedral parameters for the all atom 
force field were those presented by Weiner et al.,31,32 and new parameters 
specific to anthramycin were given by Rao et al.15 The resulting structure
(28) States, D. J.; Habverkorn, R. A.; Ruben, D. J. J. Magn. Resort. 1982,
2 8 6 .
(29) Bax, A.; Sarkar, S. K. J. Magn. Reson. 1984, 60, 170.
(30) Weiner, S. J.; Kollman, P. A.; Case, D.; Singh, U. C.; Ghio, C.; 
Aiagona. G.; Profeta, S., Jr.; Weiner, P. K. J. Am. Chem. Soc. 1984, 106, 765.
(31) Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. J. Comp. 
Chem. 1986. 7, 230.
(32) Weiner, P. K.; Kollman, P. A. J. Comp. Chem. 1984, 2, 287.
was minimized with the program a m b e r 31 with a distance-dependent 
dielectric constant, and refinement continued until the rms gradient was 
less than 0.1 kcal/mol-A. This minimized structure was docked in the 
appropriate location and orientations on the hexanucleotide duplex with 
the aid of the interactive graphics program m i d a s ,33 and then the binding 
energies were minimized with a m b e r  and the parameters described 
above. The helix energy was determined by subtracting the energy of 
the helix in the anthramycin adduct from that of the separately mini­
mized isolated helix. Distortion energy induced in the anthramycin 
molecule was determined in the same way.
Structural effects of water and counterions on complexing were ne­
glected in the energy calculations. Although these effects influence the 
absolute values of binding energies, they should be minimal in comparing 
relative binding energies wherein the same molecule is used at the same 
binding site on the duplex.
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DNA Sequence Specificity of the Pyrrolo[l,4]benzodiazepine Antitumor 
Antibiotics. Methidiumpropyl-EDTA-Iron(II) Footprinting Analysis of DNA 
Binding Sites for Anthramycin and Related Drugs*
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a b s t r a c t :  Anthramycin, tomaymycin, and sibiromycin are members o f the pyrrolo [1,4] benzodiazepine 
[P(1,4)B] antitumor antibiotic group. These drugs bind covalently through N 2 o f  guanine and lie within 
the minor groove of D N A  [Petrusek, R. L., Anderson, G. L., Garner, T. F., Fannin, Q. L., Kaplan, D. J., 
Zimmer, S. G., & Hurley, L. H. (1981) Biochemistry 20, 111 1-1119]. The D N A  sequence specificity of 
the P(1,4)B antibiotics has been determined by a footprinting method using methidiumpropyl-EDTA-iron(II) 
[MPE*Fe(II)], and the results show that each of the drugs has a two to three base pair sequence specificity 
that includes the covalently modified guanine residue. While 5TuGPu is the most preferred binding sequence 
for the P (l,4 )B s, 5'PyGPy is the least preferred sequence. Footprinting analysis by M PE-Fe(II) reveals 
a minimum of a three to four base pair footprint size for each of the drugs on D N A  with a larger than expected 
offset (two to three base pairs) on opposite strands to that observed in previous analyses o f noncovalently 
bound small molecules. There is an extremely large enhancement of MPE*Fe(II) cleavage between drug 
binding sites in AT rich regions, probably indicating a drug-induced change in the conformational features 
of D N A  which encourages interaction with MPE*Fe(II). In the presence o f sibiromycin or tomaymycin 
the normally guanine-specific methylene blue reaction used in Maxam and Gilbert sequencing cleaves at 
other bases in defined positions relative to the drug binding sites. Finally, modeling studies are used to 
rationalize the differences and similarities in sequence specificities between the various drugs in the P(1,4)B 
group and their reactions with DNA.
^Anthramycin, tomaymycin, and sibiromycin (see Figure 1) 
are members of the pyrrolo[ 1,4] benzodiazepine [P(1,4)B]‘ 
class of antitumor antibiotics [for reviews, see Hurley (1977) 
and Thurston & Hurley (1983)]. The potent antitumor ac­
tivity of these agents is believed to be due to their ability to 
react covalently with N 2 of guanine (see Figure 2) in dou­
ble-stranded DNA (Hurley & Petrusek, 1979; Graves et al., 
1984). The resultant drug adducts lie snugly cradled within 
the minor groove of DNA (Petrusek et al., 1981), with the 
right-handed twists of the drug molecules (Mostad et al., 1978; 
Arora, 1979, 1981) tightly following the curvature of the 
double helix in B-form DNA. The close match between the 
twists of the drugs and of DNA led us to hypothesize that, 
in their reaction with DNA, these agents might be sensitive 
to sequence-dependent variations in DNA helical structure and 
that alterations in the twists of the drug molecules might also 
result in alteration of DNA binding selectivity [for reviews 
of sequence specificity in drug-DNA interactions, see Da- 
browiak (1983) and Wilkins (1984)].
Several lines of evidence support the suggestion that the 
P(l,4)Bs react with DNA in a sequence-specific fashion. First, 
competitive binding experiments have demonstrated incomplete 
competition for binding sites between anthramycin and to­
maymycin (Hurley et al., 1977) and between anthramycin and 
CC-1065 (Swenson et al., 1982), indicating that members of
* Supported by Grants CA-31232 (to L.H.H.), CA-35318 (to L.H.H.), 
and GM 3209S (to I.J.M.) from the U.S. Public Health Service and the 
Welch Foundation (L.H.H. and I.J.M.).
* Address correspondence to this author.
* Smith Kline and French Laboratories.
* Division of Medicinal Chemistry, College of Pharmacy, Drug Dy­
namics Institute.
* Department of Microbiology.
the P(1,4)B class bind preferentially to specific regions on the 
DNA. Second, a direct but imprecise demonstration of se­
quence dependence in the reaction of anthramycin with DNA 
has been obtained from studies that established that poly- 
(dG)*poly(dC) is far more receptive to anthramycin binding 
than is poly(dG-dC)*poly(dG-dC) (Petrusek et al., 1981). This 
finding is supported by the results of studies (Sumner & 
Bennett, 1981; Kaplan, 1982) that revealed that anthramycin 
inhibits the action of restriction enzymes whose recognition 
sequences include 5'GG to a greater extent than those whose 
recognition sequences include 5'GC. Additional indications 
that members of the P(1,4)B class are sensitive to structural 
variations in the D NA helix are to be found in the reduced 
reaction kinetics of anthramycin (Reynolds & Hurley, 1982) 
and sibiromycin (Kozmyan et al., 1978) toward chromatin 
relative to naked DNA and in the preference of anthramycin 
for linker DNA rather than nucleosome core DNA (Reynolds 
& Hurley, 1982). However, steric constraints due to the 
presence of histone protein may also contribute to the reduced 
preference for nucleosome core DNA.
The experiments described in this paper were designed to 
test the hypothesis that members of the P(1,4)B class react 
with DNA in a sequence-selective fashion. Two experimental 
strategies were adopted. The more general method, MPE- 
Fe(II) footprinting [for example, see Van Dyke et al., (1982), 
Van Dyke & Dervan (1983a-c), and Van Dyke & Dervan
(1984)] was used to demonstrate that the most preferred
1 Abbreviations: bp, base pair; CPK, Corey-Pauling-Koltun; DTT, 
dithiothreitol; EDTA, ethylenediaminetetraacetic acid; MPE, methidi- 
umpropyl-EDTA; P(1,4)B, pyrrolo[ 1,4]benzodiazepine; Pu, purine; Py, 
pyrimidine; TLC, thin-layer chromatography; Tris, tris(hydroxy- 
methyl)aminomethane; TBE, Tris-borate-EDTA (Maxam & Gilbert,
1980); HPLC, high-performance liquid chromatography.













f i g u r e  1: S tru c tu re s  o f  a n th ra m y c in  ( I ) , to m ay m y c in  ( I I ) ,  s ib irom ycin  
( I I I ) ,  a n d  8 - m e th y l - 9 - h y d r o x y - P ( l ,4 ) B  ( I V ) .
H ,OH
FIG U RE 2 : P la u s ib le  m e c h a n is m  fo r  th e  re a c tio n  o f  th e  P ( l ,4 ) B s  w ith  
D N A  to  fo rm  th e  P ( l , 4 ) B - ( N 2- g u a n in e ) - D N A  a d d u c ts  ( P e t ru s e k  
e t  a l . ,  1 9 8 1 ; G r a v e s  e t  a l . ,  1 9 8 4 ).
b in d in g  s e q u e n c e s  fo r  th e  d r u g s  a r e  5 'P u G P u  a n d  t h e  le a s t  
p r e fe r r e d  a t  5 'P y G P y . S in c e ,  to  o u r  k n o w le d g e , th is  is  th e  first  
e x a m p le  o f  a  c o v a le n t  D N A  b in d e r  t h a t  h a s  b e e n  s u b j e c t e d  
to  f o o t p r in t in g  a n a ly s i s  u s in g  M P E - F e ( I I ) ,  a  c o m p a r is o n  o f  
th e  c h a r a c t e r is t ic s  o f  t h e  fo o tp r in ts  o f  th e  P ( 1 ,4 ) B  a n t ib io t ic s  
to  th o s e  o f  n o n c o v a le n t  m in o r  g r o o v e  b in d e r s  a n d  in te r c a la t in g  
a g e n t s  is  p r e s e n t e d .  P o r t io n s  o f  th is  w o r k  h a v e  a p p e a r e d  in  
p r e lim in a r y  fo r m  ( R e y n o ld s  e t  a l .,  1 9 8 3 ;  H u r le y  e t  a l . ,  1 9 8 4 a ) .
M a t e r i a l s  a n d  M e t h o d s  
Drugs, Enzymes, and Chemicals. T o m a y m y c in  a n d  s ib i ­
r o m y c in  w e r e  s u p p l ie d  b y  F u j is a w a  P h a r m a c e u t ic a l  C o .  
( O s a k a ,  J a p a n )  a n d  b y  B r is to l  L a b o r a to r ie s  (S y r a c u s e ,  N Y ) ,  
r e s p e c t iv e ly ,  a n d  w e r e  c h e c k e d  fo r  p u r ity  b y  T L C  ( H u r le y ,
1 9 7 7 )  p r io r  t o  u s e .  T h e  s y n t h e t i c  d e r iv a t iv e  8 - m e t h y l - 9 -  
h y d r o x y - P ( l , 4 ) B  ( I V )  w a s  s y n t h e s iz e d  in  o u r  la b o r a to r ie s  
( T h u r s t o n  e t  a l . ,  1 9 8 4 ) .  P o ly n u c le o t id e  k in a s e  fr o m  b a c t e r ­
io p h a g e  T 4  in fe c te d  Escherichia coli w a s  iso la te d  a n d  p u r if ie d  
a c c o r d in g  t o  p u b l is h e d  p r o c e d u r e s  ( R ic h a r d s o n ,  1 9 7 1 )  o r  
p u r c h a s e d  fr o m  B o e h r in g e r  M a n n h e im  ( I n d ia n a p o l i s ,  I N ) .  
B o v in e  a lk a l in e  p h o s p h a ta s e  w a s  p u r c h a s e d  fr o m  B o e h r in g e r
M a n n h e im .  R e s t r i c t io n  e n z y m e s  w e r e  p u r c h a s e d  from  Ne» 
E n g la n d  B io la b s  ( B e v e r l y ,  M A ) .  A l l  c h e m ic a ls  used  wert 
r e a g e n t  g r a d e  o r  b e t t e r .  C h e m ic a l s  u s e d  to  p r ep a re  poly 
a c r y la m id e  g e ls  w e r e  e le c tr o p h o r e s is  g r a d e . [ y - 32P ] A T P  n  
s y n t h e s i z e d  a c c o r d in g  t o  p u b l is h e d  p r o c e d u r e s  (W alseth  1 
J o h n s o n ,  1 9 7 9 )  o r  p u r c h a s e d  fr o m  N e w  E n g la n d  Nucleai 
[ a - 32P ] d N T P ’s  w e r e  p u r c h a s e d  fr o m  N e w  E n g la n d  Nuclear 
B a c t e r io p h a g e  T 7  w a s  g r o w n  a n d  p u r if ie d  u s in g  establishec 
p r o c e d u r e s  ( S t u d ie r ,  1 9 6 9 ) .  p B R 3 2 2  a n d  S V 4 0  D N A  wcrt 
p u r c h a s e d  fr o m  B R L  ( B e t h e s d a ,  M D ) .  M P E  w a s  a  generous 
g i f t  o f  D r . P e te r  B . D e r v a n , C a lifo r n ia  In s t itu te  o f  Technology 
P a s a d e n a ,  C A .
Spectrophotometric Methods. C o n c e n t r a t io n s  o f  the fol­
lo w in g  s o lu t io n s  w e r e  d e t e r m in e d  sp ectrop h otom etr ica llyb y j  
u s in g  t h e  i n d ic a t e d  e x t in c t i o n  c o e f f ic ie n t s :  a n th ram ycin  it 
m e t h a n o l ,  i s 333 =  3 6  8 0 0  ( K a p la n  &  H u r le y ,  1 9 8 1 ) ;  tomay 
m y c in  in  m e t h a n o l ,  E 32o =  3 6 0 0  ( H u r le y ,  1 9 7 7 ) ;  sibiromycin 
in  m e th a n o l,  E 3lQ =  21  8 0 0  ( H u r le y ,  1 9 7 7 ) ;  M P E  in  deionized 
w a t e r ,  E ^ 8 =  5 9 9 4  o r  £ 286 =  5 4 7 2 5  ( H e r t z b e r g  &  Derail 
1 9 8 4 ) .
DNA Sequencing. D N A  s e q u e n c in g  w a s  c a r r ie d  out by 
u s in g  t h e  m e t h o d s  o f  M a x a m  &  G ilb e r t  ( 1 9 7 7 ,  1 9 8 0 ) . The 
r e s t r ic t io n  f r a g m e n t s  e m p lo y e d  w e r e  a s  f o l lo w s  (th e  firsi 
p o s it io n  g iv e n  is  t h a t  o f  t h e  s in g le  r a d io a c t iv e  la b e l):  fromTi 
( D u n n  &  S t u d i e r ,  1 9 8 1 )  1 - 6 8  a n d  8 3 1 5 - 7 9 1 4 ,  b o th  5 ' end 
la b e le d ;  f r o m  p B R 3 2 2  ( S u t c l i f f e ,  1 9 7 8 )  3 8 0 - 6 5 4  and 375 
( t h r o u g h  1 )—4 3 6 1 ,  b o t h  3 '  e n d  la b e le d ;  fr o m  S V 4 0  (Tooze,
1 9 8 0 )  1 4 9 4 - 1 6 4 1 ,  1 7 1 2 - 1 5 0 9 ,  2 7 7 4 - 2 5 3 3 ,  4 7 4 0 - 4 8 4 3 ,  all 5 
e n d  la b e le d  a n d  3 ' - e n d - la b e le d  f r a g m e n t s  w e r e  2770-2528, 
1 7 8 2 - 1 5 0 9 ,  1 7 8 7 - 2 2 6 0 ,  a n d  3 4 6  ( th r o u g h  1 ) - 5 1 1 9 .  Subse 
q u e n t  a n a ly s i s  d e m o n s t r a t e d  t h a t  th e  s e q u e n c e s  o f  D N A  re 
s t r ic t io n  f r a g m e n t s  u s e d  in  th is  s t u d y  e x a c t ly  m a tch ed  the 
p u b l is h e d  s e q u e n c e s  o f  b a c t e r io p h a g e  T 7  ( D u n n  &  Studier,
1 9 8 1 ) ,  S V 4 0  ( T o o z e ,  1 9 8 0 ) ,  a n d  p B R 3 2 2  ( S u t c l i f f e ,  1978)
Preparation and Determination o f  Sequence Specificity oj
the P(1,4)B-DNA Adducts. T w o  m e th o d s  w e r e  u se d  in the 
p r e p a r a t io n  a n d  a n a ly s i s  b y  M P E * F e ( I I )  fo o tp r in t in g  ofP 
( 1 , 4 ) B - D N A  a d d u c ts .  A d d it io n a l ly ,  m e th y le n e  b lu e  w as used 
to  d e te r m in e  t h e  b in d in g  s it e s  o f  s ib ir o m y c in  a n d  tomaymycin 
T h e  m o s t  im p o r t a n t  d i f f e r e n c e  b e tw e e n  m e th o d s  1 and  2 de- 
s c r ib e d  b e lo w  w a s  t h e  d r u g  to  n u c le o t id e  r a t io s  in  th e  drug 
in c u b a t io n  m ix tu r e s .  O n ly  in  th e  c a s e  o f  m e th o d  2  w a s  carrier 
c a l f  t h y m u s  D N A  u s e d  in  t h e  in c u b a t io n  m ix tu r e s .  While 
h ig h e r  c o n c e n t r a t io n s  o f  d r u g  w e r e  u s e d  w h e r e  c a rr ie r  DNA 
w a s  p r e s e n t , i t  is  l ik e ly  t h a t  th e  f in a l d r u g  to  n u c le o tid e  ratios 
d if fe r e d  m a r k e d ly  b e tw e e n  th e  tw o  m e th o d s . T h e se  differences 
w o u ld  b e  e x p e c t e d  t o  e f f e c t  t h e  k in e t ic s  o f  d r u g  binding to 
D N A  b u t  n o t  t h e  f in a l  D N A  s e q u e n c e  s p e c i f ic i t y .
Method 1. M P E » F e ( I I )  f o o tp r in t in g  r e a c t io n s  (d a ta  for 
F ig u r e s  3 a n d  5  a n d  p o r t io n s  o f  T a b le  I ) .  E a c h  r ea c tio n  (10 
uL) c o n ta in e d  5 0  o r  2 0 0  /xM  (b p )  c a l f  th y m u s  D N A  and  singly 
32P - e n d - la b e le d  D N A  r e s t r ic t io n  f r a g m e n ts  in  10  m M  Tris 
H C 1 , p H  7 .4 ,  a n d  5 0  m M  N a C l .  T h e  P ( 1 ,4 ) B  w a s  dissolved 
in  e th a n o l  a n d  a d d e d  t o  t h e  r e a c t io n  a t  th e  in d ic a te d  con­
c e n t r a t io n s  ( f i n a l  e t h a n o l  c o n c e n t r a t io n s  w a s  < 1 0 % ) . After 
4  h  a t  3 7  ° C  (s h o r te r  t im e s  a r e  in d ic a te d  in  th e  fig u r e  legends), 
M P E - F e ( I I )  w a s  a d d e d  to  a  f in a l  c o n c e n tr a t io n  o f  5 /xM. The 
r e a c t io n  w a s  in c u b a t e d  a t  r o o m  te m p e r a tu r e  fo r  15 m in , and 
c le a v a g e  w a s  in i t ia t e d  b y  th e  a d d it io n  o f  D T T  (f in a l  concen 
t r a t io n  2  m M ) .  T h e  c l e a v a g e  w a s  a l lo w e d  to  p r o c e e d  for 15 
m in  a n d  w a s  t e r m in a t e d  b y  p r e c ip ita t io n  o f  th e  D N A  in eth­
a n o l .  T h e  s a m p le s  w e r e  t h e n  e le c tr o p h o r e s e d  a s  w ill be de 
s c r ib e d .
M ethod 2. T h e  M P E - F e ( I I )  fo o tp r in t in g  p r o ced u re  de 
sc r ib e d  h e r e  w a s  u se d  t o  a c q u ir e  d a ta  fo r  F ig u r e  4  a n d  portions
DNA S E Q U E N C E  S P E C I F I C I T Y  OF A N T I T U M O R  A G E N T S
of Table I, while the methylene blue procedure was used to 
acquire the data in Figure 6A. Solutions of anthramycin, 
tomaymycin, and sibiromycin were prepared in methanol 
(HPLC grade) immediately prior to use. Drug concentrations 
were determined spectrophotometrically as described earlier. 
Aliquots of these solutions containing 1.5,0.15,0.075, or 0.015 
nmol of drug were dried under vacuum, combined with singly 
32P-end-labeled DNA in 1 mM NaCl (8 pL  final volume), and 
incubated (3 h for anthramycin and tomaymycin samples; 1 
h for sibiromycin samples) at room temperature. For samples 
that were to be subjected to the methylene blue reaction, 
unreacted drug was removed by extraction with water-satu­
rated 1-butanol (2 X 100 ph). The samples were then lyo­
philized, resuspended in 20 pL  of deionized water, subjected 
to reaction with methylene blue as described (Friedmann & 
Brown, 1978), and electrophoresed as will be described. For 
samples that were to be treated to MPE-Fe(II) digestion, the 
reaction mixtures were adjusted to 10 mM Tris-HCl, pH 7.4, 
50 mM NaCl, 90 /iM calf thymus DNA (bp), and 10 pM  
MPE*Fe(II) in a final volume of 10 fiL as described (Van 
Dyke & Dervan, 1983a). Following incubation for 30 min 
at room temperature, 1 pL  of 40 mM DTT was added, and 
digestion was carried out for 15 min at 37 °C as described 
(Van Dyke & Dervan, 1983a). In order to alleviate P (l,4)- 
B-related smearing of bands upon subsequent electrophoresis 
(Sumner & Bennett, 1981), bound drug was removed from 
the DNA by heating (90 °C, 5 min) followed by either ex­
traction with water-saturated 1-butanol or precipitation of the 
DNA in ethanol (Hurley et al., 1979). The samples were then 
dried under vacuum and electrophoresed as will be described.
Electrophoretic Analysis o f  P(1,4)B Binding Sites on DNA. 
DNA samples that had been either treated to base-specific 
sequencing reactions or analyzed for P(1,4)B binding sites as 
described earlier were resuspended in 4-10 pL  tracking dye 
(50% deionized formamide, 0.1% bromophenol blue, and 0.1% 
xylene cyanol in TBE), heated (90 °C, 5 min) to denature the 
DNA and release covalently bound P(1,4)B (Hurley et al., 
1979), and quickly chilled on ice-water. Equal amounts of 
radioactivity from the DNA samples were loaded onto thin 
denaturing polyacrylamide gels (8%; 1:20 acrylamide-bis- 
acrylamide; 50% urea) and electrophoresed at 1200-1800 V 
for 2-4 h. Autoradiograms were developed by using Kodak 
XRP-1 or XAR-2 film with the aid of intensifying screens.
Densitometric Analysis o f  Sequencing Gels. Autoradio­
grams were scanned with an LKB 2202 laser densitometer 
interfaced with an HP3390 integrator. Background absor­
bance due to the film density was subtracted from the scans. 
The data are reported as percentage cleavage, P  =  100(/4p -  
Ac), where Ap is the area of a peak corresponding to an 
MPE*Fe(II) cleavage band in the presence of P(1,4)B, and 
Ac is the area of the peak corresponding to the same MPE* 
Fe(II) cleavage band for unmodified DNA. Values of P  
greater than 100% indicate cleavage enhancement, while values 
less than 100% indicate cleavage inhibition.
Results
Our initial approach to determine the DNA sequence spe­
cificity of the P(l,4)Bs was based upon the assumption that 
because these drugs bind to DNA covalently through N 2 of 
guanine, they should inhibit a guanine-specific methylene blue 
reaction (Friedmann & Brown, 1978). Experiments were 
carried out with the expectation that the binding site of the 
drug molecule could be revealed as a diminution of band 
intensity on autoradiographs of sequencing gels in which singly 
32P-end-labeled DNA was bound with drug and then treated 
with methylene blue. To our surprise, it was found that si-
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biromycin- and toiriaymycin-treated DNA samples exhibited 
new bands at sites other than guanine upon treatment with 
methylene blue. This interesting observation points to a po­
tential problem inherent in experiments where DNA binding 
ligands can alter the normal specificity of DNA cleavage 
reagents, presumably through ligand-induced conformational 
changes in DNA. Although we were able to identify the 
binding sites on D N A  of tomaymycin and sibiromycin from 
the methylene blue experiments this technique was unfortu­
nately not general for all members of the P(1,4)B class and 
therefore an alternative, more generally applicable method was 
sought. The results to be presented in this report are largely 
derived from the MPE*Fe(II) footprinting method. A com­
parison of the results of an experiment with sibiromycin using 
the methylene blue and MPE*Fe(II) methods is also presented.
Time Course Binding o f  Anthramycin to DNA As Revealed 
by MPE'Fe{IT) Footprinting Analysis. MPE*Fe(II) cleavage 
of a 123 base pair restriction enzyme fragment labeled at the 
5' end with 32P affords a relatively uniform DNA cleavage 
pattern on a Maxam-Gilbert sequencing gel (Figure 3A, lane 
2). In contrast, pretreatment of the DNA with anthramycin 
leads to nonuniform pattern that is due to the inhibition of 
MPE*Fe(II) cleavage at sites where anthramycin is bound 
superimposed on an enhanced degree of cleavage between 
binding sites. Enhancement of MPE*Fe(II) cleavage has also 
been observed by Dervan and co-workers (Van Dyke & 
Dervan, 1983c). The D N A  fragments pretreated with an­
thramycin for incremental amounts of time (Figure 3A, lanes 
3-6) revealed three major MPE*Fe(II) footprints (sites A -C  
in Figure 3A). The arrows in lane 7 identify the locations of 
guanines on the unlabeled DNA strand, while the bands in 
lane 7 identify the guanines on the labeled DNA strand. 
Therefore, collectively the arrows and bands in lane 7 identify 
all the possible anthramycin binding sites on this fragment that 
are found up to footprint C. Significantly even at the longest 
incubation time not all of the possible guanines are modified 
by anthramycin (see, for example, the guanine between sites 
A and B), and some sites (sites A and B) are filled before 
others (site C). A  discussion of the relative affinities of an­
thramycin for these sites is given below. The footprint at site 
A increased in size from the 15-min to the 270-min exposure 
(Figure 3A, lanes 3 and 6), most likely due to the inclusion 
of a lower affinity binding site at the longer incubation times. 
In contrast, the footprint at site B appeared to decrease in size 
from lanes 3 to 5. This appeared to be related to the con­
siderable enhancement of MPE*Fe(II) cleavage at sequences 
between drug binding sites. The enhancement between sites 
A and B was most pronounced for the 270-min incubation time 
where a 12-fold increase was evident (see Figure 3B). Figure 
3B shows histogram plots derived from densitometric tracings 
of footprinting lanes 3 and 6 from Figure 3A, and clearly 
reveals both the MPE*Fe(II) footprints of anthramycin and 
the enhancement of cleavage outside drug binding sites.
Comparison o f  MPE-Fe(IT) Footprinting o f  Anthramycin, 
Tomaymycin, and Sibiromycin. While MPE-Fe(II) cleavage 
of the unmodified 204 bp fragment shown in Figure 4A af­
forded a relatively uniform DNA cleavage pattern on a 
Maxam-Gilbert sequencing gel (lane 10), the cleavage of 
drug-treated fragments (lanes 1-9) again produced a much 
more uneven pattern. The histogram plots derived from the 
densitometric tracings of lanes 2 ,6 , and 8 in Figure 4A provide 
an improved visual perception of the MPE*Fe(II) cleavage 
inhibition by sibiromycin, tomaymycin, and anthramycin 
(Figure 4B). The histograms show the relative cleavage by 
MPE*Fe(II) of drug-treated vs. control DNA. The 100% value
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f i g u r e  3: (A ) Time course autoradiogram of D N A  cleavage inhibition 
by anthramycin. A 5'-32P-end-labeled 123 bp fragment was reacted 
with anthramycin (100 //M ) and subjected to M PE-Fe(II) footprinting 
as described in method 1 (M aterials and M ethods). Lane 1, intact 
D N A ; lane 2, M PE-Fe(II) cleavage o f unprotected D N A ; lanes 3 -6 , 
M PE -Fe(II) cleavage inhibition by anthram ycin at 100 /iM  prein­
cubated for 15, 60, 120, and 270 min (lanes 3 -6 , respectively) at 37 
°C; lane 7, G-specific reaction. The D N A  concentration was 50 nM  
(bp). Arrows in lane 7 indicate positions o f  the guanines on the 
opposite (unlabeled) strand. Brackets labeled A -C  are anthramycin 
footprints. (B ) H istogram s o f  anthram ycin-induced differences in 
the susceptibility o f D N A  to M PE-Fe(II) cleavage. The data are from 
lanes 3 and 6 in (A ) and represent 15- and 270-m in preincubation  
with anthram ycin. Footprints A -C  are the sam e as those depicted  
in (A ). Values over 100% indicate percentage enhancem ent relative 
to control (see M aterials and M ethods), whereas values o f  0 -1 0 0  
indicate percentage inhibition relative to the control.
s h o w n  in  F ig u r e  4 B  th e r e f o r e  r e p r e s e n t s  z e r o  c h a n g e  in  t h e  
a m o u n t  o f  c le a v a g e  in  d r u g - tr e a te d  v s . c o n tr o l  la n e s .  A  c o m ­
p a r iso n  o f  th e  th r e e  h is to g r a m s  in  F ig u r e  4 B  s u b s ta n t ia te s  th e  
o b s e r v e d  e n h a n c e m e n t  o f  M P E - F e ( I I )  c le a v a g e  o f  f la n k in g
a )  1 5  m i n u t e  p r e - i n c u b a t i o n
In  n-rrTfT h l r l l
5C A C A A G TG G A TC TTTC C TG TA TA A TTTTC TA TTTTC A TG C TTC A TC C TC A G TA3
b )  2 7 0  m i n u t e  p r e - i n c u b a t i o n
s e q u e n c e s  a d j a c e n t  t o  d r u g  b in d in g  s i t e s  s h o w n  in  F ig u re  3 
a l t h o u g h  t h e  e f f e c t  w a s  m u c h  l e s s  p r o n o u n c e d  u n d e r  these 
p a r t ic u la r  e x p e r im e n t a l  c o n d it io n s .  T h e  tw o  m o s t  prom inent 
b in d in g  s i t e s  w e r e  a lm o s t  t h e  s a m e  fo r  a l l  th r e e  d r u g s , max­
im u m  in h ib i t io n  o f  M P E - F e ( I I )  c le a v a g e  o c c u r r in g  o n e  base 
r e m o v e d  o n  th e  3 '  s id e  o f  a  c o m m o n  s e q u e n c e  5 'A G G A . While 
s ib ir o m y c in  a n d  a n t h r a m y c in  p r o d u c e d  p r o n o u n c e d  inhibition 
o f  M P E - F e ( I I )  c l e a v a g e  ( m a x im u m  7 0 - 8 0 %  a n d  3 0 - 4 0 % ,  
r e s p e c t iv e ly ) ,  t o m a y m y c in  c le a v a g e  in h ib it io n  w a s  m u c h  less 
p r o n o u n c e d  a n d  w a s  o n l y  v i s ib le  r e la t iv e  t o  th e  enhanced  
c le a v a g e  o n  e ith e r  s id e  o f  t h e  b in d in g  s it e s .  S ib ir o m y c in  had 
a d d i t io n a l  b in d in g  s e q u e n c e s  ( i .e . ,  t o  t h e  3 '  s id e  o f  B  a n d  the 
5 '  s id e  o f  A  in  F ig u r e  4 B )  n o t  e v id e n t  in  to m a y m y c in  or 
a n t h r a m y c in  t r e a t m e n t  la n e s .
Opposite Strand Analysis fo r  Anthramycin (I), Tomay­
mycin (II), and 8-M ethyl-9-hydroxy-P(l,4)B  (IV). O n  the 
b a s is  o f  th e  r e su lts  o f  p u b lis h e d  e x p e r im e n ts  w ith  noncovalent 
m in o r  g r o o v e  b in d in g  a g e n t s  u s in g  t h e  M P E - F e ( I I )  cleavage  
te c h n iq u e , i t  w a s  e x p e c te d  th a t  a n  a s y m m e tr ic  D N A  inhibition 
p a t te r n  w o u ld  b e  fo u n d  w ith  th e  P ( l , 4 ) B s  in  a c c o r d  w ith  the 
m o d e l  p r o p o s e d  b y  V a n  D y k e  &  D e r v a n  ( 1 9 8 3 b ) .  B o th  the 
m o d e l  a n d  e x p e r im e n t a l  r e s u lt s  s h o w  th a t  th e  m a x im u m  in­
h ib i t io n  o f  D N A  c le a v a g e  is  s h i f t e d  o n e  to  tw o  b a s e  pairs to 
t h e  3 '  s id e  o f  t h e  d r u g  b in d in g  s i t e .  In  o r d e r  t o  determ ine  
w h e t h e r  t h e  s a m e  o b s e r v a t io n s  a p p ly  to  t h e  P ( l ,4 )B s ,  
M P E - F e ( I I )  w a s  a l lo w e d  t o  c le a v e  a  2 4 1  b p  fr a g m e n t  which 
w a s  e ith e r  5 '  o r  3 ' e n d - la b e le d  a t  t h e  s a m e  m o le c u la r  e n d  and 
p r e in c u b a t e d  w i t h  a n t h r a m y c in ,  I V , o r  t o m a y m y c in .  The 
a u t o r a d io g r a m  o f  t h e  5 ' - e n d - la b e le d  f r a g m e n t  is  sh o w n  in 
F ig u r e  5 A ,  a n d  th e  h is to g r a m s  o f  th e  o p p o s ite  str a n d  footprints 
d e r iv e d  fr o m  th i s  a u t o r a d io g r a m  a n d  its  3 '-en d -la b eled  
c o u n t e r p a r t  a r e  s h o w n  in  F ig u r e  5 B .
A  c o m p o s i t e  c o m p a r is o n  o f  t h e  o p p o s it e  s tr a n d  footprints 
r e v e a le d  b y  M P E - F e ( I I )  o f  a n th r a m y c in , IV , a n d  tom aym ycin  
is  s h o w n  in  F ig u r e  5 C . F iv e  m a jo r  fo o tp r in ts  o c c u r r e d  within 
th is  5 7  b p  r e g io n ,  lo c a t e d  a r o u n d  p o s i t io n s  8 , 1 9 , 3 0 , 4 2 , and 
5 3  o n  b o t h  s tr a n d s .  A l l  th r e e  d r u g s  e x h ib i t e d  fo o tp r in ts  at 
f o u r  o f  t h e  f iv e  s i t e s ,  w h i le  a n t h r a m y c in  a lo n e  h a d  a n  addi­
t i o n a l  s t r o n g  f o o tp r in t  s i t e  a r o u n d  p o s i t io n  1 9 . W ith o u t  ex­
c e p t io n  th e  p r o te c te d  z o n e s  w e r e  s ta g g e r e d  o n e  to  th r e e  bases 
t o  t h e  3 '  s id e  o f  t h e  p r e s u m e d  c o v a le n t ly  m o d if ie d  guanine, 
a s  a n t ic ip a t e d  fr o m  p r e v io u s  s t u d ie s  ( V a n  D y k e  &  Dervan, 
1 9 8 3 b ;  L o w  e t  a l . ,  1 9 8 4 a ,b ) .
In  a c c o r d  w ith  t h e  d a t a  in  F ig u r e s  3 A  a n d  4 A ,  th e r e  was 
c o n s id e r a b ly  e n h a n c e d  M P E -F e ( I I ) - in d u c e d  c le a v a g e  adjacent 
to  c e r ta in  b in d in g  s e q u e n c e s ,  e .g . ,  a r o u n d  p o s itio n  2 5  in Figure 
5 B ,  p a n e ls  a  a n d  c .  T h e  a v e r a g e  s iz e  o f  th e  fo o tp r in ts  was 
a b o u t  th r e e  to  fo u r  b a s e  p a ir s . T h e  s e v e n  to  e ig h t  b a se  pair 
fo o tp r in t  fo r  a n th r a m y c in  in  th e  r e g io n  a r o u n d  p o s itio n  43 was 
m o s t  p r o b a b ly  d u e  to  tw o  a d ja c e n t b in d in g  s ite s  in  th is  GC-rich 
r e g io n .
W h i le  fo u r  o f  th e  f iv e  b in d in g  s i t e s  w e r e  fo u n d  in  approx­
im ately  t h e  s a m e  lo c a t io n  fo r  e a c h  o f  th e  d r u g s  te s te d , the 
p r e c is e  s i t e s  o f  c o v a le n t  a t t a c h m e n t ,  th e  in t e n s i t y  o f  the 
f o o tp r in t s ,  a n d  th u s  th e  r a n k  o r d e r  o f  b in d in g  s i t e  preference 
w e r e  q u i t e  d i f f e r e n t  b e t w e e n  t h e  th r e e  d r u g s .  F o r  example, 
t h e  in d iv id u a l  fo o tp r in ts  a r o u n d  p o s it io n  8 d if fe r e d  in  location 
b y  a s  m u c h  a s  th r e e  b a s e  p a ir s  ( F ig u r e  5 C ) ,  a n d  w h ile  this 
w a s  a  p r im e  b in d in g  s it e  o f  I V  a n d  to m a y m y c in , it w a s  a lower 
r a n k in g  b in d in g  s i t e  fo r  a n t h r a m y c in  ( F ig u r e  5 B ) .  These 
d i f f e r e n c e s  a r e  p r e s u m a b ly  a  r e f le c t io n  o f  t h e  structural 
v a r ia t io n  b e t w e e n  t h e  v a r io u s  P ( l , 4 ) B s  ( v id e  in fr a ) .
Consensus Sequence Analysis fo r  Anthramycin, Tomay­
mycin, and Sibiromycin. W e  u t i l iz e d  th e  c le a v a g e  inhibition 
p a t te r n s  fr o m  th e  o p p o s i t e  s tr a n d  a n a ly s is  ( s e e  F ig u r e  5B,C)
A
S E Q U E N C E  s p e c i f i c i t y  o f  a n t i t u m o r  a g e n t s
B a) Sibiromycin
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fig u re  4: (A ) A u to ra d io g ra m s  o f  th e  D N A  c le a v a g e  in h ib itio n  p ro d u c e d  b y  th e  P (1 ,4 )B  a n tib io tic s , s ib iro m y c in , to m a y m y c in , a n d  a n th ra m y c in . 
A 5 '-end-labeled  2 0 4  b p  f r a g m e n t  w a s  p re p a re d  a n d  re a c te d  w ith  th e  P ( l ,4 ) B s  a s  d e s c r ib e d  u n d e r  M a te r ia l s  a n d  M e th o d s  ( m e th o d  2 ) . L a n e s  
1-9, P (1 ,4 )B  tre a tm e n ts . D N A  w a s  in c u b a te d  w ith  0 .0 1 5 , 0 .1 5 , o r  1.5 n m o l o f  s ib iro m y c in  ( la n e s  1 -3 ) ,  to m a y m y c in  ( la n e s  4 - 6 ) ,  o r  a n th ra m y c in  
(lanes 7 -9 ) ,  re sp e c tiv e ly , a n d  th e n  d ig e s te d  w ith  M P E - F e ( I I ) .  L a n e  10 is M P E - F e ( I I ) ,  c o n tro l  (n o  d r u g  t r e a t m e n t ) .  L a n e s  11 a n d  12 a r e  
the M a x a m -G ilb e r t  T + C  a n d  A + G  re a c t io n s ,  re sp e c tiv e ly . B ra c k e ts  la b e le d  A  a n d  B in d ic a te  fo o tp r in ts  c o m m o n  to  a l l  th r e e  d ru g s . (B )  
H istograms o f  M P E -F e (I I )  fo o tp r in ts  o f  s ib iro m y c in , to m a y m y c in  a n d  a n th ra m y c in . D a ta  a r e  ta k e n  fro m  (A ) ,  la n e s  2 , 5, a n d  8 . F o r  e x p la n a tio n  
of percent re la tiv e  c le a v a g e  see  le g e n d  fo r  F ig u r e  3B . F o o tp r in ts  A  a n d  B a r e  t h e  s a m e  a s  th o s e  d e p ic te d  in  ( A ) .
for m e m b er s  o f  th e  P ( 1 , 4 ) B  a n t ib io t i c  g r o u p  to  p r e d ic t  w ith  
some c o n f id e n c e  th e  lo c a t io n  o f  t h e  c o v a le n t ly  m o d if ie d  g u a ­
nine w ith in  e a c h  fo o tp r in t .  B y  u s e  o f  th e  d a t a  d e r iv e d  fr o m  
a variety  o f  r e s tr ic t io n  e n z y m e  f r a g m e n t s  w h ic h  h a d  b e e n  
m odified b y  e ith e r  a n th r a m y c in ,  to m a y m y c in ,  o r  s ib ir o m y c in  
and th en  s u b je c te d  to  M P E - F e ( I I )  c le a v a g e ,  t h e  s e q u e n c e s  
flanking th e  g u a n in e s  th a t  b o u n d  th e s e  d r u g s  w e r e  d e te r m in e d  
(see T a b le  I ) .  F o r  c o m p a r is o n ,  th e  s e q u e n c e s  f la n k in g  g u a ­
nines th a t d id  n o t  b in d  d r u g  m o le c u le s  w e r e  a ls o  s c o r e d . T h e  
data in T a b le  I s h o w  th a t  fo r  a n t h r a m y c in  a n d  s ib ir o m y c in  
lig h tly  less th a n  50%  o f  th e  to ta l g u a n in e s  a c tu a lly  fo o tp r in te d  
as b in d in g  s it e s ,  w h e r e a s  o n ly  a b o u t  o n e  q u a r te r  o f  th e  p o ­
tentially a v a ila b le  g u a n in e s  fo r m e d  a d d u c ts  w ith  to m a y m y c in .  
There w a s  n o  s ig n if i c a n t  p r e f e r e n c e  fo r  a  p a r t ic u la r  b a s e  o r  
base ty p e  > 1  b a s e  r e m o v e d  fr o m  e ith e r  s id e  o f  th e  c o v a le n t ly  
M odified g u a n in e . W h ile  a  p r e fe r e n c e  fo r  a  d e f in e d  b a s e  w a s  
n°t o b v io u s fo r  th e  p o s i t io n s  d ir e c t ly  f la n k in g  g u n in e ,  th e r e  
^as a s ig n if ic a n t  p r e fe r e n c e  fo r  t h e  tr im e r  5 'P u G P u  a s  a  
inding s i t e  fo r  a n t h r a m y c in  o r  s ib ir o m y c in ,  a n d  to  a  le s s e r  
*"*tent for to m a y m y c in . T h e  le a s t  fa v o r e d  tr im e r  fo r  a ll  th e s e  
f u8s w a s  5 'P y G P y ,  w ith  5 'P y G P u  s l ig h t ly  fa v o r e d  o v e r  
y P uG P y.
Sibirom ycin- and  T om aym ycin -In du ced  A lte ra tio n s  in the
0rmally Guanine-Specific M ethylene Blue Reaction. T h e
Table I: Consensus Sequence Analysis o f Footprinting Data for 

















+® (%) - c  i(%) + c (%)
_ C (%)
22 (45) 27 (55) 16 (67) 8 (33)
3 (10) 28 (90) 8 (36) 14 (64)
9 (20) 35 (80) 12 (40) 18 (60)
15 (32) 32 (68) 11 (41) 16 (59)
49 (29) 122 (71) 47 (45) 56 (55)
° All guanines were scored for the presence or absence o f drug bind­
ing on the basis o f their ability to significantly inhibit MPE-Fe(II) 
cleavage. There was no significant preference for a base or base type 
>1 base pair to either side o f the covalently modified guanine. Like­
wise, individual base analysis (G, C, A , T) at positions adjacent to the 
covalently modified guanine did not reveal any significant preferences. 
b A total o f approximately 515, 363, and 194 bp were analyzed for an­
thramycin, tomaymycin, or sibiromycin binding sites. ®Plus (+ ) and 
minus ( - )  refer to the presence or absence of a footprint as determined 
by inhibition of MPE-Fe(II) cleavage.
m e t h y le n e  b lu e  s e n s i t iz e d  p h o t o o x id a t io n  o f  D N A  ( S im o n  &  
V a n  V u n a k is ,  1 9 6 2 , 1 9 6 4 ;  S a s t r y  &  G o r d o n ,  1 9 6 6 )  h a s  b e e n  
a d a p t e d  fo r  u s e  in  D N A  s e q u e n c in g  a s  a  g u a n in e - s p e c i f ic  
r e a g e n t  (F r ie d m a n n  &  B r o w n , 1 9 7 8 )  a l t h o u g h  in  th e  e a r l ie r  
w o r k  a  lo w  r e a c t iv i t y  w ith  t h y m in e  c o m p o u n d s  w a s  n o te d  
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5'TTTG T AGAGGTTTT A CTTG CTTT AAAAAACCTCCCACACCTCCCCCTGAACCTGAAAC3' 
3AAACATCTCCAAAATGAACGAAATTTTTTGGAGGGTGTGGAGGGGGACTTGGACTTTG5'JH fl ^  PI" 1PI1H
f i g u r e  5: (A ) Autoradiogram  o f  the D N A  cleavage inhibition by anthram ycin, IV, and tom aym ycin on a 5 '-32P-end-labeled 241 base par 
fragment. Drug treatment and M PE-Fe(II) footprinting was carried out by using method 1 (see M aterials and M ethods). Lane 1, intact DNA 
lane 2, M axam -G ilbert chem ical sequencing G  reaction; lane 3, M PE*Fe(II) cleavage o f unprotected D N A ; lanes 4 -6 , M PE-Fe(II) cleavap 
o f anthram ycin-bound D N A  at 20, 50, and 200 /*M; lanes 7 -9 , M PE-Fe(II) cleavage o f IV-bound D N A  at 200 ^M , 1 m M , and 4 mM; lane 
10-12, M PE-Fe(II) cleavage o f tomaymycin-bound D N A  at 20, 50, and 200 /iM . Concentrations refer to inhibiting drug during the preincubatiu 
reaction. The D N A  concentration was 200 /xM (bp). (B ) Histogram s o f M PE*Fe(II) footprints o f  anthramycin (a ), IV (b), and tomaymycii 
(c) on opposite strands o f  the sam e fragm ent shown in panel A . The 5'-32P-end-labeled data for anthram ycin, tom aym ycin, and IV are take 
from lanes 6, 9, and 12 in panel A . (C ) C om posite o f opposite strand footprinting results for anthram ycin (unfilled bars), IV (shaded bars; 
and tomaymycin (filled bars). Bars indicate protected regions. These maps were compiled from densitometic measurements o f 3'- and 5'-32P-labele: 
fragments o f  D N A  shown in (B ).
D N A  a ls o  c a u s e d  d e s t r u c t io n  o f  t h e  s u g a r  m o ie t y  ( S a s t r y  &  
G o r d o n , 1 9 6 6 ) .  S in c e  th e  P ( 1 ,4 ) B  d e r iv a t iv e s  a r e  a ls o  g u a n in e  
s p e c i f ic ,  i t  w a s  t h o u g h t  t h a t  t h e y  m a y  in t e r f e r e  w ith  th e  
m e t h y le n e  b lu e  D N A  s e q u e n c in g  r e a c t io n  a n d  th a t  t h e  la t te r  
m a y  p r o v id e  a  m e a n s  o f  d e t e c t in g  t h e  s i t e  o f  b in d in g  o f  
D N A - b in d i n g  l ig a n d s .  I n d e e d ,  P ( 1 ,4 ) B  b in d in g  s i t e s  c a n  b e  
o b s e r v e d  a s  a n  in h ib i t io n  o f  t h e  m e t h y le n e  b lu e  r e a c t io n  
( F ig u r e  6 A )  th o u g h  t h e  t e c h n iq u e  is  l e s s  s e n s i t iv e  th a n  t h a t  
e m p lo y in g  M P E - F e ( I I ) ,  a n d  w e  h a v e  f o u n d  i t  d i f f ic u l t  to  
r e p r o d u c e  r e l ia b ly .
O f  m o r e  g e n e r a l  in t e r e s t ,  a n d  o f  p o t e n t ia l  c o n c e r n  fo r
c h e m ic a l  f o o tp r in t in g  m e t h o d s ,  is  t h e  f a c t  th a t  addition; 
b a n d s, a t  n o n -g u a n in e  r e s id u e s , w e r e  o b se r v e d  w h e n  methylene 
b lu e  w a s  u s e d  in  t h e  p r e s e n c e  o f  s ib ir o m y c in  o r  tomaymycii 
W e  h a v e  n o t , h o w e v e r , o b s e r v e d  t h e s e  “ a r t i f a c t u a l” bands n 
t h e  p r e s e n c e  o f  a n t h r a m y c in .  A n  e x a m p le  o f  sibiromycin 
in d u c e d  c h a n g e s  in  t h e  m e t h y le n e  b lu e  r e a c t io n  is shown if 
F ig u r e  6 .  T h e  f r a g m e n t  o f  T 7  D N A  u s e d  in  th is  experimei 
c o n ta in s  o n ly  tw o  p o te n t ia l  P ( 1 ,4 ) B  b in d in g  s it e s  (PuGPu)oi 
t h e  la b e le d  D N A  s tr a n d  w h o s e  s e q u e n c e  c a n  b e  resolved n 
th is  g e l .  B o th  s it e s ,  in d ic a t e d  in  F ig u r e  6 A ,  s h o w e d  a parti; 
in h ib it io n  o f  th e  G -s p e c i f ic  m e th y le n e  b lu e  r e a c tio n . Howeve
d N A  S E Q U E N C E  S P E C I F I C I T Y  O F  A N T I T U M O R  A G E N T S V O L .  2 5 ,  N O .  6 ,  1 9 8 6  1 2 5 5
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5 AT ATCGTT AGCTCCTTTGTT AC AGGTGTGTGGATAAC GG 3*
3* t a t .a g c /u a t c g a g g / M a c a a t g t c c a c a c a c c t a t t g c c  5*
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figure 6: (A ) Sibirom ycin binding sites on D N A  revealed by the 
methylene blue reaction. A  401 bp D N A  restriction fragment was 
5'-end-labeled as described under M aterials and Methods. Left side 
lanes are base-specific chemical cleavage reactions for T +C , C, A + G , 
and G; lanes labeled 1 -4  are sibiromycin-plus-methylene blue trea- 
ments. In lanes 1 -4 , D N A  was reacted with 0, 0.075, 0 .015, or 1.5 
nmol, respectively, o f  sibiromycin, butanol extracted, and treated with 
methylene blue as described under M aterials and Methods. Dou­
ble-ended arrows indicate PuG Pu sequences on the labeled strand, 
whereas the single-ended arrows indicate the position o f artifactual 
bands within the sequence o f  the labeled strand. (B ) Schem atic  
representation depicting the agreem ent o f  results between the two 
methodologies used to determ ine the D N A  sequence specificity o f  
sibiromycin. The sam e fragment was used as described in Figure 5A. 
Sites of sibirom ycin binding were then determined by either the 
methylene blue reaction or M P E -F ell) footprinting (method 2), 
followed by electrophoresis as described under Materials and Methods. 
The data for the methylene blue experiment are taken from (A). Open 
arrows point to putative sibiromycin-bound guanines. Solid arrows 
Point to sites o f  drug-induced strand scission in the m ethylene blue 
reaction. Brackets enclose M PE-Fe(II) footprints of sibiromycin (data 
lot shown). Binding sites IV and V, detected by M PE-Fe(II) foot­
printing, are only revealed by a diminution in the methylene blue 
reaction since the strand break resulting from sibiromycin adducts 
at these sites would occur on the opposite (nonisotopically labeled) 
strand. The three binding sites revealed by methylene blue at the 
end of the gel (see panel A ) were not included in this figure, since 
hey were too high in the gel to be clearly footprinted by M PE-Fe(II).
a num ber o f  p r o m in e n t  m e th y le n e  b lu e  in d u c e d  b a n d s  th a t  d o  
n°t c o r r e sp o n d  to  g u a n in e  r e s id u e s  w e r e  a ls o  a p p a r e n t  w h e n  
he r e a c tio n  w a s  c a r r ie d  o u t  in  th e  p r e s e n c e  o f  s ib ir o m y c in  
Similar r esu lts  h a v e  a ls o  b e e n  o b ta in e d  w ith  to m a y m y c in ;  d a ta  
hht sh o w n ) . T h e s e  b a n d s  o c c u r r e d  a t  p o s it io n s  c o r r e sp o n d in g  
0 th y m in e  o r  c y t o s in e  r e s id u e s ,  a n d  w h e n  o th e r  D N A s  w e r e  
Used a t a d e n in e  r e s id u e s .  T h e s e  a r t if a c t u a l  b a n d s  in v a r ia b ly  
° ^ Urred o n  th e  5 ' s id e  o f ,  a n d  tw o  b a se s  a w a y  fro m , a  p o te n tia l  
'rom ycin  b in d in g  s it e  ( P u G P u ) ,  b u t  o n  th e  o p p o s ite  s tr a n d . 
e a lte r e d  m e t h y le n e  b lu e  r e a c t io n  r eq u ire d  th e  p r e s e n c e  o f  
, e f * ( l ,4 ) B  c o m p o u n d  ( c f ,  la n e  1 w ith  la n e s  2 - 4  o f  F ig u r e  
h It is  p o s s ib le  th a t  s ib ir o m y c in  a n d  to m a y m y c in  c a u s e
a  c o n f o r m a t io n a l  c h a n g e  in  t h e  s t r u c tu r e  o f  th e  D N A  h e lix  
a n d  in  d o in g  s o  m a y  a l lo w  m e t h y le n e  b lu e  to  c a t a l y z e  a  
m o d if ic a t io n  o f  n o n - g u a n i n e  b a s e s  s u c h  th a t  t h e y  b e c o m e  
s e n s i t iv e  to  a  s u b s e q u e n t  r e a c t io n  w i t h  p ip e r id in e . I t  is ,  
h o w e v e r ,  im p o r t a n t  t o  n o t e  t h a t  s o m e  D N A - b in d i n g  l ig a n d s  
h a v e  t h e  c a p a c i t y  t o  a l t e r  t h e  m o d e  o f  a c t io n ,  a n d  a p p a r e n t  
s e q u e n c e  s p e c i f ic i t y ,  o f  o t h e r  r e a g e n t s  th a t  r e a c t  w ith  D N A .
A  c o m p a r is o n  o f  t h e  r e s u l t s  f r o m  th e  m e t h y le n e  b lu e  a n d  
M P E * F E ( I I )  m e t h o d s  u s in g  t h e  s a m e  5 ' - e n d - la b e le d  s tr a n d  
is  s h o w n  in  F ig u r e  6 B .  T h e  c o v a le n t  b in d in g  s it e s  fo r  s ib ir o ­
m y c in  t h a t  a r e  o n  t h e  o p p o s i t e  s tr a n d  w e r e  r e v e a le d  b y  a r t i­
f a c t u a l  b a n d s  ( s i t e s  I —I I I  in  F ig u r e  6 B ) ,  a n d  th e  a d d i t io n a l  
b in d in g  s i t e s  o n  t h e  la b e l e d  s t r a n d  r e v e a le d  b y  M P E * F E (I I )  
( s i t e s  I V  a n d  V  in  F ig u r e  6 B )  w e r e  o b s e r v e d  d ir e c t ly  in  th e  
m e t h y le n e  b lu e  m e t h o d  b y  t h e  d im in u t io n  o f  t h e  G - s p e c i f ic  
m e t h y le n e  b lu e  r e a c t io n  ( s e e  F ig u r e  6 A ) .  T h e  tw o  m e th o d s  
th e r e fo r e  i l lu m in a te  t h e  s a m e  b in d in g  s ite s  fo r  s ib ir o m y c in  a n d  
to m a y m y c in ;  h o w e v e r ,  a n t h r a m y c in  f a i le d  to  e l i c i t  t h e  a r t i ­
f a c t u a l  b a n d s ,  a n d  t h u s ,  s i t e s  I—I I I  o f  F ig u r e  6 B  c a n n o t  b e  
d e t e c t e d  b y  t h e  m e t h y le n e  b lu e  p r o c e d u r e .
D is c u s s io n
T h e  P ( 1 ,4 ) B  a n t i  tu m o r  a n t ib io t ic s  a r e  a  s tr u c tu r a lly  u n iq u e  
g r o u p  o f  d r u g s  t h a t  b in d  q u i t e  s p e c i f ic a l ly  th r o u g h  N 2 o f  
g u a n in e  a n d  l ie  w i t h in  t h e  m in o r  g r o o v e  o f  D N A  o v e r la p p in g  
w ith  t w o  to  th r e e  b a s e  p a ir s  (P e t r u s e k  e t  a l .,  1 9 8 1 ;  G r a v e s  e t  
a l . ,  1 9 8 4 ) .  C P K  a n d  m o le c u l a r  g r a p h ic s  m o d e l in g  s tu d ie s  
p r e d ic t  c lo s e  v a n  d e r  W a a ls  c o n t a c t s  b e tw e e n  th e  f lo o r  o f  th e  
m in o r  g r o o v e  o f  D N A  a n d  t h a t  p a r t  o f  th e  d r u g  m o le c u le  
w h ic h  h u g s  t h e  c u r v a t u r e  o f  t h e  m in o r  g r o o v e  o f  D N A .  
T h e r e f o r e ,  t h e  t w o  t o  t h r e e  b a s e  p a ir  s e q u e n c e  s p e c i f ic i t y  o f  
th e  P ( l , 4 ) B s  d e m o n s t r a t e d  in  th i s  in v e s t ig a t io n  w a s  a n t ic i ­
p a te d . In  a d d it io n  t o  t h e  P ( l , 4 ) B s ,  a  n u m b e r  o f  o th e r  p o te n t  
a n t itu m o r  a g e n ts  s u c h  a s  t h e  s a fr a m y c in s  (L o w n  e t  a l . ,  1 9 8 2 )  
a n d  n a p h t h r id in o m y c in  ( Z m i j e w s k i  e t  a l . ,  1 9 8 5 )  a l s o  b in d  
c o v a le n t ly  to  D N A  t h r o u g h  N 2 o f  g u a n in e .  H o w e v e r ,  l i t t le  
is  k n o w n  a b o u t  th e  th r e e -d im e n s io n a l  a s p e c t s  o f  th e ir  b in d in g  
to  D N A .  In  g e n e r a l  n o n c o v a le n t  m in o r  g r o o v e  D N A  b in d in g  
a g e n ts  s u c h  a s  th e  d i s t a m y c in s ,  n e tr o p s in , S N  1 8 0 7 1 , b e r e n il ,  
a n d  s t i lb a m id in e  ( Z im m e r ,  1 9 8 4 )  r e c o g n iz e  A T -  r a th e r  th a n  
G C - r ic h  r e g io n s  o f  D N A .  C C - 1 0 6 5  is  t h e  o n ly  p r e s e n t  e x ­
a m p le  o f  a n  A T - s p e c i f i c  d r u g  t h a t  b in d s  c o v a le n t ly  in  th e  
m in o r  g r o o v e  o f  D N A .  T h is  d r u g  b in d s  th r o u g h  N 3 o f  a d e n in e  
a n d  h a s  fo u r  to  f iv e  b a s e  p a ir  D N A  s e q u e n c e  s p e c i f ic i t y  
( H u r le y  e t  a l . ,  1 9 8 4 b ;  R e y n o l d s  e t  a l . ,  1 9 8 5 ) .  W h ile  th e  
s u b je c t  o f  A T  s e q u e n c e  s p e c i f i c i t y  h a s  r e c e iv e d  c o n s id e r a b le  
d is c u s s io n  ( B a g u l e y ,  1 9 8 2 ;  Z im m e r ,  1 9 7 5 ,  1 9 8 4 ) ,  l i t t l e  is  
k n o w n  a b o u t  th e  m o le c u la r  in te r a c t io n s  w h ic h  g iv e  r ise  to  G C  
s e q u e n c e  s p e c if ic ity ;  th e r e fo r e ,  t h e s e  s tu d ie s  w ith  th e  P ( l , 4 ) B s  
h a v e  a d d e d  im p o r ta n c e  b e c a u s e  th is  c la s s  o f  c o m p o u n d s  is  o n e  
o f  a  s e l e c t  g r o u p  w h ic h  b in d  c o v a le n t ly  in  th e  m in o r  g r o o v e  
a n d  r e c o g n iz e  G C  r a t h e r  th a n  A T  b a s e  p a ir s .
T h e  r e s u lt s  p r e s e n t e d  h e r e  d e m o n s t r a t e  th a t  M P E * F e ( I I )  
fo o tp r in t in g  c a n  b e  u s e d  t o  l o c a t e  c o v a le n t  a d d u c ts  th a t  b in d  
w ith in  t h e  m in o r  g r o o v e  o f  D N A .  A  s p e c ia l  p r o p e r ty  o f  th e  
P ( 1 , 4 ) B - D N A  a d d u c t s  is  t h a t  t h e  c o v a le n t  a t t a c h m e n t  is  
r e v e r s ib le ,  b e c a u s e  o f  t h e  in h e r e n t ly  la b ile  a n im a l ( N - C - N )  
l in k a g e  w h ic h  c o n n e c t s  t h e s e  d r u g s  to  N 2 o f  g u a n in e  ( s e e  
F ig u r e  2 ) .  T h e r e fo r e ,  w h i le  th e  fo o tp r in t in g  is  c a r r ie d  o u t  o n
2 Although we think it is unlikely, we cannot eliminate the possibility
that the P (l,4 )B s produce a staggered double-strand break in the pres­
ence of methylene blue. The staggered double-strand break would occur 
at the P(l,4)B-m odified guanine and at the “artifactual" position as 
defined in the text. The observed inhibition of the methylene blue re­
action by P(1,4)B would tend to argue against this possibility.
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a  d o u b le - s t r a n d e d  D N A  t e m p l a t e  w h e r e  th e  a d d u c t  is  s t a b i ­
liz e d  b y  n o n c o v a le n t  in te r a c tio n s  (P e tr u s e k  e t  a l .,  1 9 8 1 ; G r a v e s , 
1 9 8 4 ) ,  u p o n  d e n a t u r a t io n  o f  t h e  d u p le x  t h e s e  s e c o n d a r y  in ­
te r a c t io n s  a r e  lo s t  a n d  th e  d r u g  is  r e le a s e d  fr o m  th e  t e m p la te  
( H u r le y  e t  a l . ,  1 9 7 9 ) ,  l e a v in g  a n  u n m o d i f e d  s t r a n d  fo r  e l e c ­
t r o p h o r e t ic  s e q u e n c in g .  T h is  p o in t  is  im p o r ta n t ,  b e c a u s e  i t  
a v o id s  p r o b le m s  in  t h e  a n a ly s is  o f  t h e  D N A  b in d in g  s i t e s  th a t  
m a y  b e  e v id e n t  i f  a  d r u g - m o d if ie d  t e m p la t e  w e r e  s u b j e c t e d  
t o  g e l  e le c t r o p h o r e s i s .
M P E * F e ( I I )  a n d  D N a s e  I  h a v e  b e e n  u s e d  e x t e n s iv e ly  t o  
fo o t p r in t  l ig a n d  b in d in g  s i t e s  o n  D N A  [ fo r  r e v ie w , s e e  D a -  
b r o w ia k  ( 1 9 8 3 ) ] .  W h i l e  t h e  s y n t h e t i c  r e a g e n t  M P E * F e ( I I ) ,  
w h ic h  w a s  m o d e le d  o n  b le o m y c in  b y  H e r t z b e r g  a n d  D e r v a n  
( 1 9 8 2 ) ,  p r o v id e s  th e  m o r e  p r e c is e  b in d in g  s it e  lo c a t io n , D N a s e  
I is  m o r e  s e n s i t iv e  t o  D N A  s tr u c tu r e  a n d  c o n s e q u e n t ly  r e p o r ts  
o n  t h e  e x t e n t  a n d  s e q u e n c e  d e p e n d e n c y  o f  a l t e r e d  D N A  
s t r u c t u r e  ( V a n  D y k e  &  D e r v a n ,  1 9 8 3 c ) .  U n f o r t u n a t e ly ,  
n e it h e r  r e a g e n t  p r o v id e s  in f o r m a t io n  o n  t h e  o r ie n t a t io n  o f  a  
c o v a le n t ly  b o u n d  l ig a n d  in  t h e  m in o r  g r o o v e  o f  D N A ,  u n le s s  
th e  le n g t h  o f  t h e  d r u g  m o le c u le  is  a s y m m e t r ic a l ly  d is tr ib u te d  
a r o u n d  t h e  c o v a le n t  b in d in g  s i t e .  S i n c e  a t  t h e  p r e s e n t  t im e  
t h e  s i z e  a n d  p r e c is e  lo c a t io n  o f  t h e  b in d in g  s i t e s  w e r e  o f  
p a r a m o u n t  im p o r t a n c e  t o  u s ,  w e  c h o s e  M P E - F e ( I I )  a s  th e  
r e a g e n t  o f  c h o ic e  fo r  o u r  s t u d ie s .
S in c e  th e  P ( l , 4 ) B s  a r e  t h e  f ir s t  l ig a n d s  th a t  b in d  c o v a le n t ly  
t o  D N A  t o  b e  s u b j e c t e d  t o  t h e  f o o t p r in t in g  m e t h o d  u s in g  
M P E - F e ( I I ) ,  i t  w a s  im p o r ta n t  t o  c o m p a r e  t h e  c h a r a c te r is t ic s  
o f  c le a v a g e  in h ib it io n  b y  t h e s e  a g e n t s  t o  th o s e  a lr e a d y  e s t a b ­
lis h e d  fo r  in t e r c a la t in g  a g e n t s ,  s u c h  a s  th e  q u in o x a l in e  a n t i ­
b io t i c s ,  a n d  n o n c o v a le n t  b in d e r s ,  s u c h  a s  d i s t a m y c in  a n d  
n e tr o p s in . M P E * F e (I I )  r e p o r te d  a  m in im u m  th r e e  to  fo u r  b a se  
p a ir  fo o tp r in t  fo r  t h e  P ( l , 4 ) B s  w h ic h  w a s  a b o u t  t h e  s a m e  o r  
s l i g h t l y  la r g e r  th a n  th e  p r o t e c t io n  s i t e  p r e d ic te d  b y  C P K  
m o d e ls . T h is  c o m p a r e d  w e ll  w ith  th e  m in im u m  fo o tp r in t  s iz e ,  
r e la t iv e  to  m o d e l  b u i ld in g  s t u d ie s ,  fo r  d r u g s  s u c h  a s  a c t in o -  
m y c in  D  a n d  d is t a m y c in  ( V a n  D y k e  &  D e r v a n , 1 9 8 3 c ) .  T h e  
D N A  c le a v a g e  in h ib it io n  p a t te r n  w a s  s h if te d  b y  th e  P ( l , 4 ) B s  
to  th e  3 ' s id e  b y  a b o u t  tw o  t o  th r e e  b a s e s  a n d  w a s  u n d e r p r o ­
t e c t e d  o n  t h e  5 '  s id e  b y  t h e  s a m e  a m o u n t .  T h e  d ir e c t io n  o f  
th e  s h if ts  a r e  in  a c c o r d  w ith  th e  m o d e l  p r o p o se d  b y  th e  D e r v a n  
g r o u p  ( V a n  D y k e  &  D e r v a n ,  1 9 8 3 b )  b u t  q u a n t i t a t iv e ly  a p ­
p e a r e d  o n e  m o r e  b a s e  d is p la c e d  to  e a c h  s id e  o f  t h e  b in d in g  
s i t e  th a n  p r e v io u s ly  o b s e r v e d .
A lth o u g h  M P E - F e ( I I )  m a y  n o t  b e  th e  r e a g e n t  o f  c h o ic e  for  
e x a m in a t io n  o f  th e  e x t e n t  o r  s e q u e n c e  d e p e n d e n c y  o f  a l te r e d  
D N A  s tr u c tu r e  or  c o n fo r m a tio n  (V a n  D y k e  &  D e r v a n , 1 9 8 3 c ) ,  
th e  e n h a n c e d  c le a v a g e  o f  A T - r ic h  r e g io n s  o f  D N A  a d j a c e n t  
to  P ( 1 ,4 ) B  b in d in g  s i t e s  w a s  r e m a r k a b le  n o n e t h e le s s  ( s e e  
F ig u r e s  3 B , 4 B ,  a n d  5 B ) .  In  o n e  c a s e ,  a  1 2 -fo ld  e n h a n c e m e n t  
o f  c le a v a g e  o c c u r r e d  b e tw e e n  tw o  a n t h r a m y c in  b in d in g  s it e s  
in  a n  A T -r ic h  r eg io n  (F ig u r e  4 B , 2 7 0 -m in  p r e in c u b a tio n ) . T h e  
o b s e r v e d  e n h a n c e m e n t  fo r  th is  p a r t ic u la r  s e q u e n c e  is  s e v e r ­
a lfo ld  h ig h er  th a n  w e  h a v e  n o te d  in  a n y  o th e r  s e g m e n t  o f  D N A  
th a t  w e  h a v e  e x a m in e d ,  a n d  m a y  b e  p e c u lia r  t o  th is  s e q u e n c e  
a n d  o th e r s  h a v in g  s im ila r  p r o p e rtie s . W h ile  e n h a n c e d  c le a v a g e  
h a s  b e e n  o b s e r v e d  p r e v io u s ly  fo r  b o t h  n o n c o v a le n t  m in o r  
g r o o v e  b in d in g  d r u g s  su c h  a s  d is ta m y c in  (V a n  D y k e  &  D e r v a n , 
1 9 8 3 c )  a n d  i n t e r c a la t in g  a g e n t s  s u c h  a s  th e  q u in o x a l in e  a n ­
t ib io t ic s  ( L o w  e t  a l . ,  1 9 8 4 a ,b ) ,  i t  h a s  b e e n  g iv e n  t h e  m o s t  
a tte n tio n  b y  th e  W a r in g  g r o u p  (L o w  e t  a l ., 1 9 8 4 a ) .  T h is  g r o u p  
h a s  s u g g e s te d  th a t  th e  e n h a n c e d  c le a v a g e  b y  D N a s e  I , e f fe c te d  
b y  th e  q u in o x a lin e  a n t ib io t ic s ,  is  c a u s e d  b y  a  lo c a l  d is to r t io n  
o f  th e  h e lix  d u e  to  u n w in d in g  o f  a d j a c e n t  r e g io n s  o f  D N A  b y  
in te r c a la t io n  o f  th e  a n t ib io t ic .  W h ile  th is  s e e m s  a  r e a s o n a b le  
e x p la n a t io n  to  r a t io n a l iz e  t h e  e n h a n c e m e n t  o f  c l e a v a g e  b y
D N a s e  I fo r  th e  q u in o x a l in e s  a n d  o th e r  in te r c a la t in g  agents 
s u c h  a s  a c t in o m y c in  D ,  th is  r e a s o n in g  c a n n o t  b e  e x ten d ed  to 
t h e  P ( l , 4 ) B s  o r  d i s t a m y c in  s in c e  t h e s e  d r u g s  b in d  without 
i n t e r c a la t io n  in t o  D N A  ( G la u b ig e r  e t  a l . ,  1 9 7 4 ;  P etru sek  et 
a l . ,  1 9 8 1 ) .  N e v e r t h e le s s ,  it  s e e m s  p r o b a b le  fr o m  o u r  d ata  and 
fr o m  th o s e  o f  V a n  D y k e  &  D e r v a n  ( 1 9 8 3 c )  th a t  b o th  dista­
m y c in  a n d  t h e  P ( l , 4 ) B s  b in d  t o  D N A  in  a  fa s h io n  th a t pro 
d u c e s  c o n f o r m a t io n a l  c h a n g e s  w h ic h  r e s u lt  in  enhanced 
c le a v a g e  b y  M P E - F e ( I I ) .  In  th is  r e g a r d , K o p k a  e t  a l. (1985), 
in  a n  in s ig h t fu l  p a p e r , h a v e  d e m o n s tr a te d  th a t  th e  distamycir 
a n a lo g u e  n e tr o p s in , p r o d u c e s  a  “ K o sh la n d  in d u c e d  ty p e  o f fit’ 
w h e n  th i s  d r u g  b in d s  t o  a  d o d e c a m e r ,  r e s u lt in g  in  a  0.5-21 
A  w id e n in g  o f  t h e  m in o r  g r o o v e  o f  D N A .  S u c h  a n  effect on 
th e  im m e d ia te  D N A  s tr u c tu r e  is  lik e ly  to  e x te n d  s o m e  distance 
f r o m  th e  a c t u a l  d r u g  b in d in g  s i t e  a n d  p r o d u c e  reg io n a l dis­
tu r b a n c e s  in  D N A  s tr u c tu r e  a n d  d y n a m ic s .  S in c e  methidium 
in te r c a la t e s  in  th e  m in o r  g r o o v e  o f  D N A ,  th e  w id e n in g  o f this 
g r o o v e  b y  d r u g s  m a y  b e  r e s p o n s ib le  fo r  th e  e n h a n c e d  binding 
a n d  c le a v a g e  b y  M P E - F e ( I I )  a d j a c e n t  t o  d r u g  b in d in g  sites
W e  in te r p r e t  th e  s ib ir o m y c in -  a n d  to m a y m y c in -in d u c d  
a l t e r a t io n s  in  t h e  n o r m a lly  g u a n in e - s p e c i f ic  m e th y le n e  blue 
r e a c t io n  a s  fu r th e r  e v id e n c e  t h a t  t h e  P ( l , 4 ) B s  p r o d u c e  con­
fo r m a tio n a l  c h a n g e s  in  D N A  in  p r o x im ity  to  th e  d r u g  binding 
s it e .  W h ile  o n ly  a  s m a ll  fr a c t io n  o f  th e  to ta l  b o u n d  molecules 
p r o d u c e d  t h e  a d d i t io n a l  D N A  s tr a n d  b r e a k a g e s ,  e a c h  of the 
d r u g s  w a s  c o n s is t e n t  in  i t s  s i t e  o f  b r e a k a g e ,  r e la t iv e  to the 
p r e s u m e d  c o v a le n t ly  m o d if ie d  g u a n in e  o n  th e  o p p o s ite  strand 
N o t  u n e x p e c t e d ly ,  b o t h  t h e  p r o p e n s ity  to  in d u c e  n e w  strand 
b r e a k a g e  s i t e s  a n d  t h e  lo c a t io n  r e la t iv e  to  th e  d r u g  binding 
s i t e s  d i f f e r e d  b e t w e e n  e a c h  o f  t h e  d r u g  m o le c u le s  (i.e ., an 
th r a m y c in  d id  n o t  s h o w  t h e  a d d it io n a l  s tr a n d  b r e a k a g e  sites 
w h ile  s ib ir o m y c in  a n d  t o m a y m y c in  p r o d u c e d  str a n d  breakage 
o n  th e  o p p o s it e  s t r a n d  b u t  t w o  o r  th r e e  b a s e s  r em o v ed  fron 
t h e  c o v a le n t ly  m o d if ie d  g u a n in e ,  r e s p e c t iv e ly ) .  T o  accoum 
fo r  t h e s e  q u a n t i t a t iv e  a n d  q u a l i t a t iv e  d i f f e r e n c e s ,  w e  suggest 
th a t  th e r e  a r e  s u b t le  d if fe r e n c e s  in  th e  w a y  th e se  d ru gs interac 
w ith  D N A  a n d  th e r e b y  c a u s e  v a r ia b le  c o n fo r m a tio n a l changes 
in  D N A  a t  a d j a c e n t  s i t e s .
W e  h a v e  p r e v io u s ly  c o m p a r e d  th e  r e la t iv e  D N A  binding 
p r o p e r t ie s  o f  a n t h r a m y c in ,  t o m a y m y c in ,  a n d  sibiromycii 
( H u r le y  e t  a l . ,  1 9 7 7 )  a n d  d e t e r m in e d  th a t  sib irom ycin , 2; 
s a t u r a t io n  b in d in g  c o n d it io n s ,  p r o d u c e d  th e  g r e a te s t  degree 
o f  D N A  m o d if ic a t io n ,  w h i le  t o m a y m y c in  p r o d u c e d  the leasl 
T h e s e  r esu lts  a r e  su b s ta n t ia te d  b y  th e  p r esen t footprinting data 
w h e r e  b o th  th e  d e g r e e  o f  c le a v a g e  in h ib it io n  ( s e e  Figure 4B 
a n d  r e la t iv e  n u m b e r  o f  g u a n in e s  w h ic h  b in d  th e s e  drugs (s« 
T a b le  I )  a r e  in  g o o d  a g r e e m e n t .
T h e  s e q u e n c e  s p e c if ic ity  d a ta  sh o w n  in T a b le  I demonstrat 
th a t  w h i le  g u a n in e s  f la n k e d  b y  p u r in e s  a r e  p r e ferred  binding 
s i t e s ,  g u a n in e  f la n k e d  b y  p y r im id in e s  c a n  a ls o  accommodatt 
a ll  th r e e  d r u g s . It is  p o s s ib le  th a t  th e  5 'P u G P u  sequences an 
k in e t i c a l ly  fa v o r e d  s i t e s  a n d  a r e  f i l le d  f ir s t ,  w h ile  guanine 
f la n k e d  b y  p y r im id in e s  o n  o n e  o r  b o th  s id e s  a r e  less favorer 
a n d  f i l l e d  a t  a  s lo w e r  r a te .  T h is  h y p o th e s i s  is supportedb; 
t h e  r e s u lt s  o f  th e  t i m e  c o u r s e  b in d in g  e x p e r im e n t  shown is 
F ig u r e  3 . G u a n in e s  f la n k e d  b y  p u r in e s  a r e  th e  o n ly  sites filled 
d u r in g  th e  fir s t  1 2 0  m in  ( la n e s  3 - 6  in  F ig u r e  3 A ) .  Other site 
in  w h ic h  a  p y r im id in e  o c c u r s  o n  o n e  o r  b o th  adjacent sides 
o f  t h e  g u a n in e  e i t h e r  r e m a in  u n f i l l e d  ( e .g . ,  s e e  guanines® 
t h e  3’ a n d  5 '  s id e s  o f  s i t e  A )  o r  a r e  o n ly  f i l le d  a t  the longesi 
in c u b a t io n  t im e  ( e .g . ,  g u a n in e s  b e tw e e n  b in d in g  sites Banc 
C ) .  A g a in  c o n s is te n t  w ith  o u r  h y p o th e s is  is th e  results of time 
c o u r s e  k in e t ic  e x p e r im e n t s  o f  c o v a le n t  d r u g  b in d in g  to DNA 
(H u r le y  e t  a l . ,  1 9 7 7 ) .  T h e s e  e x p e r im e n ts  r e v e a l a  rapid pta 
o f  d r u g  b in d in g  w h ic h  o c c u r s  in  t h e  f ir s t  5 - 1 5  m in  follows!
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by a m uch s lo w e r  p h a s e  o f  b in d in g  ta k in g  b e tw e e n  15 m in  a n d  
1 h, d ep en d en t u p o n  t h e  p a r t ic u la r  d r u g . S in c e  t h e s e  k in e t ic s  
are d e p en d e n t u p o n  t h e  r e la t iv e  c o n c e n t r a t io n s  o f  d r u g  a n d  
D N A  an d  t h e  t im e  c o u r s e  b in d in g  o f  a n t h r a m y c in  t o  D N A ,  
shown in F ig u re  3 A ,  w a s  c a r r ie d  o u t  u n d e r  d if fe r e n t  c o n d it io n s  
to those r ep o rted  p r e v io u s ly  ( H u r le y  e t  a l . ,  1 9 7 7 ) ,  th e  k in e t ic s  
are not d ir e c t ly  c o m p a r a b le .
C PK  m o d e ls  o f  t h e  a n t h r a m y c in - ,  t o m a y m y c in - ,  a n d  s i-  
b ir o m y c in -D N A  a d d u c t s  (P e tr u s e k  e t  a l . ,  1 9 8 1 )  p r e d ic t  c lo s e  
van der W a a ls  c o n t a c t s  b e t w e e n  b o t h  t h e  f lo o r  a n d  s id e s  o f  
the m inor g r o o v e  o f  D N A  a n d  t h e  in s id e  e d g e  o f  t h e  d r u g  
molecules o n  b o th  s id e s  o f  th e  c o v a le n t  l in k a g e  b o n d . I n  fa c t ,  
str u c tu r e -a c t iv ity  r e la t io n s h ip s  c a n  b e  p r e d ic te d  r a th e r  p r e ­
cisely from  th e s e  m o d e ls  (T h u r s to n  &  H u r le y ,  1 9 8 3 ) .  S i n c e  
the co n ca v e  s id e  o f  t h e  d r u g  m o le c u le s  ( i . e . ,  p o s i t io n s  9 ,  1 0 , 
1 1 ,11a, an d  1 in  s t r u c tu r e  I o f  F ig u r e  1 ) fo l lo w s  th e  f lo o r  o f  
the m inor g r o o v e  o f  D N A ,  th e  o v e r a ll  c h a r a c t e r i s t ic  t w i s t  o f  
each m o le c u le  p r o b a b ly  is  o f  m a jo r  im p o r ta n c e  in  th e  d e t e r ­
mination o f  s e q u e n c e  r e c o g n i t io n .  B o th  t h e  d ih e d r a l  a n g le ,  
between th e  a r o m a t ic  r in g  th e  f iv e - m e m b e r e d  r in g , a n d  th e  
pucker o f  th e  p y r r o le  r in g  c o n tr ib u te  to  t h e  o v e r a ll  t w is t  a n d  
therefore to  th e  s e q u e n c e  r e c o g n it io n  p r o p e r tie s  o f  e a c h  d r u g .  
A com p arison  o f  m o le c u la r  m o d e ls  o f  a n t h r a m y c in ,  I V , a n d  
tomaymycin revea l m a jo r  d iffe r e n c e s  in  th e  o v er a ll tw is ts  w h ic h  
may explain th e  in d iv id u a l p r e fe r e n c e s  fo r  g u a n in e s  in  d if fe r e n t  
sequence e n v ir o n m en ts  sh o w n  in  F ig u r e  5 C . A n th r a m y c in  a n d  
tom aym ycin h a v e  b e e n  s h o w n  to  h a v e  3 5 °  a n d  9 °  t w is t s ,  
respectively, b e tw e e n  th e  a r o m a tic  r in g  a n d  th e  f iv e -m e m b e r e d  
ring (M o sta d  e t  a l . ,  1 9 7 8 ;  A r o r a  1 9 7 9 ,  1 9 8 1 )  w ith  l i t t l e  ( t o ­
maym ycin) or  n o  p u c k e r  (a n th r a m y c in )  in  th e  f iv e -m e m b e r e d  
ring. O n th e  o th e r  h a n d ,  w e  h a v e  s h o w n  b y  e n e r g y  m in i ­
mization th a t w h i le  IV  h a s  a b o u t  a n  e q u iv a le n t  d ih e d r a l a n g le  
to anthram ycin  b e tw e e n  th e  a r o m a t ic  r in g  a n d  th e  f iv e - m e m -  
bered ring, in IV  th e  sa tu r a te d  f iv e -m e m b e r e d  r in g  is p u c k e r e d ,  
which r esu lts  in  a n  e x t e n s io n  o f  th e  o v e r a ll  tw is t  o f  th is  
molecule. It is  l ik e ly  t h a t  a  K o s h la n d - l ik e - in d u c e d  f i t  o c c u r s  
upon drug b in d in g  to  D N A ,  a n d  b e c a u se  o f  th e  la r g e  v a r ia t io n  
in overall tw is ts  o f  t h e  P ( l , 4 ) B s ,  d r u g s  s u c h  a s  a n t h r a m y c in  
and IV having th e  la rg er  o v er a ll tw is ts  m a y  “o p e n  u p ” a d ja c e n t  
regions on th e  h e lix  a n d  fa c il ita te  in te r c a la t io n  a n d /o r  c le a v a g e  
of the d e o x y r ib o se  b y  M P E - F e ( I I )  ( s e e  F ig u r e  5 A ,B ) .  L a s t ,  
the su b stitu en ts o f  C - 8  a n d  C -9  o f  th e  a r o m a t ic  r in g  a n d  C - 2  
of the pyrrole r in g  p o in t  in to  ( C - 9 )  o r  a lo n g  th e  m in o r  g r o o v e  
of D N A  (C - 8  a n d  C - 2 )  a n d  m a y  a ls o  c o n tr ib u te  to  s e q u e n c e  
recognition.
Prim arily o n  t h e  b a s is  o f  C P K  m o d e l  b u i ld in g  s t u d ie s ,  w e  
have previously p ro p o sed  th a t  w h e n  th e  P ( l , 4 ) B s  b in d  to  D N A ,  
the s tereo ch em istry  a t  C - l  1 is  S' ( P e tr u s e k  e t  a l .,  1 9 8 1 ) .  T h e  
stereochem istry a t  C - l  1 d e te r m in e s  th e  o r ie n ta t io n  o f  th e  d r u g  
molecule in th e  m in o r  g r o o v e  o f  D N A .  I f  th e  c o n f ig u r a t io n  
at C -l I is S ,  th e n  t h e  a r o m a t ic  r in g  o f  th e  P ( l , 4 ) B s  l ie s  to  
the 3' s id e  o f  th e  c o v a le n t ly  m o d if ie d  g u a n in e  s tr a n d . O n e -  
and tw o -d im e n s io n a l *H N M R  te c h n iq u e s  h a v e  b e e n  u s e d  to  
examine th e  s t r u c tu r e  o f  th e  a n t h r a m y c i n - d ( A T G C A T ) 2 
adduct. A lth o u g h  th is  d u p le x  b e lo n g s  to  t h e  le a s t  p r e fe r r e d  
binding seq u en c e  ( 5 'P y G P y ) ,  s a tu r a t io n  b in d in g  w a s  o b se r v e d  
but only a fter  p r o lo n g e d  in c u b a t io n  t im e s  ( 4 8  h )  u s in g  a  la r g e  
excess o f  a n t h r a m y c in - 1 1 -m e t h y l  e t h e r .  T h e  d a t a  fr o m  a  
one-dim ensional d i f f e r e n c e  n u c le a r  O v e r h a u s e r  e f f e c t  e x p e r ­
iment prove th a t  th e  a r o m a t ic  r in g  o f  a n t h r a m y c in  l ie s  to  th e  
3 'side o f  th e  c o v a le n t ly  m o d if ie d  g u a n in e ,  a n d  th e r e fo r e , th e  
stereochemistry a t  C - l  1 is S  (G r a v e s  e t  a l .,  1 9 8 5 ) .  F lu o r e sc e n t  
decay m e a su r e m e n ts  o n  to m a y m y c in  b o u n d  to  D N A  d e m o n ­
strate that th e r e  a r e  tw o  fo r m s  o f  to m a y m y c in  b o u n d  to  c a l f  
thymus D N A  ( B a r k le y  e t  a l . ,  1 9 8 6 ) .  T h e s e  a r e  l ik e ly  t o  b e
t h e  t w o  C - l l  d ia s t e r o m e r ic  fo r m s  o f  t o m a y m y c in  b o u n d  in  
d if f e r e n t  o r ie n ta t io n s  o n  D N A .  M o d e ls  s h o w  th a t  t h e  le n g th  
o f  t h e  P ( 1 , 4 ) B  m o le c u l e  in  t h e  c a s e  o f  a n t h r a m y c in ,  t o m a y ­
m y c in ,  a n d  I V  is  a l m o s t  e q u a l l y  d is t r ib u te d  to  t h e  3 '  a n d  5 '  
s id e  o f  t h e  c o v a le n t ly  b o u n d  g u a n in e .  T h is  fa c t  p r e c lu d e s  th e  
d e te r m in a t io n  o f  b in d in g  o r ie n ta t io n  b y  th e  u se  o f  M P E -F e (I I )  
f o o t p r in t in g .  F o r  s ib ir o m y c in  t h e  a m in o  s u g a r  s h o u ld  t h e o ­
r e t i c a l ly  p r o d u c e  a n  a s y m m e t r ic  fo o tp r in t ,  b u t  th e r e  is  n o  
e v id e n c e  o f  th i s  f r o m  o u r  f o o t p r in t in g  d a t a  ( s e e  F ig u r e  4 B ) .  
In  o r d e r  t o  a n s w e r  th e  q u e s t io n  o f  d r u g  o r ie n ta t io n  in  th e  m in o r  
g r o o v e  o f  D N A ,  s o m e  o th e r  t e c h n iq u e  w ill  h a v e  to  b e  a p p lie d .  
O n e  p o s s ib i l i t y  w o u ld  b e  t h e  a t t a c h m e n t  o f  a  D N A  a f f in i t y  
c le a v in g  m o le c u le  s u c h  a s  E D T A - F e ( I I )  ( T a y lo r  e t  a l . ,  1 9 8 4 )  
t o  t h e s e  m o le c u le s .
In  s u m m a r y ,  w e  h a v e  d e m o n s t r a t e d  u s in g  M P E - F e ( I I )  
f o o t p r in t in g  t h a t  t h e  P ( l , 4 ) B s  b in d  to  D N A  in  a  s e q u e n c e -  
s e l e c t iv e  m a n n e r . T h e r e  is  a  m a r k e d  p r e fe r e n c e  fo r  c o v a le n t  
b in d in g  o f  th e  P ( l , 4 ) B s  to  s e q u e n c e s  fla n k e d  b y  p u r in e s  r a th er  
th a n  p y r im id in e s .  E v id e n c e  w a s  a l s o  p r e s e n te d  fo r  d r u g - in ­
d u c e d  c o n f o r m a t io n a l  c h a n g e s  in  D N A  a t  s e q u e n c e s  in  
p r o x im i t y  t o  t h e  d r u g  b in d in g  s i t e s .
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A n t h r a m y c in ,  a n  a n t i t u m o r  a n t i b i o t i c  p r o d u c e d  b y  
Streptomyces refuineus, p r o d u c e s  a  w e l l  d e f i n e d  c o v a ­
lent a d d u c t  w i t h  D N A  a n d  l i e s  w i t h i n  t h e  n a r r o w  
groove o f  D N A ,  a t t a c h e d  t h r o u g h  a  t h e r m a l - l a b i l e  c o ­
va len t a m in a l  l i n k a g e  t o  t h e  e x o c y c l i c  a m i n o  g r o u p  o f  
g u a n in e , w i t h o u t  d e t e c t a b l e  d i s t o r t i o n  o f  t h e  h e l i x  ( P e -  
trusek , R . L ., A n d e r s o n ,  G . L . ,  G a r n e r ,  T .  F . ,  F a n n i n ,  Q .  
L., K a p la n , D .  J . ,  Z i m m e r ,  S .  G .,  a n d  H u r l e y ,  L . H .  ( 1 9 8 1 )  
Biochemistry 2 0 ,  1 1 1 1 - 1 1 1 9 ) .  T h i s  p a p e r  d e s c r i b e d  r e ­
sults in  w h i c h  t h e  b i o l o g i c a l  c o n s e q u e n c e s  o f  D N A  d a m ­
age a n d  r e p a i r  b y  r e p a i r - p r o f i c i e n t  a n d  a  r e p a i r - d e f i ­
cient x e r o d e r m a  p i g m e n t o s u m  ( X P  1 2 R O )  c e l l  l i n e  a r e  
p r ese n ted . A n t h r a m y c i n  h a s  b e e n  s h o w n  t o  p r o d u c e  
e x c i s io n - d e p e n d e n t  s i n g l e  a n d  d o u b l e  s t r a n d  b r e a k s  i n  
DNA, b o t h  o f  w h i c h  a p p e a r  t o  p e r s i s t  m a n y  h o u r s  a f t e r  
rem o val o f  t h e  d r u g  f r o m  t h e  m e d i a .  T h e  l o w e r  a b i l i t y  
of th e  x e r o d e r m a  p i g m e n t o s u m  c e l l  l i n e  t o  r e m o v e  a n -  
th r a m y cin  l e s i o n s  f r o m  D N A  i s  c o r r e l a t e d  w i t h  a  d e ­
creased  c e l l  s u r v i v a l .  T h e  b i o l o g i c a l  c o n s e q u e n c e s  o f  
DNA d a m a g e  ( g e n e t i c  e f f e c t s ,  D N A  s t r a n d  b r e a k a g e ,  
and c y t o t o x i c i t y )  a r e  d i s c u s s e d  w i t h  r e s p e c t  t o  t h e  d e ­
fined s t r u c t u r e  a n d  s t a b i l i t y  o f  t h e  a n t h r a m y c i n - d e o x -  
y g u a n o s in e  a d d u c t .
A n th ram ycin  (F ig . 1) i s  a n  a n t i t u m o r  a g e n t  p r o d u c e d  b y  
Streptomyces refuineus ( T e n d le r  a n d  K o r m a n  1 9 6 3 ) , t h a t  h a s  
been d e m o n s tr a te d  t o  fo r m  a  w e l l  d e f in e d  t h e r m a l - la b i l e  c o ­
valent a d d u ct w i t h  D N A  (H u r le y  et al., 19 7 9 a ; P e t r u s e k  et 
al, 1981; O s tr a n d e r  et al., 1 9 8 1 ). B a s e d  u p o n  t h e  d e t e r m in e d  
points o f  c o v a le n t  a t t a c h m e n t  b e t w e e n  a n t h r a m y c in  ( C - l l )  
and D N A  (2 - N H 2 g r o u p  o f  g u a n in e )  (O s tr a n d e r  et al., 1 9 8 1 ) a  
CPK1 m o d el o f  a n t h r a m y c in - D N A  a d d u c t  h a s  b e e n  p r o p o s e d  
(Petrusek et al., 1 9 8 1 ) in  w h ic h  t h e  d r u g  l ie s  c o m p l e t e l y  w i t h in  
the minor g r o o v e  w i t h o u t  d e t e c t a b le  d is t o r t io n  o f  D N A  (H u r ­
ley and P e tr u s e k , 1 9 7 9 ). S in c e  a n t h r a m y c in  a p p e a r s  t o  fo r m  
a single u n iq u e  a d d u c t  w i t h  D N A  (F ig . 1) w h ic h  h a s  b e e n  w e ll  
characterized, w e  h a v e  e x p lo r e d  t h e  b io lo g ic a l  c o n s e q u e n c e s
* The costs of publication of this article were defrayed in part by 
the payment of page charges. T his article m ust therefore be hereby  
marked “advertisem en t” in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact.
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3H)thymidine; PBS, phosphate buffered saline; U D S, unscheduled  
DNA synthesis; XP, xeroderma pigmentosum; H T P, hydroxylapatite; 
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o f  D N A  d a m a g e  t o  d e t e r m in e  i f  t h e y  c a n  b e  r a t io n a l iz e d  o n  
t h e  b a s i s  o f  t h e  k n o w n  d r u g  m o d if ic a t io n  o f  D N A .
In  a  p r e v io u s  p a p e r  (H u r le y  et al., 1 9 7 9 b ), w e  h a v e  d e m ­
o n s t r a t e d  t h a t  a n t h r a m y c in  b in d in g  t o  c e l lu la r  D N A  in d u c e s  
u n s c h e d u le d  D N A  s y n t h e s i s  in  n o r m a l  b u t  n o t  x e r o d e r m a  
p ig m e n t o s u m  c e l l s  w h ic h  a r e  d e f e c t iv e  in  r e p a ir  o f  U V  le s io n s ,  
a n d  t h a t  e x c i s io n  r e m o v a l  i s  m o r e  r a p id  a n d  c o m p le t e  in  t h e  
n o r m a l  c e l l  l in e .  I n  t h e  p r e s e n t  p a p e r , w e  e x t e n d  o u r  o b s e r ­
v a t io n  o n  t h e  b io lo g ic a l  c o n s e q u e n c e s  o f  b in d in g  o f  a n t h r a ­
m y c in  t o  D N A  t o  in c lu d e  s t r a n d  b r e a k a g e  a n d  c e l l  s u r v iv a l  in  
b o t h  r e p a ir  n o r m a l  a n d  X P  c e l ls .  T h e s e  r e s u l t s  h a v e  b e e n  
r e p o r t e d  in  a  p r e l im in a r y  fo r m  (H u r le y  et al., 1 9 7 9 b ).
EXPERIMENTAL PROCEDURES 
C hem icals
Unlabeled anthramycin and [15-3H]anthram ycin were prepared 
biosynthetically and purified as described previously (Hurley e t al., 
1975 and 1979b). Stock solutions of anthramycin were made up in 
redistilled m ethanol. Hydroxylapatite (D N A  grade, Bio-Gel H TP) 
was obtained from Bio-Rad Laboratories. Reagent grade formamide 
was obtained from Fisher. B N D -cellu lose (Servacel B N D ) was ob­
tained from Accurate Chemical and Scientific Corporation, Westbury, 
NY.
C ell L in es a n d  Culture C onditions
Three lines of normal fibroblasts, (TC-97, TC-98, and TC-100) were 
used. T hese cell lines were established from explants of karyotypically  
normal primary human skin fibroblasts obtained from three normal 
individuals at the University of K entucky M edical Center. An SV40 
transformed line of X P  cells (XP 12RO) was obtained from Dr. Joyce  
Rem sen (University of Florida) whereas the non transformed line of 
X P  cells (XP 12BE) was obtained from the American T ype Culture 
Collection. B oth X P  cell lines belong to com plem entation group A, 
and show negligible repair replication following UV irradiation (Cook 
e t al., 1975). Cells were m aintained on 75 cm 2 plastic culture flasks in 
Eagle’s minimal essential m edium  supplem ented with 10% fetal calf 
serum, 2 m M  glutamine, 50 /x/ml of penicillin, and 0.05 m g/m l of 
streptom ycin. T hey were m aintained at 37 °C in a humidified atm os­
phere containing 5% CO2. The [3H ]urid in e/[HC]uracil assay of Peden  
(Peden, 1975) was used to test for mycoplasm a infection, and all lines 
were found to be free of mycoplasma.
A nth ram ycin  B in d in g  a n d  T rea tm ent
[15-3H ]Anthram ycin dissolved in m ethanol was added to the media  
of confluent monolayers of cells such that the final concentration of 
m ethanol never exceeded 1.0%. Cells were incubated for various tim es 
in the presence of anthramycin, harvested, and D N A-analyzed on 
CsCl gradients as previously described (Hurley et al., 1979b).
All drug treatm ent for the analysis of single and double strand  
breaks and for cell survival was for 2 h using nonradioactively labeled  
anthramycin. Repair at various tim es after drug treatm ent was as­
sayed by washing the cells 3 tim es to rem ove exogenous anthramycin, 
followed by addition of fresh, pre-warmed medium.
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F ig . 1. R e a c tio n  o f  a n th ra m y c in  w ith  D N A . See Ostrander et 
al., 1981.
Irra d ia tio n
A my  cell w ith a dose rate of 5400 rads/m in was used. For doses 
below 1 krad, 90% attenuators were installed. Cells to be irradiated 
were harvested and washed twice in P B S I (0.0015 m  K H2PO4, 0.008 
m  N a2H P 04, 0.14 m  NaCl, 0.0027 m  KC1, pH 7). T he cell suspensions 
were m aintained in ice before and after irradiation, and analyzed  
im m ediately after irradiation.
C ell S u rv iva l
The thin feeder layer technique of Cox and M asson (1974) was 
used with som e modifications. Cells at appropriate dilutions in m e­
dium were plated onto 100 m m 2 plastic petri dishes. T he cells were 
allowed to attach for 16-18 h and anthramycin at various concentra­
tions was added to the cells. After 2 h incubation with drug, the cells 
were washed 3 tim es in PB S I containing 0.5 m M  MgCl2, 0.85 m M  
CaCl2, and 1% fetal calf serum. A suspension of cells of the same line 
which had been irradiated with a 5-krad dose of y-rays was added to 
the dishes to provide the feeder layer. T he total final number of cells 
was 6  X  104. T he cells were incubated for 21 or 22 days w ith a change 
of medium every 7 days. At the end of the incubation period, cells 
were stained with 10% Giemsa and colonies were counted.
Velocity Sed im en ta tion
A lk a lin e  G ra d ien ts—Sucrose solutions of 5 and 20% were made 
up in 0.25 n  NaOH, 1.75 m  NaCl. Gradients of 4.8 ml were overlayered  
with 0.2 ml 0.5 n  NaOH in 0.1 m  EDTA . Cell suspensions in P B S I 
containing 1-2 X  104 cells, usually in 20 ji\, were layered on top of the  
gradients. Cells were allowed to lyse for 5-10 min in the dark before 
beginning sedim entation. T he brief lysis tim e used has been shown 
previously to facilitate the detection of small numbers of single strand 
breaks in human fibroblast cell lines (Cleaver, 1974). Cells growing on 
60-mm plates were incubated for 36-48 h in the presence of 1-2 juCi/ 
m l [3H ]dT. T he medium was changed, and the cells were then  
incubated for 12-16 h in the absence of label. In the case of drug 
treatm ent, anthramycin dissolved in m ethanol was then added to the  
medium at a dilution of 1:1000, and incubation was continued for 2 h 
prior to cell harvest and analysis. The gradients were centrifuged in 
an SW50.1 rotor (Beckman) for 1 h at 30,000 rpm. Four drop fractions 
were collected from the bottom  of the gradient using a Buchler  
peristaltic pump onto W hatman 3MM filter discs. After drying, the  
discs were washed 3 tim es in 5% ice-cold trichloroacetic acid, once in 
cold 90% ethanol and once in cold acetone. Precipitable radioactivity 
was counted in a toluene scintillation mix containing 4 g /liter  of 
2,5,diphenyloxazole and 50 m g/liter of l,4-bis-[2-(5-phenyloxazolyl)] 
benzene.
N eu tra l G ra d ien ts—Sucrose solutions of 5 and 20% were made up 
in 1 M NaCl, 0.01 M sodium citrate (pH 9) (Lehmann and Ormerod, 
1970). Gradients of 4.8 ml were overlayered with 0.2 ml of a solution  
of 0.2% SD S, 0.02 M E D TA , saline citrate (0.15 m  NaCl, 0.015 m 
sodium citrate, pH 7). Cell suspensions P B S I of 1-2 x  104 cells in 
approximately 20 jal were layered on top of the lysis layer and kept in 
the dark for 1 h prior to centrifugation. Centrifugation was carried 
out in the SW50.1 rotor for 6 h at 8,000 rpm. Incubation o f the cells 
in m edium  containing [3H]dT, incubation in unlabeled medium, and 
drug treatm ent were as described for the alkaline gradients. Collection  
of the gradients and m easurem ent of radioactivity were also carried 
out as described for alkaline gradients.
C hrom atography
B N D -cellu lose—T he m easurem ent of unscheduled D N A  synthesis 
(U D S) via the separation of double-stranded D N A  from single­
stranded D N A , or D N A  containing single strand regions, on B N D - 
cellulose has been described in detail (Scudiero et al., 1975; Hurley et 
al., 1979b). Briefly, cells were pretreated with 10 m M  hydroxyurea for
30 min, anthramycin at the appropriate concentrations was added to 
the media, and incubation was continued for 1 h. [3H ]dT (80 Ci/ 
mmol) was added to  a level of 5 juCi/ml and incubation was continued 
for another hour. Preparation of cell lysates and chromatography was 
carried out as described previously (Hurley e t al., 1979b).
H ydro x yla p a tite— B atch elution of cellular D N A  on HTP was 
carried out according to the m ethod of Kanter and Schwartz (1979a, 
1979b). Cells (1.0 m l) in P B S II (0.01 M potassium  phosphate buffer, 
0.85% NaCl, pH 7.0) were lysed by rapid addition of 1 ml of 0.08 N 
NaOH into the cell suspension. Denaturation was allowed to proceed 
for 15 min (except where otherwise specified in figure legends) at pH
12.2 in the dark at 22-24 °C in the absence of any vibration or 
agitation. Strand separation was halted by the rapid addition of 1 ml 
of 0.08 n  HC1, giving a final pH of 7.0. Suspensions were mixed 
im m ediately by manual shaking to ensure com plete neutralization. 
Following neutralization, 1.0 ml of a 2% SD S solution containing 0.02 
M sodium E D T A  (pH 7.0) was added, and the DN A  was sheared by 
6 passages through a 22-gauge needle. Lysates were then either 
processed im m ediately or stored at 4 °C for up to 1 week.
Elution of sheared lysates on H TP was carried out following 
addition of formamide to give a final concentration of 20%. DNA was 
absorbed for 15 min on H TP gels equilibrated with 0.01 m  potassium 
phosphate buffer. Single-stranded D N A  was eluted in 2 washes with 
0.12 m  potassium  phosphate buffer following 10-min incubation times. 
Double-stranded D N A  was eluted with 2 washes of 0.5 M potassium 
phosphate buffer. All buffers were pH 7.0 and contained 20% form­
amide. T he H TP gels were m aintained at 60 °C in a water bath 
throughout the adsorption and elution steps. Equilibrium CsCl gra­
dients were performed on the 0.12 and 0.5 M eluted material. Sharp, 
symmetrical peaks of 3H -labeled D N A  were obtained at densities of 
1.72 and 1.697, respectively, for the two elution buffers (data not 
shown), indicating that good separation of single- and double-stranded 
D N A  was occurring. Nondenatured lysates subjected to analysis 
yielded greater than 98% double-stranded D N A  eluting at 0.5 M 
potassium  phosphate concentration. Recovery of 3H label from the 
two elution steps was consistently 80-90% of total 3H label applied to 
the H TP gels.
V iscoelastom etry
M easurem ent of strand breaks in the native D N A  of Tetrahymena 
was carried out using the viscoelastom etry apparatus developed by 
Zimm and co-workers (Klotz and Zimm 1972a, 1972b). The method 
has also been described in detail by Kohn (1979). Cells were grown in 
protease-peptone-yeast extract medium and lysed in the viscoelasto- 
meter chamber with 0.5 m  E D TA , 2% SD S, as described previously 
(Williams e t al., 1978).
RESULTS
Anthramycin Binding and Excision from Cellular DNA
H ig h  s p e c i f ic  a c t iv i t y  [1 5 -3H ] a n t h r a m y c in  w a s  added to 
c o n f lu e n t  n o n d iv id in g  c e l l s  t o  m e a s u r e  b in d in g  a n d  excision 
r e m o v a l  in  n o r m a l  a n d  X P  h u m a n  c e l l  l in e s .  D N A  w a s  isolated 
u s in g  a  c e s iu m  c h lo r id e  d e n s i t y  g r a d ie n t ,  a n d  t h e  number of 
d r u g  m o le c u le s  b o u n d //x g  o f  D N A  w a s  c a lc u la t e d .  T h e  result 
in  F ig . 2  s h o w  t h a t  t h e  k in e t i c s  o f  a n t h r a m y c in  b in d in g  appeal 
t o  b e  a p p r o x im a t e ly  l in e a r  w i t h  t h e  t im e  o f  e x p o s u r e  to drug. 
A  2 -fo ld  d if f e r e n c e  in  t h e  a m o u n t  o f  a n t h r a m y c in  bound to 
t h e  D N A  o f  n o r m a l  f ib r o b la s t s  c o m p a r e d  t o  th e  amount 
b o u n d  t o  t h e  D N A  o f  t h e  X P  c e l l s  ( X P  1 2 B E )  w a s  found 
S im i la r  r e s u l t s  w e r e  o b t a in e d  fo r  t h e  t r a n s fo r m e d  lin e  of XP 
c e l l s  [ X P 1 2 ( S V  4 0 ) R O ]  (d a ta  n o t  s h o w n ) .  F r o m  th e  speci 
a c t iv i t y  o f  t h e  r a d io la b e le d  a n t h r a m y c in  i t  w a s  c a lcu la ted  that 
a f t e r  2 h  o f  in c u b a t io n  in  m e d iu m  c o n t a in in g  1.14 X 10" 
ju m o l/m l o f  a n t h r a m y c in ,  1 d r u g  m o le c u le  is  bound/1.12to  
2 .0 7  X 10 4 D N A  b a s e s .
T h e  r e s u l t s  o f  t h e  t i m e  c o u r s e  e x c is io n  r e m o v a l  o f  anthra 
m y c in  fr o m  c e l lu la r  D N A  in  n o r m a l  a n d  X P  c e l ls  are show 
in  F ig . 3 . W h ile  t h e  n o r m a l  c e l l  l in e  w a s  a b le  t o  rem ove 84? 
o f  t h e  b o u n d  a n t h r a m y c in  d u r in g  a  4 8 -h  in c u b a t io n  period 
t h e  X P  c e l l  l in e  r e m o v e d  o n ly  46%  d u r in g  t h e  sam e tk  
p e r io d . I n  a  c o n t r o l  e x p e r im e n t  in  w h ic h  anthramycin-modi 
f ie d  c a lf  t h y m u s  D N A  w a s  in c u b a t e d  in vitro  a t  37  °C fori:




U p t a k e  T i m e ( H r s )
Fig. 2 (left). T im e c o u r se  o f  b in d in g  o f  [15 -3H ]a n th r a m y c in  
to DNA in n o rm a l (TC-98) f ib r o b la s ts  ( • )  a n d  in  X P 12 B E  (■ ) 
cells. Anthramycin (9.34 X  10 cpm/jumol) was added to a final 
concentration of 1.14 X  10-4 jumol/ml to nondividing confluent cells 
which were harvested at various times. T he D N A  was isolated on 
CsCl equilibrium gradients.
Fig. 3 (center). T im e c o u r se  r em o v a l o f  a n th ra m y c in  fro m  
DNA by norm al (TC-98) f ib r o b la s ts  ( • ) ,  X P  c e lls  (■ ), a n d  c a lf  
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and D N A  was isolated, purified, and analyzed as described under 
“Experim ental Procedures.”
F ig . 4 (right). U n sc h e d u le d  D N A  sy n th e s is  in  n o r m a l (TC- 
100) f ib r o b la s ts  ( • )  a n d  X P  c e lls  (♦ )  a s  a fu n c tio n  o f  a n th r a ­
m y c in  c o n c e n tr a tio n . [ 3H ]dT counts/m in incorporated into double­
stranded D N A  were measured using the B N D -cellu lose chrom atog­
raphy m ethod o f Scudiero e t al. (1975). [3H ]dT incorporation by 
control cells has been subtracted from the total incorporation.
h, a loss o f  a n t h r a m y c in  s im ila r  t o  t h a t  o f  t h e  X P  c e l l  l in e  
(Fig. 3) w a s  o b s e r v e d .
Unscheduled DNA Synthesis
W hen u n s c h e d u le d  (r e p a ir )  D N A  s y n t h e s i s  w a s  m e a s u r e d  
in normal f ib r o b la s t s  (F ig . 4 )  a n  a n t h r a m y c in  c o n c e n t r a t io n  
of 1.5 X 1CT3 jU .m ol/m l r e s u l t e d  in  o p t im a l  r e p a ir  s y n t h e s i s .  
This fin d in g  i s  in  a g r e e m e n t  w i t h  p r e v io u s  r e s u l t s  u s in g  a n ­
other n o r m a l c e l l  l in e  (T C -9 8 , H u r le y  et al., 1 9 7 9 b ) . L i t t l e  o r  
no sig n ifica n t u n s c h e d u le d  D N A  s y n t h e s i s  w a s  o b s e r v e d  in  
XP cells (F ig . 4 , a n d  H u r le y  et al., 1 9 7 9 b ).
R ep lica tive  D N A  s y n t h e s i s  w a s  in h ib i t e d  b y  a p p r o x im a t e ly  
50% in a ll c e l l  l in e s  a t  t h e  a n t h r a m y c in  c o n c e n t r a t io n  w h ic h  
induced m a x im u m  u n s c h e d u le d  D N A  s y n t h e s i s  (1 0 -3  /x m o l/  
ml) (data n o t  s h o w n ) .  I n c u b a t io n  w i t h  t h i s  c o n c e n t r a t io n  o f  
anthram ycin fo r  2 h  r e s u l t e d  in  a p p r o x im a t e ly  10 m o le c u le s  
of an th ram ycin  b o u n d /1 0 4 b a s e  p a ir s .
Anthramycin-induced Single Strand Breaks; Dose- 
dependent Production of Single S trand Breaks in DNA in 
Normal and X P  Cell Lines
The h y d r o x y la p a t i t e  b a t c h  e lu t io n  m e t h o d  d e v e lo p e d  b y  
Kanter a n d  S c h w a r tz  (1 9 7 9 a )  w a s  u s e d  t o  a s s a y  fo r  s in g le  
strand b r ea k s  in d u c e d  b y  a n t h r a m y c in  t r e a t m e n t  o f  m a m ­
malian c e lls . H y d r o x y la p a t i t e  c h r o m a t o g r a p h y  h a s  b e e n  u s e d  
successfully b y  a  n u m b e r  o f  in v e s t ig a t o r s  (R y d b e r g ,  1975;  
Erixson a n d  A h n s tr o m , 1 9 7 9 ) t o  s e p a r a t e  s in g le - s t r a n d e d  a n d  
double-stranded D N A .  T h e  t e c h n iq u e  o f  K a n t e r  a n d  S c h w a r tz  
(1979a) in v o lv e s  p a r t ia l  a lk a l in e  d e n a t u r a t io n  o f  c e l lu la r  D N A ,  
shearing, a n d  s u b s e q u e n t  s e p a r a t io n  o f  t h e  s h e a r e d  s in g le ­
stranded a n d  d u p le x  fo r m s  b y  s t e p  e lu t io n  fr o m  h y d r o x y la p ­
atite gels a t  6 0  °C . B a s e d  u p o n  t h e  f r a c t io n  o f  d o u b le - s t r a n d e d  
DNA (F) o b s e r v e d  u n d e r  s ta n d a r d iz e d  c o n d it io n s  o f  d e n a t u r ­
ation, R y d b e r g  (1 9 7 5 )  o r ig in a lly  fo r m u la t e d  t h e  t h e o r e t i c a l  
relationships w h ic h  a l lo w  c a lc u la t io n  o f  s in g le  s t r a n d  b r e a k s  
from F. T h e  n u m b e r  o f  b r e a k s  (n ) p e r  a lk a l in e  u n w in d in g  u n i t  
of DNA is  g iv e n  b y  t h e  fo r m u la
1 n Fx
n = -----— -  1
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F ig . 5. H y d r o x y la p a tite  c h r o m a to g r a p h y  o n  n o rm a l f ib r o ­
b la s ts  (T C -98) a n d  X P  12 RO c e lls  su b je c te d  to  y -irra d ia tio n . A,
relationship between double-stranded D N A  recovered from hydrox­
ylapatite gels and y-ray dose for TC-98 ( • )  and X P  12 RO (O) cells. 
B, dependence of single strand breaks in D N A  on y-irradiation dose 
using hydroxylapatite chromatography for TC-98 ( • )  and X P  12 RO 
(O) cells.
m o le c u la r  w e ig h t  o f  t h e  a lk a l in e  u n w in d in g  u n i t  o f  D N A ,  is  
e s t im a t e d  fr o m  io n iz in g  ir r a d ia t io n  d a t a  b y  t h e  fo r m u la
5 X 1012 daltons/cell
8 breaks/cell/rad - D3
(Kohn and Grimek-Ewig, 1973) (2)
where th e  s u b s c r ip t s  jc a n d  0 r e fe r  t o  ir r a d ia te d  s a m p le s  a n d  F ig . 5A, s h o w s  t h e  d e c r e a s e  in  F  o b s e r v e d  a f t e r  y -r a y  
untreated s a m p le s ,  r e s p e c t iv e ly .  Mn0, t h e  n u m b e r  a v e r a g e  t r e a t m e n t  o f  n o r m a l  f ib r o b la s t s  a n d  X P  c e l ls .  T h e  e x tr a p o -
6 2 1 0 Reaction of Anthramycin with DNA
l a t e d  D 37 v a lu e s  a r e  3 0 2 5  r a d s  fo r  t h e  n o r m a l  c e l l  l in e  a n d  3 5 0 0  
r a d s  fo r  t h e  X P  c e l ls .  F r o m  t h e s e  v a lu e s ,  t h e  m o le c u la r  w e ig h t  
o f  t h e  a lk a l in e  u n w in d in g  u n i t  o f  D N A  (Mn0) is  c a lc u la t e d  t o  
b e  2 .0 7  X 1 0 8 fo r  n o r m a l  c e l l s  a n d  1 .7 9  X 10 8 fo r  X P  c e l ls .  
T h e s e  v a lu e s  a r e  in  g o o d  a g r e e m e n t  w i t h  t h o s e  f o u n d  b y  
K a n t e r  a n d  S c h w a r t z  (1 9 7 9 a )  u s in g  t h i s  t e c h n iq u e ,  n a m e ly  4 .2  
x  108 fo r  b o t h  le u k e m ia  a n d  ly m p h o m a  c e l ls .  V a lu e s  o f  Mn0 
o b t a in e d  fr o m  a lk a l in e  s e d im e n t a t io n  s t u d ie s  (R a n d o lp h  a n d  
S e t lo w ,  1975; L e t t  et al., 1 9 6 7 ) r a n g e  fr o m  1.1 t o  5 .4  X 1 0 8 
d a l  t o n s .  T h e  n u m b e r  o f  s in g le  s t r a n d  b r e a k s /M n o /r a d  o f  y- 
ir r a d ia t io n  c a n  b e  c a lc u la t e d  u s in g  E q u a t io n s  1 a n d  2 . T h e  
a v e r a g e  n v a lu e  is  6 .8  X 1 0 -3  fo r  n o r m a l  f ib r o b la s t s  a n d  5 .2  X 
1CT3 fo r  X P  c e l ls ,  a g a in  in  g o o d  a g r e e m e n t  w i t h  p r e v io u s  
in v e s t ig a t o r s  ( K a n t e r  a n d  S c h w a r tz ,  1 9 7 9 a )  w h o  e s t im a t e  6  
X 1 0 -3  b r e a k s / r a d / D N A  u n w in d in g  u n it .
T h e  n u m b e r  o f  s t r a n d  in te r r u p t io n s  in  t h e  D N A  o f  n o r m a l  
a n d  X P  f ib r o b la s t s  e x p o s e d  t o  a n t h r a m y c in  w a s  c a lc u la t e d  
(F ig . 6 B) u s in g  t h e  h y d r o x y la p a t i t e  e lu t io n  t e c h n iq u e  fo r  
m e a s u r in g  s in g le  s t r a n d  b r e a k s . S in g le  s t r a n d  b r e a k s  in  n o r m a l  
a n d  X P  f ib r o b la s t s  a r e  m in im a l ly  d e t e c t e d  a t  d o s e s  o f  a n t h r a ­
m y c in  o f  a b o u t  1CT5 a n d  1 0 -3  ^ im o l/m l,  r e s p e c t iv e ly .  In  t h e  
c a s e  o f  t h e  n o r m a l  f ib r o b la s t s  th e r e  i s  a  s h a r p  in c r e a s e  in  t h e  
r a te  o f  s in g le  s t r a n d  b r e a k s  a t  c o n c e n t r a t io n s  o f  a n t h r a m y c in  
g r e a te r  t h a n  1 0 -3  ju m o l/m l.
T h e  s e n s i t i v i t y  o f  t h e  h y d r o x y la p a t i t e  m e t h o d  (R y d b e r g ,  
1 9 7 5 ) a l lo w e d  t h e  m e a s u r e m e n t  o f  r e la t iv e ly  s m a l l  n u m b e r  o f  
b r e a k s  in  X P  c e l l s  a t  a n t h r a m y c in  d o s e s  o f  1 0 -2  j i im o l/m l o r  
g r e a te r  (F ig . 6b). H o w e v e r ,  u s in g  a lk a l in e  s u c r o s e  g r a d ie n t  
a n a ly s i s  a n d  a n t h r a m y c in  d o s e s  o f  u p  t o  6  x  1CT3 ju m o l/m l, w e  
w e r e  u n a b le  t o  d e t e c t  s in g le  s t r a n d  b r e a k s  ( s e e  F ig . 7 ). N o  
c h a n g e  in  s e d im e n t a t io n  o f  D N A  fr o m  t h e  X P  c e l l s  w a s  
o b s e r v e d  u p o n  in c u b a t io n  u p  t o  4 8  h  f o l lo w in g  d r u g  t r e a t m e n t  
a t  a  d o s e  o f  4 .8  X 1 0 -5  / im o l / m l  (d a ta  n o t  s h o w n ) .  I t  s h o u ld  b e  
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Anthramycin (pm ol/m l)
F ig . 6. H y d r o x y la p a tite  c h r o m a to g r a p h y  o n  n o r m a l fib ro ­
b la s ts  (T C -100) a n d  X P  12 RO c e lls  su b je c te d  to  a n th ra m y c in  
tr e a tm e n t. A , relationship between double-stranded D N A  recovered 
from hydroxylapatite gels and anthramycin dose for TC-100 ( • )  and 
X P 12 RO (O) cells. B, dependence o f single strand breaks in D N A  on 
anthramycin dose using hydroxylapatite chromatography for TC-100 
( • )  and X P  12 RO (O) cells. T he number of single strand breaks, n, 
was calculated using Equation 1 (see text).
F ig . 7. S e d im e n ta tio n  o f  D N A  fro m  th e  X P  12 BE c e lls  on 
a lk a lin e  su c r o se  g r a d ien t  a t  v a r io u s  d o s e s  o f  anthram ycin
fo llo w in g  a 2-h  d ru g  tr e a tm e n t p er io d . A, ------ , control, no
anthramycin in treatment; B, 4.8 X  10~5 jumol/ml; C, 1.2 X  10~3 jumol/ 
ml; D, 6.0 x  10~3 /im ol/m l. T he arrow s  in B -D  indicate the sedimen­
tation position of control D N A .
b y  t h e  h y d r o x y la p a t i t e  m e t h o d  c o u ld  b e  d u e  e i t h e r  t o  low 
l e v e l s  o f  e x c is io n  o f  t h e  a n t h r a m y c in  a d d u c t  in  X P  c e l ls ,  w hich  
a r e  a lm o s t  c o m p l e t e l y  d e f ic ie n t  in  r e p a ir  o f  U V  le s io n s  (Cook  
et al., 1 9 7 5 ) a n d  s h o w  n o  d e t e c t a b le  r e p a ir  r e p l ic a t io n  fo llo w ­
in g  a n t h r a m y c in  t r e a t m e n t  (F ig . 4 ) , o r  t o  g e n e r a l  d e g ra d a tio n  
o f  t h e  c e l lu la r  D N A .  V is u a l  o b s e r v a t io n  o f  t h e  c e l l s  in d ic a te d  
t h a t  s o m e  d e t a c h m e n t  o f  t h e  X P  c e l l s  w a s  a lr e a d y  occurring  
a t  a n t h r a m y c in  d o s e s  o f  1 0 -2 ju m o l/m l a f t e r  2 h  o f  e x p o s u r e  to 
t h e  d r u g . S u r v iv a l  c u r v e s  ( s e e  la te r )  d e m o n s t r a t e  t h a t  t h e  XP  
c e l l s  a r e  e x t r e m e ly  s e n s i t i v e  t o  a n t h r a m y c in .
A n  a b r u p t  b r e a k  in  t h e  d o s e - d e p e n d e n t  in c r e a s e  in  the 
n u m b e r  o f  s in g le  s t r a n d  b r e a k s  f o u n d  in  t h e  D N A  o f  the 
n o r m a l  f ib r o b la s t  c e l l  l in e  f o l lo w in g  a n t h r a m y c in  tr ea tm e n t  
o c c u r r e d  a t  a  c o n c e n t r a t io n  o f  a b o u t  1 0 -3  / u n o l / m l  o f  an th ra ­
m y c in  (F ig . 6 B). T h i s  c o n c e n t r a t io n  o f  a n t h r a m y c in  corre­
s p o n d s  to  t h e  c o n c e n t r a t io n  a t  w h ic h  U D S  d e c l in e s  d ra m a ti­
c a l ly  a n d  c o u ld  in d ic a t e  a n  in h ib i t io n  o f  t h e  r e p a ir  p r o c e s s .2 If 
r e p a ir  i s  in  f a c t  b e in g  in h ib i t e d ,  t h e  s u d d e n  in c r e a s e  in  the 
r a te  o f  p r o d u c t io n  o f  s in g le  s t r a n d  b r e a k s  im p l ie s  t h a t  a  step 
s u b s e q u e n t  t o  e n d o n u c le a s e  in c is io n  is  b e in g  in h ib it e d  in 
n o r m a l  c e l ls .
O n e  o f  t h e  in vitro  c h a r a c t e r i s t i c s  o f  t h e  a n th r a m y c in -D N A  
a d d u c t  is  t h a t  a n t h r a m y c in  s ta b i l i z e s  t h e  D N A  h e lix ,  i.e. the 
Tm o f  a n t h r a m y c in - t r e a t e d  D N A  is  7 ° C  h ig h e r  th a n  th e  Tm 
o f  fr e e  D N A  ( K o h n  a n d  S p e a r s ,  1 9 7 0 ) . T o  t e s t  fu r th e r  the 
r e la t iv e  s t a b i l i t y  o f  a n t h r a m y c in - t r e a t e d  D N A  t h e  e f fe c t  of 
a n t h r a m y c in  o n  t h e  d e n a t u r a t io n  r a te  o f  c e l lu la r  D N A  was 
a s s a y e d  u s in g  t h e  h y d r o x y la p a t i t e  m e t h o d .  X P  c e l l s  w e r e  used 
in  t h e s e  e x p e r im e n t s  s in c e  t h e y  u n d e r g o  n o  a p p a r e n t  U D S  
a n d  s h o w  v e r y  f e w  s in g le  s t r a n d  b r e a k s  in  t h e ir  D N A  after 
a n t h r a m y c in  t r e a t m e n t .  E x c is io n  a n d  r e p a ir  s y n t h e s i s  proc­
e s s e s  t h u s  a f f e c t  m in im a l ly  t h e  n u m b e r  o f  s in g le  s t r a n d  breaks 
a n d , t h e r e fo r e ,  t h e  d e n a t u r a t io n  r a te  o f  t h e  D N A  w h e n  bound 
w it h  a n t h r a m y c in .  T h e  f r a c t io n  o f  d o u b le - s t r a n d e d  D N A  re­
m a in in g  in  X P  c e l l  l y s a t e s  a f t e r  d e n a t u r a t io n  h a s  b e e n  allowed  
t o  p r o c e e d  fo r  v a r io u s  t im e s  in  t h e  p r e s e n c e  a n d  a b s e n c e  of
2 In a control experim ent using the same cell line but with UV in 
place of anthramycin, we found U D S plateaus at doses of 20 J/m2 
and higher as shown previously by other workers (Ahmed and Setlow, 
1979).
Reaction of Anthram ycin with DNA 6211
anthram ycin is  s h o w n  in  F ig . 8 . I t  c a n  b e  s e e n  t h a t  a n t h r a ­
mycin a t 5 .3  x  1 0 -2  ju m o l/m l s ig n if i c a n t ly  in c r e a s e s  t h e  o b ­
served fr a c t io n  o f  d o u b le - s t r a n d e d  D N A  o v e r  t h a t  f o u n d  in  
the ab sen ce o f  d r u g . T h is  in c r e a s e  in  d o u b le - s t r a n d e d  D N A ,  
and th erefore  a  d e c r e a s e  in  a p p a r e n t  s in g le - s t r a n d e d  D N A  
produced b y  a n t h r a m y c in ,  i s  a ls o  o b s e r v e d  a f t e r  y - ir r a d ia t io n  
of the c e lls  to  p r o d u c e  a  r e la t iv e ly  la r g e  n u m b e r  o f  s in g le  
strand b rea k s (F ig s . 5B  a n d  8 ) .  W e  c o n c lu d e  t h a t  a n t h r a m y c in  
stabilizes th e  h e l ix  o f  c e l lu la r  D N A ,  le a d in g  t o  a  d e c r e a s e  in  
the rate o f  d e n a tu r a t io n  o f  t h e  D N A .  T h e r e f o r e ,  t h e  n u m b e r  
of single s tr a n d  b r e a k s  c a lc u la t e d  t o  b e  in d u c e d  b y  r e p a ir  o f  
the a n th ra m y c in  a d d u c t  in  n o r m a l  f ib r o b la s t s  m u s t  b e  u n d e r ­
estimated.
Comparison of the Kinetics of Single Strand Break 
Production and Removal from Sedimentation, 
Hydroxylapatite, and UDS D ata
Previous e x p e r im e n t s  (H u r le y  et al., 1 9 7 9 b ) h a v e  s h o w n  
that norm al f ib r o b la s t s  e x p o s e d  t o  1 0 -4 /x m o l/m l  o f  a n t h r a ­
mycin e x c ise  g r e a te r  th a n  80%  o f  t h e  a n t h r a m y c in  b o u n d  to
- - - - - - - - - - - - - 1- - - - - - - - - - - - - 1_ _ _ _ _ _ _ _ _ i_ _ _ _ _ _ _ _ j_ _ _ _ _
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Fig. 8. E ffect o f  a n th ra m y c in  on  d e n a tu ra tio n  ra te  o f  D N A
of XP 12 BE c e lls . Untreated cells ( • ) ,  5.3 x  10-2 /xmol/ml of 
anthramycin for 2 h (★); 900 rad y-rays (O); 5.3 x  10-2 /xmol/ml of 
anthramycin for 2 h followed by 900 rad y-rays (■).
t h e ir  c e l lu la r  D N A  ( s e e  F ig . 3 ) . T h i s  e x c is io n ,  o r  r e m o v a l ,  o f  
b o u n d  d r u g  o c c u r s  r e la t iv e ly  s lo w ly ,  p la t e a u s  b e t w e e n  3 6  t o  
4 8  h  a f t e r  e x p o s u r e  t o  a n t h r a m y c in ,  a n d  p r e s u m a b ly  i n v o lv e s  
f o r m a t io n  o f  s in g le  s t r a n d  b r e a k s  in  t h e  D N A .  S u b s e q u e n t  
r e p a ir  w o u ld  r e q u ir e  r e m o v a l  o f  t h e s e  s in g le  s t r a n d  b r e a k s  
w it h  a  c o n c o m it a n t  in c r e a s e  in  s in g le  s t r a n d  m o le c u la r  w e ig h t .  
F ig s .  9  a n d  10  s h o w  s e d im e n t a t io n  r a t e s  o f  D N A  fr o m  n o r m a l  
f ib r o b la s t s  o n  a lk a l in e  s u c r o s e  g r a d ie n t s  a t  v a r io u s  t im e s  a f t e r  
a n t h r a m y c in  t r e a t m e n t .  A t  a  c o n c e n t r a t io n  o f  a n t h r a m y c in  
(1 .5  X 1 0 -4 /x m o l/m l)  w h e r e  u n s c h e d u le d  D N A  s y n t h e s i s  is  
50%  o f  m a x im u m  (F ig . 4 , a n d  H u r le y  et al., 1 9 7 9 ) , t h e r e  i s  a  
d e f in i t e  s h i f t  w i t h  t im e  t o  la r g e r  a p p a r e n t  m o le c u la r  s iz e  (F ig .  
9 ) .  O n  t h e  o t h e r  h a n d ,  a f t e r  e x p o s u r e  o f  t h e  c e l l s  t o  8 .7  x  1 0 -3  
/x m o l/m l  o f  a n t h r a m y c in ,  i n c u b a t io n  o f  t h e  c e l l s  l e d  t o  a  
p r o g r e s s iv e  d e c r e a s e  in  a p p a r e n t  m o le c u la r  w e ig h t  o f  t h e  
D N A  (F ig . 10 ). T h i s  f in d in g  i s  c o n s is t e n t  w i t h  t h e  o b s e r v a t io n  
t h a t  c o n c e n t r a t io n s  g r e a te r  t h a n  1 0 -3  /x m o l/m l  o f  a n t h r a m y c in  
in h ib i t  r e p a ir , o r  u n s c h e d u le d  D N A  s y n t h e s i s .  I t  s h o u ld  a l s o  
b e  n o t e d  t h a t  e v e n  a t  t h e  lo w e r  c o n c e n t r a t io n  o f  a n t h r a m y c in  
a f t e r  4 8  h  o f  p o s t - t r e a t m e n t  in c u b a t io n  (F ig . 9 ) ,  t h e  D N A  d o e s  
n o t  f u l ly  r e a c h  t h e  s e d im e n t a t io n  r a te  o f  D N A  fr o m  u n t r e a t e d  
c e l ls .  I n  a d d i t io n ,  a  c o n s i s t e n t l y  b im o d a l  s e d im e n t a t io n  p a t ­
t e r n  i s  o b s e r v e d  fo r  t h e  D N A  fr o m  d r u g - t r e a t e d  c e l ls .  T h e  
s ig n if i c a n c e  o f  t h i s  s e d im e n t a t io n  p a t t e r n  i s  u n c le a r  a t  p r e s e n t ;  
c o n c e iv a b ly  th e r e  a r e  t w o  d i s t in c t  p o p u la t io n s  o f  D N A  m o le ­
c u le s  fo l lo w in g  a n t h r a m y c in  t r e a t m e n t  a n d  d u r in g  r e p a ir  o f  
t h e  a d d u c t .
H y d r o x y la p a t i t e  c h r o m a t o g r a p h y  (F ig . 1L A ) r e v e a l s  a  t im e -  
d e p e n d e n t  in c r e a s e  in  s in g le  s t r a n d  b r e a k s  fo l lo w in g  t r e a t m e n t  
o f  n o r m a l  f ib r o b la s t s  w i t h  t w o  c o n c e n t r a t io n s  o f  a n t h r a m y c in .  
N o  s ig n if ic a n t  in d u c t io n  o f  s in g le  s t r a n d  b r e a k s  w i t h  t i m e  is  
o b s e r v e d  in  X P  c e l l s  (F ig . 1 L 4 ) .
A t  t h e  lo w e r  a n t h r a m y c in  c o n c e n t r a t io n  (1 .7  X 1CT3 /x m o l/  
m l, F ig . 1 L 4 ) ,  s in g le  s t r a n d  b r e a k s  a c c u m u la t e  in  n o r m a l  
f ib r o b la s t s  fo r  t h e  f ir s t  2 - 4  h  a n d  p e r s i s t  a t  t h e  s a m e  l e v e l  fo r  
4 8  h . A t  t h i s  a n t h r a m y c in  c o n c e n t r a t io n ,  u n s c h e d u le d  D N A  
s y n t h e s i s  c o n t in u e s  a t  a  c o n s t a n t  r a te  fo r  6  h  f o l lo w in g  t r e a t ­
m e n t ,  a f t e r  w h ic h  U D S  d e c r e a s e s  l in e a r ly  w i t h  t i m e  d o w n  to  
b a c k g r o u n d  l e v e ls  a t  4 8  h  (F ig . 1L B ). X P  c e l l s  s h o w  n o  
s ig n if ic a n t  U D S  a t  a n y  t im e  a f t e r  a n t h r a m y c in  t r e a t m e n t  
(F ig . 11B).
S in g le  s t r a n d  b r e a k s  a s  o b s e r v e d  o n  a lk a l in e  s e d im e n t a t io n  
g r a d ie n t s  a t  1 .5  X 1 0 “4 /x m o l/m l  o f  a n t h r a m y c in  (F ig . 9 ) a p p e a r  
t o  b e  r e p a ir e d  w i t h  t im e ,  a l t h o u g h  e v e n  a f t e r  4 8 -h  p o s t - t r e a t -  
m e n t  in c u b a t io n ,  a p p r o x im a t e ly  50%  o f  t h e  D N A  m o le c u le s  





F ra c tio n  No
F ig . 9. S e d im e n ta tio n  o f  D N A  
from  n o r m a l f ib r o b la s ts  (T C -97) on  
a lk a lin e  su c r o se  g r a d ie n ts  a t  v a r ­
io u s  t im e s  a fter  e x p o su r e  to  a n th r a ­
m y c in . Cells were exposed to 1.5 x  10-4 
/xmol/ml of anthramycin for 2 h. Cells 
were then washed 3 tim es with P B S I; 
fresh m edium  without drug was added, 
and incubation was continued for various
tim es before harvest. A ,  , control, no
anthramycin tr e a tm e n t;  , 2-h an­
thram ycin treatm ent, no subsequent in­
cubation; B, 12-h incubation; C, 24-h in­
cubation; D , 48-h incubation. T he a r ­
row s  in B -D  indicate the sedim entation  
position of control D N A  for comparison.
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Fig. 10. S e d im e n ta tio n  o f  DNA 
fro m  n o rm a l f ib r o b la sts  (TC-97) on 
a lk a lin e  su c r o se  g r a d ien ts  a t  var­
io u s  t im e s  a fter  e x p o su r e  to  anthra­
m y c in . Treatm ent of the cells was as 
described in Fig. 9. Anthramycin concen­
tration was 8.7 x  10-3 /xmol/ml. A ,  ,
control, no anthramycin in treatment; - 
-  2-h anthramycin treatment, no sub­
sequent incubation; B, 12-h incubation; 
C, 24-h incubation; D, 48-h incubation. 
T he arrow s  in B -D  indicate the sedi­
m entation position of control DNA.
P o s t - I n c u b a t io n  P e r io d  (Hrs)
F ig . 11. H y d r o x y la p a tite  c h r o m a to g r a p h y  a n d  u n sc h e d u le d  
D N A  sy n th e s is  in  n o rm a l f ib r o b la s ts  (T C -100) a n d  X P  12 RO  
c e lls  tr e a te d  w ith  a n th ra m y c in . A , single strand breaks as a 
function of tim e of incubation after anthram ycin treatm ent. T reat­
m ent o f the cells prior to hydroxylapatite chromatography is as 
described in Fig. 9. TC-100, 1.7 X 1CT3 /xmol/ml of anthramycin ( • ) ;  
TC-100, 1.7 x  10-2 /xmol/ml of anthramycin (O); X P  12 RO cells, 1.7 
X 10-3 /xmol/ml of anthramycin (X). B, unscheduled D N A  synthesis 
as a function of tim e of incubation after anthramycin treatm ent. U D S  
was measured by B N D -cellu lose chromatography (Scudiero e t al., 
1975). TC-100, untreated cells ( • ) ;  TC-100, exposed to 1.7 x  10-3 
/xmol/ml o f anthram ycin for 2 h (O); X P  12 RO, untreated cells (X); 
X P  12 RO, 1.9 X 10-  i /xmol/ml of anthramycin for 2 h (♦ ).
t h o u g h  b o t h  m e t h o d s  ( H T P  a n d  a lk a l in e  s e d im e n t a t io n  gra­
d ie n t s )  s h o w  persistence of single strand breaks in  D N A  after  
e x p o s u r e  t o  a n t h r a m y c in  a t  d o s e s  a t  1 .7  X 1 0 -3  /x m o l/m l  
( H T P )  a n d  1 .5  X 1 0 -4 /x m o l/m l  ( a lk a l in e  s e d im e n t a t io n  gra­
d ie n t ) ,  s o m e  d i f f e r e n c e  in  r e p a ir  k in e t i c s  is  o b s e r v e d ,  w h ich  
m a y  b e  r e la t e d  t o  t h e  d i f f e r e n c e  in  a n t h r a m y c in  d o s a g e , or 
p o s s ib le  a n a ly t ic a l  p r o b le m s  w i t h  b o t h  m e t h o d s .3
T h e  k in e t i c s  o f  s in g le  s t r a n d  b r e a k  p r o d u c t io n  a t  a n th r a ­
m y c in  c o n c e n t r a t io n s  o f  a p p r o x im a t e ly  1 0 “2 /x m o l/m l  (F ig s . 10 
a n d  1L 4.) s h o w  t h a t  s in g le  s t r a n d  b r e a k s  c o n t in u e  to  a c c u ­
m u la t e  fo r  m u c h  lo n g e r  t im e  p e r io d s  a n d  t o  h ig h e r  lev e ls . 
H y d r o x la p a t i t e  a n a ly s i s  (F ig . 1L A ) s h o w s  t h a t  s in g le  stra n d  
b r e a k s  p la t e a u  a f t e r  a b o u t  12 h , w h i le  t h e y  c o n t in u e  t o  a c c u ­
m u la t e  fo r  u p  t o  2 4  h  w h e n  c e l lu la r  D N A  is  a n a ly z e d  on  
a lk a l in e  s e d im e n t a t io n  g r a d ie n t s  (F ig . 1 0 ). T h i s  k in e t ic  d iffer ­
e n c e  i s  n o t  a s  g r e a t  a s  t h a t  o b s e r v e d  a t  lo w e r  a n th r a m y c in  
c o n c e n t r a t io n s ,  b u t  m a y  a g a in  b e  d u e  t o  a n a ly t ic a l  p r o b le m s  
d e s c r ib e d  in  F o o t n o t e  3.
T h e  h y d r o x y la p a t i t e  a n d  a lk a l in e  s e d im e n t a t io n  d a ta , h o w ­
e v e r , c o n s is t e n t l y  y i e ld  t h e  fo l lo w in g  q u a l i t a t iv e  o b s e r v a t io n s  
in  n o r m a l  f ib r o b la s t s .  A n t h r a m y c in  c o n c e n t r a t io n s  ( ~ K T 2 
/x m o l/m l)  w h ic h  a p p a r e n t ly  in h ib i t  U D S  (fig . 4 ) r e s u l t  in  a 
t i m e - d e p e n d e n t  in c r e a s e  in  t h e  n u m b e r  o f  s in g le  stra n d  
b r e a k s , a n d  t h e s e  b r e a k s  a r e  n o t  r e m o v e d  o r  r e p a ir e d  fo r  up 
t o  4 8  h  a f t e r  a n t h r a m y c in  t r e a t m e n t .  L o w e r  d o e s  o f  a n th r a ­
m y c in  w h ic h  a l lo w  U D S  a ls o  r e s u l t  in  t h e  p r o d u c t io n  o f  s in g le  
s t r a n d  b r e a k s , s o m e  o r  a l l  o f  w h ic h  p e r s i s t  a f t e r  4 8 -h  in c u b a ­
t io n  o f  t h e  c e l ls .
Production and Rem oval of Double Strand Breaks 
Following Anthramycin Treatment
T w o  m e t h o d s  w e r e  u s e d  t o  d e t e c t  d o u b le  s t r a n d  b r e a k s  in 
t h e  D N A  o f  a n t h r a m y c in - t r e a t e d  c e l ls .  V e lo c i t y  s e d im e n ta t io n  
o n  n e u tr a l  s u c r o s e  g r a d ie n t s  w a s  c a r r ie d  o u t  u s in g  n o r m a l  
f ib r o b la s t s  a n d  X P  c e l ls ,  a n d  v i s c o e la s t o m e t r y  w a s  u s e d  to  
m e a s u r e  d o u b le  s t r a n d  b r e a k  p r o d u c t io n  a n d  r e m o v a l  in  Tet- 
rahymena  c e l ls .
Velocity Sedim entation— F ig s . 12 a n d  13 s h o w  t h e  n e u tr a l  
s u c r o s e  g r a d ie n t  s e d im e n t a t io n  b e h a v io r  o f  D N A  fr o m  a n ­
t h r a m y c in - t r e a t e d  n o r m a l  f ib r o b la s t s  a n d  X P  c e l ls .  A  d ose -  
d e p e n d e n t  s h i f t  t o  m o r e  s lo w ly  s e d im e n t in g  s p e c ie s  w a s  ob-
3 T he H TP m ethod suffers from the problem of the effect of 
anthramycin on the denaturation kinetics (see Fig. 8), whereas the 
alkaline gradient m ethod is problematic due to the very large molec­
ular weight of the D N A  examined in this study.




Fract ion  No
F ig . 12. S e d im e n ta tio n  o f  D N A  
fro m  n o r m a l f ib r o b la s ts  (T C -97) on  
n e u tr a l su c r o se  g r a d ien ts . A , control 
untreated cells; B, 30 krad y-rays; C, 4.8 
X 1(T3 /xmol/ml of anthramycin; D, 4.8 
X 1(T2 /xmol/ml of anthramycin. The  
small arrow s  in B -D  indicate the sedi­







F ig . 13. S e d im e n ta tio n  o f  D N A  
from  X P  12 RO  c e lls  o n  n e u tr a l su ­
c r o se  g r a d ien ts . A , control; B, 3.6 X 
10~4 /xmol/ml of anthramycin; C, 3.6 X 
10-3 /xmol/ml of anthramycin; D, 9.1 X 
1(T3 /xmol/ml o f anthramycin. T he small 
arrow s  in B -D  indicate the sedim enta­
tion peak of control DN A.
served for  n o r m a l  f ib r o b la s t  D N A  (F ig . 1 2 ) , b u t  X P  c e l ls  
exhibited n o  a p p a r e n t  d e c r e a s e  in  t h e  m o le c u la r  w e ig h t  o f  
their D N A 4 (F ig . 13 ). T h e s e  r e s u l t s  s u g g e s t  t h a t  t h e  p r e s e n c e  
of a fu n c t io n a l  r e p a ir  s y s t e m  r e s u l t s  in  t h e  p r o d u c t io n  o f  
double s tr a n d  a s  w e l l  a s  s in g le  s t r a n d  b r e a k s  f o l lo w in g  t h e  
formation o f  a n  a n t h r a m y c in  a d d u c t  w i t h  t h e  c e l lu la r  D N A  o f  
normal, b u t  n o t  X P  c e l ls .
Fig. 12 a ls o  s h o w s  a  p r o f i le  o f  t h e  s e d im e n t a t io n  r a t e  o f  
DNA from  n o r m a l  f ib r o b la s t s  t r e a t e d  w i t h  3 0  k r a d  o f  y -r a y s  
(Fig. 12B ). T h is  d o s e  o f  y - ir r a d ia t io n  r e s u l t s  in  a p p r o x im a t e ly
4 At a dose level of 3.6 X 10“4 /xmol/ml o f anthram ycin (B),  there
is an apparent small increase in molecular weight over control DN A.
Whether this is an artifact or a real decrease is difficult to evaluate in
view of the inherent technical difficulties associated with this m ethod
(Kohn, 1979).
o n e  d o u b le  s t r a n d  b r e a k /1 0 9 d a l t o n s  o f  D N A  (L e h m a n n  a n d  
O r m e r o d , 1 9 7 0 ). T h e  n u m b e r  o f  d o u b le  s t r a n d  b r e a k s  in  
a n t h r a m y c in - t r e a t e d  D N A  is  o b v io u s ly  m u c h  lo w e r ,  s o  t h a t  
e v e n  h ig h  d o s e s  o f  a n t h r a m y c in  ( > 1 0 -2  /x m o l/m l ,  F ig . 12D) 
r e s u l t  in  l e s s  t h a n  o n e  d o u b le  s t r a n d  b r e a k /1 0 9 d a l t o n s .  A t  
t h i s  c o n c e n t r a t io n  o f  a n t h r a m y c in ,  w e  e s t im a t e  a t  l e a s t  10  
s in g le  s t r a n d  b r e a k s / 1 0 9 d a l t o n s  (F ig . 6B).
Viscoelastometry— T o  a s s a y  d o u b le  s t r a n d  b r e a k  p r o d u c ­
t io n  a n d  r e m o v a l  u s in g  a  t e c h n iq u e  c a p a b le  o f  m e a s u r in g  v e r y  
h ig h  m o le c u la r  w e ig h t  D N A ,  Tetrahymena  c e l l s  w e r e  e x p o s e d  
t o  3 .6  x  1 0 -3  /x m o l/m l  o f  a n t h r a m y c in  a n d  v i s c o e l a s t o m e t r y  
w a s  u s e d  t o  d e t e r m in e  b r e a k s  in  n a t iv e  D N A .  F ig . 14 s h o w s  
t h a t  t h e  r e la x a t io n  t im e ,  r , fo r  n a t iv e  D N A  d e c r e a s e d  fo l lo w in g  
a n t h r a m y c in  t r e a t m e n t .  P o s t - t r e a t m e n t  in c u b a t io n  o f  t h e  c e l l s  
in  d r u g - fr e e  m e d iu m  r e s u l t e d  in  s o m e  d e c r e a s e  in  t h e  n u m b e r
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F ig . 14. V i s c o e la s t ic  a n a ly s i s  o f  Tetrahymena c e l l s  f o l lo w in g  
a n t h r a m y c in  t r e a t m e n t .  Exponential growing T etrah ym ena pyri- 
form is  strain GL cells were incubated for 6 h in growth media  
containing 3.6 x  1(T3 /xmol/ml of anthramycin at room temperature  
without shaking. Cells were then centrifuged, resuspended in fresh 
growth media, and incubated for an additional 0, 5, 14, and 26 h. At 
these four post-treatm ent incubation tim es, cells were centrifuged, 
lysed in the chamber by E D T A -SD S, and measured by viscoelasto­
metry. ♦ ,  cells were grown, viscoelastic m easurem ents made, and the  
relaxation time, r, converted to molecular weight as described previ­
ously (W illiams et al., 1978). The control value for untreated cells of 
r =  2340 s (O) corresponds to a native D N A  molecular weight of 2.3 
X  1010. Error bars  represent the m ean ±  1 standard deviation for 6, 5, 












o f  d o u b le  s t r a n d  b r e a k s  a s  e v id e n c e d  b y  a n  in c r e a s e  in  r 
d u r in g  t h e  f ir s t  12 h  o f  in c u b a t io n ,  b u t  s o m e  d o u b le  s tr a n d  
b r e a k s  p e r s i s t e d  fo r  u p  t o  2 4  h  (r  n e v e r  in c r e a s e d  t o  th e  
c o n t r o l  v a lu e  o f  2 3 4 0  s , w h ic h  c o r r e s p o n d s  t o  t h e  c o n tr o l  
m o le c u la r  w e ig h t  o f  2 - 3  X  1 0 10).
Cell Survival
T h e  r e s u l t s  in  F ig . 15  s h o w  t h a t  X P  c e l l s  a r e  m u c h  m o re  
s e n s i t i v e  to  t h e  l e t h a l  e f f e c t s  o f  a n t h r a m y c in  th a n  a r e  n o r m a l  
f ib r o b la s t s .  T h e  D05 fo r  X P  c e l l s  i s  a p p r o x im a t e ly  0 .1 5  X 1(T4 
/x m o l/m l  c o m p a r e d  w it h  a  D0 o f  a p p r o x im a t e ly  1.1 X 10“4 
/x m o l/m l  fo r  n o r m a l  c e l ls ,  g iv in g  a  7 - fo ld  g r e a te r  s e n s i t i v i t y  to  
a n t h r a m y c in  o f  X P  c e l ls .
DISCUSSION
T h e  r e s u l t s  o f  t h i s  s t u d y  s h o w  t h a t  1) w h i le  a n th r a m y c in  
b in d s  t o  c e l lu la r  D N A  a t  a p p r o x im a t e ly  t h e  s a m e  l e v e l  in 
n o r m a l  a n d  X P  c e l l  l in e s ,  la r g e  d i f f e r e n c e s  in  u n s c h e d u le d  
D N A  s y n t h e s i s  a n d  p r o d u c t io n  o f  s in g le  a n d  d o u b le  str a n d  
b r e a k s  e x is t  in  t h e s e  2 c e l l  l in e s .  2 ) W h e r e a s  a n th r a m y c in  
i n d u c e s  m a x im u m  U D S  in  n o r m a l  c e l l s  f o l lo w in g  tr e a t m e n t  
w i t h  1 0 -3  /x m o l/m l  o f  a n t h r a m y c in  fo r  2 h , t h e  X P  c e l l  lin e  
d o e s  n o t  s h o w  a n y  s ig n if ic a n t  l e v e l  o f  U D S  a t  a n y  d o s e  le v e l  
m e a s u r e d .  3 ) E x c i s io n - d e p e n d e n t  s in g le  s t r a n d  b r e a k s  in  D N A  
c a n  b e  d e t e c t e d  b y  b o t h  h y d r o x y la p a t i t e  c h r o m a t o g r a p h y  and  
a lk a l in e  s u c r o s e  s e d im e n t a t io n  a f t e r  e x p o s u r e  t o  a n th r a m y c in .  
T h e s e  b r e a k s  a r e  d o s e - d e p e n d e n t  a n d  a p p e a r  t o  b e  p r o d u c e d  
a t  a  lo w  l e v e l  u p  t o  a  d o s e  o f  1 0 -3  /x m o l/m l ,  a b o v e  w h ic h  
c o n c e n t r a t io n ,  s in g le  s t r a n d  b r e a k s  in c r e a s e  l in e a r ly  w i t h  d o se . 
T h e  t h r e s h o ld  c o n c e n t r a t io n  o f  1 (T 3 /x m o l/m l  c o r r e s p o n d s  to  
t h e  d o s e  a t  w h ic h  U D S  b e g in s  t o  d e c l in e  in  n o r m a l  f ib r o b la s ts .
4 ) P o s t - t r e a t m e n t  in c u b a t io n  o f  e x c is io n - p r o f ic ie n t  c e l ls  e x ­
p o s e d  t o  a n t h r a m y c in  s h o w s  t h a t  s in g le  s t r a n d  b r e a k s  p e rs is t  
in  D N A  u p  t o  4 8  h  a f t e r  r e m o v a l  o f  t h e  d r u g  fr o m  t h e  m e d ia  
a n d  t h a t  t h e  p e r s i s t e n c e  o f  s in g le  s t r a n d  b r e a k s  is  o b s e r v e d  at 
c o n c e n t r a t io n s  o f  d r u g , b o t h  a t  a n d  a b o v e  t h a t  a t  w h ic h  U D S  
i s  o b s e r v e d .  5 ) E x c i s io n - d e p e n d e n t  d o u b le  s t r a n d  b r e a k s  in 
D N A  c a n  b e  d e t e c t e d  b y  n e u tr a l  s u c r o s e  g r a d ie n t  s e d im e n ­
t a t io n  a n d  v i s c o e la s t o m e t r y .  V i s c o e la s t ic  m e a s u r e m e n t s  in 
Tetrahymena  c e l l s  in d ic a t e  t h a t ,  l ik e  t h e  s in g le  s tr a n d  b reak s, 
d o u b le  s t r a n d  b r e a k s  a p p e a r  t o  p e r s i s t  w e l l  a f t e r  r e m o v a l  of 
t h e  d r u g  fr o m  t h e  m e d ia .  6 ) C e ll  s u r v iv a l  e x p e r im e n t s  r ev e a l  
t h a t  t h e  n o n r e m o v a l  o f  a n t h r a m y c in  l e s io n s  w h ic h  is  m ore  
p r o n o u n c e d  in  t h e  X P  c e l l s  is  m o r e  d e t r im e n t a l  t o  c e l l  su r v iv a l  
t h a n  t h e  p r o d u c t io n  o f  e x c i s io n - d e p e n d e n t  s in g le  a n d  d o u b le  
s t r a n d  b r e a k s  p r o d u c e d  b y  a n t h r a m y c in  in  r e p a ir -p r o f ic ie n t  
c e l l  l in e .
A n t h r a m y c in  p r o d u c e s  a  w e l l  d e f in e d  a n d  u n iq u e  a d d u ct  
w i t h  D N A  in  w h ic h  t h e  d r u g  m o le c u le  l ie s  c o m p le t e ly  w ith in  
t h e  n a r r o w  g r o o v e  o f  D N A ,  a t t a c h e d  v ia  a  th e r m a l- la b ile  
c o v a le n t  a m in a l  l in k a g e ,  t h r o u g h  t h e  e x o c y c l ic  a m in o  group  
o f  g u a n in e .  C P K  m o d e l s  o f  t h e  a n t h r a m y c in - D N A  a d d u c t  and  
e x p e r im e n t s  w i t h  S i  n u c le a s e  ( H u r le y  a n d  P e t r u s e k ,  1 9 7 9 ) and 
B N D - c e l l u lo s e  c h r o m a t o g r a p h y  (H u r le y  a n d  P e t r u s e k ,  1979) 
s t r o n g ly  s u g g e s t  t h a t  b in d in g  o f  t h e  d r u g  t o  D N A  d o e s  not 
d is t o r t  t h e  h e l ix  a n d  m a y  e v e n  lo c a l ly  s t a b i l iz e  t h e  D N A  to  
d e n a t u r a t io n .  L a c k  o f  d is t o r t io n ,  t h e  “ i n v is ib i l i t y ” o f  t h e  drug, 
a n d  h e l ix  s t a b i l iz a t io n  m a y  a f f e c t  t h e  a b i l i t y  o f  r e p a ir  e n z y m e s  
t o  r e c o g n iz e  a n d  s u b s e q u e n t ly  r e m o v e  t h e  d r u g  l e s io n  from  
D N A .  A d d it io n a l ly ,  i t  m a y  b e  d i f f ic u l t  i f  n o t  im p o s s ib le  for 
t h e  r e p a ir  c o m p le x  t o  d is c e r n  o n e  p a r t ic u la r  s t r a n d  t o  w h ich  
a n t h r a m y c in  i s  a s s o c ia t e d ,  s in c e  i t  is  a t t a c h e d  b y  c o v a le n t  and
5 Do, the dose (/xmol/ml) needed to reduce survival to 37% in the 
exponential region.
(pno l/m lx104 )
F ig . 15. C e ll  s u r v iv a l  f o l lo w in g  a n t h r a m y c in  t r e a t m e n t .  TC-
98, (O); XP 12 B E  (complem entation group A) (♦).
Reaction of Anthram ycin with DNA 6215
hydrogen b o n d in g  t o  b o t h  s t r a n d s  o f  D N A .  F in a lly ,  t h e  s o m e ­
what lab ile  n a tu r e  o f  t h e  a m in a l  l in k a g e  w it h  w h ic h  a n t h r a ­
mycin is a t ta c h e d  t o  D N A  m a y  e f f e c t  t h e  b io lo g ic a l  c o n s e ­
quences o f  D N A  d a m a g e  b y  t h i s  d r u g . T h e s e  u n iq u e  p r o p e r ­
ties o f th e  a n t h r a m y c in - D N A  a d d u c t  c a n  b e  u s e d  t o  r a t io n a l iz e  
some o f th e  u n iq u e  b io lo g ic a l  c o n s e q u e n c e s  o f  D N A  d a m a g e  
by an th ra m y c in , d i s c o v e r e d  d u r in g  t h i s  in v e s t ig a t io n .
T he d e m o n s tr a t io n  o f  r e p a ir - d e p e n d e n t  s in g le  s t r a n d  b r e a k s  
in cellular D N A  e x p o s e d  t o  a n t h r a m y c in  s u g g e s t s  t h e  e x i s t ­
ence o f a rep a ir  c o m p le x  c a p a b le  o f  r e c o g n iz in g  a n t h r a m y c in -  
m odified D N A . A l t h o u g h  w e  c a n n o t  r u le  o u t  t h e  p o s s ib i l i t y  
that th e se  s in g le  s t r a n d  b r e a k s  a r e  a lk a l i - d e p e n d e n t  (e.g. 
apurinic s it e s  in  D N A ) ,  w e  s t r o n g ly  s u s p e c t  t h a t  t h e y  a r e , in  
fact, break s p r o d u c e d  b y  t h e  e n d o n u c le o ly t ic  f u n c t io n  o f  a  
repair c o m p le x  o f  t h e  U V - t y p e  e x c is io n  r e p a ir , s in c e  t h e y  d o  
not occur in  t h e  X P  c e l l  l in e  e x a m in e d .  A d d i t io n a l  e v id e n c e  
that th e  U V -ty p e  e x c is io n  r e p a ir  i s  in v o lv e d  in  h a n d l in g  
anthram ycin D N A  le s io n s  s t e m s  fr o m  s t u d ie s  in  w h ic h  w e  
have sh o w n  R A D -1  a  m u t a n t  o f  Saccharomyces cerevisiae 
which is d e fe c t iv e  in  r e p a ir  o f  U V  l e s io n s  ( H a n n a n  a n d  H u r le y ,
1978) is s e n s i t iv e  t o  a n t h r a m y c in .
K inetic e x c is io n  d a t a  fo r  c e l l s  d e m o n s t r a t e  t h a t  a n t h r a m y ­
cin is m o re  r a p id ly  a n d  c o m p le t e ly  e x c is e d  fr o m  t h e  n o r m a l  
excision r e p a ir -p r o f ic ie n t  c e l l  l in e  th a n  fr o m  t h e  X P  e x c is io n -  
defective c e l l  l in e .  T h e  s ig n if ic a n t  lo s s  o f  a n t h r a m y c in  (> 5 0 %  
in 48 h) in  t h e  X P  c e l l  l in e  in  t h e  a b s e n c e  o f  a p p a r e n t  U D S  
could b e  d u e  t o  o n e  o r  m o r e  o f  a  n u m b e r  o f  f a c to r s .  F o r  
example, w e  h a v e  s h o w n  t h a t  in c u b a t io n  o f  a n t h r a m y c in - c a l f  
thymus D N A  a d d u c t s  a t  3 7  °C  fo r  4 8  h  l e a d s  t o  r e le a s e  o f  
almost 40% o f  t h e  b o u n d  d r u g , p r e s u m a b ly  d u e  t o  t h e  c h e m ic a l  
instability o f  t h e  a m in a l  l in k a g e  o v e r  p r o lo n g e d  p e r io d s  o f  
time. T h e  s t a b i l i t y  o f  t h e  a n t h r a m y c in - D N A  a d d u c t  m a y  b e  
greater, h o w e v e r , in  c h r o m a t in ,  s o  t h i s  fa c to r  a lo n e  p r o b a b ly  
does n ot fu lly  e x p la in  t h e  o b s e r v e d  l o s s  o f  a n t h r a m y c in  in  X P  
cells. It is a lso  p o s s ib le  t h a t  p a t h w a y s  o t h e r  t h a n  U V - t y p e  
excision r ep a ir  m a y  b e  o p e r a t in g  in  t h e  X P  c e l l  l in e  w h ic h  
may c o n tr ib u te  t o  t h e  r e le a s e  o f  a n t h r a m y c in .
T he g r ea ter  l o s s  o f  a n t h r a m y c in  fr o m  n o r m a l  f ib r o b la s t s  is  
presum ably d u e  t o  t h e  o p e r a t io n  o f  t h e  e x c is io n  r e p a ir  p a t h ­
way. A  c o m p lic a t in g  fa c t o r  in  t h e  m e a s u r e m e n t  o f  e x c is io n  
removal o f  a n t h r a m y c in  le s io n s  i s  t h e  p o s s ib i l i t y  o f  r e l e a s e  o f  
intact u n c h a n g e d  d r u g  m o le c u le s  d u r in g  p r o lo n g e d  in c u b a t io n  
which m a y  r e b in d  t o  D N A .  S in c e  a n t h r a m y c in  i s  in h e r e n t ly  
unstable a t  3 7  °C  o v e r  p r o lo n g e d  in c u b a t io n  t im e s ,  i t  is  
possible th a t  t h e  o b s e r v e d  r e le a s e  o f  a n t h r a m y c in  i s  d u e  t o  a  
slow d e g r a d a tio n  o f  fr e e  a n t h r a m y c in ,  c o n v e r t in g  i t  t o  a n  
unreactive fo r m  n o  lo n g e r  c a p a b le  o f  r e b in d in g  t o  D N A .
T he r e s id u a l s in g le  s t r a n d  b r e a k s  o b s e r v e d  in  n o r m a l  c e l l  
lines fo llo w in g  a n t h r a m y c in  t r e a t m e n t  m a y  b e  t h e  c o n s e ­
quence o f  th e  u n iq u e  m a n n e r  in  w h ic h  a n t h r a m y c in  b in d s  t o  
DNA, or a l t e r n a t iv e ly ,  m a y  r e s u l t  fr o m  in h ib i t io n  o f  r e p a ir , 
polym erization , a n d / o r  l ig a t io n  o f  d a m a g e d  D N A  b y  a n t h r a ­
mycin. In  th e  f ir s t  c a s e ,  w e  s u g g e s t  t h a t  r e p a ir  c o m p le x e s  m a y  
have d iff ic u lty  d is c e r n in g  w h ic h  s t r a n d  o f  D N A  is  c o v a l e n t ly  
modified b y  a n t h r a m y c in ,  s in c e  t h e  l in k a g e  is  in s id e  t h e  m in o r  
groove o f  D N A  a n d  i s  h id d e n  b y  t h e  a n t h r a m y c in  le s io n ,  a n d  
furtherm ore, t h e  D N A  h e l ix  is  n o t  d is t o r t e d  b y  a n t h r a m y c in .  
C onsequently , e x c is io n  r e p a ir  o n  t h e  w r o n g  s t r a n d  (i.e. t h a t  
strand n o t  c o v a le n t ly  a t t a c h e d  t o  a n t h r a m y c in )  w i l l  r e s u l t  in  
sin gle-stranded  r e g io n s  s t i l l  c o n t a in in g  a n  a n t h r a m y c in - m o d -  
ified gu a n in e  r e s id u e ,6 w h ic h  m a y  r e p r e s e n t  a  b lo c k  t o  c o m ­
6 Anthramycin-dinucleotide pair m elting experiments (manuscript 
in preparation) show that at 50 °C the anthram ycin-dinucleotide 
maintains its integrity for up to 2 h, suggesting that an anthramycin- 
DNA adduct on a single stranded tem plate (resulting from excision  
repair on the non-anthramycin modified strand) m ay persist over 
relatively short periods of time.
p le t io n  o f  r e p a ir . I n  t h e  s e c o n d  c a s e ,  o u r  o b s e r v a t io n  o f  a  
t h r e s h o ld  c o n c e n t r a t io n  o f  a n t h r a m y c in  a t  w h ic h  s in g le  s t r a n d  
b r e a k s  b e g in  t o  in c r e a s e  a t  a n  a c c e le r a t e d  r a te  w h i le  U D S  
b e g in s  t o  d e c l in e  s u g g e s t s  t h a t  a n t h r a m y c in  a t  h ig h  c o n c e n ­
t r a t io n s  m a y  in h ib i t  r e p a ir  p o ly m e r iz a t io n  a n d / o r  l ig a t io n  o f  
d a m a g e d  D N A .  P r e l im in a r y  o b s e r v a t io n s ,  in  f a c t ,  r e v e a l  t h a t  
in  n o r m a l  f ib r o b la s t s  a  10 -2  ju m o l/m l o f  a n t h r a m y c in  c o n c e n ­
t r a t io n  p r e v e n t s  t h e  t im e  c o u r s e  r e m o v a l  o f  U V  r e p a ir - in d u c e d  
s in g le  s t r a n d  b r e a k s  a n d  a ls o  d e c r e a s e s  t h e  l e v e l  o f  U D S  
f o l lo w in g  U V  ir r a d ia t io n  b y  a b o u t  50% .' I f  a n t h r a m y c in  in ­
h ib i t s  r e p a ir ,  t h e  in h ib i t io n  m a y  b e  d u e ,  fo r  e x a m p le ,  t o  h e l ix  
s t a b i l iz a t io n ,  o r  t o  o t h e r  f a c t o r s  a s  y e t  u n k n o w n .
E v id e n c e  p r e s e n t e d  in  t h i s  p a p e r  (F ig s .  12 a n d  1 3 ), a s  w e l l  
a s  r e s u l t s  o b t a in e d  fo r  t h e  s e n s i t i v i t y  o f  R A D  5 2 , a  m u t a n t  o f  
Saccharomyces cerevisiae  w h ic h  i s  d e f e c t iv e  in  r e p a ir  o f  d o u ­
b le  s t r a n d  b r e a k s  ( H a n n a n  a n d  H u r le y ,  1 9 7 8 ) , c o n f ir m s  t h a t  
a n t h r a m y c in  t r e a t m e n t  o f  r e p a ir - p r o f ic ie n t  c e l l s  r e s u l t s  in  
d o u b le  s t r a n d  b r e a k s  in  D N A .  T h e  m o le c u la r  e v e n t s  w h ic h  
l e a d  t o  t h e s e  d o u b le  s t r a n d  b r e a k s  in  c e l lu la r  D N A  a r e  u n ­
k n o w n  a t  t h i s  t im e .  A l t h o u g h  a n t h r a m y c in  b y  i t s e l f  d o e s  n o t  
c a u s e  e i t h e r  s in g le  o r  d o u b le  s t r a n d  b r e a k s  in  D N A  ( P e t r u s e k  
et al., 1 9 8 1 ) , n e o t h r a m y c in ,  a  s t r u c tu r a l  a n a lo g  o f  a n t h r a m y ­
c in , h a s  b e e n  s h o w n  t o  c a u s e  d e g r a d a t io n  o f  D N A  in  E. coli 
(M a r u y a m a  et al., 1 9 7 8 ) , w h ic h  m a y  b e  r e la t e d  in  a n  a s  y e t  
u n k n o w n  w a y  t o  t h e  d o u b le  s t r a n d  b r e a k s  o b s e r v e d  in  t h is  
s t u d y .  T h e  lo w  r a t io  o f  s in g le  t o  d o u b le  s t r a n d  b r e a k s  (a p ­
p r o x im a t e ly  10:1) p r o b a b ly  r u le s  o u t  c o in c id e n t  s in g le  s t r a n d  
b r e a k s  a s  a  m e c h a n is m  fo r  f o r m a t io n  o f  d o u b le  s t r a n d  b r e a k s .  
P e r h a p s  t h e  p e r s i s t e n t  s in g le  s t r a n d  b r e a k s  a n d  a n t h r a m y c in  
l e s io n s  r e s u l t  in  d o u b le  s t r a n d  b r e a k s  a s  r e p a ir  e n z y m e s  a t ­
t e m p t  t o  r e s t o r e  d u p le x  D N A  fr e e  o f  a n t h r a m y c in  le s io n s .  A  
n u m b e r  o f  m e c h a n is m s  fo r  s u c h  a  c o n v e r s io n  o f  a  s in g le  s t r a n d  
t o  d o u b le  s t r a n d  b r e a k s  c o u ld  b e  e n v is a g e d .  F o r  e x a m p le ,  t h e  
p e r s i s t e n c e  o f  a  s in g le  s t r a n d  b r e a k  n e a r  a n  a n t h r a m y c in  
l e s io n  m a y  a l lo w  a  s e c o n d  a d j a c e n t  r e p a ir  p a t c h  o n  t h e  o p ­
p o s i t e  s t r a n d ,  o r  t h e  a s s o c ia t io n  o f  a n t h r a m y c in  w i t h  b o t h  
s t r a n d s  o f  D N A  m a y  a p p e a r  t o  t h e  r e p a ir  c o m p le x  a s  a n  
i n tr a s tr a n d  c r o s s - l in k  in  D N A  a n d  r e s u l t  in  d o u b le  s t r a n d  
b r e a k s  in  D N A  a s  a  c o n s e q u e n c e  o f  r e p a ir .
W e  h a v e  p r e v io u s ly  s h o w n  t h a t  a l t h o u g h  a n t h r a m y c in  is  
o n ly  w e a k ly  m u t a g e n ic  in  t h e  A m e s  Salmonella  s y s t e m  a n d  
in  t h e  y e a s t  S . cerevisiae, i t  i s  h ig h ly  r e c o m b in o g e n ic  in  t h e  
s a m e  y e a s t  s y s t e m  ( H a n n a n  et al., 1 9 7 8 ) . T h e  g e n e t ic  e f f e c t s  
o f  a n t h r a m y c in  a r e  v e r y  s im ila r  t o  t h o s e  in d u c e d  b y  b le o m y c in  
( H a n n a n  a n d  N a s im ,  1 9 7 8 ). B le o m y c in ,  l ik e  a n t h r a m y c in ,  
p r o d u c e s  d o u b le  s t r a n d  b r e a k s  in  D N A ,  a lb e i t  b y  a n  e n t ir e ly  
d if f e r e n t  m e c h a n is m .  T h e  la c k  o f  m u t a g e n ic  e f f e c t s  o f  a n t h r a ­
m y c in  c o u ld  b e  d u e  t o  t h e  i n a b i l i t y  o f  t h e  r e p l ic a t io n  fo r k  t o  
t r a n s i t  t h e  s i t e  o f  t h e  a n t h r a m y c in  le s io n .
F in a lly ,  t h e  p r o b le m  o f  t h e  g r e a te r  s e n s i t i v i t y  o f  X P  c e l ls  
t h a n  t h e  n o r m a l  f ib r o b la s t s  t o  a n t h r a m y c in  m u s t  b e  a d ­
d r e s s e d ,  s in c e  o n e  m ig h t  h a v e  e x p e c t e d  t h e  X P  c e l l s  t o  b e  l e s s  
s e n s i t i v e  t o  a n t h r a m y c in ,  s in c e  d o u b le  s t r a n d  b r e a k s  a r e  n o t  
p r o d u c e d  in  t h i s  c e l l  l in e  a s  a  r e s u l t  o f  r e p a ir . O n e  in t e r p r e ­
t a t io n  is  t o  s u g g e s t  t h a t  t h e  n o n r e m o v a l  o f  a n t h r a m y c in  
l e s io n s  fr o m  D N A  is  a  m o r e  l e t h a l  e v e n t  th a n  in t r o d u c t io n  o f  
d o u b le  s t r a n d  b r e a k s . H o w e v e r ,  t h i s  c o n c lu s io n  m u s t  b e  d r a w n  
w it h  s o m e  c a u t io n ,  s in c e  t h e r e  i s  a  d is c r e p a n c y  b e t w e e n  t h e  
d o s e  l e v e l s  a t  w h ic h  w e  m e a s u r e  l e t h a l i t y  a n d  p e r s i s t e n t  s in g le  
o r  d o u b le  s t r a n d  b r e a k s , s u c h  t h a t  in  X P  c e l l s  a  0 .1  s u r v iv a l  
f r a c t io n  o c c u r s  a t  a b o u t  2 .5  X 1 0 ~ 5 f im o l /m l ,  w h e r e a s  s t r a n d  
b r e a k s  a r e  o n ly  d e t e c t e d  a t  a  1 0 -fo ld  h ig h e r  c o n c e n t r a t io n .  
C o n c e iv a b le  a t  t h e  lo w e r  d o s e  l e v e l  p e r s i s t e n t  s t r a n d  b r e a k s  
d o  n o t  o c c u r  a n d  t h e  l e t h a l i t y  is  r e la t e d  p u r e ly  t o  r e m o v a l  o r  
n o n r e m o v a l  o f  a n t h r a m y c in  le s io n s .
7 R. L. Petrusek and L. H. Hurley, unpublished data.
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Correlation of DNA Sequence Specificity of Anthramycin and Tomaymycin with 
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abstract: Anthramycin and tomaymycin are potent antitumor antibiotics belonging to the pyrrolo[l,4]- 
benzodiazepine [P[1,4]B] group. Their potent biological effects are thought to be due to their ability to 
react with D N A  within the minor groove, forming covalent adducts through the N 2 of guanine with the 
drug molecules overlapping with a 3-4-bp region. In spite of their small molecular weights, the P [l,4 ]B ’s 
show a surprising degree of sequence selectivity, with 5'-PuGPu sequences being the most reactive and 
5'-PyGPy sequences being the least reactive [Hertzberg, R. P., Hecht, S. M., Reynolds, V. L., Molineux,
I. J., & Hurley, L. H. (1986) Biochemistry 25, 1249-1258]. It has been proposed that inherent D N A  
flexibility may be one important component of the sequence recognition process for P[1,4]B bonding to 
D N A , and in this regard, molecular modeling studies are reflective of the experimentally determined hierarchy 
o f bonding sequences [Zakrzewska, K., & Pullman, B. (1986) Biomol. Struct. Dyn. 4, 127-136]. In this 
study, we have used chemical and enzymatic probes (hydroxyl radical, DNase I) to evaluate drug- and 
sequence-dependent changes in DNA-adduct conformation, gel electrophoresis to measure drug-induced 
bending in D N A , and HPLC to measure the reaction kinetics of anthramycin bonding to different sequences. 
The results show that tomaymycin bonding to D N A  induces greater conformational changes in the D N A  
(i.e., bending and associated narrowing of the minor groove) than anthramycin. In addition, we find that 
within each drug species (i.e., tomaymycin or anthramycin), sequence specificity correlates with the degree 
of bending and reaction kinetics such that those sequences with the highest sequence selectivity produce 
more bending of D N A  and react fa ster  with D N A  and vice versa. On the basis of these results, we propose 
that sequence-dependent conformational flexibility may be an important factor in determining the hierarchy 
of bonding sequences for the P [l,4 ]B ’s.
Anthramycin and tomaymycin (Figure 1) are antitumor 
antibiotics belonging to the pyrrolo[ 1,4] benzodiazepine 
[PfMJB^group. Reviews on the chemistry (Remers, 1988), 
mechanism of action (Kohn, 1975; Hurley, 1977; Hurley & 
Needham-VanDevanter, 1986), mechanisms for sequence 
recognition (Mountzouris & Hurley, 1992), structure-activity 
relationships (Thurston & Hurley, 1983), and multiplicity of 
drug species bound to DNA (Remers et al., 1992) have 
appeared. Like mitomycin C, the P[l,4]B ’s form covalent 
adducts through the exocyclic amino group of guanine (N2) 
and lie within the minor groove covering a 2-3-bp region 
(Hurley & Petrusek, 1979; Petrusek et al., 1981). The imine 
(Figure 2) is proposed to be the DNA-reactive species (Barkley 
et al., 1986). In spite of the relatively small size of this DNA  
ligand, the P [l,4]B ’s show a surprising degree of sequence 
specificity (Hertzberg et al., 1986; Hurley et al., 1988), but 
it is still not clear how this selectivity is achieved (Mountzouris 
& Hurley, 1992). On the basis of molecular modeling studies 
(Zakrzewski & Pullman, 1986), it has been proposed that 
inherent sequence flexibility is the origin of this sequence 
selectivity. In this study, we have used five different 21-bp 
oligomers, each containing a unique P[1,4]B bonding site 
contained in sequences covering the range of hierarchy of
t This research was supported by the Public Health Service (CA- 
49751), The Welch Foundation, and the Burroughs Wellcome Fund.
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(512) 471-4842.
1 On leave from the Faculty of Pharmaceutical Sciences, Kanazawa 
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1 Abbreviations: bp, base pair; P [ 1,4] B, pyrrolo [ 1,4] benzodiazepine; 
Tris, tris(hydroxymethyl)aminomethane; Op-Cu, 1,10-phenanthroline- 
copper complex; EDTA, ethylenediaminetetraacetic acid; HPLC, high- 
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Figure 1: Structures of anthramycin and tomaymycin.
bonding specificity in order to compare drug-induced bending 
and reaction kinetics. Overall, we find that within each drug 
species (i.e., tomaymycin or anthramycin) sequence specificity 
correlates with the degree of bending and reaction kinetics 
such that those sequences with the highest sequence selectivity 
produce more bending of DNA and react faster  with DNA  
and vice versa. Although this correlation of experimental
© 1993 American Chemical Society
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F igure 2: Proposed reaction of anthramycin with the N2 of guanine 
via the imine to form the anthramycin-DNA adduct.
data supports the theoretically based Pullman postulate 
(Zakrzewski & Pullman, 1986), there are certain experimental 
findings that do not correspond to the theoretical results.
MATERIALS AND METHODS
Chemicals and Enzymes. Anthramycin 11-methyl ether 
and tomaymycin were obtained from Hoffmann-La Roche 
and Fujisawa Pharmaceuticals, respectively. The series of 
oligonucleotides shown in Figure 2 was synthesized on an 
automated DNA synthesizer (Applied Biosystems 381 A) by 
the phosphoramidite method (Gait, 1984). The oligomers 
were deprotected separately with saturated ammonium hy­
droxide at 55 °C overnight, and the solvent was evaporated 
at room temperature. HPLC water and methanol were 
purchased from Fisher Scientific Co. Electrophoretic reagents, 
acrylamide, bis(acrylamide), ammonium persulfate, and 
N,N,N'JV-tetramethylethylenediamine were purchased from 
Bio-Rad and ICN. T4 polynucleotide kinase and T4 DNA  
ligase were from United States Biochemical Corporation. 
DNase I from bovine pancreas and bovine serum albumin 
(Cohn’s Fraction V) were from Sigma. [ t -32P] ATP was from 
ICN. X-ray film (x-OMATAR), intensifying screens, and 
developing chemicals were from Kodak. Other chemicals were 
reagent grade or better and were used as received.
Stock solutions of the antibiotics were prepared by sus­
pending anthramycin 11-methyl ether or tomaymycin in 1 
mL of annealing buffer (100 mM NaCl and 10 mM Tris Cl, 
pH 7.5) and stirring for 2 h at room temperature. The 
antibiotic stock solutions were then stored at -70  °C until use.
Kinase Reaction and Purification o f  Oligonucleotides. 
Approximately 10 ng of individual oligonucleotides were 
labeled at the 5' end with 30 *iCi of [7 -32P]ATP and 5 units 
of T4 polynucleotide kinase in 25 fiL of a solution containing 
50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, and 10 mM 
2-mercaptoethanol at 37 °C for 30 min. The solution was 
heated to 70 °C for 5 min to deactivate the kinase enzyme. 
The [7 -32P]ATP-labeled oligonucleotides were mixed with 
their complementary oligonucleotides. The combined oligo­
nucleotide solutions were heated to 55 °C and then cooled 
slowly to 4 °C to form hybridized duplexes.
For purification, the duplexes were electrophoresed [29:1 
(w/w) monoacrylamide/bis(acrylamide)] on an 8% nonde­
naturing polyacrylamide gel until the bromophenol blue 
marker had migrated 23 cm in a 30 cm X 36 cm X 0.8 mm 
gel. The electrophoresis buffer was 50 mM Tris-borate (pH 
8.3) and 1 mM Na2EDTA (TBE buffer). The gels were 
electrophoresed at room temperature at 7 V/cm. The gels 
were exposed to X-ray film, and the duplexes were excised 
from the gel, minced with a blade, and extracted with 400 fiL 
of 10 mM Tris Cl (pH 7.5), 100 mM NaCl, and 1 mM N a2- 
EDTA.
Drug Bonding to Oligomers and Ligation. For the prep­
aration of antibiotic-modified oligomers, 30 nL of a concen­
trated suspended stock solution of anthramycin or tomaymycin 
was added to 100juL(~10 ug) of [7 -32P] ATP-labeled purified 
DNA duplex. The mixtures were incubated at 4 °C for 7 
days, followed by an ethanol precipitation to remove unbound 
drug molecules.
Antibiotic-modified and unmodified oligomers were self­
ligated into multimeters in 15 nL of ligation buffer with 1 unit 
of T4 ligase at 4 °C overnight. The ligation buffer contained 
50 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 1 mM dithio- 
threitol, 5% (w/v) poly(ethylene glycol) 8000, and 0.5 mM 
ATP. These samples were used directly in the bending 
experiments.
Bending Experiments. For bending experiments, equal 
amounts of radioactivity per self-ligated sample were loaded 
onto a 6% nondenaturing polyacrylamide gel [30 cm X 36 cm 
X 0.8 mm; 29:1 (w/w) acrylamide/bis(acrylamide)] and 
electrophoresed with TBE buffer at 350 V at room temperature 
until the bromophenol blue marker had migrated 25 cm. The 
ligated multimers were located by autoradiography, and the 
ratio of apparent size to actual size (RL) for each product was 
calculated.
DNA Sequencing and Sequencing Gel Electrophoresis. 
Purine- and pyrimidine-specific sequencing reactions were 
carried out according to the methods of Maxam and Gilbert
(1980). Oligomers digested by the sequencing reaction of 
Maxam and Gilbert, by DNase I, or by the chemical reagents 
FenEDTA and Op-Cu were resuspended in sequencing gel 
loading buffer. The resulting solutions were heated to 90 °C 
for 3 min to denature the oligomers and then plunged quickly 
into ice water. Equal amounts of radioactivity per sample 
were loaded onto a 20% denaturing gel [30 cm X 35 cm X 0.35 
cm; 29:1 (w/w) acrylamide/bis(acrylamide) and 8.3 M urea] 
and electrophoresed with TBE buffer at 1800 V at room 
temperature until the bromophenol blue marker had migrated 
25 cm. Autoradiograms were made with the aid of intensifying 
screens and exposed at -70  °C. Films were scanned with an 
LKB Model 2202 laser densitometer coupled with an LKB 
Model 2220 recording integrator.
Footprinting Experiments. (A) DNase I Digestion. An­
tibiotic-modified and unmodified oligomers were suspended 
in 10 fiL of 10 mM Tris-HCl (pH 7.6), 2 mM MgCl2, 0.2 mM
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Table I: Sequences of Synthetic Oligonucleotides Used in This 
Study"
AGA 5 ' A T A T IA T C IA G A A C T C IC IT T  3 '  
3 1 ACTAGCTCTTGAGCGCAATAT 5 '
CGA 5 ' A T A T IA T C IC G A A C T C IC IT T  3 '  
3 '  ACTAGCGCTTGAGCGCAATAT 5 ’
AGC 5 ' A T A T IA T C IA G C A C T C IC IT T  3 '  
3 '  ACTAGCTCGTGAGCGCAATAT 5 ’
CGC 5 ' A T A T IA T C IC G C A C T C IC IT T  3 '  
3 '  ACTAGCGCGTGAGCGCAATAT 5 ’
TGC 5 ' A T A T IA T C IT G C A C T C IC IT T  3 '  
3 '  ACTAGCACGTGAGCGCAATAT 5 •
a Duplexes were designed to contain a unique P [l, 4]B binding site 
covering the range of hierarchy of drug-bonding specificities.
d it h io t h r e it o l ,  a n d  5 0  ng / mL  b o v in e  s e r u m  a lb u m in .  D N a s e  
I w a s  d i s s o lv e d  in  H P L C  w a t e r  a t  a  c o n c e n t r a t io n  o f  1 0 0  
ng/mL.  D N a s e  I s o lu t io n  (1  ^ L )  w a s  a d d e d  to  e a c h  o l ig o m e r  
s a m p le ,  a n d  d ig e s t io n  w a s  c a r r ie d  o u t  fo r  1 m in  a t  r o o m  
te m p e r a tu r e .  T h e  d ig e s t io n  w a s  q u e n c h e d  b y  th e  a d d it io n  o f  
a n  e q u a l  v o lu m e  o f  s to p  d y e  s o lu t io n  [9 0 %  ( v / v )  d e io n iz e d  
f o r m a m id e ,  10%  ( w / v )  s o d iu m  la u r y l  s u l f a t e ,  10  m M  E D T A ,  
0 .2 5 %  ( w / v )  x y le n e  c y a n o l  F F , a n d  0 .2 5 %  ( w / v )  b r o m o p h e n o l  
b lu e ] .  S a m p le s  w e r e  th e n  s u b j e c t e d  to  s e q u e n c in g  g e l  
e le c tr o p h o r e s is .
(B) H ydroxyl Radical Cleavage. A n t ib io t ic - m o d if ie d  a n d  
u n m o d if ie d  o l ig o m e r s  w e r e  s u s p e n d e d  in  2 0  nL  o f  1 0  m M  
T r is - H C l  ( p H  7 .6 ) .  A n  F e n E D T A  c o m p le x  w a s  p r e p a r e d  b y
m ix in g  e q u a l  v o lu m e s  o f  2  m M  ( N H ^ F e S C ^  a n d  4  m M  
E D T A  j u s t  p r io r  to  u s e .  T h e  F e ( I I )  s o lu t io n  ( 2  / iL ) ,  2  y.L o f  
3%  ( w / v )  H 2O 2, a n d  2  nL  o f  1 0  m M  s o d iu m  a s c o r b a t e  w e r e  
m ix e d  o n  th e  in s id e  w a ll  o f  th e  r e a c t io n  t u b e  a s  o n e  d r o p . T h e  
d r o p  w a s  m ix e d  w ith  th e  o l ig o m e r  s o lu t io n ,  a n d  th e  c le a v a g e  
r e a c t io n  w a s  c a r r ie d  o u t  a t  r o o m  t e m p e r a tu r e  fo r  1 0  m in . T h e  
r e a c t io n  w a s  q u e n c h e d  b y  th e  a d d it io n  o f  2  nL  o f  0 .1  M  
t h io u r e a .  T h e  o l ig o n u c le o t id e s  w e r e  th e n  is o la t e d  b y  e th a n o l  
p r e c ip ita t io n  ( 2 X ) .  T h e  D N A  p e lle t  w a s  w a s h e d  w ith  e th a n o l  
a n d  d r ie d  in  v a c u o .  T h e  p e l le t  w a s  r e s u s p e n d e d  in  s e q u e n c in g  
g e l  lo a d in g  b u f fe r  a n d  s u b je c te d  t o  s e q u e n c in g  g e l  e le c t r o ­
p h o r e s is .
( C )  1,10-Phenanthroline-Copper Cleavage. A n t ib io t ic -  
m o d if ie d  a n d  u n m o d if ie d  o l ig o m e r s  w e r e  s u s p e n d e d  in  2 0  nL 
o f  10  m M  T r is - H C l  ( p H  7 .6 ) .  T h e  c le a v a g e  r e a c t io n  w a s  
c a r r ie d  o u t  a t  r o o m  te m p e r a tu r e  fo r  2  m in  in  th e  p r e s e n c e  o f  
5 0  m M  C uSC >4, 2 0 0  mL o f  1 ,1 0 - p h e n a n t h r o l in e ,  a n d  5 m M  
2 -m e r c a p to p r o p io n ic  a c id . T h e  c le a v a g e  r ea c tio n  w a s  q u e n c h e d  
b y  th e  a d d it io n  o f  n e o c u p r o in  to  g iv e  a  f in a l  c o n c e n t r a t io n  o f  
6  m M . D ig e s t e d  o l ig o m e r s  w e r e  i s o la te d  b y  e t h a n o l  p r e c ip ­
i ta t io n  a n d  d r ie d  in  v a c u o .  T h e  o l ig o m e r s  w e r e  r e s u s p e n d e d  
in  1 0 0  mL o f  f r e s h ly  p r e p a r e d  1 M  p ip e r id in e  s o lu t io n  a n d  
h e a t e d  t o  9 0  ° C  fo r  3 0  m in  to  tr a n s fo r m  m e t a s t a b le  
in te r m e d ia r y  p r o d u c ts  to  o l ig o n u c le o t id e s  w ith  3 '-p h o s p h o  
m o n o e s te r  te r m in i .  T h e  o l ig o n u c le o t id e s  w e r e  th e n  is o la te d  
b y  e t h a n o l  p r e c ip ita t io n  a n d  d r ie d  in  v a c u o .  T h e  D N A  p e lle t s  
w e r e  r e s u s p e n d e d  in  s e q u e n c in g  g e l  l o a d in g  b u f fe r  a n d  
s u b j e c t e d  to  s e q u e n c in g  g e l  e le c tr o p h o r e s i s .
R E S U L T S
T h e  p u r p o s e  o f  th is  s tu d y  w a s  to  d e t e r m in e  w h e th e r  a n y  
c o r r e la t io n  e x is t e d  b e tw e e n  th e  D N A  s e q u e n c e  s e l e c t iv i t y  o f
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F i g u r e  3: Denaturing gel analysis o f  anthramycin (lanes 4, 9, 14, and 19) and tom aym ycin (lanes 5, 10, 15, and 20) m odified oligom ers and 
their corresponding unmodified D N A  (lanes 3, 8, 13, and 18) following l,10-phenanthroline-copper(I) footprinting. The sequences o f  AG A, 
CG A, AG C, and TG C at the top o f the gel correspond to those listed in Table I. D N A  was 5'-end-labeled with 32P on the top strand only. 
Pu (lanes 1 , 6 ,  11, and 16) and Py (lanes 2, 7, 12, and 17) represent the M axam -G ilbert purine- and pyrim idine-specific cleavage reactions.
D N A  S e q u e n c e  S p e c i f ic i t y  o f  P [ l , 4 ] B ’s
AGA CGA
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F i g u r e  4: Denaturing gel analysis o f  anthramycin (lanes 3, 7, 11, and 15) and tomaymycin (lanes 4, 8, 12, and 16) and their corresponding 
unmodified D N A  (lanes 2, 6, 10, and 14) following D N ase  I footprinting. D N A  was S'-end-labeled with 32P on the top strand only. Pu 
represents the M axam -G ilbert purine-specific cleavage reaction. The sequences A G A , CG A, AG C, and TG C at the top of the gel correspond 
to those listed in Table I.
a n t h r a y m c in  a n d  t o m a y m y c in ,  th e  b e n d in g  o f  D N A ,  a n d  th e  
k in e t ic s  o f  a n t h r a m y c in - D N A  a d d u c t  f o r m a t io n .  T h e  f iv e  
D N A  b o n d in g  s e q u e n c e s  ( T a b le  I )  u s e d  in  th is  s t u d y  w e r e  
c h o s e n  in  o r d e r  to  c o v e r  th e  r a n g e  o f  h ie r a r c h y  o f  b o n d in g  
s p e c i f ic i t i e s .  P r e v io u s  c h e m ic a l  a n d  e n z y m a t i c  fo o tp r in t in g  
s tu d ie s  o n  lo n g  D N A  r e s tr ic t io n  f r a g m e n t s  r e v e a le d  t h a t  th e  
m o s t  p r e fe r r e d  s e q u e n c e  fo r  P [ 1 ,4 ] B  b o n d in g  is  S ' - P u G P u ,  
w h i le  5 ' - P y G P y  s i t e s  a r e  th e  le a s t  p r e fe r r e d  s e q u e n c e s  
( H e r t z b e r g  e t  a l . ,  1 9 8 6 ;  H u r le y  e t  a l . ,  1 9 8 8 ) .  S e q u e n c e s  
c o n ta in in g  5 ' -P y G P u  a n d  5 ' -P u G P y  s h o w  in te r m e d ia te  b o n d ­
in g  p r e fe r e n c e s .  T h e  f ir s t  s t e p  in  o u r  s tu d y  c o n s is t e d  o f  a n  
a n a ly s i s ,  b y  th r e e  d i f f e r e n t  D N A  fo o tp r in t in g  m e t h o d s ,  o f  
d r u g - D N A  a d d u c t s  p r e p a r e d  w ith  t o m a y m y c in  o r  a n t h r a ­
m y c in .  F ir s t ,  O p -C u  f o o tp r in t in g  w a s  u s e d  t o  d e t e r m in e  th e  
location  a n d  site size  o f  th e  d r u g  o n  th e  D N A  ( S i g m a n ,  1 9 8 5 ,  
1 9 8 6 , 1 9 9 0 ) .  S e c o n d ,  D N a s e  I f o o tp r in t in g  w a s  u s e d  to  p r o b e  
th e  d r u g  bonding efficiency a n d  to  a d d r e s s  q u e s t io n s  o f  
conformation a n d  flexibility  o f  th e  d r u g -m o d if ie d  D N A  ( L a n e  
e t  a l . ,  1 9 8 3 ;  F o x  &  H o w a r th ,  1 9 8 5 ) .  T h ir d ,  h y d r o x y l  r a d ic a l  
f o o tp r in t in g  w a s  c a r r ie d  o u t  to  e x a m in e  th e  m in o r  g r o o v e  
structure  a n d  accessibility  ( S h a f e r  &  T u l l iu s ,  1 9 8 9 ) .  O u r  
n e x t  s t e p  c o n s is t e d  o f  e x p e r im e n t s  to  e x a m in e  th e  e le c t r o ­
p h o r e t ic  m o b il i t y  o f  l ig a t e d  d r u g - m o d if ie d  21  -b p  o l ig o m e r s  to  
d e te r m in e  w h e th e r  a n t h r a m y c in  a n d  t o m a y m y c in  p r o d u c e d  
b e n d in g  o f  D N A .  F in a l ly ,  a n  a n a ly t ic a l  H P L C  t im e  c o u r s e  
e x p e r im e n t  w a s  d e v e lo p e d  to  fo l lo w  th e  k in e t ic s  o f  a n t h r a ­
m y c i n - D N A  a d d u c t  fo r m a t io n .  O v e r a l l ,  th e  r e s u lt s  im p ly  
t h a t  th e r e  is  a  c o r r e la t io n  b e tw e e n  th e  s e q u e n c e  s e l e c t iv i t y ,  
t h e  d r u g - in d u c e d  D N A  b e n d in g ,  a n d  t h e  r e a c t io n  k in e t ic s ;  
t h a t  is , fo r  e a c h  d r u g  s p e c ie s ,  th e  D N A  s e q u e n c e s  th a t  r e a c te d  
m o r e  r a p id ly  w ith  th e  P  [ 1 ,4 ] B  d r u g s  w e r e  fo u n d  to  h a v e  g r e a te r  
D N A  b e n d in g  a n d  a r e  k n o w n  to  h a v e  g r e a te r  b o n d in g  
s p e c i f ic i t y .
1,10-Phenanthroline-Copper Footprinting o f  Drug-DNA  
Adducts. T h e  b o n d in g  lo c a t io n  a n d  s iz e  o f  th e  a n t h r a m y c in  
a n d  to m a y m y c in  fo o tp r in t s  o n  d i f f e r e n t  o l ig o m e r  s e q u e n c e s  
( T a b le  I )  w e r e  a n a ly z e d  o n  a  20 %  s e q u e n c in g  g e l  b y  a n  O p -  
C u  fo o tp r in t in g  a s s a y .  T h e  O p -C u  c o m p le x  b in d s  w i th in  th e  
m in o r  g r o o v e  o f  D N A  a n d  c le a v e s  a t  i t s  b in d in g  s it e  ( S i g m a n ,  
1 9 8 6 ;  Y o o n  e t a l . ,  1 9 9 0 ) .  F ig u r e  3 s h o w s  th e  O p - C u  c le a v a g e
p a t te r n  fo r  fo u r  o f  th e  2 1 -b p  o l ig o m e r s  m o d if ie d  w ith  
a n t h r a m y c in  o r  t o m a y m y c in .  T h e  f ig u r e  s h o w s  a  d e n a tu r in g  
e le c t r o p h o r e s i s  g e l  o f  t h e  fo o tp r in t in g  p a t te r n  o f  th e  D N A  
s tr a n d  th a t  is  c o v a le n t ly  m o d if ie d  w ith  e ith e r  t o m a y m y c in  or  
a n t h r a m y c in .  T h e  c o m p le m e n t a r y  D N A  s tr a n d s  th a t  a r e  n o t  
in v o lv e d  in  c o v a le n t  in t e r a c t io n s  w ith  th e  d r u g s  w e r e  a ls o  
a n a ly z e d  (d a t a  n o t  s h o w n ) .  T h e  a n a ly s i s  o f  th e  r e s u lt s  o f  th e  
t o m a y m y c i n - D N A  a d d u c t s  fo r  a l l  fo u r  o l ig o m e r  s e q u e n c e s  
r e v e a ls  a  s t r o n g  f o u r - n u c le o t id e  fo o tp r in t  o n  th e  c o v a le n t ly  
m o d if ie d  s tr a n d  s t a g g e r e d  to  th e  3 ' s id e  o f  th e  c o v a le n t ly  
m o d if ie d  g u a n in e ,  p r e s u m a b ly  d u e  to  d r u g  o c c u p a n c y  o f  th e  
m in o r  g r o o v e  in  a  r ig h t -h a n d e d  D N A  m o le c u le  ( S ig m a n ,  
1 9 8 6 ) .  O n  th e  o p p o s it e  s tr a n d  o f  D N A ,  a  s im ila r ly  p o s i t io n e d  
3 '  o f f s e t  fo o tp r in t  o f  f iv e  n u c le o t id e s  is g e n e r a t e d  w ith  
t o m a y m y c in  u s in g  O p -C u  f o o t p r in t in g  (d a t a  n o t  s h o w n ) .  A  
s u m m a r y  o f  t h e s e  r e s u lt s  is  s h o w n  in  F ig u r e  6 .
T h e  r e s u lt s  a r e  m o r e  c o m p le x  fo r  a n t h r a m y c in  th a n  
t o m a y m y c in .  W h ile  a  s t r o n g  f o u r - n u c le o t id e  fo o tp r in t  is  
g e n e r a t e d  o n  th e  c o v a le n t ly  m o d if ie d  s tr a n d  o f  th e  5 ' - A G A  
a n d  5 ' - C G A  s e q u e n c e s  ( F ig u r e  3 )  t h a t  a p p e a r s  s im ila r  to  th e  
t o m a y m y c i n - D N A  a d d u c t ,  f o o t p r in t in g  is  n o t  o b s e r v e d  o n  
t h e  5 ' - A G C  o r  5 ' - T G C  s e q u e n c e  o l ig o m e r s .  T h e  fo o tp r in t in g  
r e a c t io n s  o n  th e  n o n c o v a le n t ly  m o d if ie d  s tr a n d  p r o d u c e d  a  
w e a k  f iv e - n u c le o t id e  f o o tp r in t  o n  th e  5 ' - A G A  a n d  5 ' - C G A  
s e q u e n c e  o l ig o m e r s ,  w h i le  f o o tp r in t s  w ith  5 ' - A G C  a n d  5 '-  
T G C  s e q u e n c e  o l ig o m e r s  w e r e  a b s e n t .  W e  s u s p e c t  th a t  th e  
a b s e n c e  o f  a fo o tp r in t  o r  th e  p r e s e n c e  o f  o n ly  a  w e a k  fo o tp r in t  
o n  t h e  c o v a le n t  a n d  n o n c o v a le n t  D N A  s tr a n d s  is  p r o b a b ly  
d u e  t o  th e  O p -C u  d e s t a b i l i z a t io n  o f  th e  d u p le x ,  l e a d in g  to  lo s s  
o f  a n t h r a m y c in  fr o m  th e  D N A  in  t h e s e  g e n e r a l ly  p o o r e r  
b o n d in g  s e q u e n c e s .2
DNase I Footprinting o f  the Anthramycin and Tomaymycin 
Oligomer Adducts. T h e  d e g r e e  o f  a n t h r a m y c in  a n d  t o m a y ­
m y c in  b o n d in g  o n  d i f f e r e n t  21  -b p  o l ig o m e r  s e q u e n c e s  ( T a b le  
I )  w a s  a n a ly z e d  o n  a  20 %  s e q u e n c in g  g e l  b y  a  D N a s e  I
2 Denaturation of duplex D N A  leads to loss of the secondary stabilizing 
interactions between P[1,4]B and D N A  and exposure of the readily 
reversible aminal linkage and subsequent reversal of the covalent adduct 
formation (Hurley et al., 1977).
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DNA Sequence Specificity of P[l,4]B’s
footprinting assay. The results of the DNase I digestion of 
the drug-DNA adducts and unmodified DNA controls are 
shown in Figure4. While the DNase I digestion of unmodified 
DNA (lanes 2, 6, 10, and 14) produced an uneven cleavage 
ladder due to sequence-dependent conformational variability, 
the DNA samples covalently modified with drug produced 
the same pattern, except within and around the expected drug- 
bonding sites. The anthramycin and tomaymycin footprints 
shown for the 5'-AGA, 5'-CGA, and 5'-AGC sequence 
oligomers showed an almost total inhibition of DNase 1 
cleavage, demonstrating virtually complete drug bonding. 
Although the 5'-TGC sequence oligomer shows a footprint at 
the drug-bonding site, there is only partial inhibition of DNase 
I cleavage at this site, possibly due to some instability of this 
adduct toward DNase I cleavage. As also shown in the Cu- 
Op experiments, both anthramycin and tomaymycin bond to 
the sole guanine in the 21-bp oligomer sequences. A five- 
nucleotide footprint produced by anthramycin begins at the 
adjacent base on the 3' side of the modified guanine. There 
is an enhancement of cleavage by DNase I at the two bases 
to the 3' side of this footprint. A seven-nucleotide footprint 
is generated with tomaymycin, which also exhibits an en­
hancement of cleavage to the 3' side. For tomaymycin, this 
seven-nucleotide footprint, rather than the five-nucleotide 
footprint found for anthramycin, may suggest that tomaymycin 
has a longer range effect on DNA conformation than 
anthramycin. These results are also summarized in Figure 
6 .
H yd ro x y l R a d ica l F ootprin ting o f  the A nthram ycin  and  
T om aym ycin  O ligom er A ddu cts. Hydroxyl radical foot­
printing was used in the study of adducts of anthramycin or 
tomaymycin with the same 21-bp oligomers. This method 
was chosen in addition to the Op-Cu and DNase I footprinting 
because it has produced high-resolution structural data on a 
number of different DNA molecules, DN A-protein complexes, 
and DNA-drug adducts (Tullius et al., 1987; Tullius, 1987; 
Portugal & Waring, 1987, Cons & Fox, 1989a,b; Fox, 1988). 
Hydroxyl radical, generated by the reduction of hydrogen 
peroxide by FenEDTA is an attractive conformational probe 
due to small size and high reactivity. The hydroxyl radical 
abstracts a hydrogen atom, most likely from C4' of the 
deoxyribose in the minor groove, leading to DNA strand 
scission at the point of the attack. With complexes of drugs 
with DNA, this small, nonspecific, reactive hydroxyl radical 
probe can yield information on the physical contacts made 
between drug and DNA molecules and also on variations in 
the minor groove width.
The sequencing electrophoresis gels of the hydroxyl radical 
footprinting of the 5'-AGA, 5'-CGA, 5'-AGC, and 5'-TGC 
21-bp oligomer sequences modified with tomaymycin or 
anthramycin are shown in Figure 5 A. Both the anthramycin- 
DNA and tomaymycin-DNA adducts showed diminished 
cleavage to the 3' side of the drug-bonding region. Densi­
tometer scans of the footprinting gel lanes provide a more 
obvious representation of the change in the cleavage pattern 
of DNA following drug modification of DNA (Figure 5B). 
In all of the scans of tomaymycin and anthramycin oligomer 
DNA adducts except one (anthramycin with 5'-TGC), the
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three bases to the 3' side of the covalently modified guanine 
were less reactive to hydroxyl radical (arrows in Figure 5B), 
while at the covalently modified guanine and to the 5' side, 
dramatic changes were not observed. On the noncovalently 
modified strand, inhibition of hydroxyl radical cleavage was 
also found, which most often included the cytosine opposite 
the covalently modified guanine and the two bases to its 3' 
side (results not shown, but summarized in Figure 6). The 
extent of inhibition of hydroxyl radical was quite variable, 
dependent upon both the drug and the covalently modified 
sequence. In general, tomaymycin produced a greater 
inhibition than anthramycin, and for anthramycin, strong 
inhibition was only found for 5'-AGA and 5'-CGA sequences. 
Since drug occupancy is almost complete for all of the drug- 
modified sequences, and cleavage results from attack at the 
4' and 5' positions of the deoxyriboses, we believe that this 
uneven pattern of inhibition of hydroxyl radical is largely due 
to changes in minor groove geometry (i.e., narrowing of groove 
width). The hydroxyl radical footprinting results for both 
the covalently and noncovalently modified strands are sum­
marized in Figure 6.
D eterm ination  o f  A nthram ycin- and  T om aym ycin-Induced  
B ending o f  D N A . The same four 21-bp DNA sequences used 
in the footprinting experiments and a fifth, containing the 
least preferred bonding sequence, 5'-CGC (Table I), were 
designed in part so that they would be useful for studies to 
determine whether anthramycin and tomaymycin were capable 
of bending DNA. The purpose of this aspect of the study was 
to investigate whether or not any correlation existed between 
the drug bonding preference and drug-induced conformational 
changes, such as bending of DNA. In order to study the 
relationship between DNA sequence preference and DNA  
bending, the electrophoretic mobility of DNA was monitored 
(Koo et al., 1986; Koo & Crothers, 1988). The five different 
21-bp oligomers were fully modified with anthramycin or 
tomaymycin and ligated with T4 ligase into multimers, and 
the electrophoretic mobility was analyzed on 6% nondenaturing 
gel.
The autoradiogram of the ligation products of unmodified
(C) and drug-modified (A and T) oligomers is shown in Figure 
7A. Within the set of controls (lanes 1, 4, 7, and 10) there 
was some variability in electrophoretic mobility, such that 
5'-AGA and 5'-CGA sequences show retardation relative to 
the 5'-AGC, 5'-TGC, and 5'-CGC sequences, suggesting that 
the former two sequences show some intrinsic bending. While 
some drug-modified ligation products show considerable 
retardation in electrophoretic mobility (see lanes 3 ,6 ,9 , and 
12) when compared to the unmodified controls, other ligation 
products of drug-DNA adducts show little or no retardation 
(see lanes 2, 5, 8, and 11).
The sharp, sometimes more intense band or bands that 
appear as doublets at the higher molecular weight end of the 
gel in lanes 3 ,6 ,9 , and 12 (tomaymycin-modified) correspond 
to circular DNA molecules. This was confirmed by two- 
dimensional gel electrophoresis (data not shown). For 
tomaymycin-modified sequences (lanes 3, 6, 9, 12, and 15), 
a band occurs corresponding to circu lar  DNA (C* in Figure 
7A) that has a lower molecular weight than other circular
F igure 5: (A, top) Denaturing gel analysis of anthramycin (lanes 4 ,9 ,14 , and 19) and tomaymycin (lanes 5 ,10,15, and 20) modified oligomers 
and their corresponding unmodified DNA (lanes 3 ,8 , 13, and 18). DNA was 5/-32P-labeled on the top strand only and subjected to hydroxyl 
radical footprinting. Pu and Py represent the M axam -Gilbert purine (lanes 1, 6 , 11, and 16) and pyrimidine (lanes 2 ,7 ,1 2 , and 17) specific 
cleavage reactions, respectively. The sequences AGA, CGA, AGC, and TGC at the top of the gel correspond to those listed in Table I. (B, 
bottom) Densitometer scans of hydroxyl radical footprinting of the AGA, CGA, AGC, and TGC oligomers shown in A. Rows C, A, and T 
represent unmodified oligomers, oligomers modified with anthramycin, and oligomers modified with tomaymycin, respectively. Arrowheads 
indicate inhibition of the hydroxyl radical cleavage reaction.
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molecules (C in Figure 7A) occurring in either control or 
anthramycin-modified lanes. This is entirely consistent with 
the more pronounced bending induced by tomaymycin relative 
to anthramycin. In addition, this band of circular DNA (C*) 
and the band corresponding to the next higher molecular weight 
circular DNA in the AGA sequence lane are in large excess 
over bands of higher molecular weight circular DNA, which 
is also consistent with the more pronounced bending in this 
sequence relative to the other sequences.
For anthramycin, the evidence for bending based upon 
circularization efficiency is much weaker, which is also in 
accord with the lower, or absence of, bending calculated from 
R l  values (see below). The ratio of apparent size to true size 
( R l )  for each of the linear ligation products was calculated 
and plotted against oligomer length in base pairs (Figure 7B).3 
Unmodified DNA by definition has an R l value of 1. 
Increasing changes in the R l  value are an indication of drug- 
induced bending of DNA. The 5'-AGC, 5'-CGC, and 5'- 
TGC oligomers modified with anthramycin have R l values 
similar to those for the same sequence control DNA. 
Retardation in electrophoretic mobility was observed for 5'- 
AGA and 5'-CGA oligomers modified with anthramycin and 
for all oligomers modified with tomaymycin, indicating drug- 
induced DNA bending. These oligomers showed an increasing 
change in the R l value with the total length of ligation products. 
The increases in the R l values are much more pronounced in 
the tomaymycin-DNA than in the anthramycin-DNA ad­
ducts. As with DNase I and hydroxyl radical footprinting, 
the overall magnitude of the effects, in this case on R l values, 
is more pronounced with tomaymycin-modified DNA than 
with anthramycin-modified DNA. The estimated bending 
angles for tomaymycin- and anthramycin-modified oligomers 
are shown in Table II. The bending angles were calculated 
for each of the five sequences modified with anthramycin or 
tomaymycin by using a calibration equation for gel mobility 
anomalies derived by Koo and Crothers (1988). The values 
varied from a maximum of ~  14° for tomaymycin in 5'-AGA 
and 5'-CGC to a minimum of 0° for anthramycin in 5'-AGC, 
5'-CGC, and 5'-TGC.
Kinetic Analysis o f  DNA-Drug Adduct Formation. The 
five 21-mer oligomer sequences containing the bonding 
sequences, 5'-AGA, 5'-CGA, 5'-AGC, 5'-CGC, and 5'-TCG, 
used in this study were incubated with anthramycin, and the 
time course of the reaction mixture was studied by HPLC. An 
HPLC system was developed to separate unreacted anthra­
mycin from free DNA and drug-DNA adducts (see Materials 
and Methods). The relative quantity of unbound drug was 
then measured by UV absorption at 333 nm. Figure 8A is 
the HPLC trace of anthramycin alone, showing a retention 
time o f - 5  min. Figure 8B shows DNA (in this case, the 
5'-TGC oligomer) alone with a retention time of ~ 2  min. The 
small peak at 1.2 min is probably a small amount of single­
stranded DNA or an unknown contaminant. Examination of 
these two plots (Figures 8A,B) shows that anthramycin is 
well-separated from DNA on the HPLC column. Clean 
separation of each species is crucial, since the peak height is 
used to measure the absorbance and to calculate the con­
centration of the species involved. Figure 8C shows the entire 
reaction mixture. Briefly, DNA was mixed with an equal 
volume of anthramycin and injected onto the HPLC, and the 
retention time was monitored. The chromatograms show peaks 
at ~  5 and ~  2 min, representing free drug and unbound DNA, 
respectively. The large peak that eluted off the column (1.3 
min) just prior to the unmodified DNA peak ( ~ 2  min) 
represents the drug-DNA adduct.
Table II: Calculation of DNA Bending Angles Produced by 
Anthramycin and Tomaymycin in the 21-bp Oligomers Listed in 
Table I
oligomer sequence drug" R l value6 bending angle* (deg)
5'-AGA A 1.10 6.3-8.4
5'-CGA A 1.08 5.6-7.4
5'-AGC A 1.00 0
5'-CGC A 1.00 0
5'-TGC A 1.00 0
5'-AGA T 1.28 10.5-14.0
5'-CGA T 1.30 10.9-14.4
5'-AGC T 1.27 10.3-13.6
5'-CGC T 1.25 10.0-13.23
5'-TGC T 1.17 8.25-10.9
0 A and T represent anthramycin and tomaymycin, respectively. 6 R l 
values were calculated from 189-bp ligation products (nonamers of 21- 
bp oligomers). cThe estimate of bending angles of each sequence was 
calculated using a calibration equation for gel mobility anomalies derived 
by Koo and Crothers (1988).
The HPLC analysis of drug-DNA adduct formation was 
extended to all five oligomer sequences (Table I) used in this 
study. A time course study was conducted to determine the 
rate constants for these reactions. The plot shown in Figure 
9 shows the In of the ratio of unbound anthramycin to total 
anthramycin vs time. This plot shows that the 5'-AGA 
sequence reacts faster with anthramycin relative to the other 
sequences. The 5'-CGA and 5'- AGC oligomer sequences have 
intermediate reaction rates, and the 5'-CGC and 5'-TGC 
sequences react more slowly with the drug. The rate constants 
for anthramycin monitored here correlate well with the relative 
sequence selectivity of different sequences (i.e., 5'-PuGPu >  
" 5'-PuGpy = 5'-PyGPu > 5'-PyGPy) monitored in previous 
studies (Hertzberg et al., 1986; Hurley et al., 1988).
The reaction involved DNA and drug to form drug-DNA  
adducts, where the concentration of DNA was in vast excess 
and assumed to remain unchanged over the course of the 
reaction. The initial concentrations for DNA and anthramycin 
were ~ 5 0  and ~ 5  /xM, respectively, for each DNA sequence 
investigated. The DNA and drug react at equal stoichiometric 
amounts, i.e, one drug-bonding site per DNA oligomer 
molecule. Due to the excess of DNA, a first-order reaction 
was presumed, and the slopes of the lines in Figure 9 were 
used to calculate the rate constants. The resulting rate 
constants for each DNA sequence reacting with anthramycin 
are shown in Table III. The rate constants varied from 1.12 
X 10-1 min-1 for 5'-AGA to 5.05 X 10-3 min-1 for 5'-CGC.
DISCUSSION
The P[ 1,4] B class of drugs consists of highly potent cytotoxic 
agents that have significant efficacy as antitumor agents in 
animal model studies [reviewed in Remers (1988), Thurston 
and Hurley (1983), and Hurley (1977)], although their clinical 
use has been limited by the various toxicities they produce 
(Hurley, 1977). On the basis of a fairly detailed knowledge 
of the structures of the P[1,4]B-DNA adducts, a template- 
directed approach to the design of novel interstrand cross- 
linking molecules has been successfully executed (Wang et 
al., 1992; Bose et al., 1992). The P[ 1,4] B antitumor antibiotics 
not only show a selectivity for covalent bonding through the 
N2 of guanine in DNA (Petrusek et al., 1981) but also exhibit 
a modest sequence selectivity despite their small molecular 
weights. Upon bonding to DNA, the drugs lie within the 
minor groove overlapping with 2-3 bp (Petrusek et al., 1981; 
Boyd et al., 1990a,b). DNA footprinting studies using MPE 
(Hertzberg et al., 1986) and an exonuclease III stop assay 
(Hurley et al., 1988) have shown that anthramycin and
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F ig u r e  6: Summary o f the results o f 1,10-phenanthroline-copper footprinting, D N ase I footprinting, and hydroxyl radical cleavage pattern 
of 21-bp oligomers (Table I) modified with anthramycin (A ) and tom aym ycin (B): asterisk, covalently modified guanine; straight line, 
inhibition of Op-Cu; wavy line, inhibition o f D N ase I; arrow, enhancem ent o f D N ase I; half-arrow, inhibition of hydroxyl radical. The length 
of the arrow represents the relative amount o f cleavage inhibition.
t o m a y m y c in  p r e fe r  to  b o n d  to  5 ' -P u G P u  s e q u e n c e s ,  w h i le  5 '-  
P y G P u  a n d  5 ' -P u G P y  s e q u e n c e s  a r e  o f  in t e r m e d ia t e  p r e fe r ­
e n c e ,  a n d  th e  5 ' - P y G P y  s e q u e n c e s  a r e  th e  le a s t  p r e fe r r e d . T h e  
m o le c u la r  b a s is  fo r  th is  s e q u e n c e  s e l e c t iv i t y  is  s t i l l  u n c le a r ,  
a n d  w h i le  a v a r ie ty  o f  m o le c u la r  m o d e l in g  s tu d ie s  h a v e  b e e n  
c a r r ie d  o u t  ( R a o  &  R e m e r s ,  1 9 9 0 ;  R a o  e t  a l . ,  1 9 8 6 ;  
Z a k r z e w s k a  &  P u llm a n , 1 9 8 6 ) ,  n o  f ir m  c o n c lu s io n s  h a v e  b e e n  
m a d e ,  a l th o u g h  th e  P u llm a n  s tu d y  s u g g e s t e d  th a t  D N A  
f l e x ib i l i t y  w a s  im p o r ta n t .  T h e  p r e s e n t  s tu d y  w a s  in i t ia t e d  to  
a d d r e s s  th e  q u e s t io n  o f  th e  m o le c u la r  b a s is  fo r  D N A  s e q u e n c e  
s e l e c t iv i t y  o f  th e  P [ l , 4 ] B ’s a n d , in  p a r t ic u la r ,  to  p r o b e  th e  
im p o r ta n c e  o f  c o n fo r m a t io n a l  f l e x ib i l i t y .  In  a d d it io n  to  
c o n f o r m a t io n a l  f le x ib i l i t y ,  a  v a r ie ty  o f  m e c h a n is m s  fo r  
s e q u e n c e  r e c o g n it io n  b y  c o v a le n t ly  m o d if y in g  d r u g s , s u c h  a s  
c a t a ly t i c  a c t iv a t io n  a n d  p r e c o v a le n t  b in d in g  in te r a c t io n s ,  h a v e  
b e e n  id e n t i f ie d  [ fo r  a  r e v ie w , s e e  W a r p e h o s k i  a n d  H u r le y  
( 1 9 8 8 ) ] .
A n  a d d i t io n a l  d e g r e e  o f  c o m p le x it y  in  th e  a n a ly s i s  o f  th e  
P [ 1 , 4 ] B - D N A  a d d u c t  s t r u c tu r e , in  c o m p a r is o n  t o  m o s t  
c o v a le n t ly  m o d if y in g  D N A - r e a c t i v e  c o m p o u n d s ,  is  th e  p o s ­
s ib i l i t y  o f  th e  fo r m a t io n  o f  fo u r  d i f f e r e n t  s p e c ie s  b a s e d  u p o n  
th e  s t e r e o c h e m is t r y  a t  th e  c o v a le n t  l in k a g e  s i t e  (1 \R  o r  1 1 5 )  
a n d  th e  o r ie n ta t io n  w ith in  th e  m in o r  g r o o v e  ( a r o m a t ic  r in g  
to  th e  3 ' o r  5 '  s id e  o f  th e  c o v a le n t ly  m o d if ie d  g u a n in e ;  B a r k le y  
e t  a l . ,  1 9 8 6 ) .  G e n e r a lly ,  fo o tp r in t in g  e x p e r im e n t s  a r e  b l in d  
to  t h e s e  s tr u c tu r a l  v a r ia t io n s  u n le s s  th e  d r u g  o v e r la p  in  th e  
m in o r  g r o o v e  is  b ia s e d  to  o n e  s id e  o f  th e  c o v a le n t  a d d u c t  s i t e  
( H u r le y  e t  a l . ,  1 9 8 4 )  o r  th e r e  is  a  d is to r t io n  o f  D N A  a s s o c ia te d  
w ith  a  p a r t ic u la r  s p e c ie s  o f  a d d u c t  th a t  is  d e t e c t a b le  b y  
c h e m ic a l  o r  e n z y m a t ic  c le a v a g e  p a t te r n s .
O n  th e  o th e r  h a n d , h ig h - f ie ld  N M R  s t u d ie s  o n  d e f in e d  
P [  1 ,4 ]  B - D N  A  a d d u c t s  p r o v id e  d e f in i t iv e  in fo r m a t io n  o n  b o th  
th e  m u lt ip l i c i t y  ( o n e  o r  m o r e  s p e c ie s )  a n d  ty p e s  o f  s p e c ie s  
( e .g . ,  1 1 5 ,3 ' )  b o u n d  to  D N A  [B o y d  e t  a l . ,  1 9 9 0 a ,b ;  W a n g  e t  
a l .,  1 9 9 2 ;  C h e a t h a m  e t  a l .,  1 9 8 8 ;  B a r k le y  e t  a l . ,  1 9 8 6 ;  r e v ie w e d
in  R e m e r s  e t  a l . ,  ( 1 9 9 2 ) ] ,  a n d  in  th e  c a s e  o f  t o m a y m y c in ,  
f lu o r e s c e n c e  is  a l s o  a  u s e fu l  to o l  (B a r k le y  e t  a l . ,  1 9 8 6 ;  
C h e a t h a m  e t a l . ,  1 9 8 8 ;  B o y d e t a l . ,  1 9 9 0 b ) .  F o r  t o m a y m y c in  
o n  c a l f  t h y m u s  D N A ,  f lu o r e s c e n c e  e x p e r im e n t s  h a v e  s h o w n  
th a t  th e r e  is  a  6 5 : 3 5  m ix t u r e  o f  1 1 5  a n d  1 1 /?  s p e c ie s  a n d  o n  
a  d e f in e d  s e q u e n c e  o l ig o m e r  e ith e r  a  5 0 : 5 0  m ix tu r e  ( 5 ' - T G C )  
o f  tw o  s p e c ie s  o r  1 0 0 %  o f  o n e  s p e c ie s  ( 5 ' - C G A  o r  5 ' - A G C ) .  
F o r  a n t h r a m y c in ,  w h i le  j u s t  a  single s p e c ie s  h a s  b e e n  d e t e c t e d  
b y  h ig h - f ie ld  N M R  o n  a l l  d e f in e d  a d d u c t s  s o  fa r  e x a m in e d ,  
th e  s t e r e o c h e m is t r y  a t  C - 11 is  v a r ia b le  a n d  is  d e p e n d e n t  u p o n  
th e  b o n d in g  s e q u e n c e  (J .  A .  M o u n t z o u r is  a n d  L . H . H u r le y ,  
u n p u b lis h e d  r e s u l t s ) .  W h i le  th is  c o m p le x it y ,  p a r t ic u la r ly  in  
r e g a r d  to  t o m a y m y c in ,  m a k e s  d ir e c t  c o r r e la t io n  w i t h  s t r u c ­
t u r a l ly  d e f in e d  l e s io n s  m o r e  e lu s iv e ,  i t  d o e s  n o t  p r e v e n t  
c o r r e la t io n s  b e in g  m a d e  b e t w e e n  s e q u e n c e  s e l e c t i v i t y  a n d  
b e n d in g /d i s t o r t io n  o f  D N A .  W h a t  is  p o t e n t ia l ly  p r o b le m a t ic  
is  u s in g  m o le c u la r  m o d e l in g  to  m a k e  p r e d ic t io n s  o f  s e q u e n c e  
p r e fe r e n c e  o n  s p e c i f ic  s e q u e n c e s  w ith  th e  P [  1 ,4 ]  B ’s  w h e r e  th e  
s t e r e o c h e m is t r y  a n d  o r ie n t a t io n  o f  t h e  a d d u c t s  a r e  a s  y e t  
u n d e f in e d .  In  t h e  c a s e  o f  m o le c u la r  m o d e l in g ,  w h e r e  c o n ­
fo r m a t io n a l  f l e x ib i l i ty  w a s  p r e d ic te d  to  b e  im p o r ta n t  (Z a k r z e ­
w s k a  &  P u llm a n , 1 9 8 6 ) ,  a  s in g le  1 1 5 ,3 '  s p e c ie s  w a s  a s s u m e d  
fo r  a l l  s p e c ie s  o f  a n t h r a m y c i n - D N A  a d d u c t ,  ir r e s p e c t iv e  o f  
b o n d in g  s e q u e n c e .  W h i le  th is  a s s u m p t io n  is  a p p a r e n t ly  tr u e  
fo r  5 ' - C G T , it  d o e s  n o t  a p p e a r  to  b e  tr u e  fo r  o th e r  b o n d in g  
s e q u e n c e s ,  s u c h  a s  5 ' - C G A  o r  5 ' - A G A  (J . A .  M o u n tz o u r is  
a n d  L . H . H u r le y ,  u n p u b l is h e d  r e s u l t s ) .
N e v e r t h e le s s ,  w h i le  b e a r in g  in  m in d  th e  p o t e n t ia l  p i t fa l ls  
o f  t h e o r e t i c a l ly  b a s e d  m o le c u la r  m o d e l in g  c a r r ie d  o u t  in  th e  
a b s e n c e  o f  d e f in i t iv e  e x p e r im e n t a l  d a t a  o n  th e  id e n t i t y  o f  th e
3 Since the control lanes for 5'-AG A and 5'-CG A indicated an intrinsic 
bent D N A  structure, the /?L values for all drug-modified sequences were 
calculated relative to the control lanes for 5'-TGC. If this correction is 
not carried out, the overall bending magnitude in the final drug-modified 
duplex is underestimated.
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F i g u r e  7: (A , left) Electrophoretic behavior o f the ligation products o f A G A , CG A , AG C , CG C, and TG C oligom ers (Table I) modified  
with anthram ycin and tom aym ycin on a 6% nondenaturing polyacrylam ide gel. Lanes labeled C represent ligated multimers o f control 
oligomers (lanes 1, 4, 7, 10, and 13). Lanes labeled A  and T represent oligom ers modified with anthramycin (lanes 2, 5, 8, 11, and 14) and 
tom aym ycin (lanes 3, 6 , 9, 12, and 15), respectively. M and D represent the positions o f monomers (21-bp oligom er) and ligated dimers (42 
bp), respectively, on the gel. C* and C refer to circular D N A  (see text). (B , right) Plot o f R L values as a function o f ligated oligom er length 
in base pairs for the ligation products o f A G A  ( • ) ,  C G A  (▲), AG C (□ ) ,  CGC (O ), and TG C ( a ) (Table I) modified with anthramycin and 
tom aym ycin. R L =  apparent vs actual length.
d r u g  s p e c ie s  b o u n d  to  d i f f e r e n t  s e q u e n c e s ,  t h e  c o n c lu s io n  th a t  
D N A  f l e x ib i l i t y  m a y  b e  a n  im p o r ta n t  d e t e r m in a n t  in  s e q u e n c e  
s e le c t iv it y  a p p e a r s  to  h o ld  u p  in  t h e  p r e s e n t  e x p e r im e n t a l  s tu d y .  
T h e  e x p e r im e n t a l  r e s u lt s  p r e s e n te d  h e r e  s u g g e s t  th a t  th e  
c o r r e la t io n  b e t w e e n  t h e  s e q u e n c e  s e l e c t i v i t y  o f  a n t h r a m y c in  
a n d  t o m a y m y c in  w ith  D N A  a n d  n u c le ic  a c id  f l e x i b i l i t y  m a y ,  
a t  le a s t  in  p a r t ,  b e  r e la te d  to  d r u g - in d u c e d  D N A  b e n d in g .  
T h e  r e s u lt s  a l s o  d e m o n s t r a t e  t h a t  t h e  h ie r a r c h y  o f  s e q u e n c e  
s e l e c t iv i t y  fo r  a n t h r a m y c in  is  c o r r e la t e d  to  t h e  k in e t i c s  o f  th e  
r e a c t io n .  T h e  in fo r m a t io n  w e  h a v e  g a in e d  fr o m  t h e s e  
e x p e r im e n ts  e x te n d s  o u r  k n o w le d g e  o n  th e  r e la t io n s h ip  b e tw e e n  
th e  e f f e c t s  o f  c o v a le n t  b o n d in g  o f  t h e  P [ l , 4 ] B ’s o n  D N A  
s tr u c tu r e s  o f  d i f f e r e n t  s e q u e n c e s ,  t h e  r e a c t io n  k in e t ic s ,  a n d  
th e  s e q u e n c e  s e l e c t iv i t y .
Comparison o f  the Effects on DNA Structure o f  Covalent 
Modification o f  DNA by Tomaymycin and Anthramycin. 
W h ile  th e  o v e r a ll  t r e n d s  in  t h e  e f f e c t s  o f  a n t h r a m y c in  a n d  
t o m a y m y c in  o n  D N A  s tr u c tu r e  a r e  s im ila r ,  i .e . ,  5 ' - P u G P u  
s e q u e n c e s  a r e  m o r e  b e n t  a n d  s h o w  g r e a t e r  in h ib i t io n  o f  
h y d r o x y l  r a d ic a l  c le a v a g e  th a n  5 ' - P y G P u  a n d  5 ' - P u G P y  
s e q u e n c e s ,  w h ic h  t h e m s e lv e s  a r e  s u b j e c t e d  t o  m o r e  p r o n o u n c e d  
e f f e c t s  th a n  5 ' - P y G P y  s e q u e n c e s ,  th e  m a g n i t u d e s  o f  th e  d r u g -  
in d u c e d  e f f e c t s  o n  D N A  s t r u c tu r e  a r e  q u i t e  d i f f e r e n t  fo r  th e  
tw o  d r u g s . T o m a y m y c in  p r o d u c e s  m u c h  m o r e  b e n d in g  o f
D N A  ( a b o u t  8 . 2 - 1 4 . 5 ° )  th a n  a n t h r a m y c in  ( 5 . 6 - 8 . 9 ° ) ,  th e  
in h ib i t io n  o f  h y d r o x y l  r a d ic a l  c le a v a g e  is  g r e a te r  fo r  t o m a ­
y m y c in ,  a n d  th e  D N a s e  I i n h ib i t io n /e n h a n c e m e n t  z o n e  is  
la r g e r  fo r  t o m a y m y c in  ( s e e  F ig u r e  6 ) .  T h is  m o r e  p r o n o u n c e d  
e f f e c t  o f  to m a y m y c in  o n  D N A  s tr u c tu r e  a l s o  c o r r e la t e s  w ith  
a  u n iq u e  e f f e c t  o f  t o m a y m y c i n - D N A  a d d u c t s  o n  th e  n o r m a lly  
g u a n in e - s p e c i f ic  m e t h y le n e  b lu e  r e a c t io n  ( H e r t z b e r g  e t  a l . ,  
1 9 8 6 )  a n d  p e r h a p s  th e  s lo w e r  k in e t ic s  o f  b o n d in g  o f  t o m a ­
y m y c in  to  D N A  ( H u r le y  e t  a l . ,  1 9 7 7 ) .
Correlation o f  Sequence Specificity o f  Anthramycin and 
Tomaymycin with Drug-Induced Conformational Changes 
and Kinetics o f  Reaction o f  Anthramycin with DNA. T h e  
m o s t  s ig n if i c a n t  F in d in g  fr o m  th is  s tu d y  is  t h a t  th e  h ie r a r c h y  
o f  b o n d in g  s it e s  fo r  s e q u e n c e  s p e c i f ic i t y  p a r a l le ls  th e  h ie r a r c h y  
fo r  d r u g - in d u c e d  b e n d in g  m a g n i t u d e s  a n d  th e  r a te s  o f  
r e a c t iv i t y  o f  a n t h r a m y c in  w ith  in d iv id u a l  s e q u e n c e s .  F o r  
a n t h r a m y c in ,  t h e o r e t ic a l  c a lc u la t io n s  p r e d ic te d  t h a t  th e  
p r e fe r r e d  b o n d in g  s i t e s  w o u ld  a ls o  b e  th e  m o s t  e a s i ly  d is to r te d  
( Z a k r z e w s k a  &  P u llm a n , 1 9 8 6 ) .  I f  d is to r t io n  is  m e a s u r e d  b y  
th e  b e n d in g  o f  D N A  a n d  in h ib it io n  o f  h y d r o x y l  r a d ic a l  
c le a v a g e ,  th e n  in c r e a s e d  b e n d in g  c o r r e la t e s  w ith  a  g r e a te r  
s e q u e n c e  p r e f e r e n c e .4 I f  w e  a s s u m e  th a t  th e  r ig h t -h a n d e d  
tw is t  o f  th e  P [  1 ,4 ]  B ’s d o e s  n o t  e x a c t ly  m a t c h  th e  tw is t  o f  th e  
m in o r  g r o o v e  a n d , a s  a  c o n s e q u e n c e ,  th e  D N A  h a s  to  d is to r t




R etention  tim e ( min)
F ig u r e  8: H PLC analysis o f anthram ycin-oligom er D N A  com plex 
formation. Chromatograms: (A ) 5 mM anthramycin; (B ) TG C  
oligomer solution (diluted 2-fold with annealing buffer); (C ) reaction 
mixture o f anthramycin and TG C oligomer. The reaction mixture 
was prepared by mixing equal volumes o f 10 /iM  anthramycin solution 
with TG C oligomer solution. H PL C  conditions: colum n, Supelco  
L C -18-D B  (4 .6  mm i.d. x  15 cm ); column temperature, ambient; 
mobile phase, H 20 /M e O H  (55:45); flow rate, 1 m L /m in; detection, 
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F ig u r e  9: Sem ilogarithm ic plot o f free anthramycin vs tim e in the 
reaction mixture of anthramycin A G A  ( • ) ,  CG A (▲), A G C  (□ ) ,  
CGC (O ), and TG C ( A )  oligom er D N A  (Table I). The reaction 
mixture was prepared by mixing equal volumes o f 10 mM anthramycin 
solution and oligomer solution with an absorbency o f 30 at 260 nm 
and was maintained at 23 °C .
s l ig h t ly  a r o u n d  th e  n o n c o v a le n t ly  b o u n d  d r u g  to  p r o d u c e  a  
s t a b i l iz e d  t r a n s it io n  s t a t e  fo r  th e  c o v a le n t  r e a c t io n ,  th e n  th o s e  
s e q u e n c e s  th a t  a r e  in h e r e n t ly  m o r e  f le x ib le  a n d  in h e r e n t ly  
b e n t  ( e .g . ,  5 ' - A G A  a n d  5 ' - C G A )  w ill  r e a c t  m o r e  r a p id ly  a n d  
w ill  p r o b a b ly  r e s u lt  in  a  m o r e  d is to r te d  D N A  s tr u c tu r e .  
C o n v e r s e ly ,  le s s  p l ia b le  s e q u e n c e s  ( e .g . ,  5 ' - T G C )  w i l l  r e a c t  
s lo w e r ,  b e  m o r e  r e s is t a n t  to  d is to r t io n ,  a n d  r e s u lt  in  a le s s  
d is to r te d  d r u g - D N A  a d d u c t  s t r u c tu r e .  W h e t h e r  t h e  r a te  o f  
c o v a le n t  r e a c t io n  a t  a  p a r t ic u la r  s e q u e n c e  is  a f f e c t e d  b y  
c r e a t in g  a fa v o r a b le  n o n c o v a le n t  b in d in g  s i t e  fo r  t h e  d r u g ,
Table III: 
Oligomers
Rate Constants for the Binding of Anthramycin to 21-bp
sequence k (min-1) sequence k (min-1)
AGA 1.12 X 1(H CGC 8.77 X 10-3
CGA 2.89 x  10-2 TGC 5.05 X 10-3
AGC 2.10 X 10-2
th e r e b y  in c r e a s in g  its  e f f e c t iv e  lo c a l  c o n c e n tr a t io n ,  o r  w h e th e r  
th e  d e f o r m a t io n  is  n e c e s s a r y  to  b r in g  th e  r e a c t iv e  a t o m s  o f  th e  
d r u g  a n d  th e  ta r g e t  n u c le o t id e  in to  b o n d in g  d is ta n c e  t o  s ta b i l iz e  
th e  t r a n s i t io n  s t a t e  is  n o t  c le a r  fr o m  t h e s e  s tu d ie s .  In  m a n y  
r e s p e c ts ,  th is  m e c h a n is m  fo r  s e q u e n c e  r e c o g n it io n  h a s  a n a lo g ie s  
to  t h e  p r o p o s e d  im p o r ta n c e  o f  c o n f o r m a t io n a l  f l e x ib i l i t y  in  
th e  r e a c t io n  o f  ( + ) - C C - 1 0 6 5  w ith  D N A ,  w h e r e  th e  s e q u e n c e s  
th a t  c a n  e a s i ly  a d o p t  a  b e n t  D N A  s tr u c tu r e  s im ila r  t o  A - t r a c t s  
a r e  th o s e  t h a t  a r e  fa v o r e d  fo r  r e a c t io n  w i t h  th is  d r u g  ( H u r le y  
e t  a l . ,  1 9 8 8 ;  S u n  e t  a l . ,  1 9 9 3 ) .
T h e  v a r ia b i l i t y  in  s p e c ie s  o f  t o m a y m y c in  o r  a n t h r a m y c in  
(1  \R  v s  1 I S ,  3 '  o r  5 ' o r ie n t a t io n )  c o v a le n t ly  b o u n d  t o  D N A ,  
w h ic h  is  d e p e n d e n t  u p o n  b o th  th e  d r u g  a n d  th e  b o n d in g  
s e q u e n c e ,  is  a  u n iq u e  f e a tu r e  o f  t h e s e  d r u g  m o le c u le s .  In  
s o lu t io n ,  a p a r t ic u la r  e n a n t io m e r ic  fo r m  o f  t h e  t o m a y m y c in  
is  a s s o c ia t e d  w ith  a  s p e c i f ic  c o n f o r m a t io n a l  fo r m  ( B a r k le y  e t  
a l . ,  1 9 8 6 ) .  H o w e v e r ,  o n  D N A  t h e  e n a n t io m e r ic  fo r m  is  n o t  
th e  s a m e  o n e  th a t  is  a s s o c ia t e d  w ith  th e  c o n f o r m a t io n a l  fo r m  
fo u n d  in  s o lu t io n  (B a r k le y  e t  a l . ,  1 9 8 6 ;  B o y d  e t  a l . ,  1 9 9 0 a ,b ) .  
I t  is l ik e ly  t h a t  th e  D N A  i t s e l f  is  a b le  to  p la y  a d e c is iv e  r o le  
in  d e t e r m in in g  t h e  o p t im u m  c o n f o r m a t io n a l  fo r m  fo r  a  
p a r t ic u la r  e n a n t io m e r  fo r m  o f  d r u g  b o u n d  to  D N A .  T h e  
im p l ic a t io n  is th a t  th e  d i f f e r e n c e  in  f in a l  b in d in g  e n e r g ie s  
b e tw e e n  th e  d i f f e r e n t  s p e c ie s  o f  a n t h r a m y c in  a n d  t o m a y m y c in  
b o u n d  t o  D N A  m a y  n o t  b e  v e r y  la r g e ,  a n d  th u s  d r u g  a n d  
D N A  d is to r t io n  e n e r g ie s  th a t  a r e  s e q u e n c e - d e p e n d e n t  m a y  
p la y  a n  im p o r t a n t  r o le  in  th e  s e l e c t io n  o f  th e  s p e c ie s  fo u n d  o n  
D N A .  W h a t  r e m a in s  to  b e  d e t e r m in e d  is  th e  r o le , i f  a n y , o f  
c a t a ly t ic  a c t iv a t io n  o n  D N  A  o f  a  p a r t ic u la r  s p e c ie s  a n d  w h e th e r  
th e  k in e t i c a l ly  fa v o r e d  fo r m s  a r e  th o s e  f in a l ly  o b s e r v e d  o n  
D N A .  In  t h e  la t t e r  c a s e ,  th e  f a c i l e  r e v e r s ib i l i t y  o f  th e  a m in a l  
l in k a g e  ( N - C H - N )  m a k e s  th is  a  p o t e n t ia l ly  im p o r ta n t  fa c to r .
In  s u m m a r y ,  w h a t  h a s  e m e r g e d  fr o m  th is  s t u d y  is  th e  
im p o r ta n c e  o f  th e  f l e x ib i l i t y  o f  b o th  th e  b o n d in g  s e q u e n c e  
a n d  th e  P [ 1 ,4 ] B  a n d  th e ir  r e la t iv e  s h a p e  c o m p le m e n t a r i t y  in  
d e t e r m i n i n g  s e q u e n c e  s e l e c t i v i t y .  T h e  s u g g e s t i o n  b y  
Z a k r z e w s k a  a n d  P u llm a n  ( 1 9 8 6 )  th a t  in h e r e n t  s e q u e n c e  
f l e x ib i l i t y  is  a  d e te r m in a n t  o f  s e q u e n c e  r e c o g n i t io n  in it ia l ly  
in s p ir e d  u s  t o  c o m p a r e  d r u g - in d u c e d  d is to r t io n  o f  D N A  a c r o s s  
s e q u e n c e s  o f  d i f f e r e n t  r e a c t iv i t i e s  a n d  b e t w e e n  d r u g s  w ith  
d if f e r e n t  r e a c t iv i t ie s .  It is  im p o r ta n t  to  r e c o g n iz e  th a t  b o th  
th e  c o n f o r m a t io n a l  f l e x ib i l i t y  o f  th e  b o n d in g  s e q u e n c e  and 
th e  d r u g  a r e  in v o lv e d  in  a n  “ in d u c e d  f i t ” t o  s t a b i l i z e  th e  
t r a n s i t io n  s t a t e  fo r  th e  c o v a le n t  r e a c t io n .  In  t h is  r e s p e c t ,  th e  
a n a lo g y  o f  a n  e n z y m e - s u b s t r a t e  in te r a c t io n  is  a p p r o p r ia te .  
F o r  a n t h r a m y c in ,  in  a n  o p t im u m  b o n d in g  s e q u e n c e  ( 5 ' - A G A ) ,  
w h ic h  h a s  in tr in s ic  b e n d in g  a n d  h ig h  in h e r e n t  f l e x ib i l i t y ,  a n  
1 \R  s t e r e o c h e m is t r y  a n d  3 ' o r ie n t a t io n  a r e  fa v o r e d ,  b u t  w ith
4 It is important to note that, in the theoretical paper by Zakrzewska 
and Pullman (1984), in the final minimized structures the anthramycin- 
DN A  adduct assumed a distortion globally corresponding to a B-*-A-like 
transition. Neither the high-field data (Boyd et al., 1990a; J. M. 
Mountzouris and L. H. Hurley, unpublished results) nor the bending 
mode reported here corresponds to this transition. In addition to the 
previously noted problem with assuming an 1 IS ,3' orientation for all of 
the adducts, this theoretical study fixed the conformation of the 
phosphodiester backbone and sugar residues. Both of these factors may 
have contributed to the discrepancy between theoretical and experimental 
results.
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a less favored sequence (5'-CGT), the flexibility is less and, 
consequently, the US',3' species is found. Likewise, with 
tomaymycin, in more preferred sequences, the 115,3' species 
is favored, while in less preferred sequences, a mixture of 
species is produced.
CONCLUSIONS
We present here an experimental study of the interaction 
,of DNA with the covalently bound ligands anthramycin and 
tomaymycin. The principal results are as follows: (1) 
irrespective of bonding sequence, tomaymycin bends DNA  
upon adduct formation. Although not as dramatic, the 
anthramycin-induced DNA bending magnitudes mirror the 
I sequence selectivity (PuGPu >  PuGPy = PyGPu >  PyGPy).
I (2) Time course analytical HPLC shows that, for anthramycin,
I the more preferred the bonding site, the more rapid the reaction 
j rate. Thus, there is a correlation between the DNA sequence 
[Selectivity of anthramycin with the reaction kinetics and 
j induced bending of DNA, and the conformational flexibility 
of the drug and DNA may appear to play an important role 
in sequence recognition.
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Pyrrolo[ 1,4]benzodiazepine Antitumor Antibiotics: Relationship 
of DNA Alkylation and Sequence Specificity to the Biological 
Activity of Natural and Synthetic Compounds
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The DNA alkylation and sequence specificity of a group of natural and synthetic pyrrolo-
[1,4]benzodiazepines [P(l,4)Bs] were evaluated by using an exonuclease III stop assay, and the 
results were compared with in vitro and in vivo biological potency and antitumor activity. The 
P(1,4)B antibiotics are potent antitumor agents produced by various Actinom ycetes, which are 
believed to mediate their cytotoxic effects by covalent bonding through N-2 of guanine in the 
minor groove of DNA. In this article we describe the results of a sensitive DNA alkylation assay 
using exonuclease III which permits both estimation of the extent of DNA modification as well 
as location of the precise guanines to which the drugs are covalently bound. Using this assay, 
we have evaluated a series of natural and synthetic compounds of the P(1,4)B class for their 
ability to bind to DNA and also determined their DNA sequence preference. The compounds 
included in this study are P (l,4)B s carrying different substituents in the aromatic ring, having 
varying degrees of saturation in the five-membered ring, or differing in the stereochemistry at 
C -lla . These same compounds were evaluated for in vitro cytotoxic activity against B16 me­
lanoma cells, for potency in vivo in B6D2FX mice (LD^), and for antitumor activity (ILSmax) 
against P388 leukemia cells. A good correlation was found between extent of DNA alkylation 
and in vitro and in vivo potency. Furthermore, on the basis of electronic and steric considerations, 
it was possible to rationalize why those compounds that showed negligible biological activity 
were unable to bond covalently to DNA. Last, we have determined that the degree of saturation 
in the five-membered ring of the P(l,4)Bs has a significant effect on the DNA bonding reactivity 
and biological activity of this class of compounds.
Introduction
Anthramycin and tomaymycin (Table I) are two of the 
best known examples of the pyrrolo[l,4]benzodiazepine 
[P(1,4)B]1 group of antibiotics, which are potent antitumor 
compounds produced by various Actinomycetes (1-6). The 
biological potency of the P(l,4)Bs is generally attributed 
to their ability to bond covalently to DNA (7-9). While 
anthramycin, sibiromycin, and neothramycins A and B 
have been used experimentally in the treatment of human 
cancer (2 ,10-13), their real potential as clinical candidates 
is reported to be compromised by either cardiotoxicity (10, 
14,15), tissue necrosis at the site of injection (15), or, in 
the case of the neothramycins, lack of efficacy (13).
* Address correspondence to this author.
f Present address: School of Pharmacy and Biomedical Science, 
Portsm outh Polytechnic, King Henry 1st St., Portsm outh, H ants 
P O l 2DZ, England.
Mechanism of action studies have led to considerable in­
sight into the three-dimensional structures of the P(l,4)- 
B-DNA adducts (8,16-20), and some of the biochemical 
(21) and biological consequences (22, 23) of DNA modi­
fication have been described. The ultimate DNA-reactive 
species is proposed to be the N-10-C-11 imine form of the 
P(1,4)B which undergoes nucleophilic attack from N-2 of 
guanine to form an aminal linkage (24) (see Figure 1). 
Since the two enantiomeric C -ll carbinolamines react with 
DNA via the N-10-C-11 imine and are in equilibrium in
1 Abbreviations: bp, base pair; BAP, bacterial alkaline phosphatase; 
CPK, Corey, Pauling, Koltun; DTT, dithiothreitol; EDTA, ethylenedi- 
aminetetraacetic acid; exo III, exonuclease III; ip, intraperitoneal; MPE, 
methidiumpropyl-EDTA; P(1,4)B, pyrrolo[l,4]benzodiazepine; PNK, 
polynucleotide kinase; Pu, purine; Py, pyrimidine; SAR, structure-ac- 
tivity relationship; TAE, 40 mM Tris-acetate, pH 8.0, and 50 mM EDTA; 
TBE, 50 mM Tris-borate and 10 mM EDTA, pH 8.3; TEMED, N f l , -  
iVyV'-tetramethylethylenediamine; Tris, tris(hydroxymethyl)amino- 
methane.
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T a b le  I. In  V itro  an d  in  Vivo B io log ica l A c tiv ity  o f N a tu ra l  a n d  S y n th e t ic  P (l,4 )B s
com pounds IC,*,, LD^, m g/k g6 P388e ILSm..
h o  o h  anthram ycin 0.4 1.1 118 ±  49
tom aym ycin 0.02 2.2 87 ±  6
,ch3 I, Rg — CH3; R7 — R8 — Rg — H
II, R7 =  CH 3; R6 = R8 = Rg = H
III, Rg =  CH 3; R6 = R7 =  Rg =  H
IV, Rg = Cl; Rg = R7 = Rg = H
0CH3
V
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0 Concentration that inhibits proliferation of B16 m elanom a cells by 50% on continuous exposure. b Single ip dose which kills 50% of 
fem ale B6D 2F, mice. c Increase in lifespan produced in mice bearing ip P388 leukem ia at the m axim ally tolerated dose given ip on days 1 
and 5. d N ot determ ined.
t o  e x a m in e  t h e  e f f e c t  o f  s t r u c t u r a l  m o d i f i c a t io n  o f  v a r io u s  
p o r t io n s  o f  t h e  P ( 1 ,4 ) B  n u c le u s  a n d  i t s  s u b s t i t u e n t s .  T h e s e  
s a m e  c o m p o u n d s  w e r e  a l s o  s u b j e c t e d  t o  a  D N A  a lk y l a t i o n  
a s s a y  t h a t  m e a s u r e s  b o n d in g  r e a c t iv i t y  a s  w e l l  a s  s e q u e n c e  
s e l e c t i v i t y .  I n  a d d i t i o n  t o  d e m o n s t r a t i n g  a  r e l a t i o n s h i p  
b e t w e e n  D N A  b o n d in g  a n d  b io lo g ic a l  a c t iv i t y ,  in f o r m a t io n  
c o n c e r n i n g  t h e  r e l a t i o n s h i p  b e t w e e n  D N A  s e q u e n c e  s p e ­





h i t V n ,
F ig u r e  1. P roposed  m ech an ism  for a lky la tion  o f  D N A  by th e  
P ( l , 4 )B s to  form  th e  P (l,4 )B -C /V -2-gu an in e)-D N A  add uct.
s o l u t i o n ,  t h e y  a r e  b i o l o g i c a l l y  e q u i v a l e n t .  T h e  r e s u l t a n t  
P ( 1 , 4 ) B - D N A  a d d u c t  is  s n u g l y  c r a d le d  in  t h e  m i n o r  g r o o v e  
o f  D N A  a n d  c o v e r s  a  2 - 3  b p  r e g i o n  ( 8 )  f o r  w h i c h  a  s e ­
q u e n c e  s p e c i f i c i t y  h a s  b e e n  d e m o n s t r a t e d  (25). C P K  
m o d e l s  o f  t h e  ( N - 2 - g u a n i n e ) - D N A  a d d u c t s  h a v e  b e e n  u s e d  
t o  r a t io n a l i z e  t h e  p u b l i s h e d  S A R  fo r  a  v a r i e t y  o f  n a t u r a l  
a n d  s y n t h e t i c  P ( 1 , 4 ) B  a n a lo g u e s  (26). V e r s a t i l e  s y n t h e t i c  
r o u t e s  l e a d i n g  t o  t h e  c a r b i n o l a m i n e - c o n t a i n i n g  P ( 1 , 4 ) B  
n u c l e u s  h a v e  b e e n  r e c e n t l y  p u b l i s h e d  f r o m  t h e s e  l a b o r a ­
t o r i e s  a n d  o t h e r s  (27-35), w h i c h  n o w  a l lo w s  r e a d y  a c c e s s  
t o  a  v a r i e t y  o f  P ( 1 , 4 ) B  a n a l o g u e s .  I n  t h i s  a r t i c l e  w e  d e ­
s c r ib e  t h e  r e s u l t s  o f  in  v i t r o  a n d  in  v i v o  e v a l u a t i o n  o f  t h e  
b i o lo g i c a l  a c t i v i t y  o f  t w o  n a t u r a l l y  o c c u r r i n g  c o m p o u n d s  
a n d  a  n u m b e r  o f  s y n t h e t i c  a n a l o g u e s  ( T a b l e  I )  d e s i g n e d
Materials and Methods
E lec tro p h o r e tic  m a ter ia ls  [a cry lam id e, b is(a cry la m id e ),  
T E M E D , urea, and am m onium  persulfate] were ob ta in ed  from  
B io-R ad. R estriction  endon ucleases and exo III were from  N ew  
England B iolabs. T 4  polynucleotide kinase (T 4-P N K ) was from  
B R L . B A P  w as o b ta in ed  both  from  Sigm a and B R L , and [7 - 
32P ]A T P  was from  IC N . X -ray  film , in ten sify in g  screens, and  
develop in g  chem icals were from  K odak. M l3 m p l R F  D N A  was 
iso la ted  from  Escherichia coli J M 101 by th e  C sC l2 ultracen tr i­
fugation  m eth od  describ ed  by M essing (36). A nthram ycin  and  
tom aym ycin were obtained from Hoffmann LaRoche and Fujisawa 
Cos., respectively . C om pounds I—III (T able I) were syn thesized  
by the reductive cyclization procedure previously described (34). 
C om pound V was prepared as previously  described  from  to ­
m aym ycin  (24).
(1 li? S ',lla i? S )-8 -C h lo ro -ll-h y d ro x y -l,2 ,3 ,1 0 ,l l . l la -h e x a -  
h y d r o -5 H -p y rro lo [2 ,l-c  ][I ,4 ]b en zo d ia zep in -5 -o n e  (IV ). 4- 
C hloro-2-n itrobenzoic  acid (12 g, 60  m m ol) and SO C l2 (6.0 m L,
"conh2
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82 mmol) in dry benzene (100 mL) was heated under reflux for 
3 h, followed by evaporation of the solvent to afford 4-chloro-2- 
nitrobenzoyl chloride as a light brown oil. After stripping from 
benzene three times to remove excess SOCl2, the oil was dissolved 
in dry TH F (65 mL) and added dropwise to a stirred solution of 
proline (8.22 g, 71 mmol) and triethylamine (13 mL) in water (65 
mL) maintained at 0 °C in an ice bath. After warming to room 
temperature and stirring for a further 1.25 h, the THF was 
evaporated in vacuo, followed by the addition of water (200 mL). 
The solution was acidified with 5% HC1, decanted from the 
resulting gum, and then replaced with fresh water. The gum 
crystallized upon scratching, and the decanted solution afforded 
a precipitate upon standing at 0 °C. The combined solid was 
washed with water and then ether to afford (2i2)-N-(4-chloro-2- 
nitrobenzoyl)proline (14.90 g, 84%): 90-MHz XH NM R
(DMSO-d6) 8 1.60-2.55 (4 H, m), 3.09-3.75 (2 H, m), 4.30-4.55 
(1 H, m), 7.50 (1 H, d, J  = 9.2 Hz), 7.93 (1 H, d, J  = 9.2 Hz and 
fine coupling of 1.6 Hz), 8.38 (1 H, d, J  = 1.6 Hz).
A suspension o f the (2i?)-iV-(4-chloro-2-nitrobenzoyl)proline 
prepared above (5.0 g, 1.7 mmol), oxalyl chloride (9.6 mL, 110 
mmol), and DM F (4 drops) in dry benzene (50 mL) was stirred 
at room temperature for 30 min, followed by evaporation of the 
benzene in vacuo. The residue was dissolved in dry acetone (50 
mL), triphenylphosphine added (8.65 g, 33 mmol), and the solution 
cooled in an ice bath. (Ph3P)2CuBH4 (10.3 g, 23 mmol) was then 
added in portions and the mixture stirred at low temperature for 
a further 15 min, followed by removal of the copper salt by 
filtration. The filtrate was reduced to a low volume and additional 
copper salt filtered off. The filtrate was then evaporated in vacuo 
to afford a pale yellow oil, which was dissolved in a small volume 
of ethyl acetate and purified by flash chromatography on silica 
gel, eluting with ethyl acetate/toluene (1:1), to afford (2RS)- 
N-(4-chloro-2-nitrobenzoyl)pyrrolidine-2-carboxaldehyde (1.9 g, 
40%) as a pale yellow oil: 90-MHz XH NM R (CDC13) 8 1.50-2.42 
(4 H, m), 3.25 (2 H, t, J  = 6.4 Hz), 4.70 (1 H, t, J  = 6.9 Hz), 7.50 
(1 H, d, J  = 8.6 Hz), 7.71 (1 H, d, J  = 8.6 Hz with fine coupling 
of 1.7 Hz), 8.22 (1 H, d, J  = 1.7 Hz), 9.75 (1 H, s).
The nitro aldehyde prepared above (1.9 g, 6.7 mmol) was 
dissolved in 2,2-dimethoxypropane (10 mL) and methanol (10 mL). 
M ethanesulfonic acid (0.46 mL) was added with stirring under 
nitrogen and stirring continued for a further 2 h when the TLC 
(EtOAc/ toluene, 1:1) indicated a complete loss of starting material 
The solvent was removed by evaporation in vacuo and the residue 
stripped once from toluene, followed by purification by flash 
chromatography on silica gel (EtOAc/toluene, 1:1). The sample 
was then triturated with petroleum ether and the precipitate 
collected to yield (2RS)-N-(4-chloro-2-nitrobenzoyl)pyrrolidine- 
2-carboxaldehyde dimethyl acetal (1.5 g, 68%): 90-MHz XH NMR 
(CDC13) 8 1.59-2.50 (4 H, m), 3.00-3.33 (2 H, m), 3.57 (6 H, s), 
4.30-4.65 (1 H, m), 4.94 (1 H, d, J  = 1.2 Hz), 7.40 (1 H, d, J  =
7.6 Hz), 7.73 (1 H, d, J  = 7.6 Hz with fine coupling 1.2 Hz), 8.21 
(1 H, d, J  = 1.2 Hz).
A mixture of the nitro acetal prepared as described above (1.5 
g, 4.6 mmol) and 10% P d /C  (80 mg) was suspended in dry 
methanol (100 mL) and hydrogenated with shaking at atmospheric 
pressure for 7 -8  h, after which time TLC (silica gel, EtOAc/ 
toluene, 1:1) indicated a complete loss of starting material. After 
removal of the catalyst by filtration, the solvent was evaporated 
to a low volume. The residue was taken up in EtOAc/toluene 
(1:1) and purified by flash chromatography using the same solvent 
system. The fluorescent product of highest Rt value was 
(2RS)-iV-(2-amino-4-chlorobenzoyl)pyrrolidine-2-carboxaldehyde 
dimethyl acetal (0.4 g, 30%): 90-MHz XH NM R (CDC13) 8 
1.46-2.30 (4 H, m), 3.30-3.70 (2 H, m), 3.50 (6 H, s), 4.59-4.77 
(1 H, m), 6.65 (d, J  = 8.0 Hz), 7.02-7.32 (2 H, m). Some de­
chlorinated products of lower Rf values were also obtained.
The amino acetal prepared above (0.22 g, 0.74 mmol) was 
dissolved in 50% CH3C N /H 20  (5 mL) and trifluoroacetic acid 
(0.05 mL) added with stirring at room temperature. Reaction 
was complete after 3 h as judged by HPLC (reversed phase; 
CH3C N /H 20 , 7:3). Further stirring overnight gave a precipitate 
o f (llR S ,lla i2 S )-8 -ch lo ro -ll-h y d ro x y -l,2 ,3 ,1 0 ,ll,l la -h ex a -  
hydro-5/f-pyrrolo[2,l-c][l,4]benzodiazepin-5-one (IV) and the 
corresponding im ine (60 mg, 32%): 90-MHz XH NM R
(CDCl3/D M SO -d6) 8 1.69-2.32 (m), 3.30-3.91 (m), 4.80 (d, J  = 
8.8 Hz), 5.04 (s), 6.56-7.41 (m), 7.70 (d, J  = 2.3 Hz), 7.80 (d, J
= 3.7 Hz), 8.20 (d, J  =  1.6 Hz).
(1 IsJ tS  )-l,2,3,10,l 1,1 la-Hexahydro-7,8,1 l-trim ethoxy-5fZ- 
pyrrolo[2 ,l-c][l,4]benzodiazep in-5-one (V I). Trifluoroacetic 
anhydride (6.2 mL, 44 mmol) was added to a stirred suspension 
of 2-amino-4,5-dimethoxybenzoic acid (3.94 g, 20 mmol) in ethyl 
acetate (50 mL). After 1 h at room temperature, the resulting 
solution was evaporated to dryness and stripped twice from 
toluene to give 6,7-dimethoxy-2-(trifluoromethyl)-4H-l,3-benz- 
oxazin-4-one (5.29 g, 96%): XH NMR (90 MHz, CDC13) 5 4.04 (3
H, s), 4.05 (3 H, s), 7.17 (1 H, s), 7.57 (1 H, s). Without further 
purification, the benzoxazinone (2.75 g, 10 mmol) was added in 
portions over 15 min to a stirred solution of (S)-2-pyrrolidine- 
methanol (1.01 g, 10 mmol) in acetonitrile (20 mL). After being 
stirred for 1 h, the reaction mixture was evaporated to a residue 
of iV -[4,5-dim ethoxy-2-(trifluoroacetam ido)benzoyl]-(S)-2- 
pyrrolidinemethanol (3.76 g), which was used in the next step  
without purification.
To a solution of crude product from the previous reaction (3.76 
g, 10 mmol) in CH2C12 (150 mL) and DMSO (15 mL) were added 
sodium acetate (2.05 g, 25 mmol) and pyridinium chlorochromate 
(10.75 g, 50 mmol). After being stirred overnight, the reaction 
mixture was chromatographed on silica (110 g) eluted with CH2C12. 
Crystallization from CH3O H /EtO Ac gave 7,8-dimethoxy-
I,2,3,10,ll,lla-hexahydro-ll-hydroxy-10-(trifluoroacetyl)-5H - 
pyrrolo[2,l-c][l,4]benzodiazepin-5-one (2.33 g, 60% overall), mp 
196-198 °C. Anal. (C16H 17F3N20 5) C, H, N. XH NMR (90 MHz, 
CDC13) 8 1.8-2.2 (4 H, m), 3.18 (3 H, s), 3.2-3.6 (3 H, m), 3.81 (3 
H, s), 3.85 (3 H, s), 6.75-6.95 (2 H, m).
A suspension of the above iV-(trifluoroacetyl)benzodiazepinone 
(0.75 g, 1 mmol) and Bio-Rad AG3-X4A resin (200-400 mesh, free 
base form, 2.5 g) in CH3OH was stirred at room temperature for 
4 days. The resin was removed by filtration and the filtrate 
evaporated to a residue (1.92 g) which was recrystallized from 
EtOAc/cyclohexane to give (ll/2 ,llaR S )-l,2 ,3 ,10 ,ll,lla -h exa -  
hydro-7,8,ll-trimethoxy-5H-pyrrolo[2,l-c][l,4]benzodiazepin-5- 
one (VI) (125 mg, 21%), mp 127-129 °C (dec). AnaL (C ^H a^O ^  
C, H, N. XH NM R (90 MHz, CDC13) 8 1.7-2.4 (4 H, m) 3.32 (3 
H, s), 3.4-4.2 (3 H, m), 4.51 (1 H, d, J  = 6.3 Hz), 5.74 (1 H, d, 
J  =  6.3 Hz), 6.21 (1 H, s), 7.53 (1 H, s).
7,8-D im ethoxy-5H -pyrrolo[2,l-c ][ l,4]benzodiazepin-5-one
(V II). The synthesis was carried out in a manner similar to that 
reported (37) for 8-methyl-5H-pyrrolo[2,l-c][l,4]benzodiazepin- 
5-one. A solution of 2-amino-4,5-dimethoxybenzoic acid (4.93 g, 
25 mmol) in 150 mL of dry toluene containing 25 mL of thionyl 
chloride was heated at 100 °C for 2 h. The toluene was evaporated 
at reduced pressure, and the solid residue was dried over sodium 
hydroxide in a vacuum desiccator.
A solution of the crude sulfonamide anhydride in 200 mL of 
anhydrous ether was treated with pyrrole-2-carboxaldehyde so­
dium salt (2.92 g, 25 mmol; prepared from pyrrole-2-carbox- 
aldehyde and sodium hydride). The resulting light yellow solid 
(8.15 g) was removed by filtration, dried in vacuo over P20 5, and 
stored at -20  °C. A portion of this material (1 g) was distributed 
between 25 mL each of ethyl acetate and 5% aqueous Na2C 0 3. 
After adding more ethyl acetate to dissolve the solid that had 
precipitated, the phases were separated and the aqueous phase 
was extracted with 25 mL of ethyl acetate. The combined organic 
phases were washed twice with water, decolorized with charcoal, 
dried, and evaporated at reduced pressure to give 0.25 g (31%) 
of 7,8-dimethoxy-5//-pyrrolo[2,l-c][l,4]benzodiazepin-5-one (VII), 
which proved to be a powerful olfactory and skin irritant. IR, 
XH NMR, and X3C NMR spectra were consistent with the assigned 
structure.
(llaJ2S)-7 ,8-D im eth oxy-ll-(m ethylth io)-3 ,10 ,ll,lla -tetra-  
hydro-5tf-pyrrolo[2 ,l-c][l,4]benzodiazepin-5-one (V III). A
solution of 2-amino-4,5-dimethoxybenzoic acid (1.97 g, 11 mmol) 
in 5 mL of dry DMF was treated with a solution of 1.78 g (11 
mmol) of N,7V-carbonyldiimidazole in 10 mL of dry DMF 
dropwise over 1 h with stirring at 50 °C. The reaction was stirred 
at 50 °C for 1 h and at room temperature for 3 days. The solids 
from the reaction mixture were collected by filtration, washed 
with a small volume of cold DMF followed by EtjO, and dried 
in vacuo to give 1.50 g (67%) of 6,7-dimethoxy-2H-3,l-benz- 
oxazine-2,4(lH)-dione as white crystals, mp 270-271 °C [lit. (38) 
274-275 °C]: IR (Nujol) 1715, 1760 cm"1; XH NMR (90 MHz, 
DMSO-d6/CDCl3) 5 6.63 (1 H, s), 7.22 (1 H, s), 3.83 (3 H, s), 3.90
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(3 H, s), 6.63 (1 H, s), 7.22 (1 H, s).
A mixture of 1.20 g (5.4 mmol) of the above benzoxazinedione 
and 0.61 g (5.4 mmol) of (S)-3,4-dehydroproline in 13 mL of dry 
DMSO was heated at 100 °C for 31/ 2 h. The reaction was cooled, 
poured into 130 mL o f ice-H 20 ,  allowed to stand at 0 °C for 1 
h, filtered, washed with TH F followed by EtjO, and dried to give 
0.85 g (57%) of 7,8-dim ethoxy-3,10,ll,lla-tetrahydro-5H - 
pyrrolo[2,l-c][l,4]benzodiazepine-5,ll-dione. Recrystallization 
from 40 mL of hot acetonitrile afforded 728 mg of flocculent white 
needles, mp 245-250 °C: IR (Nujol) 1635,1685 cm"1; XH NMR  
(90 MHz, DMSO-d6/C D C l3) 8 3.83 (6 H, s), 4.22-4.47 (2 H, m),
4.70-4.93 (1 H, m), 5.80-6.27 (2 H, m) 6.71 (1 H, s), 7.32 (1 H, 
s).
A m ixture o f 728 mg (2.6 mmol) of 7,8-dimethoxy-
3.10.11.1 la-tetrahydro-5H-pyrrolo[2,l-c] [1,4] benzodiazepine- 
5,11-dione, 446 mg (5.3 mmol) of powdered NaHC03, and 706 mg 
(3.2 mmol) of P 2S5 in 14 mL of acetonitrile was refluxed for 15 
min; TLC indicated complete disappearance of starting material. 
The reaction was allowed to cool to room temperature over 30 
min, poured into 250 mL of H20 , extracted with CH2C12, washed 
once with H20 , and evaporated in vacuo. The residue was slurried 
in EtjO, filtered, and dried to give 0.62 g (81%) of crude product. 
This was crystallized from 60 mL of hot EtOH to give 418 mg 
of 7,8-dim ethoxy-3,10,ll,lla-tetrahydro-5-oxo-5H-pyrrolo[2,l- 
c][l,4]benzodiazepine-ll-thione as flocculent pale yellow needles, 
mp 250-253 °C: IR (Nujol) 1635 cm '1; XH NM R (90 MHz, 
DMSO-d6/CDCl3) 8 3.85 (6 H, s), 4.1-4.4 (2 H, m) 4.92-5.2 (1 H, 
m), 5.83-6.23 (2 H, m), 6.93 (1 H, s), 7.33 (1 H, s).
A mixture of 2.0 g (6.9 mmol) of 7,8-dim ethoxy-3,10,ll,lla- 
tetrahydro-5-oxo-5H-pyrrolo[2,l-c][l,4]benzodiazepine-ll-thione, 
1.37 mL of methyl iodide, and 1.2 g of anhydrous K2C 0 3 in 54 
mL of DMF and 54 mL of THF was stirred at room temperature 
for 4 h. The THF was removed in vacuo, and the residual syrup 
was poured into 60 mL of saturated NaCl solution. The pre­
cipitate was taken up in ethyl acetate and separated from the 
aqueous phase which was also extracted with ethyl acetate. The 
combined organic extracts were treated with charcoal, concen­
trated in vacuo, and evaporated once from carbon tetrachloride. 
The residual syrup was crystallized from 75 mL of E t0 H /H 20  
j by seeding and refrigeration to give 1.6 g (76%) of 7,8-dimeth- 
I oxy-3,1 la-dihydro-1 l-(methylthio)-5//-pyrrolo[2,l-c] [l,4]benzo- 
diazepin-5-one as a yellow powder, mp 85 °C: IR (CHC13 film)
I 1630 cm '1; XH NM R (90 MHz, CDC13) 8 2.45 (3 H, s), 3.97 (6 H, 
s), 4.3-4.52 (2 H, m), 4.67-4.83 (1 H, m), 5.88-6.31 (2 H, m), 6.75 
(1 H, s), 7.47 (1 H, s).
A mixture of 144 mg (0.45 mmol) of 7,8-dimethoxy-3,lla-di- 
hydro-11- (methylthio)-5H-pyrrolo[2,1-c] [ 1,4] benzodiazepin-5-one, 
30 mL of THF, 3 mL of saturated aqueous KH2P 0 4, and alu­
minum amalgam prepared from 184 mg of aluminum foil ac­
cording to the procedure of Keck et al. (39) was stirred efficiently 
at 0 °C for 18 h; HPLC indicated 65% conversion. The reaction 
was diluted with an additional 10 mL of THF, 1 mL of saturated 
aqueous KH2P 0 4, and A l/H g prepared from 61 mg of foil. After 
a total of 35 h conversion ceased at about 75%. The reaction 
mixture was diluted with 25 mL each of water and acetone and 
filtered while still cold. The inorganic salts were washed with 
wet acetone, and the combined filtrates were concentrated in vacuo 
at < 0  °C. The aqueous slurry was lyophilized, triturated with 
acetonitrile, and filtered, and the filtrate was evaporated to dryness 
in vacuo at <0 °C. The residue was washed with Et^O to leave 
70 mg (49%) o f (lla /?S)-7 ,8-d im ethoxy-ll-(m ethylth io)-
3.10.11.1 la-tetrahydro-5H-pyrrolo[2,1-c] [l,4]benzodiazepin-5-one
(VIII) as a pale yellow powder. This material was further purified 
by rapid dissolution in hot EtOAc followed by concentration under 
a nitrogen stream to about half the original volume; after re­
frigeration for 18 h a microcrystalline white powder separated, 
mp 127 °C (dec with evolution of methanethiol):2 IR (CHC13 film) 
1630 cm '1; XH NMR (90 MHz, CDC13) 8 2.04 (1.5 H, s), 2.12 (1.5 
H, s), 3.88 (3 H, s), 3.91 (3 H, s), 4.29-5.14 (4 H, m), 5.98-8.17
2 The facile thermal loss of methanethiol from VIII precluded char­
acterization by elemental analysis and mass determination. An X-ray 
structure determination of a single crystal grown by slow evaporation 
from methanol confirmed the expected benzodiazepine structure but, in 
addition, showed that the ll-(methylthio) substituent had been replaced 
by a methoxy group during the crystallization step.
(2 H, m), 6.32 (1 H, s), 7.29 (1 H, s).
( l la /S )-  and (H a lf)-8 -(B en zy loxy )-7 -m eth oxy -l,2 ,3 ,lla -  
tetrahydro-5H -pyrrolo[2,l-c][l,4]benzodiazepin-5-ones (IX  
and X ). The natural l l a £  isomer (IX) was synthesized by using 
the convergent diethyl dithioacetal technique of Langley and 
Thurston (35) and will be reported elsewhere. The unnatural lla/Z 
isomer (X) was synthesized by using the related linear diethyl 
dithioacetal route (35), but starting with D-proline. Analytical 
data for the l l a /2 isomer and related intermediates are given 
below.
(2i?)-7V-[4-(Benzyloxy)-5-methoxy-2-nitrobenzoyl]proline
(89.4% yield, TLC/ethyl acetate): IR (Nujol) 3680-3100 (COOH), 
2920, 2880, 2825,1725 and 1625 (C = 0 ) , 1575 (C =C ), 1510 and 
1370 (N 0 2), 1450,1280,1275,1060, 720 cm'1; XH NM R (CDC13) 
1.75-2.54 (4 H, m), 3.00-3.38 (2 H, m), 3.88 and 3.98 (3 H, s, minor 
and major rotamers of OCH3, 1:5.7), 4.68-4.99 (1 H, m), 5.14 and 
5.20 (2 H, s, minor and major rotamers of OCH2Ph, 1:4.8), 5.89 
(1 H, s), 6.86 (1 H, s), 7.40 (5 H, s), 7.77 (1 H, s); MS m /e  (rel 
intensity) 400 (M+, 1), 352 (11), 322 (10), 286 (9), 226 (12), 217
(3), 202 (6), 160 (4), 136 (8), 121 (6), 105 (7), 91 (100); mp 166-167 
°C (yellow needles from ethyl acetate/hexane); [a ]26!) +25.1° (c 
0.1552, CHC13). Anal. Calcd for CaoHaoNjjO,: 400.1270. Found: 
400.1279.
M e th y l (21? )-IV -[4 -(b e n z y lo x y  )-5 -m eth o x y -2 -n itro -  
ben zoy l]p yrro lid in e-2-car boxy la te  (88% yield, TLC /ethyl 
acetate): IR (Nujol) 2915, 2850, 1760 and 1645 (C = 0 ) , 1590 
(C =C ), 1513 and 1380 (NOa), 1452,1426,1338,1288,1227,1199, 
1175, 1071, 1020, 869, 840, 765, 737 cm '1; XH NM R (CDC13) 8
1.70-2.59 (4 H, m), 3.01-3.43 (2 H, m), 3.52 and 3.80 (3 H, s, minor 
and major rotamers of C 02CH3, 1:2.7), 3.91 and 3.98 (3 H, s, minor 
and major rotamers o f OCH3, 1:2.3), 4.64-4.87 (1 H, m), 5.19 (2
H, s), 6.81 and 6.88 (1 H, s, minor and major rotamers of H6, 1:2.3), 
7.23-7.58 (5 H, m), 7.77 (1 H, s); MS m /e  (rel intensity) 414 (M+, 
11), 355 (32), 286 (100), 198 (5), 196 (5), 190 (9), 128 (13), 121 (42), 
91 (93), 65 (25), mp 134-135 °C (yellow needles from ethyl ace­
tate/hexane); [a]26© +20.3° (c 0.3440, CHC13). Anal. Calcd for 
C2iH 22N 20 7: 414.1427. Found: 414.1418.
(21? ) - N -[4 -(B e n z y lo x y )-5 -m e th o x y -2 -n itr o b e n z o y l] -  
pyrrolid ine-2-carboxaldehyde (92.2% yield, T L C /ethyl ace­
tate): IR (Nujol) 2910, 2848,1734 and 1640 ( 0 = 0 ) ,  1578 (C=C), 
1518 and 1379 (N 02), 1453,1430,1331,1280,1219,1064,762 cm'1; 
lH  NM R (CDC13) 8 1.60-2.44 (4 H, m), 3.04-3.43 (2 H, m), 3.96 
and 4.00 (3 H, s, minor and major rotamers of OCH3, 1:3.5), 
4.58-4.91 (1 H, m), 5.21 (2 H, s), 6.89 (1 H, s), 7.25-7.60 (5 H, m), 
7.80 (1 H, s), 9.39 and 9.84 (1 H, dd, J  = 2 Hz, minor and major 
rotamers of CHO, 1:3.1); mp 160.5-162 °C (yellow plates from 
ethyl acetate/hexane/diethyl ether); [a p p  +16.8° (c 0.2672, 
CHClg).
(21? ) - N -[4 -(B e n z y lo x y  )-5 -m e th o x y -2 -n itr o b e n z o y l]-  
pyrrolid ine-2-carboxaldehyde d ieth y l d ith ioaceta l (85.7% 
yield, T L C /ethyl acetate): IR (neat) 2960, 2920, 2864, 1632 
(C = 0 ), 1573 (C=C), 1510 and 1330 (NOa), 1445,1418,1370,1270, 
1218,1179,1058, 988, 863, 792, 750, 691 cm '1; XH NM R (CDC13)
I.30 (6 H, t, J  =  8 Hz), 1.54-2.41 (4 H, m), 2.51-3.00 (4 H, m), 
3.06-3.41 (2 H, m), 3.94 (3 H, s), 4.50-4.84 (1 H, m), 4.88 (1 H, 
d, J  = 4 Hz), 5.19 (3 H, s), 6.84 (1 H, s), 7.18-7.55 (5 H, m), 7.75 
(1 H, s); MS m /e  (rel intensity) 490 (M+, 2), 355 (19), 286 (80), 
256 (2), 135 (27), 121 (8), 107 (4), 91 (100); pale yellow oil; [ a p D 
+98.6° (c 0.0792, CHC13). Anal. Calcd for C^HgoNaOgSg: 
490.1596. Found: 490.1586.
(2 /? )-N '-[2 -A m in o -4 -(b en zy lo x y )-5 -m eth o x y b en zo y l]-  
pyrrolidine-2-carboxaldehyde diethyl dithioacetal (97% yield, 
TLC /ethyl acetate): IR (neat) 3439 and 3340 (NH2), 2955,2918, 
2860,1618 (C = 0 ), 1586 (C=C), 1562,1506,1447,1400,1375,1338, 
1260,1230,1189,1168,1105,1028, 997, 863, 820, 738, 697 cm '1; 
XH NMR (CDCI3) 1.08-1.43 (6 H, m), 1.53-2.35 (4 H, m), 2.48-2.95 
(4 H, m), 3.47-3.73 (2 H, m), 3.79 (3 H, s), 4.29-4.95 (4 H, m),
5.07 (2 H, s), 6.22 (1 H, s), 6.84-7.23 (5 H, m), 7.59 (1 H, s); MS 
m /e  (rel intensity) 460 (M+, 19), 399 (3), 370 (1), 336 (9), 325 (22), 
256 (100), 217 (6), 200 (5), 166 (13), 137 (13), 107 (7), 91 (68); yellow 
oil; [ a p D +69.74° (c 0.1520, CHCI3).
(1 laf? )-8-(B enzyloxy )-7-methoxy-l,2,3,l la-tetrahydro-5H - 
p y rro lo [2 ,l-c ][l ,4 ]b en zo d ia zep in -5 -o n e  (X ) (80% yield, 
TLC/ethyl acetate, purified on a MPLC reverse-phase RP-8 Lobar 
column, eluting with 7:3 methanol/H20): IR (Nujol) 3540-3120 
(OH for carbinolamine form), 2908,2841,1700,1600 (C = 0 ), 1500,
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1452,1373,1259,1213,1198,1170,1119,1073,1014, 870, 735,693 
cm"1; *H NM R (CDC13) 1.68-2.35 (4 H, m), 3.23-3.98 (3 H, m), 
3.88 (3 H, s), 5.09 (3 H, s), 6.80 (1 H, s), 7.08-7.45 (5 H, m), 7.48 
(1 H, s), 7.55 (1 H, d, J  =  4.5 Hz, imine); MS m /e  (rel intensity) 
336 (M+, 100), 291 (26), 259 (10), 245 (66), 241 (12), 231 (21), 217 
(88), 189 (19), 179 (37), 174 (13), 91 (99); [ a p D -636.1° (c 0.0404, 
CHClg). Anal. Calcd for CaoHaoNA: 336.1474. Found: 336.1465.
In  V itro  and in  V ivo B iolog ica l E valuation. The cytotoxic 
potency of the P(l,4)B s was determined by the microtiter method 
of Mirabelli et al. (40) utilizing murine B16 melanoma cells (F10 
subline) growing in monolayer. Cells in exponential growth were 
exposed to different concentrations of P(l,4)Bs for 72 h, and the 
concentration that inhibited cell proliferation by 50% was de­
termined. In each experiment compounds were compared with 
anthramycin to assure experiment-to-experiment consistency. 
Drug concentrations were evaluated in triplicate, and concen- 
tration-response studies were repeated to obtain accurate esti­
mates of the 50% inhibitory concentration.
For in vivo studies LD50 values were initially estimated following 
administration of a single ip dose in female (B6D2FX) mice. The 
highest dose tested was 100 m g/kg. The maximally tolerated 
single dose was subsequently bracketed in studies of antitumor 
activity in female (B6D2FX) mice bearing ip P388 leukemia. In 
these studies, carried out by standard techniques as previously 
described, P(l,4)Bs were administered ip on days 1 and 5 following 
ip inoculation of 106 P388 leukemia cells. The increase in lifespan 
at the maximally tolerated dose (ILSm.T) was utilized as a measure 
of antitumor activity. Compounds were compared directly with 
anthramycin in all experiments to determine relative therapeutic 
efficacy. Anthramycin was consistently active in this tumor model
Iso la tion  o f  R estr iction  E nzym e Fragm ents. Primary re­
striction digests were performed with either M spl or BstN I in 
the appropriate buffer and at the temperature recommended by 
the supplier. Reactions were stopped by adding one-fifth volume 
neutral tracking dye (50% v /v  glycerol, 25 mM EDTA, 0.25% 
xylene cyanol, 0.25% bromophenol blue). Restriction fragments 
were separated by polyacrylamide gel electrophoresis using 5% 
preparative gels and TBE electrophoresis buffer. DNA was 
visualized by staining with ethidium bromide. The appropriate 
bands were isolated and electroeluted in dialysis bags in TAE  
electrophoresis buffer. The DNA was isolated by ethanol pre­
cipitation with sodium acetate.
5'-®P End L abeling o f  D N A  R estriction  Fragm ents. DNA  
was prepared for 5'-end labeling by dephosphorylating with BAP. 
Samples were resuspended in 100 nL  of 50 mM NaCl, 50 mM 
Tris-HCl, pH 8.0, and 0.1 unit of BAP and incubated at 65 °C 
for 90 min. Samples were then extracted twice with equal volumes 
of Tris buffer saturated phenol and once with an equal volume 
of CHCI3. DNA was isolated by ethanol precipitation and re- 
suspended in 25 fiL o f 50 mM Tris-HCl, pH 7.8, containing 10 
mM MgCl2, 10 mM spermidine, 0.5 mCi of [7 -32P]ATP, and 10 
units of T4 PNK. Samples were incubated at 37 °C for 20 min 
and ethanol precipitated. Samples were resuspended! in the ap­
propriate buffer for secondary endonuclease digest and incubated 
at the recommended temperature. The 250 bp M spl fragment 
was digested with JBsfNI, and the 137 bp BsfN I fragment was 
digested with M spl. Reactions were stopped, and samples were 
electrophoresed on preparative gels as above. Fragments were 
visualized by autoradiography, and the desired singly end labeled 
117 bp fragment was isolated by electroelution and ethanol 
precipitation as above.
D N A  S eq u en c in g  R eaction s. Singly end labeled DNA  
fragments were sequenced by the method of Maxam and Gilbert
(41) and resuspended in alkaline tracking dye (80% v /v  deionized 
formamide, 10 mM NaOH, 1 mM EDTA, 0.1% xylene cyanol) 
for electrophoresis.
D ru g  M odification . Samples were resuspended in 10 (iL of 
10 mM Tris-HCl pH 7.4,50 mM NaCl, and 50 mM bp calf thymus 
DNA, and the appropriate amount of drug was added to give final 
concentrations of 10, 50, and 200 /kM. These were incubated for 
14 h at 4 °C.
E xon u clease  III D ig estio n s. To each sample was added 
one-tenth volume of a 10X exo III buffer (660 mM Tris-HCl, pH  
8.0,770 mM NaCl, 50 mM MgCl2, 100 mM DTT). Samples were 
incubated with 20 units of exo III at 37 °C for 10 min. Nonco- 
valently bound drug was not removed prior to treatment with exo
III. Previous studies indicated that removal of unbound drug 
(by ethanol precipitation of the DNA) did not alter the exo III 
stop patterns. Reactions were stopped by adding an equal volume 
of tracking dye (80% v /v  deionized formamide, 10 mM EDTA, 
0.1% xylene cyanol). Exo III digestion of DNA immediately after 
addition of drug did not show any significant difference to control 
exo III digestions carried out in the absence of drug, except for 
minor bands associated with drug bonding to DNA.
E lectroph oresis and A utoradiography. Samples were de­
natured and covalently bound drug was removed from the DNA  
by heating to 90 °C for 3 min and quickly chilling on ice. Equal 
amounts of radioactivity per sample were loaded onto thin de­
naturing polyacrylamide gels [8 % 1:20 acrylamide/bis(acryl- 
amide), 50% urea] and electrophoresed with TBE and running 
buffer at 1200-1400 V for 3 h. Autoradiograms were made by 
using X-Omat RP film with intensifying screens.
Results
The primary purpose of this study was to determine 
whether a correlation could be established between in vitro 
DNA alkylation and in vitro or in vivo biological activity 
amongst a diverse group of P(l,4)Bs. From a larger group 
of synthetic compounds tested for biological activity, ex­
amples of both biologically active and inactive compounds 
were selected for detailed DNA alkylation and sequence 
specificity studies. Three groups of compounds were 
evaluated (see Table I); group A differed in their aromatic 
substituents but had the same five-membered ring, group 
B contained different degrees of saturation in the five- 
membered ring but had a common aromatic ring, and 
group C was the pair of enantiomers at C -lla .
C om parison  o f  B io log ica l A ctiv ity  o f  P (l,4 )B s .  
Compounds listed in Table I were tested for in vitro cy- 
toxicity against B16 melanoma cells (IC^), for potency in 
vivo in B6D2FX mice (LD^), and for antitumor activity in 
vivo against P388 leukemia (ILS^*,) (Table I). While 
tomaymycin and its 8-O-methyl analogue (V) were the 
most cytotoxic in vitro, anthramycin was 2-fold more po­
tent in vivo and had greater antitumor efficacy. On the 
basis of in vivo potency, eight of the twelve compounds 
showed activity, which were the following, in order of 
decreasing potency: anthramycin, tomaymycin, V, VI, II, 
IX, III, VIII. The same compounds showed in vivo an­
titumor activity, although there were some surprising 
differences with respect to relative potency vs antitumor 
activity. For example, III had low potency in vitro and 
in vivo yet demonstrated antitumor activity similar to 
tomaymycin when administered at its maximally tolerated 
dose. Thus, in vitro potency, although predictive for in 
vivo potency, was not always a good predictor of relative 
antitumor activity within the P(l,4)Bs tested in this study.
D N A  A lk y la tio n  and Sequence S p ec ific ity . The 
relative DNA alkylation of compounds in Table I was 
determined by using an exo III stop assay on 5'-end-labeled 
opposite strands of a 117 bp DNA fragment from M13mpl 
(see Materials and Methods). In this assay, P(1,4)B drug 
bonding sites on each strand were determined in separate 
experiments from the position of exo III stop sites. This 
offset of approximately two to three bases to the 3' side 
of the drug overlap site (see Figure 2) is presumably due 
to a drug-induced conformational change in DNA or direct 
interaction o f the enzyme with the drug molecule in the 
minor groove. This assay has been used previously to 
determine DNA alkylation sites for cis P t and to locate 
pyrimidine dimers on DNA (42).
E ffect o f  A rom atic S u b stitu en ts on P(1,4)B Bond­
in g  to D N A . Compounds I-IV, which possess unsubsti­
tuted pyrrolidine rings but have different aromatic sub­
stituents, were compared with anthramycin and tomay­
mycin for DNA bonding by using the exo III stop assay.
Pyrrolo[1,4]benzodiazepine A n titu m o r Antibiotics Chem. Res. Toxicol., Vol. 1, No. 5, 1988 263
D N A
B IN D IN G
E X O  III 
STO P  
SITE
L IG A N D
5'
3
D R U G
OVERLAP
SITES
E X d  II 
STO P  
SITE
F i g u r e  2. D iagram  o f  th e  p o sitio n  o f  exo  III  sto p  sites  relative  
to  the P (1 ,4 )B  overlap on D N A . N o te  th e  righ t-handed tw ist o f  
D N A  accou n ts for part b u t not a ll o f  th e  o ffse t o f  exo  III stop  
site s  relative  to  th e  drug overlap  site .
F ig u r e  3  s h o w s  a u t o r a d io g r a m s  o f  t h e  e x o  I I I  s t o p  p a t t e r n s  
o n  o p p o s i t e  s t r a n d s  fo r  u n m o d i f i e d  D N A  ( l a n e  1) in  c o m ­
p a r is o n  t o  a n t h r a m y c in  ( la n e  2 ) ,  t o m a y m y c in  ( la n e  3 ) ,  a n d  
c o m p o u n d s  I ( l a n e s  9 - 1 1 ) ,  I I  ( l a n e s  4 - 6 ) ,  ITI ( l a n e s  7  a n d  
8 ) ,  a n d  I V  ( l a n e s  1 2 - 1 4 ) .  E x o  I I I  s t o p  s i t e s  a t t r i b u t a b l e  
t o  d r u g  b o n d i n g  ( i .e . ,  n o t  p r e s e n t  a s  n a t u r a l  s t o p  s i t e s  in  
t h e  u n m o d i f i e d  D N A )  a r e  s h o w n  b y  a r r o w h e a d s .  W h i l e  
a n t h r a m y c i n ,  t o m a y m y c i n ,  I I ,  a n d  I I I  s h o w e d  d r u g - d e ­
p e n d e n t  e x o  I I I  s t o p  s i t e s ,  c o m p o u n d s  I  a n d  I V  d i d  n o t  
e x h i b i t  n e w  s t o p  s i t e s  in  e i t h e r  s t r a n d  ( F ig u r e  3 ) .  A n ­
t h r a m y c i n  a n d  t o m a y m y c i n  p r o d u c e d  m o r e  d r u g - r e l a t e d  
e x o  III  s t o p  s i t e s  t h a n  e i t h e r  c o m p o u n d  II  o r  I I I . A t  h ig h e r  
d r u g  c o n c e n t r a t i o n s  ( l a n e s  5  a n d  6  fo r  II  a n d  la n e  8  fo r  II I )  
m o r e  r a d io a c t iv e  m a t e r ia l  a p p e a r e d  a t  t h e  h i g h  m o le c u la r  
w e i g h t  e n d  o f  t h e  g e l .  T h i s  w a s  e x p e c t e d  s i n c e  e x o  I I I  is  
a  p r o c e s s i v e  e n z y m e  a n d  u n d e r  c o n d i t i o n s  o f  l i m i t e d  d i ­
g e s t i o n  t h e  p r e s e n c e  o f  i n c r e a s i n g  n u m b e r s  o f  a d d u c t s  o n  
t h e  D N A  m o l e c u l e  s h o u l d  p r o g r e s s i v e l y  h i n d e r  t h e  e x o ­
n u c le a s e  a c t i v i t y .  S i n c e  e x o  I I I  d i g e s t s  f r o m  t h e  o p p o s i t e  
3 ' - e n d s  o f  t h e  d u p l e x  D N A  m o l e c u l e  {43), d r u g  b o n d i n g  
s i t e s  o n  t h e  3 ' - e n d s  o f  t h e  d u p l e x  D N A  m o l e c u l e  a r e  r e ­
v e a l e d  m o r e  f a v o r a b ly  t h a n  t h o s e  o n  t h e  5 ' - e n d  ( F ig u r e  3 ) .  
C o n s e q u e n t ly ,  in  F ig u r e  3 A , t h e  d r u g - r e l a t e d  f a v o r e d  s i t e s  
fo r  t h e  e x o  I I I  s t o p  a r e  U - F ,  w h i le  in  F ig u r e  3 B  t h e  fa v o r e d  
e x o  I I I  s t o p  s i t e s  a r e  B - K .  T h e r e  a r e  s o m e  d r u g - i n d u c e d  
e x o  I I I  s t o p  s i t e s  t h a t  c a n n o t  b e  d i r e c t l y  a s c r i b e d  t o  e x ­
p e c t e d  d r u g  b o n d in g  s it e s ;  i .e .,  a  p o t e n t i a l  g u a n in e  c o v a l e n t  
b o n d in g  s i t e  i s  n o t  a v a i l a b l e .  T h e s e  s i t e s  a r e  d e n o t e d  b y  
a r r o w h e a d s  b u t  a r e  n o t  g i v e n  a  l e t t e r  d e s i g n a t i o n  ( e .g . ,  
b e t w e e n  G  a n d  K , a n d  B  a n d  D ,  in  F ig u r e  3 A ; a n d  b e t w e e n  
T  a n d  U ,  a n d  G  a n d  K , in  F i g u r e  3 B ) .
T h e  e x o  I II  s t o p  s i t e s  fo r  a n t h r a m y c in ,  t o m a y m y c in ,  a n d  
c o m p o u n d s  II  a n d  I I I  o n  t h e  1 1 7  b p  D N A  s e q u e n c e  a r e  
s h o w n  d i a g r a m m a t i c a l l y  in  F i g u r e  4  ( t o p  s t r a n d  c o r r e ­
s p o n d s  t o  F ig u r e  3 A  a n d  b o t t o m  s t r a n d  t o  F ig u r e  3 B ) .  T h e  
p o s i t io n  o f  t h e  a r r o w s  r e p r e s e n t s  t h e  e x o  I I I  s t o p  s i t e s ,  w i t h  
t h e  l e n g t h  o f  t h e  a r r o w  b e in g  p r o p o r t io n a l  t o  t h e  s e n s i t i v i t y  
o f  e a c h  s i t e  fo r  d r u g  b o n d i n g  ( s e e  l e g e n d ) .  T h e  l o n g e s t  
a r r o w s  a r e  d r u g  b o n d i n g  s i t e s  r e v e a l e d  a t  t h e  l o w e s t  d r u g  
c o n c e n t r a t i o n  t e s t e d ,  w h e r e a s  t h e  s h o r t e s t  a r r o w s  d e p i c t  
s t o p  s i t e s  p r e s e n t  o n l y  a t  t h e  h i g h e s t  d r u g  c o n c e n t r a t i o n s .  
T h e  s q u a r e s  e n c l o s e  t h e  P ( 1 , 4 ) B  t h r e e  b a s e  p a ir  o v e r la p  
s i t e  w i t h  t h e  c e n t r a l  G C  p a ir  c o n t a i n i n g  t h e  a l k y l a t e d  b a s e  
(G ) .  T o  d i f f e r e n t ia t e  d r u g  b o n d in g  s i t e s  n e a r  t o  e a c h  o t h e r  
( a n d  t h e  c o r r e s p o n d in g  e x o  I I I  s t o p  s i t e s ) ,  s o l id  o r  b r o k e n  
b o x e s  ( a n d  a r r o w s )  w e r e  u s e d .  T h e  e x o  I I I  s t o p  s i t e s  r u n  
o u t  a t  t h e  5 ' - e n d s  o f  e a c h  s t r a n d  s o  s o m e  s q u a r e s ,  p r i n ­
c i p a l l y  n e a r  t h e  e n d s  o f  t h e  D N A  s t r a n d s ,  o n l y  h a v e  a  
s i n g l e  a s s o c i a t e d  e x o  I I I  s t o p  s i t e .  W h i l e  s o m e  d r u g  
b o n d in g  s i t e s  w e r e  c o m m o n  t o  a l l  o f  t h e  c o m p o u n d s  s h o w n  
in  F ig u r e  4  (B ,  F , a n d  G ) ,  m a n y  w e r e  o c c u p ie d  b y  j u s t  o n e  
( A , K , L , T ,  a n d  U  fo r  a n t h r a m y c i n ;  H ,  C , a n d  R  fo r  t o ­
m a y m y c i n )  o r  t w o  c o m p o u n d s  ( e .g . ,  P  fo r  II  a n d  I I I ) .  
C o m p o u n d s  I I  a n d  I I I  s h o w e d  f e w e r  a l k y l a t i o n  s i t e s  t h a n
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TC AG 1 2 3 4 5 6 7 8 9 10 11 12 13 14
>   * *i t i * 3r n
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F ig u r e  3. A utoradiogram s o f  the exo III in h ib ition  by anth ra­
m ycin (anth), tom aym ycin  (tom ), I, II, III, and IV , on opp osite  
strands o f  a 5'-32P -en d-labeled  117 bp fragm ent from  M 1 3 m p l. 
Drug treatm ent and exo III digestion was carried out as described  
under M aterials and M eth ods. (A) L eft-h an d  lanes, M a x a m -  
G ilbert chem ical sequ en cing  T C  and AG reaction s (4 2 ); lane 1, 
exo III control w ith ou t prior drug m odifications; lane 2, exo  III 
digestion  o f anthram ycin-bound D N A  a t 200 ^M; lane 3, exo III 
digestion  o f tom aym ycin -bound D N A  at 200 mM; lanes 4 -6 , exo  
III digestion o f II-bound D N A  at 10, 50, and 300 /xM; lanes 7 and 
8, exo III digestion of Ill-bound D N A  at 10 and 50 mM; lanes 0-11, 
exo III d igestion  o f I-bound D N A  at 10, 50, and 200 /xM; lanes 
12-14, exo III d igestion of IV-bound D N A  at 10, 50, and 200 mM. 
C oncentrations refer to  incubation  o f  drug w ith  D N A  for 14 h 
prior to drug rem oval and exo III d ig estio n . Arrows identify  
drug-related exo III stop s (see text). (B) Sam e as (A) but on the  
opp osite  stand.
t h e  n a t u r a l  p r o d u c t s .  C o m p o u n d s  I a n d  I V  d id  n o t  in h ib i t  
e x o n u c le a s e  III  a c t iv i t y  (F ig u r e  3 ) ,  s u g g e s t i n g  t h a t  a  m e t h y l  
a t  C -6  ( I )  o r  a  c h lo r o  s u b s t i t u e n t  a t  C - 8  ( I V )  e l i m i n a t e s  
t h e  a lk y la t io n  o f  D N A  b y  t h e s e  c o m p o u n d s .  T h e s e  r e s u l t s  
c o r r e l a t e  w i t h  t h e  o b s e r v a t i o n  ( T a b l e  I )  t h a t  t h e s e  c o m ­
p o u n d s  a r e  l e s s  c y t o t o x i c  t h a n  t h e  n a t u r a l  p r o d u c t s  a n d  
a r e  n o t  t o x i c  in  v iv o .
E f f e c t  o f  S a t u r a t i o n  i n  t h e  F i v e - M e m b e r e d  R i n g  o n  
P ( 1 , 4 ) B  B o n d i n g  t o  D N A .  C o m p o u n d s  V - V I I I  ( T a b le  
I ) ,  w h i c h  p o s s e s s  t h e  s a m e  a r o m a t i c  s u b s t i t u t i o n  p a t t e r n  
b u t  d i f f e r  in  t h e  d e g r e e s  o f  s a t u r a t io n  in  t h e  f iv e - m e m b e r e d  
r in g ,  w e r e  c o m p a r e d  fo r  D N A  b o n d i n g  a n d  s e q u e n c e  
s p e c i f i c i t y  b y  u s i n g  t h e  e x o  I I I  s t o p  a s s a y  ( F ig u r e  5 A ) .  
C o m p o u n d  V , w h ic h  d i f f e r s  fr o m  t o m a y m y c in  o n l y  in  t h a t  
i t  h a s  a  m e t h o x y  a t  C - 8  i n s t e a d  o f  a  h y d r o x y  g r o u p ,  g a v e  
a n  a l m o s t  i d e n t i c a l  e x o  I I I  s t o p  p a t t e r n  t o  t h a t  f o u n d  fo r  
t o m a y m y c in .  W h ile  c o m p o u n d  V I  (w i t h  a  p y r r o lid in e  r in g )  
a n d  c o m p o u n d  V I I I  ( w i t h  a  p y r r o l i n e  r in g ;  d o u b l e  b o n d  
b e t w e e n  C - l  a n d  C - 2 )  s h o w e d  D N A  b o n d i n g ,  t h e  f u l ly  
c o n j u g a t e d  p y r r o le  c o m p o u n d  ( V I I )  d i d  n o t  s h o w  a n y
m M  ~  —
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► PO^TTTTACAACGTCGTGACTGGG 3 * 
lAGCAAAATGTTGCAGCACTGACCC 5 ’
J  GeTffTGACCATGATTAC 31 
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F ig u r e  4. D N A  seq u en ce  o f  both  stran d s o f  the 117 bp fragm ent show ing the exo III sto p  sites  (arrows) and a ssocia ted  drug overlap  
site s  for an th ram ycin , tom aym ycin , and  com poun ds II and III. D ata are from Figure 3A (top  strand ) and 3B  (b o tto m  strand ). T he  
len g th  o f  th e  arrows correspon ds to  th e  relative  occu pancy  o f  th e  drugs for th e  various bon ding  site s  (A -U ). T o  d ifferen tia te  drug 
bon ding  site s  at ad jacen t p ositio n s, fu ll-lin e  boxes (and arrows) or broken-line boxes (and arrows) were used.
T a b le  II . C la ss if ic a tio n  an d  S e n s itiv ity  o f P(1,4)B  DNA B ond ing  S ite s  on 117 B ase  P a ir  F ra g m e n t0
com pound0
ing site" sequence classification6 anthramycin tom aym ycin II III V VI VIII IX
A TGG PyG Pu 4
B GGA PuG Pu 3 4 4 4 1 1
C CGC PyG Py 4 2 3
D GGA PuG Pu 4 2 3 3 1 1 3
E TGA PyG Pu 3 3 3 3 3 2
F AGG PuGPu 4 4 4 3 4 2 2 4
G GGA PuG Pu 4 4 4 4 4 2 2 1
H TG T PyG Py 2 3 2 2
I AGC PuG Py 3 3
J AGC PuG Py 3
K TGA PyGPu 3 2 2
L GGT PuG Py 2 2 2
M GGA PuGPu 3 4 4 4
N TGA PyGPu 3 3 3
0 AGT PuG Py 2
P TGG PyGPu 3 2 2
Q GGC PuG Py 2 3 2 3 2
R GGC PuG Py 1 3
S CGG PyGPu 3
T CGT PyG Py 3
U CGA PyGPu 3
°D ata and bonding sites are taken from Figures 3 and 5. 6 Py = pyrimidine; Pu = purine. cSee Table I for structures.
d r u g - r e la t e d  e x o  I I I  s t o p  s i t e s .  T h e  i n a b i l i t y  o f  c o m p o u n d  
V I I  t o  b i n d  t o  D N A  c o r r e l a t e s  w i t h  i t s  s i g n i f i c a n t l y  d e ­
c r e a s e d  b i o lo g i c a l  a c t i v i t y  ( T a b l e  I ) .
T h e  e x o  I I I  s t o p  s i t e s  a n d  a s s o c i a t e d  d r u g  b o n d in g  s i t e s  
fo r  t o m a y m y c in  a n d  c o m p o u n d s  V , V I , a n d  V I I I  a r e  s h o w n  
d i a g r a m m a t i c a l l y  i n  F ig u r e  6 . T h e  e x o  I I I  s t o p  s i t e s  
c o r r e s p o n d i n g  t o  F ig u r e  5 A  a r e  s h o w n  o n  t h e  u p p e r  
s t r a n d s ,  w h i le  t h o s e  o n  t h e  lo w e r  s t r a n d s  w e r e  d e t e r m i n e d  
f r o m  p a r a l l e l  e x p e r i m e n t s  ( r e s u l t s  n o t  s h o w n ) .  S o m e  
s u b t l e  d i f f e r e n c e s  b e t w e e n  t o m a y m y c in  a n d  i t s  8 - 0 - m e t h y l  
d e r i v a t i v e  (V )  a r e  e v i d e n t ,  p r in c ip a l l y  o n  t h e  lo w e r  s t r a n d .  
T h e s e  m a y  r e p r e s e n t  r e a l  c h a n g e s  d u e  t o  t h e  d i f f e r e n t  
e l e c t r o n i c  o r  s t e r i c  i n t e r a c t io n s ,  b u t  i n h e r e n t  v a r i a t i o n s  in  
s u c c e s s i v e  e x o  I I I  d i g e s t i o n s  m a k e  t h e s e  d i f f e r e n c e s  l e s s  
i n t e r p r e t a b l e .  T h e  a n a l o g u e s  w i t h  p y r r o l i d in e  a n d  p y r -  
r o l in e  r in g s  ( V I  a n d  V I I I )  b o u n d  t o  f e w e r  D N A  s i t e s  a n d  
w i t h  l o w e r  a f f i n i t y  t h a n  t o m a y m y c i n - l i k e  c o m p o u n d s  
w h i c h  c o n t a i n  a n  e x o c y c l i c  d o u b l e  b o n d  a t  C - 2  ( t o m a y ­
m y c i n  a n d  V ) .
E ffect o f  th e C h ira lity  at C - lla  on P (1 ,4)B  B onding  
to D N A . T h e  n a t u r a l l y  o c c u r r i n g  a n t i b i o t i c s  in  t h e  P -
( 1 ,4 ) B  s e r ie s  h a v e  a n  l l a S  c o n f i g u r a t i o n ,  w h i c h  p r o v i d e s  
t h e s e  m o le c u l e s  w i t h  a  r ig h t - h a n d e d  t w i s t  a l o n g  t h e  l e n g t h  
o f  t h e  m o le c u l e .  S i n c e  t h e  c o n f i g u r a t i o n  a t  C - l l  i s  i n ­
t e r c o n v e r t ib le  v ia  t h e  N - 1 0 - C - 1 1  im in e  in  a q u e o u s  s o lu t io n ,  
t h i s  c e n t e r  d o e s  n o t  a f f e c t  D N A  b o n d i n g  o r  b i o lo g i c a l  
a c t iv i t y .  A  c o m p a r is o n  o f  t h e  D N A  b o n d in g  o f  c o m p o u n d s  
I X  a n d  X ,  w h ic h  d i f f e r  o n l y  in  t h e  c h ir a l i t y  a t  C - l l a ,  s h o w s  
t h a t  o n l y  c o m p o u n d  I X  w i t h  t h e  n a t u r a l  c o n f i g u r a t i o n  
( l l a S )  b o n d s  t o  D N A  ( F ig u r e  5 B ) .  A  c o m p a r i s o n  o f  t h e  
e x o  I I I  s t o p  s i t e s  o n  b o t h  s t r a n d s  fo r  c o m p o u n d  I X  w i t h  
t o m a y m y c in  a n d  r e l a t e d  c o m p o u n d s  is  s h o w n  in  F ig u r e  6 . 
( F ig u r e  5 B  c o r r e s p o n d s  t o  t h e  t o p  s t r a n d  in  F ig u r e  6 . )  A  
b e n z y l o x y  g r o u p  a t  C - 8  in  p l a c e  o f  a  m e t h o x y  g r o u p  a p ­
p e a r s  t o  in c r e a s e  t h e  o v e r a l l  b o n d in g  r e a c t i v i t y  a n d  c h a n g e  
m a n y  o f  t h e  b o n d in g  s i t e s  ( c o m p a r e  V I  t o  I X  in  F ig u r e  6 ) .
C om parison  o f  D N A  B o n d in g  S ite s  fo r  P ( l ,4 )B s  
E valuated  in T h is  In vestiga tion . T h e  s e q u e n c e s  o f  t h e
Pyrrolo[1,4]benzodiazepine A n titum or A ntibiotics
A
B
Anth Tom i-------IX------ 1 .------ X-------
G AG TC 1 2 3 4 5 6 7 8 9 1
Figure 5. Autoradiogram s o f  th e  exo III in h ib itio n  by anthra- 
ivcin(anth), tom aym ycin  (tom ), V, VI, VII, VIII, IX , and X  on  
i^-end-labeled 117 bp fragm ent from  M 13m p l (sam e strand  
ijin Figure 3A). Drug trea tm en ts and exo  III d ig estio n  were  
carried out as described under M ater ia ls and M eth od s. (A) 
Left-hand lanes, M a x a m -G ilb ert chem ica l seq u en cin g  T C  and  
Greactions (42); lanes 1 -3 , as in F igure 3A; lanes 4 -6 , exo  III 
digestions of V-bound D N A  at 10, 50, and 200 mM; lanes 7 -9 , exo  
indigestions o f V H -bound D N A  a t 10, 50, and 200 nM ; lanes
10-12,exo III digestions o f V i-bound D N A  at 10, 50, and 200 mM; 
ines 13-15, exo III d igestions o f  V U I-bound D N A  at 10, 50, and  
j '2)0|iM. Other cond itions and an n o ta tio n s are as in F igure 3A. 
B)Left-hand lanes are M a xam -G ilb ert chem ical sequ en cin g  G 
ffidAG reactions (42); lanes 1 -3 , as for F igure 3A; lanes 4 -6  and  
Hexo III digestions o f IX - and X -m od ified  D N A , respectively, 
it 10,50, and 200 mM for each  drug. O ther co n d itio n s and  
notations as in F igure 3A.
Pil,4)B D N A  b o n d in g  s i t e s  a n d  t h e i r  r e l a t i v e  a f f i n i t y  fo r  
thevarious c o m p o u n d s  e v a l u a t e d  i n  t h i s  s t u d y  a r e  s u m ­
med in T a b le  II . B o n d in g  s i t e s  F  a n d  G  w e r e  c o m m o n  
t)all com p o u n d s f o u n d  t o  b i n d  t o  D N A .  T h e s e  s i t e s  
heiong to th e  P u G P u  c la s s ,  w h i c h  i s  t h e  m o s t  f r e q u e n t l y  
immd seq u en ce  a n d  i s  g e n e r a l l y  o c c u p i e d  a t  t h e  l o w e s t  
Mg con cen tra tion s. T h e  P u G P u  c l a s s  is  m o r e  s e n s i t i v e  
laP(l,4)Bs th a n  t h e  o t h e r  b o n d in g  c la s s e s  ( P y G P u ,  P u G -  
fr,PyGPy; P u  =  p u r in e ,  P y  =  p y r im id i n e ,  s e e  b e lo w ) .  I t  
important to  n o t e  t h a t  a  b i a s  t o w a r d  h i g h e r  s e n s i t i v i t y  
teach end o f  t h e  f r a g m e n t  is  i n h e r e n t  in  e x p e r i m e n t s  
tee a p r o c e s s iv e  e n z y m e  s u c h  a s  e x o  I I I  i s  u s e d  t o  
•iasure bonding. H o w e v e r ,  t h i s  b ia s  c a n n o t  b e  r e s p o n s ib le  
Bihe strong p r e fe r e n c e  fo r  P u G P u  s e q u e n c e s  s in c e  t h e s e  
Kdistributed t h r o u g h o u t  t h e  D N A  f r a g m e n t  ( s i t e s  B ,  D ,  
f,G,and M ). In  a  p r e v i o u s  s t u d y ,  u s i n g  M P E - F e ( I I )  a s  
lisotprinting r e a g e n t ,  w e  h a v e  d e t e r m i n e d  t h e  c o n s e n s u s
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b o n d i n g  s e q u e n c e s  fo r  a n t h r a m y c i n ,  t o m a y m y c i n ,  a n d  
s i b i r o m y c i n  (2 5 ) .  T h i s  s t u d y  r e v e a l e d  t h a t  t h e  p r e f e r r e d  
t r im e r  fo r  P ( 1 , 4 ) B  b o n d i n g  w a s  P u G P u ,  f o l l o w e d  b y  
P y G P u  a n d  P u G P y ,  w h i c h  h a d  a p p r o x i m a t e l y  t h e  s a m e  
o c c u p a n c y  r a t e ,  a n d  t h e  l e a s t  f a v o r e d  w a s  P y G P y .  I n  t h e  
p r e s e n t  s t u d y  a  s im i l a r  a n a l y s i s  r e v e a l e d  t h e  s a m e  r e s u l t :  
P u G P u  w a s  b y  fa r  t h e  m o s t  f a v o r e d  s i t e ,  b e i n g  o c c u p i e d  
8 5 %  o f  p o s s i b l e  t i m e s ,  w h i l e  P u G P y  a n d  P y G P u  w e r e  o f  
i n t e r m e d ia t e  fa v o r e d  o c c u p a n c y  (2 2  a n d  1 8 % ) ,  a n d  P y G P y  
w a s  t h e  l e a s t  f a v o r e d  s e q u e n c e  ( 9 % ) .
Discussion
T h i s  s t u d y  w a s  c a r r ie d  o u t  t o  d e t e r m i n e  w h e t h e r  a n  in  
v i t r o  D N A  a l k y l a t i o n  a s s a y  c a n  b e  u s e d  t o  p r e d i c t  t h e  
c y t o t o x i c i t y  a n d  a n t i t u m o r  e f f i c a c y  o f  n a t u r a l  a n d  s y n ­
t h e t i c  P ( l , 4 ) B s .  T h e  r e s u l t s  s h o w  t h a t  t h e r e  i s  a  g o o d  
r e l a t i o n s h i p  b e t w e e n  D N A  b o n d i n g ,  a s  m e a s u r e d  b y  t h e  
e x o  I I I  s t o p  a s s a y  m e t h o d ,  a n d  b i o l o g i c a l  a c t i v i t y .  C o m ­
p o u n d s  h a v in g  a n  IC so >  1 2  a n d / o r  L D ^  >  1 0 0  m g / k g  
d i d  n o t  m e a s u r a b l y  b o n d  t o  D N A .  M o r e o v e r ,  t h e  e x o  I I I  
s t o p  a s s a y  p r o v i d e s  q u a l i t a t i v e  i n f o r m a t i o n  o n  p r e f e r r e d  
P ( 1 , 4 ) B  D N A  b o n d i n g  s e q u e n c e s  a s  w e l l  a s  q u a n t i t a t i v e  
i n f o r m a t i o n  o n  D N A  b o n d i n g  r e a c t i v i t y .
O f  t h e  s y n t h e t i c  P ( l , 4 ) B s  in  s e r i e s  A ,  c o m p o u n d s  I (6 -  
m e t h y l )  a n d  I V  (8 - c h lo r o )  w e r e  s h o w n  t o  b e  i n a c t iv e ,  w h i le  
c o m p o u n d s  I I  ( 7 - m e t h y l )  a n d  I I I  ( 9 - m e t h y l )  w e r e  s h o w n  
t o  h a v e  b i o lo g ic a l  a c t iv i t y .  T h e  la c k  o f  b i o l o g i c a l  p o t e n c y  
f o u n d  fo r  c o m p o u n d  I V ,  w h i c h  h a s  t h e  e l e c t r o n - w i t h ­
d r a w i n g  c h lo r in e  s u b s t i t u e n t  a t  C - 8 ,  is  c o n s i s t e n t  w i t h  
r e s u l t s  o b t a i n e d  w i t h  o t h e r  s y n t h e t i c  P ( l , 4 ) B s  h a v i n g  
e le c t r o n - w i t h d r a w i n g  s u b s t i t u e n t s  in  t h e  a r o m a t i c  r in g .  
F o r  e x a m p l e ,  c o m p o u n d s  w i t h  a  n i t r o  o r  c a r b o x y l i c  a c id  
g r o u p  a t  p o s i t i o n  8  o r  9  w e r e  n o t  c y t o t o x i c  ( u n p u b l i s h e d  
r e s u l t s ) .  ! H  N M R  e x p e r i m e n t s  in  p r o t i c  s o l v e n t s  h a v e  
s h o w n  t h a t  t h e  r a t e  o f  i n t e r c o n v e r s i o n  b e t w e e n  t h e  1 1 R 
a n d  1 1 S  c a r b i n o l a m i n e s  o r  c a r b i n o l a m i n e  a l k y l  e t h e r s ,  
p r e s u m a b l y  v i a  t h e  N - 1 0 - C - 1 1  i m i n e  ( F ig u r e  1 ) ,  w a s  i n ­
c r e a s e d  in  t h e  p r e s e n c e  o f  e l e c t r o n - d o n a t i n g  s u b s t i t u e n t s  
a n d  d e c r e a s e d  in  t h e  p r e s e n c e  o f  e l e c t r o n - w i t h d r a w i n g  
s u b s t i t u e n t s  ( u n p u b l i s h e d  r e s u l t s ) .  S i n c e  t h e  e f f e c t  o f  
e le c t r o n - d o n a t i n g  o r  - w i t h d r a w in g  s u b s t i t u e n t s  o n  t h e  r a t e  
o f  in t e r c o n v e r s io n  o f  t h e s e  v a r io u s  s p e c i e s  c o r r e l a t e d  w i t h  
e f f e c t s  o n  D N A  b o n d i n g  a n d  b i o l o g i c a l  a c t i v i t y  s h o w n  in  
t h i s  s t u d y ,  i t  is  l i k e l y  t h a t  t h e  N - 1 0 - C - 1 1  i m i n e  i s  t h e  
D N A - r e a c t i v e  s p e c ie s .  A  s im ila r  c o n c lu s io n  w a s  p r e v i o u s l y  
d r a w n  o n  t h e  b a s i s  o f  f l u o r e s c e n c e  a n d  *H  N M R  s t u d i e s  
o n  t o m a y m y c i n  in  p r o t i c  s o l v e n t s  a n d  o n  D N A  (2 4 ) .  
E l e c t r o n - w i t h d r a w i n g  s u b s t i t u e n t s  s u c h  a s  t h e  c h lo r in e  in  
c o m p o u n d  I V  r e d u c e  t h e  a v a i l a b i l i t y  o f  t h e  l o n e  p a i r  o f  
e le c t r o n s  o n  t h e  N - 1 0  n i t r o g e n .  T h i s  in  t u r n  r e d u c e s  t h e  
t e n d e n c y  o f  t h e  N - 1 0  t o  p r o t o n a t e ,  w h i c h  i s  c o n s i d e r e d  a  
p r e r e q u is i t e  fo r  n u c le o p h i l i c  a t t a c k .  T h e  i m in e  is  t h e r e f o r e  
s t a b l e  a n d  c o n s e q u e n t l y  b io lo g i c a l ly  i n a c t iv e .  C o n v e r s e l y ,  
e le c t r o n - d o n a t i n g  a r o m a t i c  s u b s t i t u e n t s  ( e .g . ,  - O H ,  - C H 3, 
- O C H 3) e n h a n c e  t h e  a v a i l a b i l i t y  o f  t h e  l o n e  p a ir  o f  e l e c ­
t r o n s  o n  N - 1 0  ( i .e . ,  i n c r e a s e  i t s  b a s i c i t y ) ,  f a c i l i t a t i n g  p r o ­
t o n a t i o n  a n d  s u b s e q u e n t  n u c le o p h i l i c  a t t a c k  o f  t h e  i m in e .  
A  s im i l a r  a r g u m e n t  h a s  b e e n  u s e d  t o  r a t i o n a l i z e  t h e  
s t r u c t u r e  o f  p r o d u c t s  f o r m e d  d u r in g  t h e  s y n t h e s i s  o f  P -
( l , 4 ) B s  u s i n g  t h e  h y d r id e  r e d u c t i o n  (3 2 )  a n d  r e d u c t i v e  
c y c l i z a t i o n  (3 4 )  m e t h o d s .
A  c o m p a r i s o n  o f  t h e  D N A  b o n d i n g  a n d  b i o l o g i c a l  a c ­
t i v i t y  o f  c o m p o u n d s  h a v i n g  m e t h y l  s u b s t i t u e n t s  a t  d i f ­
f e r e n t  a r o m a t ic  p o s i t io n s  r e v e a l e d  s o m e  in t r i g u i n g  r e s u l t s .  
T h e  9 - m e t h y l  c o m p o u n d  ( I I I )  h a d  m a r g in a l  in  v i t r o  a n d  
in  v i v o  c y t o x i c  p o t e n c y  b u t  s h o w e d  a n t i t u m o r  e f f i c a c y  
s im i l a r  t o  t o m a y m y c i n  a t  i t s  m a x i m a l l y  t o l e r a t e d  d o s e .  
D N A  b o n d in g  o f  I I I  w a s  c o m p a r a t i v e l y  w e a k  o n  t h e  b a s i s
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TOMAYMYCIN
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F ig u r e  6 . D N A  sequ en ce  ladder o f  both  stran d s o f  th e  117 bp fragm ent show ing th e  exo  III sto p  site s  (arrows) and associa ted  drug  
overlap site s  for tom aym ycin  and co m p o u n d s V, VI, V III, and IX . D ata are from Figure 5 (upper strand s) and un pu blished  resu lts  
(low er strand s). O ther d eta ils  are as in F igure 4.
o f  t h e  n u m b e r  o f  s i t e s  o c c u p i e d  (4  o u t  o f  a  t o t a l  o f  2 1  
p o s s i b l e  s i t e s ) .  H o w e v e r ,  I I I  w a s  h i g h l y  s e l e c t i v e  fo r  
P u G P u  s e q u e n c e s .  C P K  m o d e l i n g  s t u d i e s  (26) s u g g e s t  
t h a t  t h e  9 - m e t h y l  c o m p o u n d  m a y  b e  c lo s e  t o  t h e  m a x im u m  
s iz e  a l lo w e d  a t  c e r t a in  s i t e s  a n d  m a y  b e  s t e r i c a l ly  e x c l u d e d  
a t  o t h e r  s i t e s ,  c o n t r ib u t i n g  t o  i t s  s e q u e n c e  s e l e c t i v i t y  a n d  
r e l a t i v e l y  h i g h  a n t i t u m o r  e f f i c a c y  r e l a t i v e  t o  o t h e r  P -
( l , 4 ) B s .  H o w e v e r ,  o t h e r  e x p l a n a t i o n s  s u c h  a s  t h e  g r e a t e r  
l ip o p h i l i c i t y  a n d  t h e  i n d u c t iv e  e l e c t r o n - d o n a t i n g  c a p a b i l i t y  
o f  9 - m e t h y l  v s  9 - m e t h o x y  m a y  a l s o  b e  i m p o r t a n t .  F u r t h e r  
e x p e r i m e n t s  w o u l d  b e  r e q u i r e d  t o  d i f f e r e n t i a t e  b e t w e e n  
t h e s e  p o s s i b i l i t i e s .
T h e  la c k  o f  b io lo g ic a l  a c t iv i t y  o f  t h e  6 - m e t h y l  c o m p o u n d  
( I )  w a s  u n e x p e c t e d ,  a n d  t h e r e f o r e  t h e  r e a c t i v i t y  o f  t h e  
c a r b i n o l a m i n e  in  p r o t i c  s o l v e n t s  w a s  i n v e s t i g a t e d .  In  
m e t h a n o l - d 4 c o m p o u n d  I w a s  f o u n d  t o  b e  a  m i x t u r e  o f  t h e  
N - 1 0 - C - 1 1  i m i n e ,  t h e  1 1 5  c a r b i n o l a m i n e ,  a n d  1 1 5  c a r b i ­
n o l a m in e  m e t h y l  e t h e r  fo r m s .  T h i s  i s  in  c o n t r a s t  t o  o t h e r  
m e t h y l  P ( 1 ,4 ) B  a n a lo g u e s  w h i c h  e x i s t  a s  a  m ixture  o f  t h e  
1 1 /?  an d  1 1 5  c a r b i n o l a m i n e s  a n d  c a r b i n o l a m i n e  m e t h y l  
e t h e r  f o r m s  (35). A f t e r  r e p e a t e d l y  d i s s o l v i n g  a n d  e v a p o ­
r a t in g  c o m p o u n d  I f r o m  m e t h a n o l - d 4 t o  c o n v e r t  t h e  1 1 S  
c a r b i n o l a m i n e  t o  t h e  1 1 5  c a r b i n o l a m i n e  m e t h y l  e t h e r ,  i t  
w a s  d i s s o l v e d  in  C D C 1 3 w h i c h ,  in  t h e  c a s e  o f  n a t u r a l l y  
o c c u r r in g  P ( l , 4 ) B s ,  r e s u l t s  in  i m m e d i a t e  c o n v e r s i o n  t o  t h e  
N - 1 0 - C - 1 1  i m in e .  H o w e v e r ,  in  t h i s  c a s e  l i t t l e  c o n v e r s i o n  
t o  t h e  i m in e  o c c u r r e d .  A  D r e i d i n g  m o d e l  o f  t h e  6 - m e t h y l  
c o m p o u n d  ( I )  i n d i c a t e d  a  s t e r i c  i n t e r a c t i o n  b e t w e e n  t h e  
6 - m e t h y l  a n d  C -5  c a r b o n y l  f u n c t i o n a l i t i e s .  D i s p l a c e m e n t  
o f  t h e  c a r b o n y l  t o  e i t h e r  s id e  o f  t h e  C -6  m e t h y l  a p p a r e n t l y  
a l t e r s  t h e  t o r s io n a l  a n g le  a b o u t  t h e  N - 1 0 - C - 1 1  b o n d .  T h i s  
c h a n g e s  t h e  o v e r a l l  t w i s t  o f  t h e  P ( 1 , 4 ) B  s t r u c t u r e  a n d  
c a u s e s  t h e  a - f a c e  o f  t h e  C - l l  p o s i t i o n  t o  m o v e  i n t o  c lo s e r  
p r o x i m i t y  t o  t h e  C -3  p r o t o n s  o f  t h e  p y r r o l i d in e  r in g . T h i s  
m a y  e x p l a i n  t h e  la c k  o f  a n  l l / ? , l l a 5  f o r m  fo r  t h i s  c o m ­
p o u n d .  F o r  t h e  N - 1 0 - C - 1 1  i m in e  t o  b e  c o n v e r t e d  i n t o  t h e  
c a r b i n o l a m i n e  o r  m e t h y l  e t h e r  f o r m s ,  t h e  c a r b o n y l  m u s t  
p a s s  t h r o u g h  a s t e r i c a l l y  h i n d e r e d  f o r m a t i o n .  I f  t h e  r e ­
a c t i o n  o f  c o m p o u n d  I w i t h  D N A  r e q u i r e s  a n  1 1 R c o n f i g ­
u r a t io n  o n  D N A ,  t h e  o b s e r v e d  la c k  o f  r e a c t i v i t y  w i t h  D N A
a n d  c o n s e q u e n t  la c k  o f  b io lo g ic a l  a c t iv i t y  c a n  b e  e x p la in e d .
T h e  e f f e c t  o f  s a t u r a t i o n  in  t h e  f i v e - m e m b e r e d  r in g  o f  
t h e  P ( l , 4 ) B s  w a s  e x a m i n e d  b y  c o m p a r i n g  t h e  s e r i e s  B  
c o m p o u n d s  ( V - V I I I ) .  T h e s e  c o m p o u n d s  c o n t a i n  a  c o m ­
m o n  7 ,8 - d i m e t h o x y  a r o m a t i c  r in g  w h i c h  i s  c l o s e l y  r e l a t e d  
t o  t h e  a r o m a t ic  s u b s t i t u t i o n  o n  t o m a y m y c i n  ( 7 - m e t h o x y -  
8 - h y d r o x y ) .  C P K  m o d e l i n g  s t u d i e s  p r e d i c t  t h a t  t h e  
m e t h o x y  g r o u p  a t  C -8  s h o u l d  p o i n t  a lo n g  t h e  m in o r  g r o o v e  
a n d  s h o u l d  n o t  p r e v e n t  D N A  a l k y l a t i o n  (26). T h e  D N A  
b o n d in g  a n d  b i o lo g i c a l  p o t e n c y  o f  c o m p o u n d s  V , V I ,  a n d  
V I I I  a r e  in  a c c o r d  w i t h  t h i s  p r e d i c t i o n ,  w i t h  t h e  o r d e r  o f  
p o t e n c y  b e in g  V  >  V I  >  V I I I  >  V I I  ( T a b l e  I ) . S i m i la r ly ,
V  b o u n d  t o  m o r e  D N A  s e q u e n c e s  a n d  i n d u c e d  e x o  I I I  s t o p  
s i t e s  a t  lo w e r  c o n c e n t r a t io n s  t h a n  V I  o r  V I I I ,  w h i le  V I I  d id  
n o t  b o n d  t o  D N A .  C le a r ly ,  t h e  p r e s e n c e  o f  a n  e x o c y c l i c  
d o u b l e  b o n d  a t  C - 2  ( t o m a y m y c i n  a n d  V )  i m p r o v e s  b i o ­
lo g ic a l  p o t e n c y  o v e r  t h e  f u l ly  s a t u r a t e d  (V I )  o r  1 ,2 - d e h y d r o  
( V I I I )  c o m p o u n d s  w h i c h  l a c k  s u b s t i t u e n t s  o n  t h e  f i v e -  
m e m b e r e d  r in g .
C o m p u t e r  m o d e l in g  s t u d i e s  (25), a s  w e l l  a s  X - r a y  c r y s ta l  
s t r u c t u r e  d a t a  (44, 45), h a v e  i n d i c a t e d  t h a t  s a t u r a t i o n  in  
t h e  f i v e - m e m b e r e d  r in g  a f f e c t s  r in g  p u c k e r  a s  w e l l  a s  t h e  
t w i s t  o f  t h e  s e v e n - m e m b e r e d  d i a z e p i n e  r in g . V I  a n d  V I I I  
w e r e  f o u n d  t o  h a v e  a  la r g e r  o v e r a l l  m o le c u l a r  t w i s t  t h a n
V  (o r  t o m a y m y c in ) ,  w h i c h  m a y  a c c o u n t  fo r  t h e ir  r e d u c e d  
D N A  b o n d in g  a n d  b i o lo g i c a l  a c t i v i t y .  A l t h o u g h  t h e  f u l ly  
c o n ju g a te d  p y r r o lo  c o m p o u n d  (V I I )  h a s  n o  r in g  p u c k e r  a n d  
a  s m a l l  m o le c u l a r  t w i s t ,  i t  d o e s  n o t  b o n d  t o  D N A  a n d  is  
b i o l o g i c a l l y  i n a c t i v e .  T h i s  i s  m o s t  l i k e l y  d u e  t o  t h e  la c k  
o f  r e a c t i v i t y  o f  t h e  N - 1 0 - C - 1 1  im in e  w h e n  i t  i s  c o n j u g a t e d  
i n t o  t h e  p y r r o lo  r in g  (26) a n d  i s  in  a c c o r d  w i t h  t h e  la c k  
o f  b i o lo g i c a l  a c t i v i t y  o b s e r v e d  f o r  C l l a , C l - d i d e h y d r o s i -  
b i r o m y c i n o n e .3 W e  h a v e  a l s o  d e m o n s t r a t e d  a  la c k  o f  
b io lo g ic a l  a c t iv i t y  fo r  C l la ,C l - d i d e h y d r o a n t h r a m y c i n  (46).
T h e  p a ir  o f  e n a n t i o m e r s  ( X ,  X I )  a t  C l  l a  w e r e  s y n ­
t h e s i z e d  t o  e v a l u a t e  t h e  e f f e c t  o f  t h e  d i r e c t i o n  o f  t w i s t
3 We previously have called didehydrosibiromycin anhydrosibiromycin
(46). However, in view of the recently revised structure o f sibiromycin
(47), this should be now correctly named didehydrosibirom ycin.
Pyrrolo[1,4]benzodiazepine A ntitum or Antibiotics
along the length of the P(l,4)Bs on biological activity. The 
naturally occurring compounds (e.g., anthramycin, to­
maymycin) have an S  configuration at C lla , which imparts 
a right-handed twist (35° and 7°, respectively) along the 
length of the molecule. Presumably the right-handed twist 
is required for steric accommodation within the right- 
handed twist of B-form DNA (26). Although left-handed 
Z-DNA might accommodate the lla R  configuration of a 
P(1,4)B, the minor groove of Z-DNA is very shallow and 
is probably of insufficient depth to bind a left-handed 
P(1,4)B molecule. Only the l la S  enantiomer was found 
to bond to DNA and maintain in vivo biological activity. 
The small amount of in vitro activity observed with the 
lla i?  enantiomer (133-fold lower activity than l la S  en­
antiomer) is probably due to a low level of contamination 
with the l la S  enantiomer.
In summary, the results of this investigation establish 
that the exo III stop assay is predictive of in vitro and in 
vivo biological activity in the P(1,4)B series. This may 
prove useful to guide the design of future drugs in this 
series. Some of the SAR found in this study can be ra­
tionalized on the basis of the importance of the intercon­
version of the C - ll  carbinolamines via the N-10-C-11 
imine, a process that can be conveniently monitored by 
NMR (34). The relative importance of the saturation 
in the five-membered ring and the absolute requirement 
for the S  configuration at C lla  was demonstrated.
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pyrrolo[2,l-c][l,4]benzodiazepin-5-one, 116564-84-2; trifluoroacetic 
anhydride, 407-25-0; 2-amino-4,5-dimethoxybenzoic acid, 5653- 
40-7; 6,7-dimethoxy-2-(trifluoromethyl)-4//-l,3-benzoxazin-4-one, 
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iVjJV'-carbonyldiimidazole, 530-62-1; 6,7-dim ethoxy-2H -3,l- 
benzoxazine-2,4(l//)-dione, 20197-92-6; (S)-3,4-dehydroproline, 
4043-88-3; 7,8-dim ethoxy-3,10,ll,lla-tetrahydro-5H -pyrrolo- 
[2,l-c][l,4]benzodiazepine-5,ll-dione, 116564-90-0; 7,8-dimeth- 
oxy-3,10,11,1 la-tetrahydro-5-oxo-5ff-pyrrolo [2,1-c] [1,4] benzo- 
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116564-96-6; (llaR )-8-(benzyloxy)-7-m ethoxy-l,2 ,3 ,lla-tetra- 
hydro-5H-pyrrolo[2,l-c] [l,4]benzodiazepin-5-one, 116564-97-7.
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D N A  is believed to be the molecular target o f a 
number of clinically important antitum or antibiotics, 
including adriamycin, actinomycin D, bleomycin, and 
m itom ycin C. Based upon their diverse structural 
types, it is not surprising that these compounds have 
each been found to react in quite different ways with  
D N A  and that the biochemical consequences of D N A  
damage are equally diverse, although all can ultimately 
produce cell death. For example, while the planar ac- 
tinom ine m oiety of actinomycin D can intercalate be­
tween base pairs in D NA and is a very potent inhibitor 
of R N A  polymerase, bleomycin can form a unique 
molecular complex with DNA which in the presence of 
a divalent cation and molecular oxyen can result in a 
complex degradation of DNA.1 Other antitumor drugs 
such as m itom ycin C and cis-Pt cross-link D N A 1, and 
com pounds such as adriamycin and AM SA2 can form  
a ternary com plex with DNA, and D N A  binding pro­
teins such as topoisomerases, which may m ediate the 
potent biological effects o f these drugs.
Understanding the interactions between drugs such 
as those listed above and DNA is a necessary first step  
in elucidating the molecular basis for the potent anti- 
tumor activities o f these compounds. The availability 
of a number of techniques such as oligodeoxynucleotide 
synthesis, high-field NM R, and D NA sequencing has 
provided great im petus to the field o f drug-D N A  in­
teractions. For example, optimum binding sequences 
for D N A-reactive drugs can be determ ined by DNA- 
sequencing technology,3 and these sequences can then  
be synthesized in large enough am ounts by oligo­
deoxynucleotide synthesis technology so that their drug 
com plexes can be studied by high-field NM R. More 
recently, site-directed D N A  adducts have been made 
in much longer D NA sequences, including circular 
plasm ids, so that these can be subsequently used to  
evaluate the biochemical and biological consequences 
of structurally defined lesions on DNA.4 When these  
construction m ethods are used in combination with  
purified proteins such as those involved in DNA tran-
L aurence H. Hurley, born in the  United Kingdom, w as educated  a t the 
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scription, replication, or repair, then correlations be­
tween DN A  modification and biochemical and biolog­
ical consequences seem entirely possible. This is a great 
im provem ent upon previous experim ental strategy, 
where the type and site of modification was unknown  
and whole cell preparations were used to evaluate bio­
chemical and biological consequences.
For some years we have been studying the mechanism  
of action of the pyrrolo(l,4)benzodiazepines [P (l,4)B s] 
(Figure 1) and CC-1065. These compounds bind co­
valently to the minor groove of D N A  and exert ex­
trem ely potent biological effects. R ecent reviews on 
various aspects of the P (l,4 )B s5 and CC-10656 have 
appeared, and the reader is referred to these for in­
formation concerning chemistry, including synthesis 
and biosynthesis, and pharmacological and toxicological 
data.6,7 This Account will consider the mechanisms by 
which CC-1065 and the P (l,4 )B s associate and react 
covalently with DNA. In addition, stereochemical as­
pects of drug binding in the minor groove, m odes of 
DNA sequence recognition and selectivity, and possible 
reasons for their extremely high drug potencies will be 
described.
Several classes of DNA-reactive antineoplastic agents 
interact in some manner with the minor groove of B- 
form DNA. Adriamycin and actinomycin are stabilized 
upon intercalation by secondary noncovalent associa­
tions within the minor groove.7 N oncovalent D N A  
ligands such as distamycin and netropsin bind entirely
(1) Gale, E. F.; Cundliffe, E.; Reynolds, P. E.; Richmond, M. H.; 
Waring, M. J. The Molecular Basis of Antibiotic Action, 2nd ed.; Wiley: 
London, 1981.
(2) For a recent review on DNA topoisomerases as targets for cancer 
therapy, see: Ross, W. E. Biochem. Pharmacol. 1985, 34, 4191.
(3) For reviews on DNA sequence specificity of DNA binding drugs, 
see: Dobrowiak, J. C. Life Sci. 1983, 32, 2915. Wilkins, R, J. Mol. Cell. 
Biochem. 1984, 64, 111. Dervan, P. B. Science 1986, 232, 464.
(4) (a) Essigmann, J. M.; Green, C. L.; Croy, R. G.; Fowler, K. W.; 
Buchi, G. H.; Wogen, G. N. Cold Springs Harbor Symp. Quant. Biol. 
1982, 47, 327. (b) Johnson, D. L.; Reid, T. H.; Lee, M. S.; King, C. M.; 
Romano, L. J. Biochemistry 1986, 25, 449.
(5) For reviews on the P(l,4)Bs, see for biosynthesis: (a) Hurley, L. 
H. Acc. Chem. Res. 1980, 13, 263. For synthesis: (b) Thurston, D. E.; 
Hurley, L. H. CIPS 1983, 8, 957. More recent original papers: Kaneko, 
T.; Wong, H.; Doyle, T. W.; Rose, W. C.; Bradner, W. T. J. Org. Chem. 
1985, 28, 388. (d) Thurston, D. E.; Langley, D. L. J. Org. Chem. 1986, 
51, 705. (e) Suggs, J. W.; Wang, Y.-S.; Lee, K. S. Tetrahedron Lett. 1985, 
26, 4871. For pharmacological and toxicological aspects: (f) Hurley, L.
H. J. Antibiot. 1977, 30, 349. (g) Kohn, K. W. In Antibiotics III. 
Mechanism of Action of Antimicrobial and Antitumor Agents; Cocoran, 
J. W.; Hahn, F. E. Eds.; Springer: New York, 1975; pp 3-11.
(6) For a recent review on all aspects including chemistry, biosynthesis, 
synthesis, pharmacology, and toxicology of CC-1065, see: Reynolds, V. 
L.; McGovern, P. J.; Hurley, L. H. J. Antibiot. 1986, 39, 319.
(7) (a) Quigley, G. L.; Wang, A. M. J.; Ughetto, G.; van der Marel; G., 
von Boom, J. H.; Rich, A. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 7204. 
(b) Takusagawa, F.; Dabrow, M.; Neidle, S.; Berman, H. M. Nature 1982, 
296, 466.
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F ig u r e  1. S tru ctu res  o f  th e  P ( l,4 )B s ;  s ib irom y cin  (I), a n th ra m y cin  
(II), to m a y m y c in  (III), a n d  th e  n e o th r a m y cin s A  (IV a) a n d  B (IV b )  
(A ) a n d  C C -1 0 6 5  (B ).
w i t h i n  t h e  m i n o r  g r o o v e . 8 A  t h i r d  c l a s s  o f  a n t i n e o ­
p l a s t i c s  ( t h a t  w i t h  w h i c h  t h i s  A c c o u n t  i s  c o n c e r n e d )  
b i n d  c o v a l e n t l y  w i t h i n  t h e  m i n o r  g r o o v e  o f  B - f o r m  
D N A .  M e m b e r s  o f  t h i s  l a t t e r  g r o u p  o f  c o m p o u n d s  i n ­
c l u d e  C C - 1 0 6 5 ,  t h e  s a f r a m y c i n s ,9 n a p h t h r i d i n o m y c i n , 10 
a n d  t h e  P ( l , 4 ) B s .  T h e  l a t t e r  t h r e e  g r o u p s  c o n t a i n  t h e  
D N A - r e a c t i v e  c a r b i n o l a m i n e  o r  i t s  c h e m i c a l  e q u i v a l e n t .  
T h e  c o v a l e n t  m i n o r  g r o o v e  b i n d e r s  h a v e  b e e n  o b s e r v e d  
t o  b e  1 0 2 t o  1 0 3 t i m e s  m o r e  p o t e n t  a s  a n t i t u m o r  a g e n t s  
t h a n  t h o s e  o f  t h e  i n t e r c a l a t i n g  c l a s s ,  w h i l e  t h e  l a t t e r  
a g e n t s  p o s s e s s  s i g n i f i c a n t l y  g r e a t e r  p o t e n c y  t h a n  t h e  
n o n c o v a l e n t  m i n o r  g r o o v e  b i n d e r s . 11
E lu c id a t io n  o f  th e  C o v a le n t  D r u g -D N A  A d d u c t  
S tr u c t u r e s
A  v i g o r o u s  d e m o n s t r a t i o n  o f  t h e  p o i n t s  o f  c o v a l e n t  
a t t a c h m e n t  b e t w e e n  b o t h  t h e  P ( l , 4 ) B s  a n d  C C - 1 0 6 5  
a n d  D N A  w a s  a n  e s s e n t i a l  f i r s t  s t e p  in  i n v e s t i g a t i n g  t h e  
s t r u c t u r a l  a n d  b i o l o g i c a l  c o n s e q u e n c e s  o f  D N A  m o d i ­
f i c a t i o n .  F o r  b o t h  g r o u p s  o f  d r u g s ,  a  s e r ie s  o f  s t e p s  w e r e
(8) Kopka, M.; Yoon, C.; Goodsell, D.; Pjura, P.; Dickerson, R. E. Proc. 
Natl. Acad. Sci. U.S.A. 1985, 82, 1376.
(9) Lown, J. W.; Joshua, A. V.; Lee, J. S. Biochemistry 1982, 27, 419.
(10) Zmijewski, M. J., Jr.; Miller-Hatch, K.; Mikolajczak, M. Chem. 
Biol. Interact. 1985, 52, 361.
(11) In the stem cell assay system CC-1065 is 600 to lOOOx more potent 
than adriamycin. P(l,4)Bs are about lOx (sibiromycin) to lOOx (tomay­
mycin) less potent than CC-1065. Bhuvan, B. K.; Newell, K. A.; 
Crampton, S. L.; Von Hoff, D. D. Cancer Res. 1982, 42, 3532.
Co
F i g u r e  2 . P rop osed  m ech an ism  for a lkylation  o f DNA by I 
P ( l ,4 )B s  to  form  th e  P (l,4 )B -(N 2 -g u a n in e )D N A  adduct.
u n d e r t a k e n  t o  f i r s t  e s t a b l i s h  t h a t  D N A  w a s  t h e  primat 
t a r g e t  a n d  t h e n  g a i n  c i r c u m s t a n t i a l  a n d  f i n a l ly  unat 
b i g u o u s  s t r u c t u r a l  i n f o r m a t i o n  o n  t h e  D N A  addur 
s t r u c t u r e s .
S t r u c t u r e s  o f  th e  P (1 ,4 )B -D N A  A d d u c ts
C o v a l e n t  b i n d i n g  o f  t h e  P ( l , 4 ) B s  t o  d u p l e x  D N A  to 
f i r s t  s u g g e s t e d  b y  t h e  s t a b i l i t y  o f  d r u g - D N A  complexe 
t o  e t h a n o l  p r e c i p i t a t i o n  o r  d i a l y s i s . 12 I n  contras: 
s i m i l a r  s t a b i l i t y  e x p e r i m e n t s  f o l l o w i n g  d r u g  incubation1 
w i t h  R N A ,  p r o t e i n ,  o r  d e n a t u r e d  D N A  d i d  n o t  shot 
e v i d e n c e  o f  c o v a l e n t  b i n d i n g . 12 S u b s e q u e n t  experiment 
r e v e a l e d  t h a t  t h e  P ( l , 4 ) B s  f o r m  D N A  a d d u c t s  whici 
s i g n i f i c a n t l y  i n c r e a s e  t h e  D N A  h e l i x  m e l t i n g  tempers 
t u r e ,  d o  n o t  c a u s e  u n w i n d i n g  o f  s u p e r c o i l e d  I  
p r o d u c e  s h i f t s  i n  c i r c u l a r  d i c h r o i s m  s p e c t r a ,  a n d  indue 
b a t h o c h r o m i c  s h i f t s  i n  t h e  a b s o r b a n c e  m a x i m a  of tk 
d r u g  c h r o m o p h o r e s . 5f’13
I n d i r e c t  e v i d e n c e  f o r  t h e  s t r u c t u r e s  o f  t h e  P(1,4)B 
D N A  a d d u c t s  w a s  o b t a i n e d  b y  r e a c t i o n  o f  t h e s e  agent 
w i t h  s y n t h e t i c  D N A  p o l y m e r s . 13,14 I n  p a r t ic u la r ,  
i n a b i l i t y  o f  a n t h r a m y c i n  t o  f o r m  a  c o v a l e n t  a d d u c t  wit; 
p o l y ( d I ) - p o l y ( d C )  c o n t r a s t e d  w i t h  i t s  a v i d  binding!; 
p o l y ( d G ) - p o l y ( d C ) . 13 D e n a t u r i n g  a l k a l i n e  c e s iu m  sui 
f a t e  g r a d i e n t  c e n t r i f u g a t i o n  o f  t h e  l a t t e r  s p e c i e s  den 
o n s t r a t e d  t h a t  t r i t i a t e d  d r u g  c h r o m o p h o r e  w a s onl; 
a s s o c i a t e d  w i t h  t h e  p o l y ( d G )  s t r a n d . 14 T a k e n  togethe: 
t h e s e  r e s u l t s  s u g g e s t e d  t h a t  a n t h r a m y c i n  b in d s  cow 
l e n t l y  i n  t h e  m i n o r  g r o o v e  o f  D N A  t h r o u g h  N2 
g u a n i n e .
F u r t h e r  e v i d e n c e  f o r  c o v a l e n t  m in or  g r o o v e  DNA 
b i n d i n g  w a s  o b t a i n e d  f r o m  e x p e r i m e n t s  i n  w h ic h  it wi 
d e m o n s t r a t e d  t h a t  a n t h r a m y c i n  b i n d s  c o v a le n t ly !  
c o l i p h a g e  T 7  D N A ,  w h i c h  h a s  e x t e n s i v e  g lucosylatio: 
i n  t h e  m a j o r  g r o o v e . 15 T h e  p o s s i b i l i t y  o f  covaler 
b i n d i n g  t h r o u g h  N - 7  o r  C - 8  o f  g u a n i n e  w a s  furthc: 
e l i m i n a t e d  b y  e x p e r i m e n t s  i n  w h i c h  i n c u b a t i o n  of (A 
3H ) - g u a n i n e - l a b e l e d  D N A  w i t h  a n t h r a m y c i n  did  
s h o w  l o s s  o f  t r i t i u m . 14 F i n a l l y ,  m e l t i n g  o f  t h e  E 
s t r a n d s  i n  P ( 1 , 4 ) B - D N A  a d d u c t s  b y  h e a t  ( 1 0 0  °C fc: 
5  m i n )  r e l e a s e d  c h e m i c a l l y  u n c h a n g e d  d r u g  from  tk 
D N A . 12a
C o l l e c t i v e l y ,  t h e s e  r e s u l t s  s u g g e s t  t h a t  t h e  P(1,4)B; 
b i n d  c o v a l e n t l y  t o  g u a n i n e ,  a n d  f u r t h e r m o r e  sp e c if ic #  
t h r o u g h  t h e  e x o c y c l i c  2 - a m i n o  g r o u p ,  w h i c h  reside; 
w i t h i n  t h e  m i n o r  g r o o v e  o f  B  f o r m  D N A . 14,15 T h e  sta­
b i l i t y  o f  t h e  N - g l y c o s i d i c  l i n k a g e  o f  t h e  c o v a l e n t  mod
(12) (a) Hurley, L. H.; Gairola, C.; Zmijewski, M. Biochim. Biopk 
Acta 1977, 475, 521. (b) Kohn, K. W.; Spears, C. L. J. Mol. Biol.
51, 551.
(13) Kohn, K. W.; Glauhiger, D.; Spears, C. L. Biochim. Biophys.ki 
1974, 361, 288.
(14) Petrusek, R. L.; Anderson, G. L.; Garner, T. F.; Fannin, Q.L 
Kaplan, D. J.; Zimmer, S. G.; Hurley, L. H. Biochemistry  1981.20,1111
(15) Hurley, L. H.; Petrusek, Ft. L. N ature  1979, 282, 529.
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ified guanine to acid and alkaline hydrolysis is con­
sistent with alkylation at N2 of guanine, which does not 
disturb the purine aromaticity. DNA-binding experi­
m ents using structural analogues of the P (l,4 )B s which 
lack the carbinolam ine or its chem ical equivalent 
(N10,C11 imine or 11-alkyl ethers) failed to yield co­
valent DNA adducts,16 providing the first evidence that 
this functionality is the DNA-reactive moiety. Several 
reaction mechanisms which would lead to formation of 
an aminal linkage between C l l  of the P(1,4)B  and N2  
o f guanine were proposed,5f including nucleophilic at­
tack on the carbinolamine or the imine. As described  
later, the imine intermediate is favored as the ultimate 
D NA-reactive species17 (Figure 2). Last, the facile 
hydrolysis o f P (1 ,4)B -D N A  adducts following D N A  
m elting under neutral or acidic conditions, but not 
under basic conditions, is consistent w ith an aminal 
linkage (N -C -N ) from the drug carbinolamine carbon 
(C -ll)  to  N 2 of guanine.
1H and 13C N M R experim ents provided direct evi­
dence for the covalent linkage sites between the P-
(l,4 )B s and DNA. Anthramycin specifically enriched 
with carbon-13 at C - ll  was bound to calf thymus DNA  
and analyzed by 13C N M R .18 Upon covalent binding  
to  DNA, a 16 ppm upfield shift was observed for C - l l  
o f anthram ycin relative to an th ram ycin-ll-m ethyl 
ether, which is consistent with the carbinolamine carbon 
of anthramycin being the point of covalent attachment 
to  D N A . Additionally, the carbon-13 chem ical sh ift 
observed for C - l l  upon binding to D N A  agreed w ith  
m odel com pounds for the form ation o f an am inal 
linkage at C - l l  from the drug carbinolamine to  N 2 of 
guanine. Confirmation that N 2 of guanine was the  
point at which DNA was covalently bound to the drug 
was obtained from 1H N M R  studies on the anthramy- 
cin-5/(ATGCAT)2 oligomer adduct.18
Structure of the CC-1065-DNA Adduct
Similar studies to  those described for the P (l,4 )B s  
em ploying various cellular macromolecules such as 
RNA, protein, and synthetic or natural DNAs were used 
to dem onstrate that covalent binding occurred exclu­
sively to D N A  and subsequently to pinpoint the loca­
tion of CC-1065 binding to DN A .19 CC-1065 was shown 
to bind most avidly to synthetic poly(dA)-poly(dT), less 
avidly to poly(dA-dT)-poly(dA-dT), and did not bind  
covalently to poly(dG)-poly(dC) or poly(dG-dC)-poly- 
(dG-dC).20 CC-1065 was able to  prevent binding of  
netropsin to calf thym us D N A  and could also displace 
prebound netropsin from D N A .20 CC-1065, like an­
thramycin, binds strongly to phage T7 D N A . These  
results suggested that CC-1065 binds covalently in the  
minor groove of B-form D N A  to AT-rich regions.20 
When CC-1065 calf thymus DNA adducts were heated  
and butanol extracted, the organic phase was found to
(16) Horwitz, S. B.; Chang, S. C.; Grollman, A. P.; Borbovec, A. B. 
Science 1981, 147, 159.
(17) We have previously suggested (5f) that at least in the case of 
sibiromycin the NlO.Cll imine cannot be the ultimate DNA reactive 
species. However, recent 'H NMR experiments on natural sibiromycin 
lead us to seriously question this postulate.
(18) Graves, D. E.; Pattaroni, C.; Balakrishnan, C.; Ostrander, J. M.; 
Hurley, L. H.; Krugh, T. R. J. Biol. Chem. 1984, 259, 8202.
(19) Li, L. H.; Swenson, D. H.; Schpok, S. L. F.; Kuentzel, S. L.; 
Dayton, B. D.; Krueger, W. C. Cancer Res. 1982, 42, 999.
(20) Swenson, D. H.; Li, L. H.; Hurley, L. H.; Rokem, J. S.; Petzold,
G. L.; Dayton, B. D.; Wallace, T. L.; Lin, A. H.; Krueger, W. C. Cancer
Res. 1982, 42, 2821.
■o c h ,
F igu re 3. Reaction of CC-1065 to form the CC-1065-(N3- 
adenine)DNA adduct and the products of thermal cleavage of the 
CC-1065-DNA adduct.
contain a chromophore similar to CC-1065 which could 
be isolated by RP-HPLC, but which did not comigrate 
with CC-1065.21 In similar experim ents, but using  
D N A  which was prelabeled with tritiated adenine, 
guanine, cytosine, or thym ine, only butanol extraction  
of the CC-1065-[(3H)-adenine] D NA produced fractions 
containing excess tritum. The excess radioactivity was 
found to  comigrate with the m odified CC-1065 chre- 
mopore in the RP-HPLC system .21 Thus adenine 
seem ed a likely candidate for the base m odified by  
CC-1065. T he sole adenine nucleophile in the minor 
groove is N-3. Since alkylation of N-3 of adenine alters 
the aromaticity of the base, this would explain the base 
loss observed upon thermal treatment of CC-1065-DNA  
adducts. These observations allowed tentative identi­
fication of N-3 of adenine as the CC-1065 binding site  
on D N A . T he identity o f the C C-1065-DNA adduct 
linkage was determined by and 13C NM R studies on  
the CC-1065-adenine adduct, which was isolated as 
described before.21 The isolated species proved to be  
adenine alkylated at the N-3 position by the methylene 
carbon (C-4) of the cyclopropyl ring of the “A-subunit” 
of CC-1065 (Figure 3).
Stereochemistry at the Linkage Site and 
Orientation of Drug Molecules in the Minor 
Groove of DNA
Two possible P(1,4)B -D N A  adducts, which differ in 
the stereochemistry at the anthramycin C11-N2 guanine 
linkage site (i.e., 1LR or U S )  and also have opposite  
drug orientations in the minor groove relative to the  
covalently modified guanine, can theoretically result 
from alkylation of DNA by the P (l,4 )B s. T he adduct 
orientation in which the aromatic ring of the drug lies 
to the 3' side of the modified guanine is associated with  
a linkage stereochemistry of WS ” at C - ll , while the op­
posite drug orientation produces the reverse configu­
ration at C -ll. Molecular modeling studies carried out 
by Remers et al.22 using the united atom force-field  
parameters of AM BER (Assisted Model Building with  
Energy Refinem ent) on anthramycin and tom aym y- 
cin-d(A TG C A T)2 adducts suggested that these drugs 
might differ in their abilities to orient themselves in one 
or both possible adduct orientations in the minor 
groove. For tomaymycin, there is only a relatively small 
difference (2.3 kcal/m ole) between the energy levels o f  
the two possible orientations, whereas for anthramycin 
over a four-fold higher energy level difference (10.8
(21) Hurley, L. H.,; Reynolds, V. L.; Swenson, D. H.; Petzold, G. L.; 
Scahill, T. A. Science 1984, 226, 843.
(22) Remers, W. A.; Nlabilia, M.; Hopfinger, A. C. J. M ed. Chem., in 
revision.
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CATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACC T 
GTAC6AAACGTATGAAGACGGAC6ACCCCTCGGACCCCTGAAAGGTGT6





CTC6GACCCCTGAAAGGTGTGGC t\TTGACTGTGTGTAAGGTGTCG 5 '
I  f t  
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F ig u r e  4. D N A  sequence sp ecific ity  o f  CC-1065 w ith in  th e  early prom oter region o f SV 40. R estriction  enzym e fragm ents were single 
end-labeled  w ith  32P  and incub ated  w ith  CC-1065 and th en  h eated  under standard cond itions to  produce D N A  strand breakage. The 
♦ s show  the C C -1065-adenine covalent binding sites and the num ber o f  ind icate the relative sensitiv ity  to  strand breakage by CC-1065. 
e.g., ♦  ♦ and ♦ ♦ ♦ are 1:102 and 1:103 d ilu tions, respectively , o f a stock  solution  o f  CC-1065 which are the m axim um  dilutions at which 
stran d  breakage is still observed. I-T A T A  box; II', II" and IH "'-21 base rep eat regions; III' and III"-72 base repeat regions/
k c a l / m o l e )  i s  c a l c u l a t e d  b e t w e e n  o p p o s i t e  o r i e n t a t i o n s .  
T h e s e  p r e d i c t i o n s  a r e  s u p p o r t e d  b y  t h e  r e s u l t s  o f  
b i n d i n g  s t u d i e s  o f  P ( l , 4 ) B s  w i t h  s y n t h e t i c  o l i g o m e r s .  
F l u o r e s c e n c e  s t u d i e s  s u g g e s t  s t r o n g l y  t h a t  t o m a y m y c i n  
b i n d s  i n  t w o  o r i e n t a t i o n s  t o  c a l f  t h y m u s  D N A . 23 I n  
c o n t r a s t ,  a n t h r a m y c i n  w a s  s h o w n  t o  b i n d  i n  o n l y  o n e  
o r i e n t a t i o n  (1  I S )  r e l a t i v e  t o  t h e  c o v a l e n t l y  m o d i f i e d  
s t r a n d  o f  t h e  o l i g o m e r  5 / ( A T G C A T ) 2.24 S i g n i f i c a n t l y ,  
t h e  m o l e c u l a r  m e c h a n i c s  c a l c u l a t i o n s  b y  A M B E R  a r e  
p r e d i c t i v e  o f  t h e  c o r r e c t  a n t h r a m y c i n  o r i e n t a t i o n  o n  
5 ' ( A T G C A T ) 2.22-24
C C - 1 0 6 5  h a s  t w o  c h i r a l  c e n t e r s  w h i c h  a r e  l o c a t e d  a t  
t h e  c y c l o p r o p y l  r in g  j u n c t i o n s ,  C - 3 b  a n d  C - 4 a .  O n l y  t h e  
r e l a t i v e  c o n f i g u r a t i o n s  a t  C - 3 b  a n d  C - 4 a  o f  C C - 1 0 6 5  
w e r e  d e t e r m i n e d  b y  X - r a y  c r y s t a l l o g r a p h i c  a n a l y s i s . 25 
C P K  m o d e l i n g  s t u d i e s  s h o w e d  t h a t  n u c l e o p h i l i c  a t t a c k  
b y  N - 3  o f  a d e n i n e  u p o n  t h e  m e t h y l e n e  c a r b o n  ( C - 4 )  o f  
t h e  C C - 1 0 6 5  c y c l o p r o p y l  r i n g  m u s t  r e s u l t  i n  a  d r u g -  
D N A  a d d u c t  w i t h  t h e  b u l k  o f  t h e  C C - 1 0 6 5  m o l e c u l e  
l y i n g  e i t h e r  t o  t h e  5 '  o r  t h e  3 '  s i d e  o f  t h e  c o v a l e n t l y  
m o d i f i e d  a d e n i n e ,  d e p e n d e n t  u p o n  t h e  a b s o l u t e  s t e r e ­
o c h e m i s t r y  a t  C - 3 b .  I t  w a s  p r o p o s e d  t h a t  i f  C C - 1 0 6 5  
e x h i b i t s  a  s e q u e n c e  s e l e c t i v i t y  i n  b i n d i n g ,  t h e  d i r e c ­
t i o n a l i t y  o f  t h i s  s p e c i f i c i t y  w o u l d  r e v e a l  t h e  a b s o l u t e  
c o n f i g u r a t i o n  o f  t h e  a d d u c t ,  a n d  b y  i n f e r e n c e ,  t h e  a b ­
s o l u t e  s t e r e o c h e m i s t r y  o f  C C - 1 0 6 5  ( s e e  l a t e r ) .
(23) Barkley, M.; Cheatham, S.; Thurston, D. E.; Hurley, L. H. Bio­
chem istry ,  1986, 25, 3021.
(24) Graves, D. E.; Stone, M. P.; Krugh, T. R. B iochem is tr \  1985, 24, 
1573.
(25) Chidester, C. G.; Krueger, W. C.; Mizak, S. A.; Duchamp, D. J.;
M artin, D. G. J. Am. Chem. Soc. 1981, 103, 7629.
D e te r m in a t io n  o f  B in d in g  S e q u e n c e  Specificity  
fo r  C C-1065 a n d  th e  P ( l ,4 ) B s
C P K  m o d e l  b u i l d i n g  s t u d i e s  w i t h  b o t h  C C -1 0 6 5  and 
t h e  P ( l , 4 ) B s  s h o w e d  c l o s e  v a n  d e r  W a a l s  c o n t a c t s  be­
t w e e n  t h e  f lo o r  o f  t h e  m i n o r  g r o o v e  o f  B - f o r m  D N A  and 
t h e  c o n c a v e  e d g e s  o f  t h e  d r u g  m o l e c u l e s .  T h e s e  studies 
w e r e  s u g g e s t i v e  o f  a  D N A  s e q u e n c e  s p e c i f i c i t y  extend­
i n g  f o r  t h e  l e n g t h  o f  t h e  o v e r l a p  b e t w e e n  t h e s e  minor 
g r o o v e  b i n d i n g  a g e n t s  a n d  D N A .  B y  n e c e s s i t y ,  two 
d i f f e r e n t  m e t h o d s  w e r e  u s e d  t o  i n v e s t i g a t e  t h e  sequence 
s p e c i f i c i t y  o f  C C - 1 0 6 5  a n d  t h e  P ( l , 4 ) B s ,  b u t  b o th  in­
v o l v e d  t h e  u s e  o f  a  m o d i f i e d  M a x a m - G i l b e r t  D N A  se­
q u e n c i n g  m e t h o d .
F o r  C C - 1 0 6 5 ,  s u p e r c o i l e d  c i r c u l a r  D N A  m olecules I 
( F I )  w e r e  s h o w n  t o  u n w i n d  t o  r e l a x e d  c ir c u la r  m olecules ' 
( F I I )  f o l l o w i n g  t h e r m a l  t r e a t m e n t  ( 9 0  ° C ,  3 0  m in ) of J 
C C - 1 0 6 5 - F I - S V 4 0  D N A  a d d u c t s . 20 S u b s e q u e n t  exper­
i m e n t s  u s i n g  s i n g l y  o' o r  3 ' - 32P  e n d - l a b e l e d  D N A  re­
s t r i c t i o n  f r a g m e n t s  s h o w e d  t h a t  t h e r m a l  t r e a t m e n t  of 
C C - 1 0 6 5 - D N A  a d d u c t s  r e s u l t s  i n  a  s i n g l e  strand 
b r e a k a g e  e v e n t  a t  t h e  3 '  s i d e  o f  t h e  a d e n i n e  covalent 
a t t a c h m e n t  s i t e  ( F i g u r e  3 ) . 26 C C - 1 0 6 5 - D N A  binding 
s e q u e n c e s  w e r e  d e t e r m i n e d  o n  M a x a m - G i l b e r t  se­
q u e n c i n g  g e l s  b y  l o c a t i n g  C C - 1 0 6 5  t h e r m a l l y  induced 
D N A  s t r a n d  b r e a k s  o n  s i n g l e  S ' - 32?  e n d - l a b e l e d  DNA 
r e s t r i c t i o n  e n z y m e  f r a g m e n t s  i s o l a t e d  f r o m  t h e  early 
p r o m o t e r  r e g i o n  o f  S V 4 0  D N A 26 ( F i g u r e  4 ) .  Analysis 
o f  t h e  d a t a  f r o m  F ig u r e  4 ,  a s  w e l l  a s  f r a g m e n t s  from T i  
D N A ,  l e d  t o  t h e  i d e n t i f i c a t i o n  o f  t w o  s u b s e t s  o f  se-
(26) Reynolds, V. L.; M olineux, I. J.; Kaplan, D. J.; Swenson, D. H,; 
Hurley, L. H. Biochemistry  1985, 24, 6228.
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F i g u r e  6. Stereodiagrams of the anthramycin-d(ATGCAT)2 
duplex adduct.
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a) A n th ram yc in
b) T o m a y m y c in
Figure 5. H istogram s o f M P E -F e(II) footprints o f A nthram ycin  
(a) and T om aym ycin  (b) on o p p osite  strand s o f  a 241 base pair  
D N A  fragm ent. L ess than 100% cleavage indicates areas o f drug 
protection w hereas greater than 100% cleavage indicates regions 
o f drug-induced  enhan ced  cleavage o f  D N A .28
q u e n c e s ,  5 ' P u N T T A  ( P u  =  P u r i n e ,  N  =  a n y  b a s e )  a n d  
5 ' A A A A A ,  w h i c h  a r e  p r e f e r r e d  C C - 1 0 6 5  b i n d i n g  r e g i o n s ,  
w i t h  t h e  3 '  t e r m i n a l  a d e n i n e  o f  e a c h  o f  t h e  s e q u e n c e s  
c o v a l e n t l y  m o d i f i e d  b y  C C - 1 0 6 5 .  S i n c e  t h i s  m a r k e d  
s e q u e n c e  s p e c i f i c i t y  l i e s  s o l e l y  t o  t h e  5 '  s i d e  o f  t h e  c o ­
v a l e n t l y  m o d i f i e d  a d e n i n e ,  t h e  a b s o l u t e  s t e r e o c h e m i s t r y  
o f  C C - 1 0 6 5  m u s t  b e  3 b - /? ,  4 a - S  ( s e e  b e f o r e ) .
M o r e  i n d i r e c t  m e t h o d s  f o r  d e t e r m i n a t i o n  o f  t h e  P -
( 1 , 4 ) B  p r e f e r r e d  b i n d i n g  s e q u e n c e s  w e r e  r e q u i r e d ,  b e ­
c a u s e  t h e s e  d r u g s  d o  n o t  g e n e r a t e  D N A  s t r a n d  b r e a k s  
u n d e r  a l k a l i n e  o r  t h e r m a l  c o n d i t i o n s . 14 A  D N A  f o o t -  
p r i n t i n g  m e t h o d  u s i n g  m e t h i d i u m  p r o p y l - E D T A - F e ( I I )  
[ M P E - F e ( I I ) ] 27 o n  s i n g l y  5 ' - 32P  e n d - l a b e l e d  D N A  re*- 
s t r i c t i o n  f r a g m e n t s  w a s  u s e d  t o  i d e n t i f y  t h e  P ( 1 , 4 ) B  
c o n s e n s u s  b i n d i n g  s e q u e n c e s . 28 M P E - F e ( I I )  c u t s  u n ­
m o d i f i e d  D N A  f a i r l y  r a n d o m l y ,  b u t  t h e  p r e s e n c e  o f  
d r u g  m o l e c u l e s  i n h i b i t s  M P E - F e ( I I )  c u t t i n g ,  a n d  a  
“ f o o t p r i n t ” a p p e a r s  o n  e l e c t r o p h o r e t i c  g e l s  w h e r e  d r u g  
m o l e c u l e s  a r e  b o u n d .  T h e  f o o t p r i n t i n g  r e s u l t s  s h o w n  
in  F ig u r e  5  a r e  d e r i v e d  f r o m  a  p o r t i o n  o f  a  2 4 1  b a s e  p a ir  
f r a g m e n t  w h i c h  w a s  s u b j e c t e d  t o  M P E - F e ( I I )  f o o t -  
p r i n t i n g  a n a l y s i s  o n  s i n g l y  5 '  e n d - l a b e l e d  D N A  m o l e ­
c u l e s  t o  w h i c h  e i t h e r  a n t h r a m y c i n  o r  t o m a y m y c i n  h a d  
b e e n  b o u n d .  T h e  3 '  o f f s e t  o f  t h e  f o o t p r i n t s  o n  o p p o s i t e  
s t r a n d s  h a s  b e e n  p r e v i o u s l y  o b s e r v e d  a n d  c a n  b e  r a ­
t i o n a l i z e d  o n  t h e  h a s i s  o f  a s y m m e t r i c  p r o t e c t i o n  o f  t h e  
D N A  f r o m  M P E - F e ( I I )  d i g e s t i o n . 29 F o o t p r i n t i n g  e x -
F ig u r e  7. Stereodraw ings o f the C C -1065-D N A  adduct. Key: 
A, B, and C are the subunits o f CC-1065; A' is the adenine covalent 
binding site  for CC-1065; B' is a pair o f highly conserved bases 
im m ed iately  to  th e  5 ' side o f  aden in e covalen t binding site; C' 
is a pair o f less w ell conserved bases at the 5' end o f CC -1065  
binding site . T h e  base seq u en ce  from  top  to  b ottom  is 5' 
C G G A G T T A G G  3'.
p e r i m e n t s  s h o w e d  t h a t  t h e  P ( 1 , 4 ) B  a n t i b i o t i c s  b i n d  
m o s t  a v i d l y  t o  5 ' P u G P u  ( P u  =  P u r i n e )  s e q u e n c e s ,  a n d  
l e a s t  r e a d i ly  t o  5 T y G P y  ( P y  =  P y r i m i d i n e )  s e q u e n c e s . 28
P r e p a r a t io n  o f  S te r e o d ia g r a m s  fo r  C C-1065 a n d  
th e  P (1 ,4 )B -D N A  A d d u c ts
T h e  i n v e s t i g a t i o n  d e s c r i b e d  a b o v e  a l l o w e d  i d e n t i f i ­
c a t i o n  o f  t h e  f o l l o w i n g  c r i t i c a l  p a r a m e t e r s  f o r  t h e  r e ­
a c t i o n  o f  C C - 1 0 6 5  a n d  t h e  P ( l , 4 ) B s  w i t h  D N A :  ( a )  t h e  
c h e m i c a l  i d e n t i t i e s  o f  t h e  c o v a l e n t  l i n k a g e s ,  ( b )  d r u g  
o r i e n t a t i o n s  a n d  s t e r e o c h e m i s t r i e s  r e l a t i v e  t o  t h e  c o ­
v a l e n t  l i n k a g e ,  a n d  (c )  t h e  p r e f e r r e d  b i n d i n g  s e q u e n c e s  
o f  t h e  d r u g s .  T h i s  i n f o r m a t i o n ,  c o m b i n e d  w i t h  t h e  
X - r a y  c r y s t a l l o g r a p h i e  c o o r d i n a t e s  o f  B - f o r m  D N A ,  
a n t h r a m y c i n , 30 a n d  C C - 1 0 6 5 25 w a s  u t i l i z e d  t o  g e n e r a t e  
s t e r e o d i a g r a m s  o f  t h e  C C - 1 0 6 5  a n d  a n t h r a m y c i n - D N A  
a d d u c t s  u s i n g  m o l e c u l a r  g r a p h i c s  ( F i g u r e s  6  a n d  7 ) .  
M o l e c u l a r  m o d e l i n g  h a s  a l l o w e d  u s  t o  r e f i n e  o u r  u n ­
d e r s t a n d i n g  o f  t h e s e  d r u g - D N A  i n t e r a c t i o n s ,  a n d  t o  
p o s t u l a t e  m e c h a n i s m s  f o r  D N A  s e q u e n c e  “ r e c o g n i t i o n ” 
a n d  c o v a l e n t  b i n d i n g  t o  D N A  b y  C C - 1 0 6 5  a n d  t h e  P -
( l , 4 ) B s .
5TTTQ TA Q A 00TTTTA C TT0C T T T A A A A A A C C T C C C A C A C C T C C C C C T Q A A C C T Q A A A C 3'
3AAACATCTCCAAAATQAACQAAATTTTTTQQAQOQTQTC3GAOQOQQACTTOQACTTTQ8-I I H I I I I P f l
(27) Van Dyke, M. W., Hertzberg, R. P., Dervan, P. B. Proc. Natl.  
Acad. Sci. U.S.A.  1982, 79, 5470.
(28) Hertzberg, R. P.; H echt, S. M.; Reynolds, V. L.; M olineux, I. J.;
Hurley, L. H. Biochemistry  1986, 2.5, 1249.
(29) Van Dyke, M. W. and Dervan, P. B. Void Spring Harbor S ym p .  
Quant. Biol. 1982. 47, 34".
(30) (a) Mostad, A.; Romming, C.; Storm, B. Acta Chem. Scand. Ser. 
B. 1978, 32, 639. (b) Arora. S. K. Acta Cryst.  1979. R35, 2945.
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M e c h a n is m s  fo r  C o v a le n t  B in d in g  o f  CC-1065  
a n d  th e  P ( l ,4 ) B s  in  th e  M in o r  G roove o f  D N A .
A l t h o u g h  C C - 1 0 6 5  a n d  t h e  P ( l , 4 ) B s  b i n d  w i t h i n  t h e  
m i n o r  g r o o v e  o f  D N A ,  t h e y  e x h i b i t  m a r k e d  d i f f e r e n c e s  
i n  t h e i r  m e c h a n i s m s  o f  c o v a l e n t  b i n d i n g ,  a n d  c o n s e ­
q u e n t l y  f o r m  d i s t i n c t l y  d i f f e r e n t  c o v a l e n t  a d d u c t s .  T h e  
r e a c t i o n  o f  t h e  P ( l , 4 ) B s  w i t h  D N A  i s  p o s t u l a t e d  t o  
o c c u r  b y  s t e p w i s e  d e h y d r a t i o n  o f  t h e  c a r b i n o l a m i n e  a t  
C - l l  t o  t h e  i m i n e  s p e c i e s ,  w h i c h  i s  t h e n  s u s c e p t i b l e  t o  
n u c l e o p h i l i c  a t t a c k  b y  N 2  o f  g u a n i n e  w i t h i n  t h e  m i n o r  
g r o o v e 23 ( F i g u r e  2 ) .  T h e  e v i d e n c e  f o r  t h i s  i s  i n d i r e c t  
b i d  i s  b a s e d  u p o n  t h e  a b i l i t y  o f  t h e  P ( l , 4 ) B s  a n d  s o l ­
v e n t  a n i o n s  t o  f o r m  a d d i t i o n  p r o d u c t s  a t  C - l l ,  p r e ­
s u m a b l y  m e d i a t e d  b y  i m i n e  f o r m a t i o n .  P r i m a r y  e v i ­
d e n c e  f o r  s o l v e n t  i n t e r a c t i o n  w i t h  t h e  P ( l , 4 ) B s  s t e m s  
f r o m  13C  N M R  s t u d i e s ,  i n  w h i c h  t h e  ( l l . R , l l a S )  d i a -  
s t e r e o m e r  o f  t o m a y m y c i n  w a s  o b s e r v e d  t o  u n d e r g o  e p -  
i m e r i z a t i o n  a t  C - l l  o v e r  s e v e r a l  h o u r s  i n  13C H 3O H . 23 
F u r t h e r m o r e ,  d i s s o l u t i o n  o f  t o m a y m y c i n  m e t h y l  e t h e r  
i n  c h l o r o f o r m  y i e l d e d  t h e  N 1 0 - C 1 1  i m i n e  s p e c i e s ,  w h i c h  
w a s  r e c o n v e r t e d  t o  t h e  c a r b i n o l a m i n e  1 1 - m e t h y l  e t h e r s  
w h e n  r e d i s s o l v e d  i n  m e t h a n o l . 23 T h i s  s u g g e s t s  t h a t  
t h e s e  d r u g s  m a y  a l s o  r e a c t  w i t h  b i o l o g i c a l  n u c l e o p h i l e s  
( i . e .  p r o t e i n ,  R N A ,  a n d  o t h e r  D N A  n u c l e o p h i l e s ) ,  b u t  
i n  t h e  a b s e n c e  o f  s e c o n d a r y  s t a b i l i z i n g  f o r c e s  ( h y d r o g e n  
b o n d i n g ,  h y d r o p h o b i c  i n t e r a c t i o n s )  t h e  c o n j u g a t e  
p r o d u c t s  w o u l d  n o t  b e  e x p e c t e d  t o  b e  s t a b l e ,  a n d  
p r o b a b l y  u n d e r g o  e i t h e r  e l i m i n a t i o n  t o  t h e  i m i n e  o r  
h y d r o l y s i s  t o  t h e  c a r b i n o l a m i n e ,  t h e  e n d  r e s u l t  i n  b o t h  
c a s e s  b e i n g  r e g e n e r a t i o n  o f  f r e e  d r u g .  I n  c o n t r a s t  t o  
t h i s ,  t h e  r e a c t i o n  o f  t h e  P ( l , 4 ) B s  w i t h  N 2  o f  g u a n i n e  
k  a d s  t o  a n  a m i n a l  l i n k a g e  p r o d u c t  w h i c h ,  a c c o r d i n g  t o  
m o l e c u l a r  m e c h a n i c s  c a l c u l a t i o n s ,  i s  s t a b i l i z e d  b y  s t e r i c  
a n d  e l e c t r o s t a t i c  i n t e r a c t i o n s  a n d  c o n s e q u e n t l y  i s  l e s s  
l i k e l y  t o  u n d e r g o  h y d r o l y s i s  u n l e s s  t h e s e  n o n c o v a l e n t  
i n t e r a c t i o n s  a r e  r e d u c e d .22 M o r e o v e r ,  e x p e r i m e n t s  s h o w  
t h a t  i f  P ( l , 4 ) B - m o d i f i e d  D N A  i s  m e l t e d  u n d e r  n e u t r a l  
o r  a c i d i c  c o n d i t i o n s ,  t h e  P ( l , 4 ) B s  a r e  r e l e a s e d  i n  a c t i v e  
f o r m , 12 a t t e s t i n g  t o  t h e  s t a b i l i z i n g  e f f e c t  o f  t h e  i n t a c t  
d u p l e x  m i n o r  g r o o v e  o n  t h e  N 2  g u a n i n e  a d d u c t .  F u r ­
t h e r  e v i d e n c e  f o r  t h e  i m p o r t a n c e  o f  a n  i n t a c t  m i n o r  
g r o o v e  f o r  b i n d i n g  o f  t h e  P ( l , 4 ) B s  i s  t h a t  t h e s e  d r u g s  
d o  n o t  b i n d  c o v a l e n t l y  t o  a  s i n g l e - s t r a n d e d  D N A  
t e m p l a t e . 12
C C - 1 0 6 5  a l k y l a t e s  D N A  s p e c i f i c a l l y  a t  N - 3  o f  a d e ­
n i n e . 21 N u c l e o p h i l i c  a t t a c k  b y  N - 3  o c c u r s  a t  t h e  c y ­
c l o p r o p y l  m e t h y l e n e  c a r b o n  o f  t h e  “ A  s u b u n i t ” o f  
C C - 1 0 6 5  w i t h  c o n c o m i t a n t  r in g  o p e n i n g  a n d  r e d u c t i o n  
o f  t h e  i n d o l e  q u i n o n e  t o  a n  i n d o l e  p h e n o l  ( F i g u r e  3 ) .  
T h i s  i s  b e l i e v e d  t o  b e  a n  e s s e n t i a l l y  i r r e v e r s i b le  r e a c t i o n  
w h i c h  r e s u l t s  i n  a  n e t  p o s i t i v e  c h a r g e  o n  t h e  a d e n i n e  
r i n g  s y s t e m .  I n  c o n t r a s t  t o  t h e  P ( 1 , 4 ) B  c a r b i n o l a m i n e  
o r  i m i n e ,  t h e  r e l a t i v e  e l e c t r o p h i l i c i t y  o f  C C - 1 0 6 5  i s  
r a t h e r  w e a k ,  a n d  w e  s u s p e c t  t h a t  a  p r o x i m i t y  e f f e c t 31 
( s e e  l a t e r )  i s  i m p o r t a n t  i n  a c t i v a t i n g  C C - 1 0 6 5  t o  t h e  
m o r e  r e a c t i v e  s p e c i e s .
S e q u e n c e  R e c o g n it io n  w ith in  th e  M in o r  G ro o v e  
o f  D N A
B i n d i n g  o f  C C - 1 0 6 5  a n d  t h e  P ( l , 4 ) B s  t o  D N A  i s  
p r o p o s e d  t o  b e  a  b i p h a s i c  e v e n t .  I n i t i a l l y ,  t h e r e  i s  
p r o b a b l y  a  r a p id  n o n c o v a l e n t  a s s o c i a t i o n  o f  t h e  l i g a n d s  
w i t h i n  t h e  m i n o r  g r o o v e .  T h e  r i g h t - h a n d e d  t w i s t  o f  t h e
(31) M enger, F. M.; Venkataram, U. V. J. Am. Chem. Soc. 1985, 107,
4706.
m o l e c u l e s  a n d  t h e  r e l a t i v e l y  h y d r o p h o b ic  n a t u r e  o f  their 
c o n c a v e  “ i n s i d e  e d g e s ” i s  h i g h l y  c o m p a t i b l e  w i t h  the 
e n v i r o n m e n t  w i t h i n  t h e  m i n o r  g r o o v e .  S e v e r a l  force | 
h a v e  b e e n  i d e n t i f i e d  a s  i m p o r t a n t  i n  n o n c o v a l e n t  as 
s o c i a t i o n  o f  l i g a n d s  w i t h i n  t h e  m i n o r  g r o o v e . 8,32 Deh­
y d r a t i o n  e n e r g i e s  f o r  t h e  m i n o r  g r o o v e  a n d  t h e  liganci 
s i g n i f i c a n t l y  a f f e c t  b i n d i n g  a f f i n i t i e s ,  w i t h  m o r e  hy­
d r o p h o b i c  l i g a n d s  p r o v i d i n g  a  g r e a t e r  d r i v i n g  fo r c e  for 
a s s o c i a t i o n . 3215 E l e c t r o s t a t i c  i n t e r a c t i o n s  b e t w e e n  the 
r e c e p t o r  a n d  l i g a n d  s t a b i l i z e  a s s o c i a t i o n s , 3215 a n d  hy­
d r o p h o b i c  i n t e r a c t i o n s  b e t w e e n  l ig a n d  p r o t o n s  a n d  base 
p r o t o n s  ( s p e c i f i c a l l y ,  H - 2  o f  a d e n i n e )  i n c r e a s e  binding 
a f f i n i t i e s . 320 T h e  a b o v e  c o n s i d e r a t i o n s ,  c o m b i n e d  with 
s t e r i c  i n t e r a c t i o n s  g e n e r a t e d  f r o m  c l o s e  v a n  d e r  Waal; 
c o n t a c t s  b e t w e e n  l i g a n d s  a n d  t h e  f l o o r  o f  t h e  minoi 
g r o o v e  ( m o s t  n o t a b l y ,  N 2  o f  g u a n i n e ) ,  d e t e r m i n e  which 
s e q u e n c e s  w i t h i n  t h e  m i n o r  g r o o v e  h a v e  t h e  highes; 
a f f i n i t i e s  f o r  a  g i v e n  l i g a n d .  I n t e r e s t i n g l y ,  this , 
“s e q u e n c e  s e l e c t i v i t y , ” o r  “ r e c o g n i t i o n ” w i t h i n  t h e  minoii 
g r o o v e  d o e s  n o t  s e e m  t o  b e  m e d i a t e d  t o  a n y  g r e a t  extent! 
b y  h y d r o g e n  b o n d i n g ,  a l t h o u g h  s u c h  b o n d i n g  may 
s u b s e q u e n t l y  s t a b i l i z e  b o u n d  s p e c i e s . 9,3215 T h i s  is i l l  
s h a r p  c o n t r a s t  t o  t h e  m o r e  p r e c i s e  D N A  s e q u e n c e  rec­
o g n i t i o n  o f  p o l y p e p t i d e  D N A  l i g a n d s  s u c h  a s  repressor 
p r o t e i n s  a n d  r e s t r i c t i o n  e n z y m e s . 33 I n  t h e s e  cases 
r e c o g n i t i o n  a n d  b i n d i n g  t o  s p e c i f i c  D N A  s e q u e n c e s  i- 
p r o p o s e d  t o  o c c u r  l a r g e l y  t h r o u g h  d i s c r e t e  hydrogei 
b o n d i n g  i n t e r a c t i o n s  b e t w e e n  l i g a n d s  a n d  t h e  D N A  anc 
g e n e r a l l y  t a k e s  p l a c e  w i t h i n  t h e  m a j o r  g r o o v e  o f  DNA
T h e  P ( l , 4 ) B s  b i n d  m o s t  e f f i c i e n t l y  t o  D N A  ai 
5 ' P u G P u  s e q u e n c e s ,  a n d  l e a s t  e f f i c i e n t l y  a t  5TyGPy 
s e q u e n c e s . 28 H o w e v e r ,  a n t h r a m y c i n ,  s ib ir o m y c i n ,  anc 
t o m a y m y c i n  h a v e  b e e n  s h o w n  t o  p r e f e r  d i f f e r e n t  sub­
s e t s  o f  t h e  c o n s e n s u s  5 ' P u G P u  b i n d i n g  se q u e n c e -  
s u g g e s t i n g  l o c a l  i n t e r a c t i o n s  d i f f e r  t o  s o m e  e x t e n t  be 
t w e e n  e a c h  d r u g  m o l e c u l e  a n d  i t s  p r e f e r r e d  binding 
s e q u e n c e  i n  D N A .  S i n c e  t h e  c o n c a v e  s i d e  o f  th e  drug 
m o l e c u l e s  ( i .e . ,  p o s i t i o n s  9 ,1 0 ,1 1 ,1 1 a ,  a n d  1 in  structun 
I  o f  F i g u r e  1 )  f o l l o w s  t h e  f l o o r  o f  t h e  m i n o r  grooved  
D N A ,  t h e  o v e r a l l  c h a r a c t e r i s t i c  t w i s t  o f  e a c h  moleculf 
p r o b a b l y  i s  o f  m a j o r  i m p o r t a n c e  i n  t h e  d e t e r m in a t e  
o f  s e q u e n c e  r e c o g n i t i o n .  B o t h  t h e  d i h e d r a l  an g le  bt 
t w e e n  t h e  a r o m a t i c  r in g  t h e  f i v e - m e m b e r e d  r in g  and the 
p u c k e r  o f  t h e  p y r r o le  r in g  c o n t r i b u t e  t o  t h e  o v e r a ll  twis 
( a n d  t h e r e f o r e  t o  t h e  s e q u e n c e  r e c o g n i t i o n  properties 
o f  e a c h  d r u g .
C C - 1 0 6 5  b i n d s  c o v a l e n t l y  t o  t h e  m i n o r  grooved  
D N A  t h r o u g h  N - 3  o f  a d e n i n e .  I n  a d d i t i o n ,  i t  is  highly' 
s e l e c t i v e  f o r  A T  r i c h  s e q u e n c e s  i n  D N A ,  b in d in g  wit: 
g r e a t e s t  a f f i n i t i e s  t o  t h e  3 ' - t e r m i n a l  a d e n i n e  o f  these 
q u e n c e s  5 ' P u N T T A  a n d  5 ' A A A A A .26 A s  w a s  th e  car 
w i t h  t h e  P ( l , 4 ) B s ,  t h e  p r o x i m i t y  o f  s p e c i f i c  regionso 
t h e  C C - 1 0 6 5  m o l e c u l e  t o  g r o u p s  w i t h i n  t h e  chemically 
i n t e r a c t i v e  r a n g e  o n  t h e  D N A  m o l e c u l e  c a n  b e  usedte 
r a t i o n a l i z e  t h e  e x t e n t  a n d  o v e r a l l  n a t u r e  o f  th e  DNA 
r e c o g n i t i o n  s e q u e n c e s .  T h e  s e q u e n c e  s p e c i f i c i t y  dati 
r e v e a l s  t h a t  t h e r e  i s  a n  o v e r w h e l m i n g  p r e f e r e n c e  for AI 
p a i r s  o v e r  G C  p a i r s .  T h i s  i s  s i m i l a r  t o  t h e  data fc 
n e t r o p s i n  a n d  d i s t a m y c i n ,  w h i c h  a l s o  b i n d  in  th e  mine:
(32) (a) Zimmer, C. C om m ents  Mol. Cell. Biophys.  1983, 1, 399. ft 
Pullm an, B. In Specif ic i ty  in Biological Interactions-, Chagas, C;Pul: 
man; B., Eds.; The Vatican Press and Reidel Publishing Company 
Vatican City and Dordrecht, The Netherlands, 1984. (c) ZakraewskaJ 
Lavery, R.; Pullm an, B. Nucleic Acids Res. 1984, 12, 6559.
(33) (a) Matthews, B. VV.; Ohlendord, D. H.; Anderson, W. F.; Fishe 
R. G.; Takeda Y. Trends Biochem. Sci. (Pers. Ed.) 1983, 8 ,25. I) 
Rosenberg, J. M.; Greene, P. D N A  19S2, 1, 117.
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F ig u re  8. Structures of U-71,184 and U-71,185.35
groove but w ithout a formal covalent linkage.32® The  
snug fit of the CC-1065 molecule along the floor of the  
minor groove is suggestive that the bulky 2-amino group 
o f  guanine may discourage binding via steric interfer­
ence.
T he discovery o f two different consensus sequences 
for CC-1065 binding sites was unexpected.26 The con­
sensus analysis for CC-1065 reveals that if  the base on  
th e  57 side o f the covalently m odified adenine is an 
adenine, than the next base will m ost likely be another 
adenine, and similarly for pairs of thym ines. T he  
specificity  for the 57-proximal pair of bases in both  
consensus sequences is less well-defined. Therefore, it 
is useful to  consider the consensus sequence for both  
subclasses o f binding sites as consisting o f three basic 
units. T he first unit (A7) at the 3' end consists o f the  
alkylation site for CC-1065; the second unit (B7) is a pair 
o f highly conserved bases (AA or TT); the third unit 
(CO is a pair of less well conserved bases (AA or PuN ). 
Exam ination of the stereo drawings o f the CC-1065- 
D N A  adduct (Figure 7) reveals that the three units (A7, 
B 7, and C7) making up the consensus sequence overlap 
with subunits A, B, and C of CC-1065, respectively. 
Since the subunits o f CC-1065 are connected by amide 
linkages, there is some flexibility in the conformational 
angles between subunits A and B and between subunits 
B and C. Moreover, the rigidity within subunit B  of 
CC-1065 which overlaps with the second consensus unit 
(B7) will specify one o f a pair of hom oduplexes (AA or 
TT), depending upon the conformational angle between 
subunits A and B and between subunits B  and C. 
Presumably, the steric interactions presented by a  
heteroduplex consisting o f 57AT or 57TA are less fa­
vorable. From the sequence specificity data, the order 
of preference for unit B 7 for interaction with CC-1065 
is 57T T  greater that 57AA. The less strict preference 
for consensus unit C7 makes a similar analysis as carried 
out for unit B 7 less informative.
T he importance of proxim ity or drug juxtaposition  
to  N -3 of adenine is illustrated by the results o f ex­
periments where attem pts were made to bind the two 
optical antipodes (U71,184 and U71,185 of Figure 8) of 
a synthetic CC-1065 analogue to a 118 D N A  base pair 
restriction fragment from SV40 DNA.34 Thermal DNA  
strand break analysis o f binding of these two diaste-
(34) Lee, C-S; Hurley, L. H. Proc. Am. Assoc. Cancer Res. 1986, 27, 
962.
reomers to D N A  demonstrated that only the isom er 
(U71,184) with the same absolute stereochemistry at the 
cyclopropyl ring junctions as CC-1065 (3bR,4aS) binds 
covalently to D NA in a manner analogous to CC-1065, 
although a somewhat restricted sequence specificity and 
a temperature dependence between 4 and 37 °C not 
evident with CC-1065 was noted.34 In contrast, the  
diastereom er with the opposite stereochem istry to  
CC-1065 (U71,185) did not bind covalently to D N A  at 
temperatures up to 37 °C. M odeling studies suggest 
that the best noncovalent fit of both diastereomers in 
the minor groove of DNA is in the same location, w ith  
the concave edges of the subunits of U-71,184 and  
U-71,185 interacting through close van der Waals con­
tacts with the floor of the minor groove of DNA. T he  
diastereomer with the same absolute stereochem istry  
as CC-1065 lies in the minor groove with its electrophilic 
center (C-4) in proximity to N-3 of adenine, while th e  
cyclopropyl m ethylene carbon of the opposite isom er 
resides between base pairs and is not in proxim ity to  
N -3 of adenine. These results suggest that the align­
m ent of CC-1065-like molecules in the minor groove of  
D N A , which is dictated by noncovalent interactions, 
restricts the number of possible covalent adducts sub­
sequently formed. Significantly, only the isomer which  
binds covalently to D NA (U71,184) is biologically ac­
tive.35
Molecular Basis for Biological Activity
Molecular modeling studies on the P (l,4 )B s have  
provided com pelling evidence through predictive  
structure-activity relationships that covalent m odifi­
cation o f D N A  is necessary to maintain cytotoxic po­
tency.611 Although far less extensive evidence is avail­
able for CC-1065 and its analogues, structure-activity  
relationships can also be rationalized on the basis th at  
covalent modification of DNA is the critical event.34 In 
spite of our considerable insights into the structures o f  
the drug-receptor complexes for the P (l,4 )B s and  
CC-1065, the mechanism(s) by which these drugs exert 
their potent biological effect is far from clear. N ever­
theless, some clues are available from studies in which  
the biochemical and biological effects of these drugs on  
intact cells has been evaluated.
As noted previously, CC-1065 and the P (l,4 )B s are 
m uch more potent than their counterparts which in ­
teract with D NA noncovalently.11 Moreover, individual 
members of each series show considerable variation in 
biological potencies. Of the P (l,4)B s, sibiromycin is by  
far the m ost potent, followed in decreasing order o f  
potency by anthramycin, tomaymycin, and the neo- 
thram ycins.5f This rank order mirrors the in vitro  
stability of the adducts on D N A ,12® with sibiromycin  
producing the most stable DNA adduct. The problem, 
however, is more complex, because although N 2 of  
guanine appears to be the alkylation target on D N A , 
it is probably also crucial to define both the structural 
characteristics of the particular modified guanine-con­
taining sequence and its location within the genomic 
target. In particular, the importance of the location of 
D N A  damage by aflatoxins in actively vs. nonactively  
transcribed sequences has been previously noted,36 and
(35) Warpehoski, M. A.; Kelly, K. C.; McGovren, J. P.; Wierenga, W. 
Proc. Am. Assoc. Cancer Res. 1985, 26, 870.
(36) Irvine, R.; Wogen, G. Proc. N atl. Acad. Sci. U.S.A. 1983, 81, 664.
v o l. LV,  1300  r t f U H U i h u r
m ay provide a valuable corollary to P (l,4 )B s  and  
CC-1065 activities.
Covalent modification of DNA does not automatically 
lead to cytotoxic potency. More likely, the charge and 
steric characteristics of the DNA-adducts determine the 
resulting reaction processes which can lead to either an 
innocuous adduct (e.g. N7-methylguanine) or a possible 
mutagenic lesion (e.g., 06-methylguanine). Indeed the  
data from DNA repair experiments (see later) with both 
the P (l,4 )B s and CC-1065 suggest that the minor groove 
covalent binding agents described in this Account may 
well represent structurally problematic lesions to either 
recognized or repair in an error-free and effective  
manner. The nondistortive nature of the D N A  lesions, 
in which the covalent linkage site is between the con­
cave edge of the drug m olecule and the floor o f the  
minor groove of DN A , may require a com plex type of  
adduct recognition and repair path way (s). Possibly  
relevant to th is argument is the observation by Lip- 
pard37 who has recently noted that the nondistortive  
nature of the cis-P t-D N A  adduct apparently leads to  
a delayed removal of these lesions through D N A  repair 
pathways. In the case of CC-1065, the adduct disturbs 
the normal electronic character of the adenine nucleus, 
which m ight be recognizable by a repair com plex by  
detection of a positive charged imidazole m oiety via the  
major groove. However, the P (l,4 )B s m odify the exo- 
cyclic N 2 of guanine and would be less likely to present 
an electronically d istinct species. Indeed, while exci­
sion-deficient human cells derived from X eroderm a  
p igm en tosu m  (X P) patients are defective in removal 
of anthramycin adducts from D N A ,38 both normal and 
X P  cell lines appear equally adept at recognizing  
CC-1065 alkylation o f D N A ,39 im plying two different 
repair recognition pathways for CC-1065 and the P-
(l,4 )B s.
W orking upon the assum ption th at D N A  repair 
m ight well play an im portant role in expressing the  
potency o f the minor groove covalent adducts, we have 
carried out experim ents to  exam ine the fate and bio­
logical consequences of anthramycin lesions in bacteria, 
yeast, and human cells. W hile the P (l,4 )B s  are not
(37) Ciccarelli, R. B.; Solomon, M. J.; Varshavsky, A.; Lippard, S. J. 
B iochem istry  1985, 24, 7533.
(38) Petrusek, R. L. D.; Uhlenhopp, E. L.; Duteau, N.; Hurley, L. H.
J. Biol. Chem. 1982, 257, 6207.
(39) (a) Jacobson, M.; Hurley, L. H. Biochem istry, in press, (b) Lam­
bert, M. Proc. Am. Assoc. Cancer Res. 1985, 26, 1807.
significantly m utagenic in bacteria or yeast, they are 
highly recom binogenic.40 In human cells exposed 10 
anthramycin, excision-dependent single and d o u b le  
strand D N A  breaks are produced38 which may b e  as­
sociated with the recombinogenic characteristics of 
these drugs. We have speculated that excision repair 
m ight not always occur on the damaged D NA strand 
and may consequently lead to detrim ental repair.3841 
M uch less is known concerning the repair of CC-1065 
lesions, except that exposure of human cells to the drug 
leads to a dramatic decrease in N A D  levels associated f 
with poly(A D P)ribosylation,39a and both normal and 
X P  cells are able to recognize CC-1065-DNA lesions.391 
T he significance of these result in relation to DNA re­
pair and cytotoxicity of CC-1065 remains to be d eter­
mined.
Concluding Remarks ,
The mechanism of action work described in this Ac­
count has led to considerable insights into the structures 
of the CC-1065 and P(1,4)B -D N A  adducts. Much less 
is known about the events that lead to the potent cy­
totoxic effects of these compounds. Our present efforts 
are designed to understand in more detail the molecular 
basis for the sequence specificity of these D NA reactive 
com pounds and, through the preparation of site-di­
rected adducts in DNA, begin to unravel the biochem­
ical events th at lead to the biological consequences of 
D N A  m odification by CC-1065 and the P(l,4)Bs. 
Perhaps through som e of these experim ents a more 
rational approach to  antitum or drug design can be 
discovered.
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One- and Two-Dim ensional *H NMR, Fluorescence, and M olecular M odeling 
Studies on the Tomaymycin-d(ATGCAT)2 Adduct. Evidence for Two Covalent 
Adducts w ith  Opposite O rientations and Stereochem istries at the Covalent Linkage 
Site
Steve C heatham / Alan K ook/ Laurence H. H u r le y ,M a r y  D. Barkley/ and William Remers5
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Tomaymycin is a member of the pyrrolo [ 1,4] benzodiazepine antitumor-antibiotic group that binds covalently to 
the exocyclic 2-amino group of guanine in DNA. Previous correlation of fluorescence and NMR data suggested 
that the 11/2,l l a S  and the l lS , l l a S  diastereomers of tomaymycin could bind to DNA in two orientations relative 
to  the covalently modified guanine (Barkley, M. D.; Cheatham, S.; Thurston, D. E.; Hurley, L. H. Biochem istry  
1986,2 5 ,3021-3031). We now report on fluorescence, one- and two-dimensional proton NMR, and molecular modeling 
studies of the tomaymycin-d(ATGCAT)2 adduct, which corroborate these earlier observations. Fluorescence 
measurements show that there are two species of tomaymycin bound to d(ATGCAT)2, which are tentatively identified 
as the 11/2,l la S  and H S .l la S  diastereomers. Two distinct sets of signals for the tomaymycin molecule are present 
in the proton NM R spectrum of the tomaymycin-d(ATGCAT)2 duplex adduct. Two-dimensional correlation 
spectroscopy (2D-COSY) studies also show connectivities for four cytosine H 5-H 6 and eight thymine m ethyl-H 6  
protons and thus clearly establish the presence of two distinct species of tomaymycin-d(ATGCAT)2 adducts in solution.
A single scalar 11-1 la  XH NM R coupling in the 2D-COSY spectrum is indicative of an adduct species that has an 
S  configuration at the C - ll  position. Two-dimensional nuclear Overhauser effect (NOESY) spectra of the to- 
maymycin-d (ATGCAT) 2 duplex adduct show that the adducts are relatively nondistortive. In a NOESY experiment, 
cross-peaks were identified between both the aromatic H9 proton and the ethylidine methyl protons of tomaymycin 
and two different adenine H2 protons of d(ATGCAT)2. Molecular mechanics calculations with a m b e r  show that 
the two species with the thermodynamically most favorable binding energies are the 11/2,l la S  and H S .l la S  isomers 
with their aromatic rings to the 5' and 3' sides of the covalently bound guanine, respectively. The NOEs observed 
between tomaymycin protons and adenine H2 protons are in accord with molecular modeling studies. Taken together, 
these results strongly suggest that the two forms of tomaymycin bound to d(ATGCAT)2 me the l lS , l la S  and 11/2,lla S  
species, oriented with their aromatic rings to the 3' and 5' sides, respectively, of the covalently modified guanines.
Tomaymycin (I) (Figure 1) is a member of the potent 
PCL/tJB1 antitumor-antibiotic group, which also includes 
anthramycin, sibiromycin, and the neothramycins A and 
B2. The antitumor activity of the P(l,4)B s is attributed 
to their ability to form covalent adducts with DNA through 
N-2 of guanine3 (see Figure 2). Anthramycin has been 
shown to form an aminal linkage between its carbinolamine 
carbon at C -ll and N-2 of guanine.4 CPK model studies 
show that the P(1,4)B nucleus fits completely within the 
minor groove of B-form DNA, forming a relatively non- 
idistortive adduct.6 Tomaymycin also binds covalently to 
DNA but not as efficiently as anthramycin or sibiromy­
cin.2’6 The DNA sequence specificity of tomaymycin and 
other P (l,4)B s has been characterized by MPE*Fe(II) 
“footprinting”.6 Tomaymycin, anthramycin, and sibiro­
mycin display a three base pair sequence selectivity for 
5'PuGPu sequences. Guanines within 5'PyGPy trimers 
are the least preferred sites for covalent binding, with 
5'PyGPu and 5'PuGPy sequences being of intermediate 
preference.
The anthramycin-d(ATGCAT)2 adduct has been par­
tially characterized by using one- and two-dimensional (ID, 
2D) proton NM R techniques.7,8 Covalent adduct forma­
tion results in loss of symmetry of the duplex,7 and two- 
dimensional NMR experiments show that anthramycin 
binds through an 1LS geometry with its aromatic ring on 
the 3' side of the covalently modified guanine.8
In contrast, two distinct forms of tomaymycin-DNA  
adducts are observed by time-resolved fluorescence spec­
troscopy.9 NMR studies of tomaymycin in various 
solvents demonstrated that tomaymycin can exist as an 
equilibrium mixture of 11/2,1 la S  and 11S, l la S  diaste-
f University of Texas at Austin.
* Louisiana State University.
* University of Arizona.
reomers.9 The correlation between NMR and fluorescence 
data led us to postulate that the two species of tomaymycin 
observed on DNA were the diastereomeric 11/2,l la S  and 
H S jlla S  tomaymycin-DNA adducts bound through N-2 
of guanine.10
(1) Abbreviations: CPK, Corey, Pauling, and Koltun; COSY, 
correlation spectroscopy; DMTdTAPSi, dimethoxytrityl-2'- 
deoxythymidine aminopropyl silica gel; NOESY, two-dimen­
sional nuclear Overhauser effect; MPE, methidiumpropyl- 
ethylenediaminetetraacetic acid; Pu, purine; Py, pyrimidine; 
THF, tetrahydrofuran; TME, tomaymycin 11-methyl ether; 
TSP, sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4; P(1,4)B, 
pyrrolo [ 1,4] benzodiazepine.
Hurley, L. H. J. Antibiot. 1977, 30, 349.
Hurley, L. H.; Needham-VanDevanter, D. Acc. Chem. Res. 
1986,19, 230.
Graves, D. E.; Pattaroni, C.; Krishnan, B. S.; Ostrander, J. M.; 
Hurley, L. H.; Krugh, T. R. J. Biol. Chem. 1984, 259, 8202. 
Petrusek, R. L.; Anderson, G. L.; Garner, T. F.; Quinton, F. L.; 
Fannin, L.; Kaplan, D. J.; Zimmer, S. G.; Hurley, L. H. Bio­
chemistry 1984, 23, 1111.
Hertzberg, R. P.; Hecht, S. M.; Reynolds, V. L.; Molineux, I. 
J.; Hurley, L. H. Biochemistry 1986, 25, 1249.
Graves, D. E.; Stone, M. P.; Krugh, T. R. Biochemistry 1985,
24, 7573.
(8) Boyd, F. L.; Cheatham, S.; Hurley, L. H., submitted for pub­
lication in J. Am. Chem. Soc.
Barkley, M. D.; Cheatham, S.; Thurston, D. E.; Hurley, L. H. 
Biochemistry 1986, 25, 3021.
In this paper, the stereochemistry at the covalent linkage site 
between C -ll of tomaymycin and N-2 of guanine shown in 
Figure 6B is incorrect. The structure for Figure 6B is denoted 
in the Figure legend as the 11/2,11&S diastereomer of the to- 
maymycin-d(ATGCAT)2 adduct However, Figure 6B shows 
the l lS . l la S  diastereomer. Consequently Figures 6A,B only 
differ such that the drug molecules are oriented in opposite 
directions in the minor groove of d(ATGCAT)2. The correct 
structure for Figure 6B in ref 8 is the species D shown in 
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F ig u re  1. Structures and num bering o f  tom aym ycin  (I).
F ig u re  2. Proposed m echanism  for the reaction  o f  th e  P ( l,4 )B s  
w ith  D N A  to  form  th e  P ( l ,4 ) B - ( N 2-g u a n in e)-D N A  a d d u ct .9
Table I. Fluorescence Decay Data for Tom aym ycin Bound to 
Calf Thym us D N A  and d(ATG CAT)2°
Xex, nm Tj, ns «2 t2, ns
calf thym us D N A C 313 0.35 3.8 0.65 6.7
337 0.31 0.69
355 0.28 0.72
d(ATGCAT )2 313 0.43 2.3 0.57 5.7
337 0.52 0.48
355 0.63 0.37
“Decay parameters were obtained by global analysis o f decay 
curves m easured at the ind icated excitation  w avelengths and  
em ission wavelengths between 390 and 490 nm. 6 Fractional am ­
plitudes = 1. cData for pH 7.5, 5 °C from ref 23. Am plitudes 
and lifetim es are independent of pH in the range 6.4-9.0.
I n  t h e  p r e s e n t  p a p e r ,  w e  d e s c r i b e  t h e  r e s u l t s  o f  
f l u o r e s c e n c e ,  o n e -  a n d  t w o - d i m e n s i o n a l  N M R ,  a n d  
m o le c u la r  m o d e l in g  s t u d i e s  o f  t o m a y m y c i n - d ( A T G C A T ) 2, 
w h i c h  s u p p l y  t h e  f i r s t  d i r e c t  e v i d e n c e  t h a t  t o m a y m y c i n  
c a n  b i n d  v ia  e i t h e r  a n  H i ?  o r  a n  1 I S  c o n f i g u r a t io n  a n d  in  
t w o  o r i e n t a t i o n s  o n  D N A .  A  p r e l im in a r y  a c c o u n t  o f  t h i s  
w o r k  h a s  a p p e a r e d .11
R esu lts  and D iscu ssion
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F ig u re  3. Four possib le  sp ec ies o f  tom aym ycin  d (A T G C A T )2. 
A: 1 I S , l l a S  d iastereom er w ith  arom atic ring to th e  3 ' s id e . B: 
l l S , l l a S  d iastereom er w ith  arom atic ring to  th e  5' s id e . C: 
l l / ? , l l a S  d iastereom er w ith  arom atic ring to  th e  3' s id e . D: 
l l / ? , l l a S  d iastereom er w ith  arom atic ring to  the 5' side.
5 ' s id e  o f  t h e  c o v a l e n t ly  m o d i f ie d  g u a n in e ,  i .e .,  s p e c i e s  A - D  
in  F ig u r e  3 . T h e  c o m p l e x i t y  o f  t h e  I D  a n d  2 D  N M R  
s p e c t r a  o f  t h e  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t s  p r o ­
h i b i t e d  a b s o l u t e  a s s i g n m e n t  o f  t h e  s p e c i e s  p r e s e n t  b y  
N M R  a n a ly s i s  a lo n e .  C o n s e q u e n t ly ,  w e  h a v e  u s e d  a  c o m ­
b in a t io n  o f  f lu o r e s c e n c e ,  1H  N M R ,  a n d  m o le c u la r  m o d e l in g  
s t u d i e s  t o  d r a w  c o n c l u s io n s  o n  t h e  p r o b a b le  i d e n t i t y  o f  t h e  
a c t u a l  s p e c i e s  (A , B ,  C , o r  D  in  F ig u r e  3 )  p r e s e n t  in  t o -  
m a y m y c i n - d ( A T G C A T ) 2.
F lu orescence S tudies
T h e r e  a r e  t w o  f l u o r e s c e n t  g r o u n d - s t a t e  f o r m s  o f  t o ­
m a y m y c i n  o n  c a l f  t h y m u s  D N A  w i t h  c l o s e l y  o v e r l a p p e d  
s p e c t r a  a n d  d i f f e r e n t  e x c i t e d - s t a t e  l i f e t im e s .9 T a b le  I  g iv e s  
t h e  b e s t - f i t  p a r a m e t e r s  fo r  t h e  b i e x p o n e n t ia l  f l u o r e s c e n c e  
d e c a y  o f  t h e  c a l f  t h y m u s  D N A  a n d  d ( A T G C A T ) 2 a d d u c t s  
a t  5  ° C .  T h e  l i f e t i m e s  t j  o f  t h e  t w o  s p e c i e s  o f  t o m a y m y -  
c i n - d ( A T G C A T ) 2 a d d u c t s  a r e  2 .3  a n d  5 .7  n s ,  c o m p a r e d  t o  
3 .8  a n d  6 .7  n s  fo r  t h e  t o m a y m y c i n - D N A  a d d u c t .  I n  b o t h  
c a s e s ,  t h e  e m i s s i o n  s p e c t r a  a s s o c i a t e d  w i t h  t h e  t w o  f o r m s  
a r e  i d e n t i c a l ,  b u t  t h e  a b s o r p t i o n  s p e c t r a  a r e  s l i g h t l y  
s h i f t e d . 23 T h i s  i s  a p p a r e n t  in  t h e  d e p e n d e n c e  o f  t h e  
r e l a t i v e  a m p l i t u d e s  o n  e x c i t a t i o n  b u t  n o t  e m i s s i o n  
w a v e l e n g t h .  F o r  t h e  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t ,  
t h e  a m p l i t u d e  o f  t h e  2 .3 - n s  c o m p o n e n t  i n c r e a s e s ,  a n d  
t h e  a m p l i t u d e  a 2 o f  t h e  5 .7 - n s  c o m p o n e n t  d e c r e a s e s  w i t h  
i n c r e a s i n g  e x c i t a t i o n  w a v e l e n g t h ,  i n d i c a t i n g  t h a t  t h e  
s h o r t e r  l i f e t im e  s p e c i e s  h a s  i t s  a b s o r p t io n  b a n d  o n  t h e  r e d ,  
c o m p a r e d  t o  t h e  l o n g e r  l i f e t i m e  s p e c i e s .  F o r  t h e  t o m a y ­
m y c i n - D N A  a d d u c t ,  t h e  s h o r t e r  l i f e t i m e  c o m p o n e n t  i s  
a s s o c i a t e d  w i t h  a n  a b s o r p t i o n  b a n d  o n  t h e  b l u e ,  a n d  t h e  
lo n g e r  l i f e t im e  c o m p o n e n t  is  a s s o c i a t e d  w it h  a n  a b s o r p t io n  
b a n d  o n  t h e  r e d .9 T h e  g r e a t e r  e x c i t a t i o n  w a v e l e n g t h  d e ­
p e n d e n c e  o f  t h e  a m p l i t u d e s  fo r  t h e  d ( A T G C A T ) 2 a d d u c t  
s ig n i f i e s  a  la r g e r  s h i f t  in  t h e  a b s o r p t i o n  s p e c t r a  o f  t h e  t w o  
s p e c ie s .  W e  h a v e  a r g u e d  e l s e w h e r e  t h a t  t h e  lo n g e r  l i f e t im e  
c o m p o n e n t  r e p r e s e n t s  t h e  l l S , l l a S  d ia s t e r e o m e r ic  a d d u c t ,  
w h i l e  t h e  s h o r t e r  l i f e t i m e  c o m p o n e n t  r e p r e s e n t s  t h e  
l l i ? , l l a S  a d d u c t .9,23 S i n c e  t h e  a b s o r p t i o n  s p e c t r a  a r e  n o t  
i d e n t i c a l ,  t h e  a m p l i t u d e s  a r e  n o t  s i m p l y  p r o p o r t i o n a l  t o  
t h e  r e l a t i v e  a m o u n t s  o f  t h e  t w o  d i a s t e r e o m e r s .  N e v e r ­
t h e l e s s ,  i t  a p p e a r s  t h a t  t h e  t w o  d i a s t e r o m e r s  o c c u r  in  
r o u g h l y  e q u a l  p r o p o r t i o n s  i n  t h e  d ( A T G C A T ) 2 a d d u c t ,
(23) Barkley, M. D.; M askos, K. m anuscript in preparation.
(24) Cheatham, S.; Hurley, L. H., unpublished results.
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F ig u r e  4. P a rtia l 500-M H z sp ectru m  o f th e  to m a y m y cin -d -  
(A T G C A T )2 add ucts in D 20  at 23 °C. T h e pairs o f tom aym ycin  
H 6, H 9, and H 13 proton  signals are identified .
w h i l e  t h e  I l 5 , l l a 5  d i a s t e r e o m e r  i s  t h e  m a j o r  s p e c i e s  
p r e s e n t  i n  t h e  D N A  a d d u c t .  C a l f  t h y m u s  D N A  w i l l  c o n ­
t a i n  t h e  f u l l  s p e c t r u m  o f  b i n d i n g  s e q u e n c e  i n c l u d i n g  t h e  
m o r e  f a v o r e d  5 ' P u G P u ,  5 ' P y G P u ,  a n d  5 T u G P y  a s  w e l l  a s  
t h e  l e a s t  f a v o r e d  5 ' P y G P y  s e q u e n c e ,  w h i c h  o c c u r s  in  d -  
( A T G C A T ) 2. C o n s e q u e n t l y ,  w e  w o u l d  p r e d i c t  t h a t  t h e  
m o r e  f a v o r e d  s e q u e n c e s  w o u l d  b i n d  t h e  1 1 5 , l l a 5  d i a s t e ­
r e o m e r  w i t h  g r e a t e r  p r e f e r e n c e .  I n d e e d ,  p r e l i m i n a r y  r e ­
s u l t s  u s i n g  d ( A A G C T T ) 2 ( 5 ' P u G P y )  a n d  d ( T T C G A A ) 2 
( 5 ' P y G P u )  s e q u e n c e s  s h o w  t h a t  t h e  1 1 5 , l l a 5  s p e c i e s  is  
b o u n d  m o r e  f a v o r a b ly  t h a n  t h e  l l R , l l a 5  d i a s t e r e o m e r .24
One- and T w o-D im ensional NM R Studies
N um ber o f S p e c ie s  o f  th e  T om aym ycin -d -  
(ATGCAT)2 D uplex  Adduct and Stereochem istry at 
the Covalent L inkage S ite . T h e  s e l f - c o m p l e m e n t a r y  
d u p l e x  d ( A T G C A T ) 2 h a s  b e e n  e x t e n s i v e l y  c h a r a c t e r i z e d  
b y  P a t e l . 25-27 T h e  d ( A T G C A T ) 2 d u p l e x  e x h i b i t s  a  2 - f o ld  
s y m m e t r y  a x i s  r e s u l t i n g  in  e q u i v a l e n c e  o f  t h e  c o r r e ­
s p o n d i n g  b a s e  p r o t o n s  o f  e a c h  s t r a n d .25 T h e  s y m m e t r y  
o f  t h e  d u p l e x  i s  d e s t r o y e d  b y  e i t h e r  n o n c o v a l e n t  ( a c t i n o ­
m y c i n  D ) 28 o r  c o v a l e n t  ( a n t h r a m y c in ) 4 a s s o c i a t io n  o f  d r u g .  
C o n s e q u e n t l y ,  s i g n a l s  f r o m  e v e r y  b a s e  in  t h e  d u p l e x  a r e  
o b s e r v e d  in  t h e  p r o t o n  N M R  s p e c t r u m ,  d o u b l i n g  t h e  
n u m b e r  o f  o l i g o d e o x y n u c l e o t i d e  s i g n a l s  r e l a t i v e  t o  t h e  
d u p l e x  a l o n e .  B e c a u s e  o f  t h e  s ig n a l  d o u b l i n g ,  C O S Y  
s p e c t r a  o f  m o n o d i r e c t i o n a l  d u p l e x  a d d u c t s  s h o w  c r o s s ­
p e a k s  b e t w e e n  f o u r  t h y m i n e  m e t h y l - H 6  p r o t o n s  a n d  t w o  
c y t o s i n e  H 5 - H 6  p r o t o n s .  In  a d d i t i o n ,  o n e  s e t  o f  r e s o n a n c e  
s i g n a l s  f r o m  t h e  d r u g  m o l e c u l e  w i l l  b e  p r e s e n t .
I f  t o m a y m y c i n  i s  l i k e  a n t h r a m y c i n  a n d  b i n d s  t o  D N A  
i n  j u s t  o n e  o r i e n t a t i o n  o n  d ( A T G C A T ) 2, t h e n  t h e  l o s s  o f  
s y m m e t r y  s h o u l d  r e s u l t  i n  t h e  d o u b l i n g  o f  s i g n a l s  o f  t h e  
o l i g o n u c l e o t i d e .  H o w e v e r ,  t h e  f l u o r e s c e n c e  r e s u l t s  p r e s ­
e n t e d  a b o v e  s u g g e s t  t h a t  t o m a y m y c i n  b i n d s  t o  d -  
( A T G C A T ) 2 w i t h  b o t h  d i a s t e r e o m e r i c  l i n k a g e s  a t  C l l ,  
w h i c h  w o u l d  r e s u l t  i n  t w o  s p e c i e s  o f  t o m a y m y c i n  b o u n d  
c o v a l e n t l y  t o  g u a n i n e .  T h e  C O S Y  s p e c t r u m  o f  t w o  t o -  
m a y m v c i n - d ( A T G C A T ) 2 a d d u c t s  s h o u l d  t h e n  s h o w  c o n ­
n e c t i v i t i e s  b e t w e e n  e i g h t  t h y m i n e  m e t h y l - H 6  p r o t o n s  a n d  
f o u r  c y t o s i n e  H 5 - H 6  p r o t o n s .  I n  a d d i t i o n ,  t h e  s p e c t r u m  
s h o u l d  a l s o  s h o w  t w o  d i s t i n c t  s e t s  o f  t o m a y m y c i n  s ig n a l s .
E x a m i n a t i o n  o f  t h e  *H  N M R  s p e c t r u m  o f  t h e  t o m a y -  
m y c i n - d ( A T G C A T ) 2 a d d u c t  r e v e a l s  t w o  d i s t i n c t  t o m a y ­
m y c i n  H 9  p r o t o n s  a t  5 .9 8  a n d  6 .1 3  p p m  a n d  a  p a ir  o f  
t o m a y m y c i n  H 6  p r o t o n s  t h a t  o c c u r  c lo s e  t o g e t h e r ,  r e s o ­
(25) Patel, D. J. B ioch em istry  1974, 13, 2396.
(26) Patel, D. J. B ioch em istry  1974, 13, 3984.
(27) Patel, D. J.; Tonelli, A. E. B ioch em istry  1975, 14, 3990.
(28) Brown, S. C.; M ullis, M.; Levenson, C.; Shafer, R. H. Bio­
chem istry  1984, 23, 403.
n a t i n g  a t  6 .9 9  a n d  7 .0 3  p p m  ( F ig u r e  4 ) .  T h e s e  t o m a y ­
m y c in  H 6  p r o t o n s  c o u ld  b e  d i s t in g u is h e d  f r o m  t h e  t h y m i n e  
H 6  p r o t o n s  in  t h e  s a m e  r e g io n  b e c a u s e  a l l  t h e  t h y m i n e  H 6  
p r o t o n s  e x h i b i t e d  c r o s s - p e a k s  t o  t h e i r  r e s p e c t i v e  m e t h y l  
g r o u p s  ( F ig u r e  5 ,  b o x  A  a n d  e x p a n s i o n ) .  T h e  p a t t e r n  o f  
t h e  t o m a y m y c i n  a r o m a t i c  p r o t o n s  in  t h e  d ( A T G C A T ) 2 
a d d u c t s  i s  v e r y  s im i l a r ,  t h o u g h  n o t  i d e n t i c a l  w i t h  t h a t  
o b s e r v e d  fo r  t h e  l l R , l l a 5  a n d  I l 5 , l l a 5  d i a s t e r e o m e r s  o f  
t o m a y m y c in  in  D 20  b u f f e r  s o l u t io n .9 I n  1 0  m M  p h o s p h a t e  
b u f f e r ,  t h e  H 9  a n d  H 6  p r o t o n s  o f  t h e  l l i ? , l l a 5  a n d  
1 1 5 , 1 1 3 5  d i a s t e r e o m e r s  o f  t o m a y m y c i n  r e s o n a t e  a t  6 .2 6  
a n d  6 .5 1  p p m  ( H 9 )  a n d  a t  7 .1 1  a n d  7 .1 9  p p m  ( H 6 ) ,  r e ­
s p e c t i v e ly .  T h e  H 1 3  e t h y l i d e n e  m e t h y l  s ig n a l s  o f  t h e  t w o  
d i a s t e r e o m e r i c  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t s  r e s o ­
n a t e  d o w n f i e l d  f r o m  t h e  t h y m i n e  m e t h y l  g r o u p s  a t  1 .6 1  
a n d  1 .7 3  p p m  ( F ig u r e  4 ) .  T h e  r e m a in i n g  t o m a y m y c i n  
p r o t o n s  a r e  o b s c u r e d  b y  s i g n a l s  o r i g i n a t i n g  f r o m  t h e  o l i ­
g o m e r .  I t  i s  i m p o r t a n t  t o  n o t e  t h a t  t h e  c h e m ic a l  s h i f t s  o f  
t h e  t o m a y m y c i n  s i g n a l s  in  t h e  d ( A T G C A T ) 2 a d d u c t s  d o  
n o t  m a t c h  t h e  c h e m i c a l  s h i f t s  o b s e r v e d  fo r  t h e  f r e e  d r u g  
in  t h e  s a m e  b u f fe r .  A ls o ,  e x t e n s iv e  e x t r a c t io n  o f  t h e  d u p le x  
a d d u c t  w i t h  e t h y l  a c e t a t e ,  w h i c h  r e m o v e s  f r e e  d r u g  f r o m  
a q u e o u s  b u f f e r  s o l u t i o n s ,  d o e s  n o t  c h a n g e  t h e  * H  N M R  
s p e c t r u m  o f  t h e  d u p l e x  a d d u c t .
F o u r  c y t o s i n e  H 5 - H 6  c o n n e c t i v i t i e s  a r e  p r e s e n t  in  t h e  
C O S Y  s p e c t r u m  o f  t h e  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t  
( F ig u r e  5 , p a n e l  B ) .  C O S Y  c r o s s - p e a k s  b e t w e e n  s e v e n  o f  
e i g h t  p o s s i b l e  t h y m i n e  m e t h y l - H 6 p r o t o n s  a r e  a l s o  o b ­
s e r v e d  ( F ig u r e  5 ,  b o x  A ) .  T h i s  p a t t e r n  o f  s i g n a l s  fo r  t o ­
m a y m y c i n  a n d  t h e  d u p l e x  m o l e c u l e  in  t h e  a d d u c t  i s  o n l y  
c o n s i s t e n t  w i t h  t h e  p r e s e n c e  o f  t w o  d i s t i n c t  t o m a y m y c i n -  
D N A  a d d u c t s .
T o m a y m y c i n  b i n d in g  t o  d ( A T G C A T ) 2 c a u s e s  d r a m a t ic  
c h e m i c a l - s h i f t  c h a n g e s  i n  t h e  o l ig o m e r .  I n  g e n e r a l ,  t h e  
s ig n a l s  o c c u r  o v e r  a  la r g e r  c h e m i c a l - s h i f t  r a n g e  i n  t h e  t o -  
m a y m y c i n - d ( A T G C A T ) 2 d u p l e x  t h a n  in  t h e  d u p l e x  a lo n e  
( F ig u r e  5 ) .  T h e  e i g h t  a d e n i n e  H 8  p r o t o n s  o f  t h e  t o m a y -  
m y c i n - d ( A T G C A T ) 2 a d d u c t  r e s o n a t e  b e t w e e n  8 .4  a n d  7 .9  
p p m .  T h e y  a r e  r e a d i ly  d i s t i n g u i s h e d  f r o m  t h e  o t h e r  a r o ­
m a t i c  p r o t o n s  b y  t w o - d i m e n s i o n a l  N O E  e x p e r i m e n t s  in  
w h i c h  c r o s s - p e a k s  o c c u r  b e t w e e n  t h e  t h y m i n e  H 6  a n d  t h e  
a d e n i n e  H 8  o n  i t s  5 '  s i d e . 29 T h e  m o s t  d r a m a t i c  c h e m i ­
c a l - s h i f t  c h a n g e  o c c u r s  in  t h e  a d e n i n e  H 2  p r o t o n  a t  7 .4 8  
p p m ,  w h i c h  i s  s h i f t e d  u p f i e l d  a p p r o x i m a t e l y  0 .4  p p m  
r e l a t i v e  t o  t h e  o t h e r  a d e n i n e  H 2  p r o t o n s  i n  t h e  d u p l e x  
a d d u c t s .  A  v e r y  s i m i l a r  p a t t e r n  i s  o b s e r v e d  in  t h e  a n -  
t h r a m y c i n - d ( A T G C A T ) 2 a d d u c t  w h e r e  t h e  A n H 2  p r o t o n  
i s  a l s o  s h i f t e d  u p f i e l d . 7,8
I n  t h e  a n t h r a m y c i n - d ( A T G C A T ) 2 t h e  u p f i e l d  s h i f t  o f  
t h e  A n H 2  p r o t o n  i s  a s s o c i a t e d  w i t h  a n  N O E  c o n n e c t i v i t y  
t o  a n  a n t h r a m y c i n  p r o t o n  i n  t h e  a c r y l a m i d e  s i d e  c h a i n .8 
I f  a  p a r a l le l  s i t u a t i o n  e x i s t s  i n  o n e  o f  t h e  t o m a y m y c i n - d -  
( A T G C A T ) 2 a d d u c t s ,  b y  a n a l o g y  w i t h  t h e  a n t h r a m y c i n -  
d ( A T G C A T ) 2 a d d u c t ,  w e  w o u l d  e x p e c t  o n e  o f  t h e  s p e c i e s  
t o  b e  t h e  1 1 5 , l l a 5  d i a s t e r e o m e r  w i t h  t h e  a r o m a t i c  r in g  
t o  t h e  3 '  s i d e  o f  G .4 A s  w e  e s t a b l i s h  l a t e r ,  t h i s  i s  i n d e e d  
p r o b a b l y  t h e  c a s e .
I n  a d d i t i o n  t o  t h e  a r o m a t i c  p r o t o n s ,  t h r e e  o f  t h e  f o u r  
c y t o s i n e  H 6  p r o t o n s  a r e  d e s h i e l d e d  r e l a t i v e  t o  t h e  d u p l e x  
w h i l e  t w o  o f  t h e  H I '  p r o t o n s  a r e  m o r e  s h i e l d e d .  W h i l e  
q u a n t i t a t i v e  c h a n g e s  o c c u r  i n  t h e  c h e m i c a l  s h i f t s  o f  t h e  
a r o m a t ic  p r o t o n s  o f  t h e  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t  
r e l a t i v e  t o  t h e  d u p l e x  a l o n e ,  o v e r a l l ,  t h e  g e n e r a l  r e g i o n s  
w h e r e  t h e s e  p r o t o n s  r e s o n a t e  r e m a in  u n c h a n g e d ,  i .e . ,  t h e  
a d e n i n e  H 8  p r o t o n s  a r e  t h e  m o s t  d e s h i e l d e d .  T h e  p y r i-
(29) Feigon, J.; Denny, W. A.; Leupin; W.; Kearns, D. R. Biochem ­
is try  1983, 22, 5943.
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F ig u re  5. C O S Y  spectrum  o f  the tom aym ycin -d (A T G C A T )2 adducts in D 20  at 23 °C . B ox A show s the region containing the thym ine  
m e th y l-H 6  proton cross-peaks and its ex p an sion , box B  show s th e  cy to sin e  H 5 -H 6  proton cross-peaks and its  expansion , and box C 
show s th e  region con ta in in g  cross-peaks o f  th e  H 3', H 4', H 5', and H 5' protons o f  th e  duplex . T h e  cross-peak den oted  by th e  arrow  
is proposed  to  arise from  a tom aym ycin  H l l - H l l a  in teraction  (see tex t).
m i d i n e  H 6  p r o t o n s  r e s o n a t e  f a r t h e s t  u p f i e l d  b e t w e e n  7 .3 5  
a n d  6 .9 0  p p m , a n d  t h e  g u a n in e  H 8  a n d  a d e n in e  H 2  p r o to n s  
r e s o n a t e  b e t w e e n  7 .8 5  a n d  7 .4 5  p p m .
T h e r e  i s  a  s t r o n g  c r o s s - p e a k  in  t h e  C O S Y  s p e c t r u m  
( a r r o w  in  F ig u r e  5 )  b e t w e e n  a  p r o t o n  a t  3 .9 9  p p m  a n d  a  
d o u b l e t  a t  5 .6 0  p p m .  A  s im i l a r  c r o s s - p e a k  i s  a l s o  p r e s e n t  
in  t h e  s p e c t r u m  o f  t h e  a n t h r a m y c in - d ( A T G C A T ) 2 a d d u c t .8 
I n  b o t h  c a s e s ,  t h i s  C O S Y  c r o s s - p e a k  i s  i n d i c a t i v e  o f  c o u ­
p l in g  b e t w e e n  t h e  p r o t o n s  a t  C l l  a n d  C l l a  o f  a n t h r a m y c in  
o r  t o m a y m y c in .  T h e  p r e s e n c e  o f  t h i s  c r o s s - p e a k  p r o v i d e s  
i m p o r t a n t  s t e r e o c h e m i c a l  i n f o r m a t i o n ,  s i n c e  o n l y  t h e  
H S j l l a S  d i a s t e r e o m e r  c a n  g i v e  r i s e  t o  a  c o u p l i n g  p a t ­
t e r n .9,30 T h e  l l / ? , l l a S '  d i a s t e r e o m e r  o f  t o m a y m y c i n  h a s  
a  9 0 °  d ih e d r a l  a n g le  b e t w e e n  t h e  p r o t o n s  a t  C l l  a n d  C l l a  
a n d  c o n s e q u e n t l y  l a c k s  c o u p l i n g .
B o t h  t h e  f l u o r e s c e n c e  a n d  JH  N M R  s t u d i e s  d e m o n s t r a t e  
t h a t  t h e r e  a r e  t w o  s p e c i e s  o f  t o m a y m y c i n - d ( A T G C A T ) 2. 
T h e  f l u o r e s c e n c e  e x p e r i m e n t s  s h o w  t h e  p r e s e n c e  o f  b o t h  
d i a s t e r e o m e r i c  a d d u c t s  (A  o r  B  w i t h  C  o r  D  in  F ig u r e  3 ) .  
T h e  c o m b i n e d  f l u o r e s c e n c e  a n d  1H  N M R  r e s u l t s  l e a v e  
o p e n  f o u r  p o s s i b l e  c o m b i n a t i o n s  o f  s p e c i e s  t h a t  m i g h t  b e  
p r e s e n t  in  t h e  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t :  A  a n d  
C , A  a n d  D ,  B  a n d  C , o r  B  a n d  D .  O n  t h e  b a s i s  o f  t h e  
o r i e n t a t i o n  in  t h e  m i n o r  g r o o v e  o f  D N A ,  t h e s e  f o u r  p a ir s  
c a n  b e  d iv id e d  i n t o  t w o  s u b s e t s .  O n e  s u b s e t  is  A C  a n d  B D  
in  w h i c h  t h e  a r o m a t i c  r in g s  o f  t o m a y m y c i n  a r e  o r ie n t a t e d  
i n  t h e  s a m e  d i r e c t i o n  ( i .e . ,  b o t h  3 '  ( A C )  o r  5 '  ( B D ) ,  w h i l e  
t h e  o t h e r  s u b s e t  h a s  a r o m a t i c  r in g s  t h a t  a r e  in  o p p o s i t e  
o r i e n t a t i o n s  ( i . e . ,  A D  o r  B C ) ) .  F o r  t h e  a n t h r a m y c i n - d -  
( A T G C A T ) 2 a d d u c t  w e  h a v e  a s s i g n e d  t h e  o r i e n t a t i o n  o f  
t h e  a n t i b i o t i c  in  t h e  m i n o r  g r o o v e  o f  t h e  d u p l e x  b y  i d e n ­
(30) Tozuka, A.; Takaya, T. J. A n tib io t. 1983, 36, 142.
t i f i c a t i o n  o f  a  a n t h r a m y c i n  H l 3 - A n H 2  c r o s s - p e a k  in  t h e  
2 D - N O E S Y . 8 C o n s e q u e n t l y ,  o n e -  a n d  t w o - d i m e n s i o n a l  
e x p e r i m e n t s  w e r e  c a r r ie d  o u t  in  a n  a t t e m p t  t o  a s s i g n  t h e  
a d e n i n e  H 2  p r o t o n s  in  t o m a y m y c i n - d ( A T G C A T ) 2 a n d  
l o c a t e  N O E  c r o s s - p e a k s  b e t w e e n  k e y  p r o t o n s  o n  t o m a y ­
m y c i n  a n d  d ( A T G C A T ) 2.
Amino Proton R esonance A ssignm ent and NOE  
C onnectiv ities to the A denine H2 Protons. I n  t h e  
p r e v i o u s  s t u d i e s ,  t h e  i m in o  p r o t o n  a s s i g n m e n t s  w e r e  u s e d  
t o  a s s ig n  t h e  a d e n in e  H 2  p r o t o n s  in  d ( A T G C A T ) 2 a n d  t h e  
a n t h r a m y c i n - d ( A T G C A T ) 2 a d d u c t . 7,8 T h e  t e m p e r a t u r e  
d e p e n d e n c y  o f  t h e  i m in o  p r o t o n  r e g io n  is  s h o w n  in  F ig u r e  
6 . A t  2 4  ° C ,  t h e  t w o  s e t s  o f  G -C  i m in o  p r o t o n s  a r e  o b ­
s e r v e d  a t  1 2 .6  a n d  1 2 .9  p p m .  T h e  u p f i e l d  s i g n a l s  a t  1 0 .0  
a n d  1 0 .8  p p m  a r e  p r e s u m a b ly  t h e  p h e n o l i c  p r o t o n s  a t  C 8  
o f  e a c h  d i a s t e r e o m e r i c  t o m a y m y c i n  m o l e c u l e .  U n f o r t u ­
n a t e l y ,  a t t e m p t s  t o  p r o v e  t h i s  a s s i g n m e n t  b y  i r r a d ia t io n  
o f  t h e  e x c h a n g e a b l e  p r o t o n s  a t  1 0 .0  a n d  1 0 .8  p p m  in  o r d e r  
t o  o b s e r v e  N O E s  i n t o  t h e  t o m a y m y c in  H 9  p r o t o n s  a t  5 .9 8  
a n d  6 .1 3  p p m  w e r e  t h w a r t e d  b y  t h e  w a t e r  s u p p r e s s i o n  
s e q u e n c e ,  w h i c h  n u l l e d  t h e  r e g io n  u p  t o  a p p r o x im a t e ly  6 .9  
p p m .  T h e  1 - 1  w a t e r  s u p p r e s s i o n  s e q u e n c e 31 w a s  a t ­
t e m p t e d  b u t  d i d  n o t  s u p r e s s  t h e  w a t e r  s u f f i c i e n t l y  fo r  
c o m p l e t e  d i g i t i z a t i o n  o f  t h e  s ig n a ls .  L o w e r in g  o f  t h e  t e m ­
p e r a t u r e  r e v e a le d  t h e  i m in o  A -T  p r o t o n s  b e t w e e n  1 4 .5  a n d
1 3 .0  p p m . U n f o r t u n a t e l y ,  a s  i s  a p p a r e n t  f r o m  F ig u r e  6  (1 5  
° C ) ,  t h e  a d e n i n e  H 2  p r o t o n s  c o a l e s c e  a t  t e m p e r a t u r e s  a t  
w h ic h  t h e  in t e r n a l  a n d  e x t e r n a l  im in o  p r o t o n s  w e r e  v i s ib le ,  
t h u s  p r e v e n t i n g  u n a m b i g u o u s  a s s i g n m e n t s .  N O E  d i f f e r ­
e n c e  s p e c t r a  w e r e  r u n  a t  1 0  ° C  in  o r d e r  t o  c o n f i r m  t h e
(31) Clore, G. M.; Kimber, B. J.; Gronenborn, A. M. J. M agn. Re- 
son. 1983, 54, 170.
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F ig u r e  6. V ariable-tem perature an alysis o f  th e  sp ectra l region  
from  15.5 to  6.5 ppm  o f  to m a y m y cin -d (A T G C A T )2 duplex. 
S p ectra  were ob ta in ed  in 90%  H 2O /20%  D 20  w ith  use o f  a
1 - 3 -3 -1  w ater suppression  sequence. E ach spectrum  consists o f  
256 scans each and 32K  data points line-broadened 1 Hz. Arrows 
in d ica te  th e  G-C and A-T am ino proton resonance signals.
p r o t o n  t y p e .  T h e  i m in o  p r o t o n s  o f  A - T  b a s e  p a i r s  c a n  b e  
e a s i l y  d i s t i n g u i s h e d  f r o m  G -C  i m in o  p r o t o n s  b y  t h e  p r e s ­
e n c e  o f  n a r r o w  l in e  N O E s  b e t w e e n  t h e  A - T  i m in o  p r o t o n s  
a n d  t h e  a d e n in e  H 2  p r o t o n s 32 ( F ig u r e  7 ) .  I r r id a t io n  o f  t h e  
i m i n o  p r o t o n  r e s o n a n c e s  a t  1 2 .6  a n d  1 2 .9  p p m  c o n f i r m e d  
t h a t  t h e s e  p r o t o n s  w e r e  G -C  i m in o  p r o t o n s  a n d  t h a t  o t h e r  
d o w n f i e l d  i m i n o  r e s o n a n c e s  b e l o n g  t o  t h e  A - T  b a s e  p a ir s  
( u n p u b l i s h e d  r e s u l t s ) .
N onselective T x Inversion Recovery Experim ents 
on the Tom aym ycin-d(A TG C A T)2 A dducts. T x r e ­
l a x a t i o n  v a l u e s  fo r  t h e  a r o m a t i c  p r o t o n s  o f  t h e  t o m a y -  
m y c i n - d ( A T G C A T ) 2 d u p l e x  a r e  l i s t e d  in  T a b l e  I I .  A d e ­
n i n e  H 2  p r o t o n s  c a n  b e  e a s i l y  d i s t i n g u i s h e d  f r o m  o t h e r
(32) Chou, S.-H.; Hare, D. R.; Wemmer, D. E.; Reid, B. R. Bio­
ch em istry  1983, 22, 3037.
D
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F ig u r e  7. O ne-d im en sional N O E s from  A-T am ino protons to  
th e  adenine H 2 protons.
T able II. Chemical Sh ifts and T x Relaxation Values for the 
Aromatic Protons o f the Tom aym ycin-d(A T G C A T )2 Adduct
chem ical 
shift, ppm T x, s proton type
chem ical 
shift, ppm T x, s
proton
type
8.32 2.1 A H8 7.74 3.1 A H2C
8.19 1.9 A H8 7.59 2.5 G H8
8.14 2.0 A H8 7.48 3.4 A H2C
8.10 2.2 A H8 7.21 1.9 T  H6
8.04 1.9 A H8 7.19 1.8 T  H6
8.01 2.0 A H8 7.10 1.6 T  H 6“
7.91 2.2 A H8 7.01 1.7 T  H6
7.85 4.8 A H2 6.97 2.0 T  H6“
7.82 4.1 A H2 6.93 2.1 T  H6
7.80 4.1 A H2, G H86 7.03 2.3 Tom  H6
7.78 4.0 A H2 7.00 2.2 Tom  H6
7.77 2.3 G H8 6.15 3.2 Tom  H9
7.75 3.9 A H2 6.05 2.8 Tom  H9
“T he average T x for two signals that are overlapped. bTwo  
guanine H8 protons overlap with the adenine H2 proton. An av­
erage T x for the signal corresponding to the T x o f the adenine H2 is 
reported. “These are the two adenine H2 protons that show con­
nectivities to the tom aym ycin H9 and H 13 protons in the NOESY  
spectra (see Figure 8A,B).
a r o m a t i c  p r o t o n s  b e c a u s e  o f  t h e i r  l o n g e r  T x r e l a x a t i o n  
t i m e s . 27 A s  e x p e c t e d ,  la r g e  d i f f e r e n c e s  e x i s t  b e t w e e n  t h e  
a d e n i n e  H 2  p r o t o n s  a n d  t h e  o t h e r  a r o m a t i c  p r o t o n s .  T h e  
a v e r a g e  T x r e l a x a t io n  t i m e  fo r  p u r in e  H 8  a n d  t h y m i n e  H 6  
p r o t o n s  i s  a p p r o x i m a t e l y  2  s .  A l l  b u t  t w o  o f  t h e  a d e n i n e  
H 2  p r o t o n s  h a v e  T x v a lu e s  o f  a p p r o x im a t e ly  4  s  o r  lo n g e r .  
T h e  a d e n i n e  H 2  p r o t o n s  t h a t  r e s o n a t e  a t  7 .7 4  a n d  7 .4 8  
p p m  e x h ib i t  t o m a y m y c in  N O E  c r o s s - p e a k s  ( s e e  b e lo w )  a n d  
h a v e  r e l a x a t i o n  t i m e s  o f  a p p r o x i m a t e l y  3 .1  a n d  3 .4  s . A s  
w a s  p r e v i o u s l y  o b s e r v e d  f o r  t h e  a n t h r a m y c i n - d -  
( A T G C A T ) 2 a d d u c t s ,  T x v a l u e s  o f  t h e  a r o m a t i c  p r o t o n s  
o f  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t s  a r e  lo n g e r  t h a n  
t h o s e  o f  t h e  f r e e  d u p l e x . 7
N O E  C o n n ectiv itie s  o f  th e  T om aym ycin -d - 
(ATGCAT)2 A dducts. T w o - d i m e n s i o n a l  N O E  e x p e r i ­
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A S 3' -37.1 +12.0 +7.2 -17.9
B S 5' -36.3 +21.0 +4.1 -11.2
C R 3' -33.2 +16.8 +8.7 -7.7
D R 5' -35.5 +13.4 +0.2 -21.9
0 Refers to Figure 3. 6 Orientation of the aromatic ring of tomaymycin relative to the covalently modified guanine.
m e n t s  o n  t h e  t o m a y m y c i n - d ( A T G C A T ) 2 a d d u c t s  w e r e  
c a r r ie d  o u t  b y  u s e  o f  t h r e e  m i x i n g  t i m e s  (3 0 0 ,  5 0 0 ,  a n d  7 0 0  
m s ) .  V e r y  f e w  c r o s s - p e a k s  w e r e  o b s e r v e d  a t  3 0 0  m s ,  a n d  
m a x i m u m  c r o s s - p e a k  i n t e n s i t y  w a s  o b s e r v e d  a t  5 0 0  m s ,  b u t  
c o m p l e t e  a s s i g n m e n t  o f  t h e  d u p l e x  a d d u c t s  c o u ld  n o t  b e  
a c c o m p l is h e d  b e c a u s e  m o s t  o f  t h e  c r o s s - p e a k s  b e t w e e n  t h e  
a r o m a t ic  p r o t o n s  a n d  t h e  d e o x y r i b o s e  H I '  o r  H 2 '  a n d  H 2 "  
p r o t o n s  o f  t h e  s u g a r s  a r e  a b s e n t .  H o w e v e r ,  t h e  t w o - d i ­
m e n s i o n a l  N O E  e x p e r i m e n t s  w e r e  u s e f u l  fo r  d e t e r m i n i n g  
t h e  c o n f o r m a t io n  o f  t h e  d u p l e x  o l ig o m e r  a n d  i n d ir e c t ly  t h e  
o r ie n t a t io n  o f  t w o  s p e c ie s  o f  t o m a y m y c in  m o le c u l e s  r e la t iv e  
t o  t h e  c o v a l e n t l y  m o d i f i e d  g u a n i n e .  S t r o n g  N O E  c r o s s ­
p e a k s  b e t w e e n  t h e  a d e n i n e  H 8  p r o t o n s  a n d  t h y m i n e  H 6  
p r o t o n s  ( F ig u r e  8 A , b o x  A )  i n d i c a t e  a  B  h e l i x . 29 T o m a y ­
m y c i n  i s  s i m i l a r  t o  a n t h r a m y c i n  in  t h a t  la r g e  c h a n g e s  in  
b a s e  s t a c k i n g  in  t h e  o l ig o m e r  d o  n o t  a p p e a r  t o  o c c u r  u p o n  
d r u g  b i n d i n g . 7,8
I m p o r t a n t  N O E  c o n n e c t i v i t i e s  b e t w e e n  t o m a y m y c i n  
p r o t o n s  ( H 9  a n d  H 1 3 )  a n d  a d e n in e  H 2  p r o t o n s  a r e  s h o w n  
i n  F ig u r e  8 A ,B .  T h e s e  f i g u r e s  a r e  e x p a n s i o n s  o f  c r i t i c a l  
r e g i o n s  r e v e a l i n g  N O E  c r o s s - p e a k s  b e t w e e n  t o m a y m y c i n  
H 9  a n d  a n  a d e n i n e  H 2  p r o t o n  ( F ig u r e  8 A )  a n d  t o m a y ­
m y c i n  H 1 3  a n d  a n  a d e n in e  H 2  p r o t o n  ( F ig u r e  8 B ) .  O f  t h e  
t w o  c r o s s - p e a k s ,  t h e  o n e  b e t w e e n  t h e  t o m a y m y c i n  H 9  a n d  
i t s  a d e n in e  H 2  p r o t o n  is  t h e  m o r e  i n t e n s e ,  s u g g e s t i n g  t h a t  
t h i s  i s  t h e  c l o s e r  c o n n e c t i v i t y  o f  t h e  t w o .  T h e s e  c o n n e c ­
t i v i t i e s  a r e  p r e s e n t  i n  s p e c t r a  a t  b o t h  5 0 0 -  a n d  7 0 0 - m s  
m ix in g  t im e s .  A s  n o t e d  b e fo r e , t h e  t w o  a d e n in e  H 2  p r o t o n s  
a t  7 .4 8  a n d  7 .7 4  p p m ,  w h i c h  s h o w  c o n n e c t i v i t i e s  t o  t h e  
t o m a y m y c i n  H 1 3  a n d  H 9  p r o t o n s ,  r e s p e c t i v e l y ,  h a v e  r e ­
d u c e d  T x r e l a x a t i o n  t i m e s  ( 3 .4  a n d  3 .1  s ,  r e s p e c t i v e l y )  
r e l a t i v e  t o  o t h e r  a d e n in e  H 2  p r o t o n s  in  t h e  d u p l e x  a d d u c t  
( s e e  T a b l e  I I ) .
O n  t h e  b a s i s  o f  t h e  r e q u i r e m e n t  fo r  b o t h  l l S , l l a S  a n d  
1 1 7 2 ,l l a S  d i a s t e r e o m e r i c  D N A  a d d u c t s ,  t h e  c o m b i n e d  
f l u o r e s c e n c e  a n d  *H  N M R  r e s u l t s  l i m i t e d  t h e  p a i r s  o f  
p o s s ib le  t o m a y m y c in - d ( A T G C A T ) 2 a d d u c t s  t o  t w o  s u b s e t s  
h a v i n g  t h e  s a m e  (A C  a n d  B D )  o r  o p p o s i t e  ( A D  a n d  B C )  
o r i e n t a t i o n s  i n  t h e  m i n o r  g r o o v e  o f  d ( A T G C A T ) 2. T h e  
2 D - N O E  d a t a  r e q u i r e  t h a t  t h e  t w o  d i a s t e r e o m e r s  b e  o r i ­
e n t a t e d  in  o p p o site  d i r e c t i o n s  in  t h e  m i n o r  g r o o v e .  
T h e r e f o r e ,  o n l y  t h e  s u b s e t  A D  a n d  B C ,  w h i c h  h a v e  o p ­
p o s i t e  o r i e n t a t i o n s  in  t h e  m i n o r  g r o o v e ,  a r e  v i a b l e  a l t e r ­
n a t i v e s .  H o w e v e r ,  t h e  f l u o r e s c e n c e  a n d  * H  N M R  d a t a  
c a n n o t  d i s t i n g u i s h  b e t w e e n  t h e s e  t w o  p o s s i b i l i t i e s .
M olecular M odeling R esu lts
F o r  t h e  m o l e c u l a r  m o d e l i n g  s t u d i e s ,  t o m a y m y c i n  w a s  
c o v a l e n t ly  b o u n d  v ia  t h e  C - l l  a t o m  t o  t h e  e x o c y c l i c  a m in o  
g r o u p  o f  g u a n i n e - 3 .  A l l  f o u r  c a s e s  i l l u s t r a t e d  in  F ig u r e  3  
w e r e  u s e d  a s  t h e  s t a r t i n g  p o i n t  fo r  e n e r g y  m i n i m i z a t i o n  
u s i n g  t h e  a l l  a t o m  f o r c e  f i e l d  p a r a m e t e r s  o f  a m b e r . T h e  
n e t  b i n d in g  e n e r g y  fo r  e a c h  s p e c i e s  ( A - D )  w a s  c a l c u l a t e d  
f r o m  t h e  t o t a l  in t e r m o le c u l a r  d r u g - D N A  b i n d in g  e n e r g ie s  
m i n u s  t h e  h e l i x  a n d  d r u g  d i s t o r t i o n  e n e r g i e s  t h a t  r e s u l t  
f r o m  i n d u c e d  f i t s  ( T a b le  I I I ) .  S p e c i e s  A  a n d  D  in  F ig u r e  
3  a r e  f o u n d  t o  b e  t h e  p r e f e r r e d  b i n d i n g  f o r m s  o f  t o m a y -  
m y c i n - d ( A T G C A T ) 2. T h e  d i f f e r e n c e  in  n e t  b i n d i n g  e n ­
e r g i e s  b e t w e e n  t h e s e  t w o  f o r m s  i s  o n l y  4  k c a l / m o l .  T h e  
t o t a l  d r u g - D N A  b in d in g  e n e r g ie s  d o  n o t  d i f f e r  s ig n i f i c a n t l y
F igu re 8. NOESY spectra of tomaymycin-d(ATGCAT)2 adducts 
showing expansion of regions with NOE cross-peaks between a 
tom aymycin H9 proton and an adenine H2 proton (A) and be­
tween the tom aym ycin H13 proton and an adenine H2 proton  
(B). Spectra were recorded at 23 °C with a mixing tim e o f 500 
ms in D 20 .
in  a n y  o f  t h e  s p e c i e s  A - D  in  T a b l e  I I I . C o n s e q u e n t l y ,  t h e  
p r e f e r e n c e  fo r  s p e c i e s  A  a n d  D  i s  b a s e d  p r im a r i ly  o n  d r u g  
a n d  h e l i x  d i s t o r t i o n  e n e r g i e s .  F o r  t h e  p r e f e r r e d  b i n d i n g  
m o d e  t h e  t o t a l  d i s t o r t i o n  e n e r g y  i s  + 1 3 . 6  k c a l / m o l ,  
w h e r e a s  f o r  t h e  l e a s t  p r e f e r r e d  b i n d i n g  m o d e  t h i s  v a lu e  
i s  + 2 5 . 5  k c a l / m o l .  O n  t h e  b a s i s  o f  t h e s e  r e s u l t s ,  t h e r e  is  
a  c le a r  p r e f e r e n c e  fo r  t h e  d i a s t e r e o m e r i c  p a ir  A D  o v e r  B C  
s in c e  t h e s e  p a ir s  h a v e  c o m b i n e d  b i n d in g  e n e r g i e s  o f  - 4 9 . 8  
a n d  - 1 8 . 9  k c a l / m o l ,  r e s p e c t i v e ly .  T o  d i s t i n g u i s h  b e t w e e n  
t h e  p a ir  o f  d i a s t e r e o m e r s  f a v o r e d  b y  m o l e c u l a r  m o d e l i n g  
( A D )  a n d  t h e  o t h e r  p o s s i b l e  p a ir  o f  d i a s t e r e o m e r s  ( B C ) ,  
w h ic h  a r e  l e s s  fa v o r e d  b y  2 0 .9  k c a l / m o l ,  w e  n e e d  t o  i d e n t i f y  
a  u n i q u e  t o m a y m y c i n - b a s e  i n t e r p r o t o n  c o n n e c t i v i t y  t h a t  
w o u l d  d e f in e  t h e  o r ie n t a t io n  in  a  p a r t i c u la r  d i a s t e r e o m e r .
T h e  N O E S Y  s p e c t r a  ( F ig u r e  8 A ,B )  o f  t o m a y m y c i n - d -  
( A T G C A T ) 2 s h o w e d  c le a r  e v id e n c e  o f  c r o s s - p e a k s  b e t w e e n  
t w o  p a ir s  o f  d r u g - a d e n i n e  H 2  p r o t o n s .  T h e s e  i n t e r p r o t o n  
t h r o u g h - s p a c e  c o n n e c t i v i t i e s  a r e  b e t w e e n  a  t o m a y m y c i n  
H 9  p r o t o n  a n d  a n  a d e n in e  H 2  p r o t o n  ( F ig u r e  8 A )  a n d  t h e  
t o m a y m y c i n  e t h y l i d e n e  m e t h y l  a n d  a n o t h e r  a d e n i n e  H 2  
p r o t o n  (F ig u r e  8 B ) .  I f  t h e  m o le c u la r  m o d e l in g  p r e d i c t i o n s
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F ig u re  9. Stereodiagram s of the structures A and D from Figure 3.
o f  s p e c i e s  A  a n d  D  a r e  c o r r e c t ,  t h e n  t h e s e  N O E s  s h o u l d  
r e p r e s e n t  i n t e r p r o t o n  d i s t a n c e s  o f  l e s s  t h a n  4 .5  A. T h e  
s t e r e o d i a g r a m s  o f  s p e c i e s  A  a n d  D  a r e  s h o w n  in  F ig u r e  
9 A ,B .  I n  F ig u r e  9 A ,  t h e r e  i s  a  c l o s e  t h r o u g h - s p a c e  i n ­
t e r a c t i o n  b e t w e e n  t h e  t o m a y m y c i n  H 9  a n d  t h e  A n H 2  
p r o t o n ,  w h i c h  h a s  a  c o m p u t e d  d i s t a n c e  o f  2 .8 7  A. T h i s  is  
in  a c c o r d  w i t h  t h e  N O E  s h o w n  in  F ig u r e  7 A .  L i k e w i s e ,  
in  F ig u r e  9 B  t h e r e  i s  a  c l o s e  t h r o u g h - s p a c e  i n t e r a c t i o n  
b e t w e e n  t h e  t o m a y m y c in  e t h y l id e n e  m e t h y l  a n d  t h e  A 11H 2  
p r o t o n ,  w h ic h  h a s  a  c o m p u t e d  a v e r a g e  i n t e r p r o t o n  d i s t a n c e  
o f  3 .6 3  A. T h i s  i s  in  a c c o r d  w i t h  t h e  N O E  f o u n d  in  F ig u r e  
8 B .  S i g n i f i c a n t l y ,  t h e  s t r o n g e r  N O E  a s s o c i a t e d  w i t h  t h e  
t o m a y m y c i n  H 9  c o m p a r e d  t o  t h e  e t h y l i d e n e  m e t h y l  i s  
p r e d i c t e d  b y  t h e  s h o r t e r  i n t e r p r o t o n  d i s t a n c e  f o u n d  in  
F ig u r e  9 A  c o m p a r e d  t o  t h a t  o f  9 B .  T h u s  t h e  t w o  b e s t  
e n e r g y - m in im iz e d  s t r u c t u r e s  (A  a n d  D  o f  F ig u r e  3 )  n o t  o n ly  
h a v e  t h e  r e q u i r e d  o p p o s i t e  s t e r e o c h e m i s t r i e s  a t  C l l  a n d  
o p p o s i t e  o r i e n t a t i o n s  in  t h e  m i n o r  g r o v e  b u t  a l s o  a r e  
p r e d i c t i v e  o f  t h e  t w o  i n t e r p r o t o n  t h r o u g h - s p a c e  c o n n e c ­
t i v i t i e s  i d e n t i f i e d  in  t h e  N O E S Y  s p e c t r a .  U n f o r t u n a t e l y ,  
e x a m i n a t i o n  o f  t h e  o t h e r  s t e r e o d i a g r a m s  o f  t h e  e n e r g y -  
m i n i m i z e d  p a i r s  o f  v a r i o u s  d i a s t e r e o m e r i c  t o m a y m y c i n -  
d ( A T G C A T ) 2 a d d u c t s  h a v e  r e v e a l e d  s h o r t  i n t e r p r o t o n  
d i s t a n c e s  b e t w e e n  A n H 2  p r o t o n s  a n d  t h e  s a m e  t o m a y ­
m y c i n  p r o t o n s .  T h e r e f o r e ,  w h i l e  t h e  s t r u c t u r e s  A  a n d  D  
i n  F ig u r e  3  a r e  p r e d i c t e d  b y  m o l e c u l a r  m e c h a n i c s  c a l c u ­
l a t i o n  t o  b e  t h e  m o s t  l i k e l y  f o r m s  o f  t h e  t o m a y m y c i n - d -  
( A T G C A T ) 2, t h e  N O E ’s  d e m o n s t r a t e d  in  t h i s  s t u d y  c a n  
o n l y  e l i m i n a t e  t w o  o f  t h e  f o u r  p o s s i b l e  s e t s  (A C  a n d  B D )  
s in c e  t h e s e  d i a s t e r e o m e r i c  p a ir s  h a v e  t h e  sam e  o r ie n t a t io n  
i n  t h e  m i n o r  g r o o v e .  C o l l e c t i v e l y  t h e  f l u o r e s c e n c e ,
N M R ,  a n d  m o le c u l a r  m o d e l i n g  r e s u l t s  p r o v i d e  s t r o n g  e v ­
i d e n c e  t h a t  t h e  t w o  f o r m s  o f  t o m a y m y c i n - d ( A T G C A T ) 2 
a r e  s p e c i e s  A  a n d  D  in  F ig u r e  3 .
T h e  c o m b i n e d  r e s u l t s  o f  t h i s  s t u d y  a n d  a  p r e v i o u s  i n ­
v e s t i g a t i o n  s h o w  t h a t  t h e  s t e r e o c h e m i s t r y  a t  t h e  c o v a l e n t  
l in k a g e  s i t e  a n d  t h e  o r i e n t a t i o n  o f  P ( 1 , 4 ) B S  in  t h e  m i n o r  
g r o o v e  o f  D N A  is  d e p e n d e n t  u p o n  d r u g  s t r u c t u r e .  I t  a l s o  
s e e m s  l ik e ly  t h a t  t h e  D N A  s e q u e n c e  a r o u n d  t h e  c o v a l e n t ly  
m o d if ie d  g u a n in e  m a y  a f f e c t  t h e  g e o m e t r y  o f  d r u g  b in d in g ,  
s i n c e  t h e  p r o p o r t io n  o f  t h e  l l S , l l a S  a n d  l l R , l l a S  d i a ­
s t e r e o m e r s  d i f f e r  o n  c a l f  t h y m u s  D N A  a n d  d ( A T G C A T ) 2. 
U n p u b l i s h e d  s t u d i e s  f r o m  o n e  o f  o u r  l a b o r a t o r i e s 23 d e m ­
o n s t r a t e  t h a t  t h e  h o m o p u r i n e - h o m o p y r i m i d i n e  p o l y m e r s  
p o ly d G * p o ly d C  a n d  p o l y ( d A G ) * p o l y ( d T C )  b i n d  o n l y  o n e  
s p e c i e s  o f  t o m a y m y c i n  (A  o r  B  in  F ig u r e  3 ) ,  w h e r e a s  t h e  
a l t e r n a t i n g  p o l y m e r s  p o ly ( d G * d C )  a n d  p o l y ( d G - d T )  b i n d  
t w o  f o r m s  o f  t o m a y m y c i n .  F u r t h e r  i n v e s t i g a t i o n s  a r e  
p l a n n e d  t o  d e t e r m i n e  i n  m o r e  d e t a i l  t h e  b a s i s  f o r  t h e  
o r i e n t a t i o n  a n d  s t e r e o c h e m i c a l  s p e c i f i c i t y .
E xperim ental Section
C h em ica ls . TM E was a generous gift from Dr. Kohsuka of 
Fujisawa Pharmaceuticals. The d(ATGCAT)2 oligomer was 
synthesized by using a m odification of large-scale solid-phase 
phosphoamidite m ethod.12 The d(ATGCAT)2 oligomer was pu­
rified by HPLC on a Nucleogen 60-7 column. A gradient was set 
up with buffer A (15% acetonitrile in aqueous 15 mM N aH 2Po4, 
pH 6.8) and buffer B (1 M NaCl). During the first 10 min, the  
sodium chloride concentration was increased up to 25% and then  
in the next 30 min up to 40%. Phosphoram idites and 
D M TdT A PSi used in the synthesis were purchased from Am­
erican Bionetics, Inc. Tetrazole (Aldrich) was sublimed before
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use at 110 °C (2 mm). Acetic anhydride and trichloroacetic acid 
(Aldrich) were used without further purification. Acetonitrile was 
dried by distillation from P 20 6 followed by distillation from CaH2. 
THF (Fisher Reagent Grade) was used without further purifi­
cation. D20  (100 atom %) for NMR experiments was purchased 
from Aldrich.
P reparation  o f T om aym ycin-d(A T G C A T )2 A dduct. To-
maymycin-d(ATGCAT)2 adducts for NM R experiments were 
prepared by adding excess solid TME to a 0.5-mL solution of 
d(ATGCAT)2 in buffer (10 mM N aH P 04, pH 7.0,100 mM NaCl, 
0.1 mM EDTA) at 5 °C. After vigorous stirring of the mixture 
for 4 days, excess tomaymycin was removed by centrifugation 
followed by extraction with ethyl acetate. Samples were lyo- 
phylized against D20  three times and dissolved in 0.5 mL of D20 .  
Samples used for NOE difference spectra were lyophilized to 
remove D20  then dissolved in 0.5 mL of 90% H2O/10% D20 .
The adduct for fluorescence experiments was prepared by 
equilibrating a solution of d(ATGCAT)2 in buffer with = 16 
and 5 X 10-4 M tomaymycin for 12 days at 5 °C. The hexamer 
concentration was about 3 X 10-4 M duplex, assuming an ex­
tinction coefficient of 4.8 X 103 M_1 cm-1 estimated from the base 
sequence13 with 20% hyperchromicity as in similar oligomeric 
duplexes.14 Unbound tomaymycin was removed by extracting 
four times with ethyl acetate and once with ether. Ether was 
removed with a stream of N 2. The sample was placed in a 4 X 
10 mm stoppered cuvette.
1H N M R  S tu d ies . A. T w o-D im ensional N M R  Sp ectra . 
1H NM R spectra were run on GN-500 instrument. All samples 
were run at 23 °C unless otherwise indicated and are referenced 
to HOD at 23 °C relative to external TSP. COSY spectra of the 
tomaymycin-d(ATGCAT)2 adduct were obtained on a 2 m g/0.5  
mL solution of the duplex adduct with a 3-s presaturation pulse 
before the standard 9 0 °-t1-90° pulse sequence to minimize the 
residual HOD signal. The COSY spectra contain 512 X 2K data 
points zero filled to give a IK X IK matrix. All other two-di­
mensional spectra contain 256 X IK data points zero filled to give 
512 x  512 matrices. Two-dimensional NOE spectra were run on 
a 10 m g/0.5 mL solution of duplex adduct, with a 9 0 °-f1-9 0 ° -  
0.5tm-90°-180o-90°-0.5tin-90o acquire sequence. The composite 
180° pulse in the mixture time removes J  coupling contributions 
from the cross-peaks.
B . N O E D ifferen ce  Spectra. NOE difference spectra were 
performed at 5 °C in 90% H2O/10% D20 . A 1 -3 -3 -1  pulse 
sequence was used to suppress the H20  signal. Signals were 
irradiated for 1 s with a total recycle delay of 2.4 s.
C. N on selective  T t In version  R ecovery E xperim en ts. 
Inversion recovery experiments utilized the standard 180°-fci-90° 
pulse sequence. Samples were degassed by passing argon through 
the sample. A total of 32 t  values ranging from 0.1 to 10 s were
used with a total recycle delay of 12.9 s.
Tim e-Resolved F luorescence S tud ies. Fluorescence decay 
measurements were made by the time-correlated single-photon 
counting technique as described before.9 Decay curves were 
acquired at 5 °C to about 15 X 103 counts in the peak. The data 
were fitted by reference deconvolution15 to a sum of exponentials
=  L ai(X eiA em ) e x p H / t*)
with amplitudes a£ and lifetimes r£. The amplitude a,- of a com­
ponent i depends on a number of factors, including its molar 
extinction spectrum, fluorescence emission spectrum, radiative 
lifetime, and concentration. Decay curves measured at various 
excitation and emission wavelengths were analyzed by a global 
program,16 assuming that the lifetimes but not the amplitudes 
are independent of wavelength. Errors in amplitudes and lifetimes 
were <10% and <5% , respectively, based on repeated experi­
ments.
M olecular M odeling S tu d ies. The crystal structure of to­
maymycin methyl ether17,18 was used as the initial structure in 
this investigation. After removal of the methoxy group, partial 
atomic charges were obtained from ab initio calculations using 
GAUSSIAN-80 UCSF and a STO-3G basis set.19 The resulting
11-demethoxytomaymycin methyl ether structure was minimized 
by using the program AMBER and all-atom force field parameters 
presented by Weiner et al.21 A distance-dependence dielectric 
constant was used, and the structure was refined until the root 
mean square gradient was less than 0.1 kcal/m ol A. The mini­
mized structure was docked in the appropriate location and 
orientations on the hexanucleotide duplex with the aid of the 
interactive graphics program m idas,22 and then the binding en­
ergies were minimized by using a m b e r  and the parameters de­
scribed above. The helix distortion energy was determined by 
subtracting the energy of the helix in the tomaymycin adduct from 
that of the separately minimized isolated helix. Distortion energy 
induced in the tomaymycin molecule was determined in the same 
way.
Structural effects of water and counterions on complexing were 
neglected in the energy calculations. Although these effects 
influence the absolute values of binding energies, they should be 
negligible in comparing relative binding energies wherein the same 
molecule is used at the same binding site on the duplex.
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a b s t r a c t ;  Tomaymycin is a member of the pyrrolo[ 1,4]benzodiazepine [P(1,4)B] antitumor antibiotic 
group. This antibiotic is proposed to react with the exocyclic 2-amino group (N 2) o f guanine to form a 
covalent adduct that lies snugly within the minor groove of DNA. While DNA-footprinting experiments 
using methidiumpropyl-EDTA have revealed the favored bonding sequences for tomaymycin and related 
drugs on D N A , the stereochemistry at the covalent bonding site (C -l 1) and orientation in the minor groove 
were not established by these experiments. In previous studies using a combined fluorescence, high-field 
NM R , and molecular modeling approach, we have shown that for tomaymycin there are two diastereomeric 
species (11/? and 1 IS) on both calf thymus D N A  and d(ATGCAT)2. Although we were able to infer the 
identity (stereochemistry at C -l 1 and orientation in the minor groove) of the two species on d(ATGCAT)2 
by high-field N M R  and fluorescence studies, in combination with molecular mechanics calculations, definitive 
experimental evidence was lacking. We have designed and synthesized a self-complementary 12-mer 
[dfCICGAATTCICGJJ based on the Dickerson dodecamer ^(CGCGAATTCGCGJJ that bonds identically 
two tomaymycin molecules, each having a defined orientation and stereochemistry. Thus the bis(tomay- 
mycin)-12-mer adduct maintains the self-complementarity of the original duplex molecule. Two-dimensional 
proton /-correlated spectroscopy (COSY) of the bis(tomaymycin)-d(CICGAATTCICG)2 adduct (I *  
inosine) unequivocally shows that C - ll  of tomaymycin covalently bonds through N 2  o f guanine with an 
1 liS stereochemistry in the sequence 5'-CGA-3'. Fluorescence studies confirm the “.S'” stereochemistry at 
C - l l ,  and two-dimensional proton nuclear Overhauser (NOESY) experiments assign the orientation o f the 
drug molecule in the minor groove of DNA, i.e., with the aromatic ring o f tomaymycin to the 3' side of 
covalently modified guanine. Molecular modeling experiments with a m b e r  are consistent with the iden­
tification of the species of tomaymycin (1 IS  with 3' orientation) bound to the 12-mer. This species and 
the other 1 IS  species are favored over the two 11R  species due to a combination o f steric and electrostatic 
interactions. Analysis o f two-dimensional COSY and NOESY experiments on the bis(tomaymycin)-d- 
(CICGAATTCICG)2 adducts reveals minimal effect of covalent bonding on local helix structure. From 
these experiments the modest but most pronounced distortion is at the deoxyribose attached to the modified 
guanine and both the phosphate and adjacent deoxyribose to the 5' side. The distortion o f this phosphate 
between the covalently modified guanine and the 5' nucleoside is supported by its downfield-shifted phosphorus 
N M R  resonance signal. The discrepancy between the pairs o f most energetically favored species o f to- 
m aym ycin-DNA adducts on d(ATGCAT)2 and the 12-mer is explained by examining individual drug- 
nucleotide interactions. The results presented in this study together with previous investigations show that 
the orientation o f the drug molecule in the minor groove, and stereochemistry at the covalent linkage site, 
is dependent upon both the flanking sequence and drug structure. This conclusion mandates caution be 
used in rationalizing the biochemical and biological effects of P(1,4)B bonding to D N A  until precise structural 
information is established.
Xomaymycin and anthramyciii are members of the P(1,4)B' 
antitumor-antibiotic group (Hurley, 1977; Hurley & Need- 
ham-VanDevanter, 1986; Remers, 1988). These drugs are 
proposed to react via the C - l l ,  N-10 imine 2 to form the 
unique covalent adduct 3 through the exocyclic 2-amino group
t This work was supported by grants from the NIH (GM-35009), the 
National Cancer Institute (CA-49751 and CA-37798), the Welch 
Foundation, and the Texas Advanced Technology Program.
* To whom correspondence should be addressed.
* Drug Dynamics Institute, University of Texas at Austin.
1 Department of Chemistry, University of Texas at Austin.
1 University of Arizona.
x Louisiana State University.
(N2) of guanine (Figure 1) (Petrusek et al., 1982; Barkley 
et al., 1986). There is an excellent correlation between both 
in vivo and in vitro cytotoxic potency of the P(l,4)Bs and their 
ability to form covalent adducts through N2 of guanine on 
DNA for a variety of natural and synthetic compounds 
(Hurley et al., 1988; Thurston & Hurley, 1983). DNA- 
footprinting experiments with MPE (Hertzberg et al., 1986)
1 Abbreviations: P(1,4)B, pyrrolo[ 1,4]benzodiazepine; MPE,
methidiumpropylethylenediaminetetraacetic acid; exo-III, exonuclease 
III; COSY, correlated spectroscopy; NOE, nuclear Overhauser effect; 
NOESY, nuclear Overhauser effect spectroscopy; I, inosine; TME, to­
maymycin 11-methyl ether; XP, xeroderma pigmentosum; TSP, 3-(tri- 
methylsilyl)propionic-2,2,J,J-</4 acid sodium salt.
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FIGURE 1: Proposed reaction of the P(l,4)Bs with DNA (Barkley et al., 1986).
and an exo-III stop assay (Hurley et al., 1988) concur that 
the most favored sequences for covalent bonding are 5'-PuGPu 
and the least favored are 5'-PyGPy, with 5'-PyGPu and 5'- 
PuGPy sequences of intermediate bonding reactivity.
Tomaymycin (4) and anthramycin (5) (Figure 2) both have 
a right-handed twist along the length of the molecule (Arora, 
1981; Mostad et al., 1978) and are predicted by molecular 
modeling studies (Petrusek et al., 1982; Remers et al., 1986; 
Rao et al., 1986; Zakrzewska & Pullman, 1986) to be ac­
commodated within the minor groove of DNA without large 
distortion of the DNA helix.2 While DNA-sequencing ex­
periments using MPE or exo-III reveal the favored covalent 
bonding sequences for anthramycin and tomaymycin, they are 
blind to important questions relating to the orientation of the 
drug molecule in the minor groove and the stereochemistry 
at the covalent linkage site between C-l 1 of the P(l,4)Bs and 
N2 of guanine. In order to address these questions, we have 
examined, by a combined high-field NMR, fluorescence, and 
molecular modeling approach, short oligomers such as d- 
(ATGCAT)2 that contain a single drug bonding site. For 
anthramycin on d(ATGCAT)2 a single adduct has been 
demonstrated (Graves et al., 1985) in which the aromatic ring 
of the drug is oriented to the 3' side of the covalently modified 
guanine and most likely has an 115 linkage stereochemistry 
(Boyd et al., 1990). For tomaymycin, fluorescence studies first 
suggested that tomaymycin can bond to calf thymus DNA 
with either the R otS configuration at C-l 1 (Barkley et al., 
1986). With d(ATGCAT)2 a combined fluoresence, high-field 
NMR, and molecular modeling study showed two species of 
tomaymycin bound to the oligomer, each having the opposite 
stereochemistry at C-l 1 (Cheatham et al., 1988). Although 
not definitive, the two species bound to this duplex were ten­
tatively identified as the 115 and 11R  diastereomers with the 
drug molecule oriented to either the 3' or 5' direction, re­
spectively. In contrast, results from proton NMR experiments 
with other oligomers [d(TTCGAA)2 and d(AAGCTT)2] 
showed predominantly one species of tomaymycin bound to 
each of these oligomers (Cheatham and Boyd, unpublished 
results).
The Dickerson dodecamer [d(CGCGAATTCGCG)2] 
(Drew et al., 1981) was used as a starting point to design a 
self-complementary 12-mer sequence that would bond two
2 For anthramycin covalently bound to d(ATGCAT)2, Zakrzewska 
and Pullman (1986) predict a B- toward an A-type transition of the 
DNA.
tomaymycin molecules, each with the same defined orientation 
and stereochemistry. This dodecamer has three internal 
guanines (underlined in the 12-mer) that are potential to­
maymycin covalent bonding sites (the terminal guanine is 
unlikely to be a bonding site). Two of these guanines were 
replaced with inosine, leaving only the guanine in the CGA 
sequence as a potential tomaymycin bonding site. Inosine 
differs from guanine only in that it lacks the exocyclic 2-amino 
group. In the inosine-disubstituted dodecamer [d(CICGA- 
ATTCICG)2] the remaining tomaymycin-reactive guanine is 
contained within the sequence (5'-CGA) that is predicted from 
previous unpublished studies from our laboratories (see above) 
to bond predominantly one species of tomaymycin. In the 
present study we provide evidence for this assumption and 
determine independently by fluorescence and high-field NMR  
the stereochemistry at the covalent linkage site. NOESY 
experiments assign the orientation of tomaymycin in the minor 
groove of DNA. We also show that there is a very modest 
change in local conformation of DNA upon adduct formation. 
The results of molecular modeling using the am ber molecular 
mechanics program are in good agreement with these results. 
These calculations provide insight into the molecular inter­
actions which favor the experimentally determined species on 
this 12-mer. It has long been assumed that the P(l,4)Bs form 
covalent adducts through N2 of guanine (Hurley, 1977). The 
present proton NMR results provide the first direct evidence 
for covalency between N2 of guanine and C-l 1 of a P(1,4)B.
M aterials a n d  M ethods
Chemicals. (1 \ R t l Ia5)-TME was generous gift from Dr. 
Kohsaka of Fujisawa Pharmaceuticals. d(CICGAATT- 
CICG)2 was prepared by The Midland Certified Reagent Co. 
by solid-phase phosphoramidite chemistry.
Purification o f  d{CICGAATTCICG)2. d(CICGAATT- 
CICG)2 was purified in-house on a Machery-Nagel Nucleo- 
gen-DEAE 60-7 HPLC column with an increasing gradient 
to 1 M NaCl in 15 mM sodium phosphate and 20% aceto- 
nitrile/aqueous buffer, pH 6.8.
Preparation o f  the Bis{tomaymyciri)-d{CICGAATTCICG)1 
Adduct. {A) N M R Experiments. The bis(tomaymycin)- 
12-mer adduct was prepared by adding ~ 4  mg of the solid 
(11/?,1 Ia5)-TME to ~ 2 5 0  A 1W units of the self-comple­
mentary oligomer in 600 pL  o f 10 mM NaH2P 0 4, 100 mM 
NaCl, and 0.01 mM EDTA-buffered DzO at pH 6.8. The 
mixture was lyophilized to dryness and reconstituted in 1 mL
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(A) Comparison of the Base Proton NMR Chemical Shift Assignments (ppm) and Tt Relaxation Times of Nonexchangeable and Imino Protons of 






ssignment 3 3 A 3 assignment d(CICGAATTCICG)2, 3 3 A3
•C H6 7.62 7.58 -0.04
Aromatic Protons 
,JG H8 7.89 7.84 -0.05
JI H8 8.30 8.20 -0.10 'C H5 5.90 5.82 -0.08
*C H6 7.18 7.29 +0.11 JI H2 7.85 (4.19 ±  0.08) 7.80 (5.06 ± 0 .1 7 ) -0.05 (+0.87)
*G H8 7.81 7.62 -0.19 *C H5 5.26 5.22 -0.04
5A H8 8.10 7.86 -0.24 JA H2 7.15 (3.10 ±  0.06) 7.24 (4.51 ± 0 .1 5 ) +0.09 (+1.41)
6A H8 8.10 7.95 -0.25 ‘A H2 7.57 (3.75 ±  0.09) 7.65 (5.19 ±  0.18) +0.08 (+1.44)
7T H6 7.07 7.27 +0.20 7T Me 1.22 1.15 -0.07
•T H6 7.33 7.07 -0.26 *T Me 1.50 1.49 -0.01
*C H6 7.47 7.24 -0.23 *C H5 5.62 5.32 -0.30
,0I H8 8.25 8.06 -0.19 ,0I H2 7.66 (3.66 ±  0.06) 7.22 (3.86 ±  0.09) -0.44- (+0.20)
"C H6 7.21 7.18 -0.03 "C H5 5.35 5.22 -0.13
•C -IJG 12.70 12.80 +0.10
Imino Protons (10 °C) 
'G -’C 12.40 12.42 +0.02
2I-"C 15.38 15.41 +0.03 5A-*T 13.55 14.02 +0.47*
j C - | ° i 15.17 15.12 -0.05 •A -’T 13.60 13.60 -0.00
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mer
















T -  
12-mer A3
•C 5.59 5.55 -0.04 1.96 1.90 -0.06 2.35 2.30 -0.05 4.61 4.62 +0.01 4.03 4.01 -0.02
JI 6.15 6.18 +0.03 2.72 2.65 -0.07 2.85 2.82 -0.03 4.92 4.93 +0.01 4.42 4.38 -0.04
JC 5.67 5.39 -0.28 1.58 2.06 +0.48 2.14 2.29 +0.15 4.67 4.75 +0.08 4.03 4.16 +0.13
*G 5.26 6.00 +0.74* 2.63 2.43 -0.20 2.67 2.80 +0.13 4.88 4.92 +0.04 4.28 4.36 +0.08
5A 5.94 5.75 -0.19 2.65 2.44 -0.21 2.89 2.55 -0.34 4.98 4.88 -0.10 4.40 4.24* -0.16
‘A 6.08 5.80 -0.28 2.60 2.21 -0.39 2.88 2.79 -0.09 4.92 4.70 -0.22 4.42 3.92 -0.50
TJ 5.83 5.98 +0.15 1.95 1.95 +0.00 2.53 2.60 +0.07 4.71 4.85 +0.14 4.09 4.24* +0.15
*T 6.04 6.05 +0.01 2.12 2.15 +0.03 2.51 2.57 +0.06 4.82 4.89 +0.07 4.12 4.20* +0.08
’C 5.46 5.72 +0.26 2.05 1.80 -0.25 2.35 2.14 -0.21 4.79 4.84 +0.05 4.12 4.20* +0.08
10, 6.13 5.78 -0.35 2.70 2.55 -0.15 2.86 2.55 -0.31 4.94 4.81 -0.13 4.37 4.24 -0.13
"C 5.78 5.83 +0.05 1.64 1.52 -0.12 2.20 2.15 -0.05 4.72 4.69 -0.03 4.18 3.81 -0.37
l2G 6.09 6.09 0.00 2.24 2.29 -0.05 2.61 2.55 -0.06 4.57 4.61 +0.04 4.15 4.00 -0.15
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figure  3: Proton-decoupled 202.44-M H z phosphorus N M R  spectra 
o f (A ) the d(C IC G A A T T C IC G )2 duplex and (B ) the tom aym ycin- 
d(C IC G A A T T C IC G )2 adduct in buffered D 20  at 24 °C.
£
f i g u r e  2: Structures and numbering o f tomaymycin (4), anthramycin
(5 ), and the inosine-disubstituted d(C IC G A A T T C IC G )2 (6).
o f  th e  a f o r e m e n t io n e d  a q u e o u s  ( H 20 )  b u f fe r .  T h is  s o lu t io n  
w a s  h e a te d  a t  6 0  ° C  fo r  5 m in  a n d  th e n  s lo w ly  a llo w e d  to  c o o l  
to  4  ° C  o v e r n ig h t  T h is  m ix tu r e  w a s  stirr ed  a t  4  ° C  fo r  4  d a y s , 
a t  w h ic h  t im e  th e  r e s u lt in g  d u p le x  a d d u c t  w a s  s e p a r a te d  fr o m  
e x c e s s  d r u g  b y  c o n v e n t io n a l  c o lu m n  c h r o m a to g r a p h y . C h r o ­
m a t o g r a p h y  w a s  c a r r ie d  o u t  a t  a m b ie n t  te m p e r a tu r e  w ith  
h y d r o x y la p a t i t e  a s  t h e  a d s o r b e n t  a n d  a  s lo w  l in e a r  g r a d ie n t  
o f  a q u e o u s  s o d iu m  p h o s p h a te  b u ffe r ,  p H  6 .8 ,  in c r e a s in g  fro m  
10  to  2 0 0  m M  a n d  w a s  m o n it o r e d  b y  a b s o r b a n c e  a t  2 5 4  n m . 
T h e  a p p r o p r ia te  d u p le x  a d d u c t  fr a c t io n s  w e r e  a d so r b e d  o n to  
fo u r  W a t e r s  C - l 8  s e p - p a k s  c o n n e c t e d  in  t a n d e m . A f t e r  th e  
se p -p a k s  w e r e  w a sh e d  w ith  w a te r , th e  d u p le x  a d d u c t  w as e lu te d  
w ith  2 0 %  m e th a n o l  in  w a t e r ,  a n d  th e  e lu e n t  w a s  ly o p h iliz e d  
to  d r y n e s s .
CONH.
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figure 4: (A) 500-M Hz proton N M R  spectrum (0 .9 -9 .2  ppm) o f the b is(tom aym ycin)-l 2-mer adduct in buffered D 20  at 24 °C . The arrow 
points to the nonexchanged 4G amino proton. (B ) Contour plot o f the N O E S Y  spectrum (250-m s m ixing tim e) o f  the adduct at 24 °C . (C ) 
Contour plot of the magnitude C O SY  spectrum at 24 °C . Arrow A shows the scalar coupling between the 4G hydrogen-bonded amino proton 
uni tomaymycin HI 1. Arrow B denotes the scalar coupling predicted for the 115 diastereom er o f  this adduct between the tom aym ycin H I 1 
and H11 a protons.
(B) Fluorescence Experiments. T h e  s o lu t io n  fo r  f lu o r e s ­
cence experiments w a s  p r e p a r e d  b y  d is s o lv in g  1 7 .7  A ^  u n it s  
of a lyophilized s a m p le  o f  t h e  1 2 -m e r  a d d u c t  in  0 .9  m L  o f  
water and d ilu tin g  3 - f o ld  w ith  b u f fe r .  T h e  f in a l  s o lu t io n  h a d  
4o = 6.5 and A332 =  0 .3 3  in  a  1 -c m  c u v e t t e .  T h e  to m a y -  
mycin concentration  w a s  9 .7  X  10"5 M , b a s e d  o n  t h e  a b s o r ­
bance at 332 nm  a n d  a n  e x t in c t io n  c o e f f i c i e n t  o f  3 .4  X  1 0 3 
M 'cm"1 for th e  t o m a y m y c i n - D N A  a d d u c t  ( B a r k le y  e t  a l . ,  
1986). The d o d e c a m e r  c o n c e n t r a t io n  w a s  a b o u t  7 .6  X  10"4 
M duplex, based o n  th e  a b s o r b a n c e  a t  2 6 0  n m , a n  e x t in c t io n  
coefficient o f  7 .4  X  1 0 3 M " 1 c m -1 fo r  t h e  d u p le x ,  a n d  a n  
extinction c o e ff ic ie n t  o f  9  X  1 0 3 M _1 c m -1 fo r  t o m a y m y c in  
(Arima et al., 1 9 7 2 ) . T h e  e x t in c t io n  c o e f f ic ie n t  o f  th e  d u p le x  
was estimated fr o m  t h e  b a s e  s e q u e n c e  ( CRC Handbook o f  
Biochemistry and M olecular Biology) w i t h  2 0 %  h y p e r -  
diromicity, a s su m in g  t h a t  g u a n o s in e  a n d  in o s in e  m o n o -  a n d  
dinucleotides have th e  s a m e  e x t in c t io n  c o e f f ic ie n t s .  U n b o u n d
t o m a y m y c in  w a s  r e m o v e d  b y  e x t r a c t io n  4  t im e s  w ith  e t h y l  
a c e ta te  a n d  tw ic e  w ith  e th e r . E th e r  w a s  r e m o v e d  w ith  a  s tr e a m  
o f  N 2. T h e  s a m p le  w a s  p la c e d  in  a  4  X  1 0  m m  s to p p e r e d  
c u v e t t e .
Proton N M R  Experiments. N M R  s a m p le s  fo r  t h e  u n ­
m o d if ie d  o l ig o d e o x y n u c le o t id e  a n d  its  b is ( to m a y m y c in )  a d d u c t  
c o n ta in e d  b e tw e e n  2 1 0  a n d  2 5 0  A ^ o  u n its  in  6 0 0  pL  o f  10  m M  
N a H 2P 0 4, 1 0 0  m M  N a C l ,  a n d  0 .0 1  m M  E D T A - b u f f e r e d  
D 20 ,  p H  6 .8 .  S a m p le s  w e r e  d e g a s s e d  w i t h  a r g o n  p r io r  to  
N M R  a n a ly s i s .  O n e -  a n d  t w o - d im e n s i o n a l  p r o to n  a n d  
p h o sp h o ru s  N M R  e x p e r im e n ts  in  D 20  a n d  H 20  w e r e  r ec o rd e d  
o n  a  G N  5 0 0  F T  N M R  s p e c t r o m e t e r .  C h e m ic a l  s h i f t s  a r e  
r e p o r te d  in  p a r t s  p e r  m i l l io n  w it h  p o s i t iv e  v a lu e s  d o w n f ie ld  
f r o m  a n  e x t e r n a l  r e f e r e n c e  o f  1 m g / m L  T S P  in  D 20  fo r  'H  
a n d  a n  e x t e r n a l  r e f e r e n c e  o f  8 5 %  H 3P 0 4 in  D 20  fo r  31P  r e s ­
o n a n c e s .
O n e - d im e n s io n a l  a n d  N O E  d i f f e r e n c e  s p e c tr a l  a n a ly s e s  o f
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the nonexchangeable protons and exchangeable imino protons 
were performed on the D20  sample and the same sample that 
had been lyophilized and redissolved in 90% H2O/10% D20 .  
Suppression of the H20  signal was achieved with a 1-3-3-1 
pulse sequence (Hore, 1983), and the exchangeable protons 
were assigned at 23, IS, 10, 5, and 0 °C as before (Graves 
et al., 1985). Tx experiments were performed with the 
standard nonselective 180°-f,-90° pulse sequence (Cheatham 
et al., 1988),
For all two-dimensional experiments a presaturation pulse 
was applied to suppress the HOD signal. Homonuclear scalar 
coupling was determined by using the standard-magnitude 
two-dimensional COSY and phase-sensitive two-dimensional 
double quantum Filtered COSY. 2K complex points in f2 and 
256 points in the /j domain were acquired. Likewise, the 
phase-sensitive two-dimensional NOESY experiments were 
acquired with 2K data points in t2 and 256 points in tx. A pulse 
repetition time of 0.5 s was used for all COSY experiments 
and 2 s for each NOESY experiment. Mixing times of 50, 
100, 250, and 400 ms were used for the phase-sensitive two- 
dimensional NOESY experiments and were stochastically 
varied to suppress cross peaks arising from scalar coupling 
(States et al., 1982). For all proton two-dimensional phase- 
sensitive experiments, a 45°-shifted sine bell function was 
applied to the data in both dimensions prior to transformation. 
For all two-dimensional proton experiments, the data were zero 
filled in t x such that the final frequency domain spectra con­
sisted of 1K X IK data matrices after symmetrization. Pro­
ton-decoupled phosphorus spectra were collected at 202.44 
MHz. Phosphorus-detected, 'H-^P /-correlation experiments 
were performed according to the procedure described by Bax 
and Sarkar (1984).
Time-Resoloed Fluorescence Studies. Fluorescence decay 
measurements were made by the time-correlated single-photon 
counting technique as described before (Barkley et al., 1986). 
Decay curves were acquired at 5 °C to about 15 X 103 counts 
in the peak. The data were fitted by reference deconvolution 
'(Kolber & Barkley, 1986) to a sum of exponentials
KKvKmV) = Ea,(Xex,Xem) exp(-r/r,)
with amplitudes a, and lifetimes 7> In the case of ground-state 
heterogeneity, the amplitude a, of component / depends on its 
molar extinction spectrum, fluorescence emission spectrum, 
radiative lifetime, and concentration. Decay curves measured 
at 313-, 337-, and 355-nm excitation wavelength and 420-nm 
emission wavelength were analyzed by a global program, as­
suming that the lifetimes but not the amplitudes are inde­
pendent of wavelength (Knutson et al., 1983).
Molecular Modeling Studies. The crystal structure of TME 
(Arora, 1981) was used as the initial structure in this inves­
tigation. Partial atomic charges for tomaymycin with the 
methoxy group removed (for covalent bonding) were obtained 
from ab initio calculations as reported previously (Cheatham 
et al., 1988). The resulting structure was minimized by using 
the program amber 2.0 (Weiner & Kollman, 1984) and all 
atom force-field parameters (Weiner et al., 1984). A dis­
tance-dependent dielectric constant was used, and energy re­
finement was continued untl the rms gradient was less than
0.1 kcal/(mol A). The cutoff distance for nonbonded pairs 
was 99 A, and the nonbonded pair list was updated every 100 
cycles. The heptanucleotide duplex structure d(CICG- 
AAT-GCICTTA) was constructed and brought to a minimum 
energy in the same way. The minimized tomaymycin structure 
was docked to this duplex near *G in four different orientations 
with the aid of the interactive graphics program midas (Ferrin 
et al., 1988a,b). Each of the docked structures was brought
to minimum energy as described above. Helix distortion en­
ergies were determined by subtracting the energy of the helix 
in the covalent complex from that of the separately minimized 
helix, and distortion induced in tomaymycin in the complex 
was determined in the same way.
Structural effects of water and counterions were neglected 
in energy calculations on the complexes. Although these ef­
fects influence the absolute values of binding energies, they 
should be negligible in comparisons of relative binding energies 
wherein the same drug is used at the same bonding site on the 
duplex.
Results
Proton NM R Comparison o f  the Inosine-Disubstituted 
Dodecamer [d(CICGAATTCICG)2] 'with the Dickerson Do­
decamer [d(CGCGAA TTCGCG)^\. The chemical shifts and 
Tx relaxation times of select protons of the inosine-disubstituted 
12-mer (Figure 2) are listed in Table I. Comparison of these 
results with previously published values (Reid, 1983) for the 
Dickerson dodecamer shows that the effect of substituting 
inosine for guanine at *G and 10G on chemical shifts of oli- 
godeoxynucleotide protons is minimal. Where changes occur, 
these are restricted to the base pairs containing the inosine 
and in rare instances to the adjacent base pair. For example, 
the imino protons of 2I -UC and 3C -I0I move downfield by 
about 2 ppm, and the chemical shifts o f nonexchangeable 
aromatic protons of 2I and l0I become more characteristic of 
adenine than guanine. In the deoxyribose moieties of 2I and 
l0I the HI', H2', and H2" proton signals are shifted downfield 
relative to the equivalent guanines in the Dickerson dodecamer. 
For all other sugar protons observed, the chemical shift change 
is less than 0.05 ppm with the exception of 9C and 4G, where 
H I' protons are shifted upfield by about 0.2 ppm.
The one-dimensional proton and two-dimensional COSY 
spectra of the inosine-disubstituted dodecamer are available 
(see paragraph at end of paper regarding supplementary 
material). The expected scalar cross peaks between the two 
thymine H6 and 5-CH3 and four cytosine H5 and H6 protons 
are evident.
Symmetry o f  the Complex. (A) Phosphorus NMR Com­
parison o f  the d(CICGAATTCICG)2 Duplex and Tomay- 
mycin-d{CICGAATTCICG)2 Adduct. A comparison of the 
proton-decoupled phosphorus spectra of d(CICGAATT- 
CICG)2 and its tomaymycin adduct is shown in parts A and 
B of Figure 3, respectively. While the individual phosphorus 
chemical shifts have changed in the 12-mer adduct species 
relative to the duplex alone, the overall complexity (i.e., the 
number of 31P resonance signals) of the spectrum has not 
changed appreciably. In each case approximately 11 phos­
phorus resonances can be identified (see later in Figure 9). 
The constant number of phosphorus resonances in the duplex 
and its 12-mer adduct implies that the duplex adduct has 
maintained the self-complementarity of the duplex and 
therefore has become associated with an even number of to­
maymycin molecules (presumably two), each of which is 
equivalent in all respects. One of the phosphorus signals in 
the 12-mer adduct has shifted downfield, most likely indicative 
of a structural perturbation of the deoxyribose phosphate 
backbone as a consequence of tomaymycin bonding to the 
12-mer duplex (see later).
(B) Nonexchangeable Proton Assignments in the Tomay- 
mycin-d{CICGAATTCICG)i Adduct. The 500-MHz proton 
NM R of the tomaymycin-d(CICGAATTCICG)2 adduct is 
shown in Figure 4A. The majority of the signals are well 
resolved and have been assigned by two-dimensional NMR
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Table II: Comparison of the Nonexchangeable Proton Chemical Shift® Assignments (ppm) in 
Tomaymycin-12-mer Duplex Adduct
Tomaymycin6 Alone and in the
species H IV H 3V H6 7-OCHj H9 H ll HI la H12 H13
tomaymycin ( ll/? ,lla S )  


























‘Chemical shifts are in parts per million using TSP as an internal reference. 6 For numbering of tomaymycin, see Figure 2. 'Individual chemical 
shift assignments for each pair of HI and H3 protons were not made, and therefore A5 values are omitted. ‘'Underlined are > ± 0 .3  ppm.
W
TOM -OH ^ N H J
a. LJLI. Ji-
figure 5: (A) 500-M Hz proton N M R  spectrum (1 2 -1 6  ppm) o f  the 
bis(tomaymycin)-d(CICGAATTCICG)2 adduct in buffered 90% 
HjO/10% DjO, pH 6.8 at 24 °C . One-dimensional N O E  difference 
spectra following saturation (2  s) o f  (B ) the 14.13 ppm and (C ) the 
1159 ppm exchangeable resonances in the complex. The assignments 
of the imino protons o f  the com plex and the phenolic proton of 
tomaymycin at 10 °C  are listed in Tables I and II.
spectra u tiliz ing  t h r o u g h -b o n d  ( C O S Y )  a n d  t h r o u g h - s p a c e  
(NOESY) c o n n e c t iv it ie s  ( s e e  l a t e r ) .  T h e  p h a s e - s e n s i t iv e  
NOESY (m ix in g  t im e  2 5 0  m s )  a n d  m a g n itu d e  C O S Y  sp e c tr a  
are plotted in p a r ts  B  a n d  C  o f  F ig u r e  4 ,  r e s p e c t iv e ly .  T h e  
chemical shift a s s ig n m e n ts  fo r  th e  n u c le o t id e  a n d  to m a y m y c in  
protons in the d u p le x  a n d  t h e  t o m a y m y c in - d u p le x  a d d u c t  a r e  
listed in T a b les I a n d  II .
A com parison o f  th e  p r o to n  s p e c t r a  o f  t h e  d u p le x  a n d  to ­
maymycin-duplex a d d u c t  d o e s  n o t  r e v e a l  a n y  in c r e a s e  in  
complexity; i.e ., s a m e  n u m b e r  o f  r e s o n a n c e s  a r e  fo u n d  in  b o th  
spectra, ex cep t fo r  a n  a d d i t io n a l  s e t  o f  t o m a y m y c in  p r o to n  
resonances in th e  d u p le x  a d d u c t .  T h is  o b s e r v a t io n  c o n f ir m s  
the symmetry o f  th e  t o m a y m y c in - d u p le x  a d d u c t  r e v e a le d  a lso  
in the p h osph orus s p e c t r a  ( F ig u r e  3 ) .
Identification o f the Covalent Linkage Sites between To­
maymycin and DNA in the Bis(tomaymycin)-d(CICGA- 
ATTCICG)2 Adduct. T h e  p r o to n  N M R  o f  t h e  im in o  r e g io n  
o f  th e  b i s ( t o m a y m y c in ) - d ( C I C G A A T T C I C G ) 2 a d d u c t  in  90%  
H 20  is  p lo t t e d  in  F ig u r e  5 A .  S i x  im in o  p r o to n  s ig n a l s  a r e  
fo u n d  in  th e  r e g io n  b e tw e e n  1 2  a n d  1 6  p p m  a n d  a r e  id e n t if ie d  
in  T a b le  I . T h e s e  w e r e  a s s ig n e d  b y  o n e - d im e n s io n a l  N O E  
e x p e r im e n t s ,  a n d  a  r e p r e s e n ta t iv e  N O E  d i f f e r e n c e  s p e c tr u m  
is  s h o w n  in  F ig u r e  5 B . T h e  tw o  p r o to n s  u p f ie ld  o f  th e  im in o  
r e g io n  in  F ig u r e  5 A  a r e  th e  to m a y m y c in  p h e n o lic  p r o to n  (1 0 .5  
p p m ) a n d  th e  *G  h y d r o g e n -b o n d e d  2 -a m in o  p r o to n  (8 .9 5  p p m ). 
T h e  a s s ig n m e n t  o f  t h e  4G  h y d r o g e n - b o n d e d  2 - a m in o  p r o to n  
( N  H b)  w a s  m a d e  b y  ir r a d ia t io n  o f  t h e  4G  im in o  p r o to n  a n d  
o b s e r v a t io n  o f  t h e  n o n e x c h a n g e a b le  b a s e  a n d  a m in o  p r o to n  
r e g io n  ( 7 . 0 - 9 . 0  p p m )  ( F ig u r e  5 C ) .  I r r a d ia t io n  o f  t h e  4G - 9C  
im in o  p r o to n  r e s u lts  in  N O E s  in to  t h e  ^  N H b, 9C  N H h , a n d  
m o s t  l ik e ly  t h e  9C  H 6 .
T h e  ^  N H b p r o to n  id e n t i f ie d  th r o u g h  th e  o n e -d im e n s io n a l  
N O E  e x p e r im e n t  ( s e e  F ig u r e  5 C )  a l s o  a p p e a r s  in  th e  o n e ­
d im e n s io n a l p r o to n  sp e c tr u m  run  in  D 20  (a r r o w  in  F ig u r e  4 A ) .  
N o r m a lly  g u a n in e  a m in o  p r o to n s  in  d u p le x  D N A  a r e  r a p id ly  
e x c h a n g e d  in  D 20 ,  b u t  in  th is  c a s e  t h e  e x c h a n g e  is  r e la t iv e ly  
s lo w , s u g g e s t in g  to m a y m y c in  m o d if ic a t io n  o f  th e  d u p le x  a t  th is  
s i t e .3 In  t h e  m a g n i t u d e  C O S Y  ( F ig u r e  4 C )  s c a la r  c o u p lin g  
is  e v id e n t  b e tw e e n  4G  N H b a n d  t h e  p r o to n  a t  C - l l  o f  to ­
m a y m y c in  (a r r o w  A ) .  T h is  e s t a b l is h e s  th e  p o in ts  o f  c o v a le n t  
a t t a c h m e n t  b e tw e e n  to m a y m y c in  a n d  d ( C I C G A A T T C I C G ) 2 
a s  C - 11 a n d  t h e  ^  e x o c y c l ic  2 - a m in o  n itr o g e n , r e s p e c t iv e ly .
Determination o f the Covalent Linkage Site Geometry and 
Orientation o f Tomaymycin in the Minor Groove o f d- 
(CICG A ATTCICG) i . (A) Molecular Modeling Predictions. 
In  p r in c ip le ,  t o m a y m y c in  c a n  a s s u m e  fo u r  d i f f e r e n t  b in d in g  
m o d e s  w h i le  c o v a le n t ly  b o n d e d  th r o u g h  N 2  o f  4G  o n  d -  
( C I C G A A T T C I C G ) 2. T h u s  fo u r  d i f f e r e n t  b in d in g  m o d e s  
w e r e  m o d e le d :  t h e  R a n d  S  c o n f ig u r a t io n s  a t  C - l l  o f  t o ­
m a y m y c in ,  e a c h  w ith  th e  d r u g  p o s it io n e d  in  th e  m in o r  g r o o v e  
so  th a t  its  a r o m a t ic  r in g  w a s  p o in t in g  to w a r d  th e  3 '  e n d  o r  th e  
5 '  e n d  o f  t h e  c o v a le n t ly  b o u n d  s t r a n d  o f  d ( C I C G A A T *  
G C I C T T A ) .  F o llo w in g  e n e r g y  m in im iz a t io n  in  a m b e r ,  th e  
n e t  b in d in g  e n e r g y  fo r  e a c h  s p e c ie s  w a s  c a lc u la t e d  fr o m  its  
to ta l in te r m o le c u la r  d r u g - D N A  b in d in g  e n e r g y  m in u s  th e  h e lix  
a n d  d r u g  d i s to r t io n  e n e r g ie s  t h a t  r e s u lt e d  fr o m  th e  in d u c e d  
f i t  ( T a b le  I I I ) .  T h e r e  w a s  a  p r e fe r e n c e  b y  2 .9  k c a l / m o l  fo r  
th e  c o v a le n t  a d d u c t  w ith  1 I S  c o n f ig u r a t io n  a n d  t h e  b e n z e n e  
r in g  to w a r d  t h e  3 '  d ir e c t io n  o v e r  th e  5 '-o r ie n te d  a d d u c t  w ith  
th e  s a m e  s t e r e o c h e m is t r y .  W h i le  th e  m o le c u la r  m e c h a n ic s  
r e su lts  c le a r ly  r u le  o u t  b o th  1 1 /?  d ia s te r e o m e r s , th e  d if fe r e n c e  
o f  2 .9  k c a l / m o l  is  c o n s id e r e d  in s u f f ic ie n t  t o  d e f in i t e ly  d i f ­
f e r e n t ia t e  b e t w e e n  t h e  t w o  1 I S  d ia s t e r e o m e r s .
T h e  e x p la n a t io n  fo r  th e  g r e a te r  s t a b i l i t y  o f  th e  p a ir  o f  1 I S  
d ia s te r e o m e r s  l ie s  n o t  in  d i f f e r e n c e s  in  d is to r t io n  e n e r g ie s  b u t
3 It is pertinent to note that Gao and Patel (1989) have observed 
separate resonance signals for the guanine 2-amino hydrogen-bonded 
(N H b) and exposed protons (N H e) in the chromomycin-DNA complex 
at around 8.1-8.6 and 5.7-6.7 ppm, respectively. Presumably, the bound 
chromomycin molecule prevents the N 2 guanine protons from rapidly 
exchanging, as normally occurs in duplex molecules.
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Tabic III: Energies (kcal/mol) of Covalent Complexes between Tomaymycin and d(CICGAAT-GCICTTA)*
intermolecular distortion'
confign at C-l 1 direction* total steric elstat total drug DNA total net binding*
5  3' -443.5 -25.7 -13.4 -39.1 <M 175 -21.2
S  S' -440.6 -29.2 -9.9 -39.1 1.0 19.7 20.7 -18.3
R y  -420.9 -15.0 -8.4 -23.4 2.5 22.2 19.7 -3.7
R______________y   -432.3 -24.6_______ -7.0 -31.6________ 23_______ 19J_______ 2F6_________-10.0
"These energies are valid only for comparison within the table. They should not'be compared with other drugs or other DNA segments. 
* Direction refers to orientation in the minor groove. 3' and S' are oriented with the aromatic ing to 3' or 5' sides, respectively. 'Drug distortion and 
helix distortion energies equal their values in the complex less their values when minimized alone (18.8 and -441.1 kcal/mol, respectively). 'N et 
binding energy equals the total intermolecular binding minus the total distortion energy.
Table IV: Energies (kcal/mol) for the Interactions of Tomaymycin 





4o  Ja  uC u-12P l2I 12-I3P 13S*
5 y -3.6 -4.7 -4.0
5 S' -3.1 -4.5 -4.7
R y
©l
R S' -3.9 -3.4
"Only energies >-3.0 kcal/mol are listed. *S stands for sugar.
in intermolecular binding energies (Table IV). Through a 
combination of steric and electrostatic interactions, where steric 
binding energies predominate, the 1 15 diastereomers are fa­
vored equally over 11/? diastereomers. According to these 
calculations the 3' orientation is then marginally favored over 
the 5' orientation on the basis of the relative distortion energies 
required for bonding in tomaymycin and DNA.
(B) Fluorescence Studies. Previously we showed that there 
are two fluorescent ground-state forms of tomaymycin in protic 
solvents and on calf thymus DNA and d(ATGCAT)2 (Barkley 
et al., 1986; Cheatham et al., 1988). We argued that the 
longer lifetime component represents the 115,1 la 5  diaster- 
omeric adduct, while the shorter lifetime component represents 
the 11/? adduct. In contrast, we found essentially one 
fluorescent species of tomaymycin on d(CICGAATTCICG)2, 
corresponding to the longer lifetime component or the
115,1 la 5  diastereomer (Table V). The fluorescence decay 
of the tomaymycin-d(CICGAATTCICG)2 adduct gave an 
acceptable fit to a monoexponential function with a Xr2 value 
of 1.4 and a lifetime of 6.4 ns. A slightly better fit with x r2 
= 1.2 was obtained by assuming a biexponential function. 
Including the second exponential term in the data analysis had 
little effect on the lifetime of the predominant species. As seen 
in Table V, the 6.4-ns lifetime lies within the range of values 
associated with the 115 diastereomeric adduct in calf thymus 
DNA and d(ATGCAT)2. On the basis of the relative decay 
amplitudes at in the bis(tomaymycin)-d(CICGAATTCICG)2 
adduct, the 115 diastereomer is present in at least 10-fold 
excess over the short-lifetime species. The 1.6-ns lifetime may 
be due to small amounts of unbound tomaymycin, a second 
species of the tomaymycin-duplex adduct, or an unresolved 
mixture of the two. Molecular modeling data (Table III) 
would suggest that the second most energetically favored 
species is the 115,5'-oriented adduct Since this species should 
have the longer lifetime (6.4 ns), we propose that the small 
amount of the second species observed by fluorescence is free 
tomaymycin. Attempts to fit the fluorescence decay to a 
triexponential function were unsuccessful.
(C) Proton N M R Studies. ( / )  Stereochemistry at the 
Covalent Linkage Site. Examination of the magnitude COSY 
spectrum of the bis(tomaymycin)-d(CICGAATTCICG)2 
adduct shows scalar coupling of the 11 and 11a protons of 
tomaymycin (arrow B in Figure 4C). In addition to firmly
Table V: Fluorescence Decay Data for Tomaymycin Bound to Calf 
Thymus DNA, d(ATGCAT)2, and d(ClGCAATTCICG)2"_______
Kx (nm) «i* T| (ns) «2 r2 (ns)
calf thymus DNA' 313 0.35 3.8 0.65 6.7
337 0.31 0.69
355 0.28 0.72
d(ATGCAT)2 313 0.43 2.3 0.57 5.7
337 0.52 0.48
355 0.63 0.37
d(CIGCAATTCICG)2 313 0.11 1.6 0.89 6.4
337 0.08 0.92
355 0.08 0.92
• Decay parameters were obtained by global analysis of decay curves 
measured at the indicated excitation wavelengths and emission wave­
lengths between 390 and 490 nm. * Fractional amplitudes *= 1. 
'Data for pH 7.5, 5 °C, from M. D. Barkley, F. N. Chowdhury and K. 
Maskos (manuscript in preparation). Amplitudes and lifetimes are 
independent of pH in the range 6.4-9.0.
assigning the 5.48 ppm resonance signal to the proton at C l 1 
of tomaymycin (which is shifted downfield by 0.9 ppm relative 
to its chemical shift in free tomaymycin), the scalar coupling 
of protons at C l 1 and Cl la potentially provides stereochemical 
information on the linkage site geometry.4 In TME only the
115.1 la 5  diastereomeric species shows scalar coupling between 
protons at Cl 1 and Cl la  because the dihedral angle between 
these protons in the 11/?,1 la 5  diastereomer is close to 90° 
(Barkley et al., 1986). Molecular modeling using am ber was 
carried out on both diastereomeric species ( l l /? , l la 5  and
115.1 la5) of tomaymycin bound covalently to the inosine- 
disubstituted dodecamer with each having a 3' orientation of 
the aromatic ring of tomaymycin to 4G. Only these two species 
were modeled since the NOE data narrowed down the four 
possible species to the 3'oriented adducts (see later). The 
results showed that only the 115,1 la 5  species was predicted 
to have significant scaler coupling between protons at Cl 1 and 
Cl la; i.e., the dihedral angles between the protons at C l 1 and 
Cl la in the 115 and 11/? species are predicted to be 175.7° 
and 71.5°, respectively. The assignment of the species of 
tomaymycin bound to 12-mer duplex as the 115,1 la 5  dia­
stereomer is also consistent with the fluorescence results (see 
Table V).
(2) Orientation o f  Tomaymycin in the Minor Groove o f  the 
12-mer Duplex. In principle, the tomaymycin molecule may 
be oriented with the aromatic ring either to the 3' side or to 
the 5' side of covalently modified guanine in the 12-mer ad­
duct. To assign the orientation of tomaymycin in the minor
4 In a previous paper on tomaymycin-d(ATGCAT)2 (Cheatham et al., 
1988), we had only reported one set of scalar cross peaks for coupling 
of the 11 and 1 la protons. However, there is a second set of scalar cross 
peaks for the 11 and 1 la protons that we had overlooked. For this second 
set, reported for the first time, the proton at C-l 1 has a chemical shift 
of 4.42 ppm. Molecular modeling using amber (Remers, unpublished 
results) predicts scalar coupling between the protons at Cl 1 and Cl la 
for both tentatively identified tomaymycin-(ATGCAT)2  adducts (115, 
S' orientation, and 11R, 5' orientation), in contrast to the results reported 
here for the equivalent bis(tomaymycin)-! 2-mer adducts.
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f ig u re6: Phase-sensitive N O E S Y  (250-m s m ixing tim e) expanded contour plots o f the Pu H8 and the Py H 6 to H I' protons for the (A )  
duplex and (B) duplex adduct. Intranucleotide cross peaks are indicated and the sequential 3' to 5' walks between the base and H i '  protons 
retraced. Box A in panel B shows the tom aym ycin H 9 cross peaks to 5A  and 6 A  H 2s.





7 . 4 7 . 2 7 . 08 . 0 7 . 8 7 . 68 . 4 8 . 2
8
t - c h 3






7 . 07 . 27 . 47 . 67 . 88 . 08 . 28 . 4
T 0 M 1 3 - C H 3
8 T - C H 3
7 T - C H 3
f ig u r e  7: Phase-sensitive N O E SY  (250-ms mixing time) expanded contour plots o f  the Pu H 8 and Py H6 to H2' and H2" protons for the 
(A) duplex and (B) duplex adduct. Intranucleotide connectivities are indicated with solid lines. Internucleotide connectivities are indicated 
with broken lines. Arrow A and box B in panel B denote the cross peak(s) between l0I H2 and the tomaymycin cthylidene methyl (A ) and 
H la and H lb  (B), respectively.
g r o o v e  o f  D N A ,  s p e c if ic  in te r m o le c u la r  d r u g -n u c le o t id e  N O E s  
n e e d  to  b e  id e n t i f ie d  b e t w e e n  u n a m b ig u o u s ly  a s s ig n e d  t o ­
m a y m y c in  a n d  d e o x y n u c le o t id e  p r o to n s . M o le c u la r  m o d e l in g  
s tu d ie s  s h o w  t h a t  t h e  H 9  a n d  e t h y l id e n e  m e t h y l  p r o to n s  o f  
to m a y m y c in  a r e  in  p r o x im ity  t o  t h e  f lo o r  o f  t h e  m in o r  g r o o v e  
o f  D N A  (P e tr u se k  e t  a l . ,  1 9 8 2 ) .  A d e n in e  a n d  in o s in e  H 2 s  th a t
a r e  lo c a te d  in  th e  m in o r  g r o o v e  a r e  p o t e n t ia l  " re p o rter  a t o m s ” 
to  d e t e c t  t o m a y m y c in  p r o to n s  v ia  N O E  c r o s s  p e a k s .  In  th e  
e x p a n d e d  N O E S Y  s p e c tr u m  ( F ig u r e  6 B )  c r o s s  p e a k s  a r e  e v ­
id e n t  b e t w e e n  t h e  t o m a y m y c in  H 9  a n d  b o t h  5A  a n d  6 A  H 2  
p r o to n s  ( b o x  A ) .  In  a d d i t io n ,  a  N O E  c r o s s  p e a k  is  fo u n d  
b e tw e e n  th e  to m a y m y c in  e th y lid in e  m e th y l  a n d  a  10I H 2  p roton
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Table VI: Tomaymycin-Nucleotide Interproton Distances 
Determined in the Energy-Minimized Species Having 115 
Stereochemistry with either a 3' or 5' Orientation
protons®
species T6 12-mer distance (A)
13-CHj to 10I H2 3.59®
H9 to 5A H2 2.96
H9 to 6A H2 6.03
H la to ,0I H2 2.28
H lb to ,0I H2 2.64
13-CHj to 5A H2 3.82®
H9 to ,0I H2 2.53
'For tomaymycin numbering, see Figure 2. ^Tomaymycin. 
'Average for all three C -H  bonds.
(Figure 7B , a r r o w  A ) ,  C o n f ir m a t io n  o f  t h e s e  N O E s  w a s  
toned by o n e -d im e n s io n a l N O E  d if fe r e n c e  e x p e r im e n ts , a n d  
ihccritical a ss ig n m e n ts  o f  a d e n in e  a n d  in o s in e  H 2  p ro to n s  w e re  
made by o n e -d im e n s io n a l  N O E  d i f f e r e n c e  e x p e r im e n t s  fr o m  
lino protons (u n p u b li s h e d  e x p e r im e n t s ) .
(D) Molecular Modeling Studies on the 3'- and 5'-Oriented 
IIS Adducts. S i n c e  th e  s t e r e o c h e m is t r y  a t  t h e  c o v a le n t  
I  Huge site h a d  b e e n  u n a m b ig u o u s ly  a s s ig n e d  b y  b o th  
I iluorescence a n d  p r o to n  N M R ,  j u s t  th e  3 ' a n d  5 ' o r ie n ta t io n s  
I wremodeled w ith  a m b e r  ( T a b le  V I ) .  O f  th e  tw o  s p e c ie s  
I modeled, only th e  to m a y m y c in  a d d u c t  h a v in g  th e  3 ' o r ie n ta t io n  
pve nucleotide—d r u g  in ter p ro to n  d is ta n c e s  th a t  w e r e  in  a c c o r d  
I lithe one- an d  tw o -d im e n s io n a l  N O E  e x p e r im e n ts  (F ig u r e s  
SB and 7B). F or  e x a m p le ,  th i s  s p e c ie s  ( 3 '  o r ie n t a t io n ,  1 I S  
I stereochemistry) is p r e d ic te d  to  h a v e  d r u g - n u c le o t i d e  in te r -  
I molecular d is ta n c e s  < 4 . 0  A fo r  th e  t o m a y m y c in  1 3 - C H 3 to  
PIH2,tom aym ycin H 9  to  5A  H 2 ,  a n d  t o m a y m y c in  H l a  a n d  
1 Hlbto I01 H 2. N O E  c r o s s  p e a k s  a r e  e v id e n t  fo r  a l l  fo u r  o f  
I these sets of p roton s ( F ig u r e s  6 B  a n d  7 B ) .  In  c o n tr a s t ,  N O E  
I cm peaks that a r e  p r e d ic te d  fo r  th e  5 ' -o r ie n te d ,  1 I S  s p e c ie s  
lintheNOESY sp e c tr u m  ( i .e . ,  t o m a y m y c in  1 3 - C H 3 to  5A  H 2  
I and tomaymycin H 9  to  10l H 2 )  a r e  a b s e n t .
I (£) Conclusions from  Combined Fluorescence, N M R , and 
\Micular Modeling Studies. T h e  f lu o r e s c e n c e  a n d  C O S Y  
I data provide in d ep en d en t e v id e n c e  fo r  th e  1 I S  s te r e o c h e m is tr y  
Inthccovalent l in k a g e  s it e .  O n e -  a n d  t w o -d im e n s io n a l  N O E  
lata provide the n e c e s s a r y  in te r p r o to n  d r u g - n u c le o t i d e  c r o s s  
Ifttksto assign th e  3 ' o r ie n ta t io n  o f  to m a y m y c in  in th e  1 2 -m e r  
Ifcplex adduct. T h e r e fo r e  th e  s p e c ie s  o f  t o m a y m y c in  b o u n d  
WGin the 12-m er d u p le x  a d d u c t  h a s  a n  1 I S  s t e r e o c h e m ic a l  
■Wtage to N 2 o f gu a n in e , a n d  th e  a r o m a t ic  r in g  o f  to m a y m y c in  
Ik  to the 3' s id e  o f  4G .
I Assignments o f Deoxynucleotide Proton and Phosphorus 
Ip i iv m  in the 12-mer Adduct and Effect o f  Tomaymycin 
UMifif on Backbone and Sugar Geometry o f  d{C!CGA- 
w7TC/CG)2. ( A ) Two-Dimensional N O E SY  Experiments. 
ins A and B o f  F ig u re  6  s h o w  e x p a n d e d  c o n to u r  p lo ts  o f  th e  
Be-sensitive N O E S Y  ( 2 5 0  m s)  fo r  th e  b a s e  a n d  H I '  p ro to n s  
(d(CICGAATTCICG)2 in  b o th  t h e  1 2 -m e r  d u p le x  a n d  
is(lomaymycin)— 12 -m er  a d d u c t . T h e  o n e -d im e n s io n a l  sp e ctr a  
redrawn above th e  p lo ts  t o  i l lu s t r a t e  t h e  a m p le  r e s o lu t io n  
ttween the individual n u c le o t id e  r e s o n a n c e s ,  w h ic h  s im p lif ie d  
I*task of resonance a s s ig n m e n ts .  A s  o b s e r v e d  in  t h e s e  fig -  
topurine H8 and p y r im id in e  H 6  p r o to n s  e x h ib i t  N O E s  to  
Kir own HI' protons a n d  to  th e  H i ' s  o f  th e ir  5 '  n e ig h b o r s ,  
toeristicof a r igh t-h a n d ed  d u p le x  ( H a r e  e t  a l . ,  1 9 8 3 ; R e id ,  
7̂; Patel et al., 19 87). W ith  th e s e  c o n n e c t iv it ie s  e s ta b lish e d ,  
Sgnments of the m a jo r ity  o f  th e  o l ig o d e o x y n u c le o t id e  su g a r  
Wons(except H 5 's)  c a n  l ik e w is e  b e  m a d e  b y  u s in g  N O E  
Speaks between th e  b a s e  a n d  o th e r  s u g a r  p r o to n s  (T a b le  
I !• These assignm ents a r e  fu r th e r  c o n f ir m e d  w ith  th e  c o m ­
p le m e n ta r y  s c a la r  c o u p l in g  o b s e r v e d  in  th e  tw o - d im e n s io n a l  
C O S Y  s p e c tr u m .
T h e  a s s ig n m e n ts  o f  s u g a r  H 2 "  a n d  H 2 '  p r o to n s  in  th e  12 -  
m er  a n d  b is ( t o m a y m y c in ) -  1 2 -m e r  a d d u c t  a r e  m a d e  fr o m  th e ir  
N O E S Y  c ro ss  p ea k s  to  in ter - a n d  in tr a n u c le o t id e  b a s e  p ro to n s  
(F ig u r e  7 ) .  In a d d itio n , q u a lita t iv e  a n a ly s is  o f  th e  b a se  H 8 / H 6  
to  H 2 "  a n d  H 2 '  p r o to n  N O E S Y  c r o s s  p e a k s  a t  lo w e r  m ix in g  
t im e s  ( 5 0  a n d  1 0 0  m s )  is a  r e c o g n iz e d  m e a n s  t o  e v a lu a t e  th e  
p u r in e  O r - C , / - N 9- C 4 a n d  p y r im id in e  0 , / - C , / - N I- C 2 g ly c o -  
s id ic  d ih e d r a l a n g le  r a n g e s  s y n , a n t i ,  a n d  h ig h  a n t i  ( H o s u r  e t  
a l .,  1 9 8 6 ;  K u m a r  e t  a l . ,  1 9 8 5 ;  C h a r y  e t  a l . ,  1 9 8 7 ) .  F r o m  th e  
d a t a  in  T a b le s  V II  a n d  V I I I  w e  t e n t a t iv e ly  c o n c lu d e  th a t  a  
s ig n if ic a n t  n u m b e r  o f  g ly c o s id ic  d ih e d r a l  a n g le s  in  th e  u n ­
m o d if ie d  d u p le x  a r e  in  t h e  h ig h - a n t i  d o m a in  ( 21 , 7T , 8T , l0 I, 
l2G ) ,  w h ic h  s u g g e s t s  a  D N A  s tr u c tu r e  d e v ia n t  fr o m  th e  
c la s s ic a l  B - fo r m .5 T w o  o f  th e  h ig h -a n t i  g ly c o s id ic  a n g le s  a r e  
a sso c ia te d  w ith  su b stitu tio n  o f  d e o x y in o s in e  fo r  d e o x y g u a n o s in e  
in to  th e  d o d e c a m e r  ( 2l ,  10I ). T h e  h ig h -a n t i  g ly c o s id ic  d ih e d r a l  
a n g le  for n u c le o t id e  12G  m a y  b e  d u e  to  fr a y in g  a t  th e  o l ig o m e r  
te r m in i, b e c a u se  th is  l in k a g e  is n o t a s  r e s tr ic te d  a s  th o se  m o r e  
in te r n a l .  In th e  b i s ( t o m a y m y c i n ) - d ( C I C G A A T T C I C G ) 2 
a d d u c t ,  o n ly  n u c le o t id e  8T  c o n t in u e s  to  e x h ib i t  a  g ly c o s id ic  
d ih e d r a l  a n g le  in  th e  h ig h - a n t i  fo r m , w ith  t h e  r e m a in d e r  o f  
t h e  n u c le o t id e s  h a v in g  g ly c o s id ic  d ih e d r a l  a n g le s  in  th e  a n t i  
r a n g e , w h ic h  is  c o n s is t e n t  w ith  a  B - fo r m  D N A .
T h e  n o n sc a la r  c r o s s  p e a k s  b e tw e e n  b a s e  H 8 / H 6  a n d  s u g a r  
H 2 "  a n d  H 2 '  p r o to n s  h a v e  a ls o  b e e n  u s e d  t o  d is t in g u is h  b e ­
tw e e n  A -  a n d  B - ty p e  h e l ic e s  ( H a a s n o o t  e t  a l . ,  1 9 8 4 ) .  In th e  
c a s e  o f  A - t y p e  D N A ,  th e  C 3 ' - e n d o  s u g a r  g e o m e t r y  p r e d o m ­
in a te s  a n d  in te r n u c le o tid e  c r o s s  p e a k s  b e tw e e n  H 8 / H 6  p ro to n s  
to  th e  5 ' - n e ig h b o r in g  H 2 '  p r o to n s  a r e  s t r o n g e r  th a n  th o s e  to  
th e  c o r r e s p o n d in g  in tr a n u c le o t id e  H 2 '  p r o to n s . T h e  c o n v e r s e  
is  t r u e  fo r  B - ty p e  D N A ,  w h e r e  C 2 ' - e n d o  s u g a r  g e o m e t r y  
p r e d o m in a te s  a n d  t h e  in t r a n u c le o t id e  d i s t a n c e s  a r e  s h o r te r .  
T h e  in te n s it ie s  o f  th e s e  c r o s s  p e a k s  a t  lo w e r  m ix in g  t im e s  ( 5 0  
a n d  1 0 0  m s )  w e r e  u s e d  to  qualitatively confirm  t h e  s u g a r  
g e o m e tr y  a s s ig n m e n ts  m a d e  fr o m  th e  s c a la r  c o u p lin g  o b se r v e d  
o r  a b s e n t  in  th e  tw o - d im e n s io n a l  C O S Y  ( s e e  b e lo w ) .
( B) Two-Dimensional CO SY Experiments. S i n c e  th e  v i ­
c in a l  c o u p lin g  c o n s t a n t s  o f  D N A  s u g a r  r in g  p r o to n s  v a r y  a s  
a  fu n c tio n  o f  p se u d o r o ta tio n  a n g le  o r  su g a r  p u c k er , it is p o ss ib le  
to  a s s ig n  s u g a r  g e o m e t r ie s  to  e a c h  n u c le o t id e  o n  t h e  b a s is  o f  
ob serv ed  or  a b se n t sc a la r  c ro ss  p e a k s b e tw e e n  th e  su g a r  p roton s  
l is te d  in  T a b le  IB . A s  a n  e x a m p le ,  o n e  s t r o n g  in d ic a to r  o f  
d if f e r e n c e  in  s u g a r  g e o m e t r y  is th e  c o m p a r is o n  o f  c r o s s -p e a k  
in te n s ity  b e tw e e n  p r o to n s  o f  H I '  a n d  H 2 "  a n d  H I '  a n d  H 2 ' ,  
a s  s h o w n  fo r  t h e  b i s ( t o m a y m y c i n ) - d ( C I C G A A T T C I C G ) 2 
a d d u c t  ( F ig u r e  8 ) .  In th e  c a s e  o f  C 2 ' - e n d o  g e o m e t r y  fo r  
c la s s ic a l  B - ty p e  D N A  h e l ic e s ,  s t r o n g  s c a la r  c r o s s  p e a k s  b e ­
tw e e n  p r o to n s  o f  H I '  a n d  H 2 "  a n d  H I '  a n d  H 2 '  a r e  e x p e c te d .  
C o n v e r s e ly  fo r  C 3 ' - e n d o  g e o m e tr ie s ,  o r  A - t y p e  D N A  h e lic e s ,  
th e  J  c o u p lin g s  o f  H I '  to  H 2 '  a r e  e x p e c t e d  t o  b e  w e a k  or  
a b s e n t .  W ith  th is  c o n c e p t ,  th e  r e s u lt s  s h o w  t h a t ,  fo r  m o s t  
n u c le o t id e s  in  t h e  1 2 -m e r  a n d  th e  1 2 -m e r  a d d u c t ,  th e  s u g a r  
g e o m e t r ie s  a r e  m o s t ly  a r o u n d  o r  n e a r  C 2 ' - e n d o  o r  n e a r  
O l ' - e n d o  ( T a b le s  V II  a n d  V I I I ) .  In th e  d u p le x  3C ,  7T ,  a n d  
" C  a re  e x c e p tio n s , w h e r e  th e  a v e r a g e  C 3 '-e n d o  su g a r  g e o m e tr y  
o f  A - fo r m  h e l ic e s  p r e d o m in a te s .  U p o n  a d d u c t  fo r m a t io n  o f  
th is  d u p le x  w ith  t o m a y m y c in ,  o n ly  a t  MC  is  t h e  C 3 ' - e n d o  
g e o m e tr y  s t i l l  p r e s e n t .  F o r  n u c le o t id e s  3C  a n d  7T ,  th e r e  is  a
3 Wc are hesitant to place too much emphasis on the conclusions listed 
in Tables VII and VIII. As a referee correctly pointed out, our conclu­
sions are based upon qualitative trends in NOESY and COSY data sets. 
Until quantitative information is available, these should only be consid­
ered tentative.
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Table VII: Structural Information from the Relative Intensities' of COSY* and NOESY' Cross Peaks for d(CIGCAATTCICG)2
NOESY, NOE 
from H8/H6 to inference,glycosidic
angle
HP with
COSY, J coupling 
H3' with inference.
base H2" H2' H2" H2' H2" H2' H3' with H4' sugar pucker
•c W S anti S S W S S Ol'-endo
*1 S S high anti O (W ) M A O (M) M Cl'-exo.
3C W S anti S W W O (M) O (S ) C3'-endo
4G O O S S A W W C3'-exo
3 A o O M M A O (M) S OP-endo
‘A o O O (W ) O (M) A M O (S ) Ol'-endo
7T s S high anti M W A M s C3'-endo
•T s S high anti M W A M s Ol'-endo
*C M S anti S M A M s Ol'-endo
10, S S high anti O (M) O (M) A O (M) O (S ) Ol'-endo
"C W s anti S W A O (M) s C3'-endo
,JG S M high anti O (M) S S W s Ol'-endo
'A  = absent; W *  weak; M *  moderate; S *  strong; O = overlapping. Partially resolved cross-peak intensities are placed in parentheses. 
* Magnitude COSY and two-dimensional phase-sensitive double quantum filtered COSY cross peaks are examined. See Materials and Methods for 
details. 'Data from phase-sensitive two-dimensional NOESY experiments with mixing times of SO and 100 ms. See Materials and Methods for 
details.








COSY, J  coupling
inference, sugar pucker
HI'with H3' with
H3' with H4'H2" H2' H2" H2' H2" H2'
«C A S anti S S A S S Ol'-endo
Jl W S anti M S A W W C 1 '-exo-C2'-endo
3C W S anti M S M W O (S) Cl'-exo
*G W S anti W M A A A C 1'-exo-C2'-endo
SA (W) O (S ) anti W M A W O(W) C1'-exo-01'-endo
‘A W S anti w M A A O (M) •. Cl'-exo-Ol'-endo
7T W S anti M M A W O(W) * Cl'-exo-Ol'-endo
«T S S high anti O (M) M A W O(W) Cl'-exo-Ol'-endo
*C (W) M anti M A W O (M) O(W) Ol'-endo
10, o O O O A o
"C w S anti O(S) M A O O(S) C3'-endo
,JG (S) M anti O(S) S S S s Ol'-endo
'"'For footnotes, see Table VII.
shift toward more B-like structure upon adduct formation.
(O  Two-Dimensional Proton-Phosphorus J-Correlation 
Experiments. The majority of the phosphorus resonances in 
d(CICGAATTCICG)2 only undergo small changes in chem­
ical shift upon covalent modification with tomaymycin. 
However, one phosphorus resonance is significantly shifted 
downfield from the others (compare parts A and B of Figure 
3). This result is reminiscent of previous work in our labo­
ratory with covalent bonding of anthramycin to d(ATGCAT)2 
(Boyd et al., 1990). This observed downfield shift of the 
phosphorus resonance suggests a structural perturbation of the 
phosphate backbone as a result of covalent bonding. The 
contour plot of the phase-sensitive two-dimensional hetero- 
nuclear phosphorus-detected 3,P -‘H 7-correlation experiment 
is shown in Figure 9. Cross peaks connect the downfield- 
shifted phosphorus resonance to the 3C H3' and 4G H4', in­
dicating that the perturbation of the phosphate backbone is 
localized to the 5' side of the drug covalent bonding site.
Molecular Modeling o f  the Duplex and the Tomaymycin- 
Duplex Adduct. A 7-mer duplex [d(CICGAAT*ATTCICG)] 
containing a single tomaymycin bonding site and its 1 IS1, 
3/-oriented tomaymycin-duplex adduct were energy minimized 
by using am ber. Of the 14 sugars in the 7-mer duplex, nine 
were calculated to be C2'-endo, two Ol'-endo, and three 
Cl'-exo. Exactly the same pattern was found for the 1 IS1, 
3'-oriented tomaymycin-duplex adduct, except that it has a 
Cl'-exo pucker for the 2l sugar rather than a C2'-endo pucker. 
No significant differences were found in backbone dihedrals 
or torsional angles (x) involving base-sugar linkages. The
energy for the base pair 4G -MC is -15.3 kcal/mol in the 
tomaymycin-duplex adduct, compared with -21.6 kcal/mol 
for the 7-mer duplex. This magnitude of decrease was found 
for the base pair where a covalent bond to N2 of guanine 
occurs in anthramycin-d(ATGCAT)2 (Boyd et al., 1990). No 
other significant differences were found for base-stacking 
energies.
D iscussion
Structure o f  the Bis{tomaymycin)-l 2-mer Adduct. It has 
long been assumed on the basis of indirect evidence that the 
P(l,4)Bs covalently bond via C-l 1 to the exocyclic 2-amino 
group of guanine on DNA as shown in Figure 1 (Kohn et al., 
1974; Hurley & Petrusek, 1979). However, it is only now 
through the results described in this paper that this has been 
unequivocally demonstrated. The proton NMR assignment 
of the 4G hydrogen-bonded amino proton (Figure 5C) was 
crucial for this conclusion. Because of the covalent linkage 
of the 4G amino nitrogen to C-l 1 of tomaymycin, rotation of 
the remaining amino proton that forms one of the Watson- 
Crick hydrogen bonds between 4G and 9C is restricted, and 
consequently the normal rate of exchange with D20  is dra­
matically reduced. We are able to unambiguously assign by 
two-dimensional NMR experiments both the orientation 
(aromatic ring of tomaymycin to the 3' side of 4G) and co­
valent linkage stereochemistry (US') of the tomaymycin 
molecule at the covalent attachment site to 4G of the duplex. 
Gratifyingly, the conclusion from the proton NMR mea-
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F K 3 U R E 8 : Phase-sensitive double quantum filtered CO SY expanded contour plot o f the H I' to H2", H2' cross peaks for the bis(tom aym ycin)-l2-m er 
adduct. Solid lines connect the downfield H2"s to intranucleotide H2's.
o f  a n  a p p r o x im a t e  5 0 : 5 0  r a t io  o f  th e  s a m e  d ia s t e r o m e r s  o n  
d ( A T G C A T ) 2 (C h e a th a m  e t  a l .,  19 8 8 )  is  n o w  o n  firm  g r o u n d .
T h e  e n e r g y - m in im iz e d  s t r u c tu r e  o f  t h e  b i s ( t o m a y m y c i n ) -  
d ( C I C G A A T T C I C G ) 2 a d d u c t  h a v in g  t h e  e x p e r im e n t a l ly  
d e te r m in e d  11S  s te r e o c h e m is tr y  a n d  3 ' o r ie n ta t io n  in th e  m in o r  
g r o o v e  is  s h o w n  in  F ig u r e  1 0 . A n  o v e r la y  o f  t h e  d ( C I C G -  
A A T - A T T C I C G )  d u p le x  a n d  t h e  l l ^ ,  3 ' -o r ie n te d  t o m a y -  
m y c i n - 7 - m e r  a d d u c t  is  s h o w n  in  F ig u r e  1 1 . B o th  f ig u r e s  
p r e d ic t  m in im a l  d is to r t io n  o f  t h e  d u p le x  h e l ix ,  w h ic h  is  in  
a g r e e m e n t  w ith  th e  a n a ly s i s  o f  t h e  t w o - d im e n s io n a l  C O S Y  
a n d  N O E S Y  d a t a  (T a b le s  V I I  a n d  V I I I ) .
Effect o f  Tomaymycin Covalent Bonding on the Structure 
o f  d(CICGAATTCICG)2- C h a n g e s  in  c h e m ic a l  s h i f t s  o f  d e -  
o x y n u c le o t id e  p r o to n s  th a t  o c c u r  u p o n  t o m a y m y c in  m o d if i ­
c a t io n  a r e  m o s t ly  r e s tr ic te d  to  t h e  m in o r  g r o o v e  in  p r o x im ity  
to  th e  d r u g  o v e r la p  r e g io n , e .g . ,  I0I H 2  a n d  4G  H I '  ( s e e  T a b le
I ) .  T h e s e  c h a n g e s  in c h e m ic a l  s h i f t s  m a y  b e  in  p a r t  d u e  to  
t o m a y m y c in  s h ie ld in g  o r  d e s h ie ld in g  e f f e c t s .  H o w e v e r ,  o l i ­
g o m e r  p r o to n  c h e m ic a l  sh if t  c h a n g e s  m a y  a ls o  r e f le c t  a  c h a n g e  
in n u c le o tid e  s ta c k in g  g e o m e tr ie s  o r  a  c o n fo r m a tio n a l tr a n s itio n  
( P a t e l  e t  a l . ,  1 9 8 7 ) .  T w o - d im e n s io n a l  s p e c t r o s c o p y  r e s u lt s  
(T a b le s  V II  a n d  V I I I )  c o n fir m  c h a n g e s  in th e  g ly c o s id ic  a n g le s  
a n d  s u g a r  g e o m e t r ie s  fo r  t h e  1 2 -m e r  a f t e r  a d d u c t  fo r m a t io n .  
C o m p a r is o n  o f  J  c o u p lin g  in  T a b le s  V I I  a n d  V I I I  s h o w s  th a t  
tw o  o f  th e  m o s t  s u b s ta n t ia l  c h a n g e s  in  s u g a r  p u c k e r  o c c u r  a t  
t h e  s i t e s  o f  c o v a le n t  a t t a c h m e n t  ( 4G )  a n d  a t  i t s  5 ' - s id e  n u ­
c le o t id e  ( 3C ) .  W h ile  t h e s e  in f e r e n c e s  o f  s u g a r  g e o m e t r y  d o  
n ot re ly  o n  a  q u a n tita t iv e  m e a su r e  o f  p ro to n  c o u p lin g  c o n sta n ts , 
a s  fo r  th e  c a s e  o f  th e  D ic k e r s o n  d o d e c a m e r  ( B a x  &  L e r n e r , 
1 9 8 8 ) ,  t h e y  d o  a c c u r a t e ly  r e f l e c t  th e  p r e s e n c e  o f  d i f f e r e n t  
fu r a n o se  g e o m e tr ie s .  T h e  d o w n fie ld -s h if te d  3C - 4G  p h o sp h o ru s  
N M R  s ig n a l o f  th e  b is ( to m a y m y c in )  a d d u c t  ( s e e  F ig u re s  3 A ,B  
a n d  9 )  a l s o  s u p p o r ts  th e  p r o p o se d  c o n fo r m a t io n a l  c h a n g e s  a t  
n u c le o t id e s  3C  a n d  4G .
A  c o m p a r is o n  w a s  m a d e  o f  t h e  p s e u d o r o ta t io n  a n g le s  o f  
p u r in e  a n d  p y r im id in e  n u c le o t id e s  fr o m  th e  X - r a y  a n d  *H
0  B 1^.-—
f i g u r e  9: Expanded contour plot o f  the heteronuclear phospho­
rus-detected phase-sensitive two dimensional 31P -'H  J  correlation of 
thebis(tomaymycin)-! 2-mer adduct. Solid  lines denote definitive  
assignments. Broken lines denote tentative assignm ents.
surements concurs w ith  th e  in d e p e n d e n t  f lu o r e s c e n c e  a s s ig n ­
ment of stereo ch em istry  a t  th e  c o v a le n t  l in k a g e  s i t e .  T h is  
substantiates our p r ev io u s m o r e  t e n ta t iv e  c o r r e la t io n s  b e tw e e n  
fluorescence life tim es  a n d  in d iv id u a l  d ia s t e r e o m e r ic  a d d u c ts .  
These were in itia lly  m a d e  o n  th e  b a s is  o f  f l u o r e s c e n c e  a n d  
NMR correlations o f  fr e e  t o m a y m y c in  in  p r o t ic  a n d  a p r o t ic  
solvents. Thus our p r e v io u s ly  t e n t a t iv e  c o n c lu s io n  o f  a  6 5 :3 5  
ratio of the (1 1 5 ,1  l a S 1) -  a n d  (1 1  /? , 1 l a 5 ) - t o m a y m y c i n  d ia -  
stereomerson c a lf  th y m u s  D N A  ( B a r k le y  e t  a l . ,  1 9 8 6 )  a n d
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f ig u r e  10: Stereo drawing o f *G attached to tomaymycin showing the conformation obtained through minimization with a m b e r  (sec Materials 
and M ethods).
f ig u r e  1 1: Stereo drawing of the superimposed d(CICGAAT*ATTCICG) in orange and tom aym ycin-d(C IC G A A T*A TTC IC G ) in magenta 
and yellow.
N M R  d a t a  o f  d ( C G C G A A T T C G C G ) 2 ( D r e w  e t  a l . ,  1 9 8 1 ;  
B a x  &  L e r n e r , 1 9 8 8 )  a n d  fr o m  o u r  p r o to n  N M R  d a t a  o f  
d ( C I C G A A T T C I C G ) 2 a n d  i t s  b i s ( t o m a y m y c i n )  a d d u c t  
( s u p p le m e n t a r y  m a t e r ia l ) .  A  c o m p a r is o n  o f  th e  X -r a y - d e -  
te r m in e d  s t r u c t u r e  o f  th e  D ic k e r s o n  d o d e c a m e r  w ith  th e  s o ­
lu t io n  s tr u c tu r e  o f  t h e  in o s in e - s u b s t i t u t e d  o l ig o m e r  s h o w s  a  
p s e u d o r o t a t io n  a n g le  s h i f t  fr o m  c la s s i c a l  B - ty p e  to w a r d  
O l' - e n d o .  T h is  is  n o t  w ith o u t  p r e c e d e n t  ( C h a r y  e t  a l . ,  1 9 8 7 )  
a n d  m a y  a ls o  b e  in f lu e n c e d  b y  th e  s u b s t i tu t io n  o f  I fo r  G  w ith  
th e  a c c o m p a n y in g  lo s s  o f  o n e  h y d r o g e n  b o n d  fo r  e a c h  s u b ­
s t i tu t io n .  U p o n  fo r m a t io n  o f  t h e  b i s ( t o m a y m y c i n ) -  1 2 -m e r  
a d d u c t ,  th e  p o p u la t io n  o f  s u g a r  g e o m e t r ie s  fo r  th e  in o s in e -  
d is u b s t itu te d  1 2 -m e r  s h i f t s  b a c k  to w a r d  C 2 ' - e n d o .  F u r th e r ­
m o re , from  th is  a n a ly s is ,  it a p p e a r s  th a t  to m a y m y c in  s ta b iliz e s  
a B - ty p e  h e l ic a l  s t r u c t u r e  a f t e r  fo r m a t io n  o f  th e  c o v a le n t  
a d d u c t . M o le c u la r  m o d e l in g  r e su lts  s h o w  le s s  c h a n g e  in su g a r  
g e o m e tr ie s  o f  th e  d u p le x  u p o n  a d d u c t  fo r m a t io n , b u t  th e r e  is  
g e n e r a lly  a g r e e m e n t  b e tw e e n  th e  e x p e r im e n ta l  a n d  th e o r e tic a l  
s tu d ie s .
Relationship between Sequence Selectivity and Apparent 
Distortion o f  DNA. It is  in t r ig u in g  th a t  in  th e  a n t h r a m y -  
c i n - d ( A T G C A T ) 2 a d d u c t  two  p h o s p h o r u s  r e s o n a n c e s  a r e  
m o v e d  d o w n f ie ld  (B o y d  e t  a l . ,  1 9 9 0 ) ,  w h i le  in th e  to m a y m y ­
c in - 1 2 - m e r  d u p le x  a d d u c t  o n ly  one p h o s p h o r u s  r e s o n a n c e  is
m o v e d  d o w n fie ld . O n e  o f  th e s e  p h o s p h a te s  is c o m m o n  to  b o th  
th e  a d d u c ts  ( i .e . ,  th a t  to  th e  5 ' s id e  o f  th e  c o v a le n t ly  m o d if ie d  
g u a n in e )  w h ile  th e  o th e r  is u n iq u e  to  th e  a n th r a m y c in  a d d u c t  
a n d  is o n  th e  3 ' s id e  o f  g u a n in e  o n  th e  n o n c o v a le n t ly  m o d if ie d  
str a n d . I f  th e  d o w n f ie ld -s h if te d  p h o sp h o r u s  r e s o n a n c e  s ig n a ls  
a r e  a s s o c ia te d  w ith  d is to r t io n  o f  t h e  D N A  b a c k b o n e , w e  c a n  
te n ta t iv e ly  c o n c lu d e  th a t  u p o n  P ( 1 ,4 ) B  a d d u c t  fo r m a t io n  th e  
a n t h r a m y c in - d ( A T G C A T ) 2 a d d u c t  is m o r e  d is to r te d  th a n  th e  
b i s ( t o m a y m y c i n ) - !  2 -m e r  a d d u c t .  T h is  id e a  is  fu r th e r  s u p ­
p o r te d  b y  u n p u b l is h e d  31P  N M R  s t u d ie s  o n  a n t h r a m y c in  
b ou n d  to  a n  o l ig o m e r  c o n ta in in g  th e  c o v a le n t  b o n d in g  s e q u e n c e  
5 '-A G A -3 ' .  In th is  c a s e  d o w n fie ld -s h if te d  31P  r e so n a n c e  s ig n a ls  
a r e  n o t  o b s e r v e d . S i n c e  th is  o l ig o m e r  b e lo n g s  to  t h e  m o s t  
fav ored  P (1 ,4 )B  b o n d in g  s e q u e n c e  (5 ' -P u G P u ) ,  31P  N M R  m a y  
b e a s e n s i t iv e  to o l  to  e v a lu a t e  b a c k b o n e  d is to r t io n  o f  D N A ,  
a s  th is  r e la te s  to  P ( 1 ,4 ) B  p r e fe r r e d  s e q u e n c e  s e le c t iv it y .  T h is  
s u g g e s t s  a  s t r u c tu r a l  r a t io n a le  fo r  th e  e x p e r im e n t a l ly  d e t e r ­
m in e d  o b s e r v a t io n  th a t  5 ' - P y G P u  s e q u e n c e s  ( i .e . ,  5 ' - C G A  in  
th e  1 2 -m e r )  a r e  p r e fe r r e d  b o n d in g  s i t e s  o v e r  5 ' - P y G P y  s e ­
q u e n c e s  ( i .e . ,  5 ' - T G C  in th e  6 - m e r )  ( H e r t z b e r g  e t  a l . ,  1 9 8 6 ) .
Intermolecular Interactions Determining the Orientation 
and Stereochemistry o f  P(l,4)Bs on Different Sequences. T h e  
p h o sp h o ru s a n d  p ro to n  N M R  r e su lts  sh o w  p r e d o m in a n tly  ( i .e .,  
> 9 0 % )  o n e  s p e c ie s  ( I  I S 1, 3 ' )  o f  t o m a y m y c in  b o u n d  to  th e
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Tabic IX: Patterns for Binding of Tomaymycin with Individual Residues on Polynucleotides"
oligonucleotide
confign 
at C - l l direction residues*
d(ATGCAT)2 S 3' 5S “•S 4S 4C I0£ 10.1 lp "S "A 11.12 p ,2S
d(CICGAAT-ATTCICG) S 3' 6S 5S 5S SA 4G "C "-,2P ,2S ,2I 12.13 p ,JS
d(ATGCAT)2 R 5' 5S 4.5p 4C *G l0C "S "A ,2S
d(ClCGAAT-ATTCICG) R 5' 5,6 p 5A *G "C l2S ,}s
'Only residues that bind to tomaymycin with an energy > -2 .0  kcal/mol are included. Residues in CICGAAT-ATTCICG are shifted to one base
higher than the corresponding <ones in (ATG CA T)2 because o f the covalent bonding into *G in the former and *G in the latter. *S = sugar.
12-mer. This is in c o n tr a s t  t o  o u r  p r e v io u s ly  r e p o r te d  r e su lts  
using the d (A T G C A T )2 d u p le x  w h e r e  tw o  s p e c ie s  ( 1 1 5 ,  3 ' a n d  
11/?, 5') of to m a y m y c in  w e r e  b o u n d  in  a p p r o x im a t e ly  e q u a l  
amounts (C h eath a m  e t  a l . ,  1 9 8 8 ) .  T h u s  b o th  th e  o r ie n ta t io n  
in the minor g r o o v e  a n d  t h e  s t e r e o c h e m is t r y  o f  t o m a y m y c in  
bound to D N A  a r e  a  f u n c t io n  o f  t h e  i m m e d ia t e  f la n k in g  s e ­
quence. For the m o re  p r e fe r r e d  b o n d in g  s e q u e n c e  (5 ' -P y G P u )  
only one species is e v id e n t ,  w h i le  th e  le s s  p r e fe r r e d  s e q u e n c e  
(5'-PyGPy) sh o w s tw o  s p e c ie s .  T h e  s p e c ie s  h a v in g  a n  1 1 5  
configuration an d  3 ' o r ie n t a t io n  is  f o u n d  o n  b o th  s e q u e n c e s  
examined, but th e  s e c o n d  s p e c i e s  h a v in g  th e  o p p o s i t e  o r ie n ­
tation and s te r e o c h e m is tr y  a t  C - l  1 c o u ld  n o t  b e  d e t e c t e d  o n  
the more p referred  b o n d in g  s e q u e n c e .  W h i le  m o le c u la r  
modeling using a m b e r  is  in  a c c o r d  w it h  th e  e x p e r im e n t a l ly  
determined sp e c ie s  fo r  b o t h  o l ig o m e r s ,  th e r e  is  a  d i f f e r e n c e  
in terms o f the p r e fe r r e d  pairs o f  species t h a t  a r e  p r e d ic te d  
by modeling; i.e., on  d ( A T G C A T ) 2, th e  tw o  m o s t  e n e r g e t ic a lly  
favored species a r e  th e  1 1 5 ,  3 ' -o r ie n te d  a n d  1 1 /? , 5 '-o r ie n te d  
adducts, which d iffe r  b y  4  k c a l / m o l  ( C h e a t h a m  e t  a l .,  1 9 8 8 ) ,  
whereas on the 1 2 -m e r  t h e  t w o  fa v o r e d  s p e c ie s  a r e  t h e  1 1 5 ,
3-oriented and 1 1 5 ,  5 ' -o r ie n te d  a d d u c t s ,  w h ic h  d i f f e r  b y  2 .9  
kcal/mol.
The reason for th is  a p p a r e n t  d is c r e p a n c y  w a s  a d d r e ss e d  b y  
examining the c a lc u la te d  in te r a c t io n  e n e r g ie s  fo r  to m a y m y c in  
and individual p o ly n u c le o t id e  r e s id u e s  in  e a c h  o f  th e  s p e c ie s  
listed in Table IX . S u c h  a n a ly s e s  a r e  c o m p l ic a t e d  b e c a u s e  
the total binding e n e r g ie s  r e f le c t  c o m p le x  b in d in g  p a tte r n s  a n d  
a wide distribution o f  d i f fe r e n c e s  in  e n e r g ie s  b e tw e e n  in d iv id u a l  
residues. H ow ever, in s ig h t  in to  th e  e f f e c t s  o f  b in d in g  p a tte r n s  
can be obta ined  b y  f o c u s i n g  o n  t h e  m o s t  im p o r ta n t  
interactions— i.e ., th o s e  o f - 2 . 0  k c a l / m o l  o r  g r e a t e r  e n e r g y .  
Table IX lists th e  b in d in g  p a t te r n s  fo r  t h e  fo u r  s p e c ie s .  T h e  
construction o f  th is  ta b le  r e f le c t s  th e  in c r e a s e  o f  one in  r es id u e  
numbers in g o in g  fr o m  A T G C A T  to  C I C G A A T ,  b e c a u s e  o f  
thelocation o f  th e  g u a n in e  r e s id u e s  ( 3G  o r  4G ,  r e s p e c t iv e ly )  
to which the c o v a le n t  b o n d  is  fo r m e d . It is  e v id e n t  fr o m  th is  
table that the tw o  p a t te r n s  fo r  t h e  1 1 5 ,  3 ' b in d in g  m o d e s  a r e  
identical, except fo r  th e  p a ir  3G - 4G , w h e r e  th e  in te r a c t io n  is  
less than-2 .0  k c a l/m o l  w ith  d ( A T G C A T ) 2. E v e n  in  th is  c a s e  
its value o f - 1 .8 k c a l /m o l  is , h o w e v e r , n o t m u c h  le s s  th a n  th a t  
of the corres pond i n g  in te r a c t io n  fo r  d ( C I C G A A T - A T T C I C G )  
(-3.6 kcal/m ol). A  g r e a t e r  c o n t r a s t  o c c u r s  in  th e  b in d in g  
patterns of the tw o  11 /? , 5 '  m o d e s .  T h e r e  a r e  t w o  m o r e  in ­
teractions between to m a y m y c in  a n d  th e  p o ly n u c le o t id e  r esid u es  
iithd(ATGCAT)2 th a n  w ith  d ( C I C G A A T - A T T C I C G ) .  O n e  
of them involves a h y d r o g e n  b o n d , b e tw e e n  H N 1 0  o f  to m a y -  
mycin and N 3  o f  11 A ,  o f  1 .0 9 - A  l e n g t h  a n d  - 5 . 4  k c a l / m o l  
energy. The o th er  is  le s s  s ig n i f i c a n t  ( - 2 .1  k c a l / m o l ) .  T h e r e  
isalsoan u n fa vorab le  in t e r a c t io n  o f  + 1 . 7  k c a l / m o l  b e tw e e n  
Wof tom aym ycin a n d  0 3 '  o f  12-13P  in  th e  d ( C I C G A A T -  
ATTCICG) s e q u e n c e . ( T h e  0 3 '  o x y g e n  a t o m  o f  a  s u g a r  is  
tsually considered p a r t  o f  t h e  p h o s p h a t e  to  w h ic h  it  a l s o  is 
bonded in a m b e r  a n a ly s i s . )  T h is  in t e r a c t io n  d o e s  n o t  o c c u r  
Btheadduct w ith  d ( A T G C A T ) 2. T h e s e  fa c to r s  c o m b in e  to  
ttvor the 11 /? , 5 '  m o d e  fo r  th e  d ( C I C G A A T - A T T C I C G )  
sequence as is e v id e n t in  its  r e la t iv e ly  p o o r  n e t b in d in g  e n e r g y
( - 1 0 . 0  k c a l / m o l )  c o m p a r e d  w ith  th a t  o f  t h e  1 1 5 ,  3 '  m o d e  
( - 2 1 . 2  k c a l / m o l ,  T a b le  I I I ) .  T h e  to t a l  d is to r t io n  e n e r g ie s  o f  
th e se  tw o  m o d e s  d if fe r  b y  o n ly  3 .7  k c a l /m o l ,  w h ic h  m e a n s  th a t  
binding energies are more important than distortion energies 
in fa v o r in g  t h e  1 1 5 ,  3 '  m o d e  o n  d ( C I C G A A T * A T T C I C G ) .  
C o m p a r a b le  n e t  b in d in g  e n e r g ie s  fo r  t h e  t o m a y m y c in - d -  
( A T G C A T ) 2 a d d u c ts  a r e  - 1 7 . 9  k c a l / m o l  fo r  th e  1 1 5 ,  3 ' m o d e  
a n d  - 2 1 . 9  k c a l / m o l  fo r  t h e  1 1 R, 5 '  m o d e .  T h e  r e s u l t in g  
r e la t iv e ly  s m a l l  d i f f e r e n c e  is  c o n s is t e n t  w ith  t h e  e x is t e n c e  o f  
b o th  b in d in g  m o d e s  ( C h e a t h a m  e t  a l . ,  1 9 8 8 ) .
In c o n tr a s t  to  to m a y m y c in ,  w h e n  a n t h r a m y c in  is  b o u n d  to  
d ( A T G C A T ) 2, o n ly  o n e  sp e c ie s  o f  a d d u c t  is o b se r v e d  b y  N M R  
(B o y d  e t  a l . ,  1 9 9 0 ) .  S o l e l y  o n  t h e  b a s is  o f  a  p r o to n  N M R  
s tu d y  w e  c o u ld  u n a m b ig u o u s ly  a s s ig n  th e  3 '  o r ie n t a t io n .  
H o w e v e r , w e  c o u ld  n o t  u n a m b ig u o u s ly  d i f f e r e n t ia t e  b e tw e e n  
th e  1 1 R o r  1 1 5  s p e c ie s  b o u n d  t o  th is  o l ig o m e r ,  b e c a u s e  m o ­
le c u la r  m o d e l in g  u s in g  a m b e r  p r e d ic te d  s c a la r  c o u p l in g  b e ­
tw e e n  p r o to n s  a t  C - l  1 a n d  C - l  l a  fo r  both  s p e c ie s .  O n  th e  
b a sis  o f  e n e r g y  m in im iz a t io n  c a lc u la t io n s  a n d  in te r p r o to n  c r o ss  
p e a k s  in  th e  N O E S Y  s p e c tr u m , a  s tr o n g  c a s e  c o u ld  b e  m a d e  
fo r  1 1 5  s p e c i e s .6 A  m a jo r  d i f f e r e n c e  fo r  t h e  b i s ( t o m a y m y -  
c in ) —12 -m e r  a d d u c t  fr o m  th e  a n t h r a m y c i n - d ( A T G C A T ) 2 
a d d u c t  is th e  c o n tr ib u tio n  o f  h y d r o g e n  b o n d in g  to  s ta b iliz a t io n  
o f  th e  a n t h r a m y c in  1 1 5 ,  3 ' - o r ie n t e d  s p e c ie s .  In  t h e  a n t h r a -  
m y c i n - d ( A T G C A T ) 2 a d d u c t  th r e e  h y d r o g e n  b o n d s  w e r e  
id e n t i f ie d  b e tw e e n  th e  d r u g  a n d  D N A ,  w h e r e a s  in  th e  to ­
m a y m y c in  s p e c ie s  b o u n d  to  5 ' - C G A  th e  in t e r a c t io n s  a r e  o f  
th e  n o n - h y d r o g e n -b o n d in g  v a r ie t ie s .  W e  a r e  p r e s e n t ly  a d ­
d r e s s in g  th e  q u e s t io n  o f  w h ic h  m o le c u la r  in te r a c t io n s  b e tw e e n  
D N A  a n d  to m a y m y c in  g iv e  r is e  to  th e  h ie r a r c h y  o f  p r e fe r r e d  
b o n d in g  s e q u e n c e s .  T h u s  a  c o m p a r is o n  o f  th e  r e s u lt s  o f  
b o n d in g  a n t h r a m y c in  o r  t o m a y m y c in  t o  d ( A T G C A T ) 2 a n d  
to m a y m y c in  to  th e  1 2 -m e r  le a d s  u s  t o  c o n c lu d e  t h a t  th e  
o r ie n ta t io n  a n d  s t e r e o c h e m is tr y  o f  t h e  d r u g  s p e c ie s  b o u n d  to  
D N A  a r e  not only dependent upon sequence but also de­
pendent upon the structure  o f  th e  P ( 1 ,4 ) B  a n t ib io t i c .
Biochemical and Biological Implications. T h e  r e la t iv e ly  
n o n d is to r t iv e  n a t u r e  o f  th e  P ( 1 , 4 ) B - D N A  a d d u c t s  s h o w n  in  
th is  s tu d y  a n d  a  p r ev io u s  o n e  (B o y d  e t  a l . ,  1 9 9 0 ) ,  c o u p le d  w ith  
th e  a b s e n c e  o f  a p p a r e n t  s ig n i f i c a n t  c h a n g e s  in  e le c t r o n ic  o r  
ta u to m e r ic  c h a r a c te r is t ic s  o f  th e  c o v a le n t ly  m o d if ie d  g u a n in e ,  
ra ise s  im p o r ta n t  q u e s t io n s  o n  h o w  th e  P ( 1 , 4 ) B - D N A  a d d u c ts  
a r e  r e c o g n iz e d  b y  r e p a ir  e n z y m e s .  T h e  U V R A B C  n u c le a s e  
in c is io n  r e p a ir  c o m p le x  is  a b le  t o  r e c o g n iz e  t h e  a n t h r a m y -  
c i n - D N A  a d d u c t  a n d  a p p a r e n t ly  in c is e  b o th  3 '  a n d  5 '  s id e s
6 The IIS,  3' species of the anthram ycin-d(ATGCAT)2 adduct is
favored by about 21 kcal/mol in net binding energies over the 11/?, 3'
species. The present study on the bis(tom aym ycin)-!2-m er adduct 
demonstrates that the 1 IS and 3'-oriented species has a characteristic 
downfield shift o f the proton at C -l 1 o f the P(1,4)B; i.e., this proton is 
shifted downfield 0.9 ppm relative to the unbound drug. Since such a
large downfield shift is uniquely associated with the 1 IS  species, we
tentatively conclude that the stereochemistry of the species of anthra­
mycin bound to d(ATGCAT)2 is also the 1 IS, since in the anthramy-
cin-d(ATGCAT)2 this same resonance signal was also shifted downfield
by 1.04 ppm.
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of DNA-flanking lesions (Walter et al., 1988). We know from 
the results reported in this and previous NMR studies on 
tomaymycin that the stereochemistry at the covalent linkage 
site and orientation in the minor groove are dependent upon 
the immediate bonding sequence. This is also true for an­
thramycin, since on d(G A AG A AGCTICTTG) two anthra­
mycin adducts are formed (Boyd, unpublished results). Such 
observations complicate the overall picture for repair recog­
nition of P(1,4)B-DNA adducts, but these factors must be 
taken into account if we are to fully understand DNA repair 
recognition processes.
In both yeast and human cells anthramycin produces dou­
ble-strand breaks (Hannan & Hurley, 1978; Petrusek et al., 
1982). In human cells both the single- and double-strand 
breaks are persistent and are repair dependent, since in XP 
cells neither single- nor double-strand breaks are detected. 
This observation coupled with the more recent data on the 
nondistortive nature of the P(1,4)B adducts raises important 
questions about whether or not repair incision always takes 
place on the covalently modified strand.
C o n c l u sio n s
(1) This study provides the first unequivocal evidence for 
a covalent adduct between C-l 1 of a P(1,4)B and the exocyclic 
2-amino group of guanine. (2) The species of tomaymycin 
bound to 5'-CGA has an 1 IS1 stereochemistry and is oriented 
with the aromatic ring to the 3' side of guanine. (3) The 
minimal distortion produced upon covalent bonding is re­
stricted to the deoxyribose at the covalently modified guanine 
and the immediate 3'-phosphate and deoxyribose. (4) To­
maymycin appears to stabilize a B-type helical structure. (5) 
The orientation of a P(1,4)B on DNA and the stereochemistry 
at the covalent linkage site are dependent upon both the im­
mediate surrounding sequence and the drug structure. (6) 
Molecular modeling using am b er is predictive of the orien­
tation and stereochemistry of the P(l,4)Bs on oligodeoxy- 
nucleotides and is capable of defining the molecular interac­
tions that favor the different species on various oligomers.
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Template-Directed Design of a DNA-DNA Cross-Linker Based upon a 
Bis-Tomaymycin-Duplex Adduct
Jeh-Jeng Wang, G. Craig Hill, and Laurence H. Hurley*
College o f Pharmacy, The Drug D ynam ics In stitu te , U niversity of Texas a t A ustin , A ustin , Texas 78712. 
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A template-directed approach to the design of a D N A -D N A  interstrand cross-linker based upon the structure of 
a bis-tomaymycin-duplex adduct has been carried out. Tomaymycin is a member of the pyrrolo[l,4]benzodiazepines 
antitumor antibiotics. In a previous study (F. L. Boyd et al., Biochem istry  1990,29, 2387-2403), we have shown 
that two tomaymycin molecules can be covalently bound to a 12-mer duplex molecule, where the drug molecules 
are on opposite strands six base-pairs apart, and the stereochemistry at the drug bonding site, and orientation in 
the minor groove, was defined by high-field NMR. This bis-tomaymycin 12-mer duplex adduct maintains the 
self-complementarity of the duplex and a B-type structure. In the present study we have shown using high-field 
NM R that this same 12-mer sequence can be truncated by two base pairs so that the two tomaymycin-modified 
guanines are now only four base-pairs apart, the two species of tomaymycin molecules are still bound with the same 
stereochemistry and orientation, and the 10-mer duplex adduct maintains its self-complementarity. In a second 
10-mer duplex we have shown that changing the bonding sequence from 5'CGA to 5'AGC does not significantly 
affect the structure of the bis-tomaymycin-duplex adduct. However, when the sequence is rearranged so that the 
drugs point in a tail-to-tail orientation rather than in the previous head-to-head configuration, there are more than 
one species of tomaymycin bound to DNA, and, as a consequence, the bis-tomaymycin 10-mer duplex adduct loses 
its self-complementarity. Last, we have used the 10-mer duplex containing the 5'CGA sequence, in which the 
tomaymycin molecules are oriented head to head, to design an interstrand cross-linking species in which the two 
drug molecules are linked together with a flexible linker molecule.
Introduction
Anthramycin, tomaymycin (I), and sibiromycin are the 
best known examples of the naturally occurring pyrrolo- 
[l,4]benzodiazepines (P[1,4]B).1-3 These antibiotics react 
covalently with DNA to form an N2-guanine adduct that 
lies within the minor groove of DNA (Figure I).4,5 The 
P[l,4]Bs are not only specific for N2 of guanine, but are 
only reactive with guanines in certain sequences, and 
therefore show sequence selectivity.6,7 The most favored 
sequences for bonding are 5'PuGPu with 5'PyGPu and 
5TuGPy of intermediate reactivity (Pu = purine; Py = 
pyrimidine), while 5TyGPy sequences show the least re­
activity. In principle, there are four species of covalently
* Address correspondence to this author or call (512)471-4841.
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bound adducts that can occur as the two 115 enantiomers, 
in which the aromatic ring of the drug lies either to the
(1) Remers, W. A. In The Chemistry of Antitumor Antibiotics; 
Wiley; New York, 1988; Vol. 2, pp 28-92.
(2) Thurston, D. E.; Hurley, L. H. A Rational Basis for Develop­
ment of Antitumor Agents in the Pyrrolo(l,4)benzodiazepine 
Group. Drugs Future 1984, 8, 957-971.
(3) Remers, W. A.; Barkley, M. D.; Hurley, L. H. Pyrrolo(l,4)- 
benzodiazepines. Unraveling the Complexity of the Structures 
of the Tomaymycin-DNA Adducts in Various Sequences Using 
Fluorescence, 1H-NMR, and Molecular Modeling. A chapter 
in Nucleic Acid Targeted Drug Design; Perun, T., Propst, C., 
Eds.; Marcel Dekker, Inc.: New York, 1992, in press.
(4) Hurley, L. H.; Petrusek, R. Proposed Structure of the An- 
thramycin-DNA Adduct. Nature (London) 1979, 282, 529.
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Figure 1. Proposed reaction of tomaymycin (I) with DNA to form 
the (N2) guanine DNA adduct.11
3' or 5' direction, and as the two equivalent 11R  enan- 
tiomers. For anthramycin we have shown that in all the 
bonding sequences so far examined, which are represent­
ative of all four groups, the species of drug found on DNA 
is the 11S,3' species.8,9 For tomaymycin the situation is 
more complex, because on the least favored sequence, 
5TyGPy, tomaymycin exists as a 50:50 mixture of the 11S 
and 11R enantiomers, while on 5'CGA only the 11 S3' 
species is found.10,11
(5) Petrusek, R. L.; Anderson, G. L.; Gamer, T. F.; Fannin, Q. L.; 
Kaplan, D. J.; Zimmer, S. G.; Hurley, L. H. Pyrrolo(l,4)- 
benzodiazepine Antibiotics. Proposed Structures and Char­
acteristics of the In Vitro DNA Adducts of Anthramycin, To­
maymycin, Sibiromycin, and Neothramycins A and B. Bio­
chemistry 1981, 20, 1111-1119.
(6) Hertzberg, R.; Hecht, S.; Reynolds, V. L.; Molineux, I. J.; 
Hurley, L. H. DNA Sequence Specificity of the Pyrrolo(l,4)- 
benzodiazepine Antitumor Antibiotics. MPE Fe(II) Foot- 
printing Analysis of DNA Binding Sites for Anthramycin and 
Related Drugs. Biochemistry 1986,2 5 ,1249-1258.
(7) Hurley, L. H.; Reck, T.; Thurston, D. E.; Holden, K. G.; 
Hertzberg, R. P.; Hoover, J. R. E.; Gallagher, G., Jr.; Faucette, 
L. F.; Mong, S-M.; Johnson, R. K. Pyrrolo(l,4)benzodiazepines 
Antitumor Antibiotics. Relationship of DNA Binding and 
Sequence Specificity to Biological Activities of Natural and 
Synthetic Compound. Chem. Res. Toxicology 1988, 1, 
258-268.
(8) Boyd, F. L.; Cheatham, S. F.; Remers, W.; Hill, G. C.; Hurley, 
L. H. Characterization of Structure of the Anthramycin-d- 
(ATGCAT)2 Adduct by NMR and Molecular Modeling Stud­
ies. Determination of the Stereochemistry at the Covalent 
Linkage Site, Orientation in the Minor Groove, and Effect of 
Drug Binding on Local DNA Structure. J. Am. Chem. Soc. 
1990,112, 3279-3289.
(9) Mountzouris and Hurley, unpublished results.
(10) Cheatham, S. F.; Kook, A. M.; Hurley, L. H.; Barkley, M.;
Remers, W. One- and Two-Dimensional XH-NMR Fluores­
cence and Molecular Modeling Studies on the Tomaymycin-
d(ATGCAT)2 Adduct. Evidence for Two Covalent Adducts
with Opposite Orientations and Stereochemistry at the Cova­
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As would be expected for DNA-reactive compounds, the 
P[l,4]Bs show potent antitumor activity.12 In a com­
parison study, tomaymycin showed the most potent cy­
totoxicity in inhibition of proliferation of B16 melanoma 
cells, but anthramycin showed the highest increase in life 
span of mice bearing P388 leukemia cells.7 Other simpler 
synthetic analogs generally show reduced in vitro and in 
vivo potency.7 Although anthramycin has the best anti­
tumor activity, it produces cardiotoxicity, which has pre­
cluded its continued clinical application.13 The relatively 
poor antitumor profile of the synthetic analogs of the 
P[1,4]B encouraged us to examine the possibility of de­
signing DNA-DNA cross-linkers that would be expected 
to be more biologically potent and have increased sequence 
specificity. As a first step to the design of a P[1,4]B in­
terstrand cross-linker, we have characterized a bis-to- 
maymycin 12-mer duplex adduct (Scheme I), in which the 
drugs are covalently bound six base pairs apart on opposite 
strands.11 The results of this study were encouraging. The 
12-mer duplex maintained its self-complementarity fol­
lowing drug bonding, and the duplex showed relatively 
little distortion, which should facilitate computer-aided 
drug design. In the present study, we have examined three 
further questions relating to the design of DNA-DNA 
interstrand cross-linkers based upon tomaymycin. First, 
what is the shortest distance between the drug molecules 
that can be achieved without preventing bis-adduct for­
mation and loss of self-complementarity? Second, what 
effect does changing the bonding sequence from 5'CGA to 
5'AGC have on the species of tomaymycin bound? Third, 
can tomaymycin molecules be bound in a tail-to-tail ori­
entation rather than head-to-head, as previously defined? 
On the basis of these results, we have designed a DNA- 
DNA interstrand cross-linker using computer-aided drug 
design that should react specifically at guanines four base 
pairs apart on opposite strands without serious distortion 
of the duplex. A DNA-DNA interstrand cross-linker 
(DSB-120) has been synthesized and shown to cross-link 
as predicted and be much more potent than any of the 
monoalkylation compounds (see later).
Experimental Section
C hem icals. (llR ,llaS)-Tom aym ycin 11-methyl ether (TME) 
was a generous gift from Dr. Kohsaka of Fujisawa Pharmaceu­
ticals. The DNA oligomers were synthesized in-house on an 
automated DNA synthesizer (Applied Biosystems 381A) using 
a solid-phase cyanoethyl phosphoramidite approach. Reagents 
used to prepare NMR buffer and solvents, sodium phosphate
(11) Boyd, F. L.; Stewart, D.; Remers, W. A.; Barkley, M. D.; 
Hurley, L. H. Characterization of a Unique Tomaymycin-d- 
(CICGAATTCICG)2 Adduct Containing Two Drug Molecules 
per Duplex by NMR, Fluorescence, and Molecular Modeling 
Studies. Biochemistry 1990, 29, 2387-2403.
(12) Hurley, L. H. Pyrrolo(l,4)benzodiazepine Antitumor Antibi­
otics. Comparative Aspects of Anthramycin, Tomaymycin, 
and Sibiromycin. J. Antibiot. 1977, 30, 349-370.
(13) Cargill, C.; Bachmann, E.; Zbinden, G. Effects of Daunomycin 
and Anthramycin on Electrocardiogram and Mitochondrial 
Metabolism of the Rat Heart. J. Natl. Cancer Inst. 1974,53, 
481-486.
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3' R head-head -675.6 -32.4 - 22.2 -54.6 +17.8 +14.6 +32.4 - 22.2
3' S head-head -703.6 -42.9 -29.9 -72.8 +16.3 +7.4 +23.7 -49.1
5' R tail-tail -688.5 -36.4 -45.2 -81.6 +32.7 +15.0 +47.7 -33.9
5’ S tail-tail -703.6 -45.8 -32.3 -78.1 +10.5 +18.5 +29.0 -49.1
"Van der Waals or steric contribution. 6Electrostatic contribution. 'T he enthalpy of d(CICGATCICG)2 is -698.3 kcal/mol. ‘‘The 
enthalpy of the drug molecule in the absence of the DNA is +22.4 kcal/mol. * Net bonding is the total intermolecular bonding plus helix and 
drug distortion.
(99.99%), sodium chloride (99.99%), and D20  (99.99%) were 
purchased from Aldrich Co. High-performance liquid chroma­
tography (HPLC) grade water and methanol were purchased from 
Baxter Scientific and Fisher Co., respectively. Hydroxyapatite 
used to purify the duplex and duplex-adducts was purchased from 
Cal Biochem Co. Sephadex G-25 (superfine) was purchased from 
Pharmacia Co. Sep-Pak cartridges (C18) were purchased from 
Waters Co.
P reparation  o f  D u p lex  D ecan u cleo tid es. Single strands 
were synthesized in-house on an Applied Biosystems automated 
DNA synthesizer Model 381A. Sample deprotection with satu­
rated ammonium hydroxide solution (55 °C overnight) was fol­
lowed by evaporation at room temperature. The single strands 
were annealed in a sealed vial, containing 1 mL o f N M R buffer 
(10 mM NaH2P 0 4, and 100 mM NaCl) by heating to 70 °C fol­
lowed by cooling to room temperature overnight. The crude 
oligomers were purified on hydroxyapatite (25 X 3 cm) with a 
gradient of 10-200 mM sodium phosphate buffer (pH 6.85) at 
room temperature to remove any excess single-stranded oligomers. 
The 10-mer duplexes (25-35 mg) were then lyophilized and re­
dissolved in 3-5  mL of HPLC grade water and desalted on a 
column of Sephadex G-25 (superfine) by elution with HPLC water. 
The desalted oligomers were then lyophilized to dryness and 
redissolved in 0.5 mL of NM R buffer. The samples were lyo­
philized to dryness and redissolved in 0.5 mL of 99.99% DzO and 
transferred into a 5-mm ultrathin NM R tube.
P reparation  o f  T om aym ycin  10-Mer D u p lex  A dducts. 
TM E ( ~ 6  mg) dissolved in 0.2 mL of DMF was added to  25-35  
mg of purified 10-mer duplex in 0.5 mL of 20 mM sodium  
phosphate and 200 mM sodium chloride buffer (pH 6.85). The 
reaction mixtures were stirred at room temperature for 5 days 
in the dark, lyophilized to dryness, redissolved in 1.0 mL of HPLC 
grade water, and applied to hydroxyapatite columns (25 X 3 cm). 
Elution with a gradient of 10-200 mM sodium phosphate buffer 
(pH 6.85) at room temperature removed free drug and other 
impurities. The solutions containing the pure adducts were 
lyophilized, redissolved in 0.5 mL of NM R buffer, lyophilized, 
and redissolved in 0.5 mL of 99.99% D20  and transferred into 
5-mm ultrathin NM R tubes.
N M R  Spectroscopy. One- and two-dimensional :H  and 31P  
NM R data sets were recorded on a General Electric GN-500 FT  
NMR at room temperature. Chemical shifts were reported in parts 
per million and referenced relative to external trisodium phosphate 
(TSP) (1 mg/mL) in D20  for XH and an external reference of 85% 
H3PO4 in D20  for 31P  resonances. Mononuclear scalar coupling 
was determined by using the standard magnitude-correlated 
spectroscopy (COSY). 2K complex points in t 2 and 256 points 
in the *i domain were acquired with a repetition tim e of 0.5 s. 
Phase-sensitive two-dimensional nuclear Overhauser effect 
spectroscopy (NOESY) experiments were acquired similarly with 
a repetition time of 2.0 s. Mixing times of 125 and 250 ms were 
used for the phase-sensitive NOESY experiments and were sto­
chastically varied to suppress cross-peaks arising from scalar 
coupling.14 The data were zero filled in such that the final 
frequency domain spectra consisted of IK  X IK  data matrices 
after symmetrization. Proton-decoupled phosphorous spectra were 
collected at 202.44 MHz. Phosphorus-detected 1H -31P  two-di­
mensional heteronudear phase-sensitive correlation experiments 
were performed according to the procedure by Bax and Sarker.15
(14) States, D. J.; Haberkorm, R. A.; Ruben, D. J. A Two-Dimen­
sional Nuclear Overhauser Experiment with Pure Absorption. 
J. Magn. Reson. 1982, 48, 286.
M olecu lar  M odeling. The crystal structure of TM E16 pro­
vided the initial coordinates for these studies. Previous ab initio 
calculations with the methoxyl group removed yielded the partial 
atomic charges.10 The drug structure was minimized using am ber
3.0 revision A17 and the all-atom force-field parameters18 until 
the energy root mean square gradient was less than 0.1 kcal/mol 
A with the nonbonded pairs cutoff of 99 A and updated every 
100 cycles. The DNA duplexes were constructed in a m ber  from 
Arnott’s B-DNA coordinates19 and minimized under the same 
conditions described above. The minimized oligomers were then 
docked with two tomaymycin drug molecules via the program 
M idasPlus,20 and the docked coordinates were used as input for 
minimization and then subjected to 55 ps of molecular dynamics 
at 300 ±  5 K in a m b e r  with a gradual increase in temperature 
from 10 to 300 K over the first five ps. Attempts at longer 
simulation times were made for two of the sixteen models. After 
100 ps, the models were very similar to that found for the 50 ps 
trial, and upon minimization only slight differences existed be­
tween them. This would indicate that the system seems to  
converge to a common final complex. The resultant models were 
reminimized to < 0.1 kcal/m ol A.
Results and Discussion
I. Shortening the Distance between the Tomay­
mycin Covalently Modified Guanines from Six to 
Four Base Pairs Is Allowed and the Self-Comple­
mentarity of the 10-Mer d(CICGATCICG)2 Is Main­
tained. In a previous study using the 12-mer d- 
(CIC*GAATTCICG)2, we had shown that tomaymycin can 
bond to the two equivalent guanines indicated by an (*) 
on the opposite strands without losing the self-comple­
m e n t a r i t y  of the unmodified duplex.11 In addition, we had 
shown that the species of tomaymycin-(N2-guanine)-DNA 
formed on the 12-mer has an 1LS stereochemistry at the 
covalent modification site and is orientated with the aro­
matic ring of the drug to the 3' side of the alkylated gua­
nine (Scheme I). This 12-mer was designed based upon 
the well-characterized structure of the Dickerson dode­
camer21 [d(CGCGAATTCGCG)2] in which the two gua­
nines underlined were replaced with inosines. This sub-
US) Bax, A.; Sarker, S. K. Elimination of Refocusing Pulses in 
NMR Experiments. J. Magn. Reson. 1984, 6 0 ,170-176.
(16) Arora, S. K. Structure of Tomaymycin, a DNA-Binding Anti­
tumor Antibiotic. J. Antibiot. 1981, 34, 462-464.
(17) Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Caldwell, J. W.; 
Kollman, P. A. am ber  3.0 Revision A; Department of Phar­
maceutical Chemistry, University of California, San Francisco, 
CA 94143 (1989).
(18) Weiner, S. J.; Kollmann, P. A.; Case, D.; Singh, U. C.; Ghio, C.; 
Alagona, G.; Prafeta, S., Jr.; Weiner, P. K. A New Force Field 
for Molecular Mechanical Simulation of Nucleic Acids and 
Proteins. J. Am. Chem. Soc. 1984,106, 765-784.
(19) Arnott, S.; Campbell-Smith, P.; Chandrasekaran, R. In CRC 
Handbook of Biochemistry; Fasmay, G. D., EM.; CRC Press: 
Cleveland, 1976; Vol. 2, pp 411-422.
(20) Ferrin, T. E.; Avang, C. C.; Jarvis, L. E.; Langridge, R. The 
MIDAS Display System. J. Mol. Graphics 1988, 6, 13-27.
(21) Drew, H. R.; Wing, R. M.; Takano, T.; Broka, C.; Tanaka, S.; 
Itakura, K.; Dickerson, R. E. Structure of a B-DNA dodecam­
er Conformation and Dynamics. Proc. Natl. Sci. U.SA.. 1981, 
78, 2179-2183.
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stitution was made because inosine differs from guanine 
in that it lacks the exocyclic 2-amino group and, conse­
quently, is unreactive towards alkylation by tomaymycin. 
Since the structural analysis of this bis-tomaymycin 12-mer 
duplex adduct showed little distortion relative to the du­
plex alone (in fact, drug modification appeared to shift the 
overall structure of the duplex to a more idealized B form), 
it seemed likely that truncating the duplex between the 
two guanines by two A -T  pairs might be possible, while 
still maintaining the overall structure of the duplex adduct, 
provided steric interactions between the two drug mole­
cules did not occur. Consequently, the 10-mer (see Scheme
II) was synthesized as a template for evaluation of this 
proposal. Partial characterization of duplex by high-field 
XH NMR revealed it to have an overall B-type structure 
(J.-J. Wang, unpublished results). This 10-mer to be 
modified by tomaymycin was first subjected to molecular 
modeling studies and subsequently analyzed by high-field 
and 31P NMR.
A. Molecular Modeling of the Bis-tomaymycin 10- 
Mer[d(CICGATCICG)2] Adduct. The four possible 
species (115,3'; 1155'; l i f t ,3'; and HR,5') of tomaymycin 
on the 10-mer were modeled using a m b e r  3A. The results 
(Table I) show that of the four species modeled, the 115,3' 
is identical in net bonding energy to the 115,5' species. 
While the 11S,5' species produces better intermolecular 
interactions than the 115,3' species, it also induces more 
distortion. Previous work using only molecular mechanics 
rather than molecular mechanics and molecular dynamics 
correctly predicted the species found experimentally.8,10,11 
The current study using molecular dynamics and molecular 
mechanics is more rigorous, introduces less bias into the 
experiments, and is therefore expected to provide improved 
data for predicting which bis-tomaymycin-duplex adduct 
is the most favored and why. Nevertheless, the use of 
counterions and solvent should provide even further im­
provements. Some attempts were made in this direction, 
but we encountered considerable problems with migration 
of chlorine from the DNA, which led to unrecoverable, poor 
trajectories.
B. !H and 31P NMR Analysis of the Bis-tomaymy­
cin 10-Mer Duplex (5'CGA) Adduct. (1) Self-Com­
plementarity of the 10-Mer Duplex Adduct. A com­
parison of the one-dimensional 31P NMR of the duplex and 
its bis-tomaymycin-duplex adduct is shown in Figure 2, 
parts A and B, respectively. While there is considerable 
overlap of resonance signals in the duplex, in the bis-ad- 
duct the 31P NMR signals are well resolved and clearly 
show just nine discrete signals, indicating the duplex ad­
duct maintains its self-complementarity following tomay­
mycin modification. The resonance signal for the phos­
phorous atom between 3C and 4G is shifted upfield, which 
was also previously found in the corresponding 12-mer 
duplex adduct.11 The one-dimensional 1H NMR also 
provided evidence for the maintenance of the self-com­
plementarity of the bis-tomaymycin-duplex adduct (J.-J. 
Wang, unpublished results).
(2) Stereochemistry at the C-ll Covalent Linkage 
Site between Tomaymycin and the 10-Mer Duplex.
Wang et al.
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F ig u r e  2. Proton-decoupled 202.44-MHz phosphorus N M R  
spectra (-2 .5 -0  ppm) of (A) the 10-mer duplex shown in Scheme 
II and (B) its bis-tomaymycin 10-mer duplex adduct in 0.5 mL  
of D20  buffer containing 10 mM sodium phosphate and 100 mM  
sodium chloride, pH 6.85 at 23 °C. Arrowhead denotes upfield- 





F ig u r e  3. Two-dimensional magnitude COSY contour plot of 
the bis-tomaymycin 10-mer duplex adduct shown in Schem e II 
in 0.5 mL of D20  buffer containing 10 mM sodium phosphate and 
100 mM sodium chloride, pH 6.85 at 23 °C. Arrowhead A denotes 
the scalar coupling indicative o f the 11S diastereom er between  
tomaymycin H l l  and H l la  protons. Arrowhead B denotes scalar 
coupling between the 4G hydrogen-bonded am ino proton and 
tom aym ycin H l l .
On the basis of molecular modeling, we have previously 
argued that only the I l5 , l la 5  diastereomer of the to­
maymycin-duplex adduct with the 3' orientation will show 
scalar coupling between the C ll  and C l la  protons of to­
maymycin.11 This is because the l lR ,l la 5  diastereomer 
has a dihedral angle between these protons of almost 90°. 
Examination of the magnitude COSY spectrum (Figure 
3) of the bis-tomaymycin-d(CICGATCICG)2 adduct shows 
scalar coupling of the 11 and 11a protons (cross-peak A), 
confirming the 115,l la 5  diastereomer as the species found 
on the 10-mer, as was previously found for the 12-mer.11 
Cross-peak B in Figure 3 is due to the scalar coupling 
between the tomaymycin H l l  proton and the exocyclic 
proton on N2 of guanine, which confirms the covalent 
linkage sites. The equivalent cross-peak was also evident 
in the 12-mer duplex adduct.11 Examination of the nuclear
T e m p la te -D ir e c te d  D e s ig n  o f  C ro ss-L in k e rs  














6AH2 8.05 H9 6.51 s 2.26
8IH2 7.26 H13 1.74 m 3.24-5.01d
5AH1' 6.15 H ll 5.56 s 2.58
6AH4' 4.23 H ll 5.56 m 2.99
0 Chemical Shifts are in ppm relative to external TSP in D20 . b s = 
strong and m = medium (relative to cytosine H5 to H6 crosspeak in­
tensities). ' Distances are in angstroms. d Distances for methyl protons 
reported as a range (minimum-maximum) due to rotation.
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Overhauser effect (NOE) cross-peaks for H l l  confirms the 
assignment of the S  configuration (Table II). If tomay­
mycin adopts an Ilf? configuration upon bonding, then 
intermolecular NOEs would be expected between H ll  and 
the HI' and H4' sugar protons of 8I. Conversely, if to­
maymycin adopts an 11S configuration upon bonding, the 
intermolecular NOEs would be expected between H ll  and 
the HI' and H4' sugar protons of 5A. The NMR data 
summarized in Table II shows a strong NOE between 
5AH1' and H l l  of tomaymycin and a medium NOE be­
tween 5AH4' and H ll .  NOEs were not observed between 
H ll  and the equivalent 8I sugar protons (J.-J. Wang, un­
published results); therefore, tomaymycin adopts an S  
configuration upon covalent bonding to the 5'CGA 10-mer 
as shown in Scheme II. A parallel set of intermolecular 
NOEs was used to assign the anthramycin stereochemistry 
on a 6-mer duplex adduct.22
(3) Orientation of the Tomaymycin Molecule on 
d(CICGATCICG)2. The adenine and inosine H2 protons 
are located in the minor groove of DNA and are therefore 
reporter protons that can be used through NOE data to 
locate the orientation of the drug molecule on DNA. The 
5A and 8I adenine H2s are located on the 3' and 5' sides, 
respectively, of the covalently modified guanine, and their 
NOEs into specific tomaymycin protons are indicative of 
the orientation of the drug in the minor groove. The NOEs 
listed in Table II show that while 5AH2 shows an NOE into 
H9 of tomaymycin, 8IH2 shows an NOE into H13 of to­
maymycin. Therefore, the tomaymycin molecule is or­
iented with the aromatic ring of the drug molecule to the 
3' side of the covalently modified guanine. The upfield- 
shifted resonance signals of the 4' proton o f 5A and the H5' 
and H5" protons of 8I (J.-J. Wang, unpublished results) 
are due to their shielding by the aromatic ring of tomay­
mycin and thus confirms this orientation. In summary, 
the bis-tomaymycin 10-mer duplex adduct shown in 
Scheme II maintains the self-complementarity, stereo­
chemistry, and orientation specificity shown previously in 
the 12-mer duplex adduct,11 and this is one of the two 
species (11<S,3' and 11S,5') predicted by molecular mod­
eling.
II. What Effect Does Changing the Tomaymycin 
Bonding Sequence from 5'CGA to 5'AGC Have on the
(22) Krugh, T. R.; Graves, D. E.; Stone, M. P. Two-Dimensional 
NMR Studies on the Anthramycin-d(ATGCAT)2 Adduct. 
B ioch em istry  1989, 28, 9988-9994.
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F ig u r e  4. Proton-decoupled 202.44-M Hz phosphorus NM R  
spectra (-2.5-0.5 ppm) of (A) the 10-mer duplex shown in Scheme 
III and (B) its bis-tom aymycin 10-mer duplex adduct in 0.5 mL 
of D 20  buffer containing 10 mM sodium phosphate and 100 mM  
sodium chloride, pH 6.85 at 23 °C. Arrowhead denotes upfield- 
shifted 6C -6I phosphorus resonance.
Species of Tomaymycin Attached to the 10-Mer? To
gain a limited appreciation for how the bonding sequence 
effects the orientation and stereochemistry of the cova­
lently bound species of tomaymycin, a second bonding 
sequence, 5'AGC (see Scheme III), was evaluated for the 
species of tomaymycin-DNA adduct formed and mainte­
nance of duplex self-complementarity. This sequence 
belongs to the PuGPy group, which, along with 5'CGA 
(PyGPu), is the intermediately favored bonding sequence 
for tomaymycin.6
A. Molecular Modeling of the Bis-tomaymycin 10- 
Mer[d(CIAGCTCICG)2] Adduct. The four possible 
combinations (IIS  and HR, 3' and 5') of tomaymycin on 
the 10-mer in Scheme III were modeled using a m b e r  3A. 
The results (Table III) show that the 11S,5' species is 
predicted to be the product. This species is predicted to 
be 14.2 kcal/mol A more stable than the next best species 
(11S,3') mainly due to increased steric interactions.
B. !H and 31P NMR Analysis of the Bis-tomaymy­
cin 10-Mer Duplex (5'AGC) Adduct. (1) In the duplex 
alone, the signals are dispersed between -1.3 to -1.8 ppm, 
while in the duplex adduct they are more widely dispersed 
between -0.9 to -2.3 ppm (Figure 4, parts A and B). In 
the bis-tomaymycin-duplex adduct there are eight well- 
resolved 31P resonance signals with two signals being su­
perimposed at -1.85 ppm, giving a total of nine phosphate 
resonances, which demonstrates the self-complementarity 
of the duplex adduct. As was found for the 10-mer duplex 
adduct having the 5'CGA bonding, one of the 31P resonance 
signals is moved downfield, but in this case it is the 
phosphate between two bases to the 3' side of the cova­
lently modified guanine (i.e., 5C-6I). This is different from 
the 5'CGA sequence, where it was found to be the 3C -4G 
phosphorus resonance signal. The self-complementarity 
is also evident from magnitude COSY that shows four 
scalar cross-peaks for the 4 cytosine 5H-6H protons (box 
A in Figure 5).
(2) Stereochemistry at C-ll and Orientation of 
Tomaymycin in the Minor Groove of DNA. Similar 
arguments to that made previously for the bis-tomaymycin 
12-mer duplex adduct11 and the 10-mer in Scheme II can 
be used to assign the stereochemistry at C l 1 as S  for to­
maymycin in the 5'AGC sequence; i.e., the scalar cross­
peak (arrow in Figure 5) identified for the C ll  and C lla  
protons occurs at 3.78 and 5.56 ppm. The 11S stereo­
chemistry is also confirmed by the NOE cross-peak in-
3000 Journal of Medicinal Chemistry, 1992, Vol. 35, No. 16 Wang et al.









intermolecular distortion net bonding 
energy*vdw“ elstat6 total helix' drugd total
3' R head-head -690.4 -38.0 -31.8 -69.8 +1.5 +19.0 +20.5 -49.3
3' S head-head -699.9 -42.0 -27.6 -69.6 +3.6 +8.3 +11.9 -57.7
5' R tail-tail -697.4 -41.9 -34.0 -75.9 +4.3 +15.2 +19.5 -56.4
5' S tail-tail -714.1 -51.7 -28.8 -80.5 +1.4 +7.2 +8.6 -71.9
“Van der Waals or steric contribution. 6Electrostatic contribution. 'T he enthalpy of d(CIAGCICTCG)2 is -681.4 kcal/mol. dThe 
enthalpy of the drug molecule in the absence of the DNA is +22.4 kcal/mol. * Net bonding is the total intermolecular bonding plus helix and 
drug distortion.



























6IH2 7.84 H9 6.30 8 2.68
3 AH 2 7.44 H13 1.75 m 2.10-3.86d
5CH1' 5.32 H ll 5.56 s 2.65
5CH4' 5.73 H ll 5.56 m 3.17
“Chemical shifts are in ppm relative to external TSP in D20 . 6 8 
= strong and m = medium (relative to cytosine H5 to H6 cros­
speak intensities). 'Distances are in angstroms. dDistances for 
methyl protons reported as a range (minimum-maximum) due to 
rotation.
tensities between 5CH1' and 5CH4' and the H l l  protons 
of tomaymycin (Table IV). 3AH2 and 6IH2 provide the 
reporter atoms in the minor groove to the 5' and 3' sides 
of the covalently modified guanine (4G) and show NOEs 
to the H13 and H9 protons of tomaymycin, respectively 
(Table IV). This confirms that the orientation of tomay­
mycin in this duplex is with the aromatic ring to the 3' side 
of the covalently modified guanine. In summary for 
bonding sequences of intermediate selectivity (i.e., 
5'PyGPu and 5'PuGPy) in the examples tested (5'CGA 
and 5'AGC), the same species (11<S,3' orientation) of to­
maymycin are attached to DNA. While for the case of the 
5'CGA bonding sequence, modeling is predictive of the 
species found; for the 5'AGC bonding sequence, modeling 
predicts the 11S,5' species by 14.2 kcal/mol over the 11S,3' 
species. It is not clear why there is such a large discrep­
ancy; however, one possibility is that it is the noncovalent 
interactions that determine the orientation and configu­
ration of the covalent adduct.
III. Can Tomaymycin Molecules be Bound Tail- 
to-Tail on Opposite Strands? In principle, two to­
maymycin molecules can be juxtapositioned within the 
10-mer duplex either in a head-to-head or tail-to-tail 
configuration on opposite strands of DNA. Conceivably, 
in two different bonding sequences a head-to-tail or tail- 
to-head configuration might also be achieved. In this study 
and the previous one, head-to-head configurations have 
been predicted and found in practice. For comparison, the 
two bonding sequences were specifically arranged so that 
the tails of the drug molecules were predicted to be 
pointing towards each other (see Scheme IV). As before, 
molecular modeling was carried out to determine if steric 
interference would preclude this orientation, and 31P and
F ig u r e  5. Two-dim ensional magnitude COSY contour plot of 
the bis-tomaymycin 10-mer duplex adduct in 0.5 mL of D 20  buffer 
containing 10 mM sodium phosphate and 100 m M  sodium  
chloride, pH 6.85 at 23 °C. Box A encloses the four cytosine 
H 5-H 6 proton scalar coupling. Arrowhead denotes the scalar 
coupling indicative of the 11S diastereomer between tomaymycin 
H l l  and H l la  protons.
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NMR was used to determine the complexity and, if 
possible, the identity of the species bound.
A. Molecular Modeling. The four possible species 
(11S,3'; 11S,5'; 11R,3'; 11R,5') of tomaymycin on the 10- 
mer were modeled using a m b e r  3A. None of the possible 
species show unacceptable steric interactions. The results 
in Table V show that three of the species are within 7.6 
kcal/mol, and the 11S,3' and the 11S,5' species are 1.5 
kcal/mol A apart in energy. These small energy differences















3' R tail-tail -687.5 -40.8 -23.9 -64.7 +25.5 +7.2 +32.7 -32.0
3' S tail-tail -707.9 -54.0 -30.0 -84.0 +26.1 +6.6 +32.7 -51.3
5' R head-head -700.7 -38.9 -44.7 -83.6 +26.3 +12.1 +38.4 -45.2
5' S head-head -709.4 -57.7 -35.5 -93.2 +29.0 +11.4 +40.4 -52.8
“Van der Waals or steric contribution. bElectrostatic contribution. 'T he enthalpy of d(CITCICGACG)2 is -695.8 kcal/mol. dThe 
enthalpy of the drug molecule in the absence of the DNA is +22.4 kcal/mol. * Net bonding is the total intermolecular bonding plus helix and 
drug distortion.
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energy^vdw“ elstat6 total helix0 drug4* total
ethyl 2 -690.1 -43.5 -28.8 -72.3 +25.4 + 11.2 +36.6 +3.1 -32.6
propyl 3 -690.5 -40.9 -29.1 -70.0 + 22.0 +11.4 +33.4 - 0.6 -37.2
butyl 4 -689.9 -41.5 -27.7 -69.2 +21.4 +11.7 +33.1 + 1.1 -35.0
pentyl 5 -698.7 -47.6 -31.1 -78.7 +20.5 +12.9 +33.4 -3.6 • -48.9
“Van der Waals or steric contribution. 6Electrostatic contribution. cThe enthalpy of d(CICGATCICG)2 is -698.3 kcal/mol. dThe 
enthalpy of the drug molecule monomers in the absence of the DNA is +22.4 kcal/mol. *The enthalpy contribution of the linker [-(CH2)„_] 
atoms only. ^Net bonding is the total intermolecular bonding plus helix and drug distortion.
suggest that either the 115,3' or 5' species may be found 
experimentally. The main difference between the two 
species is that the 115,3' species has less distortion (7.7 
kcal/mol A), but this is offset by the lower intermolecular 
interaction energy of the 115,5' species.
B . O ne-D im ensional 31P  and ‘H NM R Studies. A 
comparison of the one-dimensional 3lP and *H NMR 
spectra of the duplex with the drug-modified duplex ad­
ducts shows that the duplex adduct data sets have at least 
twice the complexity of the original duplex set (J.-J. Wang, 
unpublished results). Although a full analysis of two-di­
mensional data sets was not attempted, it seems likely that 
both species have the 115 stereochemistry, since two 
partially overlapped C ll  and C lla  scalar crosspeaks are 
present in the magnitude COSY spectrum (see arrow in 
Figure 6). The loss of self-complementarity of the bis- 
tomaymycin duplex adduct is further evident in the 
magnitude COSY, because at least eight scalar cross-peaks 
for the four cytosine 5H-6H protons are present (box A 
in Figure 6). Therefore, in contrast to the head-to-head 
configurations, and using the same bonding sequences and 
a similar interdrug distance, the predicted tail-to-tail 
configuration of drug molecules results in loss of duplex 
self-complementarity. This may be because there are two 
different species (e.g., 11S,3' and 5') on this duplex or that 
the species are the same (e.g., 115,3'), but the juxtaposition 
of the two drug molecules caused distortion of the helix.
IV. D esign o f a D N A -D N A  Interstrand G uanine- 
G uanine Cross-Linker Based Upon the Head-to-Head 
L inking o f Two Tom aym ycin M olecules. Based upon 
the studies described in this investigation, the 10-mer 
duplex containing either a 5'CGA or 5'AGC sequence could 
in principle serve as a duplex template for the design of 
a tomaymycin DNA-DNA interstrand cross-linker where 
the two monoadducts are covalently bound four base-pairs 
apart on opposite strands in a head-to-head orientation. 
TTie stereochemistry at the covalent linkage site is defined 
as 115, and the drugs are orientated with the aromatic 
rings pointed to the 3' sides of the covalently modified 
guanines (see Figure 7). Because the 10-mer duplex 
maintains a B-type structure and drug modification of the 
DNA minimally distorts the helix, the computer-assisted 
drug design is a relatively straightforward process. As we 
noted in previous studies,2,3 substituents at the 8-position 
on the aromatic ring point along the minor groove of DNA, 
and in the case of the bis-tomaymycin-duplex adduct, 
point towards the aromatic ring of the drug on the opposite 
strand. The molecular modeling was carried out by re­
moval of the proton from each 8-phenol group and linking 
the two unmasked oxygens with an alkane [(CH2)J  linker, 
where n = 2 ,3 ,4 , and 5. Distances between the 8-phenolic 
group oxygens of the two tomaymycin molecules in the 
115,3'CGA and 115,3'AGC adduct models were 6.77 and
7.01 A, respectively. Using straight-chain diols as models, 
a two-carbon methylene chain (n = 2) provides approxi­
mately 3.6 A between the oxygen atoms. Similarly, a 
five-carbon methylene unit (n = 5) yields approximately 
7.4 A between oxygen atoms. Thus, the optimal chain
BOX A
8 6 2 PPM4
Figure 6. Two-dim ensional magnitude COSY contour plot of 
the bis-tomaymycin 10-mer duplex adduct in 0.5 mL of D20  buffer 
containing 10 mM sodium phosphate and 100 mM sodium  
chloride, pH 6.85 at 23 °C. Arrowhead denotes coupling between 
the tomaymycin H l l  and H l la  protons indicative of at least one 
distinct 11S diastereomeric species. Box A encloses the cytosine 
H 5-H 6 proton scalar coupling, indicating at least two different 
drug species.
Figure 7. Stereopair o f the D N A -D N A  10-mer interstrand 
cross-linked [(-CH2-)5l bis-tom aym ycin (5'CGA head-to-head) 
duplex adduct designed by computer-assisted molecular modeling.
length for linking two tomaymycin molecules on these 
10-mers would be expected at about n = 4 or 5. Models 
of each of these cross-linkers were made and subjected to 
minimization with 55 ps of molecular dynamics and rem­
inimization as before. The results in Table VI show a clear 
preference for the model in which n = 5. This pentyl 
model is some 11.5 kcal/mol more stable than the other 
shorter chain models. At n >  5, the linkers become too 
“floppy” and the correct orientation becomes more difficult 
to attain. General trends in the results are that helix 
distortion decreases as chain length increases, and while 
total distortion for the propyl, butyl, and pentyl models 
are nearly identical, it is the increase in intermolecular 
interactions that finally favors the pentyl model.
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We have recently shown that the structurally simplified 
P[1,4]B cross-linker DSB-12023 (II) (Figure 8) can form a 
DNA-DNA interstrand cross-linker between guanines in 
the 10-mer duplex shown in Scheme II without appreciable 
distortion of the duplex, as predicted by this combined 
NMR and molecular modeling study (Wang and Hurley, 
unpublished results). This compound is considerably more 
potent that the monoalkylation compound and is not ex-
(23) Bose, D. S.; Thompson, A. S.; Ching, J.; Hartley, J. A.; Ber- 
ardini, M. D.; Jenkins, T. C.; Neidle, S.; Hurley, L. H.; Thur­
ston, D. E. Rational Design of a Highly Efficient Non-Rever- 
sible DNA Interstrand Cross-Linking Agent Based on the 
Pyrrolobenzodiazepine Ring System. J. Am. Chem. Soc. 1992, 
114,4939-4941.
O O
F igu re  8. Structure of DSB-120 (II).23
pected to show the cardiotoxicity previously associated 
with anthramycin and sibiromycin.13
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M a n y  D N A  c r o ss - lin k in g  a g e n ts  w ith  s ig n if ic a n t  a n t itu m o r  
a c t iv ity 1 a r e  G C  s ite -sp e c if ic , w h ic h  m a y  c o n tr ib u te  to  th e ir  po­
te n c y , as it h a s  b e en  e sta b lish e d  th a t  a n u m b er  o f  o n c o g e n e s ,  
includ ing c -H a -ra r , con ta in  h igh ly  G C -r ich  reg ion s.2 M o st know n  
c r o ss - lin k in g  a g e n ts  a r e  o f  s u ff ic ie n t  s iz e  to  r e c o g n iz e  o n ly  tw o  
or th r e e  b a se  p a irs , a n d  e x te n s io n  o f  th is  l im ite d  s e q u e n c e  r ec ­
o g n it io n  is o f  in te r e s t , a s  su c h  a g e n ts  m a y  h a v e  th e  p o te n tia l to
Table I. In Vitro Cytotoxicity of 7 and 8fl
IC50 (mM) L1210 A D J/P C 6 CHI
7 (DSB-120) 0.01 0.0005 0.003
8 (DC-81) 0.38 0.33 0.1
0IC50 is the dose (mM) for 50% growth inhibition compared to sol­
vent controls. Drugs were dissolved in DM SO to provide a final con­
centration of 0.05% DMSO. Incubation times (37 °C) were as follows: 
L I210, 3 days; A D J/P C 6 , 4 days; C H I, 9 days.
p r o d u ce  irr ep a r a b le  c r o ss -lin k s  a t p r e c is e ly  d e fin e d  g e n o m ic  lo ­
c a tio n s .3 F u rth erm o re, c lin ic a lly -u se fu l cross-lin k in g  a g en ts  su ch  
as th e  n itrogen  m u stard s a lk y la te  w ith in  th e  m ajor groov e  o f  D N A  
w h e r e a s , w ith  fe w  e x c e p t io n s ,4-6 th e  b io lo g ic a l  c o n se q u e n c e s  o f  
m in or g roov e  c r o ss -lin k in g  h a v e  b e en  r e la tiv e ly  u n e x p lo re d . W e  
report here th e  sy n th e s is  o f  a  p y r r o lo [2 , l - c ] [  1 ,4 ] b e n z o d ia z e p in e  
( P B D )  b ifu n c t io n a l a lk y la t in g  a g e n t , D S B - 1 2 0  ( 7 ) ,  th a t  fo rm s
T University of Portsmouth.
1 University College and Middlesex School of Medicine.
* Institute of Cancer Research.
'University of Texas at Austin.
ss m m m r n -
Figure 1. Autoradiograph of a neutral agarose gel showing DN A  in­
terstrand cross-linking by 7 in linear 32P end-labeled pBR322 DNA. 
Drug reactions (2 h at 37 °C) were in 25 mM triethanolamine/1 mM 
EDTA pH 7.2 buffer with 10 ng of DN A  in a final volume of 50 pL. 
Reaction was terminated by addition of an equal volume of 0.6 M sodium 
acetate, 20 mM EDTA, and 100 Mg/mL tRNA, and the D N A  precipi­
tated with ethanol. Dried pellets were taken up in strand separation 
buffer (30% w /w  DM SO in ImM EDTA). Denaturation for 2 min at 
90 °C was followed by immediate chilling in an ice-water bath. Elec­
trophoresis was carried out on 0 .8% w /v  submerged horizontal agarose 
gels at 40 V for 16 h with tris-acetate running buffer. Double-stranded 
(ds) and single-stranded (ss) D N A  were quantitated by laser densito­
metry.
a n  irrev ersib le  in ter stra n d  c r o ss -lin k  b e tw e e n  tw o  g u a n in e  b ases  
w ith in  th e  m inor groove v ia  their ex o c y c lic  N 2  a to m s.7 A ccord in g  
to  m o le cu la r  m o d e lin g  an d  N M R  stu d ies , it sp a n s s ix  b a se  pairs, 
a c t iv e ly  r e c o g n iz in g  a  c e n tr a l 5 ' -G A T C  se q u e n c e . It is  o n e  o f  
th e  m o st  e f f ic ie n t  D N A  c r o ss - lin k in g  a g e n ts  k n o w n  a n d  is  s ig ­
n if ic a n t ly  c y to to x ic  to w a rd  tu m o r  c e l ls  in  v itro .
T h e  P B D  a n titu m o r  a n tib io tic s  m o n o a lk y la te  th e  e x o c y c lic  N 2  
o f  g u a n in e  in  th e  m in o r  g r o o v e  o f  D N A  v ia  th e ir  e le c tr o p h ilic
(1) (a) Kohn, K. W. In Molecular Aspects o f  Anticancer Drug Action; 
Neidlc, S., Waring, M. J., Eds.; Macmillan Press: London, 1983; pp 315-361.
(b) Pratt, W. B.; Ruddon, R. W. The Anticancer Drugs-, Oxford University 
Press: New York, 1979. (c) Chabner, B., Ed. Pharmacological Principles 
o f  Cancer Treatment-, W. B. Saunders and Co.: Philadelphia, 1982.
(2) Mattes, W. B.; Hartley, J. A.; Kohn, K. W.; Matheson, D. W. Car­
cinogenesis 1988, 9, 2065-2072.
(3) (a) Hopkins, P. B.; Millard, J. T.; Woo, J.; Weidner, M. F.; Kirchner, 
J. J.; Sigurdsson, S. Th.; Raucher, S. Tetrahedron 1991, 47, 2475-2489. (b) 
Millard, J. T.; Weidner, M. F.; Kirchner, J. J.; Ribeiro, S.; Hopkins, P. B. 
Nucleic Acids Res. 1991, 19, 1885-1891. (c) Thurston, D. E.; Thompson, 
A. S. Chem. Br. 1990, 26, 767-772.
(4) Tomasz, M.; Lipman, R.; Chowdary, D.; Pawlak, J.; Verdine, G. L.; 
Nakanishi, K. Science 1987, 235, 1204-1208.
(5) (a) Mitchell, M. A.; Johnson, P. D.; Williams, M. G.; Aristoff, P. A. 
J. Am. Chem. Soc. 1989, 111, 6428-6429. (b) Mitchell, M. A.; Kelly, R. C.; 
Wicnienski, N. A.; Hatzenbuhler, N. T.; Williams, M. G.; Petzold, G. L.; 
Slightom, J. L.; Siemieniak, D. R. J. Am. Chem. Soc. 1991,113, 8994-8995.
(c) Lee, C.-S.; Gibson, N. W. Cancer Res. 1991, 51, 6586-6591.
(6) (a) Farmer, J. D.; Rudnicki, S. M., Jr.; Suggs, J. W. Tetrahedron Lett. 
1988, 29, 5105-5108. (b) Farmer, J. D., Jr.; Gustafson, G. R.; Conti, A.; 
Zimmt, M. B.; Suggs, J. W. Nucleic Acids Res. 1991, 19, 899-903.
(7) British Patent Application No. 9205051.7 (9 March, 1992).
0002-7863/92/1514-4939S03.00/0 © 1992 American Chemical Society
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7 ( D S B - 1 2 0 )  8 ( D C - 8 1 )
a(a) Vanillic acid /I(C H 2)3I/aqueous N aO H /T H F; (b) dimethyl su lfate/K 2C 0 3/acetone; (c ) SnCl4/ H N 0 3/C H 2Cl2 (-2 0  °C); (d) aqueous 
N aO H /T H F; (e) (COCl)2/T H F /E t3N /H 20/(2S)-pyrrolidine-2-carbaldehyde diethyl thioacetal;12 (f) SnCl2-2H20 /M e 0 H ;  (g) HgCl2/C a C 0 3/  
CH 3C N /H 20 .
1:  fl ,  .  H.  Rj  .  COOH ( a )
2 :  R,  .  H,  R2 -  COOCHj ( b )
3 :  R,  -  N 0 2 , R2 -  COOCHj ( c )
4 :  R,  .  N 0 2 , R2 -  COOH ( d )
Scheme 1“
R
Figure 2. Stereoview of the cross-linked d(CICGATCICG)2-P B D  dimer adduct following X-PLOR refinement. The dimer 7 (shown in bold) is located 
in the minor groove of B-DNA, spanning bases C 3-I8, and is bound covalently to G4 bases on adjacent strands. All H-atoms have been removed for 
clarity.
N 1 0 - C 1 1 im in e  (o r  eq u iv a le n t) m o ie t ie s ,8 th e  p referred  b o n d in g  
seq u en ce  involving 5 '-P u G P u  m o tifs .9 O u r  o b jectiv e  w a s to  te th er  
tw o  P B D  u n its  th r o u g h  th e ir  C 3  p o s it io n s  v ia  a f le x ib le  1 ,3 -  
p r o p a n e d iy ld io x y  e th er  l in k a g e ,7 w ith  a v ie w  to  e x te n d in g  th e
(8) (a) Hurley, L. H.; Thurston, D. E. Pharm. Res. 1984, 2, 52-59. (b) 
Remers, W. A. Pyrrolof 1,4] benzodiazepines. In The Chemistry o f  Antitum ­
our Antibiotics-, Wiley-Interscience: New York, 1988; Vol. 2, pp 28-92.
(9) (a) Hertzberg, R. P.; Hecht, S. M.; Reynolds, V. L.; Molineux, I. J.; 
Hurley, L. H. Biochemistry 1986, 25, 1249-1258. (b) Hurley, L. H.; Reck, 
T.; Thurston, D. E.; Langley, D. R.; Holden, K. G.; Hertzberg, R. P.; Hoover, 
J. R. E.; Gallagher, G., Jr.; Faucette, L. F.; Mong, S.-M.; Johnson, R. K.
Chem. Res. Toxicol. 1988, 1, 258-268.
n u m b er  o f  sp a n n e d  b a se  p a irs, th u s  e n h a n c in g  D N A  s e q u e n c e  
se lec tiv ity . M o lec u la r  m o d e lin g  su g g este d  th a t C 8 - lin k e d  d im ers  
h ave grea ter  iso h e lic ity  w ith  th e  m in or  groove o f  D N A  c om p a red  
to  th e  C 7 - lin k e d  d im e rs  rep orted  b y  S u g g s .68 C 8  d im e r s  o f  th is  
ty p e  sh ou ld  h a v e  th e  p o ten tia l to  form  in tra - or in terstra n d  D N A  
cross-lin k s, in ad d ition  to  a d d u cts resu ltin g  from  m o n o a lk y la tio n .3 
T h e  n atu ral p rod u ct D C -8 1  (8 )  w as c h o sen  as th e  m o n o m er  P B D  
u n it ,10 an d  an  e ff ic ie n t  sy n th etic  p a th w a y  w as d ev e lo p e d  (S c h e m e
(10) (a) Thurston, D. E.; Murty, V. S.; Langley, D. R.; Jones, G. B. 
Synthesis 1990, 81-84. (b) Bose, D. S.; Jones, G. B.; Thurston, D. E. Tet­
rahedron 1992. 48, 751-758.
( )
I) to provide the target dimer 7 as a stable yellow oil11 in 8% overall 
yield.
DNA-binding of 7 was initially observed through thermal 
denaturation studies with calf thymus DNA13 (Arm >15.1 °C 
for a 5:1 ratio of DNAp:ligand at 37 °C for 18 h). Cross-linking 
efficiency was investigated using an agarose gel electrophoresis 
assay14 based on the principle that, following complete denaturation 
of linear pBR322 DNA, an interstrand cross-link results in re- 
naturation to the double-stranded form in a neutral gel. The 
results indicate that 7 is a remarkably efficient cross-linking agent 
(Figure 1). After 2 h at 37 °C, cross-linking is measurable down 
to at least 0.01 pM (drug:nucleotide ratio = 0.025), with >90% 
cross-linking at 0.4 /iM (drugrnucleotide ratio = 1.0). In the same 
assay, it is 50-fold more effective than the major groove cross- 
linkers mechlorethamine and cisplatin,’4 approximately 300 times 
more efficient than melphalan,14 and similar in efficiency to rigid 
CC-1065 dimers such as U77779.5® However, in contrast to the 
weaker-binding C7-linked PBD dimer,6,15,16 no reversibility of 
cross-linking was observed after incubation for 16 h at 37 °C and 
pH 4-10. In addition, compound 7 is highly cytotoxic, and 
comparison with the monomer 8 (Table I) emphasizes the bio­
logical consequences of DNA cross-linking.
Extensive modeling studies of 7 with d(CGYGXXCYCG)2 have 
suggested that spatial separation of the PBD units is optimal for 
spanning six base pairs with a preference for 5'-PuGATCPy or 
5'-PyGATCPu sequences, and that it actively recognizes the 
embedded d(GATC)2 sequence. The self-complementary 10-mer 
d(CICGATCICG)217 was designed to investigate the interstrand 
cross-linking potential of 7. 1H-NMR examination of the 1:1 
adduct showed that the duplex is cross-linked symmetrically via 
the minor groove N2 positions of the guanines, with 1 US'),! 1'- 
(S')-stereochemistry in the ligand and minimal distortion of the 
helix. The model was subsequently refined at the all-atom level 
by an interproton NOE distance-restrained dynamic annealing 
procedure using X-PLOR 2.118 (Figure 2).
In summary, C8-linked PBD dimers of this class are highly 
efficient irreversible DNA cross-linking agents that may have 
potential application in cancer chemotherapy and as biochemical 
tools.
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C om p arison  o f  a DSB-120 DNA In terstran d  C ross-L inked A d du ct w ith  th e  
C orresp on d in g  B is-tom aym ycin  A dduct: An E xam ple o f  a S u ccessfu l 
T em p la te-D irected  A pproach  to  D rug D esig n  B ased  u p on  th e  M on oalk y la tin g  
C om pound T om aym ycin
J o h n  A .  M o u n t z o u r i s ,*  J e h - J e n g  W a n g ,*  D a v i d  T h u r s t o n ,*  a n d  L a u r e n c e  H .  H u r l e y * ’*
D ru g  D y n a m ics  In s ti tu te , C ollege o f  P h a rm a cy , T he U n iv e rs ity  o f  T exas a t  A u s tin , A u s tin , T exas 78712-1074 , a n d  S ch oo l o f  
P h a rm a c y  a n d  B io m e d ic a l Scien ces, U n iv e rs ity  o f  P o rtsm o u th , K in g  H en ry  I  S tre e t, P o rtsm o u th , H a n ts  P O l 2D Z , U n ite d  
K in g d o m
R ece ived  M a y  9, 1 9 9 4 ®
The interstrand cross-linked DSB-120-d(CICG*ATCICG)2 DNA adduct (* indicates covalently  
modified guanine) was examined by two-dimensional NMR and compared to the bis-tomaymycin  
adduct on the sam e oligomer. Tomaymycin and DSB-120 form self-complementary adducts 
with the d(CICGATCICG )2  duplex sequence in which the covalent linkage sites occur between  
C l l  of either drug and the exocyclic 2-amino group of the single reactive guanine on each  
strand of d(CICGATCICG)2 . In the case of DSB-120, th is is  evidence for the formation of a 
guanine—guanine DNA interstrand cross-link. Both drugs show formation of an S  stereo­
chem istry at the covalent linkage site w ith an associated 3' orientation. W hile the majority of 
DNA in these adducts appears to be B-form, DSB-120 interstrand cross-linking induces atypical 
properties in the 81 nucleotide, indicated by broadening of the 8IH2 proton resonance, non-C2' 
endo sugar geometry, and unusually w eak internucleotide NOE connectivity to the 7C 
nucleotide. Tomaymycin does not produce th is regional dislocation. For tomaymycin, w hile  
there are strong NOE connectivities from protons on the five-membered ring to the 8IH2 proton 
on the floor of the minor groove, the equivalent internucleotide connectivities in DSB-120 are 
weaker. This indicates that the tom aymycin tail is close to the floor of the minor groove, w hile  
the five-mem bered ring of D SB-120 is more shallowly immersed, perhaps due to strain from  
cross-linking w ith  a very short linker unit. Last, the conformational stresses induced on the  
duplex by DSB-120 appear to make the region of covalent attachm ent more accessible to solvent 
than is the case for tomaymycin. The 4GN2Hb resonance appears in 100% D 2O on the  
tom aymycin adduct but is only observed in 90% H2O/10% D 2 O for the D SB-120 adduct. On 
the basis of these results, the strategies for tem plate-directed DNA cross-linker design are 
assessed.
In tro d u ctio n  h h
n ^ \ . - - oh
D S B - 1 2 0  ( 1 , l ' - (  p r o p a n e - 1 , 3 - d i y l d i o x y  ) b i s [ ( l  l a S ) - 7 -  
m e t h o x y - l , 2 , 3 , l l a - t e t r a h y d r o - 5 H - p y r r o l o [ l , 2 - c ] [ l , 4 ] -  
b e n z o d i a z e p i n - 5 - o n e ] )  i s  a  s y n t h e t i c  a n t i t u m o r  a g e n t  
i n c o r p o r a t i n g  a  p a i r  o f  D N A  a l k y l a t i n g  u n i t s  b a s e d  o n  
t h e  m o n o f u n c t i o n a l  D N A - r e a c t i v e  m o i e t y  o f  t h e  p y r r o lo -  
[ l , 4 ] b e n z o d i a z e p i n e s  ( P [ l , 4 ] B s )  ( F i g u r e  1 ) ,  w h i c h  h a v e  
b e e n  l i n k e d  t h r o u g h  0 8  b y  a  t r i m e t h y l e n e  b r i d g e . 1 T h e  
P [ l , 4 ] B s ,  w h i c h  i n c l u d e  t o m a y m y c i n ,  h a v e  b e e n  p r o ­
p o s e d  t o  c o v a l e n t l y  b o n d  t o  N 2  o f  g u a n i n e  t o  f o r m  a  
n e u t r a l  m i n o r  g r o o v e  a d d u c t 2 ( F ig u r e  2 ) ,  a l t h o u g h  r e c e n t  
e v i d e n c e  p o i n t s  t o  a  p o s i t i v e l y  c h a r g e d  s p e c i e s . 3 T h e  
c y t o t o x i c  a n d  a n t i t u m o r  e f f e c t s  o f  t h e s e  c o m p o u n d s  a r e  
b e l i e v e d  t o  a r i s e  f r o m  m o d i f i c a t i o n  o f  D N A ,  w h i c h  l e a d s  
t o  i n h i b i t i o n  o f  n u c l e i c  a c id  s y n t h e s i s 4 a n d  p r o d u c t io n  
o f  e x c i s i o n - d e p e n d e n t  s i n g l e -  a n d  d o u b l e - s t r a n d  b r e a k s  
i n  c e l l u l a r  D N A . 5 T h e  s e q u e n c e  s e l e c t i v i t y  o f  t o m a y ­
m y c i n  a n d  a n t h r a m y c i n  c o v a l e n t  b o n d i n g  t o  D N A  h a s  
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F ig u r e  1. Structures of P [l,4 ]B s tom aymycin (1) and DSB- 
120 (2 ).
u s i n g  t h e  U V r A B C  e n d o n u c l e a s e  i n d i c a t e d  t h a t  t h e r e  
a r e  d i f f e r e n c e s  b e t w e e n  t o m a y m y c i n  a n d  a n t h r a m y c i n  
a n d  t h a t  t o m a y m y c i n  s h o w s  a  p r e f e r e n c e  f o r  c y t o s i n e  
t o  t h e  3 '  s i d e  o f  t h e  c o v a l e n t l y  m o d i f i e d  g u a n i n e . 8 F o r  
a n t h r a m y c in ,  c l i n i c a l  a c c e p t a n c e  w a s  p r e c lu d e d  b y  d o s e -  
l i m i t i n g  c a r d i o t o x ic i t y .9 S y n t h e t i c  m o n o a l k y l a t i n g  a n a ­
l o g s  d e v o i d  o f  c a r d i o t o x i c i t y  m a n i f e s t  r e l a t i v e l y  p o o r  in 
vitro  a n d  in  vivo  p o t e n c y . 7
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Figure 2 . P r o p o s e d  r e a c t io n  o f  to m a y m y c in  w i t h  g u a n in e  in
D N A .20
The design inspiring the synthesis of DSB-120 rests 
on several principles. A number of antitumor agents, 
such as mitomycin C, cis-platinum, and nitrogen mus­
tards, have the capability to form intra- or interstrand 
cross-links on DNA.10 The inter strand cross-linking of 
DNA by mitomycin C and the nitrogen mustards is 
proposed to be responsible for the high potency of these 
compounds.11 The concept of synthesizing tethered 
monoalkylating DNA-reactive units to form an inter­
strand cross-linker has been previously enacted.12 For 
example, dimeric analogs incorporating the DNA-alky- 
lating cyclopropylindole (CPI) unit from the natural 
product (+)-CC-1065 have been made.123 One of these 
dimeric analogs, Bizelesin (The Upjohn Co.), which is 
in phase I clinical trials, is more potent and efficacious 
than its parent monoalkylating compound.123 Work in 
our laboratory on Bizelesin has highlighted other rea­
sons for the design of DNA cross-linkers. As a result of 
cross-linking, Bizelesin induces an unexpected struc­
tural transition to Hoogsteen base pairing in the 
internal region of cross-linked oligonucleotides,13 and 
the capability to bisalkylate DNA alters the sequence 
selectivity relative to (+)-CC-1065.14 Besides the pos­
sible therapeutic potential, creating novel distortion in 
DNA structure and targeting new sequences for alky- 
lation are attractive reasons to continue designing DNA 
cross-linking agents.
The P[1,4]B dimer DSB-120 exhibits efficient ir­
reversible interstrand cross-linking, as shown by gel 
e le c t r o p h o r e s i s .1’15 A previous cross-linking analog in 
which the P[1,4]B nucleus was linked through C7 
(Figure 1) was shown to be highly reversible by a simple 
pH change.12b Sequence specificity studies suggest that 
DSB-120 prefers a central AT base-pair motif embedded 
between the covalently modified cross-linked guanines.1
In a template-directed approach to the design of 
DN A -D NA cross-linkers, we have characterized a
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F i g u r e  3 . D N A  s e q u e n c e s  e x a m in e d  for  te m p la te -d ir e c te d  b is-  
to m a y m y c in  a lk y la t io n :  s e q u e n c e  A ,16a s e q u e n c e  B ,16b a n d  
s e q u e n c e  C .16b
series of self-complementary bis-tomaymycin-DNA ad­
ducts using the combined approach of two-dimensional 
NMR and molecular modeling (Figure 3).16 Our dis­
covery of a sequence-dependent minor groove orienta­
tion of tomaymycin and a sequence-dependent stereo­
chemistry at the covalent linkage site had important 
implications for the design of an interstrand DNA cross­
linker. Sequence A is a derivation of the well-charac­
terized Dickerson dodecamer d(CGCGAATTCGCG)2 , in 
which two guanines have been replaced by inosines to 
create a self-complementary duplex with only one 
unique bonding site for the drug at 4G on each strand. 
Tomaymycin forms a nondistortive head-to-head self- 
complementary bis-adduct with sequence A, with both 
drugs displaying S  stereochemistry at the covalent 
linkage site and the aromatic ring oriented to the 3' side 
of the covalently modified guanine.163 A 3'S self- 
complementary bis-adduct is also exhibited in the 
truncated decamer sequence B, which is formed by the 
excision of the two central AT base pairs from sequence
A.16b In this sequence, the 0 8  phenol positions are 
separated by approximately 6.8 A, appropriate for 
joining by a short aliphatic bridge. In contrast, efforts 
to use a template-directed approach to design a defined 
tail-to-tail adduct using sequence C, which has the same 
triplet bonding sequence as sequence B, resulted in a 
complex adduct mixture with more than one species of 
tomaymycin bound to DNA.16b From the template- 
directed approach to the design of a sequence-directed 
DNA bis-alkylation, a P[1,4]B-DN A interstrand cross­
linker in which two tomaymycin units were linked head 
to head by a flexible methylene bridge was proposed and 
subjected to molecular modeling.1613
The two-dimensional NMR data for the DSB-120 and 
bis-tomaymycin d(CICGATCICG) 2  10-mer adducts (se­
quence B) were examined to determine the predictive 
value of the template-directed approach.
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F igu re  4. One-dimensional proton-decoupled 202.44-MHz 
phosphorus NMR spectra in 0.5 mL of D20-buffered solution, 
pH 6.8, 100 mM sodium chloride, and 10 mM sodium phos­
phate at 23 °C for the (A) d(CICGATCICG)2 duplex, (B) bis- 
tomaymycin adduct, and (C) DSB-120 adduct.
R esu lts
P r i o r  t o  m a k i n g  a  c o m p a r i s o n  o f  t h e  D S B - 1 2 0  a n d  b i s -  
t o m a y m y c i n  1 0 - m e r  d u p l e x  a d d u c t  s t r u c t u r e s ,  i t  w a s  
n e c e s s a r y  t o  d e t e r m i n e  t h e  c o m p l e x i t y  o f  t h e  c r o s s -  
l i n k e d  s p e c i e s  f o r m e d ,  i d e n t i f y  t h e  c o v a l e n t  l i n k a g e  s i t e s  
b e t w e e n  D S B - 1 2 0  a n d  D N A ,  a n d  d e t e r m i n e  t h e  s t e r e ­
o c h e m i s t r y  a n d  o r i e n t a t i o n  o f  t h e  D S B - 1 2 0  s p e c i e s  o n  
D N A .
S ym m etry  o f  the DSB-120 10-m er D u p lex  Ad­
duct. A. P h o sp h o ru s S p ectra . T h e  p r o t o n - d e c o u ­
p l e d  p h o s p h o r u s  s p e c t r a  o f  t h e  1 0 - m e r  d u p l e x ,  t h e  b i s -  
t o m a y m y c i n  a d d u c t ,  a n d  t h e  D S B - 1 2 0  a d d u c t  i n  D 2O  
b u f f e r  a r e  p l o t t e d  in  p a n e l s  A ,  B ,  a n d  C  o f  F i g u r e  4 ,  
r e s p e c t i v e l y .  N i n e  p h o s p o r u s  r e s o n a n c e s  a r e  d e t e c t e d  
fo r  t h e  b i s - t o m a y m y c i n  a d d u c t  ( F ig u r e  4 B )  a n d  t h e  D S B -  
1 2 0  a d d u c t  ( F i g u r e  4 C ) ,  u s i n g  t w o - d i m e n s i o n a l  h e t e r o -  
n u c l e a r  p h o s p h o r u s - d e t e c t e d  31P —: H  p h a s e - s e n s i t i v e  
r e l a y e d  c o r r e l a t e d  s p e c t r o s c o p y  ( C O S Y )  c o u p l i n g  c o n ­
n e c t i v i t i e s  t o  H 3 '  p r o t o n s  i n  t h e  5 '  d i r e c t i o n  a n d  H 4 '  
p r o t o n s  i n  t h e  3 '  d i r e c t i o n  ( d a t a  n o t  s h o w n ) .  T h i s  i s  t h e  
s a m e  n u m b e r  t h a t  i s  n e c e s s a r i l y  p r e s e n t  i n  t h e  o v e r ­
l a p p e d  s p e c t r a  o f  t h e  d u p l e x  ( F i g u r e  4 A )  a n d  e s t a b l i s h e s  
t h a t  t h e  2 - f o ld  s y m m e t r y  o f  t h e  s e l f - c o m p l e m e n t a r y  
d u p l e x  i s  m a i n t a i n e d  i n  b o t h  t h e  b i s - t o m a y m y c i n  a n d  
D S B - 1 2 0  a d d u c t s .  T h e r e  i s  g r e a t e r  d i s p e r s i o n  o f  t h e  
p h o s p h o r u s  r e s o n a n c e s  i n  t h e  t o m a y m y c i n -  a n d  D S B -  
1 2 0 —D N A  a d d u c t s .  T h e  d o w n f i e l d - s h i f t e d  p h o s p h o r u s  
( 3 C —4 G  s t e p )  t o  t h e  5 '  s i d e  o f  t h e  c o v a l e n t l y  m o d i f i e d  
g u a n i n e  h a s  b e e n  p r e v i o u s l y  u s e d  a s  a  p r o b e  o f  m o d e s t  
d i s t o r t i o n  i n  t h e  d e o x y r i b o s e  p h o s p h a t e  b a c k b o n e  i n ­
d u c e d  b y  b o n d i n g  o f  t o m a y m y c i n  t o  s h o r t  o l i g o m e r s .3163  
A  s i m i l a r  p e r t u r b a t i o n  i n  c h e m i c a l  s h i f t  i s  a l s o  e v i d e n t  
fo r  t h e  D S B - 1 2 0  a d d u c t .
B. N o n ex ch a n g ea b le  P ro to n  A ssign m en ts. T h e  
o n e - d i m e n s i o n a l  ^ - N M R  n o n e x c h a n g e a b l e  a r o m a t i c  
a n d  m e t h y l  r e s o n a n c e s  fo r  t h e  b i s - t o m a y m y c i n  a n d  
D S B - 1 2 0  a d d u c t s  a r e  p l o t t e d  i n  F i g u r e  5 A ,  B ,  r e s p e c ­
t i v e l y .  T h e  m a j o r i t y  o f  t h e  s i g n a l s  a r e  w e l l  r e s o l v e d  a n d  
h a v e  b e e n  a s s i g n e d  b y  t w o - d i m e n s i o n a l  N M R  s p e c t r a  
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F igu re 5. Expansions of one-dimensional nonexchangeable 
NMR spectra in 0.5 mL of D20-buffered solution, pH 6.8, 100 
mM sodium chloride, and 10 mM sodium phosphate at 23 °C 
showing, left to right, the respective aromatic and methyl 
regions for the (A) bis-tomaymycin d(CICGATCICG)2 adduct 
and (B) DSB-120 d(CICGATCICG)2 adduct.
n u c l e a r  o v e r h a u s e r  e f f e c t  s p e c t r o s c o p y  ( N O E S Y )  c o n ­
n e c t i v i t i e s .  T h e  c h e m i c a l  s h i f t  a s s i g n m e n t s  fo r  t h e  
n u c l e o t i d e  a n d  d r u g  p r o t o n s  i n  t h e  d u p l e x  a n d  t h e  t w o  
a d d u c t s  a r e  l i s t e d  i n  T a b l e  1 . I t  i s  w o r t h w h i l e  t o  n o t e  
t h a t  8 I H 2  i s  u n u s u a l l y  b r o a d  i n  t h e  D S B - 1 2 0  1 0 - m e r  
a d d u c t  b u t  n o t  i n  t h e  b i s - t o m a y m y c i n  a d d u c t  ( F i g u r e  
5 ) .  T h i s  s u g g e s t s  t h a t  c r o s s - l i n k i n g  i n d u c e s  c o n f o r m a ­
t i o n a l  e x c h a n g e  i n  a  r e s t r i c t e d  a r e a  o n  t h e  s t r a n d  
o p p o s i t e  t h e  c o v a l e n t l y  m o d i f i e d  g u a n i n e .  O t h e r  u n ­
u s u a l  f e a t u r e s  o f  t h e  8 1  n u c l e o t i d e  u n i q u e  t o  D S B - 1 2 0 -  
D N A  i n t e r s t r a n d  c r o s s - l i n k i n g  a r e  n o t e d  l a t e r .
T h e  s a m e  n u m b e r  o f  D N A  p r o t o n  r e s o n a n c e s  e x i s t s  
i n  b o t h  t h e  d u p l e x  a n d  t h e  t o m a y m y c i n  a n d  D S B - 1 2 0  
a d d u c t s .  T h e  s i n g l e  6 T  m e t h y l  a n d  8 I H 2  r e s o n a n c e s  
a r e  d e s i g n a t e d  a s  e x a m p l e s  i n  F i g u r e  5 .  A  s i n g l e  s e t  o f  
r e s o n a n c e s  i s  a s s i g n e d  t o  b o t h  t o m a y m y c i n  m o l e c u l e s  
i n  t h e  b i s - a d d u c t ,  c o n f i r m i n g  t h e  s e l f - c o m p l e m e n t a r i t y  
o f  t h e  a d d u c t  ( T a b le  1 C ) . L i k e w i s e ,  a  s i n g l e  s e t  o f  
r e s o n a n c e s  d e s c r i b i n g  b o t h  h a l v e s  o f  D S B - 1 2 0  c o n f i r m s  
s y m m e t r y  a b o u t  t h e  m e t h y l e n e  b r id g e  i n  t h i s  D N A  
a d d u c t  ( T a b le  1 C ) .  T h e  s i n g l e  H 6  a r o m a t i c  p r o t o n s  o f  
t o m a y m y c i n  a n d  D S B - 1 2 0  i n  t h e i r  r e s p e c t i v e  1 0 - m e r  
a d d u c t s  a r e  s h o w n  a s  e x a m p l e s  ( F i g u r e  5 ) .
Id en tifica tio n  o f th e  C ovalen t L ink age S ite . 
C h e m i c a l  s h i f t  a s s i g n m e n t s  fo r  e x c h a n g e a b l e  D N A  a n d  
d r u g  p r o t o n s  a r e  l i s t e d  i n  T a b l e  1 . S i g n i f i c a n t l y ,  t h e  
d o u b l e - q u a n t u m - f i l t e r e d  c o r r e l a t e d  s p e c t r o s c o p y  ( D Q F -  
C O S Y )  e x p e r i m e n t s  e x h i b i t  s c a l a r  c o u p l i n g  b e t w e e n  t h e  
s l o w l y  e x c h a n g i n g  4 G N 2 H b  a n d  t h e  C l l  p r o t o n  i n  b o t h  
t h e  D S B - 1 2 0  (9 0 %  H 2O /10% D 2O  b u f f e r ,  p H  6 .8 )  a n d  
t o m a y m y c i n  ( D 2O  b u f f e r ,  p H  6 .8 )  D N A  a d d u c t s  ( s u p p l e ­
m e n t a r y  i n f o r m a t i o n  a n d  u n p u b l i s h e d  r e s u l t s ) .  T h e s e  
s c a l a r  c o u p l i n g s  h a v e  a  p r e c e d e n t  in  t h e  C O S Y  s p e c t r a  
o f  t h e  c o v a l e n t  D N A  a d d u c t s  o f  o t h e r  P [ l , 4 ] B s ,  i n c l u d i n g  
t o m a y m y c i n , 163 a n d  c o n c l u s i v e l y  e s t a b l i s h  t h a t  b o t h  
d r u g s  a c h i e v e  c o v a l e n t  a t t a c h m e n t  v i a  C l l  t o  t h e  4 G  
e x o c y c l i c  2 - a m i n o  n i t r o g e n s  o f  t h e  d u p l e x .  I n  t h e  c a s e  
o f  D S B - 1 2 0 ,  t h i s  i s  u n e q u i v o c a l  e v i d e n c e  fo r  t h e  f o r m a ­
t i o n  o f  a  s y m m e t r i c a l  D N A - D N A  i n t e r s t r a n d  c r o s s - l in k .
I m p o r t a n t ly ,  w h i l e  t h e  n o r m a l ly  e x c h a n g e a b l e  4 G N 2 H b  
p r o t o n  i s  r e s t r i c t e d  e n o u g h  i n  m o t i o n  a n d / o r  s o l v e n t  
e x c h a n g e  t o  b e  v i s i b l e  i n  t h e  o n e - d i m e n s i o n a l  N M R
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Table 1
A. Base Proton NMR Chemical Shifts (ppm) for d(ClCGATCICG)2 (10-mer), Bis-tomaymycin d(CICGATCICG)2 (T-mer),
and DSB-120 d(CICGATCICG)2 (DSB-120-mer) Adducts0
assignment 10-mer T-mer DSB-120-mer assignment 10-mer T-mer DSB-120-mer
Aromatic Protons
1CH6 7.60 7.60 7.72 1CH5 5.88 5.86 5.93
2IH8 8.25 8.25 8.26 2IH2 7.84 7.83 7.93
3CH6 7.36 7.36 7.50 3CH5 5.31 5.30 5.52
4GH8 7.73 7.73 7.92
5 AH 8 8.06 8.06 8.26 5AH2 7.72 8.05 8.16
6TH6 7.11 7.11 7.07 6TMe 1.30 1.34 1.27
7CH6 7.47 7.19 7.17 7CH5 5.59 5.35 5.31
8IH8 8.13 8.13 8.05 8IH2 7.76 7.26 7.54
9CH6 7.21 7.21 7.44 9CH5 5.36 5.29 5.52
10GH8 7.88 7.88 7.89
Imino Protons and 4GN2Hb (15 °C)
1C-10G 13.45 12.90 4G-7C 13.41 12.95 12.80
2I-9C 15.35 15.10 5A-6T 12.42 13.70 13.50
3C-8I 15.20 15.35 15.10 4GN2Hb 8.94 9.10
B. Deoxyribofuranose Proton NMR Chemical Shifts (ppm) for d(CICGATCICG)2 (10-mer), Bis-tomaymycin d(CICGATCICG)2 (T-mer),
and DSB-120 d(CICGATCICG)2 (DSB-120-mer) Adducts
HI' H2' H2" H3' H4'
assign­ 10- T- DSB-120- 10- T- DSB-120- 10- T- DSB-120-■ 10- T- DSB-120- 10- T- DSB-120-
ment mer mer mer mer mer mer mer mer mer mer mer mer mer mer mer
1C 5.61 5.55 5.74 1.94 1.93 1.92 2.36 2.32 2.38 4.68 4.66 4.62 4.02 4.02 3.98
21 6.21 6.18 6.21 2.75 2.69 2.81 2.90 2.85 2.81 5.01 4.97 4.94 4.441 4.37 4.37
3C 5.76 5.40 5.43 1.75 2.15 2.05 2.29 2.39 2.30 4.82 4.81 4.82 4.22 4.16 4.10
4G 5.56 6.08 6.16 2.73 2.54 2.71 2.76 2.89 3.05 5.00 5.00 5.06 4.36 4.37 4.12
5A 6.21 6.15 6.44 2.60 2.52 2.60 2.91 2.56 2.75 4.96 4.93 4.98 4.45 4.23 4.15
6T 5.88 5.67 5.78 2.00 1.88 2.03 2.45 2.45 2.19 4.83 4.58 4.62 4.26 1.98 2.61
7C 5.58 5.76 5.48 2.06 1.75 1.65 2.38 2.18 2.15 4.84 4.79 4.72 4.22 4.18 4.07
81 6.17 5.78 5.86 2.70 2.56 2.73 2.88 2.56 2.56 5.02 4.85 4.89 4.41 3.84 3.79
9C 5.82 5.80 5.83 1.65 1.49 1.82 2.21 2.21 2.34 4.80 4.73 4.72 4.22 4.03 4.08
10G 6.11 6.09 6.12 2.61 2.56 2.64 2.37 2.32 2.34 4.66 4.66 4.65 4.15 4.15 4.15
C. Tomaymycin and DSB-120 Proton NMR Chemical Shifts (ppm) in Respective d(CICGATCICG)2 Adducts
drug H1A H1B H2Ai> H2Bfc H3A H3B H6 70CH3 80HC H9 H ll H11A H12° H126 H13c H l3b
tomaymycin 2.80 3.00 3.13 3.87 7.11 3.87 9.34 6.51 5.56 4.03 5.86 1.74
DSB-120 2.05 2.30 2.03 2.14 3.58 3.83 7.09 3.87 6.59 5.75 3.83 4.28 2.33
° Chemical shifts underlined are >±0.25 ppm shifted from free duplex chemical shifts. 6 DSB-120.c Tomaymycin.
spectra in D 2 O buffer for the tomaymycin 10-mer 
adduct, it is not visible for the DSB-120 10-mer adduct 
in the one-dimensional spectrum in D2O buffer (supple­
mental information) or in the COSY experiment in D2 O 
buffer (not shown). This suggests that the region 
containing this proton has greater access to water for 
exchange in the case of the interstrand cross-linked 
adduct. This possibility is also supported by the con­
formational distortion that is unique to the D SB -120- 
DNA adduct, which is detected by the two-dimensional 
NMR results discussed later.
S tereoch em istry  and O rientation . A  priori, either 
an S or R  stereochemistry at the covalent linkage site 
C ll  of the antibiotic is conceivable in P[1,4]B-DN A  
adducts.2c d In previous studies, a combined molecular 
modeling, fluorescence, and two-dimensional NMR ap­
proach showed that, for the tomaymycin d(ATGCAT>2 
adduct, l l i?  and 1LS stereoisomers exist in approxi­
mately equal proportions.20 In contrast, for the bis- 
tomaymycin decamer adduct (sequence A, Figure 3), 
only the S  stereoisomer exists,16® and in the case of 
anthramycin—DNA adducts, single stereoisomers ex­
ist.17 The proton attached to the C l l  chiral carbon 
located at the covalent linkage site is useful as a 
diagnostic probe of the stereochemistry at this position. 
In the adduct with S  stereochemistry at this site, H l l  
would be directed toward the 3' side of the covalently 
modified guanine, while for R  stereochemistry, this
A B
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F igu re 6. Expanded contour plot of the two-dimensional 
phase-sensitive NOESY spectrum (250-ms mixing time) of the 
(A) bis-tomaymycin d(CICGATCICG)2 and (B) DSB-120 d(CIC- 
GATCICG)2 duplex adducts in D20-buffered solution, pH 6.8, 
100 mM sodium chloride, and 10 mM sodium phosphate at 23 
°C, demonstrating through-space connectivities between P[1,4]B 
H l l  and DNA protons. (A) Cross-peaks A -D  are labeled as 
follows: A, tomaym ycin(Hll)—5A(H1'); B, tom aym ycin(H ll)- 
4G(H1'); C, tomaymycin(Hll)-5A(H4'); D, tom aym ycin(H ll)- 
(H lla ). (B) Cross-peaks A -D  are labeled as follows: A, DSB- 
120(H11)-5A(H1'); B, D SB -120(H ll)-4G {H r); C, DSB-120- 
(H11)-5A(H4'); D, D S B -1 2 0 (H ll)-(H lla ).
proton would point toward the 5' side. There is a strong 
NOE between H l l  and 5AHT for both the bis-tomay­
mycin and DSB-120 10-mer adducts (cross-peak A in 
Figure 6A, B, respectively) and to 5AH2 (data not 
shown). NOESY cross-peaks of H l l  to base pairs to the
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Table 2- Relative Strength of the Intermolecular Tomaymycin and DSB-120 NOEs to DNA for Each of the d(CICGATCICG)2 
Adducts"
DNA drug protons
protons Hla Hlb H2a6 H2b* H3a H3b H6 H9 H ll H lla  H12a,b6 H13a,b6 7 OCH36 H12c H13C
3CH4'
4GH1' WM M
5AH2 S/S S M
5AH1' w / w S/S
5AH2" AM
5AH4' A/W A/W W W A M MS WM
6TH1' MM S
6TH4' w
7CH1' M W M
7CH4' S
8IH2 M/W M/W M
8IHT MAY M/W M
8IH3' A/W w
8IH4' MM A/W MM
9CH1' W
9CH4' A/W A/W W W AM AM W S
° S  =  strong, M = medium, and W =  weak (relative to the cytosine H5 to H6 cross-peak intensity). A =  absent cross-peak. For protons 
in common, intermolecular tomaymycin cross-peak intensities are listed first followed by intermolecular DSB-120 cross-peak intensities. 
6 Protons unique to DSB-120.c Protons unique to tomaymycin.
5 '  s i d e  o f  4 G  a r e  a b s e n t .  T h e s e  o b s e r v a t i o n s  p r o v i d e  
s t r o n g  e v i d e n c e  fo r  t h e  S  s t e r e o c h e m i s t r y  a t  C l l  fo r  
b o t h  c o v a l e n t  a d d u c t s .
T o m a y m y c i n  a r o m a t i c  r i n g  N O E  c o n n e c t i v i t i e s  t o  
D N A ,  i n c l u d i n g  H 9  t o  5 A H 1 ' ,  5 A H 2 ,  a n d  6 T H 1 '  ( T a b le
2 ) ,  d e m o n s t r a t e  a  h e a d - t o - h e a d  o r i e n t a t i o n  o f  t h e  t w o  
t o m a y m y c i n  m o l e c u l e s  i n  t h e  b i s - a d d u c t .  T h e  o r i e n t a ­
t i o n  o f  t h e  a r o m a t i c  r i n g s  i n  t h e  D S B - 1 2 0  i s  f i x e d  i n  
t h e  s a m e  h e a d - t o - h e a d  o r i e n t a t i o n  b y  t h e  m e t h y l e n e  
l i n k e r  u n i t .
C om parison  o f th e  S tru ctu res o f  th e B is-tom ay­
m ycin  and  DSB-120 10-m er D u p lex  A dducts. T h e
m a j o r i t y  o f  t h e  n o n e x c h a n g e a b l e  p r o t o n  r e s o n a n c e s  a r e  
w e l l  r e s o l v e d  i n  t h e  t w o - d i m e n s i o n a l  N M R  e x p e r i m e n t s  
fo r  b o t h  t h e  b i s - t o m a y m y c i n  a n d  D S B - 1 2 0  1 0 - m e r  
a d d u c t s  i n  D 2O  b u f f e r .  P r o t o n  r e s o n a n c e  a s s i g n m e n t s ,  
w i t h  t h e  e x c e p t i o n  o f  H 5 '  a n d  H 5 "  p r o t o n s ,  d u e  t o  
s p e c t r a l  o v e r la p ,  w e r e  c o m p l e t e d  b y  e s t a b l i s h e d  m e t h o d s  
u s i n g  t w o - d i m e n s i o n a l  t h r o u g h - s p a c e  ( N O E S Y )  a n d  
t h r o u g h - b o n d  ( D Q F - C O S Y )  c o u p l i n g s . 18
A. T w o-D im ension al NOESY and  COSY E xp eri­
m ents. P a n e l  B  o f  F i g u r e  7  s h o w s  a n  e x p a n d e d  N O E S Y  
c o n t o u r  p l o t  o f  t h e  r e g i o n s  e s t a b l i s h i n g  c o n n e c t i v i t i e s  
b e t w e e n  t h e  b a s e  p r o t o n s  a n d  t h e  d e o x y r i b o s e  H I '  
p r o t o n s  f o r  t h e  D S B - 1 2 0  1 0 - m e r  d u p l e x  c r o s s - l i n k e d  
a d d u c t .  E a c h  p u r i n e  H 8  a n d  p y r i m i d i n e  H 6  p r o t o n  
e x h i b i t s  N O E s  to  i t s  o w n  H I '  p r o t o n  a n d  t h e  H I '  o f  t h e  
s u g a r  o f  t h e  5 '  f l a n k i n g  n u c l e o t i d e ,  c h a r a c t e r i s t i c  o f  a  
r i g h t - h a n d e d  d u p l e x .  T h i s  p e r m i t s  t h e  c h a i n  t o  b e  
t r a c e d  f r o m  1 C  t o  1 0 G  i n  t h e  D S B - 1 2 0  s e l f - c o m p l e m e n ­
t a r y  1 0 - m e r  d u p l e x  a d d u c t  ( p a n e l  B ) .  O n ly  t h e  e x ­
p a n d e d  r e g i o n  s h o w i n g  81  N O E  c o n n e c t i v i t i e s  i s  d i s ­
p l a y e d  fo r  t h e  b i s - t o m a y m y c i n  a d d u c t  ( p a n e l  A ) .  T h e  
81  s i t e  e x h i b i t s  d i s t i n c t  b e h a v i o r  i n  t h e  D S B - 1 2 0  a d d u c t ,  
w i t h  a n  u n u s u a l l y  w e a k  c o n n e c t i v i t y  f r o m  8 I H 1 '  t o  
7 C H 6  c o m p a r e d  t o  t h a t  fo r  t h e  b i s - t o m a y m y c i n  a d d u c t  
( a r r o w h e a d s  i n  p a n e l s  A  a n d  B ,  F i g u r e  7 ) .
T h e  e x p a n d e d  D Q F - C O S Y  p l o t  s h o w i n g  t h r o u g h - b o n d  
J - c o u p l i n g s  f o r  H l ' - H 2 "  a n d  H l ' - H 2 '  fo r  t h e  D S B - 1 2 0  
d e c a m e r  a d d u c t  d e m o n s t r a t e s  a n  u n u s u a l  f e a t u r e  fo r  
t h e  81  n u c l e o t i d e  o f  t h e  D S B - 1 2 0  d u p l e x  a d d u c t  ( u n ­
p u b l i s h e d  r e s u l t s ) .  T y p i c a l l y ,  t h e  c h e m i c a l  s h i f t s  o f  H 2 '  
p r o t o n s  a r e  u p f i e l d  o f  H 2 "  w i t h i n  t h e  s a m e  n u c l e o t i d e  
o f  a  D N A  s e q u e n c e . 18 H o w e v e r ,  f o r  t h e  81  n u c l e o t i d e
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F igu re 7. Two-dimensional phase-sensitive NOESY (250-ms 
mixing time) expanded contour plots of the (A) bis-tomaymycin 
d(CICGATCICG)2 and (B) DSB-120 d(CICGATCICG)2 adducts 
in D20-buffered solution, pH 6.8, 100 mM sodium chloride, 
and 10 mM sodium phosphate at 23 °C, demonstrating NOE 
connectivities for each PuH8/PyH6 to its own deoxyribose HI' 
protons (denoted with nucleotide number corresponding to 
position in the sequence) and to the HI' proton of its 5' 
neighbor. Arrowhead denotes 8I(H8) to 7C(H1') intemucleotide 
through-space NOESY connectivity.
i n  t h e  D S B - 1 2 0  a d d u c t ,  t h i s  p a t t e r n  i s  r e v e r s e d  ( T a b le  
1 ) , a n d  i n  a d d i t i o n ,  t h e  i n t e n s e  c o u p l i n g  f o r  H l ' - H 2 '  i s  
d o w n f i e l d  o f  t h e  w e a k e r  H l ' - H 2 "  c o u p l i n g  f o r  t h e  81  
n u c l e o t i d e  ( u n p u b l i s h e d  r e s u l t s ) .  T h i s  i s  f o u n d  e x c l u ­
s i v e l y  i n  t h e  D S B - 1 2 0  d e c a m e r  a d d u c t .  T h e  r e v e r s a l  o f  
c h e m i c a l  s h i f t  fo r  t h e s e  p r o t o n s  i s  u s u a l l y  a s s o c i a t e d  
w i t h  t e r m i n a l  n u c l e o t i d e s  o r  w i t h  i n t e r n a l  n u c l e o t i d e s  
t h a t  h a v e  u n d e r g o n e  a  c o n f o r m a t i o n a l  c h a n g e .  T h e  
m a g n i t u d e  o f  t h i s  e f f e c t  i s  l e s s  i n  t h e  b i s - t o m a y m y c i n  
d e c a m e r  a d d u c t ,  w h e r e  t h e  H 2 '  a n d  H 2 "  r e s o n a n c e s
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o v e r l a p  ( T a b l e  1 ) .  H o w e v e r ,  t h e  e v i d e n c e  i s  c o n s o n a n t  
w i t h  o t h e r  s p e c t r a l  f e a t u r e s  u n i q u e  t o  t h e  D S B - 1 2 0  
a d d u c t  t h a t  h a v e  b e e n  p r e v i o u s l y  i d e n t i f i e d  a n d  a u g ­
m e n t s  t h e  e v i d e n c e  t h a t  D S B - 1 2 0  d o e s  i n d u c e  a n  
a d d i t i o n a l  p e r t u r b a t i o n  i n  s t r u c t u r e  o f  t h e  n u c l e o t i d e  
f a c i n g  t h e  c o v a l e n t l y  m o d i f i e d  g u a n i n e  i n  t h e  m i n o r  
g r o o v e .  T h i s  d e v i a t i o n  i s  n o t  f o u n d  i n  t h e  b i s - t o m a y ­
m y c i n  a d d u c t .
B. N u cle ic  A cid P roton  C hem ical Sh ifts. C h e m i ­
c a l  s h i f t s  fo r  o l i g o n u c l e o t i d e  p r o t o n  r e s o n a n c e  s i g n a l s  
a r e  l i s t e d  i n  T a b le  1 . T h e r e  a r e  u p h e l d  c h e m i c a l  s h i f t s  
o f  0 . 2 8  a n d  0 .3 0  p p m  fo r  7 C H 6  a n d  0 . 2 4  a n d  0 . 2 8  p p m  
fo r  7 C H 5  r e l a t i v e  t o  t h e  d u p l e x  fo r  t h e  b i s - t o m a y m y c i n  
a n d  D S B - 1 2 0  1 0 - m e r  a d d u c t s ,  r e s p e c t i v e l y .  F u r t h e r ­
m o r e ,  t h e r e  a r e  0 . 3 0  a n d  0 .2 1  p p m  d o w n f i e l d  s h i f t s  f o r  
3 C H 6  a n d  3 C H 5 ,  r e s p e c t i v e l y ,  t h a t  a r e  u n i q u e l y  o b ­
s e r v e d  f o r  t h e  D S B - 1 2 0  a d d u c t  r e l a t i v e  t o  t h e  d u p l e x .  
T h e s e  c h e m i c a l  s h i f t  c h a n g e s  s u g g e s t  t h a t  t h e r e  i s  a  
m o d e s t  i n c r e a s e  i n  s t a c k i n g  o f  t h e  6 T - 7 C  s t e p  fo r  b o t h  
a d d u c t s  b u t  d e s t a c k i n g  o f  t h e  2 I - 3 C  s t e p  o n l y  o c c u r s  
i n  t h e  D S B - 1 2 0  a d d u c t .  T h e  8 I H 2  r e s o n a n c e  s h o w s  a  
0 .4 0  p p m  u p h e l d  s h i f t  r e l a t i v e  t o  t h e  d u p l e x  b u t  o n l y  
fo r  t h e  b i s - t o m a y m y c i n  a d d u c t .  T h i s  c a n  b e  r a t i o n a l i z e d  
d u e  t o  t h e  l o c a t i o n  o f  8 I H 2  w i t h i n  t h e  s h i e l d i n g  z o n e  o f  
t h e  t o m a y m y c i n  e t h y l i d e n e  f u n c t i o n a l i t y ,  w h i c h  i s  a b ­
s e n t  i n  t h e  D S B - 1 2 0  s t r u c t u r e .  T h e  0 . 4 0  p p m  d o w n h e l d  
s h i f t  r e l a t i v e ,  t o  t h e  d u p l e x  o f  t h e  5 A H 2  p r o t o n  r e s o ­
n a n c e  s i g n a l  f o u n d  fo r  b o t h  D N A  a d d u c t s  c a n  b e  
a t t r i b u t e d  t o  t h e  p r o x i m i t y  o f  t h i s  p r o t o n  t o  t h e  d e s h i e l d ­
i n g  z o n e  o f  t h e  a r o m a t i c  r i n g  o f  t h e  c o v a l e n t l y  a t t a c h e d  
d r u g .  T h e  c h e m i c a l  s h i f t s  o f  t h e  i m i n o  p r o t o n s  f o r  e a c h  
a d d u c t  a r e  s i m i l a r ,  w h i c h  a r g u e s  a g a i n s t  d i f f e r e n c e s  i n  
b a s e - p a i r  h y d r o g e n  b o n d i n g  ( T a b le  1 ) .
F o r  b o t h  d r u g —D N A  a d d u c t s ,  c h a n g e s  i n  c h e m i c a l  
s h i f t s  o f  d e o x y r i b o s e  p r o t o n s  s u c h  a s  4 G H 1 '  a r e  o f  a  
s i m i l a r  m a g n i t u d e  a n d  m o s t l y  r e s t r i c t e d  t o  t h e  m i n o r  
g r o o v e  i n  p r o x i m i t y  t o  t h e  d r u g  o v e r l a p  r e g i o n  w i t h  
D N A .  U p o n  e x a m i n a t i o n  o f  t h e  m o d e l s ,  m o s t  o f  t h e s e  
s h i f t s  a r e  a t t r i b u t a b l e  t o  d r u g  s h i e l d i n g  o r  d e s h i e l d i n g  
e f f e c t s .  T h e  m o s t  d r a m a t i c  d i f f e r e n c e  b e t w e e n  a d d u c t s  
o c c u r s  f o r  6 T H 4 ' .  W h i l e  t h i s  p r o t o n  i s  s h i e l d e d  b y  t h e  
d r u g  a r o m a t i c  r i n g s  i n  b o t h  a d d u c t s ,  t h e  u p h e l d  s h i f t  
r e l a t i v e  t o  t h e  f r e e  d u p l e x  i s  a t t e n u a t e d  i n  t h e  D S B -  
1 2 0  a d d u c t  ( 1 . 6 5  p p m )  r e l a t i v e  t o  t h e  b i s - t o m a y m y c i n  
a d d u c t  ( 2 . 2 8  p p m ) .  T h i s  o b s e r v a t i o n  s u g g e s t s  t h a t  t h e  
t o m a y m y c i n  a r o m a t i c  r i n g  m o r e  d i r e c t l y  f a c e s  t h e  w a l l  
o f  t h e  m i n o r  g r o o v e ,  w h e r e  6 T H 4 '  w o u l d  r e c e i v e  t h e  f u l l  
fo r c e  o f  s h i e l d i n g ,  w h i l e  t h e  s t r u c t u r e  a s s u m e d  i n  
i n t e r s t r a n d  D N A  c r o s s - l i n k i n g  v i a  t e t h e r e d  D N A - r e a c -  
t i v e  u n i t s  c a u s e s  t h e  D S B - 1 2 0  a r o m a t i c  r i n g  t o  b e  
p a r t i a l l y  a v e r t e d  f r o m  t h e  w a l l  o f  t h e  g r o o v e  a n d  
d i r e c t e d  t o w a r d  t h e  f lo o r .
C. In term olecu lar  D ru g -D N A  C on tacts. T h e  
p r o t o n  r e s o n a n c e s  f o r  D S B - 1 2 0  a n d  t o m a y m y c i n  i n  t h e  
1 0 - m e r  a d d u c t s  h a v e  b e e n  a s s i g n e d  t h r o u g h  a n a l y s i s  
o f  t h e  N O E S Y  a n d  c o r r e l a t e d  C O S Y  s p e c t r a  r e c o r d e d  
i n  D 2O  a t  2 3  °C . N O E S Y  c r o s s - p e a k s  a r e  o b s e r v e d  t h a t  
p e r m i t  e s t a b l i s h m e n t  o f  i n t e r m o l e c u l a r  p r o t o n —p r o t o n  
c o n t a c t s  ( < 5  A) b e t w e e n  D S B - 1 2 0  o r  t o m a y m y c i n  a n d  
4 G , 5 A ,  6 T ,  7 C , a n d  8 1  r e s i d u e s  ( T a b le  2 ) .
F o r  b o t h  a d d u c t s ,  a  c o m p l e t e  n e t w o r k  o f  c r o s s - p e a k s  
f i r m l y  l o c a t e s  t h e  d r u g s  w i t h i n  t h e  m i n o r  g r o o v e  o f  t h e  
d u p l e x .  I n  b o t h  c a s e s ,  H l l  s h o w s  a  s t r o n g  c r o s s - p e a k  
c o n n e c t i v i t y  t o  5 A H T  a n d  a  m o d e r a t e  t o  w e a k  c r o s s ­
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F igu re  8. Expanded contour plot of the two-dimensional 
phase-sensitive NOESY spectrum (250-ms mixing time) of the 
(A) bis-tomaymycin d(CICGATCICG)2 and (B) DSB-120 d(CIC- 
GATCICGh adducts in 0.5 mL of D20-buffered solution, pH 
6.8, 100 mM sodium chloride, and 10 mM sodium phosphate 
at 23 °C, establishing through-space connectivities from 
P[1,4]B pyrrolo and H13 protons to DNA protons. (A) Tomay­
mycin H la  and H lb  through-space connectivities to A, 8I(H1'); 
B, tomaym ycin(Hll); C, tomaymycin(Hlla). (B) DSB-120 
through-space connectivities are A, DSB-120(H13)—DSB-120- 
(H9); B, DSB-120(Hla, Hlb)-8I(H1'); C, DSB-120(Hla, Hlb, 
H2a, H2b)-DSB-120(H11); D, DSB-120(H13)-DSB-120(H12); 
E, DSB-120(Hla, Hlb, H2a, H2b)-5A(H4'); F, DSB-120(Hla, 
H lb, H2a, H2b)-9C(H4') and DSB-120(H13)-7C(H4'); G, 
DSB-120(Hla, Hlb, H2a, H2b)-DSB-120(H3b) and DSB-120- 
(H13)-DSB-120(7OCH3); H, D SB -l20(H la, H lb , H2a, H 2b)- 
DSB-120(H3a).
r e s p e c t i v e l y ,  i n  F i g u r e  6 ) . T h e  w e a k  c r o s s - p e a k  c o n ­
n e c t i v i t y  o f  H l l  t o  5 A H 4 '  i n  t h e  b i s - t o m a y m y c i n  a d d u c t  
c o n t r a s t s  w i t h  t h e  m o d e r a t e  c r o s s - p e a k  c o n n e c t i v i t y  o f  
H l l  t o  t h e  s a m e  p r o t o n  i n  t h e  D S B - 1 2 0  a d d u c t  ( c r o s s ­
p e a k  C  i n  F i g u r e  6 ) .  A s  p r e v i o u s l y  e s t a b l i s h e d  ( s e e  
b e f o r e ) ,  t h e  d i f f e r e n c e  i n  t h e  d e g r e e  o f  u p h e l d  c h e m i c a l  
s h i f t  o f  t h e  t o m a y m y c i n  a n d  D S B - 1 2 0  6 T H 4 '  r e s o n a n c e  
s i g n a l s  s u g g e s t s  t h a t  t h e  t o m a y m y c i n  a r o m a t i c  r i n g  
a d o p t s  a  m o r e  f a c e - o n  o r i e n t a t i o n  t o  t h e  w a l l  o f  t h e  
g r o o v e  c o m p a r e d  t o  t h a t  i n  D S B - 1 2 0 .  T h i s  c o n c l u s i o n  
i s  s u p p o r t e d  b y  t h e  f a c t  t h a t  a  m o r e  e d g e - o n  s t a n c e  fo r  
t h e  i n n e r  e d g e  o f  D S B - 1 2 0  w o u l d  s w i n g  t h e  H l l  p r o t o n  
i n t o  c l o s e r  p r o x i m i t y  t o  t h e  5 A H 4 '  p r o t o n ,  r e s u l t i n g  i n  
a  m o r e  i n t e n s e  N O E .
T h e  m e t h y l e n e  p r o t o n s  o f  t h e  l i n k e r  o f  D S B - 1 2 0  
( H 1 2 a ,  H 1 2 b ,  H 1 3 a ,  a n d  H 1 3 b )  e x h i b i t  N O E S Y  c o n n e c ­
t i v i t i e s  t h a t  l o c a t e  t h e m  i n  t h e  m i n o r  g r o o v e  ( T a b l e  2 ) .  
C h a r a c t e r i s t i c  o f  t h i s  l o c a t i o n  a r e  t h e  o v e r l a p p i n g  
r e s o n a n c e  s i g n a l s  H 1 3 a  a n d  H 1 3 b ,  w h i c h  e a c h  d i s p l a y  
a  s t r o n g  c r o s s - p e a k  c o n n e c t i v i t y  t o  7 C H 4 '  ( c r o s s - p e a k  
F  i n  F i g u r e  8 B ) .  T h e  o v e r l a p p i n g  r e s o n a n c e s  H 1 2 a  a n d  
H I 2 b  a r e  s i m i l a r l y  l o c a t e d  i n  p r o x i m i t y  t o  5 A H 2  a n d  
6 T H 1 '  ( T a b le  2 ) .
A d d i t i o n a l  o b s e r v e d  N O E S Y  c r o s s - p e a k s  d e m o n s t r a t e  
t h a t  t h e  D S B - 1 2 0  i n t e r s t r a n d  c r o s s - l i n k e r  a d o p t s  a  
c o n f o r m a t i o n  i n  o t h e r  r e g i o n s  d i s t i n c t  f r o m  t h a t  o f  t h e  
b i s - t o m a y m y c i n  a d d u c t s  i n  t h e  1 0 - m e r  d u p l e x .  T h e  
e t h y l i d e n e  m e t h y l  p r o t o n s  ( H 1 3 )  o f  t o m a y m y c i n  s h o w  
c r o s s - p e a k  c o n n e c t i v i t i e s  t o  r e s o n a n c e s  8 I H 2 ,  8 I H 1 ' ,  
9 C H 1 ' ,  a n d  9 C H 4 '  o n  t h e  f lo o r  a n d  w a l l  o f  t h e  m i n o r  
g r o o v e  ( T a b le  2 ) .  F o r  D S B - 1 2 0  a n d  t o m a y m y c i n ,  H l a  
a n d  H l b  s e r v e  a s  p r o b e s  fo r  t h e  d e p t h  o f  m i n o r  g r o o v e  
p e n e t r a t i o n .  F o r  t o m a y m y c i n ,  H l a  a n d  H l b ,  w h i c h  a r e  
l o c a t e d  a l o n g  t h e  i n n e r  e d g e  o f  t h e  d r u g ,  e x h i b i t  c r o s s ­
p e a k  c o n n e c t i v i t i e s  t o  8 I H T  ( c r o s s - p e a k  A  i n  F i g u r e  8 A )  
a n d  8 I H 2  ( T a b le  2 ) .  T h e  8 I H 1 '  a n d  8 I H 2  p r o t o n s  a r e  
p o s i t i o n e d  o n  t h e  w a l l  a n d  t h e  f lo o r  o f  t h e  m i n o r  g r o o v e ,  
r e s p e c t i v e l y .  I n  t h e  c a s e  o f  D S B - 1 2 0 ,  N O E S Y  c r o s s ­
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p e a k  i n t e n s i t i e s  i n d i c a t e  a  s h a l l o w e r  i m m e r s i o n  o f  t h e  
f i v e - m e m b e r e d  r i n g  b e c a u s e  D S B - 1 2 0  H l a  a n d  H l b  
s h o w  r e d u c e d  t h r o u g h - s p a c e  N O E  c r o s s - p e a k  c o n n e c ­
t i v i t i e s  t o  8 I H 1 '  ( c r o s s - p e a k  B  i n  F i g u r e  8 B )  a n d  8 I H 2  
( T a b l e  2 ) .  A t  t h e  s a m e  t i m e ,  w e a k  D S B - 1 2 0  H l a  a n d  
H l b  c r o s s - p e a k  c o n n e c t i v i t i e s  t o  5 A H 4 '  a n d  7 C H 4 ' ,  
w h i c h  a r e  l o c a t e d  o n  t h e  p e r i p h e r y  o f  t h e  m i n o r  g r o o v e ,  
a r e  n o w  o b s e r v e d  ( c r o s s - p e a k s  E  a n d  F ,  r e s p e c t i v e l y ,  i n  
F i g u r e  8 B ) .  T h e s e  c r o s s - p e a k  c o n n e c t i v i t i e s  a r e  n o t  
o b s e r v e d  i n  t h e  t o m a y m y c i n  a d d u c t .  F r o m  t h e s e  s e t s  
o f  d a t a ,  i t  a p p e a r s  t h a t  t h e  e n d s  o f  t h e  D S B - 1 2 0  
m o l e c u l e  b o w  u p  a w a y  f r o m  t h e  f lo o r  o f  t h e  g r o o v e  i n  
t h e  i n t e r s t r a n d  c r o s s - l i n k e d  D N A  a d d u c t .  P r e v i o u s  
e n e r g y - m i n i m i z a t i o n  c a l c u l a t i o n s  o n  t h e  D S B - 1 2 0  1 0 -  
m e r  a d d u c t  h a d  i n d i c a t e d  t h a t  a  t h r e e - m e t h y l e n e  l i n k e r  
u n i t  w o u l d  b e  s h o r t e r  t h a n  t h e  o p t i m u m  d i s t a n c e  
n e e d e d  t o  c o m f o r t a b ly  a c c o m m o d a t e  c r o s s - l i n k i n g  t h e  
g u a n i n e s  f o u r  b a s e  p a i r s  a p a r t  i n  t h i s  s e q u e n c e  w i t h o u t  
d i s t o r t i o n . 1613 T h e  b o w i n g  u p  o f  t h e  p y r r o lo  r i n g s  o f  
D S B - 1 2 0  i n  t h e  c o v a l e n t  a d d u c t  m a y  b e  t h e  s t r u c t u r a l  
r e s p o n s e  t o  t h i s  s t r a i n .
D iscu ss io n
A  c o m p a r i s o n  o f  t h e  t w o - d i m e n s i o n a l  N M R  s p e c t r a  
o f  t h e  b i s - t o m a y m y c i n  a n d  D S B - 1 2 0  1 0 - m e r  a d d u c t s  
o f f e r s  s o m e  i n s i g h t  i n t o  t h e  u s e f u l n e s s  o f  s t r u c t u r a l  
c h a r a c t e r i z a t i o n  o f  D N A  b i s - a d d u c t s  a s  a  g u i d e  t o  D N A  
c r o s s - l i n k e r  d e s i g n .  T h e  s y n t h e s i s  o f  d i m e r i c  a n a l o g s  
t h a t  c r o s s - l i n k  D N A  h a s  b e e n  r e a d i l y  a c c o m p l i s h e d . 12 
T h e  c o n s e q u e n c e s  a r e  t h a t  s u c h  p o t e n t  a g e n t s  c a n ,  
d e p e n d i n g  o n  t h e  c a s e ,  i n d u c e  n o v e l  D N A  d i s t o r t i o n , 13 
e x h i b i t  a n  a l t e r e d  s e q u e n c e  s e l e c t i v i t y , 14 a n d  p o s s e s s  
d i f f e r e n t  s t a b i l i t i e s  o n  D N A  r e l a t i v e  t o  t h e  m o n o a l k y ­
l a t i n g  p a r e n t . 12615 T h e  s t u d y  d e s c r i b e d  h e r e  p e r m i t s  
a s s e s s m e n t  o f  t h e  a c h i e v e m e n t s  a n d  l i m i t a t i o n s  o f  a  
s t r a t e g y  o f  t e m p l a t e - d i r e c t e d  c r o s s - l in k e r  d e s i g n 16 b a s e d  
o n  a  m o n o a l k y l a t i n g  u n i t  s u c h  a s  t o m a y m y c i n  t h a t  
i n d u c e s  o n l y  s l i g h t  d i s t o r t i o n  o f  D N A .
A  s u m m a r y  o f  t h e  m a j o r  f i n d i n g s  o f  t h i s  s t u d y  a r e  
( 1 )  t h a t  b o t h  d r u g s  f o r m  s e l f - c o m p l e m e n t a r y  a d d u c t s  
w i t h  t h e  d ( C I C G A T C I C G )2 d u p l e x  s e q u e n c e .  ( 2 )  T h e  
c o v a l e n t  l i n k a g e  s i t e s  o c c u r  b e t w e e n  C l l  o f  e i t h e r  d r u g  
a n d  t h e  e x o c y c l i c  2 - a m i n o  g r o u p  o f  t h e  s i n g l e  r e a c t i v e  
g u a n i n e  o n  e a c h  s t r a n d  o f  d ( C I C G A T C I C G )2- I n  t h e  
c a s e  o f  D S B - 1 2 0 ,  t h i s  i s  e v i d e n c e  fo r  t h e  f o r m a t i o n  o f  a  
g u a n i n e —g u a n i n e  D N A  i n t e r s t r a n d  c r o s s - l i n k .  ( 3 )  T h e  
f o r m a t i o n  o f  a n  S  s t e r e o c h e m i s t r y  a t  t h e  c o v a l e n t  
l i n k a g e  s i t e  w i t h  a n  a s s o c i a t e d  3 '  o r i e n t a t i o n .  ( 4 )  W h i l e  
t h e  m a j o r i t y  o f  D N A  i n  t h e s e  a d d u c t s  a p p e a r s  t o  b e  
B - f o r m , D S B - 1 2 0  i n t e r s t r a n d  c r o s s - l in k in g  i n d u c e s  a t y p i ­
c a l  p r o p e r t i e s  i n  t h e  81  n u c l e o t i d e ,  i n d i c a t e d  b y  b r o a d ­
e n i n g  o f  t h e  8 I H 2  p r o t o n  r e s o n a n c e ,  n o n - C 2 ' e n d o  s u g a r  
g e o m e t r y  ( f r o m  C O S Y  c o u p l i n g  p a t t e r n s ) ,  a n d  u n u s u a l l y  
w e a k  i n t e m u c l e o t i d e  N O E  c o n n e c t i v i t y  t o  t h e  7 C  n u c l e ­
o t i d e .  T o m a y m y c i n  d o e s  n o t  p r o d u c e  t h i s  r e g i o n a l  
d i s l o c a t i o n .  ( 5 )  F o r  t o m a y m y c i n ,  w h i l e  t h e r e  a r e  s t r o n g  
N O E  c o n n e c t i v i t i e s  f r o m  p r o t o n s  o n  t h e  f i v e - m e m b e r e d  
r i n g  t o  t h e  8 I H 2  p r o t o n  o n  t h e  f lo o r  o f  t h e  m i n o r  g r o o v e ,  
t h e  e q u i v a l e n t  i n t e m u c l e o t i d e  c o n n e c t i v i t i e s  i n  D S B -  
1 2 0  a r e  w e a k e r .  T h i s  i n d i c a t e s  t h a t  t h e  t o m a y m y c i n  
t a i l  i s  c l o s e  t o  t h e  f lo o r  o f  t h e  m i n o r  g r o o v e ,  w h i l e  t h e  
f i v e - m e m b e r e d  r i n g  o f  D S B - 1 2 0  i s  m o r e  s h a l l o w l y  i m ­
m e r s e d ,  p e r h a p s  d u e  t o  s t r a i n  f r o m  c r o s s - l i n k i n g  w i t h  
a  v e r y  s h o r t  l in k e r  u n i t .  (6 )  T h e  c o n f o r m a t io n a l  s t r e s s e s  
i n d u c e d  o n  t h e  d u p l e x  b y  D S B - 1 2 0  a p p e a r  t o  m a k e  t h e  
r e g i o n  o f  c o v a l e n t  a t t a c h m e n t  m o r e  a c c e s s i b l e  t o  s o l v e n t
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5'CGA10 cross-linked adduct.
t h a n  i s  t h e  c a s e  fo r  t o m a y m y c i n .  T h e  4 G N 2 H b  r e s o ­
n a n c e  a p p e a r s  i n  1 0 0 %  D 2O  o n  t h e  t o m a y m y c i n  a d d u c t  
b u t  i s  o n l y  o b s e r v e d  i n  9 0 %  H 2 O / 1 0 %  D 2O  f o r  t h e  D S B -  
1 2 0  a d d u c t .  T h e  u n u s u a l  p r o p e r t i e s  o f  t h e  D S B - 1 2 0  1 0 -  
m e r  d u p l e x  a d d u c t  a r e  s u m m a r i z e d  i n  F i g u r e  9 .
A n alysis o f S ligh tly  D istorted  B is-drug-M odified  
Self-C om plem entary D uplex  T em p lates Is P red ic­
t iv e  o f th e  S ite  o f  C ovalen t L in k age and  the  
O rien ta tion  and  S tereo ch em istry  for A n alogous  
D im eric DNA C ross-L inkers. O n e  i m p o r t a n t  g o a l  i n  
m e d i c i n a l  c h e m i s t r y  i s  t o  s y n t h e s i z e  m o l e c u l e s  t h a t  w i l l  
r e a c t  w i t h  t h e i r  m o l e c u l a r  t a r g e t  i n  a  d e f i n e d  a n d  
p r e d i c t a b l e  w a y .  I n  t h e  c a s e  o f  D N A - r e a c t i v e  d r u g s ,  
s u c h  a s  t h e  P [ l , 4 ] B s ,  t h a t  b o n d  w i t h i n  t h e  m i n o r  g r o o v e ,  
i d e n t i f y i n g  t h e  o p t i o n s  f i r s t  e n t a i l s  d e f i n i n g  t h e  n u c l e ­
o t i d e  a n d  s e q u e n c e  s e l e c t i v i t y ,  t h e  g r o o v e  o r i e n t a t i o n ,  
a n d  t h e  s t e r e o c h e m i s t r y  a t  t h e  c o v a l e n t  l i n k a g e  s i t e .
F o r  e x a m p l e ,  f o l l o w i n g  e s t a b l i s h m e n t  o f  t h e  P [ 1 ,4 ] B  
s e q u e n c e  s e l e c t i v i t y  b y  f o o t p r in t i n g  m e t h o d s , 6 w o r k  fr o m  
t h i s  l a b o r a t o r y  d o c u m e n t e d  t h e  s e q u e n c e - d e p e n d e n c y  
o f  b o t h  s t e r e o c h e m i s t r y  a n d  d r u g  o r i e n t a t i o n  i n  t h e  
m i n o r  g r o o v e .20’16’17 B o n d i n g  s e q u e n c e s  s u c h  a s  (A T G C - 
A T ) 2 ( P [ l , 4 ] B - b o n d i n g  t r i p l e t  u n d e r l i n e d )  y i e l d e d  a  
m i x t u r e  o f  t o m a y m y c i n  3 ' S  a n d  5 'R a d d u c t s . 2d S i n g l e  
3 ' S  s e l f - c o m p l e m e n t a r y  b i s - t o m a y m y c i n  a d d u c t s  w e r e  
f o r m e d  w i t h  t h e  d ( C I C G A A T T C I C G ) 2 a n d  d ( C I C G A -  
T C I C O 2 s e q u e n c e s . 16 I n  t h e  l a t t e r  c a s e ,  t w o  t o m a y ­
m y c i n  m o l e c u l e s  o n  o p p o s i t e  s t r a n d s  w e r e  s e p a r a t e d  b y  
a  d i s t a n c e  s u i t a b l e  f o r  i n s e r t i n g  a  s h o r t  l i n k e r  b e t w e e n  
h e a d - t o - h e a d  a r o m a t i c  r i n g s .  A l l  a t t e m p t s  t o  d e s i g n  a  
s e q u e n c e - u n i q u e  t a i l - t o - t a i l  o r i e n t a t i o n  o f  a  b i s - t o m a y ­
m y c in  a d d u c t  r e s u l t e d  in  a  c o m p le x  m i x t u r e  o f  a d d u c t s .166 
M o l e c u l a r  m o d e l i n g  o f  t h e  d ( C I C G A T C I C G )2 s e q u e n c e  
l e d  t o  t h e  p r o p o s a l  fo r  ( - C H 2 - ) „ - l in k e d  t o m a y m y c i n  D N A  
i n t e r s t r a n d  c r o s s - l i n k e r s . 166 L i n k a g e  t h r o u g h  a n  e t h e r  
a t  C 8  w a s  c h o s e n  s i n c e  t h e  C 8  m e t h o x y  u n i t  o f  t o m a y ­
m y c i n  i s  d i r e c t e d  a l o n g  t h e  f l o o r  o f  t h e  m i n o r  g r o o v e  
a n d  C 7 - l i n k e d  P [ 1 ,4 ] B  d i m e r i c  a n a l o g s  h a v e  b e e n  s h o w n  
t o  b e  e a s i l y  r e v e r s i b l e  f r o m  l i n e a r  p l a s m i d  D N A . 126
W i t h  o n l y  t h i s  k n o w l e d g e ,  a  s t r a t e g y  o f  t e m p l a t e -  
d i r e c t e d  d r u g  d e s i g n  w o u l d  l o g i c a l l y  ( 1 )  s e l e c t  s e q u e n c e  
B  ( F i g u r e  3 )  a s  t h e  t e m p l a t e ,  f o r  w h i c h  t h e  b i s - a d d u c t  
i s  w e l l  d e f in e d ,  ( 2 )  f a v o r  s y n t h e s i s  o f  a  c o m p o u n d  l i n k e d  
i n  a  h e a d - t o - h e a d  f a s h i o n  a t  t h e  a r o m a t i c  r i n g s ,  fo r  
w h i c h  t h e  o r i e n t a t i o n  o f  a  s i n g l e  b i s - a d d u c t  c a n  b e  
d e f in e d ,  ( 3 )  e n a c t  t h e  l i n k a g e  t h r o u g h  C 8  o f  t h e  a r o m a t i c
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ring, and (4) predict the formation of S  stereochemistry 
at the covalent linkage site. In fact, DSB-120 does form 
a single adduct cross-linked on sequence B with covalent 
modification at 4G. This cross-linked adduct has S  
stereochemistiy at C ll ,  as in the bis-adduct. Both the 
bis-tomaymycin and DSB-120 adducts maintain self­
complementarity as well. Since the DSB-120 adduct 
with other sequences has not been structurally charac­
terized and tail-to-tail P[1,4]B—DNA cross-linkers have 
not been synthesized, it is difficult to determine how 
the behavior of such adducts would relate to the bis- 
adduct models. Nevertheless, when a uniquely defined, 
relatively nondistortive bis-adduct is chosen as a tem­
plate for an analogy-based cross-linker, the evidence 
here suggests that there is a high likelihood that it will 
cross-link DNA at a predictable location and that 
essential features of the covalent modification can be 
preserved.
A nalysis o f B is-adduct Tem plates D oes N ot Pre­
d ict th e P recise Nature o f  DNA Structural Accom­
m odation to Interstrand Cross-Linking. The P[l,4]- 
Bs induce minimal bending in DNA.19 However, they 
are considered to be relatively nondistortive compared 
to monoalkylating drugs like cis-platinum, psoralen, and 
the CPIs derived from (+)-CC-1065. The bis-adduct 
template-directed approach to drug design of an inter­
strand  DNA cross-linker was less successful for the 
CPIs, which alkylate N3 of adenine. In that case, a 
sequence designed to form an in terstrand  bis-adduct 
was instead found to form an in trastrand  bis-adduct.20 
We believe this is due to the first CPI monalkylation 
inducing significant distortion in the DNA, which alters 
the reactivity of the remaining adenines.
For the bis-tomaymycin 10-mer adduct, the formation 
of a template interstrand bis-adduct with little distor­
tion of DNA was achieved. Nonetheless, there are 
features of the DSB-120 interstrand cross-link that 
indicate changes in both DNA and DSB-120, imposed 
exclusively by the cross-linking that is not anticipated 
by the bis-adduct template. In the case of the DSB- 
120 10-mer adduct, two-dimensional NMR evidence 
indicates induced conformational changes in the 81 
nucleotide, the adoption by the antibiotic aromatic ring 
of a more face-on disposition to the floor of the minor 
groove, and a bowing up of the edges of the drug away 
from the floor of the minor groove. In the case of DSB- 
120, this last effect may be due to the methylene bridge 
being too short to comfortably accommodate cross- 
linking. The combination of these distortions appears 
to enhance solvent accessibility to the vicinity of cova­
lent modification, indicated by the enhanced exchange 
of the 4GN2Hb proton in the DSB-120 adduct relative 
to the bis-tomaymycin adduct.
Several homologs of DSB-120 have been synthesized 
that could test the basis for this distortion and, ulti­
mately, its contribution to the biological properties of 
this drug.15 Dimeric analogs containing three to six 
methylene units in the linker have been made. There 
is a significant correlation between DNA-binding affin­
ity, cross-linking efficiency, and cytotoxicity.15 Ho­
mologs with an odd number of methylenes (three or five) 
display significant effects, while those with an even 
number do not. Solution structures of these analogs 
could be of use in determining the structural basis for
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optimization of the linker distance and its contribution 
to conformational dislocation of cross-linked DNA.
E xperim ental P rocedures
C h em ica ls. Tomaymycin 11-methyl ether w as obtained 
from Fujisawa Pharmaceuticals. DSB-120 was synthesized as 
described previously.1 Reagents used to prepare the NMR 
buffer, sodium phosphate (99.99%) and sodium chloride (99.9%), 
were purchased from Aldrich. HPLC-grade water and metha­
nol were purchased from Baxter Scientific and Fisher, respec­
tively.
O lig o n u c leo tid e  P r e p a r a tio n  a n d  P u r ifica tio n , d-
(CICGATCICGh was made on an Applied Biosystems 381A  
instrument and purified across a Machery-Nagel Nucleogen- 
DEAE 60-7 HPLC column w ith an increasing gradient to 1 M 
NaCl in 15 mM sodium phosphate and 20% acetonitrile/ 
aqueous buffer, pH 6 .8 .
A ddu ct P rep a ra tio n  a n d  P u r ifica tio n . The tomaymycin 
and DSB-120 adducts were prepared by adding drug (~ 4  mg 
in 0.2 mL of HPLC-grade methanol) to buffered solutions of 
the purified 10-mer duplex (25 m g in 0.6 mL of 20 mM sodium  
phosphate, 200 mM NaCl, pH 6.85) and stirring the reaction 
mixture at room temperature for 5 days. Duplex adduct was 
separated from excess drug by fractionation on a hydroxy- 
apatite column w ith a slower linear gradient of aqueous 
sodium phosphate buffer, pH 6 .8 , increasing from 10 to 200 
mM, monitoring UV absorbance at 254 nm. The adduct 
fraction was desalted across Water Associates C18 Sep-pak 
cartridges, lyophilized, dissolved in 0.5 mL of aqueous buffer 
(10 mM sodium phosphate, 100 mM NaCl, pH 6.85), and 
relyophilized for storage a t —20 °C.
NM R E x p er im en ts. One- and two-dimensional 500-MHz 
XH- and 202.44-MHz 31P-NMR data sets were recorded at 23 
°C on a General Electric GN-500 NMR spectrometer. Chemi­
cal shifts are reported (ppm) w ith positive values downfield 
from an external reference o f 1 mg/mL TSP in  D2O for XH  
resonances (HOD resonance w as set to 4.751 ppm) and an 
external reference o f 85% H3PO4 in D2O for 31P resonances. 
Approximately 2 5 —28 mg of the buffered duplex or duplex 
adducts in 0.5 mL of 99.96% D2O was prepared.
For all two-dimensional experiments, a presaturation pulse 
w as applied to suppress the HOD signal. Two-dimensional 
heteronuclear phosphorus-detected 31P —XH phase-sensitive 
COSY experiments for the duplex adducts were performed 
according to published procedures.21 Homonuclear scalar 
coupling was determined using the standard phase-sensitive 
two-dimensional double-quantum-filtered COSY.22 Sixty-four 
scans were collected w ith a 1.0-s pulse repetition tim e for each 
of the 256 FIDs in the t\  dim ension to generate 2 x 256 x 
2048 data m atrices. D ata for the phase-sensitive two- 
dimensional NOESY spectra were collected at a 250-ms mixing 
tim e using the States hypercomplex method.23 Thirty-two 
scans with a 2-s pulse repetition tim e were collected for each 
of the 512 FIDs in  the ti  dimension to generate 2 x 512 x 
2048 data matrices. For all proton two-dimensional phase- 
sensitive experiments, a  45° shifted sine bell function was 
applied to the data in both dimensions prior to transformation. 
D ata sets were zero-filled twice in  the <1 dimension such that 
the final frequency domain spectra consisted of IK  x IK  data 
matrices.
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Abstract. Sequence-dependent variations in DNA revealed by x-ray crystallo- 
graphic studies have suggested that certain D N A-reactive drugs may react preferen­
tially with defined sequences in DNA. Drugs that wind around the helix and reside 
within one o f  the grooves o f  DNA have perhaps the greatest chance o f  recognizing  
sequence-dependent features o f  DNA. The antitumor antibiotic CC-1065 covalently  
binds through N-3 o f  adenine and resides within the minor groove o f  D N A . This drug 
overlaps with five base pairs fo r  which a high sequence specificity exists.
The antitumor antibiotic CC-1065 is 
extrem ely potent ( /)  and is produced by 
S trep tom yces zelensis (2). Our earlier 
studies have shown that CC-1065 binds 
to AT-rich sites (A, adenine; T, thymine) 
within the minor groove of DNA without 
detectable distortion o f the helix and in a 
nonintercalative mode (i). The stability 
of the com plex suggested a covalent ad­
duct, but definitive evidence for this was 
lacking (3, 4). X-ray crystallographic 
data on CC-1065 reveal a molecule with a 
right-handed twist that mimics the pitch 
of B-form DNA; thus it might be accom ­
modated within one o f the grooves of 
DN A  (5). As first steps toward determin­
ing the molecular basis for the potency of 
CC-1065, we elucidated the structure of 
the covalent adduct and determined the 
D NA sequence specificity. These results 
have enabled us to propose a molecular 
model for the CC-1065-DNA adduct in 
which CC-1065 binds covalently to N-3 
o f adenine and lies entirely within the 
minor groove of D N A , extending over a 
5-base-pair region for which sequence 
specificity exists. The orientation of the 
D NA sequence specificity of CC-1065 in 
relation to the adenine covalent binding 
site reveals the polarity of the CC-1065 
m olecule in the minor groove o f DNA  
and strongly suggests the previously un­
assigned absolute stereochemistry of 
CC-1065.
When CC-1065-DNA adducts are 
heated at 100°C for 30 minutes, a mole­
cule with the CC-1065 chromophore is 
extractable into butanol (6 ). Up to 85 
percent o f the CC-1065 chromophore can 
be released from the DNA by this proce­
dure, but chromatographically it differs 
from CC-1065. The possibility that the 
material solubilized by butanol was 
linked to a DNA base moiety was exam­
ined by using tritiated deoxyadenine, 
deoxyguanine, deoxycytidine, and deox- 
ythymidine to produce, in separate ex­
periments, labeled DNA samples modi­
fied by CC-1065. These CC-1065-(3H- 
labeled Base>-DNA samples were heat­
ed and then extracted with butanol; the 
butanol contained only minor amounts of 
tritium in all cases except for that of the 
(3H-labeled adenine)-DNA sample.
where it contained 4.3 times more tritium 
than did control. Most of the tritium 
extracted into the butanol cochromato­
graphed with the heat-released CC-1065 
chromophore rather than with adenine. 
The material extracted with butanol was
purified from a sample of the CC-1065- 
DNA adduct to obtain both 'H and l3C 
nuclear magnetic resonance spectra (Ta­
ble 1). A comparison of the additional 
five signals found in the CC-1065-ade­
nine adduct with those for the base moi­
ety of 3-methyladenine showed a close 
correlation of chemical shift values. The 
downfield shifts o f the resonance signals 
for C-4 and C-5 in the adduct were in 
accord with a structure resulting from 
opening of the cyclopropane ring (Fig. 
1). Opening of the cyclopropane ring at 
the least substituted carbon is consistent 
with the structure of the ring-opened 
product resulting from the treatment of 
CC-1065 with acetic acid (7, 8). The 
alternative mode of cyclopropane ring
Fig. 1. Reaction of 
CC-1065 with DNA to 
form the N-3 adenine 
adduct.
OMe
C C - 1 0 6 5
OH
C C - 1 0 6 5 - ( N - 3  a d e n in e ) -  
DNA adduct
Table 1. Partial n C NMR assignments and multiplicities for CC-1065. 3-methyladenine, and the 
CC-1065-N-3 adenine adduct. Spectra (500 MHz) were obtained in [: H7]dimethylformamide at 












2 124.0 d 125.0 d
3 114.1 s 112.7 s
3a 130.6 s 134.2 s
3b II II 110.4 s
3a 9.7 q 11.9 q
4 21.7 t 54.8 t
4a 21.8 d 40.2 d
5 50.2 t 50.3 t
6a 161.7 s 137.0 s
7 111.6 d 98.4 d
8 176.4 s 144.2 s
8a 128.6 s 125.6 s
Adenine-2 153.6 d 153.6 d
Adenine-4 150.4 s 151.5 s
Adenine-5 120.4 s 121.5 s
Adenine-6 160.4 s 155.9 s
Adenine-8 147.3 d 144.4 d
•N um b erin g  for C C -1065 and its N -3  ad en in e adduct is g iven  in F ig. I. +Only the n C NM R  data for the 
CC-1065 cyc lop rop an e rin g-con ta in in g  subunit is sh ow n . The ch em ica l shift va lu es and m ultip licities for 
carbon atom s in the rem ainder o f  C C -1065 are virtually  identical to the correspon d in g atom s in the C C -1065-  
adenm e adduct. tC h em ica l sh ifts are relative to  tetram ethylsilan e and referenced  to  the form yl carbon o f  
[: H 7lD M F (162.7 parts per m illion). ^M ultip licity  o f  carbon atom s w as determ ined  by in sen sitive  nuclei 
en h ancem en t by polarization  transfer (IN E P T ) and d istortion less  enh ancem en t by polarization  transfer 
(D E P T ) exp er im en ts. llThis signal w as buried under a signal from  the so lven t but appeared at 31.5 parts 
per m illion in d im eth yl su lfox id e .
o p e n in g ,  w h ic h  w o u ld  r e su lt  in d ir e c t  
a t t a c h m e n t  o f  C -5  o f  C C -1 0 6 5  to  N -3  o f  
a d e n in e ,  w a s  e lim in a te d  b y  c o n s id e r ­
a t io n  o f  th e  l3C  c h e m ic a l  sh ift  v a lu e  o f  C -  
5 in  th e  C C - 1 0 6 5 -a d e n in e  a d d u c t .  C h e m ­
ic a l sh ift  c h a n g e s  fo r  C -3 b , C -7 , C -8 . a n d  
C -9  in  th e  C C - 1 0 6 5 - N - 3  a d e n in e  a d d u c t  
w e r e  in a c c o r d  w ith  r e d u c t io n  o f  th e  
in d o le  q u in o n e  to  an  in d o le  p h e n o l .  A  
c o m p a r is o n  o f  th e  ‘H  N M R  s p e c tr a  o f  
C C -1 0 6 5  a n d  its  a d e n in e  a d d u c t  (n o t  
s h o w n )  fu r th e r  s u b s ta n t ia te d  th e  s tr u c ­
tu r e  o f  th e  C C - 1 0 6 5 - N - 3  a d e n in e  a d d u c t  
(F ig . 1).
H e a t in g  o f  C C - 1 0 6 5 - D N A  a d d u c ts  r e ­
s u lt s  in b r e a k a g e  o f  th e  D N A  stra n d  (J )  
a s  w e ll  a s  r e le a s e  o f  a  C C -1 0 6 5 -N -3  
a d e n in e  a d d u c t .  E x t e n s iv e  d e p u r in a t io n  
w o u ld  n o t b e  e x p e c t e d  to  r e su lt  in s tra n d  
b r e a k a g e  u n d e r  th e  n e u tr a l c o n d it io n s  
u s e d  in t h e s e  e x p e r im e n t s  (4 ) ,  s u g g e s t in g  
th a t  a n  in d e p e n d e n t  p r o c e s s  w a s  r e s p o n ­
s ib le  fo r  th is  e v e n t .  T o  g a in  s o m e  in s ig h t  
in to  th e  r e la t io n s h ip  o f  D N A  stra n d  
b r e a k a g e  to  th e  c o v a le n t  a t ta c h m e n t  s ite  
a s  w e ll  a s  to  e x a m in e  th e  D N A -b in d in g  
s e q u e n c e  s p e c i f ic ity  o f  C C -1 0 6 5 , w e  p r e ­
p a r e d  r e s tr ic t io n  e n z y m e  fr a g m e n ts  fr o m  
S V 4 0  (S im ia n  s a r c o m a  v ir u s )  D N A  a n d  
T 7  D N A  w ith  a  s in g le  3:P - la b e le d  p h o s ­
p h a te  a t th e  5 ' e n d s .  A  ty p ic a l  fr a g m e n t, 
m o d if ie d  w ith  C C -1 0 6 5 , w a s  h e a te d  at
100°C  fo r  30  m in u te s  a n d  a n a ly z e d  o n  a  
s e q u e n c in g  g e l (F ig .  2 ) . H e a t in g  p r o ­
d u c e d  a fr a g m e n t w ith  a p p a r e n t  b r e a k ­
a g e  at th e  r e s id u e  a d ja c e n t  to  a d e n in e  o n  
th e  3 ' s id e .  U p o n  s u b s e q u e n t  p ip e r id in e  
tr e a tm e n t  o f  th e  p r e v io u s ly  th e r m a lly  
c le a v e d  D N A  fr a g m e n t , th e  a p p a r e n t  
b r e a k  o c c u r r e d  a b o u t  o n e  r e s id u e  to  th e  
5' s id e — th a t i s ,  to  th e  a d e n in e  r e s id u e  
m e n t io n e d  e a r l ie r . T h is  p ip e r id in e - d e ­
p e n d e n t  sh ift  w a s  p r e s u m a b ly  d u e  to  3  
e lim in a t io n  at a n  a p u r in ic  s ite  th a t r e s u l t ­
e d  fr o m  l o s s  o f  th e  C C - 1 0 6 5 - N - 3  a d e n in e  
a d d u c t .
A n a ly s i s  o f  th e  s e q u e n c e  s p e c i f ic i t y  o f  
C C -1 0 6 5  w ith in  r e s tr ic t io n  e n z y m e  fr a g ­
m e n ts  d e r iv e d  fr o m  S V 4 0  D N A  a n d  T 7  
D N A  s h o w e d  th a t th e r e  a r e  tw o  c la s s e s  
o f  C C -1 0 6 5  b in d in g  s it e s :  5 ' P u N T T A  
a n d  5 ' - A A A A A  (P u , p u r in e ;  N ,  a n y  n u ­
c le o t id e  b a s e )  (9 ) . B o th  c la s s e s  h a v e  an  
a b s o lu te  r e q u ir e m e n t  fo r  a d e n in e  a t o n e  
r e s id u e  r e m o v e d  fr o m  th e  5 ' s id e  o f  th e  
a p p a r e n t  th e r m a lly  in d u c e d  b r e a k . F u r ­
th e r m o r e , th e  tw o  c la s s e s  o f  s e q u e n c e  
s p e c i f ic i t ie s  l ie  e x c l u s iv e l y  to  th e  5 ' s id e  
o f  th e  c o v a le n t  a d e n in e  b in d in g  s it e  o f  
C C -1 0 6 5  a n d  e x t e n d  u p  to  f iv e  b a s e s .  
S ig n if ic a n t ly ,  th e r e  w a s  n o  s p e c i f ic i t y  fo r  
th e  b a s e  a t th e  3 ' s id e  o f  th e  a d e n in e  
r e s id u e  a t w h ic h  th e  th e r m a lly  in d u c e d  
b r e a k  o c c u r r e d .  O n e  p o s s ib i l i t y  fo r  th is
u n u su a l  c le a v a g e  p a t te r n  is  th a t a  d ir e c t  
in te r a c t io n  b e t w e e n  C C -1 0 6 5  a n d  th e  d e ­
o x y r ib o s e  p h o s p h a te  b a c k b o n e  m a y  o c ­
c u r , r e s u lt in g  in s tr a n d  b r e a k a g e . A n a ly ­
s is  o f  th e  o p p o s i t e  s tr a n d  a r o u n d  C C -  
1065 b in d in g  s i t e s  d id  n o t  s h o w  a n y  
r e s id u a l m o d if ic a t io n  o f  th e  D N A  a fte r  
d r u g  b in d in g  (9 ) .
S te r e o  d r a w in g s  o f  th e  C C - 1 0 6 5 - ( N - 3  
a d e n in e ) - D N A  a d d u c t  w e r e  p r e p a r e d  
(F ig . 3) o n  th e  b a s is  o f  th e  k n o w n  p o s i ­
t io n  o f  c o v a le n t  a t t a c h m e n t  a n d  a n  o r ie n ­
ta t io n  w h e r e in  th e  C C -1 0 6 5  o v e r la p s  
w ith  th e  s p e c if ie d  s e q u e n c e  o f  b a s e  
p a ir s . T h e  d r a w in g s  s h o w  a r e m a r k a b ly  
s n u g  fit o f  th e  C C -1 0 6 5  in  th e  m in o r  
g r o o v e ,  in w h ic h  it is  a p p a r e n t  th a t o n ly  
c e r ta in  b a s e  p a ir in g s  c a n  b e  a c c o m m o ­
d a te d  b y  C C -1 0 6 5 . W h ile  th e  r e la t iv e  
s t e r e o c h e m is tr y  o f  th e  c y c lo p r o p a n e  r in g  
h a s  b e e n  d e te r m in e d  (5 ) ,  th e  a b s o lu te  
s t e r e o c h e m is tr y  h a s  n o t .  T h e  s t e r e o  
d r a w in g s  s h o w  th a t  th e  C C - 1 0 6 5 - N - 3  
a d e n in e  a d d u c t  c a n  o n ly  b e  a c c o m m o ­
d a te d  i f  th e  a b s o lu te  c o n f ig u r a t io n  a t C -5  
is  a s  s h o w n  in  F ig . 1.
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Fig. 2. The CC-1065 binding site within a region o f the SV40 
early promoter. A DN A  restriction fragment from the SV40 
genome [5172 to 5241; marked with a single 32P-labeled phos­
phate at the 5' end at 5172; numbered as described (10)j was 
prepared by means o f established procedures (11) and was 
subjected either to sequencing reactions or to treatments with 
CC-1065. (Lanes 1 and 2) Maxam-Gilbert C + T  and A + G  reac­
tions, respectively (C, cytosine; G, guanine). (Lane 3) DNA was 
resuspcnded in 20 p.1 o f 7.5 m M  NaCl and 0.75 mM sodium  
citrate (pH 7.4) containing 2.8 pmol o f  CC-1065 and was incubat­
ed for 24 hours at 4°C. After removal o f  unbound drug by 
precipitation o f the DNA with ethanol, the DN A was resus­
pended in 0.1 ml o f 15 mM NaCl and 1.5 mM sodium citrate (pH 
7.4) and heated at 100°C for 30 minutes in a sealed test tube. The 
DNA was then precipitated with ethanol and dried under vacu­
um. (Lane 4) Identical to lane 3 except that, after removal of 
unbound drug by precipitation o f the DN A  with ethanol, the 
DNA was subjected to heat treatment with piperidine (11). After 
sequencing reactions or CC-1065 treatments, samples were sub­
jected to electrophoresis and analyzed by autoradiography as 
described i l l ) .  Fig. 3. Stereo drawings o f the CC -1065-DNA  
adduct.
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Characterization of a 12-mer Duplex 
d(GGCGGAGTTAGG)*d(CCTAACTCCGCC) Containing a Highly 
Reactive (+)-CC-1065 Sequence by 1H and 31P NMR, 
Hydroxyl-Radical Footprinting, and NOESY Restrained Molecular
Dynamics Calculations
Chin Hsiung Lin,f G. Craig Hill,1 and Laurence H. Hurley*’™
Drug Dynamics Institu te, College of Pharmacy, and D epartm ent of Chem istry and  
Biochemistry, U niversity of Texas a t Austin, Austin, Texas 78712-1074
Received Septem ber 13,1991
The solution structure of the GC-rich non-self-complementary DNA 12-mer duplex (I), which 
contains a (+)-CC-1065 highly reactive bonding sequence 5'AGTTA* (where * denotes the
5’ ------------------------------------- ► 3'
1 2 3 4 5 6 7 8 9  10 1112
GGCGGAGTTAGG 
CCGCCTCAATCC
24 2 3 2 2 2 1 2 0 1 9  18 17 1615 1413 ,3 —- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  5
I
covalent modification site), has been examined thoroughly by one- and two-dimensional proton 
and phosphorus NMR spectroscopy, hydroxyl-radical footprinting, and NOESY restrained 
molecular mechanics and dynamics calculations. The assignments of the nonexchangeable proton 
resonances (except some of the H5' and H5" protons due to severe resonance overlap), phosphorus 
resonances, and the exchangeable resonances (except amino protons of adenosine and guanosine) 
of this 12-mer duplex have been made. The results show that this 12-mer duplex maintains 
an overall B-form DNA with all anti base orientation throughout in aqueous solution at room 
temperature. Hydroxyl-radical footprinting experiments on a 21-mer sequence that contains 
this 12-mer duplex used for NMR studies showed that the minor groove is somewhat narrowed 
at the 7G-8T and 17A-18C steps, as indicated by the inhibition of cleavage at these locations.
Although both high-field NMR and hydroxyl-radical footprinting experiments supported a 
bent-like structure for this 12-mer duplex, nondenaturing gel electrophoresis on the ligated 21-mer 
sequence that contains this 12-mer duplex did not show the abnormally slow migration char­
acteristic of a bent DNA duplex. Analysis of the NMR data sets reveals several local structural 
perturbations similar to those found on an (A)n tract DNA duplex. For example, the existence 
of a propeller twist was detected within the A*T-rich region for both the 12-mer and the (A)„ 
tract DNA duplexes. The 18CH5 aromatic resonance that is directly adjacent to the 3' side of 
the 5'TAA segment was significantly shifted upfield with a chemical shift of 5.10 ppm, which 
is almost within the region normally associated with sugar H3' protons. The sugar geometries 
for 18C and 7G, which are located to the 3' side of the 5'TAA segment, are proposed to be in 
the neighborhood of C3'-endo and Ol'-endo <=> C3'-endo, respectively. We propose that this 
unusually upfield-shifted resonance signal for 18CH5 and the average C3'-endo sugar geometry 
for 18C nucleotide on the 12-mer duplex is connected with the peculiar conformation, possibly 
a transient kink, within the 5'AC/GT step. The results of the NOESY restrained molecular 
mechanics and dynamics calculations on the 12-mer sequence reveal two kinks, which are located 
on either side of the 18C nucleotide that has an average C3'-endo sugar geometry. The two 
phosphorus resonance signals that are located at the 7G-8T and the 18C-19T steps, where the 
minor groove is narrowed as indicated by the hydroxyl-radical footprinting experiments, displayed 
unusual upfield chemical shifts. Also identified were two unusually broadened base protons 
of the 16A nucleotide and one imino proton belonging to the 9T-16A base pair within the A*T-rich 
segment We proposed that this broadening phenomenon is most likely due to a unique internal 
motion characterized by a rapid local conformational equilibrium between microstates of the 
12-mer duplex in aqueous solution at room temperature. This local conformational flexibility, 
a transient kink, and the bent-like structure are proposed to play a critical role in the se­
quence-specific recognition of the DNA duplex by (+)-CC-1065.
Introduction molecular mechanics and dynamics calculations (10) have
The recent advancements in chemical synthesis of oli- permitted the determination of the solution structures of
godeorynucleotides, high-field NMR1 techniques (1-9), and short fragments of DNA (typically 6-12 bp)* and their
complexes with drugs or proteins. The combination of
•T o  whom correspondence should be addreued. these techniques is a powerful tool to elucidate the se-
i Department of Chemistry and Biochemistry. quence-specific interactions of drugs and proteins with
* Drug Dynamics Institute, College of Pharmacy. DNA at the molecular level. The non-self-complementary
0893-228x/92/2705-0167$03.00/0 © 1992 American Chemical Society
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Schem e I. The Sequence and O rigin o f the 12-mer D uplex  
U sed in T his S tudy0
21 BP 21 BP 21 BP
___________ A      A _____________ _ ._____________ A _____________ .t   ̂ f  ̂r ^
5 ' TGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGA3'
3 ' A CCCCG CCTCTTA CCCG CC TTTA C C C G C C TC A A TC C C C G C C C TA C X C G C C TC A A TC C C C G C C C T5'
g g c g g a g t t Xg g
CCGCCTCAATCC
“ (*) indicates the covalent bonding site of (+)-CC-1065.
12-mer duplex shown in Scheme I is contained within the 
21 bp repeat sequence of the early promoter region of 
simian virus 40 DNA. This 21 bp repeat sequence contains 
the transcription factor Spl binding site 5'GGGCGG (11) 
as well as the highly reactive bonding sequence 5'AGTTA* 
(where * denotes the covalent modification site) of the 
antitumor antibiotic (+)-CC-1065 (12-15).
A consensus sequence analysis of the (+)-CC-1065 
bonding sites on DNA demonstrates that there are two sets 
of DNA sequences, 5'PuNTTA1 and 5'AAAAA, that are 
highly specific (15). As part of an effort to elucidate the 
molecular mechanisms through which the sequence-de­
pendent recognition of DNA by (+)-CC-1065 can be ex­
pressed, we have thoroughly characterized the 12-mer 
duplex shown in Scheme I by high-field NMR, NOESY1 
restrained molecular mechanics and dynamics calculations, 
and hydroxyl-radical footprinting experiments. In addi­
tion, a detailed comparison has been carried out of the 
structural features of this 12-mer duplex and a sequence 
containing an A-tract. The proton NMR assignments for 
this 12-mer duplex and the deduced DNA conformation 
provide the basis for the subsequent NMR studies on the 
covalent bonding of the antitumor antibiotic (+)-CC-1065 
within the minor groove of DNA to this sequence.2 Al­
though the 12-mer duplex (Scheme I) exhibits no intrinsic 
bending as estimated by nondenaturing gel electrophore­
sis,3 the duplex has characteristics reminiscent of an (A)n 
tract and a bent DNA structure. For example, the nu­
cleotide adjacent to the 3' side of the 5'TAA segment on 
the noncovalently modified strand displays an anomalous 
upfield-shifted H5 proton resonance and has an average 
C3'-endo sugar geometry. The A*T base pairs within the 
5'AGTTA sequence exhibit a propeller twist between base 
pairs that is similar to that observed on a bent (A)„ tract 
DNA at the corresponding nucleotide units (16). In ad­
dition, a unique internal motion characterized by the rapid 
local conformational equilibrium between microstates was 
detected for the single nucleotide unit (16A) located one 
nucleotide removed in the 3' side on the complementary 
strand of the covalent modification site. We have previ­
ously suggested that the primary molecular basis for se­
quence selectivity is through a sequence-dependent cata­
lytic activation and/or a sequence-dependent conforma­
1 Abbreviations: AMBER,  assisted model building with energy refine­
ment; bp, base pair; COSY, two-dimensional correlated spectroscopy; 
DQF-COSY, phase-sensitive double quantum filtered correlated spec­
troscopy; FID, free induction decay; N, any base; NMR, nuclear magnetic 
resonance; NOE, nuclear Overhauser effect; NOESY, two-dimensional 
NOE correlated spectroscopy; Py, pyrimidine; Pu, purine; ROESY, ro- 
tating-frame NOE spectroscopy; TSP, 3-(trimethylsilyl)propionate.
2 C. H. Lin and L. H. Hurley, unpublished results, 1991.
3 D. Sun and L. H. Hurley, unpublished results, 1991.
Lin et al.
tional flexibility (17). We propose that this unique local 
internal motion meets the sequence-dependent confor­
mational flexibility requirement for (+)-CC-1065 bonding. 
Following the covalent bonding reaction with (+)-CC-1065, 
this 12-mer duplex DNA becomes bent, and the bending 
locus is located at the 8T to 9T step (18). A detailed 
analysis of the similarities in NOE1 data between the (A)„ 
tract sequence and the 12-mer duplex provides critical 
insight into one of the molecular mechanisms for the se­
quence-specific recognition of this DNA duplex by (+)- 
CC-1065.
Materials and Methods
C hem icals. C h em ica ls  for th e  p rep a ration  o f  th e  o lig o m er  and  
N M R  b u ffe r  a n d  for  H P L C  p u r if ic a t io n  o f  th e  o lig o m e r s  h a v e  
b e e n  p r e v io u s ly  r e p o r te d  (18-20).
P rep a ra tio n  and  P u r if ic a tio n  o f  th e  N o n -S elf-C o m p le­
m en tary  12-mer D u p lex . T h e  n o n -s e lf -c o m p le m e n ta r y  d - 
(G G C G G A G T T A G G ) a n d  d (C C T A A C T C C G C C ) d o d e c a n u c le o -  
t id e s  (S c h e m e  I) for  o n e - a n d  tw o -d im e n s io n a l  h ig h -f ie ld  N M R  
s tu d ie s  w ere sy n th e s iz e d  in  h o u se  on  a  10-^ m ol sca le  b y  u s in g  th e  
s o l id -p h a s e  c y a n o e th y l  p h o s p h o r a m id ite  a p p r o a c h  (21) o n  an  
A p p lie d  B io s y s te m s  a u to m a te d  D N A  sy n th e s iz e r , M o d e l  38 1 A . 
T h e  g en er a l p r o c e d u r e s  for  d e p r o te c t io n , a n n e a lin g , a n d  H P L C  
p u r ific a tio n  o f  th e  D N A  sa m p le s  h a v e  b e e n  p r e v io u s ly  r ep o r te d  
(18-20).
H igh -F ie ld  N M R  S p ectro sco p y . A ll o n e - a n d  tw o -d im e n ­
s io n a l 5 0 0 -M H z  XH  a n d  2 0 2 .4 4 -M H z  31P  N M R  d a ta  s e t s  in  90%  
H 20  a n d  100%  D 20  b u ffered  so lu tio n  w ere  recorded  o n  a G en era l 
E le c tr ic  G N -5 0 0  F T -N M R  sp e c tr o m e te r . P r o to n  r e so n a n c e  
c h e m ic a l s h i f t s  w ere  r ec o rd e d  in  p a r ts  p er  m ill io n  (p p m ) a n d  
r e fe re n ce d  r e la tiv e  to  e x te r n a l T S P 1 (1 m g /m L )  in  9 9 .9 6 %  D 20  
or 90%  H 2O /1 0 %  D 20 .  T h e  H O D  s ig n a l w a s  s e t  to  4 .7 5  p p m  
for  e a c h  p r o to n  sp e c tr u m  r e c o r d e d  a t  ro o m  te m p e r a tu r e .  
P h o sp h o r u s  c h e m ic a l s h if ts  w ere  r e fe r e n c e d  r e la tiv e  t o  e x te r n a l  
85%  H 3P O 4 in  D 20 .
T w o -D im en sio n a l N M R  E x p er im en ts . P h a s e -s e n s i t iv e  
tw o -d im en sio n a l p roton  N O E S Y  d a ta  se ts  (1) in  D 20  in  120-, 250-, 
an d  500-m s m ix in g  tim e  w ere co llec ted  w ith  a 1.5-s p u lse  rep etitio n  
t im e , a sw e e p  w id th  o f  4 0 81  H z , a n d  a 9 0 °  p u lse  w id th  o f  14 .9 0  
m s .  T h e  carrier  fr e q u e n c y  w a s p la c e d  o n  th e  r e s id u a l H O D  r es­
o n a n c e , w h ic h  w a s  ir r a d ia te d  w ith  th e  d e c o u p le r  c h a n n e l.  
T h ir ty -tw o  sc a n s  w ere  c o lle c te d  for  e a c h  o f  th e  51 2  F I D s 1 in  th e  
d im e n s io n  to  g e n e r a te  2 x  5 1 2  X 2 0 4 8  d a ta  m a tr ic e s .
T h e  p h a se -se n s itiv e  tw o -d im en sio n a l p ro to n  N O E S Y  sp ectru m  
in  90%  H 20  (200-m s m ix in g  tim e ) w a s  reco rd ed  u s in g  th e  S ta te s  
h y p e r c o m p le x  m e th o d  (1) w ith  a  1.0-s  p u ls e  r e p e t it io n  d e la y , a 
sw eep  w id th  o f  1 0 0 0 0  H z, an d  a 9 0 ° p u lse  w id th  o f  27 .5  m s .  Carrier  
fr e q u e n c y  w a s  s e t  to  w a ter  s ig n a l, a n d  w a te r  p r e s a tu r a t io n  w as  
a p p lied . S ix ty -fo u r  sca n s w ere  c o lle c te d  for e a ch  o f  th e  5 1 2  F ID s  
in  th e  t x d im e n s io n  to  g e n e r a te  2 X 5 1 2  x  2 0 4 8  d a t a  m a tr ic e s .
T w o -d im e n s io n a l p ro to n  r o ta tin g -fra m e  N O E  (R O E S Y )1 d a ta  
s e t s  (5 , 7) in  D 20  a t  1 0 0 -m s s p in - lo c k  t im e  w e re  c o l le c te d  w ith  
a 1 .5 -s  p u lse  r e p e t it io n  t im e , a  sw e e p  w id th  o f  4 5 8 7 .2  H z , a n d  a 
9 0 °  p u lse  w id th  o f  14 .5 0  ms. T h ir ty -tw o  sc a n s  w ere  c o lle c te d  for  
e a c h  o f  th e  5 1 2  F I D s  in  th e  t x d im e n s io n  t o  g e n e r a te  2 X 5 1 2  X 
1 0 2 4  d a ta  m a tr ic e s . T h e  carr ier  fr e q u e n c y  w a s  p la c e d  o n  th e  
r es id u a l H O D  r e so n a n ce  u s in g  a m ix in g  s e q u e n c e  (/3t)„ w ith  /3 =  
3 2 °  =  5 .1 5  ms a n d  a r  =  5 1 .5 0  ms s p in - lo c k  f ie ld  (6 .1 3  k H z , cor­
r e sp o n d in g  t o  5.15-m s 3 2 °  p u ls e  w id th )  to  e l im in a te  th e  H a rt-  
m a n n -H a h n  a r tifa c ts .
T w o -d im e n s io n a l p r o to n  p h a s e -s e n s it iv e  d o u b le  q u a n tu m  f i l ­
te re d  C O S Y 1 (D Q F -C O S Y )1 sp e c tr a  in  D 20  w ere  c o lle c te d  u s in g  
th e  s ta n d a r d  p u lse  s e q u e n c e  (3, 4) w ith  a  1 .5 -s  p u ls e  r e p e t it io n  
t im e , a  sw e e p  w id th  o f  4 2 0 2  H z , a n d  a  9 0 °  p u ls e  w id th  o f  14 .2 5  
m s .  T h e  carrier  fr e q u e n c y  w a s  p la c e d  o n  th e  r e s id u a l H O D  r e s ­
o n a n c e , w h ic h  w a s  ir r a d ia te d  w ith  th e  d e c o u p le r  c h a n n e l.  O n e  
h u n d r ed  s ix ty -fo u r  sca n s  w ere  c o lle c te d  for  e a c h  o f  th e  2 5 6  F ID s  
in  th e  tx d im e n s io n  to  g e n e r a te  2 x  25 6  X 2 0 4 8  d a t a  m a tr ic e s .
F o r  a ll p r o to n  tw o -d im e n s io n a l  p h a s e -s e n s it iv e  e x p e r im e n ts ,  
a 4 5 °  s h if te d  s in e  b e ll  fu n c t io n  w a s  a p p lie d  t o  th e  d a t a  s e t s  in  
b o th  d im e n s io n s  prior  to  tr a n sfo r m a tio n , a n d  th e  d a ta  s e t s  w ere  
zero filled  tw ice  in  th e  t x d im e n s io n  su c h  th a t  th e  fined fr eq u e n cy  
d o m a in  sp e c tr a  c o n s is te d  o f  I K  x  I K  d a ta  m a tr ic e s .
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F ig u re  1. O n e -d im e n s io n a l  p r o to n  N M R  s p e c tr u m  (5 0 0  M H z ,  
0 . 9 5 - 8 . 4  p p m )  o f  t h e  d ( G G C G G A G T T A G G ) - d -  
(C C T A A C T C C G C C ) 1 2 -m er  d u p le x  in  0 .5  m L  o f  D 20  b u ffe r  
c o n ta in in g  10  m M  s o d iu m  p h o s p h a te  a n d  10 0  m M  so d iu m  
c h lo r id e , p H  6 .8 5  a t  2 3  °C .
T w o -d im e n sio n a l p r o to n  m a g n itu d e  C O S Y  d a ta  se ts  (1) in  D 20  
w e re  c o lle c te d  w ith  a  1 .5 -s  p u lse  r e p e t it io n  t im e , a  sw e e p  w id th  
o f  3 9 21  H z, a n d  a 9 0 °  p u ls e  w id th  o f  1 3 .2 5  ms. T h e  carr ier  fre ­
q u e n c y  w as p la c e d  o n  th e  r e s id u a l H O D  r e so n a n c e , w h ic h  w as  
irra d ia ted  w ith  th e  d e c o u p le r  c h a n n e l. O n e  h u n d r ed  n in e ty -tw o  
sca n s  w ere c o lle c te d  for e a c h  o f  th e  256  F ID s  in  th e  f x d im e n s io n  
to  g e n e r a te  2 X 2 5 6  x  1 0 2 4  d a ta  m a tr ic e s . T h e  C O S Y  d a ta  s e t s  
w e re  zero  f i l le d  tw ic e  in  th e  d im e n s io n  su c h  th a t  th e  f in a l  
fr e q u e n c y  d o m a in  s p e c tr a  c o n s is te d  o f  I K  X I K  d a ta  m a tr ice s .
T w o -d im e n s io n a l h e te r o n u c le a r  p h o s p h o r u s -d e te c te d  31P - 1H  
p h a s e -s e n s it iv e  C O S Y  e x p e r im e n ts  w e re  r e c o rd e d  a c c o r d in g  to  
th e  p u b lish e d  p r o c e d u r e s  (6) w ith  a 2 .0 -s  p u lse  r e p e t it io n  t im e ,  
a sw e ep  w id th  o f  8 9 6  H z  for  p h o sp h o ru s a n d  9 3 1 .0  H z  for p roton , 
a n d  a 90 ° p u lse  w id th  o f  2 8 .0  ms. O n e h u n d red  tw e n ty -e ig h t sca n s  
w ere  c o lle c te d  for  e a c h  o f  th e  5 1 2  F I D s  in  th e  t x d im e n s io n  to  
g e n e r a te  2 X 51 2  x  51 2  d a ta  m a tr ic e s .
O n e-d im en sio n a l N O E  d iffer en ce  e x p er im en ts  w ere p erfo rm ed  
a t  23  °C  w ith  an  ir r a d ia tio n  t im e  o f  0 .2 5  s. S u p p r e s s io n  o f  th e  
w a ter  s ig n a l w as a c h ie v e d  w ith  th e  s ta n d a r d  1 -3 -3 -1  s e le c t iv e  
e x c ita t io n  p u lse  s e q u e n c e  (2 ), a n d  th e  in te r p u ls e  d e la y  w a s  s e t  
to  12 0  ms-
H ydroxyl-R adical F ootp rin ting  E xperim ents. T h e  d e ta iled  
p ro ced u res  for  th e  h y d r o x y l-ra d ica l fo o tp r in tin g  e x p e r im e n ts  on  
th e  2 1 -m er  se q u e n c e  c o n ta in in g  th e  1 2 -m er  d u p le x  h a v e  b e e n  
r ep o r te d  p r e v io u s ly  (18).
M olecu lar  M od elin g  S tu d ie s . M o le c u la r  m e c h a n ic s  a n d  
d y n a m ics c a lc u la tio n s  w ere  p erfo rm ed  u s in g  th e  a m b e r 1 program , 
V e r s io n  3 .0  A  (10), o n  a S i l ic o n  G ra p h ic s  4 D -2 5 . T h e  d o d e c a -  
n u cleotid e d u p lex  w as con stru cted  in  a m b e r  usin g  A m o tt ’s B  D N A  
g e o m etr y . T h e  s e q u e n c e  w a s  e n e r g y  m in im iz e d  in  v a c u o  u s in g  
a d is ta n c e -d e p e n d e n t  d ie le c tr ic  c o n s ta n t  u n t il  th e  rm s g r a d ie n t  
w a s le s s  th a n  0 .1  k c a l/(m o l-A ) . T h e  s t e e p e s t  d e s c e n t  w a s o n ly  
u se d  for  th e  f ir s t  10 0  s t e p s  a n d  fo r  th e  f ir s t  10 s t e p s  a fte r  e a ch  
u p d a te  o f  th e  n o n b o n d e d  p air  l is t .  T h e  c u to f f  d is ta n c e  for  th e  
n o n b o n d e d  p a irs  w a s  9 9  A  a n d  w a s  u p d a te d  e v e r y  100  c y c le s .  
N O E  d a ta  fr o m  th e  tw o -d im e n s io n a l  N O E S Y  e x p e r im e n ts  (75  
an d  250 m s) w ere c la ssified  according to  in ten s ity  (strong, m ed iu m , 
w ea k , a n d  v e r y  w e a k ) a n d  a s s ig n e d  d is ta n c e s  o f  2 .7 5 , 3 .5 0 , 4 .5 0 , 
an d  5 .0  A, r e sp e c tiv e ly . A n  e n erg y  p e n a lty  o f  1 k c a l/(m o l-A ) w as  
u sed  to  constrain  th e se  a to m -a to m  (p r o to n -p ro to n ) con n ectiv itie s . 
T h e  u n u su a l su ga r  p u c k e r  a t  18C  n u c le o t id e  (a v era g e  C 3 '-e n d o )  
w a s a lso  c o n str a in e d  u s in g  an  e n e r g y  p e n a lty  o f  2 .5  k c a l/m o l  for  
ea ch  o f  th e  f iv e  a n g le s  (vo- ^ )-  T h e  d u p le x  w as m in im iz e d  to  an  
rm s va lu e < 0 .0 1  k ca l/(m ol* A ). T h e  resu ltin g  m o d e l w as su b jected  
to  5 p s  o f eq u ilib ra tio n  d y n a m ics  fo llo w ed  b y  100 p s  o f  p rod u ctio n  
d yn a m ics (c o n sta n t te m p e ra tu re  300  ±  5 K ). A  c o n s ta n t p ressu re  
o f  1 a tm  a n d  0 .0 0 2  p s  t im e  s t e p  w ith  “s h a k e ” o n  w a s u se d  
th r o u g h o u t. T h e  fin a l 1 0 0 -p s  c o o r d in a te s  o f  th e  tr a je c to ry  w ere  
averaged  a n d  rem in im ize d  w ith o u t N O E  c o n str a in ts  a n d  u sed  for  
a n a ly s is .
Results
T h e  n o n - s e l f - c o m p l e m e n t a r y  1 2 - m e r  d u p l e x  s e q u e n c e  
u s e d  in  t h i s  s t u d y  i s  p a r t  o f  t h e  2 1  b p  r e p e a t  r e g i o n  c o n ­
t a i n e d  in  t h e  e a r l y  p r o m o t e r  r e g i o n  o f  S V  4 0  v i r u s  D N A
CD
c h 3
I - — H 6
7 .  4 7 .  2
F igu re 2. T w o -d im e n sio n a l m a g n itu d e  C O S Y  e x p a n d e d  co n tou r  
p lo t  o f  th e  1 2 -m er  d u p le x  in  D 20 - b u f fe r e d  s o lu t io n  c o n ta in in g  
10 m M  so d iu m  p h o sp h a te  a n d  100 m M  so d iu m  ch lo r id e, p H  6.85  
a t  23  °C , d e m o n s tr a t in g  th e  th r o u g h -b o n d  sca la r  c o u p lin g s  b e ­
tw e e n  th e  th y m in e  m e th y l  r e so n a n c e s  (1 .1 - 1 .7 5  p p m ) a n d  th e  
th y m in e  H 6  p r o to n s  (7 .1 -7 .5  p p m ) o f  fou r  th y m in e  n u c le o tid e s .  
C ro ss-p ea k s A - D  are a ss ig n e d  as fo llow s: (A ) 1 5 T (H 6 )-1 5 T (H 5 );  
(B ) 9 T (H 6 )-9 T (H 5 );  (C ) 1 9 T (H 6 )-1 9 T (H 5 );  (D ) 8 T (H 6 )-8 T (H 5 ) .
( S c h e m e  I ) .  T h i s  2 1  b p  r e p e a t  s e q u e n c e  c o n t a i n s  t h e  S p l  
p r o t e i n  b i n d i n g  s i t e  a s  w e l l  a s  t w o  i d e n t i c a l  ( + ) - C C - 1 0 6 5  
h i g h l y  r e a c t i v e  b o n d i n g  s e q u e n c e s  5 ' A G T T A *  [ w h e r e  * 
d e n o t e s  t h e  c o v a l e n t  m o d i f i c a t i o n  s i t e  o f  ( + ) - C C - 1 0 6 5 ] .  
T h e  s e q u e n c e  a n d  t h e  n u m b e r in g  s c h e m e  o f  t h i s  1 2 - m e r  
d u p l e x  a r e  s h o w n  i n  S c h e m e  I.
(A) Assignm ents o f the N onexchangeable Protons 
in  the 12-mer D uplex. T h e  o n e - d i m e n s i o n a l  n o n e x ­
c h a n g e a b l e  p r o t o n  ( 0 .9 5 - 8 .4  p p m )  s p e c t r u m  o f  t h e  1 2 -m e r  
d u p l e x  in  D 20 - b u f f e r e d  s o l u t i o n  a t  2 3  ° C  i s  p l o t t e d  in  
F ig u r e  1. I t  i s  a p p a r e n t  t h a t  t h e  o n e - d i m e n s i o n a l  p r o t o n  
N M R  s p e c t r u m  ( F ig u r e  1 ) o f  t h i s  G -C -r ic h  1 2 - m e r  d u p l e x  
i s  e x t r e m e l y  b r o a d  a n d  c o m p l e x .  W e  s u s p e c t  t h i s  is  
p r o b a b l y  d u e  t o  t h e  r a p id  i n t e r c o n v e r s io n  b e t w e e n  t w o  o r  
m o r e  c o n f o r m e r s  o f  t h e  1 2 -m e r  d u p l e x  a t  t h i s  t e m p e r a t u r e  
( s e e  la t e r ) .  U p o n  a d d u c t  f o r m a t io n  w i t h  ( + ) - C C - 1 0 6 5 ,  t h e  
p r o t o n  r e s o n a n c e  s i g n a l s  b e c o m e  c o n s i d e r a b l y  s h a r p e r .2 
T h e  n o n e x c h a n g e a b l e  p r o t o n  r e s o n a n c e s  ( e x c e p t  s o m e  o f  
t h e  H 5 '  a n d  H 5 "  s u g a r  p r o t o n s ,  d u e  t o  s e v e r e  r e s o n a n c e  
o v e r la p )  h a v e  b e e n  a s s i g n e d  b y  u t i l i z i n g  t w o - d im e n s i o n a l  
N M R  t e c h n i q u e s :  C O S Y -  a n d  D Q F - C O S Y - t h r o u g h - b o n d  
s c a la r  c o u p l i n g s  a n d  N O E S Y -  a n d  R O E S Y - t h r o u g h - s p a c e  
c o n n e c t i v i t i e s .
T h e  t h y m i n e  H 5  ( m e t h y l )  a n d  H 6  b a s e  p r o t o n s  c a n  b e  
a s s i g n e d  b y  a n a l y z i n g  t h e  e x p a n d e d  c o n t o u r  p l o t s  o f  t h e  
1 2 - m e r  d u p l e x  b e t w e e n  t h e  7 . 1 0 - 7 . 5 0  p p m  a n d  1 . 1 0 - 1 .7 5  
p p m  r e g i o n  i n  b o t h  t h e  C O S Y  ( F ig u r e  2 )  a n d  R O E S Y  
e x p a n s i o n s  (F ig u r e  3 ) .  I n  t h e  D N A  d u p l e x ,  e a c h  t h y m i n e  
m e t h y l  p r o t o n  e x h ib i t s  w e a k  f o u r - b o n d  s c a la r  c o u p l in g  a n d  
t h r o u g h - s p a c e  c o n n e c t i v i t y  t o  i t s  o w n  H 6  p r o t o n  (8 ,9 ,22). 
F o r  t h e  r i g h t - h a n d e d  D N A  h e l i x ,  t h r o u g h - s p a c e  c o n n e c ­
t i v i t i e s  c a n  a l s o  b e  d e t e c t e d  b e t w e e n  a d j a c e n t  p u r in e  H 8  
a n d  p y r im id in e  H 5 / M e  b a s e  p r o t o n s  in  t h e  5 T u - P y 3 ' 1 s t e p  
a n d  b e t w e e n  a d j a c e n t  p y r i m i d i n e  H 6  a n d  p y r i m i d i n e  
H 5 / M e  b a s e  p r o t o n s  i n  t h e  5 ' P y - P y 3 '  s t e p  (22). F o r  e x ­
a m p l e ,  t h e  t h y m i n e  H 5  m e t h y l  s i g n a l  r e s o n a t i n g  a t  1 .1 6  
p p m  d i s p l a y s  a  s c a la r  c o u p l i n g  t o  t h e  t h y m i n e  H 6  p r o t o n  
a t  7 .1 3  p p m  ( c r o s s - p e a k  D ,  F ig u r e  2 )  a n d  a n  R O E  c o n ­
n e c t i v i t y  t o  t h e  a r o m a t i c  p r o t o n  a t  7 .4 4  p p m  ( c r o s s - p e a k  
D ,  F ig u r e  3 ) .  T h e  t h y m i n e  H 5  s i g n a l  r e s o n a t i n g  a t  1 .6 0
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F ig u r e  3. T w o -d im e n s io n a l p h a s e -s e n s it iv e  R O E S Y  (1 0 0 -m s  
sp in -lo c k  t im e ) e x p a n d e d  c o n to u r  p lo t  o f  th e  1 2 -m er  d u p le x  in  
D 20 -b u f fe r e d  so lu tio n  c o n ta in in g  10 m M  so d iu m  p h o sp h a te  a n d  
100 m M  so d iu m  ch lo r id e, p H  6 .8 5  a t  23  °C , d e m o n s tr a t in g  R O E  
c o n n e c tiv it ie s  for th e  P u H 8 /P y H 6  (7 .1 -8 .3  p p m ) to  i t s  ow n  sugar  
H 2 ' p r o to n s  (d e n o te d  w ith  n u c le o t id e  u n it s  a n d  n u m b e r s )  a n d  
to  th e  sugar H 2"  p roton s o f  th e  5' n e igh b or. F or th e  u p p er  stra n d  
from  1G  t o  12G , th e  R O E s are  c o n n e c te d  w ith  s o lid  l in e s ,  a n d  
for  th e  lo w er  s tr a n d  from  13C  to  24 C , th e  R O E s are  c o n n e c te d  
w ith  b rok en  lin es . C ro ss-p eak s A - H  are a ss ig n e d  as  fo llow s: (A ) 
8 T (H 6 )-9 T (H 5 );  (B ) 9 T (H 6 ) -9 T (H 5 ) ;  (C ) 8 T (H 6 ) -8 T (H 5 ) ;  (D )  
7 G (H 8 ) -8 T (H 5 );  (E ) 1 5 T (H 6 )-1 5 T (H 5 );  (F ) 1 4 C (H 6 )-1 5 T (H 5 );  
(G ) 1 8 C (H 6 )-1 9 T (H 5 );  (H ) 1 9 T (H 6 ) - 1 9 T (H 5 ) .
ppm exhibits a J  coupling to the thymine H6 proton at 
7.33 ppm (cross-peak B, Figure 2) and an ROE connec­
tivity to the adjacent 5'-neighbor thymine H6 proton at 
7.13 ppm (cross-peak A, Figure 3). Since only 9T in the 
12-mer sequence is adjacent to a thymine (in the 5' di­
rection), the signals resonating at 1.60 and 7.33 ppm were 
assigned to 9TH5 and 9TH6 protons, and the signals 
resonating at 1.16 and 7.13 ppm were assigned to 8TH5 
and 8TH6 protons, respectively. The aromatic proton 
resonating at 7.44 ppm was assigned to the 7GH8 proton 
because of its ROE connectivity to the 8TH5 proton 
(cross-peak D, Figure 3).
(1) Arom atic (P uH 8/P yH 6) to H I' Sugar Proton  
Connectivities. Once the H6 protons of 8T and 9T and 
the H8 proton of 7G have been assigned, this information 
can be used as the starting point for sequential assignment 
of the aromatic to HI' sugar protons in the appropriate 
expansion. The two-dimensional phase-sensitive NOESY 
(250-ms) expanded contour plots demonstrating the 
through-space connectivities for the PuH8/PyH6 (6.8-8.4 
ppm) to the HI' sugar protons (4.8-6.3 ppm) of the 12-mer 
duplex are plotted in Figure 4A for the upper strand from 
1G to 12G and in Figure 4B for the lower strand from 13C 
to 24C. For the right-handed DNA duplex, each purine 
H8/pyrimidine H6 proton exhibits NOEs to its own HI' 
sugar proton and to the HI' sugar proton of its 5' neighbor, 
except for the 5'-terminal nucleotide which lacks 5'- 
flanking sugar (8, 9 ,22). Thus, it is possible to walk along 
the complete strand of a double helix DNA and assign all 
of the PuH 8/PyH 6 base protons and the HI' sugar pro­
tons. All of the intra- and intemucleotide connectivities 
between the aromatic and the HI' sugar proton were de­
tected in the 12-mer duplex at room temperature. One 
unusual feature in this region is that the intemucleotide 



























F i g u r e  4. T w o -d im e n s io n a l  p h a s e -s e n s it iv e  N O E S Y  (2 5 0 -m s)  
e x p a n d e d  c o n to u r  p lo ts  o f  th e  1 2 -m e r  d u p le x  in  D 20 - b u f f e r e d  
so lu tio n , p H  6 .85  a t  23 °C , d e m o n stra tin g  th e  N O E  c o n n e c tiv it ie s  
for th e  P u H 8 /P y H 6  (6 .S -8 .4  p p m ) to  th e ir  ow n sugar H I '  p ro to n s  
(4 .8 -6 .3  p p m ) (d e n o te d  w ith  n u c le o t id e  u n its  a n d  n u m b e r s  co r ­
r e sp o n d in g  to  th e  p o s it io n s  in  th e  1 2 -m er  d u p le x  s e q u e n c e )  a n d  
to  th e  H I '  p r o to n s  o f  th e  5' n e ig h b o r s . (A ) U p p e r  s tr a n d , 1G  to  
12G , a n d  (B ) lo w er  str a n d , 13C  to  24 C . C r o ss-p e a k s  A  a n d  B  in  
(A ) are  a s s ig n e d  a s  fo llo w s: (A ) 7 G (H 8 ) -6 A (H T ) ;  (B ) 7 G ( H 8 ) -  
7 G (H 1 ') . C r o ss -p e a k s  A  a n d  B  in  (B ) are  a s s ig n e d  a s  fo llo w s:  
A .1 8 C (H 6 )-1 7 A (H 1 ') ;  B .1 8 C (H 6 )-1 8 C (H 1 ') .
neighbor 17A (cross-peak A in Figure 4B) is significantly 
stronger than the intranucleotide connectivity for 18CH6 
to its own HI' proton (cross-peak B in Figure 4B). In order 
to avoid effects due to spin diffusion, a 75-ms mixing time 
experiment was also run to confirm unusual intensities for 
cross-peaks (data not shown). This intensity reversal is 
uncharacteristic of a normal right-handed B-form DNA  
and is the indication of an unusual sugar pucker (possibly 
in the neighborhood of a C3'-endo geometry) for this nu­
cleotide. For the 7G nucleotide that is the complementary 
partner of 18C, the intemucleotide connectivity for the H8 
proton to the HI' proton of its 5' neighbor (cross-peak A 
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T able I. C hem ical S h ift A ssignm ents (in ppm) o f the N onexchangeable Protons o f the 12-mer D uplex  at Room Tem perature0
ch em ica l sh ifts , ppm
H 8 H 6 H 2 H 5 H I ' H 2 ' H 2 " H 3 ' H 4 ' H 5 ',H 5 "
G l 7 .83 5.63 2.51 2.67 4 .78 4 .14 3.67
G 2 7.82 5.89 2.59 2.67 4 .94 4 .35 N A 6
C 3 7.24 5 .29 5 .65 1.87 2.29 4 .79 4 .12 N A
G 4 7.76 5.47 2.57 2.67 4.95 4.27 N A
G 5 7.68 5.52 2 .55 2.70 4 .96 4.33 N A
A 6 8.02 7.58 6.01 2.64 2.88 4 .98 4.41 4 .1 4 -4 .2 1
G 7 7 .44 5 .78 2.38 2.67 4.83 4.34 4 .1 8 /4 .1 8
T 8 7.13 1.16 5.92 1.99 2.48 4.79 4 .19 4 .0 8 /4 .0 8
T 9 7.33 1.60 5.64 2.01 2.34 4.83 4.06 4 .0 1 -4 .0 8
A 10 8 .18 7 .44 5.89 2.65 2.78 4.98 4 .35 4 .0 4 -4 .1 0
G i l 7 .62 5.57 2.47 2.59 4.89 4.33 4 .1 5 /4 .1 5
G 1 2 7.64 6 .07 2.38 2 .30 4.55 4 .16 N A
C 1 3 7.76 5 .89 5.92 2.23 2.52 4.63 4 .06 3.76
C 1 4 7.62 5 .65 5.94 2 .08 2.44 4 .78 4 .15 N A
T 1 5 7.36 1.66 5.50 2.04 2.32 4 .82 4 .08 N A
A 16 8 .23 7 .04c 5 .89 2 .73 2.88 5.01 4.37 4 .0 2 -4 .1 0
A 17 8 .09 7.53 5.97 2.61 2.74 4 .96 4.43 4 .2 1 /4 .2 1
C 1 8 7.19 5 .10 5 .62 1.97 2.39 4 .49 4 .18 4 .1 3 /4 .1 3
T 1 9 7.37 1.45 5 .97 2.13 2.51 4.81 4 .15 4 .0 2 -4 .1 0
C 2 0 7.57 5 .55 5.87 2 .10 2 .38 4.81 4.12 4 .0 4 /4 .0 4
C 21 7.40 5 .55 5.51 2.03 2.34 4.81 4 .05 N A
G 2 2 7 .88 5.88 2.64 2.69 4.95 4.34 3 .9 8 /4 .0 6
C 23 7.36 5.41 5.94 2.08 2.42 4.81 4.12 N A
C 2 4 7.78 5 .65 6 .18 2.23 2.23 4.52 3.96 4 .1 1 /4 .1 1
1 S a m p le  w aa d is so lv e d in  0 .5  m L o f  D 20  b u f f e r c o n ta in in g  0.1 M  s o d iu m c h lo r id e a n d  10 m M s o d iu m  ]p h o s p h a te ,  p H 6.85  a t  23 °C .
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F igu re  5. T w o - d im e n s io n a l  p h a s e - s e n s i t iv i ty  N O E S Y  (2 5 0 -m s)  
e x p a n d e d  c o n t o u r  p l o t  o f  t h e  1 2 -m e r  d u p l e x  in  D 20  b u f f e r  s o ­
lu t io n ,  p H  6 .8 5  a t  2 3  ° C , d e m o n s t r a t i n g  t h e  N O E  c o n n e c t iv i t i e s  
fo r  t h e  a d e n in e  H 2  t o  t h e  s u g a r  H I '  p r o to n s  a n d  f o r  t h e  c y to s in e  
H 5  to  t h e  P u H 8 / P y H 6  o f  t h e  5 ' n e ig h b o r .  C ro s s -p e a k s  A - N  a r e  
id e n t i f ie d  a s  fo llow s: (A ) 1 8 C (H 5 )-1 7 A (H 8 ) ;  (B ) 3 C (H 5 ) -2 G (H 8 ) ;  
(C ) 2 3 C ( H 5 ) - 2 2 G ( H 8 ) ;  (D ) 1 4 C ( H 5 ) - 1 3 C ( H 6 ) ;  (E )  2 4 C ( H 5 ) -  
2 3 C (H 6 ) ;  (F )  6 A ( H 2 ) - 6 A ( H 1 ') ;  (G ) 6 A ( H 2 ) - 2 0 C ( H 1 ') ;  (H )  6A - 
( H 2 ) - 7 G ( H l ') ;  (I )  1 7 A ( H 2 )-1 7 A (H 1 ') ;  ( J )  1 7 A ( H 2 ) - 9 T ( H 1 ') ;  (K ) 
1 0 A ( H 2 ) - 1 0 A ( H 1 ')  a n d  1 0 A ( H 2 ) - 1 6 A ( H 1 ') ;  (L )  1 0 A ( H 2 ) -1  I G ­
O R ') ;  (M )  1 6 A ( H 2 ) -1 0 A (H 1 ')  a n d  1 6 A ( H 2 ) -1 6 A (H 1 ') ;  (N )  17A - 
( H 2 ) - 1 8 C ( H l ') .  A r r o w h e a d s  d e n o t e  t h e  c r o s s - s t r a n d  N O E  c o n ­
n e c t iv i t i e s .
c o n n e c t i v i t y  t o  i t s  o w n  H I '  p r o t o n  ( c r o s s - p e a k  B  in  F ig u r e  
4 A ) .  T h e s e  l o c a l  d e v i a t i o n s  f r o m  a  n o r m a l  r ig h t - h a n d e d  
B - f o r m  D N A  d u p l e x  a r e  o f  c o n s id e r a b le  s ig n i f i c a n c e  ( s e e  
l a t e r ) .  T h e  c h e m ic a l  s h i f t s  o f  t h e  a r o m a t i c  a n d  H I '  s u g a r  
p r o t o n s  o f  t h e  1 2 - m e r  d u p l e x  a r e  g i v e n  in  T a b l e  I .
( 2 )  A r o m a t i c  ( P u H 8 / P y H 6 )  t o  H 2 ' ,H 2 "  S u g a r  P r o ­
t o n  C o n n e c t i v i t i e s .  I n  a  r i g h t - h a n d e d  D N A  d u p l e x ,  i t  
i s  e x p e c t e d  t h a t  e a c h  b a s e  p r o t o n  ( H 8  o r  H 6 )  w i l l  b e  in  
c lo s e  p r o x i m i t y  t o  t h e  H 2 '  a n d  t h e  H 2 "  p r o t o n s  o f  i t s  o w n  
n u c l e o t i d e  a n d  t o  t h a t  o f  i t s  5 ' - n e ig h b o r  n u c l e o t i d e  (23). 
I n  a d d i t i o n ,  i f  a  r e l a t i v e l y  s h o r t  s p i n - l o c k  t i m e  i s  u s e d  in  
t h e  R O E S Y  e x p e r i m e n t ,  e a c h  b a s e  p r o t o n  ( H 8  o r  H 6 )  
s h o u l d  e x h i b i t  R O E s  t o  i t s  o w n  s u g a r  H 2 '  p r o t o n  a n d  t o  
t h e  H 2 "  p r o t o n  o f  i t s  5 ' - n e ig h b o r  n u c l e o t i d e ,  s i n c e  t h e y  
a r e  w i t h i n  3 .5  A .  T h e  t w o - d i m e n s i o n a l  R O E S Y  ( 1 0 0 - m s  
s p i n - l o c k  t i m e )  e x p a n d e d  c o n t o u r  p l o t  d i s p l a y i n g  R O E  
c o n n e c t i v i t i e s  f o r  e a c h  P u H 8 / P y H 6  t o  t h e  H 2 '  s u g a r  
p r o t o n  ( l a b e le d  w i t h  n u c l e o t i d e  u n i t  a n d  n u m b e r  c o r r e ­
s p o n d i n g  t o  t h e  p o s i t i o n  in  t h e  1 2 - m e r  d u p l e x )  a n d  t o  t h e  
H 2 "  p r o t o n s  o f  i t s  5 ' n e ig h b o r  in  t h e  1 2 -m e r  d u p l e x  in  D 20  
i s  s h o w n  in  F ig u r e  3  ( fo r  t h e  u p p e r  s t r a n d  1 G - 1 2 G  t h e  
R O E s  a r e  c o n n e c t e d  w i t h  s o l id  l in e s ;  fo r  t h e  lo w e r  s t r a n d  
1 3 C - 2 4 C  t h e  R O E s  a r e  c o n n e c t e d  w i t h  b r o k e n  l in e s ) .  T h e  
c h a r a c t e r i s t i c  R O E  c o n e c t i v i t i e s  f o r  t h e  r i g h t - h a n d e d  
B - f o r m  D N A  a r e  a l l  o b s e r v e d  in  t h e  1 2 -m e r  d u p le x ,  e x c e p t  
fo r  t h e  7 G  a n d  1 8 C  n u c l e o t i d e s .  F o r  t h e  1 8 C  n u c l e o t i d e ,  
t h e  i n t e m u c l e o t i d e  R O E  f r o m  b a s e  t o  t h e  H 2 "  s u g a r  
p r o t o n s  o f  i t s  5 '  n e ig h b o r  a n d  t h e  in t r a n u c l e o t id e  R O E  fo r  
b a s e  t o  i t s  o w n  H 2 '  s u g a r  p r o t o n  e x h i b i t e d  a  s im i l a r  b u t  
w e a k  i n t e n s i t y  ( F ig u r e  3 ) .  I n  t h e  c a s e  o f  7 G ,  t h e  i n t e r ­
n u c l e o t i d e  R O E  f o r  b a s e  t o  t h e  H 2 "  s u g a r  p r o t o n s  o f  i t s  
5 ' n e ig h b o r  a n d  t h e  i n t r a n u c l e o t i d e  R O E  fo r  b a s e  t o  i t s  
o w n  H 2 '  s u g a r  p r o t o n  a r e  o f  t h e  s a m e  i n t e n s i t y  (F ig u r e  3 ) .
T h r o u g h - s p a c e  c o n n e c t i v i t i e s  s h o u l d  b e  d e t e c t e d  b e ­
t w e e n  a d j a c e n t  p u r in e  H 8  a n d  p y r i m i d i n e  H 5 / M e  b a s e  
p r o t o n s  in  t h e  5 ' P u - P y 3 '  s t e p s  (22). A  t o t a l  o f  f o u r  s u c h  
c o n n e c t i v i t i e s  i n  t h e  1 2 - m e r  d u p l e x  w e r e  e x p e c t e d  a n d  
fo u n d :  2 G - 3 C  (c r o s s - p e a k  B ,  F ig u r e  5 ) ,  7 G - 8 T  (c r o s s - p e a k  
D ,  F ig u r e  3 ) ,  1 7 A - 1 8 C  ( c r o s s - p e a k  A , F ig u r e  5 ) ,  a n d  2 2 G -  
2 3 C  (c r o s s - p e a k  C , F ig u r e  5 ) .  T h r o u g h - s p a c e  c o n n e c t iv i t ie s  
a r e  a l s o  o b s e r v e d  b e t w e e n  a d j a c e n t  p y r i m i d i n e  H 6  a n d
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Figure 6. T w o -d im e n s io n a l  p h a s e -s e n s it iv e  N O E S Y  (2 5 0 -m s  
m ix in g  tim e ) e x p a n d e d  co n tou r  p lo t  o f  th e  12 -m er d u p le x  in  D 20  
b u ffe r  so lu t io n , p H  6 .8 5  a t  23  °C , d e m o n s tr a t in g  th e  N O E  c o n ­
n e ctiv itie s  for th e  P u H 8 /P y H 6  (7 .0 -8 .4  p p m ) to  th e  P u H 8 /P y H 6  
(7 .0 -8 .4  p p m ) p r o to n s. C ross-p eak s A - U  are a ss ig n e d  as fo llow s: 
(A ) 1 1 G (H 8 )-1 0 A (H 8 ); (B ) 1 0 A (H 8 )-9 T (H 6 ); (C) 9 T (H 6 )-8 T (H 6 );  
(D ) 8 T (H 6 )-7 G (H 8 );  (E ) 7 G (H 8 ) -6 A (H 8 );  (F ) 6 A (H 8 )-5 G (H 8 );  
(G ) 5 G (H 8 ) -4 G (H 8 );  (H ) 4 G (H 8 ) -3 C (H 6 );  (I) 3 C (H 6 )-2 G (H 8 );  
(J ) 2 4 C (H 6 )-2 3 C (H 6 );  (K ) 2 3 C (H 6 )-2 2 G (H 8 );  (L ) 2 2 G ( H 8 ) -  
2 lC (H 6 );  (M ) 2 lC (H 6 ) -2 0 C (H 6 )  a n d  2 0 C (H 6 )-1 9 T (H 6 );  (N )  
1 9 T (H 6 )-1 8 C (H 6 ); ( 0 )  1 8 C (H 6 )-1 7 A (H 8 ); (P ) 1 7 A (H 8 )-1 6 A (H 8 );  
(Q ) 1 6 A (H 8 )-1 5 T (H 6 );  (R ) 1 5 T (H 6 )-1 4 C (H 6 );  (S ) 1 4 C (H 6 )-  
1 3 C (H 6 ); (T ) 1 6 A (H 2 )-1 0 A (H 2 );  (U ) 1 6 A (H 2 )-1 7 A (H 2 ) .
pyrimidine H 5/M e base protons in the 5'Py-Py3' steps 
(22). Of a total of seven such expected connectivities in 
the 12-mer duplex, five were identified: 8T-9T (cross-peak 
B, Figure 3), 13C-14C (cross-peak D, Figure 5), 14C-15T 
(cross-peak F, Figure 3), 18C-19T (cross-peak G, Figure 
3), and 23C-24C (cross-peak E, Figure 5), and the re­
maining two were overlapped: 19T-20C and 20C-21C 
(overlapped with the cross-peak for H5 to H6 protons of 
21C and 20C, respectively).
(3) Adenine H2 to HP Sugar Proton Connectivities. 
Each adenine H2 resonance has been assigned on the basis 
of the NOE connectivities to the HI' sugar protons to its 
own, to its 3' neighbor, and to the nucleotide at the 3' side 
one base removed on the complementary strand (9, 24). 
For example, in the 12-mer duplex, we detected NOEs 
between 6AH2 and the HI' protons of 6A (cross-peak F, 
Figure 5), 7G (cross-peak H, Figure 5), and 20C (cross-peak 
G, Figure 5). Similar connectivities were detected and used 
to assign all of the remaining H2 protons of 10A, 16A, and 
17A (Figure 5). The adenine H2 protons can usually be 
identified on the basis of their long spin relaxation times 
in the DNA duplex. For this 12-mer duplex, the H2 pro­
tons of 6A and 17A exist as sharp resonances and the 
10AH2 proton is somewhat broadened. However, the ad­
enine H2 proton of 16A is unusually broad and occurs at 
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F ig u re  7. T w o -d im e n s io n a l  e x p a n d e d  c o n to u r  p lo t s  o f  th e  (A ) 
p h a s e -s e n s it iv e  D Q F -C O S Y  a n d  (B ) R O E S Y  (1 0 0 -m s  s p in -lo c k  
t im e )  o f  th e  1 2 -m e r  d u p le x  in  D 20  b u ffe r  a t  23 °C , e s t a b l is h in g  
th e  sca lar  c o u p lin g s b e tw e e n  th e  sugar H f  p roton s (5 .1 —6 .3  p p m )  
a n d  th e  H 2 ' a n d  H 2 "  p r o to n s  (1 .6 - 3 .0  p p m ) (A ) a n d  t h e  R O E  
co n n e ctiv it ie s  b e tw een  th e  H T  a n d  H 2"  sugar p rotons (B ). C O SY  
a n d  R O E S Y  c r o ss -p e a k s  a n d  c o n n e c t iv it ie s  are r e p r e s e n te d  b y  
n u c le o t id e  u n it s  a n d  n u m b e r s  (C O S Y ) a n d  n u m b e r s  (R O E S Y )  
c o r r e sp o n d in g  to  th e  p o s it io n s  o f  th e  n u c le o t id e s  in  t h e  12 -m er  
se q u e n c e . W ea k  H l ' - H 2 '  a n d  H T - H 2 "  sca la r  c o u p lin g s  o f  18C  
n u c le o t id e  are  d e n o te d  w ith  a r ro w h ea d s  in  p a n e l A .
upfield than that of the other H2 protons in the 12-mer 
duplex (for comparison, see Table I). We suspect that the 
broadening is due to a unique local internal motion asso­
ciated with the 9T*16A bp, and the upfield shitft is due to 
the high propeller twist angle of this bp. A detailed ex­
planation of these features is given in the Discussion.
(4) Arom atic (P uH 8/PyH 6) to A rom atic Proton  
C onnectivities. The two-dimensional phase-sensitive 
NOESY (250-ms) expanded contour plot of the 12-mer 
duplex in D20-buffered solution demonstrating the NOE 
connectivities for the aromatic (PuH8/PyH6) to the aro­
matic protons is shown in Figure 6. The inter nucleotide






Figure 8. T w o -d im e n s io n a l  p h a s e -s e n s it iv e  N O E S Y  (2 5 0  m s)  
e x p a n d e d  c o n to u r  p lo t  o f  th e  1 2 -m e r  d u p le x  in  D 20  b u ffe r e d  
so lu t io n , p H  6 .8 5  a t  23  °C , d e m o n s tr a t in g  in tr a n u c le o t id e  N O E  
c o n n e c t iv it ie s  fo r  th e  P u H 8 /P y H 6  (6 .8 - 8 .4 0  p p m ) to  th e ir  ow n  
sugar H 3 ' an d  H 4' p ro ton s (4 .5 -5 .1  p p m ). T h e  N O E  c o n n e ctiv itie s  
b e tw e e n  th e  b a se  a n d  th e  H 3' p r o to n s  are d e p ic te d  b y  n u c le o tid e  
u n its , a n d  n u m b er s  corresp o n d  to  th e  p o s itio n s  o f  th e  n u c le o tid e s  
in  th e  12 -m er  se q u e n c e . T h e  N O E  c o n n e c t iv it ie s  for  th e  b a se  to  
th e  H 3 ' a n d  H 4 ' p r o to n s  o f  e a c h  n u c le o t id e  are  c o n n e c te d  w ith  
so lid  lin e s  for th e  u p p er stran d  a n d  w ith  b roken  lin es  for th e  low er  
s tr a n d  in  th e  1 2 -m er  se q u e n c e .
N O E  c o n n e c t i v i t i e s  b e t w e e n  a r o m a t i c  a n d  a r o m a t i c  r e s o ­
n a n c e s  a r e  d e n o t e d  f r o m  A  t o  S .  T h e  c r o s s - s t r a n d  a n d  
t h r o u g h - s t r a n d  N O E  c o n n e c t i v i t i e s  fo r  1 6 A H 2  t o  t h e  a d ­
e n in e  H 2  p r o t o n s  o f  1 0 A  ( c r o s s - p e a k  T ,  F ig u r e  6 )  a n d  1 7 A  
( c r o s s - p e a k  U ,  F ig u r e  6 )  w e r e  d e t e c t e d .  I t  is  q u i t e  u n u s u a l  
t h a t  a  c r o s s - s t r a n d  N O E  c o n n e c t i v i t y ,  s u c h  a s  t h a t  f o u n d  
b e t w e e n  1 6 A H 2  a n d  1 0 A H 2  ( c r o s s - p e a k  T ,  F ig u r e  6 ) ,  is  
f o u n d  t o  b e  v e r y  s t r o n g .  I n  a d d i t i o n ,  t h e  1 6 A H 8  a r o m a t ic  
p r o t o n  i s  s ig n i f i c a n t l y  b r o a d e n e d  r e l a t i v e  t o  o t h e r  a d e n in e  
H 8  p r o t o n s  ( e .g . ,  6 A , 1 0 A , a n d  1 7 A )  in  t h e  1 2 - m e r  d u p l e x .
(5) HI' to H2' and H2" Sugar Proton C ou p lin gs/ 
C onnectiv ities. T h e  t w o - d i m e n s i o n a l  p h a s e - s e n s i t i v e  
D Q F - C O S Y  a n d  R O E S Y  ( 1 0 0 - m s  s p i n - l o c k  t i m e )  e x ­
p a n d e d  c o n t o u r  p l o t s  o f  t h e  1 2 - m e r  d u p l e x  in  D 20  b u f f e r  
d e m o n s t r a t i n g  t h e  c o u p l i n g s / c o n n e c t i v i t i e s  b e t w e e n  t h e  
H I '  ( 5 .4 —6 .3  p p m )  a n d  t h e  H 2 '  a n d  H 2 "  s u g a r  p r o t o n s  
( 1 .8 —3 .0  p p m )  a r e  s h o w n  in  p a n e l s  A  a n d  B ,  r e s p e c t i v e l y ,  
o f  F ig u r e  7 .  T h e  H T - H 2 '  a n d  H T - H 2 "  t h r o u g h - b o n d  
s c a la r  c o u p l i n g s  a n d  t h r o u g h - s p a c e  c o n n e c t i v i t i e s  fo r  e a c h  
n u c l e o t i d e  a r e  l a b e l e d  w i t h  t h e  n u c l e o t i d e  n u m b e r  in  
F ig u r e  7 . T h e  a s s i g n m e n t s  o f  a l l  t h e  H 2 '  a n d  t h e  H 2 "  
p r o t o n s  w e r e  a c c o m p l i s h e d  b y  a n a l y z i n g  t h e  t w o - d i m e n ­
s io n a l  D Q F - C O S Y ,  R O E S Y , a n d  N O E S Y  d a t a  s e t s  o f  t h i s  
r e g i o n .  F o r  t h e  1 2 - m e r  d u p l e x ,  e x c e p t  fo r  t h e  t e r m i n a l  
n u c le o t id e s  1 2 G  a n d  2 4 C , t h e  H 2 "  r e s o n a n c e  is  c o n s i s t e n t l y  
d o w n f i e l d  f r o m  t h a t  o f  t h e  H 2 '  r e s o n a n c e  o n  e a c h  n u ­
c l e o t i d e  u n i t  (F ig u r e  7 A ) . F o r  2 4 C  t h e r e  i s  a n  o v e r la p ,  a n d  
fo r  1 2 G  t h e  H 2 "  r e s o n a n c e  i s  u p f i e l d  f r o m  t h a t  o f  t h e  H 2 '  
r e s o n a n c e .  T h i s  c h e m i c a l  s h i f t  r e v e r s a l  fo r  t e r m i n a l  n u ­
c le o t i d e s  t h a t  la c k  s t r u c t u r a l  c o n s t r a in t s  a t  o n e  e n d  i s  v e r y  
c o m m o n  in  B - f o r m  D N A  d u p l e x  a n d  i s  a n  i n d i c a t i o n  o f
r a p id  s u g a r  c o n f o r m a t io n a l  e q u i l ib r iu m  (24-26). F o r  t h e  
C 2 ' - e n d o  s u g a r  g e o m e t r y  in  a  B - f o r m  D N A ,  e a c h  H 2 '  a n d  
H 2 "  s u g a r  p r o t o n  i s  s c a la r  c o u p l e d  t o  t h e  H I '  p r o t o n  in  
t h e  s a m e  n u c l e o t i d e  u n i t ,  a n d  t h e  H T - H 2 '  c o u p l i n g  is  
n o r m a lly  s t r o n g e r  t h a n  t h a t  fo r  t h e  H T - H 2 " .  I n  a d d i t io n ,  
t h e  H T - H 2 "  t h r o u g h - s p a c e  c o n n e c t i v i t i e s  f o r  e a c h  n u ­
c l e o t i d e  a r e  a lw a y s  s t r o n g e r  t h a n  t h a t  o f  t h e  H T - H 2 ' ,  d u e  
t o  t h e  s h o r t e r  d i s t a n c e  b e t w e e n  H I '  a n d  H 2 "  p r o t o n s  (22, 
27). A s  a  r e la t iv e ly  s h o r t  s p in - lo c k  t i m e  w a s  a p p l ie d  in  t h i s  
R O E S Y  e x p e r im e n t ,  t h e  R O E  c o n n e c t i v i t y  o f  H I '  t o  H 2 '  
fo r  e a c h  n u c le o t i d e  u n i t  i s  t o o  w e a k  t o  b e  d e t e c t e d  (F ig u r e  
7 B ) .  F o r  1 8 C  t h e  H l ' - H 2 '  a n d  H T - H 2 "  c r o s s - p e a k s  a r e  
o f  s im ila r  a n d  w e a k  i n t e n s i t y  in  t h e  D Q F - C O S Y  e x p a n s io n  
( F ig u r e  7 A ) , a n d  t h e  H 3 ' - H 4 '  s c a la r  c o u p l i n g  in  t h e  C O S Y  
e x p a n s i o n  i s  q u i t e  s t r o n g  ( d a t a  n o t  s h o w n ) ;  b o t h  o b s e r ­
v a t i o n s  s u g g e s t  a n  a v e r a g e  C 3 ' - e n d o  s u g a r  g e o m e t r y  fo r  
t h i s  n u c l e o t i d e  u n i t  (27). F o r  a l l  t h e  r e m a i n i n g  n o n t e r ­
m i n a l  n u c l e o t i d e s  t h e  c o u p l i n g s / c o n n e c t i v i t i e s  a r e  in  a c ­
c o r d  w i t h  a n  a v e r a g e  C 2 ' - e n d o  s u g a r  c o n f o r m a t io n  (F ig u r e  
7 ) .
(6) Base to H3' and H4' Proton C onnectivities. T h e
2 5 0 - m s  N O E S Y  e x p a n d e d  c o n t o u r  p l o t  d i s p l a y i n g  N O E  
c o n n e c t i v i t i e s  fo r  a r o m a t i c  ( 7 . 1 - 8 . 3  p p m )  t o  t h e  H 3 '  a n d  
H 4 '  s u g a r  p r o t o n s  ( 4 .1 - 5 .1  p p m )  in  t h e  1 2 - m e r  d u p l e x  in  
D 20  i s  s h o w n  in  F ig u r e  8 . T h e  a s s i g n m e n t s  o f  t h e  H 3 '  
s u g a r  p r o t o n s  w e r e  a c c o m p l is h e d  b y  a n a ly z in g  t h e  H 2 ' - H 3 '  
t h r o u g h - b o n d  s c a la r  c o u p l i n g  in  t h e  C O S Y  ( d a t a  n o t  
s h o w n )  a n d  t h e  b a s e  t o  t h e  H 3 '  p r o t o n  t h r o u g h - s p a c e  
c o n n e c t i v i t i e s  i n  t h e  N O E S Y  e x p a n s i o n  ( F ig u r e  8 )  a n d  
c o n f i r m e d  b y  t h e  H 2 ' - H 3 '  a n d  t h e  H 2 " - H 3 '  N O E  c o n ­
n e c t i v i t i e s  i n  t h e  N O E S Y  e x p a n s i o n  ( d a t a  n o t  s h o w n ) .  
T h e  N O E  c o n n e c t i v i t i e s  b e t w e e n  t h e  b a s e  a n d  t h e  H 3 '  
p r o t o n s  a r e  d e p ic t e d  b y  n u c le o t i d e  u n i t s  a n d  n u m b e r s  t h a t  
c o r r e s p o n d  t o  t h e  p o s i t io n s  o f  t h e  n u c le o t i d e s  in  t h e  1 2 -m e r  
s e q u e n c e .  F o r  a  C 3 ' - e n d o  s u g a r  p u c k e r ,  t h e  d i s t a n c e  b e ­
t w e e n  t h e  b a s e  a n d  i t s  o w n  H 3 '  s u g a r  p r o t o n s  i s  s h o r t e r  
t h a n  t h e  c o r r e s p o n d in g  d i s t a n c e s  in  t h e  C 2 ' - e n d o  p u c k e r  
(28). T h e  N O E  c o n n e c t i v i t y  fo r  t h e  1 8 C H 6  b a s e  p r o t o n  
t o  i t s  o w n  H 3 '  s u g a r  p r o t o n  i s  s t r o n g e r  t h a n  f o r  1 8 C H 6  
p r o t o n  t o  i t ’s  o w n  H 2 '  p r o t o n  ( d a t a  n o t  s h o w n ) .  T h i s  
o b s e r v a t i o n  i s  a s s o c i a t e d  w i t h  a n  a v e r a g e  C 3 ' - e n d o  s u g a r  
g e o m e t r y  fo r  t h e  1 8 C  n u c l e o t i d e .  F o r  t h e  7 G  n u c l e o t i d e ,  
w h i c h  i s  t h e  c o m p l e m e n t a r y  p a r t n e r  o f  1 8 C , t h e  b a s e  t o  
t h e  H 3 '  s u g a r  p r o t o n s  o f  i t s  o w n  a n d  t o  i t s  5 '  n e ig h b o r  a r e  
o f  e q u a l  i n t e n s i t y ,  w h i c h  a l s o  s u g g e s t s  a n  u n u s u a l  s u g a r  
g e o m e t r y  fo r  t h i s  n u c l e o t i d e .  F o r  t h e  r e m a i n i n g  n u c l e o ­
t i d e s  t h e  N O E  c o n n e c t i v i t i e s  a r e  in  a c c o r d  w i t h  a n  a v e r a g e  
C 2 ' - e n d o  s u g a r  c o n f o r m a t i o n .
(7) HI' to H4' Sugar Proton C onnectiv ities. T h e  
t w o - d im e n s io n a l  p h a s e - s e n s i t iv e  R O E S Y  ( 1 0 0 - m s  s p in - lo c k  
t i m e )  e x p a n d e d  c o n t o u r  p l o t  o f  t h e  1 2 - m e r  d u p l e x  in  
D 20 - b u f f e r e d  s o l u t i o n  d e m o n s t r a t i n g  t h e  t h r o u g h - s p a c e  
c o n n e c t i v i t i e s  b e t w e e n  t h e  H I '  a n d  t h e  H 4 '  p r o t o n s  is  
s h o w n  in  F ig u r e  9 .  T h e  i n t r a n u c l e o t i d e  R O E  c o n n e c t i v ­
i t i e s  fo r  t h e  H I '  t o  t h e  H 4 '  s u g a r  p r o t o n s  a r e  d e p i c t e d  b y  
n u m b e r s  t h a t  c o r r e s p o n d  t o  t h e  p o s i t io n s  o f  t h e  n u c le o t id e s  
in  t h e  1 2 - m e r  s e q u e n c e .  E a c h  H 4 '  p r o t o n  a s s i g n m e n t ,  
w h i c h  i s  m a d e  f r o m  a n a ly z i n g  t h e  a r o m a t i c  t o  t h e  H 4 '  
t h r o u g h - s p a c e  c o u p l i n g  a n d  t h e  H 3 ' - H 4 '  s c a la r  c o u p l i n g ,  
i s  f u r t h e r  c o n f i r m e d  b y  d e t e c t i o n  o f  t h e  u n i q u e  H T - H 4 '  
R O E  c r o s s - p e a k s  in  t h i s  r e g io n .
A l l  o f  t h e  n o n e x c h a n g e a b l e  p r o t o n  c h e m i c a l  s h i f t  a s ­
s i g n m e n t s  ( e x c e p t  s o m e  o f  t h e  H 5 '  a n d  H 5 "  r e s o n a n c e s )  
o f  t h e  1 2 -m e r  d u p l e x  in  D 20 - b u f f e r e d  s o l u t io n  a t  2 3  ° C  a r e  
l i s t e d  in  T a b l e  I.
(B) A ssignm ents o f the E xchangeable P rotons in 
the 12-mer D uplex. T h e  o n e - d i m e n s i o n a l  e x c h a n g e a b l e  
p r o t o n  s p e c t r u m  ( 1 2 .5 - 1 4 . 0  p p m )  o f  t h e  1 2 - m e r  d u p l e x  in  
9 0 %  H 20  b u f f e r e d  s o l u t i o n ,  p H  6 .8 5  a t  2 3  ° C ,  i s  p l o t t e d
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F ig u r e  9 . T w o -d im e n s io n a l  p h a s e -s e n s it iv e  R O E S Y  (1 0 0 -m s  
s p in - lo c k  t im e ) e x p a n d e d  c o n to u r  p lo t  o f  th e  1 2 -m er  d u p le x  in  
H 20 - b u f fe r e d  s o lu t io n , p H  6 .8 5  a t  23  °C , d e m o n s tr a t in g  R O E  
co n n ectiv itie s  for th e  H I '  p ro ton s (5 .1 -6 .3  p p m ) to  th e  H 4 ' p ro ton s  
(3 .9 -4 .5  p p m ). T h e  R O E  c o n n e c tiv it ie s  b e tw e e n  th e  H I '  a n d  th e  
H 4' p r o to n s  are d e n o te d  w ith  n u c le o tid e  n u m b er s  co rr esp o n d in g  
to  th e  p o s it io n s  o f  th e  n u c le o t id e s  in  th e  1 2 -m er  se q u e n c e .
4g ,2g
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F ig u r e  10. T h e  o n e -d im e n s io n a l  e x c h a n g e a b le  p r o to n  N M R  
sp e c tr u m  (500  M H z, 11 .8^ 14 .8  p p m , e x p a n d e d  d o w n fie ld  reg ion )  
o f  th e  12 -m er  d u p le x  in  0 .5  m L  o f  90%  H 2O /1 0 %  D 20  b u ffe r e d  
so lu tio n  con ta in in g  10 m M  sod iu m  p h osp h ate  a n d  100 m M  sod iu m  
ch lo r id e , p H  6 .8 5  a t  23 °C . T h e  b r o a d e n in g  im in o  p r o to n  r e so ­
n a n c e  o f  th e  9 T -1 6 A  b a se  p a ir  is  d e n o te d  w ith  a n  a r ro w h ea d .
in Figure 10. A total of nine resolved exchangeable proton 
resonances (2G and 4G imino protons are overlapped) were 
identified in the region from 12.5 to 13.9 ppm. Five res­
onances were guanosine HI imino protons resonating be­
tween 12.5 and 13.2 ppm (terminal imino protons 1G and 
12G are missing at this temperature), and four were thy­
mine H3 imino protons resonating between 13.5 and 13.9 
ppm.
Exchangeable proton resonances of the 12-mer duplex 
in 90% H20  buffered solution have been assigned by an­
alyzing one-dimensional NOE difference (data not shown) 
and two-dimensional NOESY spectra (Figure 11). Ex­
panded contour plot of the two-dimensional NOESY 
spectrum (200 ms) of the 12-mer duplex in 90% H20  
displaying NOE connectivities for the DNA imino to imino 
protons is shown in Figure 11 A; the expanded contour plot
r  1
I














8 7 6 P P M
F i g u r e  11. E x p a n d e d  c o n to u r  p lo ts  o f  th e  tw o -d im e n s io n a l  
p h a se -se n s it iv e  N O E S Y  sp e c tr u m  (200  m s) o f  th e  12 -m er d u p le x  
in  0 .4 5  m L  o f  90%  H 2O /1 0 %  D 20  b u ffe r e d  so lu t io n  c o n ta in in g  
10 m M  so d iu m  p h o sp h a te  a n d  100 m M  so d iu m  c h lo r id e , p H  6 .85  
a t  2 3  °C . (A ) N O E  c r o ss -p e a k s  d e m o n s tr a t in g  in te r n u c le o t id e  
c o n n e c t iv it ie s  for D N A  im in o  (1 2 .3 -1 3 .9  p p m ) to  im in o  p r o to n s  
(1 2 .3 -1 3 .9  p p m ) a n d  (B ) N O E  c r o ss -p e a k s  d e m o n s tr a t in g  c o n ­
n e c t iv it ie s  for  th e  im in o  (1 2 .3 -1 3 .9  p p m ) to  a r o m a tic  a n d  a m in o  
(5 .6 -8 .6  p p m ) p ro to n s. T h e  c ro ss-p ea k s A -C  (p a n e l A ) a n d  D - D '  
(p a n e l B ) are  la b e le d  a s  fo llo w s: (A ) 4 G ( im in o ) -5 G ( im in o ) ;  (B )  
5 G ( im in o ) -1 9 T ( im in o ) ;  (C ) 7 G ( im in o ) - 8 T ( im in o )  a n d  7G -  
( im in o O -1 9 T (im in o );  (D ) 5 G ( im in o ) -2 0 C (N H 4 b); (E ) 5 G (im i-  
n o )-6 A (H 2 );  (F ) 5 G (im in o )-2 0 C (N H 4 e); (G ) 5 G (im in o )-2 0 C (H 5 );  
(H ) 7 G ( im in o ) -1 8 C (N H 4 b); (I) 7 G ( im in o ) -6 A (H 2 );  (J ) 7 G (im i-  
n o ) -1 7 A (H 2 );  (K ) 7 G (im in o )-1 8 C (N H 4 e); (L ) l lG ( im in o ) - 1 8 4 C -  
(N H 4 b); (M ) l lG ( im in o ) -1 4 C (N H 4 e); (N ) 2 2 G ( im in o ) -3 C (N H 4 b) 
a n d  2 G ( im in o ) -2 3 C (N H 4 b); (O ) 2 2 G ( im in o ) -3 C (N H 4 e); (P )  2G - 
( i m in o ) - 2 3 C ( N H 4 e); (Q ) 4 G ( i m i n o ) - 2 lC ( N H 4 b); (R ) 20 C -  
(N H 4 b) - 2 l C ( N H 4 b); (S ) 4 G ( im in o ) - 2 lC ( N H 4 e); (T ) 1 5 T (im i-  
n o )-1 0 A (H 2 );  (U ) 1 5 T (im in o )-1 6 A (H 2 );  (V ) 9 T ( im in o )-1 7 A (H 2 );  
(W ) 9 T ( im in o ) -1 6 A (H 2 );  (X ) 8 T ( im in o ) -1 7 A (H 2 ) ;  (Y ) 8 T ( im i-  
n o )-1 6 A (H 2 );  (Z) 1 9 T (im in o )-6 A (H 2 );  (A ') 4 G (im in o )-2 1 C (H 5 );  
(B ') 9 T ( im in o )-1 0 A (H 2 );  (CO 1 9 T ( im in o ) -2 0 C (N H 4 b); (D ') 19 T -  
( im in o ) -2 0 C (N H 4 e).
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Table II. C hem ical S h ift A ssignm ents (in ppm) o f the E xchangeable Protons in the 12-mer D uplex at Room T em perature0
base pair
chemical shifts, ppm
Thy-H3 Gua-Hl Ade-H6 Ade-H6 Cyt-H4c Cyt-H4d
G1-C24 12.986 NAe NA
G2-C23 13.02 8.32 6.52
C3-G22 12.99 8.34 6.35
G4-C21 13.02 8.51 6.74
G5-C20 12.64 8.28 6.67
A6-T19 13.75 NA NA
G7-C18 12.81 7.75' 6.54
T8-A17 13.73 NA NA
T9-A16 13.68 NA NA
A10T15 13.61 NA NA
G11-C14 12.85 8.42 6.96
G12-C13 13.036 NA NA
0 Sample was dissolved in 0.45 mL of 90% water buffer containing 0.1 M NaCl and 10 mM sodium phosphate, pH 6.85 at 23 °C. 
b Chemical shifts were determined at 10 °C. c Hydrogen-bonded amino proton. d Exposed (non-hydrogen-bonded) amino proton. eNA, not 
assigned at this temperature. ^Upfield-shifted resonance.
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F ig u re  12. One-dimensional proton-decoupling 202.44-MHz 
phosphorus NMR spectrum (-0.95 to -1.90 ppm) of the 12-mer 
duplex in 0.5 mL of D20-buffered solution containing 10 mM 
sodium phosphate and 100 mM sodium chloride, pH 6.85 at 23 
°C.
of the imino to base and amino protons is shown in Figure 
11B. The NOE connectivities between the thymine imino 
and the adenine H2 protons of all four A*T base pairs in 
the 12-mer duplex were identified (cross-peaks Z, X, W, 
and T for 19T-6A, 8T-17A, 9T*16A, and 15T-10A, respec­
tively, in Figure 11B). The nonterminal guanosine imino 
protons were assigned on the basis of their NOE connec­
tivities to cytosine hydrogen-bonded and non-hydrogen- 
bonded amino protons, which again display NOE con­
nectivities to cytosine H5 protons in the G*C base pairs. 
For example, the 5G imino proton exhibited NOE con­
nectivities to the hydrogen-bonded and non-hydrogen- 
bonded amino proton of 20C (cross-peaks D and F, re­
spectively, in Figure 11B). Similar NOE connectivities 
were identified for the remaining nonterminal imino pro­
tons (see Figure 11B). The guanosine imino protons in the 
duplex can also be assigned by tracing NOE connectivities 
to the adjacent imino protons in both the 5' and 3' di­
rections (Figure 11 A). For example, the imino proton of 
5G exhibited NOE connectivities to the imino protons of 
4G (cross-peak A, Figure 11 A) in the 5' direction and to
y -2 0
6 - 7 1-17
» -1 0 13-14$-6 15-16
.21-22r-ii 3-4
23-2411-12 1 -J
5 0 4 8 4 . 6 4 .  4 4 .  2 4 .  0
F igu re  13. Two-dimensional heteronuclear phosphorus-detected 
31P -1H phase-sensitive COSY contour plot of the 12-mer duplex 
in 0.5 mL of D20  buffer containing 10 mM sodium phosphate and 
100 mM sodium chloride, pH 6.85 at 23 °C.
19T (cross-peak B, Figure 11 A) in the 3' direction.
The chemical shifts of the imino and amino exchange­
able protons of the 12-mer duplex in 90% H20  buffered 
solution at 23 °C are given in Table II. The assignments 
of the imino proton resonances of the 12-mer duplex are 
also summarized in Figure 10. Significantly, the imino 
proton belonging to the 9T-16A base pair is broadened 
(Figure 10, denoted with arrowhead), and the hydrogen- 
bonded amino proton of 18C is unusually upfield shifted 
(Table II, denoted with underline). This signal is at least 
0.5 ppm further upfield than that for other hydrogen- 
bonded amino protons of cytosines in the 12-mer duplex, 
suggestive of a reduction in the hydrogen bonding strength 
within this bp.
(C) Assignments of the 31P NMR Resonance Signals 
in the 12-mer Duplex. The one-dimensional 202.44-MHz 
proton-decoupled phosphorus spectrum of the 12-mer 
duplex in D20-buffered solution at pH 6.85 is plotted in 
Figure 12. Twenty-two phosphorus resonances are dis­
persed between -1.11 and -1.71 ppm relative to external 
85% H3P 0 4. The phosphorus resonance signals have been 
assigned by analyzing the two-dimensional heteronuclear 
phosphorus-detected 31P -1H relay COSY data sets, and the 
results in contour plot are shown in Figure 13. Each 
phosphorus resonance is scalar coupled to the H3' protons 
in the 5' direction and to the H4', H5', and H5" protons 
in the 3' direction. On the basis of the known assignments 
of these proton resonances (see Table I), the phosphorus 
resonance signals can be assigned. The chemical shifts of 
the phosphorus resonances in the 12-mer duplex are given 
in Table III. The phosphorus resonances 2Gp3C and
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Table III. C hem ical S h ift A ssignm ents (in ppm) o f the  
P hosphorus R esonance S ign als o f the 12-mer D uplex  at 








G1-G2 -1.10 C13-C14 -1.28
G2-C3 -1.39 C14-T15 -1.49
C3-G4 -1.24 T15-A16 -1.26
G4-G5 -1.15 A16-A17 -1.38
G5-A6 -1.26 A17-C18 -1.24
A6-G7 -1.36 C18-T19 -1.62
G7-T8 -1.58 T19-C20 -1.54
T8-T9 -1.15 C20-C21 -1.28
T9-A10 -1.36 C21-G22 -1.18
A10-G11 -1.23 G22-C23 -1.71
G11-G12 -1.11 C23-C24 -1.13
0 Phosphorus chemical shifts were referenced relative to external 
85% H3PO4 in D20. Sample was dissolved in 0.5 mL of D20-buff- 
ered solution containing 0.1 M sodium chloride and 10 mM sodium 
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Purine-purine Steric Clash
Figure 14. Phosphorus chemical shift vs position in 12-mer 
diagram for the duplex. Solid line connects the 31P chemical shifts 
for the phosphate resonances from the 5' to 3' end of the upper 
strand (from 1G to 12G). Broken lines connect the 31P chemical 
shifts for the complementary strand from the 3' to 5' direction 
(from 24C to 13C). Arrows indicate the positions of purine-purine 
steric clash, and arrowheads denote the unusual upfield-shifted 
phosphorus resonances in the 12-mer duplex.
22Gp23C, which are associated with the 5'-end region of 
the upper strand and the 3'-end region of the lower strand 
in the 12-mer duplex, exhibited upfield 31P chemical shifts. 
This is expected because these two phosphate resonance 
signals are affected by the nearby purine-purine steric 
clash (the locations of purine-purine steric clash are de­
noted with arrows in Figure 14) (29). The two phosphorus 
resonances, 7Gp8T and 18Cpl9T, surrounding the 5'TAA 
and 5'CTC junction also display upfield chemical shifts. 
These upfield shifts cannot be explained by a purine- 
purine steric clash and are suggestive of sequence-de­
pendent DNA conformational deviations at these locations 
(see later).
(D) H ydroxyl-Radical Footprinting. The results of 
hydroxyl-radical footprinting of the 21-mer sequence of 
SV 40 DNA, which contains the 12-mer duplex used for 
this high-field NMR study, are shown in Figure 15 and 
exhibit a pattern of inhibition of cleavage across the minor 
groove to the 5' side of the covalent attachment site on 
both strands of DNA. This result suggests that the A*T- 
rich region within the 12-mer duplex exhibits an unusual 
conformation, and the minor groove is somewhat narrowed 
at the junction between the 5'TAA and 5'CTC segments.
3-G
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Figure 15. Laser densitometer tracings of hydroxyl-radical 
footp rin ting  of the 21-mer duplex sequ en ce d- 
(5'TGGGCGGAGTTA*GGGGCGGGA3')-d(5'CCATCCCG- 
CCCCTAACTCCGC3') [where * denotes the (+)-CC-1065 
modification site] that contains the 12-mer duplex for high-field 
NMR studies. (A) The upper strand, (B) the lower strand, and 
(C) the summary scheme of the hydroxyl-radical cleavage in the 
12-mer duplex, where (1) indicates the inhibition of hydroxyl- 
radical cleavage.
A-tracts have also been demonstrated to produce an un­
dulation in the intensity of hydroxyl-radical cleavage of 
the backbone of DNA, which is consistent with a com­
pression of the minor groove at the 3' end of the tract (30).
Discussion
(A) C hoice o f the 12-mer D u p lex  for D eta iled  
Structural Studies. During our initial studies designed 
to determine the DNA sequence specificity of (+)-CC-1065, 
we had deliberately chosen to study the early promoter 
region of SV40 DNA as a biologically interesting and 
relevant DNA target sequence (11). Within this region 
there are two equivalent (+)-CC-1065 highly reactive ad­
enine-containing sequences 5'AGTTA* (where * denotes 
the covalent attachment site) that occur as part of the two 
perfect 21 bp repeats (Scheme I). These repeats are part 
of the region of 63 bps containing the six GC boxes that 
are binding sites for the transcription factor Spl.
(B) O rigin o f the D N A  Sequence S p ec ific ity  of 
(+)-CC-1065. In previous publications (13,14,17), we have 
suggested that the primary molecular basis responsible for 
the sequence selectivity of (+)-CC-1065 is a sequence-de­
pendent catalytic activation and/or a sequence-dependent 
conformational flexibility.
Using NMR in combination with 170-labeled water 
and phosphates on this same 12-mer duplex covalently 
modified with (+)-CC-1065, we have recently demonstrated 
the critical involvement of a bridging water molecule be­
tween the phenolic proton on the alkylating subunit of 
(+)-CC-1065 and the anionic oxygen in the phosphate 
between the 16A and 17A step on the noncovalently 
modified strand of DNA (20). In addition, a second or­
dered water molecule associated with the hydrogen-bonded 
amino protons on N6 of the covalently modified adenine 
was also identified. This structure has important impli­
cations for catalytic activation of the covalent reaction 
between (+)-CC-1065 and the DNA duplex and, conse­
quently, the molecular basis for sequence selective recog­
nition of DNA by the alkylating subunit of (+)-CC-1065. 
We predict that any DNA sequence that lacks such flex­
ibility and/or ability to position an ordered water molecule
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between a phosphate group on the noncovalently modified 
strand and the H8 phenolic proton of the A subunit will 
show low reactivity toward (+)-CC-1065.
The sequence of the 12-mer used in this study did not 
provide any immediate clues as to whether conformational 
flexibility might also be a component partially responsible 
for the high reactivity of (+)-CC-1065 with this sequence. 
However, the reactivity of 5'AAAAA* sequences toward 
(+)-CC-1065 (15) and the experimental finding that DNA 
bending is a consequence of covalent bonding to DNA (18) 
were suggestive of the involvement of DNA bending in the 
sequence recognition by (+)-CC-1065. Further evidence 
for the importance of an A-tract-like bending in the 
structure of the (+)-CC-1065-DNA adduct was obtained 
by high-field NMR, gel electrophoresis, and hydrpxyl- 
radical footprinting (18). In the 12-mer sequence described 
here, a bending of 17-22° was found following the covalent 
adduct formation with (+)-CC-1065, and the locus of 
bending was determined to be at the 8T to 9T step (18). 
If a propensity to bend is a component of the DNA se­
quence recognition by (+)-CC-1065, then the 12-mer se­
quence described here, which has a very high reactivity 
toward (+)-CC-1065, might be expected to possess an in­
trinsic capability to form a bent DNA structure. However, 
nondenaturing gel electrophoresis did not reveal any bent 
structure.3 Therefore, the purpose of this investigation was 
not only to determine the general conformational features 
of this 12-mer duplex, but also to determine if any evidence 
existed for this sequence to have a propensity to form a 
bent DNA structure and/or intrinsic conformational 
flexibility.
A consensus sequence analysis of the (+)-CC-1065 
bonding sites on DNA reveals that 5TuNTTA* and 
5'AAAAA* are highly specific (15). It has been demon­
strated by means of gel electrophoresis and electron mi­
croscopy that DNA sequences containing (A)„ tracts, where 
n > 3, are bent (31-36). In addition, two-dimensional 
NMR experiments on these bent DNA sequences reveal 
a compression of the minor groove from the 5' to 3' side 
of the (A)„ tract (16, 26, 37-39). Since both 5'PuNTTA 
and 5'AAAAA sequences are recognized by (+)-CC-1065, 
they might share a common sequence recognition mecha­
nism through which sequence selectivity can be achieved 
by the covalent reaction. The transient bending of the 
DNA duplex might be expected to stabilize the transition 
state for the covalent reaction; in another words, the re­
action of (+)-CC-1065 with DNA would entrap the intrinsic 
transient bend in DNA to form a drug-DNA covalent 
adduct and would be at least partially responsible for se­
quence selectivity of (+)-CC-1065. In this transition state 
for the covalent reaction, the formation of a noncovalent 
drug-DNA complex will bring the N3 of adenine within 
covalent bond distance of the reactive cyclopropyl moiety 
on the A subunit of (+)-CC-1065, and then covalent 
bonding will take place. This idea gains credibility as we 
demonstrate that this 12-mer duplex, which contains the 
highly reactive 5'AGTTA sequence, has both internal 
motion and transient kinks.
(C) General Features o f the 12-mer D uplex. Gen­
erally, the two-dimensional proton NMR data for the 12- 
mer duplex in aqueous solution is consistent with a 
structure within the broad family of B-form DNA, and the 
24 nucleotide units are all in the anti base orientation 
throughout. The characteristic internucleotide and in­
tranucleotide NOE connectivities and intranucleotide J  
coupling of a B-type DNA duplex are detected. However, 
examination of the data sets for this 12-mer duplex also 
reveals anomalous structural deviations such as unusual 
sugar geometries, upfield chemical shifts, and propeller
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twisting of the A-T bases, which are reminiscent of an (A)n 
tract DNA. These observations might provide significant 
insight into why this particular 12-mer duplex is a highly 
reactive bonding sequence for (+)-CC-1065.
The strategies to derive information about the sugar 
pucker geometry from the two-dimensional COSY spec­
trum have been previously reported (27). Since the ex­
perimental digital resolution along the f l  and /2 axes of 
the 2D COSY experiment is limited, the COSY cross-peak 
intensities are approximately proportional to the magni­
tudes of the coupling constants (JaP) between two nuclei. 
The sugar geometries for 13C and 24C nucleotides located 
at the ends of the 12-mer duplex are in equilibration be­
tween C2'-endo and C3'-endo sugar geometry. This con­
clusion is based upon the detection of strong H2"-H3' 
(data not shown), H1-H2', and Hl'-H2" (Figure 7A) scalar 
couplings in the COSY expansions. For the 12G nucleo­
tide, the COSY expansion (Figure 7A) displays equal in­
tensity for Hl'-H2' and Hl'-H2" couplings and a strong 
H3'-H4' coupling (data not shown). This suggests that the 
12G nucleotide sugar geometry is in the range of Ol'-endo 
geometry.
For the 18C nucleotide, both the DQF-COSY (Figure 
7A) and COSY (data not shown) exhibit weak Hl'-H2' and 
H l'-H2" scalar couplings, as well as a strong H3'-H4' 
coupling (data not shown). These data suggest that the 
sugar geometry for the 18C nucleotide is in the neigh­
borhood of C3'-endo. This average C3'-endo sugar con­
formation for 18C is independently confirmed by detecting 
a stronger intemucleotide NOE connectivity for the 18CH6 
base proton to the HI' proton of its 5' neighbor (17A) than 
the intranucleotide NOE connectivity to its own HI' sugar 
proton in a 75-ms NOESY data set (data not shown). In 
addition, the H6 proton of 18C displays a stronger in­
tranucleotide NOE to its own H3' sugar proton than to its 
own H2' proton (data not shown). Indeed, for an A-form 
DNA with C3'-endo sugar geometry, the PuH8/PyH6 base 
protons are expected to display much stronger inter­
nucleotide NOEs to the HI' sugar protons of their 5' 
neighbor than the intranucleotide NOEs to their own HI' 
protons and stronger intranucleotide NOEs to their own 
H3' sugar proton than to their own H2' proton (39). The 
hydrogen-bonded amino proton of 18C is extremely upfield 
shifted to 7.75 ppm (Table II). This resonance is at least 
0.53 ppm more upfield than those for other nonterminal 
cytosine hydrogen-bonded amino protons in the 12-mer 
duplex. This upfield-shifted resonance is associated with 
a reduction of the hydrogen-bond strength between the 
hydrogen-bonded C4-NH2 of cytosine and 0 4  of thymine 
in the 7G*18C base pair, which is again due to the peculiar 
conformation at the junction between 5'TAA and 5'CTC 
(Scheme II).
In the case of the 7G nucleotide, we detected a strong 
scalar coupling for H3'-H4' in the COSY spectrum (data 
not shown), and the NOE connectivity for the 7GH8 base 
proton to the HI' sugar proton of its 5' neighbor 6A is 
stronger than to its own HI' proton (Figure 4A). In ad­
dition, equal NOE intensities for 7GH8 to 7GH3' and 
7GH8 to 6AH3' were detected (Figure 8). On the basis of 
the above data, the sugar geometry for 7G nucleotide is 
proposed to be in between Ol'-endo and C3'-endo geom­
etry. This deviation from C2'-endo sugar geometry for the 
nonterminal nucleotides is also very unusual for a DNA 
duplex in aqueous solution.
The H2 proton of 16A was found to have an unusual 
upfield chemical shift of 7.04 ppm, which is at least 0.40 
ppm further upfield than those for other adenine H2 
protons in the 12-mer duplex (see Table I). This upfield 
chemical shift is most likely due to the ring current
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Figure 16. One-dimensional proton NMR spectra (500 MHz, 
6.90-8.30 ppm, expanded downfield region) of (A) the (+)-CC- 
1065-12-mer duplex adduct in 0.5 mL of D20-buffered solution 
containing 10 mM sodium phosphate and 100 mM sodium 
chloride, pH 6.85 at room temperature, and the 12-mer duplex 
in 0.5 mL of D20-buffered solution containing 10 mM sodium 
phosphate and 100 mM sodium chloride, pH 6.85 (B) at room 
temperature, (C) at 20 °C, and (D) at 15 °C. The H2 protons 
of adenosines are labeled with nucleotide numbers, and the H8  
protons are labeled with nucleotide units and numbers corre­
sponding to the positions in the 1 2 -mer duplex. The broadened 
16AH8 and 16AH2 resonances at different temperatures are 
denoted with arrowheads.
s h i e l d i n g  e f f e c t  r e s u l t i n g  f r o m  b a s e - b a s e  s t a c k i n g  o f  t h e  
a d j a c e n t  n u c le o t id e s .  T h e  r e s u l t s  o f  t h e  N O E S Y  r e s tr a in e d  
m o le c u la r  m e c h a n ic s  a n d  d y n a m i c s  c a lc u la t io n s  ( s e e  la te r )  
o n  t h e  1 2 -m e r  d u p l e x  i n d ic a t e  t h a t  i t  i s  t h e  a d e n in e  ( 1 0 A )  
l o c a t e d  t o  t h e  5 '  s id e  o f  1 6 A  o n  t h e  c o m p l e m e n t a r y  s t r a n d  
t h a t  is  t h e  l ik e ly  c a n d id a t e  fo r  c a u s in g  t h i s  u n u s u a l  u p f i e l d  
c h e m ic a l  s h i f t  o f  t h e  1 6 A H 2  r e s o n a n c e .
(D ) E vidence for an  U n u su a l S tru c tu re  w ith in  th e  
(+)-CC-1065 B in d in g  S eq u en ce  in  th e  12-mer D u p lex  
W hich  Is S u g g e s t iv e  o f  a B en t D N A  S tr u c tu r e . (1) 
H yd roxy l-R ad ica l F o o tp r in tin g . T h e  r e s u l t s  o f  h y ­
d r o x y l - r a d i c a l  f o o t p r i n t i n g  o f  t h e  2 1 - m e r  s e q u e n c e  t h a t  
c o n t a i n s  t h e  1 2 - m e r  d u p l e x  f o r  t h i s  N M R  s t u d y  a r e  c o n ­
s i s t e n t  w i t h  a n  u n u s u a l  c o n f o r m a t io n  w i t h i n  t h e  A - T - r ic h  
r e g io n  a n d  e s p e c i a l l y  a t  t h e  j u n c t i o n  b e t w e e n  5 ' T A A  a n d  
5 'C T C  ( F ig u r e  1 5 ) .  T h e  i n h i b i t i o n  o f  h y d r o x y l - r a d i c a l  
f o o t p r i n t i n g  c l e a v a g e  o b s e r v e d  fo r  t h i s  2 1 - m e r  s e q u e n c e  
i n d i c a t e s  t h e  m i n o r  g r o o v e  i s  n a r r o w e d  a t  t h e  j u n c t i o n  
b e t w e e n  5 ' T A A  a n d  5 'C T C  s e g m e n t s .
(2) P roton  and 31P  N M R  E xp erim en ts, (a) U n iq u e  
In tern a l M otion. T h e  o n e - d i m e n s i o n a l  p r o t o n  N M R  
s p e c t r u m  e x p a n d e d  d o w n f ie ld  r e g io n  ( 7 . 0 - 8 .4  p p m )  o f  t h e  
1 2 -m e r  d u p le x  in  D 20  d i s p la y s  a  b r o a d  1 6 A H 8  b a s e  p r o t o n ,  
a s  w e l l  a s  a  b r o a d  a n d  u p f i e l d - s h i f t e d  1 6 A H 2  p r o t o n  ( s e e  
F ig u r e  1 6 B - D ;  r e s o n a n c e  s i g n a l s  d e n o t e d  w i t h  a r r o w ­
h e a d s ) .  F o r  t h e  e x c h a n g e a b l e  p r o t o n s ,  t h e  i m i n o  p r o t o n  
b e lo n g in g  t o  t h e  9 T - 1 6 A  b a s e  p a ir  i s  a l s o  s i g n i f i c a n t l y  
b r o a d e n e d  r e l a t i v e  t o  t h a t  o f  t h e  o t h e r  t h y m i n e  i m i n o  
p r o t o n s  in  t h e  1 2 - m e r  d u p l e x  ( s e e  F ig u r e  1 0 ; r e s o n a n c e  
s ig n a l  d e n o t e d  w i t h  a r r o w h e a d ) .  W e  p r o p o s e  t h a t  t h i s  
s ig n a l  b r o a d e n in g  i s  d u e  t o  a  u n i q u e  i n t e r n a l  m o t i o n  
c h a r a c t e r iz e d  b y  a  r a p id  lo c a l  c o n f o r m a t io n a l  e q u i l ib r iu m  
( a r o u n d  1 6 A )  b e t w e e n  m i c r o s t a t e s  o f  t h e  1 2 - m e r  d u p l e x
Scheme II. Summary Figure of the Similarities in 
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in  a q u e o u s  s o l u t i o n  a t  r o o m  t e m p e r a t u r e  (40). F o r  c o m ­
p a r i s o n ,  t h e  e x p a n d e d  d o w n f i e l d  r e g i o n  o f  t h e  i d e n t i c a l  
1 2 - m e r  s a m p l e  a t  2 0  a n d  1 5  ° C  i s  p l o t t e d  in  F ig u r e  1 6 , 
p a r t s  C  a n d  D ,  r e s p e c t i v e l y .  A t  l o w e r  t e m p e r a t u r e s ,  t h e  
in t e r n a l  m o t io n  is  d i m i n i s h e d  s u c h  t h a t  t h e  1 6 A H 8  p r o t o n  
i s  o f  t h e  s a m e  l in e  w i d t h  a s  t h a t  fo r  t h e  o t h e r  a d e n in e  H 8  
p r o t o n s  in  t h e  1 2 - m e r  s e q u e n c e .  A l t h o u g h  t h e  r a p id  lo c a l  
c o n f o r m a t io n a l  e q u i l ib r iu m  b e t w e e n  m i c r o s t a t e s  w i l l  a f f e c t  
t h e  l in e  w i d t h  o f  t h e  r e s o n a n c e s ,  t h e  o v e r a l l  p a t t e r n  o f  t h e  
N O E  c o n n e c t i v i t i e s  fo r  t h e  D N A  d u p l e x  i s  n o t  e x p e c t e d  
t o  c h a n g e  (3 9 ) .  I n d e e d ,  t h e  s u g a r  g e o m e t r y  fo r  1 6 A  is  s t i l l  
w i t h in  t h e  n e ig h b o r h o o d  o f  a  C 2 ' - e n d o  g e o m e t r y  a n d  t h u s  
i s  n o t  a f f e c t e d  b y  t h e  lo c a l  c o n f o r m a t io n a l  e q u i l ib r iu m . W e  
p r o p o s e  t h a t  t h i s  r a p id  l o c a l  c o n f o r m a t i o n a l  e q u i l ib r iu m  
b e t w e e n  m i c r o s t a t e s ,  o r  s e q u e n c e - d e p e n d e n t  c o n f o r m a ­
t i o n a l  f l e x i b i l i t y ,  m a y  b e  i m p o r t a n t  fo r  t h e  s e q u e n c e - s p e ­
c i f i c  r e c o g n i t i o n  o f  t h i s  1 2 - m e r  d u p l e x  b y  ( + ) - C C - 1 0 6 5 .  
S i g n i f i c a n t l y ,  u p o n  a d d u c t  f o r m a t i o n  w i t h  ( + ) - C C - 1 0 6 5 ,  
t h e  H 8  a n d  H 2  p r o t o n s  o f  1 6 A  n u c l e o t i d e  in  t h e  ( + ) - C C -  
1 0 6 5 - 1 2 - m e r  d u p l e x  a d d u c t  b e c o m e  s i g n i f i c a n t l y  s h a r p e r  
( F ig u r e  1 6 A ) ,  a s  w o u l d  b e  e x p e c t e d  i f  t h e  c o n f o r m a t i o n  
f l e x ib i l i t y  p r o p o s e d  t o  b e  r e q u ir e d  fo r  t h e  c o v a l e n t  r e a c t io n  
i s  l o s t  f o l lo w in g  t h e  a d d u c t  f o r m a t i o n . 2
(b) P h o sp h o ru s C h em ica l S h if ts . I t  h a s  b e e n  p r e ­
v i o u s l y  s h o w n  t h a t  t h e  c h e m ic a l  s h i f t s  o f  t h e  31P  r e s o n a n c e  
s i g n a l s  o f  D N A  d u p l e x e s  v a r y  i n  r e s p o n s e  t o  l o c a l  s e ­
q u e n c e - s p e c i f i c  d i s t o r t i o n s  in  t h e  d u p l e x  g e o m e t r y  (41). 
T h e  a r r o w s  in  F ig u r e  1 4  i n d i c a t e  t w o  5 ' P y - P u 3 '  s t e p s  
( p u r i n e - p u r i n e  s t e r i c  c la s h )  in  t h e  1 2 - m e r  d u p l e x .  T h e  
c h e m i c a l  s h i f t s  o f  t h e s e  r e s o n a n c e  s i g n a l s  t h a t  a r e  a s s o ­
c i a t e d  w i t h  t h e s e  s t e p s  in  t h e  1 2 - m e r  d u p l e x  f o l lo w  t h e  
d o w n f i e l d  s h i f t  d i r e c t i o n  a s  p r e d i c t e d  o n  t h e  b a s i s  o f  
p r e v io u s  31P  N M R  s t u d i e s  o n  s y n t h e t i c  o l ig o m e r s  (29). I n  
a d d i t i o n ,  t h e  t w o  31P  N M R  r e s o n a n c e  s ig n a l s  ( 7 G p 8 T  a n d  
1 8 C p l 9 T )  t h a t  a r e  in  p r o x i m i t y  t o  t h e  5 ' T A A  a n d  5 'C T C  
j u n c t i o n  ( F ig u r e  1 4 )  a l s o  d i s p l a y  u n u s u a l  u p f i e l d  c h e m ic a l  
s h i f t s ,  s u g g e s t i n g  t h a t  l o c a l  s e q u e n c e - s p e c i f i c  d i s t o r t i o n s  
in  t h e  d u p l e x  g e o m e t r y  e x i s t  in  t h i s  j u n c t i o n  r e g io n .  T h i s  
r e s u l t  is  a l s o  c o n s i s t e n t  w i t h  a n  u n u s u a l  l o c a l  s t r u c t u r a l  
d i s t o r t io n  a t  t h e  5 ' A C / G T  s t e p  ( s e e  l a t e r )  t h a t  i s  d e m o n ­
s t r a t e d  in d e p e n d e n t ly  b y  h y d r o x y l- r a d ic a l  f o o t p r in t in g  a n d  
p r o t o n  t w o - d im e n s i o n a l  N O E S Y  e x p e r im e n t s  ( s e e  b e f o r e ) .
(c) P ropeller  T w istin g  o f  th e  A-T B ase  P a irs. I t  h a s  
b e e n  d e m o n s t r a t e d  b y  t w o - d im e n s i o n a l  N M R  (16, 26) a n d  
X - r a y  d i f f r a c t i o n  s t u d i e s  (42, 43) t h a t  t h e  A - T - r ic h  r e g io n  
o f  a n  ( A ) „ - t r a c t  D N A  is  h i g h l y  p r o p e l l e r  t w i s t e d .  T h e  
A -T -r ic h  r e g io n  o f  t h e  1 2 -m e r  d u p l e x  w a s  d i s c o v e r e d  t o  b e  
p r o p e l l e r  t w i s t e d  b y  m o n i t o r i n g  t h e  N O E  c o n n e c t i v i t i e s
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between adenosine H2 protons of adjacent base pairs (44). 
The NOE connectivities between 17AH2 and 16AH2 
(cross-peaks U, Figure 6) are significantly weaker than 
between 16AH2 and 10AH2 (cross-peaks T, Figure 6). 
This indicates that the distance from the (dT8-dT9)« 
(dA16-dA17) step to the (dT9-dA10)*(dT15-dA16) step is 
reduced. The reduction of distance reflects the conse­
quences of base-pair propeller twisting for the right-handed 
DNA duplex (44), in which the distance between H2 
protons on adjacent adenosines decreases in the order 
(dT8-dT9).(dA16-dA17) >  (dT9-dA10)*(dT15-dA16).
(d) U p h eld  C hem ical S h ifts . The chemical shifts of 
the nonexchangeable proton resonance signals of the 12- 
mer duplex in D20  solution at room temperature are listed 
in Table I. The resonance signal of the H5 base proton 
of 18C occurs at 5.10 ppm, which is significantly upfield 
to the expected position and is almost within the region 
normally associated with H3' sugar protons.4 A ring 
current shielding effect resulting from the base-base 
stacking of the adjacent nucleotides is the most likely cause 
for such a large upfield chemical shift (45). Since 19T is 
located on the 3' side of 18C and is further away from the 
H5 base proton of 18C in right-handed DNA duplex, this 
base is unlikely to be responsible for this upfield shift. 
This leaves 17A, which is on the 5' side of 18C, as the 
remaining candidate that could produce such a strong 
intrinsic ring current effect, and this base is therefore likely 
to produce the observed upfield chemical shift of the 
18CH5 proton. A strong base-base NOE connectivity 
between the 18CH6 and 17AH8 protons (cross-peak 0 ,  
Figure 6), but only a weak NOE connectivity between H6 
base protons of 18C and 19T (cross-peak N, Figure 6), was 
observed in the 2D NOESY expansion. Therefore, these 
NOESY data are also consistent with the notion that the 
17A nucleotide located on the 5' direction of 18C produces 
a greater base-base stacking and thus is responsible for 
the upfield chemical shift of the 18CH5 proton. We sug­
gest that this unusual upfield-shifted resonance signal for 
18CH5 and the proposed average C3'-endo sugar geometry 
for 18C nucleotide on the 12-mer duplex are connected 
with the peculiar conformation at the junction between the 
5'TAA and 5'CTC segments (see later). A similar up- 
field-shifted resonance has previously been reported for 
the guanosine H8 base proton, which is located adjacent 
to the 3' side of the (A)„ tract on a bent 12-mer duplex 
d(CGCAAAAAAGCG)*d(CGCTTTTTTGCG) (Scheme 
II). It was suggested that this upfield-shifted resonance 
was due to a junction between the (A)„ tract and the se­
quence to the 3' side (16).
(E) Gel E lectrop h oresis o f  th e 21-mer Sequence  
T hat Contains the 12-mer D uplex. A 21-mer sequence, 
which contains the 12-mer duplex utilized for one- and 
two-dimensional proton and phosphorus NMR studies, did 
not exhibit anomalous gel migration and, therefore, DNA  
bending when the monomers were ligated into multimers 
and subjected to nondenaturing gel electrophoresis at room 
temperature.3
It has recently been reported that DNA sequences that 
contain 5'AC/GT or 5'CA/TG steps exhibit anomalous 
high gel mobility (low RL values5) as compared to the 
predicted Rh values (46). Such an unusually fast migration 
in the gel electrophoresis is suggestive of a structured 
change in DNA within the 5'AC/GT or 5'CA/TG steps.
4 Following the covalent bonding reaction with (+)-CC-1065 within the 
minor groove of the 12-mer duplex, this resonance was shifted further 
upfield from 5.10 to 4.86 ppm,2 presumably due to the increasing 
shielding effect of the purine ring currents of 17A nucleotide.
5 Rl value is defined as the apparent size divided by the actual size
of each DNA sequence.
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The formation of a “transient kink” at certain weak se­
quence elements, such as the 5'AC/GT or 5'CA/TG steps, 
was suggested to be the probable basis for the structural 
change and associated fast migration (46). Larsen and 
co-workers have also published a paper (47) on the X-ray 
crystal structure of a dodecamer duplex containing a 
5'CA/TG step in which the twist angle within this step is 
smaller (i.e., unwound) than that of the other steps on this 
dodecamer duplex. Furthermore, they have speculated 
that the 5'CA step could be “bistable” (or even  
“multistable”), so that the 12-mer environment forces it 
to be unwound. Similarly, we propose that the unusual 
average C3'-endo sugar geometry for 18C and the associ­
ated conformational and dynamic changes, including 
narrowing of the minor groove in the AT region and rapid 
local conformational flexibility at 16A, are related to a 
transient kink at the 5'AC/GT step in the 12-mer studied 
here.
It has also been suggested that, in a right-handed B-form 
DNA, a kink of about 40° is produced by the change of 
sugar pucker from C2'-endo to C3'-endo, and a -10° un­
winding of adjacent base pairs occurs at the kink site (23). 
On the basis of the two-dimensional COSY and NOESY  
results reported here, the 18C nucleotide that is contained 
within the 5'AC/GT step is proposed to have an average 
C3'-endo sugar geometry, and the hydrogen-bonded amino 
proton belonging to the 18C nucleotide of the 7G*18C bp 
is shifted upfield. The unusual phenomenon observed 
through the NOESY experiments, hydroxyl-radical foot­
printing, and gel electrophoresis can best be explained by 
the occurrence of a “transient kink” within the 5'AC/GT  
step. Indeed, the NOESY restrained molecular mechanics 
and dynamics calculations on the 12-mer duplex reveal two 
major kinks that are located on either side of the 18C 
nucleotide (see later).
(F) M olecular M odeling Studies. A series of NOESY 
restrained molecular mechanics and dynamics calculations 
on the 12-mer duplex were carried out using the am ber  
program, Version 3.0A (10), based upon a total number of 
one hundred twenty-seven NOE constraints (see supple­
mentary material, Table SI) derived from a 250-ms 
NOESY data set. The result of NOESY constrained 
molecular mechanics and dynamics calculations on this 
12-mer duplex indicates that the 12-mer duplex is bent 
toward the minor groove with a bending angle of about 20°. 
In addition, the 12-mer duplex contains two major kinks. 
One, which is toward the minor groove, is located at the 
5'AC/GT step, and the other, which is also toward the 
minor groove, is located at the 5'CT/GA step on the 
noncovalently modified strand (Figure 17, top). On either 
side of the 18C nucleotide that is proposed to have an 
average C3'-endo sugar pucker,6 the backbone is distorted, 
being more compressed toward the major groove on the 
5' side (i.e., between 17A and 18C) and elongated toward 
the major groove on the 3' side (i.e., between 18C and 19T), 
such that the aromatic to aromatic proton distance be­
tween the 17A and 18C nucleotide is decreased, and be­
tween the 18C and 19T nucleotide, significiantly increased. 
This is in accord with the NOE data described here (see 
before). These kinks around the 18C nucleotide bring the 
18CH5 proton under the shielding cone of the aromatic 
ring of 17A (the H5 base proton of 18C is denoted with 
a red arrow in Figure 17, bottom), explaining the upfield
6 Short molecular dynamics runs (5, 10, 20 ps) showed that it was 
necessary to constrain 18C as C3'-endo in order to maintain the k i n k  and 
proper sugar pucker. However, at 100 ps molecular dynamics stimulation 
without using the angle constraints for C3'-endo at 18C, we found a 
structure similar to that proposed; i.e., an 04/-exo for 18C and a k i n k  at 
the 17A-18C/7G-8T step.
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F i g u r e  17. Stereoscopic diagrams generated from the restrained molecular dynamics calculation of the 12-mer duplex (for sequence 
see Scheme I): (top) full length in space-filling model; and (bottom) expanded 6 bp region 5'GAGTTA/5'TAACTC. The arrows in
both the top and bottom panels indicate the average C3'-endo sugar pucker of 18C. Two upfield-shifted 31P resonances located at
the 7G-8T step and the 18C-19T step are highlighted in yellow color.
d e s t a c k i n g  a t  t h e  5 ' C T / A G  s t e p  ( fo r  h e l i c a l  t w i s t  a n g le  
b e t w e e n  b a s e  p a ir  s t e p s ,  s e e  T a b l e  I V ) .  A s  a  r e s u l t ,  t h e  
b a s e - b a s e  N O E  c o n n e c t i v i t i e s  b e t w e e n  t h e  1 8 C  a n d  1 9 T  
( c r o s s - p e a k  N ,  F ig u r e  6 )  a r e  r e l a t i v e l y  r e d u c e d  w h e n  c o m ­
p a r e d  w i t h  t h e  a d j a c e n t  b a s e  s t e p  b e t w e e n  t h e  1 7 A  a n d  
1 8 C  ( c r o s s - p e a k  0 ,  F ig u r e  6 ) .  L i k e w i s e ,  t h e  u p f i e l d  s h i f t  
o f  t h e  h y d r o g e n - b o n d e d  a m in o  p r o t o n  o f  1 8 C , a n d  t h u s  t h e  
r e d u c t io n  o f  t h e  h y d r o g e n  b o n d  s t r e n g t h ,  c a n  b e  e x p la in e d  
b y  t h i s  b a s e  d i s p la c e m e n t .  T h i s  k in d  o f  b a s e  d i s p la c e m e n t  
t o w a r d  t h e  m a jo r  g r o o v e  h a s  p r e v i o u s l y  b e e n  r e p o r t e d  o n  
t h e  a m s a c r i n e - d ( C G C G ) 2 c o m p l e x  (48). T h e  s u m m a r y  
t a b l e  fo r  t h e  h e l i x  t w i s t  (o r  r e p e a t )  a n g le s  o f  t h e  1 2 - m e r  
d u p l e x  i s  g i v e n  in  T a b l e  I V .
Summary and Conclusions
I n  s u m m a r y ,  t h e  n o n e x c h a n g e a b l e  p r o t o n  ( e x c e p t  s o m e  
o f  t h e  H 5 '  a n d  H 5 "  p r o t o n s ) ,  p h o s p h o r u s  r e s o n a n c e  s ig n a ls ,  
a n d  m o s t  o f  t h e  e x c h a n g e a b l e  p r o t o n  r e s o n a n c e  s ig n a l s  o f  
t h e  1 2 - m e r  d u p l e x  h a v e  b e e n  a s s i g n e d  b y  o n e -  a n d  t w o -  
d i m e n s i o n a l  p r o t o n  a n d  p h o s p h o r u s  N M R  e x p e r i m e n t s .  
T h e  1 2 -m e r  d u p l e x  m a in t a in s  a n  o v e r a l l  B - f o r m  D N A  w i t h  
a l l  a n t i  b a s e  c o n f o r m a t i o n  t h r o u g h o u t .  D e t a i l e d  e x a m i ­
n a t i o n  o f  t h e  1 2 - m e r  d u p l e x  b y  h i g h - f i e l d  N M R  a n d  h y ­
d r o x y l - r a d i c a l  f o o t p r i n t i n g  e x p e r i m e n t s  r e v e a l s  s e v e r a l  
l o c a l  s t r u c t u r a l  p e r t u r b a t i o n s  s im i l a r  t o  t h o s e  a s s o c i a t e d  
w it h  a n  ( A ) t r a c t  D N A  d u p le x .  F o r  e x a m p le ,  t h e  p r o p e lle r  
t w i s t i n g  b e t w e e n  b a s e  p a ir s  t h a t  w a s  d e t e c t e d  w i t h i n  t h e  
A * T -r ic h  r e g io n  in  t h e  1 2 -m e r  d u p l e x  is  a l s o  f o u n d  in  D N A
T able IV. Sum m ary T able o f the H elical T w ist (or R epeat) 
A ngles for the d(GGCGGAGTTAGG) •d(CCTAACTCCGCC) 
12-mer D uplex












“Unwound base pair steps are underlined.
s h i f t  o f  t h i s  p r o t o n  r e s o n a n c e  i n  t h e  1 2 - m e r  d u p l e x .  
F u r t h e r m o r e ,  t h e  u n u s u a l l y  u p f i e l d - s h i f t e d  p h o s p h o r u s  
r e s o n a n c e  7 G p 8 T  o n  t h e  u p p e r  s t r a n d  ( c o v a le n t ly  m o d i f ie d  
s t r a n d )  a n d  1 8 C p l 9 T  o n  t h e  lo w e r  s t r a n d  ( n o n c o v a l e n t l y  
m o d i f i e d  s t r a n d )  c a n  a l s o  b e  e x p l a i n e d  b y  t h e  c o n f o r m a ­
t i o n a l  d i s r u p t i o n  a s s o c i a t e d  w i t h  t h e  k i n k s  a t  t h e s e  s t e p s .  
T h e  u n u s u a l l y  u p f i e l d - s h i f t e d  p h o s p h o r u s  r e s o n a n c e s  
7 G p 8 T  a n d  1 8 C p l 9 T  a r e  d e n o t e d  in  y e l l o w  in  F ig u r e  1 7 ,  
t o p .  I n  t h i s  s p a c e - f i l l i n g  m o d e l ,  t h e  d i s l o c a t i o n  o f  t h e s e  
t w o  p h o s p h o r u s  r e s o n a n c e s  i s  e v i d e n t ,  e s p e c i a l l y  f o r  
1 8 C p l 9 T  ( F ig u r e  1 7 ,  t o p ) .  L a s t ,  t h e  1 8 C  n u c l e o t i d e  i s  
d i s p l a c e d  i n t o  t h e  h e l i x  a x i s  t o w a r d  t h e  m a j o r  g r o o v e ,  
r e s u l t i n g  in  a n  u n w i n d i n g  a t  t h e  5 ' A C / G T  s t e p  a n d  a
Characterization of a 12-mer Duplex
Propeller Twisted
GGC GGAC5T TAGG ? 
CCGCCTCAATCC
•H8 and H2 are Broadened 
-Unique Internal Motion








—► 31P Resonances Upfield Shifted
Inhibition of Hydroxyl-Radical Cleavage
-  V ’Transient Kink"
F igu re 18. Summary figure of the unusual structural features 
in the 12'mer duplex.
duplexes containing (A)„ tracts. In addition, an unusual 
upfield-shifted aromatic resonance and compression of the 
minor groove is found adjacent to the 3' side of the A-T- 
rich segment for both the 12-mer duplex and (A)n-tract 
DNA duplex. The phosphorus resonances associated with 
the 7G-8T and 18C-19T steps of the 12-mer duplex, where 
the minor groove is narrowed, displayed unusual upfield 
chemical shifts. A unique local internal motion at 16A is 
detected at the nucleotide level. There is a pronounced 
local distortion centered around 18C, which is proposed 
to have an average C3'-endo sugar geometry. The NOESY 
restrained molecular mechanics and dynamics calculations 
on the 12-mer sequence showed that, on either side of 18C, 
the backbone is distorted, being more compressed toward 
the major groove on the 5' side (i.e., at the 5'AC/GT step) 
and elongated toward the major groove on the 3' side (i.e., 
at the 5'CT/AG step). A summary of these unusual 
structural features in this 12-mer duplex sequence is 
provided in Figure 18. We propose that the propensity 
for a DNA sequence to adopt a bent-type is an important 
factor for the sequence selectivity of (+)-CC-1065. Fur­
thermore, the high reactivity of this particular sequence 
with (+)-CC-1065 is at least in part due to the unique 
internal motion (i.e., conformational flexibility) and pro­
nounced local distortion centered around 18C. Upon ad­
duct formation with (+)-CC-1065, this discontinuity at 18C 
is even more pronounced, and a second discontinuity is 
induced around the covalent bonding site. The intrinsic 
internal motion of the 12-mer duplex is annulled, and the 
bonding sequence now assumes a bent DNA structure 
quite similar to an A-tract. Finally, we propose that the 
high reactivity of this sequence is not only due to this 
inherent propensity to form a bent DNA structure but is 
also due to the catalytic activation implicated from the 
experiment in which a water molecule has been shown to 
bridge between the A subunit of (+)-CC-1065 and the 
phosphate between 16A and 17A (20).
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a b s t r a c t :  ( + ) - C C - 1 0 6 5  is  a n  e x t r e m e ly  p o t e n t  a n t i t u m o r  a n t i b i o t i c  p r o d u c e d  b y  Streptom yces zelensis. 
T h e  p o t e n t  c y t o t o x i c  e f f e c t s  o f  t h e  d r u g  a r e  t h o u g h t  t o  b e  d u e  t o  t h e  f o r m a t io n  o f  a  c o v a l e n t  a d d u c t  w i t h  
D N A  t h r o u g h  N 3  o f  a d e n in e .  A l t h o u g h  t h e  c o v a l e n t  l i n k a g e  s i t e s  b e t w e e n  ( + ) - C C - 1 0 6 5  a n d  D N A  h a v e  
b e e n  d e t e r m i n e d ,  t h e  t a u t o m e r i c  fo r m  o f  t h e  c o v a l e n t ly  m o d i f i e d  a d e n in e  in  th e  (+ )-C C -1065-D N A  duplex  
adduct w a s  n o t  d e f in e d .  A  [ 6 - 15N ] d e o x y a d e n o s in e - l a b e le d  1 2  b a s e  p a ir  n o n - s c l f - c o m p l e m e n t a r y  o l ig o m e r ,  
d ( G G C G G A G T T * A G G ) - d ( C C T A A C T C C G C C )  ( a s t e r i s k  i n d i c a t e s  l5 N - l a b e l e d  b a s e ) ,  c o n t a i n in g  t h e  
( + ) - C C - 1 0 6 5  m o s t  p r e fe r r e d  b in d in g  s e q u e n c e  5 ' A G T T A ,  w a s  s y n t h e s i z e d  a n d  m o d if ie d  w i t h  ( + ) - C C - 1 0 6 5 .  
T h i s  [ 6 - ,5 N ] d e o x y a d e n o s i n e - l a b e l e d  1 2 - m e r  d u p le x  a d d u c t  w a s  t h e n  s t u d i e d  b y  *H  a n d  ,5 N  N M R .  O n e ­
d i m e n s i o n a l  N O E  d i f f e r e n c e  a n d  t w o - d im e n s i o n a l  N O E S Y  ' H  N M R  e x p e r im e n t s  o n  t h e  n o n i s o t o p ic a l ly  
l a b e l e d  1 2 - m e r  d u p l e x  a d d u c t  d e m o n s t r a t e  t h a t  t h e  6 - a m i n o  p r o t o n s  o f  t h e  c o v a l e n t l y  m o d if ie d  a d e n in e  
e x h ib i t  t w o  s ig n a l s  a t  9 . 1 9  a n d  9 .0 8  p p m . P r o t o n  N M R  e x p e r im e n t s  o n  t h e  | 6 - l5 N ] d e o x y a d e n o s in e - l a b e le d  
1 2 - m e r  d u p l e x  a d d u c t  s h o w  t h a t  t h e  t w o  r e s o n a n c e  s ig n a l s  fo r  a d e n in e  H 6  o b s e r v e d  o n  t h e  n o n i s o t o p ic a l ly  
l a b e l e d  d u p l e x  a d d u c t  w e r e  s p l i t  in t o  d o u b le t s  b y  t h e  l5N  n u c l e u s  w i t h  c o u p l i n g  c o n s t a n t s  o f  9 1 .3  H z  fo r  
n o n - h y d r o g e n - b o n d e d  a n d  8 6 .8  H z  fo r  h y d r o g e n - b o n d e d  a m i n o  p r o t o n s .  P a r a l l e l  15N  N M R  e x p e r im e n t s  
o n  t h e  [ 6 - 15N ] d e o x y a d e n o s in e - l a b e le d  ( + ) - C C - 1 0 6 5 - 1 2 -m e r  d u p l e x  a d d u c t  show  a  t r ip le t - l ik e  s ig n a l  a r o u n d  
- 2 7 6 . 9  p p m  a n d  c o u p l i n g  c o n s t a n t s  o f  9 1 .5  a n d  8 5 .6  H z .  T h e  l a r g e  d o w n f ie ld  s h i f t  ( 2 4 .0 5  p p m )  o f  t h e  ,5 N  
s ig n a l  o f  t h e  ( + ) - C C - 1 0 6 5 - 1 2 - m e r  d u p le x  a d d u c t  is in  a c c o r d  w i t h  th e  fo r m a t io n  o f  a n  e x t r a  p o s i t iv e  c h a r g e  
o n  t h e  e x o c y c l i c  n i t r o g e n  a t  t h e  N 6  p o s i t io n  a n d  a  p a r t ia l  d o u b le  b o n d  c h a r a c t e r  b e t w e e n  N 6  a n d  C 6  a t o m s  
o f  t h e  c o v a le n t ly  m o d if ie d  a d e n in e  u p o n  d r u g  m o d if ic a t io n .  W e  c o n c lu d e  th a t  th e  c o v a le n t ly  m o d if ie d  a d e n in e  
N 6  o f  t h e  ( + ) - C C - 1 0 6 5 - 1 2 - m e r  d u p le x  a d d u c t  is  p r e d o m in a n t l y  in  t h e  d o u b ly  p r o t o n a t e d  f o r m ,  in  w h i c h  
c a lc u la t io n s  p r e d ic t  t h a t  t h e  C 6 - N 6  b o n d  is  s h o r t e n e d  a n d  t h e  p o s i t iv e  c h a r g e  is  d e lo c a l i z e d  o v e r  t h e  e n t ir e  
a d e n i n e  m o l e c u l e .
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H u r le y  &  R o k e m , 1 9 8 3 ) ,  w h ic h  b o n d s  c o v a le n t ly  to  d o u b le ­
s tr a n d e d  D N A  th r o u g h  N 3  o f  a  r e a c t iv e  a d e n in e , o v e r la p p in g  
a  f iv e  b a s e  p a ir  r e g io n  in th e  m in o r  g r o o v e  ( S w e n s o n  e t  a l . ,  
1 9 8 2 ;  H u r le y  e t  a l . ,  1 9 8 4 ) .  A n  a n a lo g u e  o f  ( + ) - C C - 1 0 6 5 ,  
d e s ig n e d  a n d  s y n t h e s iz e d  b y  U p jo h n  s c ie n t is t s ,  w a s  r e c e n t ly  
in t r o d u c e d  in to  p h a s e  I c l in ic a l  t r ia ls  b y  J . P . M c G o v e r n  
( p r iv a t e  c o m m u n ic a t io n ,  1 9 9 0 ) .  S tr u c t u r a l ly ,  ( + ) - C C - 1 0 6 5  
c o n s is t s  o f  th r e e  r e p e a t in g  p y r r o lo in d o le  s u b u n it s  ( A - C  in  
s tr u c tu r e  I )  a t ta c h e d  v ia  a m id e  l in k a g e s  th a t a r e  a p p r o x im a te ly  
1 5 °  o u t  o f  p la n e ,  p r o v id in g  th e  d r u g  m o le c u le  w ith  a r ig h t -  
h a n d e d  tw is te d  b a n a n a  s h a p e  ( C h id e s t e r ,  1 9 8 1 ) .  S u b u n i t  A  
c o n t a in s  th e  D N A - r e a c t i v e  c y c lo p r o p a n e  r in g  th a t  a lk y la t e s  
N 3  o f  a d e n in e  w h e n  it b in d s  w ith in  c e r ta in  r e a c t iv e  s e q u e n c e s  
( F ig u r e  1) ( R e y n o ld s  e t  a l . ,  1 9 8 5 ) .  S in c e  o n ly  a d e n in e s  in  
c e r t a in  s e q u e n c e  c o n t e x t s  r e a c t  w ith  ( + ) - C C - 1 0 6 5 ,  th is  d r u g  
h a s  s e q u e n c e  s e l e c t iv i t y  ( H u r le y  e t  a l . ,  1 9 8 8 ) .  S u r p r is in g ly ,  
th e  A  s u b u n it  a lo n e  c o n ta in s  s u f f ic ie n t  s tr u c tu r a l in fo r m a tio n  
to  e n c o d e  th e  p r im a r y  m o le c u la r  b a s is  for  s e q u e n c e  s e le c t iv ity ,  
a n d  t h i s  s u b u n it  is  a l s o  e s s e n t ia l  fo r  a n t i t u m o r  a c t iv i t y .  
H o w e v e r , a s  w e  h a v e  p rev io u s ly  d e m o n s tr a te d , th e  n o n c o v a le n t  
b in d in g  in t e r a c t io n s  o f  th e  B  a n d  C  s u b u n its  w ith  D N A  c a n  
m o d u la t e  o r  f in e  tu n e  th is  s e q u e n c e  s e l e c t iv i t y  (W a r p e h o s k i  
&  H u r le y , 1 9 8 8 ; H u r le y  e t  a l., 1 9 9 0 ) . W e  h a v e  r e c e n tly  sh o w n  
t h a t  in  c o n t r a s t  to  ( + ) - C C - 1 0 6 5 ,  i t s  s y n t h e t ic  e n a n t io m e r ,  
( - ) - C C - 1 0 6 5  h a s  a  d i f f e r e n t  s e q u e n c e  s e le c t iv it y ;  a n d  th is  is
( + ) - C C - 1 0 6 5  ( s t r u c t u r e  I) is  a  v e r y  p o te n t  a n t itu m o r  a n -  
S u b u n it s
I
t ib io t ic  p ro d u c ed  b y  Streptomyces zelensis (H a n k a  e t a l., 1978;
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figure 1: Reaction of (+)-CC-1065 with double-stranded DNA to form the (+)-CC-1065-(N3-adenine)-DNA adduct in amino form (A) 
uid in imino form (B).
(+)CC-1065
irgely determined by the noncovalent binding interactions 
sed to th e  covalent bonding reactivity  o f  ( + ) - C C - 1 0 6 5  
lurley et a l., 1 9 9 0 ) .
Although the c o v a le n t  l in k a g e  s i t e s  b e tw e e n  ( + ) - C C - 1 0 6 5  
aid DNA have b e e n  d e t e r m in e d  ( S c a h i l l  e t  a l . ,  1 9 9 0 ) ,  th e  
tautomeric form  o f  th e  c o v a le n t ly  m o d if ie d  a d e n in e  w a s  n o t  
aperimentally d e f in e d . T h is  in fo r m a t io n  is c r it ic a l  fo r  fu tu r e  
molecular m o d elin g  s tu d ie s  a n d  in  s u b s e q u e n t  w o r k  d e s ig n e d  
I rationalize th e  c o n f o r m a t io n a l  a n d  b io c h e m ic a l  c o n s c ­
iences of D N A  a lk y la t io n  b y  ( + ) - C C - 1 0 6 5 .  W h i le  th e  
tautomeric form  o f  N 3 - a lk y la t e d  a d e n in e s  s u c h  a s  t h a t  in  
H b ro m o a ce ty l)d ista m y c in -N 3 -a d en in e  (B a k e r  &  D e r v a n ,  
TO) has been d e te r m in e d  in  isolated base adducts , w e  a r e  
totaware o f w ork  th a t  h a s  id e n t i f ie d  t h e  s p e c ie s  o f  s im ila r  
N3adenine a d d u c ts  on DNA. T h u s  th is  w o r k  p r o b a b ly  h a s  
tneral s ig n ifican ce  to  N 3 - a lk y la t e d  a d e n in e  in  D N A .  A  
metical m odeling s tu d y  o n  th e  ( + ) - C C - 1 0 6 5 - D N A  a d d u c t  
bsbeen published b y  th e  F r e n c h  g r o u p  ( Z a k r z e w s k a  e t  a l . ,  
1581) in which th e  p o s i t iv e  c h a r g e  w a s  p la c e d  a t  N 3  o f  th e  
jwlently modified a d e n in e . T h e s e  c a lc u la t io n s  su p p o r t a m in o  
automeric form s o f  t h e  ( + ) - C C - 1 0 6 5 - D N A  a d d u c t  r a th e r  
le neutral im in o  s p e c ie s  w e  h a v e  a r b it a r i ly  c h o s e n  to  
win previous p u b l ic a t io n s . In  th is  p a p e r  w e  d e m o n s t r a t e  
'Hand 15N  N M R 1 t h a t  t h e  p r e d o m in a n t  t a u t o m e r ic  
iim o fth e(+ )-C C -1 0 6 5 -m o d ified  a d e n in e  in a 1 2 -m e r  d u p le x  
alduct is in the N 6  d o u b ly  p r o to n a te d  s p e c ie s .
Materials a n d  M e t h o d s
Chemicals. ( + ) - C C - 1 0 6 5  w a s  o b t a in e d  fr o m  T h e  U p jo h n  
land used w ith o u t fu r th e r  p u r if ic a t io n .  [ 15N ] B e n z a m id e  
55.5 atom % 15N )  w a s  p u r c h a s e d  fr o m  M S D  I s o to p e s  C o .  
agents used to  p r e p a r e  N M R  b u f f e r ,  s o d iu m  p h o s p h a te  
fo), and so d iu m  c h lo r id e  (9 9 .9 9 % ) w e r e  p u r c h a se d  fr o m  
Aldrich Co. H P L C  w a te r  a n d  m e th a n o l  w e r e  p u r c h a se d  fr o m  
ater Scientific an d  F ish e r  C o .,  r e sp e c tiv e ly . H y d r o x y la p a t ite  
Kd to purify th e  1 2 -m e r  d u p le x  a n d  t h e  1 2 -m e r  a d d u c t  w a s
1 Abbreviations: NMR, nuclear magnetic resonance; NOE, nuclear 
'trhauser effect; NOESY, two-dimensional NOE correlated spectros- 
$ DEPT, distortionless enhancement by polarization transfer.
p u r c h a se d  fr o m  C a lB io c h e m . C o .  S e p h a d e x  G -2 5  ( s u p e r f in e )  
w a s  p u r c h a s e d  fr o m  P h a r m a c ia  C o .
Preparation o f  the Nonisotopically Labeled 12-mer Duplex. 
T h e  n o n - s e l f - c o m p l e m e n t a r y  d ( G G C G G A G T T A G G ) - d -  
( C C T A A C T C C G C C )  d o d e c a n u c le o t id e  fo r  N M R  w a s  s y n ­
t h e s iz e d  in  h o u s e  o n  a  10-A im ol s c a le  b y  u s e  o f  th e  s o l id -p h a s e  
c y a n o e t h y l  p h o s p h o r a m id it e  a p p r o a c h  o n  a n  A p p lie d  B io s y s ­
te m  a u to m a te d  D N A  sy n th e s iz e r ,  M o d e l  381 A . T h e  o lig o m e r s  
w e r e  th e n  d e p r o t e c t e d  s e p a r a t e ly  w i t h  s a tu r a te d  a m m o n iu m  
h y d r o x id e  a t  5 5  ° C  o v e r n ig h t. S o lv e n t  w a s  e v a p o r a te d  a t room  
t e m p e r a t u r e .
Preparation o f  the [<5-l5/V] Deoxy adenosine-Labeled 12-mer 
Duplex. [ 6 - l5N ] D e o x y a d e n o s i n e  ( 9 9 .5 %  e n r ic h m e n t )  w a s  
s y n th e s iz e d  a c c o r d in g  to  p u b lis h e d  p r o c e d u r e s  ( G a o  &  J o n e s . 
1 9 8 7 , a n d  r e f e r e n c e s  c it e d  t h e r e in ) .  T h e  [ 6 - 15N ] 10A - la b e le d  
12  b a s e  p a ir  n o n - s e l f - c o m p le m e n t a r y  o l ig o m e r  ( s t r u c t u r e  II) 
c o n ta in in g  th e  ( + ) - C C - 1 0 6 5  m o s t  p r e fe r r e d  b o n d in g  s e q u e n c e  
5 ' A G T A A *  (a s t e r is k  in d ic a t e s  c o v a le n t ly  m o d if ie d  a d e n in e )  
w a s  s y n t h e s i z e d  o n  a  10 -A im ol s c a le  a n d  d e p r o te c te d  a s  d e ­
s c r ib e d  fo r  t h e  n o n i s o t o p ic a l ly  la b e le d  o l ig o m e r .
1 2 3 4 5 6 7 8 9 10 11 12
GGCGGAGTT&GG 
CCGCCTCAATCC
24 23 22 21 20 19 18 17 16 15 14 13
—--------------------------------------------------  5'
II
Purification o f  12-mer Duplex. T h e  i s o to p ic a l ly  a n d  n o n ­
is o to p ic a l ly  la b e le d  d o d e c a m e r s  d ( G G C G G A G T T A G G )  a n d  
d ( C C T A A C T C C G C C )  w e r e  p u r if ie d  s e p a r a t e ly  o n  a  M a -  
c h e r e y - N a g e l  n u c le o g e n - D E A E  6 0 - 7  H P L C  c o lu m n  w ith  a n  
in c r e a s in g  g r a d ie n t  fr o m  15 m M  s o d iu m  p h o s p h a te  to  1 M  
s o d iu m  c h lo r id e  a n d  15  m M  s o d iu m  p h o s p h a te  in  20 %  a c e -  
t o n i t r i l e / w a t e r  ( p H  6 . 8 5 ) .  T h e  p u r if ie d  s in g le - s t r a n d e d  d o ­
d e c a m e r s  w e r e  th e n  d e s a lt e d  o n  fo u r  C lg S e p - P a k  c a r tr id g e s  
( W a t e r s ) .  S o l v e n t  w a s  e v a p o r a t e d  a t  r o o m  t e m p e r a tu r e .  
E q u a l  a m o u n t s  o f  s a l t - f r e e  s in g le - s t r a n d e d  1 2 -m e r s  w e r e  a n ­
n e a le d  b y  b e in g  h e a te d  to  6 5  ° C  fo r  2  h , a n d  th e n  th e  s o lu tio n  
w a s  a l lo w e d  to  c o o l  d o w n  t o  r o o m  t e m p e r a t u r e  s lo w ly  in  1 .0  
m L  o f  N M R  b u f f e r  ( 1 0  m M  s o d iu m  p h o s p h a te ,  1 0 0  m M
OH
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s o d iu m  c h lo r id e ,  p H  6 . 8 5 ) .  T h e  c r u d e  1 2 -m e r  d u p le x  w a s  
a p p l ie d  to  a  h y d r o x y la p a t i t e  c o lu m n  ( 2 5  c m  X  3 .0  c m )  a n d  
e lu te d  w ith  a  g r a d ie n t  fr o m  10  to  2 0 0  m M  s o d iu m  p h o sp h a te  
b u f f e r  ( p H  6 .8 5 )  a t  r o o m  t e m p e r a tu r e  to  r e m o v e  th e  fr e e  
s in g le - s t r a n d e d  o l ig o m e r .  T h e  1 2 -m e r  d u p le x  ( 2 5  m g )  w a s  
th e n  ly o p h i l i z e d  a n d  r e d is s o lv e d  in  3 - 5  m L  o f  H P L C -g r a d e  
w a te r  a n d  d e s a lt e d  o n  a  s u p e r f in e  S e p h a d e x  G -2 5  c o lu m n  ( 5 0  
c m  X  3 c m )  e lu t e d  w ith  H P L C  w a te r . T h e  d e s a lt e d  p u r e  
12 -m e r  d u p le x  w a s  ly o p h i l i z e d  a n d  r e d is s o lv e d  in  0 .5  m L  o f  
N M R  b u f fe r .  T h e  s a m p le  w a s  ly o p h i liz e d  to  d r y n e ss  a n d  
r c d is s o lv e d  in  0 .5  m L  o f  9 9 .9 9 6 %  D 20  a n d  th e n  tr a n s fe r r e d  
in to  a  5 - m m  u l t r a th in  N M R  tu b e  fo r  N M R  s tu d ie s .
Preparation and Purification o f  the (+)-CC-1065-12-mer 
Duplex Adduct. T h e  ( + ) - C C - 1 0 6 5 - 1 2 -m er  d u p le x  a d d u ct w a s  
p r e p a r e d  b y  a d d in g  6  m g  o f  ( + ) - C C - 1 0 6 5  in  0 .2  m L  o f  D M F  
v > lu tio n  to  2 5  m g  o f  t h e  p u r if ie d  1 2 -m e r  d u p le x  in 0 .5  m L  o f  
b u ffe r  c o n t a in in g  2 0  m M  s o d iu m  p h o s p h a te  a n d  2 0 0  m M  
*Jium  c h lo r id e ,  p H  6 .8 5 .  T h e  r e a c t io n  m ix tu r e  w a s  s tir r e d  
41 r o o m  te m p e r a t u r e  fo r  5 d a y s  in  th e  d a r k , ly o p h i l iz e d  to  
d r \n e s s  o v e r n ig h t ,  a n d  r e d is s o lv e d  in 1 .0  m L  o f  H P L C -g r a d e  
» j t c r .  T h is  s o lu t io n  w a s  th e n  d e s a lt e d  o n  fo u r  C 18 S e p -P a k  
c ^ 'u id g e s  to  r e m o v e  sa lts  a n d  th e  e x c e ss  u n d isso lv ed  d ru g . T h e  
o « * j l t e d  1 2 -m e r  d u p le x  a d d u c t  w a s  ly o p h i l iz e d ,  r e d is so lv e d  
<r i 0  m L  o f  H P L C - g r a d e  w a t e r ,  a n d  a p p lie d  to  a  h y d r o x -  
* n p ia t ite  c o lu m n  ( 2 5  c m  X  3 c m )  a n d  e lu te d  w ith  a g r a d ie n t  
fr .^ n  1 0  to  1 5 0  m M  s o d iu m  p h o s p h a te  b u f fe r  (p H  6 .8 5 )  a t  
r .» * n  t e m p e r a t u r e  t o  r e m o v e  th e  fr e e  d r u g  a n d  o th e r  im p u r ­
i t y  T h e  p u r e  a d d u c t  s o lu t io n  w a s  ly o p h i l iz e d ,  r e d is so lv e d  
ir  o  5 m L  o f  N M R  b u ffe r ,  ly o p h i liz e d , a n d  r e d isso lv e d  in 0 .5  
m l o f  9 0 %  H 2O /1 0 %  D 20  s o lu t io n .  T h is  y e l lo w is h  1 2 -m e r  
d u p le x  a d d u c t  s o lu t io n  w a s  th e n  tr a n s fe r e d  in to  a  5 -m m  u l-  
tr a th in  N M R  t u b e  fo r  'H  a n d  15N  N M R  s tu d ie s .
Proton N M R  Experiments. O n e -  a n d  tw o -d im e n s io n a l  'H  
N M R  d a t a  s e t s  w e r e  r e c o r d e d  o n  a  G e n e r a l E le c tr ic  G N - 5 0 0  
F T  N M R  s p e c tr o m e te r  a t  r o o m  te m p e r a tu r e . C h e m ic a l sh ifts  
w e r e  r e c o r d e d  in  p a r ts  p e r  m il l io n  a n d  r e fe r e n c e d  r e la t iv e  to  
e x te r n a l  T S P  (1  m g / m L )  in  D 20 .  A p p r o x im a te ly  2 5  m g  o f  
th e  ( + ) - C C - 1 0 6 5 - 1 2 - m e r  d u p le x  a d d u c t  in  0 .5  m L  o f  90%  
H - O /1 0 %  D 20  b u f fe r  c o n t a in in g  10  m M  N a H 2P 0 4 a n d  1 0 0  
mM N a C l ,  p H  6 .8 5 ,  w a s  u s e d  fo r  'H  N M R  e x p e r im e n ts .  
S u p p r e s s io n  o f  th e  w a t e r  s ig n a l  w a s  a c h ie v e d  w ith  a 1—3 —3 —1 
p u l \c  s e q u e n c e  ( H o r e ,  1 9 8 3 )  a n d  th e  d e la y  w a s  1 2 0  us. 
O n e -d im e n s io n a l  N O E  d if fe r e n c e  e x p e r im e n ts  w e re  p erfo rm ed  
a t  2 3  ° C .
'$N N M R Experiments. O n e -d im e n s io n a l  15N  N M R  d a ta  
s e t s  w e r e  r e c o r d e d  o n  a  G e n e r a l  E le c tr ic  G N - 5 0 0  F T  N M R  
s p e c t r o m e t e r  a t  r o o m  t e m p e r a t u r e .  C h e m ic a l  s h if t s  w e r e  
r e fe r e n c e d  r e la t iv e  t o  8 0 %  n i t r o m e t h a n e /2 0 %  C 6D 6. A p ­
p r o x im a t e ly  7 5  m g  o f  t h e  [ 6 - 15N ] d e o x y a d e n o s in e - la b e le d  
( + ) - C C - 1 0 6 5 - 1 2 - m e r  d u p le x  a d d u c t  in  0 .5  m L  o f  90%  
H 2O /1 0 %  D 20  b u f fe r  c o n t a in in g  1 0  m M  N a H 2P 0 4 a n d  1 0 0  
m M  N a C l ,  p H  6 .8 5 ,  w a s  u s e d  fo r  15N  N M R  e x p e r im e n ts .
R e s u l t s
One-Dimensional NOE Difference Assignments o f  the 6- 
Amino Protons in the Coualently Modified Adenine o f  the 
Nonisotopically Labeled (+ )-C C -1065-12-mer Duplex A d­
duct. A  p a r t ia l  'H  N M R  s p e c tr u m  ( 8 .8 - 1 5  p p m , d o w n f ie ld  
r e g io n )  o f  th e  n o n i s o t o p ic a l ly  la b e le d  ( + ) - C C - 1 0 6 5 - 1 2 -m e r  
d u p le x  a d d u c t  is  p lo t t e d  in  F ig u r e  2 A . A  to t a l  o f  16  e x ­
c h a n g e a b le  p r o to n s  ( t w o  s ig n a l s  o v e r la p )  w e r e  fo u n d  in  th e  
r e g io n  1 0 .0 - 1 4 .5  p p m , o f  w h ic h  10  w e r e  D N A  im in o  p r o to n s  
( t e r m in a l  im in o  p r o to n s  o f  'G  a n d  12G  a r e  m is s in g  a t  th is  
t e m p e r a tu r e )  a n d  6  w e r e  ( + ) - C C - 1 0 6 5  im in o  a n d  p h e n o lic  
p r o to n s . T h e  im in o  a n d  a m in o  p r o to n s  o f  th e  ( + ) - C C - 1 0 6 5 -  
12 -m e r  d u p le x  a d d u c t  in  9 0 %  w a te r  b u ffe r  h a v e  b e en  a ss ig n e d
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f i g u r e  2: (A ) 500-M H z proton N M R  spectrum (8.8-15 ppm, 
downfield region) of the (+ )-C C -1065-12-mer duplex adduct (1 equiv 
of (+)-CC-1065 per 12-mer duplex] in 0.5 mL of 90% H 2O/10% DzO 
buffer containing 10 mM  N aH 2P 0 4 and 100 mM NaCl, pH 6.85 at 
23 °C . One-dimensional N O E difference spectra following saturation 
(0.25 s) of (B) the ISTH 3 imino proton of the adduct at 11.54 ppm, 
(C) the l0A H 6b hydrogen-bonded amino proton at 9.19 ppm, and (D) 
the l0A H 6e non-hydrogen-bonded (external) amino proton at 9.08 
ppm.
b y  o n e - d im e n s io n a l  N O E  d i f f e r e n c e  ( F ig u r e  2 )  a n d  tw o - d i ­
m e n s io n a l  N O E S Y  e x p e r im e n t s  (d a ta  n o t  s h o w n )  ( L in  &  
H u r le y ,  1 9 9 0 ) .  T h e  o n e - d im e n s io n a l  N O E  d i f f e r e n c e  e x ­
p e r im e n ts  le a d in g  to  th e  a s s ig n m e n ts  o f  th e  H 6  a m in o  p r o to n s  
o n  th e  c o v a le n t ly  m o d if ie d  a d e n in e  ( l0A )  a r e  p lo tte d  in F ig u r e  
2 B - D .  T h e s e  e x p e r im e n ts  s h o w  th a t in th e  c o v a le n tly  m o d if ie d  
a d e n in e  th e  H 6  p r o to n s  a p p e a r  a s  tw o  s e p a r a te  s ig n a ls  a t 9 .1 9  
a n d  9 .0 8  p p m , a n d  t h e s e  s ig n a l s  w e r e  a s s ig n e d  to  th e  ,0A H 6  
h y d r o g e n - b o n d e d  a m in o  p r o to n  ( H 6 b) a n d  l0A H 6  e x te r n a l  
a m in o  p r o to n  ( H 6 e) ,  r e s p e c t iv e ly .2,3 A s  e x p e c te d  fo r  tw o  
p r o to n s  b o n d e d  to  th e  e x o c y c l ic  n itr o g e n  a t  N 6 ,  b o th  s ig n a ls  
s h o w  s t r o n g  N O E s  to  t h e  im in o  p r o to n  o f  th e  ,0A - ,5T  p a ir  
( p a n e l s  C  a n d  D  o f  F ig u r e  2 ) .
One-Dimensional XH and ]5N  N M R Experiments on the 
[6-x5N]Deoxyadenosine-Labeled (+)-CC-1065-12-mer Duplex 
Adduct. T h e  o n e - d im e n s io n a l  'H  N M R  s p e c tr u m  o f  th e  
( + ) - C C - 1 0 6 5 - [ 6 - 15N ] d e o x y a d e n o s in e - la b e le d  1 2 -m e r  d u p le x  
a d d u c t  is  p lo t te d  in  F ig u r e  3 B . In  c o n tr a s t  to  th e  n o n is o to p ­
ic a l ly  la b e le d  s p e c ie s  ( F ig u r e  3 A ) ,  th e  H 6 b a n d  H 6 e r e so n a n c e  
s ig n a ls  a r e  sp lit  in to  d o u b le ts ,  p r e su m a b ly  d u e  to  th e ir  c o u p lin g  
w ith  t h e  l5N  n u c le u s  lo c a t e d  a t  N 6  ( F ig u r e  3 B ) .  T h is  e x ­
p e r im e n t  c o n f ir m s  th e ir  a s s ig n m e n ts  a n d  r e v e a ls  th e  e x p e c te d  
la r g e  o n e -b o n d  15N - ' H  c o u p lin g  c o n s ta n t s  fo r  H 6 b (8 6 .8  H z )  
a n d  H 6 e ( 9 1 .3  H z )  ( F ig u r e  3 D ) .  T h e s e  c o u p lin g  c o n s ta n t s  
a r e  v e r y  c lo s e  to  th e  v a lu e  (9 1  H z )  r e p o r te d  fo r  [ 6 - 15N ] -  
d e o x y a d e n o s in e  ( G a o  &  J o n e s ,  1 9 8 7 ) .  F o r  c o m p a r is o n , th e  
l5N  N M R  s p e c tr u m  o f  t h e  /e r r -b u t y ld im e th y ls i ly l -p r o te c te d
2 In this system we found to our surprise that the l0AH6b proton 
exchanges with solvent more rapidly than the l0AH6e proton. This is due 
to a facile exchange of the l0AH6b proton with an ordered and jud i­
ciously positioned hydrogen-bonded water molecule most likely between
10AH6b and probably 0 4  of 15T  (Lin & Hurley, 1990).
3 These signals normally resonate from 7 to 8 ppm.
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f ig u r e  3: 500-M H z 'H  N M R  spectrum  (8.8— 1 5 pfwTi. downfield 
region) of the nonisotopically labeled (+ )-C C -l065  1 2-mer duplex 
adduct (A) and [6-l5N]deoxyadenosine-labeled (+ )-C ( 1065-12-mer 
duplex adduct (B) in 0.5 mL of 90% H 2O/10%  D-G buffer containing 
10 mM N aH 2P 0 4 and 100 mM  N aC l, pH 6 X5 at 23 °C . (C) 
Expanded region (8.8—9.8 ppm) of (A); (D) expanded region (8.8-9.8 
ppm) of (B).
[ 6 - 15N ] d e o x y a d e n o s in e  is  p lo t t e d  in  F ig u r e  4 A  T h e  ,5N  
N M R  s p e c tr u m  o f  t h e  ,5N - l a b e le d  1 2 -m e r  d u p le x  u n d e r  th e  
id e n t ic a l  e x p e r im e n t a l  c o n d it io n s  a s  th e  'H  N M R  s p e c tr u m  
is  p lo t t e d  in  F ig u r e  4 B .  T h is  s p e c tr u m  s h o w s  a tr ip le t - l ik e  
s ig n a l  a r o u n d  - 3 0 0 . 9 5  p p m  w ith  c o u p lin g  c o n s t a n t s  o f  9 1 .6  
a n d  7 4 .6  H z  (M a r t in  e t  a l . ,  1 9 8 1 ) .  T h is  d if fe r e n c e  in c o u p lin g  
c o n s t a n t s  in d ic a t e s  t h a t  th e  tw o  a m in o  p r o to n s  o f  l0A  a r e  a s  
e x p e c t e d  in d i f f e r e n t  c h e m ic a l  e n v ir o n m e n ts :  o n e  ( 7 4 .6  H z )  
is  h y d r o g e n  b o n d e d ,  p r o b a b ly  to  th e  0 4  a to m  o f  th y m in e  on  
th e  c o m p le m e n ta r y  s tr a n d , a n d  th e  o th e r  (9 1 .6  H z )  is e x te r m a l  
to  th e  h e lix .  T h e  15N  N M R  s p e c tr u m  o f  th e  ( 6 - IJN ] d e o x y -  
a d e n o s in e - la b e le d  ( - l - ) - C C - 1 0 6 5 - 1 2 -m e r  d u p le x  a d d u c t  is  
p lo t te d  in  F ig u r e  4 C .  T h is  t r ip le t - l ik e  s ig n a l  h a s  a c h e m ic a l  
s h i f t  o f - 2 7 6 . 9  p p m  a n d  c o u p l in g  c o n s ta n t s  o f  9 1 .5  a n d  8 5 .6  
H z .
D i s c u s s i o n
T h e  o b s e r v a t io n  o f  t w o  r e s o n a n c e  s ig n a ls  in  th e  'H  N M R  
s p e c t r u m  ( F ig u r e  2 A )  im p l ie s  th a t  th e  c o v a le n t ly  m o d if ie d  
a d e n in e  e x is t s  in  th e  d o u b ly  p r o to n a te d  fo r m  c o n s is t e n t  w ith  
t h a t  p r e d ic te d  b y  th e  F r e n c h  g r o u p  u s in g  th e o r e t ic a l  c a lc u ­
la t io n  ( Z a k r z e w s k a  e t  a l . ,  1 9 8 7 ) .  In a d d i t io n ,  th e  la r g e  
d o w n f ie ld  s h i f t  ( 2 4 .0 5  p p m )  o f  th e  ,SN  s ig n a l  in  th e  ( + ) -  
C C - 1 0 6 5 - 1 2 - m e r  d u p le x  a d d u c t  c a n  b e  r a t io n a l iz e d  b y  th e  
fo r m a tio n  o f  th e  e x tr a  p o s it iv e  c h a r g e  a n d  p a r tia l d o u b le  b o n d  
c h a r a c te r  b e tw e e n  N 6  a n d  C 6  a to m s  o n  th e  c o v a le n t ly  m o d ­
ifie d  a d e n in e  u p o n  d r u g  m o d if ic a t io n . In p r in c ip le , th e  c h a r g e d  
n itr o g e n  c o u ld  b e  a t  t h e  N 3 ,  N 6 ,  o r  N 9  p o s i t io n  ( F ig u r e  1) 
o f  th e  c o v a le n t ly  m o d if ie d  a d e n in e  o r , m o re  l ik e ly , d e lo c a l iz e d  
b e t w e e n  tw o  o r  th r e e  o f  t h e s e  p o s i t io n s .  A  q u a n tu m  m e ­
c h a n ic a l  c a lc u la t io n  u s in g  A M I  ( D e w a r  e t  a l . ,  1 9 8 5 )  o n  
A 3 ,A 9 - d im e t h y la d e n i n e  s h o w s  t h a t  th e  p o s i t iv e  c h a r g e  is  
d e lo c a l iz e d  o v e r  t h e  e n t ir e  a d e n in e  m o le c u le  ( Y u a n  a n d  
H u r le y ,  u n p u b l is h e d  r e s u l t s ) .  T h e  N 6  d o u b ly  p r o to n a te d
8 5 .6  Hz81.5 x
.74 .6  HZ81.6
8 0 SO Hz
- 3 2 0- 3 0 0- 2 6 0 - 2 8 0
f ig u r e  4: (A ) 500-M H ,5N N M R  spectrum of 3',5'-£}-bis(/e/7-bu- 
tyldim ethylsilyl)[6-15N]deoxyadenosine in CDC13. 500-M Hz ,SN 
N M R  spectrum  of [6-l5N]deoxyauenosine-labeled 12-mer duplex 
d(G G C G G A G TT*A G G )-d(C C TA A CTC CG C C) (B) and [6-^N ]- 
deoxyadenosine-labeled (+ )-C C -1065-12-mer duplex adduct (C) in 
0.5 mL of 90% H 2O /10%  D20  buffer containing 10 mM N aH 2PO< 
and 100 mM  N aC l, pH 6.85 at 23 °C . The ,5N chemical shifts are 
referenced relative to 80% nitrom ethane/20%  C6D6.
n itr o g e n  is a ls o  c o n s is te n t  w ith  th e  c o m p u te d  sh o r te n e d  C 6 - N 6  
b o n d  in  A 3 ,A 9 - d im e t h y la d e n in e  a n d  w ith  th e  X -r a y  s tr u c tu r e  





a ls o  e x h ib i t s  a  s h o r t  C 6  to  N 6  b o n d  a n d  a  d o u b ly  p r o to n a te d  
n itr o g e n  a t  th e  N 6  p o s i t io n  (F u j i i  e t  a l . ,  1 9 8 9 ) .  T h e  s m a lle r  
c o u p lin g  c o n s ta n t  b e tw e e n  th e  h y d r o g e n -b o n d e d  a m in o  p roton  
a n d  6 - 15N  a to m  o f  10A  in  th e  1 2 -m e r  d u p le x  ( 7 4 .6  H z )  r e la tiv e  
to  th a t  in  th e  ( + ) - C C - 1 0 6 5 - 1 2 - m e r  d u p le x  a d d u c t  ( 8 5 .6  H z )  
(M a r t in  e t  a l .,  1 9 8 1 )  s u g g e s t s  th a t  th e  h y d r o g e n -b o n d  s tr en g th  
is  g r e a t ly  r e d u c e d  in  t h e  d u p le x  a d d u c t .  T h is  r e s u lt  is  c o n ­
s i s t e n t  w ith  th e  m o d e l in g  s t u d ie s  ( S e a m a n  a n d  H u r le y ,  u n ­
p u b l is h e d  r e s u l t s ) ,  w h ic h  s h o w  t h a t  th e  c o v a le n t ly  m o d if ie d  
b a s e  p a ir  ( 10A - ,5T )  is h ig h ly  p r o p e lle r  tw is te d . T h is  p r o p e ller  
tw is t  is  a c c o m p a n ie d  b y  a n  in c r e a s e  o f  th e  h y d r o g e n -b o n d in g  
d is t a n c e  a n d  a c o r r e s p o n d in g  r e d u c t io n  o f  th e  h y d r o g e n -b o n d  
s tr e n g th  b e tw e e n  ,0A H 6 b a n d  a  h y d r o g e n -b o n d  a c c e p to r  in th e  
( + ) - C C - 1 0 6 5 - 1 2 - m e r  d u p le x  a d d u c t .2
C o n c l u s i o n s
In  th is  p a p e r  w e  h a v e  r e p o r te d  t h e  f ir s t  u s e  o f  th e  c o m b i­
n a t io n  o f  'H  a n d  15N  N M R  e x p e r im e n t s  o n  a  [ 6 - ,5N ] d e o x y -  
a d e n o s in e - la b e le d  D N A  t o  d e t e r m in e  th e  p r e d o m in a n t  t a u ­
t o m e r ic  fo r m  o f  t h e  c o v a l e n t ly  m o d if ie d  a d e n in e  in  th e  
( + )-C C -l065-D N A  duplex adduct. W e  c o n c lu d e  th a t  th e  
c o v a le n t ly  m o d if ie d  a d e n in e  in  th e  ( + ) - C C - 1 0 6 5 - 1 2 -m e r  d u ­
p le x  a d d u c t  is in  th e  p o s it iv e ly  c h a r g e d  6 -a m in o  fo rm , in w h ich
9507
calculations predict that the C6-N6 bond is shortened and the 
positive charge is delocalized over the entire adenine molecule.
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Structure of the (+)-CC-1065-DNA Adduct: Critical Role of Ordered Water 
Molecules and Implications for Involvement of Phosphate Catalysis in the Covalent
Reaction^
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a b s t r a c t :  (+)-CC-1065 is an extremely potent antitumor agent produced by S tre p to m y c e s  ze len sis . The 
potent effects of (+)-CC-1065 and its alkylating analogues are thought to be due to the formation of a covalent 
adduct through N3 of adenine in DNA. It has been previously postulated, on the basis of modeling studies, 
that a phosphate may be involved in stabilization of the adduct and in acid catalysis of this reaction. In 
this study, using ’H N M R  in combination with ,70-labeled water and phosphate, we demonstrate the 
in volvement of a bridging water molecule between a phenolic proton on the alkylating subunit of (+)-CC-1065 
and an anionic oxygen in the phosphate on the noncovalently modified strand of DNA. In addition, a second 
ordered water molecule associated with one of the protons on N 6 of the covalently modified adenine is also 
identified. This structure has important implications for catalytic activation of the covalent reaction between 
(+)-CC-1065 and DN A  and, consequently, the molecular basis for sequence-selective recognition of DNA  
by the alkylating subunit o f (+)-CC-1065. On the basis of the example described here, the use of 'H NM R  
in ,70-labeled water may be a powerful probe to examine other structures and catalytic processes for 
water-mediated hydrogen-bonded bridges that occur between small molecules and D N A  or enzymes.
(+)-CC-1065 is an antitumor antibiotic with a unique 
structure (Hanka et al., 1984; Chidester et al., 1981) (Figure
1) and mechanism of action (Hurley et al., 1984; Warpehoski 
& Hurley, 1988). Previous studies have demonstrated that 
this antibiotic is extraordinary for both its base and DNA 
sequence specificity (Hurley et al., 1984,1988,1990; Reynolds 
et al., 1985). An analogue of (+)-CC-1065 designed and 
synthesized by Upjohn scientists was recently introduced into 
phase I clinical trials (J. P. McGovren, The Upjohn Company, 
I personal communication, 1990). Structurally, (+)-CC-1065 
I consists of three repeated pyrroloindole subunits (A, B, and 
C in Figure 1) attached via amide linkages that are approx­
imately 15° out of plane, providing the drug molecule with 
a right-hand twisted banana shape (Hanka et al., 1984; 
Chidester ct al., 1981). Subunit A contains the DNA-reactive 
cyclopropane ring that alkylates N3 of adenine when it binds 
within certain reactive sequences (Lin & Hurley, 1990; Scahill 
et al., 1990) (Figure 1). Since only adenines in certain se­
quence contexts react with (+)-CC-1065, this drug has se­
quence selectivity (Hurley et al., 1988). Surprisingly, the A
f This research was supported by grants from the Public Health 
Service (CA-49751), the Welch Foundation, and the Burroughs Well­
come Scholars Program.
*To whom correspondence should be addressed.
1 Department of Chemistry.
*Drug Dynamics Institute and Division of Medicinal Chemistry, 
College of Pharmacy.
subunit alone contains sufficient structural information to 
encode the primary molecular basis for sequence selectivity 
(Hurley et al., 1988), and this subunit is also essential for 
antitumor activity (Warpehoski et al., 1988). However, as 
we have previously demonstrated, the noncovalent binding 
interactions of the B and C subunits with DNA can modulate 
or fine-tune this sequence selectivity (Hurley et al., 1988). We 
have previously suggested that the primary basis for sequence 
selectivity is through a sequence-dependent catalytic activation  
a n d /o r  a  sequence-dependen t con form ation a l f le x ib i l i ty  
(Warpehoski & Hurley, 1988). In this report we provide 
structural evidence that is in accord with bifunctional catalysis 
of adduct formation in a mechanism that involves two critically 
positioned hydrogen-bonded water molecules at opposite ends 
of the covalent reaction site.
M a t e r i a l s  a n d  M e t h o d s
Chem icals. (+)-CC-1065 was obtained from The Upjohn 
Company and used without further purification. [l70]Water 
(60 and 45 atom % 170 )  was purchased from Cambridge 
Isotope Laboratories. Reagents used to prepare the NMR 
buffer, sodium phosphate (99.99%), and sodium chloride 
(99.99%) were purchased from Aldrich. HPLC water and 
methanol were purchased from Baxter Scientific and Fisher, 
respectively. Hydroxylapatite used to purify the 12-mer duplex 
and the 12-mer adduct was purchased from Calbiochem. 
Sephadex G-25 (superfine) was purchased from Pharmacia.
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figure I: Reaction of (+ )-C C -1065 with double-stranded DNA at N3 of adenine to form the (+ )-C C -1065-D N A  adduct. The covalently 
modified adenine is in the doubly protonated 6-amino form (Lin & Hurley, 1990).
Preparation and Purification o f  the 12-mer Duplex and 
( +)-C C -l065 12-mer Duplex Adduct. The non-self-com ple­
m entary d (G G C G G A G T T A G G M C C T A A C T C C G C C ) 12- 
mer duplex for N M R  studies was synthesized  in-house on a 
10-Mmol scale by using autom ated solid-phase phosphotriester 
and phosphoram idite chem istry (G ait, 1984) on an Applied  
Biosystem  autom ated D N A  synthesizer, M odel 381 A . T he  
general procedures for synthesis, deprotection, drug bonding,
HPLC, and chromatographic purification o f the 12-mer duplex 
and (+ )-C C -1065  12-mer duplex adduct have been previously 
reported (Lin & H urley, 1990).
Preparation o f  the n O-Labeled 12-mer Duplexes and the 
Corresponding (+ )-C C -1065 12-mer Duplex Adducts. O xy­
gen- 17-labeled d (G G C G G A G T T A G G )-(C C T A A C T C C G -  
C C ) 12-mer duplexes were synthesized  by using autom ated  
solid-phase phosphotriester and phosphoram idite chem istry  
(G ait, 1984). O x y g en -17 was regiospecifically  incorporated  
into the anionic oxygen  o f " G -I2G , l6A -17A , and 17A -18C  
phosphate groups in three d ifferent o ligom ers by selectively  
oxidizing the appropriate phosphite interm ediate with 0.1 M 
io d in e /1 g o f [ l70 ] w a t e r /10 m L o f  p yrid in e/40  m L o f  T H F  
solution.
Proton-NMR Experiments. One- and two-dim ensional 'H  
N M R  data sets were recorded on a General E lectric G N -5 0 0  
FT N M R  spectrometer at room temperature. C hem ical shifts 
were recorded in parts per m illion and referenced relative to 
external T SP  (1 m g /m L ) in D 20 .  A pproxim ately  28 mg o f  
the ( +  )-C C -1065 12-m er duplex adduct in 0 .5 m L o f  90%
H 2O /l0 %  D 20  buffer containing 10 m M  N a H 2P 0 4 and 100 
mM  N aC l, pH 6 .85 , was used for 'H N M R  experim ents.
Suppression of the water signal was achieved with 1-3-3-1 pulse 
sequence (H ore. 1983) with a delay o f  120 ms. O ne-d im en­
sional N O E 1 difference experim ents were performed at 23 °C .
T | Inversion-Recovery Experiments. T] m easurem ents in 
90% H 20 / 10% D 20  were made on a General Electric G N -500  
N M R  instrument by the conventional inversion-recovery  
method executed with a 1-3-3-T selective excitation  pulse se­
quence. The 1-3-3-T routine w as optim ized to provide exact 
90° and 180° flip angles on the resonances o f  interest. The 
pulse repetition delay is 5 s.
1 A b b r e v ia t io n s :  N M R .  n u c le a r  m a g n e t i c  r e s o n a n c e ;  N O E ,  n u c le a r  
O v e r h a u s e r  e f fec t ;  N O E S Y ,  t w o - d i m e n s i o n a l  N O E  c o r r e la t e d  s p e c t r o s ­
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figure 2: (A) Proton N M R  spectrum (500 M Hz; 8.5-15 ppm, 
downfield region) of the nonisotopically labeled (+)-CC-1065 12-mer 
duplex adduct (1 equiv of (+)-C C -1065 per 12-mer duplex) in 0.5 
mL of 90% H2O /10%  D20  buffer containing 10 mM N aH 2P 0 4 and 
100 mM NaCl, pH 6.85, at 25 °C . The assignments of the 12-mer 
imino and the covalently modified adenine 6-amino protons are based 
on one-dimensional N O E difference and two-dimensional N OESY  
experiments. Also shown are 500-M H z 'H  N M R  spectra (8.5-15 
ppm, downfield region) of the [6-l5N]deoxyadenosine-labeled (+ )- 
CC-1065 12-mer duplex adduct in (B) [160 ]w a te r and in (C) 40.5% 
[170]enriched water. The l5T  imino and 7"-OH  proton resonances 
overlap.
R e s u l t s  a n d  D i s c u s s i o n
(+ )-C C -1065  was reacted with the non-self-com plem entary  
12-mer duplex (C hart 1) that contains one o f the preferred  
bonding sequences 5'A G T T A * (where an asterisk denotes the 
covalently m odified aden ine). T he duplex and its ( +  )-C C - 
1065-m odified sequences were characterized  by one- and
A c c e l e r a t e d  Publications
C h a r t  I: S e q u e n c e  a n d  N u m b e r i n g  o f  t h e  ( + ) - C C - 1 0 6 5  1 2 - m e r  
D u p l e x  A d d u c t 0
5 . -----------------------------------------------------------------------------------------------------------►
1 2  3  4  5  6  7  8  9  1 0  11 1 2
G G CG G A G T T A GG 
C C G C C T C A A T C C
2 4  2 3  2 2  21  2 0  1 9  1 8  1 7  1 6  1 5  1 4  1 3
—   5'
° T h c  l70  la b e l s  w e r e  s p e c i f i c a l l y  in t r o d u c e d  on  t h e  a n i o n i c  o x y g e n s  
o f  p h o s p h a t e  b a c k b o n e  b e t w e e n  UG  a n d  l2G ,  l6A  a n d  l7A ,  a n d  l?A  and
18C .
two-dimensional 'H N M R  (Lin & Hurley, 1990; C. H. Lin 
and L. H. Hurley, unpublished results). A partial 'H N M R  
spectrum (downfield region) of the nonisotopically labeled 
(+ )-C C -1065 12-mer duplex adduct is plotted in Figure 2A. 
The assignments of the exchangeable protons in the (+)-C C - 
1065 12-mer D N A  duplex adduct have been made previously 
(Lin & Hurley, 1990; C. H. Lin and L. H. Hurley, unpub­
lished results) and are noted in Figure 2, panels A and C. Of 
particular significance are the upfield-shifted 10A -15T imino 
proton (2.07 ppm) and the downfield-shifted 6 -amino protons 
( ~ 2  ppm) of l0A (the covalently modified adenine) that occur 
at 9.19 and 9.08 ppm in the duplex adduct relative to the 
duplex alone. These latter signals were assigned to the 10A H 6  
hydrogen-bonded am ino proton (H 6 b) and 10A H 6  external 
amino proton (H 6 C) respectively .2 Confirmation of the as­
signments for the 10A H 6  amino protons was made by syn­
thesizing [6 - l5N ]- ,0A-deoxyadenosine-labeled (+)-C C -1065  
12-mer duplex adduct (Lin & Hurley, 1990) (Figure 2B). As 
expected, the 10A H 6 b and ,0A H 6 e resonance signals are split 
into doublets due to coupling with the 15N nucleus located at 
N 6 . Upon heating the sample to 45 °C , we found, contrary 
to our expectation, that the resonance signal assigned to the 
l0A H 6 b proton exchanged more rap id ly  than that assigned to 
the l0A H 6 c proton (C. H. Lin, J. M. Beale, and L. H. Hurley, 
unpublished results). Since the 6 -amino group of adenine is 
in the doubly protonated form (Lin & Hurley, 1990) and the 
l0A -l5T imino proton is shifted upfield, which is indicative of 
reduced hydrogen bonding strength, we considered the pos­
sibility that the observed rapid exchange of the 10A H 6 b proton 
might be due to a facile exchange with an ordered and judi­
ciously positioned hydrogen-bonded water molecule. To 
evaluate this possibility, the [6 - l5N ]- 10A-deoxyadenosine-la- 
beled (+ )-C C -1065 12-mer duplex adduct was dissolved in 
l70-labeled  water to attain a 40.5% overall enrichment. To 
our surprise, not only was the doublet for the ,0A H 6 b proton 
broadened but the (+ )-C C -1065  8 -phenolic proton of the A 
subunit was also broadened relative to the equivalent resonance 
signals in 160-w ater (compare Figures 2B and 2C ) . 3 An 
expansion of the regions containing the broadened proton 
N M R  signals in comparison with the l60-w ater sample is 
shown in Figure 3. Most likely, the broadening of these 
protons is due to their interaction with the 170  nucleus. Ox-
2 T h e  a s s i g n m e n t s  o f  t h e  H 6 b and  H 6 C pro to n s  w e r e  m a d e  o n  the  bas is  
o f  c o m p a r i s o n  o f  c o u p l i n g  c o n s t a n t s  to  th e  e q u iv a le n t  p r o to n s  in th e  
[ 6 - l5N ] - 10A - d e o x y a d e n o s i n e - l a b e l e d  d u p l e x  ( L i n  & H u r l e y ,  1 9 9 0 ) .
1 T h e  s a m p l e  in [ l70 ] H 20  w a s  p r e p a r e d  b y  l y o p h i l i z in g  th e  [ 6 - 15N ]- 
d e o x y a d e n o s in e - la b e le d  ( + ) - C C - 1 0 6 5  1 2 -m e r  d u p le x  a d d u ct  in [ l60 ] H :0  
s o lu t io n  to c o m p l e t e  d r y n e s s  a n d  t h e n  a d d i n g  0 . 4 5  m L  o f  a 45 %
1170 ]  1 1 , 0 / 0 . 0 5  m L  o f  D 20  m i x t u r e  t o  t h e  a b o v e  s a m p l e .  T h e  o n ly  
d i f f e r e n c e  b e t w e e n  th e  t w o  s a m p l e s  u se d  to  p ro v id e  th e  s p e c tra  in F ig ure  
2, p a n e ls  B and C .  is th e  [ l70 ] H - , 0  c o n t e n t .  O t h e r  fa c to rs  s u c h  a s  D N A  
c o n c e n t r a t i o n ,  a m o u n t  o f  m e t a l ,  a n d  v o l u m e  o f  th e  s a m p l e  a r e  for all 
p r a c t i c a l  p u r p o s e s  the  s a m e .
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Ti = 20-8 22.7
100.0
— i— i— |— i— i— i— i— |— i— i— i— i— |— i i— i ] 1 i 1 | 1 1 1 | 1 1 r ~
1 4 . 5  1 4 . 0  1 3 . 5  9 . 4  9 . 2  9 . 0  8 . 8
f i g u r e  3: 'H  N M R spectra (500 MHz; expanded downfield regions, 
8.7-9.5 and 13.4-14.8 ppm) of the [6-,5N]deoxyadenosine-labeled 
(+)-CC-1065 12-mer duplex adduct in (A) regular w ater (B) 40.5% 
l70-enriched water N M R  buffer containing 10 mM N a H 2P 0 4 and 
100 mM NaCl, pH 6.85, at 25 °C . 7j measurements were made on 
a General Electric G N -500 N M R  instrum ent by the conventional 
inversion-recovery method executed with a 1-3-3-1 selective excitation 
pulse sequence. The 1-3-3-T routine was optimized to provide exact 
90° and 180° flip angles on the resonances of interest. Both the 
8-phenolic proton of (+ )-C C -1065 and l0A H 6b of the covalently 
modified adenine have smaller 7 j  values in l70-enriched water solution. 
The 7j relaxation time of l0A H 6e remained the same, regardless of 
the solvent.
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f i g u r e  4 :  ( A )  ' H  N M R  s p e c t r u m  ( 5 0 0  M H z ;  8 . 5 - 1 5  p p m ,  d o w n f i e l d  
r e g i o n )  o f  t h e  l60 - l a b c l e d  ( + ) - C C - 1 0 6 5  1 2 - m e r  d u p l e x  a d d u c t  a s  
d e s c r i b e d  in  t h e  l e g e n d  f o r  F i g u r e  2. ( B ) ,  ( C ) ,  a n d  ( D )  a r e  t h e  
5 0 0 - M H z  'II  N M R  s p e c t r a  o f  t h e  [ l70 ] p h o s p h a t c - l a b e l e d  " G - I2G ,  
l6A - l7A ,  a n d  l7A - l8C  s a m p l e s .
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f i g u r e  5: Proposed mechanism for the catalytic activation of the reaction of the (+)-C C -1065 with DNA involving two strategically placed 
w ater molecules.
y g e n - 1 7 ,  w ith  a  s p in  /  =  5/ ?, p o s s e s s e s  a n  u n s y m m e tr ic a l  
c h a r g e  d is t r ib u t io n  a n d  th e r e fo r e  a n  e le c t r o n ic  q u a d r u p o le  
m o m e n t . T h e  p r o x im ity  o f  th e  8 -p h e n o lic  a n d  10A H 6 b p r o to n s  
t o  th e s e  f lu c t u a t in g  m a g n e t ic  d ip o le s  e n h a n c e s  th e ir  s p i n -  
la t t i c e  (a n d  p r e s u m a b ly  a ls o  s p i n - s p in )  r e la x a t io n  r a te s ,  
c o r r e s p o n d in g ly  r e d u c in g  th e ir  T{ v a lu e s .  T h e s e  c o m p a r a t iv e  
m e a s u r e m e n t s  in  [ ,60 ] w a t e r  a n d  [ l70 ] w a t e r  s o lu t io n s  a r e  
s h o w n  in F ig u r e  3 . F o r  th e  8 - p h e n o lic  p r o to n  in [ l70 ] w a t e r ,  
a  50 %  r e d u c tio n  in T , r e la x a t io n  t im e  is  n o te d  in  c o m p a r is o n  
w ith  th e  n o n is o to p ic a l ly  la b e le d  w a te r , a n d  w h ile  th e  7 |  o f  th e  
10A H 6 b p r o to n  in [ ,70 ] w a t e r  is  a l s o  r e d u c e d  (2 2 % ) , it is  n o t  
s o  s ig n if i c a n t ly  r e d u c e d  a s  th e  8 - p h e n o l i c  p r o to n . F o r  c o m ­
p a r is o n  w e  a ls o  m e a s u r e d  th e  7"! v a lu e s  fo r  th e  tw o  o th e r  
p h e n o l ic  p r o to n s  a n d  im in o  p r o to n s  in  t h e  B a n d  C  s u b u n it s  
o f  ( + ) - C C - 1 0 6 5  a n d  o th e r  e x c h a n g e a b le  p r o to n s , in c lu d in g  
th e  H I  in th e  A  s u b u n it s  o f  ( + ) - C C - 1 0 6 5  in  b o th  160 -  a n d  
,70 - la b e ! e d  w a te r . S ig n if ic a n t  d i f f e r e n c e s  b e tw e e n  7 ,  v a lu e s  
in  l60 -  a n d  l70 - l a b e l e d  w a te r  w e r e  n o t  o b s e r v e d  (C . H . L in ,  
J . M . B e a le ,  a n d  L . H . H u r le y ,  u n p u b l is h e d  r e s u l t s ) .
A  t w o -d im e n s io n a l  'H  N M R  s tu d y  o f  th e  ( + ) - C C - 1 0 6 5  
1 2 -m e r  d u p le x  a d d u c t  s h o w s  th a t  th e r e  is a  d is c o n t in u i ty  b e ­
tw e e n  th e  ’ T -'^ A  a n d  l0A - 15T  b a se  p a irs, w h ic h  is c h a r a c te r iz e d  
b y  a  h ig h ly  p r o p e lle r  tw is t e d  ,0A - I5T  ( L in  &  H u r le y ,  u n ­
p u b lish e d  r e s u lt s ) .  T h e  l0A  d e o x y a d e n o s in e  h a s  a C 3 '- e n d o -  
l ik e  c o n fo r m a t io n  a n d  th e  ,0A - 15T  im in o  p r o to n  r e s o n a n c e  is 
s h i f t e d  u p f ie ld  b y  2 .0 7  p p m , in d ic a t iv e  o f  a  c o n s id e r a b ly  
w e a k e n e d  h y d r o g e n -b o n d in g  in te r a c t io n .  T h is  d is c o n t in u i t y  
m a y  w e ll b e  r e s p o n s ib le  fo r  th e  b e n d in g  o f  D N A  in d u c e d  b y  
( + ) - C C - 1 0 6 5 ,  w h ic h  a p p e a r s  to  b e  a t lea st s u p e r fic ia lly  s im ila r  
in m a g n itu d e , d ir e c tio n , a n d  s tr u ctu r a l o r ig in  to  th a t a s so c ia te d  
w ith  in tr in s ic  A - t r a c t  b e n d in g  (L in  e t  a l . ,  1 9 9 1 ) .  In v ie w  o f  
th e  d is c o n t in u i t y  b e tw e e n  9T - I6A  a n d  l0A - ,5T , it is  p e r h a p s  
n o t to o  s u r p r is in g  th a t  a  w a te r  m o le c u le  m a y  b e  r e q u ir e d  to  
b r id g e  th e  l0A H 6 b p r o to n , a n d  w e  s u s p e c t  th a t  th e  0 4  o f  
th y m in e  o n  th e  o p p o s ite  str a n d  in th e  s a m e  b a se  p a ir  s ta b iliz e s  
th e  o th e r w is e  b a d ly  d is to r te d  d u p le x .
In p r e v io u s  p u b l ic a t io n s ,  m o le c u la r  m o d e l in g  s tu d ie s  fr o m  
b o th  th e  F r e n c h  g r o u p  ( Z a k r z c w s k a  e t  a l . ,  1 9 8 7 )  a n d  th e  
U p jo h n -T e x a s  g r o u p  (H u r le y  e t a l ., 1 9 9 0 )  h a v e  su g g e s te d  th at
th e  a n io n ic  o x y g e n  o f  th e  17A - ,8C  p h o s p h a te  o n  th e  n o n c o -  
v a le n t ly  m o d if ie d  s tr a n d  th a t  is  tw o  b a s e  p a ir s  to  t h e  5 ' s id e  
o f  th e  c o v a le n t ly  m o d if ie d  a d e n in e  m a y  b e  in v o lv e d  in  a h y ­
d r o g e n -b o n d in g  in te r a c t io n  w ith  th e  8 -p h e n o lic  p r o to n  o f  th e  
A  s u b u n it  o f  ( + ) - C C - 1 0 6 5  12 -m e r  a d d u c t .  It w a s  a l s o  s u g ­
g e s te d  th a t th is  in te r a c t io n  m ig h t  b e  in v o lv e d  in g e n e r a l  a c id  
c a t a ly s i s  o f  th e  c o v a le n t  b o n d in g  r e a c t io n  a n d  b e  im p o r ta n t  
in th e  o b se rv ed  s e q u e n c e  s e le c t iv ity  ( H u r le y  e t a l .,  1 9 9 0 ) .  T h e  
~ 2  p p m  d o w n f ie ld  s h i f t  o f  th e  8 - p h e n o l ic  p r o to n  o f  th e  A  
su b u n it  r e la tiv e  to  th e  c o r r e s p o n d in g  B  a n d  C  s u b u n it  p r o to n s  
is in a c c o r d  w ith  th is  id e a  ( F ig u r e  2 C ) .  T o  fu r th e r  e v a lu a te  
th is  p r o p o sa l, w e  p r e p a r e d  th r e e  in d iv id u a l  s a m p le s  o f  th e  
1 2 -m er  d u p le x  u sed  in th is  s tu d y  w ith  ,70  la b e ls  in th e  a n io n ic  
o x y g e n s  o f  th e  " G - ,2G ,  l6A - l7A , a n d  ,7A - I8C  p h o s p h a te s .4 
T h e  p o s it io n  o f  th e  n O  la b e ls  in  e a c h  s a m p le  w a s  c o n f ir m e d  
b y  th e  b r o a d e n in g  o f  th e  c o r r e s p o n d in g  p h o s p h a te  r e so n a n c e s  
in th e  3IP  N M R  s p e c tr u m  (C . H . L in , J . M . B e a le ,  a n d  L . H . 
H u r le y , u n p u b lish e d  r e s u lt s ) .  U n e x p e c te d ly ,  w e  fo u n d  it w a s  
th e  l70 - l a b e l e d  ,6A -nA phosphate sam ple  r a th e r  th a n  th e  
l70 - l a b e l e d  ,7/ 4 - l8C phosphate sample  th a t  p r o d u c e d  a v e r y  
s ig n if ic a n t  sh a r p e n in g  o f  th e  r e so n a n c e  s ig n a l o f  th e  8 -p h e n o lic  
p r o to n  o f  th e  A  s u b u n it  (F ig u r e  4 ) .  A  c o m p a r is o n  o f  th e  7 '1 
r e la x a t io n  t im e s  o f  th e  8 -p h e n o lic  p r o to n  for  th e  th r e e  a n io n ic  
o x y g e n  170 - l a b e l e d  p h o s p h a te  s a m p le s  is  s h o w n  in F ig u r e  4 . 
W h ile  th e  n G - ,2G  a n d  17A - ,8C  l70 - p h o s p h a t e  la b e le d  s a m p le s  
d id  not revea l a n y  s ig n if ic a n t  c h a n g e  in th e  Tx r e la x a t io n  t im e  
o f  th e  8 -p h e n o lic  p r o to n , th e  ,6A - ,7A  [ I70 ] p h o s p h a t e - la b e le d  
s a m p le  (F ig u r e  4 C )  s h o w e d  a s ig n if ic a n t  in c r e a s e  ( 2 0 .8  to  37  
m s) in T , r e la x a t io n  t im e  in c o m p a r is o n  to  th e  n o n is o to p ic a l ly  
e n r ic h e d  s a m p le . T h e  s h a r p e n in g  o f  th e  8 - p h e n o lic  p r o to n  
r e so n a n c e  s ig n a l a n d  a s s o c ia te d  78%  increase in 7 ,  r e la x a t io n
4 In a d d i t io n  to  p r e p a r i n g  t h e  l70  la b e l  a t  l7A - l8C ,  w e  d e c i d e d  to  
e v a l u a t e  p O  labe l at  n G - l2G  an d  l6A - ,7A  s t e p s  as  p o s s ib l e  a l t e r n a t iv e  
p h o sp h ates  invo lved in s ta b i l i z a t io n  o f  the  a d d u c t  b e c a u s e  m o d e le d  results  
s h o w e d  the  d i s t a n c e s  b e t w e e n  th e  a n io n ic  o x y g e n  in e a c h  p h o s p h a t e  and  
t h e  A - s u b u n i t  q u i n o n e - o x y g e n  w e r e  7 . 3 5 ,  4 . 6 9 ,  a n d  5 . 4 6  A in t h e  c o v a ­
le n t ly  b o un d  c o m p l e x  a n d  6 . 8 1 ,  7 . 8 8 ,  a n d  4 . 2 6  A in t h e  n o n c o v a lc n t ly  
b o u n d  c o m p l e x  for " G - I2G ,  l6A - l7A ,  a n d  I7A - ' * C ,  r e s p e c t i v e ly  ( u n p u b ­
l i sh ed  results').
Accelerated Publications Biochemistry, Vol. 30, No. 15, 1991 3601
f i g u r e  6: Stereoscopic diagram s o f  (+)-C C -1065 covalently bound to the 12-mer duplex (C hart I). The drug molecule is shown in yellow, 
the covalently modified adenine (A*) and the phosphate group ( l6A -17A) are shown in green, and the two bridging water molecules are shown
i n  t u r q u o i s e .
time is presumably due to the competing dipolar coupling of 
the l70  nucleus in the phosphate for the relaxation potential 
of the bridging water molecule located between the anionic 
oxygen of the phosphate at ,6A -17A and the 8 -phenolic proton 
of the A-subunit o f the (+ )-C C -1 0 6 5 -D N A  adduct.
On the basis o f the results o f this study, we are now able 
to further refine the proposed reaction mechanism that results 
in covalent modification of N 3 of adenine in D N A  by (+ )-  
CC-1065 (Figure 5). The important additions are the two 
water molecules, one of which is demonstrated to bridge the 
8 -phenolic proton of (+)-C C -1065 and the phosphate between 
l6A -l7A and a second that is hydrogen-bonded to l0A H 6 b and 
perhaps bridges to 0 4  of l5T, although we lack direct data that 
would support the 0 4  bridging position (Figure 6 ). The 
observation of significantly reduced T, relaxation times caused 
by quadrupole-induced relaxation of protons by specifically 
n O-labeled water molecules suggests these water molecules 
are ordered and have considerable residence times as part of 
the (+ )-C C -1065-D N A  adduct structure. To the best of our 
knowledge, the critical importance of ordered water molecules 
in relaying the catalytic activation of covalent bond formation 
or stabilizing the resulting D N A  adducts has not previously 
been demonstrated. Flowever, their importance in noncovalent 
complexes of drugs with D N A , such as beneril (Brown et al., 
1990), and in D NA structure (Drew' et al., 1981: Kopa et al., 
1982) has been documented. Just as we propose here that an 
ordered water molecule may relay the general acid catalysis
of CPI in its covalent reaction with N 3 of adenine, the pro­
posed general acid catalysis o f BPDE hydrolysis by an acidic 
phosphate group (Gupta et al., 1987) may also involve an 
ordered water molecule. How general this involvement of 
ordered water molecules may be in providing bridging hy­
drogen bonds in covalent or noncovalent com plexes of 
drug/carcinogen-DNA adducts remains to be seen. Moreover, 
their importance in mechanisms of molecular recognition 
between drug/carcinogens and D N A  remains largely unre­
cognized. On the basis of the example described here, the use 
of 'H N M R  with 170-labeled  water or phosphates may be a 
powerful probe for detecting such water bridging systems in 
complexes, as well as in catalytic processes that occur on 
enzymes and D N A .
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ABSTRACT Using DNase I and Alu I endonuclease anal­
ysis of a site-directed CC-1065-FV3-<wfewrte]DNA adduct in a 
117-base-pair fragment from M13mpl DNA, we have demon­
strated that CC-1065 produces an asymmetric effect on DNA 
conformation that extends more than one helix turn to the 5' 
side of the covalently modified adenine. CC-1065 is a potent 
antitumor antibiotic produced by Streptomyces zelensis, which 
is believed to mediate its cytotoxic effects through covalent 
binding to DNA. Previous studies have demonstrated that 
CC-1065 binds covalently to N 3 of adenine and lies within the 
minor groove of DNA spanning a 4-base-pair sequence to the 
5' side of the modified adenine. DNase I footprinting of this 
site-directed CC-1065-DNA adduct on the noncovalently mod­
ified strand shows that inhibition of cleavage occurs over a 
12-base region, which is bordered on the 3' side by a site of 
2-fold enhancement of cleavage. On the covalently modified 
strand a much less pronounced inhibition/enhancement pat­
tern of cleavage occurs as far as 11 bases to the 5' side of the 
covalently modified adenine. While Hae III is able to cleave the 
DNA on both strands on the 3' side of the covalently modified 
adenine, Alu I is only able to cleave the covalently modified 
strand on the S' side of the adduct. By taking into account the 
recently published structure of DNase I, we are able to 
interpret these results and develop a model for the effect of 
CC-1065 on local DNA structure. In this model, we propose 
selective drug-induced distortion of the covalently modified 
strand as a consequence of the alkylation of adenine by 
CC-1065.
CC-1065 is an extremely potent antitumor agent produced by 
Streptomyces zelensis (1). The structure was solved by x-ray 
crystallography (2), and a variety of synthetic routes to the 
subunits of CC-1065 have been reported. Recent reviews of 
the synthesis, pharmacological activity and toxicity (3), and 
the mechanism of action of CC-1065 (4) have appeared. 
Previous studies have shown that CC-1065 alkylates duplex 
DNA to form a 7V3-adenine adduct (5) (Fig. 1). The drug 
molecule lies within the minor groove of DNA spanning a 
4-base-pair (bp) region to the 5' side of the covalently 
modified adenine for which a predominantly A+T sequence 
selectivity exists (6). Thermal treatment of CC-1065-DNA 
adducts leads to loss of the CC-1065-JV3-adenine adduct and 
DNA backbone strand breakage directly to the 3' side of the 
covalently modified adenine (5, 6) (see Fig. 1). CC-1065 has 
been shown to produce depletion of NAD levels in repair 
proficient and deficient (xeroderma pigmentosum) human 
cells, which appears to be related to poly(ADP) ribosylation 
and persistent DNA strand breakage (7).
We have recently developed a method to construct a 
CC-1065-[A/3-flf/e/ime]DNA adduct in a 117-bp restriction
The publication costs of this article were defrayed in part by page charge 
payment. This article must therefore be hereby marked " advertisement” 
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
enzyme fragment from M13mpl DNA at A-6229 (8). This 
method is based on a knowledge of the sequence specificity 
of CC-1065 and its selectivity to bind to duplex DNA in a 
relatively nondistortive manner. We now wish to report the 
unexpected and unusual effect that covalent binding of 
CC-1065 to DNA has on DNA local structure as revealed by 
both DNase I “footprinting” and a unidirectional strand- 
selective inhibition of restriction enzyme cleavage.
MATERIALS AND METHODS
Materials
CC-1065 was obtained from Upjohn. Electrophoretic re­
agents (acrylamide, bisacrylamide, ammonium persulfate, 
and N,N,N',N'-tetramethylethylenediamine) were from Bio- 
Rad. DNase I and bacterial alkaline phosphatase were from 
Sigma. T4 polynucleotide kinase, DNA polymerase I (large 
fragment), and restriction endonucleases Rs/NI, Msp I, Alu 
I, and Hae III were from New England Biolabs. Methidium- 
propyl-EDTA (MPE) was a generous gift of P. Dervan 
(California Institute of Technology). Materials used for 
construction of the site-directed CC-1065-DNA adduct have 
been reported previously (8). X-ray film, intensifying screen, 
and developing chemicals were from Kodak.
Methods
Construction of the Site-Directed CC-1065-DNA Adduct.
The construction of a site-directed CC-1065 adduct into a 
117-bp DNA restriction fragment isolated from the lac insert 
of M13mpl was performed exactly as described (8).
Characterization of CC-1065-Modified DNA Fragments. 
MPE footprinting. The footprinting of the site-directed CC- 
1065-DNA adduct was performed as described (8).
DNase I footprinting. The site-directed CC-1065-DNA 
adduct was footprinted with DNase I by a modification of the 
method of Low et al. (9). in which DNA was suspended in 10 
p\ of 10 mM Tris*HCl (pH 7.5). A freshly diluted DNase I 
solution (2 p\ of 0.35 unit/ml in 20 mM NaCl/5 mM MgCl2) 
was added. After 30 min. 10 pX of tracking dye containing 80% 
formamide, 10 mM EDTA, and 0.1% xylene cyanol was 
added to stop the reaction.
3'-End-Labeling of (-)-Strand of 117-bp Fragment. The 
250-bp fragment obtained from an Msp I digestion of M13mpl 
replicative form DNA was dissolved in 30 p\ of 10 mM 
Tris-HCl, pH 8.0/5 mM MgCl2/7.5 mM dithiothreitol/0.1 
mCi of [a-32P]dCTP (1 Ci = 37 GBq). One unit of the DNA 
pol I (large fragment) was added and incubated for 20 min at
Abbreviation: M PE, methidiumpropyl-EDTA.
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Fic. 1. Reaction of CC-1065 with N i of adenine in DNA and products from thermal cleavage reaction (5,6). The exact nature of the species 
generated on the 5' side of the strand break is unknown.
r o o m  te m p e r a tu r e . O n e  m ic r o lite r  o f  a  10  m M  d G T P  c h a s e  
w a s  a d d e d  a n d  in c u b a te d  a n o th e r  10  m in . A f te r  e th a n o l  
p r e c ip ita t io n ,  s e c o n d a r y  d ig e s t io n  b y  R s /N I  w a s  c a r r ie d  o u t  
t o  o b t a in  th e  1 1 7 -b p  fr a g m e n t.
D N a s e  I F o o tp r in t in g  of the Non-Site-Directed Adduct. A  
C C -1 0 6 5  s o lu t io n  (0 .5  /xl o f  2 .8  /xM  s to c k )  w a s  a d d e d  to  5 /xl 
o f  th e  3 ' -e n d - la b e le d  1 1 7 -b p  D N A  fr a g m e n t a n d  in c u b a te d  fo r  
2 h r  a t 3 7 °C . D N a s e  I d ig e s t io n  w a s  c a r r ie d  o u t  a t  r o o m  
te m p e r a tu r e  fo r  30  m in  w ith  1 ^1 o f  a  fr e s h ly  p r e p a r e d  s o lu t io n  
(0 .3 5  u n i t /m l  in  2 0  m M  N a C l /5  m M  M g C l2). R e a c t io n s  w e r e  
s t o p p e d  w ith  5 /xl o f  tr a c k in g  d y e  a s  d e s c r ib e d .
Restriction Endonuclease Digestion. T h e  s i t e -d ir e c t e d  C C -  
1 0 6 5 - D N A  a d d u c t  w a s  1 0 -fo ld  o v e r d ig e s te d  w ith  e i th e r  A lu  
1 o r  Hae III r e s tr ic t io n  e n d o n u c le a s e s  b y  in c u b a t io n  o f  4 0 0 0  
d p m  o f  u n m o d if ie d  o r  C C -1 0 6 5 -m o d if ie d  D N A  in  1 /xg o f  
u n la b e le d  M 1 3 m p l  r e p lic a t iv e  fo r m  D N A  w ith  5 u n it s  o f  
r e s tr ic t io n  e n d o n u c le a s e  fo r  2 hr a t 37 °C  in  10  /xl of r e a c t io n  
b u ffe r .  R e a c t io n s  w e r e  te r m in a te d  b y  a d d it io n  of 1 0  /xl o f  
tr a c k in g  d y e  a s  fo r  D N a s e  I tr e a tm e n ts  d e s c r ib e d  a b o v e .
D N A  Sequencing Reactions. S in g ly  5 ' o r  3 ' 32P -!a b e le d  D N A  
fr a g m e n ts  w e r e  s e q u e n c e d  u s in g  th e  M a x a m  a n d  G ilb e r t  
b a s e - s p e c i f ic  c le a v a g e  m e th o d  (1 0 ) a n d  s u s p e n d e d  in  a lk a l in e  
t r a c k in g  d y e  fo r 's u b s e q u e n t  p o ly a c r y la m id e  g e l  e le c t r o p h o ­
r e s is .
Polyacrylamide Gel Electrophoresis. A n a ly s e s  o f  M P E ,  
D N a s e  I , a n d  r e s tr ic t io n  e n d o n u c le a s e  d ig e s t io n s  w e r e  p e r ­
fo r m e d  b y  e le c t r o p h o r e s i s  o f  p r o d u c ts  o n  8%  d e n a tu r in g  
p o ly a c r y la m id e  g e ls ,  a s  d e s c r ib e d  (8 ) , a d ja c e n t to  M a x a m -  
G ilb e r t  D N A  s e q u e n c in g  r e a c t io n s .
RESULTS
T h e  a b i li ty  to  c o n s tr u c t  a  s it e -d ir e c te d  C C - 1 0 6 5 - D N  A  a d d u c t  
in  a  1 1 7 -b p  r e s tr ic t io n  e n z y m e  fr a g m e n t  fr o m  M 1 3 m p l D N A  
p r o v id e d  u s  w ith  th e  o p p o r tu n ity  to  p r o b e  th e  e f f e c t  o f  
C C -1 0 6 5  o n  lo c a l D N A  str u c tu r e  w ith o u t  th e  c o m p l ic a t io n s  o f  
m u lt ip le  a d d u c ts  o r  a m b ig u ity  in  a s s ig n in g  th e  s it e  o f  c o v a le n t  
m o d if ic a t io n .  A  c o m b in a t io n  o f  M P E -F e (I I )  fo o tp r in t in g  (1 1 )  
a n d  th e r m a l str a n d  b r e a k  a n a ly s is  a l lo w s  b o th  th e  p o s i t io n  o f  
c o v a le n t  b in d in g  a n d  th e  o v e r la p  o f  th e  d ru g  m o le c u le  o n  
D N A  to  b e  d e te r m in e d  (8 ).
DNase I Footprinting of the Site-Directed CC-1065-DNA 
Adduct in the 117-bp Restriction Enzyme Fragment. D N a s e  I 
h a s  b e e n  p r e v io u s ly  u s e d  to  lo c a te  d r u g -b in d in g  s i t e s  o n  D N A  
an d  to  m o n ito r  th e  in f lu e n c e  o f  d r u g s  o n  lo c a l D N A  s tr u c tu r e  
( 1 2 - 1 4 ) .  In th e  la tte r  r e s p e c t ,  D N a s e  1 is  a m o r e  s e n s i t iv e  
p r o b e  th a n  M P E -F e (I I )  (1 5 ). F ig .  2 s h o w s  th e  r e s u lt s  o f  
D N a s e  I fo o tp r in t in g  o f  th e  s it e -d ir e c t e d  C C - 1 0 6 5 - D N A  
a d d u c t  o n  th e  11 7 -b p  fr a g m e n t. L a n e s  1 - 4  are  d e r iv e d  fr o m  
a  s in g le  5 ' 32P  la b el o n  th e  c o v a le n t ly  m o d if ie d  (-t-)-s tr a n d  (8 ) .
T h e  s ite  o f  c o v a le n t  a t ta c h m e n t  (A -6 2 2 9 )  is  r e v e a le d  b y  th e  
th e r m a lly  in d u c e d  s tra n d  b rea k  (8 ) ( la n e  1). L a n e s  5 - 9  a r e  
fr o m  a  s in g le  5 ' 32P  la b e l o n  th e  n o n c o v a le n t ly  m o d if ie d  
( - ) - s t r a n d .  T h e  lo c a t io n  o f  th e  C C -1 0 6 5  m o le c u le  o n  th is  
stran d  is  r e v e a le d  b y  M P E -F e (II )  fo o tp r in t in g  (1 1 ) ( c o m p a r e  
la n e s  5 a n d  6 ) . D N a s e  I fo o tp r in t in g  o f  e a c h  o f  th e  t w o  
C C -1 0 6 5 -m o d if ie d  5 ' 32P -la b e le d  d u p le x  m o le c u le s  s h o w s  a  
m a r k e d ly  d if fe r e n t  in h ib it io n  p a tte r n  b e t w e e n  th e  tw o  s tr a n d s  
(c o m p a r e  la n e  2 w ith  3 a n d  la n e  8  w ith  9 ) . T h e  ( - ) - s t r a n d  
s h o w s  a  c le a r  in h ib it io n  o f  D N a s e  I c le a v a g e  e x t e n d in g  w e ll  
b e y o n d  th e  C C -1 0 6 5  M P E -F e (II )  fo o tp r in t  (b r a c k e t  Y  in  F ig .
2 ) . A  la rg e  e n h a n c e d  D N a s e  I c le a v a g e  s i t e  a t G -6 2 2 1  w ith  
s m a lle r  e n h a n c e m e n ts  a t 1 an d  2 b a s e s  t o  th e  3 ' s id e  (T -6 2 2 0  
an d  A -6 2 1 8 )  are  a l s o  v is ib le  a t th e  3 ' e n d  o f  th e  in h ib it io n  
z o n e .  A n a ly s is  o f  th e  (+ ) - s t r a n d  t o  th e  3 ' s id e  o f  th e  c o v a le n t  
b in d in g  s it e  (A -6 2 2 9 )  is  c o m p lic a te d  b y  th e  a t t a c h m e n t  o f  th e  
C C -1 0 6 5  m o le c u le s  to  fr a g m e n ts  o n  th is  s id e  o f  th e  C C -1 0 6 5  
a d d u c t , w h ic h  r e s u lt s  in  in h ib it io n  o f  th e ir  m ig r a t io n  r e la t iv e  
to  n o n -d r u g -m o d if ie d  fr a g m e n ts .  C o n s e q u e n t ly ,  o n ly  th e  
p o r tio n  o f  th e  g e l t o  th e  5 ' s id e  o f  A -6 2 2 9  c a n  b e  a n a ly z e d  fo r  
c o m p a r a t iv e  D N a s e  I c u tt in g . S o m e  s ig n if ic a n t  c h a n g e s  in  
D N a s e  I c u tt in g  o c c u r s  in  th is  r e g io n  in c lu d in g  a n  e n h a n c e ­
m e n t a t T -6 2 1 8  a n d  a  n e w  b an d  a t  C -6 2 2 2 .
DNase I Footprinting of Non-Site-Directed CC-1065 DNA 
Adducts on the (-)-Strand of the 117-bp Restriction Enzyme 
Fragment. T o  e n s u r e  th a t th e  s tr ik in g  in h ib i t io n /e n h a n c e -  
m e n t p a tter n  o b s e r v e d  o n  th e  ( - ) - s t r a n d  w a s  b o th  r e p r o d u c ­
ib le  an d  n o t  a  p e c u lia r ity  o f  th e  b in d in g  s e q u e n c e  a t A -6 2 2 9 ,  
a  m u lt ip le  C C -1 0 6 5 -m o d if ie d  fr a g m e n t  w a s  p r e p a r e d . F o r t u ­
n a te ly ,  th e  M 1 3 m p l fr a g m en t w e  h a d  u s e d  fo r  th e  c o n s t r u c ­
t io n  o f  th e  s it e -d ir e c te d  a d d u c t h a s  a ll o f  th e  h ig h -a f f in ity  
C C -1 0 6 5  b in d in g  s i t e s  o n  th e  ( + ) - s t r a n d  (8 ) . C o n s e q u e n t ly ,  
a lth o u g h  th e  a n a ly s is  o f  th e  ( + ) - s t r a n d  is  b lu rr ed  b y  th e  
p r e s e n c e  o f  C C -1 0 6 5  m o le c u le s  a t  m u lt ip le  s i t e s  (r e s u lt s  n o t  
s h o w n ) ,  th e  ( - ) - s t r a n d  is  a m e n a b le  t o  a n a ly s i s .  F ig .  3 s h o w s  
th e  r e s u lts  o f  D N a s e  I fo o tp r in t in g  o f  th e  3 ' 32P - la b e le d  
n o n -s ite -d ir e c te d  C C - 1 0 6 5 - D N A  a d d u c t  o n  th e  ( - ) - s t r a n d  o f  
th e  1 1 7 -b p  fr a g m e n t. T h e  u se  o f  a  3 ' 32P  la b e l  p r o d u c e s  a  m o r e  
r e a d ily  in te r p r e te d  r e su lt  than  th e  5 ' la b e l ,  s in c e  th e  D N a s e  
I c le a v a g e  s ite  w ith  a  3' lab el c o r r e s p o n d s  to  th e  p r o d u c t  o f  
a M a x a m  an d  G ilb er t r e a c t io n . F o u r  C C -1 0 6 5 -b in d in g  s i t e s  
are  fo u n d  in th e  r e a d a b le  p o r tio n  o f  th e  g e l  a n d  t h e s e  a re  
b r a c k e te d  A - D .  A lo n g s id e  th e  b r a c k e t s  a r e  th e  a c tu a l  C C -  
1 0 6 5 -b in d in g  s e q u e n c e s ,  w h ic h  c o r r e s p o n d  to  th e  ( +  )-s tr a n d  
w ith  th e  c o v a le n t ly  m o d if ie d  a d e n in e  d e n o te d  w ith  an  a s t e r ­
isk . F o r  e a c h  C C -1 0 6 5  b in d in g  s i t e ,  a  z o n e  o f  D N a s e  1 c u t t in g  
in h ib itio n  1 3 -1 5  b a s e s  lo n g  ( A ' ,  B ' ,  C ' ,  D ' b a r s  in  F ig . 3) 
s tr a d d le s  th e  d r u g -b in d in g  s it e  w ith  a s it e  o f  D N a s e  I 
e n h a n c e m e n t  (a r r o w s  in F ig . 3) l o c a t e d  at th e  3 ' t e r m in u s  o f  
th e  in h ib it io n  z o n e .  A  c o m p a r i s o n  o f  th e  i n h ib i t io n /
6 4 1 4  B i o c h e m i s t r y :  H u r l e y  et al. Proc. Satl. Acad. Sc i. USA 84 (1987)
F ig . 2. DNase 1 footprinting of 5' 32P-labeled (+)- and (-)-strands of a site-directed CC-1065-DNA adduct on a 117-bp fragment from 
M13mpl DNA. Lanes: 1-4, 5'-(+)-labeled DNA; 5-9, 5 '-(-)-labeled DNA. Lanes 1, 3, 6, and 8. CC-1065-DNA adduct present at A-6229 of 
(+ ) drug strand. Lane 1. thermal treatment (90°C for 30 min) to induce strand breakage at drug-binding site. Lanes 2, 3, 8, and 9, DNase I 
digestion. Lanes 5 and 6. MPE'Fe(II) digestion (11). Lanes 4 and 7, Maxam-Gilbert purine- and pyrimidine-specific cleavage. The bracket Y 
identifies the region across the groove corresponding to inhibition of DNase I on the (-)-strand. T-6218, C-6222, and G-6221 are positions of 
enhanced DNase 1 cleavage.
enhancement pattern for the CC-1065-binding site B in Fig. 3, 
which corresponds to the site-directed CC-1065 adduct in 
Fig. 2, shows a reasonably close match. The inhibition zone 
appears to be somewhat larger for non-site-directed adduct 
(13—15 vs. 12 bases), but the main DNase 1 enhancement site 
is at the same base location. Significantly, the general pattern 
of inhibition/enhancement holds for all four CC-1065 binding 
sites on the (-)-strand and, consequently, we conclude that 
the results o f the site-directed CC-1065-DNA adduct are 
representative o f CC-1065 lesions on DNA.
Alu 1 and Hae III Restriction Enzyme Digestion of the 117-bp 
Fragment Containing the Site-Directed CC-1065-DNA  
Adduct. The 117-bp fragment containing the site-directed 
CC-1065-DNA adduct has single restriction enzym e cleav­
age sites for Alu I and Hae III, 14 and 12 bp to the 5' and 3' 
side of the covalently modified adenine, respectively (Fig. 2). 
This permitted an analysis of the effect o f CC-1065 on 
restriction enzyme recognition and catalytic activity. The 
results in Fig. 4 show that while Hae III is able to cut both 
the ( - ) -  and ( + )-strands in the presence o f  CC-1065 (lanes 6  
and 12), Alu I is only able to cut the ( + )-strand in the presence 
o f CC-1065 (lanes 4 and 10). The slower migration o f the 
fragments in lanes 2 and 6  relative to lanes 1 and 5 is due to 
the presence of CC-1065 at A-6229.
D I S C U S S I O N
CC-1065, like other covalent minor groove-binding agents 
such as the pyrrolo[1.4]benzodiazepines (16), is considerably 
more potent as a cytotoxic agent than the noncovalent minor 
groove binders distamycin and netropsin (4). Consequently, 
we can conclude that simple occupation of the minor groove
is not sufficient for high potency, but som e inherent property 
of the covalent modification o f D N A  is also required. 
Furthermore, since CC-1065 and the distamycin group have 
similar sequence specificities (9), cytotoxic potency is not 
apparently related to A +T  versus G +C  specificity, a fact 
further substantiated by the G +C  specificity o f  the pyr- 
rolo[l,4]benzodiazepines (17). Consequently, it is of consid­
erable importance to elucidate the structural (steric and 
electronic) features of the CC-1065-|7V3-ad£,w>ie] DNA  
adduct that might mediate the potent cytotoxic effects o f  
CC-1065 and possibly other minor groove covalent binders. 
Several properties of these D N A  adducts might be important 
in this regard. For example, the stabilizing but relatively 
nondistortive nature of the CC -1065-D NA  adduct might be a 
potent cytotoxic combination o f  properties o f a drug-DNA  
adduct. This type of DNA lesion might be difficult to detect 
and/or repair, or, alternatively, covalent binding might 
predispose the DNA in the near vicinity o f  the adduct to 
assume an unusual or anomalous form that has detrimental 
biological consequences. The availability o f a site-directed 
CC-1065-DNA adduct in a 117-bp restriction enzyme frag­
ment from M13mpl has allowed us to probe the effect o f drug 
binding on the local DNA structure.
The results presented in Figs. 2 -4  demonstrate that cova­
lent binding of CC-1065 to DN A  induces an asymmetric effect 
on DNA structure as revealed by the strand-selective inhi­
bition of DNase I and Alu I cleavage. Several features of the 
drug-induced changes in the D Nase 1 cleavage pattern are 
significant. This includes the strand-selective inhibition o f  
cleavage spanning a 12-bp region on the (-)-strand  and the 
presence of enhanced sites o f cleavage on both (+)- and 
( -  )-strands in the direction o f  drug overlap from the covalent
B i o c h e m i s t r y :  H u r l e y  et al. Proc. Natl. Acad. Sri. USA H4 (19X7) 6 4 1 5
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F ig . 3. DNase I footprinting of 3' 32P-labeled (-)-s trand  of a 
non-site-directed CC-1065-DNA adduct on a 117-bp fragment from 
M13mpl DNA. Lanes: 1 and 2, Maxam and Gilbert purine- and 
pyrimidine-specific cleavage; 3 and 4. subjected to DNase I diges­
tion. Lane 3. control (no drug modification); lane 4, CC-1065 
modification at sites indicated by brackets A, B, C, and D. These 
brackets correspond to the CC-1065-binding sequences (8), which are 
identified as they correspond to the covalently modified (+)-strand, 
with the covalent modified adenine denoted by an asterisk. DNase 
1-enhanced cleavage sites are indicated by arrows; A8, etc ., corre­
sponding to the CC-1065-binding site and distance between the 
covalent binding site and the enhancement site. Vertical bars, zones 
of DNase 1 inhibition corresponding to each drug-binding site—i.e., 
A ' corresponding to CC-1065 binding site A.
binding site (A-6229) (Fig. 5). Superficially, the selective 
inhibition of Alu 1 cleavage on the same strand as D N ase I 
inhibition suggests that drug modification may cause a 
selective conformational change in the structure o f the 
(-)-strand . However, as we discuss below, a consideration of 
the structures and mechanisms of cleavage o f D N A  by 
DNase I leads to a quite different interpretation o f these data.
The structure of DNase I at 2.0 A resolution (18) permitted 
Suck and Oefner to propose a mechanism for binding to and 
cutting of DNA. One feature of this model, which has
1 2 3 4 5
(+) l a b e l e d
7 8 9 10 11 12
l a b e l e d
c o n t r o l Alu I Haell l  control  Alu I H ae l l l
i  r i  r
Fig. 4. Denaturing electrophoretic analysis of Hae 111 and Alu I 
digestion of the site-directed CC-1065-DNA adduct in the 117-bp 
fragment from M13mpl DNA. Lanes: 1-6, 5' 32P-(+)-Iabeled DNA; 
7-12, 5' 32P-(-)-labeled DNA. Odd-numbered lanes, no drug mod­
ification; even-numbered lanes. CC-1065 modification of adenine 
6229 of the (-t-)-strand. Lanes 3. 4. 9, and 10, 10-fold overdigestion 
with Alu I; lanes 5, 6,11, and 12 .10-fold overdigestion with Hae 111. 
For an explanation of slower migration of bands in lanes 2 and 6, see 
text.
recently been confirmed (18) by x-ray structure analysis o f a 
DNase I-DNA complex, is penetration of an exposed loop of 
the protein into the minor groove, 2-3 bp to the 5' side o f  the 
DNase I cutting site. Consequently, steric interactions in the 
minor groove between the covalently bound CC-1065 and the 
exposed loop of the protein predict inhibition o f D Nase I 
cleavage between G6222 and T6226 on the (-)-strand  and 
between T6228 and G6232 on the (+)-strand [A( + ) and A(-) in 
Fig. 5]. This accounts partially for the inhibition zone on the 
(-)-strand and for the visible part (T-6228) o f the inhibition 
zone on the ( + )-strand. A second important feature o f the 
mechanism of DNase I binding to DNA is van der Waals 
interactions, which occur between the protein and two 
phosphates on the opposite strand to the cutting site, 5 -6  bp 
on the 5' side. Consequently, the observed inhibition of  
DNase I cutting between A6227 and T6233 on the (-)-strand  
could result from a drug-induced change in the conformation 
of the ( + )-strand between C6222 and T6228, which could 
prevent the correct alignment o f D Nase I required for 
cleavage in this region (Fig. 5, brackets B' and B"). In 
contrast, the normal or sometimes enhanced cleavage by 
DNase I on the (-t-)-strand to the 5' side o f the covalent 
binding site implies that the backbone conformation of the 
(-)-strand in the vicinity of the drug-binding site is not 
adversely affected. Unlike the results o f previous studies 
with noncovalently binding drugs (9, 14), the CC-1065- 
induced changes in DNase 1 cleavage pattern observed here 
are generally not staggered 2-3 bases in the 3' direction 
across the strands as would be expected if these represent 
changes purely in groove width.
6 4 1 6  B i o c h e m i s t r y :  H u r l e y  et al. Proc. Natl. Acad. Sci. USA 84 (1987)
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Fig. 5. Schematic representation of the DNase I cleavage pattern in the vicinity of the CC-1065-DNA adduct and its interpretation based 
on the structure of DNase I (18). CC-1065 is covalentiy bound at A-6229 and covers 4 bases to the 5' side of A-6229. Bases enclosed in boxes 
represent sites of CC-1065-induced inhibition of DNase 1 cleavage and circled bases represent sites of enhanced cleavage. Brackets A1-1 and 
A(+> represent predicted inhibition of DNase 1 cleavage due to steric interaction between the exposed loop of DNase I and CC-1065 in the minor 
groove on the ( + )- and (-)-strands, respectively. Bracket B' includes the region of the (-)-strand  that shows inhibition of DNase 1 cleavage, 
which is proposed to be due to a CC-1065-induced alteration in structure on the (-t-)-strand enclosed by bracket B". The sites of Alu 1 cleavage 
[( + )-strand] and inhibition [(-)-strand] are also shown.
S in c e  th e  str u ctu r e  o f  Alu 1 is  u n k n o w n , it is  im p o s s ib le  to  
p r e d ic t  w ith  c o n f id e n c e  w h y  c le a v a g e  o n  o n ly  o n e  o f  th e  s tr a n d s  
( - )  is  in h ib ited . A s  d e sc r ib e d  a b o v e , in te r p r e ta t io n  o f  th e  
a s y m m e tr ic  D N a s e  I c le a v a g e  p attern  le a d s  u s  to  s u s p e c t  th a t  
it is  th e  c o v a le n t ly  m o d if ie d  stran d  that u n d e r g o e s  th e  c o n fo r ­
m a tio n a l c h a n g e . C o n s e q u e n t ly ,  w e  m igh t e x p e c t  th e  a s y m m e t ­
ric e f f e c t s  o n  Alu I c le a v a g e  to  a ls o  resu lt fr o m  a  c h a n g e  in  
s tr u c tu r e  o n  th e  (+ )-s tr a n d . H o w e v e r ,  th e  r e su lts  s h o w  s e le c ­
t iv e  in h ib itio n  o f  c le a v a g e  o c c u r s  o n  th e  ( - ) - s t r a n d .  A  p o s s ib le  
e x p la n a t io n  fo r  th is  ap p a re n t a n o m o lo u s  r esu lt  c a n  b e  fo u n d  i f  
w e  a s s u m e  an  a n a lo g o u s  str u ctu r e  fo r  Alu I to  th a t o f  £ c o R I ,  
w h ic h  is  a n o th e r  ty p e  II e n d o n u c le a s e  fo r  w h ic h  a  c r y s ta l  
s tr u c tu r e  o f  its  c o m p le x  to  a n  o lig o n u c le o t id e  is  a v a ila b le  (1 9 ),  
a n d  th e  im p o r ta n c e  o f  th e  e n fo ld in g  arm s in  th e  c le a v a g e  
r e a c t io n  h a s  b e e n  e s ta b lish e d  (2 0 ). E c o R I  is a  h o m o d im e r  w ith  
t w o  a r m s th a t w r a p  a rou n d  th e  D N A  an d  c la m p  th e  b a c k s id e  o f  
th e  D N A  d ir e c t ly  a c r o s s  th e  d o u b le -s tr a n d e d  h e lix  fr o m  e a c h  
s c i s s i le  b o n d . E n z y m a tic  r e m o v a l o f  th e se  a r m s r e su lts  in  lo s s  
o f  D N A  c le a v a g e  a c t iv ity , a lth o u g h  s e q u e n c e  s p e c if ic ity  fo r  
b in d in g  is  r e ta in e d  (2 0 ), C o n s e q u e n t ly ,  w e  s u g g e s t  th a t a  
d r u g -in d u c e d  c h a n g e  in th e  D N A  c o n fo r m a tio n  o n  th e  ( + ) -  
str a n d  at a r o u n d  A 6 2 1 7  a n d  T 6 2 1 8  r esu lts  in  lo s s  o f  cr itic a l  
c o n ta c t s  th a t a r e  req u ired  fo r  Alu I c le a v a g e  t o  th e  5 ' s id e  o f  
C 6 2 1 4  o n  th e  ( - ) - s t r a n d  (F ig . 5 ).
B a s e d  o n  th e  in te r p r e ta t io n  o f  th e  D N a s e  I fo o tp r in t in g  
e x p e r im e n t s  a n d  th e  s e l e c t iv e  in h ib it io n  o f  Alu I c le a v a g e  o n  
th e  ( - ) - s t r a n d .  w e  te n ta t iv e ly  c o n c lu d e  th a t C C -1 0 6 5  p r o ­
d u c e s  a  s e l e c t i v e  c o n fo r m a t io n  c h a n g e  in th e  s tr u c tu r e  o f  th e  
( + ) - s t r a n d ,  w h ic h  e x te n d s  p e r h a p s  a s  far  a s  11 b a s e s  to  th e  
5 ' s id e  o f  th e  c o v a le n t  m o d if ic a t io n  s it e .  S in c e  th e  d r u g -  
in d u c e d  c h a n g e s  o n  th e  ( - ) - s t r a n d  s e e m  fa r  l e s s  s ig n if ic a n t ,  
w e  s u g g e s t  th a t th e  d u p le x  D N A  in th e  v ic in it y  o f  C C -1 0 6 5  
la c k s  th e  id e n t ic a l  a n t ip a r a lle l  s tr a n d  c o m m o n ly  a s s o c ia t e d  
w ith  A - ,  B - ,  a n d  Z - D N A . S in c e  c o v a le n t  b in d in g  o f  C C -1 0 6 5  
to  D N A  a p p e a r s  to  r eq u ire  a  d e fo r m a tio n  o f  D N A  s tr u c tu r e  
in  th e  v ic in it y  o f  th e  a d d u c t ,  it is  th e n  p o s s ib le  th a t th e  r e la t iv e  
p r o p e n s ity  o f  d iffe r e n t  s e q u e n c e s  to  u n d e r g o  th is  c o n f o r m a ­
t io n a l  c h a n g e  m a y  p la y  a  r o le  in s e q u e n c e  s e l e c t i v i t y  fo r  
c o v a le n t  b in d in g . S u c h  an  a r g u m e n t h as b e e n  p u t fo r w a r d  
b a s e d  o n  th e o r e t ic a l  m o d e l in g  to  a c c o u n t  fo r  th e  e x p e r im e n ­
ta l ly  d e te r m in e d  s e q u e n c e  s p e c i f ic i t y  o f  th e  p y r r o lo [ l ,4 ] b e n -  
z o d ia z e p in e s  (2 1 ). T h e  m a n n e r  in w h ic h  t h e s e  d r u g - in d u c e d  
c o n fo r m a t io n a l  c h a n g e s  in D N A  s tr u c tu r e  r e la te  to  th e  
b io lo g ic a l  p o t e n c y  o f  C C -1 0 6 5  r e m a in s  to  b e  d e te r m in e d .
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Determination of the Structural Features of (+)-CC-1065 That 
Are Responsible for Bending and Winding of DNA
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Analysis o f the anomalous migration in electrophoretic m obilities of (+)-CC-1065-m odified  
oligomers following ligation reveals that (+)-CC-1065 induces DN A  bending and winding of the  
helix. (+)-CC-1065 is a potent antitumor antibiotic produced by S trep tom yces zelensis. This 
drug selectively bonds covalently to N3 of adenine and lies in the minor groove of DNA, reacting 
in a highly sequence-selective manner. Structurally, (+)-CC-1065 consists of three subunits: 
two identical pyrroloindole units (subunits B  and C) and a third subunit containing the  
DNA-reactive cyclopropane ring (subunit A). While the bonding reaction is the main determinant 
of D N A  sequence selectivity of (+)-CC-1065, binding interactions between the inside edge 
substituents of the B and C subunits and the floor of the minor groove of D N A  can m odulate  
or fine tune th is sequence selectivity [Hurley, L. H., Lee, C.-S., McGovren, J. P., M itchell, M. 
A., Warpehoski, M. A., Kelly, R. C., & Aristoff, P. A. (1988) B iochem istry  27, 3886-3892]. The  
A subunit of (+)-CC-1065 is responsible for the bending of DNA, and close van der Waals contacts 
between the inside edge of (+)-CC-1065 and the floor of the minor groove of D NA cause winding 
equivalent to  about 1 base pair per alkylation site and stiffening of DNA. The m agnitude of  
D N A  bending induced by (+)-CC-1065 and related com pounds is about 14-19°, which is 
equivalent to  that produced by an adenine-thym ine tract o f about 5 -6  base pairs in length. 
Experiments using oligomers containing both an adenine tract and a unique (+)-CC-1065 bonding 
site approxim ately one helix turn apart dem onstrate that the directionality of drug-induced  
bending is in toward the minor groove and the locus of bending is about 2 -3  base pairs to the  
5'-side of the covalently m odified adenine. A circularization efficiency assay shows that the  
optimum size of circles produced by (+)-CC-1065 and related drugs is between 168 and 180 base 
pairs. T hese results are discussed in relation to the molecular basis o f the D N A  sequence 
selectivity of (+)-CC-1065, and the (+)-CC-1065-induced D N A  bending is compared with the  
intrinsic bending associated with adenine tracts. Since (+)-CC-1065 induces effects on local 
DN A  structure that appear similar to those produced naturally by adenine tracts and certain 
DN A  binding proteins, the relevance of this phenom enon to biological effects of (+)-CC-1065  
and related drugs is considered.
4 Introduction
It has been demonstrated that bending occurs naturally 
in DNA fragments containing short runs of adenine (A- 
f tracts)1 (1-3), and it can be induced by site-specific DNA  
binding protein such as CAP (4,5), RNA polymerase (6), 
| and Escherichia coli integration host factor (7-9). Several 
models have been proposed to explain the phenomenon 
of DNA curvature at the molecular level ( 1 ,10-13), but 
the junction-bend model (1,14) appears to have the most 
support. The anomalies in electrophoretic mobilities of 
bent DNA on nondenaturing polyacrylamide gels have 
been used to investigate bending induced by intrastrand 
platinum cross-linking (15), interstrand psoralen cross- 
linking (16), and UV-induced thymine dimer (17) in duplex 
DNA. The major groove direction of the platinum-induced 
bends was determined by copolymerizing a duplex con­
taining the platinum adducts with a series of synthetic 
decamers containing an A5 tracts (15).
CC-1065 is an extremely potent antitumor antibiotic 
produced by Streptom yces zelensis (18-20). It is active
* Address correspondence to this author.
* On leave from Faculty of Pharmaceutical Sciences, Kanazawa 
University, 13-1, Takara-machi, Kanazawa 920, Japan.
0893-228x/91/2704-0203$02.50/0
against several experimental murine tumors in vivo and 
is about 100 times more potent than adriamycin against 
a broad spectrum of tumors in the cloning assay (21). 
CC-1065 bonds covalently through N3 of adenine (22,23) 
and lies within the minor groove of DNA, covering a 3 and 
1 bp region to the 5'- and 3'-side, respectively, of the co­
valently modified adenine (24). Upon thermal treatment 
of CC-1065-(N3-adenine)-DNA adducts, cleavage of the 
N-glycosidic linkage and subsequent backbone breakage 
occur to the 3'-side of the covalently modified adenine to 
leave a 5'-phosphate on the 3'-side of the break and, pre­
sumably, a modified deoxyribose on the 5'-side (25) (Figure 
1). This strand breakage assay has been used to determine 
the DNA sequence selectivity of CC-1065: two subsets of 
consensus bonding sites [5'PuNTTA* and 5'AAAAA*, 
where (*) indicates the covalently modified adenine and 
N indicates any of the four bases in DNA] were identified 
in the first study (25), and in the second study (26) the 
consensus sequence 5'(A /T)(A /T)A * was found. The
1 Abbreviations: CAP, catabolite activator protein; bp, base pair(s); 
EDTA, ethylenediaminetetraacetic acid; TEMED, NjlJN'JI'-tetra- 
methylethylenediamine; DSC, 15 mM NaCl and 1.5 mM sodium citrate, 
pH 7.4; Tris, tris(hydroxymethyl)aminomethane; A-tracts, adenine tracts; 
A6, five adenines; A$, six adenines; Pu, purine nucleotide; TBE, Tris- 
borate-EDTA; N, any nucleotide.
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F ig u r e  1. R e a c t io n  o f  C C -1 0 6 5  w ith  N 3  o f  a d e n in e  in  D N A  a n d  
p r o d u c ts  fr o m  th e r m a l c le a v a g e  r e a c tio n . S p e c ie s  “A ” is  th e  
p r o d u c t  p r o d u c e d  b y  th e r m a l t r e a tm e n t , a n d  s p e c ie s  “B ” is  th e  
p r o d u c t  p r o d u c e d  b y  th e r m a l a n d  s u b s e q u e n t  p ip e r id in e  t r e a t ­
m e n t . T h e  e x a c t  n a tu r e  o f  th e  s p e c ie s  g e n e r a te d  o n  th e  5 '-s id e  
o f  th e  s tr a n d  b r ea k  is u n k n o w n  (25 ).
c o n s t r u c t i o n  o f  a  s i t e - d i r e c t e d  C C - 1 0 6 5 - ( N 3 - a d e n i n e ) -  
D N A  a d d u c t  in  a  1 1 7 - b p  f r a g m e n t  o f  M 1 3 m p l  D N A  (27) 
a l lo w e d  d e t e r m i n a t i o n  o f  t h e  e f f e c t  o f  c o v a l e n t  a t t a c h m e n t  
o n  l o c a l  D N A  s t r u c t u r e .  D N a s e  I  f o o t p r i n t i n g  a n d  r e ­
s t r i c t i o n  e n z y m e  a n a l y s i s  d e m o n s t r a t e d  t h a t  C C - 1 0 6 5  a d ­
d u c t  f o r m a t io n  p r o d u c e s  a n  a p p a r e n t  s t r a n d - s e l e c t i v e  a n d  
u n i d i r e c t i o n a l  e f f e c t  o n  D N A  s t r u c t u r e ,  w h i c h  e x t e n d s  
m o r e  t h a n  o n e  h e l i x  t u r n  t o  t h e  5 ' - s i d e  o f  t h e  c o v a l e n t  
b o n d i n g  s i t e  (28).
T h e  C C - 1 0 6 5  m o l e c u l e  ( F ig u r e  1 )  c o n s i s t s  o f  t h r e e  r e ­
p e a t i n g  p y r r o l o i n d o l e  s u b u n i t s ,  o n e  o f  w h i c h  ( t h e  A  s u b ­
u n i t )  c o n t a i n s  a  D N A - r e a c t i v e  c y c l o p r o p y l  f u n c t i o n .  
N a t u r a l l y  o c c u r r i n g  C C - 1 0 6 5  a n d  s y n t h e t i c  a n a l o g u e s  
h a v i n g  t h e  s a m e  s t e r e o c h e m i c a l  c o n f i g u r a t i o n  o f  t h e  c y ­
c l o p r o p a n e  r in g  in  t h e  A  s u b u n i t  a r e  d e s i g n a t e d  ( + ) - e n -  
a n t i o m e r s .2 A n a l o g u e s  c o n t a i n i n g  t h e  a l k y l a t i n g  s u b u n i t  
l i n k e d  t o  a c e t y l  o r  o n e  o r  t w o  i n d o l e  s u b u n i t s  a r e  d e s i g ­
n a t e d  A , A B ,  a n d  A B C ,  r e s p e c t i v e ly .  A n  a n a lo g u e  h a v in g  
t h e  s a m e  s t r u c t u r e  o f  C C - 1 0 6 5  e x c e p t  t h a t  i t  l a c k s  t h e  
h y d r o x y l  a n d  m e t h o x y l  s u b s t i t u e n t s  o n  t h e  B  a n d  C  s u b ­
u n i t s  i s  t e r m e d  A B 'C ' .  T h e  s t r u c t u r e s  o f  n a t u r a l l y  o c ­
c u r r in g  C C - 1 0 6 5  a n d  s e l e c t e d  s y n t h e t i c  ( + ) - e n a n t i o m e r i c  
a n a l o g u e s  u s e d  in  t h i s  i n v e s t i g a t i o n  a r e  s h o w n  in  F ig u r e  
2 .
F a c i l i t a t e d  b y  t h e  e x t e n s i v e  a r r a y  o f  a n a l o g u e s  s y n ­
t h e s i z e d  b y  U p j o h n  s c i e n t i s t s  (29-31), s t r u c t u r e - a c t i v i t y  
r e l a t i o n s h ip s  h a v e  b e e n  s h a r p ly  d e f in e d  (32). O f  p a r t ic u la r
2 Since only (+)-enantiom ers [i.e., those having the sam e stereochem ­
istry o f the cyclopropyl ring as the natural product (+)-CC-1065] were 





































F ig u r e  2. S tr u ctu re s  o f  C C -1065  an d  its  sy n th e tic  analogues 
in  th is  in v e s t ig a t io n . C o m p o u n d s  sh o w n  a ll h a v e  the same 
s te r e o c h e m is tr y  a s  th e  n a tu r a lly  o c cu r r in g  (+ )-C C -106 5 .2
s i g n i f i c a n c e  i s  o u r  o b s e r v a t i o n  t h a t  t h e  A  subunit 
C C - 1 0 6 5  h a s  s u f f i c i e n t  s t r u c t u r a l  i n f o r m a t i o n  t o  elicit the 
s e q u e n c e  s p e c i f i c i t y  o f  A B C ,  a l t h o u g h  t h e  p r e c is e  struc­
t u r a l  n a t u r e  o f  t h e  B  a n d  C  s u b u n i t s  c a n  m o d u la te  or fine 
t u n e  t h i s  s p e c i f i c i t y  (33). I n  p r e v io u s  p u b l ic a t io n s  (19, 
w e  h a v e  a r g u e d  t h a t  t h e  p r im a r y  b a s i s  fo r  t h e  sequence 
s e l e c t i v i t y  o f  C C - 1 0 6 5  i s  a  sequence-dependent catalytic 
activa tion  a n d / o r  a  sequence-dependent conformation 
flexibility. I n  c o n t r a s t  t o  t h i s  c o n c lu s io n ,  w e  h a v e  recently 
d e m o n s t r a t e d  t h a t  t h e  s e q u e n c e  s e l e c t i v i t y  o f  (-)-C C -lf ’ 
t h e  s y n t h e t i c  e n a n t i o m e r ,  i s  l a r g e l y  d e t e r m i n e d  by r 
c o v a l e n t  b i n d i n g  i n t e r a c t i o n s  (26).
T h e  p u r p o s e  o f  t h e  w o r k  d e s c r ib e d  h e r e  w a s  to  further 
d e f i n e  t h e  e f f e c t  o f  C C - 1 0 6 5  c o v a l e n t  b o n d in g  reactivity 
a n d  b in d in g  i n t e r a c t io n s  o n  lo c a l  D N A  s tr u c tu r e  and, more 
s p e c i f ic a l ly ,  t h e  p o s s i b le  a b i l i t y  t o  c a u s e  o r  e n tr a p  bending 
o f  D N A .  F o r  t h e s e  s t u d ie s ,  C C -1 0 6 5  a n d  s e le c t e d  synthetic 
a n a l o g u e s  w e r e  r e a c t e d  w i t h  a  s e r i e s  o f  oligodeoxy- 
n u c le o t i d e s  c o n t a in in g  a  u n iq u e  d r u g  b o n d in g  s ite  
l i g a t e d  i n t o  m u l t i m e r s  t o  a m p l i f y  a n y  s t r u c t u r a l  
in  t h e  d o u b l e  h e l i x  (1). T h e  a n o m a l o u s  m igration  
e l e c t r o p h o r e t i c  m o b i l i t y  o f  l ig a t io n  p r o d u c t s  w a s  analyzs 
b y  n o n d e n a t u r i n g  g e l  e l e c t r o p h o r e s i s  t o  d e t e c t  structural 
a n o m a l i e s  s u c h  a s  b e n d s .  T h e  r e s u l t s  s h o w  that CO 
1 0 6 5 - i n d u c e d  D N A  b e n d i n g  o c c u r s  a s  a  con seq u en ce oi
CC-1065'Induced DNA Bending




















0 Duplexes were designed to expose three nucleotide asymmetric 
overhangs so as to ensure both head-to-tail ligation and that a 
unique bonding site (5'GATTA*) for drugs was contained in the 
center of the sequences. (A) 17,19, 20, 21, 22, and 23 bp oligomers 
were used to study the effect of varying the distance between 
CC-1065 bonding sites on electrophoretic mobility, and the 20- and 
21-mer were also used to determine the percentage of circular vs 
noncircular DNA in CC-1065- and ABC-modified oligomers, re­
spectively. (B) 21-A-I, 21-A-II, 21-A-III, and 21-A-IV bp oligomers 
were used to determine the direction and locus of ABC- and CC- 
1065-induced bends relative to A5-tract bends.
covalent bonding reaction of the A subunit with DNA. 
Furthermore, the directionality of the CC-1065-induced 
DNA bending is in toward the minor groove of DNA. 
Interactions between the inside edge substituents of 
CC-1065 and the floor of the minor groove of DNA lead 
to winding of the DNA helix. The possible importance of 
CC-1065-induced DNA bending to sequence selectivity, 
relationship to bending in naturally occurring A-tracts, and 
biological activity are discussed. We have recently shown, 
using hydroxyl radical cleavage and two-dimensional *H 
NMR studies, that the CC-1065-induced DNA bending 
appears to have structural characteristics (i.e., narrowing 
of the minor groove) that are similar to those associated 
intrinsically with A-tracts (34).
Materials and Methods
C hem icals and E nzym es. CC-1065 was isolated from the 
fermentation broth of S. zelensis (18). The synthetic analogues 
(Figure 2) used in this study were obtained from J. Patrick 
McGovren at the Upjohn Co., Kalamazoo, MI (29-31). Elec­
trophoretic reagents [acrylamide, TEMED, ammonium persulfate, 
and bis(acrylamide)] were purchased from Bio-Rad. T4 poly­
nucleotide kinase and T4 DNA ligase were from Bethesda Re­
search Laboratories. [7 -32P]ATP was from ICN. X-ray film, 
intensifying screens, and developing chemicals were from Kodak.
Preparation o f Oligonucleotides. A series of oligonucleotides 
(17, 19, 20, 21, 22, and 23 bp) (Table IA) and 21-A-I, 21-A-II, 
21-A-III, and 21-A-IV were synthesized on an automated DNA  
synthesizer (Applied Biosystems 381A) by the phosphoramidite 
method. The oligomers were then deprotected separately with 
saturated ammonium hydroxide at 55 °C overnight. Solvent was 
evaporated at room temperature.
K in ase R eaction  o f  O ligon u cleo tid es. Approximately 10 
Mg of each oligonucleotide of complementary sequence was mixed 
in 23 mL of solution containing 70 mM Tris-HCl (pH 7.6), 10 mM 
MgCl2, and 5 mM dithiothreitol and 5'-labeled with 30 nCi of
Chem. Res. Toxicol., Vol. 4, No. 2, 1991 205
[7 -32P]ATP and 6 units of T4 polynucleotide kinase at 37 °C for 
20 min. After labeling with [7 -32]ATP, 1 fih of 0.1 M cold ATP 
and an additional 6 units of T4 polynucleotide kinase were added, 
and kinasing reaction was continued in the same buffer at 37 °C 
for an additional 1 h.
P u rifica tion  o f K inased O ligonucleotides. Kinased oligo­
nucleotides were heated to 55 °C and cooled slowly to 4 °C to 
form hybridized duplexes. Duplexes were electrophoresed on the 
8% nondenaturing polyacrylamide gel until the bromophenol blue 
marker had migrated 23 cm in a 30 cm X 36 cm X 0.8 mm gel. 
The ratio of monoacrylamide to bis(acrylamide) was 29:1 (w/w). 
The electrophoresis buffer was 50 mM Tris-borate (pH 8.3) and 
1 mM EDTA (TBE buffer). The gels were electrophoresed at 
room temperature at 7 V/cm. After the gels were exposed to X-ray 
film, duplexes were excised from the gel, minced with a blade, 
and extracted with 400 juL of annealing buffer [100 mM NaCl, 
10 mM Tris-HCl (pH 8.0)].
D N A  Strand Breakage A ssay. The DNA strand containing 
the CC-1065 alkylation site on 21 bp oligomers was 5'-end-labeled, 
hybridized with the unlabeled complementary strand, and purified 
as described above. Aliquots of purified 21 bp duplexes were 
modified with 2.8 nM CC-1065 as described above. Drug-modified 
duplexes were resuspended in 100 nL of DSC and heated at 90 
°C for 30 minutes to produce strand breakage at the covalent 
modification site (25). The DNA samples were denatured by 
heating at 90 °C for 30 min in formamide (80%)-NaOH (10 mM) 
solution and then subjected to 12% denaturing gel electrophoresis 
in parallel with DNA sequencing reactions.
DNA  Sequencing. Purine- and pyrimidine-specific sequencing 
reactions were carried out according to the methods of Maxam 
and Gilbert (35), and an adenine-specific sequencing reaction was 
carried out according to the method of Iverson and Dervan (36).
D ru g  B ind ing , L igation , and Gel A n a lysis . Both of the 
complementary oligonucleotides (approximately 10 ng) were la­
beled with [7 -32P]ATP (Amersham) by T4 polynucleotide kinase 
as described before, and the duplex DNA was gel purified by an 
8 % nondenaturing polyacrylamide gel electrophoresis. For drug 
modification, duplex oligomers (10 mL) were incubated with the 
same volume of 2.8 mM A, 0.28 mM AB, and 28 nM  ABC, AB'C', 
and CC-1065 at room temperature for 3 days, followed by an 
ethanol precipitation to remove unbound drug molecules. 
Drug-modified and nonmodified duplexes were self-ligated to 
produce multimers in 25 fiL of ligation buffer with 1 unit (1 mL) 
of T4 DNA ligase at room temperature overnight. The ligation 
buffer contains 25 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 2.5% 
(w /v) poly(ethylene glycol) 8000, 0.5 mM ATP, and 0.5 mM  
dithiothreitol. Ligated multimers were electrophoresed on an 8% 
nondenaturing polyacrylamide gel and the radiolabeled bands 
located by autoradiography.
C ircu lar iza tion  E xperim ent. In the first-dimensional 
electrophoresis, ligated multimers of drug-modified or control 
oligomer were electrophoresed on an 8 % nondenaturing poly­
acrylamide gel until the bromophenol blue marker reached the 
bottom of gel, and the gel fragment containing the DNA was cut 
from the gel. After equilibration of the gel fragment with TBE  
buffer containing 50 n g /m h  chloroquine phosphate for 15 min, 
it was laid down on top of a glass plate and allowed to polymerize 
with 8 % polyacrylamide containing 50 fig /m h  chloroquine 
phosphate. After second-dimensional electrophoresis in the 
presence of the same concentration of chloroquine as the gel, the 
radiolabeled spots representing both DNA families were removed 
from the gel and crushed, and DNA was extracted with double­
distilled water from the gel. The solution containing the eluted 
DNA was lyophilized and dissolved in 90% (w /v) formamide in 
0.1 M Tris-HCl (pH 7.8), boiled for 30 minutes, and cooled in ice, 
before 8 % denaturing polyacrylamide gel electrophoresis (7 M 
urea) was used to determine lengths of DNA in each radioactive 
spot. The lengths of DNA in each radioactive spot (linear DNA  
and circular DNA) were measured from comparison with the 20 
bp ladder-size markers, which were produced by ligation of the 
20 bp oligomer duplex.
C h loroquine U n w in d in g  E xp erim en ts. To probe the 
winding effect of CC-1065 and its analogues, chloroquine was 
added to the polyacrylamide gel and running buffer at concen­
trations between 0.05 and 2 ng/m L  during the electrophoresis. 
In the presence of different concentrations of chloroquine, the
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F i g u r e  3. Autoradiogram of the thermally induced strand 
breakage assay of CC-1065-modified 21 bp oligomers. Lanes 1, 
2, and 3 reactions are A, AG, and TC specific reactions, respec­
tively. Lanes 4 and 5 contain the non-drug-modified oligomers 
and CC-1065-modified oligomer (0.28 mM), respectively, following 
thermal cleavage. The DNA samples were prepared as described 
under Materials and Methods and electrophoresed on a 12% 
denaturing polyacrylamide gel until the bromophenol blue marker 
had migrated 10 cm in a 30 cm X 36 cm X 0.4 mm gel.
changes in the electrophoretic migratory rate of ligated multimers 
of drug-modified 21-mer oligomers (Table IA) were analyzed by 
determining Rh values.
Results
Characterization of D rug-O ligonucleotide Adducts 
by Gel E lectrophoresis and D N A  Strand B reakage  
A ssay. A  c o m p a r i s o n  o f  t h e  e l e c t r o p h o r e t i c  m o b i l i t y  o f  
C C - 1 0 6 5 ,  A B 'C ' ,  A B C , a n d  n o n - d r u g - m o d i f i e d  m o n o m e r s  
r e v e a l e d  t h a t  w h i l e  n o n - d r u g - m o d i f i e d  m o n o m e r s  o f  1 5 ,  
1 7 , a n d  1 9  b p  o l ig o m e r s  a r e  m e l t e d  t o  s in g le - s t r a n d e d  D N A  
b y  i n c u b a t i o n  a t  r o o m  t e m p e r a t u r e  f o r  3  d a y s ,  d r u g -  
m o d i f i e d  m o n o m e r s  o f  1 5 , 1 7 , a n d  1 9  b p  o l ig o m e r s  m a i n ­
t a i n  d u p l e x  D N A  s t r u c t u r e  ( u n p u b l i s h e d  r e s u l t s ) .  T h e s e  
r e s u l t s  a r e  c o n s i s t e n t  w i t h  t h e  m a r k e d  s t a b i l i z i n g  e f f e c t  
o f  C C - 1 0 6 5  (27, 37-38). T h e  a b s e n c e  o f  d e t e c t a b l e  s i n ­
g l e - s t r a n d e d  D N A  in  d r u g - m o d i f i e d  m o n o m e r s  s u g g e s t s  
t h a t  a l l  t h e  d u p l e x e s  w e r e  s a t u r a t e d  w i t h  C C - 1 0 6 5 .  N o n ­
d r u g - m o d if ie d  m o n o m e r s  o f  2 1  b p  o l ig o m e r s  a r e  n o t  m e l t e d  
u n d e r  t h e  s a m e  r e a c t i o n  c o n d i t i o n s  a n d  h a v e  a l m o s t  t h e  
i d e n t i c a l  e l e c t r o p h o r e t i c  m o b i l i t y  a s  d r u g - m o d i f i e d  m o ­
n o m e r s .
T h e  c o v a l e n t  m o d i f i c a t i o n  s i t e  o f  C C - 1 0 6 5  o n  2 1  b p  
o l i g o m e r s  w a s  a n a l y z e d  o n  a  1 2 %  s e q u e n c i n g  g e l  b y  t h e  
t h e r m a l l y  i n d u c e d  s t r a n d  b r e a k a g e  a s s a y  (25) ( F ig u r e  3 ) .  
D N A  s e q u e n c i n g  r e a c t i o n s  o f  A  ( l a n e  1 ) ,  A G  ( l a n e  2 ) ,  a n d  
T C  ( la n e  3 )  r e v e a l  t h e  e x p e c t e d  s e q u e n c e s  o f  t h e  c o v a l e n t ly  
m o d i f i e d  s t r a n d .  T h e r m a l  t r e a t m e n t  o f  C C - 1 0 6 5 - D N A  
a d d u c t s  ( l a n e  5 )  p r o d u c e s  t h e  m a j o r  p r o d u c t  o f  D N A  
s t r a n d  b r e a k a g e  (a r r o w  A ; s p e c i e s  “A ” in  F ig u r e  1 ) c o r r e ­
s p o n d i n g  t o  a  f r a g m e n t  t h a t  s t i l l  c o n t a i n s  t h e  a p u r in ic  a c id  
a n d  t h e r e f o r e  m i g r a t e s  a p p r o x i m a t e l y  1 .5  b p  h i g h e r  t h a n  
t h e  e x p e c t e d  a d e n in e  r e s id u e  w i t h i n  t h e  5 ' T T A  s e q u e n c e .  
T h e  m in o r  p r o d u c t  (a r r o w  B ; s p e c i e s  “ B ” in  F ig u r e  1 ) t h a t  
c o m ig r a t e s  w i t h  t h e  p r o d u c t  o f  a n  a d e n in e - s p e c i f ic  r e a c t io n  
a r i s e s  f r o m  t h e  p r e s u m e d  s e c o n d  /3 - e l im in a t i o n  r e a c t i o n ,  
w h i c h  l e a d s  t o  l o s s  o f  t h e  m o d i f i e d  d e o x y a d e n o s i n e .
S u b s e q u e n t  p i p e r i d i n e  t r e a t m e n t  p r o d u c e s  quantitative 
c o n v e r s i o n  o f  t h e  m a j o r  p r o d u c t  ( a r r o w  A )  t o  th e  minor 
p r o d u c t  (a r r o w  B )  ( u n p u b l i s h e d  r e s u l t s ) .  In  addition, 
v i r t u a l l y  a l l  t h e  f u l l - l e n g t h  c o v a l e n t ly  m o d i f ie d  strands are 
c o n v e r t e d  i n t o  s h o r t e r  D N A  f r a g m e n t s  a f t e r  thermal 
t r e a t m e n t ,  i n d ic a t i n g  t h a t  a l l  t h e  d u p l e x e s  w e r e  saturated 
w i t h  C C - 1 0 6 5  ( l a n e  5 ) .
E ffect o f V arying the D istan ce between CC-1065 
B onding S ites  on the E lectrophoretic Mobility of 
Ligated M ultim ers under Nondenaturated Condi 
tions. W h e n  A - t r a c t s  o c c u r  in  p h a s e  w i t h  t h e  helical turn, 
t h e  i n d i v i d u a l  b e n d s  a d d  u p  t o  a  la r g e  o v e r a ll  bend in 
l i g a t e d  m u l t i m e r s ,  w h i c h  s h o w s  a n  i n c r e a s i n g  change in 
R l v a l u e s  ( r a t i o  o f  a p p a r e n t  s i z e  t o  t r u e  s iz e )  at higher 
m o le c u l a r  w e i g h t .  I n  c o n t r a s t ,  w h e n  A - t r a c t s  occur 180° 
o u t  o f  p h a s e  w i t h  t h e  h e l i c a l  t u r n ,  t h e  b e n d s  cancel out 
e a c h  o t h e r ,  r e s u l t i n g  in  a  c o n s t a n t  c h a n g e  in  RL values at 
h i g h e r  m o l e c u l a r  w e i g h t  (1). I n  o r d e r  t o  s t u d y  the effect 
o f  v a r y in g  t h e  d i s t a n c e  b e t w e e n  C C - 1 0 6 5  b o n d in g  sites on 
e le c t r o p h o r e t ic  m o b i l i t y ,  1 7 ,1 9 ,  2 0 , 2 1 , a n d  2 3  b p  oligomers 
w e r e  m o d i f i e d  w i t h  C C - 1 0 6 5  a n d  l i g a t e d  in t o  multimers, 
a n d  t h e ir  e l e c t r o p h o r e t i c  m o b i l i t y  w a s  a n a ly z e d  on an 81 
n o n d e n a t u r i n g  p o l y a c r y l a m i d e  g e l .
T h e  a u t o r a d io g r a m  o f  l i g a t i o n  p r o d u c t s  o f  non-drug- 
m o d if ie d  (C  la n e s )  a n d  C C - 1 0 6 5 - m o d if i e d  (D  lanes) 17,19, 
2 0 , 2 1 , a n d  2 3  b p  o l ig o m e r s  is  s h o w n  in  F ig u r e  4A. While 
d r u g - m o d i f i e d  l i g a t i o n  p r o d u c t s  o f  2 0  b p  oligom ers (lane 
6 )  a n d  2 1  b p  o l ig o m e r s  ( a b o u t  2  t i m e s  t h e  n orm al helical 
t u r n  o f  1 0 .5  b p )  ( l a n e  8 )  s h o w  c o n s id e r a b le  retardation in 
e l e c t r o p h o r e t i c  m o b i l i t y  c o m p a r e d  t o  c o n tr o l  ligation 
p r o d u c t s  ( l a n e s  5  a n d  7 ) ,  d r u g - m o d i f i e d  l ig a t io n  products 
o f  1 7 , 1 9 , a n d  2 3  b p  o l i g o m e r s  ( l a n e s  2 ,  4 , a n d  10) show 
l i t t l e  r e t a r d a t io n  in  e l e c t r o p h o r e t i c  m o b i l i t y  compared to 
c o n t r o l  l i g a t i o n  p r o d u c t s  ( l a n e s  1 , 3 ,  a n d  9 ) . T h e  ratio of 
a p p a r e n t  s i z e  t o  t r u e  s i z e  (Rh) f o r  e a c h  o f  th e  ligation 
p r o d u c t s  in  F ig u r e  4 A  w a s  c a l c u l a t e d  a n d  p lo tte d  against 
m o le c u l a r  w e i g h t  ( F ig u r e  4 B ) .  T h e  in c r e a s in g  changein 
RL v a l u e s  o f  l i g a t i o n  p r o d u c t s  o f  2 0  a n d  2 1  bp  oligomers 
i n d i c a t e s  t h a t  C C - 1 0 6 5 - in d u c e d  b e n d s  a r e  am plified a s s  
c o n s e q u e n c e  o f  c o h e r e n t  a d d i t i o n  o f  in -p h a s e  CC-1065 
i n d u c e d  b e n d s .  L i g a t i o n  p r o d u c t s  o f  1 7 , 19, and 23 bp 
o l ig o m e r s  p r o d u c e  l i t t l e  c h a n g e  in  R L v a lu e s  because tin 
b e n d s  a r e  p r e s u m a b ly  o u t  o f  p h a s e .  T h e s e  resu lts indicate 
t h a t  i n c r e a s i n g  c h a n g e  in  R L v a lu e  is  c a u s e d  by CC-1065 
in d u c e d  b e n d in g  o f  D N A ,  n o t  b y  lo c a l iz e d  frictional effects 
o f  C C - 1 0 6 5 - D N A  a d d u c t s  o r  t h e  p o s i t i v e  charge on the 
6 - a m i n o  t a u t o m e r i c  f o r m  (22) o f  t h e  c o v a le n t ly  modified 
a d e n i n e  in  t h e  C C - 1 0 6 5 - D N A  a d d u c t s .  T h e  maxima 
r e t a r d a t i o n  in  e l e c t r o p h o r e t i c  m o b i l i t y  is  achieved in 2d 
b p  o l ig o m e r s ,  t h u s  i n d i c a t i n g  t h a t  t h e  CC-1065-modified 
2 0  b p  o l i g o m e r s  a r e  t h e  m o s t  c l o s e l y  p h a se d  with the 
h e l ic a l  t u r n  a f t e r  d r u g  b o n d in g  t o  D N A .  T h is  suggests that 
C C - 1 0 6 5  i n d u c e s  n o t  o n l y  D N A  b e n d in g  b u t also DNA 
w in d in g  e q u iv a le n t  t o  a b o u t  1 b p  p e r  c o v a le n t  modification 
s i t e ,  b e c a u s e  m a x i m u m  b e n d in g  o c c u r s  in  20  bp  oligomat 
(2  X 1 0 )  r a t h e r  t h a n  2 1  b p  o l i g o m e r s  (2  X 10.5).
E ffect o f Chloroquine on the R L of 11 Multimen 
of a 21 bp Oligom er M odified by CC-1065, AB'C', and 
ABC. E x p e r i m e n t s  w e r e  d e s i g n e d  u s in g  chloroquine,! 
k n o w n  in t e r c a la t o r  t h a t  u n w in d s  D N A ,  to  further examine 
t h e  q u e s t io n  o f  C C - 1 0 6 5 - in d u c e d  w in d in g  th a t  is produced 
in  a d d i t i o n  t o  t h e  D N A  b e n d i n g  d e m o n s tr a te d  in the 
p r e v io u s  s e c t i o n .  I f  l ig a t io n  p r o d u c t s  o f  th e  21 bp oligoma 
h a v e  r e d u c e d  R Ls  r e l a t i v e  t o  t h e  2 0 - m e r  w h en  modified 
w i t h  C C - 1 0 6 5 ,  b e c a u s e  o f  d r u g - i n d u c e d  w ind ing , then in­
c r e m e n t a l  a d d i t i o n  o f  c h lo r o q u in e  s h o u ld  first increase the 
R l o f  l ig a t io n  p r o d u c t s  o f  t h e  2 1 - m e r  a s  th e  unwindinghf 
c h lo r o q u in e  a n n u ls  t h e  C C - 1 0 6 5 - in d u c e d  winding. Beyond
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L en gth  in B a s e  Pairs
F i g u r e  4. P a n e l A: A u to r a d io g r a m  o f  th e  l ig a t io n  p r o d u c ts  o f  
17, 19, 20 , 21 , an d  23  b p  o lig o m e r s  m o d if ie d  w ith  C C -1 0 6 5  o n  an  
8%  n o n d e n a tu r in g  p o ly a c r y la m id e  g e l. L a n e s  1, 3 , 5 , 7, a n d  9 
are c o n tr o l l ig a tio n  p r o d u c ts  (C ), a n d  la n e s  2, 4 , 6 , 8 , a n d  10 are  
l ig a tio n  p ro d u cts  o f  28  ^ M  C C -1 065  m o d if ie d  o lig o m ers (D ). T h e  
lig a tio n  p ro d u cts  w ere p rep a red  as d e scr ib ed  u n d er M a ter ia ls  and  
M e th o d s . A rrow h ead s in d ic a te  th e  lo c a tio n  o f  th e  m o n o m er  (M ) 
a n d  d im e r  (D ). P a n e l  B: P lo t  o f  RL v a lu e s  v s  to ta l  le n g th  o f  
o lig o m e r s  in b a se  p a ir s  fro m  th e  l ig a t io n  p r o d u c ts  o f  1 7 ,1 9 ,  20 , 
21 , a n d  23  bp  o lig o m e rs  m o d if ie d  w ith  C C -1 065 . RL v a lu e s  w ere  
o b ta in e d  from  th e  r e s u lts  o f  e x p e r im e n ts  sh o w n  in  p a n e l A .
a  c e r t a i n  c o n c e n t r a t i o n  o f  c h lo r o q u i n e ,  w h e n  t h e  a m o u n t  
o f  c h l o r o q u i n e - i n d u c e d  u n w i n d i n g  o f  D N A  e x c e e d s  t h e  
w i n d i n g  e f f e c t  o f  C C - 1 0 6 5 ,  t h e  R L w i l l  d e c r e a s e  a s  t h e  
C C - 1 0 6 5 - in d u c e d  b e n d s  a r e  n o  lo n g e r  p h a s e d .  T h e  r e s u l t s  
o f  t h e s e  e x p e r i m e n t s ,  w h i c h  a r e  s u m m a r iz e d  in  F ig u r e  5 , 
s h o w  e x a c t l y  t h i s  p r e d i c t e d  p a t t e r n  ( i .e . ,  i n i t i a l  i n c r e a s e  
in  Rl f o l lo w e d  b y  a  s u b s e q u e n t  d e c r e a s e )  w h e n  a n  a n a ly s i s  
o f  t h e  R hs o f  t h e  11  m u l t i m e r s  o f  t h e  C C - 1 0 6 5 -  a n d  
A B 'C ' - m o d i f i e d  2 1  b p  o l ig o m e r  a t  in c r e a s i n g  c h lo r o q u i n e  
c o n c e n t r a t i o n s  i s  c a r r ie d  o u t .  S i g n i f i c a n t l y ,  w h i l e  A B 'C '  
m i m i c s  C C - 1 0 6 5  in  s h o w i n g  a n  in c r e a s e  in  JRL v a lu e ,  p r io r  
t o  a  d e c r e a s e  a s  t h e  c h lo r o q u in e  c o n c e n t r a t io n  is  in c r e a s e d ,  
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F ig u r e  5. P lo t  o f  /?L v a lu e s  a g a in s t  in c r e a s in g  c o n c e n tr a t io n  o f  
c h lo r o q u in e  o f  th e  11 m u lt im e r  o f  th e  21 b p  o lig o m e r  m o d if ie d  
w ith  C C -1 065 , A B 'C ', a n d  A B C . (F ille d  c ir c le s )  11 m u lt im e r s  o f  
th e  21 b p  o lig om er  m o d if ie d  w ith  C C -1065; (o p en  sq u ares) AB 'C '; 
(o p e n  c ir c le s )  A B C .
t e r p r e t  t h i s  t o  i m p l y  t h a t  i t  is  t h e  i n s id e  e d g e  s u b s t i t u e n t s  
t h a t  a r e  u n i q u e  t o  C C - 1 0 6 5  a n d  A B 'C '  w h i c h  a r e  r e s p o n ­
s i b l e  fo r  t h e  o b s e r v e d  w i n d i n g  e f f e c t .
E ffect of V arying the S tru ctu re o f the B and C 
S u b u nits of CC-1065 on DN A B ending. T o  f u r t h e r  
e x a m i n e  t h e  e f f e c t  o f  t h e  f i n e  s t r u c t u r e  o f  t h e  B  a n d  C  
s u b u n i t s  o f  C C - 1 0 6 5  o n  D N A  b e n d in g ,  t h e  e le c t r o p h o r e t ic  
m o b i l i t i e s  o f  l i g a t i o n  p r o d u c t s  m o d i f i e d  w i t h  C C - 1 0 6 5 ,  
A B 'C ' ,  a n d  A B C  in  2 0  a n d  2 1  b p  o l ig o m e r s  w e r e  c o m p a r e d  
(F ig u r e  6 A ) . W h i le  C C -1 0 6 5 -  a n d  A B 'C ' - m o d if i e d  l ig a t io n  
p r o d u c t s  p r o d u c e  m o r e  r e t a r d a t i o n  in  e l e c t r o p h o r e t i c  
m o b i l i t y  in  2 0  b p  o l ig o m e r s  ( l a n e s  2  a n d  3 )  t h a n  in  2 1  b p  
o l ig o m e r s  ( la n e s  6  a n d  7 ) ,  t h e  r e v e r s e  is  t r u e  fo r  A B C  ( la n e s  
4  a n d  8 ) .
A  h i s t o g r a m  o f  t h e  R L -  1 v a l u e s  o f  o c t a m e r s  o f  1 9 , 2 0 ,  
2 1 , a n d  2 3  b p  o l ig o m e r s  m o d if ie d  w i t h  C C -1 0 6 5 , A B 'C ',  a n d  
A B C  is  s h o w n  in  F ig u r e  6 C - A . W h i l e  C C - 1 0 6 5  a n d  A B 'C '  
p r o d u c e  a  h ig h e r  RL -  1 v a lu e  in  2 0  b p  o l ig o m e r s  t h a n  in  
2 1  b p  o l ig o m e r s ,  A B C  p r o d u c e s  a  h i g h e r  R L -  1 v a lu e  in  
2 1  b p  o l ig o m e r s  t h a n  in  2 0  b p  o l ig o m e r s .  S i n c e  t h e  m a x ­
i m u m  a m o u n t  o f  b e n d i n g  i s  a p p r o x i m a t e l y  t h e  s a m e  fo r  
C C -1 0 6 5 ,  A B 'C ' ,  a n d  A B C  b u t  i s  a c h ie v e d  in  e i t h e r  l ig a t e d  
2 0  o r  2 1  b p  o l ig o m e r s ,  t h e s e  r e s u l t s  s u g g e s t  t h a t  t h e  
b i n d i n g  i n t e r a c t i o n s  b e t w e e n  t h e  B  a n d  C  s u b u n i t s  a n d  
D N A  m o d u l a t e  t h e  a m o u n t  o f  D N A  w i n d i n g  b u t  d o  n o t  
g r e a t l y  e f f e c t  t h e  m a g n i t u d e  o f  D N A  b e n d in g .
D eterm ination o f the Im portance o f the Covalent 
B onding R eaction in C ontributing to D NA B ending  
Produced by ABC. S i n c e  t h e  A  s u b u n i t  a l o n e  h a s  s u f ­
f i c i e n t  s t r u c t u r a l  i n f o r m a t i o n  t o  m e d i a t e  t h e  s e q u e n c e  
s e l e c t i v i t y  o f  t h e  e n t i r e  A B C  m o l e c u l e  {33), i t  w a s  i m ­
p o r t a n t  t o  d e t e r m i n e  w h e t h e r  t h e  c o v a l e n t  b o n d in g  o f  t h e  
A  s u b u n i t  t o  t h e  N 3  o f  a d e n in e  is  s u f f i c i e n t  t o  m e d i a t e  t h e  
D N A  b e n d in g .  A  c o m p a r i s o n  o f  t h e  e l e c t r o p h o r e t i c  m o ­
b i l i t y  o f  l i g a t io n  p r o d u c t s  m o d i f i e d  w i t h  A , A B ,  a n d  A B C  
in  2 0  a n d  2 1  b p  o l i g o m e r s  i s  s h o w n  in  F ig u r e  6 B .  T h e  A  
s u b u n i t  m o d if ie d  l ig a t io n  p r o d u c t s  o f  2 1  b p  o l ig o m e r s  ( la n e  
8 )  p r o d u c e  s i g n i f i c a n t  r e t a r d a t io n  in  e l e c t r o p h o r e t i c  m o ­
b i l i t y  c o m p a r e d  t o  t h o s e  o f  c o n t r o l  2 1  b p  o l ig o m e r s  ( l a n e
5 ) .  F u r t h e r m o r e ,  t h e  A  s u b u n i t  m o d i f ie d  l ig a t io n  p r o d u c t s  
o f  2 1  b p  o l ig o m e r s  ( l a n e  8 )  p r o d u c e  m o r e  r e t a r d a t i o n  in  
e le c t r o p h o r e t i c  m o b i l i t y  t h a n  A B  ( l a n e  7 ) a n d  A B C  ( la n e
6 ) .  T h e s e  r e s u l t s  s h o w  t h a t  D N A  b e n d i n g  o c c u r s  a s  a  
c o n s e q u e n c e  o f  t h e  c o v a l e n t  b o n d i n g  r e a c t i o n  o f  t h e  A
3 Furthermore, high concentrations of chloroquine (over 50 ng/mL) 
completely abolished the retardation of electrophoretic mobility, indi­
cating that the phasing property of bent DNA can be annulled by the 
DNA unwinding effect on DNA of chloroquine intercalation (data not
shown).
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Figure 6. Panel A: Autoradiogram of ligation products of 20 and 21 bp oligomers modified with CC-1065, AB'C', and ABC on an 
8% nondenaturing polyacrylamide gel. Lanes 1 and 5 are control ligation products. Lanes 2 and 6 are 28 mM CC-1065 modified ligation 
products, lanes 3 and 7 are 28 ^M AB'C' modified ligation products, and lanes 4 and 8 are 28 j*M ABC modified ligation products. ( 
The ligation products were prepared as described under Materials and Methods. Arrowheads indicate the location of monomer (M) 
and dimer (D). Panel B: Autoradiogram of ligation products of 20 and 21 bp oligomers modified with ABC, AB, and A on an 8% 
nondenaturing polyacrylamide gel. Lanes 1 and 5 are control ligation products. Lanes 2 and 6 are 28 mM ABC modified ligation products, 
lanes 3 and 7 are 0.28 mM AB modified ligation products, and lanes 4 and 8 are 2.8 mM A modified ligation products. The ligation 
products were prepared as described under Materials and Methods. Arrowheads indicate the location of the monomer (M) and the 
dimer (D). Panel C: Histogram of the RL -  1 values of octamers of 19, 20, 21, and 23 bp oligomers modified with 2.8 mM A, 0.28 mM 
AB, and 28 /uM ABC, AB'C', and CC-1065. (A) /?L — 1 values for CC-1065, AB'C', and ABC. (B) RL -  1 values for A, AB, and ABC. i
s u b u n i t  w i t h  D N A .  C o n s e q u e n t ly ,  t h e  A  s u b u n i t  a lo n e  h a s  
s u f f i c i e n t  s t r u c t u r a l  i n f o r m a t i o n  t o  m e d i a t e  t h e  D N A  
b e n d in g  p r o d u c e d  b y  A B C . I n  c o n t r a s t  t o  t h e  r e s u l t s  w i t h  
C C -1 0 6 5  a n d  A B 'C '  in  F ig u r e  6 A , A B C , A B ,  a n d  A  s u b u n i t  
m o d i f i e d  l i g a t i o n  p r o d u c t s  p r o d u c e  m o r e  r e t a r d a t i o n  in  
e le c t r o p h o r e t ic  m o b i l i t y  in  2 1  b p  o l ig o m e r s  ( la n e s  6 - 8 )  th a n  
2 0  b p  o l ig o m e r s  ( l a n e s  2 - 4 ) ;  s e e  a l s o  a  h i s t o g r a m  o f  t h e  RL 
-  1 v a l u e s  o f  o c t a m e r s  o f  1 9 , 2 0 ,  2 1 ,  a n d  2 3  b p  o l ig o m e r s  
m o d if ie d  w i t h  A , A B ,  a n d  A B C  in  F ig u r e  6 C - B . T h i s  r e s u l t  
is  c o n s i s t e n t  w i t h  t h e  s u g g e s t i o n  m a d e  p r e v i o u s l y  t h a t  t h e  
i n s i d e  e d g e  s u b s t i t u e n t s  o f  C C - 1 0 6 5  a n d  A B 'C '  a r e  a s s o ­
c i a t e d  w i t h  w i n d i n g  o f  D N A ,  s i n c e  A , A B ,  a n d  A B C  la c k  
t h e s e  s u b s t i t u e n t s .
D eterm ination o f the M agnitude o f the B ending  
A ngles Produced by CC-1065, AB'C', ABC, AB, and 
A from R l  V alues. T h e  e s t i m a t e  o f  b e n d i n g  a n g l e s  in  
t h e  5 ' G A T T A *  (A *  is  t h e  c o v a l e n t  m o d i f i c a t i o n  s i t e )  s e ­
q u e n c e  p r o d u c e d  b y  C C -1 0 6 5 ,  A B 'C ' ,  A B C , A B ,  a n d  A  w a s  
c a lc u la t e d  b y  u s in g  a  c a l ib r a t io n  e q u a t i o n  fo r  g e l  m o b i l i t y  
a n o m a l ie s  d e r iv e d  b y  K o o  a n d  C r o t h e r s  (39). T h e  1 4 0  b p  
( h e p t a m e r s  o f  2 0  b p  o l ig o m e r s )  fo r  C C -1 0 6 5  a n d  A B 'C '  a n d  
1 4 7  b p  ( h e p t a m e r s  o f  21  b p  o l ig o m e r s )  fo r  A , A B ,  a n d  A B C  
w e r e  c h o s e n  b e c a u s e  t h e y  a r e  w i t h in  t h e  o p t im a l  r a n g e  fo r  
t h e  a p p l i c a t i o n  o f  a  c a l i b r a t i o n  e q u a t i o n ,  a n d  m a x i m u m  
r e t a r d a t io n  in  e l e c t r o p h o r e t i c  m o b i l i t y  i s  a c h i e v e d  in  2 0  
b p  o l ig o m e r s  fo r  C C - 1 0 6 5  a n d  A B 'C '  a n d  in  2 1  b p  o l ig o m -
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Table II. Calculation of DNA Bending Angles Produced by A, AB, ABC, AB'C', and CC-1065 in the 5'GATTA* Sequence












































0Ri values were calculated from 147 bp ligation products for 21 bp oligomers and from 140 bp ligation products for 20 bp oligomers. 6The 
estimate of bend angles of each compound was calculated by using a calibration equation for gel mobility anomalies derived by Koo and 
Crothers (.39). cNot determined. dThe bond angles of CC-1065 and ABC from the circularization experiment were determined by the 
i method described in Husain et al. (17).
e r s  fo r  A , A B ,  a n d  A B C . T h e  s iz e s  o f  o l ig o m e r s ,  RL v a lu e s ,  
a n d  c a lc u la t e d  b e n d  a n g le s  fo r  e a c h  c o m p o u n d  a r e  s h o w n  
in  T a b l e  I I . A n  e s t i m a t e  o f  A B -  a n d  A B C - i n d u c e d  b e n d  
a n g l e s  ( 1 4 - 1 8 ° )  i s  s m a l l e r  b y  1 - 2 °  t h a n  t h a t  o f  t h e  A  
s u b u n i t  i n d u c e d  b e n d  a n g le  ( 1 5 - 2 0 ° ) ,  s u g g e s t i n g  t h a t  a t ­
t a c h m e n t  o f  t h e  B  a n d  C  s u b u n i t s  t o  t h e  A  s u b u n i t  r e d u c e s  
s l i g h t l y  t h e  m a g n i t u d e  o f  t h e  b e n d i n g  a n g le .  A B 'C '  a n d  
C C - 1 0 6 5  a p p a r e n t l y  p r o d u c e  t h e  s a m e  m a g n i t u d e  o f  D N A  
b e n d i n g  a s  t h e  A  s u b u n i t .
D eterm ination  o f the D N A  B ending Produced by 
CC-1065 and ABC by A nalysis o f the Tw o-D im en­
siona l Gel E lectroph oresis for C ircular DN A in 
Drug-M odified Oligom ers fo llow ing Ligation. I n  a d ­
d i t i o n  t o  b e n t  D N A ,  o t h e r  u n u s u a l  D N A  s t r u c t u r e s ,  s u c h  
a s  c r u c i f o r m s ,  l a r i a t s ,  a n d  g a p s ,  c a n  c a u s e  a n o m a l o u s  
e l e c t r o p h o r e t i c  m o b i l i t y  (40-43). T o  c o n f i r m  w h e t h e r  
A B C -  a n d  C C - 1 0 6 5 - in d u c e d  D N A  b e n d i n g  i s  r e s p o n s i b l e  
fo r  t h e  o b s e r v e d  a n o m a l o u s  r e t a r d a t io n  in  e l e c t r o p h o r e t i c  
m o b i l i t y ,  t w o - d im e n s i o n a l  g e l  e le c t r o p h o r e s i s  e x p e r im e n t s  
w e r e  c a r r ie d  o u t  ( 3 ,  17). F ig u r e  7  s h o w s  t y p i c a l  a u t o r a ­
d io g r a m s  o f  a  t w o - d i m e n s i o n a l  g e l  c o n t a i n i n g  t h e  l ig a t io n  
p r o d u c t s  o f  d r u g - n o n m o d i f i e d  o l ig o m e r  a n d  t h e  2 1  b p  
o l ig o m e r  ( T a b le  I A ) m o d i f i e d  w i t h  A B C . T h e  r a d io a c t iv e  
s p o t s  c o r r e s p o n d in g  t o  b o t h  c ir c u la r  a n d  n o n c ir c u la r  D N A  
in  t h e s e  g e l s  w e r e  c u t  o u t ,  a n d  t h e  D N A  w a s  e x t r a c t e d  
s e p a r a t e ly .  T h e  s t r u c t u r e  a n d  s iz e  o f  D N A  in  e a c h  i s o la t e d  
r a d io a c t iv e  s p o t  w a s  d e t e r m i n e d  b y  a n a ly s i s  o n  d e n a t u r in g  
g e l s ,  a s  d e s c r i b e d  u n d e r  M a t e r i a l s  a n d  M e t h o d s .  T h e  
u p p e r  f a m i l i e s  o f  r a d io a c t iv e  s p o t s  w e r e  d e t e r m i n e d  t o  b e  
c ir c u l a r  D N A  ( s l o w e r  m i g r a t i o n  in  s e c o n d - d i m e n s i o n a l  
e l e c t r o p h o r e s i s  t h a n  t h e  l o w e r  f a m i l y ) ,  a n d  t h e  lo w e r  
f a m i l i e s  w e r e  n o n c ir c u la r .4 L i g a t i o n  p r o d u c t s  o f  n o n ­
d r u g - m o d i f i e d  o l ig o m e r s  c o u ld  o n l y  b e  s h o w n  t o  p r o d u c e  
l in e a r  D N A  in  t h e  m o l e c u l a r  w e i g h t  r a n g e  t h a t  c o u ld  b e  
e v a l u a t e d  ( F i g u r e  7 A ) ,  w h i l e  t h e r e  w e r e  s i g n i f i c a n t  
a m o u n t s  o f  s m a l l  c ir c u la r  D N A s  in  l i g a t e d  p r o d u c t s  o f  
A B C - m o d i f i e d  o l i g o m e r s  in  t h e  s a m e  m o le c u l a r  w e i g h t  
r a n g e .  A  g r a p h i c a l  r e p r e s e n t a t i o n  o f  c ir c u l a r i z a t io n  e f f i ­
c ie n c y  v s  t h e  m o le c u la r  w e ig h t  o f  m u lt im e r s  o f  c o n t r o l-  a n d  
A B C - m o d i f i e d  o l i g o m e r s  is  s h o w n  in  F ig u r e  8 . F o r  t h e  
A B C - m o d i f i e d  o l i g o m e r ,  t h e  p e r c e n t a g e  o f  r a d i o a c t i v i t y  
in  a  c ir c le  v s  t h e  t o t a l  in  c ir c u la r  a n d  l in e a r  D N A  is  p l o t t e d  
a g a i n s t  t h e  l e n g t h  o f  D N A  i n  b a s e  p a i r s  fo r  e a c h  o f  t h e  
l i g a t e d  p r o d u c t s .  F r o m  t h e  o p t i m a l  s i z e  o f  D N A  r e q u ir e d  
fo r  c ir c u la r iz a t io n  b y  A B C , t h e  a p p r o x im a t e  v a lu e  fo r  D N A
4 The upper family of DNA molecules (Figure 7) was determined to 
be circular species from an analysis on sequencing gels with appropriate 
marker standards (data not shown). Although these DNA molecules were 
small-sized, they showed remarkably slow mobility in comparison to the 
same-sized noncircular DNA molecules on 8% nondenaturing polyacyl- 
amide gel. Furthermore, these molecules showed little change in mobility 
on electrophoresis in nondenaturing polyacrylamide gels that contained 
chloroquine (50 ng/mL), while noncircular bent DNA molecules were 
distorted into out-of-phase bends and showed faster migration with the 
addition of chloroquine (Figure 7).
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Figure 7. Analysis of ligation products of 21 bp oligomers (Table 
IA) without drug modification (A) or following modification with 
ABC (B) by two-dimensional gel electrophoresis. In (B), the 
radioactive spots in the upper family are circular 6-9  multimer 
of the 21 bp oligomer, and those in the lower family are noncircular 
multimers of 21 bp oligomer. The numbers indicate the mul­
tiplicity of the oligomers in the radioactive spots, which were 
determined as described under Materials and Methods.
b e n d in g  m a g n i t u d e  c a n  b e  d e t e r m in e d  a s  fo l lo w s :  fo r  A B C ,  
b y  d i v id i n g  3 6 0 °  b y  1 6 8 °  ( t h e  n u m b e r  o f  b a s e  p a ir s  in  t h e  
c ir c l e ) ,  a n  a v e r a g e  2 .1 4 °  o f  b e n d i n g  p e r  b a s e  p a ir  w a s  o b ­
t a i n e d .  S i n c e  t h e  i n h e r e n t  f l e x i b i l i t y  o f  D N A  i s  a b o u t  
1 . 3 ° / b p  (2 ,  3, 44), w e  d e t e r m i n e  t h a t  fo r  t h e  e i g h t  d r u g -  
i n d u c e d  b e n d s  i n t r o d u c e d  a t  o p t i m u m  c i r c u l a r i z a t i o n ,  a  
t o t a l  o f  ( 2 .1 4  -  1 .3 )  X 1 6 8  =  1 4 1 .1  o f  b e n d i n g ,  o r  a b o u t
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Figure; 8. Circularization efficiency for ABC, as expressed by 
the per centage of radioactivity in the circular DNA, to the total 
amount of radioactivity in the ligation products of the same size. 
The radioactivity of each spot was measured by scintillation 
counting, and the percentage of circular DNA at the given length 
of DNA in the total species of DNA was calculated.
1 7 .7 °  p e r  b e n d ,  is  c a lc u la t e d .  T h i s  n u m b e r  a g r e e s  w e ll  w i t h  
t h e  b e n d in g  m a g n i t u d e  v a lu e  c a lc u la t e d  fr o m  t h e  RL v a lu e  
( s e e  T a b l e  I I ) .  A  s im i la r  t w o - d im e n s i o n a l  a n d  s u b s e q u e n t  
o n e - d i m e n s i o n a l  g e l  a n a l y s i s  w a s  c a r r ie d  o u t  f o r  C C - 1 0 6 5  
b u t  u s in g  t h e  2 0 -m e r  ( T a b le  IA )  r a th e r  t h a n  2 1 -m e r ,  w h ic h  
c o n t a i n e d  t h e  s a m e  b o n d in g  s e q u e n c e  ( 5 'G A T T A * )  a s  w a s  
u s e d  f o r  A B C . In  c o m p a r i s o n  t o  t h e  A B C - m o d i f i e d  o l i ­
g o m e r ,  t h e  o p t i m u m  s i z e  fo r  c i r c u l a r i z a t io n  i s  i n c r e a s e d  
f r o m  1 6 8  t o  1 8 0  b p  fo r  t h e  C C - 1 0 6 5 - m o d if i e d  o l ig o m e r ,  a n d  
t h e  c ir c u l a r i z a t io n  e f f i c i e n c y  i s  s l i g h t l y  lo w e r  fo r  C C - 1 0 6 5  
t h a n  A B C  ( u n p u b l i s h e d  r e s u l t s ) .  F o r  t h e  C C - 1 0 6 5 - in d u c e d  
b e n d ,  t h e  c ir c u la r iz a t io n  e x p e r im e n t  p r o v id e s  a  c a lc u la t e d  
b e n d i n g  a n g le  o f  a b o u t  1 4 .0 ° ,  w h ic h  is  s o m e w h a t  l e s s  t h a n  
t h a t  o b t a i n e d  f r o m  c o n s i d e r a t i o n  o f  R L v a l u e s  ( s e e  D i s ­
c u s s i o n ) .
D eterm ination o f the D irection  and Locus o f the 
D rug-Induced B ends in DNA. T o  d e t e r m i n e  t h e  d i ­
r e c t i o n a l i t y  o f  b e n d i n g  o f  D N A  b y  C C - 1 0 6 5  a n d  r e l a t e d  
d r u g s ,  a n d  a l s o  t h e  l o c u s  o f  t h e  d r u g - i n d u c e d  b e n d in g ,  t h e  
f o u r  o l ig o m e r s  s h o w n  in  T a b l e  I B  w e r e  u s e d .  I t  h a s  b e e n  
p r e v i o u s l y  s h o w n  t h a t  t h e  d i r e c t i o n  o f  A - t r a c t - i n d u c e d  
b e n d i n g  is in  t o w a r d  t h e  m in o r  g r o o v e  a n d  t h a t  t h e  c e n t e r  
o f  t h e  b e n d  c o r r e s p o n d s  t o  t h e  c e n t e r  o f  t h e  A - t r a c t  (1 , 39). 
T h e  fo u r  o l i g o m e r s  I ,  I I ,  I I I ,  a n d  I V ,  l i s t e d  in  T a b l e  I B ,  
w e r e  d e s ig n e d  t o  v a r y  in  d i s t a n c e  b e t w e e n  t h e  c e n t e r  o f  
t h e  A - t r a c t  a n d  t h e  f o l l o w i n g  d r u g  c o v a l e n t  m o d i f i c a t i o n  
s i t e  b y  10 , 1 1 , 1 2 , a n d  1 3  b p ,  r e s p e c t i v e l y .
N o n d e n a t u r in g  g e l  e le c t r o p h o r e s i s  o f  t h e  o l ig o m e r s  I - I V  
( T a b le  IB ) s h o w s  t h a t  m o d if ic a t io n  w i t h  A B C  a n d  C C -1 0 6 5  
l e a d s  to  in c r e a s e d  r e ta r d a t io n  o f  g e l  m o b i l i t y  in  c o m p a r is o n  
t o  n o n - d r u g - m o d i f i e d  o l ig o m e r s  ( u n p u b l i s h e d  r e s u l t s ) .  
S i n c e  o l ig o m e r s  I , I I ,  I I I ,  a n d  I V  c o n t a i n  a n  A - t r a c t  t h a t  
i s  s e p a r a t e d  b y  a b o u t  o n e  h e l i c a l  t u r n  f r o m  t h e  d r u g  
b o n d in g  s i t e ,  w e  c o n c l u d e  t h a t  b o t h  b e n d s  a r e  in  t h e  s a m e  
d i r e c t i o n ,  i .e . ,  in  t o w a r d  t h e  m i n o r  g r o o v e  o f  D N A .  A  
c o m p a r i s o n  o f  R L v a l u e s  f o r  a  5  m u l t i m e r  o f  t h e s e  f o u r  
o l ig o m e r s  m o d i f i e d  w i t h  C C - 1 0 6 5  a n d  A B C  l e a d s  t o  s o m e  
i m p o r t a n t  c o n c l u s i o n s  ( F ig u r e  9 ) .  F o r  A B C - m o d i f i e d  
o l ig o m e r s  t h e  m a x i m u m  b e n d i n g  o c c u r s  i n  o l i g o m e r  I I I ,  
in  w h ic h  1 2  b p  s e p a r a t e  t h e  c e n t e r  o f  t h e  A - t r a c t  f r o m  t h e  
c o v a l e n t  m o d i f i c a t i o n  s i t e .  T h i s  s h o w s  t h a t  o p t i m u m  in -  
p h a s e  b e n d in g  a r is e s  w h e n  o n e  h e l i c a l  t u r n  s e p a r a t e s  t h e  
c e n t e r  o ' t h e  A - t r a c t  f r o m  t h e  p o s i t i o n  b e t w e e n  t h e  t w o  
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Distance between Center of A tract and Alkylation site(bp).
F ig u re  9. Effect of distances in base pairs between the center 
of A5-tract and the drug covalent modification site on RL values 
of 5 multimer of 21-A-I, 21-A-II, 21-A-III, and 21-A-IV modified 
with CC-1065 and ABC. These oligomers were designed to vary 
in distance between the center of the A-tract and the following 
drug covalent modification site by 10, 11, 12, and 13 bp, re­
spectively. O = ABC-modified oligomers; •  = CC-1065-modified 
oligomers.
( G A T T A * )  a n d  c o n s e q u e n t l y  p r o v id e s  c o m p e l l in g  e v id e n c e  
fo r  t h e  l o c u s  o f  d r u g - i n d u c e d  b e n d in g  b e t w e e n  t w o  t h y ­
m i d i n e  w i t h in  t h e  r e c o g n i t io n  s e q u e n c e .  H o w e v e r ,  fo r  t h e  
C C - 1 0 6 5 - in d u c e d  b e n d ,  o p t im u m  b e n d in g  o c c u r s  w h e n  11  
b p  s e p a r a t e  t h e  c e n t e r  o f  t h e  A - t r a c t  f r o m  t h e  a d j a c e n t  
d r u g - D N A  a d d u c t  s it e ;  i .e .,  o l ig o m e r  I I  (F ig u r e  9 )  p r o d u c e s  
m a x i m u m  r e t a r d a t io n .  T h i s  is  e x a c t l y  w h a t  is  e x p e c t e d ,  
t a k i n g  i n t o  a c c o u n t  t h e  e a r l ie r  o b s e r v a t i o n  t h a t  C C - 1 0 6 5  
i n d u c e s  t h e  w i n d i n g  o f  D N A  b y  t h e  e q u i v a l e n t  o f  a b o u t  
1 b p  p e r  c o v a l e n t  m o d i f i c a t i o n  a n d  c o n s e q u e n t l y  r e d u c e s  
t h e  b a s e  p a ir  n u m b e r  p e r  t w o  h e l i c a l  t u r n s  t o  2 0 .0 .  T h e  
o v e r a ll  d e c r e a s e  in  R L v a lu e s  o f  a ll  o l ig o m e r s  m o d if ie d  w i t h  
C C - 1 0 6 5  a n d  t h e  r e l a t i v e l y  s m a l l  d i f f e r e n c e  o f  R L v a l u e s  
b e t w e e n  o l ig o m e r  I I  a n d  I I I  m o d i f i e d  w i t h  C C - 1 0 6 5  c o m ­
p a r e d  t o  t h o s e  m o d i f i e d  w i t h  A B C  c a n  b e  e x p l a i n e d  a s  
f o l lo w s .  F i r s t ,  t h e  o v e r a l l  d e c r e a s e  in  R L o f  a l l  o l ig o m e r s  
m o d if ie d  w i t h  C C -1 0 6 5  r e la t iv e  t o  A B C  is  b e c a u s e  C C -1 0 6 5  
p r o d u c e s  a  d e c r e a s e  in  b a s e  p a ir s  p e r  h e l i c a l  t u r n  b e t w e e n  
t h e  A - tr a c t s  a n d  c o n s e q u e n t l y  c r e a te s  o u t - o f - p h a s e  b e n d in g  
o f  A - t r a c t s .  S e c o n d ,  t h e  r e l a t i v e l y  s m a l l  d i f f e r e n c e  in  RL 
b e t w e e n  o l ig o m e r s  II  a n d  I II  fo r  C C -1 0 6 5 , r e la t iv e  t o  A B C ,  
i s  b e c a u s e  o l ig o m e r  I I  i s  l e s s  o u t  o f  p h a s e  c o m p a r e d  t o  
o l ig o m e r  I I I , s in c e  t h e r e  i s  1 b p  m o r e  p e r  h e l i c a l  t u r n  a f t e r  
C C - 1 0 6 5  m o d i f i c a t i o n  t h a n  b e f o r e .  M o s t  i m p o r t a n t l y ,  
t h e s e  r e s u l t s  t a k e n  t o g e t h e r  s h o w  t h a t  t h e  lo c u s  o f  b e n d in g  
is  a t  t h e  s a m e  s i t e  in  t h e  r e c o g n i t io n  s e q u e n c e  ( i .e .,  b e t w e e n  
t h e  t w o  t h y m i d i n e s )  fo r  b o t h  A B C  a n d  C C - 1 0 6 5 .
Discussion
S t u d i e s  f r o m  t h i s  l a b o r a t o r y  in  c o l l a b o r a t i o n  w i t h  o u r  
c o l l e a g u e s  a t  t h e  U p j o h n  C o . a r e  a i m e d  t o w a r d  u n d e r ­
s t a n d i n g  t h e  m o le c u l a r  b a s i s  fo r  t h e  p o t e n t  b i o l o g i c a l  e f ­
f e c t s  o f  C C - 1 0 6 5  a n d  i t s  s y n t h e t i c  a n a lo g u e s  (19). S t r u c -  
t u r e - a c t i v i t y  r e l a t i o n s h i p s  c le a r l y  d e f i n e  D N A  a s  t h e  
m o le c u l a r  t a r g e t  fo r  t h e  m o s t  p o t e n t  c y t o t o x i c  a n d  a n t i ­
t u m o r  p r o p e r t i e s  o f  C C - 1 0 6 5  (32). T h e  a b i l i t y  t o  a l k y l a t e  
D N A  is  c r u c ia l  fo r  b o t h  t h e  p o t e n t  c y t o t o x i c  e f f e c t s  a n d  
a n t i t u m o r  a c t i v i t y  o f  C C - 1 0 6 5  a n a lo g u e s .  H o w e v e r ,  s o m e  
b i o l o g i c a l  e f f e c t s ,  s u c h  a s  d e l a y e d  d e a t h ,  r e q u i r e  o t h e r  
s t r u c t u r a l  f e a t u r e s  o f  C C -1 0 6 5  in  a d d i t io n  t o  t h e  a lk y la t in g  
p o t e n t i a l  o f  t h e  d r u g  m o l e c u l e  (31). O n e  o f  t h e  m o s t
CC-1065-Induced D N A  Bending
s u r p r i s in g  p r o p e r t i e s  o f  t h e  C C - 1 0 6 5  m o l e c u l e  i s  t h a t  i t s  
D N A  s e q u e n c e  s e l e c t i v i t y  c a n  b e  m e d i a t e d  b y  t h e  a l k y l a ­
t i n g  s u b u n i t  a l o n e  (33). T h e  B  a n d  C  s u b u n i t s  s e r v e  
p r im a r i ly  t o  in c r e a s e  t h e  k i n e t i c s  o f  t h e  a lk y la t io n  r e a c t io n .  
W e  h a v e  a r g u e d  e l s e w h e r e  (19) t h a t  t h e  m o l e c u l a r  b a s i s  
fo r  t h e  D N A  s e q u e n c e  s e l e c t i v i t y  i s  d u e  t o  a  sequence- 
d ep en d en t conform ational flex ib ility  a n d  p e r h a p s  a  se ­
quence-dependent ca ta ly tic  role o f  D N A .  T h e  r e s u l t s  in  
t h i s  p a p e r  a l lo w  u s  t o  a s s i g n  C C - 1 0 6 5 - in d u c e d  c h a n g e s  in  
D N A  s t r u c t u r e ,  s u c h  a s  b e n d i n g  a n d  w i n d in g ,  t o  i n t e r a c ­
t i o n  b e t w e e n  D N A  a n d  s p e c i f i c  r e g i o n s  o f  t h e  C C - 1 0 6 5  
m o l e c u l e .  I n  a d d i t i o n ,  t h e  i n f o r m a t i o n  w e  h a v e  g a in e d  
f r o m  t h e  e x p e r i m e n t s  d e s c r i b e d  in  t h e  p r e s e n t  p a p e r  e x ­
t e n d s  t h e  k n o w n  r e l a t i o n s h i p  b e t w e e n  t h e  e f f e c t s  o f  c o ­
v a l e n t  b o n d i n g  o f  C C - 1 0 6 5  o n  l o c a l  D N A  s t r u c t u r e  a n d  
b o t h  t h e  m o le c u la r  b a s i s  fo r  D N A  s e q u e n c e  s e l e c t i v i t y  a n d ,  
m o r e  t e n t a t i v e l y ,  b i o l o g i c a l  e f f e c t s .
S tr u c tu r a l O rig in  o f  D ru g -In d u ced  B en d in g  and  
W in d in g  o f  D N A  in  th e  CC-1065 M olecu le . T h e  C C -  
1 0 6 5 - i n d u c e d  b e n d i n g  o f  D N A  is  c l e a r l y  a s s o c i a t e d  w i t h  
t h e  A  s u b u n i t  a n d  i s  t h e r e f o r e  a  c o n s e q u e n c e  o f  t h e  c o ­
v a l e n t  b o n d i n g  r e a c t i o n .  F o r  c o m p o u n d s  s u c h  a s  A , A B ,  
a n d  A B C , w h ic h  la c k  t h e  in s id e  e d g e  s u b s t i t u e n t s  c o m m o n  
t o  t h e  B  a n d  C  s u b u n i t s  o f  A B 'C '  a n d  C C - 1 0 6 5  ( F ig u r e  2 ) ,  
m a x i m u m  r e t a r d a t i o n  o f  g e l  m o b i l i t y  o c c u r s  w h e n  t h e  
c o v a l e n t  m o d i f i c a t i o n  s i t e s  a r e  s e p a r a t e d  b y  1 0 .5  b p .  
H o w e v e r ,  f o r  A B 'C '  a n d  C C - 1 0 6 5 ,  m a x i m u m  r e t a r d a t io n  
o f  g e l  m o b i l i t y  a n d ,  c o n s e q u e n t l y ,  m a x i m u m  c o h e r e n t  
a d d i t i o n  o f  i n - p h a s e  b e n d i n g  o c c u r  w h e n  t h e  c o v a l e n t  
m o d i f i c a t i o n  s i t e s  a r e  s e p a r a t e d  b y  1 0  b p ,  i n d i c a t i n g  t h a t  
t h e  i n s i d e  e d g e  s u b s t i t u e n t s ,  w h i c h  a r e  u n i q u e  t o  A B 'C '  
a n d  C C - 1 0 6 5 ,  w i n d  t h e  D N A  h e l i x  b y  t h e  e q u i v a l e n t  o f  
a b o u t  1 .0  b p  p e r  a l k y l a t i o n  s i t e .  T h i s  t r a n s l a t e s  i n t o  a  
w i n d i n g  a n g le  o f  3 4 ° ,  b u t  t h i s  n u m b e r  c o u ld  e a s i l y  v a r y  
b y  a s  m u c h  a s  ± 8 ° ,  s i n c e  t h e  a c c u r a c y  o f  t h e  e x p e r i m e n t  
i s  l i m i t e d  b y  t h e  a v a i l a b i l i t y  o f  o n l y  w h o l e - n u m b e r  o l i ­
g o m e r s  fo r  a n a l y s i s .  W h i l e  t h e  D N A  b e n d i n g  a n g le s  c a l ­
c u l a t e d  f r o m  Rl  v a l u e s  a n d  c i r c u l a r i z a t io n  e f f i c i e n c y  a r e  
in  g o o d  a g r e e m e n t  fo r  A B C ,  in  t h e  c a s e  o f  C C - 1 0 6 5  t h e  RL 
v a l u e  d e t e r m i n e d  a p p e a r s  t o  o v e r e s t i m a t e  t h e  b e n d i n g  
a n g le ,  a s  c a l c u l a t e d  a c c o r d i n g  t o  t h e  c i r c u l a r i z a t i o n  e f f i ­
c i e n c y  a s s a y ,  b y  a b o u t  2 - 3 ° .  W e  b e l i e v e  t h e  m o s t  l i k e l y  
r e a s o n  fo r  t h i s  d i s c r e p a n c y  i s  t h a t  t h e  C C - 1 0 6 5  m o l e c u l e  
s t i f f e n s  t h e  D N A  h e l i x ;  a n d  c o n s e q u e n t l y ,  t h e  i n h e r e n t  
f l e x i b i l i t y  o f  D N A  is  r e d u c e d ,  r e s u l t i n g  in  a n  i n c r e a s e  o f  
t h e  o p t im u m  s iz e  fo r  t h e  c ir c u la r iz a t io n  a n d  u n d e r e s t im a t e  
o f  b e n d in g  m a g n i t u d e ,  b e c a u s e  c ir c u la r iz a t io n  is  d e p e n d e n t  
u p o n  t h e  i n h e r e n t  f l e x i b i l i t y  o f  D N A  a s  w e l l  a s  t h e  l o c a l  
b e n d i n g  m a g n i t u d e  c o n t r i b u t e d  b y  t h e  d r u g  b o n d i n g  t o  
D N A .  S in c e  t h e  D N A  s t i f f e n in g  e f f e c t s  a r e  a l s o  f o u n d  w it h  
A B 'C '  ( u n p u b l i s h e d  r e s u l t s )  w e  c o n c l u d e  t h a t ,  j u s t  l ik e  
w i n d i n g  o f  t h e  h e l i x ,  D N A  s t i f f e n i n g  i s  a l s o  a  p r o p e r t y  
a s s o c i a t e d  w i t h  t h e  i n s id e  e d g e  s u b s t i t u e n t s  o f  t h e  B  a n d  
C  s u b u n i t s .  T h e s e  r e l a t i o n s h i p s  b e t w e e n  t h e  s t r u c t u r a l  
c h a r a c t e r i s t i c s  o f  C C - 1 0 6 5  a n d  t h e  c o n f o r m a t i o n a l / d y ­
n a m i c  e f f e c t s  o n  D N A  a r e  s u m m a r i z e d  in  F ig u r e  1 0 .
M o lecu la r  O rig in  o f  C C -1065-Induced B en d in g  in  
D N A  and C om p arison  to th e  In tr in s ic  B en d in g  A s­
soc ia ted  w ith  A -T ra cts . T h e r e  a r e  a  n u m b e r  o f  s t r u c ­
tu r a l  s im ila r i t i e s  b e t w e e n  t h e  b e n d s  in t r in s ic a l ly  a s s o c ia t e d  
w i t h  A - t r a c t s  a n d  t h o s e  i n d u c e d  b y  C C - 1 0 6 5  a n d  r e l a t e d  
d r u g s .  T h e  m o s t  o b v io u s  s im i l a r i t i e s  a r e  t h e  d i r e c t i o n a l i t y  
o f  D N A  b e n d i n g ,  w h i c h  in  b o t h  c a s e s  i s  i n t o  t h e  m i n o r  
g r o o v e ,  a n d  t h e  m a g n i t u d e s  o f  D N A  b e n d in g .  F o r  C C -1 0 6 5  
a n d  r e l a t e d  d r u g s ,  in  t h e  e x p e r i m e n t s  d e s c r i b e d  h e r e  t h e  
b e n d i n g  a n g le  i s  a b o u t  1 4 - 1 9 ° ,  a n d  fo r  A 5- o r  A t t r a c t s  i t  
i s  a b o u t  1 2 - 1 6 °  a n d  1 9 - 2 2 ° ,  r e s p e c t i v e l y  ( 3 9 ) .  T h e  e x ­
p e r i m e n t a l  d e t e r m i n a t i o n  o f  t h e  e x a c t  m a g n i t u d e  o f
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F i g u r e  10. D ia g r a m  r e p r e se n t in g  th e  c o r r e la t io n  b e tw e e n  th e  
b e n d in g  a n d  w in d in g  e f fe c ts  a n d  s tr u ctu r a l fe a tu r e s  o f  C C -1065 .
b e n d i n g  b y  C C - 1 0 6 5  a n d  r e l a t e d  d r u g s  i s  i n  s o m e  c a s e s  
( e .g . ,  C C - 1 0 6 5  a n d  A B 'C ' )  c o m p l i c a t e d  b y  t h e  a s s o c i a t e d  
w i n d i n g  a n d  s t i f f e n i n g  e f f e c t s  d o c u m e n t e d  h e r e .  F u r ­
t h e r m o r e ,  t h e  m a g n i t u d e  o f  b e n d in g  is  d e p e n d e n t  n o t  o n l y  
u p o n  t h e  i m m e d i a t e  b o n d in g  s e q u e n c e  ( e .g . ,  A G T T A *  v s  
G A T T A * )  b u t  a l s o  b y  t h e  f l a n k i n g  r e g i o n s  (45). T o  e x ­
a m i n e  in  m o r e  d e t a i l  t h e  s t r u c t u r a l  b a s i s  f o r  t h e  D N A  
b e n d i n g  p r o d u c e d  b y  C C - 1 0 6 5 ,  w e  h a v e  u s e d  h y d r o x y l -  
r a d ic a l  f o o t p r in t i n g  a n d  o n e -  a n d  t w o - d i m e n s i o n a l  p r o t o n  
N M R  t e c h n i q u e s  (34). T h e  c o n c l u s i o n s  d r a w n  fr o m  t h e  
r e s u l t s  o f  b o t h  t e c h n i q u e s  a r e  in  a g r e e m e n t  a n d  s u p p o r t  
t h e  id e a  t h a t  c o m p r e s s io n  o f  t h e  m in o r  g r o o v e ,  s a n d w ic h e d  
b e t w e e n  w i d e n e d  r e g i o n s ,  i s  r e s p o n s i b l e  fo r  t h e  o b s e r v e d  
d r u g - i n d u c e d  b e n d in g  o f  D N A .  T h i s  i s  a n a lo g o u s  to  t h a t  
f o u n d  fo r  A - t r a c t s  (47). I n  a d d i t i o n ,  t h e  c o m p r e s s io n  a n d  
w i d e n i n g  o f  t h e  m i n o r  g r o o v e  c o m m o n  fo r  b o t h  A  t r a c t s  
a n d  C C - 1 0 6 5 - i n d u c e d  b e n d s  i s  a s s o c i a t e d  w i t h  a  d i s c o n ­
t i n u i t y  a t  t h e  3 ' - e n d  o f  t h e  A - t r a c t  ( 3 9 )  o r  b e t w e e n  t h e  
c o v a l e n t l y  m o d i f i e d  b a s e  p a ir  a n d  t h e  b a s e  p a ir  t o  t h e  
3 ' - s id e  o n  t h e  c o v a l e n t ly  m o d i f ie d  s t r a n d ,  r e s p e c t iv e ly  (34). 
M a x i m u m  c o m p r e s s i o n  o f  t h e  m i n o r  g r o o v e  b y  C C - 1 0 6 5  
i s  l o c a l i z e d  b e t w e e n  t h e  t w o  t h y m i d i n e s  in  t h e  5 '  T T A *  
b o n d in g  s e q u e n c e  (34), in  a c c o r d  w i t h  t h e  r e s u l t s  r e p o r te d  
h e r e  fo r  t h e  l o c u s  o f  D N A  b e n d in g  p r o d u c e d  b y  C C -1 0 6 5 .
R e la tio n sh ip s  b e tw een  C C -1065-Induced B ead in g  
and W inding o f D N A  and D N A  S eq u en ce Selectiv ity . 
C C - 1 0 6 5  c a u s e s  b e n d in g  o f  D N A ,  w h i c h  a p p e a r s  in  o v e r a ll  
r e s p e c t s  t o  b e  a n a lo g o u s  t o  A - t r a c t s ,  a l t h o u g h  t h e  p r e c is e  
d e t a i l s  m a y  d i f f e r  (34). T h e  A  s u b u n i t  o f  C C -1 0 S 5  h a s  
s u f f i c i e n t  s t r u c t u r a l  i n f o r m a t i o n  t o  m e d i a t e  b o t h  t h e  
b e n d in g  o f  D N A  a n d  t h e  s e q u e n c e  s e le c t iv i t y .  S tr u c tu r a lly ,  
t h e  A  s u b u n i t  c o n t a i n s  t h e  a l k y l a t i n g  a b i l i t y  o f  C C -1 0 6 5  
( F ig u r e  1 ) . T h e r e f o r e ,  i t  is  t h e  c o v a l e n t  b o n d in g  r e a c t io n  
t h a t  i s  r e s p o n s i b l e  fo r  b o t h  t h e  b e n d i n g  o f  D N A  a i d  t h e  
s e q u e n c e  s e l e c t i v i t y .  I t  w a s  a n  u n e x p e c t e d  r e s u l t  to  f i n d  
t h a t  t h e  A  s u b u n i t  h a d  s u f f i c i e n t  s t r u c t u r a l  i n l o m a t i o n  
t o  m e d i a t e  t h e  s e q u e n c e  s e l e c t i v i t y  o f  t h e  e n t ir e  C C -1 0 6 5  
m o l e c u l e .  O u r  o b s e r v a t i o n  t h a t  t h e  s e q u e n c e  s e l e c t i v i t y  
o f  C C - 1 0 6 5  i s  p r im a r i ly  d e t e r m i n e d ,  n o t  b y  s e q i e n c e -  
r e c o g n i z i n g  n o n c o v a l e n t  b i n d i n g  b u t  b y  t h e  s e q u e n c e  r e ­
q u i r e m e n t s  o f  t h e  b o n d i n g  s t e p ,  h a s  l e d  t o  o u r  p o s t u la t e  
o f  a  sequence-dependen t conform ational flexibil t y  a l ­
l o w i n g  a d e n i n e  in  c e r t a i n  e n v i r o n m e n t s  t o  a p p r o a c h  t h e  
e le c t r o p h i l i c  c e n t e r  s u f f i c i e n t ly  c lo s e ly  fo r  b o n d  f o r n a t io n .  
I t  m i g h t  a l s o  b e  p o s t u la t e d  t o  i n v o lv e  sequence-depm dent 
electrophilic  ac tiva tion  o f  t h e  A  s u b u n i t  s im u lt a n e o u s ly  
w i t h  a d e n in e  N 3  n u c l e o p h i l i c  a t t a c k ,  in  a  p r o c e s s  s m i l a r  
t o  t h e  b i f u n c t i o n a l  c a t a l y s i s  o b s e r v e d  in  m a n y  e n c y m e -  
s u b s t r a t e  r e a c t i o n s  (48). T h e  b e n t  D N A  s t r u c t u i e  t \ a t  w e  
o b s e r v e  a f t e r  c o v a l e n t  a d d u c t  f o r m a t i o n  w i t h  C C -1 0 6 5  
w o u l d  l i k e l y  r e q u i r e  t h e  i n h e r e n t  s e q u e n c e - d e p e n d e n t  
c o n f o r m a t i o n a l  f l e x i b i l i t y  t h a t  w e  h a v e  p o s t u l a t e d  i s  i m ­
p o r t a n t  in  s e q u e n c e  r e c o g n i t io n .  F u r t h e r m o r e ,  s e q v e n c e s  
s u c h  a s  A - t r a c t s ,  i f  t h e i r  o v e r a l l  b e n t  s t r u c t u r e  is  s m i l a r
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to that induced by CC-1065, should be optimum bonding 
sites for CC-1065. Indeed, our observations that bonding 
of CC-1065 to A-tracts produces only a modest overall 
increase in bending of DNA and that these are one of the 
subsets of consensus bonding sequences for CC-1065 are 
in accord with this postulate (34). Moreover, the overall 
direction of bending and magnitude of bending induced 
by CC-1065 corresponds well to an A5- or Ag-tract. How­
ever, it is important to recognize that because sequences 
such as 5'TTA are also equally, if not more, reactive to 
CC-1065 than A-tracts, and since these sequences do not 
have an intrinsic bent DNA structure, other factors, such 
as catalytic  activation, may also play an important role 
in sequence recognition. We have recently demonstrated 
that a critically placed hydrogen-bonded water molecular 
may play a role in this catalysis (49).
The precise structure of the B and C subunits can 
modulate or fine tune the sequence selectivity of CC-1065 
analogues (33). While new covalent bonding sites are not 
created over that observed with the A subunit, the binding 
interactions of the B and C subunits increase or decrease 
the rate of reaction at individual bonding sites. Our 
present observation that the precise structure of the B and 
C subunits can cause winding (CC-1065 and AB'C') or 
modulate bending (ABC and AB) provides a possible ra­
tionale for these fine-tuning effects.
Recently, Powers and Gorenstein (50) published a model 
based upon molecular dynamics refinement for the 
structure of the AB'C'-DNA adduct, in which the drug- 
induced bending of DNA is both q u an tita tively  and  
qualita tively  different from that reported here for (+)- 
CC-1065. Their model shows a 600 kink in the DNA with 
an associated widening  of the minor groove of DNA. 
Clearly, both of these predictions are in sharp disagreement 
with the experimental results reported in this paper and 
previously published by us (34), where the bending of DNA 
is estimated to be within the range of 17-22° and is as­
sociated with a distinct narrowing of the minor groove.
B io logica l Im plications. The covalent bonding reac­
tion of CC-1065 is crucial for the potent biological effects, 
such as cytotoxicity and antitumor activity. Trisubunit 
compounds, which lack the ability to covalently bond to 
DNA, show cytotoxic activity several orders of magnitude 
less than CC-1065 and negligible antitumor activity. On 
the other hand, the A subunit, although considerably less 
cytotoxic, shows moderate antitumor activity at elevated 
doses (32). Since we have now demonstrated that CC-1065 
and the A subunit produce bending of DNA into the minor 
groove in quite a similar manner to a naturally occurring 
A-tract, it is interesting to speculate how this may be re­
sponsible for the cytotoxic and antitumor activity of 
CC-1065 and its synthetic analogues. Bends in DNA are 
found naturally or may be induced by DNA binding pro­
teins (for an insightful view of the biological significance 
of bends in DNA, see ref 51). These occur at the origin 
of replication (52), in a site-specific recombination site (7, 
9, 53), and in transcriptional regulatory regions of DNA  
(4, 5, 53, 54). The covalent bonding of CC-1065 at such 
regions in DNA may mimic DNA binding protein effects 
on DNA or may entrap bent DNA structures that are 
normally in equilibrium with nonbent structures. This 
may have profound effects on one or more of the replica­
tion, recombination, and transcriptional events and per­
haps therefore be responsible for some of the potent bio­
logical effects of CC-1065.
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a b s t r a c t : (+ )-C C -1065 is a biologically potent DNA-reactive antitumor antibiotic produced by 
Streptom yces zelensis. In a previous study we have reported that (+ )-C C -1065 produces bending of D N A  
that has similarities to that intrinsically associated with A-tracts [Lin, C. H., Sun, D., & Hurley, L. H. 
(1991) Chem. Res. Toxicol. 4 , 21-26]. In this article we provide evidence using a combination o f non­
denaturing gel analysis, hydroxyl-radical footprinting, and high-field N M R  for both distinctions between 
the two types of bends and the importance of junctions in both types of bends. For A-tracts we demonstrate 
that the locus of bending is at the center of an A-tract and that upon modification o f the 3' adenine with 
(+ )-C C -1065 this locus is moved less than 1 base pair to the 3' side, and the bending magnitude is significantly 
increased. For drug bonding sequences such as 5'-AGTTA* or 5'-GATTA* (where * denotes the drug 
bonding site), the locus o f bending is found to be between the two thymines, and the bending is focused 
over a 2-base-pair sequence rather than a 5-base-pair sequence, as is the case for the A-tract. An important 
distinction between an A-tract intrinsic bend and a (+)-CC-1065-induced bend is the effect o f temperature. 
While, as shown previously, the magnitude of A-tract bending increases with decrease in temperature for 
drug-induced bending of 5'-AGTTA* the bending magnitude increases with increased temperature. Hydroxyl- 
radical footprinting o f the drug-modified 5'-AGTTA* sequence shows a decrease in cleavage centered 
around the TT sequence, which is presumably associated with a decrease in minor groove width. In a 
parallel study, the non-self-complementary 12-mer duplex (5/-GGCGGAGTTA*GG-3/)*(5'-CCTAACTC- 
CGCC-30 (Figure 2B) and the corresponding (+)-CC-1065-modified duplex adduct were examined 
thoroughly by one- and two-dimensional1H N M R  and NOESY restrained molecular mechanics and dynamics 
calculations. Both the 12-mer duplex and the (+ )-C C -1065-12-mer duplex adduct maintain an overall 
B-form D N A  with the anti base orientation throughout in aqueous solution at room temperature. The 18C 
nucleotide o f both the 12-mer duplex and its drug-modified adduct has an average C3'-endo sugar pucker. 
The 12-mer duplex exhibits a unique internal motion at the 16A nucleotide, which is located to the 3' side 
of the complementary partner of the covalently modified adenine, and a major kink at the 18C-19T step. 
Following covalent bonding with (+)-C C -1065, the discontinuity around 18C is entrapped and further 
exaggerated. In addition, the 12-mer duplex adduct displays a compression of the minor groove at the 8T 
to 9T step and widening on both sides, but especially abruptly at the covalent modification site. Structurally, 
the 12-mer duplex adduct bears many similarities to a bent D N A  structure, which is intrinsically associated 
with A-tracts. The major drug-induced distortion on D N A  is localized at the 9T and 10A step of the 
covalently modified strand. A  truncated junction model for the drug-entrapped/induced bending of DNA  
is proposed, and a comparison to intrinsic A-tract bending is made.
(+)-CC-1065 (Figure 1) is an extremely potent antitumor 
antibiotic produced by Streptomyces zelensis (Hanka et al., 
1978). (+)-CC-1065 reacts with double-stranded DNA  
through N3 of a reactive adenine, forming a covalent adduct 
that overlaps a 5-bpl region in the minor groove (Swenson et 
al., 1982; Hurley et al., 1984; Scahill et al., 1990). (+)-CC- 
1065 consists of a CPI subunit (subunit A in Figure 1) and
t This research was supported by grants from the Public Health Service 
(CA-49751), the Welch Foundation, The Upjohn Company, and the 
Burroughs Wellcome Scholars Program.
* To whom correspondence should be addressed.
1 Drug Dynamics Institute, College of Pharmacy.
§ Department of Chemistry and Biochemistry.
two repeating pyrroloindole subunits (subunits B and C in 
Figure 1) attached via amide linkages that are approximately 
15° out of plane, providing the drug molecule with a right- 
handed twisted banana shape (Chidester et al., 1981). The 
CPI subunit contains the DNA-reactive cyclopropane ring 
that alkylates N3 of adenine when it bind* within certain
1 Abbreviations: A-tract, adenine tract; bp, base pair; CPI, cyclo- 
propylpyrroloindole; DDW, double-distilled water; DQF-COSY, phase- 
sensitive double quantum Filtered correlated spectroscopy; HPLC, high- 
performance liquid chromatography; NMR, nuclear raagEetic resonance; 
NOE, nuclear Overhauser effect; NOESY, two-dimensional NOE 
correlated spectroscopy; ppm, parts per million; Pu, purine;Py, pyrimidine; 
ss, single strand; TEMED, NJV,N 'JV-tetramethyletbylenediamine; TSP, 
3-(trimethylsilyl)propionic acid; ROE, rotating frame NOE.
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O (+ )-A B C
(+ )-A B C
b . x o
II H ̂ O
(+)-A B
F ig u re l :  Structures of (+ )-C C -1065, (+ )-A B C ", (+ )-A B C , and 
(+)-AB. Arrows point to subunits A, B, and C in (+ )-C C -1065.
reactive seq u e n c e s  ( R e y n o ld s  e t  a l . ,  1 9 8 5 ) .
The covalen t l in k a g e  s it e s  b e t w e e n  ( + ) - C C - 1 0 6 5  a n d  D N A  
have been d e ter m in ed  ( H u r le y  e t a l . ,  1 9 8 4 ;  S c a h i l l  e t a l . ,  1 9 9 0 ) ,  
and the p r e d o m in a n t ta u t o m e r ic  s p e c ie s  o f  t h e  c o v a le n t ly  
modified a d e n in e  is  th e  d o u b ly  p r o to n a te d  6 - a m in o  fo r m  w ith  
the additional p o s i t iv e  c h a r g e  d e lo c a l iz e d  o v e r  t h e  e n t ir e  
adenine m o le c u le  ( L in  &  H u r le y ,  1 9 9 0 ) .  A  c o n s e n s u s  
sequence a n a ly s is  o f  th e  ( + ) - C C - 1 0 6 5  b o n d in g  s i t e s  o n  D N A  
reveals that th e r e  a r e  t w o  s u b s e t s  o f  D N A  s e q u e n c e s ,  5 '-  
PuNTTA*2 a n d  5 ' - A A A A A * ,  t h a t  a r e  h ig h ly  s p e c i f ic  
(Reynolds e t  a l . ,  1 9 8 5 ) .  S u r p r is in g ly ,  th e  a lk y la t in g  s u b u n it  
alone contains s u f f i c i e n t  s t r u c tu r a l  in fo r m a t io n  to  e n c o d e  th e  
primary m o le c u la r  b a s is  fo r  s e q u e n c e  s e le c t iv i t y  ( H u r le y  e t  
al,, 1988), a n d  th is  s u b u n it  is  a l s o  e s s e n t ia l  fo r  a n t itu m o r  
activity (W a r p e h o sk i  e t  a l . ,  1 9 8 8 ;  W a r p e h o s k i  &  H u r le y ,  
1988). H o w e v e r , a s  w e  h a v e  p r e v io u s ly  d e m o n s t r a t e d ,  th e  
noncovalent b in d in g  in t e r a c t io n s  o f  t h e  B  a n d  C  s u b u n i t s  w ith  
DNA can m o d u la te  o r  f in e - t u n e  th is  s e q u e n c e  s e l e c t iv i t y  
(Hurley et a l., 1 9 8 8 )  a n d , in  th e  c a s e  o f  ( + ) - C C - 1 0 6 5 ,  p r o d u c e  
winding o f  D N A  ( L e e  e t  a l . ,  1 9 9 1 ) .
The co v a len t b o n d in g  r e a c t io n  o f  ( + ) - C C - 1 0 6 5  w ith  D N A  
has been p rop o sed  t o  in v o lv e  c a t a ly t i c  a c t iv a t io n  o f  th e  c o v a le n t  
reaction b e tw e e n  ( + ) - C C - 1 0 6 5  a n d  D N A  a n d  to  b e  a t  le a s t  
partially r e s p o n s ib le  fo r  t h e  m o le c u la r  b a s is  fo r  s e q u e n c e -  
selective r e c o g n it io n  o f  D N A  b y  t h e  a lk y la t in g  s u b u n i t  o f  
(+)-CC-1 0 65  (W a r p e h o sk i  &  H u r le y ,  1 9 8 8 ;  L in  e t a l . ,  1 9 9 1 a ) .  
In addition to  c a t a ly t i c  a c t iv a t io n ,  w e  h a v e  a l s o  p r o p o s e d  th a t  
DNA c o n fo r m a tio n a l  f l e x ib i l i t y  is  a n  im p o r ta n t  c o m p o n e n t  
ofsequence r e c o g n it io n  in  th e  ( + ) - C C - 1 0 6 5  b o n d in g  r e a c t io n  
(Hurley e t a l . ,  1 9 8 8 ) .
As a p o ss ib le  m e a n s  o f  d e f in in g  t h e  m o le c u la r  b a s is  o f  th e  
potent c y to to x ic i ty  s h o w n  b y  ( + ) - C C - 1 0 6 5  a n d  i t s  a n a lo g u e s ,
: Here and th rou ghout th e  m an u scr ip t, an asterisk  d en o tes  th e  
covalently m odified aden in e.
th e  s tr u c tu r a l  c h a n g e s  o c c u r r in g  in  D N A  m o le c u le s  a s  a  r e s u lt  
o f  c o v a le n t  a d d u c t  fo r m a t io n  w ith  d r u g  m o le c u le s  h a v e  b e e n  
e x t e n s iv e ly  s tu d ie d  (L in  e t  a l . ,  1 9 9 1 b ;  L e e  e t  a l . ,  1 9 9 1 ;  S u n  
&  H u r le y ,  1 9 9 2 a ,b ) .  U s i n g  a  c o m b in a t io n  o f  g e l  e le c t r o ­
p h o r e s is  a n d  h ig h - f ie ld  N M R ,  w e  h a v e  p r e v io u s ly  s h o w n  t h a t ,  
fo l lo w in g  th e  c o v a le n t  r e a c t io n  w i t h  ( + ) - C C - 1 0 6 5  a n d  th e  
s y n th e t ic  a n a lo g u e s  s h o w n  in  F ig u r e  1, t h e  D N A  h e lix  b e c o m e s  
b e n t , w ith  th e  lo c u s  o f  b e n d in g  b e in g  b e tw e e n  t h e  tw o  t h y m in e s  
w ith in  th e  b o n d in g  s e q u e n c e  5 ' - A G T T A *  ( L in  e t  a l . ,  1 9 9 1 b ) .  
T h e  m a g n i t u d e  o f  th is  b e n d  is  a b o u t  1 7 - 2 2 ° ,  a n d  t h e  d ir e c t io n  
is  in  to w a r d  th e  m in o r  g r o o v e  o f  D N A ;  s t r u c tu r a l ly  i t  b e a r s  
m a n y  s im ila r it ie s  to  th e  b e n t  D N  A  s tr u c tu r e  th a t  is  in tr in s ic a l ly  
a s s o c ia t e d  w ith  A - t r a c t s  ( L in  e t a l . ,  1 9 9 1 b ;  L e e e t  a l . ,  1 9 9 1 ) .  
T h e  p u r p o s e  o f  th is  s tu d y  w a s  t w o f o ld .  F ir s t ,  b e c a u s e  o f  th e  
b io lo g ic a l  s ig n if ic a n c e  o f  A - t r a c t  b e n d in g  [r e v ie w e d  in  T r a v e r s  
( 1 9 9 0 ) ] ,  i t  w a s  im p o r ta n t  to  m a k e  a m o r e  r ig o r o u s  s t r u c tu r a l  
a n d  d y n a m ic  c o m p a r is o n  o f  th e  d r u g - in d u c e d  b e n d  to  a n  
in tr in s ic  A - t r a c t  b e n d . S e c o n d ,  a n  u n d e r s ta n d in g  o f  th e  u n iq u e  
r e a c t iv i t y  o f  3 ' a d e n in e s  in  A - t r a c t s  t o  ( + ) - C C - 1 0 6 5  m ig h t  
p r o v id e  a d d i t io n a l  in s ig h t  in t o  b o t h  t h e  s t r u c tu r e  o f  A - t r a c t s  
a n d  th e  m o le c u la r  b a s is  fo r  th e  s e q u e n c e  s e l e c t iv i t y  o f  ( + ) -  
C C - 1 0 6 5 .
N o n - d e n a t u r in g  p o ly a c r y la m id e  g e l  a n a ly s i s  w a s  u s e d  to  
m o n ito r  t h e  m o b il i t y  s h i f t s  o f  T 4 - l i g a t e d  o l ig o m e r s  c o n t a in in g  
A 5- tr a c t s  a n d  th e  ( + ) - C C - 1 0 6 5  r e a c t iv e  b o n d in g  s e q u e n c e  
5 ' - A G T T A *  w ith  a n d  w it h o u t  d r u g  m o d if ic a t io n .  H y d r o x y l-  
r a d ic a l  f o o tp r in t in g  w a s  u s e d  t o  e s t im a t e  v a r ia t io n  in  m in o r  
g r o o v e  w id th .  T h e  r e s u lt s  o f  t h e s e  s t u d ie s  w e r e  c o m b in e d  
w ith  th e  r e s u lt s  o f  o n e -  a n d  t w o - d im e n s io n a l  !H  N M R  
e x p e r im e n t s  a n d  N O E S Y  c o n s t r a in e d  m o le c u la r  m e c h a n ic s  
a n d  d y n a m ic s  c a lc u la t io n s  to  d e f in e  t h e  s o lu t io n  s t r u c t u r e  o f  
a  1 2 -m e r  d u p le x  c o n t a in in g  t h e  h ig h ly  r e a c t iv e  ( + ) - C C - 1 0 6 5  
s e q u e n c e  S ' - A G T T A *  a n d  i t s  d r u g - m o d if ie d  a d d u c t .  O v e r a l l ,  
w e  c o n c lu d e  t h a t  th e  1 2 -m e r  d u p le x  a d d u c t  b e a r s  m a n y  
s im ila r i t ie s  to  th e  b e n t  D N A  s t r u c t u r e  in t r in s ic a l ly  a s s o c ia t e d  
w ith  A - t r a c t s .  A  j u n c t io n  b e n d  m o d e l  is  p r o p o s e d  fo r  th e  
( + ) - C C - 1 0 6 5 - e n t r a p p e d / i n d u c e d  b e n d  in  D N A ,  w h ic h  is  a  
t r u n c a te d  v e r s io n  o f  th a t  p r o p o s e d  fo r  A - t r a c t  b e n d in g  ( K o o  
e t  a l . ,  1 9 8 6 ) .
M A T E R I A L S  A N D  M E T H O D S
Chemicals and Enzymes. ( + ) - C C - 1 0 6 5  a n d  i t s  a n a lo g u e s  
u s e d  in  th is  s tu d y  w e r e  o b t a in e d  f r o m  t h e  U p j o h n  C o m p a n y  
a n d  u s e d  w i th o u t  fu r th e r  p u r if i c a t io n .  E le c t r o p h o r e t ic  r e ­
a g e n t s  [ a c r y la m id e ,  T E M E D ,  a m m o n iu m  p e r s u l f a t e ,  a n d  b is -  
(a c r y la m id e ) ]  w e r e  p u r c h a s e d  fr o m  B io - R a d .  T 4  p o ly n u ­
c le o t id e  k in a s e  a n d  T 4  D N A  l ig a s e  w e r e  fr o m  U n i t e d  S t a t e s  
B io c h e m ic a l  C o . [7 - 32P ] A T P  w a s  fr o m  I C N .  X - r a y  f i lm ,  
in t e n s i f y in g  s c r e e n s ,  a n d  d e v e lo p in g  c h e m ic a ls  w e r e  fr o m  
K o d a k . R e a g e n t s  u s e d  to  p r e p a r e  N M R  b u ffe r  a n d  to  p r e p a r e  
a n d  p u r ify  th e  1 2 -m e r  d u p le x  a n d  t h e  c o r r e s p o n d in g  ( + ) -  
C C - 1 0 6 5 - 1 2 -m e r  d u p le x  a d d u c t  h a v e  b e e n  r e p o r te d  p r e v io u s ly  
(L in  &  H u r le y ,  1 9 9 0 ;  L in  e t  a l . ,  1 9 9 1 a ,b ) .
Preparation o f  Oligonucleotides. T h e  o l ig o n u c le o t id e s  
( F ig u r e  2 )  w e r e  s y n th e s iz e d  o n  a n  a u t o m a t ic  D N A  s y n th e s iz e r  
( A p p l ie d  B io s y s t e m s  3 8 1  A )  b y  t h e  p h o s p h o r a m id it e  m e th o d  
( G a i t ,  1 9 8 4 ) .  T h e  d e p r o t e c t io n  w a s  p e r fo r m e d  a s  d e s c r ib e d  
p r e v io u s ly  ( L e e  e t  a l . ,  1 9 9 1 ) .
DNA Bending Experiments. A p p r o x im a t e ly  5 fig o f  e a c h  
o l ig o n u c le o t id e  o f  th e  c o m p le m e n t a r y  s e q u e n c e s  w a s  la b e le d  
w ith  [ y - 32P ]  A T P  b y  T 4  p o ly n u c le o t id e  k in a s e  a n d  h y b r id iz e d  
t o g e th e r ,  a n d  th e  r e s u l t in g  d u p le x  w a s  g e l - p u r i f ie d  b y  12%  
n o n -d e n a tu r in g  p o ly a c r y la m id e  g e l  e le c tr o p h o r e s is  a s  d e s c r ib e d  
p r e v io u s ly  ( L e e  e t  a l . ,  1 9 9 1 ) .  D u p le x e d  o l ig o m e r s  w e r e  
m o d if ie d  w ith  ( + ) - C C - 1 0 6 5 ,  ( + ) - A B C // , o r  ( + ) - A B C  ( s e e
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A
2 1 - c 5 ’ GAGGACCGGAAAAACGGATTC3•
3 ’ CTGGCCTTTTTGCCTAAGCTC 5  *
A T - 1 5 ' AAAAAGGGCCCTTTTTCCGGG 3 ’
3 ' TTCCCGGGAAAAAGGCCCTTT 5  *
A T - 2 5 ' AAAAAGGCCCTTTTTCCCGGG3 *
3 ' TTCCGGGAAAAAGGGCCCTTT 5 ’
A T - 3 5 ' AAAAAGGGGCCCTTTTTCCGG 3 '
3 ' TTC C C CG G G AAAAA GG CC TTT5'
S P - A 1 5 ' AAAAAGCGGAGTTAGGGGCGG3'
3 ' TTC GC C T C A A T C C C C G C C T TT 5'
S P - A 2 5 ' AAAAAGGCGGAGTTAGGGGCG3 '
3 ' TTC CGCCTCAATCCCCGCTTT 5 '
S P - A 3 S ' AAAAAGGGCGGAGTTAGGGGC 3 '
3 ' TTC CCGCCTCAATCCCCGTTT 5 *
2 1 —S P 5 ' TGGGCGGAGTTAGGGGCGGGA3'
3 ' C G C C TC A ATC CCCG CC CTA CC5'
41M E R 5 ' TCCCG CC CCTAACTCCGCCCACAGTGTTCGATTACAGGCAT3'
"  1 2  3 4 5 6 7 6 9  10  11 12
5 ' GGCGGAGTTAGG 3 '
3 ' CCGCCTCAATCC5'
2 4  2 3  2 2  21  2 0  1 9  16 17  16  I S 14  13
F igure 2: Sequences of oligomers used in this study (A ) and the 
12-mer duplex (B).
F ig u r e  1) (F ina l c o n c e n tr a t io n :  2 8  / iM )  a t  r o o m  te m p e r a tu r e  
fo r  3 d a y s . U n b o u n d  d r u g  m o le c u le s  w e r e  r e m o v e d  b y  p h e n o l /  
c h lo r o fo r m  e x t r a c t io n ,  a n d  d r u g -m o d if ie d  d u p le x e s  w e r e  
fu r th e r  p u r if ie d  b y  e t h a n o l  p r e c ip ita t io n .  D r u g - m o d if ie d  a n d  
u n m o d if ie d  d u p le x e s  w e r e  s e l f - l ig a t e d  in  2 0  /*L  o f  l ig a t io n  
b u ffe r  w ith  1 u n it  o f  T 4  D N A  l ig a s e  a t  r o o m  te m p e r a tu r e  
o v e r n ig h t  to  p r o d u c e  m u lt im e r s ,  w h ic h  w e r e  e le c tr o p h o r e s e d  
o n  8%  p o ly a c r y la m id e  g e l ,  a n d  th e  b a n d s  w e r e  lo c a t e d  b y  
a u to r a d io g r a p h y .
Hydroxyl-Radical Footprinting. A  p a r t ia l  d u p le x  o f  D N A  
c o n ta in in g  a  u n iq u e  d r u g  b o n d in g  s e q u e n c e  w ith in  th e  d u p le x  
r e g io n  w a s  p r e p a r e d  b y  a n n e a l in g  th e  4 1 - m e r  a n d  t h e  2 1 -  
S P - m e r  ( to p  s t r a n d )  s h o w n  in  F ig u r e  2 . T h is  p a r t ia l  d u p le x  
w a s  m o d if ie d  w ith  e ith e r  ( + ) - C C - l  0 6 5 ,  ( + ) - A B ,  o r  ( + ) - A B C " ,  
a s  d e s c r ib e d  a b o v e , a n d  t h e  s i t e - d ir e c t e d  d r u g - m o d if ie d  ss  
2 1 -m e r  w a s  s e p a r a te d  b y  d e n a tu r in g  p o ly a c r y la m id e  g e l  
e le c tr o p h o r e s is ,  a s  d e s c r ib e d  p r e v io u s ly  ( S u n  &  H u r le y ,  
1 9 9 2 b ) .  P u r if ie d  d r u g - m o d if ie d  s s  D N A  w a s  a n n e a le d  to  th e  
5 '- e n d - la b e le d  2 1 - S P ( - ) - m e r  a n d  r a d io - la b e le d  w ith  [ t - 32P ] -  
A T P , a n d  th e  r e s u lt in g  d u p le x  w a s  p u r if ie d , a s  d e s c r ib e d  a b o v e . 
H y d r o x y l-r a d ic a l  c le a v a g e  o f  t h e  d r u g -m o d if ie d  a n d  u n m o d ­
i f ie d  o l ig o m e r s  w a s  c a r r ie d  o u t  a t  r o o m  te m p e r a t u r e  fo r  5 m in  
w ith  th e  s a m e  r e a g e n t s  a s  p r e v io u s ly  p u b l is h e d  ( B u r k o f f  &  
T u ll iu s ,  1 9 8 8 )  e x c e p t  fo r  c h a n g e s  in  t h e  c o n c e n t r a t io n  o f  
h y d r o g e n  p e r o x id e  ( L in  e t  a l . ,  1 9 9 1 b ) .
Strand Breakage Assay and DNA Sequencing. D r u g -  
m o d if ie d  d u p le x e s  w e r e  s u b je c te d  to  th e r m a l  t r e a t m e n t  fo r  3 0  
m in  a t  9 5  ° C  in  D D W  to  lo c a t e  th e  d r u g  b o n d in g  s i t e  a n d  
d e te r m in e  th e  e x t e n t  o f  r e a c t io n  a t  th e  d e s ir e d  s e q u e n c e  o n  
t h e  o l ig m e r  d u p le x . H e a t - t r e a t e d  s a m p le s  w e r e  d r ie d , r e ­
d is s o lv e d  in  fo r m a m id e  ( 8 0 % ) - N a O H  ( 1 0  m M )  d y e  s o lu t io n ,  
a n d  th e n  s u b je c te d  t o  d e n a tu r in g  20%  p o ly a c r y la m id e  g e l  
e le c tr o p h o r e s is  ru n  in  p a r a l le l  w ith  th e  D N A  s e q u e n c in g  
r e a c tio n . P u r in e -  a n d  p y r im id in e -s p e c if ic  s e q u e n c in g  r e a c t io n s  
w e r e  c a r r ie d  o u t  a c c o r d in g  t o  th e  m e th o d s  o f  M a x a m  a n d  
G ilb e r t  ( 1 9 8 0 ) .
Preparation and Purification o f  the 12-mer Duplex and 
the (+ )-C C -1065-12-mer Duplex Adduct. T h e  n o n - s e l f -  
c o m p le m e n t a r y  1 2 -m e r  d u p le x  ( F ig u r e  2 )  fo r  N M R  s tu d ie s  
w a s  s y n th e s iz e d  in -h o u s e  o n  a 10 -/^ m ol s c a le ,  a s  d e s c r ib e d
T A T A
C G 1 2 3 4 5 6 7 8  9 C G
3' 
- * A *
A
*  m  A
* -  • -  A
5 ’
F i g u r e  3: Autoradiogram of the therm ally induced strand breakage 
assay on oligomer 21-C after covalent modification with (+ )-C C - 
1065, (+ )-A B C , and (+ )-A B C ". Outside lanes are  AG- and TC- 
specific reactions. Lanes 1-3, 4 -6 , and 7 -9  contain oligomers 
modified with (+ )-C C -1065, (+ )-A B C , and (+ )-A B C ", respectively. 
Drug concentrations used in this experiment were 2.8 in lanes 
1, 4, and 7; 28 /xM in lanes 2, 5, and 8; and 280 /xM in lanes 3, 6, 
and 9. The appearance of more than one band following therm al 
cleavage is due to incomplete chemical degradation of the deoxyribose 
at the 3' end of the fragm ent (Reynolds et al., 1985).
a b o v e .  T h e  g e n e r a l  p r o c e d u r e s  fo r  s y n t h e s i s ,  d e p r o t e c t io n ,  
d r u g  b o n d in g , H P L C , a n d  c h r o m a t o g r a p h y  p u r if i c a t io n  o f  
th e  12-m e r  d u p le x  a n d  t h e  ( + ) - C C - 1 0 6 5 - 1 2 - m e r  d u p le x  
a d d u c t  h a v e  b e e n  r e p o r te d  p r e v io u s ly  ( L in  &  H u r le y ,  1 9 9 0 ;  
L in  e t  a l . ,  1 9 9 1 a ,b ) .
High-Field NM R Spectroscopy. O n e -  a n d  tw o -d im e n s io n a l
5 0 0 - M H z 1H  N M R  d a ta  s e t s  in  9 0 %  H 2O / 10%  D 2O  o r  9 9 .9 6 %  
D 20  b u f fe r e d  s o lu t io n  c o n t a in in g  1 0  m M  s o d iu m  p h o s p h a te  
a n d  1 0 0  m M  s o d iu m  c h lo r id e  a t  p H  6 .8 5  w e r e  r e c o r d e d  o n  
a  G e n e r a l  E le c tr ic  G N - 5 0 0 F T  N M R  s p e c t r o m e t e r .  P r o to n  
c h e m ic a l  s h i f t s  w e r e  r e c o r d e d  in  p a r ts  p e r  m i l l io n  ( p p m )  a n d  
r e fe r e n c e d  r e la t iv e  to  e x t e r n a l  T S P  (1  m g / m L )  in  D 2O  ( H O D  
s ig n a l  w a s  s e t  to  4 .7 5 1  p p m ) .  T w o - d im e n s io n a l  N M R  d a t a  
s e t s  w e r e  r e c o r d e d  a c c o r d in g  t o  th e  p r o c e d u r e s  d e s c r ib e d  
p r e v io u s ly  (L in  e t  a l . ,  1 9 9 2 ) .
R E S U L T S
Unique Reactivity o f  the 3 ' Adenine in A-Tracts to  ( + ) -  
CC-1065, ( +)-A B C ", and  (+ )-A B C . ( + ) - C C - 1 0 6 5  r e a c t s  
p r e f e r e n t ia l ly  a t  tw o  c o n c e n s u s  s e q u e n c e s ,  5 ' - P u N T T A *  a n d  
5 '-A A .A A A *  ( R e y n o ld s  e t a l . ,  1 9 8 5 ) .  S ig n if ic a n t ly ,  in  A - t r a c t s  
th e  a lm o s t  e x c lu s iv e  b o n d in g  s i t e  fo r  ( + ) - C C - 1 0 6 5  is  t h e  3 '  
a d e n in e ,  w h ic h  s u g g e s t e d  t o  u s  a n d  o th e r s  ( K o o  e t  a l . ,  1 9 8 6 )  
th a t  th e  3 '  a d e n in e  o f  a n  A - t r a c t  h a s  u n iq u e  s t r u c t u r a l  f e a t u r e s  
th a t  m a k e  it  e s p e c ia l ly  r e a c t iv e  to  ( + ) - C C - 1 0 6 5 .  I t  is  w e ll  
k n o w n  t h a t  t h e  3' t e r m in a l  a d e n in e  ju n c t io n  in  A - t r a c t s  h a s  
a u n iq u e  s t r u c tu r e  ( K o o  e t  a l . ,  1 9 8 6 ;  K o o  &  C r o t h e r s ,  1 9 8 8 ;  
N a d e a u  &  C r o th e r s ,  1 9 8 9 ;  K a ta h ir a  e t  a l . ,  1 9 9 0 ) .  C o n f ir ­
m a t io n  o f  th is  u n iq u e  r e a c t iv i t y  o f  th e  3 ' a d e n in e  in  a n  A 5- 
tr a c t  to w a r d  ( + ) - C C - 1 0 6 5 , ( + ) - A B C " ,  a n d  ( + ) - A B C  is  s h o w n  
in  F ig u r e  3 . O v e r a l l ,  th is  r e s u lt  s u p p o r ts  t h e  j u n c t io n  m o d e l  
( K o o  e t  a l . ,  1 9 8 6 ;  K o o  &  C r o t h e r s ,  1 9 8 8 )  t h a t  e m p h a s i z e s  th e  
p r e s e n c e  o f  a u n iq u e  s t r u c tu r e  a t  t h e  3'j u n c t io n  o f  t h e  A - t r a c t .  
In  a d d i t io n ,  th is  im p lie s  a h ig h  le v e l  o f  s e q u e n c e  s e l e c t iv i t y  
o f  ( - F ) - C C - 1 0 6 5  a n d  its  a n a lo g u e s  in  o r d e r  fo r  th e m  t o  b e  a b le  
to  d is c r im in a t e  b e tw e e n  th e  s u b t le  d i f f e r e n c e s  in  r e a c t iv i t y  o f  
th e  d i f f e r e n t  a d e n in e s  in  a n  A s - t r a c t .
Determination o f  the Locus o f  Bending in an A 5-Tract and 
in ( + ) - ABC-M odified 21-mers Containing the Drug Bonding
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Figure 4: Panel A (top left): (I, left) A utoradiogram  of the ligation products of oligomers AT-1, AT-2 and AT-3 and (-f)-ABC-modified 
oligomers AT -1, AT-2, and AT-3. Lane 1 is control containing ligation products of oligomer 21-SP as a size m arker, and lanes 2—4 contain 
oligomers AT-1, AT-2, and AT-3, respectively. (II, right) Lanes 5-7 contain ligation products of oligomers AT-1, AT-2, and AT-3 modified 
»ith(+)-ABC respectively. (II) Lanes 1-7 are the sam e ligated products as lanes 1-7 in panel (I), respectively, but electrophoresis was carried 
mil in the presence of M g2+ (10 mM ). M and D correspond to monomer and dimer. Panel B (top right): Plot of R l values vs total length 
ofligated multimers in multiplicity of oligomers from the experiment shown in panel A. The plots are shown for ligation products of oligomer 
Al-1 (0), oligomer AT-1 modified with (+ )-A B C  ( • ) ,  oligomer AT-2 (A), oligomer AT-2 modified with (+ )-A B C  ( a ) ,  oligomer AT-3 (□ ), 
2nd oligomer AT-3 modified with (+ )-A B C  (■). Panel C (bottom left): Plot of /?L values of the ligated products of ( + )-ABC-modified 
tiigomers SP-A1 (O), SP-A2 (□ ), and SP-A3 ( a )  and unmodified oligomer SP-A1 ( • ) .  Panel D (bottom  right): Effect of distances in bp 
between the center of the A5-tract and the (+ )-A B C  covalent modification site on R L values of the six m ultim ers of unmodified A T I, AT2, 
indAT3 (■); of (-l-)-ABC-modified A T I, AT2, and AT3 (□ ); and of (+)-A BC-m odified SP-A1, SP-A2, and SP-A3 (O).
Sequences 5 '-A AAA A * and 5 '-AGTTA*. T h e  h e l ic a l  in -p h a s e  
bending of A - tr a c ts  c o n ta in e d  in  m u lt im e r s  p r o d u c e d  b y  
iigation of o lig o m e rs e a c h  c o n ta in in g  A - t r a c t s  r e s u lt s  in  o v e r a ll  
arvatureof th e  r e s u lt in g  m o le c u le ,  a n d  i f  s u f f i c i e n t  o l ig o m e r s  
are ligated, c ir c u la r  D N A  is  fo r m e d . O v e r a l l  c u r v a tu r e  o f  
the multimer r e su lts  in  r e ta r d a t io n  o f  t h e  e le c t r o p h o r e t ic  g e l  
mobility of the  D N A  m o le c u le s ,  w h ic h  is  m a x im a l  w h e n  th e  
bends are in h e lic a l p h a s e  ( i .e . ,  in  B - fo r m  D N A  s p a c e d  e v e r y  
10.3 bp). In su b s e q u e n t  s e c t io n s  w e  d e s c r ib e  e x p e r im e n t s  in  
*tich we d e ter m in e  th e  lo c u s  o r  c e n te r  o f  b e n d in g  o f  d r u g -  
aluced bending. T h e  lo c u s  o f  b e n d in g  o f  A - t r a c t s  is  p r e s u m e d  
lobe at the c en te r  o f  th e  r u n  o f  A ’s , i .e . ,  a t  A 3 in  a n  A 5 tr a c t ,  
lo verify this a s s u m p t io n , th r e e  d i f f e r e n t  2 1 - m e r s  ( A T - 1 ,  
(R an d  A T -3  in  F ig u r e  2 )  w e r e  d e s ig n e d .  T h e  c e n t e r  o f  
heT-tract is p o s it io n e d  1 1 , 1 0 , a n d  12  b p  fr o m  t h e  c e n t e r  o f  
A-tract in A T - 1 ,  A T - 2 ,  a n d  A T - 3 ,  r e s p e c t iv e ly .  B y  
imrting the T - a n d  A - t r a c t s  w e  t e s t  w h e th e r  t h e  c e n t e r  o f  
Wing occurs a t  th e  c e n tr a l A  or  T . In  c o n tr a s t ,  i f  th e  A - t r a c t s  
we on the sa m e  s tr a n d , th e n  w h e th e r  th e  lo c u s  o f  b e n d in g  
sat the center or a t  e ith e r  e n d  o f  th e  A - t r a c t  w o u ld  p r o d u c e  
ksame result. I f  th e  lo c a l  b e n d in g  c e n te r  o f  th e  A 5- t r a c t
is  p r e c is e ly  a t  t h e  c e n te r  o f  t h e  f iv e  a d e n in e s ,  o r  in  o th e r  w o r d s ,  
i f  t h e  A 5- t r a c t  a n d  th e  T 5- t r a c t  a r e  id e n t ic a l  in  b o t h  th e  
d ir e c t io n  a n d  t h e  c e n te r  o f  b e n d in g ,  th e n  w e  e x p e c t  t h a t  th e  
l ig a t e d  m u lt im e r s  o f  b o t h  o l ig o m e r s  A T - 1  a n d  A T - 2  s h o u ld  
s h o w  n e a r ly  id e n t ic a l  e le c t r o p h o r e t ic  m o b i l i t ie s  w ith  m o r e  
r e ta r d a t io n  c o m p a r e d  to  t h a t  o f  o l ig o m e r  A T - 3 .  H o w e v e r ,  
th e  l ig a t e d  m u lt im e r  o f  o l ig o m e r  A T - 2  or A T - 3  s h o u ld  s h o w  
th e  g r e a t e s t  r e ta r d a t io n  in  m o b i l i t y  i f  th e  b e n d in g  lo c u s  o f  th e  
A - t r a c t  is  b ia s e d  to w a r d  t h e  5 '  o r  3’ s id e  o f  t h e  A - t r a c t ,  
r e s p e c t iv e ly .
N o n - d e n a t u r in g  g e l  a n a ly s i s  o f  t h e  T 4 - l ig a t e d  2 1 -b p  
o l ig o m e r s  ( A T - 1 ,  A T - 2 ,  a n d  A T - 3 )  w a s  u s e d  to  e v a lu a t e  th e  
r e la t iv e  p h a s in g  o f  th e  A s - t r a c t s  in  t h e s e  th r e e  o l ig o m e r s ;  th e  
g e l  r e s u lt s  a r e  s h o w n  in  F ig u r e  4 A ,  a n d  th e  c a lc u la t e d  R l 
v a lu e s  o f  t h e  m u lt im e r s  a r e  p lo t t e d  in  F ig u r e  4 B  (o p e n  
s y m b o ls ) .  R l v a lu e s  fo r  A T - 1  a n d  A T - 2  a r e  e s s e n t ia l ly  
id e n t ic a l ,  c o n f ir m in g  t h a t  th e  c e n t e r  o f  b e n d in g  c o r r e s p o n d s  
t o  th e  a d e n in e  in  th e  m id d le  o f  th e  A s - t r a c t ,  w h i le  th e  R l 
v a lu e  fo r  A T - 3  is  d e c r e a s e d  r e la t iv e  to  th o s e  o f  A T -1  a n d  
A T - 2 ,  in d ic a t in g  th a t  th e  b e n d s  c o r r e s p o n d in g  to  t h e s e  A s -  
t r a c t s  a r e  r e la t iv e ly  o u t  o f  p h a s e .  W h e n  th e  T s - t r a c t  in th e
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middle of the duplex was replaced with an As-tract, R l values 
of the multimers were nearly identical between AT-1 and 
AT-2 (Sun & Hurley, unpublished results). To determine 
the effect of drug modification of the 3' adenine in an A5-tract 
on both the magnitude and the locus of bending, AT-1, AT-2, 
and AT-3 were modified at the 3' adenine with (+)-ABC. 
(+)-ABC was used rather than (+)-CC-1065 since the latter 
compound also produces winding of DNA (Lee et al., 1991), 
the equivalent of about 1 bp in addition to bending, which 
complicates the analysis of the results. The gel results in 
Figure 4A-I and the R l values plotted in Figure 4B (filled 
symbols) show that in all three cases the R l values are increased 
upon (+)-ABC bonding, relative to the unmodified As-tracts, 
but the R l value of drug-modified AT-1 is increased more 
than that of AT-2, and that of AT-3 is intermediate between 
those of AT-1 and AT-2. Taken together, these results reveal 
that after drug modification the magnitude of bending is 
significantly increased, and the locus of bending of the As- 
tract is moved about 0.5 bp to the 3' side of the central adenine 
in the drug-modified A5-tract. When non-denaturing gel 
electrophoresis was carried out in the presence of Mg2+ (10 
mM), the overall bending magnitude of both A-tract and drug- 
induced DNA bends was only slightly decreased, but the 
bending locus was not changed (see Figure 4A-II).
To determine the locus of bending induced by (+)-ABC in 
the 5'-AGTTA* bonding sequence, similar ligation experi­
ments using the 21-mers SP-A1, SP-A2, and SP-A3 shown 
in Figure 2 were carried out. The results plotted in Figure 
4C show that SP-A2, in which the bonding site is 12 bp removed 
from the center of the A-tract, produced the maximum increase 
in R l- Thus, the locus of bending is between the two A*T base 
pairs to the 5' side of the covalently modified adenine. A 
summary of the comparison of R l values of the six multimers 
for the As-tract and for the (+)-ABC-modified As-tract and 
5'-AGTTA* is shown in Figure 4D. Significantly, the curve 
that links together the (+ )-ABC-modified S'-AGTTA* and 
As-tract (open symbols) is steeper than that associated with 
the unmodified As-tract (filled symbols), suggesting that drug- 
induced bending is more focused than the A-tract intrinsic 
bending (see later).
Comparison o f  the Temperature Dependency o f  the M o­
bility Shifts o f  Ligated 21-mers Containing an As-Tract, the 
Drug-Modified A 5-Tract, and the 5'-AGTTA* Bonding 
Sequence. It has already been well established that the gel 
mobility is retarded, and the corresponding magnitude of 
intrinsic bending of As tracts is increased, at lower temper­
atures (Koo et al., 1986; Koo & Crothers, 1988; Abagyan et 
al., 1990), presumably because lower temperature favors the 
conformation associated with the bent DNA structure. This 
expectation was confirmed for the As-tract contained within 
oligomer 21-C, as shown in Figure 5. At 7 °C the bending 
magnitude is increased for oligomer 21-C relative to that at 
20 °C [compare open (7 °C) and filled (20 °C) symbols]. 
After drug modification of the 3' adenine in the As-tract, the 
temperature dependency of bending is greatly decreased, and 
only in multimers of 7 and 8 oligomers does the lower 
temperature produce an increased R l  value (Figure 5). In 
sharp contrast to these results, increasing the temperature of 
the ligated 21-mer containing the drug-modified sequence 
5'-AGTTA* produced an increase in bending magnitude 
(Figure 5). This is presumably because at the higher 
temperatures the DNA becomes more flexible, allowing the 
drug molecule that is conformationally restrained by DNA  
to now bend the DNA even more. In addition, these results 
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F i g u r e  5: Temperature dependency of electrophoretic mobility of 
ligated multimers of oligomers of an A s-tract (21-C), of (+)-ABC- 
modified oligomer 21-C, and of (+)-ABC-modified oligomer 21-SP. 
Open and filled symbols represent the experiment at 7 and 20 °C, 
respectively. RL plots are of the ligated multimers of 21-C (A, ▲), 
(+)-ABC-modified 21-C (O, • ) ,  and (+)-ABC-modified oligomer 
21-SP (□ , ■).
the preexisting bent structure of A-tract DNA upon drug 
modification of the 3'-side adenine of the A-tract DNA, but 
take advantage of the intrinsic bent structure to achieve a 
drug-entrapped bent D NA structure.
Hydroxyl-Radical Footprinting o f  the Noncovalently 
Modified Strand o f  a 21-mer with Either an Unmodified or 
a Drug-Modified 5-AG TTA* Sequence. As-tracts show a 
pattern of inhibition of hydroxyl-radical cleavage within the 
bending region (Burkhoff & Tullius, 1987,1988). The locus 
of bending occurs at the sites of greatest inhibition, which 
presumably correspond to the region of maximum narrowing 
of the minor groove. In comparison to the unmodified 21-SP 
duplex (panel A in Figure 6), the drug-modified 21-mers 
(panels B, C, and D, corresponding to (+)-CC-1065, (+ )- 
ABC", and (+)-AB, respectively) all show an increased 
inhibition of cleavage to the 3' side of the covalently modified 
adenine. In general, inhibition occurs maximally 1-3 bp to 
the 3' side of this covalently modified base, which is in good 
agreement with the locus of bending determined by non­
denaturing gel analysis (see before).
High-Field NM R Studies on the 12-mer Duplex and Its 
(+)-CC-1065-Modified Adduct. As an adjunct to our 
macroscopic structural data on the (+)-CC-1065-induced 
bending of DNA obtained by non-denaturing gel analysis and 
hydroxyl-radical footprinting (see before), high-field NM R  
studies on a 12-mer duplex adduct containing the same S'- 
AGTTA* bonding sequence were carried out. This data, in 
comparison to high-field NM R studies on A-tracts (Katahira 
et al., 1990), provides us with more definitive information 
with which to propose a model for the (+)-CC-1065- 
entrapped/induced bending of DNA and make a comparison 
with A-tract bending.
The non-self-complementary 12-mer duplex sequence (Fig­
ure 2B) is part of the early promoter region of SV40 DNA  
and is contained within the 21-bp repeat region. This 21-bp 
repeat region contains the Spl protein binding sites (Kadonaga 
et al., 1986; Courey et al., 1990) as well as two identical 
highly reactive (+)-CC-1065 bonding sequences, 5'-AGTTA* 
(Reynolds et al., 1985). This 12-mer duplex has been 
thoroughly characterized by one- and two-dimensional 'H 
and 31P NMR, hydroxyl-radical footprinting, and molecular 
dynamics calculations and exists as an overall right-handed 
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F i g u r e  7: Two-dimensional phase-sensitive N O ESY  (250 ms) 
expanded contour plots of (A ) the 12-mer duplex and (B) the (+ )-  
C C -1065-12-mer duplex adduct in D 20  buffered solution, pH 6.85, 
as 23 °C , demonstrating N O E  connectivities for the P uH 8/P yH 6 
(6.8-8.4 ppm) protons to their own sugar H i '  protons (4.8-6.3 ppm) 
(denoted with nucleotide units and numbers corresponding to the 
positions in the 12-mer duplex sequence shown in Figure 2B) and to 
the H P protons of their 5' neighbors. Only the noncovalently modified 
strand in both the 12-mer duplex and the (+ )-C C -1065-12-mer duplex 
adduct is shown. Cross peaks A to B 'a re  assigned as follows: A & A ', 
18C (H 6)-18C (H 1'); B&B', 18C (H 6)-17A (H 1 ').
5 ’ TGGGCGGAGTTAGGGGCGGGA31
3 ’CGCCTCAATCCCCGCCCTACC5 ’•
F i g u r e  6: Comparison of the laser densitometer tracings of the 
hydroxyl-radical footprinting of the noncovalently modified strand 
of oligomer 21-SP without modification (A) and with drug modi­
fication by (+ )-C C -1065 (B), (+ )-A B C " (C), and (+ )-A B  (D).
Bonding o f  ( +)-CC-1065 to the 12-mer Duplex Entraps 
the Transient Kink at the 17A -18C  and 18C -19T  Steps and 
Freezes the Internal Motion at 16A. A l t h o u g h  t h e  1 2 -m e r  
d u p le x  e x is t s  a s  a n  o v e r a ll  r ig h t -h a n d e d  B - fo r m  D N A  d u p le x ,  
i t  a ls o  h a s  a  n u m b e r  o f  u n iq u e  f e a tu r e s  th a t  a r e  u n u s u a l  fo r  
B -fo r m  D N A .  In  p a r t ic u la r ,  t h e  12 -m e r  d u p le x  h a s  tr a n s ie n t  
k in k s  a r o u n d  1 8 C , in te r n a l  m o t io n  a t  1 6 A ,  a n d  a  C 3 ' - e n d o -  
l ik e  g e o m e t r y  fo r  1 8 C  a n d  is  p r o p e lle r  tw is te d  w ith in  th e  5 '-  
T A A  s e q u e n c e  ( L in  e t  a l . ,  1 9 9 2 ) .  A  c o m p a r is o n  o f  th e  tw o -  
d im e n s io n a l  N O E S Y  ( 1 2 0  m s )  e x p a n d e d  c o n to u r  p lo t  o f  th e  
1 2 -m e r  d u p le x  a n d  its  ( - F ) - C C - 1 0 6 5 - 1 2 -m e r  d u p le x  a d d u c t  
d e m o n s t r a t in g  t h e  tw o  N O E  c o n n e c t iv i t ie s  fo r  th e  a r o m a t ic  
p r o to n s  t o  th e  H  1' s u g a r  p r o to n  fo r  n u c le o t id e  1 8 C  is  p lo t te d  
in  F ig u r e  7 A ,B .  F o r  t h e  ( + ) - C C - 10 6 5 - 1 2 - m e r  d u p le x  a d d u c t ,  
th e  in t e r n u c le o t id e  N O E  c o n n e c t iv i t y  fo r  1 8 C H 6  t o  th e  H I '  
p r o to n  o f  i t s  5 ' n e ig h b o r ,  1 7 A  (c r o s s  p e a k  B ' in  F ig u r e  7 B ) ,  
is  much stronger th a n  th e  in t r a n u c le o t id e  N O E  c o n n e c t iv i t y  
fo r  1 8 C H 6  to  i t s  o w n  H 1' p r o to n  ( c r o s s  p e a k  A '  in  F ig u r e  7 B ) .  
W h e n  t h e  in t e n s i t ie s  o f  t h e s e  c r o s s  p e a k s  a r e  c o m p a r e d  w ith  
th e  e q u iv a le n t  N O E  in t e n s i t ie s  b e tw e e n  1 8 C H 6  a n d  1 8 C H 1 '  
a n d  b e tw e e n  1 8 C H 6  a n d  17 A H  1' fo r  th e  1 2 -m e r  d u p le x  (c r o s s  
p e a k s  A  v s  A '  a n d  B  v s  B ' in  F ig u r e  7 A ,B ) ,  a d d u c t  fo r m a t io n  
a p p e a r s  to  n o t  o n ly  e n tr a p  b u t  a l s o  e x a g g e r a t e  th e  C 3 ' - e n d o  
s u g a r  g e o m e t r y  fo r  t h e  1 8 C  n u c le o t id e  in  th e  d u p le x .  In  
a d d i t io n ,  th e  s c a la r  c o u p l in g s  b e tw e e n  t h e  H I '  a n d  th e  H 2 '  
a n d  H 2 "  s u g a r  p r o to n s  o f  n u c le o t id e  1 8 C  in  th e  ( + ) - C C -  
1 0 6 5 - 1 2 -m e r  d u p le x  a d d u c t  a r e  o f  th e  s a m e  w e a k  in te n s i ty  
(w e a k  c o u p l in g s  a r e  d e n o te d  w ith  a n  a r r o w h e a d  in  F ig u r e  
8 B )  a n d  a r e  e v e n  w e a k e r  th a n  th o s e  fo r  th e  u n m o d if ie d  12 -  
m e r  d u p le x  ( c o m p a r e  p a n e ls  A  a n d  B  o f  F ig u r e  8 ) .  F u r ­
th e r m o r e , th e  p r o p e lle r  tw is t  a n g le  fo r  th e  ( + ) - C C - 1 0 6 5 -  
1 2 -m e r  d u p le x  a d d u c t  is  a l s o  e x a g g e r a t e d  b y  th e  p r e s e n c e  o f  
( + ) - C C - 1 0 6 5 ,  a s  s h o w n  b y  c o m p a r is o n  o f  th e  r e la t iv e  N O E  




















F i g u r e  8: Two-dimensional expanded contour plots of the phase- 
sensitive DQF-COSY of (A ) the 12-mer duplex and (B) the (+ )-  
C C -1065-12-mer duplex adduct in D20  buffer a t 23 °C , establishing 
the scalar couplings for the H 1' to the H 2 ' sugar protons and the H 1' 
to the H 2" sugar protons. W eak H l '- H 2 ' and H l '- H 2 "  scalar 
couplings of nucleotide 18C are denoted with arrowheads.
th e  1 2 -m e r  d u p le x  a n d  t h e  c o r r e s p o n d in g  N O E s  in  t h e  ( + ) -  
C C - 1 0 6 5 - 1 2 -m e r  d u p le x  a d d u c t  ( S  a n d  T  in  th e  s u p p le m e n ta r y  
m a t e r ia l ) .  In  s u m m a r y ,  a f t e r  t h e  c o v a le n t  r e a c t io n  w it h  ( + ) -  
C C - 1 0 6 5 ,  t h e  s u g a r  g e o m e t r y  fo r  t h e  1 8 C  n u c le o t id e  o f  t h e  
1 2 -m e r  d u p le x  s e q u e n c e  b e h a v e s  e v e n  m o r e  C 3 ' - e n d o - l ik e ,  
a n d  th e  A * T -r ic h  r e g io n  is  m o r e  p r o p e lle r  t w is t e d  t h a n  in  th e  
u n m o d if ie d  1 2 -m e r  d u p le x .
Bonding o f  ( +)-CC-1065 to the 12-mer Duplex Induces a 
Discontinuity at the 9T-10A  S tep and Produces an Overall 
Narrowing o f  the Minor Groove o f  DNA in the 8 T / 17A ,9T /  
16A Region. ( + ) - C C - 1 0 6 5  c r e a t e s  a  n e w  d i s c o n t in u i t y  in  th e  
1 2 -m e r  d u p le x  th a t  o c c u r s  a t  t h e  9 T - 1 0 A  s t e p  o n  t h e  D N A  
d u p le x  w h e n  it  b o n d s  to  th e  1 2 - m e r  d u p le x  s e q u e n c e .  O n  t h e  
c o v a le n t ly  m o d if ie d  s tr a n d , t h e  a r o m a t ic  t o  H 1' in te r n u c le o t id e  
N O E  c o n n e c t iv it y  fo r  th e  9 T - 1 0 A  s te p  is  d r a m a t ic a l ly  r e d u c e d ,  
a n d  th e  a r o m a t ic  to  H 2 "  in t e r n u c le o t id e  R O E  c o n n e c t iv i t y  
fo r  th e  s a m e  s t e p ,  w h ic h  is  p r e s e n t  in  t h e  u n m o d if ie d  1 2 -m e r  
d u p le x  (L in  e t  a l . ,  1 9 9 2 ) ,  is  n o w  lo s t  in  t h e  a d d u c t  ( C .  H .  L in  
a n d  L . H . H u r le y ,  u n p u b l is h e d  r e s u l t s ) .  In  a d d i t io n ,  th e  
r e la t iv e  c h e m ic a l  s h i f t s  o f  t h e  H 2 '  a n d  H 2 "  p r o to n s  fo r  b o th  
th e  9 T  a n d  1 0 A  n u c le o t id e s  a r e  r e v e r s e d  w ith  r e s p e c t  t o  th e  
1 2 -m e r  d u p le x  ( F ig u r e  8 B ) .  T h e s e  r e s u lt s  in d ic a t e  t h a t  th e  
D N A  b a c k b o n e  c o n fo r m a t io n  a t  th is  s t e p  is  h ig h ly  p e r tu r b e d  
u p o n  c o v a le n t  m o d if ic a t io n  b y  ( + ) - C C - 1 0 6 5 .
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DISCUSSION
Previous work from this laboratory has shown that covalent 
modification of D NA by (+)-CC-1065 results in bending of 
DNA into the minor groove by 17-22° (Lee et al., 1991). On 
the basis of non-denaturing gel electrophoresis, hydroxyl- 
radical footprinting, and the relative intensity of NOE cross 
peaks for interresidue protons across the minor groove, we 
have proposed that this bending has structural features that 
resemble the intrinsic bending associated with A-tracts (Lin 
et al., 1991b). In this investigation, we have examined in 
more detail the structural and dynamic features of an As- 
tract modified with (+)-CC-1065 and a highly reactive (+ )-  
CC-1065 bonding sequence (5'-AGTTA*) and its covalent 
adduct.
The special reactivity of the 3' adenine in A-tracts to (+ )-  
CC-1065 led us first to consider the possibility that (+)-CC- 
1065 and related compounds might entrap or induce bending 
of DNA. We were particularly intrigued by the junction bend 
model (Kooet al., 1986) and the idea that (+)-CC-1065 might 
be recognizing a junction site rather than just an adenine at 
the 3' end of the sequence lacking a G*C base pair. In this 
paper we have addressed three questions: (1) What are the 
structural consequences of modifying an As-tract with (+ )-  
CC-1065? (2) What are the similarities and differences 
between a drug-induced bend at a highly reactive bonding 
sequence such as 5'-AGTTA* and an A-tract? (3) Can we 
develop a model for the (+)-CC-1065-induced bend that 
permits us to gain a greater understanding of the structural 
features of this drug-DNA adduct and further insight into 
how (+)-CC-1065 achieves its sequence selectivity?
Structural Consequences o f  Modifying an As-Tract with 
(+)-CC-1065. Upon modification of an As-tract by (+ )-  
CC-1065, the center of bending is shifted from the central 
adenine to between this adenine and the next one to the 3' 
side. The bending magnitude of the As-tract modified with 
(+)-CC-1065 is approximately equal to the summation of its 
intrinsic bending and that due to (+)-CC-1065 bending of a 
sequence such as 5'-AGTTA*.3 The increased magnitude of 
bending of an A-tract by drug-DNA adduct formation can 
most plausibly be understood by considering the junction bend 
model for the structure of DNA containing an A-tract. 
According to the junction bend model, DNA curvature arises 
from a change in the direction of the helical axis at or near 
the junctions of these tracts with flanking base pairs. 
Therefore, drug-DNA adduct formation at the 3'junction of 
the A-tract might be expected to increase the magnitude of 
discontinuity at the 3'junction and, consequently, the overall 
magnitude of bending. The special reactivity of the 3' adenine 
to (+)-CC-1065, the consequent shift in the locus of bending 
of an As-tract toward the 3' side after drug modification, and 
the additive effect on the magnitude of bending are all in 
accord with the junction bend model (Koo et al., 1986). 
Furthermore, the loss of temperature dependency of As-tract 
bending after drug modification is proposed to be due to the
3 We had previously noted (Lin et al., 1991) that, in contrast to the 
results shown here, modification of an A2-tract by (+)-CC-1065 d id  not 
markedly increase the overall intrinsic bending of the As-tract. We believe 
that the difference between these two results is due to incomplete drug 
modification of DNA, in the case of these previous results. In subsequent 
experiments we have evaluated a series of oligomers containing A-tracts 
following modification by (+)-CC-1065, and in all cases, including the 
sequence previously evaluated, the intrinsic bending of the A-tract was 
significantly increased upon drug modification, as noted in the present 
paper.
the minor groove of the As-tract, which also shifts the 
equilibrium between the bent and nonbent conformations to 
favor the bent DNA structure. Presumably, the junction site 
at the 3' end of the A 5-tract is stabilized more than the one 
at the 5' end, and the contribution of the 3' junction of the 
A-tract to overall DNA bending becomes greater after drug 
modification.
Similarities and Differences between the Intrinsic Bend o f  
anA-Tract and a (+)-CC-7065-Induced Bend in a  5 -AGTTA* 
Bonding Sequence. Overall, the general features of a bend 
associated with an As-tract and a drug-induced bend in the 
bonding sequence 5'-AGTTA* are similar, i.e., magnitude, 
direction of bending, and associated narrowing of the minor 
groove. However, a more in-depth analysis also reveals some 
important differences. First, while the intrinsic bend of an 
A5-tract appears to be spread over the entire A-tract region, 
in the drug bonding sequence 5'-AGTTA* it is concentrated 
over just two base pairs, i.e., 5/-(AA)*(TT) in this sequence 
(see Figure 4D). Second, it is the torque of the drug molecule 
that overrides the DNA conformational preference to assume 
a nonbent DNA structure, a fact clearly revealed by the 
temperature dependency studies.
Previously, it was reported that the mobilities of A-tract- 
containing oligomers depend crucially upon whether the 
A-tracts are arranged in the same orientation or with one or 
more tracts inverted with respect to the others, as in the case 
of electrophoresis in the absence of EDTA or in the presence 
of magnesium ion (Diekmann, 1987; Travers, 1989; Hager- 
man, 1990). The ligated products of AT-1, AT-2, and AT-3, 
either unmodified or modified with (+)-ABC, were electro­
phoresed in the presence of magnesium ion (10 mM) without 
EDTA, in order to test the effect o f magnesium ion on 
electrophoretic mobility. Somewhat surprisingly, magnesium 
ion did not have a significant effect on the mobility of ligated 
multimers of oligomers AT-1, AT-2, and AT-3 or those 
modified with (+)-ABC (Figure 4A-II), although ligated 
multimers of AT-1 showed slightly more retardation in 
electrophoretic mobility than those of AT-2 in the presence 
of magnesium. Since the relative order of the bending 
magnitude of each oligomer, and each of the (+)-ABC- 
modified oligomers, was unchanged in the presence of 
magnesium ion, this also implies that the bending locus 
remained the same. The results reported here are in accord 
with the idea that the direction and magnitude of bending is 
largely independent of the orientation of the (dA)-(dT) tract 
(Koo et al., 1986; Koo & Crothers, 1988; Wu & Crothers, 
1984). Moreover, upon drug modification of A-tract-con- 
taining oligomers, the magnesium ion dependence was in­
significant, indicating that the drug-induced DNA bending 
was not sensitive to the presence of magnesium.
A Truncated Junction Bend M odel fo r  the Entrapped j  
Induced Bending ofDNA in the {+ )-C C -l065-12-mer Duplex 
Adduct and as a Mechanism fo r  Sequence Recognition o f  
DNA. When a 21-mer containing the 12-mer duplex used in 
the NM R studies is ligated and subjected to non-denaturing 
gel electrophoresis, it does not show anomalous gel migration 
and therefore is unlikely to be bent (D. Sun and L. H. Hurley, 
unpublished results). However, hydroxyl-radical footprinting 
of the same 21-mer sequence shows inhibition of cleavage at 
16A and 18C (see Figure 6). In addition, the proton NMR 
data reported here and elsewhere (Lin et al., 1992) provides 
further evidence for propeller twisting and corresponding 
narrowing of the minor groove in the A*T region between 
7G-18C and 10A-15T. An unusual feature of this region of 
the duplex is the rapid local conformational flexibility of 16 A.
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This local conformational flexibility is temperature dependent 
but is lost upon adduct formation with (+)-CC-1065 (Lin et 
al., 1992). We propose that this inherent conformational 
flexibility of the 5'-AGTTA* sequence is a contributing factor 
to sequence recognition by (+)-CC-1065.
The NOESY restrained molecular mechanics and dynamics 
calculations on this 12-mer duplex indicate that the DNA  
sequence contains two major kinks, one located at the 17 A to 
18C step and the other located at the 18C to 19T step (Lin 
etal., 1992). In addition, the 18C nucleotide has an average 
C3'-endo sugar geometry and is displaced into the helix axis 
toward the major groove, resulting in an unwinding at the 
5'-(AC)*(GT) step and a destacking at the 5'-(CT)-(AG) step. 
This kind of base displacement toward the major groove has 
previously been reported on the Amsacrine-<i(CGCG)2 com­
plex (Graves & Wadkins, 1990). Thekinkaround 18C brings 
the 18CH5 proton under the shielding cone of the aromatic 
ring of 17 A, which explains the upfield shift of this proton in 
the 12-mer duplex (Lin et al., 1992).
Shortly after we characterized the unusual conformation 
around 18C, Bolshoy et al. (1991) published a paper in which 
they reported that DNA sequences containing 5'-(AC)*(GT) 
or 5'-(CA)*(TG) steps exhibit anomalous high gel mobility 
(low Ri values) compared to the predicted computed R i  values. 
On the basis of these results, it is suggested that a transient 
kink occurs at the 5'-(AC)*(GT) or the 5/-(CA)-(TG) step. 
In line with this idea, we propose that the unusual C3'-endo 
sugar geometry for 18C and the associated conformational 
and dynamic changes, including narrowing of the minor groove 
in the AT region and rapid local conformational flexibility 
at 16A, are related to a transient kink at the 5'-(AC)*(GT) 
step in the 12-mer. It has also been suggested that in a right- 
handed B-form DNA a kink of about 40° is produced by the 
change of sugar pucker from C2'-endo to C3'-endo and 
unwinding of adjacent base pairs at the kink site by -10°  
(Saenger, 1983).
Upon reaction with (+)-CC-1065, the unusual structural 
features of the 12-mer duplex become entrapped and exag­
gerated. The A T  region of the (+)-CC-1065—12-mer duplex 
adduct is even more highly propeller twisted than in the 12- 
mer duplex, and the sugar geometry of the 18C nucleotide 
moves more toward the C3'-endo region (C. H. Lin and L. 
H. Hurley, unpublished results). In addition, the kink angle 
at the 18C to 19T step is dramatically increased when 
compared with that of the same kink in the unmodified 12- 
mer duplex (Lin et al., 1992). These kinks create a junction 
around the 18C nucleotide on the noncovalently modified 
strand. In addition to this entrapped junction, another junction 
between 9T and 10A on the covalently modified strand is also 
induced upon adduct formation. Overall, it appears that (+)- 
CC-1065 takes advantage of an existing propensity of this 
12-mer to bend and, after covalent reaction at A10, consol­
idates and exaggerates this tendency. Our recent observations 
that (+)-CC-1065 can form an unusual covalent adduct with 
the guanine in the sequence 5'-AATTG* and a stable, 
noncovalent complex with the sequence 5'-G AATTC strongly 
support this hypothesis (H. J. Park and L. H. Hurley, 
unpublished observations; M. Hansen and L. H. Hurley, 
unpublished observations). We propose a “truncated junction 
bend model”, based upon the junction bend model for an 
A-tract (Koo et al., 1986), for the (+ )-CC-1065-entrapped/ 
induced bend in the highly reactive sequence 5'-AGTTA* 
(see Figure 9). An intriguing observation is that upon binding 
ofSpl molecules to either side of this 5'-AGTTA* sequence 
the DNase I and hydroxyl-radical footprinting data shows
—a_4------b'------4—b—
 ̂ GGdTTTTTTjGCG * 
31 CCGtAAAAAAjCGC *
B
—------------B ------------- — . f l  ——
sG G C G G A drri^G G *  
* CCGCCTCiAAjTCC *
F ig u re  9: Models for bending of DNA. (A) The junction bend 
model for A-tracts (Koo & Crothers, 1986) and (B) the truncated 
junction bend model for the (+)-CC-1065-entrapped/induced bend 
of 5'-AGTTA*.
changes in DNA structure, implicating the possible importance 
of this same transient kink in protein-DNA interactions (D. 
Sun and L. H. Hurley, unpublished results).
The possibility has recently been raised of the functional 
importance of bent DNA, because of the surprising ubiquity 
of inherently curved DNA segments in biological systems 
(Koudelka et al., 1988; McAllister & Achberger, 1989; 
Travers, 1990; Hagerman, 1990). In addition, it was recently 
reported that DNA-protein interactions can be attenuated 
by the presence of intrinsic sequence-dependent DN A  cur­
vature (Shatzky-Schwarz et al., 1992). It is interesting to 
speculate whether a (+)-CC-1065-entrapped or -induced bent 
conformation of DNA might mimic an intrinsic or protein- 
induced curved DNA found in the regulatory regions of a 
genome, such as the promoter regions, or in replication origins 
(i.e., serve as a surrogate protein). Alternatively, (+)-CC- 
1065 could attenuate a DNA-protein interaction at the region 
containing a highly reactive (+)-CC-1065 bonding site. 
Experiments to test these hypotheses are in progress in this 
laboratory.
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SUPPLEMENTARY MATERIAL AVAILABLE
Two-dimensional phase-sensitive NOESY expanded con­
tour plots of the 12-mer duplex and the (+)-CC-1065-12- 
mer duplex adduct (3 pages). Ordering information is given 
on any current masthead page.
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IV. (+)-CC-1065 Mechanism of Action
B. Sequence Specificity and Biochemical
Consequences
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a b s t r a c t :  C C - 1 0 6 5  is a  u n iq u e  a n t itu m o r  a n t ib io t ic  p r o d u c e d  b y  Streptom yces zelensis. T h e  p o t e n t  c y t o t o x ic  
e f f e c t s  o f  t h i s  d r u g  a r e  t h o u g h t  t o  b e  d u e  t o  i t s  a b i l i t y  t o  f o r m  a  c o v a l e n t  a d d u c t  w i t h  D N A  t h r o u g h  N 3  
o f  a d e n in e . T h e r m a l  t r e a t m e n t  o f  C C - 1 0 6 5 - D N A  a d d u c t s  l e a d s  t o  D N A  s t r a n d  b r e a k a g e .  W e  h a v e  s h o w n  
that th e  C C - 1 0 6 5  s tr u c tu r a l  m o d if ic a t io n  o f  D N A  t h a t  le a d s  t o  D N A  s tr a n d  b r e a k a g e  is  r e la te d  t o  t h e  p r im a r y  
a lk y la t io n  s i t e  o n  D N A .  T h e  t h e r m a l l y  i n d u c e d  D N A  s t r a n d  b r e a k a g e  o c c u r s  b e t w e e n  t h e  d e o x y r i b o s e  
at th e  a d e n in e  c o v a l e n t  b i n d in g  s i t e  a n d  t h e  p h o s p h a t e  o n  t h e  3 '  s id e .  N o  r e s id u a l  m o d i f i c a t i o n  o f  D N A  
is d e t e c t e d  o n  t h e  o p p o s i t e  s t r a n d  a r o u n d  t h e  C C - 1 0 6 5  l e s io n .  U s i n g  t h e  e a r l y  p r o m o t e r  e l e m e n t  o f  S V 4 0  
D N A  a s  a  t a r g e t ,  w e  h a v e  e x a m i n e d  t h e  D N A  s e q u e n c e  s p e c i f i c i t y  o f  C C - 1 0 6 5 .  A  c o n s e n s u s  s e q u e n c e  
a n a ly s is  o f  C C - 1 0 6 5  b in d in g  s i t e s  o n  D N A  r e v e a l s  t w o  d i s t i n c t  c l a s s e s  o f  s e q u e n c e s  fo r  w h i c h  C C - 1 0 6 5  
is h ig h ly  s p e c i f ic ,  i .e . ,  5 ' P u N T T A  a n d  5 ' A A A A A .  T h e  o r ie n t a t io n  o f  t h e  D N A  s e q u e n c e  s p e c i f i c i t y  r e la t iv e  
to  th e  c o v a l e n t  b in d in g  s i t e  p r o v id e s  a  b a s i s  fo r  p r e d ic t in g  t h e  p o la r i t y  o f  d r u g  b i n d in g  in  t h e  m in o r  g r o o v e .  
S te r e o  d r a w i n g s  o f  t h e  C C - 1 0 6 5 - D N A  a d d u c t  a r e  p r o p o s e d  t h a t  a r e  p r e d i c t i v e  o f  f e a t u r e s  o f  t h e  C C -  
1 0 6 5 - D N A  a d d u c t  e l u c i d a t e d  in  t h i s  i n v e s t i g a t i o n .
V /C -1065 is a n  a n t itu m o r  a g e n t  p r o d u c e d  b y  Streptomyces 
telensis (H a n k a  e t  a l . ,  1 9 7 8 ;  H u r le y  &  R o k e m , 1 9 8 3 ) .  T h e  
cytotoxicity o f  C C -1 0 6 5  is a ttr ib u te d  to  th e  a b ili ty  o f  th is  d r u g  
to bind c o v a le n tly  to  D N A  ( S w e n s o n  e t  a l . ,  1 9 8 2 ;  H u r le y  e t  
al., 1984). S tr u c t u r a l ly ,  C C - 1 0 6 5  c o n s is t s  o f  th r e e  su b u n its :  
two identical b e n z o d ip y r r o le  u n it s  ( s u b u n it s  B  a n d  C )  a n d  a  
third subunit c o n ta in in g  th e  D N A - r e a c t iv e  c y c lo p r o p a n e  r in g  
(subunit A ) w h ic h  is c o n ju g a te d  w ith  a n  in d o le q u in o n e  s y s te m  
(Figure 1). X - r a y  c r y s ta l lo g r a p h ic  s tu d ie s  ( C h id e s t e r  e t  a l .,
1981) have s h o w n  th a t  C C - 1 0 6 5  is  c h a r a c t e r iz e d  b y  a  p r o ­
nounced r ig h t -h a n d e d  t w is t  a lo n g  th e  lo n g  a x is  o f  th e  d r u g  
molecule w ith  its  h y d r o p h o b ic  g r o u p s  a l ig n e d  a lo n g  th e  in s id e  
edge while th e  h y d r o p h i l ic  s u b s t i t u e n t s  a r e  d is p la y e d  o n  th e  
outside edge. T h e r m a l  tr e a t m e n t  o f  C C - 1 0 6 5 - D N A  a d d u c ts  
leads to th e  r e le a s e  o f  a  b a s e  c o v a le n t ly  a t t a c h e d  to  th e  
CC-1065 m o ie ty . T h is  a d d u c t  h a s  b e e n  p u r if ie d  a n d  id e n t if ie d  
by 'H and 13C  N M R  a s  th e  N 3  a lk y l a d e n in e  C C - 1 0 6 5  a d d u c t  
(Hurley et a l . ,  1 9 8 4 )  ( F ig u r e  2 ) .
Our in itia l in te r e s t  in  th is  a n t ib io t ic  w a s  s t im u la t e d  b y  its  
significant c y to to x ic i ty  in  v itr o  a n d  a n t itu m o r  a c t iv i t y  in  v iv o  
(Bhuyan et a l . ,  1 9 8 2 ;  M a r t in  e t  a l . ,  1 9 7 8 ) .  C C - 1 0 6 5  is  o n e  
of the most p o te n t a g e n ts  te s te d  a g a in s t  L I  2 1 0  c e l ls  in  c u ltu r e .  
This drug, a t 0 .0 5  n g / m L ,  c a u s e d  9 0 %  in h ib i t io n  o f  g r o w th  
ofL1210 c e lls . T h is  m a y  b e  c o m p a r e d  to  th e  9 0 %  in h ib it io n  
of L1210 g r o w th  b y  o th e r  c y t o t o x ic  a n t itu m o r  a g e n t s  in  th is  
assay system : a c t in o m y c in  D  a t 4  n g / m L  a n d  a d r ia m y c in  a t  
20 ng/m L (L i e t  a l . ,  1 9 8 2 ) .  In  th e  tu m o r  c lo n in g  a s s a y ,  
CC-1065 c a u sed  a > 5 0 %  d e c r e a s e  in  th e  c o lo n y - fo r m in g  u n its  
of tumor c e l ls  fr o m  p a t ie n t s  w ith  c a n c e r  o f  lu n g ,  b r e a s t ,  
pancreas, ovary , e tc .,  a t  a  c o n c e n tr a tio n  o f  0 .1  n g / m L  (B h u y a n  
etal, 1982). It w a s  g r e a te r  th a n  1 0 0 - fo ld  m o r e  le th a l  to  B 1 6
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a n d  C H O 1 c e l ls  in  c u lt u r e  th a n  a d r ia m y c in ,  a c t in o m y c in  D ,  
a n d  m - d ia m m i n e d ic h lo r o p l a t i n u m  ( B h u y a n  e t  a l . ,  1 9 8 1 ,
1 9 8 2 ) .  I t  w a s  a l s o  a c t iv e  in  v iv o  a g a in s t  th e  m u r in e  tu m o r s ,  
P 3 8 8  a n d  L 1 2 1 0  le u k e m ia , B 1 6  m e la n o m a , C D 8F  m a m m a r y ,  
a n d  c o lo n  2 6  a t  d o s e s  r a n g in g  fr o m  1 to  5 0  M g /k g  ( M a r t in  
e t  a l ., 1 9 7 8 ; N e i l  e t  a l . ,  1 9 8 1 ) .  C C - 1 0 6 5  c a u s e d  le th a l d e la y e d  
h e p a t o t o x ic i t y  in  m ic e  a t  t h e r a p e u t ic  a n t in e o p la s t ic  d o s e s  
( M c G o v r e n  e t  a l . ,  1 9 8 4 ) .
T h e  r e a c t io n  o f  C C - 1 0 6 5  w ith  D N A  a n d  o th e r  m a c r o ­
m o le c u le s  h a s  b e e n  e x te n s iv e ly  s tu d ie d . In  a d d it io n  t o  h a v in g  
a n  a b s o lu te  r e q u ir e m e n t  fo r  d o u b le - s t r a n d e d  n u c le ic  a c id  (L i  
e t  a l . ,  1 9 8 2 )  C C - 1 0 6 5  b in d s  p r e f e r e n t ia l ly  t o  A T - c o n t a in in g  
s y n th e t ic  p o ly m e r s  ( S w e n s o n  e t  a l . ,  1 9 8 2 ) .  C o v a le n t ly  b o u n d  
C C - 1 0 6 5  d o e s  n o t  a l t e r  th e  e le c t r o p h o r e t ic  m o b i l i t y  o f  s u ­
p e r c o ile d  D N A  in  a g a r o s e  g e ls  a n d  th u s  d o e s  n o t  a p p e a r  to  
in te r c a la t e  th e  D N A  h e lix  ( S w e n s o n  e t  a l .,  1 9 8 2 ) .  A lk y la t io n  
s t u d ie s  a n d  e x p e r im e n t s  u s in g  g lu c o s y la t e d  T 4  D N A  le d  to  
th e  c o n c lu s io n  th a t  C C - 1 0 6 5  b in d s  in  th e  m in o r  g r o o v e  o f  
D N A  (S w e n s o n  e t  a l ., 1 9 8 2 ) .  T h is  c o n c lu s io n  is a lso  su p p o r te d  
b y  th e  o b se r v a t io n  th a t  C C - 1 0 6 5  a n d  n e tr o p s in  h a v e  c o m m o n  
b in d in g  s it e s  in  D N A  (C h id e s t e r  e t  a l .,  1 9 8 1 )  w h i le  C C - 1 0 6 5  
a n d  a n t h r a m y c in  h a v e  o n ly  p a r t ia l  o v e r la p  o f  s i t e s  (S w e n s o n  
e t  a l .,  1 9 8 2 ) .  B o th  n e tr o p s in  a n d  a n t h r a m y c in  a r e  k n o w n  to  
b in d  in  th e  m in o r  g r o o v e ,  n e tr o p s in  a t  A T - r ic h  s i t e s  a n d  a n ­
t h r a m y c in  c o v a le n t ly  a t  N 2  o f  g u a n in e  ( K o lc h in s k i i  e t  a l . ,  
1 9 7 5 ;  H u r le y  &  P e tr u s e k ,  1 9 7 9 ) .
T h e  m in o r  g r o o v e  c o v a le n t  b in d in g  s it e  ( N 3  o f  a d e n in e )  for  
C C - 1 0 6 5  ( H u r le y  e t  a l . ,  1 9 8 4 )  a n d  th e  r ig h t -h a n d e d  tw is t  o f  
th e  d r u g  m o le c u le  s u g g e s te d  th a t  it m ig h t  r e s id e  in  its  e n t ir e ty  
w ith in  th e  m in o r  g r o o v e  o f  D N A .  In  th is  s it u a t io n ,  C C - 1 0 6 5  
m ig h t  b e  e x p e c te d  to  e x h ib i t  D N A  s e q u e n c e  s p e c i f ic i t y ,  a n d  
w e  h a v e  r e c e n t ly  d e m o n s tr a te d  th a t  C C - 1 0 6 5  fo r m s  a d e f in e d
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d ia m in e te tr a a c e t ic  ac id ; Pu . p u r in e  n u c leo tid e ; P y, p y r im id in e  n u c leo tid e ;
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f i g u r e  1: Structure of CC-1065 showing the absolute stereochemistry 
at C3b and C4a deduced during this investigation.
CC 1065
CC 1065 -(N3-Adenine) DNA 
Adduct
CC 1065-N 3-A denine
A dduct
f i g u r e  2: Reaction of CC-1065 with D N A  to form the CC-
1065-(N 3-adenine)-D N A  adduct, and the structure of the CC- 
1065-N  3-adenine adduct released upon therm al treatm ent of the 
C C -1065-D N A  adduct (H urley et al., 1984).
d u p le x  a d d u c t  w ith  th e  1 4 -m e r  ( 5 'C G G A G T T A G G G G C G 3 ')  
in  w h ic h  t h e  a d e n in e  b in d in g  s e q u e n c e  is  5 ' T T A 3 '  ( N e e d ­
h a m -V a n D e v a n te r  e t  a l .,  1 9 8 4 ) .  T h e  in v e s t ig a t io n s  d e s c r ib e d  
in  th is  p a p e r  w e r e  d e s ig n e d  to  fu r th e r  e x a m in e  th e  D N A -  
b in d in g  s p e c i f ic i t y  o f  C C - 1 0 6 5  a n d  to  p r o v id e  m o r e  d ir e c t  
e v id e n c e  fo r  t h e  lo c a t io n  o f  t h e  D N A  s tr a n d  b r e a k a g e  th a t  
o c c u r s  w h e n  th e  a d d u c t  is s u b je c t  to  th e r m a l tr e a tm e n t . S in c e  
C C - 1 0 6 5  b in d s  p r e fe r e n t ia lly  to  A T -r ic h  r e g io n s , w e  p u r p o se ly  
c h o s e  th e  e a r ly  p r o m o te r  e le m e n t  o f  S V 4 0  D N A  fo r  t h e s e  
s t u d ie s  s o  t h a t  w e  c o u ld  d e t e r m in e  w h e t h e r  C C - 1 0 6 5  m ig h t  
h a v e  a  p r e fe r e n c e  fo r  a  s p e c i f ic  r e g u la to r y  r e g io n , s u c h  a s  th e  
T A T A  b o x ,  w h ic h  m ig h t  h e lp  to  e x p la in  th e  r e m a r k a b le  p o ­
te n c y  o f  th is  d r u g . N o t  o n ly  d o  th e  r e s u lt s  d e m o n s t r a t e  th a t  
C C - 1 0 6 5  h a s  a  m a r k e d  D N A  s e q u e n c e  s e l e c t iv i t y ,  b u t  t h e y  
a ls o  p r o v id e  im p o r ta n t  s t r u c tu r a l  in f o r m a t io n  o n  th e  C C -  
1 0 6 5 - D N A  a d d u c t  a n d  fu r th e r  in s ig h t  in to  p o s s ib le  r e a s o n s  
fo r  th e  e x t r e m e  c y t o t o x ic  p o t e n c y  o f  C C - 1 0 6 5 .  S o m e  o f  th is  
w o r k  h a s  a p p e a r e d  in  p r e lim in a r y  fo r m  (S w e n s o n  e t  a l . ,  1 9 8 3 ) .
M a t e r i a l s  a n d  M e t h o d s
Drugs, Enzymes, and Chemicals. C C - 1 0 6 5  w a s  s u p p l ie d  
b y  T h e  U p jo h n  C o . ( K a la m a z o o ,  M I )  a n d  w a s  u s e d  w ith o u t  
fu r th e r  p u r if ic a t io n . P o ly n u c le o t id e  k in a se  fr o m  b a c te r io p h a g e  
T 4  in f e c t e d  Escherichia coli w a s  i s o la t e d  a n d  p u r if ie d  a c ­
c o r d in g  to  p u b l is h e d  p r o c e d u r e s  ( R ic h a r d s o n ,  1 9 7 1 ) .  A P  
e n d o n u c le a s e  ( H e L a  A P  e n d o n u c le a s e  II; K a n e  &  L in n , 1 9 8 1 ;  
M o s b a u g h  &  L in n , 1 9 8 2 )  w a s  a g e n e r o u s  g i f t  o f  D a l e  W .  
M o s b a u g h , D e p a r tm e n t  o f  C h e m is tr y , T h e  U n iv e r s ity  o f  T e x a s  
a t  A u s t in .  R e s t r i c t io n  e n z y m e s  w e r e  p u r c h a s e d  fr o m  N e w  
E n g la n d  B io la b s .  [ y * 32P ] A T P  w a s  s y n t h e s iz e d  a c c o r d in g  to  
p u b lish e d  m e th o d s  (W a ls e th  &  J o h n so n , 1 9 7 9 ) .  B a c te r io p h a g e  
T 7 ,  o r ig in a l ly  fr o m  F . W . S t u d ie r ,  w a s  g r o w n  a n d  p u r if ie d  
a c c o r d in g  to  e s t a b l is h e d  p r o c e d u r e s  ( S t u d ie r ,  1 9 6 9 ,  1 9 7 9 ) .  
S V 4 0  D N A  a n d  0 X 1 7 4  R F  D N A  w e r e  p u r c h a s e d  fr o m  
B e t h e s d a  R e s e a r c h  L a b o r a to r ie s .
V O L .  2 4 ,  N O .  2 2 , 198 5
onfim  pTIl211211 I 7 2  | 1 7 2  1______ ^
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f i g u r e  3: Scheme of restriction digestion strategy used to examine 
the interaction of CC-1065 with the SV40 early promoter. Singly I 
32P-end-labeled DNA restriction fragments spanning both strandsof 
the SV40 early promoter were obtained by using the restriction enzyme 
sites depicted. The tail of the arrow represents the 5' 32P-radiolabeled 
end. Symbols: ori, origin of replication; TATA, TATAbox;Hl. 
21-base repeats; 72, 72-base repeats.
DNA Sequencing. D N A  s e q u e n c in g  w a s  carried out ac­
c o r d in g  to  t h e  m e th o d s  o f  M a x a m  &  G ilb e r t  (1 9 8 0 ). SV40 
D N A  r e s tr ic t io n  f r a g m e n t s  u s e d  in  th is  s tu d y  spanned both 
s tr a n d s  o f  t h e  e n t ir e  S V 4 0  e a r ly  p r o m o te r  reg ion  and were 
o b t a in e d  b y  u s in g  th e  s t r a t e g y  d e p ic t e d  in  F igu re 3. The 
r e s tr ic t io n  f r a g m e n t  fr o m  b a c te r io p h a g e  T 7  w as obtained bj 
i s o la t in g  th e  4 0 1 -b p  Taq\ r e s tr ic t io n  d ig e s t io n  product of the 
d o u b ly  32P - e n d - la b e le d  M bol D  fr a g m e n t .  0 X 1 7 4  RFDNA 
w a s  in i t ia l ly  c u t  w ith  PstI , a n d  a f t e r  it w a s  lab eled  with [o-
32P ] d id e o x y A T P  (A m e r s h a m )  a n d  te r m in a l transferase, it was 
t r e a t e d  w ith  H pal a n d  th e  s in g ly  e n d - la b e le d  364-base-pair 
fr a g m e n t  p u r if ie d .  S u b s e q u e n t  a n a ly s e s  dem onstrated that 
th e  s e q u e n c e  o f  D N A s  u s e d  in  th is  s tu d y  m a tc h e d  exactly the 
p u b l is h e d  s e q u e n c e  o f  S V 4 0  ( R e d d y  e t  a l . ,  1978; Van Hen- 
v e r sw y n  &  F ie r s , 1 9 7 9 ) ,  b a c te r io p h a g e  T 7  (D u n n  & Studier,
1 9 8 1 ) ,  a n d  0 X 1 7 4  ( S a n g e r  e t  a l . ,  1 9 7 7 ) .
Reaction o f  CC-1065 with DNA and Production of Druf 
Related Single-Strand Breaks. A  s to c k  so lu tio n  o f CC-1065 
w a s  p r e p a r e d  b y  d i s s o lv in g  a  s m a l l  a m o u n t  o f  CC-1065 in.' 
d r o p s  o f  D M F .  A d d i t io n  o f  1 m L  o f  D S C  y ie ld ed  a viscous 
s u s p e n s io n  t h a t ,  b y  u s in g  t 365 =  4 8  0 0 0 ,  w a s  adjusted to 0.14 
/am ol o f  C C - 1 0 6 5 /m L  b y  a d d it io n  o f  D S C . T h is  concentration 
o f  C C -1 0 6 5  is r e fe rr ed  to  a s  th e  s to c k  so lu tio n . Serial dilutions 
( 1 : 1 0 )  o f  th e  s t o c k  w e r e  p r e p a r e d  w ith  D S C  as a diluent. 
W h e n  s to r e d  fr o z e n  ( - 3 0  ° C ) ,  th e s e  d r u g  so lu tio n s were stable 
fo r  sev er a l w e e k s  a s  ju d g e d  b y  'H  N M R .  C C -1 0 6 5  was mixed 
w ith  r a d io la b e le d  D N A  in  2 0  fxL o f  0 .5  X  D S C  and incubated 
a t  4  ° C  fo r  t h e  d e s ir e d  le n g t h  o f  t im e  ( ty p ic a l ly  24 h),and 
u n r e a c te d  d r u g  w a s  r e m o v e d  b y  p r e c ip ita t io n  o f  the DNA in 
e t h a n o l ,  u s in g  2 0  pL  o f  t R N A  (1  m g / m L )  a s  carrier nucleic 
a c id . E th a n o l p r e c ip ita t io n  o f  D N A  r e m o v e s  all noncovalenth 
b o u n d  C C - 1 0 6 5 .  T h e  s a m p le s ,  n o w  c o n ta in in g  D N A  bound 
w ith  C C -1 0 6 5 ,  w e r e  r esu sp e n d ed  in  1 0 0  ^ L  o f  D S C  and heated I 
in  s e a le d  v e s s e l s  a t  1 0 0  ° C  (u n le s s  o th e r w is e  stated) for 301 
m in . T h e  D N A  w a s  th e n  p r e c ip ita te d  a g a in  in ethanol, washed j 
o n c e  w ith  1 m L  o f  e th a n o l ,  d r ie d  u n d e r  v a c u u m , and elec-1 
tr o p h o r e s e d  a s  d e s c r ib e d  b e lo w . T w o  a d d it io n a l  procedure 
w e r e  c a r r ie d  o u t  in  e x p e r im e n ts  to  c h a r a c te r iz e  more fully the 
C C - 1 0 6 5 - D N A  a d d u c t .
( i )  P ip e r id in e  t r e a t m e n t ;  C C - 1 0 6 5 - D N A  adducts were 
p r e p a r e d  a s  d e s c r ib e d  a b o v e . F o l lo w in g  p rec ip itation  of the 
D N A  in  e t h a n o l  to  r e m o v e  u n r e a c te d  d r u g , th e  DNA was 
r e s u s p e n d e d  in  1 0 0  /uL o f  p ip e r id in e  ( f r e s h ly  diluted  1:10ia 
d e io n iz e d  w a t e r )  a n d  h e a te d  in  a  s e a le d  tu b e  a t 100 °C for 
3 0  m in . T h e  s a m p le  w a s  th e n  tr a n s fe r r e d  to  a clean tube, 
ly o p h i l iz e d  r e p e a te d ly  to  r e m o v e  a ll  t r a c e s  o f  piperidine,and 
e le c t r o p h o r e s e d  a s  d e s c r ib e d  b e lo w .
( i i )  A P  e n d o n u c le a s e  tr e a tm e n t:  C C - 1 0 6 5 - D N A  adducts 
w e r e  p r e p a r e d , h e a te d  in  D S C , a n d  p r e c ip ita te d  as described 
a b o v e . T h e  D N A  w a s  th e n  r e s u s p e n d e d  in  5 0  juL of 0.05 M
6230 B I O C H E M I S T R Y R E Y N O L D S  E T  A L .
Tris, pH 7 .5 , a n d  0 .0 1  M  M g C l 2 a n d  in c u b a te d  w ith  4 0  u n its  
of AP e n d o n u c le a se  II a t  3 7  ° C  fo r  1 h . T h e  D N A  w a s  th e n  
precipitated w ith  e t h a n o l ,  d r ie d , a n d  e le c t r o p h o r e s e d  a s  d e ­
scribed b e lo w .
Electrophoretic Analysis o f  CC-1065 Binding S ites on 
DNA. C o n tro l la n e s  o f  D N A  f r a g m e n t s  w e r e  t r e a t e d  a c ­
cording to th e  p r o c e d u r e s  o f  M a x a m  &  G ilb e r t  ( 1 9 8 0 ) .  T h e  
DNA sam p les w e r e  th e n  r e su s p e n d e d  in  80 %  ( v / v )  d e io n iz e d  
formamide, 10  m M  N a O H ,  1 m M  E D T A ,  0 .1 %  ( w / v )  x y le n e  
cyanol, and 0 .1 %  ( w / v )  b r o m o p h e n o l  b lu e .  F o r  s a m p le s  
containing M a x a m - G i lb e r t - t r e a t e d  o r  C C - 1 0 6 5 -  p lu s  h e a t -  
treated D N A , e q u a l a m o u n ts  o f  r a d io a c t iv ity  w e r e  lo a d e d  o n to  
thin d en atu r in g  p o ly a c r y la m id e  g e ls  a n d  e le c t r o p h o r e s e d  a t  
1600 V. A u to r a d io g r a p h s  w e r e  d e v e lo p e d  w ith  K o d a k  X R P -1  
film.
Densitometric Analysis o f  Autoradiograms. A  B e c k m a n  
DU-8 s p e c tr o p h o to m e te r  e q u ip p e d  w ith  a  g e l  s c a n  p r o g r a m  
was used to  q u a n t i t a t e  t h e  a u t o r a d io g r a p h s .  C o m p a r a t iv e  
values w ere d e t e r m in e d  b y  in t e g r a t in g  t h e  a r e a  u n d e r  th e  
curve.
Results
The ob serv a tio n  th a t  th e r m a l tr e a t m e n t  o f  C C - 1 0 6 5 - D N A  
adducts c a u se d  c o n v e r s io n  o f  s u p e r c o i le d  D N A  to  r e la x e d  
DNA (S w en so n  e t  a l .,  1 9 8 2 )  le d  u s  to  in v e s t ig a te  w h e th e r  th is  
cleavage r e a c t io n  c o u ld  b e  u s e d  a s  a  m e a n s  to  p in p o in t  t h e  
location o f  C C - 1 0 6 5  b in d in g  s i t e s  w i th in  D N A .  A  s in g ly  
32P-end-labeled r e s tr ic t io n  e n z y m e  f r a g m e n t  ( f r a g m e n t  1 in  
Figure 3) from  th e  S V 4 0  D N A  g e n o m e  w a s  u se d  a s  a  te m p la te  
to determ ine t h e  d e p e n d e n c e  o n  d o s e ,  t e m p e r a t u r e ,  a n d  in ­
cubation t im e  o f  C C - 1 0 6 5 - d ir e c t e d  D N A  b r e a k s .
Dose Dependency o f  DNA Strand Breakage Produced by 
CC-1065. T e n fo ld  d i lu t io n s  o f  th e  s to c k  s o lu t io n  o f  C C - 1 0 6 5  
were used to  t r e a t  a l iq u o t s  o f  D N A  f r a g m e n t s ,  w h ic h  w e r e  
subsquently h e a te d  a t  1 0 0  ° C  fo r  3 0  m in . T h e  r e su lts , sh o w n  
as the c o m p le te  a u t o r a d io g r a m  a n d  a ls o  a s  d e n s it o m e t r ic  
tracings a t tw o  o f  th e  d r u g  c o n c e n tr a t io n s  u s e d , a r e  s h o w n  in  
Figure 4A . A t  th e  m o r e  d i lu te  C C - 1 0 6 5  c o n c e n tr a t io n s  ( la n e s  
5 and 6) th e  m a jo r ity  o f  t h e  m a te r ia l  a p p e a r s  a t  th e  h ig h  
molecular w e ig h t  e n d  o f  th e  g e l 2 w h e r e  b a n d  s e p a r a t io n  is  
incomplete, b u t  th is  s h i f t s  to  lo w e r  m o le c u la r  w e ig h t  b a n d s  
that are s e p a r a b le  a t  m o r e  c o n c e n tr a te d  d r u g  s o lu t io n s  ( la n e s  
7-11). T h e  m o s t  p r o m in e n t  b a n d s  p r o d u c e d  b y  C C - 1 0 6 5 -  
induced strand b r e a k s  o c c u r  a t  tw o  s e q u e n c e s ,  5 ' A A A A A  a n d  
5'AATTA, a n d  a r e  e v id e n t  a t  u p  to  10 5- fo ld  d i lu t io n  o f  th e  
stock so lu tio n  o f  C C - 1 0 6 5 .  T h e s e  a r e  t h e  m o s t  s e n s i t iv e  
binding s ite s  in  th e  r e a d a b le  p a r t  o f  th e  g e l  ( i .e . ,  f r o m  th e  5 '  
end to the T A T A  b o x ) .  I n te r e s t in g ly , s a tu r a t io n  o f  t h e s e  tw o  
most prom inent b in d in g  se q u e n c e s  o c c u r s  a t  a  1 0 3-fo ld  d ilu t io n  
of stock C C - 1 0 6 5 ,  w h i le  h ig h e r  m o le c u la r  w e ig h t  m a te r ia l  is  
still evident a t  h ig h e r  c o n c e n tr a t io n s  o f  C C - 1 0 6 5 .  I t  is  l ik e ly  
that at th ese  h ig h e r  c o n c e n tr a t io n s  o f  C C - 1 0 6 5 ,  e f f ic ie n t  c o ­
valent drug b in d in g  o c c u r s  a t  le s s  r e a c t iv e  s e q u e n c e s  a n d  th u s  
precludes a n y  in te r a c t io n  a t  p r e fe r r e d  s it e s ;  i .e . ,  t h e  f ir s t  h it  
can affect th e  a f f in i t y  o f  s u b s e q u e n t  h i t  s i t e s .
The p o ly (d A ) s e q u e n c e  a t  th e  lo w e r  p o r tio n  o f  th e  g e l  sh o w s  
predominantly o n e  b in d in g  s i t e  a t  t h e  3 ' e n d  o f  t h e  s e q u e n c e .
2 For this particular fragment (fragment 1 in Figure 3) we consistently 
found some degradation that was dependent upon heating at 100 °C for
30 min. This results in a smear of bands at the high molecular weight 
part of this gel (see lanes 5, 6, and 12). While this heat-induced deg­
radation of DNA masks some of the more sensitive CC-1065 binding 
sites in high molecular weight regions, it did not significantly affect the 
distribution of binding sites in the lower molecular weight region of this 
fragment.
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f i g u r e  4: Effect of the CC-1065 dose on D N A  strand breakage 
produced by thermal treatm ent of CC-1065-D N A  adducts. (A) The 
reaction of CC-1065 with SV40 DNA was examined by using frag­
ment 1 depicted in Figure 3. Lanes 1-4, M axam -G ilbert sequencing 
reactions: G, A +  G, C, and T -I- C, respectively. Lanes 5-12, 
CC-1065 treatm ents. CC-1065 D N A  adducts were prepared by 
incubating the DNA for 24 h at 4 °C  with various dilutions of a parent 
stock solution of CC-1065: lanes 5, 6, 7, 8, 9, 10, and 11 are 1:106, 
1:105, L104, 1:103, 1:102, and 1:10 dilutions and undiluted stock solution 
of CC-1065, respectively. Lane 12 is no drug treatm ent. The DNA 
was then precipitated in ethanol, resuspended in DSC, heated (100 
°C, 30 min), precipitated again, and electrophoresed as described under 
Materials and Methods. Densitometric analysis of the autoradiograph 
was performed as described under M aterials and M ethods, and 
representative examples are depicted. The open arrows indicate the 
adenine that is covalently bound to CC-1065. The solid arrow rep­
resents the site of a single-strand break indirectly produced by CC-1065 
(see text). (B) The reaction of CC-1065 with the TATA  box in the 
SV40 early promoter was examined by using fragment 2 depicted in 
Figure 3. Sequencing reactions and drug treatm ents are as described 
for panel A.
A t  1 0 3- fo ld  h ig h e r  c o n c e n tr a t io n s  o f  C C - 1 0 6 5 ,  th e  5 ' a d e n in e  
is  a l s o  r e c e p t iv e  to  b in d in g  b y  C C - 1 0 6 5 ,  i .e . ,  t h e  f a s t e s t  m i­
g r a t in g  b a n d s  in  la n e s  9 - 1 1 .  T h e  5 ' A A T T A  s e q u e n c e  c o n ­
ta in e d  w ith in  th e  T A T A  b o x  is  a c c o m p a n ie d  b y  a  s h o u ld e r  
in  th e  d e n s i t o m e t e r  t r a c in g  a t  1 0 - fo ld  d i lu t io n  o f  th e  d r u g ,  
w h ic h  is  d u e  to  C C - 1 0 6 5  b in d in g  a t  th e  s e q u e n c e  5 ' A A T A A .  
F ig u r e  4 B  s h o w s  a  p o r t io n  o f  t h e  a u t o r a d io g r a m  fr o m  a n  
e x p e r im e n t  in  w h ic h  f r a g m e n t  2  ( s e e  F ig u r e  3 )  h a s  b e e n  
s u b je c te d  to  v a r io u s  c o n c e n tr a t io n s  o f  C C - 1 0 6 5 .  T h e  r e s u lts  
fr o m  th is  a u to r a d io g r a m  r e v e a l in  g r e a te r  d e ta i l  th e  h ie r a r c h y  
o f  C C - 1 0 6 5  b in d in g  s ite s  o n  o n e  str a n d  a r o u n d  th e  T A T A  b o x . 
In  a g r e e m e n t  w ith  t h e  d a t a  in  F ig u r e  4 A ,  th e  tw o  m o s t  s e n ­
s it iv e  s it e s  to  C C - 1 0 6 5  b in d in g  a r e  5 'A A T T A  a n d  5 'A A T A A .  
O th e r  s i t e s  o f  lo w e r  s e n s i t iv i t y  o c c u r  w i t h in  th e  p o l y ( d A )  
s e q u e n c e  o f  th e  T A T A  b o x  (p o s i t io n s  2 1 ,  2 5 ,  a n d  2 6 )  a n d  o n  
th e  5 ' s id e  o f  th is  s e q u e n c e  (p o s it io n s  17 a n d  1 9 ) . In te r e s t in g ly ,
R E A C T I O N  O F  A N  A N T I T U M O R  A G E N T  W I T H  D N A V O L .  2 4 ,  N O .  2 2 ,  1 9 8 5  6231
n o t  a l l  a d e n in e s  w ith in  th e  p o l y ( d A )  s e q u e n c e  a r e  e q u a lly  
s e n s it iv e , a n d  s o m e  d o  n o t sh o w  a n y  C C - 1 0 6 5  b in d in g  a f f in ity . 
A  d e ta i le d  a n a ly s is  o f  th e  p a tte r n  o f  C C - 1 0 6 5  b in d in g  o n  b o th  
s t r a n d s  a r o u n d  th e  T A T A  b o x  r e g io n  is  g iv e n  la te r .
It is c le a r  fr o m  th e  d a ta  in F ig u r e  4 A  th a t  C C - 1 0 6 5  e x h ib its  
s e l e c t iv i t y  in  t h e  s e q u e n c e s  to  w h ic h  it b in d s  a n d ,  fo l lo w in g  
h e a t  t r e a t m e n t ,  c a u s e s  s tr a n d  b r e a k a g e .  I t  is  a l s o  c le a r  th a t  
d if f e r e n t  s e q u e n c e s  h a v e  d i f f e r e n t  a f f in i t ie s  fo r  C C - 1 0 6 5 .  
H o w e v e r ,  a s  is  d i s c u s s e d  in  m o r e  d e t a i l  la t e r ,  e v e n  t h e  s a m e  
p e n ta n u c le o t id e  b in d in g  s e q u e n c e s  c a n  r e sp o n d  d i f f e r e n t ly  in  
a  q u a n t i t a t iv e  s e n s e .  T h e s e  d i f f e r e n c e s  m a y  b e  d u e  t o  th e  
p r o x im ity  o f  a n  e n d  o f  th e  D N A  m o le c u le  ( t h e r e  a r e  s o m e  
q u a n t i t a t iv e  d i f f e r e n c e s  b e tw e e n  p a n e ls  A  a n d  B  o f  F ig u r e  4  
in  th e  r eg io n  o f  th e  T A T A  b o x )  o r  to  th e  D N A  s e q u e n c e s  th a t  
f la n k  th e  b in d in g  s it e  o f  th e  d r u g . N e v e r t h e le s s ,  q u a n t ita t iv e  
a n a ly s e s  a r e  o f  s ig n if ic a n c e ;  th e  d a t a  a r e  h ig h ly  r e p r o d u c ib le ,  
a n d  it s h o u ld  b e  n o te d  th a t  th e  s e q u e n c e  5 'A G T T A  is e q u a lly  
r e c e p t iv e  to  C C - 1 0 6 5 - in d u c e d  s tr a n d  b r e a k a g e  ( F ig u r e  4 A )  
w h e n  it is p art o f  a  lo n g e r  c o n se r v e d  s e q u e n c e  ( tw o  o f  th e  th r ee  
2 1 -b p  r e p e a ts  o f  S V 4 0  D N A  c o n ta in  th is  s e q u e n c e ,  a n d  th e s e  
s i t e s  a r e  th e  m o s t  s e n s i t iv e  to  C C - 1 0 6 5 - in d u c e d  c le a v a g e  s o  
fa r  d i s c o v e r e d ) .
T h e  b a n d  b e tw e e n  th e  T A T A  b o x  a n d  th e  fir s t  o f  th e  2 1 -b p  
r e p e a t s  ( F ig u r e  4 A ;  s e e  a ls o  F ig u r e  8 )  is  in t e r e s t in g  fr o m  a  
d if fe r e n t  p e r sp e c t iv e . T h is  b a n d  is p r e se n t e v e n  in  th e  a b s e n c e  
o f  d r u g  t r e a t m e n t ,  a n d  s tr a n d  b r e a k a g e  is  lo c a t e d  a t  t h e  c y -  
t id in e  r e s id u e  w i t h in  th e  s e q u e n c e  5 'G G G G C G G . T h e  c o ­
v a le n t  a t t a c h m e n t  o f  C C - 1 0 6 5  is s p e c i f ic  fo r  a d e n in e  r e s id u e s  
( H u r le y  e t  a l . ,  1 9 8 4 ) ,  a n d  th u s  th e  d r u g  s h o u ld  n o t  p r o d u c e  
d ir e c t  s tr a n d  b r e a k a g e  w ith in  th is  s e q u e n c e .  H o w e v e r ,  w h e n  
C C - 1 0 6 5  is  b o u n d  to  th e  D N A ,  p r e s u m a b ly  a t  d is ta n t  s it e s ,  
it d r a m a t ic a l ly  in c r e a s e s  th e  in t e n s i t y  o f  th is  b a n d . A n  
a n a lo g o u s  e f f e c t  o n  o th e r  D N A  s e q u e n c e s  h a s  a ls o  b e e n  n o te d  
w ith  b le o m y c in - t r e a t e d  D N A  ( M ir a b e l l i  e t  a l . ,  1 9 8 3 ) .  T h e  
b a s is  fo r  th is  p h e n o m e n o n  is  u n c le a r ,  b u t  it  m a y  b e  r e la te d  
to  th e  c h a n g e s  in  o v e r a ll  h e lix  s t a b i l i t y ,  a n d  th u s  D N A  c o n ­
fo r m a t io n , f o l lo w in g  d r u g  b in d in g  ( S w e n s o n  e t a l .,  1 9 8 2 ) .  It  
sh o u ld  b e  n o te d  th a t  th e  s a m e  s e q u e n c e  ( 5 'G G G C G G ) ,  w h ic h  
o c c u r s  in  th e  tw o  o t h e r  2 1 -b p  r e p e a t s  ( s e e  F ig u r e  8 ) ,  is  n o t  
a ta r g e t  fo r  e ith e r  s p o n t a n e o u s  o r  C C - 1 0 6 5 - e n h a n c e d  b r e a k ­
a g e .
Temperature and Time Dependency o f  DNA Strand  
Breakage Produced by CC-1065. W e  h a v e  r o u tin e ly  e m p lo y e d  
a  2 4 - h  in c u b a t io n  o f  D N A  w ith  C C - 1 0 6 5  to  e n s u r e  th a t  
b in d in g  w a s  c o m p le t e ;  s im ila r ly ,  w e  h a v e  s ta n d a r d iz e d  th e  
h e a t in g  s t e p  ( t o  in d u c e  s tr a n d  b r e a k a g e )  fo r  3 0  m in  a t  1 0 0  
° C .  In  o r d e r  to  s h o w  th a t  t h e s e  c o n d it io n s  a r e  o p t im a l ,  th e  
t e m p e r a t u r e  a n d  t im e  d e p e n d e n c ie s  o f  C C - 1 0 6 5 - in d u c e d  
b r e a k s  w e r e  e v a lu a te d  b y  u s in g  D N A  fr a g m e n t  1 ( F ig u r e  3 ) .  
F o l lo w in g  a 2 4 -h  in c u b a t io n  a t  4  ° C  o f  th e  D N A  w ith  C C -  
1 0 6 5  a n d  r e m o v a l o f  u n b o u n d  d r u g , s e p a r a t e  a l iq u o t s  o f  th e  
m o d if ie d  D N A  w e r e  h e a te d  fo r  3 0  m in  a t  v a r io u s  t e m p e r a ­
tu r e s .  I n te g r a t io n  o f  th e  d e n s it o m e t r ic  r e s u lt s  d e m o n s t r a t e s  
th a t ,  in  a 3 0 -m in  p e r io d , s ig n if i c a n t  s tr a n d  b r e a k a g e  o c c u r s  
o n ly  a t  t e m p e r a t u r e s  a b o v e  7 0  ° C  ( F ig u r e  5 A ) .  T h e  b a c k ­
g r o u n d  level o f  str a n d  b r e a k a g e  o b se rv ed  a t lo w er  te m p e r a tu r e s  
is  m o s t  p r o b a b ly  d u e  to  th e  fa c t  th a t  a l l  s a m p le s  a r e  h e a te d  
a t  9 0  ° C  fo r  1 m in  in  o r d e r  to  d e n a t u r e  th e  D N A  p r io r  to  
lo a d in g  th e  s e q u e n c in g  g e l.  M a x im u m  s tr a n d  b r e a k a g e  is  
o b t a in e d  w ith in  3 0  m in  a t  1 0 0  ° C ;  a l t e r n a t iv e ly ,  h e a t in g  a t  
7 0  ° C  fo r  12 h a l s o  le a d s  to  c o m p le t e  s tr a n d  s c i s s io n  ( d a t a  
n o t s h o w n ) .
T o  sh o w  th a t a 2 4 -h  in cu b a tio n  o f  D N A  w ith  C C -1 0 6 5  le a d s  
to  m a x im u m  b in d in g , a  1 0 3-fo ld  d i lu t io n  o f  th e  s to c k  s o lu t io n  
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f i g u r e  5: Tem perature and time dependence of CC-1065-induced ' 
breaks. DNA fragment 1 (Figure 3) was treated with a 1:103 dilution 
of the stock CC-1065 solution and processed as described under 
Materials and Methods except that in (A) the DNA-CC-1065 adduct 
was heated for 30 min at various temperatures and in (B) the duration 
of incubation at 4 °C  of DNA and CC-1065 was varied. The data 
are expressed as the percentage of strand scission at the sequence 
5'AAAAA relative to, in (A), 100 °C  and, in (B), a 9-h incubation.
t im e s  b e fo r e  th e  d r u g  w a s  r e m o v e d  a n d  s tr a n d  b r e a k a g e  in ­
d u c e d  ( 1 0 0  ° C  fo r  3 0  m in ) .  T h e  r e s u lt s  ( F ig u r e  5 B )  d e m ­
o n s t r a t e  t h a t  D N A  s tr a n d  b r e a k a g e  a t  th e  s e q u e n c e s  
5 ' A A A A A  is  d e t e c t a b le  fo l lo w in g  th e  s h o r te s t  in c u b a t io n  o f  
C C - 1 0 6 5  w ith  D N A  e x a m in e d  (1  m in )  a n d  r e a c h e s  a m a x i ­
m u m  b e tw e e n  3 a n d  5 h . H o w e v e r ,  o th e r  s e q u e n c e s  th a t  a r e  
le s s  s e n s i t iv e  to  C C - 1 0 6 5  b in d in g  r e q u ir e d  lo n g e r  in c u b a t io n  
p e r io d s  (d a ta  n o t  s h o w n ) .
Relationship o f  the CC-1065-Directed DNA Strand Break 
to the Adenine Covalent Binding Site. T h e  i s o la t io n  o f  th e  
C C - 1 0 6 5 - N 3 - a d e n i n e  a d d u c t  ( s e e  F ig u r e  2 )  r e s u l t in g  fr o m  
th e r m a l tr e a t m e n t  o f  C C - 1 0 6 5 - m o d if ie d  D N A  p r o v id e d  firm  
e v id e n c e  fo r  th e  p r im a ry  s ite  o f  c o v a le n t  m o d if ic a t io n  o f  D N A  
b y  C C - 1 0 6 5  ( H u r le y  e t  a l . ,  1 9 8 4 ) .  In o r d e r  to  o b t a in  in fo r -  ] 
m a tio n  on  th e  s it e  a n d  a p o ss ib le  m e c h a n is m  fo r  th e  th e r m a lly  
in d u c e d  C C -1 0 6 5  str a n d  b r ea k , th e  r e la t io n sh ip  o f  th e  p o s itio n  
o f  th e  s tr a n d  b r e a k a g e  to  th e  A P  s i t e  w a s  in v e s t ig a t e d .  E x -  i 
a m in a tio n  o f  se q u e n c in g  g e ls  in w h ic h  C C -1 0 6 5 - in d u c e d  stra n d  
b r e a k a g e  h a d  o c c u r r e d  s h o w s  a m in o r  p r o d u c t  ( F ig u r e  6 A ,  
la n e  5 ) th a t c o m ig r a te s  w ith  th e  p r o d u c t o f  a n  a d e n in e -s p e c if ic
6232 B I O C H E M I S T R Y R E Y N O L D S  E T  A L .
mm mm
FIGURE 6: (A) Relationship of the adenine to which CC-1065 is 
covalently bound and the point of CC-1065-induced strand breakage 
as revealed from a S'-end-labeled fragment. The relationship between 
the site of covalent linkage of CC-1065 to DNA and the drug-directed 
single-strand break was examined by using DNA fragment 3 (Figure 
3). Lanes 1-4, M axam -G ilbert sequencing reactions: C, T +  C, G, 
and A + G, respectively. Lanes 5-7 , CC-1065 treatm ents. CC- 
1065-DNA adducts were prepared by incubating CC-1065 (1:103 
dilution of stock CC-1065 solution) with DNA for 24 h at 4 °C. After 
I precipitation of the DNA in ethanol to remove unbound drug, samples 
were treated as follows: In lane 5, thermal treatm ent was used. The 
modified DNA was resuspended in 100 juL of DSC and heated at 100 
°C for 30 min. In lanes 6 and 7, the sample was resuspended in 100 
iiL of DSC and heated at 100 °C  for 30 min. The D N A  was then 
precipitated in ethanol, dried under vacuum, and treated with either 
HeLa AP endonuclease II as described under M aterials and Methods 
(lane 6) or piperidine at 100 °C  for 30 min (lane 7). Samples were 
then electrophoresed as described under M aterials and Methods. (B) 
Relationship of the adenine to which CC-1065 is covalently bound 
and the point of CC-1065 therm ally induced strand breakage as 
revealed by a 3'-end-labeled fragment. A 364-base-pair fragm ent 
isolated from 0 X 174 R F D NA  3' end labeled with [a -32P]dideoxy- 
ATPwas used in this experiment (see Materials and Methods). Lanes 
1-4, Maxam-Gilbert sequencing reactions: G, A -I- G, T +  C, and 
C,respectively. Lane 5, CC-1065 treatm ent as for lane 5 in panel
A.
reaction as d e f in e d  b y  th e  M a x a m - G i lb e r t  s e q u e n c in g  p r o ­
tocol. This m in or  p r o d u c t, w h ic h  a p p e a r s  in  v a r ia b le  a m o u n ts , 
has therefore a r ise n  fr o m  c le a v a g e  o n  th e  5 ' s id e  o f  th e  a d e n in e  
residue that r e a c te d  w ith  C C - 1 0 6 5  a n d  is th e r e fo r e  p r o b a b ly  
a3 '-phosphate-term inated  m o le c u le  ( a s  a r e  th e  D N A  m o le ­
cules following c h e m ic a l  c le a v a g e  b y  th e  m e th o d s  o f  M a x a m  
and Gilbert). T h e  m a jo r  p r o d u c t  ( F ig u r e  6  A ,  la n e  5 )  is  o n e  
that migrates m o r e  s lo w ly  o n  e le c tr o p h o r e s is ,  s u g g e s t in g  th a t  
in this case stran d  s c is s io n  o c c u r s  to  th e  3' s id e  o f  th e  a d e n in e  
that has rea c te d  w ith  C C - 1 0 6 5 .  T h is  m o d if ie d  a d e n in e  is , 
however, r e lea sed  b y  h e a t in g  ( H u r le y  e t  a l . ,  1 9 8 4 ) ,  a n d  th u s ,  
the major product o f  C C -1 0 6 5 - in d u c e d  s tr a n d  sc is s io n  is lik e ly  
toretain the r e su lt in g  A P  s it e .  I f  th is  is in d e e d  th e  c a s e ,  th e n
th e  D N A  f r a g m e n t  th a t  p r o d u c e s  th e  m a jo r  b a n d  in  la n e  5 
( F ig u r e  6 a )  s h o u ld  b e  s u s c e p t ib le  to  p ip e r id in e  d e g r a d a t io n .  
L a n e  7 in  F ig u r e  6 A  s h o w s  th a t  p ip e r id in e  t r e a t m e n t  o f  th e  
p r e v io u s ly  th e r m a l ly  t r e a t e d  C C - 1 0 6 5 - D N A  a d d u c t  q u a n t i ­
t a t iv e ly  r e m o v e s  th e  s lo w e r  m ig r a t in g  p r o d u c t  a n d  p r o d u c e s  
a  s in g le  b a n d  c o r r e s p o n d in g  to  th e  a d e n in e  o n  th e  5 ' s id e  o f  
th e  th e r m a l  b r e a k . T h is  p r o v e s  th a t  th e  c o v a le n t  b in d in g  s it e  
( N 3  o f  a d e n in e )  fo r  C C - 1 0 6 5  o n  D N A  is o n  th e  5 ' s id e  o f  th e  
t h e r m a l  c le a v a g e  p o s i t io n .
F u r th e r  e v id e n c e  t h a t  a n  A P  s i t e  w a s  r e s p o n s ib le  fo r  th e  
p ip e r id in e - in d u c e d  b r e a k  a t  a d e n in e  w a s  o b t a in e d  b y  in c u ­
b a t in g  th e  th e r m a l ly  t r e a t e d  f r a g m e n t  w ith  H e L a  A P  e n d o ­
n u c le a s e  I I . T h e  r e s u lt s  o f  th is  e x p e r im e n t  ( F ig u r e  6 A ,  la n e  
6 )  s h o w  th a t  th e  m a jo r  p o in t  o f  s tr a n d  b r e a k a g e  c o r r e s p o n d s  
to  a  f r a g m e n t  m ig r a t in g  a t  a n  in t e r m e d ia t e  p o s i t io n  b e tw e e n  
t h e  t h e r m a l-  a n d  p ip e r id in e - in d u c e d  b a n d s .  T h is  is  to  b e  
e x p e c te d , s in c e  it is  k n o w n  th a t  th e  A P  e n d o n u c le a s e  p r o d u c e s  
a  s t r a n d  b r e a k  o n  t h e  5 '  s id e  o f  t h e  A P  s i t e  a n d  le a v e s  a  
3 ' - h y d r o x y l  ( in  c o n t r a s t  t o  th e  S ' -p h o s p h a t e  r e s u l t in g  fr o m  
p ip e r id in e  t r e a t m e n t )  o n  th e  la b e le d  f r a g m e n t  (M o s b a u g h  &  
L in n , 1 9 8 2 ) .
E v id e n c e  fo r  th e  p o s i t io n  o f  th e r m a l  c le a v a g e  o n  t h e  C C -  
1 0 6 5 - D N A  a d d u c t  c o m e s  fr o m  f r a g m e n t s  32P  la b e le d  o n  th e  
3' t e r m in u s  r a th e r  th a n  th e  5' e n d  ( s e e  F ig u r e  6 B ) .  In  th is  
c a s e ,  th e  c h a in  b r e a k  n e a r e s t  th e  3' e n d  o f  th e  m o le c u le  g a v e  
r is e  t o  a  p r o d u c t  t h a t  c o m ig r a t e d  w ith  th e  A  b a n d  in  th e  
M a x a m - G i lb e r t  s e q u e n c in g  la n e s  ( F ig u r e  6 B , la n e  5 ) .  T h u s ,  
t h e  t h e r m a l  b r e a k a g e  y ie ld e d  a  32P - 3 ' - e n d - la b e le d  f r a g m e n t  
w ith  a  5 ' - p h o s p h a t e  t e r m in u s ,  th e  la t t e r  o f  w h ic h  is  to  th e  3' 
s id e  o f  t h e  C C - 1 0 6 5 - m o d i f i e d  d e o x y a d e n o s in e  s it e .  T h is  
c o n c lu s io n  is  a t  v a r ia n c e  w ith  t h a t  o f  o u r  e a r l ie r  r e p o r t  
( N e e d h a m - V a n D e v a n t e r  e t  a l .,  1 9 8 4 ) ,  w h ic h  w a s  b a se d  o n  th e  
in a b il ity  to  la b e l ,  w ith  p o ly n u c le o t id e  k in a s e  a n d  [7 - 32P ] A T P ,  
a n y  o f  th e  D N A  fr a g m e n ts  th a t  r e su lt  fr o m  th e r m a lly  in d u c e d  
c le a v a g e  o f  a  C C - 1 0 6 5 - D N A  a d d u c t  e v e n  a f t e r  p h o s p h a ta s e  
t r e a t m e n t .  T h e  r e a s o n ( s )  fo r  th is  n e g a t iv e  r e s u lt  is  ( a r e )  
u n c le a r , b u t  th e  d a t a  in  F ig u r e  6 B  c le a r ly  s h o w  e le c tr o p h o r e t ic  
c o m ig r a t io n  o f  t h e  3 ' - e n d - la b e le d  f r a g m e n t s  w ith  a  m a r k e r  
D N A  th a t  is  k n o w n  to  c o n t a in  a  5 ' - p h o s p h a t e  ( M a x a m  &  
G ilb e r t ,  1 9 8 0 ) .
W h i le  t h e  d a t a  fr o m  t h e  3 ' - e n d - la b e l in g  e x p e r im e n t  d e m ­
o n s t r a t e  th a t  th e  C C - 1 0 6 5 - d ir e c t e d  th e r m a l  c le a v a g e  r e s u lt s  
in  p r o d u c t io n  o f  a  5 ' - p h o s p h a t e ,  th e  id e n t i t y  o f  th e  3 ' -e n d  
t e r m in u s  o f  th e  5 ' - e n d - la b e le d  f r a g m e n t  is  le s s  c le a r . P r e l im ­
in a r y  r e s u lt s  s u g g e s t  t h a t  th e  t e r m in u s  is  a  m o d if ie d  d e o x y -  
r ib o se  r e su lt in g  fr o m  a  s in g le  ^ -e l im in a t io n  r e a c tio n  (S w e n s o n ,  
u n p u b l is h e d  r e s u l t s ) .
Lack o f  Residual DNA Strand Modification on the Com­
plementary Strand at CC-1065 Covalent Binding Sites. T h e  
e x p e r im e n t s  o f  F ig u r e  6  c o n c lu s iv e ly  s h o w  th a t  th e  th e r m a lly  
in d u c e d  D N A  s tr a n d  b r e a k  o c c u r r e d  o n  th e  s a m e  s t r a n d  a s  
t h e  C C - 1 0 6 5 - N 3 - a d e n i n e  c o v a le n t  m o d if ic a t io n  s it e ,  b u t  th e y  
d o  n o t  r e v e a l  w h e t h e r  C C - 1 0 6 5  a ls o  m o d if ie d ,  o r  p e r h a p s  
c le a v e d ,  th e  c o m p le m e n t a r y  s tr a n d  o f  D N A  o p p o s i t e  th e  
C C - 1 0 6 5  le s io n . T o  e v a lu a te  th is  p o s s ib il it y ,  D N A  m o le c u le s  
( f r a g m e n t s  2  a n d  6  o f  F ig u r e  3 )  w e r e  p r e p a r e d  w h e r e  th e  
u n iq u e  32P  la b e l  w a s  o n  c o m p le m e n t a r y  s t r a n d s .  T h e s e  
fr a g m e n ts  w e re  m o d if ie d  a n d  h e a te d  u n d e r  s ta n d a r d  c o n d it io n s  
a n d  e x a m in e d  fo r  D N A  s tr a n d  b r e a k s  b y  g e l  e le c tr o p h o r e s is .  
A s  e x p e c te d  fr o m  p r e v io u s  e x p e r im e n t s ,  th e r m a l  t r e a t m e n t  o f  
t h e  C C - 1 0 6 5  a d d u c t  p r o d u c e d  a  s in g le  b r e a k  in  f r a g m e n t  2  
o n  t h e  3' s id e  o f  t h e  a d e n in e  in  t h e  s e q u e n c e  
5 ' G G A G T T A G G G G  ( F ig u r e  7 ) .  T h e  c o m p le m e n t a r y  s e ­
q u e n c e  sh o w e d  n o  d e te c ta b le  r e s id u a l m o d if ic a t io n  b y  th e r m a l  
t r e a t m e n t  o r  t h e r m a l  p lu s  p ip e r id in e  t r e a t m e n t .  T h e r e f o r e ,
R E A C T I O N  O F  A N  A N T I T U M O R  A G E N T  W I T H  D N A V O L .  2 4 ,  N O .  2 2 ,  19 8 5 6233
. » u u .  .
5' GGAGTTAGGGG 3' 
3' CCTCAATCCCC 5'
i
f i g u r e  7: Reaction of CC-1065 with overlapping com plem entary 
strands of D N A . The reaction of CC-1065 with SV40 D N A  was 
examined in separate experiments using overlapping complementary 
strands from the 21-bp repeats of the SV40 early prom oter region. 
The D N A  restriction fragm ents used correspond to fragm ent 2 (for 
5 'G G A G T TA G G G G ) and to fragm ent 6 (for the com plem entary 
5 'C CC C TA A CTC C) depicted in Figure 3. C C-1065-D N A  adducts 
were prepared as described in the legend to Figure 4. Densitometric 
tracings were obtained from autoradiogram s and are presented for
(a) control sample (D N A  heated in the absence of drug treatm ent) 
and DNA heated after incubation with (b) 1:105 and (c) 1:103 dilutions 
of a stock CC-1065 solution. The densitom etric tracings for the 
5'CCCCTAACTCC sequence are virtually identical and are presented 
on offset axes for clarity.
C C - 1 0 6 5  d o e s  n o t  c le a v e  o r  l e a v e  a n y  d e t e c t a b l e  r e s id u a l  
m o d if ic a t io n  o n  D N A  o p p o s it e  t h e  p r im a r y  C C - 1 0 6 5  le s io n .
DNA Sequence Specificity o f  CC-1065. A  v a r ie t y  o f  
o v e r la p p in g  r e s t r ic t io n  e n z y m e  f r a g m e n t s  w e r e  p r e p a r e d  
c o v e r in g  b o t h  s t r a n d s  o f  t h e  c o n tr o l  e le m e n t  b e t w e e n  th e  
Him1III B - C  ju n c t io n  a n d  th e  H pall  s i t e  o n  S V 4 0  D N A ,  a s  
d e s c r ib e d  u n d e r  M a t e r ia l s  a n d  M e t h o d s  ( s e e  F ig u r e  3 ) .  In  
a d d it io n  t o  t h o s e  s e q u e n c e s  s u m m a r iz e d  in  F ig u r e  8 ,  o th e r  
fr a g m e n ts  fr o m  S V 4 0  a n d  T 7  D N A  w e r e  u s e d  in  th e  a n a ly s is .  
In  a l l ,  o v e r  1 0 0 0  b a s e  p a ir s  w e r e  e x a m in e d  fo r  C C - 1 0 6 5  
b in d in g  s i t e s .  F o l lo w in g  C C - 1 0 6 5  m o d if ic a t io n  o f  t h e s e  
f r a g m e n t s  a n d  t h e r m a l  t r e a t m e n t  to  p r o d u c e  D N A  s tr a n d  
b r e a k a g e , g e l  e le c tr o p h o r e s is  w a s  u se d  to  d e te r m in e  th e  D N A  
s e q u e n c e  s p e c if ic ity .  In  a ll c a s e s  s tu d ie d , th e  a d e n in e  c o v a le n t  
b in d in g  s i t e  is  a s s u m e d  to  b e  o n  t h e  5 ' s id e  o f  t h e  p o s i t io n  o f  
s tr a n d  b r e a k a g e  ( t h e  m in o r , v a r ia b le  p r o d u c t  h a s  b e e n  ig n o r e d  
fo r  th is  a n a ly s is ) .  A  c a t a lo g  o f  a ll C C - 1 0 6 5  b in d in g  s e q u e n c e s  
r e v e a le d  tw o  s u b s e ts  o f  s it e s ,  in  w h ic h  th e  s e q u e n c e  s p e c if ic ity  
a lw a y s  l ie s  to  th e  5 ' o f  th e  a d e n in e  b in d in g  s it e .  T h e  g r e a te r  
n u m b e r  o f  s e q u e n c e s  a n d  th o s e  g e n e r a l ly  m o r e  s e n s i t iv e  to  
C C - 1 0 6 5  b e lo n g  t o  t h e  c o n s e n s u s  s e q u e n c e  5 ' P u N T T A ,  
w h e r e a s  t h e  s u b s e t  h a v in g  f e w e r  e x a m p le s  b e lo n g s  to  th e  
c o n s e n s u s  s e q u e n c e  5 ' A A A A A .  A  s t a t i s t i c a l  a n a ly s i s  o f  th e  
fr e q u e n c y  o f  o c c u r r e n c e  o f  b a s e s  a t  e a c h  s id e  o f  th e  c o v a le n t ly  
m o d if ie d  a d e n in e  fo r  b o th  s u b s e t s  is g iv e n  in  p a r ts  A  a n d  B  
o f  T a b le  I .3 T h e  5 ' P u N T T A  s u b s e t  s h o w s  a n  a b s o lu t e  s p e ­
c if ic i ty  fo r  5 'T A  a n d  a n  a lm o s t  c o m p le t e  s p e c if ic ity  fo r  5 T T A  
a t  1 0 4- fo ld  a n d  g r e a t e r  d i lu t io n s  o f  s t o c k  C C - 1 0 6 5  s o lu t io n s  
( 0 . 1 4  ^ m o l / m L ) .  I n t e r e s t in g ly ,  w h i le  th e r e  is  n o  s p e c i f ic i t y  
fo r  th e  a d j a c e n t  b a s e  o n  th e  5 ' s id e  o f  th e  5 'T T A  s e q u e n c e ,  
th e r e  is  a  s t r o n g  p e r f e r e n c e  fo r  a p u r in e  a t  th e  n e x t  p o s i t io n  
( s e e  T a b le  I A ) .  W ith  o n e  e x c e p t io n  a ll m e m b e r s  o f  th e  s e c o n d
3 A complete list of the actual binding sequences and their location
in SV40 DNA and T7 can be obtained from L.H.H.
Table I: Analysis of the Two Subsets of DNA Sequences Flanking 
the Covalent Binding Site of CC-10650
frequencies of occurrence (%)
5' -3  -2 -1 + 1 3'
(A) Analysis of 5'PuNTTA3' Sequences
G 30 33 10 0 0 23
A 53 33 20 0 100 30
C 3 17 17 0 0 23
nT 13 17 53 100 0 23
Pu 83 67 30 0 100 53
Py 17 33 70 100 0 47
GC 33 50 27 0 0 47
AT 67 50 73 100 100 53
consensus Pu N T T A N
(B) Analysis of Poly(A) Sequences
G 7 13 0 0 0 40
A 67 67 87 100 100 27
C 7 7 0 0 0 7
T 20 7 13 0 0 27
Pu 73 80 87 100 100 67
Py 27 20 13 0 0 33
GC 13 27 0 0 0 47
AT 87 73 100 100 100 53
consensus A A A A A N
0 A* represents the adenine to which CH-1065 is covalently bound. 
The frequencies of occurrence of individual bases or base combinations 
in the regions adjacent to A* are computed from a total of 30 (A) and 
15 (B) binding sites on SV40 and bacteriophage T7 DNA which were 
sensitive to 0.14 x  10-3 to 0.14 X 10-6 /xniol of CC-1065/mL. The 
consensus sequences were determined by x 2 analysis (a = 0.005, part 
A; a = 0.05, part B) using the raw frequency values observed. .
s u b s e t  o f  b in d in g  s i t e s  h a v e  t h e  s e q u e n c e  5 'A A A  at which 
c o v a le n t  b in d in g  o c c u r s  a t  th e  3 ' a d e n in e  p o s it io n . There is 
a  le ss  s ig n if ic a n t  p r e fe r e n c e  fo r  a d e n in e s  a t  th e  fou rth  and fifth 
b a s e  fr o m  th e  a d e n in e  c o v a le n t  b in d in g  s it e ,  b u t th is should 
n o t  b e  o v e r e m p h a s iz e d  s in c e  t h e  D N A  s e q u e n c e s  we have 
s t u d ie d  a r e  o v e r r e p r e s e n te d  w i t h  p o l y ( d A )  tr a c t s  relative to 
o t h e r  D N A s  o f  t h e  g e n e r a l  s e q u e n c e  5 ' N N A A A .
T h e  n u c le o t id e  s e q u e n c e s  o f  a ll  D N A  r e s tr ic t io n  fragments 
u se d  in  th e s e  e x p e r im e n ts  w e r e  e x a m in e d  to  lo c a te  and identify
( 1 )  a p p a r e n t  c o n s e n s u s  s e q u e n c e s  th a t  fa il  to  b in d  CC-1065 
a n d  ( 2 )  D N A  s e q u e n c e s  a t  w h ic h  s tr a n d  b r e a k a g e  occurs due 
to  th e  p r e s e n c e  o f  C C - 1 0 6 5  b u t  w h ic h  d o  not f it  either of the 
c o n s e n s u s  s e q u e n c e s  d e te r m in e d  in  p a r ts  A  a n d  B  o f  Table 1, 
T h r e e  c o n s e n s u s  s e q u e n c e s  w e r e  lo c a te d  a t  w h ic h  CC-1065- 
in d u c e d  s t r a n d  s c i s s io n  w a s  n o t  d e t e c t e d  ( s e e  T a b le  1IA). 
T h e s e  a r e  th e  a d e n in e s  a t  S V 4 0  p o s it io n s  2 7 , 2 8 , and  3909 and 
a r e  l ik e ly  th e  r esu lt  o f  s ite -e x c lu s io n  e f fe c t s  p rod u ced  by nearby 
C C - 1 0 6 5  b in d in g  s it e s .  F o r  e x a m p le , th e  C C -1 0 6 5  adduct at 
p o s i t io n  3 9 0 5  m a y  p r e c lu d e  b in d in g  a n d  s u b se q u e n t  strand 
s c i s s io n  a t  p o s i t io n  3 9 0 9 .  In  a d d i t io n  to  p r e v e n tin g  adduct 
fo r m a t io n ,  th e  p r e s e n c e  o f  a  n e a r b y  C C - 1 0 6 5  adduct may 
in f lu e n c e  th e  position  o f  s u b s e q u e n t  C C - 1 0 6 5 - D N A  adduct 
fo r m a t io n .  F o r  e x a m p le ,  i t  is  o b s e r v e d  th a t  th e  3'-terminal 
a d e n in e  in  th e  5 ' A A A A A  s u b s e t  o f  s e q u e n c e s  is th e  preferred 
s i t e  o f  c o v a le n t  b in d in g  b y  C C - 1 0 6 5 . H o w e v e r ,  a t the SV40 
D N A  p o s i t io n  5 3 3 ,  C C - 1 0 6 5  s e l e c t s  th e  m id d le  o f  a triplet 
o f  a d e n in e s .  T h is  m a y  b e  d u e  to  th e  p r e s e n c e  o f  a CC-1065 
m o le c u le  a t  p o s i t io n  5 2 8  w h ic h  w o u ld  b e  e x p e c te d  to occupy 
th e  m in o r  g r o o v e  u p  t o  p o s i t io n  5 3 2 .  F u r th e r , th e  complex 
b in d in g  p a tte r n  in  a n d  a r o u n d  th e  T A T A  b o x  (s e e  below) may 
b e  d u e  to  e n d -to -e n d  c lu s te r in g  o f  d r u g  m o le c u le s  on  the DNA. 
H o w e v e r ,  w ith  th e  e x c e p t io n  o f  th e  e x a m p le s  n o te d  in Table 
II A ,  n o  o th e r  5 'P u N T T A  se q u e n c e s  or  p o ly (d A )  tracts of three 
o r  m o r e  a d e n in e s  w e r e  fo u n d  th a t  f a i le d  to  b in d  CC-1065. 
F u r th e r m o r e , u n d e r  th e  c o n d it io n s  u s e d  to  g e n e r a te  the data 
in  T a b le  I, th e r e  w e r e  o n ly  th r e e  s e q u e n c e s  a t  w h ich  drug- 
r e la te d  s tr a n d  s c i s s io n  o c c u r r e d  a t  nonconsensus sequences4
6234 B I O C H E M I S T R Y  R E Y N O L D S  E T A L .
5' AGCTTTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCGGCCTCTGCtTAAATAkAAAAAA 
CGTTTT CGGATCCGGAGGTTTTTT CGGAGGAGT GAT GAAGACCTT ATCGAGT CT CCGGCTCCGCCGGAGCCGGAGACGrATTTAT ITTTTTT
:    1- - - - - - u  I T Ti





GGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGG/ TGGGCGGAGTTAGGGGCGGG; CT7 FGGTTGCTGACTAATTGAGATG 
CCCCGCCTCTTACCCGCCTTP\CCCGCCTCAATCCCCGCCCl»\CCCGCCTCAATCCCC6CCCliGAllACCAACGACTGATTAACTCTAC












figure 8: DNA sequence specificity of CC-1065 within the early prom oter region of SV40. Restriction enzyme fragm ents were prepared 
as described under M aterials and M ethods and were singly end labeled with 32P, incubated with CC-1065 (24 h at 4 °C ), and then heated 
under standard conditions to produce D N A  strand breakage. The diamonds (♦ )  show the C C-1065-adenine covalent binding sites, and the 
number of diamonds indicates the relative sensitivity to strand breakage by CC-1065; e.g., ♦ ♦ and ♦ ♦ ♦  are 1:102 and 1:103 dilutions, respectively, 
of a stock solution of CC-1065, which are the m aximum dilutions at which strand breakage is still observed. Symbols: I, TATA  box; II', 
II", and III'", 21-base repeat regions; II I ' and III" , 72-base repeat regions, (a) S trand breakage site tha t is enhanced by CC-1065 binding 
particularly between 1:102 and 1:103 drug dilutions of a CC-1065 stock solution (see also Figure 3). (b) Strand breakage in the poly(G) sequence 
present in the control. The intensity of this band is relatively weak and is not influenced by CC-1065 binding. A com parable band deriving 
from the other 72-bp repeat ( I II" )  has not been observed, (c) S trand breakage site at an apparent nondrug binding site. This site for strand 
breakage is absent in the control and is present only a t relatively high concentrations of CC-1065. The equivalent sequence in the other 72-bp 
repeat (III") is unaffected by CC-1065.
(Table I IB ) . I t  is  n o t  c le a r  a t  th is  t im e  w h a t  fa c t o r s  c a u s e d  
these even ts.
Sequence Specificity o f  CC-1065 within the Early Control 
Element o f  SV40 DNA. C C - 1 0 6 5  is  e x t r e m e ly  c y t o t o x i c  
(Bhuyan e t  a l . ,  1 9 8 2 ;  M a r t in  e t  a l . ,  1 9 7 8 ) .  A  p a r t ia l  e x p la ­
nation for th e  p o t e n c y  o f  th e  d r u g  m a y  b e  its  s p e c i f ic i t y  fo r  
sequences o f  D N A  t h a t  a r e  c o m m o n ly  fo u n d  in  c o n tr o l  e l e ­
ments (e .g ., th e  T A T A  b o x )  in  e u k a r y o t ic  D N A .
Figure 8 su m m a r iz e s  th e  p a tte r n  o f  C C - 1 0 6 5  b in d in g  to  th e  
early control e le m e n t  o f  S V 4 0  D N A .  T h e  tw o  p e r fe c t  2 1 -b a s e  
repeat regions c o n ta in  th e  m o s t  s e n s it iv e  C C -1 0 6 5  b in d in g  s ite s  
(5'AGTTA) so  fa r  d is c o v e r e d .  T h is  s a m e  s e q u e n c e  is  fo u n d  
elsewhere in  S V 4 0  D N A  a n d  a t  l e a s t  in  th e  c a s e s  e x a m in e d  
is a sen sitive b in d in g  s e q u e n c e  fo r  C C - 1 0 6 5 .  T h e  7 2 - b a s e  
repeat r eg io n s  c o n t a in  v e r y  s e n s i t iv e  C C - 1 0 6 5  b in d in g  s e ­
quences on o p p o s ite  s tr a n d s  th a t  a r e  o n ly  o n e  b a s e  p a ir  a p a r t  
(118 and 1 1 9 ) .  O f  th e  tw o  s e q u e n c e s ,  o n ly  th e  5 ' A A T T A  
(position 1 1 9 )  f i t s  th e  c o n s e n s u s  s e q u e n c e  e x a c t ly  a n d  m a y  
be the p referred  s i t e ,  s in c e  a l t h o u g h  s tr a n d  b r e a k a g e  c a n  b e  
detected a t a  1 0 5- fo ld  d i lu t io n  o f  C C - 1 0 6 5  o n  b o th  s tr a n d s ,  
the intensity o f  th e  b a n d  is m a r k e d ly  g r e a te r  fo r  th e  5 'A A T T A  
sequence.5
The T A T A  b o x  r e g io n  b e tw e e n  p o s it io n s  16  a n d  31 r e c e iv e s  
the greatest c o n c e n t r a t io n  o f  h it  s i t e s  in  th e  e a r ly  c o n tr o l  
element o f  S V 4 0  D N A  ( 1 0  h its  o u t  o f  3 2  p o s i t io n s ) .  T h e  tw o
4 In addition to th e seq u en ces  listed  in T a b le  IIB , en h a n ce d  strand  
breakage resulting from  C C -1 0 6 5  b in d in g  at d istan t sites  has a lso  been  
noted previously (see  d iscu ssion  o f  F igure 4 A ) .
5 We are hesitant to  p lace too  m u ch  em p h a sis  on th is point s in ce  it 
isdifficult to relate intensities o f  bands on opp osite strands. Factors such  
as the location and nu m ber o f  o th er  C C -1 0 6 5  b in d ing s ites can  d ra ­
matically affect th e in ten sity  o f  a particu lar strand break.
m o s t  s e n s i t iv e  s it e s  to  C C - 1 0 6 5  b in d in g  w ith in  th is  r e g io n  a r e  
5 'A A T T A  a n d  5 'A A T A A . F u r th e r m o r e , w e  c a n  c o n c lu d e  th a t  
o f  th e s e  tw o  b in d in g  s it e s ,  th e  5 ' A A T T A  s e q u e n c e  is  th e  m o r e  
s e n s i t iv e  to  C C - 1 0 6 5 .  T h is  c o n c lu s io n  is  b a s e d  u p o n  tw o  
o b s e r v a t io n s . F ir s t , th is  b in d in g  s it e  w ill  o n ly  b e  e v id e n t  i f  th e  
a l t e r n a t iv e  b in d in g  s it e  ( i .e . ,  5 ' A A T A A )  n e a r e r  to  th e  5 ' 32P  
la b e l is n o t  o c c u p ie d  s in c e  c le a v a g e  a t  th e  la tte r  s ite  w o u ld  le a d  
to  t h e  5 ' A A T T A  b e in g  in  a  n o n r a d io a c t iv e  a n d  th u s  u n d e ­
t e c t a b le  m o le c u le .  S e c o n d ,  s i t e  e x c lu s io n  is  a b s o lu t e  a t  th e  
5 'A A T T A  b in d in g  s it e  w h e r e a s  a t  th e  5 ' A A T A A  b in d in g  s it e  
a lm o s t  e q u a lly  s e n s it iv e  b in d in g  s it e s  o c c u r  w ith in  th e  d is ta n c e  
e x p e c te d  to  b e  o c c u p ie d  b y  C C - 1 0 6 5 .  W e  s u g g e s t  th a t  a f t e r  
th e  5 'A A T T A  s ite  is o c c u p ie d , o th e r  b in d in g  s ite s  fo r  C C -1 0 6 5  
a r e  n o t  s o  s t r ic t ly  e n fo r c e d .  W e  a r e , h o w e v e r , u n a b le  a t  th is  
t im e  to  o f f e r  a  Firm  r a t io n a l iz a t io n  a s  to  w h y  th e  a d e n in e s  o f  
1 8 , 2 3 ,  a n d  2 4  a r e  s o  u n r e a c t iv e  to w a r d  C C - 1 0 6 5 .  C o n c e iv ­
a b ly ,  e n d - t o - e n d  c lu s t e r in g  o f  C C - 1 0 6 5  m o le c u le s  m a y  b e  
fa v o r e d .  In  th is  w a y ,  b in d in g  a t  a p p r o x im a t e ly  5 - b a s e - p a ir  
in te r v a ls  m a y  b e  fa v o r e d  a n d  t h e r e b y  r e d u c e  th e  l ik e l ih o o d  
o f  b in d in g  to  t h e s e  p a r t ic u la r  a d e n in e s .
D i s c u s s i o n
T h e  r e s u lt s  d e s c r ib e d  in  th is  p a p e r  p r o v id e  im p o r ta n t  n e w  
in fo r m a tio n  o n  th e  in te r a c t io n  o f  C C - 1 0 6 5  w ith  D N A  a n d  th e  
s e l e c t iv i t y  w ith  w h ic h  C C - 1 0 6 5  is  a b le  to  d is c e r n  s e q u e n c e -  
d e p e n d e n t  fe a tu r e s  in  D N A .  T h e  r e su lts  o b ta in e d  th r o u g h  th is  
s tu d y ,  ta k e n  t o g e th e r  w ith  th e  p r e v io u s ly  a c q u ir e d  s tr u c tu r a l  
in fo r m a t io n  o n  th e  C C - 1 0 6 5 - D N A  a d d u c t ,  p r o v id e  a n  e x ­
c e l le n t  b a s is  to  p o s tu la t e  a m o d e l  fo r  th e  s p e c i f ic  in te r a c t io n  
o f  th is  d r u g  w ith  D N A .
Structural M odification o f  DNA by CC-1065 following  
Chemical and Enzymatic Treatment o f  the CC-1065-DNA  
Adduct. R e s id u a l  m o d if ic a t io n s  o f  D N A  b y  C C - 1 0 6 5  fo l-
R E A C T I O N  O F  A N  A N T I T U M O R  A G E N T  W I T H  D N A V O L .  2 4 ,  N O .  2 2 ,  1 9 8 5  6235
Table II: Negative Analysis of CC-1065 Binding Sequences in
Select Regions of SV40 DNA and T7
(A) Consensus Sequences That Fail To Bind CC-1065
DNA sequence flanking the expected
(designated ])* adenine covalent binding
position0 site
SV40 27 and 28 ♦ . * ♦
♦ ♦ ♦ * 1 1 ♦
♦ ♦ ♦ ♦ X 1  ♦♦ ♦ ♦ ♦ T T ♦
5' A A A A A A A A T T ^ G  
1 ♦
▼ ♦
5' T G R G T T T  A A A A T
SV40 3909
(B) DNA Sequences in Which CC-1065 Induced Strand Breakage
That Was Unexpected
DNA sequence flanking the unexpected base















5' C C C A G G C T C C C C A G C
SV40 1020
SV40 158
°See footnote to Table I. *The diamonds (♦ ) indicate the position
and sensitivity of CC-1065 binding sites (see legend to Figure 8). cThe
diamonds (♦ ) indicate the position of DNA strand breakage induced
by CC-1065.
lo w in g  th e r m a l,  p ip e r id in e , a n d  A P  e n d o n u c le a s e  II  tr e a tm e n t  
c a n  o n ly  b e  d e t e c t e d  o n  o n e  s tr a n d  a n d  in c lu d e  th e  th e r m a l ly  
in d u c e d  s t r a n d  b r e a k  a n d  t h e  A P  s i t e .  T h e  D N A  s tr a n d  
b r e a k a g e  p r o d u c e d  a s  a r e s u lt  o f  th e r m a l  t r e a t m e n t  o f  C C -  
1 0 6 5 - D N A  a d d u c t s  is  l o c a t e d  in  c lo s e  p r o x im it y  to  th e  c o ­
v a le n t  b in d in g  s it e .  S in c e  b o th  e v e n t s  ( A P  s it e  fo r m a t io n  a n d  
D N A  s tr a n d  b r e a k a g e )  a r e  in d u c e d  d u r in g  th e r m a l tr e a tm e n t  
o f  t h e  C C - 1 0 6 5 - D N A  a d d u c t ,  i t  s e e m s  l ik e ly  t h a t  t h e y  a r e  
b o t h  r e la t e d  to  th e  s a m e  le s io n .  T h e  d a t a  s u g g e s t  t h a t  m o s t  
l ik e ly  a s in g le  /3 -e l im in a t io n  a t  t h e  C C - 1 0 6 5 - m o d i f i e d  d e o x -  
y a d e n o s in e  p r o d u c e s  a  b a c k b o n e  s tr a n d  b r e a k  y ie ld in g  a  5 '-  
p h o s p h a t e  a n d  a  S ' - m o d if ie d  d e o x y r ib o s e .  S i g n i f ic a n t l y ,  
s u b s e q u e n t  t r e a t m e n t  w ith  p ip e r id in e  o r  A P  e n d o n u c le a s e  o f  
th e  p r e v io u s ly  t h e r m a lly  c le a v e d  C C - 1 0 6 5 - D N A  a d d u c t  d o e s  
n o t  r e v e a l  new b in d in g  s i t e s  fo r  C C - 1 0 6 5  t h a t  w e r e  n o t  p r e ­
v io u s ly  r e v e a le d  b y  t h e r m a l  t r e a t m e n t  a lo n e .  W e  in te r p r e t  
th is  to  m e a n  th a t  all A P  s it e s  p r o d u c e d  a s  a  r e s u lt  o f  th e r m a l  
t r e a t m e n t  o f  t h e  C C - 1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  a d d u c t  a r e  
a c c o m p a n ie d  b y  s tr a n d  b r e a k a g e  a t  a n  a d j a c e n t  o r  n e a r b y  
p o s i t io n s .
Effect o f  the CC-1065-DNA Adduct on the Reactivity o f  
DNA at Sites outside the Immediate Drug Binding Region. 
P r e v io u s  s tu d ie s  h a v e  s h o w n  th a t  C C - 1 0 6 5  p r o d u c e d  d r a m a tic  
s t a b i l iz a t io n  o f  D N A  u p o n  d r u g  b in d in g . F o r  e x a m p le ,  C C -  
1 0 6 5 - D N A  a d d u c t s  h a v e  s ig n if ic a n t ly  e le v a te d  m e lt in g  t e m ­
p e r a t u r e s  a n d  a r e  fa r  le s s  s u s c e p t ib le  to  d ig e s t io n  b y  S I  n u ­
c le a s e  a n d  in te r c a la t io n  b y  e th id iu m  b r o m id e  (S w e n s o n  e t  a l .,
1 9 8 2 ) .  S e v e r a l  o b s e r v a t io n s  m a d e  d u r in g  th is  in v e s t ig a t io n  
s u p p o r t  t h e  c o n c e p t  t h a t  C C - 1 0 6 5  c a n  e x e r t  s t a b i l i z in g  a n d  
t e le s ta b i l i ty  e f f e c t s  ( W e l ls ,  1 9 7 7 ) .  A s  n o te d  in  F ig u r e  8 (n o te s  
a  a n d  c ) ,  th e r e  a r e  tw o  s tr a n d  b r e a k a g e  s it e s  in  D N A  th a t  a r e
in f lu e n c e d  indirectly b y  C C - 1 0 6 5  b in d in g  a t  d is ta n t  positions. 
In o n e  c a s e  ( n o t e  a in  F ig u r e  8 ) ,  e n h a n c e m e n t  o f  background 
s tr a n d  b r e a k a g e  o c c u r s  a t  h ig h e r  d r u g  b in d in g  ratios of 
C C - 1 0 6 5 ,  w h ile  in th e  se c o n d  c a se  (n o te  b  in  F ig u re  8), a DNA 
s tr a n d  b r e a k a g e  p o s itio n  o c c u r s , p r e su m a b ly  a t a non-CC-1065 
b in d in g  p o s i t io n ,  th a t  is  a b s e n t  in th e  n o n -d r u g -tr e a te d  lane. 
In  b o th  c a s e s ,  d e s t a b i l iz a t io n  o f  th e  h e lix  is o c c u r r in g  at sites 
r e m o te  fr o m  th e  p r im a r y  d r u g  b in d in g  s ite  (te le s ta b ility  effect).
Sequence Specificity o f  CC-1065. T h e  p r im e  purpose be­
h in d  s e l e c t in g  t h e  e a r ly  p r o m o te r  e le m e n t  o f  S V 4 0  DNA as 
t h e  t a r g e t  fo r  d e t e r m in in g  t h e  D N A  s e q u e n c e  specificity of 
C C - 1 0 6 5  w a s  to  in v e s t ig a t e  th e  p o s s ib i l i t y  th a t  th is region 
m ig h t  c o n t a in  a  b io lo g ic a l ly  im p o r ta n t  s e q u e n c e  that was 
e x q u is i t e ly  s e n s i t iv e  to  C C - 1 0 6 5 .  O u r  p r io r  k n ow led ge  that 
C C - 1 0 6 5  s h o w e d  h ig h  s p e c i f ic i t y  fo r  A T  p o ly m e r s  (Swenson 
e t  a l . ,  1 9 8 2 )  s u g g e s t e d  th a t  t h e  T A T A  b o x  m ig h t  be a prime 
t a r g e t  fo r  C C - 1 0 6 5 .  W h i le  th e  T A T A  b o x  reg io n  received 
m u lt ip le  h it s  b y  C C - 1 0 6 5  ( 1 0  p o s s ib le  b in d in g  s ite s  in a 16- 
b a s e -p a ir  r e g io n , w h ic h  is c o n s id e r a b ly  m o r e  th a n  the number 
th a t  a n y  o th e r  c o m p a r a b ly  s iz e d  s e q u e n c e  rece iv es  that we have 
e x a m in e d ) ,  o th e r  s e q u e n c e s  a p p e a r  to  h a v e  m o re  sensitive 
C C - 1 0 6 5  b in d in g  s i t e s ,  e .g . ,  th e  5 ' A G T T A  seq u en c e  in the 
2 1 -b p  r e p e a t  ( s e e  F ig u r e  8 ) .  A  n e g a t iv e  a n a ly s is  o f  the DNA 
s e q u e n c e s  s c r e e n e d  fo r  C C - 1 0 6 5  b in d in g  s it e s  reveals that the 
la c k  o f  C C - 1 0 6 5  b in d in g  s ite s  w ith in  o th e r  S V 4 0  and T7 DNA 
r e g io n s  c a n  b e  e x p la in e d  b y  th e  a b s e n c e  o f  appropriate se­
q u e n c e s .  F u r th e r m o r e , th e r e  a r e  n o  c o n s e n s u s  sequences that 
fa il  to  b in d  d r u g  e x c e p t  w h e r e  s ite  e x c lu s io n  b y  higher affinity 
b in d in g  s i t e s  e x is t s  a t  a d j a c e n t  s e q u e n c e s .
W h ile  th is  s tu d y  e s t a b l is h e s  th e  m o s t  s e n s i t iv e  binding se­
q u e n c e s  in  th e  r e s t r ic t io n  e n z y m e  f r a g m e n ts  exam ined for 
S V 4 0  a n d  T 7  D N A ,  it  is  im p o r ta n t  to  r e c o g n iz e  that the 
s e q u e n c e  s p e c if ic ity  m a y  a ls o  b e  d e p e n d e n t  u p on  the topology 
o f  t h e  s u b s tr a te .  F o r  e x a m p le ,  M ir a b e l l i  e t  a l. (19 83) have 
d e m o n s t r a t e d  th e  s ig n if i c a n t  e f f e c t  o f  c h a n g e s  in topological 
c o n f o r m a t io n  o f  D N A  o n  th e  s e q u e n c e - s p e c i f ic  breakage of 
D N A  b y  b le o m y c in  a n d  ta l is o m y c in . T h e r e fo r e , som e caution 
m u st b e  ta k e n  in  e x tr a p o la t in g  ou r  in v itro  lin ea r  D N A  results 
w ith  C C - 1 0 6 5  to  th e  in tr a c e l lu la r  a n d  a c tu a l  chromatin in­
t e r a c t io n s  w i t h  th is  d r u g .
Development o f  a M odel fo r  the CC-1065-DNA Adduct. 
T h e  e s t a b l is h e d  p r im a r y  s i t e  o f  c o v a le n t  b in d in g  o f  CC-1065 
th r o u g h  N 3  o f  a d e n in e  a t ta c h e s  th e  d r u g  m o le cu le  to the inside 
o f  th e  m in o r  g r o o v e  o f  D N A .  F u r th e r m o r e , th e  right-handed 
tw is t  o f  th e  C C -1 0 6 5  m o le c u le  p ro v id es  th e  d ru g  molecule with 
a  s u i t a b le  p i tc h  to  b e  a c c o m m o d a t e d  c o m fo r ta b ly  within the 
m in o r  g r o o v e  o f  B - fo r m  D N A .  C o m p e t it io n  experiments with 
n e tro p sin  a n d  a n th r a m y c in  ( s e e  th e  in tro d u ctio n ) support these 
f in d in g s . C P K  m o d e ls  o f  th e  C C -1 0 6 5 -(N 3 -a d e n in e )-D N A  
a d d u c t  p r e d ic t  th a t  th e  d r u g  m o le c u le  sh o u ld  cover about five 
b a s e  p a ir s . H o w e v e r ,  s in c e  o n ly  th e  r e la t iv e  stereochemistry 
a t  C 3 b  a n d  C 4 a  is  k n o w n  fr o m  X - r a y  crysta llograp h y  (Chi- 
d e s te r  e t  a l . ,  1 9 8 1 ) ,  th e  p o la r ity  o f  th e  d r u g  m olecule in the 
m in o r  g r o o v e  in  r e fe r e n c e  to  th e  c o v a le n t  b in d in g  site cannot 
b e  p r e d ic te d . T h e  d a ta  p r e se n te d  in  T a b le  I confirm  the CPK 
m o d e l  p r e d ic t io n  th a t  C C - 1 0 6 5  s h o u ld  sp a n  about five base 
p a ir s , s in c e  th is  is th e  e x te n t  o f  th e  D N A  seq u en ce  specificity 
( i .e . ,  5 ' P u N T T A  a n d  5 ' A A A A A ) .  F u rth er m o r e , the strict 
o r ie n t a t io n  o f  th e  s e q u e n c e  s p e c i f ic i t y  to  th e  5' side of the 
a d e n in e  c o v a le n t  b in d in g  s i t e  in  b o th  s u b c la s s e s  is predictive 
o f  th e  p o la r ity  o f  d r u g  b in d in g  in  th e  m in o r  groove. The CPK 
m o d e l o f  th e  C C - 1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  adduct can only 
b e  a c c o m m o d a t e d  to  a g r e e  w ith  th e  p o la r ity  o f  drug binding 
i f  th e  s te r e o c h e m is tr y  a t  th e  C 4  p o sitio n  o f  th e  CC-1065-DNA 
a d d u c t  m o le c u le  is R. T h e r e fo r e , th e  a b so lu te  stereochemistry






figure 9: Stereo drawings of the C C -1065-D N A  adduct. Key: A, B, and C are the subunits of CC-1065; A ' is the adenine covalent binding 
site for CC-1065; B' is a pair of highly conserved bases immediately to the 5' side of the adenine covalent binding site; C ' is a pair of less well 
conserved bases at the 5' end of CC-1065 binding site. The base sequence from top to bottom is 5 'C G G A G TTA G G 3'. For readers having 
difficulty visualizing this figure in three dimensions, the use of stereo glasses is recommended.
of CC-1065 m u s t  b e  C 3b(R ),C 4a(S). T h is  is  i l lu s t r a t e d  in  
Figure 1. T o  o u r  k n o w le d g e ,  th is  is  th e  f ir s t  t im e  th a t  D N A  
has been u se d  a s  a c h ir a l  r e a g e n t  to  d e t e r m in e  th e  a b s o lu t e  
stereochemistry o f  a s e c o n d  m o le c u le .  A n  in te r e s t in g  c o n s e ­
quence of th e  c o n s tr u c t io n  o f  a  C C - 1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  
adduct in w h ic h  th e  u n n a tu r a l  a n t ip o d e  o f  C C - 1 0 6 5  [C 3 b -  
(S),C4a(/?)] is  u se d  is  th a t  th e  s e q u e n c e  s p e c i f ic i t y  s h o u ld  l ie  
to the 3' s id e  o f  th e  a d e n in e  c o v a le n t  b in d in g  s it e  r a th e r  th a n  
the 5' side as is th e  c a s e  w ith  th e  n a tu r a lly  o c c u r r in g  a n t ip o d e .  
Model of the CC-1065-(N 3-Adenine)-D N A Adduct and 
Its Use To Rationalize the Chemical and Biological Conse­
quences of CC-1065 Binding to DNA. F o l lo w in g  th e  c o n ­
struction o f  th e  C P K  m o d e l  o f  th e  C C - 1 0 6 5 - ( N 3 - a d e n i n e ) -  
DNA addu ct, a n  E v a n s  a n d  S u t h e r la n d  c o m p u t e r  g r a p h ic s  
system w as u s e d  to  p r e p a r e  a  p a ir  o f  s t e r e o  d r a w in g s  o f  th e  
same adduct. T h e  d o c k in g  w a s  c a r r ie d  o u t  b e tw e e n  th e  D N A  
sequence 5 'C G G A G T T A G G  a n d  t h e  c y c lo p r o p a n e  r in g  o p ­
ened C C -1065 m o le c u le  d e p ic te d  in  F ig u r e  2 . T h e  c o o r d in a te s  
of the D N A  m o le c u le  w e r e  t a k e n  fr o m  a  p r o g r a m  p r e p a r e d  
by Arnott ( 1 9 7 2 ) ,  w h i le  th e  c o o r d in a t e s  o f  th e  m o d if ie d  
CC-1065 w ere  ta k e n  p r e d o m in a n t ly  fr o m  th e  X - r a y  s tr u c tu r e  
prepared by C h id e s te r  e t  a l. ( 1 9 8 1 ) .  A f te r  th e  c o v a le n t  l in k a g e  
between C 4  o f  C C - 1 0 6 5  a n d  N 3  o f  a d e n in e  w a s  fo r m e d , th e  
conformations a b o u t  th e  a m id e  l in k a g e s  b e t w e e n  s u b u n it s  A  
and B and b e tw e e n  su b u n its  B  a n d  C  w e r e  a d ju s te d  to  r e d u c e  
the number o f  c lo s e  c o n ta c ts  b e tw e e n  th e  D N A  a n d  C C - 1 0 6 5  
toa minimum. T h e  s te r e o  d r a w in g s  o f  th is  a d d u c t  a r e  s h o w n  
in Figure 9.
Both the C P K  m o d e l  a n d  th e  s t e r e o  d r a w in g s  o f  th e  C C -  
1065-DNA a d d u c t  r e v e a l  a  r e m a r k a b ly  s n u g  f i t  o f  th e  d r u g  
molecule w ith in  th e  m in o r  g r o o v e  o f  D N A .  C C - 1 0 6 5  s p a n s  
the five-base-pair r e g io n  s p e c i f ie d  b y  th e  C C - 1 0 6 5  D N A  s e ­
quence sp e c ific ity . A  c a r e fu l  e x a m in a t io n  o f  th e  C P K  m o d e l  
reveals that th e  flo o r  o f  th e  m in o r  g r o o v e  is in  c lo s e  p r o x im ity  
to the inside e d g e  o f  th e  C C - 1 0 6 5  m o le c u le .  T h e  w id th  a n d  
depth of the m in o r  g r o o v e  a p p e a r  ju s t  s u f f ic ie n t  fo r  C C - 1 0 6 5  
in be a c c o m m o d a te d  w ith o u t  d is r u p t io n  o f  th e  h e l ix  o r  p r o ­
trusion o f the d r u g  m o le c u le  o u t s id e  o f  th e  m in o r  g r o o v e . T h e  
doseness o f  th e  f it  o f  C C - 1 0 6 5  w ith in  th e  m in o r  g r o o v e  o f
D N A  is p r e d ic t iv e  o f  th e  c o n s id e r a b le  D N A  s e q u e n c e  s p e ­
c i f i c i t y  e x h ib i t e d  b y  C C - 1 0 6 5 .  W e  s p e c u la t e  th a t  a  la y e r  o f  
w a t e r  m o le c u le s  c o u ld  b r id g e  th e  h y d r o p h i lic  s u b s t i t u e n t s  o n  
th e  o u t s id e  e d g e  o f  C C - 1 0 6 5  w ith  p h o s p h a te  g r o u p s  o n  D N A .  
T h is  w o u ld  p r o v id e  a d d i t io n a l  s t a b i l i z in g  in t e r a c t io n s  t h a t  
w o u ld  in h ib it  b o t h  D N A  m e lt in g  a n d  in t e r c a la t io n  o f  o th e r  
a g e n t s  in  th e  v ic in it y  o f  th e  C C - 1 0 6 5  b in d in g  s i t e .  W h ile  
h y d r o g e n  b o n d in g  m a y  f a c i l i t a t e  s t a b i l i z a t io n  o f  t h e  C C -  
1 0 6 5 - D N A  a d d u c t ,  it  is  p r o b a b ly  n o t  in v o lv e d  in  th e  o r ig in a l  
b in d in g  m e c h a n is m  ( B r a i t h w a it e  &  B a g u le y ,  1 9 8 0 ) .
T h e  p r o x im ity  o f  s p e c i f ic  r e g io n s  o f  th e  C C - 1 0 6 5  m o le c u le  
to  g r o u p s  w ith in  th e  c h e m ic a lly  in te r a c t iv e  r a n g e  o n  th e  D N A  
m o le c u le  c a n  b e  u s e d  to  s p e c u la t e  o n  t h e  r e a s o n  fo r  th e  tw o  
su b c la s s e s  o f  D N A  b in d in g  se q u e n c e s . F ir st , th e  d a ta  in  T a b le  
I r ev e a l th e r e  is  a n  o v e r w h e lm in g  p r e fe r e n c e  fo r  A T  p a irs  o v er  
G C  p a ir s .  T h is  is  s im ila r  to  th e  d a t a  fo r  n e tr o p s in  a n d  d is -  
t a m y c in ,  w h ic h  a ls o  b in d  in  th e  m in o r  g r o o v e  b u t  w i t h o u t  a  
fo r m a l c o v a le n t  l in k a g e . T h e  sn u g  fit  o f  th e  C C - 1 0 6 5  m o le c u le  
a lo n g  th e  flo o r  o f  th e  m in o r  g r o o v e  is s u g g e s t iv e  th a t  th e  b u lk y  
2 - a m in o  g r o u p  o f  g u a n in e  m a y  d is c o u r a g e  b in d in g  v ia  s t e r ic  
in t e r f e r e n c e .  A  s t r ik in g  e x a m p le  o f  t h e  d r a m a t ic  e f f e c t  o f  
s u b s t itu t io n  o f  a  G C  p a ir  fo r  a n  A T  p a ir  o n  C C - 1 0 6 5  b in d in g  
t o  D N A  is  fo u n d  in  th e  S V 4 0  D N A  s e q u e n c e  b e t w e e n  p o s i ­
t io n s  5 1 8 0  a n d  5 2 0 2 ,  i .e .
♦ ♦
5'CAAAAGCCTAGGCCTCCAAAA AGCCT
In  th is  r e g io n  o n  S V 4 0  D N A ,  th e  b in d in g  s e q u e n c e  5 ' C A A A A  
is  o n ly  r e c e p t iv e  to  C C - 1 0 6 5  b in d in g  a t  d r u g  c o n c e n t r a t io n s  
1 0 3- f o ld  h ig h e r  th a n  th o s e  th a t  r e a c t  w ith  th e  v e r y  s im ila r  
b in d in g  s e q u e n c e  5 ' A A A A A .
T h e  d is c o v e r y  o f  th e  tw o  d i f f e r e n t  c o n s e n s u s  s e q u e n c e s  for  
C C - 1 0 6 5  b in d in g  s it e s  w a s  u n e x p e c te d .  A  c o m p a r is o n  o f  th e  
c o n s e n s u s  a n a ly s i s  in  p a r ts  A  a n d  B  o f  T a b le  I r e v e a ls  th a t  
i f  th e  b a s e  o n  th e  5 ' s id e  o f  th e  c o v a le n t ly  m o d if ie d  a d e n in e  
is  a n  a d e n in e  th e n  th e  n e x t  b a s e  w i l l  m o s t  l ik e ly  b e  a n o th e r  
a d e n in e  a n d  s im ila r ly  fo r  p a ir s  o f  t h y m in e s .  T h e  s p e c i f ic i t y  
fo r  th e  5 '-p r o x im a l p a ir  o f  b a s e s  in  b o th  c o n s e n s u s  s e q u e n c e s  
is  le s s  w e ll -d e f in e d .  T h e r e fo r e ,  it is p o s s ib le  to  c o n s id e r  th a t
R E A C T I O N  O F  A N  A N T I T U M O R  A G E N T  W I T H  D N A
t h e  c o n s e n s u s  s e q u e n c e  fo r  b o t h  s u b c la s s e s  o f  b in d in g  s i t e s  
c o n s is t s  o f  th r e e  b a s ic  u n its .  T h e  f ir s t  u n it  ( A ' )  a t  th e  3 ' e n d  
c o n s is t s  o f  t h e  a lk y la t io n  s i t e  fo r  C C - 1 0 6 5 ;  t h e  s e c o n d  u n it  
(B ')  is  a  p a ir  o f  h ig h ly  c o n s e r v e d  b a s e s  ( A A  o r  T T ) ;  th e  th ird  
u n it  ( C ' )  is  a  p a ir  o f  le s s  w e ll  c o n s e r v e d  b a s e s  ( A A  o r  P u N ) .  
E x a m in a t io n  o f  th e  s t e r e o  d r a w in g s  o f  t h e  C C - 1 0 6 5 - D N A  
a d d u c t  (F ig u r e  9 )  r e v e a ls  th a t  th e  th r e e  u n it s  (A ' ,  B ', a n d  C ')  
m a k in g  u p  th e  c o n s e n s u s  s e q u e n c e  o v e r la p  w ith  s u b u n i t s  A ,
B , a n d  C  o f  C C - 1 0 6 5 ,  r e s p e c t iv e ly .  S i n c e  th e  s u b u n it s  o f  
C C - 1 0 6 5  a r e  c o n n e c t e d  b y  a m id e  l in k a g e s ,  th e r e  is  s o m e  
f l e x i b i l i t y  in  th e  c o n f o r m a t io n a l  a n g le s  b e t w e e n  s u b u n it s  A  
a n d  B  a n d  b e tw e e n  s u b u n it s  B  a n d  C . M o r e o v e r , th e  r ig id ity  
w ith in  s u b u n it  B  o f  C C - 1 0 6 5  w h ic h  o v e r la p s  w ith  t h e  s e c o n d  
c o n s e n s u s  u n it  (B ')  w ill  s p e c ify  o n e  o f  a  p a ir  o f  h o m o d u p le x e s  
( A A  o r  T T ) ,  d e p e n d in g  u p o n  t h e  c o n f o r m a t io n a l  a n g le  b e ­
t w e e n  s u b u n i t s  A  a n d  B  a n d  b e t w e e n  s u b u n it s  B  a n d  C .  
P r e su m a b ly , th e  s te r ic  in te r a c tio n s  p r e se n ted  b y  a  h e te r o d u p le x  
c o n s is t in g  o f  5 'A T  o r  5 'T A  a r e  le s s  fa v o r a b le .  F r o m  th e  d a ta  
in  T a b le  I , th e  o r d e r  o f  p r e fe r e n c e  fo r  u n it  B ' fo r  in te r a c t io n  
w ith  C C - 1 0 6 5  is  5 'T T  >  5 'A A .  T h e  le s s  s tr ic t  p r e fe r e n c e  fo r  
c o n s e n s u s  u n it  C' m a k e s  a  s im ila r  a n a ly s i s  a s  c a r r ie d  o u t  fo r  
u n it  B ' le s s  in f o r m a t iv e .
W h ile  t h e s e  r e s u lts  d o  n o t  d ir e c t ly  p r o v id e  a  s in g le  r a t io n a l  
b a s is  to  e x p la in  t h e  e x t r e m e  c y t o t o x i c  p o t e n c y  o f  C C - 1 0 6 5 ,  
a t  le a s t  th r e e  p o s s ib i l i t ie s  c a n  b e  s u g g e s t e d .  T h e  r e m a r k a b le  
D N A  s e q u e n c e  s p e c i f ic ity  o f  C C - 1 0 6 5  m ig h t  le a d  t o  s e le c t iv e  
r e a c t io n s  w ith  a  c r i t ic a l  t a r g e t  w ith in  D N A .  A l t h o u g h  s u c h  
a  t a r g e t  is  s t i l l  u n c le a r ,  w e  a r e  s c r e e n in g  la r g e r  p o r t io n s  o f  
D N A  fo r  s u c h  b in d in g  s it e s .  A l t e r n a t iv e ly  (o r  a d d i t io n a l ly ) ,  
C C - 1 0 6 5  m ig h t  a l t e r  D N A  h e l ix  o r  c h r o m a t in  s tr u c tu r e  a n d  
a f f e c t  g e n e  e x p r e s s io n  a t  c r i t ic a l  s i t e s  s o m e  d is t a n c e  fr o m  th e  
a c t u a l  d r u g  b in d in g  p o s i t io n .  F in a l ly ,  t h e  C C - 1 0 6 5 - D N A  
a d d u c t  m a y  r e p r e s e n t  a n  in t r a c t a b le  l e s io n  to  D N A  r e p a ir  
e n z y m e  p r o c e s s e s  o r  o n e  t h a t  r e s u l t s  in  d e t r im e n t a l  r e p a ir  
a n d / o r  t h e  p r o d u c t io n  o f  a  l e t h a l  l e s io n  in  D N A .  S o m e  o f  
t h e s e  p o s s ib i l i t ie s  a r e  p r e s e n t ly  b e in g  e x p lo r e d  in  o u r  la b o r a ­
to r ie s .
A c k n o w l e d g m e n t s
W e  t h a n k  R a y m o n d  B e n a v id e s  fo r  e x c e l l e n t  t e c h n ic a l  a s ­
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Sequence Specificity of DNA Alkylation by the Unnatural 
Enantiomer of CC-1065 and Its Synthetic Analogues
Laurence H. H urley,*1* Martha A. W arpehoski,*16 Chong-Soon Lee,1*
J. Patrick McGovren,lb Terrence A. Scahill,lb Robert C. Kelly,lb M ark A. M itchell,lb 
Nancy A. W icnienski,lb Ilse Gebhard,lb Paul D. Johnson,lb and V. Susan Bradford16
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Abstract (-)-CC-1065, the unnatural enantiomer of the potent and sequence-selective, DNA-reactive antibiotic, (+)-CC-1065, 
was prepared by synthesis and its covalent reaction with DNA was studied and compared to that of the natural product. Although 
(-)-CC-1065 also formed covalent adducts in which the cyclopropyl carbon was bonded to the N3 atom  of adenine, and the 
thermal strand breakage that it produced paralleled that seen for (+)-CC-1065, it lay in the opposite direction along the minor 
groove and exhibited a m arkedly different sequence requirem ent for the covalently modified adenine. W hile (-)-C C -1065 
and its full carbon framework analogue, (-)-A B 'C ', reacted readily at adenines near to, but generally distinct from, (+ )- 
CC-1065-reactive adenines and exhibited potent cytotoxicity, their simpler analogues did not alkylate DNA under the conditions 
employed and were biologically nonpotent. A t relatively high concentrations, the smallest such analogue, (-)-A , reacted detectably 
only a t the same sites selected by (+ )-C C -1065. An analysis of the reactivity patterns of (+ )-  and (-)-C C -1065  and their 
analogues with D NA  restriction fragm ents supported the conclusion that the mode of sequence recognition for (-)-C C -1065 
adduct formation is fundam entally different from tha t of (+)-C C -1065 and is primarily controlled by specific minor groove, 
AT-selective binding interactions, rather than by sequence requirements of the covalent step, as occurs for (+ )-C C -1065 and 
the (+ )-C P I analogues. Models are proposed comparing the interactions of the enantiom eric alkylating moieties variously 
oriented in the minor groove a t potential reaction sites. The evolutionary significance of both the alkylating moiety and the 
minor groove binding segments of the natural product is discussed.
The concept o f D N A  as a ta rget of d rug  action  has undergone 
considerable refinem ent in recent years, as in fo rm ation  accrues 
on the range of s truc tu ra l and dynam ic diversity available to this 
critical biomacromolecule.2 In particu lar, drugs and  carcinogens 
that react with nucleic acid bases in D N A  to form covalent adducts 
have been found to exhibit som etim es rem arkab le  discrim ination 
toward the sequence contexts o f th e  bases undergoing  m odifica­
tion.3"7 The m echanism s m ediating  th is recognition  o f specific 
sequences of D N A  by sm all m olecules m ay include sequence- 
dependent m olecular e lec tro s ta tic  po ten tia l,4* confo rm ational 
flexibility,56 ca ta ly tic  functional g roup  jux tapositions,6 and  pre- 
covalent binding affin ities .7
Our previous w ork w ith C C -1065 , an  ex trem ely  po ten t an ti- 
tumor antibiotic produced by S trep to m yces  z e le n s is f9 revealed 
a DNA alkylating agen t ex trao rd in a ry  bo th  for th e  base-het- 
eroatom specificity and  th e  sequence selectiv ity  o f its covalent 
reaction with double-helical D N A .10 T h e  C C -1065  m olecule 
consists of th ree repeating  pyrrolo indole subun its , one o f w hich 
(the CPI, or cyclopropyljoyrroloindole subun it) contains a  poten­
tially reactive cyclopropyl fun c tio n .11 N a tu ra lly  occurring
(1) (a) U n iversity  o f  T ex a s , (b )  T h e  U p jo h n  C o.
(2) (a) D ick erson , R. E. J. M ol. B iol. 1983, 166, 4 1 9 . (b )  C a lla d in e , C . 
R.). Mol. Biol. 1982,161, 3 4 3 . ( c )  D ick er so n , R. E .; K op k a , M. L.; P jura, 
P. E. In D N A -L igan d  In teraction s. From  D ru gs to  Proteins-, G u sch lb a u er , 
W., Saenger, W ., Eds.; P len u m  Press; N e w  Y o rk , 1987; pp  4 5 - 6 2 .
(3) W arpehoski, M . A .; H u rley , L. H . C hem . R es. T ox ico l.  1988, / ,  3 1 5 .
(4) (a) K ohn, K . W .; H a r tle y , J. A .; M a tte s , W . B . N u cle ic  A cid s  R es. 
1987,15, 10531. (b )  B en a su tti, M .; E jad i, S .;  W h it lo w , M . D .; L o ech ler , E . 
L. Biochemistry 1988, 27, 472.
(5) (a) H ertzb erg , R . P.; H e c h t, S . M .; R ey n o ld s , V . L .; M o lin eu x , I. J.; 
Hurley, L. H . B ioch em istry  1986, 25, 1 2 4 9 . (b )  Z a k rze w sk a , K.; P u llm a n ,
B. J. Biomol. S tru c t. Dyn. 1986, 4, 127.
(6) Buckley, N . J. A m . Chem . Soc. 1987, 109, 7 9 1 8 .
(7) Baker, B. F.; D ervan , P. B. J. A m . C hem . S oc . 1989, 111, 2 7 0 0 .
(8) (a) H anka, L. J.; D ie tz , A .; G erp h eid e, S . A .; K u en tze l, S .  L.; M artin ,
D. G. J. A ntibiot. 1978, 31, 1211 . (b )  M a r tin , D . G .; C h id e ste r , C . G .; 
Duchamp, D . J.; M izsa k , S . A . J. A n tib io t. 1980, 33, 902.
(9) Reviews: (a )  R ey n o ld s, V . L.; M c G o v ren , J . P.; H u r ley , L. H . J. 
Amibiot. 1986, 39, 319 . (b )  H u r ley , L. H .; N e e d h a m -V a n D e v a n te r , D . R . 
Ac. Chem. Res. 1986, 19, 2 30 .
(10) (a) H u rley , L. H .; R ey n o ld s, V . L .; S w e n so n , D . H .; P e tzo ld , G . L.; 
Scahill, T. A . Science  1984, 226, 8 4 3 . (b )  R ey n o ld s , V . L .; M o lin eu x , I. J.; 
Kaplan, D. J.; S w en so n , D . H .; H u rley , L. H . B io ch em istry  1985, 24, 6 2 2 8 .
(11) C hidester, C . G .; K ru eger , W . C .; M izsa k , S . A .; D u c h a m p . D . J.;
Martin, D. G . J. A m . Chem . Soc. 1 981 , 103, 7 6 2 9 .
Scheme I. Reaction of (+)-CC-1065 with N3 of Adenine in DNA 
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C C -1065 has the  7b i? ,8aS  stereochem ical configu ra tion  o f the 
cyclopropane ring12 and  is d ex tra ro ta to ry  a t the  sodium  D line .13 
(+ )-C C -1065  binds strongly  and  reversibly in the  m inor groove 
o f A -T  regions in doub le-stranded  D N A  or duplex  o ligom ers14
(1 2 )  M artin , D . G .; K e lly , R . C .; W a tt, W .; W ic n ien sk i, N .;  M izsa k , S .
A .; N ie lse n , J. W .; P ra ir ie , M . D . J. Org. C hem . 1 9 8 8 , 53, 4 6 1 0 .
(1 3 )  K e lly , R . C .; G e b h a rd , I.; W ic n ien sk i, N .;  A r is to ff , P . A .; Joh n son , 
P. D .; M artin , D . G . J. A m . C hem . Soc. 1 9 8 7 , 109, 6 8 3 7 .
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Chart I. Structures of (+ )- and (-)-Cyclopropylpyrroloindole (CPI) 
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and then bonds covalen tly  to  th e  N 3  o f  ad en in e  in target seq u en ces, 
with opening o f  th e  c y c lo p r o p y l r in g  (S c h e m e  I ) . 10 T h e  r ea c ted  
molecule lies sn u g ly  w ith in  th e  m in or  g ro o v e  c o v e r in g  a fou r base  
pair region to  th e  5 '-s id e  o f  th e  c o v a le n t ly  m o d if ie d  a d e n in e .10,15 
Upon therm al tr e a tm e n t o f  ( + ) - C C - 1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  
adducts, c le a v a g e  o f  th e  N - g ly c o s id ic  l in k a g e  a n d  su b se q u e n t  
backbone break age occu rs to  th e  3 '-s id e  o f  th e  c o v a len tly  m o d ified  
adenine to lea v e  a 5 '-p h o sp h a te  o n  th e  3 '-s id e  o f  th e  b r ea k  an d , 
we presume, a m o d if ie d  d e o x y r ib o s e  on  th e  5 ' - s id e .10a U s in g  a 
heat-induced strand b rea k a g e  a ssa y  b a sed  on  th is  o b serv a tio n , w e  
determined th a t th e  m o st r e a c tiv e  a d e n in e s  in  a s e t  o f  d if fe r e n t  
DNA fr a g m en ts  w e r e  g e n e r a l ly  fo u n d  in  tw o  s e q u e n c e s ,  
5'AAAAA* or 5 'P u N T T A * , w h e r e  * in d ic a te s  th e  c o v a le n t ly  
modified adenine and N  in d ica tes a n y  o f  th e  fou r b ases in D N A .10b 
The c o n str u ctio n  o f  a  s i t e - d ir e c t e d  ( + ) - C C - 1 0 6 5 - ( N 3 -  
adenine)-DNA a d d u ct in a 11 7  b a se  p a ir  fr a g m e n t16 a llo w e d  us  
to determine th e  e f fe c t  o f  c o v a le n t  b o n d in g  o n  lo c a l D N A  
structure. A n a ly s is  o f  D N a s e  I fo o tp r in tin g  e x p e r im e n ts  an d  
restriction e n z y m e  c u t t in g  p a tter n s  u s in g  th e  D N A  fr a g m e n t  
containing th e  s ite -d ir e c te d  a d d u c t  d e m o n s tr a te d  th a t ( + ) - C C -  
1065 adduct fo r m a tio n  c o r r e la te s  w ith  an  a s y m m e tr ic  e f fe c t  on  
DNA structure that ex ten d s m ore than  o n e  h elix  turn to  th e  S'-side  
of the covalen t b o n d in g  s i t e .17
Despite th is  n ov el m e c h a n ism  o f  a c t io n  o f  ( + ) - C C - 1 0 6 5 ,  and  
its highly potent in v itr o 18 an d  in v iv o 19 a n titu m o r  a c tiv ity , c lin ica l  
development o f  th e  n atu ra l p ro d u ct w a s  p r ec lu d ed  b y  an  u n u su a l
(14) (a) S w enson , D . H .; L i, L. H .; H u r ley , L . H .; R o k e m , J . S .; P etzo ld , 
G. L.; Dayton, B. D .; W alla ce , T . L.; L in , A . H .; K rueger, W . C . Cancer R es. 
1982,42, 2821. (b ) K ru eger , W . C.; L i, L. H .; M o sc o w itz , A .; P ra ir ie , M . 
D; Petzold, G . L.; S w e n so n , D . H . B iopo lym ers  1 9 8 5 , 24, 1549 .
(15) Scahill, T . A .; Jen sen , R . M .; S w e n so n , D . H .; H a tz en b u h ler , N . T.; 
Petzold, G. L.; W ieren g, A . W .; B rah m e, N . M . B iochem istry  1 990 , 29, 2852 .
(16) N eed h am -V an D evan ter, D . R .; H u rley , L. H . B iochem istry  1 986 , 25, 
8430.
(17) Hurley, L. H .; N eed h a m -V a n D ev a n ter , D . R.; L ee , C .-S . Proc. N atl. 
Acad Sci. U .S.A . 1 987 , 84, 6 4 1 2 .
(18) (a) Li, L. H .; S w e n so n , D . H .; S ch p o k , S .; K u en tze l, S . L.; D a y to n ,
B.D.; Krueger, W . C . Cancer Res. 1982 , 42, 9 9 9 . (b ) B h u yan , B. K .; N ew e ll , 
K. A.; Crampton, S . L.; V on H o ff , D . D . C ancer R es. 1 9 8 2 , 42, 3 5 3 2 .
(19) Martin, D. G .; B iles, C .; G erp h eid e, S . A .; H an k a , L . J.; K rueger, W .
C.; McGovren, J. P.; M izsa k , S . A .; N e i l ,  G . L.; S te w a r t , J. C .; V isse r , J . J. 
Antibiot. 1981, 34. 1119.
to x ic ity , w h ich  led  to  d e la y e d  d e a th  in  m ic e  rec e iv in g  th e r a p e u tic  
d o se s .20 S y n t h e t ic  a n a lo g u e s  h a v e  b e en  p rep a red  th a t a r e  m o re  
e ffic a c io u s, d o  n ot c a u se  d e la y ed  d e a th , a n d  th a t, th ere fo r e , sh o w  
c o n s id e r a b le  p r o m ise  a s  c h e m o th e r a p e u t ic  a g e n t s .21 C h ir a lly  
reso lv e d  s y n th e t ic  a n a lo g u e s  a r e  sh o w n  in C h a r t  1.
L ik e  ( + ) - C C - 1 0 6 5 ,  a n a lo g u e s  o f  th e  lbR,SaS  c y c lo p r o p y l  
c o n fig u r a tio n  [ ( + ) - C P I  a g e n ts ]  r e a c t  w ith  d o u b le -h e l ic a l  D N A  
to  produce ad d u cts  th a t, on  th erm al trea tm en t, c a u se  strand breaks  
a t a lk y la te d  a d e n in e s .22 W e  r e c e n t ly  d e sc r ib e d  th e  u n e x p e c te d  
find ing th at an  a cety l-su b stitu ted  ( + ) - C P I  [ ( + ) - A ,  C h art I], w h ich  
sh o w s  l it t le  or n o  e v id e n c e  o f  th e  n o n c o v a le n t  b in d in g  to  D N A  
s o  c h a r a c te r is t ic  o f  ( + ) - C C - 1 0 6 5 ,  n e v e r th e le s s  h a s  s u f f ic ie n t  
str u ctu r a l in fo r m a tio n  to  m e d ia te  th e  s e q u e n c e  sp e c if ic ity  o f  th e  
e n tire  d ru g  m o le cu le , i.e ., ( + ) - A  p re fe re n tia lly  a lk y la te s  th e  sa m e  
se q u e n c e s  in  D N A  a s  d o e s  ( + ) - C C - 1 0 6 5 .23 T h is  s u g g e s ts  th a t  
th e  s e q u e n c e  s p e c if ic ity  o f  ( + ) - C C - 1 0 6 5  d e p e n d s , n o t o n  th e  
r e la t iv e  n o n c o v a le n t  b in d in g  a f f in i ty  o f  th e  d if fe r e n t  se q u e n c e s  
a s o r ig in a lly  th o u g h t ,10 b u t on  se q u e n c e -d e p e n d e n t s ite  r e a c tiv ity  
( i .e ., upon co v a len t b o n d in g  d y n a m ic s ) . It w a s  su g g e s te d  th a t th e  
p r im e  fu n c tio n  o f  th e  m id d le  a n d  r ig h t -h a n d  s e g m e n ts  in  th e  
( + ) - C P I  se r ie s  is to  in c r e a se  th e  e q u ilib r iu m  c o n s ta n t  fo r  n o n ­
sp ecific  reversib le in teraction  w ith  th e  m in or groov e  o f  D N A  w h ere  
a lk y la t io n  c a n  o c c u r , a c c o u n t in g  for  th e  d if fe r e n c e s  in a b so lu te  
r e a c tiv ity  a m o n g  th e  a n a lo g u e s .  S e v e r a l  s e q u e n c e s  in a n  S V 4 0  
fr a g m e n t th a t  r e a c te d  w ith  ( + ) - C C - 1 0 6 5  a n d  ( -P )-A B 'C ' fa ile d  
to  b e  a lk y la te d  b y  ( + ) - A B C ,  in d ic a t in g  th a t  s p e c if ic  r e v e r s ib le  
in ter a c tio n s  b e tw ee n  th e  in s id e  e d g e  o f  th e  B a n d  C  su b u n its  an d  
th e  floor o f  th e  m inor g ro o v e  o f  D N A  c a n  “m o d u la te  or fin e  tu n e ” 
th e  s e q u e n c e  s p e c if ic ity  o f  th e  ( + ) - C P I  s u b u n it .23
O n e  rem ark ab le  fea tu re  o f  th is stran d  b reak age  a ssa y  as app lied  
to  th e  ( + ) - C C - 1 0 6 5  a n a lo g u e s  w a s  th a t  th e  a b s o lu te  r e a c t iv ity ,  
ga u ged  by th e  con cen tration  o f  drug required  to  p roduce d e tec ta b le  
c lea v a g e  under g iven  in cu b a tio n  c o n d itio n s, correla ted  c lo se ly  w ith  
b io lo g ic a l  p o te n c y  ( in  v itro  c y to to x ic i ty  a n d  in  v iv o  to x ic  a n d  
th era p eu tic  d o se s ) .23 W e  h av e  p rev iou sly  reported  th e  p reparation  
o f  c h ir a lly  reso lv e d  s y n th e t ic  C C -1 0 6 5  a n a lo g u e s  ( + ) - A B C  a n d  
( - ) - A B C ,  a lo n g  w ith  th e  in te r e s t in g  o b se r v a tio n  th a t , w h ile  
( + ) - A B C  w a s  a  h ig h ly  p o te n t  a n d  e f f ic a c io u s  a n t itu m o r  a g e n t ,  
( - ) - A B C  w a s  e sse n tia lly  d ev o id  o f  b io lo g ica l a c t iv ity .218 W e  h av e  
a lso  d isc lo se d  th e  fir s t  s y n th e s is  o f  th e  u n n a tu r a l e n a n t io m e r  o f  
C C -1 0 6 5 ,  n a m e ly  ( - ) - C C - 1 0 6 5 ,  a n d  th e  su r p r is in g  o b se r v a tio n  
[in  v ie w  o f  th e  in a c t iv ity  o f  ( - ) - A B C ]  o f  its  e x tr e m e ly  p o te n t  
c y t o t o x ic i t y .13 O th e r  in v e s t ig a to r s  h a v e  r e c e n t ly  c o n f ir m e d  th e  
p o te n t c y to to x ic i ty  o f  s y n th e t ic  ( - ) - C C - 1 0 6 5  a n d , fu r th e r , h a v e  
reported  th a t th e  d id eh y d ro x y , d id e m e th o x y  c o m p o u n d  ( - ) - A B 'C '  
is l ik e w ise  a p o te n t  c y to to x in .24
W e  fe lt  th a t  th e se  o b se r v a tio n s  w a r r a n te d  a  s y s te m a t ic  s tu d y  
o f  th e  in tera ctio n s o f  ( - ) - C C - 1 0 6 5  a n d  its ( - ) - C P I  a n a lo g u e s  w ith  
D N A .  T h e  o b je c t  o f  th e  p r e se n t  s tu d y  w a s  to  e x p e r im e n ta lly  
d e te r m in e  [b y  m e th o d s  p r e v io u s ly  a p p lie d  to  ( + ) - C C - 1 0 6 5 ]  th e  
fo llo w in g : ( 1 )  th e  b a se  s p e c if ic ity  a n d  s tr u c tu r e  o f  th e  ( - ) - C C -  
1 0 6 5 - D N A  a d d u c t (s ) ;  ( 2 )  th e  n a tu r e  o f  th e  p r o d u c ts  o f  D N A  
stran d  c le a v a g e  r esu ltin g  fro m  th e se  a d d u cts;  (3 )  th e  o r ie n ta t io n  
o f  c o v a len tly  b on d ed  ( - ) - C C - 1 0 6 5  in th e  D N A  m in or  groov e; (4 )  
th e  s e q u e n c e  s p e c if ic ity  o f  ( - ) - C C - 1 0 6 5  a d d u c t  fo r m a tio n ;  a n d
( 5 )  th e  in f lu e n c e  o f  th e  m id d le  a n d  r ig h t -h a n d  s u b u n its  o n  th e  
reactiv ity  an d  seq u en ce  se lec tiv ity  o f  ( - ) - C P I  a lk y la tio n  o f  D N A .25 
F u ll e x p e r im e n ta l  d e ta i ls  fo r  th e  p r e p a r a tio n  o f  ( + ) -  a n d  ( - ) -  
C C -1 0 6 5  a n d  th e ir  a n a lo g u e s ,  a n d  p e r tin e n t b io lo g ic a l  d a ta  for
(2 0 )  M cG o v ren , J. P.; C la rk e , G . L .; P r a tt, E. A .; D eK o n in g , T. F. J. 
A n tib io t. 1984, 37, 6 3 .
(2 1 )  (a )  W a rp eh o sk i, M . A . T etrah edron  L ett. 1986, 27, 4 1 0 3 . (b )  
W arp eh osk i, M . A .; G eb h a rd , I.; K e lly , R . C .; K ru eger , W . C .; L i, L . H.; 
M cG ovren , J. P.; Prairie, M . D.; W icn ien sk i, N .;  W ieren ga , W . J. M ed. Chem. 
1988, 31, 5 9 0 . (c )  D eK o n in g , T . F.; K e lly , R . C .; W a lla c e , T . L.; L i, L . H. 
Proc. A m . A ssoc. C ancer R es. 1989, 30, 4 9 1 .
(2 2 )  S w e n so n , D . H .; P e tzo ld , G . L. U n p u b lish ed  resu lts .
(2 3 )  H u rley , L. H .; L ee , C .-S .;  M cG o v ren , J. P.; W a rp eh o sk i, M . A .;  
M itch e ll. M . A .; K e lly , R . C .; A r is to ff , P. A . B ioch em istry  1988, 27, 3 8 8 6 .
(2 4 )  B oger, D . L.; C o lem a n , R . S . J. A m . C hem . Soc. 1988, 110, 4 7 9 6 .
(2 5 )  S o m e  o f  th ese  resu lts  h ave been  p resen ted  in p re lim in ary  form ;
M cG ovren , J. P.; L ee , C .-S .;  H u rley , L. H .; L i, L . H .; K elly , R . C . Proc. A m . 
A ssoc. Cancer R es. 1987, 28, 2 6 2 .
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Scheme II. Synthetic Routes to Compounds Used in This Study
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(a) L-Trp(Boc). EDC. DMAP; (b) NaOH; (c) Red-AI; (d) Boc-ON; (e) 1) MsC!, pyr; 2) LiCI, DMF; 
(f) EDC, RCOOH; (g) MsCl. pyr; (h) LiCI. DMF; (i) N H /H C 0 2\  Pd'C; (j) HCI (gas); (k) Et3N, H20 . 
CH3CN.
these compounds, a re  provided.
Results
Synthesis. The starting m aterial (1, Schem e II) for the synthesis 
has been described previously in a full p ap er,21b and  the  details 
of the conversions to some of the final products have been disclosed 
in preliminary reports13’21® as has the resolution o f 1 to its natural 
and unnatural enantiom ers, 2 and 3, respectively .21®
In our previously described route to CC-1065 analogues through 
mesylate (e.g., 11) w ithout th e  in term ed iacy  o f the  ch loride,21 
problems were encoun tered  in the debenzylation  reaction . A t­
tempted hydrogenolysis of the  benzyl e ther under mild conditions 
often produced no reaction  and  under m ore forcing conditions 
resulted in num erous side reactions, including hydrogenolysis of 
the mesylate. A lternatively, cleavage of the  benzyl e ther with in 
situ generated trim ethylsilyl iodide26 proceeded m ore dependably 
but always generated  a m u ltitude  o f unknow n byproducts in 
addition to the  desired spirocyclopropyl com pounds. T hese d if­
ficulties in the benzyl e th e r cleavage reaction  w ere avoided by 
conversion of the m esylate to the ch loride (e.g ., 11 to 12). The 
chlorides in general a re  both  m ore soluble and  m ore stab le  and 
these properties com bine to allow phase-transfer hydrogenolysis 
of the benzyl e ther to  proceed in reproducib le , high yield. T he 
stability of the chlorides carried  through to the next step and they 
gave no or only partial closure in the presence of a tertiary  amine 
in anhydrous solvents, conditions th a t readily  cyclized the m e­
sylates. S tronger bases such as N aH , K O -/-B u, or N aO M e gave 
substantial decom position when a ttem p ted  in the  cyclization. 
Happily, it was found th a t large excesses o f te r tia ry  am ine in
(26) O lah, G . A.; N aran g , S . C.; G u p ta , G . B.; M alhorta , R . J. Org. Chem. 
1979, 44. 1247.
highly aqueous solvents p roduce rap id , rep roducib le , and  high- 
yielding spirocyclization.
T he above procedure read ily  p roduced  a  w ide range  o f a n a ­
logues in excellent yield (40-60%  from  2 and 3) bu t suffered from 
two m ajor shortcom ings. I t required  five steps for each analogue 
(e.g., 2 —► 7  —► 10 —► 11 —► 15 —► A B C ) and it did not w ork w ith 
all the  desired  B and  C  subun its , includ ing  th e  P D E -I d im er of 
C C -1065. T he failure w ith P D E -I d im er was principally  due to 
the dehydration  o f th e  u rea  group  d u rin g  the  m esylation  or clo- 
rination  reaction . Both o f these prob lem s w ere avoided by first 
protecting 7 as its Boc derivative 8 and  carry ing  th is th rough  the 
mesylation, chlorination, and debenzylation chem istry to  13. The 
stability and improved solubility o f 8 and subsequent interm ediates 
resulted in improved yields and ease o f handling in all those steps. 
From  13, each analogue requ ired  only rem oval o f th e  Boc and  
coupling w ith the desired side-chain carboxylic acid, a ll o f which 
was done in one pot, followed by the spirocyclopropyl ring closure. 
T he overall yield from  12 for these  conversions ranged  from  60 
to 85% w ith the lower yield being for C C -1065 itse lf and  its 
enantiom er. In th is m anner, all th e  n a tu ra l and  enan tiom eric  
m aterials used in this study  w ere p repared  w ith th e  exception of 
(-F)-A BC, which was synthesized by th e  five-step procedure 
through 12. The (+ )-C C -1065 used in the experim ents with D N A  
was isolated as described previously.8,19
Schem e III sum m arizes our route to the dihydropyrroloindoles 
23 and 24 used in the synthesis o f (+ )-  and (-)-A B 'C ' as previously 
repo rted .27,28
( 2 7 )  W arpehoski, M . A .; Bradford, V . S . Tetrahedron Lett. 1986 , 27 , 2735 .
(2 8 )  W arpehoski, M . A .; B radford , V . S . T etrahedron L ett. 1 988 , 29, 131.
( 2 9 )  T h e  co n sen su s se q u e n c e  is a c o m p o s ite  se q u e n c e  d erived  by d e ter ­
m in in g  w h ich  o f  th e  n u c leo tid e  b ases  or b a se  c o m b in a tio n s  o ccu r  w ith  th e  
h igh est freq u en cy  a t a g iven  p osition  re la tiv e  to  th e  a lk y la te d  a d en in e.
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CHEMICAL SH IR  (PPM RELATIVE TO TMS)
figure 1. I3C  N M R  o f  ( - ) - C C - 1 0 6 5  (u p p e r  s p e c tr u m )  a n d  th e  ( - ) - C C - 1 0 6 5 - N 3 - a d e n i n e  a d d u c t  ( lo w e r  s p e c tr u m )  (p p m  r e la t iv e  to  T M S ) .
Scheme III. S y n th e t ic  R o u t e  to  B ' a n d  C '  S e g m e n t s
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r - 2 0  
22
R = H
U 21 R c Boc 3  01 R e CONH,
(a) CH3SCH2C 0 2Et. SC^C^, ProtonSponge, CHjC^, -78°; (b) Et^N; (c) HOac; (d) Lawesson's reagent; 
(e) Raney nickel; (f) BH3*SMe2, TEA, THF. 0°; (g) Boc-ON; (h) KOCN. HOAc. (i) LiOH
DNA Base Specificity of (-)-C C -1065  Alkylation and Structure 
of the Adduct. As with (+ )-C C -1065 , when (-)-C C -1 0 6 5 -D N A  
adducts were heated  a t 100 °C  for 30 m in, a m olecule w ith the 
CC-1065-like chrom ophore was ex trac tab le  in to  bu tanol. Each 
of the bases in L I 210 m ouse leukem ia cell D N A  was labeled 
separately by 3H -precurso r incorporation  and  then the  isolated
(30) For most D N A  fragm en ts , under th e  co n d itio n s  o f  D N A -d r u g  incu-  
taiion used, c leavage s ite s  a p p earin g  at low  d ru g  co n ce n tra tio n s  rem ain ed  
visible at higher drug con cen tra tion , w ith  a d d ition a l c lea v a g e  s ites  appearing. 
Aiiexception was th e ( - )  strand o f  th e 117 b ase pair M 1 3 m p l D N A  fragm ent 
mils reaction with (+ )-C C -1 0 6 5 . A t 2 .8 -2 8  n M  (+ ) -C C -1 0 6 5 , three c leavage  
sues were observed (se e  C h ar t II, b ottom  stra n d ). A t 2 8 0  n M  and  h igh er  
concentrations o f  (+ ) -C C - 1 0 6 5 , th ese  c lea v a g e  s ites  d isap p eared  and instead  
there appeared c lea v a g e  s ite s  2 5 - 3 0  b a se  pairs to  th e  3 '-s id e  o f  th e  in itia lly  
alkylated adenines, su g g e st in g  th a t th e in itia lly  a lk y la te d  fra g m en ts  w ere  
hyperreactive to su b seq u en t d ru g-in d u ced  c le a v a g e  a t th e  d istan t sites.
T a b le  I. R e a c t io n  o f  ( + ) - C C - 1 0 6 5  a n d  ( ~ ) - C C - 1 0 6 5  w ith  D N A  





dpm recovered in hot butanol extract
no drug (+)-C C -1065 (-)-C C -1065
A 165 000 31 2781 6891
T 153 000 18 0 0
G 34 000 0 11 126
C 146000 11 0 3
a In p r e l im in a r y  e x p e r im e n t s ,  c a . 85%  o f  D N A - a d d u c t e d  ( + ) - C C -  
1 0 6 5  a n d  ( - ) - C C - 1 0 6 5  a b s o r b a n c e  e q u iv a le n t s  w e r e  e x tr a c te d  in to  b u ­
ta n o l a f te r  h e a t in g  a t  1 0 0 ° ,  4 5  m in .
D N A  was reacted w ith either ( + ) -  or (-)-C C -1 0 6 5 , subjected to 
thermal treatment, and butanol-extracted. T he D N A  tha t released 
the predom inant am ount o f  tritium  had been prelabeled  w ith
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[3H]adenine (T able 1). A very sm all am oun t o f excess tr itium  
was also released from the sam ple labeled in the guanine nucleus, 
which, in the case of (-)-C C -1 0 6 5 , was 2% of the am ount o f the 
radioactivity released from  the [3H ]adenine-labeled  D N A . [The 
comparable figure for (+ )-C C -1065  was 0.5%.] T he significance 
of these results is unknow n.
In previous work w ith (+ )-C C -1 0 6 5  bound covalently  to  calf 
thymus DNA, a product was purified from a hot butanol ex tract 
and, on the basis o f ’H and  13C  N M R , was assigned th e  C C - 
1065-(N3-adenine) ad d u c t s tru c tu re  (Schem e I ) . ,0a A sim ilar 
experiment with (-)-C C -1 0 6 5  gave a p roduct th a t e lu ted  iden­
tically upon reversed-phase H P L C  with tha t previously found with 
(+)-CC-1065 (data not presented). T he ,3C  N M R  spectra of the 
purified product ob tained  from  (-)-C C -1 0 6 5  (F igu re  1) was in 
all respects identical with tha t obtained from the analogous product 
with (+)-CC-1065. Five aden ine signals in the  arom atic  region 
(121.5-155.9 ppm) correspond closely to the chemical shift values 
for 3-methyladenine.IOa T he resonance signals for C 4 and C 4a 
are downfield-shifted in accord  w ith a s tru c tu re  resu lting  from  
opening of the cyclopropyl ring. A rgum ents sim ilar to th a t m ade 
previously distinguish betw een the  assigned s tru c tu re  and the 
alternate one in which ring opening of the cyclopropane ring occurs 
at the more substituted carbon (C 4 a).31 C hem ical shift changes 
for C3b, C6a, C 7, C 8, and  C 8a in th e  C C -1 0 6 5 -(N 3 -ad en in e ) 
adduct are in accord w ith conversion of th e  cyclohexadienone to 
a phenol. 'H  N M R  spectra for (+ )-  and (-)-C C -1065  were also 
identical (data not p resen ted).
Identical adduct s tru c tu re  b u t w ith opposite stereochem istry  
was strongly supported by m irror-im age circular dichroism spectra 
of the (+ )- and (-)-C C -1 0 6 5  adducts w ith aden ine (d a ta  not 
presented).
Thermal and Piperidine Treatment o f CC-1065-Modified DNA  
Restriction Fragments. E lectrophore tic  analysis o f  3 '- and  5'- 
32P-Iabeled DNA reacted with (+ )-C C -1065 and then heat-treated 
has demonstrated th a t s trand  b reakage occurs on th e  3 '-side of 
the covalently m odified adenine. T he products o f th is reaction  
appear to be a 5 '-phosphate  on the  3 '-side of the  b reak  site and 
a modified sugar on the 5'-side. Consequently, therm al treatm ent 
of (+)-C C -1065-D N A  adducts on 3'-labeled D N A  leads directly 
to a product tha t m igrates a t a sim ilar position to the M axam  and 
Gilbert adenine sequencing reaction  p ro d u c t.106 H ow ever, w ith 
5'-labeled D N A  fragm ents, the  hea t cleavage p roduct m igrates 
at a higher molecular weight than  an adenine sequencing reaction 
product due to the presumed presence of the modified deoxyribose 
moiety (species A in S chem e I). U pon subsequent p iperidine 
treatment, a second reaction  (perhaps a /3-elim ination) leads to 
loss of the m odified sugar, resu lting  in a p roduct (species B in 
Scheme 1) which then  com igrates w ith th e  M axam  and  G ilbert 
adenine reaction .10
A comparison o f therm al in aqueous buffer and therm al in 
piperidine treatm ents o f (+ )-  and  (-)-C C -1065-m odified  5'- and 
3'-labeled D N A  fragm ents is shown in Figure 2. T he sam e D N A  
strand of the 117 base pair fragm en t w as e ither 3 '- or 5 '-32P-la- 
beled. Although (+ )-  and  (-)-C C -1 0 6 5  trea tm en t led to strand  
breakage at d ifferen t adenines, the  appearance  and  behavior of 
the bands were identical for each enantiom er. U sing 5 '-labeled 
DNA, therm al cleavage led to  pairs of closely m igra ting  bands 
(lanes 1 and 3). W e believe that the m ajor band observed a t higher 
molecular weight is the  therm al cleavage product still containing 
the modified sugar, w hile th e  m inor p roduct is a sm all am ount 
of the presumed second /3-elim ination product. Q uan tita tive  
conversion of the h igher m olecu lar w eight product to  the m inor 
product took place upon p iperid ine trea tm en t (lanes 2 and 4). 
Using 3'-labeled D N A , therm al treatm ent led directly to a product 
emigrating with an adenine sequencing reaction fragm ent (lanes 
5 and 7). M igration o f th is fragm ent was unchanged upon sub­
sequent piperidine treatm ent (lanes 6 and 8). Thus, the chem istry 
of strand b reakage o f bo th  (+ ) -  and  ( - ) -C C -1 0 6 5 -(N 3 -  
adenine)-DNA adducts seem s to  be purely a function o f N 3
5 ’- L a b e le d  DNA
(+K C -1Q 65 (-X C -1 0 6 5  
a  P 1 Pu Py ' a  p'
3 - L a b e le d  DNA
(+K C -1 0 6 5(-)-CC-1065
' a P ' P uP yA  P '
1 2 3 4
746.
(3!) M artin, D . G .; M izsa k , S . A .; K ru eger , W . C . J. A n tib io t. 1 9 8 5 , 38,
Figure 2. Products of thermal and piperidine cleavage o f (+ )-  and 
(-)-C C -1065-D N A  adducts on the 117-bp D N A  fragment from 
M 13m pl. DN A  fragments were modified with 28 fiM  o f either (+ )-  or 
(-)-CC-1065 subjected to either thermal treatment (▲) or thermal fol­
lowed by piperidine treatment (P) as described. The center lanes are 
Maxam and Gilbert purine (Pu) and pyrimidine (Py) sequencing lanes. 
The arrow heads point to the covalently modified adenines, and the 
remainder of the 5-mer sequences are the drug overlap region. The larger 
amount of product in lane 1 vs lane 2 is due to a decreased recovery of 
radioactivity for the sample in lane 2 following the additional manipu­
lations associated with piperidine treatment.
alkylation  and  is independent o f o th e r variab les such as th e  
stereochem istry  a t th e  linkage site  and  o rien ta tion  in th e  m inor 
groove o f D N A .
Orientation o f (+ ) -  and (-)-C C -1 0 6 5  M olecules Following 
N3-Adenine Alkylation in D N A . M olecu lar m odeling o f  the  
(+ )-C C -1065 -D N A  adduct had  led us to  p redict th a t the  m iddle 
and  righ t-hand  subun its  w ould be orien ted  to  th e  5 '-side o f the  
covalently m odified ad en in e .10 F oo tp rin ting  o f a  site -d irec ted  
adduct in a  117 base pa ir D N A  frag m en t from  M 1 3 m p l16 and  
one-dim ensional d ifference N O E  ex perim en ts15 w ere in accord  
w ith th is p rediction . T he D N A  alky la tion  sequence specific ity  
o f (+ )-C C -1 0 6 5  also lies to  th e  5 '-side o f  th e  covalent adduc t, 
a lthough  th is is a less re liab le  in d ica to r o f o rien ta tio n  specific i­
ty iob,23 M odeling o f th e  (- )-C C -1 0 6 5 -D N A  ad d u c t suggested  
tha t it would have the opposite orientation; i.e., lying to the  3'-side 
of the covalent adduct. Footprinting o f the covalently bound (+ )-  
and (-)-C C -1065 molecules on 5'- and 3'-labeled D N A  fragm ents, 
respectively, using M P E *Fe(II) is show n in F igu re  3. A  com ­
parison o f contro l (u n trea ted ) D N A  lanes (1 and  3) w ith (+ ) -  
and (- )-C C -1 0 6 5 -p re trea ted  D N A  lanes (2 and  4, respectively) 
shows four (+ )-C C -1 0 6 5  bonding sites and  five (-)-C C -1 0 6 5  
bonding sites w ithin the in terpre table areas of the au toradiogram . 
In lane 4 the unidentified footprint in the center o f the gel reflects 
drug covalently bound on the nonlabeled strand  and  consequently 
the results o f this experim ent do not reveal its o rien tation . In all 
o ther cases for both  (+ ) -  and  (- )-C C -1 0 6 5 , each  foo tp rin t site 
is associated w ith a s trand  b reakage  site  a t the  high m olecu lar 
w eight end o f the footprin t. S ince th e  foo tprin ting  experim ents 
for (+ )-  and (-)-C C -1065 were carried out with 5'- and 3'-labeled 
D N A  fragm ents, respectively, this resu lt fixes th e  orientations of 
(+ )-  and (-)-C C -1065  to the 5 '- and 3'-sides, respectively, o f the 
covalent-bonding sites, in ag reem en t w ith m olecu lar m odeling 
predictions.
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Figure 3. MPE*Fe(II) footprinting of (+ )-  and (-)-C C -1065 on a 5'- 
tabeled 106-bp fragment from SV40 D N A  [(+)-C C-1065] or on a 3'- 
labeled 117-bp DN A fragment from M13mpl [(-)-C C -1065]. DNA  
fragments were modified with 28 of either (+ )- or (-)-CC-1065 and 
subjected to MPE-Fe(II) footprinting as described in the Experimental 
Section. Samples were denatured by heat (90 °C , 2 min) in alkaline 
tracking dye (80% formamide and 10 mM NaO H ) and then electro­
phoresed adjacent to Maxam-Gilbert purine (Pu) and pyrimidine (Py) 
sequencing lanes. Lanes 1 and 3 are control MPE*Fe(II) digestions and 
lanes 2 and 4 (+ )- and (-)-CC-1065-treated samples, respectively. The 
arrow heads point to the covalently modified adenines, and the remainder 
of the 5-mer sequence is the drug overlap site. The pronounced bands 
at the 3'- and 5'-ends of the footprints in lanes 2 and 4, respectively, are 
due to heat-induced cleavage (90 °C for 2 min) at (+ )- or (-)-CC-1065  
alkylation sites. MPE does not detect noncovalent binding sites23 except 
as described in ref 40.
Comparison of (+ )-  and (-)-C C -1065 Sequence Selectivity. The
heat-induced strand breakage assay with (-)-C C -1 0 6 5  was carried 
out on two D N A  restriction fragm ents from  S V -4 0  (one strand  
each of a 276 base pair fragm ent and a 118 base pair fragm ent), 
and three restriction fragm ents from  M 1 3 m p l (o n e  strand o f  a 
180 base pair fragm ent and both strands o f  a 117 base pair 
fragment). E xclusion o f  base pairs further from  the end label 
than the largest c leavage  fragm ent identified  on each  gel, and 
closer to the end label than the sm allest identified  cleavage  
fragment (i.e., experim entally unevaluable regions), leaves about 
470 base pairs in these five restriction fragm ents that can be 
analyzed for sequence context o f  ( - ) -C C -1 0 6 5  alkylation . This 
sampling of D N A  is A - T  rich, w ith 34% adenine, 32% thym ine, 
and about 17% each o f  guan ine and cy tosin e  bases. T he D N A  
was incubated with the drug at a range o f  concentrations. Figure 
4 illustrates the gel results obtained with one o f  the D N A  frag­
ments. The appearance o f  each band on the polyacrylam ide gel
Table II. Most Reactive (~)-CC-106S


































































"*, reactive (covalently modified) adenine.
Table III. Analysis of the DN A Sequences Flanking the Covalent 
Bonding Sites of (-)-C C -1065
frequency of occurrence," (%)
-3 - 2 -1 A* +  1 + 2 +3 + 4
A (34)* 34 26 53 100 70 43 30 34
T (32) 30 42 42 28 32 36 32
G (17) 23 17 4 11 11 17
C (17) 13 15 2 2 13 23 17
A /T (66) 64 68 94 100 98 75 66 66
consensus" N N A /T A* A /T N N N
“A* represents the adenine to which (-)-C C -1065 is covalently 
bonded. Columns to the left and right of the A* column represent 
bases to the 5'- and 3'-sides, respectively, o f the alkylated adenine. The 
frequencies of occurrence of individual bases or base combinations in 
the region adjacent to A* are computed from a total of 53 sites on 
SV40 and M13 DN A, which were shown by thermal cleavage assay to 
be (-)-C C -1065 alkylation sites at 28 nM  or lower drug concentra­
tions. Individual sequences are shown in supplementary material. 
* Random frequency of occurrence of each base in the evaluable region 
(ca. 470 base pairs) of the five D N A  fragments used in this study. 
"The consensus sequences were determined by x 2 analysis (a  =  0.0005) 
using the raw frequency values observed.





c <  28 mM
no. reacted 
c <  0.28 ^M
patterns correlated to 
lower reactivity
5'AA*A 23 19 14 5'AA*AG
5'TA*A 20 15 10 5'TA*AG; TA*AAG
5'AA*T 13 8 7 5 'A /T  AA*TT
5'TA*T 19 7 0 none
"A* identifies potentially reactive adenine.
ind icates that a d etecta b le  level o f  heat-indu ced  c lea v a g e  has 
occured at that adenine (S ch em e I). S in ce  relative band intensity  
is not sensitive to the heat-induced strand scission variables under 
the conditions em ployed, w e infer that this intensity is proportional 
to the rate o f  a lky lation  o f  th e  aden in e at w h ich  subsequent 
c leavage  occurs. U nder a g iven  set o f  d r u g -D N A  incubation  
conditions, the cleavage bands produced at the lowest concentration  
o f  a drug identify the m ost reactant adenines for that drug. Each  
reactive adenine, w hen p la c e d  in th e  c o n te x t o f  i ts  consensus  
sequence  (vide infra) iden tifies a reactive a lk y la t io n  site  for the 
drug under consideration .
A t 2 .8 -2 8  nM  ( - ) -C C -1 0 6 5 , only  eigh t heat-induced cleavage  
bands (and thus alkylation  sites) were detected . T hese are listed  
in T able  II. A t 280  nM  (- ) -C C -1 0 6 5 , 24  add itional a lkylation  
sites are produced. T h ese  32 reactive  sites include 14 5 'A A * A ,  
10 5 'T A * A , and 7 5 'A A * T  sequ en ces, and a sing le  5 'A A * C  
sequence (A *  refers to th e  cova len tly  m odified  aden in e). T hus, 
while the alkylated adenine can be flanked by one thym ine in this 
set o f  sequences, e ither on the 5'- or 3 '-side, there is a lw ays at 
leat one adjacent adenine. W hen th e  D N A  is incubated  w ith  
2 .8 -2 8  mM  ( - ) -C C -1 0 6 5 , 21 add itional a lkylation sites are gen ­
erated, one-third o f  w hich now contain the 5 'T A *T  sequence not 
seen at lower drug concentrations. T he com posite tabulated base 
frequency for all 53 reaction sites is given in T able  III, w ith the  
resulting consensus seq u en ce29 5 'A /T  A *  A /T .
O f the 53 a lkylated  sequ en ces, 49  contain  5 'A A * A , T A * A ,  
A A * T , or T A *T . If the D N A  sequ en ces evaluable in this study
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Table V. Most Reactive (+ )-C C -l065  Sequences0
*, reactive (covalently modified) adenine.
*
5' G G A T A A C A 3'
T G A T T A C G
G T T T T A C A
T T G T A A A A
G T A A A A C G
T T G T T A T C
G A T T T A A A
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Figure 4. Concentration dependence of alkylation by (+)-C C-1065 and 
H-CC-1065 of the 117-bp M sp\-B stN \ fragment of M l3m pl DNA. 
Single 5'-32P-labeled (-f)-strand of the 117-bp D N A  fragment was iso­
lated and labeled as described in the Experimental Section. Fragments 
were modified with 2.8 nM (lanes labeled -5 ), 28 nM (-4 ), 280 nM (-3),
2.8 mM (~2), or 28 mM (-1 )  of either (+)-C C-1065 (left-hand lanes) or 
(-)-CC-1065 (right-hand lanes). Thermal cleavage was as described in 
the Experimental Section, and samples were electrophoresed adjacent to 
Maxam-Gilbert purine- and pyrimidine-specific DNA cleavage reactions. 
The drug alkylation sequences are shown and arrows indicate adenines 
modified by either (+ )-  or (-)-C C -1065.
are examined for these four trip lets (supp lem en tary  m a teria l), 
it is found th a t they occur 75 tim es. T hus, ab o u t a  th ird  o f the 
“consensus sequences” a re  not alkylated by 28 p M  (-)-C C -1065 . 
Slightly more than  a th ird  a re  alky la ted  by only 0.28 giM ( - ) -  
CC-1065. T able IV describes fea tu res o f th e  reactiv ity  of each 
of the four sets of consensus trip lets. It can  be seen th a t m ost 
of the sequences con tain ing  the  first th ree  trip le ts  reac t to  some 
extent, with the frequency o f a lkylation roughly in proportion to 
the frequency o f occurrence. T he question  arises as to  why the 
several consensus sequences in each  category  fail to alkylate. 
Several apparen t pa tte rn s em erge from  analysis o f individual 
sequences. For exam ple, 5 'A A G  sequences frequently  are  asso­
ciated with w eak or unreactive sites. In 5 'N A A T T  sequences, 
the 3'A is reactive w hen N  is C, b u t not generally  w hen it is A 
or T, since then  the 5 'A  is able to react instead . T he 5 'T A T  
sequence is clearly less reactive, since a m uch sm aller percentage 
of TAT sequences a re  a lky lated , and then  only a t h igher d rug  
concentrations.
Previous analysis of (+ )-C C -1065 alkylation sites on restriction 
fragments from SV 40 and T7 D N A  represen ting  a som ew hat 
larger sampling of base pairs had  revealed th a t th e  sequences 
5'PuNTTA* and 5 'A A A A A * w ere m ost reactive (i.e., were 
cleaved at 1.4-0.14 m M  (+ )-C C -1 0 6 5 , th e  lowest d rug  concen­
trations leading to detectable cleavages).103 They also represented 
the consensus sequences for all cleavages produced by 140 nM  
or less (+)-CC-1065 in these D N A  fragm ents under the conditions 
employed. These conditions differed  from  those o f the present
Table VI. Analysis of the DN A  Sequences Flanking the Covalent 
Bonding Sites of (+)-C C-1065
frequency of occurrence," %
-4 -3 -2 -1 A* +  1 + 2
A (34)* 27 36 31 44 100 36 42
T (32) 45 27 58 55 27 24
G (17) 18 29 4 9 24
C (17) 9 7 7 2 27 11
A /T (66) 73 64 89 98 100 64 65
consensus*7 N N A /T A /T A N N
°A* represents the adenine to which (+)-C C -1065 is covalently 
bonded. Columns to the left and right o f the A* column represent 
bases to the 5'- and 3'-sides, respectively, of the alkylated adenine. The 
frequencies of occurrence of individual bases or base combinations in 
the region adjacent to A* are computed from a total of 55 sites on 
SV40 and M13 DN A, which were shown by thermal cleavage assay to 
be (+)-CC-1065 alkylation sites at 28 fiM or lower drug concentra­
tions. Individual sequences are shown in supplementary material. 
* Random frequency of occurrence of each base in the evaluable region 
(ca. 470 base pairs) of the five D N A  fragments used in this study. 
°The consensus sequences were determined by x 2 analysis (a  =  0.0005) 
using the raw frequency values observed.





c <  28 /iM
no. reacted 
c <  0.28 gM
patterns correlated to 
lower reactivity
5'TTA* 20 18 13 5'CTTA*
5TAA* 20 14 13 5'TAA*T; 5'A/C NTAA*
5'AAA* 23 9 7 5'AAA* A /T /G
5'ATA* 14 7 2 5'ATA*A
“A* identifies potentially reactive adenines.
study in th a t the  D N A -d ru g  incubations w ere carried  ou t for 24 
h a t 4 °C  ra th e r than  for 2 h a t  37 °C . T o allow  a m ore d irec t 
com parison, the  alkylation  sites for (+ )-C C -1 0 6 5  in th e  presen t 
set of D N A  fragm ents, under conditions identical w ith those used 
for (-)-C C -1 0 6 5 , w ere determ ined . T h e  e igh t m ost reactive 
(28-2 .8  nM  drug) sequences for (+ )-C C -1065  are  listed in T able  
V. A t 280 nM  (+ )-C C -1065 , 30 additional alkylation sites were 
detec ted .30 T hree trip lets com prised  th e  g rea t m a jo rity  o f these 
38 reactive sites: 5 'T TA * (13 sites), T A A * (13 sites), and A A A * 
(7 sites). T he high frequency o f 5 'T A A * in these experim en ts 
is a featue not found in ea rlie r w ork10b and  m ay possibly reflect 
the  h igher tem p era tu re  o f d ru g  incubation  used in th e  p resen t 
study. A t still higher (+ )-C C -1065  concentrations, 17 additional 
alkylation sites a re  produced. T ab le  VI tab u la te s  the  frequency 
of occurrence o f the bases a t each position surround ing  these 55 
alkylated adenines, giving the  consensus sequence 5 'A /T  A /T  A*.
O f these 55 alkylated sequences, 48 contain the triplets 5 'A A A *, 
TTA *, TA A *, and A TA *. Exam ination  o f the evaluable regions 
o f these D N A  fragm ents shows these tr ip le t sequences to  occur 
77 times. M ore than  a th ird  o f these “consensus sequences” a re  
not alkylated by 28 g M  (+ )-C C -1 0 6 5 . T ab le  V II sum m arizes 
the reactivity o f each o f the  four sets o f consensus trip lets. T he 
5 'T T A * sequence appears to be in trin sica lly  reactive: v irtua lly  
all such sites a re  a lky lated  by (+ )-C C -1 0 6 5 . In teresting ly , th e  
only two such sequences not found to  be alky la ted  in th is work 
were the only two 5 'C T T A *  sequences presen t in these D N A  
regions. In earlier sequencing w ork on (+ )-C C -1 0 6 5 , however, 
a t least one 5 'C T T A * sequence w as found to be highly reactive
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Chart II. Diagrammatic Presentation of the (+ )-  and (-)-CC-1065 Bonding Sequences on the 117 Base Pair M spI-B stN I  Fragment of M 13m pla
•O* 0 0* •  c
o* o oo* 9  •  ,
6170 6180 6190 o« 6200 6210 6220 6230 6240 6250 •  6260 6270
GGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGGATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCC 
CCGAGCATACAACACACCTTAACACTCGCCTATTGTTAAAGTGTGTCCTTTGTCGATACTGGTACTAATGCCTAAG1GACCGGCAGCAAAATGTTGCAGCACTGACCCTTTTGGGA
OO •  OO O •  OO
0 •  O 0 •  00
0 * 0  0 •  O
•
■
"The data are taken from concentration-dependency experiments in which 10-fold dilutions of a standard (+ )-  or (-)-C C -1065 stock solution (280 
(iM) were incubated for 2 h at 37 °C and then heated under standard conditions to produce DN A strand breakage. The O show the (-)-C C -1065  
bonding sites and the •  show the (+)-C C-1065 bonding sites. The number of circles reflects the relative reactivity toward alkylation as indicated by 
the minimum concentration of drug producing detectable strand breakage at that site: • • • ,  2.8-28 nM; 280 nM; • ,  2 .8-28 /*M.
to alkylation.106 T he subset o f 5 'T A A * sequences th a t are  not 
alkylated by 28 /iM  (+ )-C C -1 0 6 5  include th ree  o f the  four 
5'TAA*T sequences p resen t and, independently , five of the  six 
5'A/C NTAA* sequences present in this D N A . O nly 40% of the 
5'AAA* sequences available were alkylated  by 28 /iM  (+ )-C C - 
1065 under these conditions. All six such sequences containing 
a 3'C (5'A AA *C) were highly reactive to  (+ )-C C -1 0 6 5 . Any 
other base in th is position was co rre la ted  w ith w eak or no a l­
kylation. In particu la r, o f  seven 5 'A A A *A  sequences present, 
only one was alkylated, and only a t the higher drug concentrations. 
No correlation o f reactiv ity  o f 5 'A A A * w ith th e  identity  o f the 
bases lying to the 5 'side was discerned. T he 5 'A T A * sequences 
showed limited reactivity, m ainly a t h igher d rug  concentrations. 
While half of these sequences in the  D N A  exam ined contained 
a3'A (5'ATA*A), only one such sequence was alkylated; in most 
cases the resulting 5 'T A A * site is m ore reactive.
It is clear th a t (+ )-C C -1 0 6 5  and (-)-C C -1 0 6 5  have d istinct 
sequence requirem ents, even though both  favor A T -rich  D N A . 
The most striking difference is tha t (+ )-C C -1065  strongly prefers 
two A/T base pairs in the 5'-direction from its adenine alkylation 
site, where (-)-C C -1065  requires A /T  flanking on both  sides of 
the reactive adenine. C om parison of these two drugs, not merely 
with respect to flanking sequence requirem ents, bu t w ith respect 
to the location o f reaction  sites along the D N A  strands as illus­
trated in Figure 4 for one D N A  fragm en t, leads to  several in­
triguing observations. C h a rt II shows a 117 base pair fragm ent 
from M13mpl on which a re  indicated  for bo th  s trands the ade­
nines alkylated by (+ )-  or (-)-C C -1065 . In this D N A  fragm ent, 
one adenine reacts w ith both  enan tiom ers o f C C -1065 . I t m ust 
beemphasized tha t the sequence context (i.e., consensus sequence) 
for (+)- and (-)-C C -1065 is different, and hence, while the specific 
adenine that is alkylated by (+ )-  or (-)-C C -1065  is the  same, the 
alkylation sites  them selves a re  not identical. (W e use the  term  
"alkylation site” to include both the alkylated base and its sequence 
context.) All o f th ree favorable 5 'T T A * (+ )-C C -1 0 6 5  sites are 
accompanied by a favorable 5 'T A *A  (-)-C C -1 0 6 5  reaction  site 
directly opposite on the com plem entary strand. A nother common 
motif, occurring five tim es in this sam pling, is th e  occurrence of 
a (-)-CC-1065 a lky lated  adenine one or tw o base pairs in the 
.'•direction from a (+ )-C C -1 0 6 5  reactive aden ine on the  sam e 
strand. Since the footprinting experim ents discussed above show 
that (+ )-C C -1065 extends in the 5 '-d irec tion  from  its m odified 
adenine, while (-)-C C -1 0 6 5  extends in the  3 '-d irection  from  its 
covalent link, this indicates tha t alkylation with either enantiom er 
icads to occupation of the sam e or overlapping spaces in the minor 
groove in many instances. A sim ilar analysis o f the  set of (+ )-  
and (-)-C C -1065 reaction  sites on all o f the five restric tion  
fragments used in the  (-)-C C -1 0 6 5  consensus studies (supple­
mentary material) is sum marized in C hart III. O f the 53 adenines 
.hat react with (-)-C C -1065, 24 can also react with (+ )-C C -1065 
(i.e., these adenines belong to both th e  set o f (+ )-C C -1 0 6 5  al- 
kylation sites and the set o f (-)-C C -1 0 6 5  a lky la tion  sites]. O f 
tie remaining adenines ta rge ted  by (~ )-C C -1065 , 15 occur one 
or two base pairs 5 ' to a (+ )-C C -1065  alkylated  base. O f the 14 
-(•CC-1065 reactive adenines th a t do not ap p ea r to be near 
i+)-CC-l 065 alkylation sites (in some cases it is possible that such 
action would occur on the  com plem entary  s tran d ), 8 a re  in or
Chart III. Relative Locations of Adenines That Are Alkylated by 
(+ )- or H -C C -1065
S3 (-)-sites SS (+  )-sites
2 9 ( - ) o n ly  24 ( + ) a n d  (-) 3 1 (  + ) o n ly
1S 1 o r 2 b ase  pairs 14 12 1 o r  2 b ase  pairs  19
5' to  (+  > site  I 3 ' to  (-)-site
I  1 I- - - - - - - - -
8 n ea r 5'-AATT ® 9 n o  (-) c o n sen su s
6 S'-TTAT 4
ad jacen t to  5 'A A T T  sequences. F our o f these a re  rep resen ted  
in the most reactive (-)-C C -1 0 6 5  sites listed in T ab le  II. In this 
sequence the  (-)-C C -1 0 6 5  m olecule p refers to  re ac t a t  th e  5 '- 
adenine (5 'A *A T T ) w henever th e  5 ' flanking A /T  requ irem en t 
is honored. If not, it will reac t a t th e  3 '-aden ine  (5 'A A * T T ).
O f the 55 (+ )-C C -1065 alkylation sites identified in th is D N A  
sam ple a t 28 /tM  drug , nearly  tw o-th irds occur a t  adenines th a t 
also react w ith (-)-C C -1 0 6 5  or a re  one or tw o base pairs 3 ' to 
adenines th a t reac t w ith (-)-C C -1 0 6 5 . O f  th e  19 exceptions, 9 
do not contain  th e  consensus sequence ( A /T  A * A /T )  for ( - ) -  
CC-1065. Six of the rem aining 10 are  5 T T A * T  sequences, which 
are predicted to have reactive (-)-C C -1 0 6 5  sites on th e  opposite 
strand , leaving only four (+ )-C C -1 0 6 5  sites th a t do not have an 
obvious reason for failing to react w ith (-)-C C -1065. O ne o f these 
sites, 5 'C TA *TG , reacts w ith (+ )-C C -1065  only a t relatively high 
concentrations. T he o ther th ree  sites con ta in  5 'A A G  sequences 
ad jacen t to, or inco rpora ting , th e  ta rg e t adenine.
In sum m ary, w ithin the  constrain ts o f the ir distinct consensus 
sequence requirements, (+ )-  and (-)-C C -1065 tend to react within 
the sam e A /T -rich  sequences such th a t m uch o f the  sam e space 
in the m inor groove is accessib le to  e ith e r enan tiom er. N early  
h a lf o f the  alkylation  sites for each  o f the  enan tiom ers perm it 
covalent bond form ation w ith th e  sam e adenines. A nother large 
fraction of sequences contains a (-)-C C -1 0 6 5  alky lated  adenine 
one or two base pairs 5 ' to  an adenine ta rg e ted  by (+ )-C C -1065  
on the sam e strand, or directly across on the com plem entary strand 
such th a t the  consensus sequences overlap. T he relatively small 
num ber o f exceptions to  th is ap p ea r to  fall m ainly in to  th ree 
categories: (1) 5 'A A T T  sequences, w hich a re  excellent ( - ) -C -  
C-1065 alkylation sites, b u t w hich react poorly or not a t all with 
(+)-C C -1065; (2) sequences th a t can accom m odate (+)-C C -1065, 
but not the stringent 5 'A /T  A* A /T  (-)-C C -1065  consensus; and 
(3) nom inally consensus (- )-C C -1 0 6 5  sequences in w hich the 
target adenine is within or directly 5' to a 5 'A A G  sequence. While 
these are usually highly reactive sequences for (+ )-C C -1065 when 
A /T  base pairs lie in th e  5 '-d irection , they  a re  generally  poorl) 
reactive or unreactive with (-)-C C -1065 . Indeed three of the five 
5 'A *A G  cleavage sites th a t appear a t the h igher concentrations 
of (-)-C C -1 0 6 5  a re  highly susceptib le (+ )-C C -1 0 6 5  sites an 
could conceivably arise a t least partly  from traces of c n a n t i o m c n c
contam ination . a
Com parison o f (+ ) -  and ( - ) -C P I  Analogues o f C C ' ^  . / r  
Sequence Specificity and Reactivity of DNA Alkylation. c
and ( - )-C P I analogues listed in C h a rt I w ere subjected to
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sequences alkylated at 
A* at earliest detectn, 5' to 3'
(+)-CC-1065 Alkylation Sites




0.028 TTTTA*, GGAAA*, GATAA*
(+)-AB 2.8 GATTA*, GGAAA*, GATAA*
(+)-A 28 TTTTA*, GATTA*, GATAA*
(-)-AB'C' 28° GATTA*, GGAAA*, GATAA*
H-CC-1065 28° GATTA*, GATAA*
(-)-A 280 TTTTA*, GATTA*, GATAA*
(-)-AB 2800- GATTA*
(-)-ABC 280* no (+)-CC-1065 sites
(-)-CC-1065 Alkylation Sites
(-)-AB'C' 0.028 ATA*AC, CAA*TT
H-CC-1065 0.028 ATA*AC
0.28 CAA*TT, GAA*AC
(+)-ABC 0.28 ATA*AC, CAA*TT
(-)-ABC 28 CAA*TT, GAA*AC
(+)-AB 28 ATA’ AC, CAA*TT
(+)-A 2800 (GAA*TT)ATA*AC, CAA’ TT, GAA*AC
(-)-AB 2800 CAA*TT, GAA*AC
(-)-A 2800* no (H-CC-1065 sites
(+)-AB'C 28* no (H-CC-1065 sites
(H-CC-1065 28* no (H-CC-1065 sites
'D etectable c lea v a g e  m a y  b e d u e  to  co n ta m in a tio n  b y ( + ) .  * M a x im u m  
concentration stud ied .
thermally induced strand breakage assay using the 5'-labeled 117 
base pair (+  s trand ) M 13m pl D N A  fragm en t, w ith a range of 
concentrations for each drug . T his fragm ent contains five iden­
tified (+)-C C -1065 alky lation  sites, and  four identified ( - )-C - 
C-1065 sites (Figure 4 and C hart II, top strand). Figure 5 presents 
the results for (+ )- and (-)-A , -AB, and -ABC. The gels obtained 
for (+)- and (- )-A B 'C ' were virtually identical with those of (+ )-  
and (-)-C C -1065 in F igure 4 (d a ta  not presen ted). T ab le  V III 
summarizes these d a ta .
In confirmation of our earlier results,23 T able V III shows th a t 
the same set of sequences tha t reacts with (+)-C C -1065 also reacts 
with all of the (+ )-C P I agents (a lthough  consensus studies were 
not carried out for each analogue, th e  consistent and  exact co r­
respondence of covalently reactive adenines strongly suggests th a t 
the alkylation sites them selves correspond as w ell).23 W hile the 
10-fold dilutions provide only approxim ate quantitation, the overall 
reaction rate a t all of the  sensitive sequences increases m arkedly 
as the molecular s truc tu re  o f the  d rug  is lengthened from  (+ )-A  
to(+)-ABC, since correspondingly lower concentrations o f drug 
are needed to produce detec tab le  cleavage. W ith  (+ )-A B C  this 
effect reaches a p la teau , and  no fu rth e r increase in alkylation  
reactivity results from further elaboration of the CC-1065 structure 
for these sequences. A t very high concentrations [1000-fold higher 
than required for detection of cleavage by their respective (+ )-C P I 
enantiomers], (-)-C C -1 0 6 5 , ( - ) -A B 'C ', and (- )-A B  produce 
detectable cleavage a t these (+ )-C C -1065 sites. This is most likely 
due to traces of enan tiom eric  co n tam in an t in these synthetic  
agents, since as little as 0.1% (+ )-en an tio m er could produce the 
observed bands. A  very d iffe ren t situa tion  ob ta ins for ( - )-A , 
however, whose reactivity with the set of adenines in (+ )-C C -1065 
sites is within an o rder of m agn itude  o f the reactiv ity  o f (+ )-A . 
Since all of the ( - )-C P I com pounds are  prepared from the sam e 
resolved in term ediate 3, ( - ) -A  cannot contain  sufficient (+ )-en - 
antiomer con tam inan t to accoun t for th is result.
Some in teresting  differences em erge for the  (-)-C C -1 0 6 5  a l­
kylation sites. W hile these d is tinc t a lky lation  sites are  highly 
reactive tow ard (H -C C -1065  and  its close analogue (H -A B 'C ', 
they are som ew hat less reactive than  the  (+ )-C C -1 0 6 5  sites are  
toward the corresponding (+ )-C P I agents, judging by the higher 
concentrations required to produce detectable cleavage. A second 
difference is th a t (-)-A B C  is very poorly reactive w ith adenines 
at these (-)-C C -1065-sensitive  sequences, requiring  100- to 
1000-fold g reater concentrations than  the  more structu ra lly  e la­
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(+)-A (-)-A  (+)-AB (-)-A B  (+)-ABC (-)-ABC
Pu Py 0  - I '  +1 0  -1 '-1  -2 ' +1 0  - I ' - 4  - 5 1 'o -1  - 2  - 3 - 4 '
S
m
Figure 5. Concentration dependence o f alkylation by (+ )-  and (-)-A , 
(+ )- and (-)-A B , and (+ )-  and (-)-A B C  of the 117-bp M sp l-B stN l 
fragment of M 13m pl. Aliquots of 5Mabeled 117-bp D N A  fragment 
were incubated with appropriate concentration of (+ )-  or (-)-A , (+ )- or 
(-)-A B , or (+ )-  or (-)-A B C  as described in the Experimental Section. 
+  1,0, - 1 ,- 2 ,  -3 , and -4  denote 2.8 mM and 280, 28, 2.8, 0.28 and 0.028 
nM, respectively. Thermal cleavage conditions are described in the 
Experimental Section. Pu, purine; Py, pyrimidine.
borated (-)-C C -1065  and (- )-A B 'C '. This large ra te  discrepancy 
continues w ith th e  sm aller ( - )-A B , and  no aden ine  reactions 
corresponding to  (-)-C C -1 0 6 5  alkylation  sites could be detec ted  
for (-)-A  a t the highest concentration tested. Indeed, (- )-A  reacts 
a t (+ )-C C -1 0 6 5  sites m uch m ore read ily  th a n  it w ould appear 
to react a t  (-)-C C -1 0 6 5  sites. T he  th ird  in trigu ing  observation  
from this p a rt o f T ab le  V III is th a t th e  less e labo ra te  (+ )-se ries  
analogues, (+ )-A B C , (+ )-A B , and  (+ )-A , react to  a  small extent 
a t adenines associated with (-)-C C -1065 sites. To be sure, reaction 
a t these adenines requires 10- to  100-fold h igher concentrations 
o f each d rug  th an  reaction  a t aden ines in (+ )-C C -1 0 6 5  sites. 
However, this still allows these (+ )-C P I analogues to  be far more 
reactive than  their respective (- )-C P I enantiom ers w ith these same 
adenines. Indeed, the  adenine (A *) in th e  5/C A A *T T  sequence, 
which is one of the few (-)-C C -1065  alkylated sequences not near 
to  a (+ )-C C -1 0 6 5  bonding site, appears to reac t as read ily  w ith 
(+ )-A B C  as it does w ith (-)-C C -1 0 6 5 . A  5 'G A A * T T  sequence 
ra ther near the  labeled end o f th is D N A  fragm en t, w hich would 
be expected to have a good bonding site  for (-)-C C -1 0 6 5 , also 
provides an  alky lation  site for (+ ) -A  and  (+ )-A B  a t 2800 and 
280 mM , respectively. [T he observation th a t intense bands from 
heat-treated, 5'-end-labeled D N A  are  often accom panied by traces 
of slower runn ing  cleavage p roduct presum ed to  resu lt from  /?- 
e lim ination o f the  m odified deoxyribose, as show n in F igure 2, 
m ight m ake it som ewhat difficult to unam biguously identify weak 
bands resulting  from  reaction  a t adenines in (-)-C C -1 0 6 5  sites, 
w hich frequently occur immediately 5' to (+ )-C C -1065 sites. Such 
a com plication does not occur, however, for the  5 'C A A * T T  and 
G A A *T T  sequences in th is D N A  fragm en t.] A t th e  h ighest 
concen trations tested , (+ ) -A B 'C ' and  (+ )-C C -1 0 6 5  did not 
produce de tec tab le  cleavage a t adenines associated  w ith ( - ) -  
C C -1065 sites. Because o f the lower reactiv ity  of (-)-C C -1 0 6 5  
sites, traces o f ( -)-en an tio m eric  co n tam in an t in syn thetic  (+ )-  
A B 'C ' m ight not be detec ted  a t these concen trations.
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LI 210 leukemia 
ID*,,4 nM






(+)-CC-1065 29.8 0.03 60 50 yes
(-1-CC-1065 12.7 0.007 50 12 no
(+)-AB'C' 22.8 0.01 75 100 yes
H-AB'C' 12.4 0.01 50 50 no
(+)-ABC 19.1 0.004 (4 /6 / 25 no
(-)-ABC 7.5 1.0 55 200 no*
(+)-AB 13.3 0.1 100 250 no*
(-)-AB 3.3 20 80 10000 no'
(+)-A 1.4 10 90 1200 no
(-)-A 0 100 75 50000* nt
'Thermal melting of calf thymus DNA compared with or without 
the drug in 0.01 M phosphate buffer, pH 7.2, after the drug-DNA 
mixture, drug alone, or DNA alone was incubated at 25 °C for 24 h. 
The molar ratio of DNA (measured as nucleic acid phosphate) and 
drug was 13 with a drug concentration of 0.85 X 10"5 M. AT m , T m  
(drug-DNA mixture) -  T m  (DNA alone). The T m  of calf thymus 
DNA is 65.6 °C. 4 Drug concentration causing 50% inhibition of cell 
growth with 3-day drug incubation. L1210 cells were at a concentra­
tion of 5 X 103 cells/mL at the start of the experiment. 'Mice bearing 
ip-implanted P388 leukemia with ip drug treatment on days 1, 5, and 
9; % ILS, percent increase in life span of treated compared to control 
mice. Most values are rounded averages of two or more experiments 
with repeat experiments showing good reproducibility. OD, optimum 
dose. ‘'Groups of CD2F1 mice received a single iv dose over a range of 
dose levels including acutely lethal doses and deaths were recorded 
daily for 90 days. Deaths occurring later than 20 days were classified 
as “delayed*. 'Tested as racemic mixture of (+)- and (-)-enantiomers. 
N̂umber of day 30 survivors/total. *Highest dose tested.
in summary, those sequences in the M13mpl DNA strand 
described as (+)-CC-1065 alkylation sites appear to be intrinsically 
more reactive and more generally chirally discriminating than 
those sequences described as (-)-CC-1065 alkylation sites. Their 
relative reactivity is largely independent of the structural ap­
pendages attached to the (+)-CPI subunit, although binding 
enhancement by those appendages accelerates reaction at all 
susceptible sequences.23 Only the smallest (-)-CPI agent, (-)-A, 
can react at these sequences, and this occurs with a 10-fold loss 
of rate relative to (+)-A. The sequences identified as (-)-CC-1065 
alkylation sites are only chirally discriminatory to the structurally 
elaborated (+)-CC-1065 and (+)-AB'C/. The react, although 
more slowly than (+)-CC-1065 sites, with other (+)-CPI ana­
logues [presumably with the bonded (+)-CPI lying to the 5'-side 
of the alkylated adenine, opposite to the 3'-orientation of (-)- 
CC-1065]. The (-)-CPI analogues in general appear to be in­
trinsically less reactive alkylating agents for DNA. The smaller 
analogues, (-)-A, (-)-AB, and (-)-ABC, are less reactive at any 
sequence than their (+)-enantiomers. This low reactivity of the 
(-)-CPI subunit is overcome, however, only by (-)-CC-1065 and 
(-)-AB'C, which contains the full carbon skeleton of (-)-CC-1065, 
and may react at adenines that react relatively poorly with smaller 
(+)-CPI analogues, and not at all with (+)-CC-1065 and (+)- 
AB'C'.
B. DNA T h erm al M e ltin g . Table IX lists the change in the 
melting temperature of calf-thymus DNA in the presence of (+)- 
and (-)-C C -10 65  and their analogues. This experimental pa­
rameter can reflect the density of binding (covalent or noncovalent) 
sites on the DNA, as well as the average strength of the nonco­
valent interactions at these sites and the stabilization of the helix 
organization resulting from the bound or bonded complexes. All 
of these factors probably contribute to the high A T m of (+)- 
CC-1065. At the other extreme, (+)-A and (-)-A have little or 
no measurable effect when incubated with calf thymus DNA under 
the same conditions. There is a monotonic decrease in A T m for 
the (+)-CPI analogues as the right-hand portion of the molecule 
is progressively truncated, consistent with the expected contribution 
of this structure to hydrophobic interactions within the minor 
groove.21*5 (- ) -C C -1 0 6 5 , as well as its analogues, has a strikingly
lower net stabilizing effect on calf thymus DNA than do the 
corresponding (+)-CPI analogues under these conditions of tem­
perature and stoichiometry.
C. Biological Activity. Table IX summarizes some important 
biological characteristics of the (+)- and (-)-CPI compounds 
described above. These include the cytotoxicity against LI 210 
tumor cells in suspension culture, antitumor efficacy against P388 
leukemia cells in mice and the dose required to achieve it, and 
the ability to cause delayed death in nontumored mice. In com­
paring the activities of enantiomers, three types of relationships 
are evident from Table IX: (1) (+)- and (—)-CC-1065, and also 
(+)- and (-)-AB'C', show comparable, high potency both in vitro 
and in vivo, as well as comparable efficacy against P388 leukemia 
in mice. However, the (+)- and (-)-compounds are strikingly 
differentiated in their biological action by the ability of only the 
(+)-agents to cause delayed death in nontumored mice. (2) (+)- 
and (-)-ABC, and also (+)- and (-)-AB, in sharp contrast to the 
more complex structures, show very disparate potencies between 
(+) and (-) counterparts. Since these potency differences ap­
proach 2 orders of magnitude or more, it becomes experimentally 
impossible to distinguish the contribution of a minor, potent 
contaminant from that of the bulk agent. Thus, the ID*, value 
for (-)-ABC might be due to the possible presence of 0.5% 
(+)-ABC. Similarly, the 55% increased life span observed with 
200 Mg/kg (-)-ABC could in part be due to contamination by 
(+)-ABC. Thus, the cytotoxicities and efficacies reported for 
(-)-ABC and (-)-AB must be interpreted with caution. What 
can be said with assurance is that these (-)-CPI agents are dra­
matically less active biologically than are their (+)-enantiomers.
(3) (+)-A and (-)-A show yet another relationship. They differ 
in in vitro cytotoxic potency by only an order of magnitude. Since 
all of the various enantiomers shown in Chart I were prepared 
from the same diasteriomerically resolved intermediate, and since 
the observed potencies of (-)-ABC and (-)-AB are inconsistent 
with high (10%) levels of (+) contamination, it follows that the 
cytotoxic potency observed for (-)-A is real and does not reflect 
a significant contribution by (+)-A contamination.
Discussion
A recent analysis of sequence-dependent features of the DNA 
major and minor grooves noted that the narrower minor groove 
contains only half of the hydrogen-bonding information available 
in the wide major groove.20 A ligand in the minor groove cannot 
distinguish, through hydrogen bonding, an A-T base pair from 
a T-A base pair, or a G-C from a C-G base pair. Despite this 
reduced discrimination, groove-binding drugs almost invariably 
prefer the deeper, narrower cleft of the minor groove, most likely 
due to the powerful driving force of hydrophobic interaction as 
the tightly held spine of hydration in this groove is displaced into 
the aqueous medium.20,32 Natural products such as distamycin 
and netropsin further refine this hydrophobic interaction to include 
specific favorable van der Waals contacts with AT bases lining 
the minor groove.33 Interestingly, this binding specificity does 
not seem to preclude binding of these drugs in both possible 
orientations (e.g., 5' to 3' or 3' to 5') for most sequences, according 
to affinity cleavage studies.34 A large and diverse class of linearly 
linked aryl or heteroaryl oligomeric molecules, generally bearing 
a positive charge, all bind noncovalently in the minor groove, and 
all have a more or less pronounced preference for stretches of A-T 
and T-A base pairs.35 This AT preference has been described 
as a GC avoidance:20 the minor groove cleft is interrupted by the 
protruding 2-amino group of guanine. The bias for AT regions 
of the groove is strong, and synthetic “lexitropsins” designed to 
“recognize” GC bases36 may simply be more tolerant of those bases 
than the noncovalent, groove-binding agents designed by Nature.20
(32) M arky, L. A.; Breslauer, K. J. Proc. Natl. Acad. Sci. U S.A . 1987, 
84, 4359.
(33) Kopka, M. L.; Yoon, C.; Goodsell, D.; Pjura, P.; Dickerson, R. E. 
Proc. Natl. Acad. Sci. U S.A . 1985, 82, 1376.
(34) Youngquist, R. S.; Dervan, P. B. Proc. NatL Acad. Sci. US.A. 1985, 
82 2565
(35) Braithwaite, A. W.; Baguley, B. C. B iochem istry  1980, 19, 1101.
(36) Lown, J. W.; Krowicki, K.; Bhat, U. G. Biochem istry  1986. 25, 7408.
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Figure 6. Stereoscopic diagrams of the adducts of (+ )-A  (I, top) and (-)-A  (II, middle, and III, bottom) with the duplex 5'CGTTA*ACG (showing 
only 5'GTTA*A) generated as described in the text. The drug moiety is shown in blue, and the covalently modified adenine (A*) and the phosphate 
group on the opposite strand, two base pairs away, are shown in magenta. White dotted lines depict some distances that are discussed in the text.
Footprinting and affin ity  cleavage studies confirm  that drugs 
such as netropsin and distam ycin bind strongly to D N A  fragments 
or oligomers at sites o f four or five contiguous A -T  or T -A  base 
pairs.20’34*37 A s discussed above, there appears to be no clear  
distinction betw een A -T  and T - A  pairs.20 R ecently , this A T  
binding selectiv ity  was exploited  in the design o f  A’-brom o- 
acctyldistamycin, which can covalently m odify D N A  at adenine  
N3 in the minor groove, at som e o f the A T-rich sites that tightly  
bold the ligan d .37
(+ )-C C -1 0 6 5  is a lso  a natural product that binds strongly to 
the D N A  minor groove in A T -rich regions, but unlike distam ycin. 
it reacts with D N A  to form  a covalent ad d u ct.8-11 T he irre­
versibility o f  this m olecular lesion undoubtedly contributes to the 
6 orders of m agnitude greater cytotoxic potency o f (+ )-C C -1 0 6 5 8b 
relative to d ista m y c in .38 H ow ever, ( +  )-C C -1 0 6 5  is not sim ply
(37) Baker, B. F.; Dervan, P. D. J. A m . Chem. Soc. 1989, I I I ,  2700.
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i  natural product version  o f  iV -b ro m oa cety ld ista m ycin , in w hich  
sequence- (A T -) se lec tiv e  m inor g roov e  b in d in g  con stra in s a re­
luctant alkylating c en ter  to  rea c t w ith  n u c le o p h ilic  a to m s in 
proximity to the b in d in g  s ite .3 I f  th is  w ere  th e  c a se , it w ou ld  be  
expected that tru n ca ted  ( + ) - C P I  a n a lo g u e s  o f  (+ ) -C C -1 0 6 5 ,  
whose properties, such  as  th e  ab ility  to  a ffec t th e  therm al m eltin g  
of DNA (T able I X ) ,  in d ic a te  m u ch  w eak er  b in d in g , w ou ld  be  
unable to a lkylate D N A  seq u en c e  se le c t iv e ly , i f  a t  a ll. In fa c t,  
while the overall ra tes o f  th e  a lk y la tio n  reaction s w ith  D N A  are  
lower for the less s tro n g ly  b in d in g  ( + ) - C P I  a g e n ts , it  has been  
shown that the se t  o f  seq u en ces  in  w h ich  a d en in es are  a lk y la ted  
is the same for (+ ) -C P I  an a log u es regardless o f  b inding ab ility .23 
We have interpreted this result as dem onstrating that the sequence  
selectivity o f (+ ) - C P I  c om p o u n d s is p r im arily  d e term in ed , n ot  
by sequence-recognizing noncovalent binding, b ut b y  th e  seq uence  
requirements inherent in th e  c ova len t-b on d in g  ste p  itse lf .23 T h is  
might be postulated to  a r ise  from  a  seq u en ce-d ep en d en t con for ­
mational flexib ility  a llo w in g  a d en in e  in c er ta in  en v iron m en ts to  
approach the e le c tr o p h ilic  cen te r  su ff ic ie n t ly  c lo se ly  for  bond  
formation. It m ig h t a lso  b e  p o stu la ted  to  in vo lve  seq u en c e-d e ­
pendent electrophilic  a c tiv a tio n  o f  th e  ( + ) - C P I  m o ie ty  s im u lta ­
neously with aden in e N 3  n u cleop h ilic  a ttack , in a  p rocess sim ilar  
to the bifunctional c a ta ly sis  observed  in m a n y  e n zy m e-su b stra te  
reactions.39 From  a purely structural perspective, su ch  a  process 
resembles su icid e su b s tr a te -e n z y m e  in a ctiv a tio n .
Consensus seq u en ce  an a lysis  o f  co v a len t a d d u ct form ation  by  
(+)-CC-1065,10 a s  w ell as com parative footprinting experim ents,23 
also indicates th a t ( + ) -C C -1 0 6 5  an d  d is ta m y c in  rec o g n ize  th e  
minor groove through different m echanism s. In  the  work described  
here, in which in cu b a tio n s o f  d ru g  an d  D N A  w ere  carr ied  ou t  
at 37 °C, an a lm o st u n iversa l r ea c tio n  w ith  5 'T T A *  seq u en ces  
was observed (T a b le  V II ) . W h ile  5 'T A A *  seq u en ces w ere m ore  
often reactive than  not, in terch an ge o f  th e  b ase  pair m ore d istant  
from the adduct, a s  in 5 'A A A *  an d  5 'A T A * , h ad  a  pronounced  
effect on the p robab ility  o f  reaction  a t th e se  seq u en ces , i.e ., on ly  
a small fraction o f  su c h  seq u en ces  w ere  rea c tiv e  tow ard  ( + ) -  
CC-1065. T h us, (+ ) -C C -1 0 6 5 ,  th rou gh  its  cov a len t reaction , is 
able to discriminate betw een A - T  and T - A  base  pairs in the  m inor  
groove.
The strand breakage assay  used in th ese  stud ies can  on ly  d etect  
covalent reaction s ites  o f  (+ ) -C C -1 0 6 5 .40 R e c e n t sp ectrosco p ic  
studies o f ( + ) -C C -1 0 6 5  w ith  va riou s sy n th e tic  o lig o m ers reveal 
that the drug m a y  b ind stron g ly  to  certa in  seq u en ces  w ith  w hich  
it does not reac t co v a len tly .41 T h e  m o st d r a m a tic  e x a m p le  o f  
this behavior is  provided  b y  th e  stron g  n on co v a len t c o m p lex  b e­
tween (+ )-C C -1 0 6 5  an d  th e  d u p lex  o f  5 'C G C G A A T T C G C G .  
This oligomer also  provides an  exce llen t b inding site  for netropsin, 
and indeed, th e  first c ry sta l stru ctu re  o f  a  n e tro p s in -o lig o m er  
complex w as ob ta in ed  w ith  a  5 -b ro m o c y to s in e -m o d ified  d u p lex  
of this sequence.33 S u c h  ev id en ce  o f  rev ersib le  b in d in g  o f  ( + ) -  
CC-1065 to the sam e m inor groove locations selected  b y  netropsin  
or distamycin su g g ests  th a t th e  p u rely  n o n c o v a le n t recogn itio n  
mechanisms o f  (+ )-C C -1 0 6 5  are not grea tly  d ifferen t from  th ose  
of other m inor g roov e  b in d in g  a g en ts . It a lso  em p h a size s  th e  
overlying, pow erful A  vs T  d iscr im in atin g  a b ility  o f  th e  (+ ) -C P I  
covalent reaction .
drug +  D N A  ^  (d r u g .D N A )noncov —  ( d r u g - D N A ) ^  (1 )
In terms o f  the  gen eralized  k in etic  sch em e  in eq  1, a  d rug m a y  
preferentially react w ith  a p articu lar  seq u en c e  th rou gh  e ith er  a  
very high b ind ing a ff in ity  ( Kb) a t  th a t seq u en c e , or a cov a len t
(38) Lown, J. W.; Kxowicki, K.; Balzarini, J.; DeClercq, E. J. Med. Chem. 
1986, 29, 1210.
(39) Fersht, A. In Enzyme Structure and Function, 2nd ed.; W. H. 
Freeman and Co.: New York, 1985.
(40) Footprinting studies with MPE-Fe(II) were initially thought to reveal 
only covalent bonding sites for (+)-CC-1065 (ref 23); however, the footprint 
labeled B in Figure 3 of that reference may possibly reflect a strong nonco­
valent complex, particularly in view of the spectroscopic studies of ref 41. The 
attribution of that footprint to a covalent adduct on the opposite strand is an 
error; there is no evidence of a covalent adduct a t that site on the opposite 
strand.
(41) Theriault, N. Y.; Krueger, W. C.; Prairie, M. D. Chem.-Biol. Interact.
1988, 65, 187.
reaction  w h o se  a c tiv a tio n  e n er g y  is  e sp ec ia lly  fav o ra b le  for  th a t  
seq u en c e .3 I f  kx is n o t seq u en ce-d ep en d en t, th e  s ite s  o f  cov a len t  
r ea c tio n  w ill b e  th o se  h av in g  th e  h ig h est o n -ra te  o f  n on co v a len t  
bind ing ( i f  kr is fa st re la tive  to  d isso c ia tio n ) or th e  h ig h est Kb ( i f  
kT is  s lo w ). ( + ) - C C - 1 0 6 5 ,  a lth o u g h  it h as a  very  h ig h  b in d in g  
a ff in ity  for  A T -r ic h  seq u en c es , is a lso  co n str a in e d  b y  a se ­
quence-dependent kr S im p le  (+ ) -C P I  ana logues w ith  low  binding  
a ff in ity  to  D N A  s till  react, th o u g h  a t a  low er overa ll rate , a t  th e  
sam e sequences that react w ith  (+ )-C C -1 0 6 5 , seq uences that allow  
a fa v orab le  kt for  c o v a len t r ea c tio n  b e tw ee n  a d e n in e  and  th e  
( + ) - C P I  m o ie ty .
Im p lic it in  th e  seq u en ce  reco g n itio n  ca p a b ility  o f  th e  ( + ) -C P I  
alkylating segm ent is that a lterations to  th e  structure o f  that m oiety  
could  have sign ifican t e ffec ts  on  its ab so lu te  reactiv ity  and relative  
r ea c tiv ity  (se q u e n c e  s e le c t iv ity )  w ith  D N A . T h e  a c c e ss ib ility ,  
through  syn th esis, o f  th e  u n n atu ra l en a n tio m er  o f  th e  a lk y la tin g  
se g m e n t,214 an d  th e  m e th o d o lo g y  to  prepare ( - ) - C C - 1 0 6 5  and  
oth er  ( - ) - C P I  a n a lo g u e s ,13 h a v e  p rov id ed  an  id ea l sy s te m  w ith  
w h ich  to  exp lo re  th e se  im p lic a tio n s . T h e  id en tica l p h y sica l and  
c h em ic a l p rop erties o f  th e  ( - ) - C P I  a n d  ( + ) - C P I  a g e n ts  focu s  
com parison  on  th e  d ifferen ces o f  their in teractions w ith  th e  chiral 
D N A  h e lix . In d eed , w e  h a v e  fou n d  th a t ( - ) - C C - 1 0 6 5 ,  w h ile  it 
su p erfic ia lly  resem b les (+ ) -C C -1 0 6 5  in reac tin g  co v a len tly  w ith  
certain  ad en in es in th e  m inor groov e  o f  D N A  in A T -r ich  regions, 
sh o w s su b tle  b u t s ig n if ic a n t  d iffe r en c e s . It lie s  in th e  o p p o site  
direction  in th e  groove, it a lk y la tes  a non id en tica l se t  o f  aden in es, 
it reveals a  d ifferent consensus requirem ent for the  covalent adduct, 
an d , fin a lly , its  s im p lif ied  ( - ) - C P I  a n a lo g u es  fa il  to  r ea c t w ith  
D N A . T h e  so le  e x ce p tio n  is  ( - ) - A ,  w h ich  r ea c ts  a t  th e  ( + ) -  
C C -1 0 6 5  s ite s  rath er th a n  a t  th e  ( - ) - C C - 1 0 6 5  s ite s . H o w  can  
th e se  ob serv ation s b e  ra tio n a liz ed  in  term s o f  s tru ctu ra l m o d els  
o f  d r u g -D N A  b on d in g?  T h e  fo llo w in g  d iscu ssio n  d escr ib es , not 
a  rigorou s m o d elin g  stu d y , b u t a  q u a lita tiv e  a ttem p t to  illu stra te  
so m e  o f  th e  p ossib le  in ter a c tio n s  th a t  m ig h t u n d erlie  th e  e x p er ­
im en ta l o b serv a tio n s d escr ib ed  in  th is  w ork.
F igu re 6 p resents stereo  v iew s o f  ( + ) - C P I  (I )  an d  ( - ) - C P I  (II  
or I I I )  a d d u cts w ith  th e  d u p lex  o lig o m e r  o f  5 'C G T T A * A C G -3 '  
(o n ly  th e  5 'G T T A * A -3 '  p or tion  is sh o w n  for  c la r ity ) . T h ese  
stru ctu res w e re  g en era ted  b y  th e  m o d e lin g  p rogram  m o s a ic ,  an  
U p jo h n -d evelop ed  program  b ased  on  M a c r o m o d e l42 U s in g  the  
A M B E R  se t  o f  force  fie ld  p a ram eters,43,44 w e  p erform ed  en ergy  
m in im iza tio n s  sta r tin g  fr o m  id e a liz e d  D N A  h e lic e s  to  w h ich  a  
ring-opened C P I m o iety  h ad  b een  a tta ch ed . T h ese  structures are  
intended to  help  illustrate possib le interactions o f  these  agen ts w ith  
rec o g n itio n  e le m e n ts  in  th e  m in or  gro o v e  o f  D N A . T h e  a d d u ct  
is a ssu m ed  to  r esem b le  th e  a c tiv a te d  c o m p lex  in  th e  tran sition  
sta te  for the a lkylation  reaction . T h e  covalen tly  m odified  aden in e  
(A * )  is  in a  g o od  con sen su s b o n d in g  seq u en ce  for b o th  ( + ) -C C -  
10 65  (5 'T T A * ) an d  ( - ) - C C -1 0 6 5  ( 5 T A * A ) .  In  stru ctu re  I, the  
b on d ed  ( + ) - C P I  is  o r ie n te d  to  p la ce  th e  a c y l a p p e n d a g e  [for  
s im p lic ity  th e  ad d u ct o f  ( + ) - A  w a s u sed  for th e  m o d elin g ] in th e  
m inor gro o v e , ly in g  to  th e  5 '-s id e  o f  th e  c o v a le n tly  m o d ified  
a d en in e . T h e  e n e r g y -m in im iz e d  s tru ctu re  p la ce s  th e  p h en o lic  
hydroxyl group w ithin  hydrogen-bonding d istance o f  the  phosphate  
oxygen  ( 0 - 0  d istance =  2 .6  A, I; F igure 6 ) on  th e  opposite  strand, 
tw o  base  pairs dow n from  th e  co v a len tly  bond ed ad en in e. W h ile  
th e  proxim ity o f  th ese  groups in th e  energy-m in im ized  m odel m ost 
lik e ly  re flec ts  th e  m a g n if ic a t io n  o f  su c h  d ip o la r  in ter a c tio n s in  
th e  g a s -p h a se  c a lc u la t io n s  e m p lo y e d , it a lso  su g g e s ts  th a t su ch  
an in tera ctio n  is p o ssib le  a n d  th u s m ig h t p la y  a ro le  in protic  
activ a tion  o f  th e  (+ ) - C P I  m o ie ty . T h is  or ien ta tion  a lso  positions  
th e  pyrrolid ine m e th y len e  carb o n  for  a  fav orab le  van  der W a a ls  
co n ta c t (C —C  d ista n ce  =  3 .3  A) w ith  th e  C 2  o f  th e  ad e n in e  one  
b a se  pair d ow n , on  th e  o p p o site  stran d , an d  c lo se  to  th e  0 2  o f  
th e  th y m in e  o f  th a t b a se  p a ir  ( C - O  d is ta n c e  =  3.1 A, I; F igu re  
6 ) .  T h er e  is a  fa v o ra b le  van  der W a a ls  d is ta n c e  b e tw een  the  
carbon  a to m  o f  th e  a c y l a p p e n d a g e  (m e th y l, in I) and  th e  C 2  o f
(42) Still, C. W „ Columbia University.
(43) Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C : 
Alagona, G.; Profeta, S., Jr.; Weiner, P. J. Am. Chem. Soc. 1984, 106, 76.
(44) Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. J. C om put. 
Chem. 1986, 7, 230.
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the adenine on  th e  o p p o site  stran d , tw o  b a se  pa irs in th e  5 '-d i- 
rection from the bonded aden in e ( C - C  d istan ce =  3 .8  A, I; F igure
6).
All o f the observed con tacts in I lie  o n  th e  5 '-side o f  th e  adduct. 
Even the in d o le  m e th y l su b stitu en t, w h ile  it fa c e s  th e  3 '-s id e  o f  
the adduct, lies far from  th e  base pair to  th e  3'-side o f  the  alkylated  
adenine. T h u s, th is  m o d el is  c o n s is te n t w ith  th e  (+ ) -C C -1 0 6 5  
consensus d ata , w h ich  o n ly  sh ow  a  gen eral seq u en ce  requirem ent  
in the 5'-direction from  th e  ad d u ct, and  w ith  foo tprin ting, as w ell 
as N M R  d a ta .15 It fu rth er su g g e s ts  th a t a  fa v o ra b le  d ip olar  
interaction b e tw een  th e  o x o  g ro u p  o f  ( + ) - C P I  an d  a p h osp h ate  
group in th e  b a ck b o n e  o f  th e  h e lix  is  c o m p a tib le  w ith  fav orab le  
van der W aals in ter a c tio n s o f  th is  a lk y la tin g  m o ie ty .
With such a  s ig n ific a n t n u m b er  o f  p ossib le  recogn itio n  poin ts  
for (+)-C PI a t th is reactive seq uence it is not surprising that chiral 
discrimination is h ig h . In  fa c t, th e  grea ter  su rp rise  is th a t ( - ) - A  
reacts as w ell a s  it  d o e s  a t  th e  se t  o f  a d e n in es  corresp o n d in g  to  
(+)-CC-1065 reactive sites. O n e  possib le  m od el for  th is reaction  
is shown in II, th e  d iastereom er o f  I, in w h ich  th e  (~ )-C P I  m oiety  
has been turned  c a . 1 8 0 °  arou n d  th e  a x is  r u n n in g  th rou gh  th e  
original cyclohexadienone carbonyl group. T h is orientation  allow s  
covalent bond ing  to  N 3  o f  th e  sa m e  a d e n in e  b on d ed  in  I, w h ile  
still maintaining th e  c lose  phenolic  hydroxy group interaction w ith  
the phosphate tw o  b a se  p a irs in  th e  5 '-d ire ctio n  ( 0 - 0  d is ta n ce  
= 2.7 A, II; F ig u re  6 ) . T h is  m in im ize d  s tru ctu re  u n d o u b ted ly  
benefits in th e  m o d elin g  from  th e  a d d itio n a l h y d rog en  b ond  o f  
the indole N - H  to  th e  p h osp h ate  ( H - O  d is ta n c e  =  1.8 A). T h e  
indole methyl carbon has favorab le con tacts w ith  th e  5' T - A  base  
pair (m ethyl carb o n  to  th y m in e  0 2  d is ta n c e  =  3.1 A, II; F igu re  
6). This or ien tation  o f  ( - ) - C P I  p la ces  th e  a c y l ap p en d ag e  in th e  
3'-direction from  th e  a d d u ct s ite , b u t in  ord er  to  m a in ta in  th e  
phenol phosphate in teraction , th e  m o lecu le  is  sk ew ed  in a m anner  
that pulls th is  a p p en d a g e  o u t from  th e  groov e. In II , w h ere  th is  
group is m eth y l, it  is  q u ite  d is ta n t fro m  th e  3 ' A - T  b a se  pair  
(carbon to ad en in e  N 3  d is ta n ce  =  5 .4  A, II; F ig u re  6 ) .  I t is th is  
model that w e  su g g est to  ex p la in  th e  o b serv ed  reaction  o f  ( - ) - A  
at the adenines o f  (+ )-C C -1 0 6 5  sites. T h e  10-fold  low er reactivity  
of (-)-A  rela tive  to  ( + ) - A  in d ic a te d  b y  th e  c o n cen tra tio n  d e ­
pendence o f  th e  c le a v a g e  a ssa y  w o u ld  su g g e s t  th a t II  represents  
only a slightly higher energy pathw ay than I. T h e  lack  o f  reactivity  
of (-)-C P I com p o u n d s w ith  a c y l ap p en d a g es larger th a n  m eth y l 
at these (+ )-C C -1 0 6 5  s ite  ad en in es  w ou ld  in d ica te , acco rd in g  to  
this model, th a t ( 1 )  lea v in g  su ch  la rg e  h y d rop h o b ic  a p p en d ag es  
protruding ou t o f  th e  groov e  is n o t a  fa v orab le  s itu a tio n , and (2 )  
reorientation to  optim ize  groove binding o f  th ese  appendages could  
rotate the ( - ) - C P I  m o ie ty  a w a y  from  th e  fa v o r a b le  or ien ta tio n  
for alkylation d e p ic ted  in  II.
The 10-fold  low er  a lk y la tio n  r ea c tiv ity  o f  ( - ) - A  a t  th e  ( + ) -  
CC-1065 s ite  a d en in es  c o rr e la te d  w ith  its  1 0 -fo ld  low er  in v itro  
cytotoxic potency (T ab le  IX ). W e  had  previously noted  a  positive, 
rank order co rrela tion  b e tw ee n  r e la tiv e  D N A  rea c tiv ity  (a s  re­
flected by the  dru g  con cen tration  required  in th e  c lea v a g e  assay )  
of a series o f  ( + ) - C P I  a n a lo g u e s  an d  th e ir  in  v itro  c y to to x ic  
potency and in v iv o  p o ten c y .23 T h e  o b serv ed  la ck  o f  p o ten t c y ­
totoxicity o f  ( - ) - A B  an d  ( - ) - A B C  (T a b le  I X )  is  c o n sisten t w ith  
their observed la ck  o f  rea c tiv ity  w ith  th e  (+ ) -C C -1 0 6 5  s ite  a d e­
nines (Table V III) and further exten ds the correlation o f  reactivity  
at these s ites on  n ak ed  D N A  w ith  c y to to x ic  p o ten c y  for th ese  
compounds.
Model II can  a c co u n t for  th e  o b serv ed  (+ ) - C C - 1 0 6 5  s ite  re­
activity o f  ( - ) - A . W h ile  a ltern ative  m o d els  m ig h t b e  considered , 
including one in w hich  th e  acy l m eth y l group  o f  th e  ( - ) - A  addu ct 
lies in the 5 '-d irection  from  th e  c o v a len tly  m o d ified  ad en in e  (n o t  
shown), II appears to  be th e  m ore a ttractive  conform ation  for th e  
(-)-A adduct. A  d iffer en t m o d el ( I I I , F ig u re  6 )  is required  to  
account for the observed reactivity o f  ( - ) -C C -1 0 6 5  and ( - ) -A B 'C '  
at the ( - ) - C C -1 0 6 5  a lk y la tio n  s ite s . [R e c a ll  th a t w e  are  u sin g  
the term “alkylation  s ite ” to  refer not o n ly  to  th e  sp ecific  aden in e  
involved in bonding but a lso  to  the sequence con tex t as sum m arized  
in the consensus seq u en c e  for th e  drug . H e n c e , w h ile  m od els I 
and II dep ict p ossib le  ( + ) -  an d  ( - ) - C P I  a d d u ct in tera c tio n s a t  
a 5'TTA* “ (+ ) -C C -1 0 6 5  a lk y la tio n  s ite ”, m o d el III d escr ib es a
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p ossib le  ( - ) - C P I  a d d u ct ( ( - ) - A  is  sh ow n  for  s im p lic ity )  a t  th e  
overlap p ing but d istin ct 5 'T A * A  “( - ) - C C -1 0 6 5  a lk y la tion  s ite ”.]
In III, th e  acyl appendage lies in  th e  m inor groove to  th e  3'-side  
o f  th e  c o v a len tly  m o d ified  a d e n in e . T h is  m o d el a c co m m o d a te s  
th e  foo tp r in tin g  fin d in g s for  ( - ) - C C - 1 0 6 5 ,  th e  r ecovery  o f  e s­
sen tia lly  o n ly  ad en in e  N 3  ad d u cts , and  th e  h igh  d e g ree  o f  m inor  
grooves overlap betw een  (+ )-C C -1 0 6 5  sites and ( - ) -C C -1 0 6 5  sites  
on  th e  D N A  fr a g m en ts  e x a m in e d  in  th is  w ork  (C h a r t  I I I ) . In  
th e  en er g y -m in im ize d  str u ctu r e  I I I , th e  a c y l m e th y l g rou p  is 
b rou gh t in to  fav o ra b le  c o n ta c t  w ith  th e  a d e n in e  ly in g  3 ' to  th e  
ad d u ct, p articu la r ly  w ith  its  a n o m e r ic  carb o n  ( C - C  d is ta n c e  =  
3 .6  A) and  its  N 3  a to m  ( C - N  d is ta n c e  =  3 .8  A, III; F ig u re  6 ) .  
T his proxim ity suggests th a t larger acy l appendages can  a lso  enjoy  
c lo se  in tera ctio n  w ith  th e  gro o v e  in  th e  3 '-d irectio n , to  a  m u ch  
greater  ex ten t than  is p ossib le  in stru ctu re  II. T h e  in d o le  m eth y l 
group  en joys c o n ta c t w ith  th e  th y m in e  0 2  ( C - O  d is ta n c e  =  3 .3  
A, III; F igure 6 ) and th e  ad en in e C 2  ( C - C  d istan ce  =  3 .4  A) and  
adenin e N 3  ( C - N  d istan ce  =  3 .8  A) in  th e  base  pair im m ed ia tely  
5 ' to  th e  ad d u ct. T h is  5' b a se  pair r ec o g n itio n  o f  III  p rovid es a  
m o d elin g  ra tio n a le  for th e  ob serv ed  5 ' flan k in g  A T  req u irem en t  
o f  ( - ) - C C - 1 0 6 5 ,  ev en  th o u g h  th e  a c y l a p p e n d a g e  lie s  in  th e  3 '- 
d irection  from  th e  a d d u ct. T o  a c h ie v e  th e  fav o ra b le  3 '-co n ta c ts  
o f  th e  addu ct structure III, th e  phenol hydroxyl grou p  interaction  
w ith  th e  p h osp h ate  grou p  ( 0 - 0  d ista n c e  =  5 .3  A, III; F ig u re  6 )  
has been  sa cr ificed . I f  in d eed  th e  p h o sp h a te  p r o x im ity  in  I and  
in II is  im p ortan t to  p rovid e  e le c tr o p h ilic  a c tiv a tio n  o f  th e  c y -  
c lop rop y lcy clo h ex a d ien o n e  m o ie ty  (n u c le o p h ilic  r in g  o p en in g  o f  
C P I com pounds in so lu tion  is stron gly  ac id  ca ta ly z ed ),21W1,45 then  
( - ) - C P I  co m p o u n d s w o u ld  b e  e x p ec te d  to  su ffe r  a sev er e  loss o f  
reactiv ity  w ith  D N A  w h en  orien ted  as in  III.46 T h e  observations  
(T a b le  V I I I )  th a t  ( - ) - A ,  ( - ) - A B ,  a n d  ( - ) - A B C  a r e  e x tre m e ly  
u n rea ctive  a t ( - ) - C C - 1 0 6 5  s ite s  is  c o n s is te n t w ith  th is  m o d el. 
P articu la rly  in th e  c a s e  o f  ( + ) -  an d  ( - ) - A ,  w h ere  d iffer en tia l  
binding interactions are m in im ized , it is apparent th a t ( - ) - A  reacts  
a t  ( - ) - C C -1 0 6 5  s ite s  ( I I I )  a t  le a s t  2  ord ers o f  m a g n itu d e  m o re  
slow ly than ( + ) - A  reacts a t  (+ )-C C -1 0 6 5  s ites (I ) . Indeed , ( - ) - A  
appears better ab le  to  react a t (+ ) -C C -1 0 6 5  s ites (II , v id e  supra). 
C lea r ly  th e  ( - ) - C P I  a lk y la tin g  s tru ctu re  b y  itse lf , in  c o n tra st to  
( + ) - C P I ,  d o es  n o t en jo y  u n iq u e ly  fa c il ita te d  a lk y la tio n .
W h y then d o  (-)-C C -1 0 6 5  and ( - ) -A B 'C ' readily alkylate D N A  
a t  the (-)-C C -1 0 6 5  sites?  T h e  answ er m u st lie  w ith  th e  interaction  
o f  th e  la rg e , b is (p y r ro lo in d o le ) a c y l  a p p e n d a g e  w ith  th e  m in or  
g roov e  w h en  th e  d ru g  is  o r ie n te d  a s  d e p ic ted  in  III . T h e  low  
reactiv ity  o f  ( - ) - A B  and ( - ) - A B C  a t th ese  s ites  su g g ests  th a t th e  
less sp ecific  hydrophobic b ind ing interactions th a t th ese  m olecu les  
allow  (a s  indicated , for exa m p le , b y  their m easu rab le  stab ilization  
o f  D N A  tow ard  th erm a l m e lt in g , s e e  T a b le  I X )  a r e  s im p ly  in ­
ad e q u a te  to  fa c il ita te  th e  less  fa v o r a b le  c o v a len t r ea c tio n . T h e  
d ram atic  a lk ylation  rate  en h a n cem en t resu ltin g  from  a tta ch m en t  
o f  th e  fu ll carb on  sk e le ton  o f  th e  natu ra l p roducts to  th e  ( - ) - C P I  
m oiety  strongly  im plies th a t sp ec ific  A T  recogn izin g  in teractions, 
such as favorable van  der W aals con tacts involving th e  rigidly held  
fram ew ork o f  pyrro lid ine m eth y len e  groups, p lay  a  d om in a n t role  
in  both th e  ab so lu te  an d  rela tive  reactiv ities  o f  ( - ) - C C -1 0 6 5  and  
( - ) - A B 'C '  w ith  D N A .
T h at the pyrrolidine m ethylene groups o f  the  B' and C ' segm ents  
ca n  p lay  a d ec is iv e  ro le  in  m inor g r o o v e  b in d in g  is su p p orted  by  
th e  ob servation  o f  a n  in d u ced  c ircu la r  d ich ro ism  o f  th is  d im eric  
fra g m en t [fro m  th e  a lk a lin e  h y d ro ly sis  o f  (+ ) - C C - 1 0 6 5 ]  in  th e  
p resen ce  o f  c a l f  th y m u s D N A .31 In  co n tr a st, th e  a m id e  lin k ed  
bis(indo!e-2-carboxylate) from  th e  a lkaline hydrolysis o f  ( + ) -A B C  
sh ow s n o  in d u ced  c ircu la r  d ich r o ism  w ith  D N A .47 Im p o rta n t  
synth etic48 and com putational49 stud ies b y  B oger h ave contributed
(45) Warpehoski, M. A.; Harper, D. E. Unpublished results.
(46) Another feature distinguishing model I from the diastereomeric model 
III is the steric conformation around the newly formed N -C bond. Viewed 
along the axis of this bond, the adenine ring in structure I is almost fully 
staggered relative to the nearest carbon-carbon bond of the drug moiety. In 
structure III, in contrast, the adenine ring is nearly eclipsed by this carbon- 
carbon bond. An interaction such as this might significantly add to the 
instability of a transition state resembling III.
(47) Warpehoski, M. A.; Krueger, W. C. Unpublished results.
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to an appreciation o f  th e  str o n g  m in or  gro o v e  a ff in ity  o f  B '-C '  
oligomers. Indeed , th ese  s tu d ies  are  h ig h ly  relevant to  th e  D N A  
sequence recogn itio n  c h a ra cte r is tic s  o f  (—)-C C -1 0 6 5 .
Interestingly, ( - ) - C C -1 0 6 5  d o e s  n o t d iscr im in a te  sig n ifica n tly  
among 5 'A A *A , 5 'T A * A , an d  5 'A A * T  seq u en ces (T a b le  IV ), as  
expected from  an  a g en t w h o se  p r im ary  rec o g n itio n  m o d e  fu n ­
damentally resem bles that o f  n on covalen t m inor groove b inders.20 
There is, how ever, c learly  a low er d e g ree  o f  r eactiv ity  a t 5 T A * T  
sequences, and  th is  m a y  r e flec t a  p a r ticu la r  b o n d in g  lim ita t io n  
in III at that sequence. It is in triguing th at th e  seq uencing studies  
show (Chart III) that o f  the  14 ( - ) -C C -1 0 6 5  sites not overlapping  
(+)-CC-1065 alkylation  sites, 8 are w ith in  or adjacent to  5 'A A T T  
sequences. F our o f  th e se  a re  a m o n g  th e  m o st r ea c tiv e  ( - ) - C -  
C-1065 sites (T a b le  I I ) . T h is  seq u en c e , a s  d iscu ssed  ab ove, is a  
highly favorable b in d in g  s ite  for  netropsin  an d  rela ted  reversib le  
binding agents and is an  e x ce p tio n a lly  sta b le , reversib le  (n o n co ­
valent) binding s ite  for  ( + ) -C C -1 0 6 5 .  T h e  im p lica tio n  o f  th ese  
observations is th a t A T -sp ec ific  m inor groove binding interactions  
attributable to  th e  B ' and  C ' se g m e n ts  ap p ea r  to  b e  th e  m ain  
determinant o f  the  reactivity o f  ( - ) -C C -1 0 6 5  at its target adenines. 
In terms o f  eq  1, kT for ( - ) - C C -1 0 6 5  is  n o t grea tly  fa c ilita ted  by  
favorable tra n sitio n -sta te  s ta b iliz a tio n  a t p a r ticu la r  seq u en ces. 
Rather, h igh b in d in g  a ff in ity  for c er ta in  seq u en c es  is  n ecessa ry  
for significant a lk y la tio n  to  o ccu r  th ere .
The similar level o f  cy to to x ic  p oten cy  ( I D 50 va lues) o f  ( + ) -  and  
(-)-CC-1065 ag a in st several ce ll lin es observed  b y  us (T a b le  IX )  
and others24 is som ew hat fortu itous and  m islead ing. C ytotox ic ity , 
of course, m ay be the  result o f  diverse lethal b iochem ical processes. 
While (-)-C C -1 0 6 5  and ( - ) - A B 'C '  are, i f  an yth in g , s ligh tly  m ore  
potent in the b iological sy stem s tested  than  are (+ )-C C -1 0 6 5  and  
(+)-AB'C' (T ab le  IX ), th ey  are about an  order o f  m a gn itu d e  less  
reactive than th e ir  ( + )  cou n terp a rts  tow ard  D N A  under th e  
reaction con d ition s u sed  in th e  a lk y la tio n  ex p er im en ts  (T a b le  
VIII). Thus, th e  rank order correlation  o f  p oten cy  and reactiv ity  
observed for com p o u n d s rea c tin g  a t  ( + ) -C C -1 0 6 5  s ite s  m u st be  
considered sep a ra te ly  from  a s im ila r  co rre la tio n  for com p o u n d s  
reacting at ( - ) - C C -1 0 6 5  s ites . T h is  is e x p ec te d  i f  d ifferen t b io­
chemical m ech an ism s for c y to to x ic ity  r esu lt fro m  th e  d iffer en t  
molecular lesions on D N A . B eca u se  it seem s reasonab le  th at the  
observed low level o f  reaction  o f  th e  s im p ler  ( + ) - C P I  a g en ts  a t  
adenines in (-)-C C -1 0 6 5  sites (T ab le  V III) produces adducts lying  
to the 5'-side o f  th e  a lk y la ted  ad en in e, rather th an  to  th e  3 '-side , 
these (+ )-C P I  a g en ts  sh o u ld  n o t b e  in clu d ed  in  corre la tio n s o f  
reactivity and p oten cy  o f  ( - ) - C P I  a g e n ts  a t  ( - ) - C C - 1 0 6 5  s ites . 
Further delineation o f  th e  b io lo g ica l an d  b io ch em ica l d ifferen ces  
between ( + ) -  and  ( - ) - C C - 1 0 6 5  is in  progress. O n e  str ik in g  
difference already noted (T a b le  IX ) is th a t ( - ) -C C -1 0 6 5  does not 
cause delayed d eath  in  m ice .
The full carbon structure right-hand appendage has a  som ew hat 
more subtle, b u t n everth eless, s ig n ifica n t e ffe c t  on  th e  properties  
of (+)-C PI as  w e ll.23 A t  so m e  seq u en c es , it  ap p ea rs th a t th e  
specific noncovalent in teractions o f  th e  tw o  pyrrolid ine rings w ith  
the minor groove can  e ith er  p rom o te  an  o th erw ise  less favorab le  
bonding reaction [operationally sim ilar to  ( - ) -C C -1 0 6 5 ]  or inhibit, 
perhaps through a com p etitive  b in d in g  m o d e, a  b on d in g  reaction  
that is availab le  to  sim p ler  ( + ) - C P I  a n a lo g u es . W h ile  th ese  
specific binding in teractio n s are  c le a r ly  n ot resp on sib le  for th e  
large majority o f  (+ )-C C -1 0 6 5 -r e a c tiv e  a lk y lation  s ites on  D N A  
restriction fragm en ts,23 th e y  ap p ear  to  h av e  profoun d  b io lo g ica l  
significance. O n ly  (+ ) -C C -1 0 6 5  an d  (-F )-A B 'C ' [and n ot th e  
simpler (+ )-C P I  a g en ts] c a u se  d e la y ed  d e a th  in m ice  a t th e ra ­
peutic doses.20,21’28 T h is d ifference could  conceivably reflect adduct 
formation at unique sites w ith th ese  agen ts. A lternatively , unique  
structural and fu n ction al con seq u en ces  to  D N A  cau sed  by th ese  
specific binding in teractions, a v a ila b le  on ly  to  (+ ) -C C -1 0 6 5  and  
(+)-AB'C' cov a len t ad d u cts , m a y  b e  cr itic a l for  th e  exp ressio n  
of this toxicity .
(48) Boger, D . L.; C olem an, R . S .; Invergo, B. J. J. Org. Chem. 1987 , 52,
1521.
(49) Coleman, R. S .; Boger, D . L. In S tu dies in N atural Products Chem­
istry, Atta-ur-Rahm an, Ed.; Elsevier: A m sterd am , 1988; V ol. 2.
In earlier  b io sy n th e s is  s tu d ie s ,50 w e  had  c o n clu d ed  th a t S. 
zelensis in corp orated  a  s in g le  c a rb o n  a to m  fro m  m e th io n in e  to  
form  th e  c y clop rop y l g ro u p  o f  ( + ) - C C - 1 0 6 5 .  W a s it s tr ic tly  
fortu itou s th a t th e  7 b /? ,8a/? en a n tio m e r  w a s  fo rm ed , or w as th is  
the  result o f  selective  pressure? O n ly  th e  (+ ) -C P I  m oiety  appears 
to  rec o g n ize  th e  m in or  gro o v e  th r o u g h  seq u en c e-d e p e n d en t c o ­
valent reactivity. T h e  synth etica lly  prepared unnatural enantiom er  
o f  th e  natu ra l p roduct, w h ile  it  is a lso  a p o ten t c y to to x in , h a s a 
fu n d a m en ta lly  d ifferen t u ltim a te  in teractio n  w ith  d ou b le -h e lica l 
D N A  and a t least so m e  d iffer en t resu ltin g  b io lo g ica l properties. 
It is sp e cu la tiv e  b ut c o n c e iv a b le  th a t th e se  d iffe r e n t b io lo g ica l  
properties w ou ld  n ot h av e  g iv en  th e  m icro o rg a n ism  a p articu lar  
survival advantage. L ikew ise, it is in teresting to  n ote  that th e  WCf 
pyrrolid ine carbon  a to m s a re  n ot in corp orated  th rou gh  tyrosin e, 
as m ight, a  priori, be supposed . In stead , tw o carbon  a to m s from  
ser in e  are in corp orated  in to  e a c h  o f  th e  tyrosin e-d er iv ed  in d o les  
o f  the B 'C ' seg m en t.50 I t is  th is  ad d ition al stru ctu ral e lab oration  
th a t lea d s to  th e  su b tle  m o d u la tio n  o f  th e  ( + ) - C P I  c o v a len t re­
actio n  site  or ad d u ct stru ctu re, w h ich  in  turn appears to  underlie  
delayed tox icity  in rodents. C onceivably , this structural elaboration  
m ight a lso  result from  se lective  pressure. A n  excitin g  and general 
im p lica tion  o f  th e se  co n s id e ra tio n s  is th a t th e  very  b io sy n th esis  
o f  natural product tox ins m a y  provide im portant c lu e s  ab ou t their  
e ssen tia l rea c tiv ity  fe a tu r e s . I f  th e se  o fte n  e la b o ra te  m o le cu les  
have evo lved  th rou gh  m u ltip le  lev e ls  o f  s tru ctu ra l r efin em en t to  
o p tim iz e  k e y  b io lo g ica l in ter a c tio n s , th en  a  k n o w le d g e  o f  th e  
b io sy n th etic  or ig in s o f  th e  stru ctu ra l c o m p o n en ts  co u ld  serve  as  
a  va lu a b le  in sp ira tion  to  s tr u c tu r e -a c t iv ity  in v est ig a tio n s .
T h e  syn th etic  tox in  ( - ) - C C -1 0 6 5  ap p ears to  h ave “p irated ” an  
A T -sp e c if ic  m inor gro o v e  b in d in g  lig a n d  th a t w a s e x q u is ite ly  
d esig n ed  th rou gh  e v o lu tio n  to  o p t im iz e  th e  c r itic a l ( to  th e  pro­
ducing organ ism ) D N A  in teraction  o f  (+ ) -C C -1 0 6 5 . It uses th is  
structural k ey  to  ga in  en try  to  A T  r eg io n s g en era lly  favorab le  to  
(+ ) -C C -1 0 6 5  (an d  o th er  m in or g r o o v e  b in d ers). O n ce  th ere , 
however, the  rules governing the  critical covalent reaction are quite  
d ifferen t th a n  for th e  n atu ra l p rod u ct. O n e  m ig h t a lso  regard  
th e  sy n th etic  ( + ) - C P I  a n a lo g u e s , su c h  a s  ( + ) - A B C , a s  h av in g  
“p irated ” th e  seq u en c e-d iscr im in a tin g  a lk y la tin g  m o ie ty  o f  th e  
natural product. S ep arated  from  th e  n atural b in d in g  liga n d , and  
e ff ic ie n tly  d e livered  to  th e  r ea c tiv e  D N A  s ite  b y  le ss  sp e c ific  
binding ligands, th ese  an a log u es a r e  proving to  be h igh ly  e ffective  
and  p oten t an titu m o r  a g e n ts  in  a n im a l te s t in g .21
It has b een  su g g ested  th a t  th e  p r ed ilectio n  o f  n atu ra l product 
d e fen se  m o lecu les  for th e  m in or  gro o v e  is a n  e vo lu tio n ary  a d a p ­
ta t io n  to  th e  a c c e ss ib ility  o f  th is  g r o o v e , w h ich  is  n o t o c cu p ie d  
b y en d ogen ou s p rote in s.20 T h e  ex tra ord in a ry  an d  h ig h ly  evolved  
D N A  b in d in g  an d  b o n d in g  in ter a c tio n s  o f  ( + ) -C C -1 0 6 5  in v ite  
even  fu rth er in tr ig u in g  sp e c u la tio n s . T h e  “r ec o g n itio n ” b y  
(+ )-C C -1 0 6 5  o f  its critical reactive seq uences in  D N A  m a y  involve  
both  c o g n itiv e  an d  resp on se  fe a tu r es , i .e .,  th e se  D N A  seq u en ces  
m a y  be p h arm a co log ica l r ecep to rs.51 T h ey  m ig h t, for e x a m p le , 
b e norm al b in d in g  r eg ion s for  r eg u la to ry  p rote in s , an d  m o d if i­
ca tio n s o f  th o se  seq u en c es  c o u ld  a ffe c t  p rote in  b in d in g , and  u l­
tim ately  th e  p rocesses th a t th o se  p rotein s con tro l. A ltern ative ly , 
unusual D N A  loca l structures th a t are  seq u en ce  dep en d en t could  
be receptors for selective  d rug action . O ur c learer  understanding, 
resu ltin g  from  th e  p resen t w ork , o f  th e  s tru ctu ra l b a sis  for th e  
bin d in g  an d  b on d in g  s e le c t iv ity  o f  ( + ) - C C - 1 0 6 5  an d  related  
m olecules w ill help  to focu s the study  o f  th e  consequ ences o f  those  
in teraction s and the e ffo r ts  to  e x p lo it th e m  for th era p eu tic  ends.
E x p erim en ta l S e c t io n
Instrumentation and Reagents. Melting points were taken on a Kofier 
hot-stage or a Thomas-Hoover Unimelt apparatus and are uncorrected. 
Combustion analysis and IR and mass spectra were obtained by the 
Physical and Analytical Chemistry Research Department of The Upjohn 
Co. Fast atom bombardment (FAB) mass spectra were run on a JG 
ZAB 2F instrument, and electron-impact (El) mass spectra were run at 
70 eV on a CEC 21-110B mass spectrometer. Proton NMR spectra were
(5 0 ) H u rley , L . H .; R okem , J. S . J. A n tib io t. 1983 , 36, 383.
(5 1 )  H u rley , L. H . J. M ed. Chem. 1989 , 32, 2 0 2 7 .
Sequence Specificity and Synthetic Analogues
recorded on a Varian 390 (90-MHz) or a Bruker Aspect 3000 (300- 
MHz) instrument, and ,3C NMR spectra were recorded on a Varian 
CFT-20 (20-MHz) instrument. Chemical shifts are reported in parts per 
million relative to internal tetramethylsilane. Ultraviolet spectra were 
recorded on a Perkin-Elmer Lambda 3 spectrophotometer. Analtech 
silica gel GF (0.25-mm) plates were used for TLC, with visualization by 
UV light. Column chromatography was performed on silica gel (70-230 
mesh, gravity; 230-400 mesh, low-medium pressure) supplied by E. 
Merck, Darmstadt. Tetrahydrofuran (THF) was dried by distillation 
under nitrogen from sodium/benzophenone ketyl. Acetonitrile was dis­
tilled from calcium hydride. Dry pyridine was obtained by distillation 
from sodium hydroxide. All other solvents were reagent grade or reagent 
grade distilled from glass (Burdick & Jackson). Ammonium formate was 
dried in vacuo, in the presence of H2S04, for 24 h. All other reagents 
were used as purchased and were reagent grade where available. In order 
to minimize the health risks posed by these potent cytotoxic agents to 
analytical service personnel outside of our own laboratory and to allow 
preparation of only the very limited quantities needed for testing, com­
bustion elemental analyses were not obtained on the final analogues, 
except for ABC. These substances were, however, homogeneous by TLC. 
Experimental details of the resolution of 1 to 2 and 3 are provided in the 
supplementary materials.
(S)-l,6-Dihydro-l-(hydroxymethyI)-8-methyl-5-(phenylinethoxy)- 
benzo[l,2-Z>:4,3-6/]dipyrrole-3(2//)-carboxylic Acid 1,1-Dimethylethyl 
Ester {(5)-8J. Under a nitrogen atmosphere, a solution of 1.0 g (2.6 
mmol) of 2 in 50 mL of anhydrous THF and 50 mL of toluene was 
treated dropwise, with stirring, with 5.0 mL (17 mmol) of a 3.4 M 
solution of REDAL in toluene. The solution was quickly heated under 
a nitrogen flow, allowing the escape of THF until the temperature 
reached 85 °C. After 0.5 h, the reaction mixture was cooled in an ice 
bath and carefully treated with 50 mL of 15% aqueous potassium car­
bonate. The mixture was partitioned between water and ethyl acetate, 
which had previously been purged with nitrogen. The aqueous layer was 
separated and twice more extracted with nitrogen-purged ethyl acetate. 
The combined organic layers were dried over sodium sulfate and con­
centrated in vacuo to give ( S )-7 as a tan foam. This material is exqui­
sitely sensitive to air and light and was used directly in the next reaction. 
Under a nitrogen atmosphere, crude ( S ) - l  was dissolved in 10 mL of 
anhydrous THF and the resultant solution treated with 0.38 mL (5.1 
mmol) of triethylamine and 0.70 g (2.8 mmol) of BOC-ON. After 90 
h, the reaction mixture was concentrated in vacuo and the residue 
chromatographed over 180 g of silica gel, eluting with 10% ethyl acetate 
in hexane to 50% ethyl acetate in hexane. This afforded 0.75 g (71%) 
of ( S ) - 8 :  »H NMR (CDC13) 6  8.5 (s, 1 H), 7.8-7.2 (m, 6 H), 6.9 (s, 1 
H), 5.15 (s, 2 H), 4.4-3.4 (m, 6 H), 2.3 (s, 3 H), 1.6 (s, 9 H); MS calcd 
for C24H2gN204 m / e  408.2049, found 408.2051. Analogously, (/?)-8 was 
prepared from 3.
(S)-l-(Chloromethyl)-l,6-dihydro-8-methyl-5-(phenyImethoxy)- 
benzo[l,2-b:4,3-h']dipyrrole-3(2//)-carboxylic Acid 1,1-Dimethylethyl 
Ester [(S)-9J. A 120-mg (0.29-mmol) quantity of alcohol (S)-8 was 
dissolved in 2 mL of pyridine under a nitrogen atmosphere and the 
solution cooled to 0 °C and treated with 0.10 mL (0.145 g, 1.27 mmol) 
of methanesulfonyl chloride. The reaction was allowed to warm to room 
temperature and stand for 6 h. It was then recooled to 0 °C and treated 
with a few drops of water. After about 10 min, the reaction was parti­
tioned between methylene chloride and 5% aqueous sodium bisulfate. 
The aqueous layer was separated and reextracted with methylene chlo­
ride. The combined organic solutions were dried over sodium sulfate and 
concentrated under vacuum leaving the mesylate: ’H NMR (CDC13) b
8.4 (s, 1 H), 1 . 1 - 1 . 2  (m, 6 H), 6.9 (s, 1 H), 5.1 (s, 2 H), 4.6-3.6 (m, 5 
H), 2.8 (s, 3 H), 2.4 (s, 3 H), 1.6 (s, 9 H); R f  0.31 (20% ethyl acetate 
in hexane). The crude mesylate was dissolved in 3 mL of dry DMF and 
treated with 40 mg (0.95 mmol) of lithium chloride. The solution was 
heated to 80 °C under nitrogen and stirred at that temperature for 25 
min. The reaciton was then partitioned between methylene chloride and 
water. The aqueous layer was separated and reextracted with methylene 
chloride. The combined organic solutions were dried over sodium sulfate 
and evaporated to dryness in vacuo. The crude solids were chromato­
graphed over 10 g of silica gel, eluting with 20% ethyl acetate in hexane. 
There was obtained 105 mg (85%) of (S ) - 9 : >H NMR (CDC13) 5 8.3 
(s, 1 H), 7.7-7.3 (m, 6 H), 7.0 (s, 1 H), 5.2 (s, 2 H), 4.5-3.2 (m, 5 H),
2.4 (s, 3 H), 1.6 (s, 9 H); MS calcd for C24H27C1N20 3 m / e  426.1710, 
found 426.1721. A similar conversion of (/?)-8 afforded ( R ) - 9 .
(S)-l-(ChIoromethyl)-l,6-dihydro-5-hydroxy-8-methyIbenzo[l,2- 
b :4,3-6'}dipyrrole-3(2H)-carboxylic Acid 1,1-Dimethylethyl Ester ((S)- 
13]. To 110 mg (0.26 mmol) of (*S)-9 dissolved in 2 mL of THF and 2 
mL of methanol was added 120 mg of 10% palladium on carbon and 130 
mg (2.1 mmol) of ammonium formate. The mixture was stirred at room 
temperature for 20 min. The reaction mixture was then filtered and the 
collected solids washed with THF. The combined filtrates were parti­
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tioned between water and ethyl acetate. The aqueous layer was separated 
and reextracted with ethyl acetate. The combined organic layers were 
dried over sodium sulfate and concentrated in vacuo. This left 69 mg of 
tan solid (78%), which was pure enough to use direclty in the next step. 
Purified (S)-13 was obtained with 94% recovery after chromatography 
over silica gel eluted with 30:60:10 ethyl acetate-toluene-chloroform 
followed by the same solvent mixture in the proportions of 50:40:10: IR 
(film) 3383,2961,2853, 2867, 1681, 1500, 1458,1415, 1377, 1369 cm"1; 
UV (ethanol) 245 nm (23 500), 277 (9000), 285 (sh, 8200), 307 (5130), 
320 (4890), 345 (3630); ‘H NMR (CDC13 + acetone-d6) 5  9.7 (s, 1 H),
8.9 (s, 1 H), 7.4 (s, 1 H), 7.1 (s, 1 H), 4.4-3.3 (m, 5 H), 2.4 (s, 3 H),
1.6 (s, 9 H); MS calcd for C|7H2|C1N20 3 m / e  336.1241, found 336.1230; 
[ « ] 25Hg = -20.0° ± 1.2 (DMF, 0.170 g/100 mL). In like manner, (/?)-9  
was converted to (/?)-13: [a]25Hg = +19.3° ± 0.6 (DMF, 0.187 g/100 
mL).
(S)-l-(Chloromethyl)-l,6-dihydro-5-bydroxy-8-metbylbenzo(1,2- 
b̂ -̂bOdipyrrole [(S)-14]. Since 14 is unstable, it was prepared directly 
before use for each analogue. A 50-mg (0.15-mmol) quantity of (S')-13 
was dissolved in 2 mL of ethyl acetate saturated with hydrogen chloride 
gas. After 40 min, the reaction was evaporated to dryness in vacuo and 
the residue reevaporated three times with methylene chloride to remove 
traces of HCI. The residue was then used directly in the coupling re­
actions. The enantiomer (/?)-14 was prepared analogously.
(S)-6-AcetyI-8-(chIoromethyl)-3,6,7,8-tetrahydro-l-methylbenzo{l,2- 
b  :4,3-A/]dipyrrol-4-ol [(S)-15a]. The hydrochloride salt (S)-14 from a 
100-mg (0.30-mmol) conversion of (S)-13 was dissolved in 3 mL of 
anhydrous dimethylacetamide (DMA) and the solution stirred under 
nitrogen in the dark. To this was added 33 mg (0.3 mmol) of acetyl 
imidazolide and the resultant solution stirred at 45 °C for 2.5 h and at 
room temperature for 16 h. The reaction was then partitioned between 
water and ethyl acetate. The aqueous layer was separated and reex­
tracted with ethyl acetate. The combined organic layers were dried over 
sodium sulfate and concentrated in vacuo. The residue was chromato­
graphed over 20 g of silica gel, eluting with 50% acetone in hexane, to 
afford 63 mg (77%) of (S)-15a: >H NMR (DMSO-d6) 5  10.61 (s, 1 H), 
9.67 (s, 1 H), 7.61 (s, 1 H), 7.0 (s, 1 H), 4.18 (dd, J  = 11, 8 Hz, 1 H), 
4.10-4.04 (d, J  = 11 Hz, 1 H), 3.94 (br t, 1 H), 3.85 (dd, J  = 11, ~3  
Hz, 1 H), 3.54 (t, J  = 10 Hz, 1 H), 2.32 (s, 3 H), 2.16 (s, 3 H); MS m / e  
279, 278, 229, 199, 187; R j 0.28 (40% acetone, 60% hexanes, silica). 
Likewise, (/?)-15a was prepared from (/?)-13.
(+)-(7b/?,8aS)- and (-)-(7bS,8aR)-A. Compound (S')-15a (0.23 
mmol) was dissolved in 14 mL of acetonitrile, 3.5 mL of triethylamine, 
and 3.5 mL of water and the resultant mixture stirred for 30 min at 
ambient temperature, under nitrogen. The reaction was complete by 
TLC. The mixture was partitioned between ethyl acetate and water. The 
phases were separated and the aqueous layer was reextracted with ethyl 
acetate. The combined organic phases were dried (Na2S04) and con­
centrated to afford 54 mg (96%) of (+)-A (16) as a solid with spectral 
properties identical with those reported previously for the racemic com­
pounds2011 and exhibiting in addition a CD spectrum as follows: CD 
(methanol) 318 nm, br (-7700) 306 (0), 281 (61000), 257 (0). Analo­
gously, (-)-A was prepared from (/?)-15a in 79% yield: CD (DMF) 329 
nm, br (19000), 311 (0), 284 (-71 000).
(S )-6-(l//-Indol-2-y lcarbonyl)-8-(chloromethyl)-3,6,7,8-tetrahy dro- 
l-methylbenzo[l,2-6:4,3-6/]dipyrrol-4-ol [(S')-15b]. The hydrochloride 
salt (S')-14 from a 50-mg (0.15-mmol) conversion of (S)-13, was dis­
solved in 2 mL of anhydrous DMA and the solution stirred under ni­
trogen in the dark. To this was added 0.15 mmol of indole-2-carboxylic 
acid and 29 mg (0.15 mmol) of EDC as a solid in one portion. After 
stirring about 45 min at room temperature, an additional 0.04 mmol of 
indole-2-carboxylic acid and 7 mg (0.04 mmol) of EDC were added. 
After an additional 1.5 h, the reaction mixture was partitioned between 
water and ethyl acetate. The aqueous layer was separated and reex­
tracted with ethyl acetate. The combined organic layers were dried over 
sodium sulfate and concentrated in vacuo. Chromatography on silica gel, 
eluting with 50% acetone-50% hexane, afforded 50 mg (88%) of (S)-15b: 
UV (methanol) 292 nm (26000), 316 (sh, 18000), 330 (sh, 15000); l H  
NMR (DMSO-<4) 5 11.68 (s, 1 H), 10.74 (s, 1 H), 9.8 (br s, 1 H), 
7.71-7.63 (m, 2 H), 7.50 (d, J  = 8 Hz, 1 H), 7.24 (t, /  = 8 Hz, 1 H),
7.1-7.05 (m, 3 H), 4.65 (br t, J  = 8 Hz, 1 H), 4.53 (d, J  = 11 Hz, 1 H),
4.02 (br t, 1 H), 3.90 (dd, 7 = 11, 2 Hz, 1 H), 3.59 (t, J  = 10 Hz, 1 H),
2.36 (s, 3 H); MS (FAB) calcd for C21HlgCIN30 2 m / e  379.1087, found 
379.1070; Rf 0.41 (40% acetone, 60% hexane, silica). Likewise (7?)-15b 
was obtained from (i?)-13.
(+)-(7bR,8aS)- and (~)-(7bS,8aR)-AB. A 0.11-mmol quantity of 
(S)-15b was dissolved in 9 mL of acetonitrile and the solution treated 
with 2.4 mL of triethylamine and 2.4 mL of water. The resultant solution 
was stirred 15 min at room temperature and then partitioned between 
ethyl acetate and water. The water layer was separated and reextractcd 
several times with ethyl acetate. The combined organic layers were dried
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over sodium sulfate and concentrated in vacuo leaving (+)-AB in quan­
titative y ie ld , homogeneous by TLC, and identical in spectral properties 
with previously  described racemic material:201* 'H NMR (DMSO- d 6)  8  
11.81 (s, 1 H), 11.55 (s, 1 H), 7.68 (d, J  = 8 Hz, 1 H), 7.48 (d, /  = 8 
Hz, 1 H), 7.26 (m, 1 H), 7.17 (s, 1 H), 7.08 (m, 1 H), 6.88 (s, 1 H), 6.70 
(«, 1 H), 4.52 (dd, J  = 10, 5 Hz, 1 H), 4.42 (d, J  = 10 Hz, 1 H), 3.16 
(m, 1 H), 2.0 (s, 3 H), 1.97 (m, 1 H), 1.39 (t, J  » 4 Hz, 1 H); CD 
(methanol) 370 nm, br (-4000), 357 (0), 329 (31000), 303 (0), 284 
(25000), 263 (0).
In like manner, (-)-AB was obtained: CD (DMF) 359 nm, br (9500), 
339 (0), 32 0  (-25000), 285 (-20000).
(+)-(7bR,8aS)-ABC. [While (+)- and (-)-ABC have also been 
prepared according to the route described above, the actual samples used 
in this study  were prepared by the earlier and longer routes as indicated 
in Scheme II. Experimental details up to the preparation of intermediate 
12 are available in the supplementary material.] To (5 -̂12 (5.0 g, 8.0 
mmol) dissolved in 125 mL of freshly distilled THF and 125 mL of dry 
methanol, under nitrogen, at 0-5 °C, and protected from light, was added 
5.0 g (80 mmol) of dry ammonium formate and 5.0 g  of 10% palladium 
on charcoal. The mixture was stirred for 30 min and then quickly filtered 
through Celite, rinsing the filter cake with two 25-mL portions of freshly 
distilled THF. The filtrate was eluted with 500 mL of ethyl acetate, 
washed twice with 200 mL of water and once with 200 mL of brine, dried 
(Na2,S 0 4) , and concentrated to 4.1 g (95%) of (S')-15c, a pale yellow 
solid. T h is solid was dissolved in 350 mL of acetonitrile and 300 mL of 
freshly distilled triethylamine, under nitrogen, and 500 mL of pure water 
was added. The mixture was stirred, at room temperature, protected 
from light, for 30 min, and at 0-5 °C for an additional 30 min. The 
yellow solid that precipitated was collected by vacuum filtration and dried 
in vacuo to afford 3.5 g (88%) of (+)-ABC. (CAUTION! Extremely 
toxic substance. Potential carcinogen.) This substance gave IR, UV, !H 
NMR, and mass spectra identical with those of the previously prepared 
racemic material20'’ and, in addition, gave the following: CD (methanol) 
335 nm (28000), 327 (0), 314 (-60000), 297 (0), 283 (53000), 266 (0); 
[apD = +175° (DMF, 0.54 g/100 mL). Anal. Calcd for CjoHyNjC :̂ 
C, 71.84; H, 4.62; N, 13.96. Found: C, 72.02; H, 4.85; N, 14.08.
(-)-(7bS,8aJ?)-ABC. (-)-ABC was prepared from 3 by the procedure 
described previously for its racemic compound.2"* Its spectra were 
identical with those of (+)-ABC and racemic ABC, but with the fol­
lowing differences: CD (methanol) 335 nm (-33000), 326 (0), 314 
(51000), 297 (0), 283 (-54000), 264 (0). The identical compound was 
also prepared via (/?)-8 (see below).
(+)-(7b/?,8aS)- and (-)-(7bS,8a/? )-AB'C\ Details of the preparation 
of acids 23 and 24 are available in the supplementary material. Com­
pound (S)-13 (56 mg, 0.165 mmol) was converted to (S)-14 in 5 mL of 
HCl-saturated ethyl acetate. This was taken up in a solution of distilled 
DMA containing the dissolved acid 23 (50 mg, 0.165 mmol). Solid EDC 
(63 mg, 2 equiv) was added and the coupling was allowed to proceed for 
3 h. The reaction mixture was cooled in ice, and water was added to 
precipitate the product. The solid was washed twice with water and 
dried. Extraction of the aqueous portions with 1:1 ethyl acetate-THF 
gave a mixture of product and starting acid. The combined crude product 
was chromatographed on silica gel (80:17:3 methyl ethyl ketone-ace- 
tone-water) to yield 50 mg (58%) of (5)-15d: ’H NMR (acetone - d 6)  
i 10.75 (br s, 1 H), 10.07 (br s, 1 H), 7.85 (s, 2 H), 7.45 (d, 1 H, J  = 
9 Hz), 7.10 (m, 2 H), 4.8-3.0 (m, CH2CH2 + H20), 2.40 (s, 3 H), 1.57 
(s, 9 H); MS (FAB) calcd for CjgH^ClNA m / e  521.1955, found 
■ 521.1911; (M + H+) 520,465,421,285, 237,236,229,201. Compound 
(S)-15d (19 mg, 0.0366 mmol) was deprotected in 1.5 mL of HCl-sat­
urated ethyl acetate. The salt 15e was dissolved in a solution of 0.9 mL 
of DMA containing 9 mg (0.037 mmol) of 24. Solid EDC (21 mg, 3 
equiv) was added and the mixture was stirred under nitrogen for 2 h. 
(The reaction was followed by TLC densitometry.) Product (SJ-lSf was 
precipitated with water, collected by centrifugation, and washed with 
water twice. Extraction of the aqueous portions with ethyl acetate pro­
vided further (S)-15f and small amounts of 24. The combined precipitate 
and extract were dissolved in DMF, adsorbed onto silica gel, and placed 
on a silica gel column. DMF eluted 16 mg of a mixture of (S,)-15f and 
(+)-AB'C. The mixture was suspended in 2.0 mL of acetonitrile, 0.5 
mLof triethylamine, and 0.5 mL of water for 30 min under nitrogen in 
the dark. The reaction mixture was cooled on ice, water was added, and 
the cyclized product was collected by centrifugation. The pellet was 
washed with water and dried to give 12.6 mg of (+)-AB'C' as a brown 
solid. Extraction of the aqueous portions with 1:1 ethyl acetate-THF 
provided an additional 3.4 mg to give a 60% yield of (+)-AB'C' from 
(S)-I5f: IR (KBr) 3398, 1622, 1612, 1582, 1505, 1431, 1394, 1363, 
1336, 1264 cm"1; UV (methanol) 318 nm (40000), 355 (34000); !H 
NMR (DMF-</7, verified by 500-MHz COSY) 8 11.82 (s, 1 H, NH),
11.52 (s, 2 H, NH), 8.39 (br s, ArH), 8.14 (d, 1 H, J  =  9  Hz), 7.48 (d, 
1H,; = 9 Hz), 7.38 (d, 1 H, J = 9 Hz), 7.26 (s, 1 H), 7.08 (s, 1 H),
6.99 (s, 1 H), 6.79 (s, 1 H), 6.15 (s, 1 H), 4.74 (t, J  -  8 Hz, 2 H) 4 57 
(m, 2 H), 4.15 (t, J  = 8 Hz, 2 H), 3.53 (t, /  = 9 Hz, 2 H), 3 40 ( i  j  
= 9 Hz, 2 H), 3.24 (m, 1 H), 2.07 (s, 3 H), 2.04 (m, 1 H), 1.49 (m 1 
H); MS (FAB) calcd for C35H29N70 4 m / e  612.2359, found 612.2385- 
7?/0.32 (80% methyl ethyl ketone, 17% acetone; 3% H20, silica gel) R  
0.61 (70% DMF, 30% saline LKC18D Linear K reversed phase/ 
(+)-AB'C': [«]25d = +90° (DMA, 0.1 g/100 mL); CD (DMF) 385-335 
nm, br (7000), 328 (0), 315 (-20000), 302 (0), 287 (35000). An 
analogous route afforded (-)-AB/C/: [A]25D = -80° (DMA, 0.1 g /100 
mL); CD (methanol) 385-335 nm, br (-5000), 331 (0), 315 (44000) 
298 (0), 287 (-44000).
In a separate preparation, (S)-I5f was isolated: *H NMR (DMF-</7)
8  11.69 (br s, 1 H), 11.51 (br s, 1 H), 10.85 (br s, 1 H), 8.33 (br s, 1 H)
8.09 (d, 1 H, J  = 9 Hz), 7.72 (br s, 1 H), 7.44 (d, 1 H, J  = 9 Hz), 7 34 
(d, 1 H, /  = 9 Hz), 7.12 (s, 1 H), 7.11 (s, 1 H), 7.05 (s, 1 H), 6.15 ( 
s, 2 H), 4.1-3.3 (m, 4 H), 2.38 (s, 3 H); MS (FAB) calcd for CjjHjq- 
CIN7O4 m / e  648.2126, found 648.2115; R f 0.28 (70% DMF, 30% saline, 
LKC18-D Linear K reversed phase).
(S)-15g and (7?)-15g. The PDE(I) dimer carboxylic acid31 obtained 
from the alkaline hydrolysis of the fermentation product, (+)-CC-1065 
(36.5 mg, 0.07 mmol) was dissolved in 1.5 mL of dry DMA and the 
solution added to the amine salt (S')-14 from a 24-mg (0.07-mmol) 
conversion of (5)-13. To this solution was added EDC (13.3 mg, 0.07 
mmol) and the reaction was stirred at room temperature under nitrogen 
for 2 h. The reaction was then quenched with water and centrifuged. 
The pellet was washed with water and dried overnight under vacuum. 
The resultant solid was adsorbed onto 1 g of silica gel from DMF and 
placed on top of a 7-g silica gel column. The column was eluted with 
(8:17:75) DMF-acetone-methylene chloride and the product, (5)-15g, 
was isolated: 28 mg, 54% yield; IR (mull) 3341, 3208,1638,1610,1566, 
1516, 1331, 1169, 1024 cm"1; UV (ethanol) 260 nm (31000), 300 
(26000), 360 (41000); >H NMR (DMSO-</6) 8  12.93 (s, 1 H), 11.37 (m, 
2 H), 10.93 (s, 1 H), 10.72 (s, 1 H), 9.80 (s, 1 H), 7.6 (br s, 1 H),
7.1-6.88 (m, 5 H), 4.79-4.41 (m, 4 H), 4.12-3.93 (m, 3 H), 3.90 (s, 3
H), 3.93-3.85 (m, 1 H), 3.83 (s, 3 H), 3.58 (t, 1 H), 3.45-3.27 (m, 4 H),
2.36 (d, 3 H); MS (FAB) calcd for C ^ ^ O N A  m / e  740.2235, found 
740.2204; R f  0.54 (20% DMF-80% toluene, silica); RyO.41 (8% DMF, 
17% acetone, 75% methylene chloride, silica). Analogously, (/?)-15g was 
prepared from (7?)-13 and showed 'H NMR, UV, and mass spectra and 
chromatographic properties identical with (.S)-15g.
(+)-CC-1065 and (-)-CC-l065. A 58-mg (0.078-mmol) quantity of
(5)-15g was dissolved in 14 mL of acetonitrile and 4 mL of freshly 
distilled triethylamine and the solution treated with 4 mL of water. The 
reaction was kept in the dark and stirred 60 min at room temperature. 
The resultant precipitate was collected by filtration and dried under 
vacuum, giving 37 mg (67% yield) of (+)-CC-1065 as a yellow solid. The 
filtrate from above was diluted with ethyl acetate and washed twice with 
water and once with saturated brine. The organic layer was dried 
(MgS04) and concentrated under vacuum giving an additional 11 mg of 
(+)-CC-1065. The •H NMR and UV spectra and chromatographic 
retention were identical with those of natural CC-1065 obtained from 
fermentation.19 In addition, [a]25D = +98° for synthetic (+)-CC-1065 
and +97° for natural CC-1065 (DMF, 0.2 g/100 mL). Natural and 
synthetic (+)-CC-1065 also gave identical CD spectra (DMF): 385 nm, 
br (9000), 365 (0), 330 (-25000), 317 (0), 295 (40000). Reaction of 
(/?)-15g as above afforded (-)-CC-1065 in comparable yield: [a]25,) = 
-96° (DMF, 0.2 g/100 mL); CD (DMF) 385 nm, br (-2000), 377 (0), 
330 (32000), 317 (0), 295 (-43000). This material had 3H NMR and 
UV spectra and chromatographic properties identical with (+)-CC-1065.
Compounds Used In Alkylation Sequence Specificity Studies. (+)- 
CC-1065 isolated from the fermentation broth of S .  z e  l e n s  i s * '19 was used 
in the sequencing experiments. All of the other compounds were syn­
thetic analogues (Chart I) synthesized at The Upjohn Co. as described 
above.
DNA Fragments. The 117 base pair M s p l - B s t N l  fragment of 
M13mpl bacteriophage DNA was isolated as described previously.16 The 
180 base pair fragment of M13mpl DNA was isolated by successive 
restriction endonuclease treatments with H i n p l  and A l u l .  Similar 
methods were used to isolate 118 and 276 base pair fragments from SV40 
DNA using M b o l  and H i n j l .
3'- and 5'-32P-End Labeling. 3'- and 5'-32P-end-labeling methods were 
as described previously.16-23
Modification of DNA with CC-1065 and Analogues. Various 10-fold 
dilutions of a 280 ^M stock solution of CC-1065 or analogues were added 
to aliquots of 3'- or 5'-32P-labeled DNA fragments and incubated at 37 
°C for 2 h, followed by ethanol precipitation to terminate the reaction.
MPE-Fe(II) Footprinting and Thermal Breakage of CC-1065-Modified 
Fragments. MPE-Fe(II) footprinting and heat-induced breakage of DNA 
fragments containing CC-1065-DNA adducts were performed as de­
scribed.I0b-16
Sequence Specificity and Synthetic Analogues
Characterization of Base Specificity of Alkylation by {+)- and (-)-C- 
C-1065. CHO (J-116) cells were grown in Ham’s F-10 cell culture 
medium supplemented with glutamine and 15% fetal calf serum. Specific 
base-labeled DNA was obtained by growing the cells in the presence of 
(2,8-3H2)adenine, (me?/iy/-3H3) thymidine, deoxy(5-3H)cytidine, or (8- 
l4C)guanosine hydrochloride (Amersham Corp). DNA from the cells 
was isolated, after addition of carrier calf thymus DNA, by phenol ex­
traction and ribonuclease treatment.52 Separate portions of DNA were 
then reacted with (+)-CC-1065 or (-)-CC-1065. Specific base-labeled 
DNA with or without bound drug was extracted at 100 °C in a butanol 
emulsion as described previously.10* The amount of base label extracted 
into the organic layer for drug-treated samples was compared to extracts 
of labeled unreacted DNA.
In preliminary experiments, the recovery of drug-DNA chromophore 
in butanol extracts was determined by reacting 0.1 /tmol of (-)-CC-1065 
with 1.0 /imol of calf thymus DNA at 37 °C overnight in pH 7.4 phos­
phate buffer. The adducted DNA was precipitated with high salt and 
ethanol and rinsed with 70% ethanol to remove unreacted drug. The 
pellet was resuspended in 1.0 mL of pH 7.4 phosphate buffer and ab­
sorbance at 365 nm was read. Water-saturated butanol (1 mL) was 
added to the aqueous solution and this emulsion was heated at 100 °C 
for 45 min. After cooling and centrifugation to clear the two phases, each 
phase was transferred to a cuvette and absorbance at 365 nm read. 
Results showed that 85% of the total drug-associated absorbance equiv­
alents were recovered in the butanol extract. To assure that the (-)-C- 
C-1065 adduct had a similar extinction coefficient in an aqueous phos­
phate buffer as in organic butanol, 6 Mg of the adduct was dissolved in 
1 mL of phosphate-buffered saline and centrifuged to precipitate any 
adduct not in solution. The supernatant was drawn off and absorbance 
read at 365 nm. Extinction coefficients were not significantly different.
Isolation and Characterization of Adduct. (+)-CC-1065 and (-)-C- 
C-1065 (52 mg, 72 Mmol) in 26 mL of dimethylformamide (DMF) were 
reacted separately with calf thymus DNA (1 g) in 500 mL of 10 mM 
sodium phosphate buffer, pH 7.4. After precipitation with sodium ace­
tate and ethanol, the DNA was dissolved in 500 mL of 10 mM sodium 
phosphate buffer, pH 7.4, and heated at 100 °C with 500 mL of 1-bu­
tanol. The sample was shaken frequently to emulsify. At 25 min, the 
phases were separated and the aqueous phase was further heated with 
400 mL of 1-butanol for 25 min. The butanol extracts were combined 
and analyzed for CC-1065 chromophore.
The combined butanol extracts were dried at 40 °C in vacuo and the 
residue was dissolved in 7.7 mL of 70% DMF and applied to a 2 X 30 
cm open column of C-18 stationary phase in 70% DMF. After the 
residue was washed into the column with 4 mL of 70% DMF, the column 
was eluted at about 0.45 mL/min with 70% DMF. Fractions (9 mL) 
were taken, and aliquots of those with significant absorbance at 365 nm 
were examined by chromatography on Whatman CS5 Multi-K re- 
versed-phase thin-layer plates in 70% DMF. High-pressure liquid 
chromatography was then employed to isolate the adduct for NMR 
analysis.
All NMR spectra were obtained on a Bruker AM-500 spectrometer 
equipped with an Aspect-3000 computer and digital phase shifters. 
Proton spectra (both 1-D and 2-D) were obtained with the following
(52) Frei, J. V.; Swenson, D. H.; Warren, W.; Lawley, P. D. Biochem. J. 
1978, 174, 1031.
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typical parameters. 1-D: sweep width, 10000 Hz; pulse width, 3 ms, data 
table, 64K; relaxation delay, 1 s. All FIDs were resolution-enhanced with 
a Gaussian function, then Fourier transformed. All 13C spectra (1-D and 
DEPT) were obtained at 125.76 MHz with Waltz decoupling.53 2-D: 
correlated spectroscopy (COSY) was obtained by using the sequence of 
Ave et al.54
A total of 512 FIDs (64 scans each) were collected by using 2K of 
complex points in T2 while incrementing /, from 2 to 1024 ms in steps of 
2 ms. The time domain data were treated with sine-bell windows and 
Fourier transformed to yield a final real matrix of IK X IK data points.
Heterocorrelated spectroscopy was performed by use of the pulse 
sequence of Bodenhausen and Freemen55 with a final matrix of 4K X 1K 
data points. A total of 256 FIDs (96 scans each) were collected in /2. 
The time domain spectra were multiplied in both dimensions by a sine- 
bell window (phase shifted by v /2  in t2 and x/8 in /,).
Long-range heterocorrelated spectra (COLOC) were collected by use 
of the sequence of Kessler et al.56
DNA Melting Temperature. DNA melting temperature experiments 
were performed on a Perkin-Elmer Lambda 7 equipped with a Digital 
temperature programmer and thermoelectric cells. The solvent for the 
interaction studies was aqueous buffer, 0.01 M sodium phosphate, pH 
7.2. Mixtures for spectral analysis were prepared by injecting the ap­
propriate amount of a concentrated solution of (+)-CC-1065 or one of 
its analogues dissolved in dimethylformamide or dimethylacetamide into 
a predetermined volume of aqueous buffer containing the calf thymus 
DNA. The final drug concentration was 0.85 X 10-5 M, and the con­
centration of DNA, calculated from the absorbance spectra by using ̂ 2 6 0  
= 6600, was 11 x 10-5 M, giving a molar DNA to drug ratio of 13.
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a b st r a c t : C C - 1 0 6 5  is  a n  e x tr e m e ly  p o t e n t  a n t itu m o r  a n t ib io t ic  th a t  fo r m s  a  w e ll -d e f in e d  a d d u c t  w i th  D N A  
in w h ic h  th e  m o le c u le  l ie s  w ith in  th e  m in o r  g r o o v e  a n d  is  c o v a le n t ly  a t t a c h e d  th r o u g h  N 3  o f  a d e n in e . A d d it io n  
o f  C C -1 0 6 5  to  h u m a n  f ib r o b la s t  c e l ls  p r o d u c e d  a  p r o lo n g e d  d e p le t io n  o f  t h e  n ic o t in a m id e  a d e n in e  d in u c le o t id e  
( N A D )  p o o l  e v e n  a t  e x t r e m e ly  lo w  d r u g  c o n c e n tr a t io n s  (0 .0 1  pg /m L ). T h e  d e p le t io n  o f  N A D  b y  C C - 1 0 6 5  
w a s  b lo c k e d  b y  3 - a m in o b e n z a m id e ,  w h i c h  i s  c o n s is t e n t  w i t h  a  N A D  d e p le t io n  m e c h a n is m  in v o lv in g  p o ly -  
( A D P - r ib o s e )  s y n t h e s is  in  r e s p o n s e  t o  a  r e p a ir - in d u c e d  D N A  s tr a n d  b r e a k a g e  e v e n t .  S ig n i f ic a n t ly ,  s im ila r  
e x te n ts  o f  N A D  d e p le t io n  w e r e  a l s o  e v id e n t  in  x e r o d e r m a  p ig m e n t o s u m  c e l l s  o f  c o m p le m e n t a t io n  g r o u p s  
A  a n d  D  f o l lo w in g  e x p o s u r e  t o  C C - 1 0 6 5 .  S i n c e  th i s  N A D  d e p le t io n  is  p r e s u m a b ly  a s s o c ia t e d  w i t h  r e ­
p a ir - in d u c e d  in c is io n ,  t h e  r e p a ir  o f  C C - 1 0 6 5 - D N A  a d d u c t s  c a n  p r o b a b ly  t a k e  p la c e  b y  a  p a t h w a y  d i s t in c t  
fr o m  t h a t  in v o lv e d  in  r e p a ir  o f  m o r e  c o n v e n t io n a l  b u lk y  D N A  a d d u c t s .  T h e  p r o lo n g e d  d e p le t io n  o f  N A D ,  
e v e n  a t  lo w  d o s e s  o f  d r u g ,  s u g g e s t s  t h a t  C C - 1 0 6 5  c a u s e s  D N A  d a m a g e  t h a t  r e s u l t s  in  a  d e la y  o r  b lo c k  in  
D N A  e x c i s io n  r e p a ir  b e t w e e n  t h e  e x c i s io n  a n d  l ig a t io n  s t e p s .
C c - 1 0 6 5  is an  an titu m o r  p rod u ced  b y  Streptomyces zelensis 
(Hanka e t a l .,  1 9 7 8 ) .  T h is  d r u g  is  o n e  o f  th e  m o s t  p o te n t  
agents te sted  a g a in s t  L I 2 1 0  c e l ls  in  c u ltu r e , b e in g  a t  le a s t  8 0  
and 400 tim es m o re  p o te n t o n  a  m o la r  b a s is  th a n  a c t in o m y c in  
Dand a d r ia m y c in , r e sp e c t iv e ly  (L i  e t  a l .,  1 9 8 2 ) .  In  a  tu m o r  
cloning a ssa y , C C -1 0 6 5  c a u s e d  a  50%  d e c r e a s e  in  th e  c o lo ­
ny-forming u n its  o f  tu m o r  c e lls  fr o m  p a t ie n ts  w ith  c a n c e r s  o f  
lung, breast, p a n c r e a s , o v a r y , e tc .  a t  a  c o n c e n tr a t io n  o f  0 .1  
Hg/kg (B h u y a n  e t  a l . ,  1 9 8 2 ) .  In  B 1 6  a n d  C H O 1 c e l ls  in  
culture, C C -1 0 6 5  is  m o r e  th a n  1 0 0 - fo ld  m o r e  le th a l  th a n  
adriamycin, a c tin o m y cin  D , a n d  m -d ia m m in e d ic h lo r o p la tin u m  
(Bhuyan e t  a l ., 1 9 8 2 ) . U n fo r tu n a te ly , C C -1 0 6 5  c a u s e s  le th a l  
delayed h e p a to to x ic ity  in  m ic e  a t  th e r a p e u t ic  a n t in e o p la s t ic  
doses (M c G o v r e n  e t  a l . ,  1 9 8 4 ) .  T h e  c h e m is tr y , m e c h a n is m  
of action, a n d  b io lo g ic a l  p r o p e rtie s  o f  C C -1 0 6 5  h a v e  r e c e n tly  
been rev iew ed  (R e y n o ld s  e t  a l . ,  1 9 8 6 ) .
The r ea c tio n  o f  C C - 1 0 6 5  w ith  D N A  a n d  o th e r  m a c r o ­
molecules h a s  b e e n  e x te n s iv e ly  s tu d ie d  (L i  e t  a l . ,  1 9 8 2 ;  
Swenson e t a l ., 1 9 8 2 ) . C C -1 0 6 5  b in d s  c o v a le n tly  th r o u g h  N 3  
of adenine (F ig u r e  1) a n d  l ie s  w ith in  th e  m in o r  g r o o v e  o f  
DNA, o v er la p p in g  w ith  a b o u t  f iv e  b a s e  p a ir s  (H u r le y  e t  a l .,
1984). W h ile  b in d in g  o f  C C - 1 0 6 5  to  D N A  d o e s  n o t  in d u c e  
spontaneous stran d  b rea k a g e  in  D N A ,  u p o n  th e rm a l tr ea tm e n t  
of the C C - 1 0 6 5 - D N A  a d d u c t  a  s tr a n d  b r e a k  is  p r o d u c e d  
between th e  d e o x y r ib o se  o f  th e  a d e n in e  c o v a le n t  b in d in g  s ite  
and the p h osp h ate  on  th e  3' s id e  (R e y n o ld s  e t  a l., 1 9 8 5 ) . U s in g  
thermally in d u c e d  s tr a n d  b r e a k a g e  a s  a  m e a n s  o f  lo c a t in g  
CC-1065 c o v a le n t  b in d in g  s ite s  o n  D N A ,  w e  h a v e  d isc o v e r e d  
two distinct c la s se s  o f  s e q u e n c e s  fo r  w h ic h  C C -1 0 6 5  is  h ig h ly  
specific, i .e .,  5 'P u N T T A  a n d  5 ' A A A A A  (R e y n o ld s  e t  a l .,
1985). S te r e o  d r a w in g s  o f  th e  C C - 1 0 6 5 - D N A  a d d u c t  a r e  
predictive o f  th e  s e q u e n c e  s p e c i f ic ity  a n d  a r e  c o n s is te n t  w ith  
the e x p er im en ta lly  d e te r m in e d  n o n d is to r t iv e  b u t h ig h ly  s ta -
+ This work was supported by U.S. Public Health Service Grants 
CA-23994 (to M.K.J.) and CA-30349 and the Welch Foundation (to 
L.H.H.).
b iliz in g  e ffe c ts  o f  d ru g  b in d in g  o n  D N A  (R e y n o ld s  e t  a l., 1985; 
S w e n s o n  e t  a l . ,  1 9 8 2 ) .
S tu d ie s  o f  D N A  a lk y la t in g  a g e n ts  h a v e  sh o w n  th a t  th e s e  
a g e n ts  a lte r  N A D  m e ta b o lis m  v ia  a  m e c h a n is m , w h ic h  le a d s  
to  a n  in c r e a s e d  r a te  o f  c o n v e r s io n  o f  N A D  to  c h r o m a t in -a s ­
s o c ia te d  p o ly m e r s  o f  A D P -r ib o s e  (S m u ls o n  e t  a l .,  1 9 7 7 ; G o ­
o d w in  e t  a l ., 1 9 78; J u a r e z -S a lin a s  e t  a l ., 1 9 7 9 ; J a c o b so n  e t  a l.,
1 9 8 0 ) ,  a n  a lte r a t io n  th a t  c a n  a ls o  le a d  to  d e p le t io n  o f  th e  
c e l lu la r  N A D  p o o l. W e  p r e se n t  h e r e  a s tu d y  o f  th e  e f f e c t  o f  
C C -1 0 6 5  o n  th e  N A D  c o n te n t  o f  h u m a n  f ib r o b la s ts . O u r  
r e s u lts  s h o w  th a t  th is  a g e n t  is  v e r y  p o te n t  in  c a u s in g  N A D  
d e p le t io n  in  b o th  n o r m a l a n d  X P  f ib r o b la s ts . T h e s e  d a ta  
s u g g e s t  th a t  C C - 1 0 6 5 - D N A  a d d u c ts  c a n  b e  r e c o g n iz e d  b y  
D N A  r ep a ir  e n z y m e s  o th e r  th a n  th o se  n o r m a lly  a s s o c ia te d  
w ith  b u lk y  D N A  a d d u cts  a n d  th a t  th e  C C - 1 0 6 5 - D N A  a d d u ct  
c a u s e s  a  d e la y  or  b lo c k  in  D N A  e x c is io n  r ep a ir  b e tw e e n  th e  
e x c is io n  a n d  l ig a t io n  s te p s .
M a t e r i a l s  a n d  M e t h o d s
Materials. C C - 1 0 6 5  w a s  o b ta in e d  fr o m  D r . D . M a r t in  
(U p jo h n  C o m p a n y , K a la m a z o o , M I )  a n d  w a s  d is so lv e d  in  
D M F  prior to  u se  a n d  a ssa y ed  a s  b e fo re  (S w e n so n  e t  a l., 1 9 8 2 ).
Cell Culture. N o r m a l h u m a n  sk in  fib ro b la sts  (C C D - 4 5 S K ,  
A T C C  C R L  1 5 0 6 )  a n d  x e r o d e r m a  p ig m e n to s u m  ( X P )  c e l l  
lin e s  X P 1 2 B E  (A T C C  C R L  1 2 2 3  c o m p le m e n ta tio n  g r o u p  A )  
a n d  X P 6 B E  ( A T C C  C R L  1 1 5 7  c o m p le m e n ta t io n  g r o u p  D )  
w e re  o b ta in ed  fr o m  th e  A m e r ic a n  T y p e  C u ltu re  C o lle c t io n  a n d  
r o u t in e ly  c u ltu r e d  a s  d e sc r ib e d  p r e v io u s ly  (J a c o b s o n  e t  a l . ,  
1 9 8 3 ) .  F o r  e x p e r im e n ts ,  c e l ls  w e r e  s e e d e d  in  3 5 -m m  d ish e s  
a n d  g r o w n  w ith  r e p la c e m e n t o f  fr esh  m e d iu m  tw ic e  p er  w e e k  
u n t i l  th e y  r e a c h e d  c o n f lu e n c e . C o n f lu e n t  c u ltu r e s  w e r e  
m a in ta in e d  in  m e d iu m  w ith  r e d u c e d  se r u m  a s  d e sc r ib e d  p re-
1 Abbreviations: DMF, dimethylformamide; CHO, Chinese hamster 
ovary; Pu, purine; N , any nucleotide; XP, xeroderma pigmentosum; 
NAD, nicotinamide adenine dinucleotide; ADP, adenosine 5'-di- 
phosphate; M NNG, A-methyl-TV-nitro-A-nitrosoguanidine.
0006-2960/86/0425-5929$01.50/0 © 1986 American Chemical Society









CC-1065 CC-1065 -fj3-Adenin«^-DNA Adduct
f i g u r e  1: Reaction o f C C -1065 with D N A  to form the C C -1065- 





H R S — ► H R S — ►
f i g u r e  2: Tim e course of N A D  content in confluent normal human 
fibroblasts after treatment with C C -1065 in the absence (A ) or 
presence (B) o f 10 mM 3-aminobenzamide. For dishes treated with 
CC -1065, a 0.5 Mg/mL dose (final concentration) was added at zero 
time to dishes having N A D  levels o f 2.8 x  103 p m o l/1 0 6 cells (A )  
and 3.5 X 103 pm ol/106 cells (B). Control (O); treated with CC-1065 
(•)•
v io u s ly  (J a c o b s o n  e t  a l . ,  1 9 8 3 ) .  In  s o m e  e x p e r im e n t s ,  c e l ls  
w e re  tr e a te d  w ith  d r u g s  w h ile  th e y  w e r e  s till  in  th e  lo g a r ith m ic  
p h a s e  o f  g r o w th .  F o r  d r u g  t r e a t m e n t ,  m e d iu m  w a s  r e p la c e d  
w ith  fr e sh  m e d iu m  c o n ta in in g  th e  in d ic a te d  d r u g s , w h ic h  h a d  
b e e n  d is so lv e d  in  D M F . D M F  w a s  p r e s e n t  a t  a  F inal le v e l  o f  
1% in  a l l  c a s e s  a n d  b y  i t s e l f  h a d  n o  e f f e c t  o n  c e l lu la r  N A D  
c o n te n t .
Determination o f  NAD Content. T h e  to ta l  N A D  p o o l w a s  
e x tr a c te d  a s  d e s c r ib e d  p r e v io u s ly  (J a c o b s o n  e t  a l .,  1 9 7 9 ) ,  a n d  
N A D  c o n te n t  w a s  d e te r m in e d  b y  a n  e n z y m a t ic  c y c l in g  a s s a y  
d e s c r ib e d  in  d e t a i l  e ls e w h e r e  (J a c o b s o n  &  J a c o b s o n ,  1 9 7 6 ) .
R e s u l t s
Effect o f  CC-1065 on the Cellular NAD Content o f  Normal 
Human Skin Fibroblasts. C C -1 0 6 5  w a s  fo u n d  to  b e  e x tr e m e ly  
e f f e c t iv e  in  c a u s in g  N A D  d e p le t io n  in  h u m a n  sk in  f ib r o b la s ts . 
F ig u r e  2 s h o w s  a  t im e  c o u r s e  o f  N A D  d e p le t io n  f o l lo w in g  
tr e a tm e n t  o f  a  c o n f lu e n t  c u ltu r e  o f  c e l ls  w ith  0 .5  /u g /m L  d r u g .  
A f t e r  a  la g  p e r io d  o f  a p p r o x im a te ly  4  h , a  p r o g r e s s iv e  N A D  
d e p le t io n  w a s  o b se rv ed . T h e  la g  w a s  o b se r v e d  a t  d o s e s  o f  d r u g  
u p  to  4 0  ug/m L . T h is  p a t te r n  o f  d e p le t io n  w a s  a ls o  v e r y  
s im ila r  fo r  c u lt u r e s  th a t  w e r e  d iv id in g  a t  th e  t im e  o f  d r u g  
tr e a t m e n t  ( d a t a  n o t  s h o w n ) .
S t u d ie s  o f  th e  m e c h a n is m  o f  N A D  d e p le t io n  w ith  o th e r  
D N A  a lk y la t in g  a g e n t s  h a v e  s h o w n  th a t  d e p le t io n  is  d u e  to  
a  r a p id  in c r e a s e  in  th e  r a te  o f  c o n v e r s io n  o f  N A D  to  n u c le a r  





f i g u r e  3: T im e  course o f  N A D  content o f  con flu en t norm al hum an  
fibroblasts after treatm ent with either C C -1065  or netropsin. C C -1065  
and netropsin were added to a 0.5 ug/mL final concentration to dishes 
having N A D  levels o f  2.8 X 103 p m o l/1 0 6 cells. Control (O); C C -1065  
( • ) ;  netropsin  (■ ) .
a l .,  1 9 7 8 ;  J u a r e z - S a l in a s  e t  a l . ,  1 9 7 9 ;  J a c o b s o n  e t  a l . ,  1 9 8 0 ) .  
T h e  r e s p o n s ib le  e n z y m e ,  p o l y ( A D P - r ib o s e )  p o ly m e r a s e ,  c a n  
b e  in h ib it e d  in  s it u  b y  b e n z a m id e  a n d  r e la t e d  a n a lo g u e s  in ­
c lu d in g  3 - a m in o b e n z a m id e  ( J a c o b s o n  e t  a l . ,  1 9 8 4 ) .  F ig u r e  
2 B  s h o w s  th a t  a d d i t io n  o f  1 0  m M  3 - a m in o b e n z a m id e  to  th e  
c u lt u r e  m e d iu m  c o m p le t e ly  p r e v e n te d  th e  N A D  d e p le t io n  
in d u c e d  b y  C C - 1 0 6 5 .
Comparison o f  CC-1065 and Netropsin on NAD Content 
o f  Normal Skin Fibroblasts. N e t r o p s in  is a n  a n t iv ir a l  a g e n t  
th a t  b in d s  n o n c o v a le n t ly  in  th e  m in o r  g r o o v e  o f  D N A  to  
A T -r ic h  r e g io n s  (K o p k a  e t a l .,  1 9 8 5 ) .  C C - 1 0 6 5  a n d  n e tr o p s in  
sh a r e  th e  s a m e  b in d in g  s it e s  o n  D N A ,  b u t  b e c a u s e  o f  th e  
c o v a le n t  n a tu r e  o f  th e  C C - 1 0 6 5 - D N A  a d d u c t ,  n e tr o p s in  c a n  
e v e n t u a l ly  b e  d is p la c e d  b y  C C - 1 0 6 5  ( S w e n s o n  e t  a l . ,  1 9 8 2 ) .  
F ig u r e  3 c o m p a r e s  th e  t im e  c o u r s e  o f  N A D  c o n t e n t  o f  c e l ls  
fo l lo w in g  t r e a t m e n t  w ith  0 .5  ug/m L  C C - 1 0 6 5  o r  n e tr o p s in .  
W h ile  N A D  d e p le t io n  o c c u r r e d  w ith  C C - 1 0 6 5 ,  n e tr o p s in  h a d  
n o  e f f e c t  o n  th e  N A D  c o n te n t .  T h u s ,  th e s e  d a t a  s u g g e s t  th a t  
th e  c o v a le n t  m o d if ic a t io n  o f  D N A  b y  C C - 1 0 6 5  is  r e q u ir e d  to  
e l i c i t  N A D  d e p le t io n .
Effect o f  CC-1065 on NAD Content in Xeroderma Pig­
mentosum Fibroblasts. P r e v io u s  s tu d ie s  h a v e  sh o w n  th a t  th e  
o c c u r r e n c e  o f  D N A  s tr a n d  b r e a k s  is  th e  c o m m o n  fa c to r  o f  
D N A  d a m a g e  th a t  e l i c i t s  p o l y ( A D P - r ib o s e )  s y n t h e s i s  ( J a ­
c o b so n  e t  a l ., 1 9 8 3 ; B e r g e r  e t  a l ., 1 9 8 0 ;  M c C u r r y  &  J a c o b so n ,
1 9 8 1 ) .  C e ll s  h o m o z y g o u s  fo r  th e  X P  g e n o t y p e  a r e  g r o s s ly  
d e fe c t iv e  in  th e  in tr o d u c t io n  o f  D N A  s tr a n d  b r e a k s  (a n d  th u s  
in  th e  in it ia t io n  o f  D N A  e x c is io n  r e p a ir )  fo r  s p e c i f ic  ty p e s  o f  
D N A  d a m a g e  in c lu d in g  p y r im id in e  d im e r s  a n d  a  v a r ie ty  o f  
b u lk y  D N A  a d d u c t s .  X P  c e l ls  a r e  a l s o  d e f e c t iv e  in  t h e  s y n ­
th e s is  o f  p o ly (A D P -r ib o s e )  fo r  su c h  le s io n s  (B e r g e r  et a l ., 1980;  
M c C u r r y  &  J a c o b s o n ,  1 9 8 1 ) .  T h u s ,  it  w a s  o f  in te r e s t  to  
d e te r m in e  i f  C C - 1 0 6 5 ,  w h ic h  r e s u lt s  in  a  b u lk y  b u t  n o n d is -  
to r tiv e  D N A  a d d u c t , w o u ld  e lic it  N A D  d e p le t io n  in  th e se  ce lls . 
P a r ts  A  a n d  B  o f  F ig u r e  4  c o m p a r e  th e  t im e  c o u r s e  o f  N A D  
le v e ls  fo l lo w in g  C C - 1 0 6 5  e x p o s u r e  in  n o r m a l a n d  X P  c e l ls  o f  
c o m p le m e n t a t io n  g r o u p s  A  ( X P 1 2 B E )  a n d  D  ( X P 6 B E ) .  T h e  
N A D  c o n te n t, e x p r e sse d  a s  th e  p e r c e n ta g e  o f  N A D  in th e  c e lls  
a t  t im e  z e r o , d e c r e a s e d  in  a  s im ila r  m a n n e r  in  n o r m a l a n d  
X P 1 2 B E  c e l l s  ( F ig u r e  4 A ) .  T h e  a b s o lu t e  a m o u n t  o f  N A D  
d e p le t e d  fr o m  th e  X P 1 2 B E  c e l ls  w a s  a c t u a l ly  t w ic e  t h a t  o f  I 
n o r m a l c e l ls  s in c e  th e  N A D  c o n te n t  o f  X P 1 2 B E  w a s  tw ic e  th a t  
o f  n o r m a l c e l ls .  T h e  r a te  o f  N A D  d e p le t io n  o f  X P 6 B E  c e l ls  j







f i g u r e  4: Time course o f N A D  content o f confluent normal human 
fibroblasts and XP Fibroblasts of complementation groups A  (XP12BE) 
(panel A) and D (X P6B E ) (panel B). CC-1065 was added to a final 
concentration o f 0.5 /ag/m L to dishes at zero time having N A D  levels 
of 2.2 X 103 p m ol/106 cells (normal cells), 4.9 X 103 p m ol/106 cells 
(XP12BE), and 2.4 X  103 p m o l/1 0 6 cells (X P 6B E ). Control and 
CC-1065 treated are open symbols and filled sym bols, respectively; 
panel A, normal human fibroblasts (O and • )  and X P12B E  (□  and
I); panel B, normal human fibroblasts (O and • )  and X P6B E  (□  
and ■).
Table I: Effect of CC-1065 on N A D  Levels of Normal Human 
Fibroblasts'1
N A D  content
treatment pmol / 1 06 cells %
control 864 ±  90 100
CC-1065
0.5 Mg/mL 30 ±  5.6 3.5
0.5 Mg/mL, 10 mM benzamide 474 ±  85 55
0.1 Mg/mL 33 ±  0.5 3.8
0.05 Mg/mL 52 ±  6.8 6.0
0.01 Mg/mL 362 ±  46 42
0.005 Mg/mL 840 ±  14 97
“Confluent cultures of CCD cells were treated with the indicated 
doses of CC-1065, and 24 h later, N A D  content was determined. 
Values shown are the mean values of four dishes ±  standard deviations.
was som ew hat le s s  th a n  th a t  o f  n o r m a l c e l ls  b u t  s t i l l  o c c u r r e d  
to a s ig n ific a n t e x t e n t .
CC-1065 and Prolonged NAD Depletion. S t u d i e s  w ith  
several o th er  D N A  a lk y la t in g  a g e n t s  h a v e  s h o w n  th a t  N A D  
depletion is  u s u a l ly  t r a n s ie n t  f o l lo w in g  D N A  d a m a g e  
(Goodwin e t  a l .,  1 9 7 8 ) .  In  c o n tr a s t ,  t r e a t m e n t  w ith  C C - 1 0 6 5  
resulted in a p r o lo n g e d  N A D  d e p le t io n  e v e n  a t  v e r y  lo w  d o s e s  
of drug. F ig u r e  5 s h o w s  a t im e  c o u r s e  o f  u p  to  2 4  h , a t  d r u g  
doses of 0 .1 , 0 .5 ,  a n d  1 .0  ju g /m L . A t  2 4  h , e a c h  o f  th e s e  d o se s  
resulted in a n  a lm o s t  to t a l  d e p le t io n  o f  N A D .  F u r th e r m o r e ,  
in additional e x p e r im e n ts , N A D  d e p le t io n  w a s  d e te c te d  a t  d r u g  
doses as low  a s  0 .0 1  pg /m L  a f t e r  2 4  h ( T a b le  I ) .
Discussion
The r esu lts  d e s c r ib e d  h e r e  s h o w  t h a t  C C - 1 0 6 5  is  a  v e r y  
potent a g e n t fo r  e f f e c t i n g  N A D  d e p le t io n  in  h u m a n  c e l ls .  
Previous s tu d ie s  o f  t h e  m e c h a n is m  o f  N A D  d e p le t io n  u s in g  
other D N A  a lk y la t in g  a g e n t s  h a v e  p r o v id e d  a  l ik e ly  m e c h a ­
nism of this e f fe c t  (S m u ls o n  e t a l ., 1 9 7 7 ;  G o o d w in  e t  a l .,  1 9 7 8 ;  
Juarez-Salinas e t a l ., 1 9 7 9 ; J a c o b so n  e t  a l .,  1 9 8 0 , 1 9 8 4 ;  B e r g e r  
et al., 1980; M c C u r r y  &  J a c o b s o n ,  1 9 8 1 ) .  D N A  a lk y la t io n  
results in th e  a p p e a r a n c e  o f  D N A  str a n d  b r ea k s  e ith e r  d ir e c t ly  
or indirectly d u e  to  e n z y m e s  in v o lv e d  in  D N A  e x c is io n  r ep a ir .  
The occurrence o f  D N A  str a n d  b r e a k s  r e su lts  in  a n  a c t iv a t io n  
of the c h r o m a t in -a s s o c ia te d  e n z y m e ,  p o ly (  A D P - r ib o s e )  p o ­
lymerase, w h ic h  u t i l i z e s  N A D  a s  i t s  s u b s t r a t e .  U n d e r  c o n -  










f i g u r e  5: Time course o f N A D  content o f normal human fibroblasts 
after treatment with various concentrations of C C -1065. Drug was 
added at zero time to final CC-1065 concentrations of 0 (O), 0.1 (■), 
0.5 ( • ) ,  and 1.0 Mg/mL (▼) to flasks having N A D  levels o f 2.9 X  
103 p m o l/1 0 6 cells.
is  s u f f i c i e n t ly  h ig h ,  th e  r a te  o f  p o l y ( A D P - r ib o s e )  s y n t h e s is  
e x c e e d s  th e  r a te  o f  N A D  s y n th e s is  w ith  a  r e s u lt in g  p a r t ia l  or  
to ta l  d e p le t io n  o f  th e  c e l lu la r  N A D  p o o l. O u r  o b se r v a t io n  th a t  
in h ib i to r s  o f  p o l y ( A D P - r ib o s e )  p o ly m e r a s e  e f f e c t i v e l y  b lo c k  
N A D  d e p le t io n  in d u c e d  b y  C C - 1 0 6 5  (F ig u r e  2 B )  is  c o n s is te n t  
w ith  a n d  fu r th e r  s u p p o r ts  th is  b a s ic  m e c h a n is m  o f  N A D  d e ­
p le t io n  b y  D N A  a lk y la t in g  a g e n t s .  F u r th e r ,  t h e  o b s e r v a t io n  
t h a t  a n  e q u iv a le n t  c o n c e n t r a t io n  o f  n e tr o p s in  d o e s  n o t  c a u s e  
N A D  d e p le t io n  ( F ig u r e  3 )  s u g g e s t s  t h a t  i t  is  t h e  a b i l i t y  o f  
C C - 1 0 6 5  t o  b in d  c o v a le n t ly  t o  D N A  th a t  u l t im a t e ly  le a d s  to  
N A D  d e p le t io n .
C e l l s  t h a t  a r e  h o m o z y g o u s  fo r  th e  X P  g e n o t y p e  h a v e  b e e n  
s h o w n  to  b e  g r o s s ly  d e f ic ie n t  in  th e ir  a b i l i t y  to  r e p a ir  s p e c i f ic  
ty p e s  o f  D N A  le s io n s . T h e s e  le s io n s  in c lu d e  p y r im id in e  d im e r s  
a n d  a  v a r ie t y  o f  b u lk y  D N A  a d d u c t s .  A  c o m m o n  f e a t u r e  o f  
th e  v a r io u s  c o m p lm e n ta t io n  g r o u p s  w ith in  th is  g e n o ty p e  is  th e  
i n a b i l i t y  to  c a u s e  D N A  in c is io n s  p r e r e q u is it e  to  s u b s e q u e n t  
s t e p s  o f  D N A  e x c i s io n  r e p a ir . I t  h a s  b e e n  p r e v io u s ly  s h o w n  
t h a t  X P  c e l ls  a r e  a l s o  u n a b le  to  c a u s e  N A D  d e p le t io n  in  
r e s p o n s e  to  U V  l ig h t  ( M c C u r r y  &  J a c o b s o n ,  1 9 8 1 ) .  S i n c e  
C C - 1 0 6 5  c a u s e s  a  b u lk y  b u t  n o n d is t o r t iv e  D N A  a d d u c t  
( R e y n o l d s  e t  a l . ,  1 9 8 5 ) ,  it  w a s  o f  c o n s id e r a b le  in t e r e s t  to  
d e t e r m in e  w h e t h e r  X P  c e l l s  c o u ld  c a u s e  N A D  d e p le t io n  in  
r e s p o n s e  to  th is  d r u g . O u r  r e s u lts  s u g g e s t  th a t  th e s e  c e l ls  c a n  
r e c o g n iz e  th e  C C - 1 0 6 5 - D N A  a d d u c t  a n d  c a n  c a u s e  D N A  
in c i s io n s  in  r e s p o n s e  to  t h is  d r u g . S i n c e  o th e r  b u lk y  b u t  
n o n d is t o r t iv e  D N A  a d d u c t s  s u c h  a s  t h a t  p r o d u c e d  b y  th e  
p y r r o lo [  1 ,4 ]  b e n z o d ia z e p in e s  a r e  n o t  e x c i s e d  b y  X P  c e l l s  
( P e t r u s e k  e t  a l . ,  1 9 8 2 ) ,  th is  in fe r s  t h a t  s o m e  u n iq u e  f e a t u r e  
o f  t h e  C C - 1 0 6 5 - D N A  a d d u c t  m u s t  le a d  to  r e c o g n i t io n  a n d  
s u b s e q u e n t  in c is io n  b y  a  r e p a ir  e n z y m e  o r  c o m p le x .  O n e  
d is t in c t  f e a t u r e  o f  t h e  C C - 1 0 6 5 ( N 3 - a d e n i n e ) - D N A  a d d u c t  
is  a  p o s i t iv e ly  c h a r g e d  p u r in e  n u c le u s  a b s e n t  in  t h e  p y r r o lo -  
[ l ,4 ] b e n z o d i a z e p i n e - D N A  a d d u c t s  w h ic h  a r e  b o u n d  th r o u g h  
th e  e x o c y c l ic  2 - a m in o  g r o u p  o f  g u a n in e  (P e tr u s e k  e t  a l . ,  1 9 8 1 ;  
G r a v e s  e t  a l . ,  1 9 8 4 ) .
W h i le  o u r  s t u d ie s  a r e  c o n s is t e n t  w ith  th e  m e c h a n is m  o f  
N A D  d e p le t io n  d e v e lo p e d  fr o m  s t u d ie s  o f  o th e r  D N A  a lk y l ­
a t in g  a g e n t s ,  w e  h a v e  a ls o  o b s e r v e d  u n iq u e  f e a tu r e s  th a t  m a y  
p r o v id e  a v e n u e s  fo r  in s ig h t  in t o  th e  m e c h a n is m  o f  th e  r e ­
m a r k a b le  c y t o t o x ic  p o t e n c y  o f  C C - 1 0 6 5 .  F ir s t ,  w e  h a v e  o b ­
s e r v e d  a  p r o n o u n c e d  la g  p e r io d  p r io r  to  t h e  o n s e t  o f  N A D  
d e p le t io n .  T h is  is  in  c o n t r a s t  to  a  v e r y  r a p id  o n s e t  o f  N A D  
lo w e r in g  o b s e r v e d  w ith  o th e r  a lk y la t in g  a g e n t s  ( G o o d w in  e t
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al., 1978; Juarez-Salinas et al., 1979; Jacobson et al., 1980). 
Second, the drug can cause NAD depletion at very low doses, 
in comparison to other alkylating agents. For example, it 
causes NAD depletion at doses 100-500 times less than that 
of the potent DNA alkylating agent MNNG (Jacobson et al., 
1980). Third, the drug causes prolonged NAD depletion even 
at low doses, which is in marked contrast to other DNA al­
kylating agents where depletion is usually transient (Goodwin 
et al., 1978). There are two possible mechanisms that might 
explain the prolonged NAD depletion. First, it is possible that 
the drug not only causes activation of poly(ADP-ribose) 
synthesis but also inhibits NAD biosynthesis. This possibility 
has been examined for some other DNA alkylating agents but 
was not found to be valid (Jacobson et al., 1980). Second, 
it is also possible that this drug effects NAD depletion by 
causing a unique type of DNA damage that, while permitting 
recognition and DNA incisions to be made at a normal rate, 
does not allow DNA excision repair to be completed to the 
point where the incisions are resealed. Thus, poly(ADP-ribose) 
polymerase activation is prolonged, which in turn leads to 
NAD depletion.
Superficially, depletion of NAD levels caused by prolonged 
poly(ADP-ribose) polymerase activity due to incomplete repair 
of CC-1065-DNA lesions seems an attractive hypothesis to 
explain the high cytotoxic potency of this drug. Indeed, Berger 
and co-workers (Sims et al., 1983; Berger, 1985) have proposed 
that, at high doses of DNA damage, cytotoxicity results from 
NAD depletion, which in turn leads to an inability of the cell 
to substain normal energy metabolism and cell death. How­
ever, for CC-1065 this may not be the prime cause of cell death 
since in a B16 melanoma cell line a greater than 90% cell kill 
was found following a 2-h exposure to a 1 ng/mL concen­
tration of CC-1065 (Bhuyan et al., 1982). Nevertheless from 
a mechanistic standpoint, the NAD depletion observed in our 
experiments can be rationalized by a block or delay in DNA  
excision repair between the excision and ligation steps.
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a b s t r a c t : The recognition and repair o f the helix-stabilizing and relatively nondistortive CC-1065-(N3- 
adenine)-DNA adduct by UVRABC nuclease has been investigated both in vivo with 0 X  174 RFI D NA  
by a transfection assay and in vitro by a site-directed adduct in a 117 base pair fragment from M 13mpl. 
CC-1065 is a potent antitumor antibiotic produced by Streptom yces zelensis which binds within the minor 
groove o f D N A  through N 3 o f adenine. In contrast to the helix-destabilizing and distortive modifications 
of D N A  caused by ultraviolet light or Ar-acetoxy-2-(acetylamino)fluorene, CC-1065 increases the melting 
point o f D N A  and decreases the SI nuclease activity. Using a viral D N A -E scherichia coli transfection 
system, we have found that the uvrA, ttvrB, and uvrC  genes, which code for the major excision repair proteins 
for UV- and NAAAF-induced D N A  damage, are also involved in the repair o f C C -1065-D N A  adducts. 
In contrast, the uvrD  gene product, which has been found to be involved in the repair o f U V  damage, has 
no effect in repairing C C -1065-D N A  adducts. Purified UVRA, UVRB, and UVRC proteins must work 
in concert to incise the drug-modified 0X174 RFI DNA. Using a site-directed and multiple CC-1065 modified 
(M spI-B stN I)  117 base pair fragment from M 13m pl, we have found that UVRABC nuclease incises at 
the eighth phosphodiester bond on the 5' side o f the C C -1065-D N A  adduct on the drug-modified strand. 
The enzymes do not cut the noncovalently modified strand. At low drug binding ratios, o f the four CC-1065 
binding sites identified in the (M spI-BstNT) 117 base pair fragment, GATTA*, GGAAA*, GATAA*, and 
TTTTA* (* indicates the covalently modified adenine), only the adduct at the high-affinity binding site, 
GATTA*, is incised by the UVRABC nucleases. N o  difference in the effect o f CC-1065 on local D N A  
structure, as determined by the D N ase I cleavage pattern, was evident among these sites. A t high drug 
binding ratios, a fifth drug binding site, AGCTA*, is identified. At this concentration UVRABC nucleases 
are unable to incise any o f these five C C-1065-DNA adducts. The D N A  sequence and/or helix-stabilizing 
effect o f multiple adducts may determine the recognition and/or incision o f the drug-D N A  adduct by 
UVRABC nuclease. These results are discussed in relation to the.structure o f the C C -1065-D N A  adduct 
and the effect o f drug binding on local D N A  structure.
JLhe uvrA, uvrB, and uvrC  genes in Escherichia coli cells 
control the initial steps of excision repair of DNA damage 
induced by UV1 radiation and by bulky chemical carcinogens 
and drugs such as NAAAF, benzo[a] pyrenediol epoxide, 
cft-platinum, and psoralen (Seeberg et al., 1983; Sancar et 
al., 1985; Beck et al., 1985). These agents induce various 
extents of deformation in DNA helix; DNA damaged by these 
agents is more sensitive to SI nuclease digestion (Grunberger 
& Weinstein, 1978) and also exhibits a decreased melting 
temperature (Trifonov et al., 1968; Fuchs & Duane, 1974; 
Pulkrabek et al., 1978). Purified uvrA, uvrB, and uvrC gene 
products have been shown to work in concert in incising both 
the 5' side (eighth phosphodiester bond) and the 3' side (fifth 
or fourth phosphodiester bond) of the damaged base(s), such 
as cyclobutane dipyrimidines, (6 -4 ) photoproducts, m-plat- 
inum adducts, and dG-C8-AAF.
CC-1065 is a potent antitumor antibiotic produced by 
Streptomyces zelensis [Hanka et al., 1978, for recent reviews, 
see Hurley and Needham-VanDevanter (1986) and Reynolds 
et al. (1986)]. The three benzodipyrrolesubunits of CC-1065
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ES 03124, and CA 30349) and the Welch Foundation.
* Address correspondence to these authors.
* Science Park—Research Division.
* University of Texas at Austin.
1 Present address: University of Texas Health Science Center, San
Antonio, TX 78284.
are joined by out of plane amide bridges that impart a shallow 
right-handed twist along the length of the molecule (Chidester 
et al., 1981). The overall twisted banana shape of the CC-1065 
molecule presumably facilitates the nonintercalative binding 
of the drug in the minor groove of DNA. A presumed 
proximity effect between the exocylic carbon atom of the 
cyclopropane ring of CC-1065 and N3 of adenine in duplex 
DNA then leads to covalent binding (Figure 1). Although 
we arbitrarily represent the CC-1065 covalently modified 
adenine as the neutral species, it could also occur as purine 
species with a positive charge at one of the nitrogen atoms. 
As is common to N3 adenine alkylated species, thermal 
treatment (90 °C for 30 min) at neutral pH leads to cleavage 
of the N-glycosidic linkage and subsequent strand breakage 
at the AP site (Reynolds et al., 1985) (Figure 1). This strand 
breakage assay has been used to determine the sequence 
specificity of CC-1065 (Reynolds et al., 1985). In contrast 
to “UV-like" agents as described above, CC-1065 increases
1 Abbreviations: UV, ultraviolet light; NAAAF, 7V-acetoxy-2-(ace- 
tylamino)fluorene; dG-C8-AAF, Af-(deoxyguanos-8-yl)-2-(acetyl- 
amino)fluorene; bp, base pair; 7V-OH-AF, W-hydroxy-2-aminofluorene; 
BAP, bacterial alkaline phosphatase; PNK, polynucleotide kinase; AP, 
apurinic acid; NOESY, nuclear Overhauser enhancer spectroscopy; 
MPE, methidiumpropyl-EDTA; TAE, 50 mM Tris, 5 mM sodium ace­
tate, and 1 mM EDTA, pH 7.6; dTTP, thymidine triphosphate; Tris, 
tris(hydroxymethyl)aminomethane; EDTA, ethylenediaminetetraacetic 
acid.
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f i g u r e  1: Reaction o f  C C -1065 with N 3  o f  adenine in D N A  and 
products from the therm al cleavage reaction. The exact nature o f  
the species generated on the 5' side o f  the strand break is unknown.
the melting point of D N A  and decreases the sensitivity to SI 
nuclease (Swenson et al., 1982). The stabilization of the helix 
to SI nuclease and thermal denaturation is consistent with 
molecular models of the CC-1065-(N3-adenine)-DNA adduct 
(Figure 2) that show a snug fit of the drug in the minor groove 
spanning a four base pair region to the 5' side of the covalently 
modified adenine (Hurley et al., 1984). Recently, we have 
prepared a site-directed C C -1065-D N A  adduct in which 
CC-1065 is bound to A-6229 in a 117-bp restriction fragment 
from M 13mpl (Needham-VanDevanter & Hurley, 1986). 
DNase I and restriction enzyme analysis of this single adduct 
in the 117-bp fragment shows that CC-1065 produces an 
asymmetric effect on D N A  structure such that the confor­
mation of the covalently modified strand o f CC-1065 is pro­
p o se d  to  b e  a l t e r e d  u p  to  a b o u t  o n e  h e l ix  tu r n  t o  th e  5 '  s id e  
o f  A - 6 2 2 9  ( H u r le y  e t  a l . ,  1 9 8 7 ) .
T h e  u n iq u e  f e a t u r e s  o f  th e  C C - 1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  
a d d u c t  h a v e  p r o m p t e d  u s  t o  in v e s t ig a t e  w h e t h e r  th is  w e ll-  
d e f in e d  le s io n  m a y  b e  u s e fu l  in  e lu c id a t in g  th e  s tr u c tu r a l  a n d  
e le c t r o n ic  f e a t u r e s  r e s p o n s ib le  fo r  r e c o g n i t io n  o f  c o v a le n t ly  
m o d if ie d  D N A  b y  U V R A B C  n u c le a se s . T h e  r e su lts  sh o w  th a t  
w h i le  a l l  th r e e  p r o te in s  a r e  r e q u ir e d  fo r  b o t h  in  v iv o  a n d  in  
v itr o  r e c o g n it io n  a n d  r e p a ir ,  t h e  e f f i c i e n c y  o f  r e c o g n i t io n  in  
v it r o  is  p o o r  in  c o n t r a s t  t o  t h a t  o f  m o r e  d i s t in c t iv e  D N A  
a d d u c ts .  T h e s e  r e s u lts  a r e  d is c u s s e d  in  r e la t io n  to  th e  k n o w n  
e f f e c t s  o f  C C - 1 0 6 5  o n  lo c a l  D N A  s tr u c tu r e .
M a t e r i a l s  a n d  M e t h o d s
DNA Transfection. E. coli s tr a in s  M S T 1 3 (uvrA6 ), M S T 3  
( uvrB5) ,  M S T 8  ( uvrC34) ,  a n d  M S T 1 7  ( uvrD3)  w e r e  c o n ­
s tr u c te d  b y  P I  o r  T 4 G T 7  t r a n s d u c t io n  ( T a n g  e t  a l . ,  1 9 8 2 ) .  
T h e  p a r e n ta l  s tr a in  H F 4 7 0 4  ( M S T 1  w ild  t y p e )  w a s  o b ta in e d  
fr o m  D r . T . K u n k e l.  T h e  p u r if ic a t io n  o f  0 X 1 7 4 a m 3 c s 7 O  R F I  
D N A  a n d  t h e  D N A  t r a n s f e c t io n  w e r e  p e r fo r m e d  e x a c t ly  a s  
d e s c r ib e d  p r e v io u s ly  ( T a n g  e t  a l . ,  1 9 8 2 ) .
Purification o f  U VRA , UVRB , and UVRC Proteins. 
U V R A ,  U V R B ,  a n d  U V R C  p r o t e in s  w e r e  p u r if ie d  fr o m  E. 
coli K 1 2  str a in  C H 2 9 6  ( recA endAl/F'lacf*)  c o n ta in in g  U V R  
p r o te in  o v e r p r o d u c in g  p la s m id s  p U N C 4 5  ( urvA ) ,  p U N C 2 1 1  
( urvB) ,  a n d  p D R 3 2 7 4  ( uvrC) . T T iese p la sm id s  a n d  th e  E. coli 
s t r a in s  w e r e  g i f t s  o f  D r .  A .  S a n c a r .  T h e  d e t a i l s  o f  th e  p u r i­
f ic a t io n  p r o c e d u r e  w i l l  b e  p u b l is h e d  e ls e w h e r e .  U V R D  p r o ­
t e in s  w e r e  g i f t s  o f  D r .  T .  L o h m a n .  A l l  t h e  p r o te in s  w e r e  
p u r if ie d  to  t h e  e x t e n t  s h o w n  in  F ig u r e  3 .
12 P 5 'or 3' End Labeling, ( a )  Site-Directed CC-1065-DNA  
Adduct. T h e  la b e l in g  m e t h o d  w a s  p e r fo r m e d  a s  d e s c r ib e d  
p r e v io u s ly  ( N e e d h a m - V a n D e v a n t e r  &  H u r le y ,  1 9 8 6 ) .
(b) M ultiple CC-1065-D N A Adduct. T h e  2 5 0 - b p  f r a g ­
m e n t s  is o la te d  fr o m  M spl  d i g e s t io n  o f  M 1 3 m p l  w e r e  5' 32P  
e n d  la b e le d  b y  s e q u e n t ia l  B A P  a n d  T 4  P N K  tr e a tm e n t . D N A  
f r a g m e n t s  in  5 0  p.L o f  5 0  m M  N a C l  a n d  5 0  m M  T r is - H C l ,  
p H  8 .0 ,  w e r e  in c u b a t e d  w it h  1 u n i t  o f  B A P  fo r  1 .5  h  a t  6 5  
° C  f o l lo w e d  b y  p h e n o l / c h lo r o f o r m  e x t r a c t io n  a n d  e th a n o l  
p r e c ip ita t io n .  T h e  D N A  p e l l e t s  w e r e  r e s u s p e n d e d  in  2 5  /xL  
o f  5 0  m M  T r i s - H C l ,  p H  7 .8 ,  1 0  m M  M g C l 2, 5  m M  d ith io -  
th r e i t o l ,  1 m M  s p e r m id in e ,  a n d  0 .5  m C i  o f  [-y -32P ] A T P  to
f i g u r e  2: Stereo diagram  o f a C C -1 0 6 5 -D N A  adduct. The computer graphic representation o f  a C C -1 0 6 5 -D N A  adduct using the X-ray  
crystal coordinates for ring-opened C C -1065 (Chidester et al., 1981) and B-form D N A  generated by the M ID A S  graphics program. The 
sequence used is that o f  the center o f  a 14 base pair oligo deoxy duplex shown to bind a single C C -1065 m olecule, a  bonds around amide 
linkages between the drug subunits (see Figure 1) were rotated to reduce d ose  drug-D N A  contacts upon docking. CC -1065 A, B, and C subunits 
are labeled.
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FIGURE 3: Gel electrophoresis o f purified U V R A , U V R B , UV RC, 
and UVRD (helicase II) proteins. The proteins were electrophoresed 
in a 10% polyacrylamide gel with sodium dodecyl sulfate and were 
stained with Coom assie blue.
which 4 u n its  o f  T 4  P N K  w a s  a d d e d . S a m p le s  w e r e  in c u b a te d  
20 min a t 3 7  ° C  a n d  p r e c ip i ta te d  b y  e t h a n o l .  A  s e c o n d  d i ­
gestion b y  2?.yfNI w a s  c a r r ie d  o u t  t o  o b t a in  t h e  1 1 7 -b p  f r a g ­
ment. For 3 ' e n d  la b e lin g , th e  1 3 7 -b p  fr a g m e n ts  o b ta in e d  fro m  
fofNI d ig e s t io n  o f  M 1 3 m p l  R F  D N A  w e r e  d is s o lv e d  in  3 0  
mL of 10 m M  T r i s - H C l ,  p H  8 .0 ,  5  m M  M g C l 2, 7 .5  m M  
dithiothreitoL, a n d  0 .1  m C i o f  [ a - 32P ]d T T P . O n e  u n it  o f  D N A  
polymerase I (K le n o w  fr a g m e n t)  w a s  a d d e d  a n d  in c u b a te d  for  
20 min a t r o o m  t e m p e r a tu r e .  A f t e r  e t h a n o l  p r e c ip i ta t io n ,  a  
secondary d ig e s t io n  b y  M spl w a s  c a r r ie d  o u t  t o  o b t a in  th e  
117-bp fr a g m e n ts .
Modification o f  DNA with CC-1065. (a) <fiX174 RFI DNA. 
Purified 0 X 1 7 4  R F I  D N A  w a s  r e a c te d  w ith  v a r io u s  c o n c e n ­
trations o f  C C - 1 0 6 5  in  D S C  s o lu t io n  ( 1 5  m M  N a C l ,  1 .5  m M  
sodium c itr a te ,  p H  7 .4 )  a t  r o o m  te m p e r a t u r e  fo r  9 0  m in  to  
produce v a r io u s  e x t e n t s  o f  m o d if ic a t io n .
{b) Site-Directed CC-1065-DNA Adduct. C o n s tr u c t io n  o f  
the s ite -d ire c ted  C C - 1 0 6 5 - D N A  a d d u c t  w a s  p e r fo r m e d  a s  
described p r e v io u s ly  ( N e e d h a m - V a n D e v a n t e r  &  H u r le y ,
1986).
(c) Multiple CC-1065-DNA Adduct. V a r io u s  1 0 - fo ld  d i ­
lutions o f  a  s ta n d a r d  2 8 0  / tM  s o lu t io n  o f  C C - 1 0 6 5  w a s  a d d e d  
to 5 ' or 3 ' 32P - la b e le d  (M sp l-B stN l)  1 1 7 -b p  f r a g m e n t  o f  
M13mpl a n d  in c u b a t e d  a t  3 7  ° C  fo r  2  h .
All th e  a b o v e  m o d if ic a t io n s  o f  D N A  b y  C C - 1 0 6 5  w e r e  
terminated b y  e t h a n o l  p r e c ip i ta t io n .
MPE-Fe(II) or DNase I Footprinting and Thermal 
Breakage o f  CC-1065-Bound Fragments. T h e  (M spl-B stN l) 
117-bp fr a g m e n ts  5 '  32P  e n d  la b e le d  o n  th e  ( + )  s tr a n d  w e r e  
digested w ith  M P E - F e ( I I )  ( N e e d h a m - V a n D e v a n t e r  &  H u r ­
ley, 1986), s u b je c te d  t o  th e r m a l  t r e a t m e n t  ( 9 0  ° C ,  3 0  m in )  
(Reynolds e t  a l . ,  1 9 8 5 ) ,  o r  fo o tp r in te d  w ith  D N a s e  I (H u r le y  
et al., 1 9 8 7 ) t o  c o n f ir m  b o th  t h e  lo c a t io n  a n d  t h e  o r ie n ta t io n  
of the C C - 1 0 6 5 - D N A  a d d u c t  a c c o r d in g  to  t h e  m e th o d  d e ­
scribed p rev io u s ly  (N e e d h a m - V a n D e v a n t e r  &  H u r le y , 1 9 8 6 ) .  
Reaction o f  UVR Protein with CC-1065-M odified DNA. 
For the in cis ion  a s s a y , U V R  p r o te in s  ( 0 .2  p m o l o f  U V R A ,  2 .2  
pmol o f U V R B , a n d  0 .2 8  p m o l o f  U V R C )  w e r e  a d d e d  s in g ly  
or in com b in ation  to  C C -1 0 6 5 -m o d if ie d  0 X 1 7 4  R F I  D N A  ( 0 .2  
/ig) in a r e a c t io n  m ix t u r e  w h ic h  c o n t a in e d  5 0  m M  T r is ,  p H  
7.5,10 m M  M g C l 2, 8 5  m M  K C 1, 1 m M  A T P ,  a n d  1 m M  
dithiothreitoL T h e  in c u b a t io n s  w e r e  c o n d u c t e d  a t  3 7  ° C  in  
the dark fo r  9 0  m in . W e  h a v e  fo u n d  th a t  u n d e r  t h e s e  c o n ­
ditions U V R A B C  n u c le a s e s  in c is e  th e  d r u g -m o d if ie d  0 X 1 7 4  
RFI DNA o p t im a l ly .  T h e  r e a c t io n s  w e r e  s to p p e d  b y  th e  
addition o f  sod ium  d o d e c y l  s u l f a t e  (0 .1 % ) a n d  h e a te d  a t  65 
°C for 2 m in. T h e  re s u lta n t D N A s w ere  su b jec ted  to  e lec ­
t r o p h o r e s is  in  1% a g a r o s e  in  T A E  b u ffe r  a t  1 V / c m  fo r  16  
h . F o r  t h e  32P - la b e le d  D N A  fr a g m e n t ,  th e  a m o u n t  o f  U V R  
p r o te in s  a d d e d  to  t h e  r e a c t io n  m ix tu r e  a n d  t h e  in c u b a t io n  
c o n d it io n s  w e r e  t h e  s a m e  a s  d e s c r ib e d  a b o v e , e x c e p t  th a t  th e  
r e a c t io n s  w e r e  s to p p e d  b y  p h e n o l /c h lo r o f o r m  e x tr a c t io n s  a n d  
s u b s e q u e n t ly  e th a n o l  p r e c ip ita t io n . T h e  U V R  p r o te in  r ea c te d  
D N A  f r a g m e n t s  w e r e  d e n a tu r e d  b y  h e a t  ( 9 0  ° C ,  2  m in )  in  
f o r m a m id e  ( 8 0 % ) - N a O H  ( 1 0  m M )  s o lu t io n  a n d  th e n  s u b ­
j e c t e d  to  s e q u e n c in g  e le c tr o p h o r e s i s  in  p a r a lle l  w ith  M a x a m  
a n d  G i lb e r t  ( 1 9 8 0 )  A + G  a n d  T + C  r e a c t io n s .
R e s u l t s
uvrA, uvrB , a n d  uvrC  g e n e s  c o n tr o l  th e  e x c is io n  r e p a ir  o f  
U V - i n d u c e d  a n d  b u lk y  c h e m ic a l  c a r c in o g e n  in d u c e d  D N A  
d a m a g e  in  b o t h  c h r o m o s o m a l  a n d  e x tr a c h r o m o s o m a l  D N A  
( H a n a w a l t  e t  a l . ,  1 9 7 9 ) .  T h is  c o n c lu s io n  is  m a in ly  d e r iv e d  
fr o m  t h e  f o l lo w in g  r e s u lt s :  ( 1 )  c o m p a r e d  to  w i ld - t y p e  c e l ls ,  
uvrA, uvrB, a n d  uvrC  m u t a n t  c e l l s  a r e  s e n s i t iv e  to  c e l l  d e a th  
w h e n  e x p o s e d  t o  t h e s e  D N A  d a m a g in g  a g e n t s  (H o w a r d -  
F la n d e r s  e t  a l . ,  1 9 6 4 ) ,  a n d  ( 2 )  U V - ir r a d ia te d  o r  c h e m ic a l  
c a r c in o g e n  m o d if ie d  p h a g e , p h a g e  D N A ,  or  p la sm id  D N A  h a s  
a  lo w e r  in f e c t iv i t y ,  t r a n s fe c t iv i ty ,  o r  tr a n s fo r m a tio n  a b i l i ty  in  
uvrA, uvrB, o r  uvrC  m u ta n t  c e l ls  in  c o m p a r iso n  w ith  w ild -ty p e  
c e l l s  ( T a n g  e t  a l . ,  1 9 8 2 ;  F u c h s  &  S e e b e r g ,  1 9 8 3 ;  T a k e t o  e t  
a l . ,  1 9 7 9 ) .
Transfection Experiments with CC-1065-Modified <J>X174 
RFI DNA in E. coli uvr M utant Cells. In  o r d e r  to  t e s t  th e  
r o le  o f  uvrA, uvrB, a n d  uvrC  g e n e s  in  th e  r e p a ir  o f  C C -  
1 0 6 5 - in d u c e d  D N A  d a m a g e ,  p u r if ie d  <pX174 R F I  D N A  w a s  
r e a c t e d  w i t h  d i f f e r e n t  c o n c e n t r a t io n s  o f  C C - 1 0 6 5  fo r  tr a n s ­
f e c t io n  a s s a y .  T h e  n u m b e r  o f  C C - 1 0 6 5  a d d u c ts  p e r  m o le c u le  
o f  D N A  c o u ld  n o t  b e  c a lc u la te d  b e c a u s e  r a d io a c t iv e ly  la b e le d  
C C - 1 0 6 5  is  n o t  a v a ila b le .  H o w e v e r , w e  h a v e  fo u n d  th a t u n d e r  
t h e  r e a c t io n  c o n d it io n s  w e  h a v e  u s e d  th e  n u m b e r  o f  D N A  
a d d u c t s  fo r m e d  is  p r o p o r t io n a l  t o  t h e  c o n c e n tr a t io n  o f  C C -  
1 0 6 5  ( u n p u b l i s h e d  r e s u l t s ) .  W h e n  t h e s e  C C - 1 0 6 5 - m o d if i e d  
D N A s  w e r e  t r a n s f e c t e d  in t o  E. coli, th e  t r a n s f e c t iv i t y  w a s  
in v e r s e ly  p r o p o r t io n a l  t o  t h e  c o n c e n tr a t io n  o f  C C - 1 0 6 5  u s e d  
fo r  m o d if ic a t io n  ( F ig u r e  4 ) .  T h e s e  m o d if ie d  D N A s  h a v e  a  
lo w e r  t r a n s f e c t i v i t y  in  uvrA, uvrB, a n d  uvrC  m u ta n t  c e l ls  
c o m p a r e d  w i t h  w i ld - t y p e  c e l l s .  H o w e v e r ,  th e  t r a n s fe c t iv i t ie s  
o f  t h e  m o d if ie d  D N A  in  uvrD  m u t a n t  c e l ls  a r e  th e  s a m e  a s  
in  w i ld - t y p e  c e l ls .  T h e s e  r e s u lt s  in d ic a te  th e  uvrA, uvrB, a n d  
uvrC, b u t  n o t  uvrD, g e n e  p r o d u c t s  a r e  in v o lv e d  in  th e  r e p a ir  
o f  C C - 1 0 6 5 - in d u c e d  D N A  d a m a g e .
In Vitro Repair o f  CC-1065-DNA Adducts by UVRABC  
Nucleases in <f>X174 RFI DNA. In  o r d e r  to  te s t  w h e th e r  th e se  
g e n e  p r o d u c t s  w o r k  in  c o o r d in a t io n  o r  in d e p e n d e n t ly  in  r e ­
p a ir in g  th e  C C - 1 0 6 5 - D N A  a d d u c ts ,  p u r ified  U V R A ,  U V R B ,  
a n d  U V R C  p r o te in s  s in g ly  o r  in  c o m b in a t io n  w e r e  rea c te d  w ith  
C C - 1 0 6 5 - m o d if i e d  0 X 1 7 4  R F I  D N A  in  th e  p r e se n c e  o f  A T P  
a n d  M g 2+ io n .  A n y  r e p a ir  p r o c e s s  th a t  c a u s e s  a  D N A  str a n d  
b r e a k a g e  w i l l  c o n v e r t  t h e  s u p e r c o i le d  R F I  D N A  to  r e la x e d  
R F I I  o r  l in e a r  D N A .  T h e  e le c tr o p h o r e t ic  m o b il i t ie s  o f  th e s e  
th r e e  k in d s  o f  D N A  a r e  s ig n if ic a n t ly  d iffe r en t (F ig u r e  5 ) . T h e  
r e s u lt s  in  F ig u r e  5  s h o w  t h a t  t h e s e  th r e e  p r o te in s  m u s t  w o r k  
to g e t h e r  to  c u t  t h e  C C - 1 0 6 5 - m o d i f i e d  D N A  ( c o m p a r e  la n e  
8  t o  la n e s  1 - 7 ) .  T h e  b a c k g r o u n d  c u t t in g s  in d u c e d  b y  a d d in g  
U V R  p r o te in s  s in g ly  o r  in  p a ir s  a r e  l ik e ly  d u e  to  n o n s p e c if ic  
e n d o n u c le a s e  c o n ta m in a t io n  in  th e  U V R  p r o te in  p r ep a ra tio n s ,  
s in c e  U V R  p r o te in s ,  s in g ly  o r  in  p a ir w is e  c o m b in a t io n , d o  n o t  
in d u c e  D N A  s tr a n d  b r e a k s  c o r r e s p o n d in g  to  C C -1 0 6 5  m o d ­
i f ic a t io n  s i t e s  in  D N A  s e q u e n c in g  g e ls  (d a ta  n o t s h o w n ) . T h e  
a d d it io n  o f  U V R D  p r o te in  o v e r  a  c o n c e n tr a t io n  r a n g e  fr o m
1.3  X  10~3 t o  2.5 X  1 0 -2 p m o l h a s  n o  effect o n  th e  ac tiv ity  o f  
U V R A B C  nucleases tow ard  C C -1065-m odified  D N A  (F ipure
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f i g u r e  4: Relative transfectivity o f  CC -1065-m odified 0X 174  RFI 
D N A  in wild-type E. c o li  ( • )  and uvrA  (O ), uvrB  (□ ) ,  uvrC  ( a ) ,  
and uvrD  ( O )  m utant cells.
C C - 1 0 6 5  UV C o n t r o l
D N A  D N A  D N A
1 2  3  4  5  6  7  8  9  10 11 12
U vrA |- j - - j  | | +
U v r B ---------+ _  +  _ +  +  _ + _  +
UvrC---------- +  -  +  - F + -  +  -  +
f i g u r e  5: Incision o f  CC -1065-m odified 0 X 1 7 4  R FI D N A  by 
UV RABC nucleases. U V R A , UV RB, and U V R C  protein was added 
singly or in com bination as indicated by ( + )  and ( - )  signs to CC- 
1065-modified 0X 1 7 4  RFI D N A  (lanes 1 -8 ) solution. The reaction 
conditions were described in the text. Lanes 9 and 10 represent 
UV-irradiated 0 X 1 7 4  RFI D N A , and lanes 11 and 12 represent 
control 0 X 1 7 4  R FI D N A .
6 ) .  W e  h a v e  fo u n d  t h a t  t h e  a m o u n t  o f  U V R D  p r o te in  u se d  
in  th is  e x p e r im e n t  e n h a n c e s  U V R A B C  n u c le a s e  a c t iv i t y  t o ­
w a r d  U V -  a n d  A - O H - A F - in d u c e d  D N A  d a m a g e  b y  5 0  a n d  
2 0 0 % , r e s p e c t iv e ly  ( T a n g  e t  a l . ,  u n p u b l is h e d  r e s u l t s ) .
Recognition and Incision o f  Site-D irected CC-1065-{N3- 
Adenine)-DNA at A-6229 in a 117-bp Fragment by the 
UVRABC Nucleases. I t  h a s  b e e n  fo u n d  th a t  U V R A B C  n u ­
c le a s e s  in c is e  b o th  a t th e  5 ' s id e  ( e ig h th  p h o s p h o d ie s te r  b o n d )  













— • —  Uvr A B C 





o 1 2 3 4 5
pmol C C -1065/ng 4>x174 RFI DNA
FIGURE 6: U V R D  protein effect on the incision o f CC-1065-modified  
0X 174 RFI D N A  by U V R A B C  nucleases. CC-1065-modified 0X 174  
RFI D N A s were reacted with U V R A B C  nucleases in the presence 
(dotted line) or absence (solid line) o f  U V R D  protein (2.5 X 10"3 
pmol). The amount o f  U V R  proteins and D N A  used and the incu­
bation conditions arc the sam e as in Figure 5.
c y c lo b u t a n e  d ip y r im id in e ,  ( 6 - 4 )  p h o t o p r o d u c t ,  p s o r a le n  a d ­
d u c t ,  a n d  d G - C 8 - A A F  ( S a n c a r  &  R u p p , 1 9 8 3 ;  Y e u n g  e t  a l . ,  
1 9 8 3 ;  S a n c a r  e t  a l . ,  1 9 8 5 ) .  I t  is  o f  in t e r e s t  t o  d e te r m in e  
w h e th e r  U V R A B C  n u c le a s e s  h a v e  t h e  s a m e  m o d e  o f  a c t io n  
to w a r d  t h e  C C - 1 0 6 5 - in d u c e d  D N A  d a m a g e ,  w h ic h  c a u s e s  
g r e a t ly  d i f fe r e n t  e f f e c t s  o n  t h e  D N A  s tr u c tu r e  fr o m  U V -  a n d  
N A A A F - i n d u c e d  D N A  d a m a g e .  T h e  s i t e - d ir e c t e d  C C -  
1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  a d d u c t  o f  A - 6 2 2 9  in  th e  1 1 7 -b p  
fr a g m e n t  fr o m  M 1 3 m p l  w a s  p r e p a r e d  e i t h e r  3' o r  5 '  la b e le d  
o n  e i th e r  t h e  c o v a le n t ly  ( + )  o r  n o n c o v a le n t ly  ( - )  m o d if ie d  
s tr a n d s  ( N e e d h a m - V a n D e v a n t e r  &  H u r le y ,  1 9 8 6 ) .  T o  d e m ­
o n s t r a t e  t h e  p r e s e n c e  o f  a  s in g le  C C - 1 0 6 5 - D N A  a d d u c t  a t  
A - 6 2 2 9 ,  th e r m a l tr e a tm e n t  ( 9 0  ° C  fo r  3 0  m in )  o r  M P E - F e ( I I )  
fo o tp r in t in g  a n a ly s i s  w a s  c a r r ie d  o u t  a s  d e s c r ib e d  p r e v io u s ly  
(N e e d h a m -V a n D e v a n te r  &  H u r le y ,  1 9 8 6 ) .  T h e  r e su lts  o f  th is  
a n a ly s i s  fo r  t h e  ( + )  s t r a n d  a r e  s h o w n  in  F ig u r e  7 .  L a n e  5  
s h o w s  th e  s in g le - s t r a n d  b r e a k a g e  s i t e  a t  A - 6 2 2 9  a n d  la n e  3  
th e  M P E - F e ( I I )  f o o t p r in t in g  t o  t h e  5 '  s id e  o f  A - 6 2 2 9 .  A  
s im ila r  e x p e r im e n t  w i t h  t h e  ( - )  s t r a n d  d o e s  n o t  r e v e a l  a n y  
a d d it io n a l  s tr a n d  b r e a k a g e  s i t e s ,  b u t  a  M P E - F e ( I I )  fo o tp r in t  
o p p o s it e  t h e  e x p e c t e d  s i t e - d ir e c t e d  a d d u c t  s i t e  a t  A - 6 2 2 9  is  
fo u n d  ( N e e d h a m - V a n D e v a n t e r  &  H u r le y ,  1 9 8 6 ) .
W h e n  th e  s a m e  o r  s im ila r ly  c o n s t r u c t e d  s i t e - d ir e c t e d  C C -  
1 0 6 5 - D N A  a d d u c t s  w e r e  r e a c t e d  w ith  t h e  U V R A B C  n u ­
c le a s e s ,  th e  r e s u lt s  e x a m p l i f ie d  b y  t h o s e  in  F ig u r e  8  w e r e  
o b ta in e d . T h e  U V R A B C  n u c le a s e s  d id  n o t  c u t  th e  ( - )  s tr a n d  
( la n e  3 )  w h ile  e n z y m e - m e d ia t e d  in c is io n  w a s  o b t a in e d  in  b o th  
C C - 1 0 6 5 - m o d if i e d  5 '  a n d  3' ( + )  s t r a n d s  ( l a n e s  6  a n d  9 ,  r e ­
s p e c t iv e ly ) .  W e ,  t h e r e f o r e ,  c o n c lu d e  t h a t  t h e  U V R A B C  n u ­
c le a s e s  a r e  a b l e  t o  d i f f e r e n t ia t e  b e t w e e n  t h e  c o v a l e n t ly  a n d  
n o n c o v a le n t ly  m o d if ie d  s tr a n d s . F o r  b o th  th e  5 ' a n d  3 '  la b e le d  
fr a g m e n t  m o d if ie d  a t  A - 6 2 2 9  w ith  C C - 1 0 6 5  a n d  s u b je c te d  to  
th e  U V R A B C  n u c le a s e s ,  tw o  s tr a n d  b r e a k a g e  s it e s  a r e  e v id e n t. 
In e a c h  c a s e  o n e  o f  th e s e  is  d u e  t o  th e  th e r m a lly  in d u c e d  s tra n d  
b r e a k a g e  a t  A - 6 2 2 9  w h i le  t h e  o t h e r  is  a  S' in c i s io n  b y  th e  
U V R A B C  n u c le a s e .  T h e  a b s e n c e  o f  a  U V R A B C - i n d u c e d  
in c is io n  o n  th e  3' s id e  o f  t h e  C C - 1 0 6 5  a d d u c t  in  th e  3 '  la b e le d  
f r a g m e n t  ( l a n e  9 ) ,  t o g e t h e r  w i t h  t h e  5 '  in c is io n  s i t e  a t  s e v e n  
n u c le o t id e s  to  th e  5 '  s id e  o f  A - 6 2 2 9 ,  p r o v e s  th a t  th e  U V R A B C  
n u c le a s e  is o n ly  a b le  to  c u t  o n  o n e  s id e  ( 5 ' )  o f  t h e  C C - 1 0 6 5 -  
D N A  a d d u c t .  T h is  is  in  s ta r k  c o n tr a s t  t o  th e  m o d e  o f  a c t io n  
o f  U V R A B C  n u c le a s e s  o n  o t h e r  d r u g -  o r  c a r c i n o g e n - D N A  
a d d u c ts  (s e e  b e fo r e ) . M o r e o v e r , th e  m a jo r ity  o f  th e  r a d io a c tiv e  
m a te r ia l r e m a in s  a t th e  h ig h  e n d  o f  th e  g e l, d e m o n s tr a t in g  th at
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figure 7: Thermal strand break and M P E -F e(II)  footprinting  
analysis of the site-directed C C -1 0 6 5 -D N A  adduct. S ingle 5' 32P- 
labcled site-directed C C -1 0 6 5 -D N A  adducts were analyzed for 
CC-1065 adduct location by the thermal strand scission assay (lanes 
Sand 6) and M P E -F e(II) digestion (lanes 3 and 4 ). Analyses were 
performed on 5' 32P-labeled (+ )  strand. D N A  fragments with (lanes 
marked X). or without C C -1065 m odification. Reactions were 
dectrophoresed adjacent to unm odified D N A  (lanes 4 and 6) and 
Maxam-Gilbert sequencing reactions (lanes 1 and 2).
UVRABC c le a v a g e  a t  C C - 1 0 6 5  b in d in g  s i t e s  i s  n o t  v e r y  e f ­
ficient.
Recognition and Incision o f  M ultiple CC-1065-DNA Ad- 
kctsby the UVRABC Nucleases in the 117-bp Fragment. 
In order to d e te r m in e  w h e th e r  C C - 1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  
adducts in d if f e r e n t  s e q u e n c e s  w e r e  e q u a l l y  w e l l  r e c o g n iz e d  
the U V R A B C  n u c le a s e s ,  th e  s a m e  r e s t r ic t io n  e n z y m e  
pnent w as m o d if ie d  w ith  C C - 1 0 6 5 ,  w ith o u t  t h e  s ite -d ir e c te d  
adduct strategy. W e  h a v e  p r e v io u s ly  s h o w n  fo r  th is  f r a g m e n t  
that the h igh  a f f in i t y  b in d in g  s i t e s  a r e  a l l  f o u n d  o n  t h e  ( + )  
strand (N e e d h a m -V a n D e v a n te r  &  H u r le y ,  1 9 8 6 ) .  T h e  s a m e  
four CC-1065 b in d in g  s it e s  a r e  e v id e n t in  b o th  3 ' a n d  5 ' la b e le d  
figments (F ig u r e  9 ) .  W h e n  t h e s e  C C - 1 0 6 5 - m o d i f i e d  f r a g ­
ments were in c u b a te d  w ith  U V R A B C  n u c le a s e s  ( t h e  r e s u lt s  
are shown in F ig u r e  9 ,  la n e s  5  a n d  1 2 ) ,  o n ly  o n e  a d d i t io n a l  
cleavag e  s i t e  is  e v id e n t  o v e r  t h e  C C - 1 0 6 5  t h e r m a l  
sites p r e s e n t  in  la n e s  4  a n d  1 1 . T h is  c le a v a g e  s i t e  
corresponds to  th e  s a m e  n u c le a s e  in c is io n  s i t e  s e e n  in  F ig u r e  
ifor the s ite -d ir e c te d  a d d u c t ;  i .e . ,  U V R A B C  in c is io n  o c c u r s  
adusively to  th e  5 ' s id e  o f  th e  C C - 1 0 6 5  c o v a le n t  a d d u c t  s it e  
r.a distance o f  s e v e n  n u c le o t id e s  f r o m  A - 6 2 2 9 .  T h e r e  a r e  
a least tw o p o s s ib i l i t ie s  t o  a c c o u n t  fo r  t h e  a b s e n c e  o f  
JVRABC n u c le a s e  in c i s io n  a t  C C - 1 0 6 5  b in d in g  s i t e s  
GATAA*, G G A A A * ,  a n d  T T T T A * )  o th e r  th a n  t h e  A - 6 2 2 9  
sition: (1 ) C C - 1 0 6 5  d o e s  n o t  in d u c e  e q u iv a le n t  e f f e c t s  o n  
wl DNA s tr u c tu r e  a t  th e  v a r io u s  b in d in g  s i t e s ,  a n d  ( 2 )  th e
x = C C -1 0 6 5  m o d i f i e d
FIGURE 8: Reaction o f U V R A B C  nucleases with 5' and 3 ' labeled  
(M s p l-B s tN l)  117-bp fragment with site-directed C C -1 0 6 5 -D N A  
adducts. (Lanes 1, 4, and 7) M axam -G ilbert sequencing reactions. 
(Lane 2) Unm odified S' labeled ( - )  D N A  fragm ent. (L ane 3) S' 
labeled site-directed adduct fragment. (Lane 5) Unmodified 5' labeled 
(+ )  fragment. (Lane 6) S' labeled site-directed adduct ( + )  fragment. 
(Lane 9 ) 3' labeled site-directed adduct ( + )  fragm ent. (L ane 8 )  
Unmodified 3' labeled (+ )  D N A  fragment. (Lanes 2 , 3, 5, 6 , 8, and 
9 ) D N A  reacted with U V R A B C  nucleases.
m u lt ip le  C C - 1 0 6 5  a d d u c t s  o n  e i t h e r  t h e  ( + )  o r  ( - )  s tr a n d  
in h ib i t  U V R A B C  c le a v a g e .  T o  e x a m in e  w h e t h e r  C C - 1 0 6 5  
m ig h t  p r o d u c e  d iffe r e n tia l e f f e c t s  o n  lo c a l  D N A  s tr u c tu r e  th a t  
c o u ld  p r o d u c e  th e  a p p a r e n t  a d d u c t  s p e c i f ic i t y  fo r  c le a v a g e  b y  
th e  U V R A B C  n u c le a s e ,  w e  h a v e  u s e d  D N a s e  I  a s  a  p r o b e  o f  
d r u g - in d u c e d  c o n fo r m a t io n a l  c h a n g e s  o f  D N A .  F o r tu ito u s ly ,  
a ll  o f  th e  h ig h -a f fm ity  c o v a le n t  b in d in g  s it e s  fo r  C C - 1 0 6 5  o c c u r  
o n  t h e  s a m e  s tr a n d , a n d  c o n s e q u e n t ly ,  t h e  D N a s e  I c le a v a g e  
p a t te r n  o n  th e  ( - )  o r  n o n c o v a le n t ly  m o d if ie d  s t r a n d  is  n o t  
c o m p l ic a t e d  b y  th e  p r e s e n c e  o f  r e s id u a l  C C - 1 0 6 5 - D N A  a d ­
d u c ts  a s  it  w o u ld  b e  o n  th e  ( + )  s tr a n d . U s in g  th e  s it e -d ir e c te d  
a d d u c t ,  w e  h a v e  p r e v io u s ly  d e m o n s t r a t e d  t h a t  t h e  D N a s e  I 
in h ib it io n /e n h a n c e m e n t  p a tte r n  o n  th e  ( - )  s tr a n d  is  a  r e f le c t io n  
o f  e v e n t s  o c c u r r in g  o n  t h e  ( + )  s t r a n d  ( H u r le y  e t  a l . ,  1 9 8 7 ) .  
T h e  r e s u lt s  o f  th e  D N a s e  I f o o t p r in t in g  a r e  s h o w n  in  F ig u r e  
10 . T h e  s a m e  p a tter n  o f  c le a v a g e  in h ib it io n  o v e r  a  1 2 - 1 5 - b a s e  
r e g io n  a n d  e n h a n c e m e n ts  a t  t h e  3 '  t e r m in u s  o f  t h e  in h ib it io n  
z o n e  a r e  s e e n  fo r  a l l  fo u r  b in d in g  s i t e s .  T h e r e f o r e ,  i f  t h e  
s e l e c t iv i t y  o f  U V R A B C  n u c le a s e  c l e a v a g e  fo r  t h e  C C - 1 0 6 5  
a t  A - 6 2 2 9  is  d u e  to  d i f f e r e n c e s  in  e f f e c t  o f  C C - 1 0 6 5  o n  lo c a l  
D N A  s tr u c tu r e ,  it  e s c a p e s  d e t e c t io n  b y  t h e  D N a s e  I f o o t ­
p r in t in g  m e th o d .
T h e  se c o n d  p o ss ib il ity  is  th a t  t h e  p r e s e n c e  o f  m o r e  th a n  o n e  
C C - 1 0 6 5 - D N A  a d d u c t  in h ib i t s  r e c o g n i t io n  a n d / o r  in c is io n  
b y  th e  U V R A B C  n u c le a s e s .  C o n s i s t e n t  w ith  th is  n o t io n  a r e  
th e  r e su lts  sh o w n  in  F ig u r e  9 ,  w h ic h  s h o w  t h a t  t h e  a d d u c t  a t
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nGURE 9: Reaction o f  U V R A B C  nucleases with 5' (left panel) or 
3' (right panel) end labeled (M s p l- B s tN l ) 117-bp fragment with 
multiple C C -1065 adducts. Lanes 2 and 7 and lanes 3 and 8 are 
Maxam and Gilbert sequencing reactions for purines and pyrimidines, 
respectively. Lanes 4, 5 ,9 , and 10 are treated with 0.028 nM  CC-1065, 
lanes 11 and 12 are treated with 0.28 nM  C C -1065, and lanes 13 and 
14 are treated with 2.8 C C -1065. (Lanes 4, 9, 11, and 13)
Modified fragments with thermal treatment (90  °C , 30 min) in DSC. 
(Lanes 5, 10, 12, and 14) M odified fragm ents with U V R A B C  nu­
cleases and subsequent thermal treatm ent (90  °C , 2 min) in form- 
am ide-alkaline dye as described in the text. (Lanes 1 and 6) U n­
modified fragments with the same U V R A B C  nucleases and thermal 
treatment as in lanes 5, 10, 12, and 14. The precise CC-1065 binding 
and U V R A B C  incision sites are indicated by arrows.
A - 6 2 2 9  is  r e c o g n iz e d  in  th e  D N A  f r a g m e n t s  m o d if ie d  w ith  
2 8 0  X  1(T» to  2 8 0  X  1Or3 /xM  b u t n o t  2 8 0  X  1(T2 nM  C C -1 0 6 5 .  
A  f if th  d r u g  b in d in g  s it e  a p p e a r s  a t  p o s it io n  A - 6 2 1 7 ,  in  D N A  
m o d if ie d  w ith  2 8 0  X  1 0 -2 C C - 1 0 6 5 .  T h is  e x tr a  d r u g
b in d in g  s it e  m a y  in te r fe r e  w ith  t h e  r e c o g n it io n  a n d / o r  in c is io n  
o f  a d d u c t  a t  A - 6 2 2 9  b y  U V R A B C  n u c le a s e s .
T h e r e  a r e  w e a k  b in d in g  s it e s  a t  c o m p le m e n t a r y  s e q u e n c e s  
o f  G A T A A  a n d  T T T T A  ( b u t  n o t  G G A A A ) ;  h o w e v e r ,  s in c e  
th e  C C - 1 0 6 5  a d d u c t  c r a d le s  in  th e  m in o r  g r o o v e , it  is  e x p e c te d  
th a t  th e  d r u g  b in d in g  a t  G A T A A ,  a n d  T T T T A ,  p h y s ic a l ly  
e x c lu d e s  th e  p o s s ib i l i t y  o f  b in d in g  a t  th e ir  c o m p le m e n t a r y  
s e q u e n c e  b y  a n o th e r  d r u g . T h e  f r a g m e n ts  w ith  d r u g - in d u c e d  
b r e a k a g e  a t  G A T A A * ,  G G A A A * ,  a n d  T T T T A *  s it e s  (F ig u r e  
9 )  l ik e ly  r e p r e s e n t  th e  p o p u la t io n s  o f  D N A  f r a g m e n t s  w ith  
C C - 1 0 6 5  b in d in g  a t  th e s e  s ite s  b u t  n o t  a t  th e ir  c o m p le m e n ta r y  
s e q u e n c e s .  T h e r e f o r e ,  i t  is  u n l ik e ly  t h a t  t h e  in a b i l i t y  o f  
U V R A B C  to  in c is e  a t  G A T A A  a n d  T T T T A  s it e s  r e su lts  fr o m  
th e  d r u g  b in d in g  a t  th e  o p p o s i t e  s t r a n d ,  w h ic h  w o u ld  c o n s e ­
q u e n t ly  in te r fe r e  w ith  t h e  in c is io n .
D i s c u s s i o n
T h e  v e r s a t i l i t y  o f  th e  uvr e x c i s io n  r e p a ir  s y s t e m  in  E. coli 
c e l ls  in  r e p a ir  o f  D N A  d a m a g e  h a s  lo n g  b e e n  r e c o g n iz e d ;  
h o w e v e r , th e  r u le s  th a t  d e t e r m in e  th e  r e c o g n i t io n  o f  D N A
dam age  bv the  U V R A B C  nuclease com plexes arc still largely
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FIGURE 10: D N ase  I footprinting o f  3' 32P-labeled ( - )  strand o f  the 
(A/jpI-ZtaNI) 117-bp fragment with multiple C C -1065-D N A  adducts 
from M 13m pl D N A . Lanes 1 and 2 are M axam  and Gilbert purine- 
and pyrmidine-specific cleavage. Lanes 3 and 4 have been subjected 
to D N ase I digestion. Lane 3 is the control (no drug modification); 
lane 4 has C C -1065 m odification at sites indicated by brackets A , 
B, C, and D. T hese brackets correspond to the C C -1065 binding 
sequences that are identified as they correpond to the covalently  
modified (+ )  strand, with the covalently m odified adenine denoted  
by an asterisk. D N a se  I enhanced cleavage sites are indicated by 
arrows, and A 8 etc. refer to the corresponding C C -1065 binding site  
and distance between the covalent binding site and the enhancement 
site. The vertical bars represent the zones o f  D N a se  I inhibition  
corresponding to each drug binding site, i.e., A ' corresponding to  
CC -1065 binding site  A .
u n k n o w n . T h e  p u r p o se  o f  o u r  c u r r e n t  s tu d y  is  to  c h a r a c te r iz e  
s o m e  o f  th e  f a c t o r s  t h a t  in f lu e n c e  D N A  d a m a g e  r e c o g n it io n  
b y  u s in g  p u r if ie d  r e p a ir  p r o te in s  a n d  a  D N A  c o n s t r u c t  w ith  
a  s it e -d ir e c t e d  a d d u c t  o f  a n t i t u m o r  a n t ib i o t i c  C C - 1 0 6 5 .  T h e  
e f fe c ts  o f  C C - 1 0 6 5  o n  lo c a l  D N A  s tr u c tu r e  h a v e  b e e n  p a r tia lly  
c h a r a c t e r iz e d  r e c e n t ly  in  o n e  o f  o u r  l a b o r a t o r ie s  ( H u r le y  e t  
a l .,  1 9 8 7 ) .  W e  d e s c r ib e  th e  r e s u lt  o f  in  v iv o  e x p e r im e n t s  th a t  
e s ta b lis h  th e  im p o r ta n c e  o f  th e  U V R A B C  n u c le a s e s  in  r e p a ir  
o f  C C - 1 0 6 5 - D N A  a d d u c t s  a n d  in  v i t r o  e x p e r im e n t s  th a t  
c h a r a c t e r iz e  t h e  r e c o g n i t io n  a n d  in c i s io n  p a t te r n  u s in g  a  
s i t e - d ir e c t e d  C C - 1 0 6 5 - D N A  a d d u c t .  T h e  c o m p l ic a t io n s  o f  
u s in g  a m u lt ip le  C C - 1 0 6 5 - D N A  a d d u c t  a r e  a l s o  d is c u s s e d .  
T h e  r e la t io n s h ip  o f  t h e s e  r e s u l t s  t o  t h e  e s t a b l i s h e d  s tr u c tu r e  
o f  th e  c o v a le n t  C C - 1 0 6 5 - D N A  a d d u c t  a n d  e f f e c t  o f  d r u g  
b in d in g  o n  lo c a l  D N A  s t r u c t u r e  is  e x p lo r e d .  I n te r p r e ta t io n
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incision HaelU B slN I♦ • Cl,, f •▼ 6170 6190 :  6 2 1 0 :m$ l :  O  .  " 6250 ;  6270 “V
(♦JCGGCTCGTaTGTTGTGTGGflflTTGTGflGCGGflTHHCflflTTTCflCflCflGGflflACRGCTflTGflCCflTGflTTflCGGflTTCRCTGGCCGTCGTTTTflCflflCGTCGTGflCTGGGflflflflCCC 
( - )  CGflGCflTflCflflCflCflCCTTflHCflCTCGCCTflTTGTTflBflGTGTGTCCTTTGTCGRTflCTGGTACTflflTGCCTflHGTGflCCGGCflGCflRHflTGTTGCflGCflCTGTCCCTTTTGGGH
♦  •  •
figure 11: DNA sequence of (MspI-ZtaNI) 117-bp fragment. The CC-1065 binding sites are indicated by (*), and the number of asterisks 
represents the relative affinity o f drug binding. The UVRABC incision site is indicated by an arrow. A lul and HaeIII restriction enzyme 
sites are indicated by (y ) . The numerical system is the same as in M13mpl.
of these results provides important information on recognition 
of DNA damage by UVRABC nucleases.
The results of the transfection experiments with CC-1065- 
modified 0X174 RFI DNA in uvr A, uvrB, and uvrC mutant 
cells compared to wild type establish the importance of the 
UVRABC nuclease system in recognition and repair of CC- 
1065-damaged DNA. Although we were not able to accu­
rately quantify the CC-1065 lesions on 0X174 RFI DNA, it 
appears that, in comparison to NAAAF-modified or UV-ir- 
radiated DNA (Tang et al., 1982), the UVRABC systems may 
not be so critical for phage survival, suggesting that there may 
be other, as yet unidentified, repair systems involved in repair 
of CC-1065-modified DNA. Consistent with this notion are 
the results from in vitro experiments using both the site-di? 
rected adduct and multiple adducts of CC-1065 in the 117-bp 
fragment which demonstrate that the incision efficiency is 
relatively low in comparison to those of other DNA adducts 
such as dG-C8-AAF or cyclobutane dipyrimidines. In various 
experiments the efficiency o f UVRABC incision at the site- 
directed CC-1065-DNA varied between about 5 and 20%. 
Interestingly, Jacobson et al. (1986) recently found that 
Xeroderma pigmentosum  cells, which are deficient in repair 
of UV-induced and polycyclic carbon induced DNA damage 
(Hanawalt et al., 1987), show normal nicotinamide adenine 
dinucleotide depletion as normal human cells after CC-1065 
treatment. These results indicate that in human cells there 
are different repair pathways for repairing UV- and CC- 
1065-induced DNA damage. A  second important difference 
from damage caused by UV (Kumura et al., 1985; Husain et 
al., 1985; Caron et al., 1985) and A-OH-AF (Tang et al., 
unpublished results) is the lack of enhanced UVRABC activity 
both in vivo and in vitro toward CC-1065-damaged DNA in 
the presence of the UVRD protein. Thus, while both in vivo 
and in vitro experiments demonstrate that all three proteins 
of the UVRABC nuclease are required for recognition and 
repair of C C-1065-DNA adducts, there are important dif­
ferences from other DNA damage examined in this system.
By virtue of the availability of a single CC-1065 site-directed 
adduct in a 117-bp fragment, we were able to unambiguously 
describe the UVRABC nuclease cutting pattern in the vicinity 
of a CC-1065-DNA lesion. The results, which are summa­
rized in Figure 11, reveal a single incision at seven nucleotides 
to the 5' side of the covalently modification is produced by 
the UVRABC nucleases. While the selectivity toward the 
covalently modified strand was anticipated, the single incision 
on the 5' side rather than breaks to both the 3' and 5' sides 
was unexpected. In other cases, such as cyclobutane di­
pyrimidines, (6 -4 ) photoproducts, psoralen, c/s-platinum- 
DNA adducts, and dG-C8-AAF lesions, cuts are found on both 
sides of the adducts (Sancar & Rupp, 1983; Sancar et al., 
1985; Yeung et al., 1983). We have excluded the trivial 
explanation that the UVRABC nucleases we have prepared 
cut only the 5' side of the damaged base(s) since we have found 
that these proteins cut both the 5' and 3' side of dG-C8-AAF 
(Tang and Pierce, unpublished results). This difference is 
unlikely to be due to the effect of physical hindrance by drug 
binding in the minor groove, since our MPE-Fe(II) foot­
printing results have demonstrated that bound CC-1065 points 
toward the 5' end from the covalent binding site rather than 
toward the 3' end. Last, and again unexpectedly, we show that 
there is a vide discrepancy of efficiency of UVRABC nuclease 
incision among the adducts formed on DNA located at dif­
ferent sequences. Using DNase I as a probe to monitor the 
effect of CC-1065 on local DNA structure for each of the four 
different CC-1065-DNA lesions, we do not detect any sig­
nificant differences.
Identification of the factors that determine the recognition 
of DNA adducts by the UVRABC nuclease is dependent upon 
an accurate and complete picture of the ligand-modified base 
as well as determination of the effect of DNA binding on local 
DNA structure and possibly dynamics. Other factors such 
as superhelical density and whether the lesion is in a region 
of DNA available for expression are probably also important 
considerations for repair of drug-modified cellular DNA. 
While we do not have a complete picture of the in vitro CC- 
1065-DNA adduct, the covalent structure of adducts is known 
(Hurley et al., 1984), and a gross appreciation for the effect 
of CC-1065 binding on local DNA structure is known from 
studies using nuclease cleavage probes of the site-directed 
adduct at A-6229 (Hurley et al., 1987).
CC-1065 binds snugly in the minor groove of D N A  cova­
lently attached through N3 of adenine (Figures 1 and 2). In 
contrast to other minor groove binding agents such as an- 
thramycin (Hurley et al., 1981), which binds through the 
exocyclic amino group of guanine and consequently does not 
disturb the electronic character of the purine base, CC-1065 
binding at N3 of adenine is expected to have a profound effect 
on the electronic character of adenine. The CC-1065-DNA  
adduct may be represented in the imino tautomeric form with 
N3 quantemized or as the neutral amino tautomeric form as 
shown in Figure 1. As a consequence of covalent binding to 
the “A" subunit of CC-1065, it is perhaps not surprising that 
the local DNA structure in the vicinity of the adduct is 
changed dramatically. Two-dimensional ‘H NMR NOESY 
experiments confirm that the inside edge of CC-1065 lies in 
the vicinity of the floor of the minor groove of DNA to the 
5' side of the covalent binding site (Scahill et al., 1986). 
However, using DNase I and restriction enzyme cleavage 
analysis of the same site-directed CC-1065-DNA adduct in­
vestigated in this study, we have shown that drug binding has 
an asymmetric effect on local DNA structure. While changes 
in the DNase I cleavage pattern reveal some changes in local 
structure on the noncovalently modified strand, the major 
change appears to occur on the covalently modified strand to 
the 5' side of the adduct site. An Alul restriction enzyme 
cleavage site between G-6214 and C-6215 (15 bp to the 5' side 
of the covalently modified adenine) is inhibited from cleavage 
in the presence of CC-1065 but just on one (-) strand of D N A  
The DNase I inhibition pattern shows a footprint over a 12 
base pair region on the same strand. On the basis of the X-ray 
structure of DNase I (Suck & Oefner, 1986) and the structure 
of type II restriction enzyme typified by iscoRI (McClarin et 
al., 1986), we interpret these results to mean that the binding 
of CC-1065 to DNA changes the structure of the covalently
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modified strand to the 5' side of the adduct over about one 
and one-half turns of DNA, (Hurley et al., 1987). Previously 
we have shown by inhibition of SI nuclease activity and an 
increase in thermal melting temperature of CC-1065-DNA 
adducts (a single adduct in 27-bp duplex increases the ATm 
by 15-20 °C) (Needham-VanDevanter & Hurley, 1986; 
Swenson et al., 1982) that CC-1065 dramatically stabilizes 
the helical structure of DNA.
On the basis of the UVRABC nuclease incision sensitivity 
and cleavage pattern of the site-directed CC-1065-DNA ad­
duct and our knowledge of the CC-1065-DNA adduct 
structure, it is possible to draw some important conclusions 
about the rules for recognition of DNA damage by the 
UVRABC nuclease system. First, the presently accepted 
recognition spectrum for the UVRABC nuclease should be 
extended to include the relatively nondistortive and helix- 
stabilizing type of adduct examplified by CC-1065. We note, 
also, that other covalent minor groove stabilizing and non­
distortive lesions such as the anthramycin-(N2-guanine)-DNA 
adduct are also recognized by the UVRABC nuclease system 
(Tang et al., unpublished results). Furthermore, the strand 
selectivity of UVRABC nuclease activity for CC-1065-DNA 
adducts may be related to the electronically altered base on 
the (+) strand.
The inability of the UVRD gene product to enhance the 
UVRABC nuclease activity is most probably related to the 
absence of or even CC-1065-mediated reduction in the ability 
to form single-stranded DNA in the vicinity of the CC- 
1065-DNA adduct. This may be a common feature of he­
lix-stabilizing adducts such as CC-1065 and anthramycin, 
which likewise shows no UVRD enhancement of UVRABC 
nuclease activity (Tang et al., unpublished results).
The relatively low efficiency of UVRABC nuclease cleavage 
of CC-1065-DNA adducts in contrast to other covalent ad- 
,ducts may be due to the stabilizing effect of the adduct and/or 
to the relatively nondistortive effect of CC-1065 on local DNA 
structure. This may also be related to the inability to cleave 
on the 3' side of CC-1065-DNA adduct Significantly, there 
is a correlation between DNA distortion as measured by in­
hibition of DNase I and A lu l cleavage and cleavage by the 
UVRABC nuclease on the 5' side of the adduct.
Why the UVRABC nuclease recognizes the CC-1065-DNA 
adduct at A-6229 but fails to recognize other CC-1065-DNA 
adducts on the same fragment is an important question. Since 
the covalently modified adenines in -TTTTA*- and 
-GATAA*- are 23 and 33 bases, respectively, away from the 
ends of the fragment, it is unlikely that the inability of 
UVRABC nucleases to cut CC-1065-adenine adducts in these 
sequences is due to the proximity of the adducts to the end 
of the DNA fragment since Van Houten et al. (1986) have 
shown that UVRABC nucleases are able to cut DNA damage 
14 bp from the DNA terminal. In some experiments a minor 
amount of cleavage on the 5' side was noted with the other 
CC-1065-DNA adducts, but the adduct at A-6229 was always 
recognized and cleaved at the 5' side well in excess of cleavage 
of the other CC-1065-DNA adducts, except at drug concen­
trations in which a fifth CC-1065 binding site appears in DNA. 
The DNase I cleavage patterns of the various CC-1065-DNA 
adducts (Figure 10) showing inhibition of cleavage over a 
12-13-bp region and enhancements 8 bp to the 5' side of the 
covalently modified adenines are quite similar and therefore 
do not provide a rationale for the differential recognition of 
these CC-1065-DNA adducts by the UVRABC nucleases. It 
is possible that the UVRABC nucleases are able to recognize 
d if fe r e n t ia l  features among the various CC-1065-DNA a d ­
ducts that are not detected by DNase I. Alternatively, a 
property associated with sequence independent of the CC- 
1065-DNA adduct is critical for UVRABC recognition. 
Lastly, it is possible that because of the considerable helix- 
stabilizing property of CC-1065, which consequently inhibits 
nuclease activity, that UVRABC nuclease only cleave the 
subpopulation of (MspI-ifr/NI) 117-bp fragments that have 
a single CC-1065-DNA adduct. If this is the case, then the 
predominant CC-1065 single adduct formed in the 117-bp 
fragment will be located at A-6229 since CC-1065 has the 
highest affinity toward this adenine in this particular fragment 
sequence. At this time we cannot differentiate these possi­
bilities. However, our results illuminate one of the dangers 
of interpretation of results that rely solely on multiple car­
cinogen modified or drug-modified DNA species.
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Structure-A ctivity  Relationships o f ( +  )~CC-1065 Analogues in the Inhibition of 
Helicase-Catalyzed Unwinding o f Duplex DNA1
Daekyu Sun* and Laurence H. Hurley*
Drug D ynam ics In stitu te , College of Pharmacy, The U niversity of Texas a t A ustin, A ustin , Texas 78712-1074.
R eceived N ovem ber 7,1991
(+)-CC-1065 is a potent antitumor antibiotic produced by S treptom yces zelensis. Previous studies have shown 
that the potent cytotoxic and antitumor activities of (+)-CC-1065 are due to the ability of this compound to covalently 
modify DNA. (+)-CC-1065 reacts with duplex DNA to form a (N3-adenine)-DNA adduct which lies in the minor 
groove of DNA overlapping with a five base-pair region. As a consequence of covalent modification with (+)-CC-1065, 
the helix bends into the minor groove and also undergoes winding and stiffening. In the studies described here, 
we have constructed templates for helicase-catalyzed unwinding of DNA that contain site-directed (+)-CC-1065 
and analogue DNA adducts. Using these templates we have shown that (+)-CC-1065 and select synthetic analogues, 
which have different levels of cytotoxicity, all produce a significant inhibition of unwinding of a 3'-tailed oligomer 
duplex by helicase II when the displaced strand is covalently modified. However, the extent of helicase II inhibition 
is much more significant for (+)-CC-1065 and an analogue which also produced DNA winding when the winding 
effects are transmitted in the opposite direction to the helicase unwinding activity. This observed pattern of inhibition 
of helicase-catalyzed unwinding of drug-modified templates was the same for a 3'-T-tail, for different duplex region 
sequences, and with the Escherichia coli rep  protein. Unexpectedly, the gel mobility of the displaced drug-modified 
single strand was dependent on the species of drug attached to the DNA. Last, strand displacement by helicase 
II coupled to primer extension by E. coli DNA polymerase I showed the same pattern of inhibition when the lagging 
strand was covalently modified. In addition, the presence of helicase II on single-stranded regions of templates 
caused the premature termination of primer extension by DNA polymerase. These results are discussed from the 
perspective that (+)-CC-1065 and its analogues have different effects on DNA structure, and these resulting structural 
changes in DNA molecules are related to the different in vivo biological consequences caused by these drug molecules.
Introduction
In order for DNA to serve as an efficient substrate for 
polymerases, the duplex DNA must be unwound. The task 
of unwinding DNA rapidly is carried out by a special class 
of enzymes called helicases.1,2 These enzymes progress 
in a unidirectional or bidirectional manner through the 
helix utilizing energy derived from hydrolysis of nucleotide
Abbreviations: DDW, double-distilled water; EDTA, ethyl- 
enediaminetetraacetic acid; N, any nucleotide; pu, purine nu­
cleotide; py, pyrimidine nucleotide; ss, single-stranded; TEMED, 
iV^N^/V'JV'-tetramethylethylenediamine; Tris, tris(hydroxy- 
methyl)aminomethane.
triphosphates to fuel this process. The precise mechanisms 
of helicase-catalyzed unwinding of DNA are not known, 
but in general they require a single-stranded region to  
which the protein initially binds. Helicase-catalyzed un­
winding of DNA is important in replication, transcription, 
recombination, and repair.3-5 While most in vitro studies
(1) Geider, K.; Hoffmann-Berling, H. Proteins Controlling the 
Helical Structure of DNA. Annu. Rev. Biochem. 1981, 50, 
233-260.
(2) Gefter, M. DNA Unwinding Enzymes. In The Enzymes; 
Boyer, P. D., Ed.; Academic Press: New York, 1981; Vol. 14, 
pp 367-372.
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of DNA helicases involve naked duplex DNA with sin­
gle-stranded tails, in vivo, the DNA is probably rarely 
presently as naked DNA, but rather as protein-bound 
templates.6
Both in studies of the molecular mechanisms of carci­
nogenesis and antitumor drug action, there is a consider­
able body of published work on recognition and repair of 
covalently modified DNA and the effect of covalent drug 
modification of DNA on DNA or RNA polymerase activ­
ity.7-9 In contrast to these extensive studies, very little 
has so far appeared in the literature on how covalent 
modification on DNA effects helicase-catalyzed unwinding
(3) A lb e r ts , B . M .; B a rry , J .;  B e d in g e r , P .; F o rm o s a , T .;  Jo n g e n e e l,
C . V .; K re u z e r ,  K . S tu d ie s  o n  D N A  R e p l ic a t io n  in  th e  T 4  
B a c te r io p h a g e  In  V itro  S y s te m . Cold Spring Harbor Symp. 
Quant. Biol. 1982, 47, 6 5 5 -6 6 8 .
(4) S o p ta ,  M .; B u r to n ,  Z. F .; G r e e n b la t t ,  J .  S t r u c t u r e  a n d  A sso ­
c ia te d  D N A -H e lic a s e  A c tiv i ty  o f  a  G e n e ra l  T r a n s c r ip t io n  I n i ­
t i a t io n  F a c to r  T h a t  B in d s  to  R N A  P o ly m e ra s e  II . Nature 
1989, 341, 4 1 0 -4 1 4 .
(5) H u s a in , I.; A b d e l-M o n e m , M .; V a n  H o u te n , B .; T h o m a s , D . C.; 
S a n c a r ,  A. E f f e c t  o f  D N A  P o ly m e ra s e  1 a n d  D N A  H e lic a s e  II  
o n  th e  T u r n o v e r  R a te  o f  U v rA B C  E x c is io n  N u c le a s e . Proc. 
Natl. Acad. Sci. U.S.A. 1985, 82, 6 7 7 4 -6 7 7 8 .
(6) B o n n e -A n d re a , C .; W o n g , M . L .; A lb e r ts , B . M . In  V itro  R e p ­
lic a tio n  th ro u g h  N u c le o so m e 8  w i th o u t  H is to n e  D is p la c e m e n t .  
Nature 1990, 343, 71& -726.
(7) M y le s , G . M .; S a n c a r ,  A . D N A  R e p a ir .  Chem. Res. Toxicol. 
1989, 2, 1 9 7 -2 2 5 .
(8) B rb w n , W . C .; R o m a n o , L . J .  E f f e c ts  o f  B e n z o [ a ]p y r e n -D N A  
A d d u c ts  o n  a  R e c o n s t i tu te d  R ep lic a tio n  S y s te m . Biochemistry 
1991, 30, 1 3 4 2 -1 3 5 0 .
(9) P ie p e r ,  R . O .; E r ic k so n , L . C . D N A  A d e n in e  A d d u c ts  In d u c e d
b y  N i t ro g e n  M u s ta r d s  a n d  T h e i r  R o le  in  T r a n s c r ip t io n  T e r ­











F i g u r e  2 . S t r u c t u r e s  o f  ( + ) - C C - 1 0 6 5  a n d  i t s  a n a lo g u e s  u s e d  in  
t h i s  s t u d y .
of duplex DNA. We believe this is a serious omission, 
since, according to current models of replication and re­
combination, the helicase is likely to be the first component 
of the “protein machines” to encounter the modified 
DNA.1-3 Consequently, if the covalently modified DNA 
stalls the helicase and subsequently inhibits unwinding of 
duplex DNA, the direct effect of the DNA lesion on DNA 
polymerase activity becomes irrelevant.
As an initial approach to addressing this deficiency, we 
have constructed stable DNA templates for helicase-cat­
alyzed unwinding that contain site-directed (+)-CC-1065 
and related drug-DNA adducts. (+)-CC-1065 is an ex­
tremely potent antitumor antibiotic produced by S trep ­
tomyces zelensis.10 It is active against several experi­
mental murine tumors in vivo and is about 100 times more 
potent than adriamycin against a broad spectrum of tu­
mors in the cloning assay.11-13 There is overwhelming
(10) H a n k a ,  L . J . ;  D ie tz , A .; G e rp h e id , S . A .; K u e n tz e l ,  S . L .; 
M a r t in ,  D . G . C C -1 0 6 5  (N S C -2 9 8223 ), a  N e w  A n t i tu m o r  A n ­
t ib io t ic .  P r o d u c t io n  In  V itro  B io lo g ic a l A c tiv i ty , M ic ro b io ­
lo g ica l A ssa y s , a n d  T a x o n o m y  o f  th e  P ro d u c in g  M ic ro o rg a n ­
ism s . J. Antibiot. 1978, 31, 1 2 1 1 -1 2 1 7 .
(11) M c G o v re n , J .  P .; C la rk e , G . L .; P r a t t ,  E . A .; D e k o n in g , T . F . 
P re l im in a ry  T o x ic i ty  S tu d ie s  w i th  t h e  D N A -B in d in g  A n t ib i ­
o t ic  C C -1065 . J. Antibiot. 1984, 37, 6 3 -7 0 .
(12) B h u y a n , B . K .; N e w e ll, K . A .; C ra m p to n ,  S . L .; V o n  H o f f , D .
D . C C -1 0 6 5  (N S C -2 9 8 2 2 3 ), a  M o s t  P o t e n t  A n t i tu m o r  A g e n t:  
K in e t ic s  o f  In h ib i t io n  o f  G ro w th , D N A  S y n th e s is ,  a n d  C e ll 
S u rv iv a l. Cancer Res. 1982 , 42, 3 5 3 2 -3 5 3 7 .
(13) L i, L . H .; S w e n s o n , D . H .; S c h p o k , S . L . F .; K u e n tz e l ,  S . L .; 
D a y to n , B . D .; K ru e g e r , W . C . C C -1065 (N S C -2 9 8 2 2 3 ), a  N ove l 
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evidence that DNA is the principal biological target of 
(+)-CC-1065 and that the alkylating properties of this drug 
molecule are believed to be responsible for its potent cy­
totoxic effect.13,14 Previously we have shown that (+)- 
CC-1065 forms a covalent adduct with duplex DNA  
through N3 of adenine15 in a highly sequence specific 
manner,15,16 in which the drug molecules lie within the 
minor groove covering a three and one has e-pair region to 
the 5'- and 3'-sides, respectively, of the covalently modified 
adenine (Figure I).17 (+)-CC-1065 is the first DNA-re- 
active drug in which the involvement of critically ordered 
water molecules has been demonstrated and catalytic ac­
tivation of the covalent reaction involving phosphate has 
been implicated (Figure l ) .18 However, in addition to 
DNA-alkylating properties, these drug molecules induce 
local bending, winding, and helix stiffening of DNA  
molecules, which can be attributed to both the covalent 
bonding and associated binding interactions.19
In previous studies we have examined how (+)-CC-1065 
and the structurally related drugs shown in Figure 2 affect 
DNA polymerases and T4 DNA ligase.20,21 The activity
(14) Reynolds, V. L.; McGovren, J. P.; Hurley, L. H. The Chemis­
try, Mechanism of Action, and Biological Properties of CC- 
1065, a Potent Antitumor Antibiotic. J. Antibiot. 1986, 39, 
319-334.
(15) Reynolds, V. L.; Molineux, L J.; Kaplan, D. J.; Swenson, D. H.; 
Hurley, L. H. Reaction of the Antitumor Antibiotic CC-1065 
with DNA. Location of the Site of Thermally Induced Strand 
Breakage and Analysis of DNA Sequence Specificity. Bio­
chemistry 1985, 24, 6228-6237.
(16) Hurley, L. H.; Warpehoski, M. A; Lee, C.-S.; McGovren, J. P.; 
Scahill, T. A.; Kelly, K. C.; Wicni^nski, N. A.; Gebhard, I.; 
Bradford, V. S. Sequence Specificity of DNA Alkylation by the 
Unnatural Enantiomers of CC-1065 and Its Synthetic Analogs. 
J. Am. Chem. Soc. 1990,112, 4633-4649.
(17) Scahill, T. A.; Jensen, R. M.; Swenson, D. H.; Hatzenbuhler, 
N. T.; Petzold, G. L.; Wierenga, W.; Brahme, N. D. An NMR 
Study of the Covalent and Noncovalent Interactions of CC- 
1065 and DNA. Biochemistry 1990, 29, 2852-2860.
(18) Lin, C. H.; Beale, J. M.; Hurley, L. H. Structure of the (+)- 
CC-1065-DNA Adduct: Critical Role of Ordered Water Mol­
ecules and Implications for Involvement of Phosphate Cata­
lysis in the Covalent Reaction. Biochemistry 1991, 30, 
3597-3602.
(19) Lee, C.-S.; Sun, D.; Kizu, R.; Hurley, L. H. Determination of 
the Structural Features of (+)-CC-1065 That Are Responsible 
for Bending, Winding, and Stiffening of DNA. Chem. Res. 
Toxicol. 1991, 4, 203-213.
(20) Sun, D.; Hurley, L. H. Inhibition of T4 DNA Ligase Activity
by (+)-CC-1065: Demonstration of the Importance of the
Stiffening and Winding Effects of (+)-CC-1065 on DNA.
Anti-Cancer Drug Des. 1992, 7, 13-34.
of these enzymes is highly sensitive to changes on DNA  
structures, so that it is possible to differentiate between 
the subtle difference induced in DNA structure by dif­
ferent drug molecules in the (+)-CC-1065 group of anti­
tumor agents. We have recently demonstrated that the 
DNA-helix stabilizing and stiffening effect of select ana­
logues of (+)-CC-1065 induces both proximal and distal 
inhibition of the DNA ligation reaction mediated by T4 
DNA ligase, and that the winding effect of (+)-CC-1065 
exerts a more significant inhibitory effect on the proximal 
ligation reaction.20 In addition, we have found that 
(+)-CC-1065 and its structurally related analogue-DNA  
adducts act as strong blocks against the progression of 
DNA polymerase through the adduct site, which may 
partly explain the molecular mechanism of their cytotoxic 
effects.21 We have also recently shown that (+)-CC-1065 
strongly inhibits the DNA-unwinding process that is me­
diated by helicase II and T4 dda helicases, because the 
covalently modified DNA template traps the helicases.22 
To determine which of the structural consequences of 
covalent bonding or binding interactions produces this 
effect, we have now compared (+)-CC-1065 with the four 
analogues shown in Figure 2 and also examined how he­
licase II unwinding of gapped duplex adducts can effect 
the DNA polymerase I primer extension reaction. These 
(+)-CC-1065 analogues are available to us through a highly 
successful synthetic program at the Upjohn Co. in which 
one of these analogues [(+)-ABC" or adozelesin] has been 
introduced into Phase I clinical trials.25 This compound 
has superior in vivo antitumor activity and lacks the de-
(21) Sun, D.; Hurley, L. H. The Effect of the (+)-CC-1065-(N3- 
Adenine)-DNA Adduct on In Vitro DNA Synthesis Mediated 
by Escherichia coli DNA Polymerase. Biochemistry 1992,31, 
2822-2829.
(22) Maine, L R.; Sun, D.; Hurley, L. H.; Kodadek, T. The Antitu­
mor Agent CC-1065 and Its Analogs Inhibit Helicase-Catalyzed 
Unwinding of DNA. Biochemistry, in press.
(23) Warpehoski, M. A.; Bradford, V. S. Bis-des-hydroxy, Bis-des- 
methoxy CC-1065. Synthesis, DNA Binding, and Biological 
Activity. Tetrahedron Lett. 1988, 2 9 ,131-144.
(24) Warpehoski, M. A.; Gebhard, I.; Kelly, R. C.; Krueger, W. C.; 
Li, L. H.; McGovren, J. P.; Prairie, M. D.; Wicnienski, N.; 
Wierenga, W. Stereoelectronic Factors Influencing the Bio­
logical Activity and DNA Interaction of Synthetic Antitumor 
Agents Modeled on CC-1065. J. Med. Chem. 1988, 31, 
590-603.
(25) Li, L. H.; Kelly, R. C.; Warpehoski, M. A.; McGovren, J. P.; 
Gebhard, I.; Dekonig, T. F. Adozelesin, a Selected Lead among 
Cyclopropylpyrroloindole Analogs of the DNA-Binding Anti­
biotic, CC-1065. Invest. New Drugs 1991, 9 ,137-148.
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laved lethality associated with (+)-CC-1065 and (+)-
AB'C'.23-25
In accord with our previous studies,22 the results de­
scribed in this paper clearly demonstrate that unwinding 
of a 3'-tailed oligomer duplex was significantly inhibited 
when (+)-CC-1065 was covalently bound to the displaced 
strand. The amount of helicase inhibition is much more 
significant for (+)-CC-1065- and (+)-AB'C'-modified 
templates than with the other templates modified with 
other analogues that lack the DNA-winding effects. Also, 
strand displacement coupled to primer extension by Es­
cherichia coli DNA polymerase showed the same pattern 
of inhibition when the lagging strand was covalently 
modified. We discussed the possibility that because 
(+)-CC-1065 and its analogues have different effects on 
DNA structure, some of these drug-induced structural 
changes in DNA molecules (i.e., winding) can be associated 
with unique biological consequences (i.e., delayed lethality) 
caused by some of these drug molecules.
E xp er im en ta l S ec tio n
Chemicals and Enzymes. (+ ) - C C - 1 0 6 5  a n d  t h e  s y n t h e t i c  
a n a lo g u e s  (F ig u re  2) u s e d  in  th i s  s tu d y  w e re  p r o v id e d  b y  J .  P a t r i c k  
M c G o v re n  a t  t h e  U p jo h n  C o . (K a la m a z o o ,  M I) .  E l e c t r o p h o r e t i c  
r e a g e n t s  [ a c r y la m id e ,  T E M E D ,  a m m o n i u m  p e r s u l f a t e ,  a n d  b is -  
( a c r y la m id e ) ]  w e re  p u r c h a s e d  f r o m  B io - R a d .  O t h e r  c h e m ic a l s  
fo r  c h e m ic a l  D N A  s e q u e n c in g  w e re  f r o m  A ld r i c h  C h e m ic a l  C o .; 
[7 -32P ] A T P  w a s  f r o m  IC N ; a n d  X - r a y  f i lm , i n t e n s i f y in g  s c r e e n s ,  
a n d  d e v e lo p in g  c h e m ic a ls  w e re  f r o m  K o d a k .  U v r D  g e n e  p r o d u c t  
(h e lic a s e  I I )  a n d  E. coli rep p r o t e i n  w e re  g e n e r o u s ly  p r o v id e d  b y  
P ro fe s s o r  K o d a d e k  a t  t h e  U n iv e r s i ty  o f  T e x a s  (A u s t in ,  T X ) .  T h e  
K le n o w  f r a g m e n t ,  E. coli D N A  p o ly m e r a s e  I ,  T 4 - p o ly n u c le o t id e  
k in a s e ,  a n d  r e a g e n t s  f o r  d id e o x y - D N A  s e q u e n c i n g  w e re  f r o m  
U n i t e d  S t a t e s  B io c h e m ic a l .
Oligonucleotide Synthesis. T h e  o l ig o n u c le o t id e s  t h a t  w e re  
a n n e a l e d  t o  f o r m  t h e  t a i l e d  o r  g a p p e d  d u p le x e s  ( T a b l e  I )  w e re  
s y n t h e s i z e d  o n  a n  a u t o m a t e d  D N A  s y n t h e s i z e r  ( A p p l i e d  B io ­
s y s t e m  3 8 1 A ) b y  t h e  p h o s p h o r a m i d i t e  m e t h o d .  T h e  o l ig o m e r s  
w e re  t h e n  d e p r o t e c t e d  s e p a r a t e l y  b y  h e a t in g  a t  5 5  ° C  o v e r n ig h t  
w i th  s a t u r a t e d  a m m o n i u m  h y d r o x id e ,  d r i e d  u n d e r  v a c u u m , a n d  
r e d is s o lv e d  in  D D W .
Construction of Tailed and Gapped Duplexes. 3 '-S in g le -  
s t r a n d e d - t a i l e d  d u p le x e s  ( T D l ,  T D 2 ,  T D 3 ,  a n d  T D 4  in  T a b l e  I) 
w e re  d e s ig n e d  to  h a v e  a  u n iq u e  d r u g  b o n d in g  s i te  ( 5 '- G A T r A * - 3 ';  
* in d ic a te s  d ru g -m o d if ie d  a d e n in e )  w i th in  t h e  d u p le x  re g io n . D ru g  
m o le c u le s  c a n  fo r m  c o v a le n t  a d d u c t s  w i th  e i t h e r  t h e  s h o r t  ( T D l  
a n d  T D 3 )  o r  t h e  lo n g  (T D 2  a n d  T D 4 )  s t r a n d .  F o r  t h e  g a p p e d  
d u p le x e s  (G D I  a n d  G D 2 ) , t h e  d r u g  b o n d in g  s i te  w a s  d e s ig n e d  t o  
b e  w i th in  t h e  l e f t  d u p l e x  r e g io n  s o  t h a t  e i t h e r  t h e  s h o r t  ( G D I )  
o r  t h e  lo n g  (G D 2 )  s t r a n d  c a n  b e  s e le c t iv e ly  c o v a le n t ly  m o d i f i e d  
w i th  d r u g  m o le c u le s .
T o  c o n s t r u c t  5 '- 32P  la b e le d  s u b s t r a t e s ,  t h e  lo n g  s t r a n d s  o f  T D 2  
a n d  T D 4 , th e  s h o r t  s t r a n d s  o f  T D l  a n d  T D 3 , o r  b o th  s h o r t  s t r a n d s  
o f  G D I  a n d  G D 2  w e re  k i n a t e d  s e p a r a t e l y  f o r  1 h  a t  3 7  ° C  in  2 5  
mL  o f  s o lu t.  j n  c o n ta in in g  7 0  m M  T r is -H C l  (p H  7 .6 ), 10 m M  M g C l2, 
5  m M  d i t h r o t h r e i t o l ,  3 0  /iC i o f  [ y - 32P ] A T P ,  a n d  10  u n i t s  o f  T 4  
p o ly n u c le o t id e  k in a s e .  R e a c t io n  m ix tu r e s  w e re  h e a t e d  a t  9 5  ° C  
fo r  1 0  m in  t o  in a c t i v a t e  t h e  r e m a in in g  T 4  p o ly n u c le o t id e  k in a s e  
a n d  a n n e a le d  t o  t h e  c o m p l e m e n t a r y  c o ld  s t r a n d  t o  g e n e r a t e  t h e  
d e s i r e d  t a i l  o r  g a p p e d  d u p le x e s .  T h e  r e s u l t in g  t a i l e d  a n d  g a p p e d  
d u p le x e s  w e re  p u r i f i e d  f r o m  8 %  n o n d e n a t u r i n g  p o ly a c r y la m id e  
g e l  a f t e r  e l e c t r o p h o r e s i s ,  a c c o r d in g  t o  t h e  m e t h o d  p r e v io u s ly  
d e s c r i b e d .19
Construction of Drug-Modified Templates and Thermal 
Strand Breakage Assay. T o  c o n s t r u c t  d ru g - m o d if ie d  s u b s t r a t e s  
fo r  h e l ic a s e  a s s a y , t a i l e d  o r  g a p p e d  d u p le x e s  w e re  m o d i f i e d  w i th  
t h e  d r u g  m o le c u le s ,  s h o w n  in  F ig u r e  2 , a s  p r e v io u s ly  d e s c r i b e d .19 
U n b o u n d  d r u g  m o le c u le s  w e re  r e m o v e d  b y  e t h a n o l  p r e c ip i ta t io n .  
F o r  t h e  t h e r m a l  s t r a n d  b r e a k a g e  r e a c t i o n ,  d r u g - m o d i f i e d  s u b ­
s t r a t e s  w e re  h e a te d  in  D D W  fo r  2 h  a t  95  ° C , d r ie d  u n d e r  v a c u u m , 
a n d  r e d is s o lv e d  in  s e q u e n c in g  d y e  [9 0 %  ( w /v ) ]  f o r m a m id e  in  0 .1  
M  T r i s - H C l  ( p H  7 .8 ) ] .  A f te r  h e a t in g  o f  t h e  D N A  s a m p l e s  f o r  3 
m in  a t  9 5  ° C ,  s a m p l e s  w e re  a p p l i e d  t o  a  1 2 %  d e n a t u r i n g  p o ly ­
a c r y la m id e  g e l e l e c t r o p h o r e s i s  a n d  r u n  in  p a r a l l e l  w i t h  M a x a m
Sun and Hurley
” P5‘--------- GATTA-----------------------  3’ 5’ ----------------------------------------- -3'
3’ ------------------------------5' 3‘ ------- ATT AG ----------  5 1SP
Drug M odification of ta iled  
|  Duplex with (+J-CC -1065 j
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Unwinding of Duplex DNA 
with H e licase  II
M easu rem en t of th e  Amount of R e le ase d  ssDNA
Figure 3 . S t r a te g y  fo r  t h e  c o n s t ru c t io n  o f  tw o  d i f f e r e n t ly  o r ie n te d  
t a i l e d  d r u g - D N A  d u p l e x  a d d u c t s  t o  e v a l u a t e  t h e  e f f e c t  o f  d r u g  
m o d if ic a t io n  o n  t h e  D N A  u n w in d in g  c a ta ly z e d  b y  D N A  h e lic a se s .
a n d  G i l b e r t  D N A  s e q u e n c i n g  r e a c t io n .
Helicase II-Catalyzed Unwinding of Drug-Modified or 
Non-Drug-Modified Tail or Gapped Duplexes. E a c h  r e a c t io n  
w a s  c a r r ie d  o u t  in  10 nL o f  h e l ic a s e  I I  u n w in d in g  b u f f e r  c o n ta in in g
10 n g  o f  D N A  s u b s t r a t e  a n d  t h e  i n d i c a t e d  a m o u n t  o f  h e l ic a s e  I I  
o r  E. coli rep h e l ic a s e .  A f te r  p r e in c u b a t io n  fo r  5  m in , a n  8  m o la r  
e x c ess  o f  u n la b e le d  ss  D N A  ( th e  s a m e  s t r a n d  a s  t h e  la b e le d  s t r a n d )  
w a s  a d d e d  t o  t h e  re a c t io n  a s  a  t r a p  to  p r e v e n t  t h e  r e le a s e d  la b e le d  
s t r a n d  f ro m  re a n n e a l in g .  E a c h  r e a c t io n  w a s  in c u b a te d  f o r  4 5  m in  
a t  3 0  ° C  a n d  t h e n  q u e n c h e d  w i th  h e l ic a s e  s t o p  b u f f e r .  H e lic a s e
11 a n d  E. coli rep p r o t e i n  u n w in d in g  b u f f e r  c o n s i s t s  o f  2 5  m M  
T r i s - H C l  ( p H  7 .5 ) , 2 5  m M  N a C l ,  1 0 %  g ly c e ro l ,  5  m M  d -m e r -  
c a p to e th a n o l ,  2 5  m M  M g C l2, 10 0  ng/m L  b o v in e  s e r u m  a lb u m in ,  
a n d  1.5 m M  A T P .  A n  A T P - r e g e n e ra t io n  s y s te m  in c lu d in g  10  m M  
c r e a t i n e  p h o s p h a t e  a n d  1 u n i t / m L  c r e a t i n e  p h o s p h o k i n a s e  w a s  
a ls o  p r e s e n t .  H e l i c a s e  s t o p  b u f f e r  is  10  m M  E D T A  a n d  2 %  
s o d iu m  d o d e c y l s u l f a t e .
DNA Polymerase Reaction. T e m p la te  D N A  (g a p p e d  d u p le x , 
2 0  n g )  w a s  i n c u b a t e d  w i th  1 u n i t  o f  K le n o w  o r  E. coli D N A  
p o ly m e r a s e  I  in  2 0  nh  o f  h e l ic a s e  I I  u n w in d in g  b u f f e r  in  t h e  
p r e s e n c e  o f  t h e  i n d i c a t e d  a m o u n t  o f  d N T P s .  R e a c t io n s  w e re  
q u e n c h e d  b y  t h e  a d d i t io n  o f  a  h a lf -v o lu m e  o f  s e q u e n c in g  d y e  [9 0 %  
f o r m a m id e ,  1 0 0  m M  T r i s - H C l  ( p H  7 .8 ) , a n d  10  m M  E D T A ] .
R e su lts
D esign  and C onstruction  o f T ailed  D u p lex  A dducts  
T o E v a lu a te  th e  E ffe c t o f  D ru g  M o d ifica tio n  on  th e  
U n w in d in g  R eaction  C atalyzed by H elicase  II. E. coli 
helicase II is a ss DNA-dependent ATPase with helicase 
activity that translocates progressively along ss DNA in 
a 3'- to 5'-direction.26 In order to evaluate the effect of 
drug modification of DNA on the efficiency of helicase II, 
partial duplexes were constructed to have a 3' ss tail and 
to contain a unique drug bonding site (5'-GATTA*-3', 
where * represents the drug modification site) on either 
the long or the short strand. The rationale for using both 
substrates (i.e., drug modification on either the long or 
short strand) was gleaned from our previous study,20 which 
showed that the drug-induced winding and helix-stabilizing 
effects on DNA molecules occurred predominantly to the 
5'-side of the covalently modified adenine (i.e., toward the 
drug overlap site). Thus, if drug molecules are positioned 
in both orientations relative to the direction of helicase 
translocation, it is possible to test the differential effect 
of drug orientation on helicase II-catalyzed unwinding of 
DNA. In this study, we have also included select analogues 
of (+)-CC-1065 (see Figure 2) to attempt to relate these 
results to the differential biological activities of these drug 
molecules. In order to measure in the same experiment 
both the helicase unwinding activity and the extent and 
selectivity of drug modification at the desired site (using 
the thermal strand breakage assay), only the drug-modified 
strands were labeled with 7 -32P at the 5'-end. The overall
(26) M a ts o n , S . Escherichia Coli H e lic a se  II  (U v r D  G e n e  P ro d u c t)
T ra n s lo c a te s  U n id ire c t io n a l ly  in  a  3 ' to  5 ' D ire c t io n . J. Biol.
Chem. 1986, 261, 1 0 1 6 9 -1 0 1 7 5 .
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Figure 4. Autoradiograms showing the thermally induced strand 
breakage assay15 for determination of the location and extent of 
drug modification of oligomers TDl (panel A) and TD2 (panel 
B). Pu and Py represent purine-specific and pyrimidine-specific 
reactions, respectively. For panels A and B, lane 1 contains the 
non-drug-modified oligomer and lanes 2-6 contain (+)-CC-1065-, 
(+)-AB'C'-, (+)-ABC"-, (+)-ABC-, and (+)-AB-modified oligomers, 
respectively. The S'-^-labeled DNA samples were prepared and 
subjected to thermally induced strand breakage as described in 
Experimental Section. The drug-bonding sequences are shown 
to the left of each panel and the (*) pinpoints the covalently 
modified adenine. The higher and lower molecular weight material 
corresponds to species A and B in Figure 1.
strategy for the construction and execution of th is ex­
perim ent is shown in Figure 3.
C haracterization  o f  D ru g-O ligon u cleotid e  A dducts  
U sin g  th e  D N A  T h erm a l S tra n d  B rea k a g e  A ssa y .15 
Upon thermal treatment of (+)-CC-1065 and its analogue 
(iV3-adenine)-DNA adducts, cleavage of the N-glycosidic 
bond and subsequent backbone cleavage occurs to the  
3'-side of the covalently m odified adenine to leave a 5'- 
phosphate on the 3'-side of the break and, presumably, a 
modified deoxyribose on the 5'-side. Further thermal 
treatment or piperdine treatm ent of 5'-labeled substrates 
causes release of a m odified deoxyribose to produce a 
product identical to that of a Maxam and Gilbert adenine 
sequencing reaction (Figure l ) .15 This strand breakage 
assay was used to identify the drug-modified adenine and 
to monitor the extent o f drug modification at the desired 
site. As shown in Figure 4A, thermal treatm ent induced  
almost quantitative strand cleavage of drug-modified T D l 
oligomers (lanes 2-6) at the expected site (5'-GATTA*-3') 
on the DNA backbone, while non-drug-modified single­
stranded D N A  (lane 1) remained intact after this treat­
ment. In oligomer TD2 (Figure 4B), exclusive bonding at 
5'-GATTA* was observed for each of the drugs except for 
(+)-CC-1065 or (+)-AB'C/ (lanes 2 and 3, respectively), 
where minor bonding o f these drug m olecules to 5'- 
GACCA*-3' occurred. However, for the latter cases, the 
possibility that these two drug molecules were bound to  
the same D N A  molecule can be excluded, since the two 
bonding sites are too close together for both drug molecules 
to form covalent adducts on the same tem plate molecule.
D eterm ination  o f  th e  O ptim um  T im e T o Add C hase  
D N A  T o E x h ib it M axim um  H elica se  U n w in d in g  A c­
tiv ity . The enzymatically released ss DNA induced by the 
unwinding activity of helicase II will be readily reannealed 
to the complementary strand to reform duplex molecules. 
To circumvent this problem, an 8 molar excess o f nonla­
beled ss DNA (the same strand as the labeled strand) was 
included to act as a trap to compete with the released  
labeled strand for reannealing. The optimum time to add
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Figure 5. Determination of the optimum time to add chase DNA 
after addition of helicase II to show maximum helicase unwinding 
activity. Five nanograms of chase DNA was added after 0,5,10, 
20, 30, and 50 min to the reaction mixture containing 10 ng of 
helicase II and 10 ng of substrate TD3, and the amount of un­
winding was determined as described in Experimental Section.
cold chase D N A  to show the maximum am ount of un­
winding activity was determined by the addition of ss DNA  
at 5 ,10, 20,30, and 50 min. The results show the optimum  
tim e to  be 5 min after mixing helicase II and substrate 
(Figure 5).
H elicase  II-C atalyzed U n w in d in g  o f  D rug-M odified  
or N o n -D ru g-M od ified  O ligom ers. T he effect of (+ )- 
CC-1065 and related drugs on helicase II-catalyzed un­
winding of D N A  following covalent m odification of T D l  
and TD2 is shown in Figure 6A,B. Figure 6 A 3  shows the 
gel analysis using increasing am ounts o f helicase II, and 
these results are also graphically represented using the 
densitom etric scanning results of the gels, which are 
plotted in Figure 6C,D. Parts A and C of Figure 6 show  
the results from T D l, in which the drug winding and 
stiffening effects are orientated in the opposite direction 
to helicase II unwinding, while parts B and D represent 
the drug-induced effects oriented in the sam e direction  
relative to the helicase II unwinding direction. Irrespective 
of orientation, all of the drugs produced a pronounced 
inhibition o f helicase II unwinding of DNA; however, 
(+)-CC-1065 and (+)-A B /C/ produced a more significant 
inhibitory effect in T D l than in TD 2 and than with the 
other analogues (Figure 6A,B). T his more pronounced 
effect o f (+)-CC-1065 and (+)-AB'C' in inhibition of he­
licase II-catalyzed unwinding of T D l is also revealed by 
the densitom etric analysis (Figure 6C), where it is also 
evident that (+)-ABC" and (+)-ABC produce moderate 
inhibitory effects at the lower helicase EL levels. In the case 
of the drug orientation where the winding and stiffening  
effects are in the sam e d irection  o f helicase II unwinding 
(Figure 6B,D), and drug-induced effects are more uniform 
(i.e., no pronounced effect of (+)-AB'C' and (+)-CC-1065, 
relative to (+)-ABC and (+)-A B ), but like the results in 
Figure 6A,C the drugs produce a moderate inhibition at 
low helicase II levels. Overall, what is particularly striking 
about these results is the selective inhibitory effect of 
(+)-CC-1065 and (+)-AB'C' on helicase II when they are 
orientated so that the winding effect o f the drug molecules 
is op posite  to the helicase II unwinding direction. It is 
unlikely that the thermal stabilizing effect o f drug mole­
cules on duplex DNA (i.e., A Tm) is primarily responsible 
for th is inhibitory effect, since both (+)-A B'C / and (+)- 
ABC", which have quantitatively differen t inhibitory ef­
fects on helicase II unwinding, produce relatively the same 
increase in Tm  of duplex D N A .16
G el M o b ility  o f  th e  R elea sed  D ru g -M o d ified  S in ­
g le -S tra n d ed  D N A  fo llo w in g  H e lic a se  II-C a ta ly zed
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F ig u r e  6. Gel electrophoresis (panels A and B) and kinetics 
(panels C and D) o f the helicase II-catalyzed unwinding of  
drug-modified and non-drug-modified oligomers. T he D NA  
substrates used in the helicase reaction were oligomers T D l (panel 
A and graph C) and T D 2 (panel B and graph D), prepared as 
shown in Figure 3 and described in Experimental Section. In panel 
A, lane 1 is w ithout helicase II and lanes 2, 3, and 4 contain 10, 
50, and 100 ng of helicase II, respectively; and in panel B , lane 
1 is w ithout helicase II and lanes 2, 3, and 4 contain 20 ,40 , and 
80 ng of helicase II, respectively. D N A  sam ples were electro- 
phoresed on 8% nondenaturing polyacrylamide gel (acrylamide, 
bisacrylamide 29:1) for 3 h at 0.7 V /cm . Graph C shows the kinetic 
analysis o f unwinding of non-drug-modified and drug-modified 
oligomer T D l using 0 ,1 0 , 20, 50 ,100 , and 200 ng o f helicase II. 
Graph D shows the sam e experim ent as shown in C, but using 
oligomer T D 2 (□ =  control, O =  (+)-CC-1065, A = (+)-AB'C'; 
•  = (+)-ABC", ■  =  (+)-ABC, ▲ = (+)-A B).
Sun and Hurley
showed a gel m obility on nondenaturing polyacrylamide 
gel electrophoresis that was dependent on the species of 
drug attached (panel B o f Figure 7). This drug depen­
dency of gel m obility could be elim inated by heating the 
samples at 95 °C for 1 min (panel C of Figure 7, lanes 1-6). 
Further thermal treatm ent induced the expected strand 
breakage15 at the drug modification site (panel D of Figure 
7, lanes 2-6). We propose that the drug-modified ss DNA  
is converted into a drug-dependent secondary structure 
during unwinding o f the duplex by helicase II, which is 
disrupted at high temperature, so that the unique sec­
ondary structure, which is associated with abnormal gel 
m obility, is no longer drug dependent.
D ru g  M od ifica tion  o f  O ligo-dT -T ailed  P a r tia l D u ­
p le x e s  S h o w ed  a S im ila r  P a tte r n  o f  In h ib itio n  o f  
U n w in d in g  by H elicase  II. To investigate the generality 
of the inhibitory effects of (+)-CC-1065 and analogues on 
helicase II-catalyzed unwinding o f DNA, two further tailed 
duplexes each having oppositely orientated drug molecules 
were constructed. These tailed duplexes (TD3 and TD4  
in Table I) differed from T D l and TD 2 in that they had 
3'-T-tails and different duplex region sequences. Overall, 
the results (Figure 8A,B) show the same pattern of drug- 
induced inhibition o f helicase II-catalyzed unwinding of 
DNA. In particular, the most marked inhibition was found 
with (+)-CC-1065 and (+)-AB'C' when the drug-induced 
winding effects were orientated in the opposite  direction 
to helicase II unwinding (Figure 8A). T his parallels the 
observation made with the other pair of tailed duplexes 
(see before). It is also im portant to note that the 3'-T- 
tailed partial duplexes are more favorable substrates for 
helicase II-catalyzed unwinding than partial duplexes 
containing random sequences on the 3'-tailed region. In 
the case of 3'-T-tailed partial duplexes, the extent o f the 
inhibitory effect on helicase II-catalyzed unwinding caused 
by drug modification is also dependent on the orientation 
of drug molecules in the duplex region.
D u p lex  U n w in d in g  C atalyzed  by E . co li r e p  Protein  
A lso S b ow s tb e  Sam e P a ttern  o f In h ib ition  Produced  
by D ru g  M od ification  o f  D N A . Like helicase II, the E. 
coli rep  protein also translocates in a 3'- to 5'-direction with 
respect to the D N A  strand to which it is bound.27 rep  
protein was also evaluated in this investigation, since this 
protein has an important function in replication of E. coli 
DNA. The results show that when rep  protein was used 
to catalyze the unwinding of drug-modified substrates, the 
same general pattern of inhibition as previously shown for 
helicase II was produced by each of the drug molecules 
(Figure 9). Taken together, these results suggest that the 
pattern of (+)-CC-1065-mediated inhibition of unwinding 
of duplex D N A  drug may be common to  other DNA un­
winding proteins such as phage T7 gene 4 protein, phage 
gene 41 protein, and SV40 T  antigen.
H e lica se  II-C a ta ly zed  U n w in d in g  o f  G apped D u ­
p lex es  Is  A lso  In h ib ited  by D r u g  M od ifica tion . The 
gapped duplexes G D I and GD2 (Table I and Figure 10) 
were designed to determine whether primer extension by 
polymerase I would be facilitated by the combined action 
of helicase II. Drug-modification sites are within the left 
duplex region so that either the short (G DI) or the long 
(GD2) strand can be selectively covalently modified with 
drug molecules. After drug modification, the drug-bonding 
sites were confirmed by the strand-breakage assay.15 In 
oligomers G DI and GD2, exclusive drug bonding at 5'- 
GATTA*-3' was achieved for all o f the drugs except
U n w in d in g  Is  D ep en d en t on th e  S p e c ie s  o f  D r u g  (27) Yarranton, G. T.; Gefter, M. L. Enzyme-Catalyzed DNA Un- 
A ttached to  D N A . Following unwinding of drug-modified winding: Studies on Escherichia coli rep Protein. Proc. Natl.
D NA by helicase II, it was observed that the ss D N A  Acad. Sci. U.S.A. 1979, 7 6 ,1658-1662.
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Figure 7. Demonstration of dependence of the gel mobility of the enzymatically released drug-modified ss DNA on the species of 
drug attached to DNA. Reactions in panels A-D contain 10 ng of non-drug-modified, (+)-CC-1065-, (-t-)-AB'C'-, (+)-ABC"-, (+)-ABC-, 
and (+)-AB-modified oligomer T D l in lanes 1-6, respectively. Panel A is without helicase II. Panels B -D  were incubated with 100 
ng of helicase II at 30 °C for 50 min, and then the reaction mixtures were electrophoresized on 8% nondenaturing polyacrylamide 
gel without further treatment (panel B), with heating at 95 °C for 1 min (panel C) or with heating at 95 °C for 30 min. Duplicate 
bands at the top of the gel for (+)-CC-1065-, (+)-AB'C'-, (+)-ABC//-, and (+)-ABC-modified oligomer T D l in panels A and B appeared 
to be interconvertible, since isolated DNA from both bands show the same pattern of gel mobility on 8% nondenaturing gel electrophoresis. 
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Figure 8. Unwinding reaction of non-drug-modified and drug- 
modified oligomer TD3 (graph A) and TD4 (graph B) at various 
helicase II concentrations. Reaction mixture contains 10 ng of 
DNA substrate with the indicated amount of helicase II (□ = 
control, O = (+)-CC-1065, A = (+)-AB'C', •  = (+)-ABC", ■ = 
(+1-ABC, ▲ = (+)-AB).
(+)-CC-1065- and (-f)-AB'C'-m odified GD2, in which  
minor bonding o f these drug m olecules to 5'-GACCA*-3' 
occurred at about 15% (data not shown). The possibility  
that two drug molecules m e bound to the same D N A  
molecule can be excluded, since the two bonding sites are 
too close together for two drug molecules to form covalent 
adducts on the same D N A  molecule. As anticipated, the 
unwinding of GDI by helicase II was virtually completely 
blocked by (+)-CC-1065 and (+ )-AB'C' modification (see 
lanes 8 and 9 of Figure 10A), while (+)-ABC" and (+)-ABC
F igure 9. Unwinding reaction of non-drug-modified and drug- 
modified oligomer catalyzed by E. coli rep  protein at various 
helicase II concentrations. Reaction mixture contains 10 ng of 
DNA substrate (TD l) with the indicated amount of rep  protein 
(□ = control, O = (+)-CC-1065, A = (+)-AB'C\ •  = (+)-ABC", 
■ = (-f)-ABC, ▲ = (+)-AB).
showed a moderate inhibition (lanes 10 and 11 o f Figure 
10A). In contrast, in the case of the drug-modified GD2 
substrate, irrespective of the analogue tested, only a weak 
inhibition of unwinding was observed at the concentration 
of helicase II utilized in this experim ent (Figure 10B).
H e lic a se  II S ta lle d  on  a S in g le -S tr a n d e d  D N A  
T em p late  P rev en ts  P rim er E xten sio n  by P olym erase  
I. To assess the combined action of helicase II and DNA  
polymerase I, DNA polymerase I and a four dN TP mixture 
were added to a drug-modified GDI substrate (Table I and 
Figure 11), which had been preincubated with helicase II. 
Primer extension was measured using 12% denaturing 
polyacrylamide gel electrophoresis. As a control, drug- 
m odified gapped tem plates were incubated with D N A  
polymerase I and a four dN T P  mixture in the absence of 
helicase II (lanes 1-6 in Figure 11). The results show that, 
unexpectedly, even without drug modification preincuba­
tion in the presence of helicase II prevents D N A  polym ­
erase from extending primers by D N A  synthesis (compare 
lanes 1 and 7 in Figure 11). Band “c” in lane 7 shows the 
position o f stalled D N A  synthesis. Presum ably, the  
presence o f helicase II stalled on the tem plate after un­
winding of the left region of the gapped duplex prevents 
full extension of the primer. In the case of (+)-CC-1065- 
and (+)-AB'C'-modified GDI substrate, primer extension
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5AATCCGTAATCATGGTCTCAGTTACGTAGATCACGAGATCAGCGCTAGCAGT3' 
3TTAGGCATTAGTACCAGAG5'“ p 3'CTCTAGTCGCGATCGTCA5'“ P
5'ACCATGATT ̂ CGG ATTGAGAGTT ACGT AG ATCACG AG ATCAGCGCT AGCAGT3' 
3TGGT ACT AATGCCTAACTC5'MP S’CTCTAGTCGCGATCGTCAS^P
5'AATCCGTAATCATGGTCTCAGTTACGTAGA'fcACG
F igure 10. Helicase II-catalyzed unwinding of gapped duplexes 
GDI and GD2 modified with the drug molecules, shown in Figure 
2. Panels A and B represent unwinding reactions of non-drug- 
modified and drug-modified gapped duplexes GDI and GD2, 
respectively. In panel A, each reaction contains 10 ng of either 
control DNA (lanes 1 and 7), (+)-CC-1065-modified DNA (lanes 
2 and 8), (+)-AB'C'-modified DNA (lanes 3 and 9), (+)-ABC"- 
modified DNA (lanes 4 and 10), (+)-ABC-modified DNA (lanes 
5 and 11), or (+)-AB-modified DNA (lanes 6 and 12). For panel 
A, lanes 1-6 are without helicase II (control) and lanes 7-12 are 
with 100 ng of helicase II. DNA substrate was preincubated with 
helicase II for 5 min, and an 8 molar excess of the unlabeled, 
displaced DNA strand was added and further incubated for 45 
min at 30 °C. In panel B, the amount of DNA-substrate and 
helicase II used in this experiment is the same as in panel A. 
However, in this case lanes 1 ,3 ,5 ,7 ,9 , and 11 represent reactions 
without helicase containing the non-drug-modified (+)-CC-1065-, 
(+)-AB'C'-, (+ )-A B C '\ (+)-ABC-, and (+)-AB-modified DNA, 
respectively, while lanes 2, 4, 6, 8, 10, and 12 represent the re­
actions containing 100 ng of helicase II and the same DNA sub­
strates as in the preceding lanes. Bands “a” and “b" are most likely 
two different conformations of the same drug-modified template 
GD2.
was terminated even more prematurely than in the control 
and in the other drug-modified tem plate lanes (see band 
“d" in lanes 8 and 9 of Figure 11). We propose th is is 
because helicase II is prematurely blocked from progression 
to the end of the tem plate due to the presence o f drug 
molecules. In contrast, D N A  polymerase alone can fully  
extend the primer by using intrinsic strand-displacement 
activity coupled with DNA synthesis (lane 1 in Figure 11). 
For drug-modified G DI, premature term ination of DNA  
synthesis occurred about seven to  nine base pairs away 
from the drug modification site (lanes 2 -6  in Figure 11), 
even though it is not the template DNA that is covalently 
modified with drug molecules. Moreover, by using  
nondenaturing polyacrylamide gel electrophoresis, we have 
shown that D N A  polymerase can produce unwinding ss 
DNA from duplex in the presence of dN T P s, but th is is 
also inhibited by the (+)-CC-1065- and (+)-AB'C'-modified 
substrates (unpublished data). The results o f these ex­
periments im ply that DNA polymerase I alone cannot 
dissociate helicase II from tem plate DNA, and other pro­
teins m ight participate in the turnover of the helicase II 
bound to tem plate DNA.
D isc u ss io n
DNA plays a vital role in maintaining the biological 
activities of all living cells, since the cellular processes 
necessary for life depend ultim ately on the precise regu­
lation of gene expression and genome replication. These
3TTAGGCATTAGTACCAGAG5,32P





Figure 11. Primer extension of the gapped duplex (GDI) by DNA 
polymerase I alone (lanes 1-6) or by the combined action of 
helicase II and polymerase I (lanes 7-12). Reactions in lanes 1-12 
contain 20 ng of DNA substrate, 50 mM of the four dNTPs, and 
1 unit of DNA polymerase I in helicase II unwinding buffer. 
Reactions were carried out at 30 °C for 30 min. For reactions 
in lanes 7-12, where helicase was included, DNA substrates were 
unwound by 100 ng of helicase II for 15 min and then further 
incubated for 30 min with the addition of 1 unit of DNA polym­
erase I and 50 mM of dNTPs. Reactions contain unmodified DNA 
in lanes 1 and 7, (+)-CC-1065-modified DNA in lanes 2 and 8, 
(+)-AB'C'-modified DNA in lanes 3 and 9, (+)-ABC//-modified 
DNA in lanes 4 and 10, (+)-ABC-modified DNA in lanes 5 and 
11, and (+)-AB-modified DNA in lanes 6 and 12. Band “a” 
represents ss DNA displaced by DNA polymerase I coupled to 
DNA synthesis. Band “b” represents the strand breakage product 
of drug-modified strands. Bands “c" and “d” represent prema­
turely terminated DNA synthesis. The four lanes on the left-hand 
side are the dideoxy-DNA sequencing lanes. The sequence 
complementary to the covalent modification site is shown on the 
le ft  The sequence of GDI is shown at the bottom of the figure, 
identifying the drug bonding site and the position of bands “c” 
and “d”, as well as the pausing sites for DNA polymerase near 
the adduct sites for (+)-ABC", (+)-CC-1065, and (+)-AB'C'.
D N A  processes are m ediated by the D N A  itself together 
with its interactions with D N A  binding proteins. There­
fore, it is to be expected that DNA-interactive small 
molecules, such as intercalators, groove binders, and al­
kylating agents, will have profound effects on the function 
of DNA m olecules, resulting in potent cytotoxicity. 
Physical studies on D N A-drug com plexes have been car­
ried out extensively in the past few years in attem pts to  
correlate the biological activities of drugs with the manner 
and extent to which drug molecules interact with the DNA  
double helix.28-30
(+)-CC-1065 is the lead candidate for a group of largely 
synthetic drugs that alkylate D N A , in th is case, through  
N 3 of adenine in a surprisingly highly sequence-selective 
manner.15 The DNA alkylating properties of (+)-CC-1065 
and related drug m olecules are believed to be primarily
(28) Hurley, L. H. DNA and Associated Targets for Drug Design. 
J. Med. Chem. 1989, 32, 2027-2033.
(29) Covey, J. M.; Kohn, K. W.; Kerrigan, D.; Tilchen, E. J.; Pom- 
mier, Y. Topoisomerase U-Mediated DNA Damage Produced 
by 4'-(9-acridinylamino)methane8ulfon-m-anisidide and Re­
lated Acridines in L1210 Cells and Isolated Nuclei: Relation 
to Cytotoxicity. Cancer Res. 1988, 48, 860-865.
(30) Lambert, B.; Jones, B. K.; Roques, B. P.; Le Pecq, J.-B. The 
Noncovalent Complex between DNA and the Bifunctional In- 
tercalator Ditercalinium Is a Substrate for the UvrABC En­
donuclease of Escherichia Coli. Proc. Natl. Acad. Sci. U.SA. 
1989, 86, 6557-6561.
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Figure 12. S t r u c t u r e - a c t i v i t y  r e l a t io n s h i p  o f  ( + ) - C C -1 0 6 5  a n d  
r e l a t e d  c o m p o u n d s .16,19,20,23
responsible for the cytotoxicity and antitum or activity  
shown in in vivo studies.11,16,24 However, it has also been 
dem onstrated that (+)-CC-1065 induces D N A  bending, 
winding, and stiffening as a result of covalent modification 
of D N A .19,20 Furthermore, the DNA-winding effect is 
unique to (+)-CC-1065 and (+)-AB'C', while the DNA- 
stiffening effect is only observed for (+)-CC-1065, (+ )- 
AB'C', and (+)-ABC". Thus, in previous studies the in­
clusion o f select (+)-CC-1065 analogues in addition to  
(+)-CC-1065 has made it possible to define quite precisely 
the structure-activity relationship of (+)-CC-1065 and 
related m olecules (Figure 12). As an extension of these 
studies, we are presently examining the biochemical con­
sequences o f these drug-induced structural changes in 
DNA molecules by using defined in vitro system s, in­
cluding DNA-metabolizing proteins such as D N A  polym­
erase, T4 DNA ligase, and other DNA-binding proteins.26-22 
These studies have shown that (+)-CC-1065 and its ana­
logues are strong blocks to in vitro DNA synthesis m edi­
ated by the Klenow fragment, E. coli DNA polymerase I, 
and T4 D N A  polymerase as a result of covalent m odifi­
cation of adenine, and that the D N A  winding and stiff­
ening effects of (+)-CC-1065 and its select analogues cause 
the proximal and distal inhibition o f oligomer ligation  
mediated by T4 DNA ligase, respectively.20,21
In this present study, we have primarily focused on the 
helix-stabilizing and -winding effects of these drug mole­
cules on DNA and their resulting consequences on the 
DNA-unwinding processes m ediated by D N A  helicases 
such as helicase II (UvrD E. coli) and E. coli rep  protein. 
These drug-induced effects will presumably inhibit the 
physical separation o f DNA duplex by increasing the 
stabilization of the D N A  duplex or changing the helical 
periodicity o f the DNA duplex by virtue o f their DNA- 
winding effects. The results of this study clearly dem on­
strate that the extent of inhibition of D N A  unwinding 
mediated by both helicase II and E. coli rep  protein is 
partially correlated with the drug-induced DNA-stabilizing 
effect. However, drug-induced stabilization of DNA is in 
itself insufficient to explain all the helicase inhibition. For 
example, while the effect o f (+)-AB'C' on the A Tm  of 
DNA is almost the same as that of (+)-ABC",16 (+)-AB'C' 
produced a dramatically increased inhibition of DNA un­
winding compared to (+)-ABC". The additional extent 
of helicase II inhibition common to (+)-CC-1065 and 
(+)-AB'C' appears to be correlated with their unique 
winding effects.19 Significantly, the increase in the amount 
of helicase inhibition is also dependent upon the orienta­
tion of the winding effect of drug molecules, which has to 
be opposite w ith respect to the direction o f helicase II 
translocation. There is a striking correlation o f the ori­
entation specificity of the winding effect o f (+)-CC-1065
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and a similar orientation specificity o f the £er-binding 
protein, which also produces contra-helicase activity.31 It 
is interesting to speculate whether the m echanism s for 
helicase inhibition m ight be related. The (+)-CC-1065 
molecule has its major interactions with DNA to the 5'-side 
of the covalently modified adenine, and the drug-induced 
winding and helix-stiffening effects occur predominantly 
to the 5'-side of the covalently modified adenine (i.e., to­
ward the drug overlap site). Our results show that helicases 
have more difficulty in unwinding a duplex, having a drug 
adduct on the displaced strand compared to  that on the 
helicase-bound strand. We speculate that the presence of 
drug molecules may prevent helicases from entering the  
drug modification site by stabilizing or winding the duplex 
when drug m olecules were positioned on the displaced  
strand, whereas helicases have difficulty in translocation  
through the covalently modified strand because o f steric 
interaction due to the drug-adenine adduct when drug 
molecules are present on the helicase-bound strand.
The inclusion in this study of gapped duplexes (GDI and 
GD2) as substrates for helicase II and E. coli polymerase 
I has provided to us important insights into understanding 
the effect of drug-induced inhibition of D N A  unwinding 
m ediated by helicase II and the possible further impact 
on DNA metabolism, such as the DNA-repair process. It 
is well-known that one pathway for repair o f oligo­
nucleotides containing D N A  damage is through the com­
bined actions of the UvrD protein (helicase II) and DNA  
polymerase after the UvrA, UvrB, and UvrC gene products 
of E. coli have identified the damaged site and produced 
3'- and 5'-incisions.5,26,32 These proteins recognize DNA  
damaged by bulky adducts, such as pyrimidine-pyrimidine 
cyclobutane dimers, and produce incision at the fourth or 
fifth phosphodiester bond on the 3'-side of the damage and 
at the eighth phosphodiester bond on the 5'-side.32 Our 
results reported here indicate that the (+)-CC-1065- and 
(+)-AB'C'-damaged nucleotide might be resistant to ex­
cision by the combined action of UvrD and D N A  polym­
erase, resulting in persistent D N A  strand breaks after 
incision by UvrAB and C protein. The real possibility of 
generation of persistent D N A  strand breaks during the 
repair process was suggested in a previous study using a 
eukaryotic system, in which it was shown that (+)-CC-1065 
produces depletion of NAD levels in repair-proficient and 
-deficient (xeroderma pigmentosum) human cells, which 
appears to be related to poly(ADP)ribosylation and per­
sistent DNA strand breakage.32 If persistent D N A  strand 
breaks are generated as a result of the normal repair 
processes, we can speculate that drug m olecules such as 
(+)-CC-1065 and (+ )-AB'C' are likely to have much more 
potent biological effects in vivo compared to other ana­
logues lacking these DNA-winding effects. This leads us 
to  pose the question as to whether the unique winding 
effects of (+)-CC-1065 and (+)-AB'C' may be related to  
the delayed lethality produced in mice by these same 
compounds.23 To further evaluate this hypothesis, we are 
carrying out experim ents using the E. coli repair system  
and the normal and xeroderma pigmentosum human cell
(31) L ee , E . H .; K o m b e rg , A.; H id a k a , M .; K o b a y a a h i, T .;  H o r iu c h i, 
T . Escherichia coli R e p lic a t io n  T e r m in a t io n  P r o te in  Im p e d e s  
th e  A c tio n  o f  H e lic a s e  II . Proc. Natl. Acad. Sci. U.S.A. 1989, 
86, 9 1 0 4 -9 1 0 8 .
(32) S a n c a r ,  A .; R u p p ,  W . D . A N o v e l R e p a i r  E n z y m e : U v rA B C  
E x c is io n  N u c le a s e  o f  Escherichia coli C u ts  a  D N A  S t r a n d  o n  
B o th  S id e s  o f  th e  D a m a g e d  R e g io n . Cell 1983, 33, 2 4 9 -2 6 0 .
(33) J a c o b s o n , M . K .; T w e h o u s e , D .; H u r le y , L . H . D e p le t io n  o f  
N A D  in  N o r m a l  a n d  X e re d e rm a  P ig m e n to s u m  F ib r o b la s t s  
C ells  b y  t h e  A n t i tu m o r  D ru g  C C -1065. Biochemistry 1986, 25, 
5 9 2 9 -5 9 3 2 .
1782
lines with the analogues utilized in this investigation.
The results of our recent study concerning the mecha­
nistic aspects of the inhibition of DNA-unwinding medi­
ated by helicase II suggest that drug modification of DNA  
slows down the turnover rate of helicase II, which results 
in an increase of retention time of helicase II on drug- 
damaged DNA.22 Likewise, the stalling of helicase II on 
drug-damaged DNA, particularly (+)-CC-1065- and (+)- 
AB'C'-modified DNA, was also observed in the primer 
extension experiment with the combined action of helicase 
II and polymerase I (see Figure 11). The distance between 
the drug modification site and termination of primer ex­
tension (about 20 nucleotides) appears to represent a 
critical length of coverage of DNA by helicase II, which 
is constant from one drug-modified sample to another, and 
is also about the same length of helical coverage revealed 
in the nonmodified gapped duplex. A similar observation
i
I
was made in the previous study.22 1
Conclusively, the results presented in this paper clearly 
define some of the biochemical consequences of drug-in-, 
duced winding and helix-stabilizing of DNA molecules on 
the activity of unwinding enzymes such as helicase II and
E. coli rep protein. Studies are in progress that use a DNA. 
transcription system in combination with eukaryotic 
transcriptional factors (e.g., S p l) to determine the bio­
chemical consequences of structural changes in DNA  
molecules that result from covalent adduct formation with 
(+)-CC-1065 and its analogues. j
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T ab le  I: S eq u en ces  o f  T em p la te s  an d  P rim e rs  U sed  in T h is  S tu d y 0
T - 4 4MER 5 ' -TGGGCGGAGTTAGGGGCGGGTGGATCAGGCAGTCAGTTACGTAG-3 '
1 6MER 3 ' -CGTCAGTCAATGCATC-5 '
2 ONER 3'-ACCCGCCTCAATCCCCGCCC-5'
T - 4  SMER 5 ' -ACCATGATTACGGATTCGAGATCAGCAGTCAGTTACGTAGATCAC-3 '
16M ER  3 '-CGTCAGTCAATGCATC-5'
2 1M E R  3 '-CGTCAGTCAATGCATCTAGTG-5 '
3 SMER 3 ' -GCCTAAGCTCTAGTCGTCAGTCAATGCATCTAGTG-5 '
2 0M ER 3'-TGGTACTAATGCCTAAGCTC-5'
T -5 1 M E R  5 ' -CTCGAATCCGTAACTATGGTCGGTGATTACGTAGAGATCAGCGCTAGCATG-3 ' 
2 1M ER 3 ' -CATCTCTAGTCGCGATCGTAC-5  '
2 0 ME R 3 ' - ACCAGCCACTAATGCATCTC- 5 '
GATTA
1 Bold le tte rs  ind ica te  d ru g  m od ifica tio n  sites.
separately with saturated ammonium hydroxide at 55 °C  
overnight, dried under vacuum, and redissolved in DDW .
Preparation o f  5 -End-Labeled Primers. Approximately 10 
Mg of each primer was separately 5'-end-labeled with 
[7 32P]A T P and T4 polynucleotide kinase mixed in 25 yiL of 
solution containing 70 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 
and 5 m M  dithiothreitol for 1 h at 37 °C . Labeled oligo­
nucleotides were electrophoresed on a 12% denaturing poly­
acrylamide gel and located by autoradiography. Gel fragments 
containing D N A  were excised from the gel, minced with a 
blade, extracted with D DW , and ethanol-precipitated. D N A  
pellets were dried under vacuum and redissolved in DDW .
Preparation o f  S ite-D irected  A dducts on S ingle-Stranded  
D N A  Tem plates. The oligomers (T-44, T-45, and T-51 in 
Table I) containing 5'-G A TTA-3' or 5'-AG TTA-3' as the 
drug-bonding sequence (Table I) were separately annealed in 
a solution of 100 mM  N aC l and 10 mM Tris-HCl (pH 7.5) 
to the complementary 20-mer single-stranded oligomer to form 
a partial duplex D N A . The drug-bonding site was positioned 
within the duplex region so that the reaction occurred exclu­
sively within this region to form a covalent adduct with T-44, 
T-45, or T-51. The resulting partial duplexes were modified 
with drug molecules [(+ )-C C -1065, (+ )-A B 'C ', (+)-A B C ", 
(+ )-A B C , and (+ )-A B ], as previously described (Lee et al., 
1991). Unbound drug molecules were removed by ethanol 
precipitation, and resulting D N A  pellets were redissolved in 
sequencing dye solution [90% w /v ) formamide in 0.1 M 
Tris-HCl (pH 7.8)]. After the D N A  samples were heated for
1 min at 95 °C , they were subjected to denaturing 12% po­
lyacrylamide gel electrophoresis (7 M urea) to separate 
drug-modified ss D N A  from the complementary strand by the 
size difference between two species. After electrophoresis, the 
gel was transferred to plastic wrap and placed over a TLC  
plate containing fluorescent indicator, and the locations of 
D N A  molecules were visualized under short-wavelength UV  
light. Gel fragments containing the desired D N A  fragments 
were cut from the gel, minced with a blade, extracted with 
distilled water, and dried under vacuum. Dried D N A  pellets 
were dissolved in distilled water, ethanol-precipitated, and 
redissolved in distilled water. Purified drug-modified ss D N A s  
were annealed to appropriate 5'-32P-end-labeled primers in 2 X  
polymerase buffer by incubating at 50 °C  and slowly cooling 
to room temperature, and these were then used as a D N A  
template.
Preparation o f  Tem plate D N A  M odified  with D rug M ol­
ecules a t the Prim ing S ite. The oligomer T-45-mer was an­
nealed to the primer, 5'-end-labeled 21-mer, to form a partial 
duplex, and the resulting duplex was modified with (+ )-C C -  
1065 or select analogues. Unbound drug molecules were re­
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fig u r e  2: Schematic diagram showing the strategies used to construct 
site-directed (+J-CC-1065- and analogue-modified template for the 
DNA polymerase experiments. A partial duplex of DNA containing 
a unique drug-bonding sequence within the duplex region was prepared 
and modified with drug, and the strands were separated by denaturing 
polyacrylamide gel electrophoresis to purify a site-directed drug- 
modified single strand, as described in Materials and Methods. DNA 
polymerization extension was carried out from a primer annealed to 
the 3' end of the drug-modified ss DNA template. Solid fold bars 
represent drug molecules covalently attached to DNA.
were further purified by electrophoresis on nondenaturing 8% 
polyacrylamide gels as described above.
H eat-Induced S tran d  Breakage A ssay o f  D rug-M odified  
S ingle-S tranded D N A. (+ )-C C -1 0 6 5 - and analogue-(7V3- 
adenine)DNA adducts can be released from the D N A  strand 
by thermal treatment to also induce D N A  strand breakage 
(Reynolds et al., 1985). After 5'-end-labeling with [7 32P]ATP, 
drug-modified ss D N A s were subjected to thermal treatment 
for 2 h at 95 °C to locate the drug-bonding site and determine 
the extent of reaction at the desired sequence on ss D N A . 
Heat-treated samples were dried, redissolved in formamide 
(80% )-N aO H  (10 m M ) dye solution, and then subjected to 
denaturing 12% polyacrylamide gel electrophoresis run in 
parallel with D N A  sequencing reactions.
D N A P olym erase Reaction. Template D N A  (about 50 
nM ) was incubated with 1 unit o f Klenow fragment, E. coli 
D N A  polymerase I, or T4 D N A  polymerase in 10 mL o f 50 
mM Tris-HCl (pH 7.5), 5 mM  2-mercaptoethanol, and 10 
mM M gCl2 for 30 min in the presence of the indicated amount 
of dNTPs. Reactions were quenched by addition of the same 
volume of sequencing dye.
R e s u l t s
Design and C haracterization  o f  D rug-M odified  D N A  
Tem plates fo r  DN A Polym erization Experiments. Template 
D N A  molecules for polymerization experiments were designed 
to have the drug-bonding sequence (5'-G ATTA -3' or 5'- 
AGTTA-3') on the 5' side of the ss region with at least a 4-bp 
gap remaining between the 3' terminus of the primer and the 
drug-modified adenine. This tem plate was used to monitor 
the effect of drug-D N A  adducts on the in vitro D N A  synthesis 
mediated by D N A  polymerase. The overall strategy for 
preparation of drug-modified templates is shown in Figure 2. 
The stability of covalently attached drug molecules on the 
D N A  template during the preparation of the template was 
confirmed by chemical footprinting and a spectrophotometric 
assay (unpublished results). In the latter assay, ss D N A  
(T-45-m er in Table I) modified with (+)-C C -1065 exhibits 
a second absorption peak around 360 nm, which can be at-
(+ )-C C -1065 Inhibition of D N A  Polymerase
Pu Py 1 2 3 4 5 6 7 8 9 10 11 12
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5ACCATGATTACGGATTCGAGATCAGCAGTCAGTTACGTAGATCAC3' 
  CGTCAGTCAATGCATC5'1JP
(+ K C -1065 (♦f-AB’C  (+)-ABC" (+>-ABC (+)-AB Control
A G T C  1 2 3 1 2 3 1 2 3  1 2 3 1  2 3  1 2 3
f ig u r e  3: Autoradiogram of the results of the thermally induced 
strand breakage assay (Reynolds et al., 1985) of 5Mabeled site-directed 
drug-modified T-45-mer used to locate the drug-modified adenine 
and determine the extent of drug modification. Pu and Py are AG- 
and TC-specific chemical sequencing reactions, respectively. Lane
1 refers to control DNA and lanes 3, 5, 7, 9, and 11 refer to T-45-mer 
modified with (+)-CC-1065, (+)-AB'C', (+)-ABC", (+)-ABC, and 
(-l-)-AB, respectively. Lanes 2, 4, 6, 8, 10, 11, and 12 are the same 
as the preceding lanes, except that they were heat treated (95 °C for
2 h). The DNA sequence around the drug-bonding site and the 
drug-modified adenine (arrowhead) are shown at left. The multiplicity 
of the bands is explained in footnote 2.
tributed to drug molecules when compared to the unmodified 
T-45-mer (data not shown). In addition, 5'-32P-end-labeled 
drug-modified ss D N A s were subjected to thermal treatment 
(Reynold et al., 1985) to induce D N A  strand breakage in order 
to identify the drug-modified adenine and also to monitor the 
extent of drug modification at the desired site. As shown in 
Figure 3, thermal treatment induced almost quantitative strand 
cleavage of drug-modified ss D N A  (lanes 4, 6, 8, 10, and 12) 
at the expected site on D N A  backbone2 (5'-GATTA*; asterisk 
indicates drug-modified adenine), while non-drug-modified ss 
D N A  subjected to thermal treatment (lane 2) or drug-modified 
ss D N A  not subjected to heating (lanes 3, 5, 7, 9, and 11) 
remained intact, indicating that all the templates were satu­
rated with drug molecules at the desired site.
Determination o f  the Extent o f  the Polymerization Reaction 
by Klenow Fragment on S ingle-S tranded D N A  Tem plates 
M odified  by (+)-C C -1065 and Select Analogues. When the 
drug-modified ss D N A  template was used, (+)-C C -1065 and 
its analogues were found to be strong blocks to progression 
of D N A  polymerase. While in control experiments using the 
highest concentration of dNTPs the major product was fully 
elongated primers, in the presence of drug-modified templates 
only small amounts of full-length molecules were synthesized 
(Figure 4). The same two major termination sites were found 
for all five drug-modified templates, in which at the highest 
concentration of dNTP (lane 3) the termination step was one 
nucleotide further than at the lower dNTP concentrations. The
2 The higher molecular weight bands appearing just above the band
corresponding to the covalently modified adenine (arrow) are attributed
to intermediates in the DNA backbone degradation (Reynolds et al.,
1985). Subsequent thermal treatment under alkaline conditions results
in conversion to the product migrating with the adenine sequencing re­
action. The bands appearing at the bottom of the gel are an artifact
created during electrophoresis and not a second species of DNA.
f ig u r e  4: Effect of dNTP concentration on the termination site of 
in vitro DNA synthesis by Klenow fragment on the ss drug-modified 
template shown at the top of the figure. Lanes A, G, T, and C refer 
to the dideoxy sequencing reactions carried out with Klenow fragment 
on 5'-32P-end-labeled 16-mer annealed to the T-45-mer. Lane headings 
refer to drug molecules used in template modification. Lanes 1, 2, 
and 3 are reactions containing 1,10, and 100 uM dNTPs, respectively. 
5'-32P-End-labeled 16-mers (50 nM) annealed to either the T-45-mer 
or the T-45-mer containing drug-DNA adduct were incubated with 
0.1 unit/VL (180 nM) Klenow fragment at 30 °C for 0.5 h as a 
function of dNTP concentration. The sequence within brackets is 
that of the primer-extended strand at the end of the sequence, and 
lower and upper arrowheads indicate the predominant termination 
sites of DNA synthesis at 10 and 100 /xM dNTPs, respectively. The 
nucleotide indicated by an asterisk is the nucleotide opposite the 
drug-modified adenine.
termination sites were mapped exactly by using dideoxy se­
quencing of a control template. The primary termination step 
that was found at 10 mM dN T P concentration (lane 2) was 
mapped at the second nucleotide prior to the drug-modified  
adenine, while at the highest concentration of dNTP (100 nM , 
lane 3) this termination site disappeared and a new one ap­
peared just one nucleotide prior to the drug-modified adenine. 
All the d ru g-D N A  adducts caused the same pattern of ter­
mination in D N A  synthesis mediated by the Klenow fragment, 
implying that each d ru g-D N A  adduct changed the D N A  
structure in a manner such that the base-pairing step was 
impaired at the nucleotide prior to the modified adenine, as 
well as at the drug-modified adenine. The amount o f bypass 
product was measured by densitometric scanning after auto­
radiography and expressed as a function of time at 10 and 100 
dNTP concentrations (Figure 5, top and middle panels), 
and the effect o f the amount of Klenow fragment on the 
formation of bypass product was also monitored (Figure 5, 
bottom panel). The extent of bypass product was reproducibly 
found to be dependent upon both d N T P  concentration and, 
to a lesser extent, concentration of Klenow fragment. This 
observation suggests that the cause of the termination o f D N A  
synthesis is predominantly the impairment of the base-pairing 
step at the adduct site, and this is a more significant factor 
than the lowering of the affinity of the Klenow fragment for 
the drug-modified D N A  template. D N ase I footprinting o f  
the Klenow fragment on D N A  in the presence and absence 
of drug also showed that D N A  polymerase binds equally well 
to the drug-modified D N A  template even after the polymerase 
reaches the drug-modified adenine (data not shown).
D eterm ination o f  the F idelity  o f  D N A  P olym erase in In­
corporation o f  a N ucleotide One Base Prior to  the (+)-C C -  
1065 M odification S ite. The D N A  polymerase incorporates 
the nucleotide 1 bp prior to the (+)-CC -1065 modification site 
only with low efficiency at 10 /xM dN T P concentrations. 
Therefore, we evaluated whether this step might also be carried 
out with lower than usual fidelity. For this experiment, four 
parallel incubations were prepared containing, in each case,
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f i g u r e  5: Effect of time of incubation (top and middle panels) and 
amount of Klenow fragment (bottom panel) on the extent of polym­
erase bypass product at a given concentration of dNTPs. In the top 
and middle panels are (5 - P-end-labeled 16-mer (50 nM) annealed 
to T-45-mer or drug-modified T-45-mer incubated with 10 and 100 
mM dNTPs, respectively. In the bottom panel the same amount of 
template DNA was incubated with 10 /xM dNTPs for 0.5 h with 
different amounts (in units) of Klenow fragment. Reactions were 
carried out with control template (O) and (+)-CC-1065- ( A ) ,  
(+)-AB'C'- ( • ) ,  (+)-ABC"- (A), (+)-ABC- (■), and (+)-AB- 
modified template (□).
10 nM  dNT P, but individual tubes contained just one of the 
four dNTPs at 100 mM. As expected, at 100 /xM dGTP, the 
primary pausing at the second nucleotide from the covalently 
modified adenine was removed, since dGTP is the comple­
mentary nucleotide for incorporation at the next site (Figure 
6, lane 3). However, while supplements with 100 nM  dTTP  
and dCTP did not cause elongation past the primary pausing 
site, a 100 nM  dATP supplement in the presence of 10 nM  
of each of the other dN T Ps allowed considerable passage to 
the secondary pausing site, which is presumably due to mis- 
incorporation of adenine opposite cytosine.
To further explore the possibility of misincorporation of 
bases at the site opposite this cytosine in the presence of
Sun and Hurley 
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f i g u r e  6 : Effect of dNTP concentration bias on Klenow fragment 
termination sites in the presence of site-directed (+)-CC-1065-modified 
ss templates. 5'-32P-End-labeled 16-mer (50 nM) annealed to T- 
45-mer modified with (+)-CC-1065 was incubated with 0.1 unit/^iL 
Klenow fragment for 30 min in the presence of the indicated amount 
of dNTPs. A, G, T, and C refer to dideoxy sequencing reactions with 
non-drug-modified templates. Lanes 1-6 contain 10 nM  dNTPs; 10 
mM dNTPs and 100 nM dATP; 10 nM dNTPs and 100 mM dGTP; 
10 mM dNTPs and 100 uM dTTP; 10 mM dNTPs and 100 mM dCTP; 
and 100 nM dNTPs in reaction mixtures, respectively.
5'CTGGAATCCGTAACTATGGTCGGTGATTACGTAGAGATCAGCGCTAGCATG3'
 1 CATCTCTAGTCGCGATCGTAC5,SIP
Control (+FCC-1065 (♦FAB'C' <+)-ABC" (+)-ABC
dAdG dT dC dAdGdTdC A G T C dA dG dTdC dA dGtfTdC dAdGcfTdC
f j .
f i g u r e  7: Misincorporation experiment without competing dNTPs 
for (+)-CC-1065-, (+)-AB'C-, (+)-ABC"-, and (+)-ABC-modified 
51-mer. To construct the template, which has a one-nucleotide gap 
between the 3'-end of the primer and the drug-modified adenine, a 
5'-32P-end-labeled 21-mer (45 nM) was annealed to T-52-mer or a 
site-directed drug-modified T-52-mer. Template DNA (45 nM) was 
incubated with 0.1 unit/juL Klenow fragment for 10 min in the 
presence of 100 /xM dATP (lane heading dA), dGTP (lane heading 
dG), dCTP (lane heading dC), or dTTP (lane heading dT). Lanes 
A, G, T, and C refer to dideoxy sequencing reactions with non­
drug-modified template.
(+ )-A B 'C ', (+ )-A B C ", and (+ )-A B C , as well as (+)-C C - 
1065, a second template (see Figure 7) was constructed in 
which the primer is complete up to the position at which 
guanine should be incorporated. Upon addition o f D N A  po­
lymerase and, in separate experiments, each dN T P at 100 nM  
concentrations, only in the case of (+ )-C C -1065  and dATP  
is misincorporation found to any significant extent (Figure 7). 
This experiment differs from the previous one in that no 
competing dNTPs were present in the inhibition mixture; 
nevertheless, it confirms the result shown in Figure 6.
Com parison o f  the D N A  P olym erase Term ination S ites  
Using Different Polym erases and Drug-Bonding Sequences. 
Since the bonding sequence 5'-AGTTA* shows such different 
reactivity with (+)-C C -1065 than 5'-GATTA* (Theriault et 
al., 1988), this sequence was also used in this investigation for 
comparison of termination sites using the Klenow fragment
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f ig u r e  8: Comparison of the extent of polymerization using Klenow 
fragment, E. coli DNA polymerase, and T4 DNA polymerase using 
a 5'-AGTTA drug-bonding sequence. 5'-32P-End-labeled 16-mer (50 
nM) was annealed to the T-44-mer or a drug-modified T-44-mer. The 
polymerization reaction was carried out with 0.1 unit/ML Klenow 
fragment, E. coli DNA polymerase, or T4 DNA polymerase in the 
presence of 100 mM dNTPs for 30 min. Lanes 1-5 refer to polym­
erization reactions with control, (+)-CC-1065-, (+)-AB/C/-, (+)- 
ABC"-, and (+)-ABC-modified templates, respectively. The sequence 
around the drug-bonding site is given to the left of the gel.
(Figure 8). Unexpectedly, even with the lowest dN T P con­
centration used (10 mM), the major termination site occurred 
at one nucleotide prior to the drug-modified adenine, and the 
minor termination site also occurred at the drug-modified 
adenine, in contrast to the previous experiments with the 
bonding sequence, 5 '-G A T T A -3\ in which termination oc­
curred two nucleotides prior to this adenine except at high 
concentration of dNTPs. Different kinds of D N A  polymerase 
were also used in this study and found to show a similar pattern 
of termination sites. This pattern of further extension of primer 
was observed irrespective of the 3'-side flanking sequence of 
the drug-bonding site and also with the different polymerases 
(data not shown). These results suggest that two different 
bonding sequences (5'-GATTA-3' and 5'-AGTTA-3') result 
in different types of association of the drug-modified template 
with D N A  polymerase and, consequently, different polymerase 
termination sites.
Determination o f  the Effect o f  Drug M odification o f  the 
Priming Site on the Polymerization Process. (+)-C C -1065  
and (+)-A B 'C ' are unique in this class o f compounds in that 
they are known to produce an unusual D N A  winding effect, 
which affects the periodicity of D N A  duplexes (Lee et al., 
1991). Our recent studies on the effect o f (+)-C C -1065 and 
related d ru g-D N A  adducts on T4 D N A  ligase (Sun & 
Hurley, 1992a) and helicase II (Sun & Hurley, 1992b) activity 
have also provided strong evidence that this D N A  winding 
exerted by (+)-C C -1065 and (+)-A B 'C ' on D N A  interferes 
significantly with the D N A  ligation or unwinding process. 
These observations led us to suspect that (+ )-C C -1065 and 
(+ )-A B 'C ' modification in the vicinity of the priming site of 
the template could potentially affect overall D N A  synthesis, 
since these drug molecules can affect the stability and the 
orientation of the 3' terminus of the D N A  primer. For this 
experiment, template D N A  molecules modified with each of 
the drug molecules shown in Figure 1 in proximity to the 
priming site were constructed and used in the polymerase 
reactions to monitor any differences in efficiency of D N A  
synthesis between different drug molecules. As shown in 
Figure 9, the modification of template D N A  with (+ )-C C -  
1065 and (+ )-A B /C/ severely blocked the elongation of primer 
D N A , while the modification with other analogues had little 
effect on this process. Since f+j-A B 'C ' and (+)-C C -1065 are
Control (+F-CC-1065 (+)-AB'C’ (+)-ABC" (♦)-AB
3 4 A G  T C  1 2 3 4  1 2 *  4 12 3 4
: : :  *W
a t
- • I
f ig u r e  9: Effect of drug modification of the template strand in the 
vicinity of the primer on the polymerase extension reaction. Templates 
(50 nM) modified with the drug molecules indicated by the lane 
heading were incubated with 1 unit (0.1 unit/VL) of Klenow fragment 
for 30 min in the presence of 10 mM (lane 1), 20 ^M (lane 2), 60 
mM (lane 3), and 80 uM (lane 4) dNTPs.
unique in producing winding of D N A , in addition to the 
bending and stiffening of D N A  that is common to all o f the 
drugs used in this study, we propose that it is the change in 
helical periodicity on the priming site produced by drug 
modification that is mainly responsible for the inhibition of 
the polymerization process. It is also important to note that 
the D N A  polymerase can still utilize the bent D N A  template 
produced by drug modification on the priming site.
D is c u s s io n
Using a ss tem plate containing a site-directed drug-(./V3- 
adenine)DNA adduct, we have shown that (+)-C C -1065 and 
its analogues (Figure 1) block in vitro D N A  synthesis mediated 
by Klenow fragment, E. coli D N A  polymerase I, and T4 D N A  
polymerase, presumably due to covalent modification of ad­
enine. This result is consistent with the previous reports that 
the cytotoxicity of (+)-C C -1065 is primarily mediated by the 
inhibition of D N A  synthesis rather than inhibition o f R N A  
or protein synthesis (Bhuyan et al., 1982), and the Sequenase 
results recently published (W eiland & Dooley, 1991). The 
ss templates used for the studies reported here were constructed 
from partial duplex D N A  molecules that contain a site-directed 
d ru g-D N A  adduct in the duplex region. The ss D N A  con­
taining the d ru g-D N A  adduct was purified by strand sepa­
ration on denaturing polyacrylamide gel electrophoresis. This 
was then annealed with a primer that is complementary to a 
sequence to the 3' side of the d ru g-D N A  adduct site. The 
stability of the covalent drug adduct during this treatment was 
determined by a spectrophotometric assay and an OP-Cu- 
phenanthrene footprinting assay of the drug-duplex adduct 
(unpublished results). In the latter case, the duplex for 
footprinting was constructed by annealing a complementary 
strand to a drug-modified ss D N A  prepared in the usual way. 
The saturation of the drug-bonding site and the location of 
the adduct on the template were determined by a thermal 
cleavage strand breakage assay (Reynolds et al., 1985). Each 
D N A  template that was constructed contained only one 
drug-modified adenine at full saturation at the desired site, 
which allowed us not only to quantitate the amount of po­
lymerase bypass product through the d ru g-D N A  adduct but 
also to determine the polymerase pausing site(s) caused by this 
adduct.
The results o f this study show that (+ )-C C -1 0 6 5 - and 
analogue-(7V3-adenine)DNA adducts were not absolute blocks 
for the different kinds of D N A  polymerase used in this study, 
since up to 25% full-length products were reproducibly ob­
served in (+)-A B -m odified  and other analogue-m odified  
templates. However, for the formation of bypass product, high
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concentrations of dNTP and DNA polymerase were required, 
together with longer time incubation compared to control 
template, which do not compare to the in vivo situation. 
Moreover, it is important to recognize that this work was 
carried out in vitro with an incomplete replication system. 
These results also suggest that drug modification of the 
template prevents the base-pairing process, rather than low­
ering the affinity of the DNA polymerase for the template at 
the drug-DNA adduct site, since polymerase binds equally 
well to drug-modified and unmodified templates (unpublished 
results).
Since (+)-CC-1065 is one of the most potent mutagenic 
agents known (Bhuyan et al., 1982), we also tested the pos­
sibility of drug-induced base misincorporation near the adduct 
site during the polymerization process. The results showed 
that the (+)-CC-1065-DNA adduct was particularly prone 
to produce misincorporation of the nucleotide prior to modified 
adenine when it was covalently attached to the sequence 5'- 
GATTA*-3' (* indicates the drug-modified adenine), while 
other (+)-CC-1065 analogues did not induce significant mis­
incorporation. This appears to be an unusual case, since most 
mutagenic compounds cause the base mispairing at the lesion 
site (Palejwala et al., 1991). However, in the particular se­
quence examined, only dA was significantly misincorporated 
for dG at the nucleotide prior to the modified adenine. Overall, 
these results imply that the potent mutagenicity of (+)-CC- 
1065 (Harbach et al., 1986) may be caused by the misin­
corporation of nucleotides during DNA synthesis. What has 
not been addressed in this present study is the possibility of 
misincorporation of nucleotides opposite the covalent adduct 
site and in the drug overlap region. Experiments are in 
progress using an M l3 viral DNA bearing a site-specific 
(+)-CC-1065-DNA adduct in a transfection system to in­
vestigate this possibility.
The DNA polymerase termination site could be modulated 
more significantly by increased dNTP concentration than by 
higher polymerase concentration. While the exact termination 
site was dependent upon the covalent bonding sequence, it was 
independent of drug structure within the (+)-CC-1065- 
evaluated series and type of DNA polymerase. Specifically, 
the primary (pausing) termination site for the polymerases was 
one nucleotide prior to the covalently modified adenine for the 
bonding sequence 5'-AGTTA*, but for 5'-GATTA* the pri­
mary pausing site was two nucleotides prior to the drug- 
modified adenine. The only difference between the two 
bonding sequences is the AG vs the GA step, 4 and 3 bps, 
respectively, to the 5' side of the covalently modified adenine. 
Since this apparent minor difference causes a change in the 
pausing site for the DNA polymerase, this is suggestive of a 
more significant conformational difference in the two drug- 
DNA adducts. We have noted other differences between these 
two sequences in relative reactivity to (+)-CC-1065 (Theriault 
et al., 1988), recognition by UvrA (Sun and Hurley, unpub­
lished results), and magnitude of drug-induced bending (Sun 
and Hurley, unpublished results). In addition, our recent 
two-dimensional *H- and 31P-NMR study on a 12-mer con­
taining the 5'-AGTTA sequence has revealed a transient kink 
associated with the 5'-AC and 5'-CT steps on the comple­
mentary strand opposite 5'-AGT (Lin et al., 1992). This 
observed difference in polymerase pausing site may be yet 
another indication of the unique structure of the highly reactive 
sequence 5'-AGTTA and, consequently, its unique secondary 
structure as the drug-DNA adduct (Lin & Hurley, 1992).
The main purpose of this investigation was to determine the 
effect of (+)-CC-1065-modified DNA template on polymerase
extension past the adduct site. The results show that, irre­
spective of the (+)-CC-1065 analogue tested, the in vitro DNA  
synthesis on a ss template is inhibited to about the same extent. 
This was surprising, since (+)-CC-1065 and the analogues 
used here show different levels of cytotoxicity and antitumor 
activity, and only (+)-CC-1065 and (+)-AB/C/ show the 
delayed lethality (McGovren et al., 1984; Warpehoski et al., 
1988). However, what is dramatically different is the effect 
(+)-CC-1065 and (+)-AB'C' have on polymerization from a 
primer site containing a drug lesion in the duplex region 
relative to (+)-ABC, (+)-AB, and (+)-ABC". While (+)- 
CC-1065 and (+)-AB'C/ selectively inhibit DNA synthesis 
from a primer in a duplex region containing the adduct (see 
template inset in Figure 9), the other drugs have little effect 
on the polymerase activity. (+)-CC-1065 and (+)-AB/C/ are 
unique not only in this selective effect on DNA polymerase 
but also in producing an unusual winding effect alongside the 
bending and stiffening of the helix common to other members 
of this drug series (Lee et al., 1991). This winding effect, 
which changes the periodicity of DNA by about the equivalent 
of 1 base pair per adduct site, is associated with the inside-edge 
substituents of the pyrrole rings of subunits B and C (see 
Figure 1) and has also been associated with a much stronger 
inhibition of T4 ligase (Sun & Hurley, 1992a) and helicase 
II catalyzed unwinding of DNA (Sun & Hurley, 1992b). 
Since these compounds are also unique in producing the de­
layed lethality in mice, the winding effect is a possible can­
didate.
In conclusion, covalent modification of DNA molecules with 
(+)-CC-1065 and its analogues was found to be a strong 
hindrance to in vitro DNA synthesis mediated by E. coli DNA 
polymerase, Klenow fragment, and T4 polymerase and to cause 
pretermination of polymerization around the adduct site, which 
then inhibits the DNA replication process.
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Inhibition of T4 DNA ligase activity 
(+)-CC-1065: demonstration of the 
importance of the stiffening and winding 
effects of (+)-CC-1065 on DNA
Daekyu Sun & Laurence H. Hurley
Drug Dynamics Institute, College o f  Pharmacy, University o f  Texas at Austin, 
Austin, T X  78712, USA
Summary: Non-denaturing gel electrophoresis analysis demonstrates that the stiffen­
ing and winding effects of (+)-CC-1065 produce unusual proximal and distal inhibition 
of T4 DNA ligase-catalysed ligation of covalently modified DN A. (+)-CC-1065 is a 
potent antitumor antibiotic produced by Streptomyces zelensis. This drug selectively 
bonds through N3 of adenine in DNA and lies in the minor groove of D NA, reacting 
in a highly sequence-selective manner. Previous studies (Lee et al., 1991) have shown 
that (+)-CC-1065 produces bending and winding of DNA. The DNA bending and 
sequence specificity is mediated by the alkylating ‘A ’ subunit of (+)-CC-1065, while 
the close van der Waals contacts between the non-alkylating B and C subunits of (+ )-  
CC-1065 and the floor of the minor groove of DNA are responsible for the winding of 
DNA. Covalent modification of oligomers with (+)-CC-1065 and structurally related 
drugs leads to preferential inhibition of T4 DNA ligase on the non-covalently modified 
strand to the 5' side of the covalent adduct site, but enhanced ligation of the covalently 
modified strand. We speculate that the differential effect on proximal strand ligation is 
due to a drug-induced winding and helix-stabilizing effect which occurs predominantly 
to the 5' side of the adduct. In addition to the proximal inhibition of ligation, we also 
describe a distal inhibition of T4 DNA ligase activity which occurs exclusively with 
drug-modified oligomers and that, if successful, would result in 180° out-of-phase bent 
DNA following ligation. In this case, two 25 mers or a 21 plus a 29 mer are inhibited 
from ligation when modified with (+)-CC-1065. This distal ligation is unique to (+ )-  
CC-1065 and its analogs that cause stiffening of the DNA helix. The (+)-CC-1065- 
induced stiffening effect was demonstrated using a circularization assay and was found to 
be associated with the close van der Waals contacts between the inside edge of (+)-CC- 
1065 and the floor of the minor groove, and also to the benzofuran moiety of (+)-ABC" 
(Adozelesin), a (+)-CC-1065 analog. We conclude from these studies that the DNA- 
winding and helix-stabilizing effects of these drug molecules can dramatically affect the 
efficiency of proximal ligation mediated by T4 DNA ligase, and the unusual helix- 
stiffening effect of (+)-CC-1065, (-f-)-AB'C' and (+)-ABC" can stabilize the structure 
of bent DNA formed by drug modification, which results in distal ligase inhibition. 
Key words: (+)-CC-1065/DNA ligase inhibition/DNA stiffening/DNA winding
Introduction
D N A  is believed to be the ultimate target for many of the drugs that show potent cyto­
toxicity and antitumor efficiency (Hurley, 1977; Dickerson e ta l., 1987 ;Tomasz eta l., 1987;
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Received 20 June J99J; accepted 29 August 1991
16 D. SUN & L.H. HURLEY
Hurley & Boyd, 1988). A s a possible means o f defining the molecular mechanisms of  
selective drug action, the structural changes occurring in D N A  molecules as a result of 
interactions between DNA-active drugs and D N A  have been extensively studied (Gale et 
al., 1981). These structural changes in D N A  presumably affect important biological 
processes, such as replication, transcription and recombination, that occur on D N A  
(Pommier et a l., 1987; Haran & Crothers, 1988; Rice et al., 1988; Travers, 1990; Lee et 
al., 1991). Recently, we have suggested that it is insufficient to merely consider D N A  as 
the ultimate intracellular target, but the real receptors may be D N A -protein  complexes 
(Hurley & Boyd, 1987, 1988; Hurley, 1989, and references therein).
Previous studies from Texas and the Upjohn Company with (+)-CC-1065, an anti­
tumor antibiotic produced by Streptomyces zelensis, have revealed that the D N A  alkyla- 
tion by this drug is responsible for the potent cytotoxic and antitumor effects that are 
produced as a consequence of formation of the (+ )-C C -1065-D N A  adduct (Swenson et 
al., 1982; Hurley & Needham VanDevanter, 1986; Reynolds e ta l.,  1986; Warpehoski et 
al., 1988). Alkylation of D N A  by (+)-CC-1065 produces an (N 3-adenine)-D N A  adduct 
in which the drug molecule lies within the minor groove covering a four and one base pair 
region to the 5' and 3' side, respectively, o f the covalently modified adenine (Hurley et 
al., 1984; Scahill et a l., 1990). Thermal treatment of the (+ )-C C -1065-D N A  adducts 
le&ds to loss of the (+)-C C -1065-N 3-adenine adduct and subsequent D N A  backbone 
strand breakage to the 3' side of the covalently modified adenine (Figure 1) (Reynolds et 
al., 1986). This drug-induced strand breakage assay has been used in two different 
studies to determine the D N A  sequence selectivity of (+)-CC-1065. In the first study 
(Reynolds et a l., 1986), two subsets of consensus bonding sites [5'PuNTTA*3' and 
5 'A A A A A *3', where (*) indicates the covalently modified adenine and N  indicates any 
of four bases in D N A ] were identified, while in a more recent study the consensus 
sequence (5 'A /T , A /T , A*3') was found (Hurley et a l., 1990). In previous publications, 
we have argued that the primary basis for the sequence specificity o f (+)-CC-1065 is a 
sequence-dependent catalytic activation and/or sequence-dependent conformation flexi­
bility (Hurley e ta l., 1988; Warpehoski & Hurley, 1988). Using high-field NM R on a (+ )-  
C C -1065-12 mer duplex adduct, we have recently provided circumstantial evidence for 
the involvement o f two water molecules and phosphate catalysis in this reaction (Lin et 
al., 1991b). M oreover, we have demonstrated that (+)-CC-1065 induces local bending 
(between 17 and 19° in towards the minor groove), winding and stiffening o f the D N A  
helix as a consequence o f covalent adduct formation (Lee et al., 1991). Using a combina­
tion o f hydroxylradical footprinting analysis, non-denaturing analysis and high-field 
NM R studies, we have also shown that (+)-CC-1065-induced D N A  bending appears to 
have structural characteristics (i.e. narrowing of the minor groove and bending in 
towards the minor groove o f D N A ) that are quite similar to those that are intrinsically 
associated with A-tracts (Lin et al., 1991a).
In spite of this novel mechanism of action of (+)-CC-1065 and its high in vivo  and in 
vitro antitumor activity, clinical development of the natural product was precluded by an 
unusual toxicity, which led to delayed lethality in mice receiving therapeutic doses 
(M cGovren et a l., 1984). To circumvent this problem, analogs have been synthesized  
that are more efficacious, do not cause delayed death and that, therefore, show consider­
able promise as chemotherapeutic agents. One such agent, Adozelesin, has recently 
been introduced into phase I clinical trials (J.P. McGovren, Upjohn C o., private com­
munication).
The (+)-C C -1065 molecule consists o f three repeating pyrroloindole subunits, one of  
which, the ‘A ’ subunit, contains the DNA-reactive cyclopropyl function (Figure 2). 
Naturally occurring (+)-CC-1065 and synthetic analogs having the same stereochemical 
configuration of the cyclopropane ring in the ‘A ’ subunit are designated (+ )-
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Figure 1 Reaction of (+)-CC-1065 with D N A  to form the (+)-C C -1065-(N 3- 
adenine)-D N A  adduct and products of heat-strand breakage of modified D NA. 
Species ‘A ’ is the first product produced by thermal treatment and is converted into 
species B ’ by further thermal treatment or subsequent piperidine treatment 
(Reynolds et al., 1985)
en an tiom ers. T h e structures o f  ( +  )-C C -1065 and se lec t syn th etic  ( +  )-en an tiom eric  ana­
logs used  in this in vestigation  are show n in F igure 2. F acilitated  by the ex ten sive  array o f  
an alogs syn th esized  by U p joh n  scien tists (W arp eh osk i, 1986; K elly  et a l.,  1987; W arp e­
h oski & B radford , 1988; W arpehosk i e t a l . ,  1988), stru ctu re-activ ity  relationships have 
b een  sharply defined  (L ee  et a l.,  1991). O f particular sign ificance is our ob servation  that 
the ‘A ’ subunit o f  (+ )-C C -1 0 6 5  has sufficient structural in form ation  to  elicit the primary  
basis for the seq u en ce specificity  o f  (+ )-C C -1 0 6 5  and to  induce an d /or entrap D N A  
b en din g through the form ation  o f  the D N A  adduct (H u rley  e t a l . ,  1988; L ee et a l.,  1991). 
H o w ev er , there are still som e u ncerta in ties con cern in g  the precise structural features o f
















Figure 2 Structures of (+)-CC-1065 and selective analogs used in this study
(+)-C C -1065 that are responsible for D N A  duplex winding, helix stiffening and stabiliz­
ing effects, and, of equal importance, the biological consequences associated with these 
unusual effects of drug binding and bonding on D N A  structure.
T4 D N A  ligase was used as a molecular target in this study in an attempt to under­
stand more clearly the biochemical consequences of the helix-stabilizing and D N A - 
winding effects of (+)-C C -1065 and related molecules. T4 D N A  ligase catalyzes the 
formation o f a phosphodiester bond between a directly adjacent 3 '-hydroxyl and acti­
vated 5'-phosphoryl groups in duplex D N A  (Lehman, 1974; Shore et al., 1981). We 
suspected that phosphodiester bond formation catalyzed by T4 might be adversely 
affected by the restricted mobility and change in the relative orientation of the 3'- 
hydroxyl and 5'-phosphoryl groups, which would be achieved by the helix-stabilizing and 
DNA-winding effects o f drug molecules, respectively (Goffin et a l., 1987). The helix- 
stiffening effects o f (+)-C C -1065 and its analogs were also investigated by using two­
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dimensional gel electrophoresis. In this case, the efficiency of circular D N A  formation 
was monitored since the circularization of bent D N A  would be expected to be affected 
by change in D N A  flexibility that could be induced by the DNA-stiffening effects of drug 
molecules (Shore et a l., 1981; Ulanovsky et a l., 1986; Zahn & Blattner, 1987). In this 
paper, we have characterized two types of inhibition of ligation. The first type we have 
called proxim al ligase inhibition and the second, distal ligase inhibition. While the 
proximal ligase inhibition occurs near the drug bonding site and diminishes as the 
distance between the two sites is increased, the distal ligase inhibition occurs only when 
the two drug bonding sites are on opposite sides o f the helix (i.e . 180° out of phase) and is 
unrelated to the proximity of the ligation site to the drug bonding site.
Materials and methods
Materials
(+)-CC*T065 and the synthetic analogs (Figure 2) used in this study were obtained from 
J. Patrick McGovren at the Upjohn Company, Kalamazoo, MI. Electrophoretic re­
agents [acrylamide, N ,N ,N ’ ,N'-tetra. methylethylenediamine (TEM ED ), ammonium  
persulfate and bis-(acrylamide)] were purchased from Biorad. T4 D N A  ligase and T4 
polynucleotide kinase were from BRL. [r-32P]ATP was from ICN, and X-ray film, inten­
sifying screens and developing chemicals were from Kodak.
Methods
Design and synthesis o f  oligonucleotides. A  series of oligonucleotides (see Table I) was 
designed to contain a unique drug bonding site and synthesized on an automated D N A  
synthesizer (Applied Biosystem 381A) using the phosphoramidite method (Gait, 1984). 
The oligomers were then deprotected separately with saturated ammonium hydroxide at 
55°C overnight, dried under vacuum and redissolved in double-distilled water (D D W ).
Preparation o f  labeled duplexes, nicked duplexes, and unlabeled duplexes. About 10 |xg 
of each oligonucleotide o f complementary sequence was kinased in 23 p.1 of solution 
containing 70m M  Tris-H C l (pH 7.6), lOmM MgCl2, and 5m M  dithiothreitol, [r- 
32P]ATP and 10U  T4 polynucleotide kinase at 37°C for l h .  After labeling with [r- 
32P]ATP, 1 (xl of 0.1 M cold ATP and an additional 5 U  of T4 polynucleotide kinase were 
added, and the kinasing reaction was continued at 37°C for 1 h. Reaction mixtures were 
heated to 55°C and cooled slowly to room temperature to form duplex D N A .
For the labeling of only one strand o f duplex, the chosen strand of the duplex was 
labeled with [r-32P]ATP separately and hybridized to an excess of a complementary 
strand kinased with cold ATP. Nicked duplexes (42/40 and 40/42 in Table I) were 
constructed by annealing labeled 21-11 (+ )  or ( —) strand oligomer with the comple­
mentary 40m ers.
Purification o f  labeled duplexes, nicked duplexes, and non-labeled duplexes. After 
annealing both of the complementary strands, resulting duplexes labeled with 
[r-32P]ATP were electrophoresed on 8% non-denaturing polyacrylamide gel electro­
phoresis for 5 h at 7 V /cm  and located by autoradiography. Duplexes were excised from 
the gel, minced with a blade and extracted with 800 |xl o f annealing buffer [100 mM NaCl, 
10mM Tris-H C l (p H 8.0)]. The location of non-labeled duplexes was visualized under 
short U V  light against a fluorescent background.
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Table I Sequence of synthetic oligonucleotides used in this study
21-1: 5 ' T G G G C G G A G T T A G G G G CG G G A  3 '
3 ' C G C C T C A A T C C C C G C C C T A C C 5 '
21-11: 5 ' T G G C G A G T T A G G G G G G CG G G A  3 '
3 ' G C T C A A T C C C C C C G C C C T A C C 5 '
21-111: 5 ' T G G A G T T A G CG G G G G G C G G G A  3 '
3 ' T C A A T C G C C C C C C G C C C T A C C 5 '
21: 5 ' G A G G A C C A T G A T T A C G G A T T C 3  '
3 ' C T G G T A C T A A T G C C T A A G C T C 5 '
23: 5 ' G A G T G A C C A T G A T T A C G G A T T C A 3 '
3 ' A C T G G T A C T A A T G C C T A A G T C T C 5 '
25: 5 ' G A G G T G A C C A T G A T T A C G G A T T C A C  3 '
3 ' C A C T G G T A C T A A T G C C T A A G T G C T C 5 '
27: 5 ' G A G T G T G A C C A T G A T T A C G G A T T C A C T 3  '
3 ' A C A C T G G T A C T A A T G C C T A A G T G A C T C 5 ' 
29: 5 ' G A G C T G T G A C C A T G A T T A C G G A T T C A C T G 3  '
4 2 / 4 0 :
3 ' G A C A C T G G T A C T A A T G C C T A A G T G A C C T C  5 '
i
5 ' T G G C G A G T T A G G G G G G C G G G A T G G C G A G T T A G G G G G G C G G G A  3 '
3 ' C C G C T C A A T C C C C C C G C C C T A C C G C T C A A T C C C C C C G C C C 5 ' 
4 0 / 4 2 :
5 ' G A G T T A G G G G G G C G G G A T G G C G A G T T A G G G G G G C G G G A T G 3 '
3 ' G C T C A A T C C C C C C G C C C T A C C G C T C A A T C C C C C C G C C C T A C C  5 '
 t__________________________
O l i g o m e r s  21, 23, 25, 27 a n d  29 c o n t a i n  a  ‘5' G A T T A 3”  a s  a  d r u g  b o n d i n g  s i t e ,  a n d  21-1,11 
a n d  I I I  c o n t a i n  a  ' 5' A G T T A 3' ’ a s  a  d r u g  b o n d i n g  s i t e .  U n d e r l i n e d  l e t t e r s  i n d i c a t e  t h e  d r u g  
b o n d i n g  s i t e .  B a s e d  o n  a  t h e r m a l  c l e a v a g e  s t r a n d - b r e a k  a s s a y  ( R e y n o l d s  e t  al., 1985) ,  d r u g  
b o n d i n g  a t  t h e  d e s i g n a t e d  s e q u e n c e  w a s  a t  l e a s t  95%  s p e c i f i c  f o r  t h i s  a d e n i n e  a n d  v i r t u a l l y  
c o m p l e t e  s a t u r a t i o n  b o n d i n g  w a s  o b t a i n e d .  A s  a  s e c o n d  m e a n s  t o  c h e c k  b o n d i n g  s p e c i f i c i t y ,  
w e  h a v e  f o u n d  t h a t  u n l e s s  s a t u r a t i o n  b o n d i n g  o c c u r s  a t  j u s t  o n e  s i t e ,  w e  d o  n o t  o b s e r v e  
d i s c r e t e  b a n d s ,  a s  s h o w n  in  F i g u r e s  4 a n d  8. ( | ) a n d  ( | )  i n d i c a t e  t h e  n i c k i n g  s i t e  o n  t h e  
n i c k e d  d u p l e x e s .
D ru g  m o d ifica tion  a n d  liga tion  reaction . For drug m odification , 50 |xl a liq u ots o f  d up lex  
o lig o m ers ( ~  1 |xg D N A )  w ere in cu bated  with the sam e volum e o f  eith er 28 ptM o f  ( + ) -  
A B C , ( +  ) -A B 'C ', (+ )-A B C " , or (+ )-C C -1 0 6 5  at room  tem perature for 3 days, fo llow ed  
by an eth an o l p recip itation  to rem ove unbound drug m olecu les. In b en din g exp er im en ts , 
d ru g-m odified  and n on -m od ified  d u p lexes w ere se lf-ligated  to produce m ultim ers in 25 |xl 
o f  ligation  buffer w ith 1 U  T 4 D N A  ligase at room  tem perature overnight. T h e ligation  
b uffer con ta in s 25 m M  T r is -H C l (p H  7 .6 ) ,  5 m M  M gC l2, 2.5%  (w /v ) p o lyeth y len e  g lycol 
8000 , 0 .5  m M  A T P  and 0 .5  m M  d ith iothreito l. L igated  m ultim ers w ere e lec tro p h o resed  
on  an 8% n on-denaturin g  p olyacrylam ide gel and visualized  by autoradiography. N ick ed  
d u p lex es (4 0 /4 2  and 4 2 /4 0  in T ab le  I) w ere drug m odified  as described  ab ove and ligated  
in 25 |jl1 o f  ligation  reaction  m ixtures con ta in ing  0 .2  |xg o f  D N A  and 1 U  o f  ligase at room  
tem p eratu re for 12 h.
C ircu lariza tion  experim en t. T w o-d im en sion a l gel e lectrop h oresis was carried out 
accord in g  to  the m eth od  d escrib ed  by U lan ovsk y  (U lan ovsk y  et a l.,  1986) to  m on itor
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the formation of circular D N A  as a consequence of the ligation of drug-modified 21-1 
(Table I). In the first dimension of electrophoresis, the ligation reaction mixtures of 
drug-modified or control oligomer were electrophoresed on an 8% non-denaturing 
polyacrylamide gel until the bromophenol blue marker reached the bottom of the gel. 
The gel slice containing the D N A  was then cut out of the gel, soaked in 1 x  T ris-borate- 
E D T A  (TBE) buffer [2mM  E D T A  and 90 mM Tris-boric acid (pH 8.3)] containing 
50 (xg/ml chloroquine phosphate and then positioned on top o f a glass plate, followed by 
polymerization with 8% polyacrylamide solution containing 50 p-g/ml chloroquine phos­
phate. The second dimension of electrophoresis was carried out in the presence of 
chloroquine phosphate (50 p-g/ml) in running buffer and the gel was then exposed to X- 
ray film overnight to locate the position of each species of D N A  molecule.
D N A  size determination. The size and species of ligated multimers were analyzed by 
using denaturing polyacrylamide gel electrophoresis. The location of radioactive spots 
representing D N A  molecules was determined by autoradiography and these correspond­
ing gel slices were removed from the gels (two-dimensional gels or bending experi­
m ents), crushed and the D N A  was extracted with distilled water. The solution containing 
the eluted D N A  was lyophilized, redissolved in 100 pi o f D D W , ethanol precipitated and 
dried under vacuum. Dried D N A  pellets were dissolved in 90% (w/v) formamide in 
0.1 M Tris-H C l (p H 7.8), boiled for 15 min and cooled in ice just before running 8% 
denaturing polyacrylamide gel electrophoresis (7 M urea) in the presence of molecular 
size markers.
Results
(+)-C C -1065 and its analogs preferentially inhibit the T4 D N A  ligase-catalyzed 
reaction on the non-drug-modified strand o f  D N A
To determine the effect o f drug modification on the ligation o f 21 bp oligomer duplexes 
mediated by T4 D N A  ligase, three different oligomers (21-1, 21-11 and 21-111 in Table I) 
were designed to vary in distance from the 5' end of the oligomers to the drug modifica­
tion site by 12, 10 and 8 bp, respectively. The three oligomers were self-ligated to 
produce multimers and electrophoresed on 8% polyacrylamide gel electrophoresis. As 
shown in Figure 3, drug-modified D N A  showed the expected retardation of electrophoretic 
mobility after ligation into multimers, in accord with the previously demonstrated drug- 
induced D N A  bending, which results from covalent modification of the oligomers (Lee et 
a l., 1991). These oligomers were 5'-labeled with [r-32P]ATP in separate experiments on 
each strand in order to measure the efficiency o f the ligation on both strands. Both 42 
and 63 bp D N A  molecules, which represent dimers and trimers, respectively, were 
isolated from the gel and analyzed on denaturing gels to measure the efficiency of the 
ligation reaction. Inhibition of ligation was not observed on the drug-modified strand in 
the presence o f any of the drugs with 21-1, 21-11 or 21-111 (data not shown). Figure 4 
shows a comparison of the ligation efficiency on the non-drug-modified strand of the 42 
and 63m ers between oligomers 21-1, 21-11 and 21-111 in control experiments (non-drug 
modified) or modified with (+)-C C -1065, (+ )-A B 'C ', (+)-ABC", and (+ )-A B C . While 
the 42 and 63m ers representing ligation products from control 21-11 and 21-111 show 
ligation efficiencies o f >70% , those from drug-modified 21-11 and 21-111 show dramatic­
ally decreased ligation of non-drug-modified strands, in order of decreasing efficiency 
from (+ )-A B C >  (+ )-A B C " >  (+ )-A B 'C ' =  (+)-CC-1065. (The percentage efficiency 
of ligation was calculated by comparing the amounts of 63 and/or 42m ers to the total 
amount of radioactivity in each sample.) This is the same relative order as the increasing
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Figure 3 Electrophoretic behavior of ligated multimers of 21-1, II and III oligomers 
modified with drug molecules on 8% non-denaturing polyacrylamide gel. Lane 1 of 
each panel is ligated multimers of control 21-1, II and III, respectively. Lanes 2, 3, 4 
and 5 are ligated multimers of each oligomer modified with ( + )-CC-1065, (-l-)-AB'C', 
(-t-)-ABC and (-l-)-ABC", respectively. 21, 42 and 63 refer to the size of ligated 
multimers. The upper, more intense and narrow bands in 21-1 and 21-11 are circular 
D N A
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DNA-stabilizing effect (i.e . from (+ )-A B C <  (+ )-A B C " < (+ )-A B 'C ' <  (+)-C C -1065), 
suggesting that the drug-induced DNA-stabilizing effect is directly related to the extent 
of proximal ligation inhibition. In unpublished experiments (D . Sun and L .H . Hurley), 
we have shown that the ligation of the covalently modified strand is normal even when 
the drug modification site is only 7 bp away from the ligation site. The major finding is 
that proximal ligation inhibition was only observed when the drug modification site was 
within 10 bp from the 5' end of the duplex, and then only on the non-drug-modified 
strand.
(+ )-CC-1065 and analogs prevent T4 D N A  ligase from  nick sealing only on the non-drug- 
m odified strand
To further define the underlying mechanism of the proximal ligation inhibition caused by 
drug modification, two kinds of nicked duplexes (40/42 and 42/40 in Table I) were 
constructed, each of which contained a nick near the center of the duplexes on either the 
drug-modified or non-drug-modified strand. The drug bonding site was designed to be 
located 7 bp from the nick in duplex 40/42 and 10 bp from the nick in duplex 42/40. A  
comparison of the efficiency of nick-sealing activity by T4 ligase between drug-modified 
and non-drug-modified nicked duplexes is shown in Figure 5. The amount of ligated 
products was quantified by laser scanning of the autoradiogram. As shown in Table II, 
drug modification caused inhibition o f ligation on non-drug-modified strands (in du­
plexes 40/42) in the order (+)-CC-1065 =  (+ )-A B 'C ' >  (+)-A BC " >  (+ )-A B C , whereas 
the nick-sealing activity o f T4 D N A  ligase on drug-modified strands was enhanced after 
drug modification relative to control ligation. The kinetics o f the nick-sealing efficiency 
of T4 D N A  ligase on these nicked duplexes modified with different drug molecules was 
studied to elucidate the difference between modification with the different drug m olecules. 
The results in Figure 6 show that drug modification suppresses the ligation of a non-drug- 
modified strand, but enhances the ligation of drug-modified strands. These apparent 
opposite effects of drug modification in the nick-sealing activity of T4 D N A  ligase can be 
rationalized based on our understanding of the basic mechanism for T4 D N A  ligation 
(Lehman, 1974; Shore e ta l ., 1981). It is known that in the ligation reaction the activated 
5'-phosphoryl group undergoes nucleophilic attack by the 3'-hydroxyl group to form a 
new phosphodiester bond between the adjacent 3 '-hydroxyl and 5'-phosphoryl groups in 
duplex D N A . We propose that the helix-stabilizing effect of drug molecules can restrict 
the motion of the 3'-hydroxyl group, which results in a lowering of the efficiency of 
formation of the new phosphodiester bond in the non-drug-modified strand, while 
immobilization of the 5 '-activated phosphoryl group facilitates the nucleophilic attack of 
the 3 '-hydroxyl group to the 5 '-phosphoryl group in the drug-modified strand. Moreover, 
since only (+)-CC-1065 and (+ )-A B 'C ' have the unique DNA-winding effect that 
presumably changes the juxtaposition of the 3'-hydroxyl and 5'-phosphoryl groups in 
normal B-type duplex D N A , their winding effect causes an increased inhibition of 
ligation compared to (+)-A BC " and (+ )-A B C . This observation provides an explanation 
for the greater inhibitory effect o f (+)-CC-1065 and (+ )-A B 'C ' on the proximal ligation 
catalyzed by T4 D N A  ligase. The observation of an adenylated intermediate in the case 
of the non-drug-modified strand is additional support for our proposed mechanism for 
inhibition of ligation.
(+)-CC -1065, (+ )-A B 'C ' and (+ )-A B C ' cause distal inhibition o f  T4 D N A ligase
In the course of studying D N A  bending produced as a consequence of drug modification 
of D N A , it was observed that (+)-C C -1065, (-l-)-AB'C' and (+)-A BC " caused an
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inhibition o f ligation of oligomers in which the drug bonding sites in the products would 
be spaced 25 bp apart, while oligomers having shorter distances between the drug 
bonding sites (i.e . 21 and 23 bp) were ligated with greater efficiency. Since this was an 
unexpected result, we designed a series of oligomers in which the distances between the 
drug bonding sites in the ligation products would be 23, 25 ,27  and 29 bp (Table I). Figure 
7 shows the autoradiogram of the ligation products of 23, 25, 27 and 29 bp oligomers 
(Table I) modified with (+)-C C -1065, (+ )-A B 'C , (+)-A BC " and (+ )-A B C . The size 
distribution of ligated products of these oligomers in control D N A  and D N A  modified 
with (+)-C C -1065 is plotted in Figure 8A  and B , while the size distribution of 25mers 
modified with (+)-C C -1065, (+ )-A B 'C ', (+)-ABC" and (+ )-A B C  is plotted in Figure 
8C. These results show that the (+)-C C -1065-, (+ )-A B 'C '-, and (+)-ABC"-modified  
25m er oligomers are unfavorable substrates for T4 D N A  ligase, while the ( + ^ABC- 
modified 25m er and the other oligomers (23, 27 and 29 bp) modified with any of these 
drugs did not show any remarkable inhibition o f ligation. A  unique feature of those sub­
strates that show inhibition o f the ligation reaction is that the ligation products from 
these 25m ers would be D N A  molecules containing bends that would be 180° out of 
phase, since the drug-modification sites on the two substrate molecules are separated 
from each other by ~ 2 .5  helical turns. These results pose two questions: (1) why is 
T4 D N A  ligase unable to effectively ligate monomeric bent D N A  to form out-of-phase 
bent D N A  and (2) why is this inhibitory effect on ligation found with (+)-CC-1065, 
(+ )-A B 'C ' and (+)-A B C ", but not with (+ )-A B C ?
(+ )-C C -1065 inhibits T4-mediated ligation o f  monomeric bent oligom er D N A  molecules 
that would produce out-of-phase bent D N A
The results in Figure 7 clearly show the overriding tendency of the T4 D N A  ligase to 
avoid the formation o f 180° out-of-phase bent D N A  from the monomeric bent oligomer 
D N A , which is produced as a consequence of the drug modification. In order to farther 
probe the question o f why the formation by T4 D N A  ligase of out-of-phase bent D N A  is 
preferentially excluded from the ligation process, co-polymerization experiments were 
carried out between radioactively labeled 21 oligomers modified with (+)-CC-1065 or 
(+ )-A B C  and, in each case, a 4M  excess of unlabeled 23, 25, 27 and 29m er oligomer 
modified with the same drug molecules. Unlabeled oligomer D N A  molecules can be 
ligated to labeled oligomer, since they were designed to have the same cohesive ends.
Figure 9 shows that the heterodimerizing process between 21 and 29m er oligomers 
modified with (+)-C C -1065 is prohibited, while the homodimerization of the 21 mer 
oligomer modified with (+)-CC-1065 is predominant, despite the presence of a 4molar
Figure 4 Proximal ligation inhibition caused by drug modification within 10 bp from 
the 5' end of the oligomer duplex. For this experiment, only non-drug-modified 
strands of 21-1, II and III oligomers were labeled with [r-32P]ATP and ligated to 
produce multimers after drug modification. From the non-denaturing polyacrylamide 
gel in Figure 3, 42 and 63mers were extracted and analyzed on sequencing gel 
electrophoresis, as described in Materials and methods, to monitor the amount of 
ligation of the non-drug-modified strand.
(A) Analysis of 42mers ligated from 21-1 (a), II (b) and III (c) modified with drug 
molecules. Lanes 1-5 represent control, (+)-CC-1065, (+ )-A B 'C \ (+)-ABC  
and (+)-ABC", respectively. The numbers indicate the size of single-strand 
D NA and (I) refers to the adenylated intermediate present in ligation mixtures, 
which shows slower migration than 21 bp single-strand DNA.
(B) As for (A ), except this is an analysis of 63 mers ligated from 21-1 (a), II (b) and 
III (c) modified with drug molecules
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T4 DNA 
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Figure 5 The effect of drug modification on nick sealing activity of T4 DNA ligase.
(A) Schematic diagram showing the nick-sealing reaction of nicked duplexes medi­
ated by T4 D N A  ligase and the subsequent strand breakage reaction to monitor 
the extent of ligation. For the heat-strand breakage reaction, DNA samples 
were heated for 2h  at 95°C.
(a) Non-drug-modified strands are converted into 42m ers after complete liga­
tion.
(b) Drug-modified strands are ligated into a 42m er containing two adducts 
and, subsequently, cleaved by thermal treatment into a 5' end-labeled  
9m er and a 20mer labeled internally.
(B) Denaturing gel analysis o f ligated products of nicked duplexes after thermal 
treatment. Panels a and b refer to the analysis of non-drug-modified and drug- 
modified strands, respectively. Lanes 1 -5  represent control, (+)-CC-1065-, 
(-l-)-AB'C'-, (+)-ABC"- and (-f-)-ABC-modified nicked duplexes, respectively. 
The numbers indicate the size of single-strand D N A  and (I) refers to the 
adenylated intermediate of ligation products. The two different species of 9 bp 
single-strand D N A  were generated as described in Figure 1
ex cess  o f  the 2 9 m e r  o lig o m er m odified  w ith (+ )-C C -1 0 6 5  in the reaction  m ixture. In the  
case o f  the h eterod im er iz in g  p rocess b etw een  th e 21 m er o lig o m er  m odified  with ( + ) -  
C C -1065 and 23 , 25 and 27 m er o ligom ers m odified  w ith  (+ )-C C -1 0 6 5 , h eterod im ers are 
form ed  p red om in an tly , indicating that o th er  o lig o m ers m od ified  w ith (+ )-C C -1 0 6 5 ,  
excep t 29 m er o lig o m ers, are still co m p etitiv e  for the substrate o f  T 4 D N A  ligase. S ince  
the d im er that w ould  b e form ed  from  the 21 and 29 m er o ligom ers m odified  w ith (+ ) -C C -  
1065 con ta in s co m p lete ly  o u t-o f-p h a se  b en t D N A , w e con clu d e that ou t-o f-p h ase D N A  
is on ly  form ed  w ith  d ifficulty by th e ligation  reaction  m ed ia ted  by T 4  D N A  ligase. T h e  
form ation  o f  a h eterotr im er is a lso  p red om in an t b etw een  tw o  21 m er and 25 m er  
o ligom ers m od ified  w ith  (+ )-C C -1 0 6 5 , and b etw een  o n e  21 m er and tw o 29 m er o lig o m ers, 
w h ereas that b etw een  a 21 m er and tw o  25 m er o lig o m ers , and b etw een  tw o 21 m er and  
o n e  29 m er o lig o m ers , w as su p p ressed , again  d u e to  the req u irem en t to form  o u t-o f­
p hase b en t D N A  in th e  ligase reaction . In con trast to  th is, o u t-o f-p h ase  bent D N A  can  
b e easily  form ed  by T 4  D N A  ligase from  th e m on om eric  b en t o lig o m er D N A  m odified  
with ( + ) - A B C  (se e  p anel C  o f  F igure 9). W e p rop ose  that this o b v io u s d ifferen ce in the  
ex ten t o f  distal ligation  inhib ition  b etw een  ( +  )-C C -1065 and ( + ) - A B C  can b e ration al­
ized  as fo llow s: (i)  (+ )-C C -1 0 6 5  has a u n iq ue h elix -stiffen in g  effec t on d up lex  D N A  to  
render b en t D N A  m ore stab ilized; (ii)  for su ccessfu l liga tion , T 4 ligase m ay h ave to  
distort th e  b en t D N A , w hich  is in du ced  by drug m od ifica tion , to  op tim ize th e con tacts
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b etw een  D N A  and an en zym e m o lecu le . S ince this d istorting  p rocess m ay be h indered  by 
the stiffen in g  effec t o f  (+ )-C C -1 0 6 5 , this resu lts in a d ecrease in the form ation  o f  ou t-o f­
phase bent D N A . S ince this effec t is u n iq u e to  the 2 5 m er s  (or 21 -I- 2 9 m er s)  that would  
result in ou t-o f-p h ase b en d in g , th ese  su bstrates m ust require the m ost d istortion  for a 
su ccessfu l ligation process.
(+ )-C C -1 0 6 5 -  a n d  (+ ) -A B 'C '-m o d if ie d  D N A  h ave a m uch  lo w er  c ircu lariza tion  
efficiency than (+ ) - A B C -  a n d  ( + ) - A B C " -m o d ified  D N A
It has b een  found  that bent D N A  fragm en ts show  an om alou sly  slow  m igration on  non­
denaturing p olyacrylam ide gel e lec tr o p h o re sis , and this e ffec t is cau sed  by the higher 
friction that the m ore b en t D N A  m o lec u le  en cou n ters in the narrow  p ores o f  the 
p olyacrylam ide gel (K o o  et a l ., 1986). In addition  to slow  e lec tro p h o retic  m obility , 
system atic b ending o f  D N A  is ex p ec ted  to  greatly  in crease the cyclization  probability  of  
sm all D N A  fragm ents (U la n o v sk y  e t a l ., 1986). W e also  con sid ered  the p ossib ility  o f  a 
correlation  b etw een  the ex ten t o f  retard ation  o f  e lec tro p h o retic  m ob ility  (R L) and the 
p roportion  o f  linear versus circular D N A  m o lecu les  form ed  during the ligation o f  the 
drug-m odified  21-1 o ligom er. T h e resu lts in F igure 3 sh ow  that all the drug m olecules  
used  in this study cau sed  about the sam e ex ten t o f  retardation  o f  e lectrop h oretic  m obility
28 D . SUN & L.H. HURLEY
Table II
Drug Ligation efficiency (%)* 
(+ ) Strand ( —) Strand
Tm value (°C)b
Control 43 65 66.5
(+)-CC-1065 50 0 96.5
(+)-A B 'C ' 57 0 87.8
(+)-ABC" 64 10.5 87
(+)-A B C 73 25 85.5
a Ligation efficiency was calculated by scanning the autoradiogram obtained 
from the experiment described in Figure 5B and the numbers are expressed as 
the percentage of ligated species to the total amount of DNA. For 100% 
ligation, equal amounts of radioactivity should be distributed between 5' end- 
labeled 9 mer and 20 mer labeled internally. Therefore, to obtain the percent 
ligation efficiency, the percentage of 20 mer found was multiplied by 2 (i.e. for 
equal amounts of 9 mer and 20 mer, the ligation efficiency is 100%; for one- 
third the amount of 20 mer versus 9 mer, the ligation efficiency is 67%). 
b Tm values are from the data described in Hurley et al. (1990).
of covalently modified D N A . The amount o f small-sized circular D N A  m olecules formed 
during the T4-catalyzed ligation of different drug-modified oligomers was monitored by 
using two-dimensional gel electrophoresis. While non-drug-modified oligomers did not 
form circular D N A  molecules in the mol. wt range that could be evaluated, there were 
significant amounts o f small-sized circular D N A  molecules in the ligation products of  
drug-modified oligomers in the same molecular range (Figure 10). A  graphical represen­
tation of circularization efficiency (i.e . the ratio of the amount o f circular D N A  to the 
total amount of D N A ) is shown in Figure 11 for different sizes o f multimers. There is a 
significant difference between the various drug-modified molecules in the percentage of  
circular D N A  formed at a given size of multimer and also differences in the optimum size 
for circularization (i.e . the location o f the efficiency peak of circularization). W hile the 
(+)-CC-1065-m odified oligomer D N A  showed low levels o f circularization efficiency 
(<10% ) during the ligation process to form multimers, (+ ) -ABC-modified oligomer 
D N A  showed >80%  efficiency at the maximum level. We propose that these differences 
in the circularization efficiency of each drug-modified D N A  molecule are related to the 
differences in the magnitude of the stiffening effect of the various drug molecules on 
D N A  molecules. From the previous results using T4 D N A  ligase, we suspected that (+ )-  
CC-1065, (+ )-A B 'C ' and (+)-A BC " might have an unusual stiffening effect on the D N A  
helix, resulting in stabilization of a bent D N A  structure. A  similar drug-induced D N A - 
stiffening effect would be expected to reduce the thermal motion of bent D N A  molecules 
and, consequently, make the joining process between each end o f the D N A  molecules 
more difficult, which would result in a reduced probability of circularization for each 
drug-modified oligomer.
Discussion
(+)-C C -1065 is a potent antitumor antibiotic that can alkylate N3 o f adenine in D N A  in a 
sequence-specific manner and induce bending, winding and stiffening of D N A  as a result 
o f covalent modification (Hurley et al., 1988; Lee et a l., 1991). D espite these novel 
properties, (+)-CC-1065 is not a clinically useful drug due to the delayed lethality
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Figure 6 K inetics o f nick-sealing activity o f T4 D N A  ligase on nicked duplexes.
(A ) Effect o f drug m odification on the ligation o f non-drug-m odified strands. N icked  
duplexes (40/42) were labeled radioactively only on the non-drug-m odified  
strand and modified with drug m olecules. R eaction mixtures contained 0 .2  pg  
D N A  and 1.5 U  o f T4 D N A  ligase, and w ere incubated for the given tim es at 
room tem perature.
(B ) E ffect o f drug m odification on the ligation o f the drug-m odified strand. N icked  
duplexes (42 /40) were labeled only on the drug-m odified strand and reaction  
mixtures w ere incubated for 1 h with 0 .2  pg D N A  and a given am ount o f ligase 
at room tem perature
p r o d u c e d  in  r o d e n ts  at th e r a p e u tic  d o sa g e  (M c G o v r e n  et al. , 1 9 8 4 ). T o  a v o id  th is  d o se -  
lim itin g  to x ic ity  an d  to  im p ro v e  a n titu m o r  e ff ic a c y , an e x te n s iv e  array o f  a n a lo g s  has 
b e e n  sy n th e s iz e d  by U p jo h n  sc ie n t is ts , an d  from  th e se  c o m p o u n d s  n ew  d ru g  c a n d id a te s  
h a v e  b e e n  id e n t if ie d , o n e  o f  w h ich  ( A d o z e le s in )  is in c lin ica l tr ia ls. F rom  p r e v io u s  stu d ies  
(H u r le y  et al. ,  1988; W a rp eh o sk i & H u r le y , 1988; L e e  et al., 19 9 1 ), s tr u c tu r e -a c t iv ity  
r e la t io n sh ip s  h a v e  b e e n  sh arp ly  d e fin e d  fo r  (+ ) -C C -1 0 6 5  and  its a n a lo g s . H o w e v e r , it is 
still n o t e x a c tly  k n o w n  h o w  th e  stru ctu ra l fe a tu r e s  o f  (+ ) -C C -1 0 6 5  an d  r e la te d  drugs 
a ffe c t  b io lo g ic a l p r o c e s s e s  b e c a u se  o f  in su ffic ien t d a ta  in  su ita b le  b io c h e m ic a l an d  b io lo g ica l  
sy s te m s .
T o  p a rtia lly  a d d ress  th is  d e f ic ie n c y , w e  h a v e  c h o se n  T 4  D N A  lig a se  as a m o d e l sy stem  
b e c a u se  lig a se  is ty p ica l o f  e n z y m e s  u sin g  D N A  m o le c u le s  as its su b s tr a te , an d  the  
stru ctu ra l c h a n g e s  o ccu rr in g  in D N A  m o le c u le s  m a y  a ffe c t  th e  lig a tio n  rea c tio n  m e d ia te d  
b y th e  D N A  lig a se . T 4  D N A  lig a se  can  m e d ia te  th e  fo r m a tio n  o f  a p h o sp h o d ie s te r  b on d  
o n  d u p le x  D N A  b e tw e e n  th e  3 '-h y d r o x y l g ro u p  and  th e  a d ja c e n t 5 '-p h o sp h o r y l grou p  
u sin g  A T P  as an e n e r g y  so u r c e . W e  e x p e c te d  th a t th e  in tr o d u c tio n  o f  d if fe r e n t k in d s o f  
d ru g  m o d if ic a t io n  n ea r  th e  a n n e a lin g  s ite  o f  tw o  o lig o m e r  D N A  m o le c u le s  m ig h t a ffec t  
th e  lig a tio n  p r o c e ss  d if fe r e n tly  b e tw e e n  d ru g m o le c u le s ,  s in c e  th e  e x te n ts  o f  e le v a t io n  in 
th e  m e lt in g  te m p e r a tu r e  (T m ) b y  th e  c o v a le n t  m o d if ic a t io n  o f  D N A  w ith  d ru g  w o u ld  b e  
d if fe r e n t b e tw e e n  m o le c u le s  u se d  in  th is s tu d y , an d  (+ ) -C C -1 0 6 5  an d  ( + ) - A B ' C '  h ave  
u n u su a l D N A -w in d in g  e ffe c ts  th a t can  a ffe c t  th e  re la t iv e  o r ie n ta t io n  b e tw e e n  th e  3 '-  
h y d ro x y l g ro u p  an d  th e  a d ja c e n t 5 '-p h o sp h o r y l g ro u p  o f  an  a n n e a le d  in te r m e d ia te  
b e tw e e n  tw o  p ie c e s  o f  D N A . A s  w e  e x p e c te d , ( + ) - A B C  an d  (+ ) -A B C "  in d u c e d  a
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Figure 7 D istal inhibition o f T4 D N A  ligase by ( + )-C C -1065, (+ ) -A B 'C '- , (+ ) -  
ABC"- and ( + ) - A B C -m odified  oligom er D N A  using 23, 25, 27 an d 29m ers. Lanes 1-5  
refer to  the ligation products o f control, (+ )-C C -1065-, (+ ) -A B 'C '- , ( +  )-ABC"- and 
(-t-)-A B C -m odified oligom ers, respectively
m o d e r a te  in h ib it io n  o f  th e  lig a tio n  o f  th e  n o n -d r u g -m o d if ie d  stran d  w ith in  10 bp  fro m  th e  
5 ' e n d  o f  th e  d ru g  m o d if ic a t io n  s i t e ,  w h ile  (+ ) -C C -1 0 6 5  an d  ( - f ) - A B 'C '  in d u c e d  a m o re  
s ig n ifica n t in h ib it io n , im p ly in g  th a t th e  D N A -w in d in g  e f f e c t  o f  th e s e  la tter  d ru gs can  
c h a n g e  th e  re la t iv e  o r ie n ta t io n  o f  th e  3 '-h y d ro x y l g ro u p  an d  th e  a d ja cen t 5 '-p h o sp h o r y l  
g r o u p , a n d  m a k e  it m o re  d ifficu lt fo r  n u c le o p h ilic  a tta ck  o f  th e  a c tiv a ted  5 '-p h o sp h o r y l  
g r o u p  b y  th e  3 '-h y d r o x y l g r o u p . In  c o n tra s t to  th e  o b se r v e d  in h ib it io n  o f  lig a tio n  o f  n o n -
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Figure 8 Plot o f the relative distribution o f multimers following ligation of (+ )-C C - 
1065-, (+ )-A B 'C '-, ( + )-ABC"- and (+ ) -ABC-m odified 2 3 ,2 5 ,2 7  and 29m ers with T4 
ligase.
(A) Population distribution o f ligated multimers present in the ligation mixtures o f 
control 23, 25, 27 and 29 mer D N A . The amount of multimer present at the 
highest concentration in the reaction mixture is given a value of 100.
(B) Population distribution of ligated multimers o f 23, 25, 27 and 29 mer oligomer 
D N A  modified with (+)-C C -1065.
(C) Population distribution o f ligated multimers o f 25 mer modified with (+ )-C C - 
1065, (+ ) -A B 'C \ (+)-A B C " and (+ )-A B C
d r u g - m o d i f i e d  s t r a n d  b y  d r u g  m o l e c u l e s ,  d r u g  m o d i f i c a t i o n  e n h a n c e d  t h e  l i g a t i o n  r a t e  o f  
t h e  d r u g - m o d i f i e d  s t r a n d .  T h i s  i s  p r e s u m a b l y  b e c a u s e  d r u g - i n d u c e d  f i x a t i o n  o f  t h e  5 ' -  
p h o s p h o r y l  g r o u p  r e n d e r s  i t  e a s i e r  f o r  t h e  3 ' - h y d r o x y l  g r o u p  t o  a t t a c k  t h e  a c t i v a t e d  5 ' -  
p h o s p h o r y l  g r o u p ,  w h i c h  i s  r e q u i r e d  f o r  t h e  f o r m a t i o n  o f  a  p h o s p h o d i e s t e r  b o n d .  W e  
s p e c u l a t e  t h a t  t h i s  d i f f e r e n t i a l  e f f e c t  o f  ( + ) - C C - 1 0 6 5  o n  l i g a t i o n  o n  e a c h  s t r a n d  i s  
b e c a u s e  t h e  d r u g - i n d u c e d  w i n d i n g  a n d  h e l i x - s t a b i l i z i n g  e f f e c t s  o c c u r  p r e d o m i n a n t l y  t o  
t h e  5 '  s i d e  o f  t h e  c o v a l e n t l y  m o d i f i e d  a d e n i n e  ( i . e .  t o w a r d s  t h e  d r u g  o v e r l a p  s i t e ) .  T h e  
o v e r a l l  c o n c l u s i o n  i s  t h a t  t h e  h e l i x - s t a b i l i z i n g  e f f e c t  r e s t r i c t s  t h e  m o b i l i t y  o f  t h e  5 ' -  
p h o s p h o r y l  g r o u p  o f  t h e  ( + ) - C C - 1 0 6 5 - m o d i f i e d  s t r a n d  a n d  t h e  3 ' - h y d r o x y l  g r o u p  o n  t h e
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Figure 9 C o-polym erization experim ents betw een 21 mers and 23, 25, 27 and 29 mer 
D N A  m odified with either (+ )-C C -1065  or (+ )-A B C . C hloroquine phosphate  
(50 p-g/ml) was added to the gel and running buffer during electrophoresis to  cancel out 
phased D N A  bending in order to separate ligated D N A  only according to size.
(A ) R adioactively labeled 21 mer 0 .2  p.g was self-ligated (lane 1) or co-ligated with 
4 molar excess o f  non-labeled 23, 25, 27 and 29 mer (lanes 2 -5 ,  respectively). In 
the presence o f com petitor D N A , ligation betw een individual 21 mers was in­
hibited and co-polym erization betw een 21 and larger oligom ers was predom inant.
H D  and H T D  refer to the hom odim er o f  21 mer and the heterodim er betw een  
21 mer and com petitive oligom ers, respectively. A lso , H T, HT1 and HT2 repre­
sent hom otrim er o f 21 m er, heterotrim er betw een tw o 21 mer and one com petitive  
oligom er, and heterotrim er betw een one 21 mer and tw o com petitive oligom ers.
(B ) R adioactively labeled 21 mer m odified with (+ )-C C -1065  was self-ligated (lane  
1) or ligated with the 4 molar excess o f 2 3 ,2 5 ,2 7  and 29 mer m odified with the sam e 
drug m olecule (lanes 2 - 5 ,  respectively).
(C ) A s for B , except that (-l-)-A B C  was used in place o f (+ )-C C -1065
n o n -d r u g -m o d if ie d  stra n d . F u r th e r m o r e , th e  w in d in g  e f fe c t  o f  (+ ) -C C -1 0 6 5  an d  ( + ) -  
A B 'C '  c h a n g e s  th e  p r o x im ity  b e tw e e n  th e  3 '-h y d r o x y l g ro u p  an d  th e  a d ja c e n t 5 '-  
p h o sp h o r y l g r o u p , r e su lt in g  in m o re  in h ib it io n  in th e  lig a tio n  o f  (+ ) -C C -1 0 6 5 -  an d  ( +  )-  
A B 'C '-m o d if ie d  D N A .
In a d d it io n  to  th e  p ro x im a l in h ib ito ry  e ffe c t  o f  d ru g  m o le c u le s  o n  D N A  lig a t io n , a 
d is ta l in h ib ito ry  e f f e c t  o f  ( + ) -C C -1 0 6 5 , A B 'C ' an d  A B C "  w as a lso  o b s e r v e d , in d ica tin g  
th a t th e s e  d ru g  m o le c u le s  can  c h a n g e  th e  flex ib ility  o f  D N A  m o le c u le s ,  as w e ll as h a v e
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Figure 10 Circularization experim ents with oligom er 21-1 (A ) and the sam e oligom er  
D N A  m odified  with (+ ) -A B C  (B ), (+ )-A B C "  (C ) (+ )-C C -1065  (D ). Two- 
dim ensional electrophoresis was carried out to  separate the circular D N A  from the 
linear ligated m ultim ers. The spots o f the upper family are circular 5 to 10 mers o f the 
drug-m odified 21 bp precursor. The spots o f the low er fam ily are non-circular ligated  
products. N um bers represent the m ultiplicity o f ligated oligom ers. D eterm ination of  
the size and am ount o f each species o f D N A  m olecule from ligation reaction was as 
described in M ethods
o th e r  e f f e c t s  o n  D N A ,  su ch  as b e n d in g  a n d  w in d in g . T h e  m o le c u la r  b a sis  fo r  d ista l 
lig a tio n  in h ib it io n  by  d ru g  m o le c u le s  is still n o t c o m p le te ly  c le a r , b u t tw o  im p ortan t  
p o in ts  h a v e  b e e n  a d d r e sse d  from  th is  stu d y . F irst, it w as d is c o v e r e d  th a t T 4  D N A  ligase  
d o e s  n o t fa v o r  th e  fo r m a tio n  o f  180° o u t-o f -p h a se  b en t D N A  fro m  in d iv id u a l b en t  
o lig o m e r s . T h is  c o n c lu s io n  m a y  b e  ra tio n a liz e d  as fo llo w s . T 4  D N A  lig a se  m ay  req u ire  
m a x im u m  c o n ta c t  w ith  th e  tw o  D N A  su b stra te s  fo r  su c c e ss fu l lig a tio n  to  o ccu r . I f  b en t  
D N A  m o le c u le s  are  a lig n ed  in a 180° o u t-o f-p h a se  m a n n e r , T 4  D N A  lig a se  ca n n o t  
a tta in  th e  r e q u ir e d  a m o u n t o f  c o n ta c ts  w ith  th e  D N A  su b s tr a te s , c o m p a r e d  to  lin ea r  or
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Figure 11 Graphical representation o f circularization efficiency at the given size of  
multimers. Circularization efficiency is represented as the ratio o f circular species of  
D N A  to  the total amount o f D N A  at the given size o f D N A
i n - p h a s e  b e n t  D N A  m o l e c u l e s .  T h i s  m i g h t  b e  a n a l o g o u s  t o  t h e  o b s e r v a t i o n  t h a t  a n  i 
o v e r a l l  i n - p h a s e  b e n t  s t r u c t u r e  i n  t h e  p r o c a r y o t i c  u p s t r e a m  p r o m o t e r  r e g i o n  c a n  e n h a n c e  ;j 
t h e  t r a n s c r i p t i o n  r a t e  b y  a c h i e v i n g  m a x i m u m  c o n t a c t  b e t w e e n  t h e  p r o m o t e r  r e g i o n  a n d  j 
R N A  p o l y m e r a s e ,  w h i c h  f a c i l i t a t e s  t h e  f o r m a t i o n  o f  a n  o p e n  c o m p l e x  f o r  t r a n s c r i p t i o n  jJ 
i n i t i a t i o n  ( M c A l l i s t e r  a n d  A c h b e r g e r ,  1 9 8 9 ) .  S e c o n d l y ,  t h e  f o r m a t i o n  o f  o u t - o f - p h a s e  || 
b e n t  D N A  w a s  o n l y  i n h i b i t e d  w h e n  ( + ) - C C - 1 0 6 5 - ,  ( + ) - A B ' C ' -  a n d  ( + ) - A B C " - i n d u c e d  j 
b e n t  o l i g o m e r  D N A  m o l e c u l e s  w e r e  u s e d  a s  l i g a s e  s u b s t r a t e s ,  w h e r e a s  t h e  b e n t  o l i g o m e r  
D N A  i n d u c e d  b y  ( + ) - A B C  c a n  f o r m  o u t - o f - p h a s e  b e n t  D N A  j u s t  a s  e f f i c i e n t l y  a f t e r  t h e  
l i g a t i o n  r e a c t i o n  a s  c o n t r o l  D N A .  T o  r a t i o n a l i z e  t h i s  o b s e r v a t i o n ,  w e  p r o p o s e  t h a t  T 4  
l i g a s e  c a n  s t i l l  d i s t o r t  D N A  s t r u c t u r e  s u f f i c i e n t l y  t o  e n s u r e  t h e  m a x i m u m  c o n t a c t  b e t w e e n  
e n z y m e  a n d  D N A  s u b s t r a t e s  w i t h  ( + ) - A B C - m o d i f i e d  b e n t  D N A ,  b u t  b e n t  D N A  m o d i -  I 
f i e d  w i t h  ( + ) - C C - 1 0 6 5  c a n n o t  b e  s o  e a s i l y  d i s t o r t e d  b y  T 4  D N A  l i g a s e  b e c a u s e  o f  i t s  
h e l i x - s t i f f e n i n g  e f f e c t .  T h e  r i n g - c l o s u r e  e x p e r i m e n t s  d e s c r i b e d  h e r e  a l s o  s u p p o r t  t h e  
s t i f f e n i n g  e f f e c t  o f  ( + ) - C C - 1 0 6 5 ,  ( + ) - A B ' C '  a n d  ( + ) - A B C " .  R e s u l t s  f r o m  t h e  g e l  m o b i l i t y  
s t u d y  o f  l i g a t e d  m u l t i m e r s  o f  2 1  o l i g o m e r  m o d i f i e d  w i t h  d r u g s  s h o w  t h a t  t h e  d i f f e r e n t  
d r u g  m o l e c u l e s  i n d u c e d  D N A  b e n d i n g  w i t h  a  r e l a t i v e l y  s i m i l a r  m a g n i t u d e  ( ~  1 7 - 2 0 7  
d r u g  a d d u c t ) .  H o w e v e r ,  t h e  c i r c u l a r i z a t i o n  e f f i c i e n c y  w a s  o b s e r v e d  t o  v a r y  s i g n i f i c a n t l y  
b e t w e e n  d r u g  m o l e c u l e s ,  s u c h  t h a t  t h e  l i g a t i o n  p r o d u c t  o f  t h e  ( + ) - C C - 1 0 6 5 - i n d u c e d  b e n t  
o l i g o m e r  s h o w e d  < 1 0 %  c i r c u l a r i z a t i o n ,  w h i l e  A B C  s h o w e d  > 8 0 %  c i r c u l a r i z a t i o n .  I t  i s  
k n o w n  t h a t  t h e  l o c a l  b e n d i n g  m a g n i t u d e  o f  D N A  c o n t r i b u t e s  p r i m a r i l y  t o  t h e  i n c r e a s e  i n  
c i r c u l a r  D N A  f o r m a t i o n  w i t h i n  s m a l l - s i z e d  D N A  m o l e c u l e s ,  b u t  i n t r i n s i c  f l e x i b i l i t y  o f  
D N A  m o l e c u l e s  c a n  a l s o  c o n t r i b u t e  t o  t h e  c i r c u l a r i z a t i o n  e f f i c i e n c y  ( U l a n o v s k y  et al . , 
1 9 8 6 ) .  W e  b e l i e v e  t h a t  t h e  D N A  h e l i x - s t i f f e n i n g  e f f e c t  o f  ( + ) - C C - 1 0 6 5  a n d  ( + ) - A B ' C '  
o r i g i n a t e d  f r o m  t h e  r i g i d  s t r u c t u r e  o f  t h e s e  d r u g  m o l e c u l e s  c o n t r i b u t e d  b y  t h e  i n s i d e -  
e d g e  r i n g  s t r u c t u r e ,  a n d  t h e  b e n z o f u r a n  r i n g  s t r u c t u r e  o f  ( - f ) - A B C "  a l s o  c o n t r i b u t e s  t o  a s  
y e t  u n d e f i n e d  i n t e r a c t i o n s  b e t w e e n  d r u g  m o l e c u l e s  a n d  D N A  s t r u c t u r e ,  r e s u l t i n g  i n  a  
g r e a t e r  s t i f f e n i n g  e f f e c t  o n  D N A  d u p l e x  c o m p a r e d  t o  ( + ) - A B C .  C o n c l u s i v e l y ,  w e  s h o w  
t h a t  t h e  u n u s u a l  h e l i x - s t i f f e n i n g  e f f e c t  o f  ( + ) - C C - 1 0 6 5 ,  ( + ) - A B ' C '  a n d  ( + ) - A B C "  d e ­
c r e a s e s  t h e  i n t r i n s i c  f l e x i b i l i t y  o f  t h e  D N A  h e l i x ,  w h i c h  r e s u l t s  i n  a  d e c r e a s e  i n  t h e  
f o r m a t i o n  o f  c i r c u l a r  D N A  f r o m  t h e  b e n t  o l i g o m e r  D N A .
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In su m m a ry , w e  h a v e  sh o w n  th a t ( +  )-C C -1 0 6 5  and  its a n a lo g s  c a u se  th e  p rox im a l 
in h ib it io n  o f  T 4  D N A  lig a se  th ro u g h  th e ir  h e lix -s ta b iliz in g  e f fe c t  and  u n u su a l w in d in g  
e f fe c t .  F u r th e r m o r e , w e  h a v e  d e m o n s tr a te d  th e  h e lix -s t if fe n in g  e f fe c t  o f  ( +  )-C C -1 0 6 5 , 
( + ) - A B ' C '  and (+ ) -A B C "  by  u sin g  c irc u la r iza tio n  e x p e r im e n ts , and  ra tio n a liz e d  th e  
d ista l lig a tio n  in h ib it io n  e ffe c t  as b e in g  th e  c o n s e q u e n c e  o f  th e  h e lix -s t if fe n in g  e ffe c t  o f  
d ru g  m o le c u le s .  F in a lly , w e  p r o p o se  th a t th e  d e la y e d  le th a lity  in r o d e n ts  ca u se d  by ( + ) -  
C C -1 0 6 5  and  ( + ) - A B ' C '  th at is a ss o c ia te d  w ith  th e  in s id e -e d g e  su b s titu e n ts  m ig h t resu lt 
fro m  th e s e  u n u su a l D N A -w in d in g  e ffe c ts  an d  s tro n g  h e lix -s t if fe n in g  e ffe c ts  o f  th e s e  drug  
m o le c u le s  on  D N A .
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DNA interstrand cross-linking, D N A  
sequence specificity, and induced 
conformational changes produced by a 
dimeric analog of (+)-CC-1065
Z.-M. Ding & L.H. Hurley*
Drug Dynamics Institute, College o f  Pharmacy, The University o f  Texas at Austin, 
Min, TX 78712, USA
Summary: U -77779 is a sym m etrical dim er o f the spirocyclopropyl allkylating  
subunit of (+ )-C C -1065 in which the linker consists o f  tw o indole subunits 
separated by a ureido group. This com pound was synthesized by scientists o f the 
Upjohn Company and was found to be m ore active in both anti-tum or efficacy and 
cytotoxicity than its m ono-alkylating analogs. U sing three different 21-base pair 
DNA duplexes containing U -77779 reactive sequences, we have shown that U -77779  
produces a stable interstrand cross-linked species that loses its internal self 
complementarity. A  com parison o f U -77779 with the m ono-alkylating analogs of 
(+)-CC-1065 shows that it appears to have an increased sequence selectivity such 
that, while m onoalkylating com pounds like ( +  )-CC-1065 react at m ore than one  
site, U-77779 reacts only at sites where there are two suitably positioned  alkylation  
sites. Chemical footprinting with 1 ,10-phenanthroline-copper com plex revealed a 
six base pair cross-linked region betw een  the two covalently m odified adenines with 
modulated cleavage outside this region. In the case o f hydroxyl radical footprinting, 
considerable variability o f the extent o f cleavage within the cross-linked sequence  
was found. T hese results are discussed in term s o f likely induced conform ational 
changes in D N A . In contrast to (+ )-C C -1065 , non-denaturing gel electrophoresis 
did not reveal any net bending o f D N A  due to U -77779, which w e believe is due to  
the 180° out-of-phase bending produced on opposite strands o f  D N A  by the 
cross-linker.
U-77779 (M itch e ll et al., 1991) (F ig u r e  1) is a s y n th e t ic a lly  d e r iv e d  d im er ic  a n a lo g  o f  
-)-CC-1065, a p o te n t  a n ti-tu m o r  a n tib io tic  p r o d u c e d  b y  Streptomyces zelensis 
lHanka et al., 1978; R e y n o ld s  et al., 1986; W a r p e h o sk i &  H u r le y , 1 9 8 8 ). H o w e v e r ,  
due to the d e la y e d  an d  ir re v ers ib le  to x ic ity  in  r o d e n ts  o f  ( + ) -C C -1 0 6 5  at th e r a p e u tic  
doses, it has n e v e r  b e e n  c lin ic a lly  e v a lu a te d . B e c a u s e  o f  th is  to x ic ity , a s e r ie s  o f  
analogs o f (+ ) -C C -1 0 6 5  w ere  d e s ig n e d  an d  sy n th e s iz e d  b y  sc ie n tis ts  a t T h e  U p jo h n  
Company w ith  th e  o b je c t  o f  r e ta in in g  a n ti-tu m o r  e f f ic a c y  an d  e lim in a t in g  d o se  
uniting tox ic ity . In a d d it io n  to  a s e r ie s  o f  m o n o -a lk y la t in g  a n a lo g s , w h ich  in c lu d e  
idozelesin, a c o m p o u n d  p r e se n t ly  in  p h a se  I c lin ic  tra ils  (M c G o v r e n , 1 9 9 1 ), tw o  
.lasses of a lk y la tin g  d im ers  w e r e  a lso  sy n th e s iz e d , o n e  c o n ta in in g  a f le x ib le  d im er
Abbreviations: E D T A , ethylenediam inetetra-acetic acid; T E M E D , N ,N , A .T V -tetram inethylethylenediam ine; 
Iis,tris(hydroxymethyl) am inom ethane; A -tract, adenine tract; O p , 1 ,10-phenanthroline; O p-C u , 1,10-phen- 
Mhroline-copper com plex; P N K , T4 polynucleotide kinase; H ep es , N -2-h ydroxyethylp iperazine-A '-2- 
shanesulfonic acid.
Correspondence: L . H .  H u r le y
keived 16 A pril 1991; accep ted  6 June 1991
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Figure 1 Structure o f U -77779 and its m ono-alkylating analogs (+ ) -A B , (+)-ABC, 
and (+ )-C C -1065
(M itc h e ll et al. , 1989 ) an d  th e  o th e r  a r ig id  d im er  (M itc h e ll et al. , 1991) (Figure 1), 
S o m e  o f  th e  sy n th e tic  f le x ib le  d im e r s  are 5 - 1 0  fo ld  m o r e  p o te n t  in vitro and inm 
th an  (+ ) -C C -1 0 6 5  (M itc h e ll et al., 1 9 8 9 ). T h e r a p e u tic a lly , th e  m o st attractive analog 
sy n th e s iz e d  to  d a te  is o n e  o f  th e  r ig id  d im e r s , U -7 7 7 7 9 , w h ich  is h igh ly  active bothifl 
vitro an d  in vivo to  v a r io u s  k in d s  o f  tu m o r  c e lls  in  a n ti-tu m o r  e ffica cy  but does no! 
sh o w  th e  d e la y e d  to x ic ity  a s s o c ia te d  w ith  (+ ) -C C -1 0 6 5 .  Its c e ll growth inhibition 
e ffe c t  is m u ch  m o r e  p o te n t  th a n  th e  (+ ) -C C -1 0 6 5  in h ib it io n  o f  D N A , RNA, and 
p r o te in  sy n th e s is . T h is  u n iq u e  ch a r a c te r is tic  d is t in g u ish e s  it fro m  any of the other 
(+ ) -C C -1 0 6 5  a n a lo g s . U -7 7 7 7 9  (N S C  6 1 5 2 9 1 ) h as b e e n  a c c e p te d  into the National 
C a n c e r  In s titu te  D e c is io n  N e tw o r k  (M c G o v r e n  et al., 1 9 8 9 ).
A  n u m b e r  o f  c lin ic a lly  u se fu l a n ti-tu m o r  a g e n ts  are  D N A - D N A  cross-linkers. Most 
o f  th e m  c o v a le n t ly  m o d ify  th e  b a se s  o n  o p p o s ite  s tra n d s and  thereby induce
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interstrand cro ss-lin k in g . E x a m p le s  in c lu d e  th e  n itr o g e n  m u sta rd s  (E w ig  & K o h n , 
1977; Kohn et al., 1981; M u rn a n e  &  B y f ie ld , 1 9 8 1 ), m ito m y c in  C  (T o m a s z  et al., 
1987; 1988; B o r o w y -B o r o w sk i et al., 1 9 9 0 ), an d  c h lo r o e th y ln itr o u r e a  (K o h n  et al., 
1981). Other c o m p o u n d s  su ch  as d s -p la t in u m  (R o b e r ts ,  1 981 ) in d u c e  b o th  in ter - and  
intrastrand cro ss -lin k in g . In terstra n d  cr o ss - lin k e r s  are  u su a lly  m o r e  p o te n t  th an  
intrastrand cro ss-lin k ers  and  th e ir  m o n o -a n a lo g s  in  th e ir  b io lo g ic a l e f f e c t s ,  p o ss ib ly  
because this le s io n  is a m o re  e f f e c t iv e  b lo c k  o f  D N A  r e p lic a tio n  an d  it is a lso  d ifficu lt  
to repair (E w ig  &  K o h n , 1977; K o h n , 1 9 8 1 ). A  c o m m o n  fe a tu r e  o f  th e  m a jo r ity  o f  
DNA-DNA cr o ss -lin k e r s  is th a t th e y  c o v a le n t ly  m o d ify  D N A  w ith in  th e  m ajor  
groove and are o fte n  g u a n in e  sp e c if ic . N itr o g e n  m u sta rd  (M u r n a n e  &  B y f ie ld , 1981) 
and cA-platinum (S h erm a n  &  L ip p a rd , 1 9 87 ) are  ty p ic a l in  th is  regard  an d  b o n d  
through N7 o f  g u a n in e . P so r a le n , w h ile  b e in g  ty p ic a l in  th a t it b o n d s  D N A  w ith in  th e  
major groove, is u n u su a l in  th a t th e  c o v a le n t  m o d if ic a t io n  o ccu rs  at 5 , 6  d o u b le  b o n d  
of thymine, and  it fo rm s a c y c lo b u ta n e  b r id g e  b e tw e e n  tw o  th y m in e s  o n  o p p o s ite  
strands (K anne et al., 1982; L e e  et al., 1988; Y e u n g  et al., 1 9 8 8 ). M ito m y c in  C , w h ile  
being typical in th a t it is g u a n in e  s e le c t iv e ,  is u n u su a l in  th a t th e  a lk y la tio n  o c c u r s  at 
N2 of guanine w ith in  th e  m in o r  g r o o v e  (T o m a s z  et al., 1987; N o r m a n  et al., 19 9 0 ). 
The majority o f  D N A - D N A  cr o ss - lin k e r s  su ch  as n itr o g e n  m u sta rd , m ito m y c in  C , 
psoralen and d s -p la t in u m  o v e r la p  a tw o  b a se -p a ir  r e g io n  o n  th e  D N A  m o le c u le ,  
while ch lo ro eth y ln itro u rea  o n ly  c o v e r s  o n e  G /C  b a se  p a ir . T h e  c r o ss - lin k in g  e ff ic ie n c y  
of all interstrand cr o ss - lin k e r s  k n o w n  to  d a te  is v ery  lo w  in vitro. T h e  cr o ss -lin k in g  
efficiency is a b o u t 25%  for  p so r a le n  (C im in o  et al., 1985; Y e u n g  et al., 1 9 8 8 ), 5%  or  
less for m itom ycin  C  (T e n g  et al., 1 9 8 9 ) , an d  le s s  th a n  1%  fo r  d s -p la t in u m  (S h erm a n  
k Lippard, 1 9 8 7 ). U -7 7 7 7 9  is d e s ig n e d  to  b e  d if fe r e n t fro m  a ll o f  th e s e  p r e v io u s  
groups in that it sh o u ld  b e  A T  s e le c t iv e ,  b o n d  in  th e  m in o r  g r o o v e  o f  D N A ,  and  sp a n  
six base pairs.
(+)-CC-1065 b o n d s  th ro u g h  N 3  o f  a d e n in e  an d  lie s  w ith in  th e  m in o r  g r o o v e  o f  th e  
DNA, covering  a th r e e  and  o n e  b a se -p a ir  r e g io n  to  th e  5 '-  an d  3 '- s id e , r e sp e c t iv e ly , 
of the co v a len tly  m o d if ie d  a d e n in e  (H u r le y  et al., 1 9 8 4 ) . T h e r m a l tr e a tm e n t o f  
5-labeled ( + ) -C C -1 0 6 5 - (N 3 -a d e n in e ) -D N A  a d d u c ts  g e n e r a te s  tw o  p r o d u c ts  ( s p e c ie s  
A and B in F ig u re  2 ) . A fte r  p ip e r id in e  tr e a tm e n t , th e  s lo w e r  m ig ra tin g  p r o d u c t ( A )  is 
converted to  B , an d  c o -m ig r a te s  w ith  th e  p r o d u c t o f  a M a x a m - G ilb e r t  a d e n in e  
sequencing r e a c tio n . T h is  s ite  o f  stran d  b r e a k a g e  r e v e a ls  th e  c o v a le n t  b o n d in g  s ite  o f  
(+)-CC-1065 o n  D N A  (R e y n o ld s  et al., 1 9 8 5 ). S u b se q u e n t ly , th e  stran d  b r e a k a g e  
assay has b e e n  u se d  to  d e te r m in e  th e  c o v a le n t  D N A  se q u e n c e  s e le c t iv ity  o f  
(t)-CC-1065. O u r  p r e v io u s  w o rk  d e m o n s tr a te d  th a t ( + ) -C C -1 0 6 5  s e le c t iv e ly  b o n d s  
with three su b se ts  o f  c o n se n s u s  b o n d in g  se q u e n c e s  (5 ' P u N T T A * , 5 ' A A A A A * ,  and  
j1 (A /T )(A /T )A * , w h e r e  (* )  in d ic a te  th e  c o v a le n t ly  m o d if ie d  a d e n in e s  an d  N  
represents an y  o f  th e  fo u r  b a se s  o n  D N A )  (R e y n o ld s  et al., 1985; H u r le y  et al.,
1990). B ased  u p o n  o u r  p r e v io u s  w o r k , w e  h a v e  p o s tu la te d  th a t th e  p r im a ry  m o le c u la r  
basis for s e q u e n c e  se le c t iv ity  o f  (+ ) -C C -1 0 6 5  is a sequence-dependent catalytic 
mation and/or a sequence-dependent conformational flexibility (H u r le y  et a l., 1988; 
Warpehoski & H u r le y  1 9 8 8 ). W e  h a v e  r e c e n tly  d e m o n s tr a te d  th e  cr itica l r o le  o f  
ordered w ater  m o le c u le s  in  th e  stru ctu re  o f  th e  ( + ) - C C - 1 0 6 5 - D N A  a d d u ct an d  th e  
likely in v o lv em en t o f  D N A  a u to c a ta ly s is  b y  a w a te r -b r id g e d  p h o sp h a te  o n  th e  
ion-covalently m o d if ie d  stran d  o f  D N A  (L in  et al., 1 9 9 1 ).
The b on d in g  o f  (+ ) -C C -1 0 6 5  w ith  D N A  in d u c e s  or  en tra p s  at le a s t  tw o  ty p e s  o f  
informational c h a n g e s  in  D N A . F ir s t , (+ ) -C C -1 0 6 5  b e n d s  D N A  in  to w a rd  th e  m in o r  
groove by a b o u t 1 4 ° -1 9 ° , an d  th e  lo c u s  o f  b e n d in g  is a b o u t 2 - 3  b a se  p a irs  to  th e  
Aside o f th e  c o v a le n t ly  m o d if ie d  a d e n in e  (L e e  et al., 1 9 9 1 a ). T h is  d r u g -in d u ced  
ending p o s s e s se s  a g e n e r a l s im ila r ity  w ith  th e  in tr in s ic  b e n d in g  a s s o c ia te d  w ith
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Figure 2 R eaction  o f (+ )-C C -1065  with N 3 o f adenine in D N A  and products from 
therm al cleavage reaction. Species ‘A ’ is the product produced by thermal treat­
m ent and species ‘B ’ is the product produced by therm al and subsquent piperidine 
treatm ent. The exact nature o f the species generated on the 5' side of the strand 
break is unknown (R eynolds et al., 1985)
a d e n in e  tracts (L in  et al., 1 9 9 1 ). H y d r o x y l ra d ica l fo o tp r in tin g  and  N .M .R . expen- 
m e n ta l r e su lts  s h o w e d  th a t th e r e  is a p r o g r e ss iv e  c o m p r e s s io n  o f  th e  minor groove to 
th e  5 '- s id e  o f  th e  c o v a le n t  m o d if ic a t io n  s ite  an d  a d is c o n tin u ity  to  the 3'-side of the 
b en t s e q u e n c e . S e c o n d , (+ ) -C C -1 0 6 5  a lso  w in d s  D N A  b y a b o u t  th e  equivalent of one 
b a se  p a ir  p er  d ru g  le s io n  (L e e  et al., 1 9 9 1 ). T h e s e  c o n fo r m a tio n a l changes may have 
p r o fo u n d  e ffe c ts  o n  r e p lic a t io n , r e c o m b in a tio n , a n d /o r  tra n scr ip tio n a l events, and are 
th e r e fo r e  lik e ly  to  b e  r e la te d  to  th e  p o te n t  b io lo g ic a l e f fe c ts  o f  (+ )-C C -1 0 6 5 .
T h e  (+ ) -C C -1 0 6 5  m o le c u le  c o n s is ts  o f  th r e e  r e p e a t in g  p yrroloindole subunit 
(F ig u r e  2 ) ,  o n e  o f  w h ich  ( th e  C P I o r  c y c lo p r o p y l p y r r o lo in d o le  su b u n it or subunit Al 
c o n ta in s  a D N A  r e a c tiv e  c y c lo p r o p y l fu n c t io n . S u b u n it A  c o n ta in s  sufficient structural 
in fo r m a tio n  to  m e d ia te  b o th  th e  s e q u e n c e  sp e c if ic ity , D N A  b en d in g  (Lee et at.
1 9 9 1 ), an d  a n ti-tu m o r  e f f ic a c y  o f  (+ ) -C C -1 0 6 5  (W a r p e h o sk i & Hurley, 1988).
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Subunits B an d  C  ca n  m o d u la te  or  fin e  tu n e  th e  s e q u e n c e  sp e c if ic ity  o f  su b u n it A  
(Warpehoski & H u r le y , 1988; H u r le y  et al., 1 9 9 0 ). T h e  in s id e  e d g e  r in g  stru ctu re  o f  
subunits B and C  are r e sp o n s ib le  fo r  w in d in g  an d  s t if fe n in g  e f fe c ts  w h e n  th e y  in tera ct  
with the floor  o f  th e  m in o r  g r o o v e  D N A  m o le c u le  (L e e  et al., 1 9 9 1 ). U -7 7 7 7 9  is a 
symmetrical d im er  o f  th e  sp ir o c y c lo p r o p y l a lk y la tin g  su b u n it o f  ( + ) - C C - 1 0 6 5 ,  in  
which the lin k er  c o n s is ts  o f  tw o  in d o le  su b u n its  se p a r a te d  b y  a u r e id o  g ro u p  (F ig u re  
1).
The purpose o f  th e  stu d y  d e sc r ib e d  in  th is  p a p e r  w as to  d e te r m in e  w h e th e r  U -7 7 7 7 9  
was able to p ro d u ce  in terstra n d  D N A - D N A  cr o ss - lin k in g  an d  to  d e te r m in e  th e  m o st  
favored cross-lin k in g  d is ta n c e  b e tw e e n  tw o  a d e n in e s  o n  o p p o s ite  stra n d s fo r  U -7 7 7 7 9 .  
Since U -77779 is m o r e  a c tiv e  b o th  in  a n ti-tu m o r  e f f ic a c y  an d  c y to to x ic ity  th a n  its 
mono-alkylating a n a lo g s , w e  c o m p a r e d  th e  s e q u e n c e  s e le c t iv ity  o f  U -7 7 7 7 9  w ith  th at 
of its m on o-a lk y la tin g  a n a lo g s . W e  a lso  c o m p a r e d  th e  c o n fo r m a tio n a l c h a n g e s  an d  th e  
electrophoretic m o b ility  ch a n g e  o n  n o n -d e n a tu r in g  g e l in d u c e d  b y  U -7 7 7 7 9  w ith  th o s e  
induced by its m o n o -a lk y la t in g  a n a lo g s . T h e  re su lts  sh o w e d  th a t U -7 7 7 7 9  c o v a le n t ly  
modifies tw o  a d e n in e s  o n  o p p o s ite  stra n d s o p t im a lly  sp a c e d  6 b a se  p a irs  ap art and  
induces D N A - D N A  in terstra n d  c r o ss - lin k in g . U -7 7 7 7 9  s h o w e d  h ig h e r  s e q u e n c e  
selectivity th an  ( - t - ) -A B , ( + ) - A B C ,  an d  (+ ) -C C -1 0 6 5 .  H y d r o x y l ra d ica l fo o tp r in tin g  
showed sign ifican t a ltera tio n  o f  th e  c le a v a g e  p a ttern  o f  th e  D N A  a fter  D N A - D N A  
interstrand cro ss -lin k in g  b y  U -7 7 7 7 9 . T h e s e  re su lts  are d isc u sse d  in  term s o f  lik e ly  
induced c o n fo r m a tio n a l c h a n g e s . N o n -d e n a tu r in g  g e l e le c tr o p h o r e s is  d id  n o t r e v e a l  
any net d ru g -in d u ced  b e n d in g  W e  c o n c lu d e  th a t b o n d in g  o f  U -7 7 7 7 9  to  o p p o s ite  
strands o f D N A  6  b a se  p airs ap art c a n c e ls  o u t  th e  d ru g  in d u c e d  b e n d in g  o f  th e  D N A .
Materials and  m eth o d s
Materials
U-77779 w as o b ta in e d  from  T h e  U p jo h n  C o m p a n y  an d  w a s  u se d  w ith o u t fu rth er  
purification. E le c tr o p h o r e t ic  r e a g e n ts  (a c r y la m id e /b is (a c r y la m id e ) , T E M E D , an d  a m ­
monium p e r su lfa te ) w ere  p u r c h a se d  fro m  B io -R a d . T 4  p o ly n u c le o t id e  k in a s e , T 4  
ligase, and D N A  p o ly m e r a se  I (la rg e  fr a g m e n t)  w e r e  p u rch a sed  fro m  U n ite d  S ta te s  
Biochemical C o . (y -  : P ) -A T P  an d  ( o ,- 32P )-d N T P  w e r e  p u r c h a se d  fro m  IC N . X -ra y  
film, in ten sify ing  sc r e e n s , an d  d e v e lo p in g  c h e m ic a ls  w e r e  p u rch a sed  fro m  K o d a k . 
1.4-Diaminobutane d ih y d r o c h lo r id e  (p u tr e s c in e ) ,  1 ,1 0 -p h e n a n th r o lin e , 2 ,9 -d im e th y l-
1,10-phenanthroline (n e o c u p r o in e  m o n o h y d r a te ) ,  an d  3 -m e c a p to p r o p io n ic  acid  
(MPA) w ere p u rch a sed  from  A ld r ic h .
Methods
knthesis o f oligonucleotides. T h e  o l ig o n u c le o t id e s  (S c h e m e s  1 , 2 , 3 )  w e r e  s y n th e s iz e d  
on an au tom atic  D N A  sy n th e s iz e r  (A p p lie d  B io s y s te m  3 8 1 A )  b y  th e  p h o sp h o r a m id ite  
method. T h e  d e p r o te c t io n  w a s p e r fo r m e d  as d e sc r ib e d  p r e v io u s ly  (L e e  et al., 1 9 9 1 ).
)’• and 3 '-32P-end-labeling o f  oligonucleotides. F o r  5 '-e n d  la b e lin g , 10 /xg s in g le -  
handed o lig o m e r  w a s d is so lv e d  in  23  /jl\ o f  s o lu t io n  c o n ta in in g  100  mM T r is - H C l  (p H  
8.0), 10 mM M g C l2 , an d  5 mM d ith io th r e ito l. F ifty  /xC i o f  ( y - 3“P ) -A T P  an d  10 u n its  o f  
14 polynucleotide k in a se  (P N K ) w e r e  a d d e d . T h e  m ix tu re  w a s in c u b a te d  at 37°C  for  
50min. T h en  an  a d d it io n a l 5 u n its  o f  P N K  w e r e  a d d e d  an d  th e  m ix tu re  w a s in c u b a te d
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Schem e 3
under the sa m e  c o n d it io n  fo r  an  a d d it io n a l 1 h . F o r  3 '- la b e lin g , d u p le x  D N A  w as  
dissolved in 20  yu,l o f  b u ffer  c o n ta in in g  100 mM T r is - H C l  (p H  8 .0 ) ,  10 mM M g C l2, an d  
:mM d ith io th re ito l. F i f t y / iC i  o f  (or- ~ P )-d N T P  an d  5 u n its  o f  th e  D N A  p o ly m e r a se  I 
(large fragm en t) w e r e  a d d e d  an d  in c u b a te d  at r o o m  te m p e r a tu r e  fo r  30  m in . A n  
additional 5 u n its  o f  p o ly m e r a se  I ( la r g e  fr a g m e n t)  w e r e  a d d e d  an d  in c u b a te d  a n o th e r  
30min at ro o m  te m p e r a tu r e  (A u s u b e l  et al., 1 9 8 9 ).
Purification o f  5 '-  and 3 '-32P-end-labeled oligonucleotides. P h o sp h o r y la te d  s in g le  
strands w ere  m ix ed  w ith  c o ld  c o m p le m e n ta r y  stra n d s an d  h e a te d  to  5 5 °C , an d  c o o le d  
down slow ly  to  4°C  to  fo rm  h y b r id ized  d u p le x e s . 5 '-  a n d  3 ' - 32P -e n d -la b e le d  d u p le x e s  
were purified o n  8%  n o n -d e n a tu r in g  p o ly a c r y la m id e  g e l. A  3 0  cm  x  36  cm  x  0 .8  m m  
gel was e le c tr o p h o r e se d  at 3 5 0  V  u n til th e  b r o m o p h e n o l b lu e  m a rk er  h ad  m ig ra ted  
20cm. T h e d u p le x e s  w ere  e x c is e d  fro m  th e  g e l ,  m in c e d  w ith  b la d e , an d  ex tr a c te d  
with 300 /d  o f  a n n e a lin g  b u ffer  (1 0 0  mM N a C l, 10 mM T r is - H C l ,p H  8 .0 ) .
Drug modification o f  DNA and purification o f  drug-D N A  adducts. A liq u o t s  o f  
purified d u p le x  w e r e  m o d if ie d  w ith  0 .2 8  mM o f  ( + ) - A B ,  28  /am o f  ( - t - ) -A B C , 2 . 8 /am 
of U-77779, an d  2 . 8 /am o f  ( + ) -C C -1 0 6 5  at r o o m  te m p e r a tu r e  fo r  3 d a y s  in  a n n e a lin g  
buffer (100  m M  N a C l, 10 m M  T ris  HC1 p H  8 .0 ,  1 m M  E O T A ) .  T h e  r e a c tio n  w as  
terminated by  e th a n o l p r e c ip ita tio n . U -7 7 7 7 9 -m o d if ie d  D N A  w as d is so lv e d  in  20  /a1 
alkaline track in g  d y e  (80%  (v /v )  fo r m a m id e , 10 mM N a O H , 1 mM E D T A , 0 .1%  
xylene c y a n o l)  an d  h e a te d  at 65°C  fo r  5 m in  to  d e n a tu r e  th e  n o n -c r o s s - l in k e d  D N A .  
After th erm al tr e a tm e n t, th e  D N A  w a s e le c tr o p h o r e s e d  o n  12%  d e n a tu r in g  g e l to  
separate cr o ss - lin k e d  D N A  fro m  m o n o a d d u c ts  an d  n o n -d r u g -m o d if ie d  D N A  an d  any
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m o n o -a d d u c ts  fo r m e d . T h e  b a n d  c o r r e sp o n d in g  to  th e  n o n -d r u g -m o d if ie d  DNA would 
a lso  c o n ta in  m o n o -a lk y la te d  D N A . W h e n  th is  m a ter ia l w a s  th erm a lly  treated under 
c o n d it io n s  su ita b le  fo r  stran d  b r e a k a g e  at m o n o -a lk y la t io n  s ite s , additional bands 
w e r e  n o t p r o d u c e d  (u n p u b lish e d  r e su lts ) .
Thermal and putrescine treatment o f  U-77779 and its mono-alkylating analogs. For 
th erm a l tr e a tm e n t , d r u g -m o d if ie d  D N A  w a s d is so lv e d  in  10 /zl o f  alkaline tracking 
d y e  an d  h e a te d  at 100°C  fo r  3 0  m in . In  th e  c a se  o f  p u tr e sc in e  trea tm en t, drug-modi­
f ie d  D N A  w a s d is so lv e d  in  2 0  /zl p u tr e sc in e  b u ffe r  c o n ta in in g  0 .0 5  m  Hepes, 0,1 m 
KC1, 0 .5  m M  E D T A , 0 .0 5  m  g ly c in e , 0 .0 1  m  p u tr e s c in e , p H  7 .4 ,  and  incubated at 70;C 
fo r  18 h . T h e  r e a c tio n  w a s te r m in a te d  b y  e th a n o l p r e c ip ita t io n . T h e  D N A  pellet was 
d is so lv e d  in  100 p\ o f  1 m  p ip e r id in e  a n d  in c u b a te d  at 90°C  fo r  30  m in . Piperidine was 
r e m o v e d  b y  ly o p h iliz a t io n . B o th  th erm a l- a n d  p u tr e s c in e -tr e a te d  sam p les were healed 
at 100°C  fo r  3 m in  p r ior  to  e le c tr o p h o r e s is ,  k e p t o n  ic e ,  an d  lo a d e d  on  sequencing gel 
im m e d ia te ly .
1,10-Phenanthroline-copper complex footprinting. 1 ,1 0 -P h en a n th ro lin e -co p p er  (OP-Cui 
fo o tp r in tin g  w a s carr ied  o u t  a c c o r d in g  to  th e  m e th o d  d e sc r ib e d  by Sigman (1985). 
B r ie f ly , e q u a l a m o u n ts  o f  4 0  mM 1 ,1 0 -p h e n a n th r o lin e  (in  100%  eth a n o l) and 9.0m\! 
C u S 0 4 w e r e  m ix e d  ju st p r io r  to  u se . T h is  m ix tu re  w a s  su b seq u e n tly  diluted to a 
2 .0  mM 1 ,1 0  p h e n a n th r o lin e  (O P )  an d  0 .4 5  mM C u S 0 4 so lu t io n  for  oligomer diges­
t io n . S in g ly , 5 '-  o r  3 ' - 32P -e n d -la b e le d  d r u g -m o d ifie d  an d  n on -d ru g-m od ified  oligomers 
w e r e  d is so lv e d  in  2 0  /zl o f  5 0  mM T r is - H C l  (p H  8 .0 )  b u ffe r . T h e  reaction  was initiated 
b y  a d d in g  2  p\ o f  2 .0  mM O P  an d  0 .4 5  mM C u S 0 4 s o lu t io n  and 2 /zl of 58 mv 
3 -m e c a p to p r o p io n ic  ac id  ( M P A ) . A f te r  3 m in  in c u b a t io n  at ro o m  temperature, the| 
r e a c tio n  w a s q u e n c h e d  b y  a d d in g  5 p\ o f  2 8  mM 2,9-d im ethyl-l,10-phenanthrolinelit 
100%  o f  e th a n o l) ,  an d  fo l lo w e d  b y  e th a n o l p r e c ip ita tio n .
Hydroxyl radical footprinting. S in g ly , 5 '-  o r  3 ' - 32P -e n d -la b e le d  drug-modified and 
n o n -d r u g -m o d if ie d  o l ig o m e r s  w e r e  d is so lv e d  in  35 p\  o f  50  mM T ris-H C l (pH 8.(1 
b u ffer  in  1 .5  m l E p p e n d o r f  tu b e s . T h e  F e ( I I ) - E D T A  m ix tu re  w as made by mixing 
e q u a l v o lu m e s  o f  2  mM ( N H 4) 2F e S 0 4 .6 H 20  an d  4  mM E D T A  just prior to use 
F iv e  /zl o f  th e  F e ( I I ) - E D T A  m ix tu r e , 1 .5%  H 20 2, an d  10 mM ascorbic acid were 
a d d e d  c o n s e c u t iv e ly  o n to  th e  in n e r  w a ll o f  th e  E p p e n d o r f  tu b e s . T he reactions were 
sta r ted  b y  m ix in g  th e  r e a g e n ts  an d  th e  o lig o m e r s . A fte r  5 m in  incubation at room 
te m p e r a tu r e , th e  r e a c tio n s  w e r e  q u e n c h e d  b y  a d d in g  5 /zl o f  0 .1  m  thiourea and 5/il 
o f  0 .2  m  E D T A , an d  fo l lo w e d  b y  e th a n o l p r e c ip ita t io n  (S h a fe r  et al., 1989).
Sequencing gel .electrophoresis. P u r in e - an d  p y r im id in e -sp e c if ic  sequencing reactions 
w e r e  ca rr ied  o u t a c c o r d in g  to  th e  m e th o d  o f  M a x a m  an d  G ilb e r t  (1980). Both OP-Cu 
d ig e s t io n  p r o d u c ts  an d  h y d r o x y l ra d ica l c le a v e d  p r o d u c ts  w ere  applied on 20s: 
d e n a tu r in g  g e l e le c tr o p h o r e s is  a d ja cen t to  M a x a m -G ilb e r t  D N A  sequencing reactions
Densitometric analysis o f  autoradiograms. T h e  a u to r a d io g r a m s w ere scanned with! 
la ser  d e n s ito m e te r  (L K B  2 2 0 2 ) c o u p le d  to  a re c o r d in g  in te g r a to r  (L K B  2220).
Ligation and non-denaturing gel electrophoresis. D r u g -m o d if ie d  and non-drug-modi- 
f ie d  o l ig o m e r s  w e r e  s e lf - l ig a te d  to  fo rm  m u ltim e r s  b y  a d d in g  1 un it o f T4 ligase in i 
25 /zl o f  lig a tio n  b u ffer  (2 5 0  mM T r is - H C l  p H  7 .6 ,  5 0  mM M g C l2, 5 mM ATP, 5nw 
d ith io th r e ito l , 25%  (W /V )  p o ly e th y e n e  g ly c o l 8 0 0 0 ) . T h e  ligation  reaction was
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performed at ro o m  te m p e r a tu r e  o v e r n ig h t . T h e  lig a te d  m u ltim e r s  w e r e  e le c tr o ­
phoresed on  a 6%  n o n -d e n a tu r in g  p o ly a c r y la m id e  g e l at r o o m  te m p e r a tu r e  u n til th e  
bromophenol b lu e  m a rk er  h ad  m ig r a te d  23  cm . T h e  r a d io la b e le d  b a n d s w e r e  lo c a te d  
by autoradiography (L e e  et al., 1 9 9 1 ).
Results
determination o f  the relative efficacy o f  D N A -D N A  interstrand cross-linking by 
U-77779 between adenines spaced 5, 6, and  7  base pairs apart
Three d ifferen t 21 b a se  pa ir  o l ig o m e r s  in w h ich  th e  tw o  a d e n in e s  o n  o p p o s ite  stra n d s  
are 5, 6 and 7 b a se  p a irs (2 1 -5 , 2 1 -A , an d  2 1 -7  in  S c h e m e  1) w e r e  d e s ig n e d  to  s e le c t  
the most fa v o red  cr o ss -lin k in g  d is ta n c e  fo r  U -7 7 7 7 9 . T h e  e f fe c t  o f  su b s titu tin g  a G C  
base pair for  an  A T  b a se  p a ir  in  th e  c r o ss - lin k in g  s e q u e n c e  w a s a lso  e v a lu a te d  by  
comparing 2 1 -a  w ith  2 1 -7 b  (S c h e m e  1 ). T h e  o l ig o m e r s  w e r e  m o d if ie d  w ith  U -7 7 7 7 9  at 
room tem p eratu re  fo r  3 d a y s . D e n a tu r in g  g e l e le c tr o p h o r e s is  r e su lts  s h o w e d  th a t a 
considerable a m o u n t o f  c r o ss - lin k e d  D N A  w a s  fo r m e d  in  th e  s e q u e n c e s  in  w h ich  th e  
two adenines o n  o p p o s ite  stra n d s w e r e  6 an d  7 b a se  p a irs  ap art (F ig u r e  3 a ) .  T h e  
results in F igu re  3a  sh o w  th a t tw o  p r o d u c ts  w e r e  p r o d u c e d  fro m  th e  o lig o m e r s  
Modified w ith  U -7 7 7 7 9 . O n e  o f  th e  b a n d s ( A )  r e p r e se n ts  D N A  c r o ss - lin k e d  b y  
U-77779. T h e  o th e r  b a n d  ( B ) ,  w h ich  w a s p r o v e d  a lso  to  b e  U -7 7 7 7 9  c r o ss - lin k e d  
species (resu lts  n o t s h o w n ) , m a y  b e  an  a r tific ia l p r o d u c t p r o d u c e d  as a re su lt  o f
2 1 - 5  2 1 - A  2
C D C D C D C 
1 2 3 4 5 6 7
A
B
Figure 3a D eterm ination o f cross-linking efficacy o f different 21 base-pair se ­
quences in which tw o covalently m odified adenines are 5, 6, or 7 base pairs apart 
on opposite strands. Singly, 5 '-32P-labeled D N A  w ere incubated with 2 .8  /hm o f 
U-77779 at room  tem perature for 3 days. D rug-m odified 2 1 -5 , 2 1 - A ,  2 1 -7 a , and 
21-7b oligom er (Schem e I) (lanes 2, 4 , 6, and 8 ), and corresponding non-drug-m o- 
dified D N A  (lanes 1, 3, 5, and 7) w ere heated  at 65°C for 5 min and subjected to  
12% of denaturing gel electrophoresis. Band A  represents cross-linked D N A ; band  
B also represents cross-linked D N A , (see footnote on next page) and C represent 
single-stranded D N A
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d e n a tu r in g  g e l e le c tr o p h o r e s is * . Q u a n t ita t io n  r e v e a le d  th a t th e  m a x im u m  cross-linking 
e ff ic ie n c y  (4 4 % ) w a s a c h ie v e d  in  th e  s e q u e n c e  in  w h ich  th e  tw o  co v a len tly  modified 
a d e n in e s  o n  o p p o s ite  stra n d s are  6  b a se  p a irs  ap art (2 1 - A ) .  T h e  cross-linking 
e f f ic ie n c y  o f  th is  s e q u e n c e  is a b o u t 3 -fo ld  h ig h e r  th a n  th e  o n e  in  w hich the two 
a d e n in e s  are sp a c e d  7 b a se  p a irs  ap art w ith  a ll A T  b a se  p a irs  in  b e tw e e n  (21-7a), and 
5 -fo ld  h ig h e r  th a n  th e  sa m e  s e q u e n c e  b u t w ith  o n e  G C  b a se  pa ir  in  b etw een  (21-7b). 
T h e  o lig o m e r  in  w h ic h  th e  tw o  a d e n in e s  w e r e  sp a c e d  5 b a se  p a irs apart (21-5) is the 
le a s t  fa v o r e d  se q u e n c e  fo r  cr o ss - lin k in g . L e ss  th a n  0 .5 %  o f  th e  D N A  w as cross-linked 
D N A  in th is  s e q u e n c e  (F ig u re  3 b ).
Determination o f  the sites o f  D N A cross-linkage induced by U-77779
T h e  th erm a l stran d  b r e a k a g e  a ssa y  h a s b e e n  u se d  p r e v io u s ly  to  determine the 
a lk y la tin g  s ite s  an d  s e q u e n c e  s e le c t iv ity  o f  ( + ) -C C -1 0 6 5  (R e y n o ld s  et a l 19851.
2 1 - 5  2 1 - A  2 1 - 7 a  2 1 -7 b
Figure 3b C ross-linking efficiency am ong the sequences in Schem e I with varying 
distances (5 - 7  base pairs) betw een  the tw o adenines on opposite strands. The data 
w ere obtained from Figure 3a. T he autoradiogram  was scanned by a laser 
densitom eter with the recording integrator. The intensities o f the cross-linked and 
single-stranded bands were recorded separately. The cross-linking efficiency is the 
ratio o f the cross-linked D N A  vs total D N A . The height o f each column represents 
the percentage o f cross-linking efficiency o f each oligom er
*Purified cross-linked D N A  (band A ) w as extracted and re-electrophoresed  on a denaturing gel and band B 
was still observed  (result not show n). R ecent analysis o f  the structure o f  a U -77779-1-m er duplex adduct h 
high-field *H N M R  show s that the cross-linked sp ecies is a mixture o f  tw o stable conformations at room 
tem perature (Seam an and H urley , unpublished resu lts). Band B m ay therefore represent the second 
conform ational form  that is generated  from species A  during the elevated  tem perature o f electrophoresis.
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T h e r m a l  t r e a t m e n t  o f  5 ' - l a b e l e d  D N A  a l k y l a t e d  b y  ( + ) - C C - 1 0 6 5  t y p i c a l l y  p r o d u c e s  a  
m a j o r  p r o d u c t  a n d  a  m i n o r  p r o d u c t .  T h e  m i n o r  p r o d u c t  o f  t h e r m a l  t r e a t m e n t  ( s p e c i e s  
B ’ i n  F i g u r e  2 ) ,  w h i c h  a r i s e s  f r o m  t h e  p r e s u m e d  s e c o n d  ^ - e l i m i n a t i o n  r e a c t i o n  a n d  
a f t e r  d e p u r i n a t i o n ,  c o m i g r a t e s  w i t h  t h e  p r o d u c t  o f  t h e  a d e n i n e - s p e c i f i c  s e q u e n c i n g  
r e a c t i o n .  T h e  m a j o r  p r o d u c t  ( s p e c i e s  ‘A ’ i n  F i g u r e  2 ) ,  w h i c h  c o r r e s p o n d s  t o  a  
f r a g m e n t  c o n t a i n i n g  t h e  m o d i f i e d  d e o x y r i b o s e ,  m i g r a t e s  1 . 5  b a s e  p a i r s  h i g h e r  t h a n  t h e  
m i n o r  p r o d u c t  ( R e y n o l d s  et al.,  1 9 8 5 ) .  S u b s e q u e n t  p i p e r i d i n e  t r e a t m e n t  ( u n p u b l i s h e d  
r e s u l t s )  p r o d u c e s  q u a n t i t a t i v e  c o n v e r s i o n  o f  t h e  m a j o r  p r o d u c t  ( s p e c i e s  A )  t o  t h e  
m i n o r  p r o d u c t  ( s p e c i e s  B )  ( L e e  et a l. ,  1 9 9 1 ) .  S i n c e  U - 7 7 7 7 9  c o n t a i n s  t w o  D N A  
a l k y l a t i n g  c y c l o p r o p y l  p y r r o l o i n d o l e  s u b u n i t s ,  e a c h  i s  e x p e c t e d  t o  a l k y l a t e  N 3  o f  
a d e n i n e  i n  a  s i m i l a r  m a n n e r  t o  ( + ) - C C - 1 0 6 5 .  T h e r e f o r e ,  t h e  s t r a n d  b r e a k a g e  a s s a y  
h a s  b e e n  u s e d  t o  d e t e r m i n e  t h e  c r o s s - l i n k a g e  a l k y l a t i o n  s i t e s  o f  U - 7 7 7 7 9  o n  D N A .  
C r o s s - l i n k e d  2 1 - A  D N A  ( t h e  s e q u e n c e s  o f  2 1 - A ,  2 1 - B ,  a n d  2 1 - C  a r e  s h o w n  i n  
S c h e m e  2 )  w a s  p u r i f i e d  o n  a  1 2 %  d e n a t u r i n g  g e l .  T h e  U - 7 7 7 7 9  c r o s s - l i n k e d  D N A  
s h o w s  a  q u i t e  d i f f e r e n t  m i g r a t i o n  f r o m  t h a t  o f  n o n - d r u g - m o d i f i e d  D N A  ( c o m p a r e  
l a n e s  2  a n d  1 5  w i t h  l a n e s  1  a n d  1 6  i n  F i g u r e  4 ) .  A f t e r  t h e r m a l  t r e a t m e n t  i n  p i p e r i d i n e ,  
th e  s t r a n d  b r e a k a g e  p r o d u c t s  a p p e a r e d  o n  b o t h  s t r a n d s  ( l a n e s  8  a n d  9  i n  F i g u r e  4 )  b u t  
th e  p r o p o r t i o n  o f  p r o d u c t s  ( s p e c i e s  ‘A ’ a n d  ‘B ’ a s  d e f i n e d  a b o v e )  i s  d i f f e r e n t  f r o m  
t h a t  f o r  ( + ) - C C - 1 0 6 5 .  T h i s  a s  y e t  u n e x p l a i n e d  d i f f e r e n c e  b e t w e e n  U - 7 7 7 7 9  a n d  
(+ ) -C C -1 0 6 5  i s  d u e  t o  t h e  d i f f e r e n t  c h e m i c a l  s t a b i l i t i e s  o f  t h e  D N A  a d d u c t s  t o  
t h e r m a l  t r e a t m e n t  ( 1 0 0 ° C ,  3 0  m i n )  f o l l o w e d  b y  p i p e r i d i n e  t r e a t m e n t .  F o r
(+ ) -C C -1 0 6 5  a l m o s t  c o m p l e t e  c o n v e r s i o n  t o  a  p r o d u c t  ( p r e s u m a b l y  B  i n  F i g u r e  2 )  
w h i c h  m i g r a t e s  a l o n g s i d e  t h e  M a x a m - G i l b e r t  a d e n i n e  r e a c t i o n  i s  f o u n d ,  w h i l e  f o r  
U - 7 7 7 7 9  o n l y  a b o u t  a  5 0 %  c o n v e r s i o n  o f  t h e  i n i t i a l  s t r a n d  b r e a k a g e  p r o d u c t  ( A  i n  
F i g u r e  2 )  t o  t h i s  p r o d u c t  i s  a c h i e v e d .  T h e  q u a n t i t a t i o n  s h o w s  t h a t  t h e r m a l  t r e a t m e n t  
i n d u c e d  9 0 %  c l e a v a g e  o f  c r o s s - l i n k e d  D N A  s p e c i f i c a l l y  a t  A l l  a n d  A 2 1  o f  2 1 - A  
( S c h e m e  2 ) .  P u t r e s c i n e  t r e a t m e n t  ( 1 7  h )  i s  m o r e  e f f i c i e n t ,  i n d u c i n g  a l m o s t  q u a n t i t a t ­
ive ( > 9 8 % )  c l e a v a g e  o f  c r o s s - l i n k e d  D N A  a t  t h e  s a m e  s i t e s  ( c o m p a r e  l a n e s  6  a n d  1 1  
w ith  7  a n d  1 2 ) .  T h e s e  r e s u l t s  d e m o n s t r a t e d  t h a t  U - 7 7 7 7 9  w a s  p r e s u m a b l y  c o v a l e n t l y  
b o n d e d  t h r o u g h  N 3  o f  A l l  a n d  A 2 1  a n d  i n d u c e d  D N A  i n t e r s t r a n d  c r o s s - l i n k i n g .  T h e  
c r o s s - l i n k e d  D N A  u s e d  i n  f u r t h e r  e x p e r i m e n t s  w a s  h i g h l y  h o m o g e n e o u s .  S i m i l a r  
r e s u l t s  w e r e  o b s e r v e d  u s i n g  2 1 - B  a n d  2 1 - C  D N A  ( r e s u l t s  n o t  s h o w n ) .
Comparison o f the DNA sequence specificity o f U-77779, (+)-CC-1065, (+)-ABC, and 
f + J-AB
T h e  t h e r m a l  s t r a n d  b r e a k a g e  a s s a y  ( R e y n o l d s  et a l. , 1 9 8 5 )  w a s  u s e d  t o  c o m p a r e  t h e  
s e q u e n c e  s p e c i f i c i t y  o f  U - 7 7 7 7 9  w i t h  t h a t  o f  i t s  m o n o - a l k y l a t i n g  a n a l o g s  o n  t h e  
o l i g o m e r  2 1 - A  D N A .  T w o  a n d  t h r e e  s u b u n i t s  m o n o - a l k y l a t i n g  a n a l o g s  ( + ) - A B ,  
(+ )-A B C , a n d  ( + ) - C C - 1 0 6 5  ( F i g u r e  1 )  w e r e  c h o s e n  t o  c o m p a r e  s e q u e n c e  s e l e c t i v i t y  
w ith  t h a t  o f  U - 7 7 7 7 9 .  T h e  r e s u l t s  i n  F i g u r e  5  s h o w  t h a t  U - 7 7 7 7 9  h a s  a  h i g h e r  
s e q u e n c e  s e l e c t i v i t y  t h a n  a n y  o f  t h e  m o n o - a l k y l a t i n g  s p e c i e s .  I t  h a s  a  u n i q u e  b o n d i n g  
site o n  e a c h  s t r a n d  o f  t h e  2 1 - A  D N A  ( 5 ' - T  A  A T T  A * ,  l a n e s  4  a n d  1 1  i n  F i g u r e  5 .  ( * )  
r e p r e s e n t s  c o v a l e n t l y  m o d i f i e d  b a s e ) ;  ( + ) - A B C  h a s  t w o  b o n d i n g  s e q u e n c e s  
(5 'A T T A * a n d  5 ' - G C A A * ,  l a n e s  6  a n d  9  i n  F i g u r e  5 ) ,  a n d  ( + ) - C C - 1 0 6 5  m o d i f i e d  
th r e e  b o n d i n g  s e q u e n c e s  ( 5 ' A T T A * ,  5 ' C T A A * ,  a n d  5 ' G C A A * ,  l a n e s  7  a n d  8  i n  
F i g u r e  5 ) .  ( - l - ) - A B  s h o w e d  t h e  l o w e s t  s e q u e n c e  s e l e c t i v i t y ,  b e c a u s e ,  i n  a d d i t i o n  t o  t h e  
b o n d i n g  s i t e s  o f  ( + ) - C C - 1 0 6 5 ,  ( + ) - A B  a l s o  b o n d e d  t o  5 ' G C T A *  ( l a n e s  5  a n d  1 0  i n  
F i g u r e  5 ) .
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Figure 4 D enaturing gel analysis o f  U -77779 cross-linked D N A  following putres­
cine and therm al treatm ent. 5 '-32P -(+)-strand-labeled  (lanes 1 -8 )  and (-)-strand- 
labeled 21-A  D N A  (lanes 9 -1 6 )  w ere incubated with U -77779 as described under 
M aterials and M ethods. C ross-linked D N A  was purified by 12% denaturing gel 
electrophoresis. N on-drug-m odified and cross-linked D N A  were subjected either to 
putrescine treatm ent (lanes 5, 6, 11, and 12) as described under Materials and 
M ethods or to therm al treatm ent at 100°C for 30 min (lanes 7, 8, 9, and 10). 
R eaction  products were electrophoresed  adjacent to non-drug-m odified (lanes 1 and 
16) and cross-linked D N A  (lanes 2 and 15) w ithout subsequent treatment and 
M axam -G ilbert A G  and TC sequencing reactions (lanes 3, 4, 13, and 14)
1,10-Phenanthroline-copper footprinting o f  U-77779-modified DNA
T h e  1 ,1 0 -p h e n a n th r o lin e -c o p p e r  (O p -C u )  c o m p le x  b in d s  w ith in  th e  m inor groove of 
D N A  an d  c le a v e s  at th e  b in d in g  s ite  (S ig m a n , 1 9 8 6 , Y o o n  et al., 1990). Figures 6a 
an d  6b  sh o w  th e  th e  O p -C u  c le a v a g e  p a tte r n s  fo r  U -7 7 7 7 9 -m o d if ie d  21 -A , 21-B and
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AGTC C CrAB<CC-1065 <ABCrC TCAG 


















Figure 5 Denaturing gel analysis o f U -77779 and its m ono-alkylating analogs 
(+)-CC-1065-, (+ ) -A B C -, and (-l-)-A B -m odified  21-A  follow ing putrescine treat­
ment. 5'-32P -(+)-strand-labeled  (lanes 1 -7 )  and ( —)-strand-labeled 21-A  duplex  
DNA (lanes 8 -1 4 )  were incubated with 0 .28 m o f  (-l-)-A B , 28 mM o f (+ ) -A B C , and 
2.8/im  of ( +  )-CC-1065 and U -77779 at room  tem perature for 3 days. C ross-linked  
DNA was purified as described under M aterials and M ethods. N on-drug-m odified  
21-A (lanes 3 and 12) and U -77779 cross-linked 21-A  (lanes 4 and 11), (-l-)-A B  
(lanes 5 and 10), (-f)-A B C  (lanes 6 and 9 ), and (+ )-C C -1065  m ono-alkylated 21-A  
oligomer (lanes 7 and 8) w ere treated with putrescine as described under M aterials 
and Methods. T he reaction products w ere electrophoresed  adjacent to M axam -G il-  
bert AG and TC sequencing reactions (lanes 12, 13, and 14). T he drug bonding  
sequences are shown
11C. In each ca se  th e  U -7 7 7 7 9  c r o ss - lin k e d  D N A  sh o w s  a 7 b a se  p a ir  O p -C u  
lotprint, o ffset to  th e  3 's id e  b y  2 b a se  p a irs in a cco rd  w ith  m in o r  g r o o v e  o c c u p a n c y  
(the D N A . T h e  lo c a t io n  an d  s ize  o f  th e  fo o tp r in t  is e x p e c te d  b a se d  u p o n  th e  
brlap of U -7 7 7 7 9  w ith  D N A  th a t o c c u r s  1 - 2  b a se  p a irs  to  th e  3 's id e  o f  th e  
svalently m od ified  A l l  an d  A 2 1 . T h e  c le a v a g e  ra te s  o f  A l l  an d  A 2 1  are  a r tific ia lly  
jihanced b ecau se  o f  a sm a ll a m o u n t o f  b a c k g r o u n d  th e r m a lly  in d u c e d  c le a v a g e  o f
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Figure 6a D enaturing gel analysis o f U -77779-m odified 21-A  following 1,10-phen- 
anthroline-copper digestions. U -77779 cross-linked 21-A  (lanes 6 and 7) and 
corresponding non-drug-m odified D N A  (lanes 5 and 8) w ere dissolved in 20 /d of 
50 mM T is-H C l pH  8 .0 , respectively. O P-C u digestion was carried out as described 
under M aterials and M ethods. L anes 1-6 are 5 '-32P -(+ )  strand-labeled 21-A DNA. 
Lanes 7 -1 2  are 5 '-32P - ( - )  strand-labeled 21-A  D N A . L anes 1 -2  and 11-12 are 
therm al treatm ent (100°C for 30 m in) o f non-drug-m odified (lanes 1 and 12) and 
U -77779-m odified (lanes 2 and 11) 21-A . Lanes 3, 4, 9, and 10 are Maxam-Gilbert 
A T  and G C  sequencing reactions
a lk y la te d  a d e n in e s . T h e  5 b a se  p a ir  fo o tp r in t  r e g io n  b e tw e e n  A l l  and A21 presuc- 
a b ly  c o r r e sp o n d s  to  th e  U -7 7 7 7 9  c r o ss - lin k e d  r e g io n . F o r  a ll th ree  sequences theres 
tw o  h y p e r se n s it iv e  s ite s  a t th e  5 's id e  o f  th e  fo o tp r in ts  o n  th e  to p  strand.
Hydroxyl radical footprinting o f  U-77779-modified DNA
In c o m p a r iso n  w ith  O P -C u , h y d ro x y l ra d ica l g e n e r a te d  in  so lu tion  is a diffusibi 
s p e c ie s  an d  is a sm a ll p r o b e . T h e r e fo r e , it ca n  b e  u se d  to  rev ea l fine conformation!
INDUCED D N A  INTERSTRA ND CROSS-LINKING BY U-77779 441
A. B . C .
3 4 5 6 7 8 9 1011 121314
T G C T A A T T A G C A
A C G A T T A A T C G T11 19 202122 2324 2526 27 2829
 T
3 4 5 6 7 8 9 1011 121314
T G C T T T T T A G C A
A C G A A A A A T C G T
18 192021 22 232425 26 27 28 f9
.................................. c
3 4 5 6 7 8 9 1011 12 1314
T G C T A T T T A G C A  
A C G A T A A A T C G T
1 8 1 9  2 0212223242526  27 2829
^ F iT T m jE
Figure 6b D ensitom eter quantitation o f gels follow ing OP-C u digestion o f cross- 
linked 21-A , 21-B , and 21-C oligom ers (panels A , B , and C , respectively). The 
histograms w ere prepared from a com posite o f results from 3' and 5' 32P-labeled  
(+) and ( —) strands. T he autoradiogram s were scanned by laser densitom eter, and 
the intensity o f each band was recorded by a recording integrator. T he solid  
columns represent the digestion pattern o f non-drug-m odified D N A , and the open  
columns represent the digestion pattern o f cross-linked D N A . T he heights o f the 
solid and open colum ns are proportional to  intensity o f  the bands on the 
autoradiograms
varability in th e  v ic in ity  o f  th e  c r o ss - lin k e d  d u p le x e s ,  e sp e c ia lly  in  th e  d ru g  o v e r la p  
region. For e x a m p le , h y d ro x y l ra d ica l fo o tp r in t in g  h a s b e e n  u se d  to  lo c a te  th e  
conformational c h a n g e s  in  D N A  d u e  to  m ito m y c in  C  c r o ss - lin k in g  (W e id n e r  et al. ,  
1989). U -77779  cr o ss - lin k e d  D N A  sh o w s  d im in ish e d  c le a v a g e  w ith in  th e  c r o ss - lin k e d  
region (F igure 7 a ) . R e su lts  fro m  d e n s ito m e te r  sc a n s  o f  3 ' an d  5' la b e le d  o lig o m e r s  
iFigure 7b) p ro v id e  m o re  d e ta i le d  in fo r m a tio n  a b o u t th e  c h a n g e  in  c le a v a g e  p a ttern  
following cro ss-lin k in g  o f  D N A  b y  U -7 7 7 7 9 . In  th e  d ru g  o v e r la p  r e g io n , th e  c le a v a g e  
rates of A l l  an d  A 2 1  are a r tif ic ia lly  e n h a n c e d  fo r  th e  sa m e  r e a so n  m e n t io n e d  
before*. T h e th r e e  b a se s  at th e  5 's id e  to  e a c h  c o v a le n t ly  m o d if ie d  a d e n in e  (T 1 0 , T 9 , 
and A8; T 22 , T 2 3 , an d  A 2 9 )  w e r e  le s s  r e a c t iv e , w h ile  T 9  a n d  T 23  w e r e  th e  lea st  
reactive b a ses . A t  th e  3 's id e  o f  th e  r e g io n  n o  d ra m a tic  c h a n g e  w a s o b se r v e d  (r e su lts  
not shown). T h e  h y d ro x y l ra d ica l c le a v a g e  p a ttern  o n  c o m p le m e n ta r y  stra n d s is 
different, sh o w in g  th a t cr o ss - lin k in g  by  U -7 7 7 7 9  re su lts  in a sy m m e tr ic a l e f fe c ts  in  th e  
vicinity o f  th e  b o n d in g  r e g io n . T h e  c le a v a g e  p a tte r n s  o f  2 1 -B  an d  2 1 -C  p o s s e s s  th e  
same ch aracteristics, b u t th e  a sy m m e tr ic  c h a n g e s  o n  c o m p le m e n ta r y  stra n d s are  n o t as  
significant as 2 1 -A  (F ig u re  7 c ) . In  2 1 -B  th e  c o m p le m e n ta r y  b a se s  o f  c o v a le n t ly  
modified a d e n in e s  sh o w  e n h a n c e d  c le a v a g e s  (F ig u r e  7 c ) .
M-denaturing gel electrophoresis
The bending o f  D N A  in d u c e d  b y  (+ ) -C C -1 0 6 5  r e d u c e s  th e  e le c tr o p h o r e t ic  m o b ility  o f  
drug-modified m u ltim ers  w h e n  th e  b e n d in g  lo c u s  is p h a se d  o n  th e  sa m e  fa c e  o f  th e
‘Since less than 5% o f  the total D N A  is cleaved  in the chem ical reaction with hydroxyl radical, even  a 
small amount o f background therm al cleavage due to the 2 min heat denaturation at 100°C prior to loading  
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Figure 7a D enaturing gel analysis o f U -77779-m odified  21-A  D N A  following 
hydroxyl radical footprinting. U -77779 (lanes 6 and 7) and corresponding non-drug- 
m odified D N A  (lanes 5 and 8) w ere dissolved in 35 /x 1 o f 50 mM o f Tris-HCl pH 
8.0 . H ydroxyl radical cleavage reaction was carried out as described under 
M aterials and M ethods. Lanes 1 -6  are 5 '-32P -(+ )-strand-labeled  D N A . Lanes 7-12 
are 5 '-32P -(—)-strand-labeled D N A . L anes 1 -2 ,  1 1 -1 2  are therm al treatment (100°C 
for 30 min) o f non-drug-m odified (lanes 1 and 12) and U -77779 m odified (lanes 2 
and 11) 21-A  D N A , respectively. Lanes 4, 5, 12, and 13 are M axam -G ilbert AG 
and TC sequencing reactions
h e lix  (L e e  et al., 1 9 9 1 ). T h e  e le c tr o p h o r e t ic  m o b ility  o f  U -7 7 7 7 9 -m o d ifie d  21 base 
p a ir  m u lt im e r s  w a s  q u ite  d if fe r e n t  fro m  th a t o f  its  m o n o -a lk y la t in g  an a logs, because 
th e  lig a tio n  p r o d u c ts  o f  c r o ss - lin k e d  2 1 -A , 2 1 -B , an d  2 1 -C  d id  n ot show any 
r e ta r d a t io n  in  m o b ili ty , b u t m ig r a te d  su rp r is in g ly  fa s ter  th a n  th e  corresp on d in g  ligated 
n o n -d r u g -m o d if ie d  o l ig o m e r  (c o m p a r e  o d d  an d  e v e n  n u m b e r e d  la n e s  in  Figure 8). To 
c o m p a r e  th e  d if fe r e n c e s  b e tw e e n  U -7 7 7 7 9  an d  its m o n o -a lk y la t in g  an a logs following 
l ig a tio n  an d  n o n -d e n a tu r in g  g e l e le c tr o p h o r e s is ,  th e  m o n o -a lk y la tin g  analog
I N D U C E D  D N A  I N T E R S T R A N D  C R O S S -L I N K I N G  B Y  U -7 7 7 7 9  443
1 2 3  4 5 6 7  8 9  10 1112 13 1415
5 1 TATGCTTGCTAATTAGCATGA 
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Figure 7b D ensitom eter scan o f hydroxyl radical footprinting o f  cross-linked 21-A  
DNA. The upper panel is the cleavage pattern o f non-drug-m odified D N A , and the 
bottom panel is the cleavage pattern o f U -77779 cross-linked D N A
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Figure 7c Summary o f the results o f hydroxyl radical cleavage pattern of 21-A, 
21-B , and 21-C . The solid-line arrow represents enhanced cleavage, while the 
broken-line arrow represents inhibited cleavage. The length o f the line represents 
the m agnitude o f enhancem ent or inhibition; the longer the line, the greater the 
m agnitude o f enhancem ent or inhibition
( + ) - C C 1 0 6 5 ,  ( + ) - A B C  an d  ( + ) - A B  w e r e  b o n d e d  to  th e  U -7 7 7 7 9  reactive sequence 
2 1 -A  D N A . T h e  lig a te d  2 1 -A  o lig o m e r s  sh o w e d  s lo w e r  g e l m igration  and, thus.in 
p h a se  c o h e r e n t  b e n d in g  b y  ( + ) - C C - 1 0 6 5 ,  ( + ) - A B C  a n d  ( + ) - A B  (F igures 9a and 9b|. 
W e  w e r e  p u z z le d  b y  th e  fa s te r  m ig r a tio n  o f  U -7 7 7 7 9  m o d if ie d  multimers of 21-A.
2 1 -B  a n d  2 1 -C  r e la t iv e  to  c o n tr o l D N A . O n e  p o ss ib il ity  is  th a t th e se  non-drug-modt 
f ie d  o lig o m e r s  h a v e  in tr in s ic  b e n d in g  an d  U -7 7 7 7 9  r e m o v e s  th is  bending. To explore 
th is  p o ss ib il ity  an  o lig o m e r  (2 1 -D )  c o n ta in in g  an  id e n t ic a l f la n k in g  sequence to 21A 
e x c e p t  fo r  th e  d ru g  r e a c tiv e  s e q u e n c e  5 ' - T A A T T A  w a s d esign ed . The slow
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Figures A utoradiogram  o f ligation products o f  21 -A , 21-B , and 21-C  D N A  
modified with U -77779 on 6% non-denaturing gel. Lanes 1, 3, and 5 are ligation  
products o f non-drug-m odified 21-A , 21-B , 21-C , respectively. Lanes 2, 4, and 6 are 
ligation products o f U -77779-m odified D N A , respectively. M onom er and dim er 
were indicated by M and D , respectively
migration o f  m u ltim ers  o f  2 1 -A  in  c o m p a r iso n  w ith  2 1 -D  c o n fir m s th a t th e  b o n d in g  
sequence 5 '- T A A T T A  d o e s  h a v e  in tr in s ic  b e n d in g . U p o n  m o d if ic a t io n  w ith  U -7 7 7 7 9 ,  
le multimers o f  2 1 -A  sh o w  id e n tic a l g e l m o b ility  to  2 1 -D  m u ltim e r s , im p ly in g  th at 
ross-linking b y  U -7 7 7 7 9  e lim in a te s  th e  in tr in sic  b e n d in g  a s s o c ia te d  w ith  th is  s e ­
quence. 21-B  and  2 1 -C  co n ta in  A -tr a c ts , an d  u p o n  m o d if ic a t io n  w ith  U -7 7 7 7 9 , th e  
multimers m igra te  fa s ter  th an  th e  c o n tr o ls  in  a cco rd  w ith  e lim in a t io n  o f  th e  b e n d in g  
associated w ith  th e s e  s e q u e n c e s  (G r iff ith  et al., 1986; K o o  et al., 1 9 8 6 ).
It is known th a t o n e  m o le c u le  o f  ( + ) -C C -1 0 6 5  w in d s  D N A  b y  a b o u t th e  e q u iv a le n t  
of 1 base pair  u p o n  a d d u ct fo r m a tio n  (L e e  et al., 1 9 9 1 ). In o r d e r  to  d e te r m in e  if  
U-77779 w inds D N A , a se r ie s  o f  o lig o m e r s  w e r e  d e s ig n e d , e a c h  o f  w h ich  c o n ta in s  an
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Figure 9a A utoradiogram  o f ligation products o f 21-A  D N A  modified with 
U -77779 and its m ono-alkylating analogs (-t-)-A B , (-t-)-A B C , and (+)-CC-1065 on 
6% non-denaturing gel. Lane 1 is ligation products o f non-drug-modified 21-D. 
which contains the sam e flanking sequence as 21-A  except for U-77779 reactive 
sequence 5 'T A A T T A . Lane 2 is ligation products o f non-drug modified 21-A 
D N A . Lanes 3 - 6  are ligation products o f 2 1 -A  D N A  m odified with U-77779, 
(+ ) -A B , (+ ) -A B C , and (+ )-C C -1065 , respectively. M onom er and dimer are 
indicated by M and D , respectively
A -tr a c t  a d if fe r e n t n u m b e r  o f  b a se  p a irs fro m  th e  d ru g  b o n d in g  sites (the sequence 
are sh o w n  in  S c h e m e  3 ) . T h e  s e lf - l ig a te d  p r o d u c ts  w e r e  electrophoresed on ft 
n o n -d e n a tu r in g  g e l. F ig u re  10a an d  10b  sh o w  th a t th e  m a x im u m  retardation in p
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Figure 9b RL v a l u e s  o f  l i g a t i o n  p r o d u c t s  o f  2 1 - A  D N A  m o d i f i e d  w i t h  U - 7 7 7 7 9 ,  
( + ) - A B ,  ( + ) - A B C ,  a n d  ( + ) - C C - 1 0 6 5 .  R L v a l u e s  w e r e  o b t a i n e d  f r o m  t h e  r e s u l t s  o f  
F i g u r e  9 a .  2 1 - D  m u l t i m e r  w a s  c h o s e n  a s  a  c o n t r o l  t o  c a l c u l a t e  RL v a l u e .  R L i s  t h e  
r a t i o  o f  a p p a r e n t  c h a i n  l e n g t h  ( i n  b a s e  p a i r s )  t o  a c t u a l  c h a i n  l e n g t h  ( i n  b a s e  p a i r s )
m o b i l i t y  w a s  a c h i e v e d  i n  2 1  b a s e  p a i r  s e q u e n c e ,  i n d i c a t i n g  t h a t  U - 7 7 7 7 9  d i d  n o t  s h o w  
a n y  w i n d i n g  e f f e c t  b e c a u s e  t h e  A - t r a c t - i n d u c e d  b e n d i n g  w a s  e x a c t l y  i n  p h a s e  a t  1 0 . 5  
b a s e  p a i r / h e l i c a l  t u r n .
D i s c u s s i o n
T h e  e l u c i d a t i o n  o f  t h e  c o v a l e n t  s t r u c t u r e  o f  t h e  ( + ) - C C - 1 0 6 5 - ( N 3 - a d e n i n e ) - D N A  
a d d u c t  a n d  s u b s e q u e n t  i n s i g h t  i n t o  t h e  t h r e e - d i m e n s i o n a l  s t r u c t u r e  o f  t h e  d r u g - D N A  
d u p l e x  a d d u c t  l a i d  t h e  g r o u n d w o r k  f o r  t h e  d e s i g n  o f  D N A - D N A  i n t e r s t r a n d  
c r o s s - l i n k e r s .  T h e  w o r k i n g  h y p o t h e s i s  w a s  t h a t  t w o  ( - l - ) - A - s u b u n i t s  j o i n e d  t o g e t h e r  b y  
th e  a p p r o p r i a t e  l i n k e r  w o u l d  b e  a b l e  t o  a l k y l a t e  o p p o s i t e  s t r a n d s  o f  D N A  a  
p r e d e t e r m i n e d  n u m b e r  o f  b a s e  p a i r s  a p a r t ,  w h i c h  w o u l d  b e  d e p e n d e n t  u p o n  t h e  
l e n g t h  o f  t h e  l i n k e r .  T w o  t y p e s  o f  l i n k e r  u n i t s  w e r e  d e s i g n e d  a n d  s y n t h e s i z e d  b y  
U p j o h n  s c i e n t i s t s ,  t h e  f i r s t  c h a r a c t e r i z e d  a s  f l e x i b l e  ( M i t c h e l l  et a l.,  1 9 8 9 )  a n d  t h e  
s e c o n d  a s  r i g i d  ( M i t c h e l l  et a l.,  1 9 9 1 ) .  M o l e c u l a r  m o d e l i n g  s t u d i e s  w e r e  p r e d i c t i v e  o f  
ih e  s i z e s  o f  f l e x i b l e  l i n k e r  w h i c h  w o u l d  b e  o p t i m a l  f o r  c r o s s - l i n k i n g  a n d  b i o l o g i c a l  
p o t e n c y  ( M i t c h e l l  et a l.,  1 9 8 9 ) .  I n  s t u d i e s  i n  w h i c h  f l e x i b l e  a n d  r i g i d  c r o s s - l i n k e r s  w e r e  
c o m p a r e d  s i d e  b y  s i d e ,  i t  w a s  f o u n d  t h a t  t h e  r i g i d  c r o s s - l i n k e r s  w e r e  m o r e  p o t e n t  a n d  
e f f i c a c i o u s  t h a n  t h e  f l e x i b l e  c r o s s - l i n k e r s .  T h e  p u r p o s e  o f  t h i s  s t u d y  w a s  t o  e x a m i n e  
ih e  U - 7 7 7 7 9 - D N A  a d d u c t  f o r  t h e  o p t i m u m  s i z e  o f  D N A  c r o s s - l i n k i n g  a n d  t o  
d e t e r m i n e  t h e  o v e r a l l  f e a t u r e s  o f  t h e  c o m p l e x  i n c l u d i n g  d i s t o r t i o n ,  b e n d i n g ,  a n d
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Figure 10a A u t o r a d i o g r a m  o f  l i g a t i o n  p r o d u c t s  o f  1 8 - W ,  1 9 - W ,  2 0 - W ,  2 1 - W ,  a n d  
2 1 - A  D N A  m o d i f i e d  w i t h  U - 7 7 7 7 9  o n  6 %  n o n - d e n a t u r i n g  g e l .  L a n e s  1 ,  3 ,  5 ,  7 ,  a n d  
9  a r e  l i g a t i o n  p r o d u c t s  o f  n o n - d r u g - m o d i f i e d  2 1 - A ,  2 1 - W ,  2 0 - W ,  1 9 - W ,  a n d  1 8 - W  
D N A ,  r e s p e c t i v e l y .  L a n e s  2 ,  4 ,  6 ,  8 ,  a n d  1 0  a r e  l i g a t i o n  p r o d u c t s  o f  U - 7 7 7 7 9 - m o d i -  
f i e d  2 1 - A ,  2 1 - W ,  2 0 - W ,  1 9 - W ,  a n d  1 8 - W  D N A ,  r e s p e c t i v e l y .  M o n o m e r  a n d  d i m e r  
w e r e  i n d i c a t e d  b y  M  a n d  D  r e s p e c t i v e l y
w i n d i n g  o f  t h e  h e l i x .  T h e  r e s u l t s  s h o w  t h a t  U - 7 7 7 7 9  o p t i m a l l y  c r o s s - l i n k s  b e t w e e n  
a d e n i n e s  6  b a s e  p a i r s  a p a r t  o n  o p p o s i t e  s t r a n d s  a n d  p r o d u c e s  a s y m m e t r y  w i t h i n  the 
c r o s s - l i n k e d  s e q u e n c e  i n  w h i c h  t h e  m o s t  p r o n o u n c e d  e f f e c t  i s  i n  t h e  c e n t e r  o f  the 
d u p l e x .  S i g n i f i c a n t l y ,  U - 7 7 7 7 9  s h o w s  a  h i g h e r  l e v e l  o f  s e q u e n c e  s e l e c t i v i t y  t h a n  the 
m o n o - a l k y l a t i n g  c o m p o u n d s ,  s u c h  a s  ( + ) - C C - 1 0 6 5 ,  b u t  s h o w s  n o  n e t  b e n d i n g  or 
w i n d i n g  o f  t h e  c r o s s - l i n k e d  d u p l e x .
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F i g u r e  1 0 b  RL v a l u e s  o f  l i g a t i o n  p r o d u c t s  o f  1 8 - W ,  1 9 - W ,  2 0 - W ,  a n d  2 1 - W  D N A  
m o d i f i e d  w i t h  U - 7 7 7 7 9 .  RL v a l u e s  w e r e  o b t a i n e d  f r o m  t h e  r e s u l t s  o f  F i g u r e  1 0 a .  RL 
v a l u e s  w e r e  c a l c u l a t e d  a s  d e s c r i b e d  i n  t h e  l e g e n d  t o  F i g u r e  9 b
tincture o f the U-77779-duplex adduct
C l e a r l y ,  U - 7 7 7 7 9  i s  a b l e  t o  q u i t e  e f f i c i e n t l y  p r o d u c e  D N A - D N A  i n t e r s t r a n d  c r o s s ­
i n k s ,  w h i c h  a r e  o p t i m a l l y  f o r m e d  6  b a s e  p a i r s  a p a r t .  S i n c e  a  7  b a s e - p a i r  r e g i o n  c a n  
ie  c r o s s - l i n k e d  a t  a b o u t  o n e - t h i r d  o f  t h e  e f f i c i e n c y  o f  a  6  b a s e - p a i r  r e g i o n  b u t  a  5  
b a s e - p a i r  r e g i o n  i s  o n l y  v e r y  w e a k l y  c r o s s - l i n k e d ,  w e  c o n c l u d e  t h a t  t h e  D N A  h a s  
m o re  f l e x i b i l i t y  t h a n  t h e  d r u g  m o l e c u l e  t o  a c c o m m o d a t e  t h e  l a r g e r  c r o s s - l i n k e d  
s p e c i e s .  A l t h o u g h  m o r e  h a r s h  c o n d i t i o n s  a r e  r e q u i r e d  t o  i n d u c e  s t r a n d  b r e a k a g e  t h a n  
n t h  m o n o - a l k y l a t i n g  p r o d u c t s  o f  ( + ) - C C - 1 0 6 5 ,  t h e  c h e m i s t r y  o f  s t r a n d  c l e a v a g e  o n  
J e n a t u r i n g  g e l  a p p e a r s  t o  b e  s i m i l a r  t o  ( + ) - C C - 1 0 6 5  o n  b o t h  s t r a n d s ,  w h i c h  p r o v i d e s  
e x c e l l e n t  e v i d e n c e  f o r  a  N 3 - a d e n i n e  D N A  b i s a d d u c t  s p e c i e s .  H i g h - f i e l d  ^ - N . M . R .  
s tu d i e s  o n  a  1 0 - m e r  c o n t a i n i n g  t h e  b o n d i n g  s e q u e n c e  s h o w n  i n  2 1 - A  c o n f i r m s  t h i s  
l o t i o n  ( S e a m a n  &  H u r l e y ,  u n p u b l i s h e d  r e s u l t s ) .  W h i l e  t h e  b o n d i n g  r e g i o n  o f  2 1 - A  
( f - T A A T T A - 3 ' )  a n d  U - 7 7 7 7 9  a r e  b o t h  s y m m e t r i c a l ,  h y d r o x y l  r a d i c a l  f o o t p r i n t i n g  
m o w s  t h a t  u p o n  a d d u c t  f o r m a t i o n  t h e  s y m m e t r y  i s  l o s t  w i t h i n ,  a s  w e l l  a s  p e r i p h e r a l  
t o . t h e  c r o s s - l i n k e d  s e q u e n c e .  T h e  m a j o r  h e l i x  d i s t o r t i o n  a p p e a r s  t o  o c c u r  a r o u n d  T 9  
n a i l  o f  t h e  s e q u e n c e s  e x a m i n e d .  T h i s  c o n c l u s i o n  i s  v e r i f i e d  b y  t h e  h i g h - f i e l d  N . M . R .  
s tu d i e s  ( u n p u b l i s h e d  r e s u l t s ) .
T h e  r e s u l t s  o f  n o n - d e n a t u r i n g  g e l  a n a l y s i s  s h o w  t h a t  c r o s s - l i n k i n g  b y  U - 7 7 7 7 9  d o e s  
D t p r o d u c e  a n y  n e t  b e n d i n g  o f  D N A ,  a n d  i n  s e q u e n c e s  t h a t  h a v e  i n t r i n s i c  b e n d i n g  
s s o c i a t e d  w i t h  A - t r a c t s ,  t h e  b e n d i n g  i s  a p p a r e n t l y  e l i m i n a t e d .  T h e  a p p a r e n t  a b s e n c e  
if  D N A  b e n d i n g  a s s o c i a t e d  w i t h  a l k y l a t i o n  b y  U - 7 7 7 7 9  i s  n o t  u n e x p e c t e d ,  s i n c e  
i o u g h  m o n o - a l k y l a t i o n  b y  ( + ) - C C - 1 0 6 5  a n d  i t s  a n a l o g s  p r o d u c e s  b e n d i n g  o f  D N A ,
450 Z.-M. DING & L. H. HURLEY
5  ' T A T G C T T P n r A i # T A S O A T G A
6  b p  |
C G A A C G A T # \ A T C G T A C T A T A  5
* I = >
Figure 11 S u m m a r y  o f  t h e  c l e a v a g e  p a t t e r n  c h a n g e s  o f  U - 7 7 7 7 9 - c r o s s - l i n k e d  D N A  
d e t e r m i n e d  b y  1 , 1 0 - p h e n a n t h r o l i n e - c o p p e r  a n d  h y d r o x y l  r a d i c a l  f o o t p r i n t i n g .  T h e  
a d e n i n e s  w i t h  s t a r s  r e p r e s e n t  c o v a l e n t l y  m o d i f i e d  b a s e s  b y  U - 7 7 7 7 9 .  T h e  b r o k e n -  
l i n e d  b o x  r e p r e s e n t s  t h e  l e s s  r e a c t i v e  b a s e ,  a n d  t h e  s o l i d - l i n e  b o x  r e p r e s e n t s  t h e  
h y p e r r e a c t i v e  b a s e  t o  1 , 1 0 - p h e n a n t h r o l i n e - c o p p e r  d i g e s t i o n .  T h e  s h a d e d  c i r c l e  
r e p r e s e n t s  t h e  l e a s t  r e a c t i v e  b a s e  t o  h y d r o x y l  r a d i c a l  c l e a v a g e .  T h e  s o l i d  a r r o w  
r e p r e s e n t s  t h e  d r a m a t i c  c h a n g e  i n  c l e a v a g e  p a t t e r n ,  a n d  t h e  o p e n  a r r o w  r e p r e s e n t s  
t h e  l e s s e r  c h a n g e  i n  c l e a v a g e  p a t t e r n
b i s - a l k y l a t i o n  o n  o p p o s i t e  s t r a n d s  a p p r o x i m a t e l y  o n e - h a l f  a  h e l i c a l  t u r n  a p a r t  w o u l d  
b e  a n t i c i p a t e d  t o  c a n c e l  o u t  a n y  n e t  b e n d i n g .  W e  t h e r e f o r e  a n t i c i p a t e  t h a t  th e  
s t r u c t u r e  w i l l  s h o w  d r u g - i n d u c e d  b e n d i n g  i n t o  t h e  m i n o r  g r o o v e  o n  o p p o s i t e  s i d e s  o f 
t h e  h e l i x ,  w h i c h  w i l l  e f f e c t i v e l y  c a n c e l  o u t  n e t  b e n d i n g  o v e r  t h e  e n t i r e  l e n g t h  o f  th e  
c r o s s - l i n k e d  r e g i o n .
D N A  sequence selectivity o f  cross-linking by  U-77779
T h e  c r o s s - l i n k i n g  s e q u e n c e  5 ' - T A A T T A  w a s  c h o s e n  b e c a u s e  5 ' - T T A  i s  a  h i g h l y - r e a c -  
t i v e  s e q u e n c e  f o r  ( + ) - C C - 1 0 6 5 ,  a n d  t h i s  s e q u e n c e  w o u l d  p r o v i d e  t w o  s u c h  s i t e s  6 b a s e  
p a i r s  a p a r t  o n  o p p o s i t e  s t r a n d s .  W i t h i n  t h i s  s e q u e n c e ,  m o n o - a l k y l a t i o n  c o m p o u n d s  
s u c h  a s  ( + ) - A B  a n d  ( + ) - C C - 1 0 6 5  r e a c t  a t  e a c h  o f  t h e  5 ' - T T A  s e q u e n c e s  b u t  a lso  
r e a c t  a t  3 ' a d e n i n e  i n  t h e  a d j a c e n t  5 ' - A A  s e q u e n c e .  ( + ) - C C - 1 0 6 5  i s  p a r t i c u l a r l y  
r e a c t i v e  a t  t h i s  s e c o n d  b o n d i n g  s e q u e n c e .  ( + ) - A B C  a n d  U - 7 7 7 7 9  r e a c t  e x c l u s i v e l y  at 
t h e  5 ' - T T A  s e q u e n c e  within  t h i s  b o n d i n g  r e g i o n ,  b u t ( + ) - A B C  i s  a l s o  r e a c t i v e  t o  a 
5 ' - C A A  outside  t h e  b o n d i n g  r e g i o n .  ( + ) - C C - 1 0 6 5  a n d  ( - l - ) - A B  a l s o  r e a c t  w i t h  th is  
s e q u e n c e .  O v e r a l l ,  U - 7 7 7 7 9  h a s  t h e  h i g h e s t  s e q u e n c e  s e l e c t i v i t y ,  r e a c t i n g  e x c l u s i v e l y  
a t  t h e  5 ' - T T A  s e q u e n c e s  o n  b o t h  s t r a n d s .  S i g n i f i c a n t l y ,  U - 7 7 7 7 9  d o e s  n o t  f o r a  
m o n o - a l k y l a t i o n  p r o d u c t s  a t  o t h e r  s e q u e n c e s ,  s u c h  a s  5 ' T A A  a n d  5 ' - C A A ,  b u t  o n ly  
r e a c t s  a t  s e q u e n c e s  t h a t  c o n t a i n  a d e n i n e s  6  b a s e  p a i r s  a p a r t .  I n  a n  a n a l y s i s  of 
a l k y l a t i o n  s i t e s  p r o d u c e d  b y  U - 7 7 7 9  o n  r e s t r i c t i o n  e n x y m e  f r a g m e n t s ,  w e  h a v e  n o «  
f o u n d  a  n u m b e r  o f  w e a k  m o n o - a l k y l a t i o n  s i t e s .  H o w e v e r ,  t h e  o v e r w h e l m i n g  p r e f e r ­
e n c e  i s  f o r  c r o s s - l i n k a g e  r a t h e r  t h a n  m o n o - a l k y l a t i o n .  W e  a r e  p r e s e n t l y  e x p l o r i n g  the 
m o l e c u l a r  b a s i s  f o r  t h i s  s e q u e n c e  s p e c i f i c i t y .
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Abstract: T h e  s e q u e n c e  s p e c i f i c i t y  o f  b i z e l e s i n ,  a n  i n t e r s t r a n d  D N A - D N A  c r o s s - l i n k e r  r e l a t e d  t o  t h e  m o n o a l k y l a t i n g  
c o m p o u n d  ( + ) - C C - 1 0 6 5 ,  w a s  s t u d i e d  u s i n g  r e s t r i c t i o n  e n z y m e  f r a g m e n t s .  B i z e l e s i n ,  l i k e  ( + ) - C C - 1 0 6 5 ,  f o r m s  
m o n o a l k y l a t i o n  a d d u c t s  t h r o u g h  N 3  o f  a d e n i n e  b u t  c a n  a l s o  f o r m  D N A - D N A  c r o s s - l i n k s  s i x  b a s e  p a i r s  a p a r t  o n  
o p p o s i t e  s t r a n d s .  C o m p a r e d  t o  m a n y  o t h e r  m i n o r  g r o o v e  c r o s s - l i n k i n g  c o m p o u n d s ,  b i z e l e s i n  i s  v e r y  e f f i c i e n t  a t  c r o s s -  
l i n k i n g  D N A .  T h e r e  i s  a  h i g h e r  t h a n  e x p e c t e d  p r o p o r t i o n  o f  c r o s s - l i n k e d  a d d u c t s  b a s e d  u p o n  t h e  r e l a t i v e  n u m b e r  o f  
c r o s s - l i n k e d  v s  m o n o a l k y l a t e d  a d d u c t s .  T h i s  i s  r a t i o n a l i z e d  b a s e d  u p o n  t h e  r e l a t i v e  t h e r m o d y n a m i c  s t a b i l i t y  o f  t h e  
c r o s s - l i n k e d  v s  m o n o a l k y l a t e d  s p e c i e s .  W h e r e  b i z e l e s i n  m o n o a l k y l a t i o n  o c c u r s ,  t h e  s e q u e n c e  s p e c i f i c i t y  i s  s i g n i f i c a n t l y  
h i g h e r  t h a n  t h o s e  o f  ( + ) - C C - 1 0 6 5  a n d  o t h e r  m o n o a l k y l a t i n g  ( + ) - C P I  a n a l o g s .  T h e  b i z e l e s i n  G C  t o l e r a n c e  a t  c r o s s -  
l i n k i n g  s i t e s  i s  t w i c e  a s  h i g h  a s  f o r  t h e  m o n o a l k y l a t i o n  s i t e s .  T h i s  i n c r e a s e d  G C  t o l e r a n c e  c a n  b e  l a r g e l y  e x p l a i n e d  
b y  t h e  c o v a l e n t  i m m o b i l i z a t i o n  o f  t h e  s e c o n d  a l k y l a t i o n  a r m  a t  s e q u e n c e s  t h a t  a r e  n o t  n o r m a l l y  r e a c t i v e  t o w a r d  C P I  
m o n o a l k y l a t i o n  c o m p o u n d s  b u t  a r e  m a d e  r e a c t i v e  d u e  t o  a  p r o x i m i t y  e f f e c t .  T h i s  s a m e  r a t i o n a l e  c a n  b e  u s e d  t o  e x p l a i n  
t h e  r e a c t i v i t y  o f  t h e  s e c o n d  a l k y l a t i o n  a r m  o f  b i z e l e s i n  w i t h  g u a n i n e ,  c y t o s i n e ,  a n d  t h y m i n e  o n  s o m e  s e q u e n c e .  T h e r e  
a r e  s o m e  s e q u e n c e s  t h a t  a p p e a r  t o  b e  u n u s u a l  i n  t h e i r  r e a c t i v i t y  w i t h  b i z e l e s i n  i n  t h a t  b i z e l e s i n  f o r m e d  c r o s s - l i n k i n g  
s p a n n i n g  s e v e n  b a s e  p a i r s ,  a n d  b i z e l e s i n  f o r m s  m o n o a k y l a t i o n  a d d u c t s  o n  g u a n i n e .  I n  t h e s e  c a s e s ,  i t  i s  p r o p o s e d  t h a t  
b i z e l e s i n  m a y  t r a p  o u t  r a r e  c o n f o r m a t i o n a l  f o r m s  d u r i n g  t h e  s e c o n d  a l k y l a t i o n  s t e p ,  o r  b i z e l e s i n  m a y  a l k y l a t e  u n u s u a l
s i t e s  d u e  t o  t h e  s t r o n g  p r e c o v a l e n t  a f f i n i t y  o f  b i z e l e s i n  f o r
Introduction
T h e  u n d e r l y i n g  m e c h a n i s m s  f o r  s e q u e n c e  r e c o g n i t i o n  o f  D N A  
b y  s m a l l  m o l e c u l e s  a r e  o f  c o n s i d e r a b l e  i n t e r e s t  i n  m o l e c u l a r  
r e c o g n i t i o n  a n d  a n t i t u m o r  d r u g  d e v e l o p m e n t . 1 D r u g s  t h a t  
c o v a l e n t l y  m o d i f y  D N A  a r e  c o n s i s t e n t l y  a t  o r  n e a r  t h e  t o p  o f  t h e  
lis t o f  t h e  m o r e  p o t e n t  c y t o t o x i c  c o m p o u n d s .2 T h e s e  c o m p o u n d s  
o f t e n  s h o w  c o n s i d e r a b l e  s e q u e n c e  s e l e c t i v i t y  b e y o n d  w h a t  m i g h t  
b e i n t u i t i v e l y  o b v i o u s  f r o m  e x a m i n a t i o n  o f  t h e i r  s t r u c t u r e s  a n d  
m o l e c u l a r  w e i g h t s .2 A m o n g  t h e  m e c h a n i s m s  m e d i a t i n g  t h i s  
s e q u e n c e  s e l e c t i v i t y  a r e  s e q u e n c e  d e p e n d e n t  m o l e c u l a r  e l e c t r o ­
s t a t i c  p o t e n t i a l ,3 c o n f o r m a t i o n a l  f l e x i b i l i t y ,4 c a t a l y t i c  f u n c t i o n a l  
g r o u p  j u x t a p o s i t i o n s ,5 a n d  p r e c o v a l e n t  b i n d i n g  a f f i n i t i e s .6 O f  
p a r t i c u l a r  i n t e r e s t  t o  u s  i s  h o w  t h e  s e q u e n c e  s e l e c t i v i t y  o f  
m o n o a l k y l a t i o n  o f  D N A  b y  a  c o m p o u n d  s u c h  a s  ( + ) - C C - 1 0 6 5  
r e l a t e s  t o  t h e  s e q u e n c e  s e l e c t i v i t y  o f  c r o s s - l i n k i n g  c o m p o u n d s  
t h a t  a r e  d e r i v e d  f r o m  t h e  a p p r o p r i a t e  j o i n i n g  o f  t w o  s u i t a b l y  
p o s i t i o n e d  m o n o a l k y l a t i o n  m o i e t i e s  o f  t h e  s a m e  t y p e .  T h e  
c o m p o u n d  u s e d  i n  t h i s  s t u d y ,  b i z e l e s i n ,  i s  s u c h  a  s y n t h e t i c a l l y  
d e r i v e d  c o m p o u n d  d e s i g n e d  a n d  s y n t h e s i z e d  b y  U p j o h n  s c i e n t i s t s .7 
T h e  t w o  m a i n  q u e s t i o n s  w e  h a v e  a d d r e s s e d  i n  t h i s  s t u d y  a r e  
w h e t h e r  t h e  s e q u e n c e  s e l e c t i v i t y  o f  b i z e l e s i n  c a n  b e  p r e d i c t e d  
f ro m  a  k n o w l e d g e  o f  t h e  s e q u e n c e  s e l e c t i v i t y  o f  m o n o a l k y l a t i o n  
c o m p o u n d s  s u c h  a s  ( + ) - C C - 1 0 6 5 ,  a n d  w h a t  u n i q u e  p r o p e r t i e s  
the c r o s s - l i n k i n g  c o m p o u n d s  m a y  p o s s e s s  r e l a t i v e  t o  t h e  m o n o a l k y -  
l a t i o n  c o m p o u n d s . _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
(1) (a) Dickerson, R. E.; Kopka, M. L.; Pjura, P. E. In DNA Ligand 
Interactions; Guschlbauer, W., Saenger, W., Eds.; Plenum Press: 1987; pp 
45-62. (b) Advances in DNA Sequence Specific Agents-, Hurley, L. H., Ed.; 
JAI Press Inc.: Greenwich, 1992; Vol. 1.
(2) Warpehoski, M. A.; Hurley, L. H. Chem. Res. Toxicol. 1988, 7,315.
(3) Kohn, K. W.; Hartley, J. A.; Mattes, W. B. Nucleic Acids Res. 1987, 
15,10531.
(4) Zakrzewska, K.; Pullman, B. J. Biomol. Struct. Dyn. 1986, 4, 127.
(5) Buckley, N. J. Am. Chem. Soc. 1987, 109, 7918.
1 (6)Baker, B. F.; Dervan, P. B. J. Am. Chem. Soc. 1989, 111, 2700.
(.1) Mitchell, M. A.; Kelly, R. C.; Wicnienski, N. A.; Hatzenbuhler, N . T.;
Williams, M. G.; Petzold, G. C.; Slighton, J. L.; Siemieniak, P. R. J. Am.
Chem. Soc. 1991, 113, 8994.
0002-7863/93/1515-5925$04.00/0
s i t e s .
B i z e l e s i n  ( F i g u r e  1 )  i s  a n  a n t i t u m o r  a g e n t  t h a t  i s  a  s y n t h e t i c a l l y  
d e r i v e d  d i m e r i c  a n a l o g  o f  ( + ) - C C - 1 0 6 5 ,  a  p o t e n t  a n t i t u m o r  
a n t i b i o t i c  p r o d u c e d  b y  Streptomyces zelensis.8 L i k e  ( + ) - C C -  
1 0 6 5  a n d  o t h e r  c y c l o p r o p y l p y r r o l i n d o l e s  ( C P I s ) ,  b i z e l e s i n  a l k y ­
l a t e s  N 3  o f  a d e n i n e  w i t h  c o n c o m i t a n t  o p e n i n g  o f  c y c l o p r o p a n e  
r i n g  o f  t h e  C P I  m o i e t y 9 a n d  i s  a b l e  t o  c r o s s - l i n k  a t  5 ' - T A A T T A  
s e q u e n c e s 7 ( F i g u r e  2 ) .  T h e r a p e u t i c a l l y ,  b i z e l e s i n  s h o w s  h i g h  
a n t i t u m o r  e f f i c a c y  b o t h  in vitro  a n d  in vivo  t o  v a r i o u s  k i n d s  o f  
t u m o r  c e l l s , 10 a n d  i t  d o e s  n o t  s h o w  t h e  d e l a y e d  t o x i c i t y  a s s o c i a t e d  
w i t h  ( + ) - C C - 1 0 6 5 . 1 1  I t s  p a t t e r n  o f  i n h i b i t i o n  o f  m a c r o m o l e c u l a r  
s y n t h e s i s  i s  d i f f e r e n t  f r o m  a n y  o f  t h e  m o n o a l k y l a t i o n  a n a l o g s ,  
a n d  b i z e l e s i n  h a s  b e e n  a c c e p t e d  i n t o  t h e  N C I  D e c i s i o n  N e t w o r k  
( M c G o v r e n ,  J .  P . ,  p r i v a t e  c o m m u n i c a t i o n ) .  A s  a  f i r s t  s t e p  t o w a r d  
u n d e r s t a n d i n g  t h e  m o l e c u l a r  b a s i s  f o r  t h e s e  u n i q u e  b i o c h e m i c a l  
a n d  b i o l o g i c a l  c h a r a c t e r i s t i c s  o f  b i z e l e s i n ,  w e  h a v e  c o m p a r e d  t h e  
m o l e c u l a r  i n t e r a c t i o n s  o f  b i z e l e s i n  a n d  C P I  m o n o a l k y l a t i o n  
a n a l o g s  w i t h  D N A ,  t h e  p r e s u m e d  p r i n c i p a l  t a r g e t  o f  b o t h  g r o u p s  
o f  c o m p o u n d s .  I n  a  p r e v i o u s  s t u d y ,  e m p l o y i n g  a  v e r y  l i m i t e d  
n u m b e r  o f  d e f i n e d  o l i g o m e r s ,  o n e  o f  w h i c h  c o n t a i n e d  a  h i g h l y  
r e a c t i v e  c r o s s - l i n k i n g  s e q u e n c e  f o r  b i z e l e s i n ,  i t  h a s  b e e n  s h o w n  
t h a t  b i z e l e s i n  p r o d u c e s  a  s t a b l e  i n t e r s t r a n d  c r o s s - l i n k e d  s p e c i e s  
a n d  a p p e a r e d  t o  s h o w  a n  i n c r e a s e d  s e q u e n c e  s e l e c t i v i t y  r e l a t i v e  
t o  i t s  m o n o a l k y l a t i n g  a n a l o g s .9
I n  t h e  p r e s e n t  s t u d y  w e  h a v e  i n v e s t i g a t e d  i n  m o r e  d e t a i l  t h e  
s e q u e n c e  s e l e c t i v i t y  o f  b i z e l e s i n  b y  s c r e e n i n g  a b o u t  4 . 0  K b  o f
(8) (a) W arpehoski, M . A. In Advances in DNA Sequence Specific Agents-, 
Hurley, L. H., Ed.; JAI Press Inc.: Greenwich, 1992; Vol. 1 pp 217-246. (b) 
Reynolds, V. L.; McGovren, J. P.; Hurley, L. H. J. Antibiotics 1986, 39, 319. 
(c) Hurley, L. H.; Needham, VanDevanter, D. K. Acc. Chem. Res. 1986,19, 
230. (d) Warpehoski, M. A. Drugs o f  the Future 1991, 16, 131.
(9) Ding, Z.-M.; Hurley, L. H. Anti-Cancer Drug Design 1991, 6, 427.
(10) For example, a single iv injection of bizelesin at 10 M g /K g  cured 
(30-day survivors) 50% of the mice. For comparison, adozelezin [(+)-ABC" 
in Figure 1 ] increased the life span of such mice by 94% at an optimum dose 
of 100 fig but with no cures.
(11) (a) Reynolds, V. L.; McGovren, J. P.; Hurley, L. H. J. Antibiotics 
1986, 39, 319. (b) Warpehoski, M. A.; Bradford, V. S. Tetrahedron Lett. 
1988, 29, 131.
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Figure 2. Proposed reaction of bizelesin to form the DNA-reactive CPI 
and its subsequent reaction with DNA.
DNA from restriction fragments generated from plasmids or 
viral genomic DNA for monoalkylation and cross-linking sites. 
Some of these fragments were chosen purposely to address specific 
questions. As a consequence of this investigation, highly reactive 
cross-linking or monoalkylating sequences have been identified 
on the restriction fragments. An analysis of the potential cross- 
linking sites and monoalkylation sites on these fragments shows 
that the cross-linking sites have a higher tolerance for GC base 
pairs (bps) than the monoalkylation sites and that alkylation 
appears to be favored for certain cross-linking sites over 
monoalkylation sites. There is also evidence for an effect of drug 
concentration on specific alkylation sites where these are over­
lapping. Alkylation at nonadenine bases is also evident within 
certain specific sequence contexts.
Results
Comparison of the DNA Sequence Specificity of Bizelesin with 
Monoalkylating Cyclopropylpyrroloindoles. The gel electro­
phoretic results of a thermal strand breakage assay12 following 
drug treatment of the (+)- and (-)-strands of a 134-bp fragment 
(bp of duplex region) from plasmid pSP6/T3 (Figure 3) with 
(+)-CC-1065, (+)-AB'C', (+)-ABC//, (+)-ABC, (+)-AB, and 
bizelesin (for structures, see Figure 1) reveal an initial comparison 
of the sequence selectivity of these various alkylating molecules 
(lanes 1-6, respectively, in Figure 3). While there are some sites 
on both (+)- and (-)-strands that are alkylated by all of the drugs 
to about the same extent (i.e., 5'-CCAATA* and 5'-ACTAAA* 
on the (-)-strand) ,13 other sites (e.g., 5'-AATTCA* on the (+) 
strand) show considerable difference in reactivity both between 
individual monoalkylation compounds (e.g., (+)-CC-1065 vs (+)- 
ABC) and in comparison to the cross-linking compound bizelesin. 
As we have noted previously,14 while (+)-CC-1065 and (+)- 
AB'C' have quite similar sequence selectivities, these drugs also 
alkylate some sites that are either more or less reactive to (+)-AB 
and (+)-ABC; meanwhile, (+)-ABC" appears to be related to 
both subtypes of molecules because it shares most of the bonding 
sites of both groups of drugs. Unexpectedly, it was found that 
(+)-CC-1065, (+)-AB'C', and (+)-ABC" could alkylate the 
guanine on the sequence 5/-GCGTTG*-3/ [(-)-strand], while 
(+)-ABC, (+)-AB, and bizelesin lack the ability to alkylate that 
site.15 However, most important from the perspective of this 
study are the differences in sequence specific alkylation that exist 
between bizelesin and the monoalkylating CPIs. While bizelesin 
is most like (+)-ABC and (+)-AB in sequence selectivity, in 
certain instances it differs from these compounds quite dramat­
ically. For example, bizelesin appears unique in bonding at 5'- 
TTCAGA* and 5'-TAGTGA* [(+)-strand] and 5'-AATTAA* 
[(-)-strand] sequences. Some sites are notably much more 
reactive to bizelesin than the monoalkylating CPIs [e.g., 5'- 
TAATTA* and 5'-AATTCA* on the (+)-strand].
A quantitative comparison of the sequence selectivity of 
bizelesin and (+)-AB derived from the results shown in Figure
(12) Reynolds, V. L.; Molineux, I. J.; Kaplan, D. J.; Swenson, D. H.; Hurley, 
L. H. Biochemistry 1985, 24, 6228.
(13) The asterisk here and elsewhere indicates the covalently modified 
base.
(14) Hurley, L. H.; Lee, C.-S.; McGovren, J. P.; Warpehoski, M. A.; 
Mitchell, M. A.; Kelly, R. C.; Aristoff, P. A. Biochemistry 1988,27, 3886.
(15) This is the first report of (+)-CC-1065 modification of guanine, and 
a more complete description of these results has been submitted for publication 
(H. J. Park, D. Sun, and L. H. Hurley).
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Figure 3. Comparison of sequence selectivity of bizelesin and its 
monoalkylating analogs on the (+ )-  and (-)-strands of a 134-bp restriction 
fragment. 5 ' 32P-labeled restriction fragm ent (134 bps) was modified 
with 1.4 >iM of (+)-C C -1065, (+ )-A B 'C ', (+ )-A B C ", and (+ )-A B C , 
and 14 fiM of (+ )-A B  and bizelesin for 2 days a t room tem perature. 
Asterisks indicate the covalently modified adenine or guanine. AG and 
TC represent the purine- and pyrimidine-specific chemical cleavage 
reaction. Lanes 1-6 reveal the strand breakage products12 of the 134-bp 
restriction fragm ent previously modified with (+)-C C -1065, (+ )-A B 'C ', 
(+)-ABC", (+ )-A B C , (+ )-A B , and bizelesin, respectively.
3 i s  p r e s e n t e d  i n  F i g u r e  4 ,  p a r t s  A  a n d  B ,  r e s p e c t i v e l y .  A n
e x a m i n a t i o n  o f  t h i s  c o m p a r a t i v e  d a t a  s h o w s  t h a t  t h e  m o s t  r e a c t i v e
a l k y l a t i o n  s i t e s  o f  ( + ) - A B  ( F i g u r e  4 B )  d o  n o t  c o r r e s p o n d  t o  t h e
m o s t  r e a c t i v e  a l k y l a t i o n  s i t e s  o f  b i z e l e s i n  ( F i g u r e  4 A ) ,  a l t h o u g h
m a n y  o f  t h e  s i t e s  a r e  c o m m o n .  S i g n i f i c a n t l y ,  b i z e l e s i n  b o n d i n g
s i t e s  w i t h  h i g h  r e a c t i v i t y  a r e  o f t e n  f o u n d  six bps t o  t h e  3 '  s i d e
o f  t h y m i n e  a n d  a r e  t h e r e f o r e  p o t e n t i a l  i n t e r s t r a n d  A - A  c r o s s -
l i n k i n g  s i t e s  ( e . g . ,  5 ' - T A A T T A * ) ,  a n d  w h e r e  u n i q u e  b i z e l e s i n
a l k y k l a t i o n  s i t e s  a r e  f o u n d  ( e . g . ,  5 ' - T A G T G A *  a n d  5 ' - T T C A -
G A * ) ,  t h e s e  a r e  a l s o  i n t e r s t r a n d  c r o s s - l i n k i n g  s i t e s .  I n  o n e  c a s e ,
a s m a l l  a m o u n t  o f  7 - b p  p o t e n t i a l  i n t e r s t r a n d  c r o s s - l i n k i n g  s e q u e n c e
[ J ' - T A A T T A A *  i n  t h e  ( - ) - s t r a n d ]  w a s  i d e n t i f i e d ,  w h i c h  w a s
c o n f i r m e d  b y  n o n d e n a t u r i n g  g e l  a n a l y s i s  e m p l o y i n g  o l i g o m e r i c
D N A .16 ( + ) - A B  r e a c t s  u n i q u e l y  a t  s o m e  s i t e s  ( 5 ' - G G G T T A *
a n d  5 ' - G C T C G A A * )  w h e r e  m o n o a l k y l a t i o n  i s  p r e c l u d e d  f o r  
b i z e l e s i n .  T h i s  s u g g e s t s  t h a t  t h e  m o n o a l k y l a t i o n  s e q u e n c e  
s e l e c t i v i t y  o f  b i z e l e s i n  i s  h i g h e r  t h a n  f o r  m o n o a l k y l a t i o n  ( + ) -  
C P I s  ( s e e  l a t e r ) .
Concentration Dependency of Sequence Alkylation by Bizelesin.
T o  d e t e r m i n e  i n  a  q u a n t i t a t i v e  m a n n e r  t h e  h i e r a r c h y  o f  b i z e l e s i n  
a l k y l a t i o n  s i t e s  o n  t h e  s a m e  f r a g m e n t s  a s  u s e d  i n  t h e  p r e v i o u s  
e x p e r i m e n t ,  a  s e r i e s  o f  f i v e  b i z e l e s i n  s o l u t i o n s  s p a n n i n g  a  10 4 -  
f o l d d i l u t i o n  w e r e  r e a c t e d  i n d i v i d u a l l y  w i t h  t h i s  1 3 4 - b p  f r a g m e n t .  
T h e  b i z e l e s i n  a l k y l a t i o n  s i t e s  a t  e a c h  o f  t h e  c o n c e n t r a t i o n s  w e r e  
s c o r e d ,  a n d  t h e  r e s u l t s  a r e  d i a g r a m m a t i c a l l y  p o r t r a y e d  i n  F i g u r e  
5 . T h e  m o s t  s e n s i t i v e  s i t e s  ( > 0 . 0 1 4  m M )  f o r  a l k y l a t i o n  b y  b i z e l e s i n  
a r e  t h o s e  s h o w n  w i t h  f i v e  c i r c l e s  ( 5 ' - T A A T T A * )  a n d  t h o s e  l e a s t  
s e n s i t i v e  ( >  1 4 0  m M  )  w i t h  o n e  c i r c l e  ( e . g . ,  5 ' - C T C G  A A  * ) .  B a s e d  
u p o n  t h i s  a n a l y s i s ,  t h e  m o s t  s e n s i t i v e  a l k y l a t i o n  s i t e s  a r e  t h o s e  
a s s o c i a t e d  w i t h  t h e  p o t e n t i a l  c r o s s - l i n k e d  s e q u e n c e  ( 5 ' - T A A T -  
T A * ) .  I n  p r e v i o u s  e x p e r i m e n t s  u s i n g  n o n d e n a t u r i n g  g e l  a n a l y s i s
w i t h  a  2 1 - b p  s e q u e n c e  c o n t a i n i n g  t h i s  s e q u e n c e ,  t h i s  s i t e  w a s  
c o n f i r m e d  t o  b e  a n  i n t e r s t r a n d  c r o s s - l i n k e d  s e q u e n c e .9 O f  t h e  
m o n o a l k y l a t i o n  s i t e s  s h o w n  o n  t h i s  f r a g m e n t ,  f o u r  o u t  o f  a  t o t a l  
o f  e l e v e n  a l k y l a t e d  a d e n i n e s  o n  t h e  u p p e r  ( + ) - s t r a n d  a r e  s i x  b p s  
f r o m  a n  a d e n i n e  o n  t h e  o p p o s i t e  s t r a n d  a n d  a r e  t h u s  p o t e n t i a l  
i n t e r s t r a n d  c r o s s - l i n k e d  s i t e s .  T h e  s e c o n d  m o s t  r e a c t i v e  s i t e  f o r  
a l k y l a t i o n  a f t e r  5 ' - T A A T T A *  i s  S ' - C C T T T A * ,  w h i c h  i s  a  
m o n o a l k y l a t i o n  s i t e  t h a t  i s  r e a c t i v e  a t  a  1 0 - f o l d  l o w e r  d r u g  
c o n c e n t r a t i o n .  T h e r e  i s  a  p o t e n t i a l  c r o s s - l i n k i n g  s i t e  ( *  i n  F i g u r e
5 )  t h a t  w a s  o b s e r v e d  t o  b e  u n r e a c t i v e  t o w a r d  b i z e l e s i n  i n  t h i s  
e x p e r i m e n t .18 C r o s s - l i n k i n g  a t  g u a n i n e  i s  n o t  a n  a u t o m a t i c  
c o n s e q u e n c e  o f  c o v a l e n t  i m m o b i l i z a t i o n  a t  a d e n i n e  s i x  b p  r e m o v e d  
o n  t h e  o p p o s i t e  s t r a n d .  T h e  a b i l i t y  t o  c r o s s - l i n k  a t  g u a n i n e  i s  a  
f u n c t i o n  o f  t h e  i n t e r v e n i n g  s e q u e n c e .
Bizelesin Alkylation at Non-Adenine Bases and the Effect of 
Drug Concentration and Alkylation in AT Sequences. B a s e d  u p o n  
t h e  a n a l y s i s  o f  t h e  r e s u l t s  o f  t h e  p r e v i o u s  e x p e r i m e n t s  u s i n g  t h e  
1 3 4 - b p  f r a g m e n t  ( s e e  b e f o r e ) ,  a  s e c o n d  r e s t r i c t i o n  f r a g m e n t  w a s  
s e l e c t e d  i n  w h i c h  l o n g e r  r u n s  o f  A T  b p s  c o n t a i n i n g  overlapping 
mono and cross-linking sites w e r e  s e l e c t e d  f o r  s t u d y .  U s i n g  t h i s  
r e s t r i c t i o n  f r a g m e n t ,  t h e  q u e s t i o n  o f  p r i o r i t y  f o r  b i z e l e s i n  b e t w e e n  
t h e s e  s i t e s  w a s  e x a m i n e d  ( s e e  F i g u r e  6 ) .  I n  t h i s  s e q u e n c e  a t  t h e  
h i g h e r  m o l e c u l a r  w e i g h t  e n d  o f  t h e  g e l ,  t h e  s e q u e n c e  5 ' -  
T A A A A A * T A *  h a s  b o t h  h i g h  r e a c t i v i t y  m o n o a l k y l a t i o n  ( 5 ' -  
A A A A T A * )  a n d  c r o s s - l i n k i n g  s i t e s  ( 5 ' - T A A A A A * ) .  T h e  r e s u l t s  
s h o w n  i n  t h e  e x p a n s i o n  o f  t h i s  r e g i o n  ( s h o w n  t o  t h e  r i g h t  o f  t h e  
m a i n  g e l  i n  F i g u r e  6 )  c l e a r l y  r e v e a l  t h a t  a t  l o w  d r u g  c o n c e n t r a t i o n s  
b o t h  s i t e s  a r e  a l k y l a t e d  a p p r o x i m a t e l y  e q u a l l y  ( l a n e s  2  a n d  3  i n  
F i g u r e  6 ) ;  w h e r e a s ,  a t  h i g h e r  c o n c e n t r a t i o n s ,  o n l y  t h e  m o n o a l k y ­
l a t i o n  s i t e  a t  t h e  3 '  e n d  o f  t h e  A T  t r a c t  i s  a l k y l a t e d .  A  p o s s i b l e  
e x p l a n a t i o n  f o r  t h i s  c o n c e n t r a t i o n - d e p e n d e n t  s h i f t  i n  a l k y l a t i o n  
s i t e s  i s  t h a t  t h e  c o m p e t i t i o n  f o r  p r e c o v a l e n t  b i n d i n g  s i t e s  a t  t h e  
h i g h e r  d r u g  c o n c e n t r a t i o n  r e s u l t s  i n  e n d - t o - e n d  d r u g  b i n d i n g  i n  
t h i s  A T - r i c h  r e g i o n  a n d  p r e c l u s i o n  o f  b o n d i n g  a t  t h e  T A A A A A *  
s e q u e n c e .
I n  t h i s  s a m e  f r a g m e n t  a t  a n  i n t e r m e d i a t e  m o l e c u l a r  w e i g h t  i n  
t h e  g e l  ( F i g u r e  6 ) ,  t w o  n o n - a d e n i n e  a l k y l a t i o n  s i t e s  ( 5 ' - T C C G C G *  
a n d  5 ' - T T C C G C * )  a p p e a r  t o  b e  r e a c t i v e  t o  b i z e l e s i n  a t  a  1 0 - f o l d  
h i g h e r  c o n c e n t r a t i o n  t h a n  t h e  m o s t  r e a c t i v e  a d e n i n e  a l k y l a t i o n  
s i t e s .  A t  l o w e r  m o l e c u l a r  w e i g h t  i n  t h e  g e l ,  a  s e r i e s  o f  f o u r  m o n o -  
a n d / o r  c r o s s - l i n k  a l k y l a t i o n  s i t e s  i s  p r e s e n t ,  i n  w h i c h  t h e  p o t e n t i a l  
c r o s s - l i n k a g e  s i t e ,  5 ' - T A T T T A * ,  i s  t h e  m o s t  r e a c t i v e .
Comparison of the Alkylation Reactivity of A5 and A7 Tracts 
and Cross-Linking Sequences in the TATA Box to Bizelesin and 
Monoalkylating CPIs. A  f u r t h e r  r e s t r i c t i o n  f r a g m e n t  w a s  c h o s e n  
f o r  e x a m i n a t i o n  b e c a u s e  i t  c o n t a i n e d  b o t h  i s o l a t e d  A 5 a n d  A 7 
t r a c t s  w i t h o u t  t h e  p o t e n t i a l  f o r  c o m p e t i t i o n  w i t h  i n t e r s t r a n d  c r o s s -  
l i n k i n g  a n d  a  T A T A  b o x  s e q u e n c e  ( 5 ' - T T T T T A T T T A ) ,  w h i c h  
h a s  t h e  p o t e n t i a l  f o r  m o n o a l k y l a t i o n  a n d  i n t e r s t r a n d  c r o s s - l i n k i n g .  
T h e  f i r s t  q u e s t i o n  a d d r e s s e d  w a s  h o w  b i z e l e s i n  c o m p a r e s  t o  t h e  
m o n o a l k y l a t i n g  c o m p o u n d s  i n  s e q u e n c e  s e l e c t i v i t y  a n d  r e a c t i v i t y  
w h e n  only m o n o a l k y l a t i o n  i s  p o s s i b l e .  T h e  r e s u l t s  ( F i g u r e  7 )  
s h o w  t h a t  b i z e l e s i n  a n d  ( + ) - A B C "  b o t h  s h o w  s e l e c t i v i t y  f o r  t h e  
3 ' - t e r m i n a l  a d e n i n e  a n d  i t s  5 ' - n e i g h b o r  i n  t h e  A 7 t r a c t  ( s i t e s  A  
a n d  B ) ,  b u t  b i z e l e s i n  h a s  a n  o v e r a l l  l o w e r  r e a c t i v i t y .  H o w e v e r ,  
b i z e l e s i n  p r e d o m i n a n t l y  a l k y l a t e s  t h e  3 ' - t e r m i n a l  a d e n i n e  ( s i t e  
A ) ,  w h e r e a s  ( + ) - A B C "  i s  e q u a l l y  r e a c t i v e  t o  b o t h  t h e  3 ' - t e r m i n a l  
a n d  i t s  5 ' - n e i g h b o r  a d e n i n e ,  a n d  ( + ) - A B  i s  m o s t  r e a c t i v e  t o  t h e  
5 ' - n e i g h b o r  a d e n i n e  o f  t h e  3 ' - t e r m i n a l  a d e n i n e  ( s i t e  B ) .  O v e r a l l ,  
t h i s  r e s u l t  i n d i c a t e s  t h a t  b i z e l e s i n  i s  s i m i l a r  t o  ( + ) - C P I  c o m p o u n d s  
i n  p r e f e r e n t i a l l y  r e c o g n i z i n g  t h e  3 ' - t e r m i n a l  a d e n i n e  i n  A - t r a c t s ,  
p r e s u m a b l y  d u e  t o  t h e i r  i n t r i n s i c  b e n t  D N A  s t r u c t u r e  a n d
(16) However, a comparison of the reactivity of the six- and seven-bp 
sequence in a 21-bp oligomer containing this same sequence confirmed the 
lower reactivity of the seven-bp site in comparison to the six-bp sequence 
5'-TAATTA* (Sun, D.; Hurley, L. H. Unpublished results).
(17) Park, H. J.; Sun, D.; Hurley, L. H. Unpublished results.
(18) However, in a subsequent experiment using a longer incubation time, 
this sequence (5'-TTTAGTGA*) was shown to be reactive.
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Figure 4. Diagram m atic representation of a comparison of the sequence selectivity o f bizelesin (A) and (+ )-A B  (B) on the 134-bp restriction fragment 
The da ta  are from Figure 3 and densitom etric m easurem ents were m ade using an LKB 2202 U ltrascan X L laser densitom eter to compute the percentage 
of the strand breakage at a given site relative to the total strand breakage. Only that portion of the 134-bp fragm ent between the 34th and the 98th 
base is shown, although the analysis is based upon alkylation sites over the entire fragm ent.
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Figure 5. Sum m ary of observed bizelesin strand breakage (alkylation) 
sites on a 134-bp restriction fragm ent from plasmid p S P 6 /T 3 . Restriction 
enzyme fragm ents were prepared as described under M aterials and 
M ethods and were singly 5' end labeled with 32P, incubated with bizelesin 
(24 h a t 20 °C ), and heated for 30 min a t 95 °C  to produce D N A  strand 
breakage. M inim um  concentrations a t which the bizelesin alkylation 
sites were observed in this experiment were 0.014 /xM (five circles), 0.14 
mM (four circles), 1.4 /xM (three circles), 14 #xM (two circles), and 140 
uM  (one circle).
a s s o c i a t e d  j u n c t i o n  s i t e s . 19 A l t h o u g h  a l l  t h e  c o m p o u n d s  t e s t e d  
r e a c t e d  w i t h  5 ' - T A A A A * ,  t h i s  s e q u e n c e  w a s  l e s s  r e a c t i v e  t h a n  
t h e  s e q u e n c e  5 ' - A A A A A * .  W e  s u s p e c t  t h i s  i s  d u e  t o  t h e  h i g h e r  
i n t r i n s i c  b e n d i n g  o f  A 5 o v e r  t h e  T A 4 t r a c t .  B o t h  m o n o a l k y l a t i n g  
C P I s  s h o w  t h e  e x p e c t e d  l o w  r e a c t i v i t y  w i t h  5 ' - C A G A A *  a n d  
5 ' - A A G T A *  s e q u e n c e s ,  a n d  b i z e l e s i n  w a s  u n r e a c t i v e  t o  b o t h  
s e q u e n c e s .  A  c o m p a r i s o n  o f  t h e  r e s u l t s  o f  t h e  a l k y l a t i o n  o f  t h e  
T A T A  b o x  r e g i o n  b y  b i z e l e s i n  a n d  t h e  m o n o a l k y l a t i n g  C P I s  
r e v e a l s  t h a t  b i z e l e s i n  s h o w s  b o t h  m o r e  r e a c t i v i t y  a n d  s e l e c t i v i t y  
f o r  t h i s  r e g i o n ,  b o t h  i n  t e r m s  o f  a d e n i n e  a l k y l a t e d  o n  t h e  A - r i c h  
s t r a n d  ( o n l y  t h o s e  a d e n i n e s  6  b p  a w a y  f r o m  t h e  a v a i l a b l e  a d e n i n e s
(19) Sun, D.; Lin, C. H.; Hurley, L. H. Biochemistry, in press.
o f  t h e  T - r i c h  s t r a n d )  a n d  t h e  a b i l i t y  t o  f o r m  c r o s s - l i n k i n g  o f  
D N A .  T h e  l o w e r  r e a c t i v i t y  o f  t h e  m o n o a l k y l a t n g  C P I s  t o w a r d  
t h i s  r e g i o n  i s  p r e s u m a b l y  d u e  t o  t h e  r e a c t i v i t y  o f  t h e s e  d r u g  
m o l e c u l e s  w i t h i n  t h e  A - t r a c t  o n  t h e  o p p o s i t e  s t r a n d ,  w h i c h  t o  
c o m p e t e s  f o r  t h e  a l k y l a t i o n  s i t e s  o n  t h i s  s t r a n d .  I n  t h e  c a s e  o f  
b i z e l e s i n ,  t h e  a l k y l a t i o n  o f  t h e  o p p o s i t e  s t r a n d  t o  t h a t  s h o w n  in  
F i g u r e  7  p r o m o t e s  t h e  a l k y l a t i o n  o f  t h e  o t h e r  s t r a n d  t o  f o r m  
i n t e r s t r a n d  c r o s s - l i n k i n g .  I n  c o n c l u s i o n ,  t h e  a p p a r e n t  h ig h  
r e a c t i v i t y  o f  b o t h  o f  t h e s e  s i t e s  i n  t h e  T A T A  b o x  r e g i o n  c a n  b e  
e x p l a i n e d  b y  e x a m i n i n g  t h e  a l k y l a t i o n  p a t t e r n  o f  t h e  o p p o s i t e  
s t r a n d ,  w h i c h  s h o w s  h i g h  r e a c t i v i t y  a d e n i n e s  s i x  b p s  a w a y  f r o m  
b o t h  b i z e l e s i n  c r o s s - l i n k a g e  s i t e s .
Relative Cross-Linking vs Monoalkylation Efficiency of Bi­
zelesin and the Consensus Sequence Analysis of Bizelesin 
Monoalkylation and Cross-Linking Sites. A  p r e v i o u s  a n a l y s i s  o f  
a  c a t a l o g  o f  ( + ) - C C - 1 0 6 5  a l k y l a t i o n  s i t e s  o n  r e s t r i c t i o n  f r a g m e n t s  
f r o m  S V 4 0  a n d  T 7  D N A  h a d  r e v e a l e d  t h a t  t h e  s e q u e n c e s  5 '-  
P u N T T A *  a n d  5 ' - A A A A A *  w e r e  m o s t  r e a c t i v e  a t  t h e  l o w e s t  
d r u g  c o n c e n t r a t i o n . 12 A  m o r e  r e c e n t  s t u d y  u n d e r  s l i g h t l y  d i f f e r e n t  
e x p e r i m e n t a l  c o n d i t i o n s  h a s  i d e n t i f i e d  t h e  s e q u e n c e  5 ' - ( T / A ) -  
( T / A ) - A *  a s  t h e  c o n s e n s u s .20 W h i l e  t h i s  i s  t h e  f i r s t  s t u d y  in  
w h i c h  t h e  h i e r a r c h y  o f  s e q u e n c e  b o n d i n g  s i t e s  f o r  b i z e l e s i n  h a v e  
b e e n  d e t e r m i n e d  u s i n g  r e s t r i c t i o n  f r a g m e n t s  f r o m  p l a s m i d  D N A ,  
a  p r e v i o u s  s t u d y  u s i n g  a  21  - b p  o l i g o m e r 9 s h o w e d  a  p r e f e r e n c e f o r  
t h e  c r o s s - l i n k i n g  s e q u e n c e  5 ' - T A A T T A * .  I n  t h e  p r e s e n t  i n v e s ­
t i g a t i o n ,  a  t o t a l  o f  a b o u t  4 . 0  K b  o f  D N A  f r o m  r e s t r i c t i o n  f r a g m e n t s  
o b t a i n e d  f r o m  p B R 3 2 2 ,  S V 4 0 ,  p C A T ,  a n d  p S P 6 / T 3  h a v e  b e e n  
s c r e e n e d  f o r  b i z e l e s i n  c o v a l e n t  b o n d i n g  s i t e s  u s i n g  f o u r  d i f f e r e n t  
c o n c e n t r a t i o n s  o f  d r u g  m o l e c u l e s  ( 0 . 0 1 4 , 0 . 1 4 , 1 . 4 ,  a n d  1 4 / t M ) .  
T y p i c a l  a u t o r a d i o g r a m s  s h o w i n g  t h e  r e s u l t s  o f  t h e  t h e r m a l  s t r a n d
(20) Hurley, L. H.; Warpehoski, M. A.;Lee,C.-S.; McGovren, J.P.;Scahill, 
T. A.; Kelly, R. C.; Mitchell, M. A.; Wicnienski, N. A.; Gebhard, I.; Johnson, 
P. D.; Bradford, V. S. J. Am. Chem. Soc. 1990, 112, 4633.
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Figure 6. Concentration dependency of bizelesin (alkylation) sites on 
DNA following therm al treatm ent of b izelesin-D N A  adduct. The D N A  
in panel A is an E ar I-H ind III fragm ent (235 bps) from plasmid pBR322 
that was 5' end-labeled on the top strand a t the E ar I site. The reaction 
mixtures (10 jiL) consisted of 10 mM  N aC l, 10 m M  Tris-H C l (pH  7.6), 
about 20 ng of DN A, and the indicated am ount (see below) of drug 
molecules and were incubated at room tem perature for 2 days. AG and 
TC represent the purine and pyrimidine specific chemical cleavage. Lanes 
1-5 contain 0 ,0 .014 ,0 .14 ,1 .4 , and 14 /xM of bizelesin, respectively. The 
inset to the right of the main gel is the same experiment, in which the 
gel electrophoresis was run for a longer period of tim e to resolve this 
region.
b r e a k a g e  a s s a y  f o l l o w i n g  b i z e l e s i n  m o d i f i c a t i o n  o f  r e s t r i c t i o n  
f r a g m e n t s  a r e  s h o w n  i n  F i g u r e s  6  a n d  7 .  I n  m o s t  c a s e s ,  o n l y  o n e  
o f t h e  t w o  s t r a n d s  w a s  e x a m i n e d  f o r  b i z e l e s i n  a l k y l a t i o n  s i t e s .
O v e r a l l ,  a  t o t a l  o f  7 7  b i z e l e s i n  a d e n i n e  a l k y l a t i o n  s i t e s  w e r e  
f o u n d  o n  t h e  4 . 0  K b  o f  D N A  a t  d r u g  c o n c e n t r a t i o n s  e v a l u a t e d  
b e t w e e n  0 . 0 1 4  a n d  1 4  pM  ( T a b l e  I ,  p a r t s  A  a n d  B ) .  O f  t h e s e  
s i te s ,  h a l f  w e r e  p o t e n t i a l  c r o s s - l i n k a g e  s i t e s  ( i . e . ,  h a d  a  t h y m i n e  
six b p s  t o  t h e  5 ' - s i d e  o f  t h e  a l k y l a t e d  b a s e ) ,  w h i l e  t h e  r e m a i n i n g  
3 9 s i t e s  w e r e  m o s t  p r o b a b l y  m o n o a l k y l a t i o n  s i t e s .  H o w e v e r ,  t h e  
r e l a t i v e  f r e q u e n c y  o f  m o n o a l k y l a t i o n  v s  c r o s s - l i n k i n g  s i t e s  o n  
d u p l e x  D N A  a r e  u n d e r e s t i m a t e d  b y  a b o u t  5 0 % ,  s i n c e  o n l y  o n e  
s t r a n d  o f  D N A  i s  m o n i t o r e d ,  a n d  w h i l e  t h i s  r e v e a l s  all  t h e  p o t e n t i a l  
c r o s s - l i n k i n g  s i t e s ,  o n l y  t h e  m o n o a l k y l a t i o n  s i t e s  o n  o n e  s t r a n d  
a r e d e t e c t e d .  T h e r e f o r e ,  w e  estimate  a  t o t a l  o f  7 8  m o n o a l k y l a t i o n  
s i te s  ( 6 7 % )  i n  a  c o m b i n e d  t o t a l  o f  1 1 6  c r o s s - l i n k i n g  a n d  
m o n o a l k y l a t i o n  s i t e s  o n  d u p l e x  D N A .  B a s e d  u p o n  t h e  o v e r a l l  
G C / A T  r a t i o  i n  t h e s e  s e q u e n c e s  ( 5 0 / 5 0 ) ,  w e  w o u l d  h a v e  o n l y  
e x p e c t e d  a  2 5 %  a l k y l a t i o n  o f  p o t e n t i a l  c r o s s - l i n k i n g  v s  m o n o a l k y ­
l a t i o n  s i t e s  i n s t e a d  o f  t h e  3 3 %  f o u n d .  T h e s e  r e s u l t s  i m p l y  t h a t  
th e r e  a r e  f a c t o r s  t h a t  p r e d i s p o s e  p o t e n t i a l  c r o s s - l i n k i n g  o v e r  
m o n o a l k y l a t i o n  s i t e s  t o  a l k y l a t i o n .  B a s e d  u p o n  t h e  o b s e r v a t i o n  
th a t  t h e  p e r c e n t a g e  o f  A  v s  G  v s  C  a t  a  p o s i t i o n  s i x  b p s  t o  t h e  
j ' - s i d e o f  t h e  a l k y l a t e d  b a s e  i s  2 1 %  v s  1 4 %  v s  1 4 % ,  r e s p e c t i v e l y ,  
ib is  e x c e s s  o f  p o t e n t i a l  c r o s s - l i n k i n g  s i t e s  c a n n o t  b e  e x p l a i n e d  b y
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Figure 7. Comparison of the reactivity of bizelesin, (+ )-A B C ", and (+ )-  
AB. The D N A  in this experiment is an N co I-H pa II fragm ent (304 bps) 
from plasmid pC A T that was 5 ' end-labeled on the top strand a t the Nco 
I site. Lanes 1—4 contain 0.014, 0.14, 1.4, and 14 /xM of bizelesin, 
respectively; lanes 5 -7  contain 0.0014,0.014, and 0.14 jxM of (+ )-A B C ", 
respectively; and lanes 8 -10  contain 0 .014,0.14, and 1.4 *xM of (+ )-A B , 
respectively. The clustered bonding sites a t the top region of the 
autoradiogram  were resolved by running the sam e sam ple on electro­
phoresis for a longer period of time.
a  p r e c o v a l e n t  b i n d i n g  p r e f e r e n c e  f o r  A T  b p s  a t  t h i s  p o s i t i o n  t h a t  
p r e d i s p o s e s  b i z e l e s i n  f o r  c r o s s - l i n k i n g .  O t h e r  f a c t o r s  p o s s i b l y  
r e s p o n s i b l e  f o r  t h i s  e n r i c h m e n t  o f  c r o s s - l i n k i n g  s i t e s  r e l a t i v e  t o  
m o n o a l k y l a t i o n  s i t e s  a r e  d i s c u s s e d  l a t e r  ( s e e  D i s c u s s i o n ) .
T h e  m o n o a l k y l a t i n g  a n d  p o t e n t i a l  c r o s s - l i n k i n g  ( i . e . ,  h a v i n g  a  
t h y m i n e  s i x  n u c l e o t i d e s  t o  t h e  5 ' - s i d e  o f  t h e  a l k y l a t e d  a d e n i n e )  
s i t e s  o f  b i z e l e s i n  w e r e  d i v i d e d  i n t o  t h r e e  g r o u p s  b a s e d  e i t h e r  u p o n  
t h e i r  c o m p a r a t i v e  a l k y l a t i o n  r e a c t i v i t y  o r  t h e  n a t u r e  o f  t h e  b a s e  
a l k y l a t e d ;  i . e . ,  T a b l e s  I ,  p a r t s  A ,  B ,  a n d  C  r e p r e s e n t  h i g h  r e a c t i v i t y  
( 0 . 0 1 4 - 0 . 1 4  m M ) ,  m e d i u m  r e a c t i v i t y  ( > 0 . 1 4  / x M  b u t  < 1 4  * x M ) ,  
a n d  a l k y l a t i o n  o f  n o n - a d e n i n e  b a s e s ,  r e s p e c t i v e l y .  I n  e a c h  t a b l e  
i n d i v i d u a l  n u c l e o t i d e  s e q u e n c e s  a r e  l i s t e d  t h a t  i n c l u d e  t h e  
c o v a l e n t l y  m o d i f i e d  b a s e  p l u s  b a s e s  f i v e  a n d  o n e  n u c l e o t i d e s  t o  
t h e  S'- a n d  3 ' - s i d e s  o f  t h i s  a d e n i n e  b a s e ,  r e s p e c t i v e l y .  I n  T a b l e s  
I ,  p a r t s  A  a n d  B ,  a  s e q u e n c e  a n a l y s i s  f o r  t h e  c r o s s - l i n k i n g  a n d  
m o n o a l k y l a t i o n  s i t e s  i n  e a c h  g r o u p  i s  a l s o  p r o v i d e d .  F o r  p o t e n t i a l  
c r o s s - l i n k i n g  s e q u e n c e s  i n  T a b l e  I ,  p a r t s  A  a n d  B ,  t h e  o v e r a l l  G C  
c o n t e n t  b e t w e e n  t h e  t w o  c o v a l e n t l y  b o u n d  a d e n i n e s  ( p o s i t i o n s  
+ 4 ,  + 3 ,  + 2 ,  a n d  + 1 )  i s  1 3 . 8 %  a n d  4 0 % ,  r e s p e c t i v e l y .  F o r  t h e  
e q u i v a l e n t  p o s i t i o n s  t h e  G C  c o n t e n t  f o r  t h e  m o n o a l k y l a t i o n  
s e q u e n c e s  ( i . e . ,  t h o s e  s e q u e n c e s  l a c k i n g  a  s u i t a b l e  a d e n i n e  s i x  b p s  
a w a y  t o  c r o s s - l i n k )  i s  7 . 1 %  a n d  1 9 . 1 %  f o r  h i g h  a n d  m e d i u m  
r e a c t i v i t y  s i t e s ,  r e s p e c t i v e l y ,  w h i c h ,  w i t h i n  e x p e r i m e n t a l  e r r o r ,  i s  
i n  b o t h  c a s e s  a b o u t  5 0 %  o f  t h a t  o f  t h e  c r o s s - l i n k i n g  s i t e s .  T h e  
s i m p l e s t  e x p l a n a t i o n  f o r  t h i s  i s  t h a t  a l k y l a t i o n  a t  o n e  a d e n i n e  s i t e  
i n  a  h i g h l y  r e a c t i v e  m o n o a l k y l a t i o n  s e q u e n c e  ( e . g . ,  5 ' - T T A * ,
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Table I
A. High Reactivity S ites<a) B. Medium Reactivity Sites 
Cross-linking Sites M onoalkylating Sites
5 'G  C A T T A* A 3' 
5 ' A T A T I  A 'C 3 'Cross-linking Sites
♦ 5 ’T A A T T A* A 3’
♦ 5 ’T A A T T A* G3 1
+ 5 ’T A T T T A* G3 ’
5 ’ T A T T T A* T3 ’
+ 5 ’T T T T T A* T3 ’
+ 5 ’T A G T T A* A3 ’
♦ 5 ’T A A A A A* T3 1
5 ’T T T A A A* G3 ’
♦5 ’ T T T A A A* T3 ’
5 ’ T C A A A A* T3 ’
♦5 ’ T A G A A A* A 3’
5 ’T T T T A A* A 3’
5 ’T A T T A A* T3 ’
5 ’ T C A A T A* A 3’
5 ’T A C A T A* G3 ’
5 ’T T T G C A* T3 ’
5 ’ T T T C T A* C3 ’





5 ’ C C T T T A* G3
5 ’G T A T T A* A3
5 ’ C A A T T A* G3
5 ’A A A A A A* T3
5 ’ C A A A A A* G3
5 1A A A A T A* G3
5 1A A A A T A* A3
5 ’G A A A T A* A3
5 ’G A A A T A* G3
5 ‘A A A T A A» A3
5 ’A A A T A A* o u>
5 ’ A C A T A A* G3
5 ’A A G T A A* A3
5 ’ A T T G T A* G3
GC
GC/N [7.1% ]
5 ’T C A T T A* A 3 ’
5 ’T C C T T A* C3 1
♦ 5 ’T G A T T A* C3 ’
5 ’T G T A A A* C3 ’
5 ’T A C A T A* T3 ’
5 ’T C T A T A* G3 ’
5 ’T G G T A A* C3 ’
5 ’T A A T G A* A 3 ’
5 ’T A A C A A* C3 ’
5 ’T T T G G A* G3 ’
5 ’T T T G G A* C3 ’
5 ’T A T G T A* T3 ’
5 ’ T A T T G A* A3 ’
5 ’T T A T C A* G3 ’
5 ’T T A T C A* T3 ’
5 ’T G A C T A* A3 ’
5 ’T G T G T A* T3 ’
5 ’T G G T C A* G3 ’
5 ’T G C T G A* C3 ’
5 ’T C C A G A* A3 ’
♦5 ♦4 +3 +2 +1 0 -1
A 0 5 7 4 3 20 5
G 0 7 2 4 6 0 4
T 20 4 7 10 8 0 4
C 0 4 4 2 3 0 7
AT 20 9 14 14 11 20 9
GC 0 11 6 6 9 0 11
GC/N [40.0% ]
5 ’A T A T T A* T3
5 ’C A T T T A* T3
5 ’A C A T T A* A3
5 ’G A G T T A* G3
5 ’G C T T T A* A3
5 ’A G G T T A* A3
5 ’G C A A A A* A3
5 ’G c A A A A* G3
5 ’C G A A A A* G3
5 ’C T A A A A* T3
5 ’C C A A T A* C3
5 ’C A A A T A* 33
5 ’G T A A T A* C3
5 ’C G T A A A* C3
5 ’G G A T A A* C3
5 ’A G T T A A* G3
5 ’C T T T A A* 33
5 ’C T C G A A* T3
5 ’G A A G T A* G3
5 ’A A A G T A* A3
5 ’A A A T C A* 33
5 ’A A T T C A* G3
5 ’A T T T c A* C3
+5 +4 +3 ♦2 +1 0 -1
A 9 8 14 8 9 15 6
G 8 5 2 3 0 0 7
T 0 7 8 14 13 0 4
C 8 5 1 0 3 0 8
AT 9 15 22 22 22 15 10
GC 16 10 3 3 3 0 15
GC/N [1 9 . 1%]
C. Unusual Adduct Sites
Cross-linking Sites Monoalkylating Sites
5 ’ T A T A T G* T3 ’ 5 ’A A A T T G* C3 ’
♦ 5 ’T T T T T G* G3 1 5 ’A T A T T G* G3 ’
5 ’T T T T T G» C3 ’ 5 ’A A G T T G* T3 ’
♦ 5 ’T A A T T G* T 3 ’ 5 ’ C » G T T G* G3 ’
5 ’T C C G C G* C3 ’ 5 ’A A C T T G* C3 ’
5 ’T G T T G G* G3 ’
5 1T A T A G G* C3 ’
5 ’T A T C T G* G3 ’
5 ’T c T C C T« T3 ’
5 ’T c T G A G* G3 ’
5 ’T T C C G C* G3 ’
a These sequences can be modified with bizelesin a t the lower concentration than 0.14 nM  bizelesin. 6 These sequences can be modified vith bizelesin 
at the range from 0.14 to 14 jzM bizelesin. c These sequences can be modified with bizelesin at the lower concentration than  14 /iM  bizeltsin. + These 
sequences have been confirmed to be cross-linked sites.
T A A * ,  A T A * ,  o r  T A A * )  d i r e c t s  t h e  a l k y l a t i o n  a t  a  s e c o n d  a d e n i n e  
s i x  b p s  a w a y ,  e v e n  i n  n o r m a l l y  l e s s  d e s i r a b l e  a l k y l a t i o n  s e q u e n c e s  
( e . g . ,  5 ' - C T A * ,  5 ' - T G A * ,  5 ' - G T A * ,  a n d  5 ' - G C A * ) ,  w h i c h  
c o n s e q u e n t l y  d i c t a t e s  a  h i g h e r  G C  t o l e r a n c e  a t  c r o s s - l i n k i n g  s i t e s .  
T h i s  e x p l a n a t i o n  m a y  a c c o u n t  f o r  t h e  a p p a r e n t  h i g h  r e a c t i v i t y  
o f  1 7  o f  t h e  1 8  s e q u e n c e s  l i s t e d  i n  T a b l e  I A  u n d e r  c r o s s - l i n k i n g .  
O f  t h e s e  1 7  s i t e s ,  1 5  c o n f o r m  t o  t h e  5 ' - ( A / T ) ( A / T )  A *  c o n s e n s u s  
s e q u e n c e  a n a l y s i s  f o r  m o n o a l k y l a t i o n  a t  t h e  c o v a l e n t l y  m o d i f i e d  
a d e n i n e .  T h e  r e m a i n i n g  s e q u e n c e ,  5 ' - T C A C A A * ,  m a y  h a v e  s o m e  
s p e c i a l  s t r u c t u r a l  o r  d y n a m i c  f e a t u r e s  t h a t  c o n f e r  i t s  i n t r i n s i c  
r e a c t i v i t y .  I n  T a b l e  I A ,  u n d e r  m o n o a l k y l a t i o n  s i t e s ,  a l l  o f  t h e s e  
s e q u e n c e s  e x c e p t  t w o ,  5 ' - A T T G T A *  a n d  5 ' - A A G T A A * ,  c o n f o r m  
t o  t h e  c o n s e n s u s  s e q u e n c e  5 ' - ( A / T ) ( A / T ) ( A / T ) A * ,  w h i c h  
r e q u i r e s  o n e  m o r e  ( A / T )  b a s e  p a i r  c o m p a r e d  t o  t h e  c o n s e n s u s  
s e q u e n c e  5 ' - ( A / T ) ( A / T ) A *  f o u n d  p r e v i o u s l y 20 t o  b e  r e a c t i v e  t o  
m o n o a l k y l a t i o n  C P I s ,  i n d i c a t i n g  t h a t  o n e  m o r e  ( A / T )  b p  i s
r e q u i r e d  t o  a c c o m m o d a t e  t h e  A  a n d  B  s u b u n i t s  o f  t i e  n o n a l k y ­
l a t i n g  l e g  o f  b i z e l e s i n  i n s i d e  t h e  m i n o r  g r o o v e  w i t h o u t  s t e r i c  
h i n d r a n c e .
A n a l y s i s  o f  t h e  m e d i u m  r e a c t i v i t y  s i t e s  f o r  p o t e i t i a l  c r o s s -  
l i n k i n g  ( T a b l e  I B )  s h o w s  t h a t  t h e s e  s i t e s  h a v e  a  g r e i t e r  t h a n  a  
2 - f o l d  t o l e r a n c e  f o r  G C  p a i r s  t h a n  t h e  h i g h  r e a c t i v i t y  c r o s s - l i n k i n g  
s i t e s .  S e v e n  o f  t h e  2 0  s i t e s  c o n f o r m  t o  t h e  5 ' - ( A / 7 ) ( A / T ) A *  
c o n s e n s u s  s e q u e n c e  f o r  m o n o a l k y l a t i o n  o f  t h e  r e a c t i v e  a d e n i n e s ,  
a n d  a  f u r t h e r  e i g h t  h a v e  a  c o n s e n s u s  m o n o a l k y l a t i o n  s i t e  o n  t h e  
o p p o s i t e  s t r a n d .  T h e s e  n u m b e r s  a r e  i n  c o n t r a s t  t o  t h e  1 4  a n d  t w o  
i n  1 9  s i m i l a r  c r o s s - l i n k i n g  s i t e s  l i s t e d  i n  T a b l e  I A .  T h t  r e m a i n i n g  
f i v e  m e d i u m  r e a c t i v i t y  s i t e s  l a c k  c o n s e n s u s  s e q u e n c e s  a t  e i t h e r  
e n d  o f  t h e  c r o s s - l i n k i n g  s e q u e n c e ,  a n d  t h r e e  o f  t h e s e  s i t e s  c o n t a i n  
t h r e e  G C  b p s .
T h e  m o n o a l k y l a t i o n  s i t e s  o f  m e d i u m  r e a c t i v i t y  ( T t b l e  I B ) ,  i n  
c o n t r a s t  t o  t h e  e q u i v a l e n t  r e a c t i v i t y  c r o s s - l i n k i n g  s i t e s ,  c o n f o r m  
m o s t l y  ( 1 9  o f  2 5  s i t e s )  t o  t h e  5 ' - ( A / T ) ( A / T ) A *  c o n s e n s u s
Sequence Specificity o f Bizelesin
sequence analysis for monoalkylation. In comparison to the high 
reactivity monoalkylation sites, a much greater proportion (six 
of 25 vs one of 14) contains one GC pair in the+1 or +2 positions.
All of the sequences in Table IC are alkylated at non-adenine 
bases: predominantly G in potential cross-linking sequences and 
exclusively G in the monoalkylation sequences. Of the sequences 
jin the cross-linked category, six of the 11 sequences have a 
consensus monoalkylation sequence 5'-(A/T)(A/T)A* at the 
j  adenine alkylation site. Not surprisingly, four of these sequences 
I are entirely AT, except for the alkylated base. However, what 
; is quite unexpected is that one of the alkylated sequences is entirely 
I made up of GC bps, except for one of the alkylated bases, which 
is adenine (5'-TCCGCG*).
The non-adenine monoalkylation group consists of five se­
quences in which the consensus is 5'-A(A/T)PuTTG*. The 
j  special reactivity of guanine in this group is of course not dependent 
j  upon a suitable positioned adenine on the opposite strand six bps 
I distant from the guanine but must be related to a special 
: characteristic of this sequence.
Discussion
Antitumor agents such as the nitrogen mustards, mitomycin
C, cjj-Pt, nitrosoureas, and carzinophilin have the capability to 
form intra- or interstrand cross-links on DNA .22 The interstrand 
cross-linking of mitomycin C and the nitrogen mustards is 
proposed to be responsible for the high potency of these 
compounds.23 Not unexpectedly, bizelesin is considerably more 
potent than monoalkylating CPIs and shows different biological 
properties to the clinical candidate adozelesin. It has been 
proposed by Hopkins24 that DNA-DNA interstrand cross-linking 
occurs preferentially at locations that will result in minimal 
distortion of DNA. The implication being that cross-links will 
form most readily at sites where the minimal energy is required 
to convert a monoadduct to a cross-linked site. With the agents 
so far investigated, the cross-links are most often formed at sites 
directly adjacent to each other or separated by one bp. However, 
with the recent design and synthesis of cross-linking agents based 
upon monoalkylation compounds such as the CPIs,7 pyrrolo( 1,4)- 
benzodiazepines,25 and cw-Pt26 a series of agents forming 
interstrand cross-links at greater interhelical distances (four to 
six bps) has emerged. With this larger span of cross-linked 
sequences comes the possibility of expressing the minimum energy 
cross-linked structure in more conformationally varied ways and 
perhaps finding exceptions to the general idea that preferred cross- 
linking sequences are those that are minimally distorted. For 
example, the energy of the transition state for formation of a 
cross-linked structure involving a particular sequence that can 
exist in a rare and unusual conformation may be much less than 
for a second sequence of quite similar sequence that cannot assume 
this conformation and thereby provide a kinetically favored 
reaction at the first site. Therefore, in addition to quantitation 
of the proportion of mono vs cross-link species formed on DNA 
with bizelesin, and determining the consensus sequence selectivity 
for both types of adducts, we were also interested in identifying 
especially reactive cross-linking sequences, or perhaps less reactive
(21) Lin, C. H.; Hill, G. C.; Hurley, L. H. Chem. Res. Toxicol. 1992, 5, 
167.
(22) (a) Pratt, W. B.; Ruddon, R. W. The Anticancer Drugs; Oxford 
University Press: New York, 1979. (b) Gale, E. F.; Cundliffe, E.; Reynolds 
P. E.; Richmond, M. H.; Waring, M. J. The Molecular Mechanism of 
Antibiotic Action, 3rd ed.; Wiley: New York, 1981. (c) Armstrong, R. W.; 
Salvati, M. E.; Nguyen, M. J. Am. Chem. Soc. 1992,114, 3144.
(23) (a) Kohn, K. W. Bioscience 1981, 31, 593. (b) Kohn, K. W. In 
Development of Target-Oriented Anticancer Drugs', Cheng, Y.-C., Goz, B., 
Minkoff, M., Eds.; Raven Press: New York, 1983; pp 181-188.
(24) Hopkins, P. B.; Millard, J. T.; Woo, J.; Weidner, M. F.; Kirchner, J. 
J.; Sigurdsson, S. T.; Raucher, S. Tetrahedron 1991, 47, 2475.
(25) Bose, D. S.; Thompson, A. S.; Ching, J.; Hartley, J. A.; Berardini, M.
D.; Jenkins, T. C.; Neidle, S.; Hurley, L. H.; Thurston, D. E. J. Am. Chem. 
Soc. 1992,114, 4939.
(26) Qu, Y.; Farrell, N. J. Am. Chem. Soc. 1991,113, 4851.
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sequences, that had unexpected cross-linked sequence lengths or 
contexts, since these might well represent unusual DNA con­
formations kinetically entrapped by bizelesin, which are not 
normally observed in significant amounts.
In previous studies at Upjohn7 and Texas,9 it has been shown 
that interstrand cross-linking occurs with high efficiency in the 
sequence 5'-TAATTA* on adenines six bps apart, which is in 
accord with expectations based upon a previous knowledge of 
CPI monoalkylation specificity and molecular modeling. This 
present, more expansive study using restriction fragments not 
only provides results that are in accord with this observation but 
also extends this finding to encompass some less expected results. 
For example, as expected, interstrand cross-linked by bizelesin 
occurs preferentially at adenines that are positioned six bps away 
from a CPI alkylation site on the opposite strand having the 
consensus sequence 5'-(A/T)(A/T)A*. However, in isolated 
cases, a potental seven-bp cross-linkage site for bizelesin was 
identified. Subsequent unpublished oligomer studies have con­
firmed this 7-bp cross-linkage site.16-17 In addition, we find that 
alkylation also occurs at non-adenine bases, most frequently 
guanine and most often six bp away from an adenine in the CPI 
consensus sequence. This non-adenine alkylation is presumbly 
mediated by the covalently immobilized second alkylation arm 
of bizelesin placed in proximity to a normally unreactive base. 
In subsequent studies, using oligomers of defined sequence, cross- 
linking at these sites has been confirmed, and the alkylation at 
the non-adenine base has been shown to be the second step and 
occurs much slower than the monoalkylation reaction.15 Based 
upon the pattern of strand breakage for 3'- and 5'-labeled 
fragments that are similar to N3-adenine, alkylation is strongly 
suspected to occur at N3 of guanine and 0 2  of cytosine.
A quantitation of the mono vs cross-linking sites shows that 
there is a somewhat higher proportion of potental cross-linkage 
sites than expected, based upon a strict statistical analysis; i.e., 
the percentage of potential cross-linkage to monoalkylation sites 
was found to be 33% to 67% vs the expected 25% to 75%. A full 
explanation for this excess of cross-linking sites will have to await 
a more complete analysis; however, there are at least three possible 
reasons. First, many of the “cross-linkage sites” are identified 
only as possible cross-linkage sites, because they have an adenine 
six bps to the 5'-side on the opposite strand. Not all cross-linkage 
sites have been confirmed by nondenaturing gel analysis (see 
Table I, parts A and B, and ref 27). Second, the analysis may 
be biased because some restriction fragments were chosen that 
had AT-rich regions amenable to cross-linking, and third, the 
inherently greater instability of monoalkylation vs cross-linking 
over long periods of time may produce a bias toward the 
thermodynamically stable cross-links rather than the kinetically 
favored monoalkylation sites and thus an apparent preference for 
cross-linkage sites.28-29 As an extreme case, the unique reactivity 
of some sequences (e.g., 5'-TAGTGA* in Figure 4) to cross- 
linking by bizelesin in the absence of monoalkylation at either of 
the sites may be rationalized if we assume that the covalent product 
of monoalkylation is thermodynamically unstable. In this case, 
it wil not accumulate at the monoalkylation site and will not be 
visible in the strand breakage assay. However, at potential cross- 
linking sites, if the monoalkylation product is trapped by the 
cross-linking reaction, which leads to a thermodynamically more 
stable product, this will accumulate at monoalkylation sites, which 
are individually unfavorable.29 While the futile reversibility of 
monoalkylation by CPIs has been noted previously, its significance 
in providing unique cross-linking sites for bizelesin has not been 
predicted. Thus, it is possible to envisage a strategy of designing 
cross-linkers that will uniquely form cross-links in the absence
(27) The sequences marked with the symbol (+) were confirmed as cross- 
linkage sites by nondenaturing gel analysis.23
(28) Ding, Z.-M.; Sun, D.; Fan, J.-Y.; Hurley, L. H. Manuscript in 
preparation.
(29) We thank an insightful referree for pointing out this special case.
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of monoalkylation adducts where the thermodynamic stability of 
the mono and cross-linked adducts differ in the manner described 
here. While we cannot discount the possibility that the analysis 
is biased by the first two reasons cited above, we suspect that the 
thermodynamic factos may play the more important role. 
Experiments using specifically designed oligomers have been 
carried out to test this important principle.
An analysis of sequence selectivity of monoalkylation and cross- 
linking sites by bizelesin leads to some important conclusions. 
First, bizelesin is more sequence selective than its monoalkylating 
CPI analogs in the monoalkylation reaction. The consensus 
sequence analysis obtained from Table I, parts A and B, has 
revealed that bizelesin is much more reactive toward the sequence 
5'-(A/T)(A/T)(A/T)A* than the consensus sequence of (+)- 
CC-1065 (e.g., PuNTTA* and (A/T)(A/T)A*). This implies 
that one more (A/T) bp is required for the accommodation of 
the AB subunit, which is not involved in the alkylation reaction. 
The preference for an (A/T) bp pair over a (GC) bp pair at the 
fourth base from the 5'-side of modified adenine also implies that 
the precovalent binding interaction through a minor groove 
involving van der Waals contacts of the other AB subunit is 
important in fine-tuning the sequence selectivity of monoalkylation 
with bizelesin. In comparison with monoalkylation CPIs, bizelesin 
alkylates a number of unique sites, which generally occur six bps 
to the 3'-side of a thymine. These are presumably driven by 
covalent immobilization of the second alkylation arm in proximity 
to a normally unreactive adenine sequence. In addition, there 
are a number of sites that are much more reactive to bizelesin 
than monoalkylation by CPIs. Many of these sites are more 
reactive by virture of having two suitably spaced adenines (six 
bps apart) both contained in highly reactive alkylation sequences. 
Thus, although these sites appear to be selective for bizelesin, 
their special reactivity can usually be explained by a highly reactive 
monoalkylation site at one end of the bizelesin followed by an 
extremely rapid second alkylation at the second site increasing 
the apparent extent of reaction at each site by 2-fold. This 
observation may in part account for the apparent higher selectivity 
of bizelesin in comparison to CPIs observed in a previous report.9
An analysis of the GC tolerance of cross-linking vs monoalky­
lation sites of bizelesin reveals that in both the high and medium 
reactivity sites there is a 2-fold higher tolerance for GC pairs in 
potential cross-link sites. However, once it is recognized that if 
alkylation has occurred at one favored monoalkylation site, the 
second alkylation is driven by a covalently immobilized arm at 
the second site, which may be normally unfavorable, the GC 
tolerance for at least most of the cross-linking sites can be 
explained. Likewise, the previously discussed alkylation at 
unfavorable bases such as guanine, cytosine, and thymine can 
also be rationalized. In these situations, cross-linking sequence 
specificity is lower than monoalkylation.
(+)-CC-1065 was the initial lead compound that provided the 
inspiration for the development of other monoalkylation CPIs 
belonging to both the (+)-series (natural configuration of the 
cyclopropyl group) and the (-)-series (unnatural enantiomer), 
and now for the interstrand cross-linking compounds represented 
by bizelesin. (+)-CC-1065 has been characterized as minor 
groove alkylating compound whose sequence selectivity is pri­
marily determined not by the sequence recognizing noncovalent 
binding but by the sequence requirements inherent in the covalent 
bonding step itself.14 The molecular processes involved in this 
recognition have been described previously2’8* and have been 
compared from a structural perspective to a mechanism-based 
or suicide-enzyme inactivation.8* Subsequent studies20 involving 
the unnatural (-)-series compounds have revealed the importance 
of minor groove binding interactions unique to CC-1065 and 
AB'C' in optimizing the critical hydrophobic interactions that 
are required to stabilize the unnatural (-)-CPI, which has less 
favorable precovalent binding interactions with DNA than (+)-
series compounds. Bizelesin is similar to (+)-ABC in its sequence 
selective monoalkylation potential, having the naturaly evolved 
(+)-CPI unit linked to a nonoptimized noncovaleit binding 
moiety. However, the cross-linking reaction is mich more 
promiscuous both in terms of base specificity and sequence context, 
presumably because of the covalent immobilization of the second 
alkylating arm in proximity to normally unreactive bases and 
sequences and also because of the thermodynamic principles 
described before. In the optimum situation for cross-inking, an 
adenine in a consensus sequence 5'-(A/T)(A/T)A* provides 
approximately the same critical DNA interactions bund in a ’ 
high reactivity monoalkylation site, and, consequently, this second 
step is very fast in comparison to the first step, e.g., S'-TaATTA*. ] 
In less favorable binding sequences (e.g., 5'-TGA*), moa probably 
due to less inherent conformation flexibility, the crcss-linking 
step is slow in comparison to the monoalkylation. List, where | 
the second base alkylated is not adenine, presumably the less 
electronically or sterically favored site on guanine, cjtosine, or 
thymine contributes significantly to the slower rate of alkylation.
While most of the putative cross-linked sequences can be 
rationalized based upon the established reactivity of nonoalky- 
lating CPIs and through covalent immobilization of a second 
alkylating arm, there are a number of unexpected findiigs. First, 
some of the unusual cross-link sites, such as 5'-TCCGCG* and , 
5'-TTCCGC*, even though they have medium or low leactivity, 
are unexpected sites for potential cross-linking, especiilly in the j 
absence of monoalkylation products at either end of ’he six-bp , 
sequence. Second, the high cross-linking reactivity of lequences ; 
such as 5'-TTAGTTA, which is a confirmed seven-bp cnss-linked 
sequence,17 suggests that these sequences may adojt special 
conformers to allow bizelesin to span these distances. Some of 
these unusual cross-linked sequences are being explored in more 
detail using structural and kinetic tools, and at least ii one case 
(5'-TAATTA*) high field NMR studies have showr that the 
cross-linked sequence contains Hoogsteen base pairs or is base 
pair opened in the central AT step.31 Last, the impict of the 
reversibility of bizelesin-monoalkylated and cross-linted DNA 
is a consideration in determining the relative proportion of different 
adducts and their sequence specificity at different tines after 
initial exposure to drug. In unpublished work, we lave dem­
onstrated that bizelesin cross-linking is reversible, and tie kinetics 
are both sequence and base dependent.28
Materials and Methods
Bizelesin and (+)-CC-1065 and its monoalkylation antlogs were 
obtained from The Upjohn Company. Electrophoretic reagmts (acryl- 
amide, bisacrylamide, ammonium persulfate, and NJf,N,N'-tetra- 
methylethylenediamine) were from BioRad. Bacterial alkdine phos­
phatase was from Sigma. T4 polynucleotide kinase and restriction 
endonucleases were from New England Biolabs. Plasmid D N /, pBR322, 
was isolated by the alkaline lysis method32 and further purifiet in cesium 
chloride gradients. SV40 viral DNA was from New Englard Biolabs, 
Vector plasmid pSP6/T3 was from BRL, and plasmid pCAl was from 
Promega.
End-Labeling of Restriction Fragments of Plasmid DNA Plasmid 
DNA was routinely digested with the first restriction enionuclease 
followed by dephosphorylation with bacterial alkaline plosphatase 
treatment.12 Restriction fragments (for origin, see figure legends and 
supplementary material) were purified by phenol/CHCl3 extaction and 
ethanol precipitation and kinated with [y-32P]ATP and polynucleotide 
kinase. 5'-End-labeled restriction fragments were digested will a second 
restriction endonuclease to generate a unique end-labeled restriction 
fragment, and the desired fragments were separated on an \% nonde­
naturing polyacrylamide gel electrophoresis. The wet gel wis exposed 
onto autoradiographic film, and the desired DNA fragment vas located
(30) Warpehoski, M. A.; Harper, D. E.; Mitchell, M. A.; Muiroe, T. J. 
Biochemistry 1992, 31, 2502.
(31) Seaman, F.; Hurley, L. H. Submitted for publication.
(32) Maniatis, T.; Fritsch, E. F.; Sambrook, J. Molecular Cloning. A 
Laboratory Manual-, Cold Springs Harbor Laboratory: Cold Sprirgs Harbor, 
NY, 1982; p 122.
I Sequence Specificity o f Bizelesin
{and excised. The DNA was removed from the gel by crushing and 
.vortexing at room temperature overnight in 10 mM Tris-HCl (pH 7.6)
I and 10 mM NaCl.
I Drug Treatments of Isolated DNA and Determination of Drug-Bonding
Sites. Single S'-end-labeled restriction fragments were incubated with 
I drugs in 10 mM Tris-HCl, 10 mM NaCl, pH 7.6, for 2 days, unless 
I otherwise indicated, and unreacted drug molecules were removed by 
, phenol/CHCU extraction followed by ethanol precipitation. DNA pellets 
, were dissolved in double-distilled water and subjected to thermal treatment 
at 95 °C for 15 min to induce DNA strand breakage at the drug 
modification site.9 After thermal treatment, samples were lyophilized, 
and the DNA pellets were redissolved in alkaline sequencing dye solution 
, (80% foramide, 10 mM NaOH) and applied to 8% denaturing sequencing 
gel electrophoresis. After electrophoresis, gels were dried over DE81 
, paper and exposed X-ray Him.
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Supplementary Material Available: SClandSC2: Summary 
of cleavage sites for bizelesin on the sequence of restriction 
fragment used in the experiment described in Figures 6 and 7, 
respectively. The numbering system used was as described in the 
manufacturer’s manual (Promega). The relative intensity of 
cleavage is represented by the number of symbols above a given 
site. One symbol indicates the medium reactive sites, two symbols 
indicate highly reactive sites. SC3: Diagrammatic representation 
of restriction fragments used in the study of sequence selectivity 
of bizelesin. The arrow head indicates the 3'-side and the end 
of the arrow indicates the 5'-side of restriction fragments. The 
5'-end of restriction fragments were labeled with [y-32P] using 
polynucleotide kinase and [t-32P] ATP (4 pages). Ordering 
information is given on any current masthead page.
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B izelesin , an intrahelical D N A -D N A  interstrand cross-linker related to  (+)-C C -1065, has 
been show n to  a lkylate D N A  through guanine in restriction  enzym e sequences in which there  
is a su itab ly  positioned  adenine contained  in a h ighly reactive m onoalkylation  sequence on th e  
opposite strand. O ligom ers contain ing th e sequence 5 '-T T T T T N * , in w hich “N ” was either G,
C, or T , were syn th esized  to  evaluate th e  cross-linking poten tia l o f b izelesin  at nonadenine  
bases. K inetic analysis o f m onoalkylation and cross-linking even ts d em onstrates th at it  is th e  
reaction at “N ” (guanine or cytosine) th a t results in th e cross-link w hich is th e slow  step . On 
the basis o f th is analysis and the norm al unreactiv ity  o f guanine and cytosine to  a lkylation by  
the cyclopropapyrroloindole a lkylating m oiety  o f (+ )-C C -1065, we propose th a t th e m olecular  
m echanism  for th is  type o f cross-linking reaction m ost likely  involves a covalent im m obilization  
of the second alkylating arm, resulting in a “proxim ity-driven” reaction.
Introduction
Bizelesin (Figure 1) is a synthetically derived D N A -  
DNA intrahelical interstrand cross-linker that consists of 
two DNA alkylating cyclopropa[c]pyrrolo[3,2-e]indol- 
4(5H)-one (CPI)1 units of (+)-CC-1065 joined by the bis- 
(carboxyindolyl)urea linker (1). T he design and synthesis 
of this compound by Upjohn scientists was based upon 
the structure and reactivity of the DNA monoalkylation  
compound (+)-CC-1065 (2, 3), which has been dem on­
strated to react in a sequence-selective way with N3 of 
adenine (4-9).  Recently, we established that bizelesin  
cross-links adenines on opposite strands separated by four 
intervening base pairs (i.e, six base pairs apart) in a highly  
sequence selective way (10, 11). This compound, which 
has been recommended for clinical trials by the NCI 
Decision Network, has increased potency and efficacy over 
adozelesin, a monoalkylating CPI compound presently in 
phase I and II clinical trials.2 For example, while a single 
intravenous injection of bizelesin at 10 Mg/kg cured (30- 
day survivors) 50% of the mice, a single intravenous dose 
of 100 Mg/kg of adozelesin produced a 94% increase in life 
span without any cures. In previous studies with both  
monoalkylation compounds such as (+)-CC-1065 and the 
cross-linker bizelesin (10-12),  alkylation of D N A  has been  
shown to occur alm ost exclusively at adenines. In this 
paper we dem onstrate that, in certain sequences, bizelesin  
is also able to alkylate at guanine and cytosine, in addition  
to adenine, to form D N A -D N A  interstrand cross-links. In 
rare cases the alkylation at guanine is as reactive as the 
m ost reactive adenine monoalkylation sites. On the basis 
of the results o f a kinetic analysis of both m ono-adduct 
formation at adenine and cross-link formation between
B iz e le s in
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1 Abbreviations: CPI, cyclopropa[c]pyrrolo[3,2-e]indol-4(5H)-one;
BAP, bacterial alkaline phosphate.
2 J. P. McGovren, The Upjohn Co., private communication.
Figure 1. S t r u c t u r e  o f  b i z e l e s i n  a n d  i t s  r e a c t i o n  w i t h  D N A  t o  
f o r m  a  D N A - D N A  i n t e r s t r a n d  c r o s s - l i n k .
adenine and guanine, we propose a “proxim ity-driven” 
(see later) alkylation of guanine by virtue of a covalently  
immobilized alkylation arm held near the normally 
unreactive base as the m ost likely molecular m echanism  
for th is unexpected reaction.
Experimental Procedures
Chemicals and Enzymes. B i z e l e s i n  w a s  o b t a i n e d  f r o m  T h e  
U p j o h n  C o .  ( K a l a m a z o o ,  M I ) .  E l e c t r o p h o r e t i c  r e a g e n t s  [ a c r y l -  
a m i d e ,  N . N . i V ' . N ' - t e t r a m e t h y l e t h y l e n e d i a m i n e ,  a m m o n i u m  p e r -
0893-228x/93/2706-0889$04.00/0 © 1993 American Chemical Society
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Chart I. Nucleotide Sequences of Oligomers Used in 
This Study*
•
5 '  ATATCATGCTAAAAAGCAAGC 3 '
3 '  A G T A C G A T TT TT C G T T C G T A T  5 '
5 '  GAGCACCGCAAAAACGGATTG 3 '
3 '  G T G G C G TTTTTG C C TA A C C TC  5 '  
o
oe
5 '  GAGTACCGAAAAAACGGATTA 3 '
3 '  A T G G C T T T T T T G C C T A A T C T C  5 '
•
5 '  GAGGACCGGAAAAACGGATTC 3 '
3 '  C T G G C C TT TT TG C C T A A G C TC  5 '  
o
0 Circles indicate bases found to be strongly (•) or weakly (O) 
reactive with bizelesin (from Figure 3).
sulfate, and bis(acrylamide)] were purchased from Bio-Rad. T4 
polynucleotide kinase was from United States Biochemical Co.; 
[y-32P] ATP was from ICN; and X-ray film, intensifying screens, 
and developing chemicals were from Kodak.
Preparation of Oligonucleotides. A series of oligonucle­
otides (Chart 1) was synthesized on an automated DNA syn­
thesizer (Applied Biosystem 381A) by the phosphoramidite 
method. The oligomers were deprotected with saturated am­
monium hydroxide at 55 °C overnight. The ammonium hy­
droxide solution was evaporated under vacuum, and the dried 
pellets were redissolved in double-distilled water.
Preparation of 5'-S2P-End-Labeled Oligomer Duplex. 
Individual strands of the 21 mer were labeled with [y-32P]ATP 
using T4 polynucleotide kinase and hybridized to an excess of 
unlabeled complementary strand, and the resulting duplex DNA 
was electrophoresed on an 8 % nondenaturing polyacrylamide 
gel. Duplex DNA was located on the gel using autoradiography, 
cut from the gel, minced with a blade, and extracted with 
annealing buffer [10 mM tris(hydroxymethyl)aminomethane 
hydrochloride (pH 7.6) and 100 mM NaCl].
y -ap .Pii d -Labeling of Restriction Fragments of Plasmid 
DNA. Ten micrograms of plasmid DNA, pCAT (Promega), was 
digested withNcoI and dephosphorylated with bacterial alkaline 
phosphate (BAP). Restriction fragments were purified by phenol/ 
CHCI3 extraction followed by ethanol precipitation. Purified 
restriction fragments were treated with [y-^PJATP and poly­
nucleotide kinase. 5'-End-labeled restriction fragments were 
digested with EcoRI to generate a desired size of DNA fragment, 
and the 301-base-pair DNA fragment was isolated by electro­
phoresis using a 6 % nondenaturing polyacrylamide gel.
Separation of Cross-Linked Duplex from Monoalkylated 
and Unreacted Species Using Denaturing Polyacrylamide 
Gel Electrophoresis. Duplex oligonucleotides (~  100 ng) were 
modified with bizelesin (final concentration 300 mM) in 100 p L  
of annealing buffer for 3 days, and unbound drug molecules were 
removed by phenol/chloroform extraction and ethanol precip­
itation. DNA pellets were dried under vacuum, redissolved in 
20 f iL  of alkaline sequencing dye (10 mM NaOH/80 % formamide), 
and incubated at 80 °C for 1 min just before loading samples on 
a prewarmed 12 % denaturing polyacrylamide gel and subjecting 
to electrophoresis.
Strand Breakage. Drug-modified oligomer duplexes were 
dissolved in distilled water and incubated in a 95 °C water bath 
for 30 min to induce strand breakage, as described previously 
(7).
Kinetic Experiment. One hundred nanograms of oligomer 
duplex was reacted with bizelesin (final concentration 300 mM) 
in 100 mL of annealing buffer. Under these conditions, the binding 
sites would be fully occupied. Five-microliter aliquots of sample 
were withdrawn at a given time and immediately frozen in -70 
°C to stop the reaction. Every sample was thermally treated at
2 IA
21G
2 IT  
21C
95 °C for 30 min (sufficient to produce complete strand breakage 
at alkylation sites) to determine the amount of alkylation and 
locate the modifed nucleotides.
Analysis of Kinetics of Monoalkylation and Cross- 
Linking of DNA by Bizelesin. Densitometric tracings were 
obtained from the autoradiogram to measure the percentage of 
the strand breakage at a given site. The amount of unmodified 
DNA was calculated by measuring the percentage of the top 
band in the autoradiogram shown in Figure 5A-a, and the amount 
of cross-linking product was from the percentage of strand 
breakage product in Figure 5A-b. The amount of monoalkylation 
product was calculated by subtracting the amount of cross-linking 
product from the amount of strand breakage product in Figure, 
5A-a. The kinetic analysis was carried out using the equations:.
A = A0e ^  B = p ^ ( e k't - e k*) C = A0~ A - B  k2 kx
A, B, and C are the concentrations of unmodified, mono-* 
adducted, and cross-linked DNA at time t, and Ao is the initial, 
concentration of DNA. The values of ki and k2 were calculated  ̂
by substitution oiA,B, and C into a homemade computer program 
and optimized by iteration.
R e su lts
A n a lysis  o f  B ize le s in  C ross-L inking in  a Restric-^ 
tion  Enzym e Fragm ent. In previous studies using 
oligomer duplexes of designed sequences, it was established, 
that bizelesin is able to  cross-link adenines placed six base, 
pairs apart on opposite strands (Figure 1) (1 ,10, 12). In 
subsequent studies using restriction enzyme fragments,* 
we have examined in more detail the sequence specificity” 
of bizelesin by screening about 4.0 kb of DNA restriction, 
fragments for monoalkylation and cross-linking sites (11). 
Using the thermal strand breakage assay (7), we found, 
that most alkylations of DNA by bizelesin occurred at 
adenine, as described previously (1, 10, 12). Surprisingly^ 
it was found that, in certain sequences, bizelesin is also, 
able to alkylate at guanine and cytosine in addition to 
adenine (11). For example, in the case of the restriction 
enzyme fragment shown in Figure 2, at the lowest drug 
concentration (0.014 jttM) an alkylation by bizelesin at, 
guanine in the sequence 5'-TATATG* (* represents the, 
covalently modified base) is found, as well as the more, 
expected alkylation at the adenine in the sequence 5'-j 
AATAAA*. A possible explanation for alkylation of 
guanine on the sequence 5'-TATATG* is that covalent^ 
immobilization of the alkylation arm at an adenine on theR 
opposite strand allows bizelesin to alkylate a normally^ 
unreactive guanine positioned six base pairs away froms 
the adenine. The apparent inability of monalkylating 
analogs such as (+)-CC-1065 to alkylate that site also, 
supports an alkylation mechanism in which the potentially; 
reactive cyclopropane ring is held in proximity to the  ̂
normally unreactive nucleophilic center on DNA, because ; 
it is covalently attached at the monoalkylation site. We; 
call this a proximity-driven alkylation by analogy with 
the proximity effect in chemical reactions (13). In this 
same fragment, at more than a 10-fold higher concentration 
(>0.14 pM), monoalkylation sites (5'-GAAAAA*, 5 '- 
GAAATA*, and 5'-CAATAA*) and potential cross-linking 
sites (5'-TGAAAA* and 5'-TTTAAA*) are also reactive; 
to bizelesin (Figure 2). While this proximity-driven: 
reaction is certainly in accord with the results described s 
here, this evidence does not constitute proof. A second, 
possibility is that monoalkylation does occur at nonadenine 
bases, but that this is readily reversible (i.e., thermody-
Bizelesin Alkylation of Guanine and Cytosine
A
A T
G C 1 2 3 4 5
B
5 ' CATATTGGCC ACGTTTAAAT CAAAACTGGT GAAACTCACC CAGGGATTGG CTGAGACGAA
AAACATATTC TCAATAAACC CTTTAGGGAA ATAGGCCAGG TTTTCACCGT AACACGCCAC 
ATCTTGCGAA TATATGTGTA GAAACTGCCG GAAATCGTCG TGGTATTCAC TCCAGAGCGA 
TGAAAACGTT TCAGTTTGCT3 '
F i g u r e  2 .  ( A )  E f f e c t  o f  b i z e l e s i n  c o n c e n t r a t i o n  o n  D N A  s t r a n d  
b r e a k a g e  p r o d u c e d  b y  t h e r m a l  t r e a t m e n t  o f  b i z e l e s i n  D N A  
a d d u c t .  T h e  r e s t r i c t i o n  f r a g m e n t  ( 3 0 1  b a s e  p a i r s )  w a s  p r e p a r e d  
b y  t h e  d i g e s t i o n  o f  p l a s m i d  p C A T  ( P r o m e g a )  w i t h  Ncol f o l l o w e d  
b y  d e p h o s p h o r y l a t i o n ,  l a b e l i n g  w i t h  [ y - 32P ] A T P ,  a n d  t h e n  a  
s e c o n d  d i g e s t i o n  w i t h  E c o R I .  A G  a n d  T C  r e p r e s e n t  p u r i n e -  a n d  
p y r i m i d i n e - s p e c i f i c  c h e m i c a l  c l e a v a g e .  L a n e s  1 - 5  c o n t a i n  0 , 0 . 0 1 4 ,  
0 . 1 4 ,  1 . 4 ,  a n d  1 4  / u M  b i z e l e s i n ,  r e s p e c t i v e l y ,  a n d  d r u g - D N A  
m i x t u r e s  w e r e  i n c u b a t e d  f o r  2  d a y s  a t  r o o m  t e m p e r a t u r e .  ( B )  
D i a g r a m m a t i c  p r e s e n t a t i o n  o f  b i z e l e s i n  b o n d i n g  s e q u e n c e  o n  3 0 1 -  
b a s e - p a i r  NcoI-EcoRI  f r a g m e n t  o f  p C A T .  T h e  d a t a  a r e  t a k e n  
f r o m  t h e  c o n c e n t r a t i o n  d e p e n d e n c y  e x p e r i m e n t  d e s c r i b e d  i n  p a n e l  
A .  T h e  a s s i g n m e n t  o f  c l u s t e r e d  b o n d i n g  s i t e s  w a s  a c h i e v e d  b y  
t h e  e x t e n d e d  e l e c t r o p h o r e s i s  t o  e x p a n d  t h o s e  s i t e s .  T h e  n u m b e r  
o f  c i r c l e s  r e f l e c t s  t  h e  r e l a t i v e  r e a c t i v i t y  t o w a r d  a l k y l a t i o n :  • • • ,  
0 - 0 . 0 1 4  nU; • • ,  0 . 0 1 4 - 0 . 1 4  m M ;  • ,  0 . 1 4 - 1 . 4  nM.
n a m i c a l l y  u n s t a b l e )  a n d  i s  o n l y  o b s e r v e d  w h e n  t r a p p e d  
b y  a  “ f i x i n g ”  s t e p  b y  a l k y l a t i o n  a t  a d e n i n e  o n  t h e  o p p o s i t e  
s t r a n d .  W h i l e  w e  c a n n o t  d e f i n i t i v e l y  r u l e  t h i s  o u t  b e c a u s e
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Figure 3 .  Autoradiography of denaturing polyacrylam ide gel 
electrophoresis (PAGE) analysis of bizelesin cross-linking reaction 
of the four 5'-32P-end-labeled D N A s shown in Chart I. (+) and 
(-) indicate upper and lower strands. Arrows a, b, and c indicate 
cross-linked DNA , m onoalkylated D NA, and unm odified DNA, 
respectively. In the (+) strands, band c also contains a small 
am ount o f monoalkylated species. 21A (+ ) and 21A (-)  showed 
similar patterns o f products.3
of unique sequence effects, we think it unlikely, because 
rates of reversal from m onoalkylated guanines in special 
sequences such as 5'-AAATTG* are slower than from 
monoalkylated adenines in similar sequences (unpublished 
results).
D e term in a tio n  o f  th e  A b ility  o f  B iz e le s in  T o  Form  
M on oalk y lated  and  C ross-L inked  S p ec ie s  on  21 -B ase- 
P a ir  O ligom ers. To further explore this unexpected  
observation, we have utilized the oligomers shown in Chart 
I to examine the reactivity of guanine, cytosine, and 
thymine to cross-linking by bizelesin when located opposite 
the CPI highly reactive sequence 5'-NAAAAA* (* indicates 
the covalent bonding site; N = any base). T he oligomers 
in Chart I were selected in this study, since the sequence  
5'-TTTTTG * was found to be a highly reactive cross- 
linking site for bizelesin also in a study using DNA  
restriction fragments (data not shown). In previous 
studies, denaturing gel analysis has been used to separate 
unm odified oligomer species from both the cross-linked  
and monoalkylated oligomer species (10, 12). In the 
present study, this technique was used to separate single­
stranded unmodified oligomers (species c) derived from  
21A, 21G, 21T, and 21C both from those cross-linked by 
bizelesin (species a) and from m onoalkylated single- 
stranded oligomers (species b in Figure 3). However, 
because of the lim ited preheating tim e (1 m in),3 not all of 
the m ono-adduct species b are denatured, and conse­
quently, the cross-linked species a contains up to  about 
20-30%  of m ono-adducted species b. The results show  
that cross-linked species were only found in radiolabeled  
21A (+ ), 21G (+ ) and (-), and 21C (+ ) and (-) [(+ ) and 
(-) identify the upper and lower strands of oligomers 
radiolabeled with 32P shown in Chart I]. In addition, 
monoalkylated species were predominant over cross-linked 
species in 21G (+ ) and 21C (+ ), while unmodified oligomer 
was the main species in 21G (-), 2IT  (-), and 21C (-). In 
2IT  (-) only unm odified oligomer was found, and in 2 IT  
(+ ) just unm odified and m onoalkylated oligomer was 
observed.
D eterm in a tio n  o f  th e  S ite s  o f  A lk y la tio n  b y  B iz e ­
le s in  on  th e  2 1 -B a se -P a ir  O ligom ers. Each species (a, 
b, and c in Figure 3) was isolated from the denaturing gel 
and subjected to therm ally induced strand breakage (7) 
followed by gel electrophoresis to determine the covalent 
m odification sites. For 21A (+ ), the cross-linked species 
showed cleavage at the expected 3'-adenine.4 In 21T (+)
3 W hile heating for 1 min is insufficient to completely denature
m onoadducts, heating for longer periods of tim e causes excessive DNA 
strand  breakage.
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Figure 4. R e s u l t s  o f  t h e  t h e r m a l l y  i n d u c e d  s t r a n d  c l e a v a g e  a s s a y  
t o  l o c a t e  b i z e l e s i n  a d d u c t  s i t e s  i n  o l i g o m e r s  2 1 G  ( - )  s t r a n d  ( A )  
a n d  2 1 C  ( - )  s t r a n d  ( B ) .  S t r a n d  b r e a k a g e  c o n d i t i o n s  w e r e  a s  
d e s c r i b e d  i n  E x p e r i m e n t a l  P r o c e d u r e s .  A G  a n d  T C  r e p r e s e n t  
p u r i n e -  a n d  p y r i m i d i n e - s p e c i f i c  c l e a v a g e  r e a c t i o n .7 L a n e  1 o f  b o t h  
p a n e l s  r e f e r s  t o  c o n t r o l  D N A .  L a n e  2  o f  p a n e l  A  a n d  l a n e  3  o f  
p a n e l  B  r e p r e s e n t  s p e c i e s  c  f r o m  F i g u r e  3 .  L a n e  3  o f  p a n e l  A  a n d  
l a n e  2  o f  p a n e l  B  a r e  s t r a n d  b r e a k a g e  p r o d u c t s 6 o f  s p e c i e s  a  f r o m  
F i g u r e  3 .  T h e  m a t e r i a l  a t  t h e  t o p  o f  t h e  g e l  i n  l a n e  3  o f  p a n e l  A  
a n d  l a n e  2  o f  p a n e l  B  i s  d u e  t o  c o n t a m i n a n t  m o n o a l k y l a t e d  d u p l e x .  
T h e  a d d i t i o n a l  b a n d s  i n  l a n e  1 ( p a n e l  A )  a r e  d u e  e i t h e r  t o  t h e  
h a r s h  t h e r m a l  t r e a t m e n t  u s e d  i n  t h e s e  e x p e r i m e n t s  ( 9 0  ° C  f o r  
3 0  m i n )  t o  e f f e c t  d r u g - i n d u c e d  s t r a n d  b r e a k a g e ,  w h i c h  s o m e t i m e s  
p r o d u c e s  u n e x p e c t e d  s t r a n d  b r e a k s ,  o r  t o  c o n t a m i n a t e d  D N A .  
I n  s u b s e q u e n t  e x p e r i m e n t s ,  t h e s e  e x t r a  b a n d s  w e r e  a b s e n t .
a n d  ( - ) ,  c r o s s - l i n k e d  m a t e r i a l  w a s  a b s e n t ,  a n d  t h e  
m o n o a l k y l a t e d  s p e c i e s  i n  2 1 T  ( + )  s h o w e d  s t r a n d  b r e a k a g e  
p r e d o m i n a n t l y  a t  t h e  3 ' - a d e n i n e ,  w i t h  a  s m a l l e r  a m o u n t  
a t  t h e  a d j a c e n t  5 ' - a d e n i n e  ( s u m m a r i z e d  i n  C h a r t  I ) .5 I n  
c o n t r a s t ,  t h e  c r o s s - l i n k e d  s p e c i e s  f r o m  2 1 G  a n d  2 1 C  s h o w e d  
e x c l u s i v e  a l k y l a t i o n  a t  t h e  3 ' - a d e n i n e s  o n  t h e  ( + )  s t r a n d s  
a n d  a t  guanine a n d  cytosine o n  t h e  ( - )  s t r a n d  ( l a n e s  3  a n d  
2  i n  p a n e l s  A  a n d  B ,  r e s p e c t i v e l y ,  o f  F i g u r e  4 ;  s u m m a r i z e d  
i n  C h a r t  I ) .6 I n  b o t h  l a n e  3  o f  p a n e l  A  a n d  l a n e  2  o f  p a n e l  
B ,  t h e r e  i s  a  s m a l l e r  a m o u n t  ( a b o u t  2 0 - 3 0 % )  o f  m a t e r i a l  
t h a t  s t a y s  a t  t h e  t o p  o f  t h e  g e l ,  r e l a t i v e  t o  t h e  a m o u n t  o f  
s t r a n d  b r e a k a g e  p r o d u c t .  A s  d e s c r i b e d  b e f o r e ,  t h i s  i s  m o s t  
l i k e l y  d u e  t o  c o n t a m i n a n t  m o n o a l k y l a t e d  p r o d u c t  ( b a n d  
b ) ,  w h i c h  i s  i n  l a r g e  e x c e s s  i n  2 1 G  ( + )  a n d  2 1 C  ( + ) .  W h e n  
t h e  s a m e  p r o c e d u r e  i s  c a r r i e d  o u t  o n  2 1 A  ( + ) ,  w h e r e  t h e r e  
i s  v e r y  l i t t l e  m o n o a l k y l a t e d  p r o d u c t ,  v i r t u a l l y  a l l  o f  t h e  
r a d i o a c t i v i t y  i s  f o u n d  a s  s t r a n d  b r e a k a g e  p r o d u c t  ( d a t a  
n o t  s h o w n ) .
4 In unpublished results, 21A (+) and (-) showed similar patterns of 
cleavage.
5 Although alkylation at thymine was not detected on this oligomer, 
in previous studies (Sun and Hurley, unpublished results) using restriction 
fragments, trace amounts of thymine adducts were detected by this assay.
8 The appearance of two bands with 5'-32P-labeled oligomers, one at 
lower molecular weight, equivalent to a Maxam and Gilbert sequencing 
reaction, and the other at higher molecular weight, due to a product 
containing a modified deoxyribose, is typical of alkylation at N3 of adenine 
and, by analogy, most likely at a ring nitrogen or oxygen of guanine or 
cytosine, respectively.
7 Sequencing of A tracts in short oligomers is particularly problematic. 
In subsequent experiments, the addition of carrier calf thymus DNA 
improved the specificity and confirmed the ladder shown in this figure.
Sin  et al.
Kinetics of Monoalkylation by Bizelesinon he (+) 
and (-) Strands of the 2 1 - G .  T h e  l a r g e  e x : e s t  o f  t h e  
a d e n i n e  m o n o - a d d u c t  o v e r  c r o s s - l i n k e d  p r o d i c t  f o r  t h e  
( + )  s t r a n d s  o f  o l i g o m e r s  2 1 G  a n d  2 1 C  a n d  i b s m c e  of 
m o n o a l k y l a t i n g  s p e c i e s  i n  t h e  ( - )  s t r a n d s  o f  o l i g n m r s  2 1 G  
a n d  2 1 C  ( F i g u r e  3 )  l e d  u s  t o  s u s p e c t  t h a t  a l i y k t i o n  of 
g u a n i n e  o r  c y t o s i n e  i s  t h e  s l o w  s t e p  i n  c r o s s - l n k h g ,  a n d  
t h e  f o r m a t i o n  o f  c r o s s - l i n k e d  a d d u c t s  a t  { u a a i n e  o r  
c y t o s i n e  i s  a  proxim ity-driven reaction f a c l i t t t e d  by 
c o v a l e n t  i m m o b i l i z a t i o n  o f  t h e  u n r e a c t e d  C P I  n o i t t y  n e a r  
a  n o r m a l l y  u n r e a c t i v e  g u a n i n e  o r  c y t o s i n e  F u r t h e r  
e v i d e n c e  f o r  t h i s  p r o p o s a l  w a s  o b t a i n e d  f r o m  , h e  r e s u l t s  
o f  k i n e t i c s  e x p e r i m e n t s  s h o w n  i n  F i g u r e  5 .  T i e  k i n e t i c s  
o f  a l k y l a t i o n  a t  a d e n i n e  a n d  g u a n i n e  i n  2 1 G  + )  a n d  ( - )  
s t r a n d s  a r e  s h o w n  i n  F i g u r e  5 A  ( p a n e l s  a  a n c  b ,  r e s p e c ­
t i v e l y ) .  I n  t h i s  e x p e r i m e n t ,  t h e r m a l  c l e a v a g e  v a s  c a r r i e d  
o u t  d i r e c t l y  o n  m a t e r i a l  f r o m  t h e  t i m e  c o u r s  r e a c t i o n .  
T h e  m a t e r i a l  m i g r a t i n g  a t  t h e  s t r a n d  b r e a k a g e s i t e  ( A *  o r  
G *  i n  F i g u r e  5 A )  r e p r e s e n t s  t h e  t o t a l  a m o u i t  o f  e i t h e r  
c r o s s - l i n k e d  s p e c i e s  ( F i g u r e  5 A ,  p a n e l  b )  o r  m o m  a n d  c r o s s -  
l i n k e d  s p e c i e s  ( F i g u r e  5 A ,  p a n e l  a ) .  T h e s e  e s u l t s  a r e  
p r e s e n t e d  g r a p h i c a l l y  i n  F i g u r e  5 B .  T h e  f o l l o v i n g  e q u a ­
t i o n  d e s c r i b e s  t h e  g e n e r a l i z e d  k i n e t i c  s c h e n e  f o r  t h e  
m o n o a l k y l a t i o n  a n d  t h e  c r o s s - l i n k i n g  r e a c t i o i .
-C A A A A A - k 1
-G T T T T T -
A
-C A A A A A -
■
-G T T T T T -
B
k 2 CAAAAA- I------- 1
G T T T T T -
c
T h e  r a t e  c o n s t a n t s  ( & i  a n d  k2) f o r  t h e  m o n o a l k d a t i o n  a n d  
c r o s s - l i n k i n g  r e a c t i o n  w e r e  c a l c u l a t e d  a s  d e c r i b e d  i n  
E x p e r i m e n t a l  P r o c e d u r e s .  A s  a n t i c i p a t e d ,  t h e  e c o n d  s t e p  
( c r o s s - l i n k i n g  a t  G )  i s  s l o w e r  t h a n  t h e  m o n o a k y l a t i o n  a t  
a d e n i n e ,  s i n c e  k\ a n d  k2 w e r e  c a l c u l a t e d  a s  4 .  X 1 0 -8  s _ l  
a n d  2 . 5  X 1 ( H  s - 1 ,  r e s p e c t i v e l y .
D iscussion
I n  t h i s  a r t i c l e  w e  d e s c r i b e  e x p e r i m e n t s  i n  7h i c h  n o n ­
a d e n i n e  b a s e s  a r e  a l k y l a t e d  b y  b i z e l e s i n ,  a  I N A - D N A  
i n t e r s t r a n d  c r o s s - l i n k e r  s t r u c t u r a l l y  a n d  m e c h n i s t i c a l l y  
r e l a t e d  t o  ( + ) - C C - 1 0 6 5 .  O u r  i n i t i a l  o b s e r v a t o n  o f  n o n ­
a d e n i n e  a l k y l a t i o n  w a s  b a s e d  u p o n  a n a l y s i s  o f e s t r i c t i o n  
e n z y m e  f r a g m e n t s  i n c u b a t e d  w i t h  b i z e l e s i n  a m  s u b j e c t e d  
t o  a  t h e r m a l  s t r a n d  b r e a k a g e  a s s a y  (11). I n  t i n  p a p e r  w e  
r e p o r t  b i z e l e s i n  a l k y l a t i o n  o f  t h e  s e q u e n c e  S ' - ^ A T A T G *  
i n  a  r e s t r i c t i o n  e n z y m e  f r a g m e n t ,  w h i c h  w s  e q u a l l y  
r e a c t i v e  a s  5 ' - A A T A A A *  t o  m o n o a l k y l a t i o n  b  b i z e l e s i n .  
T o  f u r t h e r  e x p l o r e  t h e  a l k y l a t i o n  b y  b i z e l e s n  o f  n o n ­
a d e n i n e  s e q u e n c e s ,  a  s e r i e s  o f  o l i g o m e r s  w a  d e s i g n e d  
c o n t a i n i n g  a n  A 5 t r a c t  a n d  e i t h e r  a d e n i n e  o r  n o r m a l l y  
u n r e a c t i v e  b a s e  a t  t h e  3 '  e n d  o f  t h e  t r a c t  o n  t i e  o p p o s i t e  
s t r a n d  ( C h a r t  I ) .
W e  h a v e  p r e v i o u s l y  n o t e d  t h a t  a l k y l a t i o n  i y  ( + ) - C C -  
1 0 6 5  a n d  o t h e r  m o n o a l k y l a t i o n  c o m p o u n d s  o c u r s  a l m o s t  
e x c l u s i v e l y  a t  t h e  3 ' - a d e n i n e  o f  r u n s  o f  f i v  o r  m o r e  
a d e n i n e s  (4, 7 ,  8), w h i c h  w e  a t t r i b u t e  t o  h e  s p e c i a l  
r e a c t i v i t y  o f  t h i s  a d e n i n e  a t  t h e  3 '  j u n c t i o n  s i e  (14, 15). 
T h e  r e a c t i o n  o f  b i z e l e s i n  a t  t h e  3 ' - a d e n i n e  i r  o l i g o m e r s  
2 1 A ,  2 1 G ,  a n d  2 1 C  a p p e a r s  t o  b e  s i m i l a r  i n  t h i s  e g a r d .  W e  
p r o p o s e  t h a t  t h e  u n u s u a l  r e a c t i v i t y  o f  g u a n i n e  > r  c y t o s i n e  
o n  t h e  o t h e r  s t r a n d  t o  b i z e l e s i n  i n  t h e s e  s e q u e n c e s  i s  o n l y  
b y  v i r t u e  o f  t h e  p r o x i m i t y  o f  a  c o v a l e n t l y  i i m o b i l i z e d  
s e c o n d  a l k y l a t i o n  a r m  o f  b i z e l e s i n  t o  a  n o r m a l l y  m r e a c t i v e
Bizelesin Alkylation of Guanine and Cytosine
A
a b
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A T
G C 0 0.5 1 2 4 6 8 12 24 36 48 72
A T
G C 0 0.5 1 2 4 6 8 12 24 36 48 72
B 100.0
6 0 . 0 -
1  4 0 . 0 -
Q
0.0
8 0 . 04 0 . 0 6 0 . 020.00.0
T i m e  ( h )
F i g u r e  5 .  K i n e t i c s  o f  m o n o  a n d  c r o s s - l i n k  a d d u c t  f o r m a t i o n  o n  2 1 G .  ( A )  P a r t s  a  a n d  b  o f  p a n e l  A  s h o w  t h e  r e s u l t s  o f  P A G E  a n a l y s i s  
a f t e r  t h e r m a l  t r e a t m e n t  o f  2 1 G  m o d i f i e d  w i t h  b i z e l e s i n  f r o m  t h e  32P - l a b e l e d  ( + )  a n d  ( - )  s t r a n d s ,  r e s p e c t i v e l y .  T h e  n u m b e r s  ( 0 . 5 - 7 2 )  
a t  t h e  t o p  o f  t h e  g e l  r e p r e s e n t  h o u r s  o f  i n c u b a t i o n .  ( B )  D e n s i t o m e t r i c  t r a c i n g s  w e r e  o b t a i n e d  f r o m  t h e  a u t o r a d i o g r a m s  s h o w n  i n  p a r t s  
a  a n d  b  o f  p a n e l  A  t o  m e a s u r e  t h e  p e r c e n t a g e  o f  t h e  s t r a n d  b r e a k a g e  a t  a  g i v e n  s i t e .  T h e  a m o u n t  o f  u n m o d i f i e d  D N A ,  c r o s s - l i n k i n g  
p r o d u c t ,  a n d  m o n o a l k y l a t i o n  p r o d u c t  w a s  d e t e r m i n e d  a s  d e s c r i b e d  i n  t h e  E x p e r i m e n t a l  P r o c e d u r e s .  T h e  s t i p p l e d  □ ,  • ,  a n d  ▲  s y m b o l s  
c o r r e s p o n d  t o  t h e  a m o u n t  o f  u n m o d i f i e d  D N A ,  m o n o a l k y l a t i o n  p r o d u c t ,  a n d  c r o s s - l i n k i n g  p r o d u c t ,  r e s p e c t i v e l y .
s i t e  o n  g u a n i n e  o r  c y t o s i n e .  T h e  i d e n t i t y  o f  t h e  a l k y l a t i n g  
p r o d u c t s  a t  t h e s e  b a s e s  i s  u n d e r  i n v e s t i g a t i o n ,  b u t  t h e  
l o c a t i o n  o f  t h e  d r u g  m o l e c u l e  i n  t h e  m i n o r  g r o o v e  a n d  
s u s c e p t i b i l i t y  t o  t h e r m a l  s t r a n d  b r e a k a g e  s u g g e s t s  t h a t  
a l k y l a t i o n  o c c u r s  a t  N 3  o f  g u a n i n e  a n d  0 2  o f  c y t o s i n e .  I n  
t h i s  r e g a r d ,  M i t c h e l l  a n d  c o - w o r k e r s  (16)  a n d  S u g i y a m a  
a n d  c o - w o r k e r s  (17) h a v e  r e c e n t l y  s h o w n  t h a t  d u o c a r m y c i n  
A ,  a  m o n o a l k y l a t i o n  c o m p o u n d  s t r u c t u r a l l y  r e l a t e d  t o  ( + ) -  
C C - 1 0 6 5 ,  i s  a b l e  t o  a l k y l a t e  N 3  o f  g u a n i n e  i n  D N A .  T h i s  
p r o v i d e s  a d d i t i o n a l  s u p p o r t  f o r  t h e  p r o p o s e d  N 3  g u a n i n e  
a l k y l a t i o n  a n d ,  b y  i n f e r e n c e ,  0 2  o f  c y t o s i n e  b y  b i z e l e s i n .  
H o w e v e r ,  i n  t h i s  c a s e  t h e  m e c h a n i s m  d o e s  n o t  i n v o l v e  a  
c o v a l e n t  i m m o b i l i z a t i o n  o f  a  s e c o n d  a l k y l a t i o n  a r m ,  b u t  
j s  d u e  t o  t h e  s p e c i a l  r e a c t i v i t y  o f  t h i s  s e q u e n c e  t o  
d u o c a r m y c i n  A .
T h i s  p r o p o s e d  m e c h a n i s m  f o r  a l k y l a t i o n  o f  g u a n i n e  o r  
c y t o s i n e  i n v o l v i n g  a  p r o x i m i t y - d r i v e n  r e a c t i o n  i s  i n  s h a r p  
c o n t r a s t  t o  t h e  m e c h a n i s m  f o r  s e q u e n c e  r e c o g n i t i o n  o f  
a d e n i n e  i n  m o n o a l k y l a t i o n  e v e n t s  b y  ( + ) - C P I  c o m p o u n d s ,  
w h i c h  r e l i e s  o n  a  s e q u e n c e - d e p e n d e n t  c o n f o r m a t i o n a l
f l e x i b i l i t y  a n d /  o r  c a t a l y t i c  a c t i v a t i o n  ( 5 , 6 ,8 ,9 ) .  H o w e v e r ,  
t h i s  p r e s e n t l y  p r o p o s e d  p r o x i m i t y - d r i v e n  r e a c t i o n  a t  
g u a n i n e  o r  c y t o s i n e  i s  m e c h a n i s t i c a l l y  s o m e w h a t  s i m i l a r  
t o  t h e  a l k y l a t i o n  o f  a d e n i n e  b y  ( - ) - C C - 1 0 6 5 ,  w h i c h  r e q u i r e s  
t h e  o p t i m u m  b i n d i n g  i n t e r a c t i o n s  o f  t h e  t w o  p y r r o l i d i n e  
r i n g s  w i t h  t h e  m i n o r  g r o o v e  o f  D N A  t o  p r o m o t e  a n  
o t h e r w i s e  l e s s  f a v o r a b l e  b o n d i n g  r e a c t i o n  t h a n  w i t h  ( + ) -  
C C - 1 0 6 5  ( 8 ) .
B i z e l e s i n  h a s  i n c r e a s e d  p o t e n c y  a n d  e f f i c a c y  o v e r  
a d o z e l e s i n ,  a  m o n o a l k y l a t i n g  a n a l o g .  T h e  a b i l i t y  o f  
b i z e l e s i n  t o  f o r m  D N A  i n t e r s t r a n d  c r o s s - l i n k s  i s  b e l i e v e d  
t o  b e  r e s p o n s i b l e  f o r  t h e  s t r o n g  c y t o t o x i c i t y ,  s i n c e  m o s t  
w e l l - k n o w n  c r o s s - l i n k e r s  a r e  m o r e  p o t e n t  t h a n  t h e i r  
m o n o a k y l a t i n g  a n a l o g s .  A l t h o u g h  t h e  f r e q u e n c y  o f  u n ­
u s u a l  a d d u c t  i s  l o w ,  u n u s u a l  a d d u c t s ,  p a r t i c u l a r l y  a t  
g u a n i n e  a n d  l e s s  f r e q u e n t l y  a t  c y t o s i n e  a n d  t h y m i n e ,  o c c u r  
o n  t h e  o p p o s i t e  s t r a n d  t o  a n  a d e n i n e  t h a t  i s  l o c a t e d  s i x  
b a s e  p a i r s  a w a y  a n d  c o n t a i n e d  i n  a  h i g h l y  r e a c t i v e  
m o n o a l k y l a t i n g  s e q u e n c e .  T h e  a b i l i t y  t o  f o r m  c r o s s -  
l i n k i n g  b y  a  p r o x i m i t y - d r i v e n  a l k y l a t i o n  p r e s u m a b l y  m a k e s
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b i z e l e s i n  m o r e  p o t e n t  i n  t h e  b i o l o g i c a l  a c t i v i t y  t h a n  i t s  
m o n o a l k y l a t i n g  a n a l o g s .
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a b s t r a c t : 'H  N M R  analysis o f the bizelesin adduct of d(CGTAATTACG )2 indicates that adenines six 
base pairs apart on opposite D N A  strands are cross-linked, yielding two major adduct conformations differing 
in the central duplex region (5'AATT-3'): one (major product) contains an AT step wherein both adenines 
are jy/i-oriented and Hoogsteen base paired to thymines (SHG  model); the other contains c/tf/-oriented 
AT-step adenines that show no evidence of hydrogen bonding with pairing thymines (5OP  model). The 
SOP model consists of three conformers undergoing exchange and differing in the orientation of the AT-step 
thymines. Bizelesin’s size, rigidity, and cross-linking properties restrict the D N A  adduct’s range of motion 
and freeze out D N A  conformation(s) adopted during the cross-linking process. This most reactive D N A  
sequence, 5'-TAATTA-3', yields an adduct conformation (5HG ) containing a stable region o f W atson- 
Crick (WC) to Hoogsteen (HG) to Watson-Crick base-pairing transitions. While bizelesin exercises a 
selective effect on D N A  conformation, it intrudes into regions of base stacking less than other Hoogsteen 
pairing-inducing drugs (e.g., echinomycin). Because of this capacity to induce stable Hoogsteen base 
pairing with only minimal distortion o f base-base stacking, bizelesin affords an opportunity to explore this 
unusual D N A  conformation.
Bizelesin (formerly U77779, The Upjohn Co.), a bifunc­
tional DNA cross-linking antineoplastic agent, consists of two 
open-ring homologs of the (+)-CC-1065 cyclopropa [c] pyrrolo- 
[3,2-e]indol-4(5//)-one (CPI) 1 subunit connected by a rigid 
linker moiety (Figure la; Mitchell et al., 1991). It belongs 
to a class of rigid CPI cross-linking reagents characterized by 
a right-handed twist approximating DNA minor groove 
geometry. Bizelesin forms interstrand cross-links through N 3 
of adenine (Figure lb) spaced six base pairs apart (inclusive 
of the adenines) while occupying the intervening minor groove 
(Mitchell et al., 1991; Ding & Hurley, 1991; Sun & Hurley, 
1993). Results from NOESY and ROESY experiments2 
conducted on the self-complementary oligomer (10-mer) 5'- 
CGTAATTACG-3' and its bizelesin reaction product are 
evaluated in order to determine how the B-form 10-mer adjusts 
to the introduction of the drug.
The findings of the present study indicate that two major 
conformers comprise the cross-linked reaction products. Each 
of two independent sets of NM R signals (Tables I and II) 
corresponds to a duplex adduct conformation, one with the 
AT-step adenines syn-oriented and Hoogsteen base paired to 
thymines (SHG model) and a second with the AT-step adenines 
an/i-oriented and paired (but not evidently hydrogen bonded) 
with thymines displaying extraordinary motion (5OP model).
t This research was supported by grants from the U.S. Public Health 
Service (CA-49751), the Welch Foundation, The Upjohn Co., and the 
Burroughs Wellcome Scholars Program.
* Address correpondence to either author.
® Abstract published in Advance A CS Abstracts, November 1,1993.
1 Abbreviations: N M R, nuclear magnetic resonance; NO E, nuclear 
Overhauser effect; 2QF-COSY, double-quantum-filtered correlated 
spectroscopy; ROESY, rotating frame Overhauser spectroscopy; 1H -3,P 
COSY, hydrogen-phosphorus correlated spectroscopy; ppm, parts per 
million; FID, free induction decay; DEAE, diethylaminoethyl; DM F, 
dimethylformamide; WC, W atson-Crick base pairing; HG, Hoogsteen 
base pairing; OP, open base pairing; CPI, cyclopropa [c] pyrrolo[3,2-e]- 
indol-4(5//)-one.
2 Data from other N M R  experiments (e.g., 2QF-COSY and *H-31P 
COSY) are currently being evaluated to further refine the bizelesin adduct 
structures presented here.
As (1) no NOESY or ROESY cross-peaks link the two sets 
of NM R signals and (2) each set is sufficient to characterize 
a C2-symmetrical DNA adduct, 5HG and SOP represent 
conformationally distinct products of cross-linkage. Although 
conformational exchange between the SHG and SOP con­
formers is undetectable on the NM R time scale, open AT- 
step base pairing resembling that of the SOP model must 
precede any reorientation of the AT-step adenines resulting 
in the 5HG product.
EXPERIMENTAL PROCEDURES
Chemicals. Bizelesin was a gift from The Upjohn Co. 
Reagents used to prepare the NM R buffer, sodium phosphate 
(99.99%) and sodium chloride (99.99%), were purchased from 
Aldrich. HPLC water and methanol were purchased from 
Baxter Scientific and Fisher, respectively.
Oligonucleotide Preparation and Purification. The self- 
complementary 10 -mer d(CGTAATTACG)2 was synthesized 
on a 10-pmol scale by using automated solid-phase phospho- 
triester and phosphoramidite chemistry (Gait, 1984) on an 
Applied Biosystems automated DNA synthesizer (model 
381 A). It was purified on a Machery-Nagel Nucleogen- 
DEAE 60-7 HPLC column with an increasing gradient to 1 
M NaCl in 15 mM sodium phosphate and 20% acetonitrile/ 
aqueous buffer, pH 6 .8 .
Adduct Preparation and Purification. The bizelesin adduct 
was prepared by stirring 15 mg of bizelesin in 0.2 mL of DMF 
solution with 0.03 mL of aqueous sodium bicarbonate for 20 
min before adding 40 mg of purified 10-mer in 0.75 mL of 
buffer containing 20 mM sodium phosphate and 200 mM 
sodium chloride. The reaction mixture was stirred for 4 days 
in the dark, lyophilized to dryness overnight, desalted and 
separated from excess drug on Ci8 Sep-Pak cartridges 
(Waters), and purified using HPLC conditions, as described 
above. SHG and 5OP conformers were inseparable by HPLC.
Proton NM R Experiments. One- and two-dimensional 500- 
MHz •H and 202.44-MHz 31P NM R data sets in buffered
0006-2960/93/0432-12577$04.00/0 © 1993 American Chemical Society
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Figure 1 :  ( a )  S t r u c t u r e  o f  b i z e l e s i n  a n d  t h e  n u m b e r i n g  s y s t e m  u s e d  i n  N M R  a n a l y s i s ,  ( b )  C y c l i z a t i o n  o f  t h e  p r o d r u g ,  b i z e l e s i n ,  t o  g i v e  t h e  
c y c l o p r o p y l  d e r i v a t i v e  f o l l o w e d  b y  t h e  r e a c t i o n  o f  a d e n i n e s  o f  o p p o s i t e  D N A  s t r a n d s  t o  f o r m  t h e  c r o s s - l i n k e d  a d d u c t .
f y O  a n d  D 2 0  s o l u t i o n s  w e r e  r e c o r d e d  o n  G e n e r a l  E l e c t r i c  
- 5 0 0  a n d  B r u k e r  A M X  5 0 0  F T  N M R  s p e c t r o m e t e r s .  
P r o t o n  c h e m i c a l  s h i f t s  w e r e  r e c o r d e d  i n  p a r t s  p e r  m i l l i o n  ( p p m )  
a n d  r e f e r e n c e d  r e l a t i v e  t o  e x t e r n a l  T S P  ( 1  m g / m L )  i n  D 2 0  
I ( H O D  s i g n a l  w a s  s e t  t o  4 . 7 5 1  p p m ) .  P h o s p h o r u s  c h e m i c a l  
| s h i f t s  w e r e  r e f e r e n c e d  r e l a t i v e  t o  e x t e r n a l  8 5 %  H 3P O 4 i n  D 20 .
P h a s e - s e n s i t i v e  t w o - d i m e n s i o n a l  N O E S Y  s p e c t r a  ( B r u k e r )
I w e r e  o b t a i n e d  f o r  t w o  m i x i n g  t i m e s :  1 0 0  a n d  2 0 0  m s .  A l l  
| s p e c t r a  w e r e  a c q u i r e d  w i t h  1 6  s c a n s  a t  e a c h  o f  1 0 2 4 1\ v a l u e s ,  
a s p e c t r a l  w i d t h  o f  1 0 .0 0 2  p p m ,  a n d  a  r e p e t i t i o n  t i m e  o f  1 0  
I s b e t w e e n  s c a n s .  D u r i n g  d a t a  p r o c e s s i n g ,  a  s h i f t e d  s q u a r e d  
s i n e - b e l l  f u n c t i o n  ( s h i f t  =  4 5 ° )  w a s  u s e d  i n  b o t h  W ]  a n d  w 2 
d i m e n s i o n s .  T h e  F I D  i n  w\ w a s  z e r o - f i l l e d  t o  2 K  p r i o r  t o  
F o u r i e r  t r a n s f o r m a t i o n  t o  g i v e  a  2 K  X  2 K  s p e c t r u m .  2 D  
N O E s p e c t r a  i n  9 0 %  H 2 0  a t  1 5 0 - m s  m i x i n g  t i m e  w e r e  r e c o r d e d  
I u s in g  t h e  1 - 1  e c h o  r e a d  p u l s e  s e q u e n c e  ( S k l e n a r  &  B a x ,  1 9 8 7 ;  
c e  &  S u m m e r ,  1 9 9 0 )  w i t h  a  2 . 5 - s  p u l s e  r e p e t i t i o n  t i m e ,
a  s w e e p  w i d t h  o f  2 4 . 3 9 6  p p m ,  a n d  a  9 0 °  p u l s e  w i d t h  o f  2 8 . 7 5  
m s .
E x c h a n g e  p r o c e s s e s  w e r e  s t u d i e d  b y  R O E S Y  ( B o t h n e r - B y  
e t  a l . ,  1 9 8 4 )  i n  D 2 0  w i t h  a  s p e c t r a l  w i d t h  o f  5 0 0 0  H z  i n  b o t h  
d i m e n s i o n s .  M i x i n g  t i m e s  o f  1 0 0  a n d  2 0 0  m s  w e r e  u s e d  t o  
c o l l e c t  5 1 2  F I D s ,  e a c h  o f  3 2  s c a n s ,  a n d  t o  g e n e r a t e  2 X 5 1 2  
X  1 0 2 4  d a t a  m a t r i c e s .
Restrained M olecular Dynamics.  I n t e r p r o t o n  d i s t a n c e s  
w e r e  d e r i v e d  v i a  t h e  p r o g r a m  M A R D I G R A S  ( B o r g i a s  &  
J a m e s ,  1 9 8 9 ,  1 9 9 0 )  f r o m  N O E S Y  e x p e r i m e n t s  i n v o l v i n g  
m i x i n g  t i m e s  o f  1 0 0  a n d  2 0 0  m s .  A  c o m p l e t e  2 D  N O E  
r e l a x a t i o n  m a t r i x  w a s  s e t  u p  u s i n g  t h e  g e o m e t r y  o f  a  s t a r t i n g  
s t r u c t u r e  t o  p r o v i d e  i n t e r p r o t o n  N O E s  n o t  a v a i l a b l e  f r o m  t h e  
e x p e r i m e n t a l  d a t a  s e t s .  A l t e r n a t i v e  s t a r t i n g  s t r u c t u r e s  w e r e  
( 1 )  t h e  b i z e l e s i n  1 0 - m e r  a d d u c t  n o n r e s t r a i n e d  m o l e c u l a r  
d y n a m i c s  p r o d u c t  a n d  ( 2 )  t h e  m i n i m i z e d  B - D N A  a d d u c t .  
T h e  c o m p l e t e  N O E  m a t r i x  w a s  c a l c u l a t e d  f o r  t h e  s t a r t i n g
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I ble 1: Chemical Shifts of Nonexchangeable and Exchangeable Protons of the 5-Adenine S>n-Oriented Model (5HG ) and the 5-Adenine Open 
Model (SOP)
HI ' H 2' H2" H 3' H4' H 5' H 5 '
base SHG SOP 5HG SOP SHG SOP 5HG SOP SHG SOP SHG 5 0 P SHG SOP 5HG SOP 5HG 5 0 P SHG SOP
C 5.57 5.68 1.81 1.81 2.30 2.29 4.65 4.67 4.02 4.04 3.64 3.64 3.64 3.64 7.54 7.54 5.78 5.78
G 5.90 5.82 2.58 2.57 2.64 2.58 4.95 4.96 4.31 4.30 4.07 4.07 3.93 3.92 7.90 7.91 12.53 12.51
T 5.64 5.69 2.20 2.28 2.52 2.57 4.91 4.93 4.27 4.29 4.18 4.17 4.12 4.09 7.32 7.39 1.69 1.70 11.14 11.39
A 6.06 6.06 2.58 2.63 3.00 2.81 4.83 4.91 4.03 4.09 4.18 4.30 4.11 4.22 8.24 8.30 7.36 6.96
A 5.27 6.08 2.88 2.30 2.35 2.47 4.58 4.67 3.40 3.37 3.22 3.28 3.07 2.61 7.48 7.92 7.59 7.36
T 5.78 5.50 2.00 1.52 2.49 2.28 4.51 4.35 1.99 1.38 3.24 3.35 3.24 2.48 6.75 (a)° 6.62 0.60 (a) 1.09 12.38 NO*






(a) 1.40 14.68 14.23




C 5.33 5.33 1.77 1.76 2.13 2.12 4.60 4.60 2.27 2.25 3.76 3.79 3.29 3.39 7.32 7.31 5.52 5.52
G 6.10 6.10 2.62 2.62 2.32 2.32 4.69 4.68 4.23 4.23 4.08 4.08 3.83 3.83 7.85 7.84
'Designations (a), (b), and (c) indicate the chemical shifts of the different 16T positional 
observed.
isomers a, b, and c. * N O  indicates that the signal is not
Table II: Bizelesin Adduct Drug Chemical Shifts for the SHG and SOP
H2 H3M e NH1 H4a H4A H4B H5A H5B H7 H 3' H 5 ' H 7 ' H 8 ' N H 1 ' N H 9 '
SHG 7.29 2.59 10.28 4.43 4.62 



















s t r u c t u r e  u s i n g  C O R M A  ( B o r g i a s  e t  a l . ,  1 9 8 7 , 1 9 8 9 ;  B o r g i a s  
&  J a m e s ,  1 9 8 8 ) .  M A R D I G R A S  c a l c u l a t e s  u p p e r  a n d  l o w e r  
b o u n d s  f o r  t h e  i n t e r p r o t o n  d i s t a n c e s  ( B o r g i a s  &  J a m e s ,  1 9 9 0 ) .  
S u b s e q u e n t  p r o c e d u r e s  f o l l o w e d  t h o s e  d e s c r i b e d  p r e v i o u s l y  
( K e r w o o d  e t  a l . ,  1 9 9 1 ) .
I n t e r p r o t o n  d i s t a n c e s  w e r e  i n c o r p o r a t e d  i n t o  t h e  c o n s t r a i n e d  
m o l e c u l a r  d y n a m i c s  c a l c u l a t i o n s  ( r M D )  o f  t h e  s o l v a t e d  s y s t e m .  
r M D  c a l c u l a t i o n s  w e r e  p e r f o r m e d  u s i n g  t h e  S A N D E R  m o d u l e  
o f  A M B E R ,  v e r s i o n  4 . 0 ,  o n  a n  S G I  4 D 3 5 G  P e r s o n a l  I r i s  
w o r k s t a t i o n  ( P e a r l m a n ,  1 9 9 1 ) .  T h e  A M B E R  f o r c e - f i e l d  
p s e u d o - e n e r g y  t e r m s  f o r  t h e  i n t e r p r o t o n  d i s t a n c e s  h a v e  t h e  
f o r m  o f  f l a t  w e l l s  w i t h  p a r a b o l i c  s i d e s  w i t h i n  a  d e f i n e d  d i s t a n c e .
R E S U L T S
General Strategy fo r  lH  N M R  Assignment o f  the Two 
Cross-Linked Adducts. 5HG  a n d  5 0 P  N M R  s i g n a l s 3 w e r e  
a s s i g n e d  f o l l o w i n g  c h a r a c t e r i z a t i o n  o f  t w o  N O E S Y  c r o s s ­
c o n n e c t i v i t y  n e t w o r k s .  I n  e a c h  c r o s s - c o n n e c t i v i t y  n e t w o r k ,  
P y H 6 / P u H 8  p r o t o n s  a r e  l i n k e d  t o  e a c h  o t h e r  a n d  t o  s u g a r  
H P ,  H 2 " ,  H 2 ' ,  a n d  H 3 '  a n d ,  b y  e x t e n d i n g  t h e  i n t e r n a l  s u g a r  
c o n n e c t i v i t y  v i a  H 3 '  a n d  H 4 ' ,  t o  s u g a r  H 5 '  a n d  H 5 " .  A d e n i n e  
H 2  s u b s t i t u e n t s  a n d  n e i g h b o r i n g  t h y m i n e  H 3  p r o t o n s  a r e  
i n c o r p o r a t e d  i n t o  t h i s  n e t w o r k  t h r o u g h  H 2  c r o s s - p e a k s  w i t h  
m i n o r  g r o o v e  s u g a r  H U .  B i z e l e s i n ’ s  s u b s t i t u e n t s  a r e  
i n c o r p o r a t e d  i n t o  t h e  n e t w o r k  v i a  t h e i r  c r o s s - p e a k s  w i t h  m i n o r  
g r o o v e  d u p l e x  p r o t o n s .  A l l  N O E S Y  c r o s s - p e a k s  a r e  a s s i g n e d  
t o  a  n e t w o r k ,  a n d  t h e  t o t a l  c o n f o r m a t i o n a l  a r r a y  o f  r e a c t i o n  
p r o d u c t s  i s  d e t e r m i n e d  f r o m  t h e  n u m b e r  o f  i n d e p e n d e n t  c r o s s ­
3 The multiplicity of N M R  signals is dealt with by assigning different 
number systems to the two independent 5'-(CGTAATTACG)2-3' sets of 
signals, 1C through 10G and 11C through 20G, corresponding to the 
SHG and 5 0 P  models, respectively. Sym m etry permits each numbering 
system to be applied to both duplex strands. Distinct conformational 
exchange signals are differentiated with a, b, and c suffixes (e.g., 16T 
H6aand 16T H6b). Drug proton signals (Figure la ) associated with the 
5'-lC-10G-3' sequence begin with thenum ber of the covalently modified 
adenine base, 8 (e.g., 8H 3'). A separate set of drug signals showing 
connectivity to the 5 '-l 1C-20G-3' sequence likewise begins with the 
number of the covalently modified adenine, 18 (e.g., 18H3'). Difficulty 
in unambiguously assigning deoxyribose H 5" and H5' led to the 
designation of the downfield member of the pair as H5'.
c o n n e c t i v i t y  n e t w o r k s .  F i n a l l y ,  s p e c t r a l  e v i d e n c e  c o n f i r m s  
c o n f o r m a t i o n a l  e x c h a n g e  b e t w e e n  i n t e r c o n v e r t i n g  p o s i t i o n a l  
i s o m e r s  w i t h i n  t h e  5 0 P  n e t w o r k  ( C h o e  e t  a l . ,  1 9 9 1 ) .
Bizelesin Is Attached through N3 o f  Adenine at 8A  ( 5HG )  
and 18A  (SOP) .  T h e  5HG  8  A  H 6 b  a n d  8 A  H 6 e  a m i n o  s i g n a l s  
( 9 . 1 1  a n d  8 . 5 2  p p m ,  r e s p e c t i v e l y )  r e s e m b l e  a  ( + ) - C C - 1 0 6 5  
a d d u c t ’ s  c o v a l e n t l y  m o d i f i e d  a d e n i n e  H 6 b  a n d  H 6 e  i n  c h e m i c a l  
s h i f t s  ( 9 . 1 9  a n d  9 . 0 8  p p m )  a n d  i n  t h e i r  N O E S Y  c r o s s - p e a k s  
w i t h  t h e  i m i n o  p r o t o n  o f  t h e  p a i r i n g  t h y m i n e ,  3 T  H 3  ( F i g u r e  
2 ,  H I  a n d  H 2 ) ,  a n d  w i t h  e a c h  o t h e r  ( L i n  e t  a l . ,  1 9 9 1 ) .  A  
s i m i l a r  p a t t e r n  e x i s t s  f o r  a  s e c o n d  s e t  o f  a m i n o  s i g n a l s ,  1 8  A  
H 6 b  a n d  1 8 A  H 6 e ,  a t  8 . 9 2  a n d  8 . 6 0  p p m  ( F i g u r e  2 ,  F I  a n d  
F 2 ) .  A s  i n  t h e  ( + ) - C C - 1 0 6 5  a d d u c t ,  t h e  d o w n f i e l d  s h i f t  o f  
t h e  t w o  s e t s  o f  a m i n o  s i g n a l s  f r o m  t h e  u s u a l  a d e n i n e  a m i n o  
s i g n a l  r a n g e  ( 6 . 0 - 8 .0  p p m )  a n d  t h e  u p f i e l d  s h i f t  o f  t h e  p a i r i n g  
t h y m i n e  H 3  r e l a t i v e  t o  t h e  u n m o d i f i e d  d u p l e x  ( 3 T  H 3 ,  
d i f f e r e n c e  =  2 . 3 4  p p m ;  1 3 T  H 3 ,  d i f f e r e n c e  =  2 . 0 9  p p m )  a r e  
c a u s e d  b y  d r u g  a t t a c h m e n t  a t  a d e n i n e  N 3 .
A Pair o f  Self-Complementary Aromatic PyH 6/PuH 8 to 
H I ' Walks Differing Only in the Central Region o f  the Duplex 
Represents the Two Bizelesin 10-mer Duplex Adducts.  C r o s s -  
c o n n e c t i v i t y  b e t w e e n  b a s e  p r o t o n s  a n d  t h e  H 1 '  o f  t h e  a t t a c h e d  
s u g a r  ( i n t e r n a l )  a n d  t h e  s u g a r  H I '  o f  t h e  5 ' - n e i g h b o r i n g  
n u c l e o t i d e  ( e x t e r n a l )  p e r m i t s  a  “ w a l k ”  t h r o u g h  t h e  n e t w o r k  
o f  i n t e r n a l  a n d  e x t e r n a l  c o n n e c t i v i t i e s  e x t e n d i n g  t h e  l e n g t h  o f  
5 ' - C G T A A T T A C G - 3 ' .  I n  c o n t r a s t  t o  t h e  s i n g l e  w a l k  ( n o t  
s h o w n )  o f  t h e  u n m o d i f i e d  1 0 - m e r  s p e c t r u m  ( a  s i n g l e  w a l k  i s  
a t t r i b u t a b l e  t o  t h e  C2 s y m m e t r y  o f  t h e  d u p l e x ) ,  t w o  d i f f e r e n t  
w a l k s  c a n  b e  t r a c e d  i n  t h e  N O E S Y  a r o m a t i c  b a s e / s u g a r  H I '  
r e g i o n  o f  t h e  b i z e l e s i n  a d d u c t  m i x t u r e  s p e c t r u m  ( F i g u r e  3 ) .  
T h e  t w o  w a l k s  o v e r l a p  n e a r  t h e  p e r i p h e r y  b u t  d i v e r g e  r a d i c a l l y  
a t  t h e  d u p l e x  c e n t e r .  T h i s  d i v e r g e n c e  i s  m a x i m a l l y  e x p r e s s e d  
b y  t h e  f a r - u p f i e l d  s h i f t  o f  5 A  H I '  r e l a t i v e  t o  1 5 A  H I  ( 0 . 8 1  
p p m  d i f f e r e n c e ) .  F u r t h e r ,  t h e  1 C  — ► 1 0 G  w a l k  p a t t e r n  d i f f e r s  
f r o m  t h a t  o f  t h e  1 1 C  — ► 2 0 G  w a l k  b y  t h e  f o r m e r ’ s  l a c k  o f  a  
5A  H 8  X 4 A  H I '  c r o s s - p e a k ,  a n  i n t e n s e  5A  H 8  X 5A  H I '  
c r o s s - p e a k ,  a n d  a  w e a k  5 A  H 8  X 6 T  H 1 '  c r o s s - p e a k  c o n s i s t e n t  
w i t h  5 A  syn  o r i e n t a t i o n .
Syn Orientation fo r  the 5HG A T-Step Adenines Is Revealed 
by the Five Adenine H2 and H8 Cross-Peaks. Syn  o r i e n t a t i o n






F i g u r e  2: Two-dimensional N O E S Y  (1 50-ms m ixing tim e) expanded 
con tour plot o f the bizelesin 10-m er duplex  ad duct (90%  H 2O /1 0 %  
D 20 )  show ing the cross-peaks o f (1) th e  G  H I and  T  H 3 imino 
protons and  (2) bizelesin exchangeable 'H  substituen ts: A , 7T  H3 
(4A -7T ) (1) 8A H 6e, (2 ) 4A  H 2, (3) 4A  H 6 b,e; B, 17T H 3 (14A -17T ) 
(1 ) 18H 5 ', (2 ) 14A H 2, (3 ) 14A H 6 be; C , 2G H I (2G -9C ) (1) 9C  
H 4 b, (2) 9C  H 4e; D, 12G H I  (12G -19C ) (1) 19C H 4 b, (2 ) 19C H 4 e; 
E, 6T  H 3 (5A -6T ) (1) 5A  H 8, (2) 4A  H 6 be; F, 13T H 3  (13T -18A ) 
(1 ) 18A H 6 b, (2) 18A H 6 e, (3) 18A H 2, (4) 14A H 2; G , 8 N H 1 ' (1) 
8 H 8 '; H , 3T H3 (3T -8A ) (1) 8A H 6 b, (2 ) 8a H 6 e, (3 ) 8A  H 2, (4) 
4A  H 2 , (5 ) 4A  H 6b,e; 1 ,18 N H 1' (1) 18 H 8 '; J , 8 /  1 8 N H 1 (1) 8 /1 8H 2.
r e q u i r e s  t h a t  5HG  5  A  H 2  p r o j e c t  d e e p l y  i n t o  t h e  m a j o r  g r o o v e  
a n d  H 8  e x t e n d  s h a l l o w l y  i n t o  t h e  m i n o r  g r o o v e .  5  A  H 2  c r o s s ­
p e a k s  w i t h  4 A  H 8  ( F i g u r e  4 a ,  c r o s s - p e a k  1 ) ,  4 A  H 2 "  a n d  H 2 '  
( F i g u r e  4 c ,  c r o s s - p e a k s  1 0  a n d  1 1 ) ,  4 A  H 3 '  ( F i g u r e  4 b )  a n d  
6 T  M e  ( F i g u r e  4 d ,  c r o s s - p e a k  1 2 )  a g r e e  w i t h  a  major groove 
p o s i t i o n  c l o s e  t o  t h e  5 ' - s i d e  n u c l e o t i d e ’ s  s u g a r  C 2 '  s u b s t i t u e n t s .  
I n  c o n t r a s t ,  t h e  5 A  H 8  i n t e n s e  c r o s s - p e a k  w i t h  t h e  a t t a c h e d  
s u g a r ’ s  H I '  ( F i g u r e  4 b ,  c r o s s - p e a k  7 )  a n d  m o d e r a t e  c r o s s ­
p e a k s  w i t h  4 A  H 2  ( F i g u r e  4 a ,  c r o s s - p e a k  3 )  a n d  b i z e l e s i n  
i n d o l e  s u b u n i t ’ s  H 3 '  a n d  H 5 '  ( F i g u r e  4 a ,  c r o s s - p e a k s  4  a n d  
2 ,  r e s p e c t i v e l y )  i n d i c a t e  a  minor groove  l o c a t i o n  c l o s e  t o  t h e  
5 A  s u g a r ’ s  C l '  p o s i t i o n .
Disrupted H-Bonding o f  the A T  Step o f  the 5 0 P  Product 
Is Revealed b y  Loss o f  thelmino-to-Imino Cross-Peak.  W h i l e  
a n  i n t e n s e  i m i n o - t o - i m i n o  c r o s s - p e a k  l i n k s  5HG IT  H 3  ( 4 A -  
7 T )  t o  n e i g h b o r i n g  6 T  H 3  ( 5 A - 6 T ) ,  n o  c o r r e s p o n d i n g  c r o s s ­
p e a k  w a s  f o u n d  f o r  5OP  1 7 T  H 3  ( 1 4 . 2 3  p p m ;  1 4 A - 1 7 T )  a n d  
a n y  s i g n a l  i n  t h e  c h e m i c a l  s h i f t  r a n g e  ( 1 1 - 1 5  p p m )  e x p e c t e d  
f o r  1 6 T  H 3 .  T h e  5HG  6 T  H 3  s i g n a l ’ s  d o w n f i e l d  c h e m i c a l  
s h i f t ,  s h a r p n e s s ,  a n d  i n t e n s e  c r o s s - p e a k  w i t h  5 A  H 8  s u p p o r t  
h y d r o g e n  b o n d i n g  v i a  N 7  w i t h  6 T  H 3  a n d  H o o g s t e e n  b a s e  
p a i r i n g  ( F i g u r e 2 ,  c r o s s - p e a k  E l ) .  A l l  n o n t e r m i n a l  b a s e  i m i n o  
s i g n a l s  f o r  5HG  a n d  5 0 P  p r o d u c e  t h e  e x p e c t e d  s e t  o f  N O E S Y  
( H 20 )  c r o s s - p e a k s  ( F i g u r e  2 ,  c r o s s - p e a k s  o f  s i g n a l s  A - F  a n d  
H )  e x c e p t  1 6 T  H 3  w h i c h  w a s  u n d e t e c t a b l e .  T h e  a t y p i c a l  
b e h a v i o r  o f  1 6 T  H 3  a n d  e s p e c i a l l y  t h e  l a c k  o f  a  d e t e c t a b l e  
1 7 T  H  3  i m i n o - t o - i m i n o  c r o s s - p e a k  s u g g e s t  d i s r u p t e d  h y d r o g e n  
b o n d i n g  f o r  t h e  t w o  i n t e r n a l  b a s e  p a i r s  ( 5 M 5 A - 1 6 T - 3 '  w i t h  
3 M 6 T - 1 5 A - 5 ' ) .
T h e  A l  S te p  o f  5 0 P  Is  C h a r a c te r iz e d  b y  T h re e  T h y m in e  
P o s i t io n a l  I so m e rs  I n d ic a te d  b y  C o n fo r m a tio n a l  E x c h a n g e .
A ccelerated  Publications
T h e  5OP  N O E S Y  c r o s s - c o n n e c t i v i t y  n e t w o r k  i n c l u d e s  a  
p r i m a r y  s e t  o f  “ a ”  s i g n a l s  ( c o n f o r m e r  a )  a s  w e l l  a s  a d d i t i o n a l  
“ b ”  a n d  “ c ”  s i g n a l s  ( c o n f o r m e r s  b  a n d  c )  a s s o c i a t e d  w i t h  t h e  
1 6 T  r e g i o n .  I n t e n s e  2 0 0 - m s  N O E S Y  e x c h a n g e  c r o s s - p e a k s  
l i n k  a  1 6 T  m e t h y l  s i g n a l  a t  1 . 0 9  p p m  ( 1 6 T a )  t o  t w o  s m a l l e r  
m e t h y l  s i g n a l s  a t  0 . 8 8  p p m  ( 1 6 T b )  a n d  0 . 7 0  p p m  ( 1 6 T c )  
( F i g u r e  5 ) .  T h e  1 6 T b  m e t h y l  s i g n a l  p r o d u c e s  a  c r o s s - p e a k  
w i t h  t h e  a d j a c e n t  1 7 T b  m e t h y l  ( 1 . 4 9  p p m ) ,  a n d  t h e  1 6 T c  
m e t h y l  s h a r e s  a  c r o s s - p e a k  w i t h  t h e  1 7 T c  m e t h y l  s i g n a l  t h a t  
p a r t i a l l y  o v e r l a p s  t h e  l a r g e r  1 7 T a  m e t h y l  s i g n a l .  A n  i n t e n s e  
e x c h a n g e  c r o s s - p e a k  l i n k s  t h e  o v e r l a p p e d  1 7 T a  a n d  1 7 T c  
m e t h y l  s i g n a l s  w i t h  t h e  1 7 T b  m e t h y l  s i g n a l .  C o n f o r m e r  b  
a n d  c  1 6 T  m e t h y l  s i g n a l s  d i s p l a y  c r o s s - c o n n e c t i v i t y  t o  
c o r r e s p o n d i n g  1 6 T  H 6  s i g n a l s .  T h e s e  H 6  s i g n a l s  p l u s  t h e  
m e t h y l  s i g n a l s  r e p r e s e n t  t h e  t o t a l  d e t e c t a b l e  s i g n a l s  o f  t h e  
m i n o r  b  a n d  c  c o n f o r m e r s  t h a t  d i f f e r  a p p r e c i a b l y  i n  c h e m i c a l  
s h i f t  f r o m  t h e  c o r r e s p o n d i n g  s i g n a l s  o f  t h e  a  c o n f o r m e r .
R O E S Y  “ n e g a t i v e ”  ( R O E S Y  c o n f o r m a t i o n a l  e x c h a n g e  
c r o s s - p e a k s  h a v e  a n  o p p o s i t e  s i g n  f r o m  d i p o l a r  c r o s s - p e a k s )  
t h y m i n e  H 6  X H 6  a n d  M e  X M e  c r o s s - p e a k s  i n d i c a t e  t h a t  
t h e  t h r e e  c o n f o r m e r s  a r e  i n t e r c o n v e r t i n g  o n  t h e  N M R  t i m e  
s c a l e  ( 0 .2  s )  a n d  t h a t  t h e  o n l y  s i g n i f i c a n t  d i f f e r e n c e  b e t w e e n  
t h e m  i s  t h e  p o s i t i o n  o f  t h e  1 6 T  b a s e .  1 6 T  M e  a n d  H 6  c h e m i c a l  
s h i f t s  f o r  t h e  a ,  b ,  a n d  c  c o n f o r m e r s  s u g g e s t  t h a t  t h e y  d i f f e r  
b y  t h e  p o s i t i o n  o f  t h i s  b a s e ,  w h i c h  i s  f r e e r  t o  m o v e  t h a n  a  
n o r m a l l y  b a s e - p a i r e d  t h y m i n e .  L i t t l e  d i f f e r e n c e  b e t w e e n  n o n -  
1 6 T  b a s e  s i g n a l s  f o r  t h e s e  t h r e e  c o n f o r m e r s  s u g g e s t s  t h a t  1 5  A -  
1 6 T  b a s e - p a i r  o p e n i n g  c a u s e s  o n l y  m i n o r  p e r t u r b a t i o n  o f  
n e i g h b o r i n g  b a s e  p a i r s .
Structures o f  5HG and 5 0 P  Generated by Restrained 
Molecular Dynamics. T h e  m o d e l  s t r u c t u r e s  r e s u l t i n g  f r o m  
p r e l i m i n a r y  r e s t r a i n e d  m o l e c u l a r  d y n a m i c s  c a l c u l a t i o n s  ( 1 7 2  
N M R  d i s t a n c e  c o n s t r a i n t s  f o r  5HG ,  F i g u r e  6 a ;  1 8 9  N M R  
d i s t a n c e  c o n s t r a i n t s  f o r  50P ,  F i g u r e  6 b )  a r e  i n c l u d e d  t o  a i d  
i n  v i s u a l i z i n g  t h e  t w o  a d d u c t  m o d e l s .  ( I n  o r d e r  t o  f u r t h e r  
r e f i n e  s t r u c t u r a l  d i f f e r e n c e s  b e y o n d  t h e  m a j o r  f e a t u r e s  
d e s c r i b e d  h e r e ,  a  d e t a i l e d  d i s c u s s i o n  o f  r M D  r e s u l t s  f o r  5HG 
a n d  5 0 P  w i l l  f o l l o w  i n  a  s u b s e q u e n t  p u b l i c a t i o n . )
D I S C U S S I O N
' H  N M R  a n a l y s i s  o f  t h e  b i z e l e s i n  a d d u c t  o f  d ( C G T A A T -  
T A C G ) 2 r e v e a l s  t h a t  t h e  c e n t r a l  d u p l e x  r e g i o n ,  5 ' - T A A T T A -  
3 ' ,  i s  c r o s s - l i n k e d ,  y i e l d i n g  t w o  m a j o r  a d d u c t  c o n f o r m a t i o n s :  
o n e  ( m a j o r  p r o d u c t :  6 0 % )  c o n t a i n s  a  5 ' - A T - 3 ' - s t e p  w h e r e i n  
b o t h  a d e n i n e s  a r e  s j T i - o r i e n t e d  a n d  H o o g s t e e n  b a s e  p a i r e d  t o  
t h y m i n e s  ( 5HG  m o d e l ) ;  t h e  o t h e r  c o n t a i n s  a r i f i - o r i e n t e d  A T -  
s t e p  a d e n i n e s  t h a t  s h o w  n o  e v i d e n c e  o f  h y d r o g e n  b o n d i n g  w i t h  
p a i r i n g  t h y m i n e s  ( 5 0 P  m o d e l ;  4 0 % ) .
N O E SY Data Indicate That C2 Sym m etry o f  the Unmod­
i f ie d  Duplex Is Preserved in 5HG and 5 0 P  Structures. 
D i v i s i o n  o f  t h e  s i g n a l s  i n  t h e  N O E S Y  s p e c t r a  i n t o  t w o  c r o s s ­
c o n n e c t i v i t y  n e t w o r k s  c a n  b e  e x p l a i n e d  b y  t w o  p o s s i b l e  
s c e n a r i o s :  ( 1 )  t h e  p r o d u c t  i s  a  m i x t u r e  o f  d i f f e r e n t  c o n f o r m e r s  
o r  ( 2 )  t h e  p r o d u c t  i s  a  s i n g l e  s t r u c t u r e  i n  w h i c h  e a c h  d u p l e x  
s t r a n d  p r o d u c e s  a  d i s t i n c t  c r o s s - p e a k  n e t w o r k .  I n  t h e  f i r s t  
c a s e ,  t h e  s p e c t r u m  w o u l d  c o n t a i n  t w o  o r  m o r e  s e t s  o f  e n t i r e l y  
i n d e p e n d e n t  s i g n a l s  ( n o  N O E S Y  c r o s s - p e a k  l i n k s  s i g n a l s  o f  
d i f f e r e n t  s e t s ) .  I n  t h e  s e c o n d  c a s e ,  i n t e r s t r a n d  N O E S Y  c r o s s ­
p e a k s  w o u l d  l i n k  s i g n a l s  o f  t h e  s t r a n d  1 s e t  w i t h  s i g n a l s  o f  t h e  
s t r a n d  2  s e t .  R e s u l t s  f r o m  t h e  p r e s e n t  s t u d y  i n d i c a t e  t h a t  a l l  
i n t e r s t r a n d  N O E S Y  c r o s s - p e a k s  o c c u r  b e t w e e n  m e m b e r s  o f  
t h e  s a m e  c r o s s - c o n n e c t i v i t y  n e t w o r k .  F o r  e x a m p l e ,  i n t e r s t r a n d  
c r o s s - p e a k s  l i n k  4 A  H 2  w i t h  8 A  H 2  a n d  H 1 ' ,  8 A  H 2  w i t h  4 A  
H I ' ,  1 4 A  H 2  w i t h  1 8 A H 1 ' ,  1 5 A  H 2 w i t h  1 7 T H l ' , a n d  1 8 A  
H 2  w i t h  1 4 A  H 2  a n d  H I ' .  A l t h o u g h  b i z e l e s i n  p r o d u c e s
I
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F i g u r e  3 :  T w o - d i m e n s i o n a l  p h a s e - s e n s i t i v e  N O E S Y  ( 2 0 0 - m s  m i x i n g  t i m e )  e x p a n d e d  c o n t o u r  p l o t  o f  t h e  b i z e l e s i n  1 0 - m e r  d u P ^ ^ d u c t  i n  
t  f f e r e d  D 2 0  s o l u t i o n ,  p H  6 . 8 5 ,  a t  2 3  ° C  d i s p l a y i n g  c o n n e c t i v i t i e s  f o r  P u H 8 / P y H 6  t o  s u g a r  H I  ( l a b e l e d  w i t h  b a s e  n u m b e r )  a n d  P  /  y  
t o s u g a r  H P  p r o t o n s  o f  t h e  5 ' - n e i g h b o r :  A ,  5HG w a l k  ( 1 C  t o  1 0 G ) ;  B ,  50P  w a l k  ( 10 C  t o  2 0 G ) .
n u m e r o u s  N O E S Y  c r o s s - p e a k s  w i t h  b o t h  d u p l e x  s t r a n d s ,  c r o s s ­
p e a k s  l i n k  e a c h  o f  t h e  t w o  s e t s  o f  d r u g  * H  s i g n a l s  w i t h  D N A  
'H  s i g n a l s  o f  o n l y  o n e  d u p l e x  c r o s s - c o n n e c t i v i t y  n e t w o r k .
E x c e p t  f o r  t h e  i n s t a n c e s  o f  c o n f o r m a t i o n a l  e x c h a n g e  
d e s c r i b e d  a b o v e ,  o n l y  o n e  s e t  o f  ' H  s i g n a l s  c h a r a c t e r i z e s  e a c h  
c r o s s - c o n n e c t i v i t y  n e t w o r k .  A b s e n c e  o f  a n y  c r o s s - p e a k s  l i n k i n g  
p r o t o n  s i g n a l s  o f  t h e s e  t w o  n e t w o r k s  i n d i c a t e s  t h a t  t h e  C 2 
s y m m e t r y  o f  t h e  u n m o d i f i e d  1 0 - m e r  d u p l e x  i s  p r e s e r v e d  i n  
e a c h  p r o d u c t ,  5HG  a n d  SOP.
Asymmetry o f  5HG 5A Purine about the Glycosidic Bond 
Permits Unambiguous Assignment o f  HG Stereochemistry 
in5HG. ' H  N O E S Y  c r o s s - p e a k  d a t a  c o n f i r m  t h a t  t h e  5HG  
c e n t r a l  5 ' - A T - 3 ' - s t c p  c o n s i s t s  o f  H G  b a s e  p a i r s  s t a c k e d  
b e t w e e n  f l a n k i n g  W C  b a s e  p a i r s  i n  r i g h t - h a n d e d  D N A .  
S t e r e o v i e w s  o f  t h e  A T - s t e p  r e g i o n  ( F i g u r e  6 a  f o r  5HG )  i n c l u d e  
n u m b e r e d  d a s h e d  l i n e s  t h a t  c o r r e s p o n d  t o  m o d e r a t e  o r  i n t e n s e  
c r o s s - p e a k s  ( F i g u r e  4 ) .  T h e  m o s t  d i a g n o s t i c  * H  c r o s s - p e a k s  
d i f f e r e n t i a t i n g  H G  f r o m  W C  p a i r i n g  a r e  t h o s e  a s s o c i a t e d  
w i t h  a d e n i n e  H 2  a n d  H 8  a n d  t h y m i n e  H 3 .  Anti  t o  syn  r o t a t i o n  
m o v e s  H 2  t o  a  m a j o r  g r o o v e  e n v i r o n m e n t  s i m i l a r  t o  t h a t  
o c c u p i e d  b y  H 8  p r e v i o u s  t o  r o t a t i o n  a n d  r e l o c a t e s  H 8  i n t o  t h e  
m i n o r  g r o o v e .  H o w e v e r ,  p u r i n e  a s y m m e t r y  a b o u t  t h e  g l y ­
c o s i d i c  b o n d  ( C l ' - N 9 )  a x i s  o f  r o t a t i o n  c a u s e s  H 2  {syn)  t o  b e  
d r i v e n  t o  a  p o s i t i o n  f a r t h e r  a l o n g  t h e  p e r i p h e r y  o f  t h e  m a j o r  
g r o o v e  t h a n  o c c u p i e d  b y  H 8  p r e v i o u s  t o  r o t a t i o n  {anti).  A f t e r  
r o t a t i o n ,  H 8  {syn)  p r o j e c t s  a  c o r r e s p o n d i n g l y  s h o r t e r  d i s t a n c e  
i n t o  t h e  m i n o r  g r o o v e  t h a n  p r e r o t a t i o n  H 2  {anti).
D i f f e r e n t i a t i o n  o f  H G  a n d  W C ' H  N M R  s i g n a l s  d e p e n d s  
on t h i s  a s y m m e t r y .  A n  i n t e n s e  5 A  H 8  X  H 1' ( i n t r a n u c l e o t i d e )  
N O E S Y  c r o s s - p e a i r  ( F i g u r e  4 b ,  c r o s s - p e a k  7 ,  a n d  F i g u r e  6 a )  
c o r r e s p o n d s  i n  i n t e n s i t y  t o  t h e  d i s t a n c e  f r o m  H I '  t o  s _ y r t - H 8 
( a p p r o x i m a t e l y  2 . 5  A )  i n s t e a d  o f  anti-H 8  ( a p p r o x i m a t e l y  3 .9  
A ) .  Syn-5A  H 2  i n t e n s e  c r o s s - p e a k s  w i t h  5 ' - s i d e  4 A  H 8 ,  H 2 " ,  
a n d  H 2 '  ( F i g u r e  4 c .  c r o s s - p e a k  1 ;  F i g u r e  4 c ,  c r o s s - p e a k s  1 0  
a n d  11 ,  r e s p e c t i v e ] ; ,  j  i n d i c a t e  g r e a t e r  b a s e - b a s e  s t a c k i n g  o f  
^  a n d  5 A  t h a n  v o u l d  b e  p o s s i b l e  w i t h  anti-o r i e n t e d  5 A .
° d e l i n g  p r e d i c t s  t h a t  t h e  s t a c k i n g  o f  anti-4 A  a n d  syn-SA  
P o t i o n s  t h e  3 ' - s i c e  ( 6 T )  t h y m i n e ’ s  m e t h y l  g r o u p  i n  t h e
m a x i m a l  s h i e l d i n g  z o n e  o f  t h e  5  A  r i n g  c u r r e n t  e f f e c t  ( F i g u r e
6 ) .  T h e  r e m a r k a b l e  c h e m i c a l  s h i f t  o f  t h i s  m e t h y l  g r o u p  ( 0 . 6 0  
p p m ,  F i g u r e  5 )  s u p p o r t s  t h i s  p r e d i c t i o n .  P r o p e r  b a s e - b a s e  
s t a c k i n g  a n d  m i n i m a l  d e f o r m a t i o n  o f  t h e  d u p l e x  s t r u c t u r e  i n  
t h i s  r e g i o n  p o s i t i o n  t h e  5 A  N 7  c l o s e  t o  t h e  H 3  o f  t h e  p a i r i n g  
t h y m i n e  ( 6 T ) .  A n  i n t e n s e  6 T  H 3  X  5  A  H 8  c r o s s - p e a k  ( F i g u r e  
2 ,  E l )  a n d  6 T  H 3  d o w n f i e l d  c h e m i c a l  s h i f t  ( 1 2 . 3 8  p p m )  
i n d i c a t e  h y d r o g e n  b o n d i n g  b e t w e e n  5 A  N 7  a n d  6 T  H 3 .  
F u r t h e r ,  a n  i n t e n s e  N O E S Y  ( H 2O )  7 T  H 3  X  6 T  H 3  c r o s s ­
p e a k  s u g g e s t s  a  p r o p e r l y  b a s e - p a i r e d  a n d  s t a c k e d  r e g i o n .
Disrupted Hydrogen Bonding and M obile A T -Step Thy­
mine Bases Indicate 5 OP Pairing Anomalies.  A l t h o u g h  ! H  
N O E S Y  d a t a  s h o w  t h a t  t h e  5OP  A T - s t e p  b a s e s  a r e  anti- 
o r i e n t e d  ( e . g . ,  c r o s s - p e a k s  8  a n d  9  b e t w e e n  1 5 A  H 2  a n d  1 6 T  
H I '  a n d  1 7 T  H I ' ,  r e s p e c t i v e l y ;  F i g u r e s  6 b  a n d  4 ) ,  t h e i r  o p e n  
s t a t e  ( d i s r u p t e d  h y d r o g e n  b o n d i n g )  i s  e x p r e s s e d  b y  t w o  l i n e s  
o f  e v i d e n c e :  ( 1 )  T y p i c a l l y ,  d u p l e x  t h y m i n e  H 3  i m i n o  s i g n a l s  
( N O E S Y  i n  H 2O )  o c c u r  b e t w e e n  1 2 . 0  a n d  1 5 . 0  p p m ,  d u e  t o  
t h e  h y d r o g e n  b o n d i n g  o f  b a s e - p a i r e d  t h y m i n e  H 3  ( F i g u r e  2 ) .  
H o w e v e r  i n  50P ,  t h e  1 6 T  H 3  s i g n a l  i s  u n d e t e c t a b l e  i n  t h e  
1 0 . 0 - 1 5 . 0  p p m  r a n g e ,  p r e s u m a b l y  d u e  t o  d i s r u p t i o n  o f  
h y d r o g e n  b o n d i n g .  ( 2 )  N O E S Y  a n d  R O E S Y  c o n f o r m a t i o n a l  
e x c h a n g e  c r o s s - p e a k s  ( C h o e  e t  a l . ,  1 9 9 1 )  i n d i c a t e  t h r e e  A T -  
s t e p  t h y m i n e  p o s i t i o n a l  i s o m e r s .  T h e  e x t r a o r d i n a r i l y  d i f f e r e n t  
1 6 T  m e t h y l  a n d  H 6  c h e m i c a l  s h i f t s  o f  c o n f o r m e r s  a ,  b ,  a n d  
c  a r e  e v i d e n c e  f o r  1 6 T  b a s e s  t h a t  a r e  f r e e r  t o  m o v e  t h a n  a  
h y d r o g e n - b o n d e d  t h y m i n e .  L i t t l e  d i f f e r e n c e  b e t w e e n  n o n -  
1 6 T  s i g n a l s  f o r  t h e s e  t h r e e  c o n f o r m e r s  s u g g e s t s  t h a t  1 5  A - 1 6 T  
b a s e - p a i r  o p e n i n g  c a u s e s  o n l y  m i n o r  p e r t u r b a t i o n  o f  n e i g h ­
b o r i n g  b a s e  p a i r s ,  w h i c h  i s  c o n s i s t e n t  w i t h  p r o p o s e d  m o d e l s  
f o r  b a s e - p a i r  o p e n i n g  ( R a m s t e i n  &  L a v e r y ,  1 9 8 8 ) .  T h e  
e x c h a n g e  p a t h w a y s  a n d  t h y m i n e  c h e m i c a l  s h i f t  d i f f e r e n c e s  
s u g g e s t  t h a t  t h e  1 6 T  t h y m i n e  i s o m e r s  a r i s e  f r o m  t h e  r o t a t i n g  
m o t i o n  a b o u t  t h e  g l y c o s i d i c  b o n d  a x i s  ( F i g u r e  5 ) .  A s  n o  d i r e c t  
1 6 T b  1 6 T c  e x c h a n g e  c r o s s - p e a k s  w e r e  d e t e c t e d ,  r o t a t i o n  
p r o c e e d s  p r e d o m i n a n t l y  i n  o p p o s i t e  d i r e c t i o n s  f r o m  t h e  c e n t r a l  
1 6 T a  p o s i t i o n  t o  g i v e  e i t h e r  c o n f o r m e r  b  o r  c o n f o r m e r  c .  
P r e s u m a b l y ,  i n f l u e n c e  o f  a d j a c e n t  d u p l e x  a n d  /  o r  d r u g  m o i e t i e s
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M m  A: 2D N O E S Y  ( 1 0 0 - m s )  e x p a n s i o n s  s h o w i n g  c r o s s - p e a k s  o f  5 A  a n d  1 5 A  a d e n i n e  H 2  a n d  H 8  s i g n a l s  w i t h  ( a )  o t h e r  a r o m a t i c  p r o t o n s ,  
b )  s u g a r  H I  a n d  H 3  p r o t o n s ,  ( c )  s u g a r  H 2 "  a n d  H 2 ' ,  a n d  ( d )  t h y m i n e  m e t h y l  p r o t o n s .  5HG n u m b e r i n g  f o l l o w s  a  5/ t o  3 '  d i r e c t i o n  f r o m  
1 t o  1 0  f o r  b o t h  s t r a n d s ,  5OP n u m b e r i n g  p r o c e e d s  f r o m  1 1  t o  2 0  f o r  b o t h  s t r a n d s .  N u m b e r s  i n  p a r e n t h e s e s  r e f e r  t o  ! H  c o n t a c t s  s h o w n  i n  F i g u r e
n.
s u s p e n d s  t h i s  m o t i o n  l o n g  e n o u g h  t o  “ f r e e z e  o u t ”  c o n f o r m e r s  
b  a n d  c .  A s  t h e  n e i g h b o r i n g  e n t i t i e s  a r e  a l s o  m o b i l e ,  t h e  
i n f l u e n c e  i s  t e m p o r a r y ,  a l l o w i n g  f o r  c o n t i n u e d  e x c h a n g e  
b e t w e e n  c o n f o r m e r  a  a n d  t h e  t w o  m i n o r  b  a n d  c  c o n f o r m e r s .
Minor Groove Interactions o f  Bizelesin: 5HG vs 5OP 
Structures. Syn  o r i e n t a t i o n  o f  b o t h  5HG  A T - s t e p  a d e n i n e s  
d e e p e n s  t h e  m i n o r  g r o o v e  i n  t h e  r e g i o n  w h e r e  t h e  d r u g  p i v o t s  
a b o u t  t h e  u r e a d i y l  m o i e t y  ( F i g u r e  6 a ) .  T h i s  d e p t h  d i f f e r e n c e  
i s  e v i d e n t  i n  t h e  b i z e l e s i n  8 H 5 '  a n d  H 9 '  c o n t a c t s  w i t h  t h e  
d u p l e x :  5HG  u r e a d i y l  8 N H 9 '  ( 8 . 6 4  p p m )  d i s p l a y s  a  p a i r  o f  
r e l a t i v e l y  i n t e n s e  c r o s s - p e a k s  w i t h  6 T  H I '  a n d  8 H 5 '  ( 7 . 4 5  
p p m ) .  1 8 N H 9 '  ( 7 . 6 6  p p m )  s h o w s  c r o s s - p e a k s  w i t h  1 5 A  H 2  
( s t r o n g ) ,  1 6 T  H I '  ( m o d e r a t e ) ,  a n d  1 8 H 5 '  ( w e a k ;  8 . 2 8  p p m ) .  
T h e s e  c r o s s - p e a k s  s u g g e s t  t h a t  1 8 N H 9 '  i s  c l o s e r  t o  t h e  anti- 
o r i e n t e d  1 5 A  H 2  t h a n  t o  t h e  1 8 H 5 '  o f  t h e  a d j a c e n t  i n d o l e  
m o i e t y ,  w h i l e  8 N H 9 '  i s  c l o s e r  t o  8 H 5 '  t h a n  t o  t h e  r e l a t i v e l y  
m o r e  d i s t a n t  5^ / i - o r i e n t e d  5 A  H 8 .  T h u s ,  t h e  m o s t  i n t e n s e  
8 H 9 '  c r o s s - p e a k  i s  w i t h  8 H 5 '  ( i n t r a d r u g ) ,  w h i l e  t h e  m o s t  
i n t e n s e  1 8 H 9 '  c r o s s - p e a k  i s  w i t h  1 5 A  H 2  ( d r u g  t o  D N A ) .
The Changing Role o f  Bizelesin during Cross-Linkage o f  
y-TAATTA-3'. B i z e l e s i n ’ s  i n s e r t i o n  i n t o  t h e  m i n o r  g r o o v e  
p r o v i d e s  t h e  i m p e t u s  f o r  t h e  j o i n t  r e o r i e n t a t i o n  o f  t h e  5HG 
y - A T - 3 '  a d e n i n e s ,  a n d  t h e  r e s u l t i n g  H G  b a s e  p a i r s  a r e  “ l o c k e d ”  
i n t o  p l a c e  u p o n  c o m p l e t i o n  o f  c r o s s - l i n k a g e .  A n  e x p l a n a t i o n  
o f  t h i s  a p p a r e n t  p a r a d o x  o f  a d e n i n e  r o t a t i o n a l  f r e e d o m  a n d  
r e d u c e d  d u p l e x  f l e x i b i l i t y  i s  t h a t  w h i l e  i n i t i a l  d r u g  i n s e r t i o n
a s s i s t s  i s o m e r i z a t i o n  o f  t h e  a d e n i n e s ,  t h e  c r o s s - l i n k i n g  r e a c t i o n  
b e g i n s  t o  e x e r t  a  n e g a t i v e  i n f l u e n c e  a s  c o v a l e n t  b o n d  f o r m a t i o n  
r e d u c e s  t h e  f l e x i b i l i t y  o f  t h e  c e n t r a l  d u p l e x  r e g i o n .  I n f l e x i b i l i t y  
o f  t h e  c r o s s - l i n k e d  D N A  d e n i e s  a d e n i n e  i t s  f u l l  a r c  o f  r o t a t i o n ,  
t r a p p i n g  d u p l e x  c o n f o r m e r s  t h a t  h a v e  a d o p t e d  p r e d o m i n a n t l y  
syn  o r i e n t a t i o n s  i n  t h e  A T - s t e p  r e g i o n .
A d e n i n e  anti  t o  syn  r e o r i e n t a t i o n  s w i n g s  t h i s  b a s e ’ s  s i x -  
m e m  b e r e d  r i n g  t h r o u g h  t h e  r e g i o n  o f  e i t h e r  t h e  5 ' - s i d e  a d e n i n e  
( 4 A )  o r  3 ' - s i d e  t h y m i n e  ( 6 T ) .  T h e  SOP  c o n f o r m e r ’ s  1 6 T  
c o n f o r m a t i o n a l  e x c h a n g e  d a t a  s u g g e s t  t h a t  SHG ' s  c o r r e ­
s p o n d i n g  3 ' - s i d e  t h y m i n e  ( 6 T )  i s  l e s s  l i k e l y  t h a n  4 A  a d e n i n e  
t o  b l o c k  5 A  a d e n i n e ’ s  r o t a t i o n a l  a r c .  T h i s  3 ' - s i d e  r o t a t i o n  
r e q u i r e s  t h a t  t h e  b a s e  p a i r i n g  ( h y d r o g e n  b o n d i n g )  o f  t h e  
r o t a t i n g  a d e n i n e  a n d  o f  t h e  3 ' - s i d e  t h y m i n e  b e  s i m u l t a n e o u s l y  
o p e n  w h e n  t h e  b a s e  f l i p s  f r o m  anti  t o  syn  o r i e n t a t i o n .  U n d e r  
b i z e l e s i n ’ s  i n f l u e n c e ,  5HG  6 T  t h y m i n e  i n  t h e  o p e n  s t a t e  
( p r e v i o u s  t o  a d e n i n e  r o t a t i o n )  p r e s u m a b l y  a d o p t s  a  m o t i o n  
s i m i l a r  t o  t h a t  d e s c r i b e d  a b o v e  f o r  SOP  1 6 T  t h y m i n e .
A l t h o u g h  b i z e l e s i n ’ s  m i g r a t i o n  t o w a r d  t h e  f l o o r  o f  t h e  m i n o r  
g r o o v e  a n d  c o n t a c t  w i t h  n e i g h b o r i n g  b a s e s  i n f l u e n c e  SHG 
f o r m a t i o n ,  t h e  e x t e n t  t o  w h i c h  d r u g  i n s e r t i o n  d r i v e s  a d e n i n e  
r o t a t i o n  i s  d i f f i c u l t  t o  a s s e s s .  T h e  SOP  c o n f o r m e r ’ s  b e h a v i o r  
c o n f i r m s  t h a t  b i z e l e s i n  i s  c a p a b l e  o f  s h i f t i n g  A T - s t e p  b a s c -  
p a i r  o p e n i n g  r a t e s  t o  g i v e  a p p a r e n t l y  p e r m a n e n t  o p e n  s t a t e s .  
T h u s ,  d r u g  i n s e r t i o n - i n d u c e d  b a s e - p a i r  o p e n i n g ,  w h i c h  i s  a  
p r e r e q u i s i t e  f o r  b a s e  r e o r i e n t a t i o n ,  i s  c o n t r o l l e d  b y  t h e  d r u g .
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F i g u r e  5 :  T w o - d i m e n s i o n a l  N O E S Y  ( 2 0 0 - m s  m i x i n g  t i m e )  e x p a n d e d  c o n t o u r  p l o t  o f  t h e  b i z e l e s i n  1 0 - m e r  d u p l e x  a d d u c t  s h o w i n g  t h e  5HG 
6T  a n d  7 T  a n d  50P  1 6 T  a n d  1 7 T  m e t h y l - t o - m e t h y l  i n t e r n u c l e o t i d e  c r o s s - p e a k s  a n d  d i r e c t  c o n f o r m a t i o n a l  e x c h a n g e  c r o s s - p e a k s .  1 6 T  t h y m i n e  
r e d )  i s  s h o w n  i n  t h e  t h r e e  p o s i t i o n s  s u g g e s t e d  b y  c o n f o r m a t i o n a l  e x c h a n g e  c r o s s - p e a k s .
H o w e v e r ,  t h e  e x t e n t  o f  t h e  c o n t r o l  b y  t h e  d r u g  o f  s u b s e q u e n t  
a d e n i n e  r o t a t i o n  i s  u n c l e a r .  U n q u e s t i o n a b l y ,  t h e  5HG  r o t a t i o n  
p r o d u c t  i s  a  s t a b l e  d u p l e x  a n s w e r  t o  t h e  s t e r i c  s t r e s s  a s s o c i a t e d  
t h  c r o s s - l i n k a g e .
A b s e n c e  f r o m  t h e  p r o d u c t s  o f  a n  A T - s t e p  O P / H G  m i x e d  
w n f o r m e r  i n d i c a t e s  t h a t  t h e  o n l y  t w o  5 ' - A T - 3 '  s t r u c t u r e s  a r e  
O P / O P  a n d  H G / H G .  T h e  i m p l i c a t i o n  o f  t h e  e x p e r i m e n t a l  
r e s u l t s  i s  t h a t  t h e  O P / H G  i s o m e r  e i t h e r  i s  a  s h o r t - l i v e d ,  
r e l a t i v e l y  u n s t a b l e  i n t e r m e d i a t e  o r  i s  n o t  a n  i n t e r m e d i a t e ,  a n d  
'h e  H G / H G  i s o m e r  i s  p r o d u c e d  d i r e c t l y  b y  t h e  c o n c e r t e d  
M i  t o  syn r o t a t i o n  o f  b o t h  A T - s t e p  a d e n i n e s .  I n  e i t h e r  c a s e ,  
ih e  r e s u l t s  p o r t r a y  a  c e n t r a l  5 ' - A A T T - 3 '  r e g i o n  w h e r e i n  t h e  
M p l i t u d e  o f  m o t i o n  i s  s u f f i c i e n t l y  b r o a d  t o  p e r m i t  b o t h  
a d e n i n e s  t o  r o t a t e  t h r o u g h  a  1 8 0 °  a r c  d e s p i t e  t h e  p r e s e n c e  o f  
H a n k i n g  b a s e s .
Bizelesin s Generation o f  a S tab le  H oogsteen Base-Pairing  
tgion in Otherwise “N orm al” B-Form D N A  A ffo rd s an 
tyrecedented O pportunity fo r  A n alysis o f  This M ode o f  
tot Pairing. T h e  c h i e f  o b s t a c l e  t o  H G  b a s e - p a i r i n g  a n a l y s i s
i s  t h e  l o w  p r o b a b i l i t y  t h a t  b a s e  p a i r s  w i l l  u n d e r g o  W C  t o  H G  
t r a n s i t i o n ,  d u e  t o  t h e  h i g h - e n e r g y  b a r r i e r  a s s o c i a t e d  w i t h  b a s e  
r o t a t i o n .  I n  o r d e r  t o  i n d u c e  f o r m a t i o n  o f  a  s i g n i f i c a n t  
c o n c e n t r a t i o n  o f  H o o g s t e e n  b a s e - p a i r e d  p r o d u c t ,  a  d r u g  m u s t  
( 1 )  e x t r a c t  t h e  r a r e l y  f o r m e d  H G  i s o m e r  f r o m  t h e  e q u i l i b r i u m  
W C / H G  m i x t u r e ,  ( 2 )  s t a b i l i z e  t h e  c o n f o r m e r  b y  b l o c k i n g  
syn  t o  anti  c o u n t e r r o t a t i o n ,  a n d  ( 3 )  a v o i d  r a d i c a l l y  d i s t o r t i n g  
D N A  s t r u c t u r e  i n  t h e  W C - t o - H G - t o - W C  t r a n s i t i o n  r e g i o n .  
Q u i n o x a l i n e i n t e r c a l a t o r s , t r i o s t i n - A ( W a n g e t a l . ,  1 9 8 4 , 1 9 8 6 )  
a n d  e c h i n o m y c i n  ( M e n d a l  &  D e r v a n ,  1 9 8 7 ;  G a o  &  P a t e l ,  
1 9 8 8 ;  G i l b e r t  e t  a l . ,  1 9 8 9 ) ,  p a r t i a l l y  s t a b i l i z e  H G  b a s e  p a i r s  
f o r m e d  t o  t h e  3 ' - s i d e  o f  i n t e r c a l a t i o n .  F o r  e x a m p l e ,  i n  t h e  
o c t a m e r  d ( A C G T A C G T )2  e c h i n o m y c i n  p r o d u c e s  s t a b l e  H G  
t e r m i n a l  A T  b a s e  p a i r s ,  b u t  H G  i n t e r n a l  A T  b a s e  p a i r s  b e g i n  
e x c h a n g i n g  w i t h  o p e n  o r  W C  b a s e  p a i r s  a s  p h y s i o l o g i c a l  
t e m p e r a t u r e s  a r e  a p p r o a c h e d .  U n f o r t u n a t e l y ,  i n t e r c a l a t o r  
i n s e r t i o n  d i s r u p t s  b a s e  s t a c k i n g  a n d  b a s e - b a c k b o n e  i n t e r a c ­
t i o n s  i n  t h e  H G  b a s e - p a i r  r e g i o n .  I n  c o n t r a s t ,  b i z e l e s i n  d o e s  
n o t  i n t r u d e  i n t o  t h e  b a s e  s t a c k i n g  o f  t h e  W C  t o  H G  b a s e - p a i r
a .  5 H G  r M D  P R O D U C T  C E N T R A L  R E G I O N
b. 5 0 P  rMD PRODUCT CENTRAL REGION
F ig u r e  6: M o d e l s t ru c tu re  s te re o v ie w s  o f  ( a )  5HG a n d  (b )  50P  r e s tr a in e d  m o le c u la r  d y n a m ic s  
p ro d u c ts  fo r th e  b ize le s in  a d d u c t  o f  th e  d ( C G T A A T T A C G ) 2 d u p le x  a n d  c e n t r a l  r e g io n s  sh o w in g  
m o d e ra te  to  in te n s e  N O E S Y  c ro s s -p e a k s  (d a s h e d  lin e s )  o b se rv ed  fo r  n o n e x c h a n g e a b le  a n d  
e x c h a n g e a b le  p ro to n s . C o lo rs : (fu ll  a d d u c t)  m a g e n ta ,  D N A  b ac k b o n e ; g re e n , a d e n in e ; b lu e , g u a n in e ;
re d -y e llo w  s tr ip e , c y to s in e ; re d , th y m in e ;  c y a n , b iz e le s in ; ( c e n t r a l  re g io n )  so lid  y e llo w  s t r u c tu r e  in  
m in o r  g ro o v e , b iz e le s in . N u m b e r  o n  d a s h e d  lin e s  c o r re s p o n d s  to  c ro s s -p e a k  n u m b e rs  in  p a re n th e s e s  
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transition r e g io n  a n d  y i e l d s  i n t e r n a l  A T  b a s e  p a i r s  t h a t  a r e  
tem perature s t a b l e .
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DNA containing A-tracts has been shown by means of gel 
electrophoresis and electron microscopy to be bent.1 While 
several theories have been proposed for both the nature and the 
loci of such bending, the origin still remains controversial.2’3 
Crystallographic studies on A-tract-containing sequences have 
also been inconclusive, and although some studies have shown 
conformational deviations, the structural and dynamic origins 
of DNA bending remain unclear.4’5 X-ray crystallography and 
high-field NMR studies indicate the presence of an unusually 
narrow minor groove within A-tract sequences4,5,6 and show 
that there is a high degree of propeller twist within the A-tract 
between the A*T base-pairs.7
NMR studies on several sequences reveal distinct junction 
sites at both the 3'- and 5'-ends of A-tracts.7 The origin of 
these junctions is believed to be the transition between the 
normal Watson-Crick base-pairing of the flanking sequences 
and the highly propeller-twisted adenines within the A-tracts. 
Indeed, the 3'-junction of A-tracts is found to be one of the 
preferred binding sites for the (+)-CC-1065 family of DNA 
interactive ligands, and based on sequence selectivity studies, 
it would appear that these molecules can specifically target this 
unusual junction.8
Several workers have proposed, on the basis of spectroscopic 
techniques (UV and CD), that A-tracts exist as an equilibrium 
of at least two species.9,10 Herrera and Chaires9 found evidence 
for two species in equilibrium below the melting transition of 
poly(dA)*poly(dT) but observed only one species for the 
alternating copolymer poly(dA-dT>poly(dT-dA). Because they 
observed isoelliptic points in the CD curves, they concluded 
that a conformational transition occurs between two helical 
species. Related studies on the duplex oligomer S '-GA ^C and 
homo dA*dT tracts using scanning calorimetry, CD, and UV
(1) (a) Wu, H. M.; Crothers, D. M. Nature 1984, 308, 509 -513 . (b) 
Hagerman, P. J. Biochemistry 1985 ,24, 7033—7037. (c) Koo, H.-S.; Wu, 
H. M.; Crothers, D. M. Nature 1986, 320, 501—506. (d) Hagerman, P. J. 
Nature 1986,321,449-450. (e) Haran, T. E.; Crothers, D. E. Biochemistry 
1989, 28, 2763-2767. (f) Koo, H.-S.; Crothers, D. M. Proc. Natl. Acad. 
Sci. U.SA. 1988, 85, 1763-1767.
(2) (a) Dickerson, R. E.; Goodsell, D. S.; Neidle, S. Proc. Natl. Acad. 
Sci. U.SA. 1994, 91, 3579-3583. (b) Goodsell, D. S.; Grzeskowiak, K.; 
Dickerson, R. E. J. Mol. Biol. 1994, 239, 7 9 -9 6 .
(3) Hagerman, P. J. Annu. Rev. Biochem. 1990, 59, 755—781.
(4) Nelson, H. C. M.; Finch, J. T.; Luisi, B. F.; Klug, A. Nature 1987, 
330, 221-226 .
(5) Coll, M.; Frederick, C. A.; Wang, A. H. J.; Rich, A. Proc. Natl. 
Acad. Sci. U.SA. 1987, 84, 8385-8389.
(6) Chuprina, V. P.; Fedoroff, O. Yu.; Reid, B. R. Biochemistry 1991, 
30, 561—568 and references therein.
(7) (a) Kintanar, A.; Klevit, R. E.; Reid, B. R. Nucleic Acids Res. 1987,
15, 5845—5862. (b) Nadeau, J. D.; Crothers, D. M. Proc. Natl. Acad. Sci. 
U.SA. 1989, 86, 2622—2626. (c) Katahira, M.; Sugeta, H.; Kyogoku, Y. 
Nucleic Acids Res. 1990, 18, 3, 613—618. (d) Katahira, M.; Sugeta, H.; 
Kyogoku, Y.; Fujii, S.; Fujisawa, R.; Tomita, K. Nucleic Acids Res. 1988,
16, 8619-8632.
(8) (a) Lee, C.-S.; Sun, D.; Kizu, R.; Hurley, L. H. Chem. Res. Toxicol. 
1991, 4, 203-213 . (b) Lin, C. H.; Sun, D.; Hurley, L. H. Chem. Res. 
Toxicol. 1991,4 ,2 1 —26. (c) Sun, D.; Lin, C. H.; Hurley, L. H. Biochemistry 
1993, 32, 4487-4495.
(9) Herrera, J. E.; Chaires, J. B. Biochemistry 1989, 28, 1993-2000.
(10) Chan, S. S.; Breslauer, K. J.; Hogan, M. E.; Kessler, D. J.; Austin,










F igure 1. Structures of (+)-CC-1065 and the (+)-CC-1065-based cross- 
linker bizelesin.
melting profiles indicated a premelting transition, again sug­
gesting that two different conformations may exist in solution.3,10 
In addition, Wilson and Chaires11 have also interpreted coopera­
tive binding isotherms for the interaction of propidium and 
daunomycin, respectively, with poly(dA)*poly(dT) in terms of 
an allosteric mechanism in which the intercalator preferentially 
binds to a conformer isomer of the polynucleotide. Several 
electron microscopy studies on the kDNA form Crithidia 
fasciculata have also provided further evidence for the coexist­
ence of two or more distinct A-tract conformers.12
Based on the studies described above, it is possible to 
envisage a situation where A-tracts exist as an equilibrium of 
two discrete conformations, one relatively straight and one 
significantly bent. With this hypothesis in mind, it is also 
possible to speculate that DNA interactive ligands that react 
with A-tracts may specifically target and entrap just one of the 
two conformations.
(+)-CC-1065 (Figure 1) is a potent DNA-reactive antitumor 
antibiotic produced by Streptomyces zelensis that covalently 
modifies DNA by alkylation of N3 of adenine in the minor 
groove of DNA.8,13 (4-)-CC-1065 reacts preferentially at two 
consensus sequences, 5'-PuNTTA* and 5'-AAAAA*.14 As a 
structural consequence of DNA alkylation at 5'-AGTTA*, the 
nonbent helix becomes bent into the minor groove, and high- 
field NMR and hydroxyl radical footprinting reveal a structure 
similar to that of an intrinsically bent A-tract. A truncated 
junction bend model has been proposed to account for this bent 
structure.80 Nondenaturating gel electrophoresis (PAGE) studies 
have also shown that upon DNA alkylation, (+)-CC-1065 bends 
DNA into the minor groove by about 14—IS0.83,15 The intrinsic 
bending associated with A-tracts is exaggerated by covalent 
modification with (+)-CC-1065, with the locus of bending 
within the A-tract moving by about 0.5 base pair to the 3'-side 
of the central adenine.80,15 Bizelesin (Figure 1) is a dimeric 
analog of (+)-CC-1065 that consists of two alkylating cyclo- 
propapyrroloindole units joined by a rigid linker. Bizelesin 
interstrand cross-links DNA by alkylating the N3 position of
(11) (a) Wilson, D. W.; Wang, Y.-H.; Krishnamoorthy, C. R.; Smith, J.
C. Biochemistry 1985, 24, 3991—3999. (b) Chaires, J. B. Biochemistry 
1983, 22, 4204-4211 .
(12) (a) Ray, D. S.; Hines, J. C.; Sugisaki, H.; Sheline, C. Nucleic Acids 
Res. 1986, 14, 7953-7965. (b) Griffith, J.; Bleyman, M.; Rauch, C.; 
Kitchin, P. A.; Englund, P. T. Cell 1986, 46, 71 7 -7 2 4 . (c) Laundon, C.
H.; Giffith, J. D. Biochemistry 1987, 26, 3759—3762.
(13) (a) Hanka, L. J.; Dietz, A.; Gerpheide, S. A.; Kuntzel, S. L.; Martin,
D. G. J. Antibiot. 1978 ,31, 1211-1217. (b) Hurley, L. H.; Draves, P. H. 
In Molecular Aspects o f Anticancer Drug—DNA Interactions', Neidle, S., 
Waring, M. J., Eds.; Macmillan Press Ltd.: Basingstoke, U.K., 1993; Vol.
I, pp 89 -1 3 3 .
(14) Reynolds, V. L.; Molineux, I. J.; Kaplan, D.; Swenson, D. H.; 
Hurley, L. H. Biochemistry 1985, 24, 6228—6237.
(15) Hurley, L. H.; Sun, D. J. Mol. Recognit. 1994, 7, 123—132.
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Figure 2 . DNA sequences used in the PAGE and high-field NMR studies 
(NMR sequences shown in bold), indicating the location and covalent 
modification (marked with an asterisk). The A-tract numbering scheme is 
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Figure 3. (A) Relative intensities o f the normalized cross-strand NOESY 
peak volumes between the AH2 and the HI' of the 3'-neighboring residue 
on the complementary strand for the I +  (+>CC-1065 and n  +  bizelesin 
adducts. Results are expressed as a percentage o f the normalized (see text) 
corresponding peak volumes o f the unmodified duplexes. (6 )  Rj_ values 
of the ligation products o f  21-bp oligomers o f A-tract-containing DNA 
duplexes and their respective (+)-CC-1065 and bizelesin adducts.
two adenines separated by four base pairs.16 Sequence selectiv­
ity studies have shown that bizelesin has a cross-linking 
preference for 5'-TAATTA* and the A-tract 5'-TAAAAA*, 
although several other sequences are also targeted, with much 
lower efficiency.17*18
Two different A-tract sequences (I and n, Figure 2) and their 
(+)-CC-1065 and bizelesin-modified duplex adducts have been 
examined by high-field NMR and PAGE. For NMR studies, 
10-mer sequences were examined, while for PAGE, 21-mer 
sequences were used to determine the relative bending magni­
tude. From the 'H-NMR data, the volumes of the connectivities 
between the AH2 and the H I' of the deoxyribose in the 3'- 
neighboring residue on the complementary strand were deter­
mined for each NOESY spectrum of duplexes I and II and their 
respective adducts.19 To allow for a comparison between 
individual samples (which varied in concentration), these 
volumes were then used as a percentage of the average volume 
of the cytosine H5 to H6 connectivities within that spectrum. 
To compare the effects of adduct formation on the intensities 
of the cross-strand connectives, the relative volumes were 
compared (as a percentage) between the unmodified duplexes 
and their respective adducts (Figure 3A). In both cases, the 
relative volumes of the cross-strand connectivities decreased 
significantly upon adduct formation, due to the increased proton
(16) Mitchell, M. A.; Kelly, R. C.; Wicnienski, N. A.; Hatzenbuhler, N. 
T.; Williams, M. G.; Petzold, G. L.; Slightom, J. L.; Siemieniak, D. R. J. 
Am. Chem. Soc. 1 991 ,113, 8994-8995.
(17) (a) Sun, D.; Hurley, L. H. J. Am. Chem. Soc. 1993, 115, 5525— 
5533. (b) Lee, C. S.; Gibson, N. W. Biochemistry 1993, 32, 2592-2600.
(18) Seaman, F. C.; Hurley, L. H. Biochemistry 1993 ,3 2 ,12577—12585.
(19) Two-dimensional NOESY NMR data sets in H2O and D2O buffered 
solution were recorded on a 500 MHz NMR spectrometer. Proton chemical 
shifts were referenced relative to the water signal. Phase-sensitive two- 
dimensional NOESY spectra were obtained for all four samples with a 
mixing time of 150 ms to reduce the influence o f spin diffusion. The spectra 
were acquired with 16 scans at each o f  1024 fi values, spectral width of 
10.002 ppm, and a relaxation delay o f 10 s between scans. During data 
processing, a 90°-shifted squared sine bell function was used in both w l 
and w2 dimensions. The FID in w l was zero-filled to 2K  prior to Fourier 
transformation to give a 2K  x  2K  spectrum.
density within the minor groove as a result of the bound ligand’s 
protons. However, the residual percentages showed marked 
differences for the NOE intensities between the bizelesin and 
(+)-CC-1065 adducts (Figure 3A), which indicates that the 
distances between the AH2 and the HI' of the deoxyribose in 
the 3'-neighboring cross-strand residue had significantly in­
creased in the bizelesin cross-linked adduct relative to the (+)- 
CC-1065 monoalkylated product.
The results from the PAGE study (Figure 3B), in which 21- 
mers were ligated using T4 ligase, clearly show that upon 
monoadduct formation with (+)-CC-1065, the Rl values and 
corresponding bending magnitude observed within the unmodi­
fied 5'-AAAAA* duplex are significantly increased.20 This 
observation is (at least partially) supported by the increased 
cross-strand connectivities in the (+)-CC-1065 adduct relative 
to the bizelesin adduct. These relative intensities indicate that 
there is a significantly reduced distance between the AH2 and 
the cross-strand HI' in the (+)-CC-1065 adduct, suggesting that 
the base pairs are still propeller twisted. In contrast, the 
equivalent PAGE data for die bizelesin adduct of the intrinsically 
bent 5'-TTTTTA* sequence show that the cross-linked duplex 
is now insignificantly bent. From the NMR data, it is impossible 
to precisely determine the degree of base-pair distortion within 
the bizelesin adduct.21
Evidence for junctions at both the 3'- and 5'-ends of the 
A-tract can also be seen in the NMR spectra for both unmodified 
duplexes (I and II) and the (+)-CC-1065 adduct. These 
junctions are believed to be the result of the transition between 
the highly propeller-twisted A-tract and the surrounding B-form 
DNA and can be visualized by an upfield shift in the cytosine 
H5 signal at the 3'-end of the tract and upfield shifts in the HI' 
of the base adjacent to the S'-end of the adenine tract. In 
contrast, there is no evidence from the NMR data for any 
junctions within the bizelesin cross-linked adduct, again provid­
ing support for the loss of propeller twist within the A-tract.
In conclusion, we propose that (+)-CC-1065 and bizelesin 
each entrap one of the two interconverting A-tract conformers. 
(+)-CC-1065 freezes out the bent conformer, while bizelesin 
entraps the straight conformer. While solution studies9,10 have 
previously detected more than one species in A-tract oligomers, 
to the best of our knowledge this is the first time that the two 
equilibrating conformers have been trapped and examined 
independently, although intercalation by propidium and ethidium 
has been proposed to occur preferentially to one conformer 
isomer.11
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(20) Purified [y-32P]APT-labeled duplexes were reacted with either (+ )- 
CC-1065 or bizelesin.8 The drug-modified duplexes and unmodified 
duplexes were then self-ligated in 20 fiL  of ligation buffer with T4 ligase 
to produce multimers, which were electrophoresed on polyacrylamide gel, 
and the bands were located by autoradiography.
(21) A comparison of the relative cross-strand connectivities obtained 
in a similar study with a sequence-related cross-linked bizelesin adduct, 
which is known to have little or no propeller twist within the central cross- 
linked A*T base pairs, indicates that the A-tract bizelesin adduct contains 
normal B-form AH2 to cross-strand HI' distances, suggesting that the bases 
contain little or no propeller twist.
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a b s t r a c t :  Bizelesin (formerly U77,779, The Upjohn Co.) is a bifunctional DNA cross-linking antitumor 
antibiotic consisting of two open-ring homologs of the (+)-CC-1065 cyclopropa[c]pyrrolo[3,2-e]indol- 
4(5/7)-one (CPI) subunits connected by a rigid linking moiety. Previous studies have shown that Bizelesin 
most often forms an interstrand cross-link through the N3 of two adenines 6 base pairs (bp) apart (inclusive 
of the modified adenines). However, gel electrophoresis studies have also indicated that Bizelesin forms 
7-bp cross-links in specific sequences. In most of these sequences the cross-linked adenines represent 
the only possible cross-link site (i.e., no 6-bp site is available); however, in several sequences, a 7-bp 
sequence is selected in overwhelming preference to a possible 6-bp sequence. In this study, we demonstrate 
the unique requirement for a O C  base pair within this sequence and the critical presence of the exocyclic 
2-amino group of guanine. In a subsequent two-dimensional 'H-NMR study that concentrates on the 
7-bp cross-link formed with the sequence 5'-TTAGTTA-3\ the role of the central G*C base pairs in the 
formation of a 7-bp cross-link is probed. 1 H-NMR analysis coupled with restrained molecular dynamics 
(rMD) provides evidence for distortion around the covalently modified adenines. Because of this distortion, 
the modified bases are twisted toward the center of the duplex adduct, effectively reducing the cross- 
linked distance. The rMD study also indicates that a hydrogen bond is formed between the exocyclic 
amine of the central guanine and the carbonyl of the ureylene linker. On the basis of the observation of 
the distortion in the duplex and the hydrogen bonding between the drug and DNA, it is possible to speculate 
on the role of the central G*C bases in this sequence preference and propose a mechanism by which 
Bizelesin forms a 7-bp rather than a 6-bp cross-link with this sequence.
The antitumor antibiotic (+)-CC-1065 is produced by 
itreptomyces zelensis and was first isolated by scientists at 
The Upjohn Co. (Hanka et al., 1978; Martin et al., 1981). 
>tructurally, (+)-CC-1065 consists of three repeating pyr- 
oloindole subunits, the first of which contains a DNA- 
eactive cyclopropapyrroloindole (CPI)1 function (Figure 1). 
+)-CC-1065 reacts with double-stranded DNA through the 
»I3 of a reactive adenine, forming a covalent adduct that 
iverlaps a 5-bp region in the minor groove (Swenson et al., 
982; Hurley et al., 1984; Scahill et al., 1990). Despite 
>romising activity in a variety of tumor cell lines in vitro 
Li et al., 1982; Bhuyan et al., 1982) and in vivo (Martin et
1., 1981), the development of (+)-CC-1065 as an antitumor 
ntibiotic was abruptly terminated when it was discovered 
hat the ligand caused an unusual hepatoxicity, which led to 
lelayed death in mice at therapeutic doses (McGovren et
1., 1984). Extensive SAR studies revealed the structural 
eatures of (+)-CC-1065 that lead to the observed toxicity 
Warpehoski & Bradford, 1988; Hurley et al., 1988, Warpe- 
oski & Hurley, 1988), and more efficacious analogs were 
ynthesized. Adozelesin (Figure 1) represented the first of 
lese compounds to enter clinical trials (Fleming et al., 1992;
f This research was supported by grants from the U.S. Public Health 
ervice (C A -49751), the Welch Foundation, and The Upjohn Co.
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1 Abbreviations: CPI, cyclopropapyrroloindole; bp, base pair; NMR, 
uclear magnetic resonance; NOE, nuclear Overhauser effect; NOESY, 
vo-dimensional NOE correlated spectroscopy; rMD, restrained m o­
dular dynamics; FID, free induction decay; DMF, dimethylformamide;
DTA, ethylenediaminetetraacetic acid; HPLC, high-performance liquid 
hromatography; DD W , double-distilled water.
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F ig u r e  1: Structures o f  (+ )-C C -1 0 6 5  and the cross-linking analog  
B ize lesin  and the m onoalkylation com pounds A d ozelesin  and ( + ) -  
A B .
Burris et al., 1992), and the interest in this compound led to 
the development of second-generation bifunctional analogs. 
The first bifunctional CPI analogs were linked by flexible 
linkers, and the initial success in vitro with these agents 
rapidly led to the development and synthesis of Bizelesin 
(Mitchell et al., 1991), which consists of two DNA-reactive
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5 C -  G -  T -  T -  A -  G -  T -  T -  A9 -  C -  G11
C - A - A - T  -  C -  A - A -  T - G - C  [2
F i g u r e  2: S c h e m e  d e p ic tin g  th e  c y c liz a tio n  o f  B iz e le s in  to  g iv e  
th e  c y c lo p ro p y l d e r iv a tiv e  fo llo w e d  b y  th e  re a c tio n  o f  a d e n in e s  A 9  
a n d  A 2 0  o n  th e  o p p o s ite  D N A  s tran d s  to  u lt im a te ly  fo rm  th e  
in te rs tra n d  c ro ss-lin k ed  d u p lex  ad d u c t (inc lu d in g  n u m b erin g  sy stem s 
fo r  th e  d u p le x  a n d  B iz e le s in  u se d  in  th e  h ig h -f ie ld  N M R  s tu d y ).
C P I  s u b u n i t s  l i n k e d  v i a  a  r i g i d  b i s ( i n d o l e c a r b o x y l i c  a c id )  
l i n k e r .
B iz e l e s i n  g e n e r a l l y  f o r m s  i n t e r s t r a n d  c r o s s - l in k s  w i th  
a d e n i n e s  p r i m a r i l y  s p a c e d  6  b p  a p a r t  ( i n c l u d i n g  th e  c o ­
v a l e n t ly  m o d i f i e d  a d e n in e s )  w h i l e  o c c u p y i n g  th e  in t e r v e n in g  
m i n o r  g r o o v e  ( F i g u r e  2 )  ( D in g  &  H u r le y ,  1 9 9 1 ) .  P r e v i o u s  
g e l  e l e c t r o p h o r e s i s  s tu d ie s  h a v e  s h o w n  s e v e r a l  p r e f e r r e d  
s e q u e n c e s  f o r  th e  f o r m a t io n  o f  D N A —D N A  in te r s t r a n d  c r o s s ­
l i n k s  ( S u n  &  H u r le y ,  1 9 9 3 ;  L e e  &  G i b s o n ,  1 9 9 3 a ,b ) .  T h e  
m o s t - p r e f e r r e d  s e q u e n c e  s p a n s  s ix  n u c l e o t i d e s  a n d  m im ic s  
th e  s e q u e n c e  p r e f e r e n c e  f o r  th e  m o n o a lk y la t in g  ( + ) - C C - 1 0 6 5  
a n a lo g s .  T h i s  p r e f e r r e d  t a r g e t  s e q u e n c e  c o n t a in s  t w o  5 ' -  
T T A * - 3 / s e q u e n c e s  (*  in d i c a t e s  c o v a l e n t ly  m o d i f i e d  b a s e )  
w i t h i n  th e  6 - b p  c r o s s - l in k  s i te  5 ' - T A A T T A * - 3 '.  U n e x p e c t ­
e d ly ,  N M R  s tu d ie s  o f  a  B iz e le s in  c r o s s - l in k e d  a d d u c t  f o r m e d  
w i t h  th i s  s e q u e n c e  h a v e  in d i c a t e d  th e  p r e s e n c e  o f  t w o  a d d u c t  
c o n f o r m a t i o n s ,  b o t h  c o n t a in i n g  u n u s u a l  b a s e  p a i r i n g  w i t h i n  
t h e  c e n t r a l  A *T b a s e  p a i r s  ( S e a m a n  &  H u r le y ,  1 9 9 3 ,  1 9 9 5 ) .  
I n  t h e  f i r s t  c a s e  ( 4 0 %  o f  th e  o b s e r v e d  s p e c ie s ) ,  t h e  b a s e s  
a r e  a r r a n g e d  in  a n  o p e n  c o n f o r m a t i o n ,  i n  c o n t r a s t  t o  th e  
s e c o n d  c a s e  ( 6 0 %  o f  t h e  o b s e r v e d  s p e c ie s ) ,  in  w h i c h  th e  
b a s e s  a r e  H o o g s te e n  b a s e  p a i r e d .  T h e  u n u s u a l  c o n f o r m a t io n s  
o b s e r v e d  w i t h i n  th i s  s e q u e n c e  a r e  p r o p o s e d  to  b e  p a r t i a l l y  
t h e  r e s u l t  o f  t h e  u n u s u a l l y  lo w  b a s e - p a i r  s t a b i l i t y  a t  t h e  A *T 
s t e p  in  th e  u n m o d i f i e d  d u p l e x ,  a n d  i t  h a s  b e e n  p r o p o s e d  t h a t  
B iz e l e s i n  m a y  t r a p  o u t  a n d  s t a b i l i z e  th e  o p e n  a n d  H o o g s t e e n  
c o n f o r m a t i o n s  p r i o r  to  c r o s s - l in k  f o r m a t io n  ( S e a m a n  &  
H u r le y ,  1 9 9 3 , 1 9 9 5 ) .  T h e  s e c o n d  m o s t  p r e f e r r e d  6 - b p  c r o s s -  
l i n k in g  s e q u e n c e  is  t h e  i n t r i n s i c a l l y  b e n t  A - t r a c t - c o n t a i n in g  
s e q u e n c e  5 '- T T T T T A * - 3 '.  N o n d e n a t u r i n g  g e l  e l e c t r o p h o r e -
C h a r t  1. S e q u e n c e s  o f  O l ig o m e rs  U s e d  in  T h is  Study
I 5 '-TGGCCGCAATTAATTACGGGT-3'
3 ' GGCGTTAATTAATGCCCAACC-5' 
n 5 '-TGGCCGCAGTTAGTTACGGGT-3'
3 ' -GGCGTCAATCAATGCCCAACC-5' 
01 5 '-TGGCCGCAGTTAITTACGGGT-3'
3 '-GGCGTCAATCAATGCCCAACC-5' 
I V  5 '-C G T T A G T T A C G -3'
3 '-G C A A T C A A T G C -5'
s i s  ( P A G E )  e x p e r i m e n t s  h a v e  in d i c a t e d  th a t  u p o n  cross-I 
f o r m a t io n  t h e  in t r in s ic  A - t r a c t  b e n d in g  w a s  elim inated , wh 
a  h ig h - f i e ld  N M R  s tu d y  o f  th e  a d d u c t  f o r m e d  w ith  the A-tn 
5 '- T T T T T A * - 3 '  c o n f i r m e d  th e  lo s s  o f  A - tr a c t  character, 
i n c l u d i n g  p r o p e l l e r  tw i s t i n g  a n d  j u n c t i o n s  a t  the  3' and H 
e n d s  o f  t h e  A - t r a c t  ( T h o m p s o n  e t  a l . ,  1 9 9 5 ; Thompson I  
H u r le y ,  1 9 9 5 ) .
M o l e c u l a r  m o d e l in g  s tu d ie s  a n d  g e l  e le c tro p h o re s is  studies 
in d i c a t e  t h a t  B iz e l e s i n  i s  m o s t  s u i te d  to  cross-link ing  two 
a d e n i n e s  6  b p  a p a r t .  T h e r e  a r e ,  h o w e v e r ,  e x a m p le s  of 7-bp 
c r o s s - l in k  s i te s ,  a n d  in  s e v e r a l  o f  th e s e ,  a  7 -b p  site  is 
o v e r  a  p o s s i b le  6 - b p  c r o s s - l in k  s i te . I n  th is  s tu d y , we i 
th e  i m p o r t a n c e  o f  t h e  c e n t r a l  G *C  b a s e  p a i r s  in  the center of 
th e  s e q u e n c e  5 '- T T A G T T A - 3 '  in  m e d ia t in g  a  7-bp cross­
l in k .  T h i s  o b s e r v a t i o n  l e a d s  to  t w o  im p o r ta n t  questions, 
F i r s t ,  s i n c e  B iz e l e s i n  i s  t o o  s h o r t  to  a lk y la t e  tw o  adenines 1 
b p  a p a r t  i n  n o r m a l  B - f o r m  D N A , w h a t  is  th e  location ao| 
n a t u r e  o f  B iz e l e s i n - i n d u c e d  d i s to r t io n  o f  th is  duplex? to  
o n d ,  w h a t  i s  t h e  r o l e  o f  t h e  c e n t r a l  g u a n in e  in  facilitating 
th e  f o r m a t io n  o f  a  7 - b p  c r o s s - l in k ?  W e  h a v e  addressed these 
q u e s t i o n s  u s i n g  a  c o m b i n e d  g e l  e le c t ro p h o re s is  and high- 
f i e l d  N M R  s tu d y .  I n  th e  g e l  e l e c t r o p h o r e s i s  study, we have 
d e m o n s t r a t e d  b o t h  t h e  i m p o r t a n c e  o f  th e  ce n tra l GC bast 
p a i r  a n d ,  in  p a r t i c u la r ,  t h e  2 - N H 2 g r o u p  o f  guanine® 
m e d i a t i n g  a  7 -  r a t h e r  t h a n  a  6 - b p  c r o s s - l in k a g e .  In addition, 
u s i n g  t h e  m o n o a l k y l a t i n g  C P I s ,  A d o z e le s in ,  and (+)-AB 
( F i g u r e  1 ) , w e  h a v e  d e m o n s t r a t e d  th e  u n iq u e  reactivity* 
th e  5 '- T A A *  s e q u e n c e  to  th e  c r o s s - l in k i n g  C P Is . High-field 
N M R  w a s  u s e d  t o  p r o v i d e  th e  s o l u t i o n  conform ation  of® 
7 - b p  c r o s s - l in k e d  s e q u e n c e  a n d  p i n p o i n t  th e  presence of 
d i s to r t io n  in  t h e  d u p l e x  a d d u c t  a r o u n d  th e  covalently 
m o d i f i e d  a d e n in e s .  F in a l ly ,  o n  th e  b a s i s  o f  these observs- 
t i o n s ,  w e  m a k e  s o m e  c o n c l u s i o n s  a s  to  the molecuto 
m e c h a n i s m  f o r  c r o s s - l in k i n g  th i s  7 - b p  c ro s s - lin k  site,
E X P E R I M E N T A L  P R O C E D U R E S
Chemicals and Enzymes. B iz e l e s i n ,  (+)-CC-1065,Adri 
z e le s in ,  a n d  ( + ) - A B  c o m p o u n d s  w e re  a  g i f t  fro m  The Upjohn̂ 
C o .  a n d  w e r e  u s e d  w i t h o u t  f u r th e r  p u r if ic a t io n , 
u s e d  to  p r e p a r e  th e  N M R  b u f f e r ,  s o d iu m  dihydro($j 
p h o s p h a t e  ( 9 9 .9 9 % ) ,  s o d iu m  c h l o r i d e  (9 9 .9 9 % ), and EDTA 
( 9 9 .9 9 % ) ,  w e r e  p u r c h a s e d  f r o m  A ld r ic h .  HPLC water, 
m e th a n o l ,  e th y l  a c e ta te ,  a n d  a c e to n i t r i le  w e re  purchased frajj 
B a x te r .  A m m o n i u m  a c e t a t e  ( 9 9 .9 9 % ) ,  so d iu m  
( 9 9 .9 9 % ) ,  g la c ia l  a c e t ic  a c id  (9 9 .9 9 % ) ,  a n d  hydrochloricd 
w e r e  p u r c h a s e d  f r o m  A l d r i c h .  E le c tro p h o re tic  r̂ agenE 
[ a c r y la m id e ,  A ,A ,A \iV / - te tr a m e th y le th y le n e d ia m in e ) 
n i u m  p e r s u l f a t e ,  a n d  b i s ( a c r y l a m i d e ) ]  w e re  purchased fid 
B io - R a d .  T 4 p o l y n u c l e o t i d e  k i n a s e  w a s  f ro m  United States 
B io c h e m ic a l  C o . ;  [ y - 32P ] A T P  w a s  f r o m  IC N ; andX-rayit 
i n t e n s i f y i n g  s c r e e n s ,  a n d  d e v e l o p in g  c h e m ic a ls  were fin 
K o d a k .
Preparation o f Oligonucleotides fo r  Gel Electropkod 
Studies. A  s e r ie s  o f  o l i g o n u c l e o t i d e s  (Chart 1 )1
'Bizelesin [d(CGTT AGTT ACG)*d(CGT A ACT A ACG)] Adduct Biochemistry, Vol. 34, No. 35, 1995 11007
synthesized o n  a n  a u t o m a t e d  D N A  s y n t h e s i z e r  ( A p p l i e d  
Biosystems 3 8 1  A )  b y  th e  p h o s p h o r a m i d i t e  m e th o d .  T h e  
oligomers w e re  d e p r o te c t e d  w i t h  s a t u r a t e d  a m m o n i u m  
hydroxide a t  5 5  ° C  o v e r n ig h t .  T h e  a m m o n i u m  h y d r o x i d e  
solution w as  e v a p o r a te d  u n d e r  v a c u u m , a n d  th e  d r i e d  p e l l e t s  
were re d is s o lv e d  in  D D W .
Lfreparation o f the 5'-32P End-Labeled Oligomer Duplex. 
Mividual s t r a n d s  o f  t h e  2 1 - m e r  w e r e  l a b e le d  w i th  [ y - 32P ] -  
ATP using T 4 p o l y n u c l e o t i d e  k i n a s e  a n d  h y b r i d i z e d  to  a n  
jticess o f u n la b e le d  c o m p l e m e n t a r y  s t r a n d ,  a n d  th e  r e s u l t i n g  
duplex D N A  w a s  g e l - p u r i f i e d  b y  1 2 %  n o n d e n a t u r i n g  p o l y ­
acrylamide g e l  e l e c t r o p h o r e s i s .  D u p l e x  D N A  w a s  l o c a te d  
on the gel u s in g  a u t o r a d io g r a p h y ,  c u t  f r o m  th e  g e l ,  m in c e d  
nth a b lade , a n d  e x t r a c t e d  w i th  a n n e a l i n g  b u f f e r  [1 0  m M  
Tris-HCl (p H  7 .6 )  a n d  1 0 0  m M  N a C l ] .
Drug Treatment o f Oligomer Duplexes and Determination 
Drug-Bonding Sites on Electrophoretic Gels. T h e  5' e n d -  
toeled o l ig o m e r  d u p le x e s  w e r e  r e a c t e d  w i th  d r u g  in  1 0 0  
jiof an n e a lin g  b u f f e r  f o r  2 4  h . D r u g  c o n c e n t r a t i o n s  w e r e  
100/iM fo r  B iz e le s in ,  1 0  /z M  f o r  ( + ) - A B ,  a n d  1 0  /z M  f o r  
Mozelesin. T h e  1 0 - f o ld  h i g h e r  c o n c e n t r a t i o n  b y  B iz e l e s i n  
ms used to  c o m p e n s a te  f o r  t h e  o v e r a l l  l o w e r  r e a c t i v i t y  o f  
Bizelesin. U n b o u n d  d r u g  m o l e c u l e s  w e r e  r e m o v e d  b y  
m nol/ch lo ro fo rm  e x t r a c t i o n ,  a n d  D N A  m o l e c u l e s  w e r e  
precipitated b y  e th a n o l  p r e c i p i ta t io n .  D N A  p e l l e t s  w e r e  
dried, r e d is s o lv e d  in  D D W , a n d  s u b j e c t e d  t o  th e  th e r m a l  
arand b reak ag e  a s s a y  (R e y n o ld s  e t  a l . ,  1 9 8 5 )  to  i n d u c e  D N A  
bkage at th e  d r u g - b o n d in g  s i te s .
LSeparation o f the Cross-Linked Duplex from  Monoalky- 
hted and Unreacted Species Using Denaturing Polyacry­
lamide Gel Electrophoresis. D u p le x  o l i g o m e r  ( a b o u t  1 0 0  
g) was r e a c te d  w i th  B iz e l e s i n  ( 1 0 0  /z M )  in  1 0 0  /z L  o f  
mnealing b u f f e r  f o r  th e  i n d i c a t e d  p e r io d  o f  t im e .  U n b o u n d  
drag m o lecules w e r e  r e m o v e d  b y  p h e n o l / c h l o r o f o r m  e x t r a c -  
ioa, and D N A  w a s  p r e c i p i t a t e d  b y  e th a n o l  p r e c i p i t a t io n .  
DNA pellets w e r e  d r i e d ,  r e d i s s o l v e d  in  2 0  p L  o f  a l k a l i n e  
r  (80% fo r m a m id e  a n d  1 0  m M  N a O H ) ,  a n d  in c u b a te d  a t  
D°C for 1 m in  j u s t  b e f o r e  th e  s a m p le s  w e r e  lo a d e d  o n  a  
[Bwarmed 1 2 %  d e n a tu r in g  p o l y a c r y l a m i d e  g e l .  E le c t r o -  
toresis w as c a r r i e d  o u t  a t  1 2 0 0  V  f o r  2  h  to  s e p a r a t e  th e  
Izelesin c r o s s - l in k e d  d u p le x  f r o m  th e  m o n o a l k y l a t e d  a n d  
nrcacted s p e c ie s  (S u n  e t  a l . ,  1 9 9 4 ) .  
mgonucleotide Preparation and Purification fo r  NMR 
Indies. T h e  tw o  s t r a n d s  f o r  th e  1 1 - m e r  [ d ( C G T T A G T T -  
fc j)d (G C A A T C A A T G C )] w e r e  s y n th e s i z e d  o n  a  1 0 -/z m o l 
sale by u s in g  a u to m a te d  s o l id - p h a s e  p h o s p h o t r i e s t e r  a n d  
p p h o ra m id ite  c h e m is t r y  ( G a i t ,  1 9 8 4 )  o n  a n  A p p l i e d  
pystem s a u to m a te d  D N A  s y n t h e s i z e r  ( M o d e l  3 8 1  A ) ,  
aving the t r i ty l  p r o t e c t in g  g r o u p  o n  e a c h  o f  t h e  s in g le  
Sands. T h e  tw o  s t r a n d s  w e r e  p u r i f i e d  b y  r e v e r s e - p h a s e  
HC, as o u t l in e d  p r e v io u s l y  ( T h o m p s o n  &  H u r le y ,  1 9 9 5 ) .  
iqual quan titie s  o f  th e  tw o  s t r a n d s  ( m e a s u r e d  b y  U V )  w e r e  
rod and a n n e a le d  in  N M R  b u f f e r  ( 1 0  m M  N a H 2P ( V 1 0 0  
iM N aC l/0 .1 m M  E D T A , p H  6 .8 5 )  a t  8 0  ° C  f o r  1 h  a n d  
noled slow ly . T h e  a n n e a l e d  s a m p l e  w a s  p u r i f i e d  o n  a  
lydroxylapatite c o lu m n  u s in g  a  m o b i le  s o l v e n t  ( N a H 2P 04  
ie r, pH 6 .8 5 )  g r a d ie n t  i n c r e a s i n g  f r o m  1 0  to  2 0 0  m M . 
Ibepure d u p le x  D N A  w a s  d e s a l t e d  o n  a  G - 2 5  c o lu m n .  A f te r  
tag ly o p h iliz ed  to  d r y n e s s ,  t h e  s a m p le  w a s  r e d i s s o l v e d  in  
1 /iL o f N M R  b u f f e r ,  a n d  a  o n e - d im e n s io n a l  'H - N M R  o f  
Be sample w a s  e x a m in e d .  O n ly  d u p le x  s ig n a l s  w e r e  
iscrved.
Adduct Preparation and Purification fo r  NMR Studies. 
Ike Bizelesin a d d u c t  w a s  p r e p a r e d  b y  s t i r r in g  1 0  m g  o f
IK
B iz e l e s i n  in  0 .2  m L  o f  D M F  s o l u t i o n  w i t h  0 .0 3  m L  o f  1 M  
s o d i u m  b i c a r b o n a t e  f o r  2 0  m in  b e f o r e  a d d in g  3 0  m g  o f  
p u r i f i e d  1 1 - m e r  in  0 .7 5  m L  o f  tw i c e - c o n c e n t r a t e d  N M R  
b u f f e r  c o n t a in i n g  2 0  m M  s o d i u m  d i h y d r o g e n  p h o s p h a t e  a n d  
2 0 0  m M  s o d i u m  c h l o r i d e  ( p H  6 .8 5 ) .  T h e  r e a c t i o n  m i x tu r e  
w a s  s t i r r e d  f o r  4 8  h  in  t h e  d a r k ,  l y o p h i l i z e d  to  d r y n e s s  
o v e r n ig h t ,  a n d  d e s a l t e d ,  a n d  t h e  e x c e s s  d r u g  w a s  r e m o v e d  
o n  C 18 S e p - P a k  c a r t r i d g e s  ( W a te r s ) .  T h e  s a m p le  w a s  
e x a m in e d  b y  'H - N M R  in  b u f f e r  ( 1 0  m m o l  o f  N a H 2PC >4/100 
m m o l  o f  N a C l /0 .1  m M  E D T A ,  p H  6 .8 5 )  a n d  w a s  f o u n d  to  
c o n t a in  a  m i x tu r e  o f  d u p l e x  a n d  d u p l e x  a d d u c t ,  a n d  h e n c e ,  
a  f u r th e r  2 .5  m g  o f  B iz e l e s i n  w a s  a d d e d  ( a s  a b o v e )  a n d  th e  
r e a c t i o n  a l l o w e d  to  p r o c e e d  f o r  a  f u r th e r  4 8  h .  O n c e  
c o m p l e t e d ,  t h e  s a m p le  w a s  a g a in  ly o p h i l i z e d  to  d r y n e s s  a n d  
d e s a l t e d ,  a n d  th e  e x c e s s  d r u g  w a s  r e m o v e d  o n  C 18 S e p - P a k  
c a r t r i d g e s .  O n e - d i m e n s i o n a l  'H - N M R  t h e n  i n d i c a t e d  t h a t  
th e  r e a c t i o n  h a d  g o n e  to  c o m p l e t i o n  a n d  n o  f u r th e r  p u r i f i c a ­
t i o n  w a s  r e q u i r e d .
Proton NMR Experiments. O n e -  a n d  t w o - d im e n s io n a l  5 0 0  
M H z  'H - N M R  d a t a  s e t s  in  H 20  a n d  D 20  b u f f e r e d  s o l u t i o n  
w e r e  r e c o r d e d  o n  a  B r u k e r  A M X  5 0 0  F T  N M R  s p e c tr o m e te r .  
P r o t o n  c h e m ic a l  s h i f t s  w e r e  r e c o r d e d  in  p a r t s  p e r  m i l l io n  
( p p m )  a n d  r e f e r e n c e d  r e l a t iv e  t o  th e  w a te r  s ig n a l .
P h a s e - s e n s i t iv e  tw o - d im e n s io n a l  N O E S Y  s p e c tr a  ( B r u k e r )  
w e r e  o b t a i n e d  f o r  t w o  m ix in g  t im e s ,  1 5 0  a n d  2 5 0  m s .  A l l  
s p e c t r a  w e r e  a c q u i r e d  w i th  16  s c a n s  a t  e a c h  o f  1 0 2 4 1\ v a lu e s ,  
a t  a  s p e c t r a l  w i d t h  o f  1 0 .0 0 2  p p m  a n d  a  r e l a x a t i o n  d e l a y  o f  
1 0  s b e t w e e n  s c a n s .  D u r in g  d a t a  p r o c e s s i n g ,  a  9 0 ° - s h i f t e d  
s q u a r e d  s in e - b e l l  f u n c t i o n  w a s  u s e d  in  b o t h  (Oi a n d  co2 
d i m e n s i o n s .  T h e  F I D  in  at \ w a s  z e r o - f i l l e d  to  2  K  p r i o r  to  
F o u r i e r  t r a n s f o r m a t i o n  to  g iv e  a  2  K  x  2  K  s p e c tr u m .  T w o -  
d i m e n s i o n a l  N O E  s p e c t r a  in  9 0 %  H 20  a t  1 5 0  m s  m i x in g  
t i m e  w e r e  r e c o r d e d  u s in g  th e  1 -1  e c h o  r e a d  p u l s e  s e q u e n c e  
( S k l e n a r  &  B a x ,  1 9 8 7 ;  B la k e  &  S u m m e r s ,  1 9 9 0 )  w i t h  a  2 .5  
s p u l s e  r e p e t i t i o n  t i m e  a n d  a  s w e e p  w i d t h  o f  2 4 .3 9 6  p p m .  In  
a d d i t io n ,  s e l e c t  13C  r e s o n a n c e s  w e r e  i d e n t i f i e d  u s i n g  a  
h e t e r o n u c l e a r  m u l t i p l e - q u a n t u m  c o h e r e n c e  e x p e r i m e n t  in  
D 20  ( B a x  e t  a l . ,  1 9 8 3 ) .
Restrained Molecular Dynamics. I n t e r p r o t o n  d i s t a n c e s  
w e r e  d e r iv e d  u s in g  t h e  p r o g r a m  M A R D I G R A S  ( B o r g i a s  &  
J a m e s ,  1 9 9 0 )  f r o m  N O E S Y  e x p e r i m e n t s  u s i n g  m ix in g  t im e s  
o f  1 5 0  a n d  2 5 0  m s .  A  c o m p l e t e  tw o - d i m e n s i o n a l  N O E  
r e la x a t i o n  m a t r ix  w a s  s e t  u p  u s in g  th e  g e o m e t r y  o f  a  s t a r t i n g  
s t r u c tu r e  to  p r o v i d e  i n t e r p r o to n  N O E s  n o t  a v a i la b le  f r o m  th e  
e x p e r i m e n t a l  d a t a  s e t s .  A l t e r n a t iv e  s t a r t i n g  s t r u c tu r e s  w e r e  
(1 )  B iz e le s in  1 1 -m e r  a d d u c t  n o n r e s t r a in e d  m o le c u la r  d y n a m ­
ic s  p r o d u c t s  a n d  ( 2 )  m i n im i z e d  B - D N A  a d d u c t s .  T h e  
c o m p le te  N O E  m a t r ix  w a s  c a l c u la t e d  f o r  th e  s ta r t in g  s t ru c tu re  
u s i n g  C O R M A  ( B o r g ia s  e t  a l . ,  1 9 8 9 ;  B o r g ia s  &  J a m e s ,  
1 9 8 8 ) . M A R D I G R A S  c a lc u la te s  u p p e r  a n d  lo w e r  b o u n d a r ie s  
f o r  th e  in t e r p r o to n  d i s ta n c e s  ( B o r g i a s  &  J a m e s ,  1 9 9 0 ) ,  a n d  
s u b s e q u e n t  p r o c e d u r e s  f o l l o w e d  t h o s e  d e s c r i b e d  p r e v io u s l y  
( K e r w o o d  e t  a l . ,  1 9 9 1 ) .  I n t e r p r o t o n  d i s ta n c e s  w e r e  i n c o r ­
p o r a te d  in to  t h e  r M D  a n d  r e s t r a i n e d  d y n a m i c s  c a l c u l a t i o n s  
o f  th e  s o l v a t e d  s y s t e m .  T h e  r M D  c a l c u l a t i o n s  w e r e  p e r ­
f o r m e d  u s in g  th e  S A N D E R  m o d u l e  o f  A M B E R  ( P e a r l m a n  
e t  a l . ,  1 9 9 1 ) ,  v e r s io n  4 .0 ,  o n  a n  S G I  4 D - 3 5 G  P e r s o n a l  I r is  
w o r k s t a t i o n .  T h e  A M B E R  f o r c e  f i e l d  p s e u d o e n e r g y  t e r m s  
f o r  th e  in t e r p r o to n  d i s ta n c e s  w e r e  g iv e n  th e  f o r m  o f  f l a t  w e l l s  
w i t h  p a r a b o l i c  s id e s  w i t h i n  a  d e f in e d  d i s ta n c e .  T h e  m o l e c ­
u l a r  d y n a m i c s  c a l c u l a t i o n s  w e r e  s t a r t e d  a t  0  K  a n d  r a m p e d  
to  2 0  k c a l /( m o l* A 2) o v e r  15 p s  to  3 0 0  K . D u r in g  th e  f i r s t  
1 0  p s  o f  th i s  p e r io d ,  t h e  1 8 9  N M R - d e r i v e d  d i s ta n c e  r e s t r a in t s  
w e r e  a p p l i e d  to  t h e  s y s t e m  a l o n g  w i th  a d d i t i o n a l  b a s e - p a i r
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F i g u r e  3: Comparison o f  the Bizelesin alkylation sites on the (+ )  
(upper) and ( —) (lower) strands o f the 21-mer oligomer duplexes 
(I and II in Chart 1) containing the sequences 5'-TTAGTTA-3' (A) 
and 5'-TTAATTA-3' (B). AG and TC represent the purine- and 
pyrimidine-specific cleavage reaction, respectively. In each case, 
lane 1 corresponds to the thermal strand breakage products 
(Reynolds et al., 1985) after modification o f  oligomer DNA with 
Bizelesin. Arrows correspond to the modified adenine (*) on the 
sequences.
distance and angle restraints, which were applied to the 
terminal bases to prevent duplex fraying at elevated tem­
peratures. The system was then ramped to 500 K over 20 
ps, held for 10 ps, and returned over 20 ps to 300 K. The 
solvated system was then held at 300 K for 50 ps, and the 
data from the last 50 ps were used to generate averaged 
structures (see later) and hydrogen-bonding information.
R E S U L T S
(A) Gel Electrophoresis Studies
Bizelesin Shows a Unique Cross-Linking Reactivity with 
a 7-bp Sequence That Has a Requirement fo r  a Central G'C 
Base Pair. Although Bizelesin is generally known to form 
interstrand cross-links with adenines primarily spaced 6 bp 
apart, several 7-bp cross-link sites have been identified from 
the previous studies (Sun & Hurley, 1993). In particular, in
the sequence 5'-TTAGTTA*-3' (* indicates one of the 
cross-linking alkylation sites and • indicates the thymine 
opposite the other cross-linking site), a 7-bp cross-link site 
is highly favored over the alternative 6-bp cross-link site
(5'-TTAGTTA*-3'). In the present study, two 21-bp oli­
gomer duplexes (I and II in Chart 1) were designed to 
compare both the Bizelesin reactivity and the cross-linking 
sequence specificity in the purely AT sequence 5'-TTAATTA- 
3' with the mixed AT/GC-containing sequence 5/-TTAGTTA- 
3'.2 As shown in Figure 3, Bizelesin forms almost exclusively
a 7-bp cross-link with the sequence 5'-TTAGTTA*-3' (A), 
while the 6-bp cross-link is predominant in the sequence 5'-T
TAATTA*-3' (B). These results show the apparent impor­
tant role of the central guanine in facilitating the formation 
of the 7-bp cross-link. Overall, the alkylation reactivity of 
duplex I is less than duplex II.
The Exocyclic 2-NH: Group o f Guanine Directs Cross- 
Linking Specifically at the 7-bp Cross-Linking Site. In order 
to test the importance of the exocyclic 2-amino group of
2 The base sequence to the 5'-side of the target sequence (TTANTTA) 
in oligomers II and III was also changed to eliminate the possible 
competitor 6-bp (A,G) cross-linked and monoalkylation sites.
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Figure 4: Bizelesin alkylation sites on the (+) (upper) and(-) 
(lower) strand o f the 21-mer oligomer sequence (III in Chart 1)
containing 5'-TTAITTA*-3' as the cross-linking sequence. Lancs 
1 and 2 correspond to unmodified and Bizelesin-modified DNA. 
respectively. In contrast to the results in Figures 3 and 5. the thermal 
cleavage reaction, which normally gives rise to products that migraie 
alongside Maxam and Gilbert sequence reactions, is incompli 
and therefore the major products run at higher molecular weij
g u a n i n e  in  f a c i l i t a t i n g  th e  f o r m a t io n  o f  a 7-bp cross-li 
th e  2 1 - b p  o l i g o m e r  d u p le x  c o n ta in in g  the sequence? 
T T A I T T A - 3 '  ( I I I  in  C h a r t  1) w a s  co n s tru c ted  and 
w i th  B iz e le s in  to  m e a s u r e  th e  a m o u n t  o f  the 7- vs 6-bp or® 
l in k .  A s  s h o w n  in  F ig u r e  4 ,  th e  re p la c e m e n t of the central 
g u a n i n e  w i th  i n o s in e ,  w h ic h  la c k s  th e  exocyclic 2-amino 
g r o u p  s u b s t i tu e n t ,  l e a d s  to  f o r m a t io n  o f  approx im ate ly^  
a m o u n t s  o f  th e  6 -  a n d  7 - b p  c r o s s - l in k  on  the sequence 5'- 
T T A I T T A - 3 ' .  T h i s  r e s u l t  s u g g e s t s  th a t  the exocyclic 2-XH. 
g r o u p  o f  g u a n in e  h a s  a n  im p o r ta n t  ro le  in directing the cross- 
l i n k in g  a t  a d e n i n e s  s p a c e d  7  b p  a p a r t .
Alkylation at 5'-TAA* Is Unique to the Cross-Li niinj 
CPIs, and Monoalkylation Occurs at the 5'-TTA* Sequent 
Prior to Cross-Linking at 5'-TAA*. T h e  underlying molec 
u l a r  m e c h a n i s m  o f  th e  7 - b p  c r o s s - l in k  w as further explore 
b y  a  c o m p a r i s o n  o f  th e  B iz e le s in  drug-m odification  sites on 
t h e  s e q u e n c e  5 '- T T A G T T A - 3 '  ( o l ig o m e r  II in Chart 1) wi 
th e  m o n o a l k y l a t i n g  a n a lo g s  A d o z e le s in  and  (+)-AB (Figra 
1). A s  e x p e c t e d ,  A d o z e l e s i n  a n d  (+ ) - A B  showed muc 
h i g h e r  m o n o a l k y l a t i o n  r e a c t iv i ty  w ith  th e  sequence 5'-TTA 
in  c o m p a r i s o n  to  th e  s e q u e n c e  5 '-C T A *  (compare lanes 
a n d  3  in  le f t  a n d  r ig h t  p a n e l s  o f  F ig u re  5). Furthermore 
m o n o a l k y l a t i o n  a t  th e  5 '- T A A *  s e q u e n c e  was not obsena 
In  c o n t r a s t ,  B iz e le s in  c r o s s - l in k s  a t  th e  5 '-T T A * and5'-’ 
s e q u e n c e s  ( l a n e  1 in  r ig h t  a n d  le f t  p a n e ls  o f Figure 5). 
th e  b a s i s  o f  a  c o m p a r i s o n  o f  th e  re s u l ts  o f  the cross-lid 
b y  B iz e le s in  a n d  th e  m o n o a lk y la t in g  b y  Adozelesin and (I 
A B , it c a n  b e  c o n c lu d e d  th a t  f o r  B iz e le s in  the monoalkylan 
o c c u r s  a t  th e  5 '- T T A *  s e q u e n c e  a n d  cross-linking at the 
T A A *  s e q u e n c e .
U s i n g  d e n a t u r i n g  g e l  a n a l y s i s ,  th e  tim e—course 
m o n o a lk y la t io n  a n d  c r o s s - l in k in g  a lk y la tio n  produced dm 
th e  r e a c t i o n  o f  B iz e le s in  w i th  o l ig o m e r  II (Chart 1)i 
m o n i to r e d .  T h e  r e s u l t s  s h o w n  in  F ig u re  6 reveal that 
f o r m a t io n  o f  c r o s s - l in k e d  p r o d u c t  a p p a re n tly  occurs with
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15: Comparison o f the Bizelesin and monoalkylating 
[alkylation sites on (+ )  (upper) and (—) (lower) strands of 
roligomer duplex (II in Chart 1) containing the sequence 
[AGTTA-3'. Lanes 1—3 correspond to the thermal strand 
;products of the oligomer DNA modified with Bizelesin, 
sin, and (+)-AB, respectively.
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6: Kinetics of the monoalkylation and cross-linking adduct 
by Bizelesin on the 21 -mer oligomer duplex containing 
ace 5'-TTAGTTA-3'. The oligomer duplex was reacted 
for the indicated period o f time at the lane heading 
onto the denaturing polyacrylamide gel to separate 
jedDNA from the monoalkylated and unmodified DNAs. 
pdU represent cross-linked, monoalkylated, and unmodi- 
ies, respectively.
pttion o f d e te c ta b le  a m o u n t s  o f  m o n o a l k y l a t i o n  
This su g g es ts  th a t  t h e  c r o s s - l in k i n g  r e a c t i o n  b y  
in  on this s e q u e n c e  is  v e r y  f a s t  c o m p a r e d  to  th e  
fylation re a c tio n .
hh-Field NMR Studies
if gel electrophoresis s tu d ie s  s h o w  t h a t  t h e  7 - b p  c r o s s -  
; of the s e q u e n c e  5 '- T T A G T T A  b y  B iz e le s in  is  
ntupon the e x o c y c l ic  2 - a m i n o  g r o u p  o f  g u a n in e .  In  
K  investigate th e  s t r u c tu r a l  r o l e  o f  th i s  m i n o r  g r o o v e  
Dgroup of g u an in e  in  m e d i a t i n g  th e  7 -  v s  th e  e x p e c t e d  
iss-link, a tw o -d im e n s io n a l  h i g h - f i e ld  ‘H - N M R  s tu d y  
performed.
pent of the Proton Resonances fo r  the Bizelesin 11- 
ex Adduct. (i) Duplex Base and Deoxyribose 
Imgeable Proton Assignments. T h e  g e n e r a l  s t r a te g y  
a ss ig n m en ts  o f  th e  n o n - s e l f - c o m p l e m e n t a r y  
I cross-linked B iz e le s in  a d d u c t  w a s  f o l l o w e d  a s
o u t l in e d  in  p r e v io u s  ( + ) - C C - 1 0 6 5  a n d  B iz e le s in  s tu d ie s  (L in  
e t  a l . ,  1 9 9 1 ;  S e a m a n  &  H u r le y ,  1 9 9 3 ;  T h o m p s o n  &  H u r le y ,  
1 9 9 5 ) .  A  s in g le  s e t  o f  m e th y l s  a n d  s in g le  a r o m a t ic  H 6 /H 8  
t o  H I '  w a lk s  is  o b s e r v e d  f o r  e a c h  o f  th e  n o n c o m p l e m e n t a r y  
s t r a n d s ,  i n d ic a t in g  th a t  o n ly  a  s in g le  a d d u c t  is  f o r m e d  ( F ig u r e  
7 ) .  P r e v i o u s  s tu d ie s  o n  th e  c r o s s - l in k e d  B iz e l e s i n  d u p le x  
a d d u c t  f o r m e d  w i th  5 '- T A A T T A - 3 '  s h o w e d  t h e  p r e s e n c e  o f  
H o o g s t e e n  a n d  o p e n  b a s e - p a i r  c o n f o r m a t i o n  w i th in  th e  
c e n t r a l  A *T s t e p  ( u n d e r l in e d ) .  T o  e l i m i n a t e  th e  p o s s i b i l i t y  
o f  m i s t a k in g  a d e n i n e  H 2  p r o t o n s  w i th  th e  a r o m a t ic  H 8  
p r o to n s  a n d  m is in te r p r e t in g  a n y  u n u s u a l  b a s e - p a i r  c o n f o r m a ­
t io n s  b e t w e e n  th e  c r o s s - l in k e d  a d e n in e s ,  t h e  13C  s h i f t s  f o r  
th e  c a r b o n s  c o n n e c te d  to  th e  a r o m a t ic  p r o to n s  w e r e  m e a s u r e d  
a n d  a s s i g n e d  b y  th e  u s e  o f  ‘H — 13C  c o r r e l a t i o n  e x p e r i m e n t s  
( u n p u b l i s h e d  d a ta ) .  D u e  to  th e  d i f f e r e n c e s  w i t h i n  th e  
e l e c t r o n i c  e n v i r o n m e n t ,  a  c a r b o n  c o n n e c t e d  to  a n  a d e n in e  
H 2  w i l l  t y p i c a l l y  h a v e  a  c h e m ic a l  s h i f t  b e t w e e n  1 4 8  a n d  
1 5 5  p p m ;  in  c o n t r a s t ,  a  c a r b o n  c o n n e c t e d  to  a  P y H 6  o r  P u H 8  
a r o m a t ic  p r o t o n  w i l l  h a v e  a  c h e m ic a l  s h i f t  b e t w e e n  1 3 0  a n d  
145  p p m . T h e  v a l u e s  o b t a i n e d  f o r  th e  13C  s h i f t s  c o n f i r m  
t h e  a s s i g n m e n t s  o f  th e  a d e n in e  H 2  p r o t o n s ,  a n d  o n  th e  b a s i s  
o f  th e  c o n n e c t iv i t i e s  f r o m  th e  a d e n in e  H 2  p r o to n s  in to  d u p le x  
a n d  B iz e l e s i n  p r o to n s  l o c a te d  w i t h i n  th e  m i n o r  g r o o v e ,  th e  
p o s s i b i l i t y  o f  H o o g s t e e n  a n d  n o n - b a s e - p a i r e d  b a s e s  ( p r e v i ­
o u s ly  o b s e r v e d  w i th in  th e  B iz e l e s i n  d u p l e x  a d d u c t  f o r m e d  
w i th  5 '- T A A T T A * )  c a n  b e  e l i m i n a t e d .  A  s u m m a r y  o f  th e  
D N A  n o n e x c h a n g e a b l e  p r o t o n  N M R  a s s i g n m e n t s  f o r  th e  
d u p l e x  a d d u c t  a n d  a  c o m p a r i s o n  to  t h e  d u p le x  a r e  g i v e n  in  
T a b l e  1A .
(ii) Bizelesin Nonexchangeable Proton Assignments. N o n ­
e x c h a n g e a b l e  ‘H - N M R  s ig n a l s  f o r  th e  B iz e l e s i n  m o l e c u l e  
a r e  d iv i s ib l e  in to  ( + ) - C P I  s u b u n i t  a n d  in d o le  s u b u n i t  c lu s t e r s  
( F ig u r e  2 ) .  M a n y  o f  th e  d r u g  p r o t o n s  a r e  l o c a te d  o n  th e  
i n s id e  e d g e  o f  th e  b o u n d  l ig a n d  a n d  g e n e r a t e  n u m e r o u s  d r u g -  
t o - D N A  N O E S Y  c r o s s - p e a k s .  C O S Y  c r o s s - p e a k s  f o r  o r t h o ­
r e l a t e d  a r o m a t ic  p r o t o n s  a n d  N O E s  ( H 2O )  b e t w e e n  in d o le  
H I '  p r o t o n  r e s o n a n c e s  a n d  t h e i r  n e ig h b o r i n g  H 8 '  c o n f i r m  
th e  H 3 ',  H 5 ' ,  H 7 ',  a n d  H 8 '  a s s i g n m e n t s  ( T a b le  I B ) .  T h e  
C P I  s u b u n i t  H 7  p r o t o n s  a r e  a s s i g n e d  o n  th e  b a s i s  o f  w e a k  
c o n n e c t i v i t i e s  in to  th e  H 4 '  o f  t h e  c o v a l e n t ly  m o d i f i e d  b a s e s ,  
c o n n e c t i v i t i e s  in to  th e  C P I  p h e n o l  m o i e t y ,  a n d  th e  l3C  s h i f t s  
f r o m  t h e  13C — lH  c o r r e l a t i o n  e x p e r i m e n t .
(iii) DNA and Bizelesin Exchangeable Proton Assignments. 
T w o - d im e n s i o n a l  N O E  ( H 20 )  e x p e r i m e n t s  w e r e  c o n d u c t e d ,  
a n d  th e  e x c h a n g e a b l e  im in o  s ig n a l s  w e r e  a s s i g n e d  o n  th e  
b a s i s  o f  t h e i r  c o n n e c t i v i t y  n e t w o r k s  in t o  th e  a r o m a t ic  r e g io n  
a n d  c o n n e c t i v i t i e s  in to  th e  im in o  p r o t o n s  o f  th e  n e i g h b o r i n g  
b a s e s .  A l l  e x c h a n g e a b l e  im in o  s ig n a l s  f o r  th e  d u p l e x  a n d  
d u p le x  a d d u c t  w e r e  d e te c te d  e x c e p t  f o r  th o s e  a s s o c ia t e d  w i th  
th e  t e r m in a l  b a s e s ,  G 1 1 a n d  G 2 2 .  C o n s is t e n t  w i th  p r e v io u s ly  
s t u d ie d  C C - 1 0 6 5  (L in  &  H u r le y ,  1 9 9 0 )  a n d  U - 7 7 ,7 7 9  
( S e a m a n  &  H u r le y ,  1 9 9 3 )  a d d u c t s ,  t h e  im in o  s ig n a l s  f o r  T 3  
a n d  T 1 4  ( 1 1 .3 0  a n d  1 0 .9 3  p p m ,  r e s p e c t i v e l y )  w e r e  s i g n i f i ­
c a n t ly  u p f i e ld - s h i f te d  in  th e  d u p le x  a d d u c t ,  p a r t ly  c o n f i r m in g  
th e  lo c a t i o n  o f  th e  c o v a l e n t ly  m o d i f i e d  a d e n i n e s  ( F ig u r e  8 ) . 
T h e  C P I  s u b u n i t  N H 1  a n d  in d o le  s u b u n i t  N H 1 ' p r o t o n s  f o r  
b o th  e n d s  o f  th e  l i g a n d  w e r e  a s s i g n e d  o n  th e  b a s i s  o f  th e i r  
r e s p e c t i v e  c o n n e c t i v i t i e s  to  th e  C P I  s u b u n i t  H 2  a n d  in d o le  
s u b u n i t  H 8 '.  ‘H - N M R  s ig n a l s  f o r  t h e  C P I - p h e n o l  p r o to n s  
( H 8 )  w e r e  a s s i g n e d  o n  th e  b a s i s  o f  c o n n e c t i v i t i e s  in to  th e  
B iz e l e s i n  C P I  s u b u n i t  H 7  p r o to n  a n d  d u p le x  H 4 '  p r o to n s  
( T a b le  2 ) .  T h e  r e s o n a n c e  s ig n a l s  f o r  th e  tw o  p h e n o l  p r o to n s  
w e r e  o b s e r v e d  a t  1 1 .0 6  a n d  1 1 .1 0  p p m  ( F ig u r e  8 ) , c o n t r a s t in g
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F i g u r e  3: Comparison of the Bizelesin alkylation sites on the (+) 
(upper) and (—) (lower) strands of the 21-mer oligomer duplexes 
(I and II in Chart 1) containing the sequences 5'-TTAGTTA-3' (A) 
and 5'-TTAATTA-3' (B). AG and TC represent the purine- and 
pyrimidine-specific cleavage reaction, respectively. In each case, 
lane 1 corresponds to the thermal strand breakage products 
(Reynolds et al., 1985) after modification of oligomer DNA with 
Bizelesin. Arrows correspond to the modified adenine (*) on the 
sequences.
distance and angle restraints, which were applied to the 
terminal bases to prevent duplex fraying at elevated tem ­
peratures. The system was then ramped to 500 K over 20 
ps, held for 10 ps, and returned over 20 ps to 300 K. The 
solvated system was then held at 300 K for 50 ps, and the 
data from the last 50 ps were used to generate averaged 
structures (see later) and hydrogen-bonding information.
R ESU L TS
(A) G el E lectrophoresis Studies
Bizelesin Shows a Unique Cross-Linking R eactiv ity  with  
a 7-bp Sequence That Has a Requirem ent fo r  a  C en tra l G'C  
Base Pair. Although Bizelesin is generally known to form 
interstrand cross-links with adenines primarily spaced 6 bp 
apart, several 7-bp cross-link sites have been identified from 
the previous studies (Sun & Hurley, 1993). In particular, in
the sequence 5'-TTAGTTA*-3' (* indicates one of the 
cross-linking alkylation sites and • indicates the thymine 
opposite the other cross-linking site), a 7-bp cross-link site 
is highly favored over the alternative 6-bp cross-link site
(5'-TTAGTTA*-3'). In the present study, two 21-bp oli­
gomer duplexes (I and II in Chart 1) were designed to 
compare both the Bizelesin reactivity and the cross-linking 
sequence specificity in the purely AT sequence 5'-TTAATTA- 
3' with the mixed AT/GC-containing sequence 5'-TTAGTTA- 
3'.2 As shown in Figure 3, Bizelesin forms almost exclusively
a 7-bp cross-link with the sequence 5 '-TTA G TTA *-3' (A), 
while the 6-bp cross-link is predominant in the sequence 5'-T
TAATTA*-3' (B). These results show the apparent impor­
tant role of the central guanine in facilitating the formation 
of the 7-bp cross-link. Overall, the alkylation reactivity of 
duplex I is less than duplex II.
The E xocyclic 2-NHz G roup o f  Guanine D irects C ross- 
Linking Specifically a t the 7-bp Cross-Linking Site. In order 
to test the importance of the exocyclic 2-amino group of
2 The base sequence to the 5'-side of the target sequence (TTANTTA) 
in oligomers II and III was also changed to eliminate the possible 
competitor 6-bp (A,G) cross-linked and monoalkylation sites.
F ig u r e  4 : Bizelesin alkylation sites on the (+) (upper) and (— 
(lower) strand of the 21-mer oligomer sequence (III in Chart 1)
containing 5'-TTAITTA*-3' as the cross-linking sequence. Lanes 
1 and 2 correspond to unmodified and Bizelesin-modified DNA. 
respectively. In contrast to the results in Figures 3 and 5, the therma 
cleavage reaction, which normally gives rise to products that migrate 
alongside Maxam and Gilbert sequence reactions, is incomplete 
and therefore the major products run at higher molecular weight
I
guanine in facilitating the formation of a 7-bp cross-link 
the 21-bp oligomer duplex containing the sequence 5'- 
TTAITTA-3' (III in Chart 1) was constructed and reactec 
with Bizelesin to measure the amount of the 7- vs 6-bp cross 
link. As shown in Figure 4, the replacement of the centra 
guanine with inosine, which lacks the exocyclic 2-amin( 
group substituent, leads to formation of approximately equa  
amounts of the 6- and 7-bp cross-link on the sequence 5 
TTAITTA-3'. This result suggests that the exocyclic 2-NF 
group of guanine has an important role in directing the cross 
linking at adenines spaced 7 bp apart.
Alkylation at 5 '-TAlA* Is Unique to the Cross-Linkin  
CPIs, and M onoalkylation O ccurs a t the 5'-TTA* Sequenc 
P rior to Cross-Linking a t 5'-TAA*. The underlying molec 
ular mechanism of the 7-bp cross-link was further explorei 
by a comparison of the Bizelesin drug-modification sites oi 
the sequence 5'-TTA G TTA -3' (oligomer II in Chart 1) witl 
the monoalkylating analogs Adozelesin and (+)-A B  (Figur 
1). As expected, Adozelesin and (+)-A B  showed muc 
higher monoalkylation reactivity with the sequence 5'-TTA 
in comparison to the sequence 5'-CTA* (compare lanes 
and 3 in left and right panels o f Figure 5). Furthermore 
monoalkylation at the 5'-TAA* sequence was not observec 
In contrast, Bizelesin cross-links at the 5'-TTA* and 5'-TAA 
sequences (lane 1 in right and left panels of Figure 5). O  
the basis o f a comparison of the results of the cross-linkin 
by Bizelesin and the monoalkylating by Adozelesin and (+  
AB, it can be concluded that for Bizelesin the monoalkylatio 
occurs at the 5'-TTA* sequence and cross-linking at the 5 
TAA* sequence.
Using denaturing gel analysis, the tim e—course 
monoalkylation and cross-linking alkylation produced durin 
the reaction of Bizelesin with oligomer II (Chart 1) w 
monitored. The results shown in Figure 6 reveal that tl 
formation of cross-linked product apparently occurs witho
izelesin [d(C G TTA G TTA C G )-d(C G TA A C TA A C G )J A dduct Biochemistry, Vol. 34, No. 35, 1995 11009
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I g u r e  5 : Comparison of the Bizelesin and monoalkylating
nalogs’ alkylation sites on (+) (upper) and (—) (lower) strands of 
Je 2 1-mer oligomer duplex (II in Chart 1) containing the sequence 
j-TTAGTTA-3'. Lanes 1—3 correspond to the thermal strand 
eakage products of the oligomer DNA modified with Bizelesin, 
jdozelesin, and (+)-AB, respectively.




p U R E  6 :  Kinetics of the monoalkylation and cross-linking adduct 
rmation by Bizelesin on the 21-mer oligomer duplex containing 
e sequence 5'-TTAGTTA-3'. The oligomer duplex was reacted 
th Bizelesin for the indicated period of time at the lane heading 
jfore loading onto the denaturing polyacrylamide gel to separate 
)ss-linked DNA from the monoalkylated and unmodified DNAs. 
£, M, and U represent cross-linked, monoalkylated, and unmodi- 
d species, respectively.
cumulation of detectable am ounts o f monoalkylation 
oduct. This suggests that the cross-linking reaction by 
zelesin on this sequence is very fast compared to the 
^noalkylation reaction.
p H igh-Field NMR Studies
The gel electrophoresis studies show that the 7-bp cross­
king of the sequence 5'-TTA G TTA  by Bizelesin is 
pendent upon the exocyclic 2-am ino group of guanine. In 
er to investigate the structural role of this minor groove 
ino group of guanine in mediating the 7- vs the expected 
5p cross-link, a two-dimensional high-field 'H-NM R study 
is performed.
Assignm ent o f  the Proton Resonances fo r  the Bizelesin 11- 
D uplex Adduct. (i) D uplex B ase and D eoxyribose  
unexchangeable Proton Assignm ents. The general strategy 
H-NMR assignments o f the non-self-complementary 
plex and cross-linked Bizelesin adduct was followed as
outlined in previous (+)-CC-1065 and Bizelesin studies (Lin 
et al., 1991; Seaman & Hurley, 1993; Thompson & Hurley, 
1995). A single set of methyls and single aromatic H6/H8 
to H I ' walks is observed for each of the noncomplementary 
strands, indicating that only a single adduct is formed (Figure 
7). Previous studies on the cross-linked Bizelesin duplex 
adduct formed with 5'-TAATTA-3' showed the presence of 
Hoogsteen and open base-pair conformation within the 
central A*T step (underlined). To eliminate the possibility 
of mistaking adenine H2 protons with the aromatic H8 
protons and misinterpreting any unusual base-pair conforma­
tions between the cross-linked adenines, the l3C shifts for 
the carbons connected to the aromatic protons were measured 
and assigned by the use of 'H —13C correlation experiments 
(unpublished data). Due to the differences within the 
electronic environment, a carbon connected to an adenine 
H2 will typically have a chemical shift between 148 and 
155 ppm; in contrast, a carbon connected to a PyH6 or PuH8 
aromatic proton will have a chemical shift between 130 and 
145 ppm. The values obtained for the l3C shifts confirm 
the assignments o f the adenine H2 protons, and on the basis 
of the connectivities from the adenine H2 protons into duplex 
and Bizelesin protons located within the minor groove, the 
possibility of Hoogsteen and non-base-paired bases (previ­
ously observed within the Bizelesin duplex adduct formed 
with 5'-TAATTA*) can be eliminated. A summary of the 
DNA nonexchangeable proton NMR assignments for the 
duplex adduct and a comparison to the duplex are given in 
Table 1A.
(ii) Bizelesin Nonexchangeable Proton Assignments. Non­
exchangeable 'H-NM R signals for the Bizelesin molecule 
are divisible into (+)-CPI subunit and indole subunit clusters 
(Figure 2). Many of the drug protons are located on the 
inside edge of the bound ligand and generate numerous drug- 
to-DNA NOESY cross-peaks. COSY cross-peaks for ortho­
related aromatic protons and NOEs (H2O) between indole 
H I ' proton resonances and their neighboring H8' confirm 
the H3', H5', H7', and H8' assignments (Table IB). The 
CPI subunit H7 protons are assigned on the basis of weak 
connectivities into the H4' of the covalently modified bases, 
connectivities into the CPI phenol moiety, and the l3C shifts 
from the 13C —'H  correlation experiment.
(Hi) DNA and Bizelesin Exchangeable Proton Assignments. 
Two-dimensional NOE (H20 )  experiments were conducted, 
and the exchangeable imino signals were assigned on the 
basis of their connectivity networks into the aromatic region 
and connectivities into the imino protons of the neighboring 
bases. All exchangeable imino signals for the duplex and 
duplex adduct were detected except for those associated with 
the temiinal bases, G 11 and G22. Consistent with previously 
studied CC-1065 (Lin & Hurley, 1990) and U-77,779 
(Seaman & Hurley, 1993) adducts, the imino signals for T3 
and T14 (11.30 and 10.93 ppm, respectively) were signifi­
cantly upfield-shifted in the duplex adduct, partly confirming 
the location of the covalently modified adenines (Figure 8). 
The CPI subunit NH1 and indole subunit N H L  protons for 
both ends o f the ligand were assigned on the basis of their 
respective connectivities to the CPI subunit H2 and indole 
subunit H8'. 'H-NM R signals for the CPI-phenol protons 
(H8) were assigned on the basis of connectivities into the 
Bizelesin CPI subunit H7 proton and duplex H4' protons 
(Table 2). The resonance signals for the two phenol protons 
were observed at 11.06 and 11.10 ppm (Figure 8), contrasting
1
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Figure 7: Two-dimensional phase-sensitive NOESY spectrum (250 ms mixing time) expanded contour plot of the Bizelesin cross-lutt 
duplex adduct in buffered D 20  solution, pH 6.85, at 300 K, displaying connectivities for aromatic PuH8/PyH6 to deoxyribose HI'nil 
deoxyribose H I' protons o f the 5'-neighbor (strands are shown separately in left and right panels). M issing connectivities between tie! 
protons o f adenine A9 and adenine A 20 are indicated as A and B, respectively.
Table 1
(A) Chemical Shifts (ppm) of Nonexchangeable Protons in the [d(CGTTAGTTACG)*d(GCAATCAATGC)] Bizelesin Adduct at Room Temperate!1
H8 H6 H2 H5 HI' H2' H2" H3' H4' H5f
Cl 7.58 (—0.09) 5.84 (-0 .08) 5.67 (-0 .13) 2.30 (+0.24) 1.89 (-0 .57) 4.65 (-0.07) 4.04 (-0.33)
G2 7.93 (-0 .07) 5.73 (-0 .32) 2.45 (-0 .27) 2.67 (-0 .18) 4.94 (-0.06) 4.30 (-0.10) 3.9WI
T3 7.52 (+0.21) 1.62 (+0.18) 6.16 (+0.09) 2.47 (+0.34) 2.26 (-0 .32) 4.90 (+0.03) 4.34 (-0.06) 4.M
T4 7.32 (-0 .05) 1.78 (+0.10) 5.90 (+0.15) 2.91 (+0.78) 2.34 (-0 .16) 4.62 (-0.28) 1.84 (-2.60) 32H
A5 8.14 (-0 .09) 7.67 (+0.50) 6.14 (+0.08) 2.67 (-0 .06) 2.13 (-0 .79) 4.92 (-0.13) 2.68
G6 7.31 (-0 .24) 5.24 (-0 .59) 2.24 (-0 .20) 1.92 (-0 .79) 4.62 (-0.25) 3.70 (-0.70] «
T7 6.83 (-0 .36) 0.90 (-0 .31) 5.95 (-0 .01) 2.38 (+0.32) 1.75 (-0 .79) 4.58 (-0.25) 4.09 (-0.13) 2.5KJ
T8 6.97 (-0 .40) 1.44 (-0 .20) 5.22 (-0 .56) 1.12 (-0 .95) 1.31 (-1 .18) 4.38 (-0.52) 1.75 4.1i
A9 8.48 (+0.16) 8.25 (+0.70) 5.67 (-0 .52) 2.57 (-0 .14) 3.07 (+0.22) 4.98 (-0.06) 4.57 (+0.13) 4.17/iS
CIO 7.23 (-0 .05) 5.73 (+0.38) 5.47 (-0 .19) 2.16 (+0.31) 1.66 (-0 .63) 4.57 (-0.21) 2.10 3.33/31
G il 7.86 (-0 .04) 6.10 (-0 .04) 2.36 (-0 .00) 2.64 (+0.06) 4.72* (+0.07) 4.27 (+0.H) m
C12 7.58 (-0 .07) 5.84 (-0 .08) 5.66 (—0.12) 2.30 (+0.28) 1.89 (-0 .55) 4.67 (-0.03) 4.04 (-0.33) m
G13 7.90 (-0 .08) 5.76 (-0 .20) 2.49 (-0 .17) 2.63 (-0 .15) 4.92 (-0.06) 4.29 (-0.07) 3.91MI
T14 7.37 (+0.13) 1.64 (+0.13) 5.17 (-0 .41) 2.41 (+0.39) 2.23 (-0 .12) 4.87 (0.00) 4.22 (+0.03) 4.1041
A15 8.33 (+0.09) 7.51 (+0.47) 6.29 (-0 .32) 2.95 (+0.20) 2.78 (-0 .14) 5.07 (+0.02) 4.47 4.i
A16 7.91 (-0 .20) 8.48 (+0.93) 5.83 (-0 .23) 2.70 (+0.07) 2.18 (-0 .62) 4.55 (-0.46) 1.73 (-2.74) irn
C17 6.79 (-0 .40) 4.80 (-0 .31 5.23 (-0 .42) 1.85 (-0 .01) 1.23 (-1 .17) 4.38 (-0 .21) 2.20 (-1.97) 3.73/JI
T18 7.31 (-0 .01) 1.42 (-0 .13) 5.25 (-0 .38) 2.24 (+0.20) 1.85 (-0 .55) 4.61 (-0.26) 4.15
A19 8.12 (-0 .12) 7.26 (+0.32) 5.24 (-0 .64) 2.12 (-0 .87) 2.40 (-0 .77) 4.49 (-0.57) 3.38 (-l.oi) 4 m
A20 8.37 (+0.26) 8.32 (+0.66) 5.79 (-0 .28) 2.58 (+0.02) 2.82 (+0.02) 4.97 (-0.04) 4.54 (+0.11) JjHO
C21 7.22 (+0.02) 5.63 (+0.39) 5.48 (—0.15) 2.16 (+0.34) 1.66 (-0 .60) 4.57 (-0.30) 1.85 (-2.53) 3.0®
G22 7.85 (-0 .02) 6.10 (-0 .04) 2.36 (+0.01) 2.64 (+0.07) 4.72* (+0.08) 4.27 (+0.12) 3JH
H2 H3Me
(B) Proton Chemical Shifts (ppm) for the Bound Bizelesin in the Duplex Adduct at Room Temperature" 
NH1 H4a H4A H4B H5A H5B H7 H3' H5' H7' H8' NH1' M
Bizelesin CPI and Indole Subunit (Linked to Adenine 9)
7.38 2.75 10.45 4.50 4.64 4.97 5.58 4.94 7.68 7.99 7.95
Bizelesin CPI and Indole Subunit (Linked to Adenine 20)
7.40 2.70 10.52 5.13 4.64 4.50 5.49 4.92 7.85 7.84 7.54
7.87 7.57 10.99
7.59 7.38 11.22
° Chemical shift differences, doNA-dmg ~  <5dna, are shown in italics; shift differences greater than 0.25 ppm are underlined). Sample was 
in 0.5 mL of D20  buffer containing 0.1 M sodium chloride and 10 mM sodium dihydrogen phosphate, pH 6.85, at 300 K. * Signal not visible! 
to H20  suppression.
t o  p r e v io u s  s t u d ie s  o n  a  ( + ) - C C - 1 0 6 5  a d d u c t  ( L in  e t  a l . ,  
1 9 9 1 )  a n d  a  B iz e l e s i n  a d d u c t  ( T h o m p s o n  &  H u r le y ,  1 9 9 5 ) ,  
in  w h i c h  th e  s i g n a l s  f o r  t h e  p h e n o l  p r o t o n s  w e r e  o b s e r v e d  
s ig n i f i c a n t ly  d o w n f ie ld  to  e x p e c te d  v a lu e s  [1 3 .6 2  p p m  w i th in  
t h e  ( + ) - C C - 1 0 6 5  a d d u c t  a n d  1 3 .0 5  a n d  1 3 .8 0  p p m  w i th in  
t h e  c r o s s - l in k e d  B iz e l e s i n  a d d u c t ] .  O n  t h e  b a s i s  o f  th e
u n u s u a l ly  d o w n f ie ld  s h i f t s  o b s e r v e d  w ith in  the (+)-CC-l 
a d d u c t ,  i t  w a s  p r e d ic t e d  a n d  c o n f i r m e d  by the use of1 
N M R  c o u p l e d  w i th  170 - l a b e l e d  w a te r  and  phosphatesil 
t h e  p h e n o l i c  p r o t o n  in  th e  ( + ) - C C - 1 0 6 5  duplex adducti 
h y d r o g e n  b o u n d  ( t h r o u g h  a n  o r d e r e d  w a te r  molecule itoi 
p h o s p h a t e  b a c k b o n e  ( L in  e t  a l . ,  1 9 9 1 ) . O n the basis oi
Bizelesin [d(CGTT AGTT ACG)*d(CGT A ACT A ACG)] Adduct Biochemistry, Vol. 34, No. 35, 1995 11011
Table 2: Intensities" of the NOE Connectivities between Bizelesin and the Covalently Modified Duplex
(A) Bizelesin and Indole Subunit (Linked to Adenine 9)





























(B) Bizelesin and Indole Subunit (Linked to Adenine 20) 
H4A H4B H5A H5B H2 H3' H5' H7 H7' H8'
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Tfj111111' I t | i | ■ | 1 | ! | i | 1 | 1 | 1 | i | 1 | 1 | i | i | 1 | 1 [ i | 1 | * | i i 1 |- 'it
lit 14.0 13.0 12.0 H.O 10.0ppm
fiaitE 8: One-dimensional proton NMR spectra (500 MHz; 8 .5— 
IS ppm, downfield region) o f the 11-mer duplex (A) and cross- 
ied Bizelesin adduct (B). Signals from the unreacted duplex are 
■dicated by a •, and broad signals for two CPI phenol protons are 
idicated by an *. The upfield-shifted amino signals for thymine 
BandT14 are highlighted.
Aemical shifts for the two phenolic protons in this Bizelesin 
duplex adduct, it would appear that there is no significant 
’Hydrogen bonding into the phosphate backbone. Signals for 
t amide NH protons within the ureylene linking moiety
could not be found in either the one- or two-dimensional
H-NMR data.
Bizelesin Occupies the Minor Groove and Is Covalently 
Cached Through A9 and A20. There are sufficient DNA 
ad Bizelesin protons within the minor groove to unambigu- 
oosly define the location of the Bizelesin molecule and the 
K of covalent attachment. Connectivities between the 
aeuine H2 protons along the length of the duplex into the 
EPllinkers’ H4A and H4B protons, the CPI subunits’ H5A
a n d  H 5 B  p r o t o n s ,  a n d  th e  i n d o l e s ’ H 3 '  a n d  H 5 '  p r o t o n s  
c o n f i r m  n o t  o n l y  th e  l o c a t i o n  a n d  o r i e n t a t i o n  o f  th e  l i g a n d  
b u t  a l s o  th e  a s s i g n m e n t  o f  th e  s ix  a d e n i n e  H 2  p r o t o n s  
( c o n n e c t i v i t i e s  f r o m  A 2 0 ,  A 19 , a n d  A 5  a r e  s h o w n  in  F ig u r e  
9 ;  a l l  d r u g  to  d u p l e x  c o n n e c t i v i t i e s  a r e  s h o w n  in  T a b l e  2 ) . 
T h e  i n t e n s e  c r o s s - p e a k s  f r o m  th e  H 2  p r o t o n s  o f  A 9  a n d  A 2 0  
i n to  th e  C P I  s u b u n i t s ’ H 4 a ,  H 4 A ,  H 4 B ,  H 5 A ,  a n d  H 5 B  
p r o t o n s  ( s h o w n  f o r  A 2 0  in  F ig u r e  9 ) ,  in  a d d i t i o n  to  s t r o n g  
c o n n e c t i v i t e s  i n t o  th e  H 2  a n d  m e t h y l  r e s o n a n c e s  o f  th e  C P I  
s u b u n i t s  ( A  a n d  B  in  F ig u r e  1 0 ) , c o n f i r m  t h a t  A 9  a n d  A 2 0  
a r e  t h e  c o v a l e n t ly  m o d i f i e d  a d e n in e s .  C r o s s - p e a k s  a r e  n o t  
o b s e r v e d  f r o m  t h e  d u p le x  p r o t o n s  w i t h i n  th e  b a s e  o f  th e  
m i n o r  g r o o v e  to  th e  l i g a n d  a r o m a t ic  p r o t o n s  H 7 ,  H 7 ' ,  a n d  
H 8 '.  H o w e v e r ,  w e a k  c r o s s - p e a k s  e x i s t  f r o m  th e  C P I  s u b u n i t  
H 7  a n d  th e  i n d o le  s u b u n i t s  H 7 '  a n d  H 8 '  i n to  d u p l e x  H 4 '  
p r o t o n s  ( T a b l e  2 )  lo c a te d  h ig h  o n  th e  w a l l s  o f  th e  m i n o r  
g r o o v e ,  c o n f i r m in g  t h e  a s s i g n m e n t  o f  th e  l i g a n d  p r o t o n  a n d  
in d i c a t i n g  t h a t  t h e  B iz e l e s i n  is  o r i e n t e d  e d g e  o n  i n to  th e  
m i n o r  g r o o v e .
Proton NMR Studies Indicate the Presence o f  Distortion  
in the Duplex Adduct around the Covalently M odified  
Adenines. I n i t i a l  m o l e c u l a r  m o d e l i n g  s t u d ie s  i n d i c a t e d  t h a t  
in  o r d e r  f o r  th e  B iz e le s in  to  c r o s s - l in k  7  b p  t h e r e  w o u ld  h a v e  
to  b e  a  c o n s i d e r a b l e  a m o u n t  o f  d i s to r t io n  i n t r o d u c e d  in  th e  
D N A . T h e  ‘H - N M R  d a ta  in d ic a te  th a t  th e  m o d i f i e d  a d e n in e s  
( A 9  a n d  A 2 0 )  a n d  th e  5 '- n e i g h b o r i n g  b a s e s  a r e  d i s to r t e d  a n d  
p r o p e l l e r - t w i s t e d ,  w h ic h  r e s u l t s  in  N 3  b e i n g  p u l l e d  t o w a r d  
t h e  c e n t e r  o f  t h e  d u p l e x .  S t r o n g  c o n n e c t i v i t i e s  b e t w e e n  th e  
H 8  o f  t h e  m o d i f i e d  a d e n i n e s  a n d  t h e i r  o w n  H 2 '  a n d  H 2 "  
c a n  b e  o b s e r v e d  f o r  a d e n i n e s  A 9 ,  A 1 9 , a n d  A 2 0 .  H o w e v e r ,  
f o r  t h e  s a m e  b a s e s ,  u n u s u a l l y  w e a k  c o n n e c t i v i t i e s  a r e  s e e n  
b e t w e e n  th e  H 8  p r o t o n s  a n d  t h e i r  r e s p e c t i v e  5 '  H 2 '  a n d  H 2 "  
n e i g h b o r  p r o t o n s  ( A 2 0 ,  A 19 , a n d  A 9  a r o m a t i c  H 8  to  H 2 '  
a n d  H 2 "  c o n n e c t i v i t i e s  a r e  s h o w n  in  F ig u r e  1 0 ) . F u r t h e r ­
m o r e ,  t h e  c r o s s - p e a k s  b e t w e e n  th e  H 8  o f  t h e  m o d i f i e d  
a d e n i n e s  ( A 9  a n d  A 2 0 )  a n d  t h e i r  r e s p e c t i v e  n e i g h b o r s ’ H I '
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F i g u r e  9: NOE connectivities between select adenine H2 protons and the Bizelesin geminal H4A, H4B, H5A, H5B, and H4a protons. (A) 
Contour plot o f the NO ESY data showing the various adenine H2 to ligand H4A, H4B, H5A, H5B, and H4a cross-peaks for the alkylated 
adenine at A20. (B) Relative positions o f the adenine H2 protons (red) and the key protons on the ligand (averaged rMD structure). (0 
Relative intensities o f the adenine H2 connectivities (intense cross-peaks are shown in solid white; less intense cross-peaks, in dashed 
white).
a r e  e x c e p t i o n a l l y  w e a k  a n d  m i s s i n g  in  th e  a r o m a t ic  H 6 /H 8  
to  H I '  w a lk s  f o r  e a c h  o f  t h e  n o n c o m p l e m e n t a r y  s t r a n d s  (A  
a n d  B  in  F ig u r e  7 ) .  T h e  r e l a t iv e  w e a k n e s s  in  th e  c o n n e c ­
t i v i t i e s  b e t w e e n  th e  H 8  a n d  th e  s u g a r  p r o t o n s  o f  th e  
5 '- n e i g h b o r i n g  b a s e  r e f l e c t s  a n  i n c r e a s e  in  d i s t a n c e  r e s u l t i n g  
f r o m  th e  tw i s t  a n d  d i s to r t io n  in  th e  c o v a le n t ly  m o d i f i e d  b a s e s  
a n d  t h e i r  i m m e d i a t e  5 '- n e i g h b o r s  ( s e e  p a n e l s  B  a n d  C  in  
F ig u r e  1 0 ).
Restrained M olecular Dynamics Studies on the Bizelesin  
Cross-Linked Duplex Provide a M odel fo r  Locating the 
Distortion o f  the Duplex and Insight into the Role o f the 
Linker M oiety in Determining the Sequence Specificity o f  
Bizelesin tow ard This Sequence. T h e  in i t i a l  r M D  s tu d ie s  
u s i n g  a  m i n im i z e d  B - f o r m  a d d u c t  a s  a  s t a r t i n g  s t r u c tu r e  
r e p e a t e d ly  f a i l e d  b e c a u s e  th e  d u p l e x  a d d u c t  h a s  a  t e n d e n c y  
to  lo s e  b a s e  p a i r i n g  a t  o n e  o r  b o th  o f  th e  c o v a le n t ly  m o d i f i e d  
a d e n in e s .  O n  th e  b a s i s  o f  th e  e x c h a n g e a b l e  'H - N M R  d a ta ,  
in  w h i c h  i m in o  p r o t o n  s ig n a l s  a r e  o b s e r v e d  f o r  th e  p a i r e d  
th y m in e s  o f  b o t h  c o v a l e n t ly  m o d i f i e d  a d e n in e s ,  a d d i t i o n a l  
d i s t a n c e  a n d  a n g le  r e s t r a i n t s  w e r e  a p p l i e d  to  m a i n t a i n  b a s e  
p a i r in g  a n d  s t a b i l iz e  th e  in i t i a l  s te p s  o f  th e  r M D  c a lc u la t io n s .  
O n c e  th e  in i t i a l  c a l c u l a t i o n s  h a d  b e e n  p e r f o r m e d  a n d  th e  
d u p l e x  a d d u c t s ’ s t r u c t u r e  h a d  s t a b i l i z e d  a t  3 0 0  K , t h e s e  
r e s t r a i n t s  w e r e  r a m p e d  d o w n  o v e r  a  p e r io d  o f  15 p s ,  a n d  th e  
d u p l e x  a d d u c t  w a s  f o u n d  to  b e h a v e  n o r m a l l y ,  m a i n t a i n i n g  
W a t s o n —C r i c k  b a s e  p a i r i n g  t h r o u g h o u t  th e  r e s t  o f  th e  
m o l e c u l a r  d y n a m i c s  s tu d y .
T h e  m o l e c u l a r  d y n a m i c s  s t u d ie s  p r o v id e  an average 
s t r u c t u r e  t h a t  c a n  b e  u s e d  a s  a  m o d e l  to  e x p la in  the unusual 
'H - N M R  d a ta ,  in d ic a t in g  d i s to r t io n  in  th e  d u p le x  adduct. The 
d i s to r t io n  o f  t h e  h e l ix  is  f o c u s e d  a r o u n d  th e  tw o  covalently 
m o d i f i e d  a d e n i n e s  (A 9  a n d  A 2 0 ) .  I n  o r d e r  to  accommodate 
a  l i g a n d  t h a t  is  t o o  s h o r t  t o  s p a n  th e  f iv e  b a s e  pairs between 
th e  t w o  c o v a l e n t ly  m o d i f i e d  a d e n i n e s ,  th e  immediate 5'- 
n e i g h b o r s  a r e  t w i s t e d  t o w a r d  th e  c e n t e r  o f  th e  duplex, thus 
e f f e c t i v e ly  r e d u c i n g  th e  d i s t a n c e  b e t w e e n  th e  cross-linked 
b a s e s .
W i th in  th e  f i r s t  f e w  p ic o s e c o n d s  o f  th e  rM D  study, a strong 
h y d r o g e n  b o n d  is  f o r m e d  b e t w e e n  th e  ca rb o n y l of the 
u r e y le n e  l i n k e r  a n d  th e  e x o c y c l i c  a m in e  o f  the centra! 
g u a n in e  (G 6 ) . T h is  h y d r o g e n  b o n d ,  o n c e  e s tab lish ed , showed 
1 0 0 %  o c c u p a n c y  w i t h i n  t h e  d u p l e x  a d d u c t ,  e v e n  at elevated 
t e m p e r a t u r e s  ( 5 0 0  K ) , a n d  r e s t r i c t e d  th e  m o v em en t of the 
l i n k e r  m o ie ty .  W i th in  th e  a v e r a g e d  s t r u c tu r e ,  the ureylene 
l i n k e r  w a s  f o u n d  to  b e  t w i s t e d  to  a l m o s t  9 0 °  ou t of plane 
f r o m  th e  tw o  i n d o le  r in g s  f l a n k i n g  i t  ( 8 4 °  a t  A 9  and 85°at 
A 2 0  e n d s ) .  T h i s  p r o v i d e s  th e  m o l e c u l e  w ith  a curved 
c o n f o r m a t i o n  c l o s e l y  f i t t in g  th e  s h a p e  o f  th e  m inor groove 
o f  t h e  D N A . T h e  c a r b o n y l  o f  th e  u r e y le n e  linker was in 
e x a c t l y  th e  s a m e  p la n e  a s  th e  c e n t r a l  g u a n in e  (G6) in the 
a d d u c t ,  g i v i n g  h y d r o g e n - b o n d i n g  d i s ta n c e s  to  the  exocydic 
—N H t o f  1 .5 6  A  t o  th e  n o n - h y d r o g e n - b o u n d e d  proton and 
2 .4 8  A  to  th e  p r o t o n  i n v o l v e d  in  b a s e  p a i r in g .  S ince both of 
t h e s e  d i s t a n c e s  a r e  w i th in  th e  n o r m a l  h y d ro g e n -
i
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Mure 10: Connectivities between the base H8 protons (A 20 and A 19) and the H2' and H2" o f the associated sugar and the sugar o f the 
[inmediate 5'-neighbor. (A) Contour plot o f the NOESY data showing the adenine H8 (A20, A 19, and A9) to sugar H2" and H2" protons. 
BlRelauve positions of the adenine H6/H8 protons o f the T18 to A 20 bases (red) and the H2' and H2" sugar protons (red) (averaged rMD 
juncture). (C) Relative intensities o f the adenine H8 connectivities (intense cross-peaks are shown in solid white; less intense cross-peaks, 
|3 clashed gray).
(1 .0 -2 .5  A ) ,  a n  u n b a l a n c e d  t h r e e - c e n t e r  d o n o r — 
ito r-donor a r r a n g e m e n t  c o u l d  b e  e n v i s a g e d ,  a l t h o u g h  
lie significance o f  t h e  lo n g e r  b o n d  w o u ld  b e  m in im a l .  T h e r e  
isalso a second t r a n s i e n t  h y d r o g e n  b o n d  b e t w e e n  th e  a m i d o  
protons of the u r e y le n e  l i n k e r  a n d  th e  d e o x y r ib o s e  o x y g e n  
of thymine (T 1 8 ) .  H o w e v e r ,  t h e  s i g n i f i c a n c e  o f  th i s  
iydrogen b o n d  is  u n c le a r ,  b e c a u s e  t h e  h y d r o g e n  b o n d  
knee is r e la t iv e ly  l a r g e  a n d  t h e  d e o x y r ib o s e  o x y g e n  is  a  
vely p o o r h y d r o g e n  b o n d  a c c e p to r .
The last 50  p s  ( 3 0 0  K )  o f  th e  r M D  c a l c u l a t i o n  w a s  
raged  to g iv e  th e  s t r u c t u r e  s h o w n  in  F ig u r e  1 1 ; t h e  i n s e r t  
ihows the cen tra l t h r e e  b a s e s  a n d  t h e  h y d r o g e n  b o n d  f o r m e d
b e tw e e n  th e  c a r b o n y l  in  th e  u r e y le n e  l in k e r  a n d  th e  e x o c y c l i c  
a m i n o  g r o u p  o f  t h e  c e n t r a l  g u a n i n e  (G 6 ) .
D I S C U S S I O N
O n e -  a n d  t w o - d i m e n s i o n a l  ‘H -  a n d  13C - N M R  a n a l y s e s  o f  
th e  c r o s s - l in k e d  B iz e l e s i n  a d d u c t  r e v e a l  t h a t  a  7 - b p  r e g io n  
o f  th e  c e n t r a l  d u p l e x  r e g io n  is  c r o s s - l in k e d  to  y i e l d  o n e  
a d d u c t  s p e c ie s  in  w h i c h  n o r m a l  W a t s o n —C r i c k  b a s e  p a i r i n g  
is  m a in ta in e d .  N O E  c o n n e c t iv i t i e s  b e tw e e n  n o n e x c h a n g e a b le  
p r o t o n s  o n  t h e  b o u n d  l i g a n d  a n d  th e  d u p l e x  d e t e r m in e  b o t h  
th e  l o c a t i o n  a n d  o r i e n t a t i o n  o f  t h e  d r u g  w i t h i n  t h e  m i n o r  
g r o o v e  a n d  i n d i c a t e  t h a t  t h e  l i g a n d  is  b o u n d  e d g e  o n  in to
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F i g u r e  1 1 : Stereo figures showing the average structure from the last 50 ps o f the rMD calculation for the Bizelesin 11-mer duplex addic 
(300 K). Bizelesin is shown in yellow , the duplex is shown in cyan and magenta, and the modified adenines are shown in red (tijlf 
Expansion shows the hydrogen bonds (green) between the carbonyl o f the ureylene linker and the protons on the exocyclic aminei 
guanine (G6) (bottom).
t h e  m i n o r  g r o o v e  ( F ig u r e  1 1 ). I n  a d d i t i o n ,  t h e  a d e n i n e  H 2  
c o n n e c t iv i t i e s  in to  th e  p r o to n s  o n  th e  u r e y le n e  l in k in g  m o ie ty  
a n d  B iz e l e s i n  m e th y l  p r o t o n s  c o n f i r m  th e  lo c a t i o n  o f  t h e  
c o v a l e n t ly  m o d i f i e d  a d e n i n e s  a n d  t h e  s i te  ( N 3 )  o f  c o v a l e n t  
a t t a c h m e n t .  T h e  c h e m ic a l  s h i f t s  f o r  th e  t w o  C P I - p h e n o l  
p r o t o n s  in d i c a t e  a n  a b s e n c e  o f  h y d r o g e n  b o n d i n g  i n to  th e  
p h o s p h a te  b a c k b o n e  in  th i s  d u p le x  a d d u c t .  T h is  is  in  c o n t r a s t  
t o  p r e v io u s  s tu d ie s  u s in g  ( + ) - C C - 1 0 6 5  ( L in  e t  a l . ,  1 9 9 1 )  a n d  
B iz e le s in  ( T h o m p s o n  &  H u r le y ,  1 9 9 5 ) , in  w h ic h  th e  p h e n o l ic  
p r o t o n s  o n  t h e  C P I  s u b u n i t  a r e  s h i f t e d  d o w n f ie ld  a s  a  r e s u l t  
o f  h y d r o g e n  b o n d i n g  in to  t h e  p h o s p h a t e  b a c k b o n e .
B iz e l e s i n  c r o s s - l in k i n g  s i te s  c a n  b e  c o n v e n i e n t ly  d i v i d e d  
i n t o  t h r e e  c a t e g o r i e s .  T h e  f i r s t  is  t y p i f i e d  b y  t h e  s e q u e n c e
5 '- T A A T T A * - 3 '  a n d  r e p r e s e n t s  a  s e r ie s  o f  c r o s s - l in k  s i te s  
in  w h i c h  6  b p  a r e  c r o s s - l in k e d .  S tu d ie s  w i th  t h e  s e q u e n c e  
5 ' - T A A T T A * - 3 '  i n d i c a t e d  t h a t  t h e  c e n t r a l  A *T b a s e  p a i r s  
w e r e  t r a p p e d  in to  H o o g s t e e n  a n d  o p e n  b a s e - p a i r  c o n f o r m a ­
t i o n s ,  a l t h o u g h  t h e r e  is  n o  e v i d e n c e  t h a t  t h i s  is  a  c o m m o n  
f e a t u r e  in  a l l  6 - b p  c r o s s - l in k e d  s e q u e n c e s .  T h e  s e c o n d  t y p e  
o f  s e q u e n c e  c r o s s - l in k e d  b y  B iz e le s in  c o n ta in s  a d e n i n e  t r a c t s
( e .g . ,  5 '- T A A A A A * - 3 ') .  T h e s e  h i g h l y  r e a c t i v e  s i te s ,  w h e n  
c r o s s - l in k e d  b y  B iz e le s in ,  l o s e  th e  in t r in s ic  b e n d in g  o b s e r v e d  
w i t h i n  t h e  u n m o d i f i e d  d u p l e x e s  ( T h o m p s o n  e t  a l . ,  1 9 9 5 ;  
T h o m p s o n  &  H u r le y ,  1 9 9 5 ) .  T h e  t h i r d  g r o u p  o f  s e q u e n c e s  
c o n t a in s  t w o  a d e n i n e s  7  b p  a p a r t ,  a n d  a  r e p r e s e n ta t iv e  o f
this group is studied here. In most of these 7-bp sequeiml 
the two adenines cross-linked represent the only posdn 
cross-link site (i.e., no 6-bp site available). Others, like Am 
sequence studied here, contain possible 6- or 7-bp crosJ 
link sites, and due to structural features within the sequenctl 
the 7-bp sequence is targeted in overwhelming preference! 
to the potential 6-bp site.
This study demonstrates the importance of the centralGC| 
base pair in the formation of the 7-bp cross-link in 4cI 
sequence 5'-TTAGTTA-3'. We also address the nature™ 
the distortion of the duplex that is required for the 7-bp a® I  
link to form and propose a possible mechanism forH 
formation of the 7-bp cross-link in the sequence.
Distortion around the Covalently Modified Adenmbimj 
to a Reduction in the Distance between the CroiJ-finlmL 
Bases, Allowing Bizelesin To Form the Extended Cms-UM̂  
Previous NMR and molecular modeling studies havesln 
that the Bizelesin molecule is almost the exact length reqiij 
to cross-link two adenines 6 bp apart (Seaman & HtiktJ j 
1993; Thompson & Hurley, 1995). On the basis of M j 
observation, it was clear that, in order for the ligand tocrosl 
link 7 bp, distortion would have to be induced into™ 
duplex. Analysis of the NMR data provides evidence m  
distortion around both of the covalently modified adeooAg 
(A9 and A20). These adenines are pulled toward thecal
Kzelesin [d(CGTT AGTT ACG)*d(CGT A ACT A ACG) ] Adduct
jf the duplex, r e s u l t in g  in  a  h ig h  d e g r e e  o f  p r o p e l l e r  tw i s t  
j i n  the d ru g -m o d ifie d  b a s e  p a i r s .  T h is  b a s e - p a i r  d i s to r t io n  
5 also clearly t r a n s m i t t e d  to  t h e  i m m e d i a t e  in t e r n a l  b a s e  
<m, particularly a d e n in e  A 19 , w h ic h  a p p e a r s  to  b e  s t a c k e d  
Mow the tw is te d  a d e n in e  A 2 0 .  F r o m  th e  m o l e c u l a r
E cs s tudy  i t  is  c l e a r  t h a t  t h e  c o v a l e n t ly  m o d i f i e d  
:s are p u l le d  in to  t h e  m i n o r  g r o o v e  a n d  t o w a r d  th e  
of the d u p le x , d e c r e a s in g  t h e  d i s t a n c e  b e t w e e n  th e  
ass-linking s ite s  b y  a r o u n d  h a l f  a  b a s e  p a i r .  T h i s  e f -  
atively reduces th e  d i s ta n c e  b e t w e e n  th e  r e s p e c t i v e  N 3 s  
tfeach m od ified  a d e n in e  t o  a b o u t  t h a t  f o u n d  in  t h e  6 - b p  
Kss-linked a d d u c ts .  T h e  i n d u c e d  d i s to r t io n  m a y  b e  r e -  
(onsible for th e  s u b s e q u e n t  d i s r u p t io n  o f  h y d r o g e n  b o n d i n g  
wmally seen b e tw e e n  th e  C P I - p h e n o l  p r o t o n  a n d  th e  
ksphate b a c k b o n e  in  t h e  d u p l e x  a d d u c t .  I f  t h e  l i g a n d  is  
by a r o u n d  h a l f  a  b a s e  p a i r  a t  e i t h e r  e n d  o f  th e  
|lex adduct, h y d r o g e n  b o n d i n g  w o u l d  n o  l o n g e r  b e  
because  th e  p h e n o l i c  p r o t o n  w o u l d  b e  p o s i t i o n e d  
| |  die sugar r a th e r  t h a n  th e  p h o s p h a t e  o f  t h e  b a c k b o n e .  
muence Selectivity Studies Reveal That the Central 
mine Is Essential in the Formation o f  a 7-bp Cross-Link 
0i This Sequence. A l th o u g h  th e  d i s to r t io n  in  th e  m o d i f i e d  
explains h o w  B iz e l e s i n  is  a b l e  t o  c r o s s - l in k  th e  
d is ta n c e  in  a  7 - b p  s e q u e n c e ,  i t  d o e s  n o t  im -  
Kdiately rev ea l a  m e c h a n i s m  t h a t  e x p l a in s  h o w  t h e  7 - b p  
loss-link is fo r m e d  in preference t o  th e  m o r e  u s u a l  6 - b p
loss-linked a d d u c t  ( i .e . ,  5 '- T T A G T T A *  r a th e r  th a n  5 '-
ITAGTTA*; s e e  F ig u r e  3 ) . T h e  c r i t i c a l  im p o r t a n c e  o f  th e  
wine (G6) in  th e  c e n te r  o f  th e  7 - b p  c r o s s - l in k e d  s e q u e n c e  
(demonstrated in  th e  g e l  e le c t r o p h o r e s i s  s tu d ie s .  R e p la c in g  
Sc central g u a n in e  (G 6 )  w i th  a n  a d e n i n e  r e s u l t s  i n  a  6 - b p  
ross-link fo rm e d  b e t w e e n  t h e  e q u i v a le n ts  o f  a d e n i n e  A 9  
|adenine A 19. F u r th e r m o r e ,  r e p la c e m e n t  o f  t h e  g u a n i n e  
siiinosine re s u lts  in  a  m i x tu r e  o f  a b o u t  e q u a l  a m o u n t s  o f  
It6-and 7 -b p  c r o s s - l in k e d  s e q u e n c e s  ( F ig u r e  4 ) .  T h e s e  
s d em onstra te  t h a t  i t  i s  t h e  e x o c y c l i c  2 - a m i n o  g r o u p  
anine lo c a te d  in  th e  m i n o r  g r o o v e  o f  D N A  th a t  
ntly fa c i l ita te s  t h e  a b i l i t y  o f  th e  B iz e l e s i n  t o  d i s to r t  
fe sequence s o  th a t  a  7 - b p  c r o s s - l in k  c a n  b e  a l m o s t  
dusively a c h ie v e d .
Ihe m olecular d y n a m ic s  s tu d ie s  o n  t h e  B iz e l e s i n  c r o s s -  
i d  7-bp d u p le x  a d d u c t  i n d i c a t e  t h a t  a  s t a b le  h y d r o g e n  
id  is quickly f o r m e d  b e t w e e n  th e  c a r b o n y l  o f  th e  u r e y le n e  
ierand the e x o c y c l ic  a m in e  o f  t h e  c e n t r a l  g u a n i n e  w i t h i n  
ieduplex a d d u c t ( F ig u r e  1 1 , b o t to m ) .  W e  p r o p o s e  th a t  th e  
(nation and s ta b il ity  o f  th is  h y d r o g e n  b o n d  p r o v id e s  c r i t ic a l  
t into th e  o r ig in  o f  t h e  s e q u e n c e  p r e f e r e n c e  f o r  th i s  
g u a n in e -c o n ta in in g  s e q u e n c e .  P r i o r  t o  c r o s s - l in k  
nation, a m o n o a d d u c t  m u s t  b e  f o r m e d  w i t h  a l k y l a t i o n  a t  
ather A9 or A 2 0 . T h e  g e l  e l e c t r o p h o r e t i c  s tu d ie s  s h o w  th a t  
b monoalkylating ( + ) - C C - 1 0 6 5  a n a l o g s  [ A d o z e l e s i n  a n d  
t)-AB] have a  s e q u e n c e  p r e f e r e n c e  f o r  5 '- T T A *  a n d  d o  
stalkylate 5 '-T A A *  ( s e e  F ig u r e  5 ) .  T h e r e f o r e ,  t h e  5 '- T T A *  
sequence is th e  p r e s u m e d  s i te  o f  t h e  m o n o a l k y l a t i o n  p r i o r  
iSfoss-linking, w h ic h  s u b s e q u e n t ly  o c c u r s  v e r y  r a p id ly  ( s e e  
Figure 6). O n c e  t h e  m o n o a l k y l a t e d  B iz e l e s i n  a d d u c t  h a s  
, the c a rb o n y l o f  th e  u r e y le n e  l i n k e r  w i l l  b e  p o s i t io n e d  
a the minor g ro o v e  c lo s e  to  th e  e x o c y c l i c  2 - a m i n o  g r o u p
! It is at this step that we propose the H-bonding between the 
■phenolic proton of the CPI moiety and the phosphate involved in 
kinitial catalysis (Lin et al., 1991) is lost.
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o f  t h e  c e n t r a l  g u a n i n e  ( G 6 ) .  H o w e v e r ,  o n  th e  b a s i s  o f  th e  
m o d e l  o f  th e  B iz e le s in  m o n o a lk y la t e d  d u p le x  a d d u c t ,  w i th o u t  
d i s to r t io n  a r o u n d  t h e  c o v a l e n t ly  m o d i f i e d  a d e n i n e  ( A 9 ) ,  t h e  
l i n k e r  w o u l d  n o t  b e  p o s i t i o n e d  d i r e c t ly  o v e r  th e  e x o c y c l i c  
2 - a m in o  g ro u p .  A s  th e  h y d r o g e n  b o n d  b e t w e e n  th e  u r e y le n e  
c a r b o n y l  a n d  t h e  e x o c y c l i c  a m in o  g r o u p  o f  g u a n i n e  is  
f o r m e d ,  B iz e l e s i n  is  p u l l e d  d o w n  th e  m i n o r  g r o o v e ,  p r o d u c ­
in g  d i s to r t io n  in  th e  m o d i f i e d  a d e n i n e .3 T h e  d i s to r t io n  
p r o d u c e d  a t  a d e n i n e  A 9  w o u l d  th e n  m i m i c  t h a t  o b s e r v e d  in  
t h e  c r o s s - l in k e d  a d d u c t  a n d  w o u l d  c o n s e q u e n t l y  p o s i t i o n  th e  
s e c o n d  a l k y l a t i n g  C P I  m o i e t y  c l o s e r  to  a d e n i n e  A 2 0  th a n  to  
A 19 , t h u s  l e a d in g  t o  th e  p r e f e r e n t i a l  f o r m a t io n  o f  a  7 - b p  
r a th e r  th a n  a  6 - b p  c r o s s - l in k .
T h e  r e s u l t s  o f  th i s  s tu d y  c o u p le d  w i th  th o s e  o f  t h e  p r e v io u s  
s tu d y  ( S e a m a n  &  H u r le y ,  1 9 9 3 )  o f  th e  B iz e l e s i n  d u p l e x  
a d d u c t  f o r m e d  w i th  5 '- T A A T T A - 3 '  c l e a r l y  i n d i c a t e  t h a t  t h e  
u r e y le n e  l i n k e r  c a n  p l a y  a  c r i t i c a l  r o l e  i n  t h e  s e q u e n c e  
s e le c t iv i ty  o f  B iz e le s in .  W i th in  th e  5 '- T A A T T A - 3 ' s e q u e n c e ,  
i n h e r e n t  in s ta b i l i ty  w i th in  th e  c e n t r a l  A*T b a s e s  l e a d s  to  b a s e -  
p a i r  o p e n in g .  O n c e  t h e s e  b a s e  p a i r s  a r e  o p e n e d ,  h y d r o g e n  
b o n d i n g  b e t w e e n  t h e  u r e y le n e  l i n k e r  a m id o  p r o t o n s  a n d  th e  
b a s e s  s t a b i l i z e s  t h e  n o r m a l l y  t r a n s i e n t  H o o g s t e e n  a n d  o p e n  
b a s e - p a i r  c o n f o r m a t i o n s .  I n  p a r a l l e l ,  t h e  p r e s e n t  s tu d y  o f  
th e  d u p l e x  a d d u c t  f o r m e d  w i th  5 '- T T A G T T A - 3 '  a l s o  d e m ­
o n s t r a t e s  t h e  i m p o r t a n c e  o f  u r e y le n e  l i n k in g  in  in t e r a c t i o n  
w i th  t h e  c e n t r a l  g u a n i n e  in  th e  f o r m a t io n  o f  t h e  7 - b p  c r o s s ­
l in k .  I n  c o n t r a s t  t o  t h e s e  s e q u e n c e s ,  i n  w h i c h  t h e  u r e y le n e  
l i n k a g e  p l a y s  a n  i m p o r t a n t  s t a b i l i z i n g  H - b o n d in g  r o le ,  th e  
u r e y le n e  l i n k a g e  a p p e a r s  to  p l a y  m e r e ly  a  s p a c e r  r o l e  in  
A - t r a c t  s e q u e n c e s .  O n  th e  b a s i s  o f  th e s e  o b s e r v a t io n s ,  i t  m a y  
b e  p o s s ib le ,  b y  t h e  c a r e f u l  c h o ic e  o f  l i n k e r s ,  t o  s u b t ly  c h a n g e  
th e  s e q u e n c e  s p e c i f i c i ty  a n d  r e a c t i v i t y  o f  th e s e  d im e r i c  
c o m p o u n d s ,  w i th  r e s u l t i n g  m o d u l a t i o n  o f  b i o l o g ic a l  c o n s e ­
q u e n c e s .  T h e  s e q u e n c e  s p e c i f i c i ty  o f  o t h e r  c r o s s - l i n k i n g  
C P I s  w i th  d i f f e r e n t  l i n k e r s  w i l l  b e  r e p o r t e d  in  d u e  c o u r s e .
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The DNA cross-linker bizelesin has been previously shown to form 
interhelical interstrand cross-links with adenine residues six base-pairs apart 
(including the modified adenine residues). Sequence specificity studies have 
shown that the ligand has a high affinity for the intrinsically bent A-tract 
sequence [d(CGTTTTTACG):rf(CGTAAAAACG)]. However, gel retardation 
studies have shown that the cross-linked duplex retains none of the 
characteristic A-tract bending observed within the unmodified duplex. 
Two-dimensional ’H-NMR experiments have not only confirmed the sites of 
cross-linking into the duplex, but have also shown the loss of inherent A-tract 
characteristics, including reduced crosspeak intensities between the H2s of 
the central adenine residues and the cross-strand HI' of the base one base 
removed to the 3' side. This observation suggests loss of propeller twisting 
within these central adenine residues and provides insight into the 
controversial origin of A-tract bending. This study is important because it 
validates the use of bizelesin as a probe for determining the importance of 
A-tract-induced bending in transcriptional and replicational elements.
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Introduction
(+)-CC-1065 is an extremely potent antitumor 
antibiotic isolated from Streptomyces zelensis by 
scientists at The Upjohn Co. (Figure 1; Hanka et al., 
1978; Hurley & Draves, 1993). Previous studies have 
shown that the potent cytotoxic and antitumor 
activities of (+)-CC-1065 are due to the ability of this 
compound to covalently modify DNA (Li et al., 1982; 
Martin et al., 1981). From SAR studies with a series 
of (+)-CC-1065 analogs, it appears that the alkylating 
cyclopropa[c]pyrrolo[3,2-e]-indol-4(5H)-one (CPI) 
subunit alone contains sufficient structural infor­
mation to encode for sequence selectivity and 
produce bending of DNA (Hurley et al., 1988). 
Substituents upon the non-alkylating subunits are 
believed to fine-tune the sequence selectivity and, in 
the case of (+)-CC-1065, produce winding of the
A b b r e v i a t i o n s  u s e d :  N O E , n u c l e a r  O v e r h a u s e r  e f fe c t; 
N O E S Y , tw o - d i m e n s i o n a l  N O E  c o r r e la te d  s p e c tr o s c o p y ;  
C O S Y , c o r r e l a t e d  s p e c t r o s c o p y ;  H D ,  f r e e  in d u c t io n  
d e c a y ;  D M F , d im e th y l f o r m a m id e ;  H P L C , h ig h -  
p e r f o r m a n c e  l i q u i d  c h r o m a to g r a p h y ;  M W C O , m o le c u la r  
w e ig h t  c u t -o f f ;  C P I ,  c y c lo p r o p a  [c ] p y r r o lo [3 ,2 -e  ] - in d o l-  
4 (5 H ) -o n e ;  S A R , s t r u c t u r e  a c t iv i ty  r e la t io n s h ip s ;  rM D , 
r e s t r a i n e d  m o l e c u l a r  d y n a m ic s .
DNA (Hurley et al., 1988; Warpehoski & Hurley 
1988). The winding of the DNA by (+)-CC-1065 has 
been associated with the ethano bridges of non­
alkylating subunits of (+)-CC-1065 (Lee et al., 1991), 
and these characteristics are also believed to be 
responsible for the delayed lethality observed with 
(+)-CC-1065 (McGovren et al., 1984; Warpehoski & 
Bradford, 1988). Compounds that lack the ethano 
bridges are considerably more efficacious than 
(+)-CC-1065, and several of these are undergoing 
evaluation as clinical antitumor antibiotics (Li et al., 
1990; Aristoff & McGovren, 1993).
Bizelesin (formerly U77,779, The Upjohn Co.; 
Figures 1 and 2) is a bifunctional DNA cross-linking 
antineoplastic agent, containing two open cyclo- 
propyl ring analogs of the (+)-CC-1065 CPI subunit. 
These two alkylating moieties are connected via a 
rigid linker that consists of two indole units joined by 
a ureadyl linker. Bizelesin generally forms inter­
strand cross-links with adenine residues spaced six 
base-pairs apart (including the covalently modified 
adenine residues) while occupying the intervening 
minor groove (Figure 2; Mitchell et al., 1991; Ding & 
Hurley, 1991). Previous gel electrophoresis studies 
have shown several preferred sequences for the 
formation of DNA-DNA interstrand cross-links 
(Sun & Hurley 1993; Lee & Gibson, 1993a,b). The
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most preferred sequence spans six nucleotides and 
mimics the sequence preference for the mono­
alkylating (+)-CC-1065 analogs. This preferred 
target sequence contains two 5'-TTA*-3' sequences 
(^indicates the covalently modified base) within 
the six base-pair cross-link site 5’-TAATTA*-3'. 
Quite unexpectedly the NMR studies on a bizelesin 
cross-linked adduct formed with this sequence have 
indicated the presence of two adduct conformations, 
both containing unusual base-pairing within the 
central A T bases (Seaman & Hurley, 1993 and 
unpublished results). In the first case (40% of the 
species), the base-pairs are arranged in an open 
conformation, contrasting to the second case (60% of 
the species), in which the bases are Hoogsteen 
base-paired. The unexpected conformations ob­
served within this cross-linked sequence are 
proposed to be partially the result of the unusually 
low base-pair stability at the A-T step in the 
unmodified duplex, and it has been suggested that 
bizelesin may trap out and stabilize the "open" and 
Hoogsteen conformations prior to cross-link for­
mation (Seaman & Hurley, 1993 and unpublished 
results). A second most-preferred cross-linking 
sequence is the intrinsically bent A-tract-containing 
sequence 5'-TTTTTA*-3'. This study focuses on the 
structure of the cross-linked adduct formed between 
bizelesin and a 10-mer containing this A-tract 
sequence and rationalizes the previous observations 
made from PAGE experiments that show that upon 
cross-link formation the intrinsic bending observed 
within the unmodified A-tract is eliminated.
Results
Duplex base and deoxyribose 
non-exchangeable 1H-NMR assignments
The general strategy for 1 H-NMR assignments of 
the non-self-complementary duplex and its cross- 
linked bizelesin adduct was as outlined in previous 
(+)-CC-1065 and bizelesin studies (Lin et al., 
1991; Seaman & Hurley, 1993). ’H-NMR signals 
were assigned following characterization of the 
’H-NOESY cross-connectivity networks. Within the
cross-connectivity network, PyH6/PuH8 protons 
are linked to each other and to sugar HP (Figure 3A, 
10-mer duplex; Figure 3B, 10-mer duplex adduct), 
H2', H2", H3', and H4' and, by extending the 
connectivity via HI', H3', and H4', to sugar H5' and 
H5". In the latter instance, difficulty in unambigu­
ously assigning H5' and H5" led to the designation 
of the downfield member of the pair as H5". For both 
the duplex and the duplex adduct, the NMR data 
indicate a single and complete aromatic to HI' 
walk for each of the non-complementary strands, 
indicating that the duplex adduct formed is a single 
conformation. Adenine H2 protons were assigned 
based on their diagnostic patterns of crosspeaks to 
neighboring adenine H2 protons, the HI' signals 
from neighboring nucleotides, and the thymine H3 
signal from the paired base. This cross-connectivity 
pattern of adenine H2 permits an unambiguous 
assignment of these six important probes of minor 
groove environment. Thymine methyl signals and 
cytosine H5 signals were then assigned via 
connectivities to the thymine H6 and cytosine H6 in 
both NOESY and COSY spectra. A summary of these 
’H-NMR assignments in this duplex and the 
bizelesin duplex adduct is shown in Table 1A, and 
chemical shift changes of individual protons upon 
adduct formation are shown in brackets.
Bizelesin non-exchangeable 
1H-NMR assignments
Non-exchangeable ’H-NMR signals for the bize­
lesin molecule are divisible into those found within 
the two (+)-CPI-subunits and those within the two 
indole-subunit clusters, although, due to the 
symmetry of the ligand, several of the signals from 
the two ends of the bizelesin are overlapped. Many 
of the bizelesin protons are located on the inside edge 
of the bound ligand, with respect to the minor 
groove, and these generate numerous bizelesin 
to DNA NOESY crosspeaks (see later). COSY 
crosspeaks allow assignment of the ortho-related 
aromatic protons, and NOEs (H2O) between indole 
HI' and neighboring H8' confirm the H7' and H8' 
assignments (Table IB). The aromatic H7 protons are
,nh2
‘oh







Figure 1. Structures of (+)-CC- 
1065 and the cross-linking analog 
bizelesin.
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Figure 2. Cyclization of bizelesin to give the cyclopropyl derivative followed by the reaction of adenine residues A8 
and A18 on the opposite DNA strands to form the interstrand cross-linked duplex adduct (including numbering systems 
for duplex and bizelesin used in the high-field NMR study).
assigned by elimination and their weak connectivi­
ties into H4' of the covalently modified adenines.
Duplex and bizelesin exchangeable 
1H-NMR assignments
Two-dimensional NOE experiments in 90% 
H2O/10% 2H20  were conducted, and the exchange­
able imino signals were assigned based upon their 
connectivity networks into the aromatic region and 
connectivities into the imino protons of the 
neighboring bases (Table 1A). All exchangeable 
imino signals for the DNA were detected except for 
those associated with the terminal bases, G10 and 
G20, in both the duplex and the duplex adduct. The 
imino signals for T3 and T13 are significantly
upfield-shifted within the duplex adduct relative to 
the duplex, in part confirming the location of the 
covalently modified adenine residues (Figure 4A 
and B). Variations between the chemical shifts for 
these two signals in the duplex adduct are due to the 
different base-base stacking within the sequence, the 
T13 imino proton being stacked over A14, and hence 
the signal is upfield shifted. The NH1 and indole 
NH1' of the CPI subunits at either end of the ligand 
were assigned based on connectivities to the H2 of 
the CPI subunits and the H8' of the indole subunits, 
respectively. Signals for the two CPI-phenol sub­
stituents are tentatively assigned by elimination, 
since neither shows any connectivities into either the 
ligand or duplex protons (Figure 4B). The unusual 
downfield shifts for the two phenol signals are 
similar to the shift observed in the previously
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studied (+)-CC-1065 duplex adduct (Lin et al., 1991). 
The dow n field shifts for the phenol in this 
(+)-CC-1065 duplex adduct w ere associated w ith a 
hydrogen bonding system  involving a backbone 
phosphate, the CPI phenol moiety, and  a trapped  
w ater m olecule. Based upon  the downfield shifts 
observed for the phenolic protons in this bizelesin 
duplex adduct, it w ould appear that these are also 
involved in a sim ilar hydrogen bonding. Signals for 
the am ide N H  protons w ith in  the u n ready! linking 
m oiety could not be found. This contrasts w ith  
previous studies (Seam an & Hurley, 1993 and
unpublished  results) in w hich these protons w ere 
involved in stable hydrogen bonding system s, and a 
series of intense crosspeaks w ere observed. W ithin 
the A -tract there are no suitable hydrogen bond 
acceptors w ith in  the p roxim ity  of the linking moiety, 
and  rM D studies (see later) have indicated  that there 
is alm ost free m ovem ent of the un ready l linker 
system . This free m ovem ent and  the resulting 
constantly  changing environm ent w ith in  the linker 
w ould alm ost certainly lead to u nusually  broad  
signals for these am ido protons and  explains why 
they are not observed.
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F i g u r e  3 . E x p a n d e d  c o n t o u r  p l o t  o f  t h e  t w o - d i m e n s i o n a l  p h a s e - s e n s i t i v e  N O E S Y  (2 0 0 - m s  m i x in g  t i m e )  o f  t h e  
b i z e l e s in  1 0 - m e r  d u p l e x  (A )  a n d  t h e  b i z e l e s i n  c r o s s - l i n k e d  a d d u c t  (B ) in  b u f f e r e d  2H 20  s o l u t i o n  ( p H  7 .0 )  a t  3 0 0  K , 
d i s p l a y i n g  c o n n e c t i v i t i e s  f o r  a r o m a t i c  P u H 8 / P y H 6  t o  d e o x y r i b o s e  H P  a n d  to  d e o x y r i b o s e  H P  p r o t o n s  o f  t h e  
5 ' - n e i g h b o r  ( s t r a n d  c o n n e c t i v i t i e s  a r e  s h o w n  s e p a r a t e l y  i n  le f t  a n d  r i g h t  p a n e l s ) .  A l s o  s h o w n  in  A  a r e  t h e  a d e n i n e  H 2  
c r o s s - s t r a n d  c o n n e c t i v i t i e s  to  t h e  d e o x y r i b o s e  H P  o f  t h e  3 '- n e i g h b o r i n g  r e s i d u e  o n  t h e  c o m p l e m e n t a r y  s t r a n d  ( b o x e d  g r a y  
a r e a s ) .
Table 1. Chemical shifts for the protons of the bizelesin [d(CGTTTTTACG):d(CGTAAAAACG)] adduct
H8 H6 H2 H5 HI' H2’ H2" H3' H 4’ H57H5" Imino
A. Chemical shifts (ppm) of non-exchangeable protons 
C l —  —  7.6 (-0.01) —
in the [d(CGTTTTTACG):d(CGTAAAAACG)] bizelesin adduct at room temperature1
5.85 (-0.01) 5.75 (+0.00) 2.34 (-0.08) 1.88 (-0.07) 4.68 (+0.00) 4.07 (+0.00) 3.68
G2 7.97 (-0.01) — — — — — — 5.95 (-0.12) 2.68 (-0.17) 2.36 (-0.34) 4.99 (-0.02) 4.37 (-0.02) 4.12 12.90
T3 7.56 (+0.26) 1.74 (+0.30) 6.33 (+0.20) 2.27 (-0.36) 2.70 (+0.52) 4.96 (+0.20) 4.35 (+0.03) N /A c
(-0.54)
14.05
T4 7.54 (+0.05) 1.77 (+0.10) 6.10 (-0.13) 2.48 (-0.19) 2.17 (-0 .03) (-0.21) 3.85 (-0.38) N /A
(-2.09)
14.04
T5 7.37 (-0.12) 1.66 (+0.00) 6.20 (+0.00) 2.30 (-0.37) 2.05 (-0.19) 4.62 (-0.30) 3.35 (-0.88) 2.70/3.28
(+0.84)
13.87
T6 7.13 (-0.33) 1.52 (-0.14) 5.65 (-0.45) 2.35 (-0.27) 1.73 (-0.44) 4.45 (-0.46) 1.54 (-2.80) 3.35/2.43
(+0.25)
13.78
T7 7.15 (-0.22) 1.52 (-0.21) 5.12 (-0.61) 1.83 (-0.62) 1.83 (-0.25) 4.60 (-0 .32) 4.17 (+0.05) 4.07
(+0.24)
13.50
A8 8.40 (+0.08) 8.08 (+0.38) 5.86 (-0.28) 2.75 (-0.07) 2.68 (-0.01) 4.92 (-0.12) 4.25 (-0.16) 4.28
(+0.52)
C9 — — 7.34 (+0.07) — — 5.55 (+0.20) 5.34 (-0.29) 2.14 (-0.12) 1.75 (-0.09) 4.58 (-0 .17) 2.27 (-1 .87) 3.80/3.40 —
G10 7.87 (+0.00) — — — — — — 6.13 (+0.00) 2.64 (+0.10) 2.35 (+0.01) 4.67 (+0.10) 4.25 (+0.10) 4.20/3.80 —
C ll — — 7.60 (-0.02) — — 5.85 (-0.01) 5.74 (-0.02) 2.34 (-0.08) 1.88 (-0.07) 4.67 (-0.01) 4.07 (+0.00) 3.68 —
G12 7.95 (-0.01) — — — — — — 5.83 (-0.10) 2.62 (-0.12) 2.60 (-0.04) 4.95 (-0.01) 4.30 (-0 .10) 4.07 12.77
T13 7.34 (+0.15) 1.70 (+0.20) 5.65 (+0.20) 2.54 (+0.30) 2.27 (+0.35) 4.92 (+0.10) 4.32 (+0.20) N /A
(-0.46)
13.29
A14 8.28 (+0.08) 7.67 (+0.75) 6.00 (+0.20) 2.8 (+0.00) 2.60 (-0.08) 4.92 (-0.10) 4.16 (-0.26) N /A
(-2.17)
A15 7.85 (-0.20) — — 7.67 (+0.73) — — 5.95 (+0.30) 2.53 (-0.25) 2.27 (-0.29) 4.67 (-0.33) 3.26 (-1.09) 3.96/4.07 —
A16 7.4 (-0.57) — — 7.74 (+0.80) — — 5.47 (-0.30) 2.50 — 2.00 — 4.47 (-0.50) 1.69 (-2.65) 3.47/2.35 —
A17 7.74 (-0.20) — — 7.59 (+0.51) — — 5.27 (-0.60) 2.19 (-0.69) 2.19 (-0.31) — (-0.29) 3.85 (-0.55) N /A —
A18 8.16 (+0.23) — — 8.59 (+0.84) — — 5.78 (-0.24) 2.59 (-0.22) 2.59 (+0.16) 4.85 (-0.13) 4.08 (-0.33) 3.85/2.70 —
C l 9 — — 7.30 (+0.20) — — 5.42 (+0.30) 5.35 (-0.29) 2.14 (-0.11) 1.78 (+0.01) 4.56 (-0.17) 2.25 (-1.86) 3.35/3.78 —
G20 7.87 (+0.07) — — — — — — 6.13 (+0.00) 2.64 (+0.10) 2.35 (+0.01) 4.67 (+0.00) 4.25 (+0.10) 4.20/3.80 —
B. Proton chemical shifts (ppm) for the bound bizelesin at room temperatureb
Bizelesin CPI and indole sub-unit (linked to adenine 8)
H2 H3Me NH1 H4a H4A H4B H5A H5B H7 H3' H5' H 7’ H8' N H l' NH9'
7.30 2.70 10.27 4.51 4.58 5.07 4.55 5.12 7.83 7.74 7.40 7.98 7.60 11.01 —
H2 H3Me NH1 H4a H4A
Bizelesin CPI and indole sub-unit (linked to adenine 18) 
H4B H5A H5B H7 H3' H5' H7' H8' N H l' NH9'
7.32 2.60 10.27 4.42 4.58 5.12 4.57 5.10 7.83 7.74 7.23 8.09 7.59 11.02 —
a Shifts from duplex shown in italics and underlined if difference is greater than 0.25 ppm.
b Sample was dissolved in 0.5 ml 2H 20 buffer containing 0.1 M sodium  chloride and 10 mM sodium  phosphate (pH 7.0) at 300 K. 
c Not assigned.
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ppm
F i g u r e  4 . O n e - d i m e n s i o n a l  p r o t o n  N M R  s p e c t r a  
P (5 0 0  M H z ;  3 0 0  K , 8 .5  t o  15 p p m ,  d o w n f i e l d  r e g io n )  o f  
t h e  1 0 -m e r  d u p l e x  (A )  a n d  c r o s s - l i n k e d  b i z e l e s i n  
a d d u c t  (F ). T h e  u p f i e l d  s h i f t s  o f  t h e  a m i n o  s i g n a l s  f o r  
t h y m i n e  T 3  a n d  t h y m i n e  T 1 3  a r e  s h o w n .
Bizelesin is attached through N3 of adenine 
at A8 and A18, and the ligand occupies 
the minor groove between these covalently 
modified bases
There are sufficient DNA an d  bizelesin  protons 
and  corresponding interm olecular N O E cross­
peaks resulting from  close contacts w ith in  the m inor 
groove to unam biguously  define the location of the 
ligand and the natu re  of the covalent attachm ent 
(Table 2). The sym m etrical natu re  of the b izelesin 
molecule, how ever, leads to a significant am ount of 
overlap w ith in  the ligand signals. C onnectivities 
be tw een  the adenine H2s along the length  of the 
A-tract into the linker H4A and H4B, the CPI subun it 
H5A and H5B, and  the indole H3' and  H5' confirm  
the location and  orientation of the ligand (Figure 5). 
The intense crosspeaks from  the H2 signals of A8 
and  A18 into the CPI subun it p ro tons H4a, H5A, and  
H5B (Figure 5A) and  H2 and  C H 3, coupled w ith  
strong connectivities into the linker H4A and H4B 
(Figure 5A) protons, confirm  that A8 and  A18 are the 
covalently m odified  adenines. The NOE data from  
Figure 5A are d iagram m atically  represen ted  in 
F igure 5B and  C. C rosspeaks are not observed from  
the duplex pro tons on the floor of the m inor groove 
to the outside edge ligand arom atic p ro tons H7, H7', 
and  H8'. H ow ever, w eak  crosspeaks do exist from  
the CPI subunits  H7 and  the indole su b u n its  H8' and 
H7' into duplex H4' protons (Table 2), w hich are 
located high  on the walls of the m inor groove, 
confirm ing that the ligand is oriented edge-on into 
the m inor groove. The relative in tensities of the NOE 
connectivities b e tw een  the bizelesin and  both 
s trands of the covalently m odified  duplex are 
sum m arized  in Table 2.
The covalently modified adenine residues 
exist in the N6 doubly protonated 
form, as previously observed for a 
(+)-CC-1065 adduct
Previous NM R studies on the duplex adduct of 
(+)-CC-1065 indicated that the covalently m odified 
adenine was present as a positively charged  
(doubly N6 protonated) am ino species, discounting 
previous speculation that the adenine may exist as a 
neutra l N6 im ino form. Bizelesin is covalently  
attached through N3 of adenine at residues A8 
and  A18. C om parison of the A8 and  A18 am ino 
signals in the bizelesin duplex adduct to 
those previously repo rted  w ith in  a (+)-CC-1065 
adduct (Lin et al., 1991) and  a different b izelesin 
cross-linked adduct (Seam an & Hurley, 1993) at 
first indicated that the m odified adenine residues 
m ay be s tructura lly  d ifferent from  those found in the 
above adducts. Rather than  tw o separate signals 
for the tw o am ino protons H6C and  H6b in each 
covalently m odified adenine (9.06 and  9.18 pp m  in 
the (+)-CC-1065 adduct), only an apparent single 
signal is found for each adenine w ith in  the 
exchangeable NOESY (A8-H6b, 8.87 ppm ; A18-H6b, 
8.15 ppm ) observed via NOESY connectivities to 
the H3 of T3 and  T13, respectively (crosspeaks A 
and  B in Figure 6A). These H3 protons of T3 and  
T13 can be easily identified by connectivities into 
the H2 of the paired  adenine residues A8 and A18 
(crosspeaks C and D in Figure 6A). However, 
p reparation  of a second bizelesin adduct w ith  a 
duplex incorporating tw o 13N -labeled adenine 
residues at N6 of A8 and  A18 confirm ed the 
presence of H6b and  H 6e signals for both adenine 
residues via the use of inverse-detected pro ton-nitro- 
gen correlation experim ents (Figure 6B). From  
the latter spectrum  it can be seen that the 
non-bonded H6C signals are both b road  and  close to 
the H6b signals. This observation explains w hy 
the signals for the H 6e are not visible in the 
exchangeable NOESY spectra either directly  or via a 
NOESY crosspeak to the H6b signals. This study, 
a lthough supporting  the presence of a doubly  
pro tonated am ino system  in both of the covalently 
m odified adenine residues, indicates that the 
sharper upfield signal is the hydrogen-bound H 6b, 
w hile the broader signal is the unbo u n d  H6e. It is 
reasonable to assum e that the paired  thym ine N3 
am ino signal w ould show  m ore intensely into the 
hydrogen-bound H6b, and  since only one am ino 
signal is observed in the NOESY data, then this 
signal m ust be H6b. In the previous (+)-CC-1065 
adduct (Lin et al., 1991), the dow nfield and  b roader 
of the tw o am ino signals was assigned as the 
hydrogen-bound H6b, and  it was proposed  that the 
broad  natu re  of this signal w as the resu lt of a bound  
w ater molecule. This s tu d y  appears to contradict the 
above m odel, although due to the b roadness of the 
am ino signals and  overlap into the non-exchangeable 
arom atic protons, w e w ere unable to repeat the NM R 
experim ents to look for bound  w ater m olecules 
w ith in  this adduct.
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Watson-Crick base-pairing is maintained within 
the bizelesin adduct
Previous studies on the bizelesin adduct w ith  the 
duplex [d(CGTA^TA*CG):d(CGTAATTA*CG)l in ­
dicated that the central A-T bases (underlined) are 
present in  tw o discrete forms. A "base-pair open" 
arrangem ent and a "H oogsteen  base-pairing" w ere 
observed, a lthough it appears from  the NM R data 
that there  is no exchange b e tw een  the tw o 
cross-linked conform ations. The presence of Hoogs­
teen base-pairs can be v isualized  w ith in  the NM R 
NOESY data by strong connectivities be tw een  the 
adenine H2 signals of the H oogsteen-paired  bases 
and  substituen ts from  neighboring bases w ith in  the 
major groove. (Adenine H2 protons are found deep  
w ith in  the m inor groove in W atson-Crick base-pair­
ing.) The arom atic H 6 /H 8  of the m odified bases will 
also be  in a different environm ent, extending 
shallow ly into the m inor groove. The base-pair open 
form  is m ore difficult to observe, because it will 
m anifest itself as m issing or having unusually  w eak 
connectivities around the m isplaced base-pairs.
Tw o-dim ensional NOESY experim ents on the A -tract 
bizelesin adduct do not p rov ide any evidence for 
un u su al conform ations w ith in  the central A T 
base-pairs, and  the norm al W atson-Crick base-pair­
ing is m ain tained  th roughou t the duplex adduct. 
F urtherm ore, only one set of m ethyl signals is 
observed, and a single arom atic H 6 /H 8  to H P  w alk 
is observed for each of the non-com plem entary 
strands w ith in  the duplex adduct, indicating that 
only a single cross-linked adduct is form ed 
(Figure 3B).
NMR data from the unmodified A-tract duplex 
indicates the presence of characteristic 
propeller twisting and A-tract junctions 
associated with a bent DNA structure, in 
contrast to the bizelesin duplex adduct, where 
there is no evidence for propeller twisting or 
A-tract junctions
X-ray crystallography and high-field NM R studies 
have^ indicated the presence of an unusually  narrow  
m inor groove w ith in  A -tract sequences (Nelson et al.,
B
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F i g u r e  5 . N O E  c o n n e c t i v i t i e s  b e t w e e n  t h e  a d e n i n e  H 2  p r o t o n s  a n d  t h e  b i z e l e s i n  g e m i n a l  H 4 A ,  H 4 B , H 5 A , a n d  H 5 B  
a n d  t h e  b i z e l e s i n  H 4 a  p r o t o n s .  A ,  C o n t o u r  p l o t  o f  t h e  N O E S Y  d a t a  s h o w i n g  t h e  a d e n i n e  H 2  to  l i g a n d  H 4 A ,  H 4 B , H 5 A ,  
H 5 B , a n d  H 4 a  c r o s s p e a k s .  B , R e l a t i v e  p o s i t i o n s  o f  t h e  a d e n i n e  H 2  p r o t o n s  ( r e d )  a n d  t h e  k e y  p r o t o n s  o n  t h e  l i g a n d  ( a v e r a g e d  
r M D  s t r u c t u r e ,  5 0  p s  a t  3 0 0  K ). C , R e l a t i v e  i n t e n s i t i e s  o f  t h e  a d e n i n e  H 2  to  l i g a n d  c o n n e c t i v i t i e s  ( i n t e n s e  c r o s s p e a k s  a r e  
s h o w n  in  w h i t e ,  l e s s  i n t e n s e  c r o s s p e a k s  in  b l u e  c o n t i n u o u s  l i n e s ,  a n d  w e a k  c r o s s p e a k s  i n  b l u e  b r o k e n  l in e s ) .
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T a b le  2 . I n t e n s i t i e s 3 o f  t h e  c o n n e c t i v i t i e s  b e t w e e n  t h e  b i z e l e s i n  a n d  t h e  c o v a l e n t l y  
m o d i f i e d  d u p l e x
Bizelesin and indole subunit (linked to adenine 8)
H 7 H 7' H8'H3Me H4a H4A H4B H5A H5B H3' H5'
A15-H 2






















Bizelesin and indole subunit (linked to adenine 18)
H3Me H4a H4A H4B H5A H5B H3’ H5' H 7 H7' H8'
A18-H 2 S S s W W
A17-H 2 W S s S S S M M
A16-H 2 w W M M S S
A15-H 2 W W
A16-H1' W
T5-H1' w
A17-H1' w w w
A18-H1' M s M M
C19-H1' M w
A18-H4' w
A 17-H 4’ w w
T6-H4' w w
W, weak; M, medium; S, strong (relative to cytosine H5 to H6 crosspeak intensities).
1987; Coll et al., 1987; K intanar et al., 1987; Katahira 
et al., 1988, 1990). They also show that there is a 
high degree of p ropeller tw ist w ith in  the A-tract 
betw een  the A T base-pairs (average A-tract value, 
20°). This has lead to speculation on the occurrence 
of bifurcated hydrogen bonds involving the 
adenine-N 6 pro tons w ith  the 0 4  of the 3 '-neighbor- 
ing thym ine on the com plem entary strand  (Nelson 
et al., 1987; Coll et al., 1987). H igh-field NM R studies 
have also dem onstrated  the presence of unusually  
strong cross-strand connectivities b etw een  adenine 
H2 and the H I ' of the deoxyribose in the 
3'-neighboring residue on the com plem entary strand  
(K intanar et al., 1987; Katahira et al., 1988,1990). This 
observation su p p o rts  the prev ious conclusion that in 
the presence of h igh propeller tw ist the narrow  
groove w id th  significantly decreases the d istance 
be tw een  these protons. The p ropeller tw isting 
w ith in  the  A T bases in A -tracts and associated 
narrow ing  of the m inor groove coupled w ith 
d istortion  at junctions at the 3' and  5' ends of A-tracts 
have all been  proposed  as probable causes of the 
observed bend ing  w ith in  A -tract-containing d u ­
plexes (N adeau  & Crothers, 1989; K atahira et al., 
1990).
The N M R NOESY data of the unm odified  
A-tract also show  strong evidence supporting  
the presence of both propeller tw isting  at the 
A T base-pairs an d  junctions or d istortions at the 3' 
and  5' en d s of the A-tract. P ropeller tw isting  is 
evident by enhanced  connectivity be tw een  the 
follow ing pairs of protons: H2 of adenine A18 and
H P  of thym ine T4, adenine A17-H2 and thym ine 
T5-H1', adenine A16-H2 and thym ine T6-H1', 
adenine A15-H2 and thym ine T7-H1', and  adenine 
A14-H2 and adenine A8-H1' (connectivities boxed 
in left panel of Figure 3A). The NM R data 
also provide evidence for junctions at both the 3' 
and  5' ends on the A-tract. The junction at thym ine 
T13 can be visualized by an u nusual upfield shift 
in the H T signal to 5.45 ppm  (norm al range for 
thym ine HT is 5.8 to 6.3 ppm ), and the unusual 
upfield shift in the H5 signal of C19 to 5.12 ppm  
(norm al range for cytosine H5 is 5.30 to 5.80 ppm ) 
suggests the presence of a second junction around 
cytosine C l 9.
In contrast, sim ilar enhanced  cross-strand connec­
tivities are not observed w ith in  the bizelesin duplex 
adduct (Figure 3B); the cross-strand intensities 
be tw een  the adenine H2 and the cross-strand 
H P  proton are equivalent to those observed 
w ith in  non-A-tract (+)-CC-1065 and  bizelesin 
adducts (see Discussion). These adducts are 
know n to contain little or no p ropeller tw ist and 
by inference suggest that there is no propeller 
tw ist w ith in  the A T bases in this adduct. The 
NM R data for the duplex adduct also provide 
evidence for the loss of the junctions at both the 5' 
and 3' ends of the A-tract, since the signals for 
both T13-H1' and C19-H5 protons are shifted 
dow nfield in the duplex adduct from  the 
abnorm al range in the duplex to values w ith in  the 
pred ic ted  range for D N A -ligand adducts (see 
Table 1A).
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The structure of the bizelesin duplex 
adduct generated by rMD studies 
provides insight into the contrasting role 
of the ureadyl linking moiety in 
different sequences
The coordinates from the last 50 ps of the five rMD 
calculations were averaged to give the solution 
conformers shown in Figure 7. Throughout the 
calculations, the duplex adducts remained base- 
paired, with the structure being. predominantly 
B-form rather than the B' structures normally 
associated with A-tracts (Chuprina et al., 1991). A 
total of 201 NMR-derived distance restraints were 
applied to the final rMD calculations coupled with 48 
distance and angle restraints, which were used to 
maintain and stabilize base-pairing, particularly 
around the terminal bases. The starting confor­
mations obtained at 30, 35, 40, 45, and 50 ps had 
RMS deviations (A) of 1.007, 0.931, 0.993, 0.909, and 
0.926 relative to the average conformation observed 
within the last 50 ps, respectively, and the final 
structures had RMS values of 0.725, 0.985, 0.589, 
0.692, and 0.690 relative to the average conformation 
observed within the last 50 ps, respectively With the 
exception of the 35-ps starting structure, all the 
remaining conformations showed convergence to the 
average structure (i.e. neglecting the 35-ps confor­
mation, an RMS range of 1.007 to 0.926 was found for 
the starting conformations, in comparison to a 
range of 0.725 to 0.589 for final solution confor­
mations). The resulting five solution conformations 
(Figure 7) demonstrated a good fit to the 
experimental NMR data with no significant 
NOE violations (>0.5 A), except for two restraints 
which involved the terminal base-pairs that were 
poorly constrained. The NMR data for the 
A-tract-containing sequence studied here does not 
show evidence for unusual base-pair conformations 
for the bizelesin duplex adduct, and normal 
Watson-Crick base-pairing is maintained throughout 
(see before). This is in contrast to previous NMR 
rMD studies on the adduct of bizelesin with 
[d(CGTAATTA*CG):d(CGTAATTA*CG)], which in­
dicate the presence of specific hydrogen bonding 
patterns between the central ureadyl linking 
moiety and hydrogen bond acceptors and donors 
within the central A-T base-pairs (Seaman & 
Hurley 1993, 1995). In the present study molecular 
dynamics studies indicate that specific hydrogen 
bonds are not formed between the ureadyl linker and 
the duplex. These dynamics data show that there is 
free movement for the ureadyl linker, the linker 
moiety oscillating between two conformations (A 
and B in Figure 8) in which the linker is orientated 
above (A) and below (B) the plane of the ligand. 
This relatively free movement between these 
two conformations explains why neither of the 
linker amido signals can be observed within the 
proton NMR data, since their constantly changing 
environment and increased exposure to water, 
allowing exchange, would result in unusually broad 
signals.
Discussion
One- and two-dimensional !H-NMR analysis of 
the cross-linked bizelesin 10-mer duplex adduct 
reveals that a six-base-pair region of the central 
duplex region is cross-linked to yield one adduct 
species in which normal Watson-Crick base-pairing 
is maintained. Connectivities between non-ex- 
changeable protons located on the bound ligand and 
duplex protons located in the minor groove assign 
the location and orientation of the ligand and indicate 
that the ligand is bound edge-on into the minor 
groove (Figure 7). Adenine H2 protons protrude 
directly into the base of the minor groove, and these 
in particular provide strong evidence for both the 
orientation and position of the bound bizelesin via 
connectivities into the linker and geminal protons on 
the CPI subunit and the H3 and H5 aromatic protons 
on the indole subunit. Adenine H2 connectivities into 
the protons on the linking moiety and CPI subunit 
methyl protons also confirm the location of the 
modified adenine residues and the position (N3) of 
covalent attachment. Synthesis and 15N-NMR of a 
15N-labeled A-tract bizelesin duplex adduct confirm 
that both of the covalently modified adenine residues 
exist in the positively charged doubly protonated 
6-amino form that was previously observed within 
the (+)-CC-1065 adduct (Lin & Hurley 1990). 
Unfortunately, due to the relative broadness of the 
H6b and H6e signals and their overlap with the 
aromatic signals from several bases, we were unable 
to look for the possibility of a previously reported 
bound water molecule (Lin et al., 1991).
The relative base-pair stability observed within 
the 5'-TTTTTA-3' duplex compared with the 
relative instability within the 5'-TAATTA-3' 
duplex indicates the origin of the unusual 
base-pairing observed in the bizelesin 
5'-TAATTA-3' duplex adduct
The one- and two-dimensional !H-NMR spectra of 1 
the bizelesin adduct of [d(CGTTTTTA*CG):d(CG-j 
TAAAAA*CG)] reveal that the central region of the ̂ 
duplex is cross-linked to give a single species ina 
which normal Watson-Crick base-pairing is main­
tained. This contrasts with the previous study on the 
adduct of bizelesin with [d (CGTAATTA*CG) :d (CG- 
TAATTA*CG)], which yielded two major symmetri­
cal duplex adduct conformations upon cross-link 
formation. In the major of the two duplex adducts 
(60%), the central A-T bases are syn-oriented and 
Hoogsteen base-paired, while in the second 
conformation (40%), the central A-T bases are 
anti-oriented and show no evidence of hydrogen] 
bonding to the pairing thymine residues. The origin 
of these two conformations is an intriguing problem. 
Studies on base-pair opening rates have indicated 
that within the 5'-TAATTA-3' duplex the central bases 
have relatively short half-life periods, indicating that, 
base-pair opening is a common feature within this 
sequence (F. C. Seaman & L. H. H., unpublished 
results). In contrast, similar studies upon A-tracts,
Bizelesin with [6(CGTTTTTACG):6(CGTAAAAACG)] 95
including a study conducted within this laboratory 
on the unmodified duplex, have indicated that the 
A-T base-pairs in A-tracts have extremely long 
base-pair half-life periods. These data indicate that 
an opening event within the central bases in an 
A-tract is considerably less likely than in the 
5'-TAATTA-3' sequence. This high stability of the 
bases within the A-tract makes an opening event 
very unlikely and hence it is proposed that the 
opening rate of the central cross-linked bases may at 
least in part dictate the conformation of the bases 
within the final bizelesin adduct.
rMD studies on the linker within the bizelesin 
adduct on the A-tract-containing sequence 5'- 
TTTTTA*-3' reveal that the ureadyl linker 
oscillates between two conformations, unable to 
find hydrogen bond acceptors or donators in 
either conformation. This observation is reflected 
within the 'H-NMR data in that neither of the 
exchangeable amido protons can be found within 
either the one- or two-dimensional 'H-NMR data. 
Based on the results from the rMD studies, we 
propose that the constantly changing environment 
and exchange with water resulting from this 
relatively free movement leads to broadening of the 
signals such that they cannot be seen even at low 
temperatures.
Cross-linking of an intrinsically bent A-tract by 
bizelesin traps a straight conformation
The NMR data clearly indicate that within the 
cross-linked A-tract adduct the propeller twisting 
between the bases has been eliminated. Evidence for 
junction sites at either the 3' or 5' end of the 
cross-linked A-tract is also absent. These obser­
vations are in accord with a previously published gel 
electrophoresis mobility study in which a similar 
A-tract is found to lose its intrinsic bending upon 
formation of the cross-linked bizelesin adduct 
(Thompson & Hurley, 1995). To contrast the effects of 
mono-alkylation and cross-link formation by (+)- 
CC-1065 and bizelesin, a comparative study was 
performed in which the A-tract adducts of 
(+)-CC-1065 and bizelesin were studied by high- 
field NMR and PAGE (Thompson & Hurley, 1995). 
For the NMR studies, 10-mer sequences were 
examined, while for PAGE, 21-mer sequences were 
used to determine the relative bending magnitude. 
From the 'H-NMR data, the volumes of the 
connectivities between the AH2 and the HP of the 
3'-neighboring residue on the complementary strand 
were determined for each NOESY spectrum of 
duplexes and their respective adducts. To allow for a 
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Figure 6. A, Expanded contour plot of the two-dimensional NOESY (200-ms mixing time, 90% H20 ,  5°C) of the 
cross-linked bizelesin adduct showing connectivities from (1) the imino proton of T3 into the H2 of adenine A18 (D) and 
amino proton H6b of adenine A18 (B) and (2) the imino proton of T13 into the adenine H2 of A8 (C) and am ino proton 
H6b of adenine A8 (A). Insert shows the connectivities observed within the adenine-thymine base pairs. B, 
Two-dimensional inverse-detected proton-nitrogen correlation (500 MHz, fully decoupled, pH 7.0, 300 K) of the 
15N-labeled cross-linked bizelesin adduct showing the H6b and H6C signals for both adenine residues A8 and A18.
varied in concentration), these volumes were then 
used as a percentage of the average volume of the 
cytosine H5 to H6 connectivities within that 
spectrum. To compare the effects of adduct formation 
on the intensities of the cross-strand connectivities, 
the relative volumes were compared (as a percent­
age) between the unmodified duplexes and their 
respective adducts (Figure 9). In both cases 
[(+)-CC-1065 and bizelesin] the relative volumes of 
the cross-strand connectivities decreased signifi­
cantly upon adduct formation, due to the 
increased proton density within the minor groove as 
a result of the bound ligand's protons. However, 
the residual percentages showed marked differences 
for the NOE intensities between the bizelesin and 
(+)-CC-1065 adducts (Figure 9), which indicates 
that the distances between the AH2 and the H I’ of 
the deoxyribose in the 3'-neighboring cross-strand 
residue had significantly increased in the bizelesin 
cross-linked adduct relative to the (+)-CC-1065 
mono-alkylated product. The results of this
study clearly indicate that the distances between 
the adenine H2 and the cross-strand HI' are 
significantly different between the two adducts, 
suggesting that within the (+)-CC-1065 adduct 
the A-T bases still contain a significant propeller 
twist. From the NMR data, it is impossible tQ 
precisely determine the degree of base-pair distor­
tion within the bizelesin adduct. However, a 
comparison of the relative cross-strand connectivi­
ties obtained in a similar study, with a sequence-re­
lated cross-linked bizelesin duplex adduct 
[d(CGTTAGTTA*CG):d(CGTA ACTA A*CG)], which 
is known to have little or no propeller twist within 
the central cross-linked A • T base-pairs, indicates that 
the distances between the adenine H2 and 
cross-strand HT in the A-tract bizelesin adduct are 
similar to those observed in normal 6-form DNA 
(Thompson et al., 1995). This observation provides 
evidence that the A-T bases within the A-tract in this 
study contain little or no propeller twist (Thompson 
et al., 1995).
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For several years, the study of A-tracts has 
remained a controversial area. One hypothesis for the 
origin of observed A-tract bending is that A-tracts 
exist as an equilibrium of predominantly straight 
and significantly bent conformations, and the degree 
of bending reflects the balance of this equilibrium. 
This study, coupled with the above (+)-CC-1065 
study, supports this hypothesis by suggesting that it 
is possible for these two alkylating agents to trap the 
bent and straight extremes of the equilibrium.
Based on the results of this study, concerning the 
loss of propeller twist within the duplex adduct, it is 
possible to speculate on the molecular mechanism by 
which bizelesin traps out a relatively straight A-tract.
Bizelesin is almost the optimal length to cross-link 
two adenine residues six base-pairs apart within 
normal B-form DNA. The formation of this cross-link 
would trap the two end bases into a normal B-form 
conformation and also inhibit propeller twist 
formation within the neighboring bases. This would 
effectively reduce the A-tract from five adenine 
residues to two; the surrounding bases would be 
unable to propeller twist. Previous studies on 
A-tracts have suggested that a minimum of these 
adenine residues are required to establish A-tract 
structure (Leroy et al., 1988), and hence it could be 
predicted that the bases within this adduct should be 
normally base-paired with little or no propeller
:
Figure 7. Solution conformations of the bizelesin-A-tract duplex adduct. Upper Figure shows the stereo van der Waals 
of the average structure, lower left shows the five final solution structures and lower right is a stick representation of the 
average solution conformation (50 ps, 300K). Bizelesin is shown in yellow, duplex is shown in turquoise and white.
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Figure 8. Averaged structures for the two conformations observed w ithin the ureadyl linking moiety of the A-tract 
adduct (50 ps, 300 K). Calculated from the 40-ps rMD calculation (see insert), during which the linker exchanged 
conformation betw een the two shown conformations (averaged section blocked as A and B).
twist. Previous studies on A-tracts have speculated 
that the bending observed is related to the propeller 
twist and the formation of junctions as the highly 
propeller twisted A-tract joins the normal B-form 
DNA. The loss of propeller twist within the adenine 
residues in the A-tract of this duplex adduct coupled 
with the loss of junctions supports these previous 
conclusions.
Gel electrophoresis studies have also shown that 
bizelesin is able to form a mixture of two duplex 
adducts which reacted with the A-tract 5'- 
TTTTTTA*-3', the bizelesin cross-linking six or seven 
base-pairs. From this study we can predict that the 
duplex adduct formed when bizelesin cross-links the 
two adenine residues six base-pairs apart in 
5'-TTTTTTA-3' should be predominantly straight 
and of similar structure to the duplex adduct studied 
here. The structure and relative degree of bending 
within the seven base-pair cross-linked duplex 
adduct is unlikely to resemble the six-base-pair 
cross-linked duplex adduct, and hence the ability of 
bizelesin to straighten A-tract-containing sequences 
is probably limited to five adenine A-tracts. Since 
cross-linking of A5-tracts by bizelesin leads to 
trapping out a straight DNA, the drug is potentially
useful as a probe to evaluate the importance of 
intrinsic bending or protein-induced bending in 
transcriptional or replication elements.
Experimental Procedures
Chemicals
Bizelesin was a gift from The Upjohn Com pany and was 
used w ithout further purification. Reagents used to 
prepare the NMR buffer, sodium  phosphate (99.99%), 
sodium  chloride (99.99%), and EDTA (99.99%), were 
purchased from Aldrich. HPLC water, methanol, ethylac- 
etate, and acetonitrile were purchased from Baxter. 
Ammonium acetate (99.99%), sodium  hydroxide (99.99%), 
glacial acetic acid (99.99%), and hydrochloric acid were 
purchased from Aldrich. The 15N-labeled adenine was 
prepared by synthetic methods (Lin & Hurley, 1990) and 
used as the phosphoram idite on the DNA synthesizer, t
Oligonucleotide preparation and purification
The two strands for the 10-mer [d(CGTTTT 
TACG):d(CGTAAAAACG)] were synthesised on a 10-gmo 
scale by using autom ated solid-phase phosphoramidite 
chemistry (Gait, 1984) on an Applied Biosystem: 
autom ated DNA synthesizer (model 381 A), leaving the
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trityl protecting group on each of the single strands. The 
two strands w ere purified separately by reverse phase 
HPLC using a Dynamax-300A, Cis (20 mm x 200 mm) 
HPLC column. The DNA was initially loaded onto the 
column in 100 mM ammonium acetate (pH 7.0) and then 
eluted using an increasing gradient to 40% of acetonitrile 
over a period of 40 minutes. The collected DNA was 
dialyzed using Spectra/Por CE membrane (MWCO: 1000) 
against 3 x 1000 ml of HPLC water and evaporated to 
dryness. The trityl protecting groups were then cleaved by 
stirring with 30 ml of 50% (v /v ) glacial acetic acid for a 
period of around 30 minutes, after which the sample was 
extracted with 3 x 30 ml ethylacetate to remove the acetic 
acid before evaporating to dryness. Further purification on 
the above HPLC system using an increasing gradient 
of acetonitrile (0 to 25%) over 40 minutes, followed 
by dialysis (as above), gave the two purified single 
strands the purity  of which was confirmed by 
one-dimensional ’H-NMR. Equal quantities of the two 
strands (measured by UV) were mixed and annealed 
in NMR buffer (10 mmol N aH 2P0 4 , 100 mmol NaCl 
(pH 7.0), 0.5 mM, EDTA. The annealed sample was then 
examined by one-dimensional 'H-NMR. If an excess of 
either strand was observed, the second strand was titrated 
into the NMR tube, and the sample was re-annealed. This 
process was repeated until only duplex signals were 
observed.
Adduct preparation and purification
The bizelesin 10-mer duplex adduct was prepared by 
stirring 10 mg of bizelesin in 0.2 ml of DMF solution with 
0.03 ml of aqueous sodium  bicarbonate for 20 minutes 
before adding 30 mg of purified 10-mer in 0.75 ml of buffer 
containing 10 mM sodium phosphate and 100 mM sodium 
chloride. The reaction mixture was stirred for 48 hours in 
the dark, lyophilized to dryness overnight, and desalted, 
and the excess drug was removed on Ci8 Sep-Pak 
cartridges (Waters). No further purification was required, 
and the sample was dissolved in deuterated NMR buffer 
(10 mmol N aH 2P0 4 , 100 mmol NaCl, 0.5 mM EDTA 
pH 7.0).
NMR experiments
One- and two-dimensional 500 MHz 'H-NMR data sets 
in H20  and 2H20  buffered solution were recorded on a 
Bruker AMX 500 FT NMR spectrometer. Proton chemical 
shifts were recorded in parts per million (ppm) and 
referenced relative to the water signal (4.71 ppm , 300 K).
Phase-sensitive two-dimensional NOESY spectra 
(Bruker) w ere obtained for four mixing times: 100,150,200, 
and 250 ms. All spectra were acquired with 16 scans at each 
of 1024 t\ values, spectral w idth of 10.002 ppm  and a 
relaxation delay of 10 seconds betw een scans. During data 
processing, a 90°-shifted squared sine bell function was 
used in both w \  and w2  dimensions. The FID in w  1 was 
zero-filled to 2 K prior to Fourier transformation to give a 
2 K x 2 K spectrum . Two-dimensional NOE spectra in 90% 
H20  at 150 ms mixing time were recorded using the 1-1 
echo read pulse sequence (Sklenar & Bax, 1987; Blake & 
Summers, 1990) with a 2.5 second pulse repetition time 
and a sw eep w idth of 24.396 ppm. Ammonia catalyst-me­
diated base-pairing hydrogen exchange experiments were 
conducted on the unmodified A-tract-containing 10-mer.
Inverse-detected 'H -15N correlation experiments 
(HMQC) w ere carried out by optimizing for a coupling 
constant of 90 Hz. 15N shifts were referenced externally to 
am m onium  chloride (2.9 M) in HC1 (1 M in H20 ) 
(reference: 24.9 ppm).
Restrained molecular dynamics
Interproton distances were derived via the program  
MARDIGRAS (Borgias et al., 1989, Borgias & James, 1990) 
from NOESY experiments at mixing times of 100,150, 200, 
and 250 ms. A complete two-dimensional NOE relaxation 
matrix was set up  using the geometry of a starting structure 
to provide interproton NOEs not available from the 
experimental data sets. Five alternative B-form starting 
conformations were generated from an unrestrained 
molecular dynamics calculation on the solvated bizelesin 
cross-linked adduct in which the tem perature was raised 
to 500 K over 20 ps and then held at 500 K for 30 ps. The 
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Figure 9. Relative intensities of the normalized cross-strand NOESY (150 ms) peak volumes betw een the adenine H2 
and the H I ' of the 3'-neighboring residue on the complementary strand for the bizelesin cross-linked adduct and the related 
(+)-CC-1065 A-tract adduct (Figure from Thompson & Hurley, 1995). Results are expressed as a percentage of the 
norm alized (see the text) corresponding peak in the unm odified duplexes.
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study were observed at 30, 35, 40, 45, and 50 ps, 
respectively, which were then returned to 0 K over 15 ps 
and loosely minimized without constraints. The complete 
NOE matrix was calculated for the starting structure 
(minimized average of the last 20 ps of the unrestrained 
molecular dynamics calculation) using CORMA (Borgias 
et al., 1989; Borgias & James, 1988). MARDIGRAS was then 
used to calculate the upper and lower bounds for the 
interproton distances (Borgias & James, 1990). Subsequent 
procedures for structure refinement followed those 
described previously (Kerwood et al., 1991). Interproton 
distances were incorporated into the restrained molecular 
mechanics and restrained molecular dynamics calcu­
lations (rMD) of the solvated system. The rMD calculations 
were performed using the SANDER module of AMBER 
(Pearlman et al., 1991), version 4.0, on Silicon Graphics 
4D-35G Personal Iris and R4600SC Indy workstations. The 
AMBER force field pseudo-energy terms for the 
interproton distances were given the form of flat wells with 
parabolic sides within a defined distance. The molecular 
dynamics calculations (solvated) were started at 0 K and 
ramped over 25 ps to 300 K. During the first 10 ps of this 
period, the NMR-derived distance restraints were applied 
to the system along with some additional base-pair 
distance and angle restraints, which were applied to the 
terminal bases to prevent duplex fraying at elevated 
temperatures. The solvated systems were then held at 
300 K for 75 ps, and the data from the last 50 ps were used 
to generate averaged structures (see above) and hydrogen 
bonding information.
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a b s t r a c t : A ltrom ycin B belongs to the  p luram ycin  fam ily of an titum or antib io tics, which also includes 
kidam ycin, hedam ycin, p luram ycin, neopluram ycin , D C 92-B , and rubiflavin A. These potent an titum or 
com pounds react w ith D N A  in as yet im precisely determ ined  ways. In the  present investigation, we have 
used gel electrophoresis m ethods in com bination w ith nuclear m agnetic resonance and mass spectrom etry  
to determ ine the structure of the altrom ycin B -D N A  adduct. H igh-resolution gel electrophoresis dem onstrated 
th a t guanine was the reactive base, and N 7  was im plicated  from  experim ents in which A ^-deazaguanine 
was used in place of guanine in a strand  b reakage assay. E xperim ents using supercoiled D N A  dem onstrated  
th a t altrom ycin  B and rela ted  drugs in terca la ted  into D N A , which im plicated this as a com m on m echanism  
for binding of the p luram ycin antib io tics to D N A . T he altrom ycin  B -guan ine  adduct was isolated from  
ca lf thym us D N A  after therm al depurination  of the alky lated  D N A . M ass spectrom etry  confirm ed th a t 
altrom ycin  alkylated D N A  through guanine, and  *H- and 13C -N M R  was used to  confirm  the covalent 
linkage sites between altrom ycin B and guanine. O n the basis of these results, we propose th a t altrom ycin 
B first intercalates into D N A  via a threading m echanism , rem iniscent of nogalam ycin, to insert the disaccharide 
into the m inor groove and position the epoxide in the m ajor groove in proxim ity to N 7 of guanine. Nucleophilic 
a tta ck  from  N 7 of guanine leads to an acid-catalyzed  opening of the  epoxide, resulting  in the altrom ycin 
B -D N A  adduct. On the basis of these results, a general m echanism  for the in teraction  of the pluram ycin 
fam ily o f antibiotics w ith D N A  is proposed.
Altromycin B is a new antitum or antibiotic produced by an 
actinomycete (strain AB 1246E-26) and was discovered 
through an antitum or screening program at A bbott Labo­
ratories, Chicago, IL (Jackson et al., 1990; Brill et al., 1990). 
This antibiotic and its structural analogs are members of the 
family of pluramycin antibiotics (47/-anthra[l,2-& ]pyran 
antibiotics) that also includes pluramycin A, kidamycin, 
hedamycin, and rubiflavin B [reviewed by Sequin (1986)]. 
The structures of altromycin B and related antibiotics are 
summarized in Figure 1. These compounds show antitum or 
and antimicrobial activity (Sequin, 1986; Jackson et al., 1990) 
and react in as yet imprecisely determined ways with DNA.
Altromycin B is one of a group of structurally related 
compounds (see Figure 1) that show in vitro activity against 
human and murine cell lines and in vivo activity in P388 
leukemia, M 5076 ovarian sarcoma, Lewis lung carcinoma, 
and hum an LS174T colon cancer (M cAlpine et al., 1992). In 
initial mechanism of action studies (M cAlpine et al., 1992), 
altromycin B was shown to preferentially inhibit R N A  and 
D NA synthesis relative to protein synthesis, and the inhibition 
of cell growth could be prevented by coaddition of calf thymus 
DNA. W hile intercalation was not detected using an 
unwinding assay, both grooves were implicated in the binding 
of altromycin B to DNA.
In the present study, we have used gel electrophoresis 
methods to show that altromycin B covalently modifies N7 
of guanine. 1H- and 13C -N M R  have been used to confirm the 
guanine alkylation site and show that the epoxide is the DNA 
reactive group on altromycin B. On the basis of a DNA
t This research was supported by Abbott Laboratories.
* To whom correspondence should be addressed.











C om pound R 1 R 2 R 3 R 4 R 1 R " R " ’
Altromycin A H A A B OH n h c h3
Altromycin B H A A B OH N(CH3)j
Altromycin C H A A B H n h c h3
Altromycin D H A A B H N(CH3)2
Altromycin H H OH A B N(CH3)2
Altromycin I H OH A B n h c h3
Pluram ycin A ch3 C A Acetyl
Neopluramycin A ch3 D A Acetyl
Hedamycin A ch3 B A H H
DC92-B A c h 3 B A c h 3 H
Kidamycin A c h 3 D A H
Epoxykidamycin A ch3 E A H
Rubiflavin A A ch3 C A H
F ig u r e  1: Structures of altromycins A , B, C, D, H, and I; pluramycin; 
neopluramycin; hedamycin; kidamycin; epoxykidamycin (Byrne et 
al., 1985); rubiflavin A; and DC92-B (Yasuzawa et al., 1990).
unwinding assay, intercalation is dem onstrated to be the 
general mode of precovalent binding. On the basis of these 
results, a model of the altromycin B (N 7-guanine)-D N A  
adduct is proposed, and this model is extended to provide a
© 1993 American Chemical Society
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Table I: Sequences of Oligomer DNA Used in This Study
I 5 ' CCAACCCGTAATTAGGTGCGG 3 '
3 '  TGGGCATTAATCCACGCCGGT 5 '
I I 5 ' GAGCACCGCAAAAACGGATTG 3 '
3 ' GTGGCGTTTTTGCCTAACCTC 5 '
I I I 5 ' CCACATCCAAGCATACCCAAT 3 '
3 ' GGTGTAGGTTCGTATGGGTTA 5 '
general thesis for the interaction of the pluramycin antibiotics 
with DNA. The relationship of the mechanism of action of 
the pluramycins to kapuramycin A 3 (H ara et al., 1990) and 
aflatoxin Bi (Gopolakrishnam et al., 1990) is also discussed.
M A T E R IA L S A N D  M E T H O D S
Chemicals and Enzymes. The drugs used in this study 
were obtained from Abbott Laboratories, Chicago, IL. 
Electrophoretic reagents [acrylamide,TEM ED,* ammonium 
persulfate, and bis(acrylamide)] were purchased from Bio- 
Rad. T4 polynucleotide kinase and Klenow fragm ent were 
from U.S. Biochemical Corp., and wheat germ topoisomerase 
I was from Promega. [y-32P] ATP, [a -32P]dCTP, and X-ray 
film were from ICN.
Preparation o f  Oligonucleotides. A series of oligonucle­
otides (Table I) were synthesized on an autom ated DNA 
synthesizer (Applied Biosystems 381 A) by the phosphora- 
midite method. The oligomers were then deprotected sepa­
rately with saturated ammonium hydroxide at 5 5 0C overnight, 
dried under vacuum, and redissolved in DDW .
Preparation o f  Labeled Duplexes. To construct the 5 '-32P 
single end-labeled duplex, one strand of duplex was kinated 
for 2 h at 37 °C  in 25 mL of solution containing 70 mM 
Tris-HCl (pH 7.6), 10 mM M gCh, 5 mM dithrothreitol, 30 
jiCi of [ t - 32P] A TP, 10 units of T4 polynucleotide kinase, and 
5 ng of DNA. Reaction mixtures were heated at 95 °C  for 
10 min to inactivate T4 polynucleotide kinase and annealed 
to the complementary cold strand to generate the duplexes. 
3'-32P end-labeling was achieved by a filling-in reaction with 
the cold duplex, using [a -32P]dC TP and 10 units of Klenow 
fragment incubated for 1 h at 37 °C  in 20 /iL of solution 
containing 70 m M  Tris-HCl (pH 7.6), 10 mM  M gC h, and 
5 mM dithiothreitol. Labeled duplexes were electrophoresed 
on the 8% nondenaturing polyacrylamide gel to purify DNA 
using the method described previously (Lee et al., 1991).
Drug Binding Reactions and DNA Strand Breakage Assay. 
Drug binding reactions were carried out a t room tem perature 
in a solution containing 10 mM Tris-H Cl (pH 7.6), 50 mM 
N aC l, oligomer duplex, and the indicated am ount of drug 
molecules. D rug binding reactions were stopped by phenol/ 
CHCI3 extraction and ethanol precipitation to remove unbound 
drug molecules. DNA pellets were dried and redissolved in 
DDW . For the strand breakage assay, drug-modified DNA 
samples were heated to 95 °C, with or without piperidine (1 
M ), for 30 min. DNA samples were mixed with the same
1 Abbreviations: MS, monomeric supercoiled; DS, dimeric supercoiled; 
MR, monomer relaxed; DR, dimer relaxed; DDW, doubly distilled water; 
ss, single stranded; ds, double stranded; sc, supercoiled; EtdBr, ethidium 
bromide; topo I, DNA topoisomerase I; FAB-MS, fast atom bombardment 
mass spectrometry; DMSO, dimethyl sulfoxide; TOCS Y, total correlation 
spectroscopy; NOE, nuclear Overhauser effect; NOESY, two-dimensional 
NOE correlated spectroscopy; ROESY, rotating-frame NOE spectros­
copy; HMBC, heteronuclear multiple bond correlation; AP, apurinic; 
TEMED, MA.A'JV-tetramethylethylenediamine; Tris, tris(hydroxy- 
methyl)aminomethane; ATP, adenosine S'-triphosphate.
volume of alkaline dye (80% formamide, 10 mM  N aO H ) and 
then subjected to 20% denaturing gel electrophoresis in parallel 
with DNA sequencing reactions prepared as described before 
(M axam  & Gilbert, 1980).
DNA Unwinding Assay Using Topoisomerase / . To test 
whether the pluramycins unwind DNA upon binding to DNA, 
1 Mg of sc DNA was reacted with topo I in the presence of 
drug molecules in 20 mL of solution containing 20 mM  Tris- 
H Cl (pH 7.6), 50 mM KC1, and 10 mM  N aC l for 1 h a t 37 
°C . Reactions were stopped by the addition of stop buffer 
containing 50% glycerol, 10 mM EDTA, and 2% sodium 
dodecyl sulfate. Reaction mixtures were electrophoresed on 
1% agarose gel to separate the topoisomers generated.
Preparation o f  the Altromycin B-Guanine Adduct. The 
altromycin B-guanine adduct was prepared by incubating 50 
mg of altromycin B with 1 g of calf thymus D N A  in a sodium 
phosphate buffer for 2 days, after which time the m ixture was 
extracted with 1-butanol to remove all the unreacted drug. 
The remaining altromycin B -D N A  adduct was repeatedly 
heated a t 90 °C  for 5-10 min, followed by butanol extraction 
to remove the depurinated product. The butanol phase, 
containing the altromycin base adduct, was back-extracted 
with water several times and lyophilized to dryness.
Spectroscopic Experiments. All two-dimensional N M R  
experiments were performed on a Bruker A M X 500 spec­
trom eter at 333 K in a 4:1 deuterated D M SO /benzene solvent 
system and referenced internally to the solvent DM SO  and 
externally to 15N H 4C1, except for the R O ESY  experiment, 
which was run in deuterated methanol, referenced internally 
to methanol, at 300 K. Assignments were accomplished 
through the execution of two-dimensional1H - 13C correlation, 
homonuclear TOCSY, N O ESY , and RO ESY  experiments, 
and 'H - 13C and *H -15N  two-dimensional H M B C  experi­
ments.
R E S U L T S
The presence of both a planar 4 //-an th ra  [ 1,2-b] pyran-4,7,- 
12-trione moiety and an epoxide in altromycin B (Figure 1) 
suggested both intercalation and alkylation as possible 
mechanisms for interaction with DNA. Experiments using 
sc D N A  to measure intercalative unwinding and high- 
resolution gel electrophoresis to determine D N A  strand 
breakage induced by base modification were designed to test 
these ideas.
The 4H-Anthra[l,2-b]pyran Ring System  o f  the Plura­
mycins Intercalates into DNA. The standard test for inter­
calation involves an assay using plasmid D N A  in combination 
with topo I, which converts sc D N A  (form I) to relaxed DNA 
(relaxed form I). Form III is linear duplex D N A  produced 
by the introduction of ds breaks into form I D N A . Agarose 
gel electrophoresis can be used to monitor interconversion 
between these different forms. If  an intercalative drug like 
ethidium  bromide is present, the sc D N A  is unwound, and 
topo I will relax the drug-induced positive superhelical turns. 
Removal of ethidium bromide leaves sc DNA, which migrates 
differently in agarose gel electrophoresis than relaxed DNA. 
The success of this assay depends upon the removal of drug 
from relaxed DNA after incubation with topo I. If  the drug 
either nicks DNA or remains covalently bound to the DNA, 
any associated intercalation will remain undetected by the 
assay. Since we suspected that the epoxide of altromycin B 
m ight alkylate DNA, we selected a number of anthrapyran 
antibiotics, some of which (neopluramycin and kidamycin) 
lacked this potentially DNA-reactive moiety. The results of 
this assay using altromycin B, hedamycin, neopluramycin, 
and kidamycin are shown in Figure 2. In control lane 1, two
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B
Altromycin B Kidamydn Hedamycin Neopluramycin 
SC R 1 2 3 4 1 2 3 4  1 2 3 4  1 2 3 4
Altromycin B Plursmycin
R SC 1 2 3 4 1 2 3 4
F igure 2: (A) Topo I-induced relaxation assay to analyze the unwinding ability of pluramycin antibiotics. SC and R refer to control plasmid 
DNA pUC19 and the same DNA reacted with topo I, respectively. Lane headings represent the drug molecules used in the experiment. Lanes 
1,2,3, and 4 contain 35,70,150, and 300 ng of drug molecules, respectively. (B) Mobility shift of plasmid DNA pUC 19 induced by altromycin 
B and pluramycin. Lanes 1, 2, 3, and 4 contain 50, 100, 150, and 300 ng of drug molecules, respectively. For both (A) and (B), MS and 
DS refer to monomeric and dimeric supercoiled forms of DNA. MR and DR are relaxed forms of DNA from the supercoiled form of the 
same species of DNA.
A  B C D E 
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F ig u r e  3: Comparison of the alkylating ability of the pluramycin 
antibiotics using the oligomer duplex. Panels A-E contain altromycin 
H, altromycin I, hedamycin, neopluramycin, and kidamycin, re­
spectively. AG and TC refer to the purine- and pyrimidine-specific 
chemical cleavage reaction. Lane C is without drug treatment, and 
lanes 1-3 contain 60, 20, and 5 ng of drug molecules, respectively. 
The reaction of DNA (20 ng) with drug molecules was carried out 
for 12 h at room temperature. The sequences alkylated are shown 
to the left of the gel, the asterisk indicates covalently modified 
guanines, and the arrowheads correspond to these guanines.
species of sc D N A  appear, which are a monomer (M S) and 
dimer (DS) pair. The conversion of sc (M S and DS, form I) 
to relaxed circular (M R and DR, relaxed form I) by topo I 
is evident from the comparative migration of the bands in 
lanes SC and R in Figure 2. For altromycin B and hedamycin, 
both relaxed species migrate slightly slower with increasing 
amount of drug, presumably due to covalent modification to 
DNA, resulting in the structural changes in DNA molecules. 
No direct evidence of intercalation is visible in this assay, 
which includes topo I. In contrast, for kidamycin and 
neopluramycin, well-defined bands representing different 
topological forms, which migrated faster than the relaxed 
form I, were present after incubation at the higher drug levels 
(lanes 3 and 4). In a second experiment using sc D N A  
modified with altromycin B and pluramycin, but without topo 
I (Figure 2B), the highest concentration of drug produced a 
smear of bands for MS and DS running slower than sc DNA, 
indicative of intercalation accompanying covalent adduct 
formation (lane 4). This is exactly as expected, since 
intercalation would retard migration, and in the absence of 
topo I to relax the unwinding by altromycin B and pluramycin,
this would appear as a smear of bands. Therefore, this result, 
taken in conjunction with the results of the sc DNA assay, 
including topo I with the noncovalently modifying pluramycins 
(kidamycin and neopluramycin), provides excellent evidence 
for an intercalative type of binding to D N A  common to all 
members of the pluramycin family with or without associated 
alkylation.
While Altromycins H  and I and Hedamycin Covalently 
M odify Guanine in DNA, Neopluramycin and Kidamycin 
Are Devoid o f  DNA Alkylation A bility. To follow up the 
results of the agarose gel electrophoresis experiments (Figure 
2 ), an experiment using high-resolution gel electrophoresis 
was carried out to test our hypothesis that while the altromycins 
and hedamycin both intercalate and covalently modify DNA, 
kidamycin and pluramycin are only able to intercalate into 
DNA. An oligomer (I in Table I) was singly labeled with 32P 
at the 5' end of the (+ ) strand and incubated with each of 
these drugs in separate experiments. Each sample was 
subjected to therm al treatm ent (95 °C  for 30 min) in the 
presence of 1 M piperidine prior to loading on the gel. The 
results show that strand breakage at several guanine residues 
(arrows in Figure 3) was found for both altromycins H and
I and hedamycin (A, B, and C in Figure 3). In contrast, 
neopluramycin and kidamycin (D and E in Figure 3) did not 
produce D NA strand breakage. The results of this experimenl 
support our proposal that the epoxide common to both 
altromycins H and I and hedamycin is required for alkylatior 
of DNA.
Altromycin B A lkylation at Guanine Occurs at N3 or N7. 
Several DNA-dam aging drugs produce strand breakage as a 
consequence of heat or alkali treatm ent of alkylated DNA 
Probable alkylation positions on guanine include 2N, N3, oi 
N7. The exocyclic 2-amino group (2N ) can be eliminated 
since this would not result in strand breakage of DNA aftei 
heat or alkali treatm ent. Both N3 and N7 alkylation would 
be expected to produce strand breakage, and of these N7 
seems the most likely on the basis of the well-establishec 
occurrence of N7-alkylated guanines (W arpehoski & Hurley 
1988). In either case (N3 or N7 alkylation) depurinatior 
leads to an AP site, which can then undergo two successive 
^-eliminations. For 3Mabeled DNA, the First 0-eliminatior 
leads directly to a product that comigrates with a M axam anc 
G ilbert guanine reaction, but for 5 '-labeled DNA, twc 
successive /^-eliminations are required, the second of which 
requires alkali treatm ent for completion. The results in Figuri 
4 show the expected pattern of cleavage at guanine consisteni 
with either N3 or N7 alkylation; i.e., 3' 32P-labeled oligomei
II (Table I) shows a similar pattern with either heat or hea
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F igure  4: T h e r m a l  t r e a t m e n t  o f  a l t r o m y c i n  B - m o d i f i e d  3 '  a n d  5 '  e n d - l a b e l e d  D N A  w i t h  ( + P I P )  o r  w i t h o u t  ( - P I P )  p i p e r i d i n e .  I n  p a n e l  A ,  
5 '  e n d - l a b e l e d  o l i g o m e r  D N A  B  ( l o w e r  s t r a n d )  a n d ,  i n  p a n e l  B ,  3 '  e n d - l a b e l e d  o l i g o m e r  D N A  B  ( l o w e r  s t r a n d )  w e r e  u s e d  i n  t h e s e  e x p e r i m e n t s .  
D N A  ( 1 0  n g  i n  p a n e l  A  a n d  3 0  n g  i n  p a n e l  B )  w a s  t r e a t e d  w i t h  6 0  n g  o f  a l t r o m y c i n  B  f o r  1 2  h ,  a n d  D N A  w a s  p u r i f i e d  w i t h  p h e n o l / c h l o r o f o r m  
e x t r a c t i o n  a n d  e t h a n o l  p r e c i p i t a t i o n  t o  r e m o v e  u n b o u n d  d r u g  m o l e c u l e s .  I n  e a c h  c a s e ,  l a n e s  1 - 5  c o n t a i n  D N A  s a m p l e s  h e a t e d  a t  9 5  ° C  f o r  
0 ,  4, 1 0 ,  2 0 ,  a n d  3 0  m i n ,  r e s p e c t i v e l y .  F o r  s e q u e n c e s  t o  t h e  l e f t  o f  t h e  g e l ,  s e e  t h e  l e g e n d  f o r  F i g u r e  3 .
BAT A_____________







F igure 5 :  R e a c t i v i t y  o f  a l t r o m y c i n  B  a n d  p l u r a m y c i n  w i t h  o l i g o m e r  
C  c o n t a i n i n g  e i t h e r  g u a n i n e  o r  A ^ - d e a z a g u a n i n e  a t  t h e  *  s i t e  ( s e e  
T a b l e  I ) .  P a n e l  A  r e f e r s  t o  o l i g o m e r  C ,  a n d  p a n e l  B  r e f e r s  t o  t h e  
s a m e  o l i g o m e r  b u t  c o n t a i n i n g  A ^ - d e a z a g u a n i n e  o n  t h e  ( + )  s t r a n d  a t  
I t h e  *  s i t e  i n s t e a d  o f  g u a n i n e .  O l i g o m e r  C  w a s  l a b e l e d  a t  t h e  5 '  e n d  
o f  t h e  ( + )  s t r a n d .  L a n e  C  i s  c o n t r o l  e x p e r i m e n t  w i t h o u t  d r u g  
t r e a t m e n t .  L a n e s  1 - 3  ( a n d  4 - 6 )  c o n t a i n  1 0  n g ,  5 0  n g ,  a n d  1 5 0  n g  
o f  a l t r o m y c i n  B  ( o r  p l u r a m y c i n ) ,  r e s p e c t i v e l y ,  e a c h  w i t h  2 0  n g  o f  
o l i g o m e r .
and piperidine treatm ent, but the 5' 32P-labeled oligomer 
required heat and piperidine for completion of the chemical 
degradation reaction leading to a product that comigrates 
with a Maxaim and Gilbert sequencing reaction for guanine.
N 7-Deazaguanine Is Not a Substrate fo r  A lkylation by 
Altromycin B  or Pluramycin. To potentially distinguish 
between N3 and N7 alkylation of DNA by altromycin B, 
duplex oligomers (III in Table I) containing either a single 
guanine or A^'-deazaguanine for alkylation on the upper strand 
were prepare-d. Both duplexes containing either guanine or 
A^-deazagua.nine at this unique position on the upper strand 
were reacted vwith altromycin B and pluramycin, and alkylation 
was m onitored by the strand breakage assay (see before).
While altromycin B and pluramycin produced strand breakage 
at the guanine residue (lanes 1-6 in panel A of Figure 5), the 
oligomer containing the A^-deazaguanine was unreactive, 
potentially implicating N7 as the alkylation site for both 
altromycin B and pluram ycin .2
Characterization o f  the Altromycin B-Guanine Adduct by 
Mass Spectrom etry and N M R. Because of the uncertainty 
of the results described above, further characterization of the 
site for alkylation of D NA was important. The altromycin 
B-guanine adduct was isolated from a sample of calf thymus 
DNA that had been incubated with altromycin B and 
subsequently heated at 90 °C  to produce depurination and 
release of the guanine adduct. The butanol extract containing 
the altromycin B-guanine adduct was lyophilized and sub­
jected to mass spectrometric and N M R  analysis.
Positive ion mode FAB-MS of the altromycin B-base adduct 
gave a parent ion (M  +  1) of 1077.429242 (calculated 
1077.430450), which is equivalent to a molecular formula of 
C 52H 65N 6O 19. This is consistent with the structure of the 
altromycin B-guanine adduct shown in Figure 6A. 13C- and 
‘H -N M R  spectra were obtained on a further sample of the 
same m aterial. A comparison of the chemical shifts of the 
proton N M R  resonance signals of altromycin B, the altromycin 
B-guanine adduct, and A^-methylguanine is shown in Table 
II. Characteristic of a 7-alkylated guanine adduct is the 
presence of just one nonexchangeable proton resonance signal 
(H 8 ) and the two exchangeable resonance signals for 2N Hi 
and N1 -H. The proton N M R  chemical shift of H16 of 
altromycin is consistent with nucleophilic a ttack  at C l 6 and 
acid-catalyzed opening of the epoxide ring. The 13C -N M R  
chemical shifts of C14 and C16 (76 and 59 ppm) in the 
altromycin B-guanine adduct in comparison to altromycin B 
(59.7 and 67.5 ppm) are also consistent with attachm ent of 
nitrogen (N7 of G) at C l 6 . Further evidence for the covalent 
linkage sites was obtained from *H -13C and ‘H - 15N HM BC 
experiments (Bax & Summers, 1986). The long-range ‘H -  
13C coupling indicates an intact carbon backbone extending
2  I n  c o n t r o l  e x p e r i m e n t s  w i t h  N 3  a l k y l a t i o n  o f  A ^ - d e a z a g u a n i n e ,  a n  
a d d u c t  i s  p r o d u c e d ,  p r o v i d i n g  a s s u r a n c e  t h a t  a n  a d d u c t  w o u l d  f o r m  a t  
N 3  w i t h  a l t r o m y c i n  B  i f  t h i s  w a s  t h e  a l k y l a t i o n  s i t e .
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F igure 6: ( A ,  t o p )  P r o p o s e d  r e a c t i o n  o f  a l t r o m y c i n  B  w i t h  D N A  t o  f o r m  t h e  a l t r o m y c i n  B  ( N 7 - g u a n i n e ) - D N A  a d d u c t  a n d  p r o d u c t s  o f  t h e r m a l  
a n d  p i p e r i d i n e  c l e a v a g e  o f  t h e  D N A  a d d u c t .  S p e c i e s  A  i s  t h e  p r o d u c t  o f  t h e r m a l  c l e a v a g e  a t  n e u t r a l  p H ,  a n d  s p e c i e s  B  i s  t h e  p r o d u c t  a f t e r  
a l k a l i n e  t r e a t m e n t .  ( B ,  b o t t o m )  S t e r e o d i a g r a m  o f  t h e  a l t r o m y c i n  B - D N A  a d d u c t  p r e p a r e d  u s i n g  A M B E R  4 . 0 .  T h e  s t a r t i n g  s t r u c t u r e  w a s  
d e r i v e d  b y  m o d i f y i n g  D N A  c o o r d i n a t e s  f r o m  t h e  d a u n o m y c i n - D N A  c o m p l e x  ( Q u i g l e y  e t  a l . ,  1 9 8 0 )  a n d  d o c k i n g  a l t r o m y c i n  B  t o  t h i s  o l i g o m e r .  
T h e  c o v a l e n t  l i n k a g e  s i t e  i s  s h o w n  i n  b l u e  a n d  t h e  a l t r o m y c i n  B  m o l e c u l e  i n  y e l l o w .
from C14 to C16, and the JH - 15N  experiment shows long- 
range coupling between the 17-methyl of altromycin and N7 
of guanine (supplementary m aterial). Last, through-space 
connectivities in the ROESY experiment between H 8 of 
guanine and the 17-methyl are also consistent with N 7 rather 
than N3 alkylation of guanine (unpublished results). In 
summary, th e 1H- a n d 13C -N M R  confirms N7 as the alkylation 
site on guanine and demonstrates that the epoxide is the 
reactive species that is opened up by nucleophilic attack  at 
C l 6 to give the alkylation product shown in Figure 6 .
D IS C U S S IO N
The altromycins (Figure 1) are members of the pluramycin 
group of antibiotics. Like most other members of the 
pluramycin family of antibiotics, the altromycins have potent 
antitum or activity that is believed to be related to their ability 
to interact with DNA. Although the altromycins appear to 
interact in both grooves of DNA (M cAlpine et al., 1992), a 
general understanding of their interaction with D N A  has 
remained elusive. In this study we have demonstrated that 
altromycin B and the related pluramycins intercalate between 
base pairs and, where an epoxide is present, alkylate N 7 of
guanine. On the basis of these data and a knowledge of the 
threading mechanism for the interaction of the anthracycline 
nogalamycin with D N A  (see later), a structure of the altro­
mycin B (N 7-guanine)-D N A  adduct is proposed (Figure 6B).
From a strictly structural perspective, the altromycin B 
molecule can be divided into four distinct regions: the planar 
aglycon moiety, which consists of a 4//-anthra[l,2-Z>]pyran 
ring system, the disaccharide a t CIO, the glycosidically bound 
neutral sugar at C5, and the epoxide a t C2 (Figure 1). A 
major lead in predicting how the altromycins might interact 
with DNA is the recognition that this aglycon moiety is similar 
in structure to nogalamycin and the synthetic anthracene- 
9,10-dione group of antitum or antibiotics (Tanious et al., 
1992), which interact with D N A  through a “threading 
mechanism” (Islam  et al., 1985). A key structural feature of 
DN A-threading compounds is the presence of bulky side chains 
or rings at two or more corners of a planar anthraquinone ring 
system. This is clearly the case for the altromycins (sub­
stituents at C2, C5, and CIO) and also for other members of 
the pluramycin group (e.g., substituents a t C2, C 8 , and CIO).
The prototypic DN A-threading compound is the an thra­
cycline nogalamycin. The threading mode of interaction of
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T a b l e  I I :  ' H - N M R  C h e m i c a l  S h i f t s  o f  A l t r o m y c i n  B ,  A l t r o m y c i n  B - G u a n i n e  ( A l t B - G )  A d d u c t ,  a n d  A ^ - M e t h y l g u a n i n e
c h e m i c a l  s h i f t s  ( p p m ) c h e m i c a l  s h i f t s  ( p p m )
' H  a s s i g n m e n t 0 a l t r o m y c i n  B *  A l t B - G  a d d u c t c ' H  a s s i g n m e n t 0 a l t r o m y c i n  B *  A l t B - G  a d d u c t c
3 6 . 5 2 6 . 3 0 5 a " 2 . 4 8 2 . 4 0
6 8 . 6 9 8 . 6 5 5 b " 1 . 2 5 1 . 2 5
8 7 . 8 5 7 . 8 5 6 " 5 . 5 3 5 . 5 0
9 7 . 9 8 7 . 9 5 2 " M e 1 . 6 5 1 . 6 8
1 5 1 . 9 3 1 . 8 8 4 " M e 1 . 0 4 1 . 0 5
1 6 3 . 3 5 5 . 5 5 4 " N ( M e ) 2 2 . 4 7 2 . 4 5
1 7 1 . 2 5 1 . 6 5 1 ' " 4 . 7 9 4 . 7 5
1 ' 4 . 3 1 4 . 4 0 2 a ' " 2 . 3 1 2 . 1 5
y 3 . 9 6 3 . 7 2 2 b ' " 1 . 7 8 1 . 7 5
4 ' 3 . 5 9 3 . 5 9 ' 3 " , 3 . 6 2 3 . 5 5
5 ' 4 . 6 6 4 . 6 7 ' 4  m 3 . 2 7 3 . 2 5
6 ' 4 . 5 6 4 . 4 7 ' 5 " ' 4 . 0 9 4 . 0 5
2 ' M e 1 . 7 3 1 . 5 0 5 " ' M e 1 . 2 6 1 . 1 5
2 " 4 . 3 2 4 . 3 5 G u a  8 7 . 9 5  ( 7 . 9 0 ) '
3 " 3 . 7 7 3 . 6 5 G u a  N 2 H 2 5 . 8 5  ( 6 . 0 0 )
G u a N l H 1 0 . 3 5  ( 1 0 . 7 5 )
0  F o r  n u m b e r i n g ,  s e e  F i g u r e  1 .  b C h e m i c a l  s h i f t s  t a k e n  f r o m  B r i l l  e t  a l .  ( 1 9 9 0 ) .  c  C h e m i c a l  s h i f t s  m e a s u r e d  a t  5 0 0  M H z  i n  4 : 1  d e u t e r a t e d  D M S O /  
b e n z e n e  a t  3 3 3  K .  '  T e n t a t i v e  a s s i g n m e n t s .  *  N u m b e r s  i n  p a r e n t h e s e s  a r e  c h e m i c a l  s h i f t s  o f  A ^ - m e t h y l g u a n i n e  m e a s u r e d  a t  5 0 0  M H z  i n  d e u t e r a t e d  
D M S O  a t  3 0 0  K .
Minor
Groove
F ig u r e  7 :  G e n e r a l  t h r e a d e d / i n t e r c a l a t e d  m o d e l  o f  t h e  p l u r a m y c i n  ( N 7 - g u a n i n e ) - D N A  a d d u c t  s h o w i n g  t h e  p o s i t i o n i n g  o f  s u b s t i t u e n t s  C 2  
a n d  C 5  i n  t h e  m a j o r  g r o o v e  a n d  C 8  a n d  C I O  i n  t h e  m i n o r  g r o o v e .
nogalamycin with D N A  has been thoroughly characterized 
using kinetics (G abbay e ta l., 1973; Fox & W aring, 1984; Fox 
e ta l., 1985; Tanious e ta l., 1991), molecular modeling (Collier 
et al., 1984), X-ray crystallographic (Arora, 1983; W ang et 
al., 1990; Liaw et al., 1989; W illiams et al., 1990), and N M R  
data (Searle et al., 1988; Zhang & Patel, 1990; Van Houte 
et al., 1992). This threading type of DNA binding is 
differentiated from classical intercalation because, in the case 
of threading, two side chains or rings lie one in each of the 
major and minor DNA grooves, rather than just the one groove 
occupied for classic intercalators (Baguley, 1991).
On the basis of the known structure of the nogalam ycin- 
DN A complex and the knowledge tha t altromycin B alkylates 
N7 of guanine in the major groove, a structure of the threaded 
altromycin B (N 7-guanine)-D N A  adduct is proposed (Figure 
6 B). In this model the 4 //-an th ra[l,2 -6 ]py ran  ring interca­
lates between the base pairs and positions the side chains at 
C2 (epoxide) and C5 (C-glycoside) in the major groove and
the disaccharide at C 10 in the minor groove of DNA. There 
is necessarily a disruption of DNA structure in order to 
accommodate threading of a bulky side chain from one side 
to another. This process could be most easily accommodated 
if the threading takes place from  the major to the minor groove. 
The intercalative binding of the 47/-anthra[l,2-6]pyran ring 
then positions the epoxide in the major groove in proximity 
to N7 of guanine to facilitate nucleophilic attack at C l 6 and 
acid-catalyzed opening of the epoxide ring (Figure 6 A). Thus, 
the Final d rug-D N A  adduct is an intercalated threaded 
complex tha t is covalently bound through N7 of guanine in 
the major groove of DNA.
In the proposed model the intercalation site is placed 
arbitrarily between the covalently modified GC base pair and 
the base pair to the 5' side of the covalently modified guanine. 
Although the sequence specificity lies to the 5' side of the 
covalently modified guanine (5' A G *N ), it is most likely that 
this preference is due to groove binding interactions rather
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than the intercalative binding interactions, since different 
members o f  the pluramycin fam ily (altromycin vs hedamycin) 
have different sequence specificities (Sun and H urley, un­
published results), although they possess the same intercalative 
moiety.
This intercalative threading interaction with associated  
alkylation for altrom ycin B can be extended to propose a 
general model (Figure 7) for the interaction o f the pluramycins 
with D N A . In this model the 4tf-anthra[l,2 -6]pyran  ring 
intercalates betw een the base pairs as shown, and the side 
chains at C 2 and C5 are in the major groove and those at C 8 
and CIO are in the minor groove. Presumably, these side 
chains interact either noncovalently (e.g., sugars) or covalently  
(e.g., epoxide). This model provides a novel m otif for a conjoint 
intercalation-alkylation interaction with D N A  that also  
incorporates a threading m echanism. Studies are in progress 
using high-field N M R  on a defined oligomer to provide m ore 
precise data on the proposed altromycin B -D N A  adduct 
structure.
Perhaps the m ost definitive data previously obtained on the 
interaction o f  other members o f the pluramycin group o f  
antitumor antibiotics with D N A  is available from studies on 
hedamycin (W hite & W hite, 1969; Jernigan et al., 1978; 
Bennett, 1982). In the earlier work (W hite & W hite, 1969; 
Jernigan et al., 1978), two types o f  D N A  binding by hedamycin  
were determ ined, corresponding to irreversible (type I) and 
reversible (type II). In both cases, intercalation is proposed 
to be involved with, in addition, covalent bonding for type I 
binding. In the m ore recent work, Bennett (1982) has shown  
that hedam ycin forms a stable com plex with D N A  with  
associated alkali-labile strand breaks that occur at deox- 
yguanosine. H e  also reported that 5' T G  sequences are 
especially reactive to hedamycin. On the basis o f analogies 
with other alkylating species, such as dim ethyl sulfate, N 7  o f  
guanine was postulated to be the reactive site. These data are 
in accord with our proposed general model for the reaction 
o f the pluram ycin group o f antibiotics with D N A .
Finally, it seem s likely that the mechanism  o f action o f  
kapuramycin A 3, a tetrahydroanthrapyrone antitumor an­
tibiotic produced by a Streptomyces species (Hara et al., 1990), 
and aflatoxin Bi is related to that o f the pluramycins. 
Kapuramycin A 3 has been shown to produce covalent 
m odification o f guanine either through N 3  or N 7  in D N A  
and also produce single-strand scission o f D N A . On the basis 
o f the result described here for altromycin B, we propose that 
N 7  o f guanine is the alkylation site, and the /3,7 -unsaturated
5-keto carboxylic acid threads into the minor groove and 
catalyzes the strand breakage o f D N A  by an as yet unde­
termined m echanism . A flatoxin Bi is quite analogous to the 
covalently m odifying pluramycins in that it intercalates into  
D N A  and alkylates N 7  o f guanine via an epoxide (G o- 
palakrishnam et al., 1990). However, from a structural 
perspective, the pluramycins and aflatoxin Bj are quite 
different.
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Abstract: The pluramycins are a class o f antitumor antibiotics for which a detailed structural investigation o f  their 
interaction with D NA  is lacking. Using altromycin B as a prototypical pluramycin, we have characterized the drug’s 
interaction with the self-complementary D NA  duplex [d(GAAG*TACTTC)]2 diadduct (* denotes the site o f  covalent 
modification) by two-dimensional NMR and have gained considerable insight into the role played by the drug’s 
glycosidic substituents in sequence selectivity. The drug intercalates into the D NA  molecule and stacks to the 5' 
side o f the modified guanine, thereby placing a disaccharide into the minor groove and a monosaccharide into the 
major groove. As a result o f these interactions, the epoxide is positioned in the major groove o f the D NA  to perform
electrophilic attack on N7 o f guanine.
Introduction
The members o f the pluramycin family o f antitumor antibio­
tics (Figure 1) are Streptomyces-derived natural products that 
show in vitro activity against a wide variety o f tumor cell lines, 
including P388 leukemia, adenocarcinoma, M 5076 ovarian 
sarcoma, Lewis lung carcinoma, and human LS174T colon  
cancer.1 As a group, they can be considered as being structurally 
elaborated from the anthracycline class o f antibiotics, i.e., by 
adding a pyran ring to the anthraquinone chromophore and 
various possible saccharide moieties and epoxide functionalities 
to positions on the conjugated ring system .2 Those members 
bearing an epoxide substituent attached to the C2 position on 
the pyran ring have the ability to covalently modify D N A .1,3 
On the basis o f mass spectroscopy, NMR, and gel-electro­
phoretic studies performed on the heat-induced depurination 
reaction o f these agents adducted to DNA, the mechanism of 
covalent modification has been determined to be the electrophilic 
attack o f the epoxide on N7 o f guanine. This N7 alkylation 
results in opening o f the epoxide functionality to form cationic 
lesions on the D N A  molecule (Figure 2).4
* Author to whom correspondence should be addressed.
t Abbreviations: NMR, nuclear magnetic resonance; NOE, nuclear 
overhauser effect; NOESY, nuclear overhauser effect spectroscopy; ROESY, 
rotating frame nuclear overhauser effect spectroscopy; DQF-COSY, double 
quantum filtered correlation spectroscopy; TOCSY, total correlation 
spectroscopy; tppi, time proportional phase increment; EDTA, ethylenedi- 
aminetetraacetic acid.
® Abstract published in Advance ACS Abstracts, February 1, 1995.
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Discovery and Development; Valeriote, F. A., Corbett, T. H., Baker, L. H., 
Eds.; Kluwer Academic Publishers: Boston, in press.
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The compounds o f this family o f antibiotics range in structural 
complexity from sapurimycin, the most simple representative, 
to hedamycin and altromycin B, the two most complex 
members. Altromycin B and hedamycin each represent a 
structurally distinct subgroup within the pluramycin family o f  
compounds. The classical pluramycins, represented by heda­
mycin, have amino sugars attached to the C8 and CIO positions. 
Attached to the C2 position can be a vinyl substituent (kida­
mycin),5 a vinyl epoxide (pluramycin A ),6 a single epoxide 
(epoxykidamycin),7 or a double epoxide (hedamycin) (see Figure 
l ).8 The altromycins, the newest members in the pluramycin 
family, lack the C8 amino sugar distinctive to their classical 
counterparts and are characterized by an amino disaccharide 
attached through the CIO position on the conjugated chro­
mophore. Additionally, the altromycins can have a neutral 
methyl ester-linked 6-deoxy-3-0-m ethylaltrose attached to the 
chromophore C5 position.1,9 Unlike the classical pluramycins, 
the altromycins do not vary the C2 single epoxide substituent.
Despite the many similarities among this fam ily o f DNA- 
reactive ligands, the two families o f pluramycins exhibit 
different D N A  sequence selectivities in sites o f covalent 
modification. The varying reactivity o f different members to 
the same sequences appears to be modulated by glycoside 
substitution on the main chromophore at positions C5, C8, and 
CIO. While hedamycin and pluramycin exhibit a high reactivity
(4) (a) Sun, D.; Hansen, M.; Clement, J. J.; Hurley, L. H. Biochemistry 
1993, 32, 8068-8074. (b) Hansen, M.; Hurley, L. H. Biophysical Society 
Meeting 1994, 82, A155.
(5) (a) Furukawa, M.; Iitaka, Y. Acta. Crystallogr. 1980, B36, 2270- 
2276. (b) Furukawa, M.; Iitaka, Y. Tetrahedron Lett. 1974, 37, 3287— 
3290. (c) Furukawa, M.; Hayakawa, I.; Ohta, G.; Iitaka, Y. Tetrahedron 
1975, 31, 2989-2995.
(6) (a) Kondo, S.; Miyamoto, M.; Naganawa, H.; Takeuchi, T.; Umezawa, 
H. J. Antibiot. 1977, 30, 1143-1145. (b) Maeda, K.; Takeuchi, T.; Nitta, 
K.; Yagishita, K.; Utahara, R.; Osato, T.; Ueda, M.; Kondo, S.; Okami, Y.; 
Umezawa, H. J. Antibiot., Ser. A 1956, 9, 75—81.
(7) Byrne, K. M.; Gonda, S. K.; Hilton, B. D. J. Antibiot. 1985, 38, 
1040-1049.
(8) (a) Sequin, U. R.; Bedford, C. T.; Chung, S. K.; Scott, A. I. Helv. 
Chim. Acta 1977, 60, 896—906. (b) Zehnder, M.; Sequin, U.; Nadig, H. 
Helv. Chim. Acta 1979, 62, 2525—2533.
(9) Jackson, M.; Karwowski, J. P.; Theriault, R. J.; Hardy, D. J.; Swanson, 
S. J.; Barlow, G. J.; Tillis, P. M.; McAlpine, J. B. J. Antibiot. 1990, 43, 
223-228.
© 1995 American Chemical Society





h  °  SapurimycinH
OH c h 3C lassica l P luram ycins












Figure 1. S t r u c t u r e s  o f  r e p r e s e n t a t i v e  p l u r a m y c i n  a n t i b i o t i c s .  T h e  f a m i l y  s u b d i v i d e s  b y  s t r u c t u r e  i n t o  t w o  d i s t i n c t  g r o u p s :  t h e  c l a s s i c a l  p l u r a m y c i n s  
( d e p i c t e d  b y  k i d a m y c i n ,  e p o x y k i d a m y c i n .  p l u r a m y c i n  A .  a n d  h e d a m y c i n )  a n d  t h e  n e w l y  d i s c o v e r e d  a l t r o m y c i n s  ( d e p i c t e d  b y  a l t r o m y c i n s  B  a n d  
H). S a p u r i m y c i n  r e p r e s e n t s  t h e  s i m p l e s t  a n a l o g s .
n h 2
D N A  s t r a n d  
b r e a k a g e
s i m i l a r  t o  M a x a m -  
G i l b e r t  S e q u e n c i n g
Figure 2. P r o p o s e d  m e c h a n i s m  o f  c o v a l e n t  m o d i f i c a t i o n  o f  D N A  b y  p l u r a m y c i n - t y p e  c o m p o u n d s .  T h e  N 7  o f  g u a n i n e  p e r f o r m s  n u c l e o p h i l i c  
a t t a c k  o n  t h e  e p o x i d e ,  f o r m i n g  a  c a t i o n i c  l e s i o n  o n  t h e  D N A .  S u b s e q u e n t  t h e r m a l  d e p u r i n a t i o n  r e s u l t s  i n  D N A  s t r a n d  b r e a k a g e . 4
toward 5'(C/T)G sequences, the altromycins demonstrate se­
lectivity for 5'AG sequences.3’10
In this structural study, the self-complementary [d- 
(GAAG*TACTTC)]2  decamer, which contains two highly 
reactive altromycin B intercalation/alkylation sites (underlined 
and starred), has been reacted with 2 equiv of altromycin B to 
form a C2-symmetric bisadduct (Figure 3). Two-dimensional 
NMR is used to confirm the proposed mechanism of covalent 
modification of guanine, to structurally determine the three- 
dimensional interaction of altromycin B with the DNA molecule, 
and to identify key interactions between chromophore substit­
uents and DNA, directing the DNA sequence recognition by 
the drug molecule. The altromycin B chromophore intercalates 
through the DNA helix to the 5' side of the covalently modified 
guanine, interacting with both major and minor grooves through 
its sugar moieties. It appears that the interactions of the C5 
neutral altrose moiety with the major groove and the amino
(1 0 )  S u n , D .; H a n sen , M .: H u rley . L . H . J. A m . C h em . S o c . 1995, 1 17 . 
x x x x x .
6-D co x y -3 -0 -M eth y la ltro se
H3' H2'
2 ,6 -D id eo x y -3 -0 -M eth y la ltro se
H2b
N ,N -D im ethylvancosam m e
GAAlGTAClTTC
ctticatg'aag
10 9 8  7 6 5 4  3 2  1
Figure 3 .  S t r u c t u r e s  a n d  n u m b e r i n g  s c h e m e s  o f  a l t r o m y c i n  B  a n d  t h e  
D N A  d e c a m e r  u s e d  i n  t h i s  s t u d y .  S h o w n  a r e  s i t e s  o f  i n t e r c a l a t i o n  ( 3 A .  
4 G )  a n d  c o v a l e n t  m o d i f i c a t i o n  ( 4 G ) .
disaccharide with the minor groove orient the epoxide to react 
with N7 of guanine in a sequence-dependent fashion.
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Table 1. Comprison of the Altromycin B Chemical Shifts in the 
Bis(altromyciin B~[d(GAAGTACTTC)]2  Diadduct and the Free 
Drug
Cemical Shifts (ppm) of Altromycin B
































a For numbering, see Figure 3. b Chemical shifts referenced to H20  
in 99.9% D20 .  c Chemical shifts in chloroform.12 d Not assigned in this 
study. e Distinguished from each other by chemical shift arguments and 
may be interchanged.
Results
Three oligonucleotides, [d(GAAGCTTC)]2, [d(GAAGTACT- 
TC)]2, and [d(GATAGTACTATC)]2, were initially prepared and 
reacted with altromycin B. The octamer, which lacked the two- 
base-pair spacer between modified guanines, was too unstable 
to adequately study. In the one-dimensional exchangeable and 
nonexchangeable spectra of the 2:1 bis(altromycin B)— 
[d(GAAGTACTTC)]2 diadduct, there initially exists only one 
set of proton resonances representing one adduct species. The 
existence of only four nonterminal imino resonances, coupled 
with two-dimensional analysis of the nonexchangeable spectra, 
reveals a retention of self-complementarity of the duplex 
palindrome upon adduct formation. Both the dodecamer and 
the decamer yielded similar C2-symmetric bisadducts with 
moderate chemical stability. However, each degraded over the 
span of several days from a singular set of resonances to a 
complex mixture of signals resulting from depurination of the 
cationic guanine adduct. Additionally, samples were diluted 
in an attempt to diminish signal broadening due to aggregation 
at the expense of signal intensity. Both the decamer and 
dodecamer were subjected to initial study by NMR experiments, 
and the decamer, being less complex spectrally, was character­
ized further.
Assignment of the Altromycin B Proton Resonances. The
altromycin B proton resonances (Table 1) are divided into three 
regions: the CIO sugar moiety, the C 13 sugar moiety, and the 
chromophore region bearing the site of covalent attachment to 
the DNA molecule. Protons of each region were assigned using 
TOCSY, ROESY, and NOESY experiments." The aromatic
H8 and H9 resonances, on the conjugated chromophore, adjacent 
to the CIO disaccharide, were identified by mutual, through- 
bond coupling and by NOE connectivities to the H6" sugar 
proton. In the CIO-linked, AT^V-dimethylvancosamine (desig­
nated with double prime numbering), the H6" proton coupled 
to both H5a" and H5b" resonances and showed ROESY 
connectivities to the 2"  methyl (doublet), identified through 
coupling to the H2" proton. The H5a" and H5b" were 
differentiated on the basis of a ROESY cross peak (strong 
NOESY connectivity) between H6" and H5b" and an absent 
ROESY connectivity (weak NOESY connectivity) between H6" 
and H5a". The 4" dimethylamino, easily identified by chemical 
shift and one-dimensional resonance intensity, was used to 
identify the 4" methyl (singlet) and H3" resonances through 
ROESY connectivities. The C3"-linked 2,6-dideoxy-3-0- 
methylaltrose proton resonances (designated in triple prime 
numbers) were easily assigned through mutual coupling between 
adjacent protons around the sugar ring. The H2a'" and H2b"' 
could only be tentatively distinguished from each other on the 
basis of correlation to the chemical shifts of the free drug.12
In the C13-linked 6-deoxy-3-0-methylaltrose, the 2' methyl 
(doublet) coupled to the H2' proton. The H4', H5', and H6 ' 
were all identified through mutual coupling to each other and 
by the through-space ROESY connectivities between H4' and 
the 2' methyl. The H3' proton assignment remains problematic 
and has not been assigned in this experiment. The H6 aromatic 
proton, located near this region on the chromophore, was 
identified through NOE connectivities between itself and the 
2' methyl, H2', H4', H5', and H6 '  proton resonances.
At the site of covalent attachment, the 17 methyl (doublet) 
was assigned through coupling to the H I6  proton and NOE 
connectivities to the 4GH8 proton resonance. The 15 methyl 
(singlet) was then assigned on the basis of long-range coupling 
to both the 17 methyl and H I6 . The H3 aromatic proton 
resonance could be identified by NOE connectivities to both 
former epoxide methyls. NMR results of this study strongly 
argue that the stereochemistry at the site of covalent attachment 
is R at the C 14 chiral center and S at the C 16 chiral center. It 
is known from published ROESY data on the free drug12 that 
the two epoxide methyls are trans to each other. The existence 
of only a single adduct species in this study reveals that the 
nucleophilic addition goes by an Sn2 mechanism, which would 
result in the inversion of the stereochemistry at the C16 center. 
This information limits the stereochemistry possibilities to the 
diastereomeric pair, C14J?,C16S or C14S,C16R (a and b in 
Figure 4). Pathway a, associated with the C14R,C16S stereo­
chemistry, was chosen on the basis of a medium ROESY cross 
peak between the H3 aromatic proton and the 17 methyl 
resonance (strong NOESY connectivity) and an absent ROESY 
H3—15 methyl cross peak (weak NOESY connectivity). Also, 
the 17 methyl—15 methyl cross peak is quite weak in the 
ROESY spectrum and of medium intensity in the NOESY 
spectrum. In the case of pathway b, associated with the C14S,- 
C16R stereochemistry, one would expect the H3—15 methyl 
connectivity to be greater than the H3—17 methyl connectivity 
and the 17 methyl—15 methyl to be quite intense. On the basis 
of these arguments, the as yet undetermined absolute stere­
ochemistries for the free drug would be R for both C14 and 
C16 chiral centers.
(11) (a) Bax, A.; Davis, D. J. Magn. Resort. 1985, 63, 207—213. (b) 
Bax, A.; Davis, D. G. J. Magn. Reson. 1985, 65, 355—360. (c) Drobney, 
G.; Pines, A.; Sinton, S.; Weitekamp, D. P.; Wemmer, D. Faraday Symp. 
Chem. Soc. 1987, 12, 49—55. (d) Marion, D.; Wiithrich, K. Biochem. 
Biophys. Res. Commun. 1983, 113, 967—974.
(12) Brill, G. B.; McAlpine, J. B.; Whittem, D. N. J. Antibiot. 1990,43, 
229-237.
2 4 2 4  J. Am. Chem. Soc., Vol. 117, No. 9. 1995
> °'J15CHl HI6
i 1' — 'Vns
Guanine
I7CH3
’ — y x 6











Expected ROESY or Strong 
NOESY C onnectivities
Figure 4. T w o  p o s s i b l e  p a t h w a y s  ( a  a n d  b )  f o r  e p o x i d e  a l k y l a t i o n  o f  
D N A  b y  a l t r o m y c i n  B .  S h o w n  a r e  t h e  e x p e c t e d  t h r o u g h - s p a c e  
c o n n e c t i v i t i e s  f o r  e a c h  r e s p e c t i v e  s t e r e o i s o m e r  a n d  f i n a l  s t e r e o c h e m i c a l  
c o n s e q u e n c e s .
DNA Proton Assignments. DNA assignments of the 10- 
mer duplex and its bis(altromycin) diadduct were achieved 
through established methods13 by identifying sequential NOESY 
connectivities between bases and creating walks leading from 
the 5' end to the 3' end of the DNA molecule; these are reported 
in Table 2. The aromatic to aromatic, aromatic to H I' (left 
walk in Figure 5), aromatic to H27H2", and aromatic to H3' 
(right walk in Figure 5) walks all demonstrate breaks at the 
3A—4G and the 7C—8T steps, presumably due to the separation 
of the base pairs at this position to accommodate intercalation 
by the drug chromophore. The DNA walks also show some 
irregularities caused by unusual line broadening to the 5' side 
of the alkylation site, specifically residues 2A and 3A. Bridging 
the break associated with the 7C—8T junction in the DNA's 
aromatic—H I' walk is the altromycin H9 aromatic proton. The 
7CH1' connects to the drug's H9 proton, which in turn connects 
to the 8TH1' traversing the intercalation site (seen as a dotted 
line on the left walk in Figure 5). These results unequivocally 
position the drug chromophore directly to the 5' side of the 
covalently modified guanine between the 3A’8T and 4G-7C base 
pairs.
A ltrom ycin B Is Covalently A ttached at N7 of 4G. The
chemical character of the DNA’s 4GH8 proton resonance yields 
evidence confirming the site of covalent modification. The H8 
aromatic proton of the drug-modified guanine (4G) is shifted 
to 9.7 ppm, which is 2.2 ppm downfield from its chemical shift 
in the unmodified duplex. Due to rapid exchange of this proton 
resonance with deuterium in D :0 , the aromatic proton was 
identified and characterized in NMR experiments performed in 
95% H2O. The acidic nature of this proton is the direct result 
of alkylation of guanine through N7 to form a cationic species 
in which the H8 proton has become labile (see Figure 2). This 
result agrees with previously reported N7-alkyl—guanine ad- 
ducts, most notably the aflatoxin—DNA adduct,14 in which the 
H8 proton of the modified guanine also resonates at 9.7 ppm.
Inter-D rug—DNA Connectivities in the M ajor Groove. In 
the major groove of the DNA molecule, the drug shows two 
regions of DNA NOESY contacts (summarized in Figure 6).
( 1 3 )  H a r e .  D .  R . :  W e m m e r .  D .  E . ;  C h o u ,  S .  H . ;  D r o b n y ,  G . ;  R e i d ,  B .  R .  
J .  M o l .  B i o l .  1983, 1 7 1 ,  3 1 9 - 3 3 6 .
( 1 4 )  G o p a l a k r i s h n a n ,  S . ;  H a r r i s ,  T .  M . ;  S t o n e ,  M .  P .  B i o c h e m i s t r x  1990, 
2 9 ,  1 0 4 3 8 - 1 0 4 4 8 .
Hansen and Hurley
Surrounding the site of alkylation at 4G, the proton resonances 
of the former epoxide show contacts to both sides of the 
intercalation site. The 15 methyl shows NOE connectivities to 
the 4GH8 and 3AH8 protons, reaffirming positioning of the 
intercalating chromophore between the 3A and 4G bases. The 
17 methyl resonance shows NOE connectivity to the H8 proton 
of the modified guanine, placing the opened epoxide in 
proximity of N7 of 4G in the major groove.
The C13-linked 6-deoxy-3-0-methylaltrose associates on the 
other side of the major groove with the noncovalently modified 
DNA strand and spans the opened base pair between 7C and 
8T. The hydrophobic side of the sugar appears to make van 
der Waal contacts with the hydrophobic pocket formed by 7C, 
the drug chromophore, and 8T. The 2' methyl of this sugar 
shows NOE contacts with 7CH5, 7CH6, and the 8T methyl, 
and the H4' and H6' positioned on the same face of the sugar 
show contacts to the 8T methyl. Positioned on the opposite 
side of the sugar, the H2' shows a connectivity to the 8T methyl, 
while the H5' does not show any DNA contacts, presumably 
because it faces out of the major groove. In this orientation, 
the more hydrophilic side of the sugar orients away from the 
floor of the major groove to interact with the solvent.
In ter-D rug—DNA Connectivities in the M inor Groove. 
Positioning of the CIO-linked (V,A-dimethylvancosamine can 
be unequivocally made in the minor groove side of the DNA 
molecule, based on NOE contacts with 3AH2, projecting from 
the floor of the minor groove, and H 1' and H4' resonances of 
3A, 4G, 8T, and 9T, which are located on the DNA backbone 
facing into the minor groove (Figure 7). Based upon these NOE 
contacts, this positions this substituent deep in the minor groove 
making extensive contact with the DNA. The dimethylamino 
substituent of this sugar shows medium to strong connectivities 
to 3AH2, 8TH1', 8TH4', 9TH1', and 9TH4', which positions it 
in close proximity to interact with the 8T residue on the 
noncovalent strand of the DNA duplex.
Also located in the minor groove is the neutral 2,6-dideoxy- 
3-O-methylaltrose, which is attached to the C3" position of the 
AUV-dimethylvancosamine. Unlike its neighboring amino sugar, 
this terminal sugar moiety makes only minimal specific contact 
with the DNA, showing only two weak NOE connectivities to 
the minor groove between the H2"a/b methylene of the drug 
sugar and 3AH4' of the DNA molecule. Molecular modeling 
based on NOE constraints places this sugar toward the outside 
edge of the minor groove nearest to the strand containing the 
modified guanine and is in the proximity of 3A and 4G.
The proton resonances associated with 2A and 3A, which 
are both located to the 5' side of the modified guanine, are 
particularly broad in comparison to the other resonances in 
the DNA duplex and altromycin B (see Figure 5). This 
phenomenon is duplicated in the bis(altromycin B)—[d- 
(GATAG*TACTATC)]2  diadduct, affecting the equivalent 
residues 3T and 4A. Due to the minimal NOE contacts of the 
terminal neutral sugar with the minor groove of DNA, it is 
probable that this sugar is conformationally flexible, merely 
filling space in the minor groove but not making any specific 
interactions. The broadness of the 2A and 3A DNA resonances 
may be a result of a heterogeneous chemical environment caused 
by the 3" sugar sampling multiple conformations in this region 
of the minor groove. This suggests that the fluctual motion of 
the 3" neutral sugar sweeps out a greater area of the DNA minor 
groove, including the region near 2A, than revealed by restrained 
molecular modeling.
NM R-Derived M olecular Modeling of the Bis(altromycin 
B )-(lO -m er) D iadduct. Through a 100 ps solvated molecular 
dynamics calculation using 48 inter-drug—DNA, 64 intra-drug,
te-Directed Alkylation o f Guanine N7 in Pluramycins
ible 2 .  C o m p a r i s o n  o f  t h e  D N A  P r o t o n  C h e m i c a l  S h i f t s "  o f  t h e  B i s ( a l t r o m y c i n  B ) — [ d ( G A A G T A C T T C ) ] 2  D u p l e x  D i a d d u c t  w i t h  t h e  
o m o d i f i e d  D u p l e x
a s e H 8 / H 6 H 5 / 5 C H } H 2 H I ' H 2 ' H 2 " H 3 ' H 4 '
G 7 . 7 8  ( - 0 . 0 2 ) ' ’ 5.44 (+0.22) 2 . 2 6  ( - 0 . 1 8 ) 2.40 (-0 .25 ) 4 . 7 0  ( - 0 . 1 2 ) 4 . 0 9  ( - 0 . 0 7 )
A 7.94 (-0 .26 ) a b s e n t c 5.62 (-0 .32 ) 2.37 (-0 .4 0 ) 2.55 (-0 .37 ) 4 . 9 5  ( - 0 . 1 1 ) 4 . 2 7  ( - 0 . 1 4 )
A 8 . 1 0  ( + 0 . 0 4 ) 7 . 3 3  ( - 0 . 2 0 ) 6 . 2 0  ( + 0 . 1 8 ) 2 . 6 6  ( - 0 . 0 2 ) 2.47 (-0 .36 ) 5 . 0 5  ( - 0 . 0 0 ) 4 . 3 7  ( - 0 . 0 9 )
G * 9.70 (—2.2)d 6 . 0 0  ( + 0 . 1 7 ) 2 . 4 2  ( - 0 . 0 0 ) 2 . 7 7  ( + 0 . 0 8 ) 4 . 8 2  ( - 0 . 0 6 ) 4 . 3 6  ( - 0 . 0 3 )
T 7.37 (+0.22) 1 . 3 0  ( + 0 . 0 2 ) 5 . 7 3  ( - 0 . 0 2 ) 2 . 0 0  ( - 0 . 0 5 ) 2 . 4 5  ( - 0 . 0 3 ) 4 . 8 0  ( - 0 . 0 6 ) 4 . 1 1  ( - 0 . 1 0 )
A 8.04 (-0 .21 ) 7 . 2 0  ( - 0 . 2 0 ) 6 . 0 9  ( - 0 . 1 1 ) 2.40 (-0 .31 ) 2 . 7 5  ( - 0 . 1 0 ) 5 . 0 0  ( - 0 . 0 2 ) 4 . 2 8  ( - 0 . 1 7 )
C 7 . 4 8  ( + 0 . 1 7 ) 5 . 0 9  ( - 0 . 1 1 ) 5.62 (-0 .2 1 ) 2.40 (+0.35) 2.27 (-0 .23 ) 4.95 (+0.27) 4 . 2 3  ( - 0 . 0 2 )
T 7.80 (+0.35) 1.92 (+0.35) 6 . 1 5  ( + 0 . 1 2 ) 2.45 (-0 .3 1 ) 2 . 4 5  ( - 0 . 1 2 ) 5 . 0 4  ( + 0 . 1 7 ) 4.40 (+0.23)
T 7 . 3 2  ( - 0 . 1 5 ) 1 . 6 5  ( - 0 . 0 7 ) 6 . 1 0  ( - 0 . 0 8 ) 2 . 1 0  ( - 0 . 0 8 ) 2 . 5 3  ( - 0 . 0 2 ) 4 . 7 8  ( - 0 . 1 4 ) 4 . 1 0  ( - 0 . 0 8 )
O C 7 . 6 2  ( - 0 . 0 3 ) 5 . 7 7  ( - 0 . 0 3 ) 6 . 2 7  ( - 0 . 0 0 ) 2 . 2 7  ( - 0 . 0 2 ) 2 . 2 7  ( - 0 . 0 2 ) 4 . 6 0  ( - 0 . 0 0 ) 4 . 0 1  ( - 0 . 0 4 )
J. Am. Chem. Soc., Vol. 117, No. 9, 1995 2 4 2 5
"  R e f e r e n c e d  t o  H 2 0  i n  9 9 . 9 %  D 2 0  u n l e s s  o t h e r w i s e  n o t e d .  b C h e m i c a l  s h i f t  d i f f e r e n c e s :  +  a n d  —  r e p r e s e n t  u p f i e l d  a n d  d o w n f i e l d  s h i f t s ,  
p e c t i v e l y .  S h o w n  i n  b o l d  a r e  t h o s e  g r e a t e r  t h a n  0 . 2  p p m .  c T o o  b r o a d  t o  b e  o b s e r v e d .  d  E x c h a n g e a b l e  p r o t o n  o b s e r v e d  i n  9 5 %  H 2 0 .
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>ure 5. N O E S Y  d a t a  ( 1 5 0  m s )  s h o w i n g  t h e  a r o m a t i c  t o  H I' ( l e f t )  
d  a r o m a t i c  t o  H 3 '  w a l k s  ( r i g h t ) .  I d e n t i f i e d  a r e  t h e  i n t r a - r e s i d u e  
n n e c t i v i t i e s  w i t h  a  b a s e  a n d  n u m b e r  d e s i g n a t i o n ,  b r e a k s  i n  t h e  w a l k s  
e  t o  l i g a n d  i n t e r c a l a t i o n  w i t h  a r r o w s ,  a n d  t h e  a l t r o m y c i n  H 9  r e s o n a n c e  
L h  a  d o t t e d  l i n e .  A l s o  s h o w n  a r e  c y t o s i n e  H 5  c o n n e c t i v i t i e s  t o  t h e i r  
n  H 6  p r o t o n  a n d  t h e  5 '  n e i g h b o r ' s  a r o m a t i c  p r o t o n .  F o r  7 C  a n d  
C ,  t h e s e  a r e  s h o w n  b y  a  s i n g l e  v e r t i c a l  l i n e .
d 118 intra-DNA constraints, a molecular model was achieved, 
mmarizing the NMR results (Figure 8). In this model, the 
racyclic chromophore positions its axis in a perpendicular 
ientation to the two adjacent base pairs, easily spanning the 
(lix to place glycosidic substituents into each groove. The 
A molecule undergoes extensive structural changes to 
ommodate this interaction by opening the two neighboring 
e pairs to twice their normal distance to stack on either side 
the conjugated ring system. In addition, the minor groove 
opened slightly, due to the insertion of the intercalating 
romophore and interaction with the CIO-linked disaccharide, 
the major groove, the influence of the C5-linked altrose 
oiety remains mostly nondistortive, binding snugly against 7C 
d 8T. The site of covalent modification, 4G, distorts to 
commodate N7 attachment of the drug chromophore through 
wo-carbon linker. To maintain an aromatic, planar bonding 
ometry of N7 and a tetrahedral, sp3 bonding configuration of 
attached C l6, the covalently modified guanine is forced to 
out of the base-pair plane toward both the major groove 
d the 5' phosphate.
Due to the proximity of the CIO A'.A-dimethylvancosamine 
8T, hydrogen bond formation is proposed between the 
otonated dimethylamino and 8T02 functionalities. Direct 
drogen bonding to the thymine 0 2  carbonyl and hydrogen 
rnding mediated through a water molecule with the carbonyl 
both consistent with NMR-derived constraints. However, 
rogen bonding to a water molecule, which bridges 8T02 to 
T, more favorably satisfies the modeling force field and is 
wn from direct analogy to the interaction of the amino sugar 
h the DNA minor groove in doxorubicin—DNA crystal 
ctures (see Figure 9).15
Although either stereoisomer at C l3 is feasible in the 
molecular model, the currently undetermined stereochemistry 
of the C l3 chiral center that joins the chromophore to the
6-deoxy-3-0-methylaltrose was arbitrarily modeled in the R 
configuration. In this position, the carbonyl of the methyl ester 
orients favorably to hydrogen bond to the external 7CH6 amino 
proton. Additionally, this stereochemistry orients the methoxy 
group out of the major groove to interact with the solvent. 
Positioning of a methoxy substituent facing out of a DNA 
groove to interact with the solvent is consistent with other DNA- 
reactive ligands, specifically CC-1065,16 calicheamycin,17 the 
altromycin C5-linked altrose, and nogalamycin.18
Discussion
Comparison to O ther DNA Adducts. The results published 
in this study confirm earlier proposals on the mode of DNA 
interaction of altromycin B4 and parallel results from concurrent 
NMR studies with the sapurimycin—DNA adduct19 and the 
hedamycin—DNA adduct.20 In all studies of the examples, the 
tetracyclic ring system is reported to orient perpendicular to 
the axes of the DNA base pairs in which it intercalates, 
positioning the epoxide functionality into the major groove to 
alkylate a guanine residue located on the 3' face of the molecule. 
Covalent attachment has been pinpointed by long-range 'H — 
l5N heterocorrelations between the drug molecule and N7 of 
guanine in the depurinated altromycin B—guanine adduct,4 as 
well as by identification and characterization of an acidic H8 
proton associated with the modified guanine in all three DNA 
adduct studies. Although the interaction of the chromophore 
and site of alkylation on the DNA in all three adducts are the 
same, the three compounds differ in that sapurimycin lacks 
glycoside interaction in either groove, altromycin B demonstrates 
sugar-mediated binding in both the major and the minor grooves, 
and hedamycin binds both the C8- and the CIO-linked amino 
sugars in the minor groove.
The pluramycins demonstrate characteristics of two other 
classes of DNA-reactive ligands, combining them into a novel 
mode of interaction with the DNA molecule. Like the mutagens 
aflatoxin21 and benzopyrene,22 the pluramycins have a conju-
( 1 5 )  N u n n ,  C . ;  M e e r v e l t ,  L . ;  Z h a n g ,  S . ;  M o o r e ,  M . ;  K e n n a r d ,  O .  J . M o l .  
B i o l .  1991, 2 2 2 ,  1 6 7 - 1 7 7 .
( 1 6 )  ( a )  S c a h i l l ,  T .  A . ;  J e n s e n ,  R .  M . ;  S w e n s o n ,  D .  H . ;  H a t z e n b u h l e r ,  
N .  T . ;  P e t z o l d ,  G .  L.; W i e r e n g a ,  W . ;  B r a h m e ,  N .  B i o c h e m i s t r y  1990, 2 9 ,  
2 8 5 2 - 2 8 6 0 .  ( b )  L i n ,  C .  H . ;  H u r l e y ,  L. H .  B i o c h e m i s t r y  1990. 2 9 ,  9 5 0 3 -  
9 5 0 7 .
( 1 7 )  W a l k e r ,  S . ;  M u r n i c k ,  J . ;  K a h n e ,  D .  J .  A m .  C h e m .  S o c .  1993, 1 1 5 ,  
7 9 5 4 - 7 9 6 1 .
( 1 8 )  E g l i ,  M . ;  W i l l i a m s ,  L .  D . ;  F r e d e r i c k ,  C .  A . ;  R i c h ,  A .  B i o c h e m i s t r y  
1991, 3 0 ,  1 3 6 4 - 1 3 7 2 .
( 1 9 )  L i n ,  C . ;  P a t e l ,  D .  J .  P e r s o n a l  c o m m u n i c a t i o n .
( 2 0 )  H a n s e n ,  M . ;  Y u n ,  S . ;  H u r l e y ,  L .  H .  U n p u b l i s h e d  r e s u l t s .
( 2 1 )  M c C o n n e l l ,  I. R . ;  G a r n e r ,  R .  C .  D N A  A d d u c t s :  I d e n t i f i c a t i o n  a n d  
B i o l o g i c a l  S i g n i f i c a n c e ' ,  1 9 9 4 ;  p p  4 9 — 5 5 .
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Figure 6 .  S u m m a r y  o f  k e y  N O E S Y  c o n n e c t i v i t i e s  ( l 5 0  a n d  3 0 0  m s )  ( t o p )  a n d  N O E S Y  d a t a  ( 1 5 0  m s )  ( b o t t o m ) ,  w h i c h  p o s i t i o n  t h e  C 5  s u g a r  
t h e  f o r m e r  C 2  e p o x i d e  m o i e t y  o f  a l t r o m y c i n  B  i n  t h e  m a j o r  g r o o v e .  T h e  N O E S Y  d a t a  ( b o t t o m )  s h o w  c o n n e c t i v i t i e s  o f  s o m e  o f  t h e  p r o t o n  
m e t h y l  r e s o n a n c e s  l o c a t e d  i n  t h e  m a j o r  g r o o v e .
gated ring system that is optimal for stacking between DNA 
bases and epoxide moieties that can covalently attach the planar 
ligand to N7 of guanine. By placing its sugar substituents into 
both major and minor grooves of the DNA helix, altromycin B 
has developed an additional mode of DNA interaction, similar 
to the anthracycline nogalamycin. Nogalamycin, a noncovalent 
intercalating agent, exhibits an intercalating chromophore similar 
to the pluramycins with the addition of attached sugar moieties. 
These glycosidic substitutions give nogalamycin definite se­
quence binding selectivity and increased binding affinity by 
forming a fairly rigid “dumbbell” structure that interacts with 
both grooves of the DNA molecule. 18-23
In contrast, the pluramycins demonstrate none of the binding 
selectivity exhibited by nogalamycin. In NMR studies in 
solution, while nogalamycin demonstrates specific binding to 
sites in oligomeric DNA ,23 the noncovalent pluramycin analog 
kidamycin binds with a high affinity but no observable 
selectivity to the oligomer [d(GATGTACATC)]2.24 Similar 
nonselective binding results are observed with the non-alkylating 
analogs neopluramycin and kidamycin in DNase I footprinting 
studies.10 It is therefore proposed that, upon intercalation of 
the DNA molecule by the drug chromophore, the C5, C8 , and 
CIO glycoside binding interactions primarily function in select 
sequences to orient and steer the normally unreactive epoxide 
into the proximity of the nucleophilic N7 of guanine in the major
( 2 2 )  D i p p l e ,  A .  D N A  A d d u c t s :  I d e n t i f i c a t i o n  a n d  B i o l o g i c a l  S i g n i f i a n c e ' ,  
1 9 9 4 ;  p p  1 0 7 - 1 2 9 .
( 2 3 )  ( a )  Z h a n g ,  X . ;  P a t e l ,  D .  J .  B i o c h e m i s t r y ’ 1 9 9 0 .  2 9 .  9 4 5 1  - 9 4 6 6 .  ( b )  
S e a r l e ,  M .  S . ;  H a l l ,  J .  G . ;  D e n n y ,  W .  A . ;  W a k e l i n ,  L .  P .  B i o c h e m i s t r y  1 9 8 8 .  
2 7 ,  4 3 4 0 - 4 3 4 9 .
( 2 4 )  H a n s e n ,  M . ;  H u r l e y ,  L .  H .  U n p u b l i s h e d  r e s u l t s .
groove, thereby achieving increased DNA reactivity and s 
quence selectivity.
Rationale for Sequence Selectivity. By high-resolution g 
electrophoresis studies using radiolabeled restriction enzyr 
fragments, the DNA alkylation selectivity has been determin* 
for the pluramycin class of antibiotics and a full account is giv 
in the accompanying paper. 10
In NMR studies with hedamycin and altromycin B adduct 
to their respective highly reactive sequences, the amino sugt 
show a high degree of interaction with pyrimidines in the min 
groove. Driving this interaction is the proposed hydrogen bo 
formation between the pyrimidine 0 2  carbonyl, which is high 
negative and protrudes slightly from the floor of the min 
groove, and the protonated dimethylamino substituent (s 
Figure 9). Considering the extensive contacts made by the C 
AVV-dimethylvancosamine with a pyrimidine to the 5' side 
the intercalation side in both modeled adducts, this is probat 
a fundamental interaction, giving rise to the two-base-p 
sequence selectivity demonstrated by pluramycin analogs, 
most reactive altromycin B sequence, 5'AG, places a thymi 
on the nonmodified strand in the 5' base pair position. Sequen 
selective effects arise from the association of the N,N-dimel 
ylvancosamine with this nonmodified strand to create a mic 
groove pocket for the terminal 6-deoxy-0-3-methylaltrose 
fit. In contrast, in the low reactive 5'TG bonding site, the ami 
sugar would be limited to either hydrogen bonding to t 
thymine carbonyl, which would sterically crowd the termi 
neutral sugar out of the minor groove, or forming a less optic 
hydrogen bond with N3 of the base paired adenine on the fl< 
of the minor groove.
ite-Directec Alkylation o f Guanine N7 in Pluramycins J. Am. Chem. Soc., Vol. 117, No. 9, 1995 2 4 2 7
5 ' 3 •1G I f f l l l l l l l l l l l l f l l l l l l l l l f  2A i i f i i i i i i i i i f i i i i i i if 3A 11(III I l f  III I 4G l l l l l f l l f f l f l l l  5T l l l l l l l f l l l f l l l l l f I  6A
H4‘ H2 H4' HV H4'




C H 2 -
NH(CHjJ2*
H4’ H1' H4’ H1' H1'
5 'IOC 9T l l i l l l i l l l l l f l l l l  8T H i l i i i i l l l l f l l l l i  7C l l l l l l l l l f l l l l l l l l  6A
<N





1.02.04.0 3.06.08.0 7.0 5.0
i g u r e  7 .  S u n m a r y  o f  k e y  N O E S Y  c o n n e c t i v i t i e s  ( 1 5 0  a n d  3 0 0  m s )  ( t o p )  a n d  N O E S Y  d a t a  ( 1 5 0  m s )  ( b o t t o m )  b e t w e e n  a l t r o m y c i n  B ’ s  C I O  
i a c c h a r i d e  a i d  t h e  m i n o r  g r o o v e .  I n  t h e  t o p ,  m e d i u m  a n d  s t r o n g  c o n n e c t i v i t i e s  a r e  s h o w n  i n  s o l i d  a r r o w s  a n d  w e a k  c o n n e c t i v i t i e s  a r e  s h o w n  i n  
i t c h e d  a r r o w ; .  T h e  N O E S Y  d a t a  s h o w  c o n n e c t i v i t i e s  o f  s o m e  o f  t h e  p r o t o n  a n d  m e t h y l  r e s o n a n c e s  l o c a t e d  i n  t h e  m i n o r  g r o o v e .
j u r e  8 .  N M R - d r i v e n  m o l e c u l a r  m o d e l  o f  t h e  b i s ( a l t r o m y c i n  B ) —  1 0 - m e r  d u p l e x  a d d u c t  d e p i c t i n g  i n t e r c a l a t i o n  o f  t h e  d r u g  c h r o m o p h o r e  i n t o  t h e  
I A  h e l i x  ( g r a y ) ,  s a c c h a r i d e  b i n d i n g  i n  b o t h  D N A  g r o o v e s  ( y e l l o w ) ,  a n d  a l k y l a t i o n  a t  N 7  ( c y a n ) .  T h e  1 0 - m e r  D N A  m o l e c u l a r  i s  r o t a t e d  s o  t h a t  
m a j o r  g r o o v e  f a c e s  o u t  a t  t h e  t o p  o f  t h e  h e l i x  a n d  t h e  m i n o r  g r o o v e  f a c e s  o u t  a t  t h e  b o t t o m  o f  t h e  h e l i x .
The altromycin B C5 neutral sugar substituent also plays an in the DNA major groove (Figure 10). Altromycins lacking
portant role in sequence selectivity, but through interactions the C5 neutral sugar substituent, such as altromycin H,
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Minor Groove
Figure 9. M o l e c u l a r  r e p r e s e n t a t i o n  o f  t h e  i n t e r a c t i o n  o f  t h e  a l t r o m y c i n  
B  a m i n o  d i s a c c h a r i d e  i n  t h e  m i n o r  g r o o v e .  I n  g r e e n  i s  a  w a t e r  m o l e c u l e  
m e d i a t i n g  t h e  p r o p o s e d  h y d r o g e n  b o n d  b e t w e e n  t h e  d i m e t h y l a m i n o  




Figure 10. M o l e c u l a r  r e p r e s e n t a t i o n  o f  t h e  i n t e r a c t i o n  o f  a l t r o m y c i n  
B  i n  t h e  m a j o r  g r o o v e .  S h o w n  a r e  t h e  i n t e r a c t i o n  o f  t h e  C 5  a l t r o s e  
w i t h  t h e  n o n c o v a l e n t l y  m o d i f i e d  s t r a n d ,  s i t e  o f  c o v a l e n t  a t t a c h m e n t  t o  
4 G ,  a n d  t i l t i n g  o f  4 G  t o w a r d  t h e  m a j o r  g r o o v e .
demonstrate decreased reactivity with DNA and a modified 
sequence selectivity compared to that of altromycin B .10 The 
key interaction of the C5 substituent is between the hydrophobic 
face of the C5 sugar and the hydrophobic pocket formed by
Hansen and Hurl
the drug, 7C, and 8T, which gives rise to a preference for 
pyrimidine located on each side of the intercalation site on t 
noncovalent DNA strand. The lack of the C5 altrose moie 
probably allows the altromycin H greater freedom for hydrog 
bond formation in the minor groove to either nucleotide of t 
5' base pair and, consequently, less sequence selectivity th 
those altromycins subjected to steering by both the C3" a. 
C5 altrose substituents.
Drug Design. Although the DNA lesion produced by t 
pluramycins is remarkably similar to that of the aflatoxins, 
should be noted that this class of agents also bears mu 
resemblance to the clinically efficacious anthracycline adri 
mycin in both structure and mode of interaction with DN 
Due to the large structural variance exhibited by this family 
natural products, it is hoped that future generations of synthe 
analogs can maximize therapeutic properties while minimizi 
deleterious ones. As learned in the case of the cyclopropap 
rroloindole family of DNA-reactive agents, a seemingly simj 
structural change, the removal of the ethano bridges of the nc 
alkylating subunits, yielded agents with potential therapeu 
value and without the associated delayed lethality syndrome 
This structural elucidation of the interaction of altromycin 
with DNA renders a foundation upon which rational design 
pluramycin analogs can be undertaken. The tetracyclic chi 
mophore has proven to be a versatile template upon whi 
multiple substituents can be attached to vary biochemic 
activity. At the C2 position are attached electrophiles that c 
covalently modify DNA through nucleophiles positioned in t 
major groove. It has also been shown that glycosidic substil 
tions at the C5, C8 , and CIO chromophore positions c 
modulate the C2 electrophile’s reactivity and sequence select) 
ity through interactions in both major and minor grooves. 1 
understanding the role in molecular recognition played f 
substituents attached at these three positions, it is reasonable 
pursue the synthesis of compounds with modified sequen 
affinities or altered reactivities. On a more ambitious note, 
understanding of the functional groups that interact in both Db 
grooves offers inspiration for the design of agents that c 
selectively alkylate biologically relevant DNA—RNA hybri 
or form novel groove to groove cross-links on the Db 
molecule.
Conclusions
Through the study of altromycin B, we have gained insig 
into the interaction of this family of compounds with DNA 1 
which prior structural information could only be speculat 
upon. The altromycins have proven to be a novel group 
compounds, one that includes characteristics of other class 
of DNA-reactive agents. Like the anthracycline nogalamyc 
the altromycins intercalate through the DNA molecule via 
threading mechanism, which positions saccharide structu: 
groups into the minor groove as well as the major groove, 
addition, these agents can alkylate N7 of guanine via an epoxi 
mechanism reminiscent of aflatoxin B in a sequence-selecti 
fashion. This work has shown potential sugar-mediated rt 
ognition of the DNA molecule, which could affect sequen 
discrimination exhibited by these agents. To further understa 
the sequence recognition of DNA and the role played 
different glycosidic substitutions of this family of compoum 
a two-dimensional NMR characterization of a hedamycin-Df 
adduct is in progress.
( 2 5 )  W a r p e h o s k i ,  M .  A . ;  B r a d f o r d ,  V .  S .  T e t r a h e d r o n  L e t t .  1988,
1 3 1 - 1 3 4 .
Site-Directed Alkylation of Guanine N7 in Pluramycins
Experimental Procedures
The self-complementary d(GAAGTACTTC) DNA strand was 
synthesized on an automated DNA synthesizer (Applied Biosystems 
381 A) using the solid-phase phosphoramidite method. The DNA 
synthesis was performed on a 1 0  ^mol scale, leaving the final 
dimethoxytrityl group on the 5' end of the DNA molecules. The crude 
sample was deprotected in concentrated NH4OH at 55 °C overnight 
and purified by reverse-phase chromatography on a C l8  column 
(Dynamax-300A). Purified DNA was then detritylated by dissolving 
in 80% acetic acid for 30 min, followed by an ether extraction to remove 
the acetic acid. The sample was then extensively dialyzed, and the 
buffer was adjusted to 10 mM NaH2P0 4 , 100 mM NaCl, and 0.5 mM 
EDTA (pH 6 .8 ).
The altromycin B samples (Abbott Laboratories) were used without 
further purification. Being experimental DNA-reactive agents, drug 
samples were handled with extreme caution to minimize exposure. 
Drug—DNA adduct formation was achieved by titrating altromycin B, 
dissolved in deuterated methanol, into the purified DNA until a 2:1 
ratio of drug to DNA had been achieved. The sample was mixed at 5 
°C for several hours and then checked by one-dimensional NMR to 
confirm complete alkylation of the DNA. Because of rapid sample 
degradation due to depurination, multiple samples were prepared in 
this manner. Due to aggregation problems, NMR experiments were 
performed on 1.0—2.0 mM adduct concentrations at 30 °C. In between 
experiments, samples were stored inside NMR tubes at —70 °C to 
minimize decomposition.
All NMR experiments were performed on a Bruker AMX 500 
spectrometer in 99.96% D20  or 95% H20:5% D20 . Phase-sensitive, 
tppi two-dimensional NOESY spectra in D20  were obtained for two 
mixing times at 150 and 300 ms, and ROESY, TOCSY, and DQF- 
COSY experiments11 were performed on samples dissolved in D20 . 
For these experiments, 1 K data points were acquired in t\ with a 
spectral width of 5000 Hz. To observe exchangeable protons, a two- 
dimensional NOESY spectrum was obtained with a 150 ms mixing 
delay in H20  using a 1 — 1 echo pulse sequence26 to suppress water. In 
this experiment, 1 K of data points were collected with a sweep width 
of 12 000 Hz.
Due to sample limitations, inter-proton distance constraints were 
calculated from a single 150 ms NOESY spectrum in D20 , obtained 
with 32 scans per increment, a 6000 Hz sweep width, and a 5 s 
relaxation delay between scans. Data was multiplied by a n i l  shifted 
sine bell squared window function, zero filled to 4 K, and Fourier 
transformed using Felix 2.0 NMR data-processing software. Inter­
proton cross peaks were integrated and sorted by volume into 16 distinct 
bins: four each for proton—proton cross peaks, methyl—proton cross 
peaks, dimethylamino—proton cross peaks, and methyl—dimethylamino/ 
methyl—methyl cross peaks, corresponding to very strong, strong, 
medium, and weak connectivities. The upper and lower constraint
(26) (a) Plateau, P.; Gueron, M. J. Am. Chem. Soc. 1982, 104, 7310— 
7311. (b) Sklenar, B.; Bax, A. J. Magn. Reson. 1987, 74, 469-479.
J. Am. Chem. Soc., Vol. 117, No. 9, 1995 2429
boundaries for each respective group are 2.2—3.5, 2.6—4.0, 3.0—4.5, 
3.5—5.5 A; 2 .2 —3.5, 2.6-4.0, 3.0-5.0, 3 .5-6 .0  A; 2.2-4 .0 , 2.6-4.5, 
3.0—5.5, 3.5—6.5 A; and 2.2-4.0, 2.6-4.5, 3.0-5.5, 3 .5-6 .5  A. In 
this way, 118 DNA—DNA constraints, 48 DNA—altromycin B 
constraints, and 64 intra-drug constraints were generated for the 
complete bis-adduct system.
The SANDER (simulated annealing with NMR driven energy 
restraints) module of AMBER 4.027 was used to perform energy 
refinement with these NMR-derived distance constraints to derive a 
model of the altromycin B—[d(GAAG*TACTTC) ] 2 diadduct. The 
AMBER force field was used with the addition of pseudo energy terms 
consisting of a flat well potential with parabolic boundaries for each 
interproton connectivity measured. Altromycin B partial atomic 
charges, calculated by MOP AC 5.0, were incorporated into the force 
field parameters for electrostatic energy calculations. Additionally, 
bond, torsion, and angle parameters calculated for carbohydrates28 were 
included for energy calculations concerning the saccharide moieties in 
the drug molecule. The N7 of the modified guanine was parameterized 
assuming planar, sp2 hybridization.
Initial DNA structures were created with the NUCGEN module of 
AMBER and adjusted in MIDAS29 to form intercalation sites and to 
dock the altromycin B molecule. The altromycin B structure was 
generated and minimized using stereochemistries from previously 
reported NMR structural determinations. 12 Sodium counterions were 
added to the structure, positioned approximately 4.5 A from each 
phosphate. The starting structure was then solvated with approximately 
1000 water molecules, subjected to 30 ps of belly dynamics at 300 K 
(holding the drug—DNA adduct rigid), minimized, and then slowly 
heated to 300 K over 10 ps. In the initial period of molecular dynamics, 
inter-proton distance constraints were slowly incorporated to 25 kcal/ 
(mol*A2). The system was maintained at 300 K for 90 ps and then 
minimized without constraints to obtain the reported structure.
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Hedamycin intercalates the DNA helix and, through 
carbohydrate-mediated recognition in the minor 
groove, directs N7-alkylation of guanine in the 
major groove in a sequence-specific manner
Mark Hansen, Sang Vun and Laurence Hurley*
Drug Dynamics Institute, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712-1074, USA
Background: The pluramycins are a class o f antitumor 
antibiotics that exert their biological activity through 
interaction w ith DNA. R ecent studies w ith the analog 
altromycin B have determined that these agents interca­
late into the D N A  molecule, position carbohydrate sub­
stituents into both major and minor grooves, and alkylate 
the DNA molecule by epoxide-mediated electrophilic 
attack on N7 o f guanine located to the 3' side o f the 
drug molecule. Alkylation is sequence dependent and 
appears to be modulated by glycoside substituents 
attached at the corners o f a planar chromophore. The 
altromycin B-like analogs preferentially alkylate 5'AG 
sequences; hedamycin-like analogs prefer 5'TG and 5'CG 
sequences. Although the mechanism of guanine modifi­
cation by altromycin B has been extensively studied, the 
mechanism of action o f hedamycin has not been 
previously determined.
Results: Using high-field N M R , we have shown that 
hedamycin stacks to the 5' side o f the guanine nucleotide 
at the site o f intercalation in a D N A  decamer, positioning
both aminosaccharides into the minor groove to direct 
alkylation by the epoxide moiety on N7 of guanine. The 
CIO linked N,N-dimethylvancosamine sugar moiety 
interacts to the 5' side o f the intercalation site, while the 
C8 linked anglosamine moiety interacts to the 3' side.The 
binding interactions o f the two aminosugars steer the C2 
double epoxide located in the major groove into the 
proximity o f N 7 o f  guanine. Unexpectedly, it is not the 
first epoxide that undergoes electrophilic addition to N7 
o f guanine, which would correspond to altromycin B, but 
the second, terminal epoxide.
Conclusions: We have used two-dimensional N M R  to 
elucidate the sequence-selective recognition o f DNA by 
hedamycin and the mechanism o f covalent modification 
o f guanine by this antibiotic. Characterization of the 
intermolecular interactions between both hedamycin and 
altromycin B and their targeted DNA sequences has 
yielded a better understanding o f the reasons for varia­
tions in sequence selectivity and alkylation reactivity 
among the pluramycin compounds.
Chemistry & Biology April 1995, 2:229-240  
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Introduction
Hedamycin and altromycin B are two o f the most biologi­
cally potent and structurally complex natural products o f 
the pluramycin family o f anti tum or antibiotics (Fig. 1). 
Extensive studies o f  the pluramycin analog, altromycin B, 
have clearly shown that this family o f antibiotics achieves 
activity by intercalating and alkylating the D N A  molecule
[1,2]. Structurally, hedamycin and altromycin B represent 
two distinct subgroups w ithin the pluramycin family, 
namely the classical pluramycins and the altromycins. 
A lthough bearing identical 4H -anthra[l ,2-b]pyran- 
4,7,12-trione chromophores, the subgroups differ struc­
turally in the attached substituents at the C2, C5, C8, and 
CIO positions [3—12].These differences translate into vari­
ations in biochemical activity, that is, alkylation reactivity 
and sequence selectivity [13].B oth subgroups require a C2 
epoxide functionality for high cytotoxic activity as well as 
for D N A  alkylation through N 7 o f  guanine [5]. The classi­
cal pluramycins, represented by hedamycin, bear two 
aminosugars, an anglosamine attached to the C8 position 
and an N,N-dimethylvancosamine attached to the CIO
position.Various substituents can be found at the C2 posi­
tion among m embers o f this subgroup, including a vinyl 
substituent (kidamycin) [14-16], a vinylepoxide (plura­
mycin A) [17,18], a single epoxide (epoxykidamycin) [19], 
o r a double epoxide (hedamycin) [20-22]. The 
altromycins, on the other hand, bear an aminodisaccharide 
on the CIO position, an invariant single epoxide at the C2 
position, and in many cases (altromycin B), a methyl ester- 
linked 6-deoxy-3-0-m ethylaltrose attached through the 
C5 position [23—25].
R ecen t investigations into the interaction betw een 
altromycin B and D N A  have revealed a general m ode o f 
D N A  interaction for the pluramycins as a group and have 
indicated possible roles for the C5, C8 and CIO linked 
glycosidic functionalities in D N A  sequence recognition
[1,2]. These recent studies clearly demonstrate that 
altromycin B threads the D N A  molecule, intercalates to 
the 5' side o f the modified guanine, and positions a 
neutral altrose m oiety in the major groove and an 
aminodisaccharide in  the m inor groove. Thus positioned,
^Corresponding author.
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OCHjKidam ycin (R =H ) Epoxykidam ycin  (R=H)
A ltrom ycin H
I o
Pluramycin A (R =A cetyl) H edam ycin (R=H)
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Fig. 1. S tructures of rep resen tative 
pluram ycin antibiotics. The fam ily sub­
divides by structure into tw o d istinct 
groups: the classical p luram ycins
(depicted by kidam ycin, ep oxy ­
kidam ycin, pluram ycin A, and 
hedam ycin) and the newly d iscovered  
altrom ycins (depicted by altrom ycins B 
and H). Sapurim ycin represents the 
sim plest pluram ycin analog.
altrom ycin B alkylates D N A  through N 7 o f  guanine in 
the m ajor groove by electrophilic attack by the epoxide 
attached to the C 2 position o f  the tetracyclic chro­
m ophore. To decipher the functional significance o f  the 
different structural motifs displayed by the classical 
pluram ycins and the altromycins, nam ely the C 2, C5, 
C 8 and CIO substituents, the contrasting pluramycin 
analog, hedam ycin, has been reacted w ith the 
[d(GAT G *TACATC)|-, (* denotes site o f  covalent m odi­
fication and underlined is the site o f  intercalation) duplex 
to  form  a bis-adduct (Fig. 2). R esolving the m olecular 
interactions that hedam ycin makes w ith  D N A  provides a 
basis for understanding hedam ycin’s dem onstrated 
5 '(P y)G * (Py =  pyrim idine) alkylation selectivity [13], the 
functional im portance o f  the second, term inal epoxide, 
and the increased alkylation reactivity dem onstrated by 
hedam ycin over the altromycins.
A lthough  hedam ycin  alkylates N 7  o f  guanine in a 
fashion sim ilar to  altrom ycin  B, it does so th rough  C l 8 
o f  the  term in a l epoxide as opposed  to  the  equivalent 
site (C l 6) th ro u g h  w hich  altrom ycin B alkylates 
guanine. Like altrom ycin  B, hedam ycin  also intercalates 
th e  D N A  m olecule  and  stacks to  the 5' side o f  the 
m odified  guanine, thereby position ing  bo th  the C 8 and 
C IO  am inosaccharides for in te rac tion  in the m ino r 
groove. H edam ycin  achieves its 5 '(Py)G * sequence 
selectivity  th ro u g h  in teractions b etw een  the tw o 
am inosugars and the 0 2  carbonyl o f  pyrim idines 
located in the m in o r groove.
Results
D ue to the serious stability limitations o f  guanine N7-alkyl 
adducts [2,26] (C. Lin & D.J. Patel, personal com m unica­
tion), a noncovalent classical pluramycin analog was first 
chosen for N M R  studies. T he [d(GATGTACATC)]9 
decam er duplex was initially reacted w ith the noncovalent 
analog kidamycin. As the ligand was titrated into the D N A  
duplex sample, analysis o f  one-dim ensional N M R  spectra 
revealed general broadening o f  the proton spectrum,
indicative o f  non-specific interaction with the D N A  m ole­
cule. Subsequently, an identical D N A  sample was reacted 
w ith two equivalents o f  the analog hedamycin, in w hich 
the C2 vinyl functionality o f  kidamycin is replaced w ith a 
reactive double epoxide.The addition o f  2:1 molar equiva­
lents o f  hedam ycin to the 10 base-pair D N A  duplex 
yielded a C2 symmetric diadduct that exhibited nine 
methyl resonances. Samples proved to be marginally m ore 
stable than the previously studied altromycin B diadducts, 
but degraded similarly into a complex mixture o f  products 
over the span o f  four to five days. Samples also displayed a 
high degree o f  aggregation and had to be diluted to dim in­
ish line broadening at the expense o f  signal intensity. For 
similar reasons, acquisition o f  data was carried out at 30 °C, 
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Fig. 2. The structures and num bering schem es of hedam ycin and 
the DNA decam er used in this study. Shown are sites of 
intercalation between 3T and 4G and covalent modification (4G).
H e d a m y c i n - D N A  a d d u c t  H a n s e n  e t al.
Assignment of the hedamycin proton resonances
T h e  h e d a m y c in  p r o t o n  r e s o n a n c e s  (T a b le  1) are d i v id e d  
i n t o  f o u r  r e g i o n s  o f  t h e  h e d a m y c i n  m o le c u l e :  t h e  a r o ­
m a t ic  c h r o m o p h o r e ,  t h e  C 8  l i n k e d  a n g lo s a m in e ,  t h e  
C I O  l in k e d  N ,N - d i m e t h y l v a n c o s a m i n e  a n d  t h e  C 2  
d o u b le  e p o x i d e .  P r o t o n s  i n  e a c h  r e g i o n  w e r e  a s s ig n e d  
u s i n g  to t a l  c o r r e l a t i o n  s p e c t r o s c o p y  ( T O C S Y ) ,  d o u b le  
q u a n t u m  f i l t e r e d  c o r r e l a t i o n  s p e c t r o s c o p y  ( D Q F -  
C O S Y )  a n d  n u c le a r  O v e r h a u s e r  e f f e c t  s p e c t r o s c o p y  
( N O E S Y )  N M R  e x p e r im e n t s  [ 2 7 - 3 0 ] .  I n  t h e  f ir s t  
g r o u p  o f  r e s o n a n c e s ,  t h o s e  a t t a c h e d  d ir e c t ly  t o  t h e  
in te r c a la t in g  c h r o m o p h o r e ,  t h e  H 9  r e s o n a n c e  w a s  i d e n ­
t i f ie d  b y  N O E S Y  c o n n e c t i v i t i e s  t o  t h e  H 2 ' ,  2 ' m e t h y l  
a n d  4"  m e t h y l  l o c a t e d  o n  t h e  a m in o s u g a r s  a t t a c h e d  t o  
t h e  C 8  a n d  C I O  p o s i t io n s .  T h e  5  m e t h y l  ( s in g le t )  a n d  
t h e  a d j a c e n t  H 6  p r o t o n  w e r e  a s s ig n e d  b a s e d  o n  a 
N O E S Y  c o n n e c t i v i t y  t o  e a c h  o t h e r  a n d  a w e a k  c o n t a c t  
b e t w e e n  t h e  5  m e t h y l  a n d  H 3  r e s o n a n c e s .  T h e  H 3  
p r o t o n  r e s o n a n c e  w a s  e a s i ly  a s s ig n e d  b a s e d  o n  N O E S Y  
c o n n e c t i v i t i e s  t o  r e s o n a n c e s  a s s o c ia t e d  w i t h  t h e  C 2  
e p o x i d e  a r m .
I n  t h e  C 8  l in k e d  a n g lo s a m in e  (d e s ig n a t e d  in  s in g le ­
p r im e  n u m b e r s ) ,  t h e  p r o t o n  r e s o n a n c e s  m u tu a l ly  c o u p le d  
a r o u n d  t h e  su g a r  r in g  i n  t h e  D Q F - C O S Y .  C o u p l i n g s  
b e t w e e n  H 6 '  a n d  H 5 'a , H 6 '  a n d  H 5 'b ,  H 5 'b  a n d  H 4 ' ,  H 4 '  
a n d  H 3 1, a n d  H 3 '  a n d  H 2 '  e s ta b lis h  t h e s e  p r o t o n  a s s ig n ­
m e n t s .  T h e  2 ' m e t h y l  r e s o n a n c e  (d o u b le t )  w a s  e a s ily
id e n t i f i e d  t h r o u g h  c o u p l i n g  t o  t h e  H 2 ' .T h e  4 ' d im e t h y l -  
a m in o  s ig n a l  w a s  id e n t i f i e d  b y  r e s o n a n c e  in te n s ity ,  c h e m ­
ic a l  s h if t ,  a n d  N O E S Y  c o n n e c t i v i t i e s  t o  th e  o t h e r  
p r o t o n s  o n  th is  su g a r . T h e  H 5 'a  a n d  H 5 'b  r e s o n a n c e s  
w e r e  d i s t in g u is h e d  b a s e d  o n  s t r o n g e r  N O E  c o n n e c t i v i ­
t ie s  b e t w e e n  t h e  H 5 'b  t o  th e  H 6 '  a n d  H 4 '  p r o t o n s  th a n  
t h e  e q u iv a le n t  N O E s  fo r  t h e  H 5 'a  r e s o n a n c e .
In  t h e  C I O  l in k e d  N ,N - d i m e t h y l v a n c o s a m i n e  m o i e t y  
(d e s ig n a t e d  w i t h  d o u b le - p r i m e  n u m b e r s ) ,  th e  4"  
d im e t h y l a m i n o  s ig n a l  is  e a s ily  id e n t i f i e d  b y  c h e m ic a l  
s h if t ,  o n e - d i m e n s io n a l  in te n s i ty ,  a n d  s t r o n g  N O E S Y  
c o n t a c t  t o  t h e  4" m e t h y l  r e s o n a n c e  ( s in g le t ) .  H 5 " a  a n d  
H 5 " b  p r o t o n s  b o t h  s h o w e d  N O E S Y  c o n t a c t s  t o  t h e  4" 
m e t h y l  a n d  4" d im e t h y la m in o  s ig n a ls . A d d i t io n a l ly ,  th e  
H 5 " a  p r o t o n  c o u p le s  w i t h  b o t h  t h e  H 5 " b  a n d  th e  H 6 "  
p r o to n s .  T h e  2" m e t h y l  (d o u b le t )  c o u p le d  to  t h e  H 2 "  a n d  
s h o w e d  N O E  c o n ta c t s  t o  b o t h  4" s u b s t i tu e n t s .  T h e  H 3 "  
p r o t o n  w a s  a s s ig n e d  b a s e d  o n  N O E S Y  c o n n e c t i v i t i e s  to  
b o t h  th e  4" a n d  2" m e t h y l  a n d  p r o t o n  r e s o n a n c e s .  T h e  
p r o t o n  a s s ig n m e n ts  o f  H 5 " b  a n d  H 5 " a  w e r e  d is t in g u is h e d  
b a s e d  o n  c o r r e la t io n  o f  t h e ir  c h e m ic a l  sh ifts  t o  th a t  o f  
t h e  fr e e  d r u g  a n d  a s t r o n g e r  N O E  c o n n e c t i v i t y  b e t w e e n  
t h e  4" m e t h y l  t o  th e  H 5 " b  th a n  b e t w e e n  t h e  4" m e t h y l  
t o  th e  H 5 " a  r e s o n a n c e .
P r o t o n  r e s o n a n c e s  in  th e  la st  g r o u p  a s s o c ia te d  w i t h  th e  
s it e  o f  c o v a le n t  a t t a c h m e n t  o f  t h e  d r u g  t o  th e  D N A  w e r e  
a s s ig n e d  th r o u g h  m u tu a l  c o u p l in g s  b e t w e e n  v ic in a l  
p r o t o n s  o n  t h e  C 2  e p o x i d e  a r m  (F ig . 3 ) .  T h e  H I 6  
c o u p le d  in  t h e  D Q F - C O S Y  to  th e  H 1 7  r e s o n a n c e ,  
w h i c h  in  tu r n  c o u p le d  t o  th e  H I 8  p r o t o n .T h e  H I 8  s im i­
la r ly  c o u p le d  t o  t h e  te r m in a l  1 9  m e t h y l  ( d o u b le t ) .T h e  15  
m e t h y l  ( s in g le t )  w a s  a s s ig n e d  b y  N O E S Y  c o n ta c t s  t o  th e  
H 3 ,  H 1 6 ,  H 1 7  a n d  H 1 8  p r o to n s .  C a r b o n - 1 3  c h e m ic a l  
sh ifts  fo r  th e  b a c k b o n e  o f  th e  C 2  e p o x id e  a r m  w e r e  id e n ­
t i f ie d  th r o u g h  s in g le - b o n d  a n d  m u l t i p le - b o n d  1H — 13C  
c o r r e la t io n s  t o  t h e  p r e v io u s ly  id e n t i f i e d  p r o t o n  r e s o ­
n a n c e s .  T h e  C 1 5 ,  C 1 6 ,  C 1 7 ,  C 1 8  a n d  C 1 9  r e s o n a n c e s  
w e r e  a ll a s s ig n e d  th r o u g h  c o u p l i n g  t o  t h e ir  r e s p e c t iv e  
a t t a c h e d  p r o t o n  r e s o n a n c e ,  a n d  t h e  C 1 4  r e s o n a n c e  w a s  
a s s ig n e d  b a s e d  o n  lo n g - r a n g e  c o u p l in g  to  th e  1 5  m e th y l.
Assignments of DNA proton resonances
D N A  p r o t o n  a s s ig n m e n ts  o f  th e  1 0  b a s e -p a ir  d u p le x  a n d  
its  b i s - h e d a m y c in  d ia d d u c t  (T a b le  2 ) w e r e  a c h ie v e d  
t h r o u g h  e s ta b lis h e d  m e t h o d s  [3 1 ] u s in g  T O C S Y , N O E S Y  
a n d  D Q F - C O S Y  e x p e r im e n t s  t o  c r e a te  w a lk s  le a d in g  
f r o m  th e  5' e n d  t o  th e  3' e n d  o f  th e  D N A  m o le c u l e  (F ig . 
4 ) .  T o  id e n t i f y  p r o to n s  o v e r la p p in g  t h e  w a te r  r e s o n a n c e ,  
n a m e ly  th e  5 T H 3 '  a n d  t h e  4 G H 3 '  r e s o n a n c e s ,  a 1 5 0  m s  
N O E S Y  e x p e r im e n t  w a s  c o l l e c t e d  at 4 0  °C , w h i c h  sh ifte d  
th e s e  r e s o n a n c e s  s lig h d y  d o w n f ie ld  o f  th e  w a te r  r e so n a n c e .  
T h e  a r o m a tic  t o  a r o m a tic , a r o m a tic  t o  H I ' ,  a r o m a tic  to  
H 2 ' /2 " ,  a n d  a r o m a tic  to  H 3 '  r e s o n a n c e s  a ll d e m o n s tr a te  
b r ea k s  in  th e  w a lk s  a t th e  3 T - 4 G  a n d  7 C - 8 T  ste p s  d u e  to  
in s e r t io n  o f  t h e  in te r c a la t in g  c h r o m o p h o r e  at th is  p o s i t io n  
o n  t h e  D N A  m o le c u le .  In te r e s tin g ly , th e  5 T H 1 '  r e so n a n c e  
is  u p f ie ld  s h if t e d  fr o m  5 .7 1  p p m  t o  5 .1 7  p p m  u p o n  
h e d a m y c in —d u p le x  a d d u c t  fo r m a t io n ,  p r e s u m a b ly  d u e  to
Table 1. Comparison of the hedamycin chemical shifts in the 
bis-hedamycin-[d(GATGTACATC)]2 diadduct and the free drug.
Chemical shifts (ppm) of hedamycin



















2"CH 3 1.48 1.51
H3" 3.78 3.35
4"CH 3 1.16 0.71
4"N(CH3)2 2.90 2.22
H 5"a 2.58 2.10
H 5"b 3.00 2.70
H6" 5.57 5.45
aFor numbering, see Figure 2.
bChemical shifts referenced to H20  in 99.9 % D20 .
cChemical shifts in chloroform [5,22].
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Fig. 3. Assignments for the proton resonances associated with the reacted C2 double-epoxide substituent. A DQF-COSY experim ent is 
shown left of the diagonal with a corresponding chem ical structure in w hich couplings betw een H18 and 19 methyl (A), H18 and HI 7 
(B), and H 16 and HI 7 (C) are identified. A NOESY experim ent (1 50 ms mixing time) is shown right of the diagonal with a correspond­
ing chem ical structure show ing cross-peaks betw een HI 8 and H1 6 (D), H1 7 and 19 methyl (E), H1 6 and 19 methyl (F), HI 7 and 1 5 
methyl (G), H I6 and 15 methyl (H), and 19 methyl and 15 methyl (I).
its  p r o x i m i t y  t o  t h e  a r o m a t ic  s y s t e m  o f  t h e  d r u g , w h i c h  
e x t e n d s  i n t o  t h e  m i n o r  g r o o v e .
Cl 8 of hedamycin alkylates N7 of guanine via an 
Sn2 mechanism
B o t h  th e  b a s e  a n d  th e  s it e  o f  c o v a le n t  a t t a c h m e n t  to  th e  
D N A  m o l e c u l e  are  i d e n t i f i e d  b y  t h e  c h e m ic a l  n a tu r e  o f  
th e  4 G H 8  a r o m a t ic  p r o t o n .T h is  p r o t o n ,  w h i c h  w a s  id e n t i ­
f ie d  a n d  c h a r a c te r iz e d  in  9 5  % H 20 ,  h a s b e c o m e  e x tr e m e ly  
la b ile  a n d  n o w  r e s o n a te s  a t 9 . 6  p p m , w h i c h  is ~2  p p m  
d o w n f ie ld  o f  t h e  e q u iv a le n t  p r o t o n  r e s o n a n c e  in  th e  
u n m o d i f i e d  1 0  b a s e -p a ir  d u p l e x  ( 7 .7 7  p p m ) .  T h e  u n u ­
s u a l ly  a c id ic  n a tu r e  o f  th is  H 8  a r o m a t ic  p r o t o n  is a d ir e c t  
r e s u lt  o f  a lk y la t io n  th a t  o c c u r s  t h r o u g h  N 7  o f  g u a n in e ,
th e r e b y  f o r m i n g  a c a t io n ic  d r u g —g u a n in e  l e s io n .  T h e s e  
r esu lts  are c o n s is t e n t  w i t h  o t h e r  r e p o r te d  N 7  a lk y l - g u a n in e  
a d d u c ts ,  s p e c if ic a l ly  a f la to x in , s a p u r im y c in  a n d  a lt r o m y c in  
B  [2 ,2 6 ]  (C . L in  &  D.J. P a te l, p e r s o n a l  c o m m u n ic a t io n ) .
In  c o m p a r i s o n  t o  t h e  u n r e a c t e d  C 2  d o u b l e  e p o x i d e  
f u n c t i o n a l i t y  o f  h e d a m y c i n ,  t h e  H 1 8  a n d  C 1 8  d e m o n ­
s tr a te  t h e  g r e a t e s t  c h a n g e  in  c h e m i c a l  s h i f t  u p o n  D N A  
a d d u c t  f o r m a t io n ,  ~ 2  a n d  2 0  p p m  d o w n f i e l d ,  r e s p e c ­
t iv e ly ,  w h e r e a s  H 1 7  a n d  C 1 7  d e m o n s t r a t e  o n l y  m a r g in a l  
d o w n f i e l d  sh if ts  o f  ~ 1  a n d  1 4  p p m ,  r e s p e c t i v e ly  (F ig .  5 ,  
T a b le  3 ) .  T h e  r e s o n a n c e s  a s s o c ia t e d  w i t h  t h e  C 1 4 - C 1 6  
e p o x i d e  d e m o n s t r a t e  o n l y  s m a ll  c h e m ic a l  s h if t  d i f f e r ­
e n c e s  o v e r  t h e  fr e e  d r u g .  It is t h e r e f o r e  p r o p o s e d ,  b a s e d
Table 2. Com parison of the DNA proton chem ical shifts3 of the bis-hedamycin-[d(GATG*TACATC)]2 duplex d iadduct with the 
unmodified duplex.
Base H 8/H 6 H 5/5C H 3 H2 H I' H 2‘ H2" H3' H 41
1G 7.85 (0.00) _ _ 5.58 (-0.07) 2.52 (-0.04) 2.70 (-0.05) 4.83 (-0.02) 4.12 (-0.07)
2A 8.20 (-0.13) - 7.88 (-0.07) 6.18 (-0.13) 2.60 (-0.15) 2.85 (-0.13) 5.03 (0.00) 4.40 (-0.07)
3T 7.30 (+0.15) 1.12 (-0.30) - 6.10 (+0.31) 2.25 (+0.13) 2.38 (-0.09) 5.00 (+0.14) 4.42 (-0.29)
4G* 9.60 (+1.80)b - - 5.82 (-0.11) 2.32 (-0.25) 2.47 (-0.28) 4.75 (-0.18) 4.45 (+0.07)
5T 7.10 (-0.10) 1.13 (-0.24) - 5.18 (-0.52) 2.15 (+0.07) 2.15 (-0.31) 4.75 (-0.12) 3.87 (-0.43)
6A 8.20 (-0.03) - 7.50 (+0.08) 6.11 (-0.07) 2.60 (-0.06) 2.82 (+0.01) 4.92 (-0.09) 4.40 (0.00)
7C 7.34 (+0.14) 5.20 (-0.10) - 5.68 (-0.34) 2.20 (+0.15) 2.34 (-0.03) 5.04 (+0.24) 4.24 (0.00)
8A 8.62 (+0.42) - 6.88 (-0.25) 6.40 (-0.19) 2.81 (+0.19) 3.05 (+0.17) 5.13 (+0.18) 4.20 (-0.18)
9T 7.10 (-0.12) 1.27 (-0.17) - 5.86 (-0.17) 2.03 (-0.02) 2.36 (-0.10) 4.88 (+0.04) 4.14 (-0.24)
10C 7.45 (-0.15) 5.52 (-0.18) - 6.18 (-0.17) 2.25 (0.00) 2.25 (0.00) 4.52 (-0.03) 4.19 (-0.21)
‘’Referenced to H20  in 99.9 % D20  unless otherwise noted. Chemical shift differences: (-) and (+) represent upfield and downfield 
shifts, respectively. Shown in bold are those greater than 0.2 ppm.
E xchangeab le  proton observed in 95 % H20 .
*Site of covalent modification by hedam ycin.
H e d a m y c i n - D N A  a d d u c t  H a n s e n  et al. 2 3 3
Fig. 4. NOESY data (150 ms) showing 
the aromatic to H I' (left) and aromatic 
to H3‘ walks (right). The intra-residue 
connectivities are identified with a base 
and number designation. Breaks in the 
walks due to ligand intercalation are 
indicated with arrows. Also shown are 
cytosine H5 connectivities to their own 
H6 proton and the 5' neighbor's aro­
matic proton. For 7C and 10C, these are 
shown by a single, broken vertical line. 
Note that cross-peaks associated with 
4GH8 are absent due to the rapid 













o n  c h e m ic a l  sh ifts  a n d  c h e m ic a l  sh ift  c h a n g e s ,  th a t  N 7  o f  
g u a n in e  p e r fo r m s  n u c le o p h i l i c  a tta c k  o n  C l 8 ,  l e a d in g  to  
o p e n in g  o f  th e  e p o x i d e  t o  f o r m  a h y d r o x y l  o n  C l  7  (F ig . 
6 ) .  M e d i u m  t o  s t r o n g  N O E s  b e t w e e n  4 G H 8  a n d  b o t h  
h e d a m y c in  H I 8  a n d  H I 7 ,  a n d  o n ly  a m e d i u m  t o  w e a k  
N O E  b e t w e e n  4 G H 8  a n d  h e d a m y c in  H I 6 ,  a lso  s tr o n g ly  
a r g u e  fo r  a lk y la t io n  a t C l 8 . T h e  r e la t iv e ly  u n d is tu r b e d  
c h e m ic a l  sh ifts  o f  C l 4  a n d  C 1 6  s u g g e s t  th a t  th e  fir s t , 
p r o x im a l  e p o x id e  a s s o c ia te d  w i t h  th e s e  t w o  c a r b o n  
a to m s  is c h e m ic a lly  u n m o d i f ie d  in  th e  D N A  a d d u c t .
A lk y la t io n  o f  t h e  d u p le x  o l ig o m e r  y ie ld s  o n l y  o n e  s e t  o f  
p r o t o n  r e s o n a n c e s  c o r r e s p o n d in g  t o  a s in g le  s p e c ie s  o f  
a d d u c t .  T h is  s u g g e s ts  th a t n u c le o p h i l i c  a d d i t io n  o c c u r s  
th r o u g h  a n  S N 2  m e c h a n is m ,  in v e r t in g  t h e  s t e r e o -  
c o n f ig u r a t io n  o f  th e  C l 8  c h ir a l  c e n te r .  T h e  s t e r e o ­
c h e m is t r y  r e p o r te d  in  th e  c r y s ta l s tr u c tu r e  o f  h e d a m y c in  
( 1 4 R ,  1 6 S , 1 7 R ,  1 8 S )  [2 0 ]  w o u l d  th e n  b e  c o n v e r t e d  to  
1 4 R ,  1 6 S , 1 7 R ,  1 8 R  b y  a n  S N 2  n u c le o p h i l i c  a d d i t io n  to  
N 7  o f  g u a n in e .  T h is  s t e r e o c h e m ic a l  c o n f ig u r a t io n  (se e
F ig . 3 )  is s u p p o r te d  b y  a s tr o n g  N O E  c o n n e c t i v i t y  
b e t w e e n  h e d a m y c in  H I 8  a n d  H I 6 , a w e a k e r  N O E  c o n ­
n e c t iv i t y  b e t w e e n  H I 6  a n d  H I 7  ( m e d iu m ) ,  a n d  s tr o n g  
N O E s  b e t w e e n  1 5  m e th y l  a n d  1 9  m e th y l ,  1 5  m e th y l  an d  
4 G H 8 ,  a n d  1 9  m e th y l  a n d  4 G H 8 .
Drug-DNA connectivities in the major groove
T h e  C 2  s u b s t i tu e n t  is lo c a t e d  in  th e  m a j o r - g r o o v e  s id e  
o f  th e  D N A  h e l ix  a n d  is p o s i t io n e d  n e x t  t o  th e  c o ­
v a le n t ly  m o d i f ie d  s tr a n d , m a k in g  N O E S Y  c o n ta c t s  to  
b o t h  s id e s  o f  th e  in te r c a la t io n  s ite  (F ig . 7 ) ,  c o n f i r m in g  
th e  s ite  o f  in te r c a la t io n .  O n  th e  5' s id e  o f  th e  in te r c a la ­
t io n  s it e ,  th e  3 T  m e t h y l  s h o w s  N O E  c o n ta c t s  to  
h e d a m y c in  H I 6; 3 T H 6 ,  3 T H 2 ' ,  a n d  3 T H 2 "  s h o w  N O E  
c o n ta c t s  w i t h  h e d a m y c in ’s 1 5  m e th y l .  O n  th e  3 ' s id e  o f  
th e  in te r c a la t io n  s ite , th e  4 G H 8  a n d  th e  5 T  m e t h y l  s h o w  
N O E  c o n ta c t s  to  th e  1 9  m e t h y l  a n d  H 1 8  o f  h e d a m y c in .  
A ls o  in  th is  r e g io n  o f  t h e  d u p le x  is th e  H 3  r e s o n a n c e  o f  
h e d a m y c in ,  w h i c h  s h o w s  a m e d iu m  c r o s s -p e a k  t o  th e  3 T  
m e t h y l  o f  th e  D N A .
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Fig. 5. Structure of the hedamycin C2 epoxide arm. Based on 
chem ical shifs and chemical-shift differences (Table 3), it is C18 
of the second epoxide that reacts with N7 of guanine.
Table 3 . 1H and 13C NMR chemical shifts (ppm) of the C2 side 
chain of hedamycin as the free drug and after reaction with 
the 10 base-pair duplex DNAa.
’H /^C  Assignment 1H 13C
14 __b 58.0 (+0.0)
15 1.1 (0.0) 14.0 (-0.1)
16 3.3 (0.0) 68.5 (+4.6)
17 3.8 (+0.9)c 69.0 (+13.6)
18 5.1 (+2.0) 78.7 (+23.3)
19 1.7 (+0.3) 15.6 (-1.6)
aChemical shift differences are reported in parenthesis: DNA
adduct in D ,0  minus hedamycin in CDCU [5,6,22]
bNot applicable.
cChemical shifts experiencing significant downfield shifts
upon reaction with DNA are designated in bold.
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Fig. 6. The proposed mechanism of 
covalent modification of DNA by 
hedamycin. N7 of guanine performs 
nucleophilic attack on the terminal 
epoxide, forming a cationic lesion on 
the DNA. Subsequent depurination of 
the modified guanine results in DNA 
strand breakage [1].
A d ja c e n t  t o  th e  n o n c o v a le n t ly  m o d i f ie d  str a n d  in  th e  
m a jo r  g r o o v e  is th e  5  m e t h y l  o f  th e  d r u g , w h i c h  a lso  
s h o w s  c o n ta c ts  t o  b o t h  s id e s  o f  th e  in te r c a la t io n  s ite . T h e  
5  m e th y l  s h o w s  m e d iu m  c o n n e c t iv i t ie s  to  7 C H 6  a n d  
7 C H 5  a n d  a v e r y  w e a k  c o n n e c t i v i t y  t o  8 A H 8 ,  all o f  
w h i c h  are lo c a t e d  in  th e  D N A  m a jo r  g r o o v e .  L o c a te d  
b e t w e e n  th e  g r o o v e s  is th e  h e d a m y c in  H 6  p r o to n ,  w h ic h  
s h o w s  w e a k  c o n t a c t  t o  th e  m a jo r  g r o o v e  p r o t o n  7 C H 6  
a n d  b o t h  a s tr o n g  a n d  a w e a k  c o n n e c t iv i t y  to  7 C H T  a n d  
7 C H 3 ' ,  lo c a t e d  in  th e  m in o r  g r o o v e .  A  d ia g r a m m a tic  
su m m a r y  o f  th e s e  in t e r m o le c u la r  c o n n e c t iv i t ie s  in  th e  
m a jo r  g r o o v e  is s h o w n  in  F ig u r e  7 .
Drug-DNA connectivities in the minor groove
B o t h  t h e  C 8  l in k e d  a n g lo s a m in e  a n d  t h e  C I O  l in k e d  
N , N - d i m e t h y l v a n c o s a m i n e  are  l o c a t e d  in  t h e  m i n o r  
g r o o v e  o f  t h e  D N A  m o l e c u l e  (F ig . 8 a ) .  T h e  N O E
Fig. 7. Summary of key 1H-NOESY connectivities (150 ms) 
between hedamycin and the DNA major groove. The drug shows 
connectivities to both sides of the intercalation site, reaffirming 
positioning of the tetracyclic chromophore between 3T and 4G. 
A weaker connectivity is shown with a broken arrow.
c o n n e c t i v i t i e s  b e t w e e n  t h e  m e t h y l  g r o u p s  o f  e a c h  
s u g a r  a n d  D N A  are s h o w n  in  F ig u r e  8 b . T h e  N , N -  
d im e t h y l v a n c o s a m in e  is  p o s i t i o n e d  in  t h e  m in o r  
g r o o v e ,  o r i e n t e d  t o  t h e  5' s id e  o f  t h e  i n t e r c a la t io n  s it e  
a n d  m a k in g  e x t e n s iv e  N O E S Y  c o n t a c t  w i t h  2 A ,  3 T ,  
8 A  a n d  9 T . W h i l e  s h o w i n g  o n l y  a w e a k  c o n t a c t  t o  
5 T H 4 ' ,  t h e  H 2 "  p r o t o n  s h o w s  a v e r y  s t r o n g  N O E  
c o n t a c t  t o  t h e  H 9  p r o t o n  l o c a t e d  o n  t h e  h e d a m y c in  
c h r o m o p h o r e .  B a s e d  o n  th is  c o n t a c t ,  t h e  N , N -  
d im e t h y l v a n c o s a m in e  is  r o ta te d  t o  a n  o r ie n t a t io n  
b e l o w  t h e  d r u g  c h r o m o p h o r e  in  t h e  5 ' d i r e c t i o n .  T h is  
o r ie n t a t io n  is  fu r th e r  s u p p o r t e d  b y  N O E  c o n t a c t s  
b e t w e e n  t h e  d r u g ’s H 6 "  a n d  5 T H 4 1, t h e  2"  m e t h y l  a n d  
9 T H 4 ' ,  a n d  b e t w e e n  t h e  4"  m e t h y l  a n d  2 A H 2 ,  3 T H T ,  
9 T H 1 '  a n d  9 T H 5 ' .  F u r th e r m o r e ,  th e  4" d im e t h y la m in o  
g r o u p  m a k e s  m e d i u m  t o  s t r o n g  c o n t a c t s  t o  2 A H 2 ,  
2 A H 1 ' ,  3 T H 1 ' ,  3 T H 4 '  a n d  8 A H 2 .  In  c o n tr a s t ,  t h e  C 8  
l in k e d  a n g lo s a m in e  o r ie n t s  t o  t h e  3 ' s id e  o f  t h e  m o d i ­
f i e d  g u a n in e ,  m a k in g  N O E  c o n t a c t  p r im a r i ly  w i t h  th e  
5 T , 6 A ,  7 C  a n d  8 A  r e s id u e s .  T h e  H 2 '  a n d  H 6 '  s h o w  
s t r o n g  N O E  c o n t a c t s  t o  8 A H 1 ' ,  t h e  2 ' m e t h y l  s h o w s  
N O E  c o n t a c t s  t o  8 A H 1 ' ,  9 T H 5 7 5 "  a n d  9 T H 4 ' ,  a n d  
t h e  4 ' d i m e t h y l a m i n o  s h o w s  s t r o n g  N O E  c o n t a c t s  t o  
5 T H 1 ' ,  6 A H 2 ,  6 A H 4 ' ,  7 C H 1 '  a n d  7 C H 4 ' .
NMR-driven molecular modeling
In  a 1 0 0  p s s o lv a t e d  m o le c u l a r  d y n a m ic s  s im u la t io n  
u s in g  5 4  in t e r - d r u g —D N A ,  7 6  in t r a - d r u g ,  a n d  1 6 6  
i n t r a - D N A  c o n s tr a in t s  fo r  th e  c o m p l e t e  b is - a d d u c t ,  a 
m o le c u la r  m o d e l  w a s  g e n e r a t e d  th a t  r e f le c t s  t h e  N M R  
r e su lts  (F ig . 9 ) .  In  th is  N M R - d e r i v e d  m o d e l  o f  th e  b i s -  
h e d a m y c in  d ia d d u c t ,  t h e  c o n j u g a t e d  c h r o m o p h o r e  
s ta c k s  b e t w e e n  t h e  3 T » 8 A  a n d  th e  4 G » 7 C  b a se  p a irs  in  
r o u g h ly  a p e r p e n d ic u la r  o r ie n t a t io n  t o  t h e  h y d r o g e n  
b o n d s  f o r m e d  b y  th e  f la n k in g  b a se  p a irs . T o  a c c o m m o ­
d a te  th is  in t e r a c t io n ,  t h e  D N A  h as g r o s s ly  d is to r te d ,  
o p e n i n g  t h e  b a s e  p a ir s  t o  t w i c e  th e  n o r m a l  d is ta n c e  t o  
a l lo w  i n s e r t io n  o f  t h e  d r u g  c h r o m o p h o r e .  A s p r e d ic t e d  
f r o m  t h e  r e la t iv e ly  la r g e  u p f i e ld  s h if t  e x h ib i t e d  b y  
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Fig. 8. Summary of key ^-N O ESY  connectivities (a) and NOESY data (150 ms) (b) between hedamycin's C8 and C10 sugar moieties 
and the DNA minor groove. In (a), NOE connectivities are shown in solid arrows. The NOESY data in (b) shows NOE connectivities of 
some of the proton and methyl resonances located in the minor groove.
Fig. 9. Stereoview of an NMR-driven 
molecular model of the bis- 
hedam ycin-10 base-pair DNA duplex 
adduct. The model depicts intercalation 
of the drug chrom ophore into the DNA 
helix (gray), saccharide binding in the 
DNA minor groove (yellow) and alkyla­
tion at N7 (cyan). The 10 base-pair 
DNA molecule is rotated so that the 
major groove faces out at the top of the 
helix and the minor groove faces out at 
the bottom of the helix.
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tetracyclic ch ro m o p h o re  slightly in to  the m in o r groove 
directly  u n d e r this p ro ton . D espite  placing both  
am inosaccharides in to  the m in o r groove, the  ch ro ­
m ophore  rem ains able to easily span the double helix to 
covalently attach to N 7 o f  4G  in the m ajor groove.
In the m ajor groove, hedam ycin makes the m ost signifi­
cant in te rac tio n  w ith  the D N A  m olecule, fo rm ing  a 
covalent b o n d  th ro u g h  C l 8  and N 7 o f  4G. H aving a 
fo u r-carb o n  span, th e  C 2  epoxide arm  easily jo in s  the 
ch ro m o p h o re  to  N 7  o f  guanine w ith o u t causing signi­
ficant d is to rtio n  o f  4G  o r the  su rro u n d in g  D N A . 
A ssociated w ith  the noncovalen tly  m odified  strand is 
the  hedam ycin  5 m ethyl, w h ich  is pu lled  in tow ard the 
floor o f  th e  m ajo r groove to m ake van der Waals 
contact w ith  the 7 C H 5  and H 6  protons.
Positioned in the m in o r groove (Fig. 10) are bo th  
the C 8 linked anglosam ine and the CIO  linked 
N ,N -d im ethy lvancosam ine m oieties. T h e  C IO  linked 
N ,N -dim ethylvancosam ine is directed tow ard the 5' side 
o f  the in tercalation  site to in teract w ith  the  covalently 
m odified strand, nam ely the 3T  residue. To the 3' side o f  
the in tercalation  site, the anglosam ine m oie ty  interacts 
in  the m in o r groove prim arily  w ith  7C  on  the n o n co ­
valently m odified  strand. O n  the basis o f  N M R  evi­
dence (see Fig. 8 ), ind icating  proxim ity  o f  the 
d im ethylam ino  in b o th  sugars to the negatively charged 
0 2  carbonyl o f  each respective pyrim id ine, we propose 
that a key in teraction  occurs through the form ation  o f  a 
hydrogen bond  to  the carbonyl, e ither directly o r m edi­
ated through a w ater m olecule. M olecular dynamics cal­
culations were perform ed w ith  direct hydrogen bonding  
restraints and w ith  hydrogen b o n d in g  restraints m edi­
ated by a b ound  w ater m olecule. B oth  situations satisfied 
N M R -d e riv e d  constraints; however, sim ulations using 
b o u n d  w ater m olecules, similar to  those repo rted  in the 
crystal struc tu re  w ith  daunom ycin  [32], w ere used to 
derive the reported  structure.
D i s c u s s i o n
Comparison to other pluramycin adducts
H edam ycin interacts w ith  the D N A  m olecule in a very 
similar fashion to that reported  in previous structural 
studies involving altrom ycin B adducted to 
[d(GAAG*TACTTC)]-> [2] and sapurim ycin adducted to 
[d(A A T A G *C T A T T ) ]9 (C. Lin & D.J. Patel, personal 
com m unication). Like the o th er tw o pluram ycins, 
hedam ycin threads the D N A  m olecule, covalently 
attaches to N 7 o f  guanine, and stacks to the 5' side o f  the 
m odified  guanine. Like altrom ycin B, the CIO  linked 
vancosam ine m oiety  and the closely related C 8 linked 
anglosamine are bo th  positioned in the m inor groove.
Subtle  s tru c tu ra l differences b e tw een  a ltrom ycin  B 
and  hedam ycin  give rise to  varia tions in D N A  
sequence  selec tiv ity  and reactivity. D ifferences in car­
b o h y d ra te  su b stitu tio n  at th e  C 5 , C 8 and  C IO  posi­
tions o f  an o th e rw ise  sim ilar c h ro m o p h o re  appear to 
m o d u la te  a lky la tion  sequence  selectivity. Classical
pluram ycins, characterized  by C 8 and C IO  am inosugar 
substitu tions, d em o n stra te  5 ' ( P y ) G *  selectivity, w h ile  
the  altrom ycins, charac terized  by a C IO  a m in o d i­
saccharide and a C 5 neu tra l sugar su b stitu tio n , 
d em onstra te  5 'A G * selectiv ity  [13]. B ecause b o th  
n oncovalen t analogs, neop lu ram y cin  and  k idam ycin , 
show  only  nonspecific  D N ase I fo o tp r in tin g  pa tte rn s , 
and kidam ycin shows only  nonselective b ind ing  to  the 
10 base-pair D N A  dup lex  in this study, it is p robable  
that sequence se lectiv ity  is achieved largely th ro u g h  
the covalent a lky lation  step as oppo sed  to  the  in itia l 
precovalent b ind ing  step [13].
R ecognition o f  the m inor groove by hedam ycin’s glyco­
sidic substituents affects the orientation o f  the intercalating 
chrom ophore and, consequently, the proxim ity o f  the 
reactive C2 linked double epoxide to N 7  o f  guanine in 
the m ajor groove. T he hedamycin C 8 anglosamine, w hich 
is absent in the altromycins, positions to the 3' side o f  the 
intercalation site to associate w ith the noncovalently m od­
ified strand, specifically 7C, the cytosine base-paired to the 
m odified guanine. T he CIO linked N ,N -d im ethy l- 
vancosainine present in both altromycin B and hedamycin 
orients to the 5' side o f  the m odified guanine. A lthough 
the equivalent CIO sugar in altromycin B also interacts in 
the m inor groove to the 5' side o f  the intercalation site, the 
interaction o f  the N ,N -dim ethylvancosam ine m oiety w ith 
D N A  differs betw een the tw o analogs. T h e  hedam ycin 
CIO linked aminosaccharide interacts w ith the pyrim idine 
3T  located on the covalently m odified strand. This con­
trasts w ith the altromycin B am inodisaccharide, in w hich
Fig. 10. M olecular representation  of the interaction of the 
hedam ycin am inosugars in the m inor groove. A w ater m olecule 
m ediating the proposed hydrogen bond betw een  the d im ethy l­
am ino substituents and the 3T 02  and 7C 0 2  carbonyls is show n 
in white.
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Fig. 11. A proposed evolutionary 
pathway beginning with the anthracy- 
clines and ending with the most potent 
com pounds from each pluramycin sub­
family. The com pounds identified as 
possible intermediates in the evolution 
pathway were screened for and iso­
lated based on activity and may not 
fully represent the com plete set of 
com pounds in nature.
analog (altromycin B) constrains the modified guanine 
to tilt in the major groove toward the intercalating chro­
m ophore [2,13].This induced strain is alleviated by the 
attachm ent o f hedamycin to D N A  through a longer, 
more flexible double epoxide linker. This probably is 
responsible for the modest gain in both alkylation reac­
tivity and adduct stability demonstrated by hedamycin 
over altromycin B.
Evolutionary considerations
It is striking that agents have not been discovered that 
display a combination o f  glycosidic substitutions drawn 
from both o f the pluramycin subfamilies. Specifically, a 
compound that bears an aminosaccharide at the C 8 posi­
tion and also has a C5 or C3" altrose substitution has not 
been reported. The reason for this restricted pattern o f 
glycosidic substitution is probably due to the steric limi­
tations imposed by the D N A  helix, which would 
decrease the ability o f the ligand to covalently modify 
DNA. A hypothetical compound having the CIO amino­
disaccharide and a C 8 aminosugar would not have room 
in the m inor groove to accommodate both o f these sub­
stituents. Similarly, an analog possessing a major-groove 
binding C5 substituent and a minor-groove binding C 8 
sugar substitution would not easily span the DNA 
double helix from groove to groove. O n the basis o f 
these observations, the evolutionary scheme shown in 
Figure 11 is proposed for the biosynthesis o f the 
pluramycin class o f antibiotics.
the C3" linked neutral altrose moiety interacts with the 
covalently modified strand, while the N,N-dimethylvan- 
cosamine interacts primarily with the non-modified strand 
[2]. A pyrimidine located to the 5' side o f the modified 
guanine, 5'CG* and 5'TG*, creates a preferred hedamycin 
alkylation sequence, probably through the interaction o f 
the 4" dimethylamino group and the pyrimidine 0 2  car­
bonyl. A purine in the 5' position would require the 4" 
dimethylamino group to form a less optimal hydrogen 
bond to the purine N3 position or to create a sterically 
less favorable hydrogen bond to the carbonyl associated 
with the base-paired pyrimidine on the non-modified 
strand. In the case o f altromycin B, the reverse situation 
arises in which the dimethylamino group selects for a 
pyrimidine located on the non-modified strand, giving 
rise to the altromycin-preferred sequence 5'AG* [2,13].
The site o f  attachment of hedamycin to the D N A  mole­
cule also differs from that o f other pluramycins studied. 
W hile alkylation occurs in a similar fashion through N7 
o f  guanine in all three compounds studied thus far, the 
hedamycin mechanism o f covalent modification occurs 
through C 18 o f the terminal epoxide rather than C l 6 o f 
the proximal epoxide. A ttachm ent to N7 o f  guanine 
through C l 8 o f hedamycin then creates a four-carbon 
link between the tetracyclic chromophore and the m od­
ified guanine, as opposed to a tw o-carbon link in the 
case o f  altromycin B and sapurimycin. The bonding 
geom etry o f  guanine reacted w ith a C2 single epoxide
Anthracyclines:
Pluram ycins:
Sapurim ycin  R
SF-2330
A kinom ycin IK:
H edam ycin  (R=
(T /C )G * Selective
A ltrom ycin B 1 R= 
AG* Selective
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Fig. 12. Chemical structure of the anti-leukemic xanthone 
psorospermin [36]. Structural analogies to the pluramycin chro­
mophore can be drawn to gain insight into m ode of action of 
these agents.
In  l ig h t  o f  t h e  s tr u c tu r a l  in c o m p a t i b i l i t i e s  b e t w e e n  s u b ­
f a m i l ie s ,  t h e  e a r l ie s t  p lu r a m y c in  a n t ib i o t i c  p r o b a b ly  
e v o l v e d  f r o m  t h e  a n t h r a q u in o n e s ,  c r e a t in g  a c o m p o u n d  
v e r y  s im ila r  t o  s a p u r im y c in .  I t  is  t h e n  l ik e ly  th a t  t h e  
a n t i b i o t i c - p r o d u c i n g  o r g a n is m  a d d e d  a n  N , N -  
d im e t h y l v a n c o s a m in e ,  c o m m o n  t o  b o t h  f a m i l ie s ,  t o  t h e  
C I O  p o s i t i o n  t o  y i e l d  a c o m p o u n d  s im ila r  t o  a k i n o -  
m y c i n ,  w h i c h  w o u l d  p r o b a b ly  r e a c t  e q u a l l y  w e l l  w i t h  
s e q u e n c e s  p r e fe r r e d  b y  t h e  c la s s ic a l p lu r a m y c in s  a n d  th e  
a lt r o m y c in s .  D i v e r g e n c e  o c c u r r e d  a t th is  p o i n t ,  c r e a t in g  
t w o  i n d e p e n d e n t  f a m i l ie s  o f  c o m p o u n d s .  T h e  
a lt r o m y c in s  w o u l d  b e  c r e a te d  b y  a d d in g  n e u t r a l  a ltr o se s  
t o  t h e  C 3 "  a n d  C 5  p o s i t io n s ,  a n d  t h e  c la s s ic a l  p lu r a ­
m y c in s  w o u l d  b e  c r e a t e d  b y  a t t a c h in g  a n  a n g lo s a m in e  
s u g a r  m o i e t y  t o  t h e  C 8  p o s i t i o n .  C o n s e q u e n t ly ,  t h e  
m o s t  s t r u c tu r a l ly  a d v a n c e d  a n d  b i o l o g i c a l l y  p o t e n t  
a n a lo g s  o f  e a c h  s u b fa m ily ,  a l t r o m y c in  B  a n d  h e d a m y c in ,  
h a v e  i n d e p e n d e n t l y  e v o l v e d  f r o m  a c o m m o n  a n c e s t o r  
t o  f o r m  t h e  m o s t  D N A - r e a c t i v e  c o m p o u n d s  o f  t h e  
p lu r a m y c in  fa m ily ,  e a c h  p r e f e r e n t ia l ly  r e c o g n i z i n g  
m u t u a l ly  e x c lu s iv e  D N A  s e q u e n c e  ta r g e ts .
Comparison of pluramycins to psorospermin
B y  c o m p a r i n g  c h e m ic a l  s tr u c tu r e ,  o n e  c a n  d r a w  se v e r a l  
p a r a lle ls  t o  t h e  a n t i - l e u k e m i c  a g e n t  p s o r o s p e r m in  (F ig .  
1 2 )  [3 3 ] .  T h e  p s o r o s p e r m in  s t r u c tu r e  h a s  a
d i h y d r o f u r a n o x a n t h o n e  s k e le t o n  w i t h  a n  a t t a c h e d  
e p o x i d e  th a t  a p p e a r s  t o  f u n c t i o n  s im ila r ly  t o  th a t  o f  t h e  
p lu r a m y c in s  [ 3 4 ] . T h e  x a n t h o n e  m o i e t y  c o u ld  in te r c a la te  
i n t o  t h e  D N A  m o l e c u l e ,  p l a c i n g  t h e  3 , 4  b e n z o f u r a n  
i n t o  t h e  m a jo r  g r o o v e .  T h e  e p o x i d e  a t t a c h e d  th r o u g h  
C 2  o f  t h e  b e n z o f u r a n  c o u l d  t h e n  e a s i ly  a lk y la te  N 7  o f  
g u a n in e  lo c a t e d  in  t h e  m a jo r  g r o o v e  i n  a s im ila r  f a s h io n  
t o  th e  p lu r a m y c in s .  D u e  t o  t h e  R  s t e r e o c h e m is t r y  a t th e  
C 2 1 p o s i t io n ,  h o w e v e r ,  a lk y la t io n  w o u l d  b e  r e s tr ic te d  to  
a g u a n in e  r e s id u e  l o c a t e d  t o  t h e  5' s id e  o f  t h e  D N A  
in t e r c a la t io n  s it e  as o p p o s e d  t o  t h e  3 ' s id e ,  as i n  t h e  c a se  
o f  t h e  p lu r a m y c in s .  In vivo s t u d ie s  u s i n g  p s o r o s p e r m in  
s h o w  th a t  t h e  c y t o t o x i c i t y  o f  th is  a g e n t  c o r r e la te s  w e l l  
w i t h  t h e  f o r m a t io n  o f  a b a s ic  s it e s  a n d  a b a s ic - d e p e n d e n t  
l e s io n s  s u c h  as p r o t e in —D N A  c r o s s - l in k s  a n d  D N A  
s tr a n d  b r e a k s . T h is  w o u l d  s u g g e s t  th a t  t h e  b i o lo g i c a l ly  
s ig n if ic a n t  D N A  l e s i o n  w o u l d  n o t  n e c e s s a r i ly  b e  t h e  
d r u g - D N A  a d d u c t  b u t  t h e  a b a s ic  s it e  r e s u l t in g  fr o m  
d r u g - i n d u c e d  d e p u r i n a t i o n  o f  t h e  g u a n in e  r e s id u e .  
G iv e n  t h e  i n f o r m a t i o n  f r o m  th is  s tu d y , d e s ig n  e f fo r ts
m a y  n e e d  t o  f o c u s  o n  a g e n ts  th a t  f o r m  le ss  s ta b le  
a d d u c ts  th a t  r e a d ily  d e p u r in a te .  I t m a y  a lso  b e  im p o r t a n t  
t o  c o n s id e r  t h e  p o s s ib le  r o le  th a t  a lk y la t io n  t o  th e  5' s id e  
o f  in te r c a la t io n  p la y s  in  a c h ie v in g  d e p u r in a t io n .
S ig n ifican ce
T h e  s t r u c t u r e  o f  t h e  D N A - h e d a m y c i n  c o m p l e x  
d e t e r m i n e d  i n  t h e s e  s t u d i e s ,  t o g e t h e r  w i t h  t h e  
k n o w n  s t r u c t u r e  o f  t h e  D N A - a l t r o m y c i n  c o m p l e x ,  
h a s  y i e l d e d  a n  u n d e r s t a n d i n g  o f  t h e  c a r b o h y d r a t e -  
m e d i a t e d  s e q u e n c e - d e p e n d e n t  a l k y l a t i o n  d i s p l a y e d  
b y  t h e  p l u r a m y c i n  f a m i l y  o f  D N A  i n t e r a c t i v e  
a g e n t s .  O n l y  a  f e w  c l e a r l y  d o c u m e n t e d  e x a m p l e s  
o f  c a r b o h y d r a t e - m e d i a t e d  D N A  i n t e r a c t i o n  h a v e  
b e e n  d e s c r i b e d  t o  d a t e .  T h e  p l u r a m y c i n s  e m b o d y  
t h r e e  m o d e s  o f  i n t e r a c t i o n  w i t h  D N A .  F i r s t ,  t h e y  
h a v e  a n  a n t h r a q u i n o n e  r i n g  s y s t e m  t h a t  i n t e r ­
c a l a t e s  i n t o  t h e  D N A .  S e c o n d ,  t h e y  h a v e  a n  
a t t a c h e d  a m i n o s u g a r  t h a t  b i n d s  i n  t h e  m i n o r  
g r o o v e  u p o n  D N A  c o m p l e x a t i o n .  T h i r d ,  i n  c o n ­
j u n c t i o n  w i t h  t h e  b a s i c  a n t h r a q u i n o n e  s t r u c t u r e ,  
t h e  p l u r a m y c i n s  h a v e  e v o l v e d  a  1 , 2  p y r a n  r i n g  
s y s t e m  u p o n  w h i c h  t h e y  h a v e  a t t a c h e d  m u l t i p l e  
p o s s i b l e  e p o x i d e  f u n c t i o n a l i t i e s  t h a t  c a n  c o v a l e n t l y  
m o d i f y  D N A  t h r o u g h  N 7  o f  g u a n i n e .  I n  t h i s  
r e s p e c t ,  t h e  p l u r a m y c i n - D N A  l e s i o n  i s  c l o s e l y  
a n a l o g o u s  t o  t h a t  c r e a t e d  b y  t h e  h i g h l y  m u t a g e n i c  
D N A  i n t e r c a l a t o r - a l k y l a t o r  a f l a t o x i n  [ 3 5 ] .
T o  b e  e f f e c t i v e  a g a i n s t  t u m o r s  in vivo ,  t h e  
d e s i g n e d  a g e n t s  s h o u l d  m a x i m i z e  t u m o r  c e l l -  
s p e c i f i c  c y t o t o x i c i t y .  S e l e c t i v e  u p t a k e  o f  a  c y t o ­
t o x i c  a g e n t  a t  t h e  c e l l u l a r  l e v e l  w o u l d  a p p e a r  t o  
b e  c r u c i a l  u n l e s s  u n i q u e  i n t r a c e l l u l a r  t a r g e t s  c a n  
b e  i d e n t i f i e d  w i t h i n  c a n c e r  c e l l s .  A t  t h e  i n t r a ­
c e l l u l a r  l e v e l ,  s e l e c t i v i t y  c a n  b e  a c h i e v e d  e i t h e r  a t  
t h e  l e v e l  o f  D N A  s e q u e n c e  o r  t h r o u g h  i n t e r ­
a c t i o n  w i t h  p h a r m a c o l o g i c a l l y  s e l e c t i v e  r e c e p t o r s  
o n  o r  a s s o c i a t e d  w i t h  D N A  [ 3 6 ] .  I f  l i g a n d -  
i n d u c e d  m u t a g e n i c i t y  a n d  a n t i t u m o r  a c t i v i t y  i s  a  
f u n c t i o n  o f  D N A  s e q u e n c e  s e l e c t i v i t y ,  t h e n  m o d ­
i f i c a t i o n  o f  t h e  g l y c o s i d i c  s u b s t i t u t i o n s  a t  t h e  
v a r i o u s  c o r n e r s  o f  t h e  p l u r a m y c i n  c h r o m o p h o r e  
s h o u l d  b e  a b l e  t o  m o d u l a t e  t h e s e  b i o l o g i c a l  
p r o p e r t i e s .
M a te ria ls  a n d  m e th o d s
Sample preparations
T he self-com plem entary d(GATGTACATC) D N A  strand was 
synthesized on an autom ated D N A  synthesizer (Applied 
Biosystems 381 A) using the solid phase phosphoram idite 
m ethod. T he D N A  synthesis was perform ed on a 10-jxmol 
scale, leaving the final dim ethoxytrityl group on the 5' end o f  
the D N A  molecules. T he crude sample was deprotected  in 
concentrated  N H 4O H  at 55 °C overnight and purified  by 
reverse phase chrom atography on a C l 8 colum n (D ynam ax- 
300A). Purified D N A  was then detritylated by dissolving in 
80 % acetic acid for 30 m in, followed by ether extraction to
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rem ove the acetic acid. T he sample was then  extensively dia- 
lyzed and buffer was adjusted to 10 m M  N aH 2P 0 4, 100 m M  
N aC l, 0.5 m M  EDTA, pH  6.8.
H edam ycin samples w ere a gift from  the D ru g  Synthesis and 
C hem istry  Branch, D evelopm ental T herapeutics Program , 
D ivision o f  C ancer Treatm ent, N ational C ancer Institute, and 
w ere used w ith o u t fu rther purification. D ru g -D N A  adduct 
fo rm ation  was achieved by adding a 2:1 m olar ratio o f  
hedam ycin to the purified  D N A  sample and m ixing at 5 °C 
for several hours. A dduct form ation was m onito red  by one­
dim ensional N M R  until com plete alkylation o f  the D N A  had 
occurred. A fter addition o f  drug, the pH  was checked and 
readjusted to  p H  6.8. D ue to aggregation problem s, samples 
w ere diluted to 1.0—2.0 m M  adduct concentrations and 
experim ents w ere perform ed at 30 °C. In  betw een  experi­
m ents, samples w ere stored inside N M R  tubes at —70 °C to 
m inim ize decom position  due to depurination  o f  the 
hedam ycin—guanine adduct.
NMR experiments
All N M R  experim ents w ere perform ed on  a B ruker A M X  
500 spectrom eter in  99.96 % D 20  or 95 % H 20 :5  % D 20 .  
Phase-sensitive, tppi tw o-dim ensional N OESY, T O C S Y  and 
D Q F -C O S Y  experim ents [27-30] were perform ed on 
samples dissolved in D 20 .  For these experim ents, 1 K data 
points w ere acquired in t l  w ith  a spectral w id th  o f  5000 Hz. 
To observe exchangeable protons, a tw o-dim ensional N O E SY  
spectrum  was obtained w ith  150 ms m ixing delay in H 20  
using a 1—1 echo pulse sequence [37—39] to suppress the w ater 
resonance. In this experim ent, 1 K  o f  data points were 
obtained in  t l  w ith  a sweep w id th  o f  12 000 H z. Select 
ca rb o n -13 resonances were identified and characterized using 
H M Q C  and H M B C  experim ents in D 20  [40,41].
D ue to a lim ited sample life, in terproton distance constraints 
were calculated from  a single 150 ms N O E SY  spectrum  in 
D 20 ,  obtained w ith 32 scans per increm ent, 6000 H z sweep 
w idth, and a 5 s relaxation delay betw een scans. Data was m ulti­
plied by a tt/2  shifted sinebell squared w indow  function, zero 
filled to 2 K  and Fourier transform ed using Felix 2.0 N M R  
data processing software. In terproton cross-peaks were in te­
grated and sorted by volume into sixteen distinct bins: four each 
for pro ton—proton cross-peaks, methyl—proton  cross-peaks, 
d im ethylam ino-proton cross-peaks and methyl—dim ethylamino 
cross-peaks, corresponding to  very strong, strong, m edium  and 
w eak connectivities. U pper and lower constraint boundaries 
were created using the coordinate averages for the protons in 
the m ethyl and dim ethylam inos.The respective boundaries for 
each group are: 2 .2 -3 .5 , 2 .6 -4 .0 , 3 .0 -4 .5 , 3 .5 -5 .5 ; 2 .2 -3 .5 , 
2 .6 -4 .0 , 3 .0 -5 .0 , 3.5—6.0; 2 .2-4 .0 , 2 .4 -4 .5 , 3 .0 -6 .5 , 4 .0-7 .0 ; 
and 4 .0 -5 .0 ,4 .0 -5 .5 ,5 .0 -7 .0 ,5 .5 -8 .0 .
Modeling
T he SA N D E R  (Simulated Annealing w ith N M R  Driven 
Energy Restraints) module o f  A M B ER  4.0 [42] was used to 
perform  energy refinem ent w ith these N M R -derived  
distance constraints to derive a m odel o f  the 
hedamycin—d(GATG*TACATC)2 diadduct. T he A M B E R  force 
field was used w ith the addition o f  pseudo energy terms consist­
ing o f  a flat well potential w ith  parabolic boundaries for each 
in ter-pro ton  connectivity measured. H edam ycin partial atomic 
charges, calculated by M O PA C  5.0, were incorporated into the 
force field parameters for electrostatic energy calculations. 
Additionally, bond, torsion and angle parameters calculated for
carbohydrates [43] were included for energy calculations con­
cerning the saccharide moieties in the drug molecule. T he N 7 o f 
the m odified guanine was param eterized assuming planar, 
sp2 hybridization.
Initial D N A  structures w ere created w ith  the N U C G E N  
m odule o f  A M B E R  and adjusted in  MIDAS [44] to form  
intercalation sites and to dock the hedam ycin m olecule. T he 
hedam ycin structure was generated by m inim izing the 
reported  X -ray structure [20].T h e  starting structure was then 
solvated w ith  approxim ately 600 w ater molecules, subjected to 
30 ps o f  belly dynamics hold ing the drug—D N A  adduct rigid, 
m inim ized, and then  slowly heated to 300 K over 10 ps. In the 
initial period o f  m olecular dynamics, in terproton distance con­
straints were slowly incorporated  to 10 kcal m ol-1 A-2. T he 
system was then  m aintained at 300 K for 90 ps and m inim ized 
in vacuo, w ithou t constraints, to obtain the reported structure.
Supplementary material available
Included as supplem ental m aterial is a list o f  constraints and 
final constraint violations.
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A b str a c t:  T h e  p luram ycin  antitum or antib iotics, w h ich  in clu d e  the a ltrom ycin s, p luram ycin , h ed am y cin , and rub iflavin , 
are a  group  o f  h ig h ly  e v o lv e d  D N A -r e a c tiv e  c o m p o u n d s that h a v e  structural features rem in iscen t o f  both  n o g a la m y c in  
and the a fla to x in s. A s  su ch , th e y  are ch ara cterized  as “thread ing in terca la tors” w ith  the  added ab ility  to  a lk y la te  N 7  
o f  g u a n in e  (se e  p r ec ed in g  a rtic le  in  th is  issu e ) . In th is  artic le  w e  h a v e  d em on strated  that d ifferen t m em b ers o f  th is  
grou p  o f  an tib io tics  h a v e  s e q u e n c e  s p e c if ic it ie s  that d iffer  fo r  th e  b a se  pair to  the  5 ' s id e  o f  the  a lk y la ted  g u a n in e  
and a lso  h a v e  a range o f  rea c tiv itie s  w ith  su sce p tib le  seq u en c es . S u b seq u en t ex p er im en ts  w ere  d es ig n e d  to  determ in e  
the  m o le cu la r  o r ig in  fo r  b oth  th e se  o b se rv ed  co n trastin g  seq u en c e  s p e c if ic it ie s  and c o v a len t r ea c tiv itie s. F irst, 
n e op lu ram yc in , an a n a lo g  o f  p lu ra m y c in  that la ck s  th e  e p o x id e , and thus is  u n ab le  to  c o v a le n tly  m o d ify  D N A , but 
is  in  o th er  resp ects  structurally  sim ilar , e x h ib its  n o  d isce rn ib le  seq u en c e  se le c t iv ity . T h is  su g g e s ts  that th e  seq u en c e  
se lec tiv ity  o f  the p luram ycins is  determ ined  at the cov a len t b on d in g  step  rather than the precova lent b ind ing interactions. 
S e c o n d , u s in g  A„ tracts o f  v a ry in g  len g th  (n  =  1 —5 ) to  m o d u la te  the  m in o r  g r o o v e  g e o m etr y  to  the  5' s id e  o f  th e  
c o v a len t a lk y la tio n  s ite , th is  structural param eter has b e en  sh o w n  to  h a v e  a m ajor e f fe c t  o n  both  seq u en c e  sp e c if ic ity  
and a lk y la tion  rea ctiv ity . L ast, th e  e lectr o n e g a tiv ity  o f  the  N 7  p o s itio n  o f  the  a lk y la ted  b ase  can  a lso  a ffec t rea c tiv ity  
and, to  a  le sser  ex ten t, seq u en c e  sp e c if ic ity . In order to  d e term in e  th e  m o le cu la r  d e ta ils  o f  the  in teraction s in  the  
m in o r  and m ajor g r o o v e s , w h ic h  c o u ld  g iv e  r ise  to  th e  d ifferen t se q u e n c e  s p e c if ic it ie s  o f  the n o n c la ss ic a l (ty p ified  
b y a ltrom ycin  B ) and c la ss ic a l (ty p ified  b y  h ed a m y cin ) p lu ram ycin s, w e  h a v e  u sed  m o lecu lar  m o d e ls  o f  the  a ltrom ycin  
B  and h e d a m y c in —D N A  ad d u cts that are d er iv ed  fro m  h ig h -f ie ld  N M R  data o f  their  1 0 -m er  d u p lex  d iadducts. T h e se  
s tu d ies  d em on strate  that it is  l ik e ly  that the seq u en c e-d e p en d en t r ea c tiv itie s  o f  the e p o x id e  o f  the  p lu ram ycin  to  N 7  
o f  g u a n in e  are d ep en d en t u p on  th e  re la tiv e  ex ten t o f  a “p r o x im ity  e f fe c t” . T h e  m a gn itu d e  o f  the  p ro x im ity  e f fe c t  is  
d eterm in ed  b y  a “steer in g  r ea c tio n ” , w h ic h  tak es p la ce  in  th e  m in or  and m ajor g r o o v e s  d u e to  the d ifferen t p la ce m e n t  
o f  th e  carbohydrate  su b stitu en ts o n  the  p lu ra m y c in s and th e ir  h y d ro g en  b o n d in g  and va n  der W a a ls  in teraction s w ith  
the  b ase  pairs to  the 5' s id e  o f  th e  a lk y la tio n  site . T h is  is  p rop osed  to  b e  a n o v e l m e ch a n ism  for  seq u en ce  r eco g n itio n , 
w h e re  c o o p e ra tiv e  in teractio n s in  th e  m in o r  and m ajor g r o o v e s  tran sm itted  v ia  the in terca la tion  m o ie ty  d icta te  the  
p o s it io n in g  o f  the  e p o x id e  in  th e  m ajor g r o o v e  and, thus, seq u en c e  rea c tiv ity . F in a lly , w e  p r o p o se  that th e  in creased  
rea c tiv ity  o f  the c la s s ic a l p lu ra m y c in s in  con trast to  the a ltro m y cin s is  at lea st p artia lly  d eterm in ed  b y  th e  “reach ” 
o f  th e  rea c tiv e  e p o x id e  in  the m a jo r  g r o o v e , w h ic h  va ries  from  o n e  grou p  to  another. T h e m o lecu la r  m e ch a n ism s  
for  seq u en c e  r eco g n itio n  d escr ib ed  here  p ro v id e  a n ew  parad igm  for  seq u en c e  rec o g n itio n  b y  m in or and m ajor g r o o v e  
in teractio n s m ed ia ted  b y  in ter ca la c tiv e  b in d in g  b ut a c h ie v e d  at th e  c o v a le n t  b o n d in g  step.
I n tr o d u c t io n
T h e  p lu ra m y c in  group o f  a n tib io tics  c o n s is ts  o f  a  fa m ily  o f  
antitum or co m p o u n d s that are ch ara cterized  b y  a p lanar 4 H- 
anthra[ 1,2 -6 ]p y r a n -4 ,7 ,12 -tr io n e  m o ie ty , fro m  w h ic h  a va riety  
o f  su b stitu en ts are e x ten d ed  fr o m  tw o  o r  m o re  c o m e r s  (F ig u re  
l ) . 2 T h e  p r ese n ce  o f  an e p o x id e  at p o s it io n  tw o  is  n ece ssa ry  
for  the  poten t cy to to x ic ity  and antitum or activ ity .20 In a p rev iou s  
stu d y , u s in g  g e l e le c tro p h o resis  m e th o d s  in  c o m b in a tio n  w ith  
N M R  and m a ss sp e c tr o sco p y , w e  h a v e  d em on stra ted  that the  
p lu ra m y c in s in terca late  b e tw e e n  b a se  pairs and, w h e re  an  
e p o x id e  is  p resen t, a lk y la te  N 7  o f  g u a n in e  (F ig u re  2 ) .3 In the  
p resen t stu d y , w e  h a v e  e x a m in e d , u s in g  a  therm al strand  
b reak age a ssa y  (F ig u re  2 ), th e  se q u e n c e  s p e c if ic ity  o f  se le c t  
a n tib io tics  w ith in  th is  grou p  and  a lso  d e term in ed  their  re la tiv e
* Address correspondence to this author.
® Abstract published in A d v a n c e  A C S  A b s t r a c t s ,  February 1, 1995.
(1) Abbreviations: bp, base pair; DDW, double-distilled water; TEMED, 
AWA^A^tetramethylethylenediamine.
reactiv ity  in  the a lk ylation  o f  D N A . A n  a n a lysis  o f  the seq u en ce  
s e le c t iv ity  resu lts , u s in g  m o le cu la r  m o d e ls  o f  the  a ltro m y cin  B
(2) (a) Uosaki, Y.; Yasuzawa, T.; Hara, M.; Saitoh, Y. J .  A n t i b i o t .  1991, 
4 4 , 40—44. (b) Gonda, S. K.; Byrne, K. M.; Herver, P. K.; Tondeur, Y.; 
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F o r t s c h r .  C h e m .  O r g .  N a t u r s t .  1986, 5 0 ,  57—122. (d) Sato, Y.; Watabe,
H.; Nakazawa, T.; Shomura, T.; Yamamoto, H.; Sezaki, M.; Kondo, S. J .  
A n t i b i o t .  1989, 4 2 ,  149—152. (e) Itoh. J.; Shomura, T.; Tsuyuki, T.; 
Yoshida, J.; Ito, M.; Sezaki, M.; Kojima, M. J .  A n t i b i o t .  1986, 3 9 ,  773— 
779. (f) Nadig, H.; Sequin, U. H e l v .  C h i m .  A c t a  1987, 7 0 , 1217-1288. 
(g) Nadig, H.; Sequin, U. H e l v .  C h i m .  A c t a  1987, 6 8 , 953—957. (h) Abe, 
N.; Enoki, N.; Nakakita, Y.; Uchida, H.; Nakamura, T.; Munekata, M. J .  
A n t i b i o t .  1993,4 6 , 1536—1549. (h) Jackson, M.; Karwoski, J. P.; Theriault, 
R. J.; Hardy, D. J.; Swanson, S. J.; Barlow, G. J.; Tillis, P. M.; McAlpine, 
J. B. J .  A n t i b i o t .  1990, 4 3 ,  223-228. (i) Brill, G. M.; McAlpine, J. B.; 
Whittem, D. N.; Buko, A. M. J .  A n t i b i o t . 1990,4 3 , 229—237. (j) McAlpine, 
J. B.; Karwoski, J. P.; Jackson, M.; Brill, G. M.; Kadam, S.; Shen, L.; 
Clement, J. J.; Alder, J.; Burres, N. S. In A n t i t u m o r  D r u g  D i s c o v e r y  a n d  
D e v e l o p m e n t ’, Valeriote, F. A., Crobett, T. H„ Baker, L. H., Eds.; Kluwer 
Academic Publishers: Boston, in press, (k) Byrne, K.; Gonda, S. K.; Hilton,
B. D. J .  A n t i b i o t .  1985, 3 8 , 1040-1049. (1) Hara, M.; Takiguchi, T.; 
Ashizawa, T.; Gomi, K.; Nakano, H. J .  A n t i b i o t . 1991, 4 4 ,  33—39.
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Compound R1 R2 R3 R4 R ’
altromycin B A H B A N (C H ,),
altrom ycin H OH H B A N (C H ,)2
altrom ycin I OH H B A N H C H ,
akinomycin C H , H A C H
pluramycin C H , A A D acetyl
neopluramycin C H , A A B acetyl
hedamycin C H , A A C H
rubiflavin A C H , A A D H
igure 1. Structures of altromycins B, H, and I, akinomycin, pluramycin, neopluramycin, hedamycin, and rubiflavin A.2
yV
, 0
\ N— \  J ■ v ^ C r1X1 M U ,
OH
H
D N A  s tr a n d
b r e a k a g e
s im ila r  to  M a x a m -  
G ilb e r t  S e q u e n c i n g
igure 2. Reaction of altromycin B with DNA to form the altromycin B —(N7-guanine)—DNA adduct and products o f thermal and piperidine 
leavage o f the DNA adduct.36 Analogous products are produced from the other pluramycin antibiotics.
nd  hedam yc in—D N A  adducts derived from  high-field  NM R 
tudies4 o f 10-mer duplex diadducts, provides valuable informa- 
on concerning the w ays in w hich both the position and 
la rac te r o f the substituents on the 4 //-an th ra [l,2 -6 ]p y ran  ring 
ystem  can dram atically  affect the sequence selectivity and 
Ikylation reactiv ity  o f the pluram ycin fam ily o f antibiotics. In 
am , the results provide im portant additional insights into the 
o ten tial design o f  new  sequence-selective com pounds based 
n the p luram ycin  group o f  com pounds.
(3) Sun, D.; Hansen, M.; Clement, J. J.; Hurley, L. H. Biochemistry 1993, 
2, 8068-8074.
(4) (a) Hansen, M.; Hurley, L. H. J. Am. Chem. Soc. 1995, 117, 2421 — 
429. (b) Hansen. M.; Hurley, L. H. Manuscript in preparation.
Results
Determination of the C om parative Reactivity and Se­
quence Specificity of the Pluram ycins. A. Concentration 
Dependency of Sequence Alkylation by A ltrom ycin B. A
heat-induced strand breakage assay  fo llow ing  a ltrom ycin  B 
treatm ent o f the +  and — strands o f a 64-bp  o ligom er D N A  
(64M  in T able 1) was carried ou t to reveal the d ru g ’s alkylation  
sequence selectivity. T o determ ine in a quan tita tive  m anner 
the h ierarchy of altrom ycin B a lky lation  sites, six d ifferen t 
concentrations o f altrom ycin B solutions w ere reacted  individu­
ally w ith aliquots o f the 5 '-labe led  64-bp  restric tion  enzym e 
fragm ent. The alkylation sites fo r altrom ycin  B at each 
concentration  are show n in F igure  3, and inspection  o f the
2 4 3 2  J. Am. Chem. Soc., Vol. 117, No. 9, 1995
Table 1. Sequence o f Oligomer DNA M olecules Used in This Study
Sun et c
6 4 M  5 ' -CGATCTTTGTCAAGCATCCCAGAAGGTATAAAAACGCCCTTGGGACCAGGCAGCCTCAAAC
3 ' -GCTAGAAACAGTTCGTAGGGTCTTCCATATTTTTGCGGGAACCCTGGTCCGTCGGAGTTTG
4 2  A  5 ' - GCTCATCAAGACAAAAAGACAGACAAAGTACAAAAGCAATCA- 3 '
3 ' -CGAGTAGTTCTGTTTTTCTGTCTGTTTCATGTTTTCGTTAGT-5'
2 3 G  5 ' -AAAAGTTGATCGTAAGTACAATC-3'
3 ' -CAACTAGCATTCATGTTAGTTTT-5'
231 5 ' -AAAAITTIATCITAAITACAATC-3 '
3 ' -CAACTAGCATTCATGTTAGTTTT-5'
7 7 M  5 ' -CGCAGCGCGCGATCGGGCATTATAAAAAAGCATTGCTTATCAATTTGTTGAATTAGATTTTGCACGCAACGCGCTGT- 3 '
3 ' -TCGCGCGCTAGCCCGTAATATTTTTTCGTAACGAATAGTTAAACAACTTAATCTAAAACGTGCGTTGCGCGACAGCG-5
A T
G C  1 2 3 4 5 6 7
T " * "
I
A T
G C  1 2  3 4 5 6 7









Figure 3. Concentration dependency of altromycin B alkylation sites 
on the +  (right panel) and -  (left panel) strands o f the 64-bp oligomer 
duplex (Table 1) following thermal treatment of the altromycin B —DNA  
adduct. For both the right and left panels, 5' end-labeled oligomer 
DNA was used in this experiment. The reaction mixtures (20 fiL) 
consisted o f 10 mM NaCl, 10 mM Tris-HCl (pH 7.6), about 10 ng of 
DNA, and the indicated amount o f drug (see below), and these were 
incubated at room temperature for 1 h. AG and TC represent the purine- 
and pyrimidine-specific cleavage reactions. Lanes 1 —7 in each case 
contain 0, 2, 5, 10, 20, 40, and 100 ng o f drug, respectively. 
Arrowheads point to the alkylation sites (G*) in altromycin-modified 
sequences. The multiplicity o f bands at higher molecular weight than 
the major cleavage site is due to incomplete degradation o f the initial 
depurination product.3
autoradiogram shows a remarkable degree of sequence dis­
crimination at the lowest concentrations of drug, especially for 
a 926 Da molecule. By using Maxam—Gilbert chemically 
produced markers as controls, the 5' AAG* sequence (* 
indicates the covalent reactivity site) was shown to be the most 
sensitive cleavage site, although other sequences were also 
cleaved, but at higher concentrations. A preliminary analysis 
suggested that the nucleotides to the 5' side of the alkylation 
site are the primary influence on the sequence specificity, and 
conversely, the alkylation appeared to be little effected by the 
identity of the 3' neighboring nucleotide. A more detailed 
analysis, in which other members of the pluramycin family were 
compared to altromycin B, was then carried out.
Allrnmvfin R Altromycin H Altrnmvcin I Pluramycin Rubiflavin HfdamVCin
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Figure 4. Comparison o f the DNA sequence selectivity and alkylatic 
reactivity o f altromycins B, H, and I and pluramycin, rubiflavin, ad 
hedamycin. The DNA in this experiment is an N col — PvuII fragmei 
(189 bp) from plasmid pCAT that was 5' end-labeled at the N col sit 
The reaction mixture (20 ^L), consisting o f 10 mM NaCl, 10 mM Trii 
HC1 (pH 7.6), about 5 ng o f DNA, and the indicated amount of dru 
(see below), was incubated at room temperature for 1 h. Arrowheac 
point to the alkylation sites, and the drug-modified bases are indicate 
with an asterisk. Lanes 1—4 contain 2, 10, 20, and 50 ng of dru 
molecules for altromycin B; 10, 20, 50, and 100 ng for altromycins ] 
and I; 0.5, 1, 2, and 5 ng for pluramycin and rubiflavin; and 0.1, 0.; 
1, and 2 ng for hedamycin. The complete DNA sequence is given 
Figure 5.
B . C o m p a r is o n  o f  th e  A lk y la t io n  R e a c t iv i ty  o f  A ltr o m y c i  
B  a n d  I t s  P lu r a m y c in  A n a lo g s .  Upon the basis of the analy: 
of the results of the previous experiment, in which the 64 
oligomer DNA was used, a second DNA fragment (189 b 
was selected, in which clustered GC base pairs were found (f< 
sequence, see Figure 5). Using this restriction fragment, tl 
relative reactivities of altromycin B with other epoxidi 
containing pluramycins were determined; an autoradiogram 
the results is shown in Figure 4. In general, the classic 
pluramycin antibiotics (pluramycin, rubiflavin, and hedamycin 
showed at least a 5-fold higher reactivity in the alkylation c 
DNA than altromycins B, H, and I (see Figure 4). This resu 




0 n  1111 t i t  11T i i i  t 111 r 11 rr i§  i m f  11II111 f  1111 t i > i i V i 11II i i t  i i  i T 1111T111 m i iTtT f T11 n  111111 n  Ti i H11 n  t t i T n  i »11111 t  11 r f i  i t i i  i i i  m i it i ri i T n  t t m m 11 n f i  r f i  111 ri i i i i i i i i i i i t i i T i i t i i i i i i t
c*ioooocoo»o**iooacoo»»ciaoocao»OTTAOOoocooo*TOoocoo*oTnoaoacooa*ci/
0 *n~rri 11 i i  1111111T111111 ■ ■ ■ f ■ ■ i ■ ■ ■ I ■ ■ i T111 ■ i ■ 11 ■° 11■■■i t ■■i T■■<11»i ■■ 11 ■¥ ■ 11 t i ■ f i ■ 11111"i Ti ■11■t111111■1111111f111i i11111i t i i11f1111t111f111111111i t i  11 t 1111111111111 m  11
3 -  
2-
1 -
0 xi 111111 i t  11 i i  i rti  i t t  i ri 11 n  11111111111 m f  1111 ii  11 t  ii 11111 f 111 t f  111 m 111 n  n  11 n  1111 m 11111 i t t t t i  111 i i  111 n  rf 111 f 11111111 u  11T r i f n  itt t t i  i m i  11 r r i  i t  i i i i i ii  i i i i i i  i i f 111111 111111 ii iCATaaaOCOOAOAATOOOCOOAACTOaOCOOAOrTAOOOaCOOaATOOOCSOAaTTAOaOOCOaQACTAIOailOCTOAeTAArrOAOATOetaAICTOOAATTCAeiOOCeOTCOirTTACAACaTCOTOACIOOOAAAACCCTOaCOITACCCAACTTAArCOCCrTOCAaCACArCC
Figure 5. Summary of observed alkylation sites o f  altromycins B, H, and I, pluramycin, rubiflavin, and hedamycin from the data in Figure 4. The drugs were classified (see Table 2) into groups A, B, and 
C, corresponding to panels A, B, and C. The alkylation sites for each group were classified into high-, medium-, and low-reactivity sites, based upon the amount o f strand breakage at the modified base from 
the data in Figure 4. Densitometric measurements were made using an LKB 2202 Ultrascan LX laser densitometer to compute the percentage o f strand breakage at a given site relative to the total strand 
breakage. High-, medium-, and low-reactivity sites are represented by three-, two-, and one-unit bars, respectively. Open circles indicate common alkylation sites for groups A, B, and C, and arrow heads 
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Table 2. List of Individual High- and Medium-reactivity Sites and 
Consensus Sequences for the Pluramycin Antitumor Antibiotics, 
Including the Covalently Modified Base (G*) and Bases That Are 




































































5' NTG*N 5' N^G*N T 5' ATG*  ̂G
stituents at ea ch  c o m e r  (R 1 to  R 3  in  F igu re  1) o f  the  anthrapyran  
r in g  an d /or  co m p a ra tiv e  r ea c tiv ity  o f  the  e p o x id e (s )  at R 4  
s ig n if ic a n tly  a ffe c t  th e  re la tiv e  D N A  r ea c tiv ity  o f  d ifferen t  
m e m b er s  o f  th e  p lu ra m y c in  fa m ily  o f  antitum or a n tib io tics. 
F u rth erm ore, a ltro m y cin  B  sh o w s  greater  a lk y la tio n  rea c tiv ity  
than  a ltro m y cin s H  an d  I, p resu m a b ly  b e c a u se  o f  the  p r ese n ce  
o f  an  ad d ition a l su b stitu en t ( R l )  at C 5  in  a ltro m y cin  B . L ast, 
a ltro m y c in  H  is  ab o u t 5 - fo ld  m o re  rea c tiv e  than a ltro m y cin  I, 
d u e  to  th e  p r ese n ce  o f  a  d im e th y la m in o  grou p  rather than th e  
m o n o m e th y la m in o  in  the a m in o  su ga r  in  the d isa cch a r id e  at 
C IO .
A m o n g  th e  n o n -a ltro m y c in  a n a lo g s , h e d a m y cin  sh o w e d  the  
h ig h e s t  r ea c tiv ity  to  D N A , w h ic h  m a y  b e  d u e  to  the d ie p o x id e  
g ro u p  p r esen t at C 2 , in  con trast to  the o le f in ic  m o n o e p o x id e  in  
p lu ra m y c in  and r u b ifla v in  ( s e e  later). P lu ram ycin  is  m o re  
r ea c tiv e  to  D N A  than r u b ifla v in , w h ic h  w a s  n o t c o m p le te ly  
u n e x p e c te d , s in c e  n eo p lu ra m y c in , th e  n o n c o v a le n t b in d in g  
a n a lo g  o f  p lu ra m y c in , sh o w e d  better  re la tiv e  b in d in g  a ff in itie s  
fo r  D N A  than k id a m y c in , th e  n o n c o v a le n t b in d in g  a n a lo g  o f  
ru b ifla v in  (S u n  an d  H u rley , u n p u b lish ed  resu lts).
C . C o m p a r is o n  o f  th e  D N A  S e q u e n c e  S p e c if ic ity  o f  th e  
P lu r a m y c in  A n t i tu m o r  A n t ib io t ic s .  A  q u an tita tive  c o m p a ri­
s o n  o f  the  seq u en c e  se le c t iv ity  o f  the p lu ram yc in s, d erived  from  
th e  r esu lts  sh o w n  in  F ig u re  4 ,  i s  p resen ted  in  F igu re  5 . A  
cu rso ry  e x a m in a tio n  o f  F ig u re  4  sh o w s  that w h ile  a ltro m y cin  
B  s h o w s  m a n y  s ite s  in  c o m m o n  to  a ltro m y cin s H  an d  I, w h ic h  
are th e m se lv e s  v e ry  sim ilar , th e y  are a ll three d ifferen t from  
th e  grou p  rep resen tin g  p lu ra m y c in , ru b ifla v in , and h e d a m y cin . 
F o r  th is  r ea so n , in  th e  bar s iz e  c o m p a riso n  in  F ig u re  5 and in  
T a b le  2 , th e  an tib io tics are p o o le d  tog eth er  in  three m ain  groups. 
In  F igu re  5 , p an el A  rep resen ts a ltro m y cin  B , p an el B  represents 
b oth  a ltrom ycins H  and I, and p an el C  is  c o lle c t iv e ly  p luram ycin , 
h e d a m y c in , and r u b ifla v in . T a b le  2  fo l lo w s  the sa m e  pattern. 
O f  th e  to ta l o f  3 7  s ite s  o f  a lk y la tio n  o n  ju s t  o n e  strand o f  the  
1 8 9 -m er , 10  are c o m m o n  a lk y la tio n  s ite s  fo r  a ll three crou p s
[5 ' T G *  (s e v e n  s ite s ) /5 '  A G *  ( tw o  s ite s ) /5 '  C G *  (o n e  s ite);  
d e n o te s  s ite  o f  a lk y la tio n ] and s ix  s ite s  are u n iq u e  to  ju s t  on  
o f  the grou p s [group  C  ( f iv e  s ite s )/g r o u p  A  (o n e  s ite )] . T h es  
s ite s  are d e n o te d  in  F ig u re  5 .
I f  the  h ig h -r ea c tiv ity  a lk y la tio n  s ite s  fo r  a ll th ree  grou p s ar 
com p a red , th o se  in  grou p  A  c le a r ly  p refer  a 5 ' A G *  (se v e n  ou  
o f  e ig h t  s ite s )  se q u e n c e , w h ile  th o se  in  group  B  prefer  5 '  T G ! 
(s e v e n  ou t o f  n in e  s ite s )  and th o se  in  grou p  C  prefer  5 '  C G ! 
(1 0  o u t o f  11 s ite s ) . In  grou p  C , th ere m a y  b e  a p referen ce  fo  
the  5 ' G C G *  se q u e n c e  (s e v e n  ou t o f  11 s ite s ) . F or  m e d iu n  
rea c tiv ity  s ite s , the  p re fe re n ce  to  the  5' s id e  is  d ifferen t: thosi 
in  grou p  A  prefer  5 '  T G *  ( s ix  o u t o f  n in e  sites); th o se  in  grouj 
B , 5 ' (A /T )G *  (s e v e n  ou t o f  s e v e n  s ites); and th o se  in  grou p  C  
5 ' T G *  (fo u r  ou t o f  f iv e  s ite s ) . O n ly  in  o n e  grou p  is  th ere  i 
p o s s ib le  p r efe re n ce  fo r  a  n u c le o tid e  to  the 3 ' s id e , i .e .,  th o se  ii 
grou p  C  h a v e  a p refe re n ce  fo r  G  to  th e  3 ' s id e  o f  G *  ( s e v e n  o u  
o f  11 s ite s )  fo r  h ig h  r ea c tiv ity  s ite s  and 5' G *P u  ( f iv e  o u t o  
f iv e  s ite s )  fo r  m e d iu m  r ea c tiv ity  s ite s . It i s  q u ite  str ik in g  that 
w h ile  a ltro m y cin  B  (grou p  A )  p refers 5 ' A G *  (h ig h  r ea c tiv ity  
and 5 ' T G * (m ed iu m  reactiv ity ) sites, altrom ycins H  and I (grouj 
B )  prefer  5 ' T G *  (h ig h  an d  m e d iu m ) and p lu ram ycin , h ed a m y  
c in , and r u b ifla v in  (grou p  C ) prefer  5 '  C G * (h ig h ) and 5' T G ! 
(m ed iu m ). O n ly  in  o n e  c a se  (a ltrom ycin  B ) is  a p urine preferre( 
at th e  5 ' s id e  o f  th e  a lk y la tio n  site; in  a ll the  oth er c a se s , s 
p y r im id in e , u su a lly  T , is  preferred . A n  a ltern ative  w a y  o  
su m m a r iz in g  th e  data is  that in  o n ly  o n e  c a se  (grou p  C ) is  s 
n o n -A T  b a se  pair p referred  at th e  5 ' s id e  o f  the  a lk y la tio n  site  
a lth o u g h , in  th is  c a se , the  m e d iu m  r ea c tiv ity  site  in c lu d es  T . It 
su m m ary , it appears that th e  nature and pattern o f  substituent! 
( R l  to  R 4 ) o n  a  4 / /-a n th r a [ l  ,2-£>]pyran r in g  sy s te m  determin<  
q u ite  s ig n ific a n tly  th e  se q u e n c e  se le c tiv ity , as w e ll  as reactiv ity  
o f  th e  p lu ra m y c in  fa m ily  o f  an tib io tics .
D e te r m in a t io n  o f  F a c to r s  T h a t  A f fe c t  S e q u e n c e  S p ecific ity  
o f  t h e  P lu r a m y c in  A n t i tu m o r  A n t ib io t ic s .  T h e  or ig in  o f  the 
se q u e n c e  sp e c if ic ity  c o u ld  l ie  in  the p r ec o v a le n t binding  
in teractions and/or the b on d in g  reactiv ity  o f  alkylated  seq u en ces  
A  p reced en t e x is ts  fo r  b o th  c a se s , perhaps m o st clearly  
d em on stra ted  fo r  th e  c y c lo p r o p a p y rr o lo in d o le s , w h ere  fo r  th< 
+  ser ie s  (e .g .,  (+ ) - C C - 1 0 6 5 )  b o n d in g  r ea c tiv ity  p red o m in ates  
w h ile  fo r  the — ser ie s  (e .g .,  ( —)-C C -1 0 6 5 )  p r eco v a len t binding  
in tera c tio n s p red o m in a te .5 In  order to  sh ed  so m e  lig h t o n  this 
p ro b lem , n o n -a lk y la tin g  an d  a lk y la tin g  d ru gs w ere  com parec  
for  seq u en ce  sp e c ific ity , and  sp e c ific  seq u en ces w ere  synthesizec  
in  w h ic h  e ith er  m in o r  g r o o v e  g e o m etr y  or th e  e lectron egativ ity  
o f  the  a lk y la ted  b a se  w a s  v a r ied  and th en  u se d  in  a co m p a riso i  
o f  the  a lk y la tio n  r ea c tiv ity .
A .  C o m p a r is o n  o f  A lk y la t io n  S ite s  o f  P lu r a m y c in  w i t l  
th e  N o n c o v a le n t  B in d in g  S it e s  o f  N e o p lu r a m y c in . In ordei 
to  d e term in e  w h eth er  th e  n o n c o v a le n t b in d in g  s ites o f  the 
p lu ra m y cin  an titu m or a n tib io tic s  c orresp o n d  to  the favorec  
seq u e n c e s  fo r  a lk y la tio n  o f  N 7  o f  gu a n in e , the  tw o  structurally  
sim ilar , naturally  occu rr in g  anthrapyran a n tib io tics  p lu ram ycit  
and n e o p lu ra m y c in  w e re  co m p a red  fo r  se q u e n c e  s p e c if ic ity  
Stru ctu rally , th e se  d ru gs d iffe r  o n ly  in  that n eop lu ra m y c in  has 
a s in g le  o le f in  in  p la c e  o f  th e  o le f in ic  e p o x id e  o f  p lu ra m y c it  
(s e e  F igu re  1). In para lle l exp er im en ts , the seq u en ce  sp ecific ity  
o f  th e  n o n c o v a le n t  n e o p lu ra m y c in  w a s  d e term in ed  by D N a s e  ] 
fo o tp r in tin g , and th e  se q u e n c e  s p e c if ic ity  o f  the a lkylating  
p lu ram ycin  w a s  d eterm in ed  u s in g  the therm al c le a v a g e  a ssa y .3 * 
T h e  resu lts  in  the  le ft  and  r igh t p a n e ls  o f  F ig u re  6  sh o w  that, 
w h ile  n e o p lu ra m y c in  d o e s  n o t sh o w  d e fin e d  D N a se  I footprints  
( i .e .,  n o  fa v o r ed  b in d in g  se q u e n c e s ) , p lu ra m y c in  prod u ced  the
(5) (a) Warpehoski, M. A.; Hurley, L. H. C h e m .  R e s .  T o x i c o l . 1988, 1  
315-333. (b) Hurley, L. H.; Warpehoski, M. A.; Lee, C.-S.; McGovren 
J. P.; Scahill, T. A.; Kelly, K. C.; Wicnienski, N. A.; Gebhard, I.; Bradford 
V. S. J .  A m .  C h e m .  S o c .  1990, 1 1 2 ,  4633-4649.
(6) Bennett, G. N. N u c l e i c  A c i d s  R e s .  1982, 1 0 ,  4581—4594.
Pluramycin's DNA Sequence Specificity
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Figure 6. Comparison o f the pluramycin alkylation sites (right) with 
Ihe neopluramycin DNase I footprinting sites (left). Neopluramycin 
Nvas incubated with the 77-mer DNA for 10 min, and the drug—DNA  
complex was digested with DNase I (0.2 U) for 1 min. At the same 
time, DNA was incubated with pluramycin for 10 min and samples 
were heated at 95 °C for 15 min to induce strand breakage. Lanes 
1—6 contain 0, 5, 10, 20, 50, and 100 ng o f drug molecules for 
neopluramycin and 0, 0.5, 2.5, 5, 7.5, and 15 ng for pluramycin with 
5 ng o f DNA molecules in a 20 p L  reaction. AG and TC represent the 
purine- and pyrimidine-specific cleavage reactions. Arrows point to 
the alkylated guanines, which are marked by an asterisk in the sequences 
to the right.
expected 5' PyG* sequence specificity. This result suggests 
that the precovalent binding interactions are not primarily 
responsible for the sequence selectivity of the pluramycins.
B. E ffect o f  M inor G roove G eom etry  on  A lk ylation  by  
th e  P luram ycin s o f  N 7 o f  G uan ine in the M ajor G roove. 
The consensus sequence analysis of the pluramycin family of 
antibiotics shown in Table 2 revealed that, except for perhaps 
group C, the determinant of sequence specificity lies exclusively 
with the base to the 5' side of the covalently modified guanine. 
Substituents at C8 and CIO of the pluramycins occupy the minor 
groove of DNA, with the CIO substituent to the 5' side of the 
alkylated guanine and the C8 substituent across from the 
modified base.4 Since both the sequence context (AT vs GC) 
and order (ATA vs AAA) can have a profound effect on minor 
groove geometry, a 42-mer oligomer was designed and syn­
thesized (42A in Table 1) in which the effect of sequence and 
associated minor groove geometry to the 5' side of the covalently 
modified guanine on pluramycin alkylation reactivity could be 
evaluated. Therefore, an oligomeric DNA sequence containing 
an incremental number (n =  1—5) of adenines to the 5' side of 
the targeted guanines (see Figure 7) was designed in order to 
determine the effect of local minor groove geometry on the 
covalent reactivity of DNA in the major groove, specifically at 
!N7 of guanine, of those compounds. As shown in Figure 7, 
(the precise length of the A tracts dramatically influences the 
alkylation reactivity of altromycin B, altromycin H, and 
pluramycin with N7 of the guanine to the 3' side of the A„ tract.
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Figure 7. Effect o f the length of A tracts on the alkylation reactivity 
o f the guanine base located at the 3' side o f A tracts. About 10 ng o f 
oligomer DNA (42A in Table 1) was treated with drug molecules for 
1 h at room temperature. Lanes 1—6 contain 0, 5, 10, 20, 50, and 100 
ng o f drug molecules for altromycin B; 0, 10, 20, 50, 100, and 200 ng 
for altromycin H; and 0, 1 ,2 ,  5, 10, and 20 ng for pluramycin. AG 
and TC represent the purine- and pyrimidine-specific cleavage reactions. 
The A1 to A5 tracts and associated 3' guanines are marked by an 
asterisk to the right o f the gel.
T h e  r e su lts  sh o w n  fo r  a ltr o m y c in  B in  la n e s  3 a n d  4  o f  F ig u r e  
7 p r o v id e  th e  o p t im u m  d ata  s e t  to  d e te r m in e  th e  p r e c is e  o r d er  
o f  th e  r e a c tiv ity  o f  th e  p lu r a m y c in s  w ith  th e  g u a n in e  f la n k e d  
o n  th e  5 ' s id e  w ith  A  tracts (w h e r e  n =  1 —5) ,  a lth o u g h  th e  
o th e r  tw o  d ru gs a p p ea r  to  s h o w  s im ila r  p attern s. In  o r d er  o f  
d e c r ea s in g  r ea c tiv ity , A 3 >  A 2 =  A 4 >  A |  =  A 5. T h e  m a x im u m  
r e a c t iv ity  o f  a ltr o m y c in  B w ith  g u a n in e  w a s  a c h ie v e d  w h e n  n 
=  3 , w h i le  r ea c tiv ity  d e c r e a se d  b y  ab o u t th e  sa m e  a m o u n t w h e n  
n w a s  c h a n g e d  to  2  or  4, a n d  e v e n  fu rth er  w h e n  n  w a s  1 o r  5 . 
In p r e v io u s  s tu d ie s ,7 it w a s  d e m o n str a te d  that A  tr a c ts , w h e n  n 
<  3 , p r o d u c e  o n ly  s lig h t  e le c tr o p h o r e tic  a n o m a lie s  a n d  b e n d in g  
in  D N A ;  h o w e v e r , w h e n  n > 4, th e  e f f e c t  is  su b s ta n tia l. In  
c o n c lu s io n , m o d u la tio n  o f  A -trac t g e o m e tr y  an d /or  m in o r  g r o o v e  
w id th  d r a m a tic a lly  a f f e c ts  th e  r e a c tiv ity  o f  p lu r a m y c in  w ith  
g u a n in e s  to  the  5 ' s id e  o f  A  tracts su c h  that, w h e n  g r o o v e  w id th  
is  d e c r e a s e d  o r  in c r e a se d  fr o m  th e  o p t im u m  s iz e  ( i .e . ,  w h e n  n 
=  3 ) ,  d ru g  r e a c tiv ity  d e c r e a s e s .
C . E f f e c t  o f  R e p la c in g  G u a n in e  R e s id u e s  in  D N A  w it h  
I n o s in e  o n  A lk y la t io n  R e a c t iv i t y  a n d  S e q u e n c e  S e le c t i v i t y  
o f  th e  P lu r a m y c in s .  In p r e v io u s  s tu d ie s , o n ly  g u a n in e  r e s id u e s  
w e r e  fo u n d  to  b e  a lk y la t io n  s it e s  fo r  th e  p lu r a m y c in  fa m ily  o f  
a n t ib io t ic s .36 T o  e v a lu a te  h o w  su b stitu tio n  o f  in o s in e  fo r  
g u a n in e  a f f e c ts  th e  r e a c t iv ity  a n d  se q u e n c e  s p e c i f ic i t y  o f  th e  
p lu r a m y c in s , a  pair  o f  o l ig o m e r s  w a s  s y n th e s iz e d  in  w h ic h  o n e  
d u p le x  c o n ta in e d  g u a n in e s  o n  b o th  stran d s, w h i le  th e  o th e r  
d u p le x  c o n ta in e d  g u a n in e s  o n  o n ly  o n e  stran d , w ith  in o s in e  in  
p la c e  o f  g u a n in e  o n  th e  c o m p le m e n ta r y  strand  ( s e e  2 3 G  a n d
(7) (a) Koo, H. S.; Wu, H. M.; Crothers, D. M. Nature 1986, 320, 5 0 1 -
506. (b) Koo, H. S.; Crothers, D. M. Proc. Natl. Acad. Sci. U.SA. 1988, 
85, 1763—1767. (c) Hagerman, P. J. Annu. Rev. Biochem. 1990, 59, 755— 
781.
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231 in  T a b le  1). T h e  e f fe c t  o f  r ep la c in g  g u a n in e  r es id u es  in  
D N A  w ith  in o s in e  is  to  r e m o v e  o n e  h y d r o g en  b o n d  fr o m  the  
n orm al CrC b a se  pair and the steric  b u lk  a sso c ia te d  w ith  th e  
e x o c y c l ic  2 -a m in o  grou p  o f  gu a n in e . In  ad d ition , r em o v a l o f  
th e  e x o c y c l ic  2 -a m in o  grou p  fro m  g u a n in e  is  e x p e c te d  to  
d ecrea se  th e  n u c le o p h ilic ity  o f  th e  N 7  p o s it io n .8
A  com p a rison  o f  the  reactiv ity  o f  the upper strand (con ta in in g  
I) v s  the  e q u iv a le n t strand (c o n ta in in g  G ) to  a ltro m y cin  B , 
a ltro m y cin  H , an d  p lu ra m y c in  is  sh o w n  in  F ig u re  8 (to p ). 
R e p la ce m e n t o f  g u a n in e  b y  in o s in e  d ram a tica lly  a ffe c ts  the  
reac tiv ity  o f  a ll th ree  a n tib io tics  to  the e x ten t that a grea ter  than  
1 0 -fo ld  lo s s  o f  a lk y la tio n  rea c tiv ity  is  fou n d . F urth erm ore, it  
is  apparent that r ep la c in g  th e  g u a n in e  resid u e  w ith  in o s in e  a lso  
m od u la tes the  seq u en c e  se lec tiv ity  o f  p luram ycin . For th is  drug, 
th e  m o d u la tin g  e f fe c t  o f  n u c le o tid e s  to  th e  5 ' s id e  o f  m o d if ie d  
in o s in e  b e c o m e s  s ig n if ic a n tly  d e cr ea se d , so  that there is  o n ly  a  
s lig h t d iffer en ce  in  th e  ex ten t o f  a lk y la tio n  b e tw e e n  the  
seq u e n c e s  5 '  A A I* , 5 ' T C I* , and 5 ' T T I*  (s e e  F ig u re  8 (to p )). 
T h e  e f fe c t  o f  r ep la c in g  g u a n in e  r es id u es  w ith  in o s in e  o n  the  
n o n -a lk y la tin g  strand o f  the  d u p lex  is  to  red u ce  th e  r ea c tiv ity  
o f  th e se  a n tib io tic s  to  g u a n in e  r es id u es  o n  the o th er  strand, but 
to  a m u ch  le sser  e x ten t than rep lacem en t at the co v a len t reaction  
s ite  ( s e e  F ig u re  8 (b o tto m )). F or  e x a m p le , o n ly  in  th e  c a se  o f  
altrom ycin  H  d o e s  the seq u en c e  5 ' A C G *  b e c o m e  m ore rea c tiv e  
to  a ltro m y cin  H  w h e n  the g u a n in e  o f  the  co m p lem en ta ry  strand  
w a s  r ep la ced  w ith  th e  in o s in e . T h is  resu lt in d ic a te s  that the  
m in or  g r o o v e  su b stitu en t o f  th e  b a se  pair ad jacen t to  th e  5 ' s id e  
o f  m o d if ie d  gu a n in e  a lso  a ffec ts  the  reac tiv ity  o f  th ese  an tib io t­
ic s , but th is  e f fe c t  is  m u ch  le s s  than  the c h a n g e  in  a lk y la tio n  
rea ctiv ity  a t in o s in e .
Discussion
T h e  p lu ra m y c in  an titum or a n tib io tics  rep resen t a g ro u p  o f  
h ig h ly  structurally  e v o lv e d  D N A -r e a c tiv e  drugs. It c a n  b e  
im a g in e d  that the s im p le s t D N A  in tera c tiv e  co m p o u n d  w o u ld  
h a v e  b e en  the in terca la tiv e  an thraq uinon e m o ie ty . A d d itio n  o f  
a pyran r in g  sy s te m  and an e p o x id e  at C 2  w o u ld  create  th e  first  
p lu r a m y c in  c o m p o u n d s , p e rh a p s s im ila r  in  stru ctu re  to  
sa p u r im y c in ,21 w h ic h  w o u ld  h a v e  th e  a b ility  to  m o d ify  D N A  
b y  a lk y la tio n  th rou gh  N 7  o f  gu a n in e . C on tin u ed  e v o lu tio n  to  
c o m p o u n d s  su ch  a s  a k in o m y c in , a ltro m y cin  H , and h e d a m y cin  
w a s m ad e b y  ad d in g  su b stitu en ts at the  C 8  an d  C IO  p o s it io n s , 
g iv in g  r ise  to  the sta b iliz in g  and p o ten tia lly  s e q u e n c e -se le c t iv e  
in teractio n s in  th e  m in o r  g r o o v e . F in a lly , th e  e v o lu tio n  o f  
c o m p o u n d s  lik e  a ltro m y cin  B  that h a v e  b oth  m in o r  and  m ajor  
g r o o v e  b in d in g  in teractio n s w a s  a c h ie v e d  th rou gh  the ad d itio n  
o f  m ajor g r o o v e  b in d in g  su ga r  m o ie t ie s  to  the C 5  p o s itio n .
T h is  structurally  e v o lv e d  c o m p le x ity  is  a lso  p r ed ic tiv e  o f  the  
p oten tia l c o m p le x ity  in  the m o le cu la r  m e ch a n ism s, g iv in g  r ise  
to  seq u en ce  sp e c ific ity . In p rin cip le, the  in term olecu lar  interac­
tion s that g iv e  r ise to  the seq u en ce  se lec tiv ity  m a y  occu r  through  
in terca la tiv e  an d /or  m in or/m ajo r  g r o o v e  b in d in g  fo r c e s  su c h  as 
s ta ck in g  in terac tio n s, H -b o n d in g , van  der W a a ls  c o n ta c ts , or  
e lectr o sta t ic  in terac tio n s. In  th e  s im p le st c a se , the  se q u e n c e  
se lec tiv ity  co u ld  arise  from  the n o n co v a len t b in d in g  in teractions, 
w h ic h  w o u ld  p referen tia lly  s ta b iliz e  th e  b o u n d  c o m p le x  at 
certa in  seq u e n c e s , th ereb y  in cr ea s in g  the  c h a n c e  o f  p r o d u ctiv e  
c o v a le n t rea c tiv ity . T h is  situ a tio n  is  perhaps b e st e x e m p lif ie d  
b y  ( —)-C C -1 0 6 5 , w h ere , in  con trast to  ( + ) -C C -1 0 6 5 ,  the  
cova len t a lkylation  sites are dictated b y  the b ind ing interactions.51’ 
I f  th is w e re  th e  c a se  fo r  the p lu ra m y c in s, th en  the  o p tim u m  
binding sites fo r  a  drug su ch  as n e o p lu ra m y c in , w h ic h  la ck s
(8) In previous experiments (Yuan and Hurley, unpublished results) where 
we have substituted inosine for adenine, this has resulted in lower reactivity 
of N3 with (+)-CC-1065 consistent with the reduction of N7 reactivity 
with the nluramvcins.
Sun et al
the epoxide but in most other structural respects is similar tc 
pluramycin, should be predictive o f  the covalent bonding sites 
o f pluramycin revealed by the thermal cleavage reaction. The 
results in Figure 6 show that neopluramycin does not bine 
specifically to the same sequences alkylated by pluramycin, anc 
furthermore, this antibiotic shows little if  any D N A  sequence 
selectivity. A  separate NM R study on an oligomer with 
kidamycin, which also lacks an epoxide, also failed to shov  
selective binding to a particular sequence (Hansen and Hurley, 
unpublished results). These results are in contrast to nogala- 
mycin, which, through binding interactions, does attain sequence 
selectivity.9 Therefore, while we do not rule out some minoi 
contribution to the overall sequence selectivity from the 
precovalent binding interactions (k\, in eq 1), w e favor the 
covalent bonding step (kT in eq 1) as the primary step at which 
sequence selectivity is achieved by the pluramycins.
d r u g  +  D N A  A  [ d r u g - D N A ] „  —  [ d r u g - D N A ] cov (1)
I m p o r ta n c e  o f  t h e  C o v a le n t  R e a c t iv i ty  S te p  in  D e te r m in ­
in g  S e q u e n c e  S e le c t iv i ty  o f  th e  P lu r a m y c in s .  An alternate 
source o f sequence selectivity to the noncovalent binding 
interactions is the alkylation reaction (kt in eq 1). The bonding 
step is sequence selective if  the rate constant (kT) for covalem 
bond formation is different for different sequences, i.e., if  the 
free energy o f activation to the transition state leading to the 
covalent adduct depends upon the nucleotide sequence arounc 
it. For sequence selectivity to be achieved at this step, it ii 
necessary that the dissociation rate from DNA be rapid at both 
cognate and noncognate sequences. Only in this case car 
selective reactivity at cognate sequences be expressed because 
at the noncognate sequences, dissociation takes place befon  
covalent reactivity occurs.
A second requirement is that the inherent covalent reactivity 
o f the epoxide be low  so that productive alkylation can onlj| 
occur when a “proximity effect” is achieved by the sequence-* 
dependent “steering effect” o f minor and major groove interac 
tions. As emphasized before, slow dissociation rates lead tc 
indiscriminate reactivity at many sites almost irrespective o 
the magnitude o f the proximity effect. In addition, the sun 
total o f  the electrophilicity o f the substrate (drug) and nucleo | 
philicity o f the receptor (N7 o f guanine) needs to be in a narrow 
window, where indiscriminate alkylation does not occur (i.e.! 
like the highly reactive electrophilic reagent dimethyl sulfate| 
or the sum o f the reactivity is too small, such that other les^ 
discriminating factors, such as individual site-binding times, play 
a major role. The results in Figure 8 (top), where there is  
substitution o f inosine for guanine, which causes a decrease in  
the nucleophilicity o f N 7, producing a loss o f hierarchy of 
sequence selectivity, may result from this effect. |
Since the epoxide is not intrinsically a highly reactivq 
electrophilic agent, this leads us to propose that a proximity 
effect is required for productive alkylation o f N7 o f guanine. 
This proximity effect enables juxtaposition o f N7 o f guanine 
and the epoxide for in-line Sn2 attack. Thus, both the 
positioning o f  the epoxide o f pluramycin in the major groove, 
which is achieved through minor and major groove interactions^ 
and the drug-induced repositioning o f N7 o f the targeted guanine 
are critical factors in determining if  this reaction will take place. 
There are at least two independent mechanisms by which 
sequence selectivity can be achieved at the alkylation step. First, 
binding interactions in one or both o f the grooves could “steer”
(9) (a) Zhang, X.; Patel, D. J. B i o c h e m i s t r y  1990, 29, 9451—9466. (b] 
Searle, M. S.; Hall, J. G.; Denny, W. A.; Wakelin, L. P. B i o c h e m i s t r y  1988, 
27, 4340-4349.
(10) Lin, C. H.; Beale, J.; Hurley, L. H. B i o c h e m i s t r y  1991, 30, 3597- 
3602.
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Figure 8. Effect o f replacing the guanine residues in DNA with inosine on the alkylation o f DNA by the pluramycins. (top) and (bottom) represent 
:he autoradiogram of pairs of the +  and — strand-labeled oligomers from 23G and 231 in Table 1 modified with drug molecules. For both A and 
3, the left and right panels correspond to 23G and 231, respectively. In both cases (top and bottom), lanes 1—4 contain 10, 20, 50, and 100 ng of 
Irug molecules for altromycin B (at B); 20, 50, 100, and 200 ng of drug molecules for altromycin H (at H); and 5, 10, 20, and 50 ng of drug 
nolecules for pluramycin (plu). The alkylated sequences with covalently modified guanines (G*) or inosines (I*) are shown to the right of each 
Janel.
h e  e p o x id e  in to  p r o x im ity  to  N 7  o f  g u a n in e . E x p e r im e n ts  in  
ivh ich  m in o r  g r o o v e  g e o m e tr y  h a s b e e n  m o d u la te d  b y  v a r y in g  
b e  le n g th  o f  th e  A  tract (F ig u r e  7 )  c le a r ly  p o in t  to  an im p o rta n t  
o le  fo r  m in o r  g r o o v e  g e o m e tr y  in  “ s te e r in g ” r e a c t iv ity  in  the  
(najor g r o o v e  o f  D N A . T h is  h a s  a p r e c e d e n t in  th e  p r o p o se d  
fe q u e n c e - s p e c if ic  in ter a c tio n s  o f  m ito m y c in  C  w ith  D N A , in
th at a  s p e c i f ic  h y d r o g e n  b o n d  in th e  p r e c o v a le n t  sta te  p o s it io n s  
m ito m y c in  C  to  a lk y la te  C G *  p r e fe r e n tia lly  o v e r  N G * . 11 
S e c o n d , in a n u m b er  o f  oth er  c a s e s  (r e v ie w e d  in  r e f  5 a ), c a ta ly tic  
a c tiv a tio n  b y  D N A  h as b e e n  p r o p o se d  to  b e  a  m e c h a n is m  fo r
(11) Kumar, S.; Lipman, R.; Tomasz, M. Biochemistry 1992, 31, 1399—
1407.
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se q u e n c e  r e c o g n itio n . F or  e x a m p le , a  sp e c if ic  p h osp h ate  
c a ta ly s is  o f  th e  r ea c tio n  b e tw ee n  th e  c y c lo p ro p a p y rro lo in d o le  
(+ ) -C C -1 0 6 5  an d  N 3  o f  ad e n in e  in  th e  m in o r  g r o o v e  o f  D N A  
h a s b e e n  p r o p o se d .10 In  the  c a s e  o f  th e  p lu ram ycin s, an  ac id  
ca ta lysis  in v o lv in g  w ater-bridged  p h o sp h ates in  the m ajor g roov e  
m ig h t c o n stitu te  a p ara lle l m e c h a n ism ; h o w e v e r , a s  y e t  n o  
e v id e n c e  e x is t s  fo r  th is  m e ch a n ism . M o reo v er , it m a y  n o t be  
n e c e ssa r y  to  in v o k e  an  a c id  c a ta ly s is  m e c h a n ism  in v o lv in g  a 
s p e c if ic  p h o sp h a te  b e c a u se  c o m p u ta tio n s  b y  L a m m  and P e c k 12 
h a v e  h ig h lig h te d  th e  in tr in s ic a lly  h ig h  a c id ity  a sso c ia ted  w ith  
th e  g r o o v e s  o f  D N A . W h ile  th e  p lu ra m y c in s  are n o t D N A -  
D N A  c ro ss-lin k er s  in  th e  str ict s e n se  o f  fo r m in g  tw o  c o v a len t  
attach m en ts o n  o n e  or  b o th  strands, th e y  d o  h a v e  fea tu res that 
m im ic  th is  ty p e  o f  le s io n  o n  D N A . In  particu lar, in  order for  
th e  “c r o ss - lin k in g ” rea c tio n  to  o c c u r  at N 7  o f  g u a n in e  in  the  
m ajor  g r o o v e , th e  e p o x id e  m u st b e  a b le  to  “reach ” fr o m  its 
attach m en t s ite  o n  th e  in terca la ted  m o ie ty , w h ic h  is  i t s e l f  
teth ered  in  th e  m in o r  g r o o v e  b y  b in d in g  in teractio n s. S in c e  the  
r each  o f  th e  e p o x id e  is  str ic tly  c o n tr o lled  b y  the b in d in g  
in tera ctio n s, th e  a b ility  o f  D N A , and  in  particu lar d e o x y g u a -  
n o sin e , to  d istort to  m e e t the p o s it io n e d  e p o x id e  is  an  im portant 
factor  in  d eterm in in g  both  s ite  reac tiv ity  and seq u en ce  sp e c if ic ­
ity . T h erefo re , seq u en c e-d e p e n d en t c o n fo r m a tio n a l f le x ib ility  
and th e  p r in c ip les  p r o p o se d  b y  H o p k in s ,13 in  w h ich  “m in im a l  
reorgan ization” is  p rop osed  to  b e  an  im portant factor in  seq u en ce  
r ec o g n itio n  o f  cro ss-lin k er s , m a y  a ls o  a p p ly  here.
I m p o r ta n c e  o f  S te e r in g  b y  M in o r  a n d  M a jo r  G r o o v e  
B in d in g  I n te r a c t io n s  in  A c h ie v in g  a  P r o x im ity  E f fe c t  in  t h e  
M a j o r  G r o o v e .  T h e  im p o rta n ce  o f  m o le cu la r  in teractio n s in  
th e  m in o r  and  m ajor  g r o o v e s , w h ic h  g iv e  r ise  to  the p ro x im ity  
e ffe c t , can  b e  ad d ressed  b y  e x p er im en ta l data (tw o -d im en sio n a l  
h ig h -fie ld  N M R ) and m o le cu la r  m o d e lin g .4 T h e resu lts  o f  D N A  
se q u e n c e  s p e c if ic ity  s tu d ies  rep orted  here  are q u ite  c le a r  and  
s h o w  that fo r  h ig h  r ea c tiv ity  s ite s  g ro u p  A  c o m p o u n d s  p refer  
5 ' A G * , grou p  B  co m p o u n d s  p refer  5 ' (A /T )G * , and group  C  
c o m p o u n d s p refer  5 ' C G * . M o le c u la r  m o d e lin g  o f  the  b is -  
(a ltrom ycin  B )  10-m er 5 '(G A A G * T A C IT C )2  (5 '-A G * -) and b is-  
(h e d a m y c in ) 10 -m er  5 '(G A T G * T A C A T C )2  (5 '-T G * -)  d u p lex  
d iad d u cts , b a se d  u p o n  tw o -d im e n s io n a l 1H -N M R  r esu lts , pro­
v id e s  im p ortan t in s ig h ts  in to  h o w  th is  seq u en c e  s e le c t iv ity  
m e d ia te d  th rou gh  b in d in g  in tera c tio n s m a y  b e  a c h ie v e d .
T h e se  !H -N M R  stu d ies  sh o w  that, u p o n  in terca la tion  o f  the  
planar drug ch rom op h o re  in to  th e  D N A , th e  C 5 , C 8  and C IO  
g ly c o s id e  b in d in g  in tera c tio n s fu n c tio n  to  steer  their  rea c tiv e  
e p o x id e  in to  p r o x im ity  w ith  th e  n u c le o p h ilic  N 7  o f  g u a n in e  in  
the  m ajor g r o o v e , th ereb y  in cr ea s in g  D N A  reactiv ity . O n e  k e y  
in teractio n  in  seq u en c e  r e c o g n it io n  m a d e  b y  p lu ra m y c in s w ith  
D N A  is  th rou gh  th e  C IO  a m in o  su gar. T h e  N M R  stu d ies  
in v o lv in g  a ltro m y cin  B  and h e d a m y cin  co v a len tly  bou n d  to  their  
r e sp e c tiv e  h ig h ly  rea c tiv e  s e q u e n c e s  r ev e a l a  p referen ce  fo r  th e  
d im e th y la m in o  su b stitu en ts o n  th e se  g ly c o s id e s  to  in teract 
d ire ctly  w ith  p y r im id in e s  o n  th e  noncovalently (a ltro m y cin  B )  
or  th e  covalently (h e d a m y c in ) m o d if ie d  strands in  the m in or  
g r o o v e ,4 p resu m a b ly  th rou gh  h y d r o g e n  b o n d in g  in  th e  proto-  
n ated  state  w ith  the  n e g a tiv e ly  ch a rg ed  0 2  ca rb o n y l o f  th e  
p y r im id in e .
In m o d e lin g  s tu d ies  o f  a ltro m y cin  B  c o v a le n tly  b o u n d  to  its  
m o st preferred  se q u e n c e  (5 '  A G * ) , th e  a m in o  su ga r  sh o w s  a  
p r efe re n ce  to  in teract w ith  th e  n u c le o tid e  (8 T ) o n  th e  n o n c o ­
v a le n t strand a sso c ia te d  w ith  th e  b a se  pair o n  the 5 ' s id e  o f  th e  
c o v a le n tly  m o d if ie d  gu a n in e . T h e  th y m in e  at th is  p o s itio n , 
w h ic h  is  fo u n d  in  the m o st r e a c tiv e  5 '  A G *  seq u en c e , o ffer s  an  
o p tim a l h y d r o g en  b o n d  a ccep to r , th e  0 2  carb o n y l, w h ic h  is  
h ig h ly  n e g a tiv e  an d  p rotrudes s lig h t ly  from  th e  f lo o r  o f  th e
m inor groov e, to interact w ith  the C IO  a m in o  sugar ( s e e  F igu re  
9 (top)). S equence se lec tiv e  e ffec ts  o f  th is interaction a r ise  from  
the assoc ia tio n  o f  the am in o  sugar w ith  th is noncovalent strand 
to create a m inor g roov e  pock et for the term inal neutral 6 -d e o x y -  
0-3 -m eth y la ltro se  to fit and to  favorab ly  a lign  the C 5 substituent 
for in teraction in the m ajor g r o o v e . In the le s s  r e a c tiv e  c a se , 
the 5' T G * b on d in g  site , the  a m in o  sugar is  lim ited  e ith e r  to 
h yd rogen  bon d in g  to  the th y m in e  carb on yl lo ca ted  o n  the 
co v a len tly  m o d ified  strand, w h ich  w o u ld  sterica lly  c r o w d  both  
the term inal neutral 6 -d e o x y -3 -0 -m e th y la ltr o se  in  th e  m inor  
g r o o v e  and the C 5 2 ,6 -d id e o x y -3 -0 -m e th y la ltr o se  a g a in s t  the 
floor o f  the m ajor groove, or to  form in g  a le s s  op tim al h yd ro g en  
bond  w ith  N 3  o f  the  base-paired  ad en in e  on  the f lo o r  o f  the 
m inor groove.
In addition to  the seq u en c e-se le c t iv e  e ffec ts  o f  in term o lecu la i  
m inor g roov e  in teractions, the  neutral C 5 sugar su b stitu en t, 
characteristic o f  a ltrom ycin  B , exer ts  a  s e le c tiv e  in flu e n c e  
through interactions in the D N A  m ajor g r o o v e  4 A ltro m y c in s  
la ck in g  the C 5 neutral sugar substituen t, su ch  as a ltro m y c in  H. 
dem onstrate d ecreased  reactiv ity  w ith  D N A  and a  m o d if ie d  
seq u en ce  se lec tiv ity  com pared  to  that o f  a ltro m y cin  B .  The  
k ey  interaction o f  the C 5 substituent is  b etw een  the h ydrophobic  
fa ce  o f  this sugar and the h yd rop h o b ic  p o c k e t fo r m e d  in  thej 
m ajor gro o v e  b y  the tw o  p yr im id in es (7 C  and 8T ) a d jo in in g  
the interca lation  site  on  the n o n m o d ifie d  strand in  the preferrec  
seq u en ce  (5 '-A G * -) . T h e n et e f fe c t  o f  th is  in teractio n  in  the 
m ajor gro o v e  is  to  sh ift the  drug fu n ctio n a lities  in  th e  m ajoi 
g ro o v e , n am ely  the C 2  e p o x id e  group , tow ard  the stran d  to  be 
m o d ified . A s  a resu lt, the  c la ss  A  com p o u n d s h a v e  in creasec  
their reactiv ity  tow ard D N A  o v er  the c la ss  B  a g e n ts  b) 
in creasin g  the proxim ity  e ffe c t  b e tw ee n  the e p o x id e  an d  N 7  o; 
guan ine.
In the case  o f  the C 5 a ltro se-d e fic ien t a ltro m y cin s ( i .e . ,  c la s s  
B  com p o u n d s), th ese  agents d em onstrate  d im in ish ed  s e le c t iv ity  
for  5 ' A G * o v er  5 ' T G *. T h e  lo s s  o f  steric  in teractio n s in  th e  
m ajor g roov e  p oten tia lly  a llo w s  fo r  rotation  o f  the in ter ca la t io n  
chrom ophore tow ard the c o v a len tly  m o d ified  strand ( s e e  F ig u re  
9  (to p )) in  the  m in or g r o o v e  to  p erm it h yd rog en  b o n d in g  byl 
the  C IO  am in o  sugar to  5 '  th y m in e  0 2  on  the  c o v a le n t ly  
m o d ifie d  strand. T h e  c la ss  B  co m p o u n d s therefore h a v e  le s s  
steric  co n flic ts  in  reaction s w ith  5' T G * than c la ss  A  a g en tsj  
but th ey  h av e  an ov era ll lo w er  reac tiv ity  to  D N A . 1
In the ca se  o f  the c la ss ica l p lu ram ycin  su b fa m ily , o r  grou n  
C  (e .g ., h ed am y cin ), m o d e lin g  o f  th e  m ed iu m  r ea ctiv ity  5 '  T G  
se q u e n c e s13 revea ls a  requ irem ent fo r  the CIO  a m in o  su ga r  to  
interact w ith  the n u c leo tid e  (3 T ) o n  the covalently m o d if ie d  
strand, 5' to  the m o d if ie d  g u a n in e  (F igure 9  (b o tto m )). A s j  
soc ia tio n  o f  the CIO  sugar w ith  the c o v a len t strand a l lo w |  
su ffic ien t room  in  the m inor g r o o v e  fo r  the C 8 am in o  su ga r  tq  
in teract w ith  the c y to s in e  b ase-p a ired  to  the m o d if ie d  guanine^  
In the lo w  reactiv ity  c a se , 5 ' A G * , the CIO a m in o  su gar  is  
lim ited  to  in teraction  w ith  the  5" ad en in e. In teractions w ith  the  
non cov a len t strand, sp e c ific a lly  the pyrim id ine, w o u ld  sterica lly  
cro w d  the C 8 am in o saccharide. T h erefore, th ese  in teractio n s  
lea d  to  a 5 ' (P y)G *  se lec tiv ity , w h ich  p o sitio n s a p y r im id in e  tq  
the 5 ' sid e  o f  the m o d ified  gu a n in e  on  the d ru g-m o d ified  strand  
for  in teraction  w ith  the C IO  a m in o  sugar and a p y r im id in e  on  
the n on co v a len t strand b ase-p a ired  to  the m o d if ie d  g u a n in e  fo i  
in teraction  w ith  the C 8 am in o  sugar. 1
A n a ly s is  o f  a ltrom ycin  B  and h ed a m y cin  in teractions in  the  
m in or g roov e  p rov id es in s ig h t in to  the reasons fo r  th e  low  
to leran ce o f  C*G b ase  pairs on  th e  5 ' s id e  o f  the  m o d ifiec  
gu a n in e  dem onstrated  b y  the  a ltro m y cin s, in  contrast to  the 
to leran ce exh ib ited  b y  the c la ss ic a l p luram ycins. It is  likely
(12) Lamm, G.; Peck, G. R. Proc. Natl. Acad. Sci. U.SA. 1990, 87, 
9033-9036.
(13) Hopkins, P. B.; Millard, J. T.; Woo, J.; Wiedner, M. F.; Kirchner 
J. J.; Sigurdsson, S. Th.; Raucher, S. Tetrahedron 1991, 47, 2475—2489
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igu re  9 . Molecular m odels18 o f the bis(altromycin B )—[d(GAAGTACTTC)]2 and bis(hedam ycin)-[d(GATGTACATC)h diadducts. Shown in 
le top panel is the interaction made by altromycin B with its most-preferred sequence, 5'-AG*-. On the right is the interaction o f the altromycin 
amino disaccharide (yellow) in the minor groove, and on the left is the proposed steering of the altromycin chromophore (gray) by the C5 and 
10 glycosides (yellow) to perpetuate alkylation to N7 o f guanine (cyan). Shown in the bottom panel is the parallel interaction made by hedamycin 
ith its highly reactive 5'-TG*- sequence. Shown on the right is the interaction o f the C8 anglosamine and the CIO A,A-dimethylvancosamine 
'ellow) in the minor groove, and shown on the left is the steering o f the drug chromophore (gray) by the C8 and CIO substituents (yellow) for 
kylation o f N7 o f guanine (cyan).
tat in teraction  o f  the guanine exocyclic  N 2 am ino  substituen t 
t the m inor groove provides steric and e lec trostatic  h indrance 
> the in teraction  o f  the CIO  d isaccharide to  both  sides o f  the 
linor g roove. T he classica l p lu ram ycins avoid  th is steric 
iterference by position ing  each am ino saccharide in the m inor 
roove to either side o f  the exocyclic am ino group, never directly 
tteracting  w ith it, as in the case o f the altrom ycin  C IO  am ino 
saccharide.
M o d u la t io n  o f  R e a c t iv i t y  I s  A ls o  D e p e n d e n t  u p o n  M u lt ip le  
R a n k in g  B a s e  P a ir s .  In addition  to the observed  local tw o- 
ase-pair sequence selectiv ity , there is an observed  m odulation  
t this tw o-base-pa ir selectiv ity  as a function  o f flank ing  D N A
sequences. T he m ost strik ing  exam ples o f these fluctuations 
are the enhanced  hedam ycin  reactiv ity  w ith 5 ' TG * sequences 
set in (TG)„ runs over those set in seem ingly random  sequences6 
and the observed  m odulation  o f  a ltrom ycin  B reactiv ity  show n 
in F igure 7, w hich is induced by flanking A tracts. T his second 
level o f  sequence selectiv ity  is p robably  induced by the local 
helical param eters o f the D N A  m olecule dictated by sequences 
g reater than tw o base pairs flanking each side o f the intercalation 
site.
A s w ith the tw o-base-pair selectiv ity , p luram ycin  sugar 
substituen ts govern this m ode o f  sequence recognition  as w ell. 
T he CIO  am ino sugar in teracts in the m inor groove o f the D N A
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m o le c u le  w ith  th e  5 ' b a se  pair o n  e ith er  the c o v a len tly  m o d if ie d  
strand, as in  the c a se  o f  p lu ram ycin , w h ic h  has a  C 8 substitution , 
or  th e  n o n c o v a le n tly  m o d if ie d  strand, as in  the c a se  o f  the  
a ltro m y cin , w h ic h  h as a C 5 su b stitu tio n . A rou n d  th is  p o in t o f  
in term o lecu la r  in teractio n , th e  c o n ju g a ted  ch rom op h o re  w ill  
rotate  c lo c k w ise  w h e n  v ie w e d  fro m  th e  3 ' s id e  o f  th e  m o d if ie d  
gu a n in e  w h e n  th ere  e x is ts  a C 8  a m in o  su ga r  and c o u n te rc lo c k ­
w is e  w h e n  th ere  e x is ts  a  C 5 n eutra l su gar  su b stitu en t to  steer  
the  rea c tiv e  e p o x id e  m o ie ty  tow ard  N 7  o f  g u a n in e  in  the m ajor  
g r o o v e . T h e  resu ltin g  b in d in g  or ien tation  b e tw ee n  the tw o  b a se  
pairs w ill  d eterm in e  the p ro x im ity  o f  th e  e p o x id e  to  th e  reactive  
guan ine N 7  and, con seq u en tly , its reactiv ity . It therefore fo llo w s  
that, in  ad d ition  to  r e c o g n iz in g  tw o  b a se  pairs through  inter- 
m o le cu la r  co n ta c ts , th e  p lu ra m y cin s a lso  r e c o g n iz e  lo c a l D N A  
h e lic a l param eters d icta ted  b y  fla n k in g  seq u e n c e s , w h ic h  
u ltim ate ly  a ffec t the  p o s itio n  o f  the  e p o x id e  in  the m ajor g r o o v e  
r e la tiv e  to  g u a n in e  N 7 .
I m p o r ta n c e  o f  “ E p o x id e  R e a c h ”  in  D e te r m in in g  A lk y la ­
t io n  R e a c t iv i ty  a n d  M in im iz in g  D is to r t io n  o f  th e  A lk y la te d  
B a s e . W h ile  b in d in g  in terac tio n s that steer  the e p o x id e  in to  
p r o x im ity  o f  N 7  o f  g u a n in e  a ffe c t  c o v a le n t  r ea c tiv ity  and  
seq u en c e  sp e c if ic ity , it is  a lso  apparent that th e  o v er a ll le v e l  o f  
a lk y la tio n  rea c tiv ity  d iffers  m a rk ed ly  fr o m  grou p s A  and B  to  
grou p  C  (s e e  F igu re  3 ). T h e  c la s s ic a l p lu ra m y c in s h e d a m y c in  
and r u b ifla v in  h a v e  a  5 - fo ld  grea ter  r ea c tiv ity  than a ltro m y cin  
B  (grou p  A ) , w h ic h  is  m o re  r ea c tiv e  than a ltro m y cin s H  an d  I 
(grou p  B ) . W e  p ro p o se  that th e  o r ig in  o f  th e  d ifferen t  
r ea c tiv itie s  o f  grou p  C  and g rou p s A  and B  is  in  the va riab le  
reach  an d /or  f le x ib ility  o f  th e  a lk y la tin g  su b stitu en t (R 4 ) at C 2  
o f  the anthrapyran system . T h e  a lk ylatin g  e p o x id e  at R 4  is  quite  
va riab le , from  the d ie p o x id e  o f  h e d a m y c in  to  th e  o le f in ic  
e p o x id e  o f  ru b ifla v in  and th e  u n co n ju g a te d  e p o x id e  o f  the  
a ltro m y cin s (F ig u re  1). ‘H -N M R  stu d ies  sh o w  that, w h ile  
reaction  tak es p la ce  at the lea st su b stitu ted  carbon  o f  a ltro m y cin  
B ,4a in  the c a se  o f  h e d a m y c in , c o v a le n t  r ea c tio n  tak es p la ce  at 
the m o st su b stitu ted  carb on  o f  the  term in a l e p o x id e .4b S in c e  
there is  n o  r ea so n  to  e x p e c t  the  a lk y la tin g  e p o x id e s  o f  the  
a ltro m y cin s or h e d a m y cin  to  h a v e  d ifferen t inherent reac tiv itie s, 
w e  p ro p o se  that the h ig h er  r ea c tiv ity  o f  h e d a m y c in  is  d u e  to  
the lo n g e r  reach  o f  th e  e p o x id e , w h ic h  r ed u c es  th e  n e ed  for  
guan ine to  distort from  its o p tim ally  b ase-p aired  p o sitio n  in  order 
fo r  a lk y la tio n  to  o ccu r . E v id e n c e  to  support th is  m in im ize d  
d istortion  p ro p o sa l is  a v a ila b le  fr o m  m o le cu la r  m o d e lin g  o f  
d u p lex  addu ct structures o f  th e  h e d a m y c in  and a ltro m y cin  B  
ad d u cts. W h ile  in  th e  c a se  o f  the  a ltro m y cin  B —D N A  adduct, 
the c o v a le n tly  m o d if ie d  g u a n in e  is  t ilte d  in to  the m ajor g r o o v e , 
fo r  th e  h e d a m y c in —D N A  ad d u ct (F ig u re  9  (to p )), th e  lo n g e r  
reach  a llo w s  fo r  a  planar o r ien ta tion  o f  the  e q u iv a le n t a lk y la ted  
g u a n in e  (F igu re 9  (b o ttom ). T h e  d iffer en ce  in  o v era ll reactiv ity  
o f  the a ltro m y cin s in  grou p s A  and B  m o st p rob ab ly  r e lie s  o n  
the a b ility  o f  th e  C 5 su b stitu en ts in  grou p  A  to  sh ift th e  C 2  
e p o x id e  in to  p r o x im ity  o f  N 7 .
C o n c lu s io n s
T h e  p lu ra m y c in s are a  u n iq u e  grou p  o f  D N A -r e a c tiv e  drugs  
that e x h ib it  se q u e n c e  s e le c t iv ity  d e term in ed  at th e  c o v a le n t  
b o n d in g  step  d u e  to  m in o r  and m ajor g r o o v e  steer in g  in terac­
tio n s , w h ic h  m e d ia te  a  p r o x im ity  e f fe c t  b e tw e e n  th e  e p o x id e  
and N 7  o f  g u a n in e . T h e  o v er a ll r ea c tiv ity  o f  in d iv id u a l c la s se s  
w ith in  th is  grou p  o f  an titu m or a n tib io tic s  a lso  appears to  b e  
d ep en d en t u p o n  th e  reach  o f  the  e p o x id e  in  th e  m ajor g r o o v e .
M a te r ia ls  a n d  M e th o d s
Altromycins B, H, and I, pluramycin, hedamycin, and rubiflavin were 
obtained from Abbott Laboratories, Chicago, IL. Electrophoretic
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reagents (acrylamide, TEMED, ammonium persulfate, and bis(acryla 
mide) were purchased from Biorad, T4 polynucleotide kinase from U.S 
Biochemical Corp., [y-32P]ATP and X-ray film from ICN, and pCAl 
from Promega.
Preparation of Oligonucleotides. A series of oligonucleotide* 
(Table 1) was synthesized on an automated DNA synthesizer (Applie< 
Biosystems 381A) using the phosphoramidite method.14 Labele< 
duplexes were prepared as described previously.15
Isolation and End-Labeling of a 189-mer Restriction Fragm en 
from Plasmid DNA. Plasmid DNA pCAT was digested with Nco 
followed by dephosphorylation with bacterial alkaline phosphatasi 
treatment. Restriction fragments were purified by phenol/CHCl 
extraction and ethanol precipitation and kinated with [y-32P]ATP am 
polynucleotide kinase. 5' end-labeled restriction fragments wen 
digested with PvuII to generate a unique end-labeled restrictioi 
fragment, and the desired fragment was separated on a 6% nondena 
turing polyacrylamide gel. The wet gel was exposed onto autoradio 
graphic film, and the desired fragment was located and excised. Th 
DNA was removed from the gel by crushing and vortexing at roon 
temperature overnight in 10 mM Tris-HCl (pH 7.6) and 10 mM NaC!
Drug-Binding Reactions, DNA Strand Breakage Assay, am 
DNase I Footprinting. Drug-binding reactions were carried out £ 
room temperature in a solution containing 10 mM Tris-HCl (pH 7 . 6  
10 mM NaCl, DNA, and the indicated amount of drug molecules. Thes 
reactions were stopped by phenol/CHCb extraction and ethane 
precipitation to remove unbound drug molecules. DNA pellets wei 
dried and redissolved in DDW. For the strand breakage assay t 
identify the alkylation sites, drug-modified DNA samples were heate 
to 95 °C with piperidine (1 M) for 15 min. DNA samples were driec 
resuspended in DDW, dried again, and dissolved in alkaline dye (80‘ 
formamide, 10 mM NaOH). These samples were subjected t 
denaturing polyacrylamide gel electrophoresis in parallel with DNi 
sequencing, as described previously.16 DNase I footprinting was carrie 
out as described in the legend for Figure 6.
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(14) The sequence 5'-TG*- was used rather than 5'-CG- because th 
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over 5'-TG*-, the interactions we describe here are generally applicable 
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Structures were generated using B-form DNA, which was then adjusted i 
dock the drug molecules as predicted from NMR results. Models wei 
altered either in MIDAS19 or with constrained belly dynamics to achieve 
structure consistent with inter-drug—DNA NOE connectivities and we 
then minimized in AMBER 4.O.20
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ABSTRACT 
p h a g e  Mu t r a n s p o s a s e  (A -p ro te in ) is  p rim arily  
re s p o n s ib le  for tra n sp o s itio n  o f th e  Mu g e n o m e . T he  
p ro te in  b in d s  to  six  att s i te s ,  th re e  a t e a c h  e n d  of Mu
P NA. At m o st att s i te s  in te rac tion  of a  p ro te in  m o n o m er 
ith DNA is s e e n  to  o c c u r  o v e r  th re e  m ino r a n d  tw o  
c o n se c u tiv e  m ajor g ro o v e s  a n d  to  re su lt in b en d in g  up  
to a b o u t 9 0 ° . To p ro b e  th e  d irec tio n a lity  a n d  lo c u s  of 
jh e se  A -p ro te in -in d u ced  b e n d s , w e  h a v e  u s e d  th e  
in titu m o r an tib io tic  ( +  )-CC-1065 a s  a  s tru c tu ra l p ro b e . 
&s a  c o n s e q u e n c e  of b in d in g  w ith in  th e  m ino r g ro o v e , 
+ )-CC-1065 is ab le  to  a lk y la te  N3 of a d e n in e  in a 
s e q u e n c e  se le c tiv e  m an n e r. T h is  se lec tiv ity  is partially  
d e te rm ined  by  co n fo rm a tio n a l flexibility o f th e  DNA 
S equence , a n d  th e  c o v a le n t a d d u c t h a s  a  b e n t DNA 
s tru c tu re  in w hich  n arro w in g  o f th e  m ino r g ro o v e  h a s  
Recurred. U sing th is  d ru g  in e x p e r im e n ts  in w hich  
fither g e l re ta rd a tio n  o r  DNA s tra n d  b re a k a g e  a re  u se d  
p  m o n ito r th e  stab ility  o f th e  A -pro tein  -  DNA co m p lex  
fr th e  (+  )-CC-1065 alkylation  s i te s  o n  DNA (att s ite  L3), 
ye h a v e  d e m o n s tra te d  th a t  o f th e  th re e  m ino r g ro o v e s  
jn p lica ted  in th e  In te rac tio n  w ith  A -pro te in , th e  
peripheral tw o  a re  ‘o p e n ’ o r a c c e ss ib le  to  d ru g  bond ing  
p llow ing  p ro te in  b in d in g . T h e s e  d ru g -b o n d in g  s i te s  
jery likely re p re s e n t  b in d in g  a t a t le a s t  tw o  A -pro tein- 
p d u c e d  b en d in g  s i te s .  S ign ifican tly , th e  lo c u s  of 
ten d in g  a t  th e s e  s i te s  is  s p a c e d  ap p ro x im a te ly  tw o  
pelical tu rn s  a p a r t, a n d  th e  b e n d in g  is p ro p o s e d  to  
je e u r  by  narro w in g  of th e  m ino r g ro o v e  of DNA. T he  
Ctervening m inor g ro o v e  b e tw een  th e s e  tw o  peripheral 
^ites is  p ro te c te d  from  ( + )-CC-1065 a lky la tion . T he 
e s u lts  a re  d is c u s s e d  in re fe re n ce  to  a  p ro p o se d  m odel 
pr overa ll DNA b en d in g  in th e  A -pro te in  att L3 s ite  
o m p lex . T h is  s tu d y  il lu s tra te s  th e  u tility  of ( + )-CC- 
065  a s  a  p ro b e  fo r p ro te in - in d u c e d  b e n d in g  o f DNA, 
p  well a s  for in te rac tio n s of m inor g ro o v e  DNA b end ing  
^o te in s  w ith  DNA w hich  m ay  b e  m a sk e d  in hydroxyl 
idical fo o tp rin tin g  e x p e rim e n ts .
INTRODUCTION
T r a n sp o s it io n  o f  th e  M u  g e n o m e  o c c u r s  b y  a  s e r ie s  o f  p r e c is e ly  
r e g u la te d  e v e n t s  w h e r e in  M u  D N A  e n d s  a re  c le a v e d  a n d  jo in e d  
to  ta rg et D N A  ( 1 , 2 ) .  A lth o u g h  se v e r a l s tep s in  th is  r ea c tio n  h a v e  
b e e n  e lu c id a te d , th e  d e ta ile d  m e c h a n ism s  b y  w h ic h  th e s e  a re  
e x e c u te d  a r e  u n k n o w n . T h e  M u  A -p r o te in  in it ia lly  b in d s  to  an  
arra y  o f  s ix  att s it e s ,  th r e e  a t e a c h  e n d  o f  M u  D N A  (L I  —L 3  
at att L  an d  R l  —R 3  at att R ) (3 ,  4 ) .  B y  e v en ts  p o o r ly  u n d e rsto o d , 
in v o lv in g  in ter a c tio n  o f  th e  A -p r o te in  w ith  a n  in tern a l e n h a n c e r  
e le m e n t  ( 5 - 7 )  a s  w e ll  a s  in te r a c tio n  o f  th e  E.coli H U  p r o te in  
w ith  th e  D N A  ( 8 , 9 ) ,  th e  A -p r o te in  e v e n tu a lly  fo r m s  a  te tra m eric  
h ig h er -o r d e r  n u c le o p r o te in  c o m p le x  r e sp o n s ib le  fo r  e x e c u tin g  th e  
M u  D N A  c le a v a g e  a n d  stran d  tr a n sfe r  s te p s  o f  tr a n sp o s itio n  
( 1 0 - 1 2 ) .
D N A  b e n d in g , w h ic h  s e r v e s  a n  im p o r ta n t a rch ite c tu r a l r o le  
in  th e  a s s e m b ly  o f  c o m p le x  n u c le o p r o te in  stru ctu res  in v o lv e d  in  
n e a r ly  a ll a sp e c ts  o f  D N A —p r o te in  tr a n sa c tio n s , in c lu d in g  D N A  
p a c k a g in g , tr a n scr ip tio n , r e p lic a t io n , an d  r e c o m b in a tio n  (1 3 ) ,  is  
a ls o  in v o lv e d  in  th e  fo r m a tio n  o f  th e  M u  tr a n sp o s it io n  c o m p le x .  
T h e  h a llm a r k  o f  th is  tr a n sp o sitio n  c o m p le x  is  its  u n u su a l stab ility  
(5 0 %  d isr u p tio n  in  4 . 6  M  u r e a  o r  a t 5 6 ° C )  ( 1 0 ) .  In te r a c tio n  o f  
th e  M u  A -te tr a m e r  w ith  o n ly  th r ee  att s ite s  is  s u ff ic ie n t  to  c o n fe r  
th is  e x tra o r d in a ry  s ta b ility  to  th e  c o m p le x  ( 1 4 ) .  A t  e a c h  att s ite  
a  m o n o m e r  o f  A -p r o te in  is  p r o p o s e d  to  c o n ta c t  a  2 4 -b a se -p a ir  
r e g io n  a lo n g  o n e  fa c e  o f  th e  D N A  h e l ix  a n d  b e n d  th e  D N A  (4 ,  
1 4 ) . T h e  o v e r a ll  D N A  b e n d  is  — 8 0  - 9 0 °  a t f iv e  o f  th e  str o n g  
att s it e s  a n d  — 6 0 °  at th e  w e a k e s t  att s it e ,  L 2 ,  a s  d e te r m in e d  
b y  p o ly a c r y la m id e  g e l  e le c tr o p h o r e sis . T h e  D N A  b en d s m u st p la y  
a n  in d isp e n sa b le  r o le  in  a c h ie v in g  s p e c i f ic  w r a p p in g  o f  D N A  in  
th e  tr a n sp o s it io n  c o m p le x  (4 ) .  A  k n o w le d g e  o f  th e  lo c u s  an d  
d ir e c t io n a lity  o f  th e s e  b e n d s  is  e s s e n t ia l  n o t  o n ly  fo r  e s ta b lish in g  
th e  p ath  o f  D N A  in  th e  c o m p le x  b u t a ls o  fo r  u n d e rsta n d in g  h o w  
th e  D N A  b e n d s  fa c il ita te  p r o te in —D N A  c o n ta c ts  th a t im p art  
m a x im u m  sta b ility  to  th e  c o m p le x .
T o  g a in  in s ig h t  in to  th e  s ite s  a t w h ic h  A -p r o te in - in d u c e d  b e n d s  
o c c u r , w e  h a v e  u s e d  th e  D N A -r e a c t iv e  d ru g  ( + ) - C C - 1 0 6 5  as  
a  stru ctu ra l p r o b e . ( + ) - C C - 1 0 6 5  is  a  p o te n t a n titu m o r  a n tib io tic  
th a t b in d s  o v e r la p p in g  w ith  a  4 —5  b p  r e g io n  w ith in  th e  m in o r
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Figure 1. (A) The reaction of (+)-CC-1065 with DNA to form the (+ )-  
CC-1065-(N3-adenine)-DNA adduct and products of heat-strand breakage of 
modified DNA. Species ‘A ’ is the first product produced by thermal treatment 
and is converted into species ‘B’ by further thermal treatment or subsequent 
treatment with piperidine (16). (B) Structures of related drugs (+)-ABC and (+ )-  
ABC”
g r o o v e  o f  D N A  a n d  a lk y la te s  N 3  o f  a d e n in e  (F ig u r e  1 A ) in  
c e r ta in  s e q u e n c e s  (1 5  — 1 7 ) . D N A  f l e x ib i l i t y  h a s  b e e n  id e n t i f ie d  
a s  a n  im p o r ta n t c o m p o n e n t  o f  s e q u e n c e  r e c o g n i t io n  fo r  c o v a le n t  
r e a c t io n  o f  ( + ) - C C - 1 0 6 5  w ith  D N A  a n d , in  p a r t ic u la r , th e  
p r o p e n s ity  to  fo r m  a b e n t  D N A  s tr u c tu r e  a s  a  c o n s e q u e n c e  o f  
c o v a le n t  b o n d in g  ( 1 8 ,  1 9 ) . T h e  ( + ) - C C - 1 0 6 5 - in d u c e d  b e n d in g  
o f  D N A  is  a s s o c ia te d  w ith  narrowing o f  th e  m in o r  g r o o v e  a n d  
d is c o n t in u i t ie s  o n  e ith e r  s id e  o f  th e  c o m p r e s s e d  r e g io n .  In  m a n y  
r e s p e c ts  th e  s tr u ctu r a l c h a r a c te r is t ic s  o f  ( + ) - C C - 1 0 6 5 - i n d u c e d  
b e n d s  a re  a n a lo g o u s  to  th o se  a s so c ia te d  w ith  A -tr a c t  b e n d in g  (2 0 ) ,  
a n d  a  ‘tr u n c a te d  ju n c t io n  b e n d  m o d e l ’ h a s  b e e n  p r o p o s e d  fo r  th is
s tr u c tu r e  ( 2 1 ,  2 2 ) .  A s  w o u ld  b e  e x p e c te d  fo r  a s tr u c tu r a l p r o b e  
that fa v o r s  m in o r  g r o o v e  n a r ro w in g  an d  a s s o c ia te d  h e lix  b e n d in g ,  
A -tr a c ts ,  a n d  in  p a r tic u la r  th e  3 '  a d e n in e s  o f  sh o r t A - tr a c t s ,  a r e  
f a v o r e d  s it e s  fo r  ( +  ) - C C - 1 0 6 5  m o d if ic a t io n  ( 1 6 ,  2 1 ) .
In  th is  a r t ic le  w e  h a v e  d e te r m in e d  at w h ic h  s e q u e n c e s  w ith in  
th e  A -p r o te in  b in d in g  r e g io n  o f  L 3  at att L ,  c o v a le n t  b o n d in g  
b y  ( +  ) - C C - 1 0 6 5  is  c o m p a t ib le  w ith  p r o te in - in d u c e d  b e n d in g .  
B a s e d  u p o n  th e s e  r e s u lts  w e  p r e d ic t  th a t th e r e  a r e  a t le a s t  t w o  
A -p r o te in - in d u c e d  b e n d in g  s it e s  w ith in  L 3  o f  att L . F o r  th e s e  
t w o  s i t e s ,  b e n d in g  is  in to  m in o r  g r o o v e s  s p a c e d  a p p r o x im a te ly  
t w o  h e lic a l  tu r n s  a p a rt. W e  d is c u s s  h o w  th e  o v e r a ll  9 0 °  b e n d  
m ig h t  b e  a c c o m o d a te d  a t L 3 .
M A T E R I A L S  A N D  M E T H O D S
M a t e r i a l s
( + ) - C C - 1 0 6 5 ,  ( - l - ) - A B C ,  a n d  ( + ) - A B C "  w e r e  p r o v id e d  b y  
P a tr ic k  M c G o v r e n  o f  T h e  U p jo h n  C o m p a n y ,  K a la m a z o o ,  M I .  
( y - 32P ) A T P  w a s  p u r c h a se d  fr o m  I C N , T 4  p o ly n u c le o t id e  k in a se  
a n d  d e o x y n u c le o t id e s  fr o m  U n ite d  S ta te s  B io c h e m ic a l  C o . ,  a n d  
G - 2 5  S e p h a d e x  q u i c k - s p i n  c o lu m n s  f r o m  B o e h r in g e r .  
E le c tr o p h o r e t ic  r e a g e n ts  [a c r y la m id e /b is (a c r y la m id e ) ,  T E M E D ,  
a n d  a m m o n iu m  p e r s u lfa te ]  w e r e  fr o m  B io -R a d  a n d  X -r a y  f i lm ,  
in te n s ify in g  s c r e e n s ,  a n d  d e v e lo p in g  c h e m ic a ls  fr o m  A m e r s h a m .  
M u  A -p r o te in  w a s  p u r if ie d  a s  d e s c r ib e d  p r e v io u s ly  ( 1 4 ) .
S y n t h e s i s  a n d  p u r i f i c a t io n  o f  o l ig o n u c le o t i d e s
T h e  o l ig o n u c le o t id e s  w e r e  s y n th e s iz e d  o n  an  a u to m a te d  D N A  
s y n th e s iz e r  (A p p l ie d  B io s y s t e m s  3 8 1  A )  b y  th e  p h o sp h o r a m id ite  
m e th o d . O l ig o n u c le o t id e s  w e r e  d e p r o te c te d  in  c o n c e n tr a te d  
a m m o n iu m  h y d r o x id e  a t 5 5 ° C  o v e r n ig h t ,  d r ie d  u n d e r  v a c u u m ,  
an d  p u r ified  b y  16%  d e n a tu r in g  a c r y la m id e  g e ls .  O lig o n u c le o t id e }  
w e r e  5 '-e n d  la b e le d  w ith  32P , a s  d e s c r ib e d  b e fo r e  ( 2 3 ) .
F o r m a t i o n  o f  M u  t r a n s p o s a s e - D N A  c o m p l e x e s  a n d  g e  
r e t a r d a t io n  a s s a y
M u  A -p r o te in  — D N A  c o m p le x e s  w e r e  fo r m e d  in  2 5  /d  o f  so lu tio r  
c o n ta in in g  0 .1  p m o le s  o f  5 '- la b e le d  D N A ,  2 5  m M  H E P E S -K O H  
p H  7 . 2 ,  10  m M  M g C l2 , 7 0  m M  N a C l ,  I m M  D T T ,  anc 
in d ic a te d  a m o u n ts  o f  p r o te in . T h e  s a m p le s  w e r e  in c u b a te d  a  
3 0 ° C  fo r  15 m in . P r o t e i n - D N A  c o m p le x e s  w e r e  se p a r a te d  fr o n  
fr e e  D N A  b y  g e l  e le c tr o p h o r e s is  o n  6%  n o n d e n a tu r in g  ge l: 
(a c r y la m id e :  b is a c r y la m id e ,  2 9 : 1 )  in  T B E  ( 8 9  m M  T r is -b o r a te  
p H  8 . 3 ,  2  m M  E D T A )  at 4 ° C .
P r e p a r a t i o n  o f  att L 3  s e l e c t i v e l y  m o d if ie d  o n  e i t h e r  t h e  ( +  
o r  ( - )  s t r a n d
5 ' - 32P - e n d - la b e le d  s in g le  s tr a n d e d  D N A  (to p  a n d  b o t to m  stran< 
in  F ig u r e  2 )  in  2 5 /d  o f  d is t il le d  w a te r  w a s  a n n e a le d  w ith  a  p r im e  
(5  ' - C G T G T G T G T G T T T T T C G T A T T T - T C A A T - 3 ' o r  5 ' -A C T  
T G C T T T T G T T T C A T T G A A - 3 ' ,  r e s p e c t iv e ly ) .  T h e s e  p artia  
d u p le x  D N A  m o le c u le s  w e r e  m o d if ie d  w ith  0 .2 8  m M  ( + )  
C C - 1 0 6 5  at r o o m  te m p e ra tu re  fo r  th r ee  d a y s , f o l lo w e d  b y  p h e n o  
e x tr a c t io n  to  r e m o v e  u n b o u n d  d r u g . T h e  p r im e r  w a s  exten d e<  
b y  a d d in g  3 /d  o f  0 . 2  m M  d e o x y n u c le o t id e s  a n d  10  u o f  K le n o v  
fr a g m e n t . E a c h  s p e c ie s  o f  d r u g -m o d if ie d  d u p le x  D N A  w a s  thei 
p u r if ie d  b y  8%  g e l  e le c tr o p h o r e s i s .
S e le c t i v e  p r o t e c t i o n  o f  D N A  t o  d r u g  m o d i f i c a t io n  u p o n  M i  
t r a n s p o s a s e  b i n d in g
T h e  A - p r o t e i n - D N A  c o m p le x e s  w e r e  fo r m e d  a s  d e sc r ib e d  a b o v  
in  a  m o la r  r a tio  o f  1 :3 0  ( D N A  to  p r o te in )  at w h ic h  D N a s e
A D E N I N E
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Figure 2. Sequence of oligomer encoding att site L3 used in this study. ( +  )-CC-1065 bonding sites are indicated in boldface, and the horizontal brackets indicate 
the drug overlap sites. The symbols (*) and (•) indicate major and minor sites for drug bonding. Vertical bold brackets indicate MPE/3Fe(II) footprinting data (4). 
A larger region ( ~  30 bp), which includes drug bonding site D, is protected from DNAasel cleavage at this site (3).
fo o tp r in t in g  s h o w e d  c o m p le te  o c c u p a n c y  b y  M u  A -p r o te in . D r u g  
w a s  a d d e d  to  th e  m ix tu r e  in  a  f in a l c o n c e n tr a t io n  0 . 6 5  m M  a n d  
in c u b a te d  at 4 ° C  fo r  th e  in d ic a te d  t im e .  T h e  r e a c t io n  w a s  
q u e n c h e d  b y  th r e e  p h e n o l  e x tr a c t io n s  a n d  f o l lo w e d  b y  e th a n o l  
p r e c ip ita t io n .  T h e  D N A  w a s  f in a lly  d i s s o lv e d  in  d is t i l le d  w a te r  
a n d  s u b je c te d  to  th e r m a l tr e a tm e n t at 1 0 0 ° C  fo r  4 5  m in . ( 1 6 ) .  
A f t e r  e v a p o r a t io n  o f  w a te r , th e  D N A  w a s  r e d is s o lv e d  in  
f o r m a m id e  d y e  a n d  a n a ly z e d  o n  2 0 %  d e n a tu r in g  g e ls .
I n t e r f e r e n c e  o f  M u  t r a n s p o s a s e  b i n d in g  t o  D N A  a f t e r  p a r t i a l  
m o d i f i c a t i o n  w i t h  ( + ) - C C - 1 0 6 5
D N A  w a s  m o d if ie d  w ith  1 . 2 5  m M  o f  ( + ) - C C - 1 0 6 5  fo r  th e  
in d ic a te d  t im e s .  T h e  r e a c tio n  w a s  q u e n c h e d  b y  th r e e  p h e n o l  
e x tr a c t io n s  f o l lo w e d  b y  e th a n o l p r e c ip ita t io n . T h e  p a r tia lly  d r u g -  
m o d if ie d  D N A  w a s  s u b je c te d  to  M u  A -p r o te in  b in d in g  a n d  g e l  
r e ta r d a t io n . P r o t e in -b o u n d  an d  fr e e  D N A  s p e c ie s  w e r e  e x c i s e d  
fr o m  th e  g e l ;  th e  D N A  w a s  e x tr a c te d  w ith  d is t i l le d  w a te r  a n d  
S u b je cted  to  th e r m a l tr e a tm e n t a s  b e fo r e .
I E S U L T S
+ ) - C C - 1 0 6 5  in t e r a c t s  w i t h  f o u r  ‘A - t r a c t ’ r e g i o n s  in  att L 3
h e  L 3  att L  s it e  ( s e e  F ig u r e  2 )  c o n s is t s  o f  a p p r o x im a te ly  2 4  
p , a s  d e f in e d  b y  M P E /3 F e  (II) fo o tp r in t in g  e x p e r im e n t s  (4 ;  b o ld  
n e  b r a c k e ts  in  F ig u r e  2 ) .  W ith in  th is  r e g io n  th e r e  a r e  s e v e r a l  
T - r ic h  r e g io n s  th a t a r e  p o te n tia l m in o r  g r o o v e  b e n d in g  s i t e s ,  
,s w e l l  a s  ( + ) - C C - 1 0 6 5  b o n d in g  s i t e s .  ( + ) - C C - 1 0 6 5  b o n d in g  
ith in  th is  r e g io n  o n  b o th  stran d s w a s  d e te r m in e d  u s in g  a th e r m a l  
d e a v a g e  a s s a y  ( 1 6 )  in  w h ic h ,  a fte r  in c u b a t io n  w ith  d r u g , th e  
l u p le x  o l ig o m e r  32P - la b e le d  at a  s in g le  5 '  e n d  w a s  h e a te d  at 
K )°C  fo r  4 5  m in . T h is  r esu lts  in d e p u r in a tio n  a n d  tw o  s u b s e q u e n t  
3 -e lim in a t io n s  to  y i e ld  t w o  o r  th r e e  m a jo r  p r o d u c ts ,  d e p e n d in g  
lp o n  p r e c is e  c o n d it io n s ,  o f  w h ic h  th e  o n e  fo u n d  at lo w e r  
n o le c u la r  w e ig h t  is  e q u iv a le n t  to  a M a x a m  a n d  G ilb e r t  ‘A ’ 
se q u e n c in g  r e a c t io n  [ lo w e r  m o le c u la r  w e ig h t  b a n d  o f  e a c h  p a ir  
n F ig u r e  6 A  ( s e e  la te r ) ] .  T h e  p o s i t io n  o f  th is  b a n d  r e la t iv e  to  
-e q u e n c in g  la n e s  p in p o in ts  th e  a d e n in e  at w h ic h  c o v a le n t  
n o d if ic a t io n  b y  ( + ) - C C - 1 0 6 5  h a s  o c c u r r e d .  T h e  d e te r m in e d  
•o n d in g  s it e s  o n  th e  u p p e r  ( + )  a n d  lo w e r  ( - )  s tr a n d s  o f  th e  L 3  
• l ig o m e r  a r e  in  a c c o r d  w ith  th e  e s t a b l is h e d  s e q u e n c e  s p e c i f ic i t y  
Or ( + ) - C C - 1 0 6 5  ( 1 6 ,  17 ) .  F o r  s it e s  A  a n d  D ,  th e  m a jo r  
lk y la t io n  s it e  in  th e  A -tr a c t  is  th e  3 '  a d e n in e  (*  in  F ig u r e  2 )  
/ ith  a  m in o r  a m o u n t  o f  d r u g  b o n d in g  a t th e  a d e n in e  to  t h e  5 '  
id e  ( •  in  F ig u r e  2 ) .  B e c a u s e  o f  th e  c lo s e n e s s  o f  d r u g  b o n d in g  
I a n d  D  o n  th e  ( - )  s tr a n d , it is  u n l ik e ly  th a t fu l l  sa tu r a t io n  at  
o th  s it e s  o n  th is  s tr a n d  is  a tta in e d . In  o n e  o f  th e  s u b s e q u e n t  
x p e r im e n ts  ( s e e  la te r ) ,  t w o  s y n th e t ic  a n a lo g s  o f  ( - ( - ) -C C - l  0 6 5 ,  
H -)-A B C  a n d  ( + ) - A B C "  (F ig u r e  I B ) ,  w h ic h  a r e  s tr u c tu r a lly  
s la te d  to  ( + ) - C C - 1 0 6 5  b u t h a v e  a m o r e  r e s tr ic te d  s e q u e n c e
C o n t r o l ( + ) - C C - 1 0 6 5
2  3  4 1
 »
3  4
A P r o t e i n  
b o u n d  DNA
F r e e  DNA
Figure 3. Effect of (+)-CC-1065 modification of att L3 on the binding of Mu 
A-protein. 5'-32P-labeled L3 oligomer (Figure 2) was modified with 0.28 mM 
of (+)-CC-1065 at room temperature for 3 days to achieve maximum bonding.
0.1 pmole of control (unmodified) or (+)-CC-1065-modified DNA was incubated 
with 0, 0.5, 1, and 3 pmole of A-protein (lanes 1 - 4 )  and analyzed by the gel 
retardation assay, as described in Materials and Methods.
A .  ( + ) - s t r a n d
C o n t r o l ( + ) - C C - 1 0 6 5  
3 I- - - - - - - - - - - 1
B .  ( - ) - s t r a n d  
C o n t r o l  ( + ) - C C - 1 0 6 5
1 2  3 4_ 1 2 3 4  1 2 3 4 1 2 3 4..a —  A P r o t e i r  B o u n d  DN;—  F r e e  DNA
Figure 4. Effect of (+)-CC-1065 modification of the upper and lower strands 
of att L3 on Mu A-protein binding efficiency. L3 oligomer duplex molecules 
were 5'-32P-single-end labeled, and the ( +  ) strand (A) and ( - )  strand (B) 
selectively modified with (+)-CC-1065 in two separate experiments as described 
in Materials and Methods. In both control (unmodified duplex) and in (+ )-  
CC-1065-modified experiments for both (+ )  and ( - )  strands, the duplex was 
incubated with 0, 0.5, 1, and 3 pmole of A-protein (lanes 1 - 4 ,  respectively). 
Following incubation, the efficiency of A-protein binding was determined using 
the gel retardation assay, as described in Materials and Methods.
s p e c i f ic i t y  ( 1 8 ) ,  w e r e  u s e d .  In  t h e s e  c a s e s  th e  c o v a le n t  b o n d in g  
s it e s  a r e  th e  s a m e  a s  ( + ) - C C - 1 0 6 5 ,  e x c e p t  s it e  C  o n  th e  ( — ) 
str a n d  is  l e s s  r e a c t iv e  to  t h e s e  d r u g s .
M u  A - p r o t e in  s t i l l  b i n d s  t o  att L 3  a f t e r  c o v a l e n t  m o d i f i c a t io n  
b y  ( + ) - C C - 1 0 6 5
In  a  p r e l im in a r y  e x p e r im e n t ,  th e  e f f e c t  o f  c o v a le n t  m o d if ic a t io n  
o f  th e  L 3  o l ig o m e r  o n  A -p r o te in  b in d in g  w a s  d e te r m in e d . A  g e l  
r e ta r d a t io n  a s s a y  (F ig u r e  3 )  w a s  u s e d  to  e v a lu a te  th e  r e la t iv e  
a f f in i ty  o f  M u  A -p r o te in  fo r  s it e  L 3  in  th e  a b s e n c e  a n d  p r e s e n c e  
o f  d r u g  m o d if ic a t io n .  T h e  r e s u lt s  s h o w  th a t w h i le  th e r e  is  a  
m o d e s t  a m o u n t  o f  in h ib it io n ,  th e  A - p r o te in  s t i ll  a p p e a r s  to  b in d  
to  a  s u b p o p u la t io n  o f  th e  d r u g -m o d if ie d  o l ig o m e r s ,  s u g g e s t in g  
th a t d r u g  o c c u p a n c y  o f  c e r ta in  o f  th e  m in o r  g r o o v e s  w ith  th e
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Figure 5. Binding of A-protein to att L3 (+ )  strand after partial modification 
with (+)-CC-1065. The DNA was 5'-32P-single-end labeled on the (+ )  strand 
and incubated with ( +  )-CC-1065 for limited periods of time (5 or 10 min). 
Protein-DNA complexes were separated from non-protein complexed DNA by 
gel electrophoresis as described in Materials and Methods. Lanes 1 and 2 are 
Maxam-Gilbert purine- and pyrimidine-specific seqencing reactions, respectively. 
Lanes 3 and 4 are thermal treatment of A-protein-bound DNA and free DNA, 
respectively, following a 5-min incubation with (+)-CC-1065. Lanes 5 and 6 
are thermal treatment of A-protein-bound DNA and ffee DNA, respectively, after 
a 10-min incubation with (+)-CC-1065. The drug-bonding sites (A, B), sequences, 
and drug-covalently-modified adenine (asterisk) are indicated on the left of the 
gel. In lanes 4 and 6, the multiple strand breakage sites are expected, based upon 
the thermal cleavage pattern shown in Figure 1A (species A and B). The two 
lower molecular weight bands are due to minor alkylation at 5'AAAA*TA, 
whereas the upper pair are due to alkylation at site B.
a s s o c ia te d  d r u g -e n h a n c e d  b e n d in g  o f  th e  c o r r e s p o n d in g  A -tr a c ts  
i s  to le r a te d . B a s e d  u p o n  th e s e  p r e l im in a r y  b u t e n c o u r a g in g  
r e s u lt s ,  a  s e r ie s  o f  e x p e r im e n t s  w e r e  c a r r ie d  o u t  to  d e te r m in e  
in  m o r e  d e ta il  h o w  ( + ) - C C - 1 0 6 5  o c c u p a n c y  o f  in d iv id u a l m in o r  
g r o o v e s  a n d  a s so c ia te d  d r u g -in d u c e d  b e n d in g  m ig h t b e  c o m p a tib le  
w ith  A -p r o te in  b in d in g  to  D N A .
( + ) - C C - 1 0 6 5  m o d i f i c a t io n  o f  t h e  l o w e r  s t r a n d  o f  att L 3  d o e s  
n o t  a f f e c t  A - p r o t e in  b i n d in g  e f f i c i e n c y
In  o r d e r  to  a d d r e s s  th e  q u e s t io n  o f  h o w  ( + ) - C C - 1 0 6 5  
m o d if ic a t io n  o f  e ith e r  th e  ( + )  o r  ( — ) str a n d  o f  th e  L 3  o l ig o m e r  
e f f e c te d  A -p r o te in  b in d in g , tw o  d if fe r e n t  ( +  ) - C C - 1 0 6 5  o l ig o m e r  
c o n s tr u c t io n s  in  w h ic h  e ith e r  th e  u p p e r  o r  lo w e r  str a n d  w a s  
m o d if ie d  w ith  ( + ) - C C - 1 0 6 5  to  a c h ie v e  m a x im u m  b o n d in g  at e a c h
o f  th e  s it e s  w e r e  p r e p a r e d . T h e  g e l  r e ta r d a t io n  a s s a y  w a s  th e n  
u s e d  to  e v a lu a te  th e  r e la t iv e  b in d in g  a f f in ity  o f  e a c h  ( +  ) -  
C C -1 0 6 5 -m o d if ie d  o r  u n m o d if ie d  d u p le x  to  A -p r o te in  (F ig u r e  4 ) .  
W h ile  in  th e  c o n tr o l  e x p e r im e n t s  (A  a n d  B  in  F ig u r e  4 )  th e  g e l  
r e ta r d a t io n  a s s a y  s h o w e d  a  c o n c e n tr a t io n  d e p e n d e n c y  o f  M u  A -  
p r o te in  b in d in g  to  D N A ,  o n ly  in  th e  c a s e  o f  th e  l o w e r  str a n d  
(B  in  F ig u r e  4 )  d id  A -p r o te in  b in d  e f f ic ie n t ly  to  th e  ( +  ) -  
C C - 1 0 6 5 - m o d if i e d  L 3  s it e .  D r u g  m o d if ic a t io n  o f  th e  u p p e r  
s tr a n d , o n  th e  o th e r  h a n d , w a s  d e tr im e n ta l  to  p r o te in  b in d in g .
M u  A - p r o t e in  e x c l u d e s  a n  L 3  o l ig o m e r  w h i c h  i s  ( + ) -  
C C - 1 0 6 5 - m o d i f i e d  a t  s i t e  B ,  b u t  i s  s t i l l  a b le  t o  b i n d  t o  o n e  
t h a t  is  m o d i f i e d  a t  s i t e  A  o n  t h e  u p p e r  s t r a n d
In  o r d e r  to  d e te r m in e  i f  o n e  o r  b o th  o f  th e  tw o  d r u g  b o n d in g  
s it e s  o n  th e  ( +  ) str a n d  w a s  in h ib ito r y  to  A -p r o te in  b in d in g ,  
p a r tia lly  d r u g -m o d if ie d  o l ig o m e r s  w e r e  p r e p a r e d  a n d  in c u b a te d  
w ith  A -p r o te in  p r io r  to  s e p a r a t io n  o f  A - p r o t e i n - o l i g o m e r  
c o m p le x e s  f r o m  n o n -p r o te in  c o m p le x e d  o l ig o m e r .  P a rtia l  
m o d if ic a t io n  o f  th e  L 3  D N A  w a s  c a r r ie d  o u t  b y  l im ite d - t im e  (5  
o r  10  m in )  in c u b a t io n  w ith  ( +  ) - C C - 1 0 6 5  w ith  e ith e r  th e  (  +  ) o r  
(  — ) str a n d  32P  la b e le d .  T h e  s ite  o f  m o d if ic a t io n  a n d  e x te n t  o f  
b o n d in g  o f  ( + ) - C C - 1 0 6 5  w a s  m e a s u r e d  u s in g  th e  th e r m a l  
c le a v a g e  a s s a y  ( 1 6 ) .  T h e  r e s u lts  fo r  th e  u p p e r  str a n d  a r e  s h o w n  
in  F ig u r e  5 .  M u  A -p r o te in  e x c lu d e s  o l ig o m e r s  m o d if ie d  at s it e  
B , b u t is  s t i ll  a b le  to  b in d  to  o l ig o m e r s  th at a r e  m o d if ie d  at s it e  
A  at th e  3 '  te r m in a l a d e n in e  ( c o m p a r e  la n e s  3 w ith  4  a n d  la n e s  
5  w ith  6  w h ic h  s h o w  d r u g  m o d if ic a t io n  in  b o u n d  v s  fr e e  D N A  
r e s p e c t iv e ly  a t tw o  d if fe r e n t  d r u g  m o d if ic a t io n  t im e s ) .  W ith in  
th e  d r u g -b o n d in g  s ite  A ,  ( +  ) - C C - 1 0 6 5  m o d if ic a t io n  at th e  
terminal 3 '  a d e n in e  (*  in  F ig u r e  2 )  is  th e  p r e fe r r e d  s it e  fo r  A -  
p r o te in  b in d in g  ra th e r  th a n  m o d if ic a t io n  at th e  a d e n in e  to  th e  5 '  
s id e  (c o m p a r e  p a tter n  o f  c le a v a g e  in  b o u n d  v s  fr e e  D N A  fo r  th is  
s ite ;  th e  m id d le  a n d  lo w e r  m o le c u la r  w e ig h t  b a n d s  r e p r e s e n t  th e  
c o m p le t e  r e a c tio n  p r o d u c ts  c o r r e s p o n d in g  to  e ith e r  th e  3 '  a d e n in e  
o r  its  5 '  n e ig h b o r .)
In  a  s im ila r  e x p e r im e n t  o n  th e  ( - )  s tr a n d , M u  A - p r o te in  w a s  
s e e n  to  b in d  e q u a lly  w e ll  to  u n m o d if ie d  o r  ( +  ) -C C - 1 0 6 5  m o d if ie d  
D N A  (d a ta  n o t  s h o w n ) ,  in  a c c o r d  w ith  p r e v io u s  r e s u lt s .
P r e b in d i n g  o f  M u  A - p r o t e in  t o  att L 3  p r e f e r e n t i a l l y  p r o t e c t s  
s i t e  B  o n  t h e  ( + )  s t r a n d  f r o m  c o v a l e n t  m o d i f i c a t io n  b y  ( + ) -  
C C - 1 0 6 5  a n d  i n c r e a s e s  t h e  r e a c t i v i t y  o f  s i t e  D  t o  m o d i f i c a t io n  
w i t h  ( + ) - A B C  a n d  ( + ) - A B C "
D r u g  p r o te c t io n  e x p e r im e n t s  w e r e  c a r r ie d  o u t  n e x t ,  in  o r d e r  to  
e x p lo r e  th e  a c c e s s ib i l i ty  o f  ( + ) - C C - 1 0 6 5  to  p r o te in -b o u n d  D N A .  
B o th  th e  ( + )  a n d  ( - )  s tr a n d s  o f  th e  o l ig o m e r  w e r e  32P - la b e le d  
in  s e p a r a te  e x p e r im e n t s ,  a n n e a le d  to  c o m p le m e n t a r y  u n la b e le d  
s tr a n d s , p r e in c u b a te d  w ith  M u  A -p r o te in ,  a n d  th e n  r e a c te d  w ith  
( + ) - C C - 1 0 6 5 .  T h e  o l ig o m e r s  w e r e  th e n  s u b je c te d  to  th e r m a l  
tr e a tm e n t to  r e v e a l  th e  d r u g  b o n d in g  s it e s  (F ig u r e  6 A ) .  O f  th e  
fo u r  d r u g  b o n d in g  s it e s  ( A - D )  o n  th e  ( + )  a n d  ( — ) s tr a n d s , M u  
A -p r o te in  b in d in g  s e l e c t iv e ly  p r o te c ts  s ite  B  fr o m  ( + ) - C C - 1 0 6 5  
m o d if ic a t io n  (c o m p a r e  la n e s  5  a n d  6  in  e a c h  c a s e ) .  O v e r a l l ,  th is  
r e s u lt  s u g g e s t s  th a t th r e e  o f  th e  fo u r  d r u g  b o n d in g  s it e s  r e m a in  
o p e n  to  m o d if ic a t io n  b y  ( + ) - C C - 1 0 6 5  in  th e  p r e s e n c e  o f  A -  
p r o te in . S ite  B ,  p r o te c te d  fr o m  d r u g  m o d if ic a t io n ,  l ie s  in  the  
c e n tr a l m in o r  g r o o v e  p r o te c te d  b y  th e  p r o te in  ( 4 ) .  T h is  r esu lt  
is  in  c o m p le t e  a g r e e m e n t  w ith  e a r l ie r  r e su lts  in  w h ic h  o n ly  d ru g  
m o d if ic a t io n  o f  th e  B  s ite  o n  th e  ( + )  stran d  s ig n if ic a n t ly  in h ib ite t  
A -p r o te in  b in d in g .
D r u g  p r o te c t io n  e x p e r im e n t s  u s in g  tw o  s y n th e t ic  a n a lo g s  o l  
( + ) - C C - 1 0 6 5 ,  ( -F ) -A B C  a n d  ( + ) - A B C " ,  w h ic h  s e le c t iv e ly  b in e
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Figure 6. Effect o f Mu A-protein binding to att L3 oligomer on (+ )-C C -1065, (+ )-A B C , and (+ )-A B C "  alkylation. (A) 5 '-32P-labeled upper ( + )  and lower ( - )  
strand duplex DNA molecules were prepared as described in Materials and Methods. In each case [ ( + )  and ( —) strands], lanes 1 and 2 are Maxam-Gilbert purine- 
and pyrimidine-specific sequencing reactions. Lane 3 is thermal treatment o f control (unmodified) D N A , while lane 4 is thermal treatment o f control D NA in the 
presence o f Mu A-protein. Lanes 5 and 6 are thermal treatment o f DN A  modified with (+)-C C -1065 for 10 min in the absence and presence o f A-protein, respectively. 
The bonding sites ( A - D ) ,  sequences, and the covalently modified adenine (asterisk) are indicated at the right and left o f the ( - )  and ( + )  strands. (B) As for (A) 
except that only the ( —) strand was labeled and (+ )-A B C  and (-t-)-ABC" were used in place o f (+ )-C C -1065. Lanes 3 and 4  are (+ )-A B C  and lanes 5 and 6 
are (+ )-A B C "  incubated for 5 min in the presence o f A-protein (lanes 4 and 6) and in the absence o f  A-proteins (lanes 3 and 5). For this experiment, the sequence 
outside the att L3 site was slightly different to that shown in Figure 2, but this did not effect the (+)-C C -1065 alkylation pattern or A-protein binding.
to  ju s t  s ite  D  o n  th e  ( —) stran d , are  sh o w n  in  F ig u re  6 B . T h e  
resu lts sh o w  that p rein cu b a tio n  w ith  M u  A -p r o te in  increased th e  
rea c tiv ity  o f  th is s ite  to  d ru g  m o d if ic a t io n  (c o m p a re  la n es  3 and  
5 w ith  la n e s  4  and 6 ) . It is  n o t o b v io u s  w h y  th ere  is  an  apparent  
d iffer en ce  b e tw ee n  ( + ) - C C - 1 0 6 5  and the tw o  a n a lo g s , ( + ) - A B C  
and  ( -F ) -A B C " , in  th is  rega rd  (p o ss ib ly  d u e  to  in h eren t  
d iffe r e n c e s  in  d rug r ea c tiv ity  at s ite s  C  and  D ) .  Irr esp ec tiv e  o f  
th e  e x a c t  r ea so n s  fo r  th e se  d if fe r e n c e s , it is  c le a r  that M u  A -  
p ro te in  p r ed isp o sed  th e  c o n fo r m a tio n  o f  s ite  D  to  c o v a le n t  
m o d if ic a tio n  b y  (-t- )-A B C  and  ( + ) - A B C " .  O n  th e  ( + )  strand, 
w h ile  b o th  ( + ) - A B C  and  ( - t - ) -A B C "  b in d  to  s ite  A ,  b o th  d rugs  
w e r e  p referen tia lly  inh ib ited  in b in d in g  to  site  B  b y  preincubation  
w ith  M u  A -p ro te in , a  resu lt s im ila r  to  the o n e  ob ta in ed  w ith  ( + ) -  
C C -1 0 6 5  a b o v e  (data n o t sh o w n ) .
D I S C U S S I O N
T h e  M u  tra n sp o sa se  is  a  s e q u e n c e -sp e c if ic  D N A  b in d in g  and  
b e n d in g  p r o te in  (3 ,  4 ,  14 ). D N A  r e c o g n itio n  is  u n u su a l in  that, 
u n lik e  m o st  D N A  b in d in g  p r o te in s , th e  M u  A -p r o te in  appears  
to  r e c o g n iz e  a rather la rg e  D N A  se q u e n c e  (2 4  b p ) w ith  n o  
apparent d y a d  sy m m e try  an d  b in d s to  it as a m o n o m er . M P E /3F e  
(II) and h yd rox y l-rad ica l foo tp r in ts at f iv e  o f  the s ix  att s ites  sh o w  
p r o te c tio n  o f  o n e  fa c e  o f  th e  D N A  h e lix  o v e r  th ree  c o n se c u tiv e
m in or  and tw o  m ajor g r o o v e s  (4 ) . B in d in g  sp e c ific ity  is  a ch iev ed  
p r im a rily  th ro u g h  m a jor  g r o o v e  c o n ta c ts . A lth o u g h  sev er a l runs 
o f  a d e n in es  o c c u r  in  th e  att s it e s , n o  e sse n tia l m in o r  g r o o v e  
con tacts w e r e  identified  at m o st sites in  th e  earlier  study (4 ) . S in ce  
fou r o r  m o re  aden in es in  runs (A -tracts) im part curvature to  D N A  
i f  rep ea ted  in  p h a se  w ith  the D N A  h e lic a l rep eat (2 2 ) ,  it w a s  
sp e cu la te d  that th e  p r e se n c e  o f  th e se  a d e n in e  runs m ig h t im part 
co n fo r m a tio n a l f le x ib ility  to  th e  att s ite s , thus fac ilita tin g  b in d in g  
an d  b e n d in g  o f  th e  D N A  b y  M u  A -p r o te in .
( + ) - C C - 1 0 6 5  and  its  structural a n a lo g s  ( - l - ) -A B C  an d  ( + ) -  
A B C "  are m in o r  g r o o v e  r ea c tiv e  c o m p o u n d s  that c o v a le n tly  
m o d ify  D N A  through reaction  w ith  N 3  o f  ad en in e  (1 5 , 16). O n ly  
a d e n in es  in  certa in  s e q u e n c e s , su c h  a s  5 '  P u N T T A *  and  5 '  
A A A A A *  (*  is  co v a len tly  m o d ified  ad en in e), are reactive  tow ards  
( + ) - C C - 1 0 6 5  (1 6 ) ,  and  o n e  o f  th e  m e c h a n ism s  fo r  seq u en c e  
r e c o g n it io n  is  p r o p o se d  to  in v o lv e  a  s e q u e n c e  d ep en d en t  
c o n fo r m a tio n a l f le x ib i li ty  ( 1 8 , 1 9 ) .  A  c o m m o n  structural 
c o n se q u e n c e  o f  ( + ) - C C - 1 0 6 5  c o v a le n t  b o n d in g  to  a d e n in es  in  
D N A  is  a  b en t D N A  stru ctu re in  w h ic h  th e  b e n d in g  o c c u r s  in to  
th e  m in o r  g r o o v e  (2 3 ) . S tu d ies  u s in g  g e l  e le c tr o p h o r e s is ,  
h yd ro x y l-ra d ica l foo tp r in tin g , and  h ig h -fie ld  N M R  h a v e  revealed  
that th e  structural o r ig in  o f  th e  (+ ) -C C -1 0 6 5 - in d u c e d  b en d  is  
q u ite  s im ila r  to  that a sso c ia te d  w ith  A -tr a c ts  (2 0 , 2 1 ) ,  and  a 
tru n ca ted  ju n c tio n  b en d  m o d e l (2 1 )  h as b e e n  p r o p o se d . ( + ) -
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Figure 7 . S u m m a ry  o f  A -p ro te in  (4 ) a n d  ( + ) - C C - 1 0 6 5  in te ra c t io n s  w ith  th e  a tt  
L 3  site . (A) T h e  d u p le x  s e q u e n c e  o f  a tt  L 3  o lig o m e r  sh o w in g  th e  h y d ro x y l-rad ica l 
p ro te c tio n  re g io n s  c o v e r in g  m in o r  g ro o v e s  I ,  n ,  a n d  III  a n d  d ru g  b o n d in g  s ite s  
( A - D )  in d ic a tin g  th e  d ru g  o v e r la p  in  th e  m in o r  g ro o v e s .  (B )  R ib b o n  d ia g ra m  
o f  th e  sa m e  re g io n  s h o w in g  th e  p ro p o s e d  lo c i fo r  b e n d in g  in to  m in o r  (m ) g ro o v e s  
I a n d  IH  by  s o lid  s q u a re s  w ith in  b a s e  p a irs . G u a n in e  (s tro n g )  a n d  a d e n in e  (w eak ) 
p ro te c tio n  s ite s  (4 ) a r e  s h o w n  a s  s o l id  a n d  b r o k e n  a r r o w s ,  r e s p e c t iv e ly . D ru g  
b o n d in g  s ite s  a r e  s h o w n  a s  f i l l e d  b a s e s ,  a n d  a d e n in e s  sh o w in g  m e th y la tio n  
p ro te c tio n  b u t n o t in te r fe re n c e  (4 ) a re  m a rk e d  w ith  s o l id  d o ts .  T h e  se q u e n c e  o f  
th e  u p p e r  ( + )  s tr a n d  is s h o w n .
C C - 1 0 6 5  m o d if ic a t io n  o f  A -tr a c ts  o c c u r s  p r e d o m in a n t ly  at th e  
3 '  a d e n in e ,  m o s t  p r o b a b ly  d u e  to  th e  s p e c ia l  r e a c t iv ity  o f  th e  b p  
at th e  3 '  j u n c t io n  s it e  o f  th e  A -tr a c t .  A s  a  s tr u c tu r a l c o n s e q u e n c e  
o f  c o v a le n t  m o d if ic a t io n  o f  a n  A 5-tr a c t , th e  m a g n itu d e  o f  
b e n d in g  in to  th e  m in o r  g r o o v e  is  in c r e a s e d  f r o m  a b o u t  1 4 °  to  
a b o u t  2 5 ° ,  a n d  th e  lo c u s  o f  b e n d in g  is  m o v e d  a b o u t 0 . 5  b p s  to  
th e  3 '  o f  th e  c e n te r  o f  th e  A -tr a c t  ( 2 1 ) .  B e c a u s e  o f  th e  w e ll -  
c h a r a c te r iz e d  a n d  u n iq u e  s tr u c tu r e  o f  th e  ( + ) - C C - 1 0 6 5 -  
e n tr a p p e d / in d u c e d  b e n d  in  D N A  a n d  its  s tr u c tu r a l s im ila r ity  to  
A -tr a c t  b e n d in g ,  th is  d r u g  is  p o t e n t ia l ly  a  v e r y  u s e fu l  p r o b e  fo r  
m o n it o r in g  p r o te in - in d u c e d  D N A  b e n d in g ,  w h ic h  in v o lv e s  A -  
tr a c ts  o r  o th e r  s e q u e n c e s  th a t m a y  b e n d  in to  th e  m in o r  g r o o v e .  
In  p r in c ip le ,  ( +  ) - C C - 1 0 6 5  m o d if ic a t io n  o f  A - tr a c ts  th a t a r e  th e  
s it e  o f  p r o te in - in d u c e d  b e n d in g  s h o u ld  b e  to le r a te d  o r  e v e n  
e n h a n c e d  s it e s  fo r  p r o te in  b in d in g ,  p r o v id e d  th e  d r u g  d o e s  n o t  
d isr u p t  im p o r ta n t p r o t e i n - D N A  c o n ta c t s .  C o n v e r s e ly ,  p r o te in -  
in d u c e d  b e n d in g  in to  th e  m in o r  g r o o v e  o f  D N A ,  w h ic h  ta k e s  
a d v a n ta g e  o f  in tr in s ic a l ly  b e n t  s e q u e n c e s  su c h  a s  A -tr a c ts ,  sh o u ld  
s t i l l  b e  (4 -  ) - C C - 1 0 6 5  c o v a le n t  m o d if ic a t io n  s i t e s  in  th e  p r e s e n c e  
o f  p r o te in . O n  th e  o th e r  h a n d , i f  p r o te in  b in d in g  to  a  p o te n tia l  
( + ) - C C - 1 0 6 5  b o n d in g  s e q u e n c e  p r e v e n ts  b e n d in g  o f  th e  D N A  
in to  th e  m in o r  g r o o v e  o r  s te r ic a l ly  o c c lu d e s  d r u g  b in d in g  w ith in  
th e  m in o r  g r o o v e ,  d r u g  b o n d in g  w i l l  b e  in h ib ite d . L ik e w is e ,  it 
is  a l s o  e x p e c t e d  th a t ( + ) - C C - 1 0 6 5  m o d if ic a t io n  o f  a  s e q u e n c e  
th a t is  n o t th e  s ite  o f  a  p r o te in -in d u c e d  b e n d  in to  th e  m in o r  g r o o v e  
w i l l  b e  d e tr im e n ta l  to  p r o te in  b in d in g . B a s e d  u p o n  th e  s e q u e n c e  
o f  att L 3  s it e ,  w h ic h  h a s  s e v e r a l  p o te n t ia l  A - tr a c t  b e n d in g  s it e s ,  
a n d  th e  o b s e r v a t io n  th a t b in d in g  o f  A -p r o t e in  r e s u lts  in  a  9 0 °  
o v e r a ll  b e n d  ( 1 4 ) ,  a  s e r ie s  o f  e x p e r im e n t s  w a s  d e s ig n e d  to  u s e  
( + ) - C C - 1 0 6 5  a n d  its  s tr u c tu r a l a n a lo g s  a s  s tr u c tu r a l p r o b e s  to  
d e te r m in e  th e  lo c a t io n  o f  s ite s  o f  A -p r o te in - in d u c e d  m in o r  g r o o v e  
b e n d in g  w ith in  th is  s e q u e n c e .
W e  h a v e  s h o w n  in  th is  s tu d y  th a t ( + ) - C C - 1 0 6 5  c o v a le n t ly  
b o n d s  to  fo u r  s i t e s  o n  att L 3  D N A .  O n e  c a n  s e e  (F ig u r e  7 A )
that o n  n a k e d  D N A  th e s e  fo u r  d m g  b o n d in g  s ite s  ( A - D )  in tera c t  
w ith in  o r  p a r tia lly  o v e r la p  e a c h  o f  th e  th r e e  m in o r  g r o o v e s  
( la b e le d  I - I E )  that s h o w  p r o te c tio n  b y  M u  A -p r o te in  to  h y d r o x y l-  
r a d ic a l a tta c k  ( 4 ) .  T h e s e  c o v a le n t  m o d if ic a t io n  s it e s  a r e  s h o w n  
( f i l l e d  b a s e s )  o n  th e  r ib b o n  m o d e l  o f  L 3  in  F ig u r e  7 B .  
In te r fe r e n c e  e x p e r im e n ts  s h o w  that ( +  ) - C C - 1 0 6 5  b o n d in g  w ith in  
m in o r  g r o o v e s  I a n d  III ( s i te s  A ,  C ,  D )  does not s ig n if ic a n t ly  
in te r fe r e  w ith  A -p r o te in  b in d in g  (F ig u r e s  4  a n d  5 ) ,  in  a g r e e m e n t  
w ith  p r e v io u s  r e s u lts  w h e r e  m e th y la t io n  o f  a d e n in e s  in  th e s e  
r e g io n s  d id  n o t in te r fe r e  w ith  p r o te in  b in d in g  (4 ) .  S in c e  th e  d r u g s  
in d u c e  o r  trap  b e n d s  in to  th e  m in o r  g r o o v e ,  th e s e  d a ta  s h o w  th a t  
th e  A -p r o te in  to le r a te s  s u c h  b e n d s  o v e r  m in o r  g r o o v e s  I a n d  III. 
S ig n if ic a n t ly ,  att L 3  m o d if ie d  w ith  d r u g  a t s ite  A  w ith in  m in o r  
g r o o v e  I w a s  a preferred  s ite  fo r  b in d in g  o f  A - p r o t e in ,  in  
c o m p a r iso n  to  n o n -d r u g -m o d if ie d  att L 3  (F ig u r e  5 ) .  T h is  s ite  w a s  
a ls o  r e a c t iv e  to  th e  d r u g  a fter  A - p r o te in  b in d in g . S o  a ls o ,  
m o d if ic a t io n  o f  s it e  D  in  m in o r  g r o o v e  III w a s  n o t o n ly  w e ll  
to le r a te d  b y  th e  A -p r o te in  b u t th is  s it e  w a s  a  preferred  s it e  fo r  
b o n d in g  o f  a n a lo g s  o f  ( + ) - C C - 1 0 6 5 ,  s u b s e q u e n t  to  b in d in g  o f  
A -p r o te in  (F ig u r e  6 B ) .  B e s id e s  s h o w in g  th a t d r u g  m o d if ic a t io n  
in  m in o r  g r o o v e s  I a n d  III is  n o t d e tr im e n ta l  to  p r o te in  b in d in g ,  
th e s e  r e su lts  a ls o  s h o w  th at th e  t w o  m in o r  g r o o v e s  a r e  ‘o p e n ’ 
to  th e  d r u g s  u p o n  A -p r o te in  b in d in g  a n d  th e r e fo r e  n o t p r o te c te d  
b y  th e  p r o te in . A t  f ir s t  g la n c e ,  th e  la tte r  in fe r e n c e  a p p e a r s  to  
b e  in c o n s is te n t  w ith  th e  h y d r o x y l- r a d ic a l  a n d  M P E /3 F e  (II)  
fo o tp r in t in g  d a ta  s h o w in g  p r o te c t io n  o f  th e s e  t w o  m in o r  g r o o v e s  
b y  th e  p r o te in  (4 ) .  T h e  ap p a re n t p a r a d o x  is  e x p la in e d  b y  th e  d ata  
s h o w in g  p r e fe r e n c e  o f  d r u g  b o n d in g  t o  s it e s  in  m in o r  g r o o v e s  
I a n d  III , e ith e r  b e fo r e  ( fo r  s ite  A )  o r  a f te r  ( fo r  s it e  D )  A -p r o te in  
b in d in g ,  w h ic h  s u g g e s t  th at th e s e  s i t e s  a r e  b e n t o r  c o m p r e s s e d  
in to  th e  m in o r  g r o o v e  b y  th e  A -p r o te in . H y d r o x y l- r a d ic a l  a tta ck  
i s  k n o w n  to  b e  s tr o n g ly  in f lu e n c e d  b y  th e  w id th  o f  th e  m in o r  
g r o o v e  (2 4 ,  2 5 ) .  V e r y  l ik e ly ,  su c h  n a r r o w in g  a ls o  p r e v e n ts  M P E ,  
w h ic h  in te r c a la te s  v ia  th e  m in o r  g r o o v e  ( 2 6 ) ,  f r o m  e n te r in g  th is  
r e g io n ,  th u s  r a t io n a liz in g  th e  a p p a r e n t c o n f l ic t in g  d a ta .
A  q u ite  d if fe r e n t  s itu a t io n  o c c u r s  in  th e  c e n tr a l m in o r  g r o o v e  
II, w h e r e  d r u g  b o n d in g  s tr o n g ly  in ter fer es  w ith  su b se q u e n t p r o te in  
b in d in g . A f te r  A -p r o te in  b in d in g , s it e  B  w a s  th e  o n ly  s ite  
u n a v a ila b le  fo r  d r u g  b o n d in g  (F ig u r e  6 A ) .  T h is  s u g g e s t s  th a t 
e ith e r  M u  A -p r o te in  b in d s  w ith in  th e  m in o r  g r o o v e  to  s te r ic a l ly  
p r e c lu d e  d r u g  a c c e s s  to  its b o n d in g  s ite  o r  th at th e  p r o te in  p r e v e n ts  
m in o r  g r o o v e  c o m p r e s s io n ,  w h ic h  is  r e q u ir e d  fo r  s ta b i liz in g  th e  
tr a n s it io n  s ta te  fo r  th e  c o v a le n t  r e a c t io n  w ith  ( + ) - C C - 1 0 6 5 .  T h e  
r e su lts  o f  th e  p r e v io u s  h y d r o x y l- r a d ic a l  fo o tp r in t in g  e x p e r im e n ts  
a r e  o n ly  c o n s is t e n t  w ith  th e  f ir s t  in te r p r e ta t io n  ( 4 ) .  W e  n o te  th a t  
m e th y la t io n  o f  o n e  a d e n in e  in  th is  r e g io n  (F ig u r e  7 B ,  b r o k e n  
a r r o w ) s h o w e d  w e a k  in te r fe r e n c e  at att L 3 ,  w h i le  t w o  o th e r  
a d e n in e s  (F ig u r e  7 B , so l id  d o ts)  w e r e  p r o te c te d  fr o m  m e th y la t io n  
at a ll att s i t e s  ( 4 ) .  T h e s e  d r u g  in te r fe r e n c e  a n d  p r o te c t io n  d ata  
a r e  c o n s is t e n t  w ith  p a r tia l p e n e tr a t io n  o f  m in o r  g r o o v e  II b y  A -  
p r o te in .
T h e  D N A  b e n d in g  s it e s  w ith in  m in o r  g r o o v e s  I a n d  III a r e  
p h a s e d  a p p r o x im a te ly  t w o  h e lic a l  tu r n s  a p a rt, i f  w e  a s s u m e  th e  
lo c u s  o f  b e n d in g  a t m in o r  g r o o v e s  I a n d  III is  a t th e  c e n te r  o f  
b o n d in g  s it e  A  a n d  at th e  c e n te r  o f  b o n d in g  s it e s  C  a n d  D ,  
r e s p e c t iv e ly  ( s e e  F ig u r e  7 B ) .  I n d e p e n d e n t  s u p p o r t  o f  th is  
a s s u m p t io n  is  p r o v id e d  b y  e x a m in in g  th e  h y d r o x y l- r a d ic a l  
p r o te c t io n  d a ta  ( 4 ) ,  w h e r e  th e  m a x im a  o f  p r o te c t io n  p r o f i le s  in  
m in o r  g r o o v e s  I a n d  E l  a r e  v e r y  c lo s e  to  th o s e  d e d u c e d  fr o m  
th e  d r u g  b o n d in g  d a ta . A s s u m in g  th a t b in d in g  o f  p r o te in  d o e s  
n o t s ig n if ic a n t ly  c h a n g e  th e  p itc h  o f  th e  D N A  h e l ix ,  th e s e  tw o  
f la n k in g  m in o r  g r o o v e  b e n d s  c o u ld  b e  s u f f ic ie n t  to  p r o d u c e  a
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lulative bend of up to about 60° towards the protein. Mu A- 
ein produces an overall 90° bending of L3; therefore, an 
itional 30° needs to be accounted for, exclusive of that 
dated with minor grooves I and HI. One possible explanation 
at at least part of this additional 30° bend occurs into minor 
)ve n, which is phased approximately equally between minor 
)ves I and HI. However, other possible explanations include 
ling into the major groove on either side of minor groove 
which would also produce additive bending with minor 
jves I and HI. We note that only a 60° bend has been observed 
\t L2 (14), which is missing the two important guanines in
fft major groove and shows a hydroxyl radical footprint only minor grooves I and II (4), The loss of a 30° bend into 
or groove HI at L2, is consistent with our data.
:e propose that the A-protein interacts within major grooves 
Jioned on either side of minor groove n, explaining the 
aylation protection and interference data (4) showing the 
ortance of three guanines in the two major grooves. If the 
:action of A-protein within these major grooves is proposed 
pause compression of minor grooves I and HI and 
esponding bending into these grooves, then it seems likely 
A-protein penetration into the major groove on the back side 
le helix is required. The strong methylation interference in 
najor groove behind site HI is consistent with this proposal, 
unfortunately the absense of a similar reporter guanine at site 
ŝ not provide data on this site. In addition to minor groove 
pactions, Mu A-protein is proposed to straddle minor groove 
jth limited penetration, possibly producing a bending of this 
pr groove. Although there is no obvious dyad symmetry in 
ptt L3 site, the sequence ladder and ribbon diagram 
pre 7A and B) do show elements of symmetry around the 
pr groove n. Both flanking major grooves have some 
j/alent methylation protection sites, and the minor groove 
pression sites I and HI are symmetrically opposed, as are 
Srug bonding sites. This model for bending at site L3 can 
xtended to most att sites. At site Rl, however, we note, that 
E-rich sequence is present at minor groove HI (4). 
[summary, we have exploited the known DNA bonding and 
ling properties of (+)-CC-1065 and structurally related 
rounds to identify the probable sites of two Mu A-protein- 
:ed DNA bends into minor grooves I and HI at att L3. A 
j bending site, possibly into the minor groove n, is proposed, 
all, these bends would likely result in bending the DNA 
rds the protein. Our study highlights the usefulness of these 
imor dings as probes for DNA—protein interactions and 
dally for protein-induced DNA bends. While their utility 
lited by the availability of (+)-CC-1065 bending sites within 
rotein recognition sequence and protein-induced bending into 
linor groove, these drugs should serve as general tools for 
:oming limitations of hydroxyl radical footprinting by 
iminating protein protection sites from minor groove DNA 
ing sites as shown here for the Mu transposase.
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ab stra ct: The overall structural features of the multimeric complex between Spl and the 21-base-pair 
repeat of the early promoter region of S V40 DN A have been determined using hydroxyl-radical footprinting; 
(+)-CC-1065, a sequence-specific minor groove bending probe; and circularization experiments. The results 
show that the 21-base-pair repeat region has an intrinsically in-phase bent structure that is stabilized upon 
saturation Spl binding by protein-DNA and protein-protein interactions to produce a looping structure. 
The direction of the Spl-stabilized bending of DNA occurs into the minor groove and is localized between 
each of the Spl binding sites. These results are used as the basis to propose a looping structure for the 
multimeric Spl 21-base-pair repeat region of SV40 DNA. Last, these results provide a rationale for the 
recently observed inhibition of basal transcriptional levels by site-specific triple-helical DNA complexes.
The regulation of eukaryotic gene transcription is operated 
primarily through the interaction of various trans-acting 
transcription factors (e.g., basal transcriptional factors, 
activators, and repressors) with cis-acting DNA promoter 
elements (Johnson & McKnight, 1989; Mitchell & Tjian, 
1989; Muller & Schaffner, 1990;Ptashne, 1988). The binding 
sites for transcriptional activators are generally located 
proximal to the transcriptional initiation site. Furthermore, 
both in vivo  and in v itro  transcriptional factors bound to distal 
regulatory sequences are also believed to interact with RNA 
| polymerase II and/or other proximal transcriptional factors 
; in order to facilitate the activation of transcription (Muller 
& Schaffner, 1990; Muller et al., 1989; Hai et al., 1988). It 
also appears that certain trans-acting activators can work 
synergistically in combination with other trans-acting activa­
tors to modulate gene expression (Herschlag & Johnson, 1993; 
Lin et al., 1990; Li et al., 1991).
Spl is a sequence-specific transcription factor that binds 
to G- and C-rich elements via three zinc fingers and activates 
transcription via glutamine-rich domains (Dynan & Tjian, 
1983; Gidoni et al., 1984; Kadonaga et al., 1986,1987,1988; 
Courey & Tjian, 1988; Pugh & Tjian, 1990). Transcriptional 
activation by Spl has been studied most extensively with the 
SV40 early promoter, although Spl-responsive promoters have 
been found in a wide variety of viral and cellular promoters 
(Dynan & Tjian, 1983; Gidoni et al., 1984, 1985; Janson & 
Pettersson, 1990; Dynan et al., 1985). The region upstream 
of the SV40 promoter contains six Spl binding sites (GC 
boxes) within the three 21 -bp1 repeats. Two additional tandem 
repeats of 72 bp are positioned toward the late promoter side 
of the S V40 control region. Complete deletion of three 21 -bp 
repeats, as well as both 72-bp repeats, severely limits early 
promoter function as well as virus viability (Banerji et al., 
1981; Everett et al., 1983). Although Spl is generally 
considered to be a protein that interacts with promoter- 
proximal elements, Spl also possesses the ability to mediate 
the long-range activation of transcription via protein-protein
t This research was supported by grants from the Public Health Service 
(CA-49751), The Upjohn Company, the Welch Foundation, and the 
Burroughs Wellcome Scholars Program.
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1 Abbreviations: bp, base pair(s); DDW, double-distilled water.
interactions between DNA-bound Spl molecules and other 
transcriptional factors (Courey et al., 1989).
Recently, it has been shown that site-specific triple-helical 
complexes reduce the level of basal transcription even in the 
absence of Spl (Maher et al., 1992). This suggests that the 
intrinsic DNA structure of the Spl binding region is an 
important factor in transcriptional regulation. Multiple 
binding sites appear to be one general feature of promoters 
that are Spl responsive, as exemplified in the SV40 early 
promoter region (Gidoni et al., 1984; Kadonaga et al., 1986). 
However, it is not clear why Spl binding sites are arranged 
in the manner that Spl binds once every 10-12 bp, which 
roughly corresponds to one complete turn of the DNA helix. 
This situation is similar to the TFIIIA DNA complex, where 
zinc fingers bind in successive major grooves of DNA in a 
periodic manner (Churchill et al., 1990). In this study, we 
have addressed the question of the significance of the 
periodicity of Spl binding alongside the significance of 
sequences located between Spl binding sites.
(+)-CC-1065 is a very potent antitumor antibiotic that was 
isolated from the culture broth of S trep to m yces zelensis  in 
the late 1970s (Hanka et al., 1978). The biological activity 
of (+)-CC-1065 stems from its ability to alkylate N3 of adenine 
on duplex DNA in a sequence-selective manner and modify 
the structure and local conformation of DNA (Hurley & 
Draves, 1993). Previous studies from this laboratory, in 
collaboration with scientists from The Upjohn Company, have 
shown that (+)-CC-1065 lies in the minor groove of duplex 
DNA covering a 4-5-bp region to the 5' side of modified 
adenine (Hurley et al., 1984; Reynolds et al., 1985; Scahill 
et al., 1990). As a consequence of formation of the (+)- 
CC-1065-(N3)-adenine adduct, (+)-CC-1065 induces bend­
ing, winding, and stiffening of the DNA (Lee et al., 1991; Sun 
& Hurley, 1992). Significantly, the bending produced by 
(+)-CC-1065 has characteristics similar to those of an A-tract 
(Lin et al., 1991; Sun et al., 1993a; Koo & Crothers, 1988). 
Armed with this insight, we have recently demonstrated the 
utility of (+)-CC-1065 in probing the bending sites produced 
by the A-protein of Mu transposase in the a tt  L3 sequence 
(Ding et al., 1993).
To enhance our understanding of the structural details of 
the complex between Spl and 21-bp repeats, we have used
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III IV VI
i  r l  r
5 ' GCTCATGGGGCGGAGAATGGGCGGAACTGGGCGGAQnAGGGGCGGGATGGGCGGA£ITAGGGGCGGGACCGAGCACGGCG3 • 
3 ' AGTACCCCGCCTCTTACCCGCCTTGACCCGCCTCAATCCCCGCCCTACCCGCCTCAATCCCCGCCCTGGCTCGTGCCGC5'
^  I- - - - - - - - - - - - - - - - - 1
1 2  M e r




R  fid  m p r 5 ' TGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGA3’
O  0 4  n i e r  3 , c c g c c t c t t a c c c g c c t t g a c c c g c c t c a a t c c c c g c c c t a c c c g c c t c a a t c c c c g c c c t a c c s '
P 4 9  m p r  5 ' AAAAAACGACTTAATGGGCGGAAAAAGGGGCGGGATTAACGC5’
^  3 ' TTTGCTGAATTACCCGCCTTTTTCCCCGCCCTAATTGCGTTT5'
F ig u re  1: (A ) Early promoter region of SV 40 D N A  containing the 21-bp repeat region. The 80-m er sequence containing the six GC boxes 
(I—VI) is shown as an inset. The two restriction enzym e sites used in construction of the substrates for footprinting and circularization  
experiments are shown in the lower region. In the inset, the two (+ )-C C -1 0 6 5  bonding sites (5'-A G T T A ) are underlined, and in the lower 
bracket is the 12-mer sequence (5'-G G C G G A G T T A G G ) used in the high-field N M R  study (Lin et al., 1992). (B) Sequence o f the 64-m er 
used in experiments to determine the intrinsic bending due to the intervening sequences between the GC boxes (underlined). A similar sequence 
in which the underlined sequences were replaced by 5'-CG CCG  was used as a control. (C ) Sequence of the 42-mer used to determine the 
direction of bending due to binding o f Sp l to the GC boxes.
h y d r o x y l- r a d ic a l  fo o tp r in t in g ,  c o m p e t i t io n  e x p e r im e n t s  b e ­
tw e e n  S p  1 a n d  ( + ) - C C - 1 0 6 5 , a n d  c ir c u la r iz a t io n  e x p e r im e n ts .  
O u r  r e s u lts  p r o v id e  e x c e l le n t  e v id e n c e  fo r  th e  g e n e r a l  c o n c lu ­
s io n  th a t ,  a t  s a tu r a t io n  b in d in g  o f  S p l  to  D N A ,  t h e  s ix  S p l  
m o le c u le s  e a c h  m a k e  s im ila r  c o n t a c t s  w ith  th e ir  s ix  G C  b o x e s  
b y  in te r a c t io n  th r o u g h  th e  m a jo r  g r o o v e  to  in d u c e  a n  o v e r a ll  
c u r v a tu r e  o f  th e  2 1 -b p  r e p e a ts  to w a r d  th e  m in o r  g r o o v e . In  
a d d it io n ,  w h e n  th e  2 1 -b p  r e p e a t  r e g io n  is s a t u r a t e d  w ith  s ix  
S p l  m o le c u le s ,  th e  tw o  ( + ) - C C - 1 0 6 5  b o n d in g  s i t e s  a r e  s t i l l  
a c c e s s ib le  a n d  r e a c t iv e  to w a r d  ( + ) - C C - 1 0 6 5 .  L a s t ,  w e  n o te  
th e  p r e v io u s ly  u n d o c u m e n te d  o b s e r v a t io n  t h a t  th e  “ tr a n s ie n t  
k in k ” a t  th e  5 ' - G T / A C  s te p  o f  th e  s e q u e n c e  5 ' - A G T T A  is a n  
im p o r ta n t  lo c u s  fo r  th e  in it ia l  b e n d in g  o f  D N A  u p o n  b in d in g  
o f  S p l  (L in  e t  a l . ,  1 9 9 2 ) .
EXPERIMENTAL PROCEDURES
Materials. ( + ) - C C - 1 0 6 5  w a s  a  g i f t  f r o m  T h e  U p jo h n  
C o m p a n y  ( K a la m a z o o ,  M I ) .  E le c t r o p h o r e t ic  r e a g e n t s  w e r e  
p u r c h a se d  fr o m  B io -R a d .  O th e r  c h e m ic a ls  fo r  c h e m ic a l  D N A  
s e q u e n c in g  a n d  h y d r o x y l- r a d ic a l  fo o tp r in t in g  w e r e  fr o m  
A ld r ic h  C h e m ic a l  C o m p a n y ;  [ t - 32P ] A T P  a n d  [ a - 32P ] d G T P  
w e r e  fr o m  I C N ;  a n d  X - r a y  f i lm ,  in t e n s i f y in g  s c r e e n s ,  a n d  
d e v e lo p in g  c h e m ic a ls  w e r e  fr o m  E a s tm a n  K o d a k . H u m a n  
S p l  p r o te in  a n d  D N a s e  I w e r e  fr o m  P r o m e g a .  T h e  T 4 -  
p o ly n u c le o t id e  k in a s e  a n d  D N A  p o ly m e r a s e  I ( K le n o w  
f r a g m e n t )  w e r e  fr o m  U n i t e d  S t a t e s  B io c h e m ic a l .  T 4  D N A  
l ig a s e  a n d  o th e r  r e s tr ic t io n  e n d o n u c le a s e s  w e r e  fr o m  N e w  
E n g la n d  B io la b s . W e  a r e  g r a te fu l  to  R o b e r t  T j ia n  fo r  s u p p lie s  
o f  S p l  u se d  in  th e  in it ia l  s t a g e s  o f  th is  in v e s t ig a t io n .
Oligonucleotide Synthesis. T h e  o l ig o n u c le o t id e s  w e r e  
s y n t h e s iz e d  o n  a n  a u t o m a t e d  D N A  s y n t h e s iz e r  ( A p p l ie d  
B io s y s t e m s  3 8 1  A )  b y  th e  p h o s p h o r a m id ite  m e th o d  ( G a i t ,
1 9 8 4 ) .  T h e  o l ig o m e r s  w e r e  th e n  d e p r o te c te d  b y  h e a t in g  a t
5 5  ° C  o v e r n ig h t  w ith  s a tu r a te d  a m m o n iu m  h y d r o x id e ,  d r ie d  
u n d e r  v a c u u m , a n d  r e d is s o lv e d  in  D D W .
Preparation and End-Labeling o f  DNA. T h e  8 0 -m e r  
o l ig o m e r  D N A  m o le c u le s  c o n ta in in g  th e  2 1 -b p  r e p e a ts  o f  th e  
S V 4 0  v ir a l e a r ly  p r o m o te r  r e g io n  ( F ig u r e  1A ) w e r e  c o n s tr u c te d  
b y  th e  l ig a t io n  o f  tw o  4 0 - m e r  d u p le x  D N A  m o le c u le s  a n d  
la b e le d  w ith  [ « - 32P ] d G T P  b y  s ta n d a r d  m e th o d s  a t  th e  3 ' e n d  
o f  th e  D N A .  T h is  o l ig o m e r  D N A  w a s  u se d  in  th e  c o n s tr u c t io n  
o f  th e  ( + ) - C C - 1 0 6 5  s it e -d ir e c te d  a d d u c t  a n d  in  th e  fo o tp r in t in g  
e x p e r im e n t s  w ith  th e  h y d r o x y l- r a d ic a l  a n d  D N a s e  I. F o r  
D N a s e  I a n d  h y d r o x y l- r a d ic a l  fo o tp r in t in g  o f  th e  c o d in g  s tr a n d ,  
th e  p la s m id  p C A T  ( P r o m e g a )  th a t  c o n t a in s  th e  S V 4 0  v ir a l  
e a r ly  p r o m o te r  r e g io n  w a s  d ig e s t e d  w ith  N c o l  a n d  d e p h o s -  
p h o r y la te d  w ith  c a l f  th y m u s  in te s t in a l  a lk a l in e  p h o s p h a ta s e  
( s e e  F ig u r e  1 A ) . D e p h o s p h o r y la te d  r e s tr ic t io n  fr a g m e n ts  w e r e  
la b e le d  w ith  [ t - 32P ] A T P  a n d  c le a v e d  a s e c o n d  t im e  w ith  B glll 
to  r e m o v e  th e  r a d io a c t iv e  la b e l  o n  th e  n o n c o d in g  s tr a n d .  
L a b e le d  D N A  m o le c u le s  ( 1 0 0  b p )  w e r e  s e p a r a te d  b y  e le c ­
t r o p h o r e s is  o n  a n  8%  n o n d e n a t u r in g  p o ly a c r y la m id e  g e l  a n d  
r e c o v e r e d  b y  c r u s h in g  th e  g e l  f r a g m e n t ,  e x t r a c t in g  th e  D N A  
w ith  D D W ,  a n d  ly o p h i l iz in g  th e  D N A  s o lu t io n .  L y o p h i l iz e d  
D N A  w a s  r e d is s o lv e d  in  D D W  a n d  fu r th e r  p u r if ie d  b y  p h e n o l /  
c h lo r o fo r m  e x t r a c t io n  a n d  e th a n o l  p r e c ip ita t io n .
Footprinting with DNase I. P u r if ie d  h u m a n  S p l  ( P r o m e g a )  
w a s  c o m b in e d  w ith  r a d io la b e le d  D N A  in 4 0  pL  o f  b in d in g  
b u ffe r  c o n s is t in g  o f  1 0  m M  T r is - H C l (p H  7 .6 ) ,  0 .0 1  % N o n id e t  
P - 4 0  ( N P - 4 0 ) ,  10  m M  M g C l2, a n d  5%  g ly c e r o l  a n d  in c u b a te d  
a t  3 0  ° C  fo r  10  m in . E n z y m a t ic  c le a v a g e  w a s  in it ia te d  b y  
a d d in g  0 .1  u n it  o f  D N a s e  I, a n d  in c u b a t io n  w a s  c a r r ie d  o u t  
fo r  2  m in . T h e  r e a c t io n  w a s  s to p p e d  b y  t h e  a d d it io n  o f  th e  
s a m e  v o lu m e  o f  a lk a l in e  s e q u e n c in g  d y e  (8 0 %  f o r m a m id e  a n d  
10  m M  N a O H ) .
H ydroxyl- Radical Footprinting. P u r if ie d  h u m a n  S p  1 w a s  
c o m b in e d  w ith  r a d io la b e le d  D N A  in  4 0  pL  o f  th e  s a m e  d r u g
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binding buffer, except for a different glycerol concentration 
(final 2.5%), and incubated at 30 °C for 10 min. Cleavage 
was initiated by adding 160 juL of a solution containing 10 
mM Tris-HCl (pH 7.6), 0.01 % NP-40,10 mM MgCl2, 20 nU  
Fe(II), 40 nM ethylenediaminetetraacetic acid, 0.3% H2O2 , 
and 1 mM sodium ascorbate and was stopped by the addition 
of 20 nL of 3 M sodium acetate, 10 jug of yeast tRNA, and 
3 vol of ethanol. The mixture was incubated in a -70 °C 
freezer for 2 h, and the DNA was precipitated by centrifugation 
at 4 °C. The dried DNA pellet was redissolved in DDW,
( extracted with phenol/chloroform, and precipitated with 
ethanol.
Circularization Experiment. Plasmid pCAT (Promega) 
was digested with Bglll and dephosporylated with calf thymus 
intestinal phosphatase (see Figure 1 A). Restriction fragments 
were digested with Ncol and ligated after the inactivation of 
restriction endonuclease. Ligated DNA was phosphorylated 
with [7 -32P]ATP and electrophoresed through a 6% poly­
acrylamide gel to isolate a 200-bp fragment containing 12 
Spl binding sites at the center of the fragment. This 200-bp 
restriction fragment was incubated at room temperature for 
10 min with different concentrations of human Spl protein 
in 20 /iL of a ligase buffer containing 10 mM Tris-HCl (pH 
7.8), 10 mM MgCl2, and 1 mM ATP. Ligation was initiated 
by the addition of 2000 units of T4 DNA ligase (New England 
Biolabs), and the mixture was incubated for 12 h. The ligated 
reaction products were applied to a 6% polyacrylamide gel to 
separate each species of DNA.
For the determination of the contribution of 5'-AGTTA 
and 5'-AGAAT to the circularization efficiency, a 64-mer 
(Figure IB) containing three 21-bp repeats was synthesized 
and phosphorylated with [7 -32P]ATP and polynucleotide 
kinase. As a “nonbent” control DNA, a new 64-mer DNA 
was synthesized, in which the sequences 5'-AGTTA and 5'- 
AGAAT were replaced with the sequence 5'-CGCCG. For 
the determination of the direction of Spl-induced DNA 
bending, a 42-mer oligomer DNA containing GC boxes III 
and IV (Figure 1C) with an As-tract in place of the 5'-AGTTA 
sequence was phosphorylated with [7 -32P]ATP and poly­
nucleotide kinase. Phosphorylated 42-mer oligomer DNA (2 
ng) was incubated for 10 min with a 4 molar excess of human 
Spl protein in 20 jkL of a ligase buffer, and the ligation reaction 
was initiated by the addition of 2000 units of T4 DNA ligase 
and incubated for 12 h. Ligated reaction products were applied 
to 6% polyacrylamide gel electrophoresis to separate each 
species of DNA molecules.
RESULTS
High-Resolution Hydroxyl-Radical Footprinting o f Spl 
on the 21-bp Repeats o f the SV40 Viral Early Promoter 
Region Suggests a Repetitive Pattern o f Spl Binding to This 
Region. We haive employed hydroxyl-radical footprinting to 
study in detail tlhe structure of the complex of six Spl proteins 
with the 21 -bp repeat region (Figure 1). The hydroxyl-radical 
footprinting method provides a valuable means to examine 
the interaction <of a DNA binding protein with the backbone 
of DNA, since hydroxyl radicals are small enough to cause 
strand breakage in DNA, even when complexed with DNA 
binding proteins or small DNA interactive ligands (Shafer et 
al., 1989; Burkhoff & Tullius, 1988). However, a direct 
interaction of the protein with DNA molecules through a 
minor groove site or severe changes in the DNA backbone 
conformation, such as bending in toward the minor groove, 
are also expected to cause significant reductions in the 
magnitude of hy/droxyl-radical cleavage (Churchill et al., 1990; 
Yang & Nash,, 1989).
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Hydroxyl-radical footprinting patterns of both the non­
coding [(-) strand] and coding [(+) strand] strands of the 
21-bp repeat region of the SV40 early promoter region after 
formation of the complex with Spl molecules are shown in 
Figure 2A,B, respectively. These hydroxyl-radical data are 
also presented in the form of three densitometric tracings of 
the (-) strand (Figure 2C) taken at the three different levels 
of saturation of Spl binding, corresponding to lanes 1-3 in 
Figure 2A. It is evident from both the densitqmetric tracings 
(Figure 2C) and the footprinting gels (Figure 2A,B) that, at 
the highest concentrations of Spl, there is an enhancement 
of hydroxyl-radical cleavage at the central part of each GC 
box region, while at this same concentration of Spl, the 
cleavage efficiency between each GC box is diminished (lane 
3 in Figure 2A,B and trace c in Figure 2C). This regular 
undulating pattern at the highest concentration of Spl is 
common to both the coding and noncoding strands, but there 
is about a 3-bp offset toward the 3' side of the coding strand 
(Figure 2D), which is consistent with minor groove cleavage 
by hydroxyl radical. This repeating enhancement/diminution 
pattern is evident within the region covering GC boxes II-VI, 
but is particularly obvious in regions IV-VI. The enhancement 
of hydroxyl-radical cleavage within the GC regions in which 
Spl makes contacts in the major groove suggests that some 
widening of the minor groove occurs on the opposite side. 
Conversely, the diminished hydroxyl-radical cleavage of 
regions between each GC box indicates that the Spl molecules 
might make direct contacts with those regions through the 
minor groove or that Spl binding in the major groove causes 
a structural change in the region between each GC box. We 
favor the latter explanation, since no adenine residues are 
protected from modification with dimethyl sulfate (Gidoni et 
al., 1984). This footprinting pattern is compatible with the 
current model for the Spl-DNA complex, in which three zinc 
fingers bind in the major groove of the GC box and partially 
wrap around the double helix (Pavletich & Pabo, 1991). This 
result also provides strong evidence that, at saturation binding 
of protein, each Spl molecule has a similar relationship to 
each GC box within the 21-bp repeats, since the footprinting 
patterns of each unit GC box complexed with Spl molecules 
are quite similar to each other. It is important to note that 
even in the absence of Spl (lane 1 in Figure 2A,B and trace 
a in Figure 2C), there is already a distinct trend toward this 
undulating pattern, particularly for GC boxes III-VI.
Saturation o f Spl Protein Binding to the 21-bp Repeat 
Region Does Not Inhibit (+)- CC-1065 Bonding to the 5'- 
AGTTA* Sequence. (+)-CC-1065 shows high reactivity for 
covalent bonding to the sequence 5'-AGTTA* (* indicates 
the covalent bonding site for (+)-CC-1065), which is located 
between GC boxes III and IV and V and VI of the 21-bp 
repeat region (Figure 2D) (Reynolds et al., 1985). The thermal 
strand breakage assay (Reynolds et al., 1985) can be used to 
detect both the sequence location and the extent of covalent 
reaction of (+)-CC-1065 in the 21-bp repeats. Using this 
assay, we have determined how preincubation of DNA with 
Spl affects (+)-CC-1065 bonding to the sequence 5'- 
AGTTA*. In Figure 3 A, the results of three sets of different 
but parallel incubations with the 21-bp repeat regions are 
shown. In lanes 1-4, the 21-bp region was treated with 
incrementally increasing concentrations of Spl and subjected 
to DNase I footprinting to determine the amount of Spl 
required to attain saturation binding (lanes 2-4). In lanes 
5-8, the same 21-bp region was incubated with increasing 
concentrations of (+)-CC-1065. At the highest concentration 
of (+)-CC-1065 (lane 8), strong reaction at the two 5'-AGTTA 
sequences is attained. Finally, in lanes 9-11, the same
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F i g u r e  2: Hydroxyl-radical footprinting of Spl on the 80-mer and the 100-bp Ncol-Bglll restriction fragment containing the 21-bp repeat 
region. Shown in A and B are the gel electrophoresis patterns of the hydroxyl-radical cleavage products on the noncoding and coding strands, 
respectively. AG and TC represent purine- and pyrimidine-specific cleavage reactions. Lanes 1-3 contain 0, 30, and 60 ng of Spl, respectively, 
with about 50 fmol of DNA. The GC boxes (I—VI) are shown to the right side of each gel. (C) Letters a, b, and c refer to the densitometric 
scans of lanes 1-3, respectively, from A. (D) Comparison of the hydroxyl-radical cleavage pattern of the upper (—) and lower (• • •) strands 
(Figure 1) in the presence of saturating concentrations of Spl molecules (i.e, from lane 3 in Figure 2A,B).
c o n c e n tr a t io n  o f  ( + ) - C C - 1 0 6 5  a s  th a t  u s e d  in  la n e  8 w a s  a d d e d  
to  s a m p le s  th a t  a ls o  c o n t a in e d  a m o u n ts  o f  S p l  e q u iv a le n t  to  
th o s e  u s e d  in  th e  s a m p le s  in  la n e s  2 - 4 .  In  p a r a l le l  t im e  c o u r s e  
e x p e r im e n t s ,  in c u b a t io n  o f  th e  2 1 -b p  r e p e a t  w ith  ( + ) - C C -  
1 0 6 5 ,  b o th  in  th e  a b s e n c e  a n d  p r e s e n c e  o f  s a t u r a t in g  a m o u n ts  
o f  S p l ,  w a s  c a r r ie d  o u t  ( F ig u r e  3 B ) .  T h e  r e s u lt s  o f  b o th  
e x p e r im e n t s  r e v e a l  th a t  p r e in c u b a t io n  o f  th e  5 ' - e n d - la b e le d  
r e s tr ic t io n  f r a g m e n t ,  w h ic h  c o n t a in s  t h e  2 1 -b p  r e p e a t s  w ith  
s a tu r a t in g  le v e ls  o f  S p l ,  does not s ig n if i c a n t ly  d e c r e a s e  th e  
e x te n t  o f  r e a c t io n  o f  ( + ) - C C - 1 0 6 5  a t  th e  s e q u e n c e  5 ' -A G T T A *  
( s e e  la n e s  9 - 1 1  in  F ig u r e  3 A ,B ) .  T h is  o b s e r v a t io n  is  
p a r t ic u la r ly  s ig n if i c a n t  b e c a u s e  h y d r o x y l- r a d ic a l  f o o tp r in t in g  
h a d  r e v e a le d  d im in is h e d  c le a v a g e  w ith in  th e  s e q u e n c e  5 '-  
A G T T A  in  th e  p r e s e n c e  o f  S p l  ( F ig u r e  2 D ) .
T a k e n  t o g e th e r ,  th e  r e s u lt s  o f  th e  h y d r o x y l- r a d ic a l  f o o t ­
p r in t in g  a n d  c o m p e t i t io n  e x p e r im e n t s  b e t w e e n  S p l  a n d  ( + ) -  
C C - 1 0 6 5  s t r o n g ly  s u g g e s t  t h a t  it  is  n o t  s t e r ic  o c c lu s io n  b y  S p  1 
th a t  c a u s e s  th e  d im in u t io n  o f  h y d r o x y l- r a d ic a l  c le a v a g e ,  s in c e  
th e  m in o r  g r o o v e  is  s t i l l  o p e n  to  m o d if ic a t io n  b y  ( + ) - C C -  
1 0 6 5  in  th e  p r e s e n c e  o f  S p l .  S in c e  ( + ) - C C - 1 0 6 5  d id  n o t  
s h o w  a n  in c r e a s e  in  r e a c t iv i t y  in  th e  p r e s e n c e  o f  s a t u r a t in g  
a m o u n ts  o f  S p l ,  c o n d it io n s  th a t  m ig h t  b e  a r g u e d  to  p r o v id e  
a n  e n h a n c e d  s i t e  o f  r e a c t iv i t y  o f  ( + ) - C C - 1 0 6 5 ,  w e  p r o p o s e  
th a t  e ith e r  th e  r a t e - l im it e d  s t e p  is  n o t  a s s o c ia t e d  w ith  m in o r  
g r o o v e  c o m p r e s s io n  o r , m o r e  l ik e ly ,  th e  a c t u a l  p r o te in - in d u c e d  
s h a p e  c o m p r e s s io n  is  n o t  o p t im a l  fo r  d r u g  r e a c t io n .  S in c e  it  
c o u ld  a ls o  b e  a r g u e d  th a t  ( + ) - C C - 1 0 6 5  w a s  s t i l l  a b le  to  r e a c t  
w ith  its  b o n d in g  s i t e s  o n  t h e  2 1 -b p  r e p e a t  d u e  t o  th e  r a p id  
e x c h a n g e  b e tw e e n  b o u n d  a n d  u n b o u n d  S p  1 s p e c ie s ,  t r a n s ie n t ly  
e x p o s in g  th e  ( + ) - C C - 1 0 6 5  b o n d in g  s it e s ,  a  c o n tr o l  e x p e r im e n t  
w a s  c a r r ie d  o u t  u s in g  p lu r a m y c in ,  a  s e c o n d  a lk y la t in g  a g e n t
t h a t  r e a c t s  in  th e  m a jo r  g r o o v e  w ith in  th e  G C  r e g io n  o c c u p ie d  
b y  S p  1. P lu r a m y c in  is  a n  a n t itu m o r  a n t ib io t ic  th a t  c o v a le n t ly  
m o d if ie s  N 7  o f  g u a n in e  in  D N A  v ia  an  in te r c a la t io n - th r e a d in g  
m e c h a n is m  ( S u n  e t  a l . ,  1 9 9 3 b ) .  A n  e x p e r im e n t  e s s e n t ia l ly  
s im ila r  to  th a t  d e s c r ib e d  a b o v e  w ith  p lu r a m y c in  in  p la c e  o f  
( + ) - C C - 1 0 6 5  w a s  c a r r ie d  o u t .  In  c o n tr a s t  to  th e  r e s u lt s  w ith  
( + ) - C C - 1 0 6 5  ( F ig u r e s  3 A ,B ) ,  S p l  is  a b le  to  a lm o s t  c o m p le t e ly  
p r o te c t  G C  b o x e s  I I —V I  fr o m  a lk y la t io n  b y  p lu r a m y c in  ( D .  
S u n  a n d  L . H .  H u r le y ,  u n p u b l is h e d  r e s u l t s ) .
Saturation Binding o f  S p l to the GC Boxes in the 21-bp  
Repeat Region ofSV 40 Preferentially Facilitates Formation 
o f  an Intramolecular Circularization Product o f  a 200-mer 
and Inhibits Formation o f  the Intermolecular Ligation 
Product. D ir e c t  m e a s u r e m e n t  o f  p r o te in - in d u c e d  D N A  
b e n d in g  c a n  b e  a c h ie v e d  b y  m o n it o r in g  th e  fo r m a t io n  o f  
c ir c u la r  D N A  p r o d u c e d  b y  th e  l ig a t io n  o f  l in e a r  D N A -  
c o n t a in in g  p r o te in  b in d in g  s it e s  u p o n  th e  a d d it io n  o f  p r o te in  
( K a h n  &  C r o th e r s ,  1 9 9 2 ;  L y u b s c h e n k o  e t  a l . ,  1 9 9 1 ) .  T h e r e ­
fo r e , to  in v e s t ig a te  S p  1 - in d u c e d  o r  -s ta b il iz e d  b e n d in g  o f  D N A ,  
a 2 0 0 - b p  D N A  f r a g m e n t  w a s  c o n s tr u c te d  to  c o n t a in  six  2 1 -  
b p  r e p e a t s  ( 1 2  G C  b o x e s )  o f  th e  S V 4 0  e a r ly  p r o m o te r  in  th e  
c e n tr a l  r e g io n  ( s e e  F ig u r e  1 A ) .  U p o n  l ig a t io n  o f  th is  fr a g m e n t  
in  t h e  p r e s e n c e  o f  subsaturating  c o n c e n t r a t io n s  o f  S p l  
m o le c u le s ,  l in e a r  m u lt im e r s  ( 4 0 0 - m e r ,  6 0 0 - m e r ,  a n d  8 0 0 - m e r )  
o f  th e  2 0 0 - b p  D N A  fr a g m e n t  w e r e  g e n e r a t e d  in  s ig n if ic a n t  
a m o u n ts ,  c o n s t i tu t in g  33%  a n d  34%  o f  th e  to ta l  l ig a t io n  p r o d u c t  
( la n e s  3 a n d  4 ,  r e s p e c t iv e ly ,  in  F ig u r e  4 A ) .  A t  s u b s a tu r a t in g  
le v e ls  o f  S p l ,  th e  o v e r a ll  c y c l iz a t io n  e f f ic ie n c y  is  r e d u c e d ,  
p r e s u m a b ly  d u e  to  p r o te in - in d u c e d  s t i f f e n in g  o f  D N A ,  a n d  
th e r e  is  a ls o  a  p r e fe r e n t ia l  in h ib it io n  o f  in tr a m o le c u la r  o v e r  
in t e r m o le c u la r  l ig a t io n  o f  2 0 0 - m e r s .  T h e  p r e fe r e n t ia l  in h ib i-
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Figure 3: Effect of prebinding of Sp 1 to the 21 -bp repeats on covalent modification of 5'-AGTTA* with (+)-CC-1065. (A, left) Gel electrophoretic 
analysis of the 5'-32P single-end-labeled 100-bp Nco\-BglU  restriction fragment after treatment with Spl (lanes 1-4), (+)-CC-1065 (lanes
5-8), or Spl and (+)-CC-1065 (lanes 9-11). Samples containing 0, 15, 30, and 60 ng of Spl (lanes 1-4, respectively), with about 20 fmol 
of DNA, were digested with DNase I. Lanes 5-8 contained 0, 0.6, 3, and 15 pmol of (+)-CC-1065 with about 20 fmol of DNA. In lanes 9-11, 
DNA (20 fmol) was incubated at 30 °C for 10 min with 15, 30, and 60 ng of Spl, respectively, and then reacted with 15 pmol of (+)-CC-1065 
for 10 min. For lanes 5-11, reactions were stopped by adding 80 / j l L  of solution containing 10 n g  of calf thymus DNA and heating the sample 
at 95 °C for 10 min to induce strand breakage at the drug modification sites. Thermally treated samples were phenol/chloroform extracted 
and ethanol precipitated. DNA pellets were dried and redissolved in sequencing dye (10 mM NaOH and 80%formamide) prior to electrophoresis. 
(B, right) Time course of the modification of the 5'-AGTTA* sequence between GC boxes III and IV with (+)-CC-1065 in the presence of 
60 ng of Spl (O) or in the absence of Spl ( • ) .  The amounts of strand breakage (%) at different times were determined by laser scanning 
of the autoradiogram.
t io n  o f  in tr a m o le c u la r  l ig a t io n  is  m o s t  l ik e ly  a t t r ib u t a b le  to  
th e  b in d in g  o f  S p l  m o le c u le s  to  G C  b o x e s  s e p a r a te d  b y  a n  
u n o c c u p ie d  S p l  s i t e  ( i .e . ,  b in d in g  a t  s i t e s  III  a n d  V  in  th e  
2 1 -b p  r e p e a t  r e g io n ) .  T h is  d im e r ic  p r o t e i n - D N A  c o m p le x  
w o u ld  n o t  le a d  to  th e  p r o t e in - p r o t e in  in t e r a c t io n s  n e c e s s a r y  
to  s t a b i l i z e  th e  b e n t  D N A  s tr u c tu r e ,  w h ic h  a r e  r e q u ir e d  fo r  
e f f ic ie n t  in tr a m o le c u la r  c y c l iz a t io n .  O n  th e  o th e r  h a n d ,  
in te r m o le c u la r  l ig a t io n  w o u ld  n o t  b e  a d v e r s e ly  a f f e c t e d  b y  
th is  p h e n o m e n o n . H o w e v e r ,  a t  saturating  le v e ls  o f  S p l  
m o le c u le s  ( la n e s  5 a n d  6  in  F ig u r e  4 A ) ,  th e  l in e a r  m u lt im e r ic  
fo r m  o f  th e  2 0 0 -b p  D N A  w a s  s ig n i f i c a n t ly  d im in is h e d  (9 .8 %  
a n d  2 .5 % , r e s p e c t iv e ly ,  o f  th e  t o t a l  l ig a t io n  p r o d u c t ) ,  a n d  
m u lt im e r  l in e a r  fo r m s  h ig h e r  th a n  4 0 0 - b p  D N A  w e r e  n o t  
d e te c ta b le  in  la n e  6 . In c o n tr a s t ,  th e  p r o d u c t  o f  m fr a m o le c u la r  
c y c l iz a t io n  in c r e a s e d  fr o m  67%  o f  to t a l  l ig a t io n  a t  s u b s a t u ­
r a t in g  le v e ls  to  9 7 .5 %  a t  s a tu r a t in g  l e v e ls  o f  S p l . In a c c o r d  
w ith  th e  r e s u lt s  o f  th e  h y d r o x y l- r a d ic a l  f o o tp r in t in g  e x p e r i ­
m e n ts  in  th e  a b s e n c e  o f  S p l ,  s ig n if ic a n t  a m o u n ts  o f  in t r a m o ­
le c u la r  c y c l iz a t io n  p r o d u c ts  w e r e  p r o d u c e d  in  th e  a b s e n c e  o f  
S p l  ( s e e  la n e  2 ,  F ig u r e  4 A ,B ) .  H is t o g r a m  r e p r e s e n ta t io n  o f  
th e  l ig a t io n  e x p e r im e n t  is  s h o w n  in  F ig u r e  4 B . T h e s e  r e s u lt s  
s u g g e s t  th a t  s a tu r a t io n  b in d in g  le v e ls  o f  S p  1 m o le c u le s  c o n v e r t  
th e  l in e a r  2 0 0 - b p  D N A  m o le c u le s  in to  th e  n o n l ig a te d  c ir c u la r  
2 0 0 - b p  s t r u c tu r e , w h ic h  is  th e n  a n  u n fa v o r a b le  s u b s t r a t e  fo r  
fu r th e r  l ig a t io n  to  fo r m  l in e a r  m u lt im e r s .  It is  s ig n i f i c a n t  
th a t  th e  c ir c u la r  fo r m  o f  D N A  w a s  fo r m e d  e v e n  in th e  a b s e n c e  
o f  S p l ,  im p ly in g  th a t  th e s e  l in e a r  D N A  m o le c u le s  h a v e  a  
s tr o n g  in tr in s ic  t e n d e n c y  to  fo r m  c ir c u la r  D N A  m o le c u le s  
( s e e  f o l lo w in g ) .
Intervening Sequences between the GC Boxes Are an 
Important Determinant o f  the Intrinsic Bending o f  the 21-bp  
Repeat Region o f S  V40. T h e  s ig n if i c a n t  a m o u n t  o f  m o n o m e r  
c ir c u la r  D N A  fo u n d  e v e n  in  th e  a b s e n c e  o f  S p l  ( s e e  F ig u r e  
4 A ,B )  s u g g e s t s  th a t  th e  21 -b p  r e p e a t  h a s  s o m e  p h a s e d  in tr in s ic
b e n d in g  p r o p e r ty . T h e  h y d r o x y l- r a d ic a l  fo o tp r in t in g  p a t te r n  
in  t h e  a b s e n c e  o f  S p l  o f  th is  s a m e  r e g io n  r e v e a ls  c o m p a c t io n  
o f  th e  m in o r  g r o o v e  a t  th e  5 ' - A G T T A  s e q u e n c e s  a n d  a ls o  a t  
s e q u e n c e s  s e p a r a te d  fr o m  t h e s e  p o s i t io n s  b y  o n e  h e l ic a l  tu r n  
( s e e  F ig u r e  2 C ,  s c a n  a ) .  T h e s e  o b s e r v a t io n s  s u g g e s t e d  th a t  
th e  in te r v e n in g  s e q u e n c e s  b e tw e e n  th e  G C  b o x e s  m ig h t  
c o n t r ib u t e  to  t h e  o v e r a ll  in tr in s ic  b e n d in g  o f  th e  21 -b p  r e p e a t  
r e g io n .  In o r d e r  to  t e s t  th is  p o s s ib i l i t y ,  a  6 4 - m e r  s e q u e n c e  in  
w h ic h  th e  in te r v e n in g  s e q u e n c e s ,  5 ' - A G T T A  a n d  5 ' - A G  A  A T ,  
w e r e  r e p la c e d  b y  5 ' - C G C C G  w a s  p r e p a r e d  a n d  c o m p a r e d  to  
th e  n a tu r a l  s e q u e n c e  fo r  in tr in s ic  b e n d in g  b y  a c ir c u la r iz a t io n  
e f f ic ie n c y  a s s a y .  T h e  r e s u lt s  in  F ig u r e  5 A  s h o w  a  c o m p a r is o n  
o f  th e  T 4 - c a t a ly z e d  l ig a t io n  la d d e r s  o f  th e  n a tu r a l  6 4 -m e r  
a n d  its  G C - s u b s t i t u t e d  o l ig o m e r .  In  th e  o l ig o m e r  ( 6 4 - m e r  in  
F ig u r e  I B ) ,  in  w h ic h  th e  5 '-A G T T A  a n d  5 ' - A G A A T  s e q u e n c e s  
h a v e  b e e n  s u b s t i t u t e d  b y  5 ' - C G C C G  s e q u e n c e s ,  th e  a m o u n t  
o f  c ir c u la r  D N A  ( C 3 ,  C 4 )  is  s ig n i f i c a n t ly  r e d u c e d  r e la t iv e  to  
th e  n a tu r a l  s e q u e n c e  D N A  (c o m p a r e  la n e s  1 a n d  2 in  F ig u r e  
5 A ) ,  a n d  th e  o p t im a l  c ir c u la r iz a t io n  s iz e  is  in c r e a s e d  fr o m  C 3  
to  a b o v e  C 5  ( F ig u r e  5 B ) .  L a s t ,  a c o m p a r is o n  o f  R l  v a lu e s 2 
fo r  t h e  n a tu r a l  v s  th e  G C - s u b s t i t u t e d  o l ig o m e r  ( F ig u r e  5 C )  
s h o w s  th a t  th e  n a tu r a l  D N A  h a s  a n  in tr in s ic  b e n d in g  th a t  is 
d e c r e a s e d  u p o n  s u b s t i t u t io n  o f  th e  in te r v e n in g  s e q u e n c e s  w ith  
a G C - r ic h  r e g io n . T a k e n  t o g e t h e r ,  t h e s e  r e s u lt s  s tr o n g ly  
s u g g e s t  th a t  t h e  5 ' - A G T T A  s e q u e n c e  a n d  its  h e l i c a l ly  p h a se d  
A T - r ic h  r e g io n s  a r e  r e s p o n s ib le  fo r  th e  in tr in s ic  b e n d in g  o f  
th e  2 1 -b p  r e p e a t  r e g io n  o f  S V 4 0  D N A .
Spl-InducedB endingof DNA Occurs in a Direction toward 
the Minor Groove o f  DNA. T h e  direction  o f  S p l - in d u c e d  
D N A  b e n d in g  w a s  d e t e r m in e d  u s in g  a 4 2 - m e r  o l ig o m e r  
( F ig u r e  1 C ) ,  w h ic h  c o n t a in s  o n e  o f  th e  2 1 -b p  r e p e a ts  o f  th e
2 /?L is defined as the ratio of apparent size to true size for each of the 
ligation products.
Spl Bending of DNA
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Figure 4: (A , left) Effect of Sp l on the circularization efficiency of 200-bp D N A  substrate. Lane headings (1 -6 )  indicate the molar ratio 
(0 -3 )  o f S p l molecules toG C  boxes o f  D N A  substrate. Reactions containing 50 fmol o f D N A  with 2000 units o f T4 D N A  ligase in the presence 
of the indicated amounts o f S p l were incubated at room temperature for 12 h. (B , right) Histogram representation o f the autoradiogram  
described in A.
S V 4 0  e a r ly  p r o m o te r  in  th e  c e n tr a l  r e g io n ,  e x c e p t  t h a t  th e  
5 ' - A G T T A  s e q u e n c e  is  r e p la c e d  w ith  a n  A s - t r a c t ,  w h ic h  is  
e x p e c te d  to  a m p li fy  th e  o v e r a ll  c ir c u la r iz a t io n  p r o c e s s .  U p o n  
l ig a t io n  o f  th is  o l ig o m e r ,  a n  A 6 - tr a c t  is  a l s o  g e n e r a t e d  e x a c t ly  
tw o  h e lic a l  tu r n s  a w a y  fr o m  th e  c e n te r  o f  th e  A s - t r a c t  s e q u e n c e .  
I f  S p l  m o le c u le s  in d u c e  D N A  b e n d in g  to w a r d  th e  m a jo r  
g r o o v e  o f  D N A ,  it  w o u ld  b e  e x p e c t e d  t h a t  out-of-phase  b e n t  
D N A  w o u ld  b e  p r o d u c e d  in  th e  p r e s e n c e  o f  S p l  m o le c u le s ,  
r e s u lt in g  in  a  s ig n if ic a n t  decrease in  t h e  a m o u n t  o f  c ir c u la r  
D N A .  A s  s h o w n  in  F ig u r e  6 , in  th e  p r e s e n c e  o f  S p l  th e  
fo r m a t io n  o f  f iv e  a n d  s ix  linear m u lt im e r s  ( L 5  a n d  L 6 )  w a s  
s ig n if ic a n t ly  d e c r e a s e d  r e la t iv e  to  a  c o n tr o l  e x p e r im e n t  c a r r ie d  
o u t  in  th e  a b s e n c e  o f  S p l , w h i le  th e  a m o u n t  o f  circular D N A  
o f  s ix  a n d  e ig h t  m u lt im e r s  ( C 6  a n d  C 8 )  w a s  increased.3 T h is  
r e s u lt  s t r o n g ly  s u g g e s t s  th a t  S p l  m o le c u le s  in d u c e  D N A  
b e n d in g  to w a r d  th e  m in o r  g r o o v e  u p o n  b in d in g  to  G C  b o x e s ,  
w h ic h  is  c o n s is t e n t  w ith  t h e  h y d r o x y l- r a d ic a l  fo o tp r in t in g  
r e s u lt s  s h o w n  in  F ig u r e  2  a n d  t h e  c o m p e t i t io n  d r u g  b o n d in g  
e x p e r im e n t s  c a r r ie d  o u t  in  th e  p r e s e n c e  o f  S p l  ( F ig u r e  3 ) .
D I S C U S S I O N
U s in g  a  c o m b in a t io n  o f  h y d r o x y l- r a d ic a l  fo o tp r in t in g ,  
c ir c u la r iz a t io n  e x p e r im e n t s ,  a n d  c o m p e t i t io n  e x p e r im e n t s  
b e tw e e n  S p l  a n d  ( + ) - C C - 1 0 6 5 ,  w e  h a v e  g a in e d  c o n s id e r a b le  
in s ig h t  in to  th e  s tr u c tu r a l  f e a t u r e s  o f  t h e  c o m p le x  b e tw e e n  
S p l  a n d  th e  2 1 -b p  r e p e a t  r e g io n  o f  t h e  S V 4 0  v ir a l  e a r ly  
p r o m o te r  r e g io n . T h e  m a in  p o in t  is  th e  b e n d in g  o f  th e  2 1 -b p  
r e p e a ts  b y  c o o p e r a t iv e  b in d in g  o f  s ix  S p l  m o le c u le s .  In  
a d d it io n ,  th e  h i th e r to  u n d o c u m e n te d  im p o r t a n c e  o f  t h e  5 '-
3 An anonymous referee pointed out that the odd-numbered circles are
weaker in intensity than the even-numbered circles and that a possible
explanation for this end alignment or writhe effect is that the 42-mers
produce in- and out-of-phase ligamers.
A G T T A  s e q u e n c e  lo c a te d  b e tw e e n  G C  b o x e s  I I I  a n d  IV  a n d  
V  a n d  V I  in  p r o v id in g  a lo c u s  fo r  b e n d in g , r e s u lt in g  in  th e  
c lu s te r in g  o f  S p l  m o le c u le s ,  is  im p lic a te d . L a s t ,  th e  r e la t io n ­
s h ip  b e tw e e n  th e  h ig h  r e a c t iv ity  o f  th is  s e q u e n c e  to  ( + ) - C C -  
1 0 6 5  a n d  its  im p o r ta n c e  in  S p l  b in d in g  to  t h e  2 1 -b p  r e p e a t  
r e g io n  is  r e v e a le d . T h is  w o r k  h a s  im p o r ta n t  im p l ic a t io n s  in  
u n d e r s ta n d in g  th e  m e c h a n is m s  fo r  tr a n s c r ip t io n a l  r e g u la t io n  
b y  S p  1 a n d  h o w  d r u g s  s u c h  a s  ( + ) - C C - 1 0 6 5 , w h ic h  c a n  m im ic  
a  b e n t  D N A  s tr u c tu r e  u p o n  r e a c t io n  w ith  D N A ,  m a y  se r v e  
a s  u s e fu l  p r o b e s  fo r  d e te r m in in g  p r o te in - in d u c e d  b e n d s  in  
D N A .
Importance o f  the Propensity o f  the 5'-A G TTA  Sequence 
To Form a Bent DNA Structure in the Molecular Mechanisms 
fo r  Recognition o f  the 21-bp Repeat Region by S p l and (+)- 
CC-1065. ( + ) - C C - 1 0 6 5  is  a  p o t e n t  a n t i t u m o r  a g e n t  th a t  
r e a c t s  c o v a le n t ly  w ith  D N A  in  a  s e q u e n c e - s p e c i f i c  m a n n e r  to  
fo r m  a n  N 3  a d e n in e  a d d u c t  w ith in  t h e  m in o r  g r o o v e  o f  D N A  
( H u r le y  &  D r a v e s ,  1 9 9 3 ;  H u r le y  e t a l . ,  1 9 8 4 ;  R e y n o ld s  e t a l . ,
1 9 8 5 ) .  A s  a c o n s e q u e n c e  o f  c o v a le n t  r e a c t io n  w ith  D N A ,  th e  
m in o r  g r o o v e  is  n a r r o w e d  a n d  th e  D N A  a s s u m e s  a b e n t  
s t r u c tu r e ,  w h ic h  h a s  s t r u c tu r a l  f e a tu r e s  (d ir e c t io n  a n d  
m a g n it u d e )  th a t  a r e  s im ila r  to  th o s e  a s s o c ia t e d  w ith  th e  
in tr in s ic  b e n d in g  o f  A - t r a c t s  ( L in  e t  a l . ,  1 9 9 1 ;  S u n  e t  a l . ,  
1 9 9 3 a ) .  W e  h a v e  r e c e n t ly  p r o p o s e d  a “ tr u n c a te d  j u n c t io n  
b e n d ” m o d e l  fo r  th is  b e n t  D N A  s tr u c tu r e ,  w h ic h  is  a n a lo g o u s  
to  C r o th e r s ’s j u n c t io n  b e n d  m o d e l  fo r  A - t r a c t s  ( K o o  &  
C r o th e r s ,  1 9 8 8 ) ,  e x c e p t  th a t  th e  b e n d  is m o r e  s h a r p ly  fo c u s e d  
(S u n  e t  a l . ,  1 9 9 3 a ) .  O u r  m o d e l  w a s  b a s e d  u p o n  th e  c o m b in e d  
r e s u lt s  o f  h ig h - f ie ld  N M R  s t u d ie s ,  h y d r o x y l- r a d ic a l  f o o t ­
p r in t in g , a n d  g e l  e le c tr o p h o r e s i s  o f  a  ( + ) - C C - 1 0 6 5 - m o d i f i e d  
1 2 -m e r  c o n t a in in g  th e  h ig h ly  r e a c t iv e  5 ' - A G T T A *  s e q u e n c e  
a n d  f la n k in g  b a s e s  fr o m  th e  2 1 -b p  r e p e a t  r e g io n  ( s e e  F ig u r e
1 ). P a r t ic u la r ly  in tr ig u in g  to  u s  w a s  th e  v e r y  h ig h  r e a c t iv ity  
o f  th is  s e q u e n c e  to  ( + ) - C C - 1 0 6 5  a n d  its  ju x t a p o s i t io n  in  th e
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Figure 5: (A ) Autoradiogram of the first-dimensional gel electrophoresis o f the ligation reactions o f the 64-m er oligom er containing the 21-bp 
repeat region (Figure IB) and the equivalent 64-m er oligom er containing a 5'-CG CCG  sequence in place o f the 5'-A G T T A  and 5'-A G A A T  
sequences (lanes 2 and 1, respectively). The upper family o f bands (C 3 -C 6 ) is circular 3 -6-m ers o f the 64-bp precursor. The lower family 
o f bands (L 1 -L 6 ) is linear 1-6-m ers. Both types o f species o f  D N A  were further separated in the second dimension by electrophoresis in a 
6% polyacrylamide gel containing 50 n g /m L  chloroquine phosphate (D . Sun and L. H. Hurley, unpublished results). Each band was then 
extracted from the gel and loaded onto a 4%  denaturing polyacrylamide gel to determine the size o f  the D N A , using the methods described 
previously (Ulanovsky et al., 1986; Husain et al., 1988). (B ) Graphical representation of the circularization efficiency for each given size of 
D N A . Each band was isolated, and the radioactivity was measured using scintillation counting to determine the ratio o f the amount o f circular 
species o f D N A  to the total amount of D N A  at each given D N A  size (from lane 1 ( • )  and lane 2 (O ) in part A ). (C ) Plot o f the /?L values 
of the native 64-m er vs the total length of ligated multimers o f the 64-mer containing the 21-bp repeat region calculated from the comparative 
gel migration distances determined for the two samples shown in panel A.
21 -b p  r e p e a t  r e g io n  w ith  th e  tw o  highest a f f in i t y  S p l  b in d in g  
s i t e s  ( I I I  a n d  V  in  F ig u r e  1 A ) .
A  s tr u c tu r a l  s tu d y  ( L in  e t  a l . ,  1 9 9 2 )  u s in g  h ig h - f ie ld  N M R ,  
m o le c u la r  m o d e l in g ,  a n d  h y d r o x y l- r a d ic a l  fo o tp r in t in g  o n  th e  
12 -m e r  duplex  c o n ta in in g  th is  5 ' -A G T T A *  s e q u e n c e  p r o v id e d  
s o m e  im p o r ta n t  o b s e r v a t io n s .  F ir s t ,  a l t h o u g h  th is  1 2 -m e r  
d u p le x  d o e s  n o t  s h o w  in tr in s ic  b e n d in g ,  th e  m in o r  g r o o v e  is  
n a r r o w e d  a n d  h ig h ly  p r o p e lle r  tw is t e d  w ith in  th e  5 ' - T T / A A  
r e g io n . T h e r e  is  r a p id  lo c a l  in te r n a l  m o t io n  a t  o n e  o f  th e  
a d e n in e s  a c r o s s  fr o m  th e  c o v a le n t  m o d if ic a t io n  s it e  (u n d e r lin e d  
in  5 ' - T A A C * T )  a n d  d is to r t io n ,  b o th  a t  th e  c y t o s in e  (C * )  a n d  
o n  th e  b a c k b o n e  o n  e ith e r  s id e  o f  th is  s it e .  T h is  r e s u lt s  in  a  
“tr a n s ie n t  k in k ” a t  th e  5 ' - G T / A C  s te p . U p o n  a d d u c t  
fo r m a t io n  w ith  ( + ) - C C - 1 0 6 5 ,  t h e s e  f e a tu r e s ,  e x c e p t  fo r  th e  
in te r n a l  m o t io n ,  a r e  e n tr a p p e d  a n d  in  s o m e  c a s e s  e x a g g e r a t e d ,  
a n d  in  a d d i t io n ,  a d i s c o n t in u i t y  a t  th e  5 ' - T A * / A T  s te p  
( c o v a le n t  m o d if ic a t io n  s i t e  A * )  is  in d u c e d . T h e  ju n c t io n s  in  
th e  m o d e l  a r e  p o s i t io n e d  o n  e ith e r  s id e  o f  th e  5 ' - T T / A A  
s e q u e n c e ,  a n d  th e  lo c u s  o f  b e n d in g  is  lo c a te d  b e tw e e n  th e  tw o  
th y m in e s .  A  s u m m a r y  o f  th e s e  s tr u c tu r a l  f e a t u r e s  in  th e  12 -  
m e r  d u p le x  a n d  th e  ( + ) - C C - 1 0 6 5  12 -m e r  d u p le x  a d d u c t  is  
s h o w n  in  F ig u r e  7 .
In  th e  p r e s e n t  s tu d y ,  w e  h a v e  u s e d  h y d r o x y l- r a d ic a l  
f o o tp r in t in g  t o  p r o b e  th e  s t r u c tu r a l  c h a n g e s  in  D N A  u p o n
S p l  b in d in g  to  th is  r e g io n , g e l  e le c t r o p h o r e s is  to  e x a m in e  
S p  1 - in d u c e d  b e n d in g  o f  D N  A ,  a n d  ( + ) - C C - 1 0 6 5  to  p r o b e  fo r  
o v e r a ll  g r o o v e  s t r u c tu r e  a n d  r e a c t iv i t y  a f t e r  S p l  b in d in g  to  
th e  2 1 -b p  r e p e a ts .  T h e  d im in is h e d  c le a v a g e  o f  th e  r e g io n  
b e tw e e n  e a c h  G C  b o x  ( s e e  F ig u r e  2 )  r e v e a ls  a n  im p o r ta n t  
s tr u c tu r a l  a s p e c t  o f  th e  S p  1 21 -b p  r e p e a t  c o m p le x .  G e n e r a lly ,  
d im in is h e d  h y d r o x y l- r a d ic a l  c le a v a g e  o f  th e  D N A  b a c k b o n e  
c a n  b e  a t t r ib u te d  t o  e ith e r  c lo s e  c o n t a c t s  b e tw e e n  th e  su g a r  
p h o s p h a te  b a c k b o n e  a n d  D N A  b in d in g  l ig a n d  ( e .g . ,  s m a ll  
m o le c u le s  o r  D N A  b in d in g  p r o te in s )  o r  a  s t r u c tu r a l  c h a n g e  
in  m in o r  g r o o v e  g e o m e tr y  ( B u r k h o f f  &  T u ll iu s ,  1 9 8 8 ;  C h u r c h ill  
e t  a l . ,  1 9 9 0 ) .  D N A  b e n d in g ,  w h ic h  r e s u l t s  in  d im in is h e d  
h y d r o x y l- r a d ic a l  c le a v a g e  a s  a  c o n s e q u e n c e  o f  c o m p r e s s io n  o f  
th e  m in o r  g r o o v e  ( S h a f e r  e t  a l . ,  1 9 8 9 ;  B u r k h o f f  &  T u ll iu s ,  
1 9 8 8 ;  C h u r c h i l l  e t  a l . ,  1 9 9 0 ) ,  is  th e  m o s t  w e l l - c h a r a c t e r iz e d  
s t r u c tu r a l  c h a n g e  in  m in o r  g r o o v e  g e o m e t r y .  S u s p ic io n  th a t  
th e  c o r r e c t  e x p la n a t io n  in v o lv e s  bending o f  D N A  r a th e r  th a n  
s t e r ic  o c c lu s io n  fo r  th e  d im in is h e d  h y d r o x y l- r a d ic a l  c le a v a g e  
s t e m s  fr o m  th e  o b s e r v a t io n  t h a t  b o th  5 ' - A G T T A  s e q u e n c e s  
lo c a t e d  b e tw e e n  G C  b o x e s  I I I  a n d  I V  a n d  V  a n d  V I  s h o w  
r e la t iv e ly  d im in is h e d  c le a v a g e  c o m p a r e d  to  t h e  o th e r  r e g io n s  
( s e e  p a n e l  a  in  F ig u r e  2 C ) ,  e v e n  in  th e  absence o i S p l . P e r h a p s  
m o r e  p e r s u a s iv e  is  t h e  c o m p a r is o n  o f  th e  in tr in s ic  b e n d in g  o f  
th e  6 4 - m e r  c o n t a in in g  th e  5 ' - A G T T A  v s  th e  s t r a ig h t  c o n tr o l
S p l  B e n d in g  o f  D N A
C Sp1
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Figure 6: Autoradiogram of the first-dimensional gel electrophoresis 
of the ligation reaction of oligomer 42A without Spl (C) and with 
Spl (Spl). The bands of the upper family (C6-C9) are circular
6-9-mers of the 42-bp precursor. The bands of the lower family 
(L2-L6) are noncircular 2-6-mers. The size of the DNA was 
determined as described in the legend for Figure 5A.
D N A  in  w h ic h  th is  s e q u e n c e  h a s  b e e n  r e p la c e d  b y  a  G C  
s e q u e n c e  th a t  e l im in a te s  th is  in tr in s ic a l ly  b e n t  D N A  s tr u c tu r e .  
T h e s e  d a t a  d e m o n s t r a t e  th a t  th is  s e q u e n c e  h a s  a t e n d e n c y  to  
fo r m  a b e n t  D N A  s tr u c tu r e .
F u r th e r m o r e , w e  p r o p o se  th a t  th e  b in d in g  o f  S p l  m o le c u le s  
to  th e  21  -b p  r e p e a t  ta k e s  a d v a n ta g e  o f  t h e  p r e e x is t in g  t e n d e n c y  
o f  th is  5 ' - A G T T A  s e q u e n c e  in  o r d e r  to  fo r m  a b e n t  D N A  
s tr u c tu r e  to  c r e a te  a  b o u n d a r y  b e tw e e n  c o n s e c u t iv e  S p  1 b in d in g  
s it e s .  O u r  r e s u lt s  s h o w  th a t  u p o n  S p l  b in d in g  to  th e  2 1 -b p  
r e p e a t  r e g io n ,  th e  m in o r  g r o o v e  o f  th e  5 ' - A G T T A  s e q u e n c e  
is fu r th e r  n a r r o w e d  ( c o m p a r e  a a n d  c  in  F ig u r e  2 C )  a n d ,  
s ig n if ic a n t ly ,  ( + ) - C C - 1 0 6 5  is  s t i l l  a b le  to  r e a c t  a t  th is  s e q u e n c e  
in  a n  a p p a r e n t ly  n o r m a l w a y  ( F ig u r e  3 ) .  T h a t  S p l  b in d in g  
to  G C  b o x e s  III  a n d  IV  o r  V  a n d  V I  d o e s  n o t  c r e a t e  more 
r e a c t iv e  s i t e s  fo r  ( + ) - C C - 1 0 6 5  b y  f r e e z in g  th e  5 ' - A G T T A *  
s e q u e n c e s  in to  a  b e n t  D N A  s tr u c tu r e  c a n  b e  r a t io n a l iz e d  i f  
it is  a s s u m e d  th a t  th e  S p l  - in d u c e d  b e n t  D N A  s tr u c tu r e  is  n o t  
o p t im a l  fo r  d r u g  r e a c t io n  w ith  D N A  o r  th a t  th is  is  n o t  th e  
r a t e - l im it e d  s te p  fo r  th e  r e a c t io n .  W e  p r o p o s e  t h a t ,  j u s t  l ik e  
( + ) - C C - 1 0 6 5 ,  S p l  is  a b le  to  ta k e  a d v a n t a g e  o f  th e  tr a n s ie n t  
k in k  a t  t h e  5 ' - G T / A C  s te p  a n d  t h e  a s s o c ia t e d  p r o p e n s ity  to  
fo r m  a  b e n t  D N A  s tr u c tu r e , a n d  th is  is  w h y  S p l  h a s  th e  
h ig h e s t  a f f in i t y  fo r  th e  G C  b o x e s  a t  th e  I I I  a n d  V  s it e s .  
F u r th e r m o r e , u p o n  s a tu r a t io n  b in d in g  o f  th e  2 1 -b p  r e p e a ts  
w ith  S p l ,  w e  p r o p o s e  th a t  th e  S p l  m o le c u le s  b o u n d  a t  G C  
b o x e s  I I I  a n d  IV  a n d  V  a n d  V I  s t a b i l i z e  a  b e n t  D N A  s tr u c tu r e ,  
w ith  th e  lo c u s  o f  b e n d in g  a r o u n d  th e  c e n te r  o f  th e  5 ' - A G T T A  
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Figure 7: Summary of unusual structural features of the 12-mer 
duplex (Lin et al., 1992) and the (+)-CC-1065-modified 12-mer 
duplex adduct (Sun et al., 1993a).
1 0 6 5  a t  th is  s e q u e n c e ,  e v e n  in  th e  p r e s e n c e  o f  s a tu r a t io n  le v e ls  
o f  S p  1, p r o v id e s  c o m p e l l in g  e v id e n c e  fo r  S p  1 - in d u c e d  b e n d in g  
r a th e r  th a n  s t e r ic  o c c lu s io n  b e in g  r e s p o n s ib le  fo r  th e  in h ib it io n  
o f  h y d r o x y l- r a d ic a l  c le a v a g e .
T h e  e v id e n c e  fo r  S p  1 - in d u c e d  b e n d in g  o f  th e  21 -b p  r e p e a ts  
is  s t r o n g ly  s u p p o r te d  b y  th e  r e su lts  o f  th e  c ir c u la r iz a t io n  
e x p e r im e n t s  ( F ig u r e s  4 - 6 ) .  In  th e  f ir s t  e x p e r im e n t ,  a  2 0 0 -b p  
D N A  fr a g m e n t  w a s  c o n s tr u c te d  to  c o n ta in  in v e r te d  r e p e a ts  
o f  th e  tw o  s e t s  o f  s ix  S p l  b in d in g  s it e s  o f  th e  S V 4 0  v ir a l  e a r ly  
p r o m o te r  r e g io n . E v e n  in  th e  a b s e n c e  o f  S p l  b in d in g , th is  
2 0 0 - b p  D N A  p r o d u c e d  s ig n if ic a n t  a m o u n ts  o f  th e  c ir c u la r  
fo r m  o f  th e  2 0 0 - b p  D N A ,  a s  w e ll  a s  l in e a r  m u lt im e r s ,  im p ly in g  
th a t  th e  tr a n s ie n t  k in k  in  th e  5 ' - A G T T A  s e q u e n c e  m ig h t  a ls o  
h a v e  a n  im p o r ta n t  r o le  in  th e  c ir c u la r iz a t io n  o f  2 0 0 - b p  D N A .  
M o r e o v e r , in  t h e  p r e s e n c e  o f  a  s u b s a tu r a t in g  le v e l  o f  S p  1, th e  
c ir c u la r  fo r m  o f  th e  2 0 0 - b p  fr a g m e n t  w a s  d e c r e a s e d  a n d  l in e a r  
m u lt im e r s  w e r e  in c r e a s e d .  W e  a t t r ib u te  th is  p r e fe r e n c e  fo r  
in te r m o le c u la r  o v e r  in tr a m o le c u la r  l ig a t io n  to  th e  la c k  o f  
p r o t e in - p r o t e in  in t e r a c t io n s  in  p r o t e in - D N A  c o m p le x e s  in  
w h ic h  S p l  b in d in g  o c c u r s  a t  s it e s  ( I I I  a n d  V )  th a t  a r e  s e p a r a te d  
b y  o n e  G C  b o x  n o t  o c c u p ie d  b y  S p l . T h e s e  d im e r ic  p r o t e in -  
D N A  c o m p le x e s  w o u ld  n o t  b e  e x p e c te d  to  s t a b i l iz e  th e  b e n t  
D N A  s tr u c tu r e ,  w h ic h  w o u ld  fa v o r  in tr a m o le c u la r  l ig a t io n ,  
a n d  th u s  in t e r m o le c u la r  l ig a t io n  b e c o m e s  m o r e  p r e v a le n t .  
H o w e v e r ,  u p o n  s a tu r a t io n  o f  th e  2 0 0 -b p  D N A  w ith  S p l ,  th e  
fo r m a t io n  o f  l in e a r  m u lt im e r s  fr o m  th e  2 0 0 - b p  D N A  w a s  
severly inhibited , w h i le  th e  fo r m a t io n  o f  2 0 0 -b p  c ir c u la r  D N A  
w a s  increased. T h e s e  r e s u lt s  s u g g e s t  th a t  th e  2 0 0 - b p  D N A  
c o m p le x e d  w ith  12  S p l  m o le c u le s  a t t a in s  a  n e a r ly  c ir c u la r  
fo r m . T h e  d e c r e a s e  in  fo r m a t io n  o f  l in e a r  m u lt im e r s  fr o m  
m o n o m e r  2 0 0 - b p  D N A  a ls o  s u g g e s t s  th a t  S p l  m o le c u le s ,  
th r o u g h  p r o t e in - p r o t e in  in te r a c t io n s ,  c a n  s t a b i l iz e  D N A  
m o le c u le s  to  fo r m  a r ig id  c ir c u la r  fo r m  a n d  m a k e  th is  D N A
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Figure 8: Proposed scheme for the formation of a looping structure 
(1) facilitated by interaction of Spl with the 21-bp repeats. While 
the linear structure predominates in the absence of saturating amounts 
of Sp 1, small amounts of the looping structure (2) can be spontaneously 
produced in the absence of Spl, but this conversion is blocked by 
triple-helical complexes (Maher et al., 1992).
a n  u n fa v o r a b le  s u b s t r a t e  fo r  fu r th e r  m u lt im e r iz a t io n .  In  th e  
s e c o n d  e x p e r im e n t ,  a  4 2 - b p  o l ig o m e r  w a s  u s e d  to  p r o v id e  
f u r th e r  e v id e n c e  fo r  th e  S p l - i n d u c e d  D N A  b e n d in g  a n d  to  
d e t e r m in e  th e  direction  o f  b e n d in g  b y  S p l , w h ic h  w a s  s h o w n  
to  b e  in  to w a r d  th e  m in o r  g r o o v e . In  th e  S V 4 0  v ir u s , th e  e a r ly  
p r o m o te r  r e g io n  c o n t a in s  s ix  S p l  b in d in g  s it e s  in  th r e e  2 1 -b p  
r e p e a t s  b e tw e e n  th e  T A T A  b o x  a n d  th e  7 2 - b p  e n h a n c e r s .  
T a k in g  a l l  o f  t h e s e  r e s u l t s  t o g e t h e r ,  w e  p r o p o s e  th a t  th e  s ix  
c lu s t e r e d  S p l  m o le c u le s  b in d in g  w ith in  th is  r e g io n  in te r a c t  
t o g e t h e r  to  fo r m  a m u l t i p r o t e i n - D N A  c o m p le x  h a v in g  th e  
lo o p in g  s t r u c tu r e  s h o w n  in  F ig u r e  8 . P r e s u m a b ly ,  th e  lo o p in g  
s t r u c tu r e  is  s t a b i l i z e d  to  p r o t e in - p r o t e in  in t e r a c t io n s  a s  w e ll  
a s  p r o t e i n - D N A  in t e r a c t io n s .
Transcriptional Implications o f  the Proposed M odel fo r  
the Complex between S p l and the 21-bp Repeat Region. 
E le c tr o n  m ic r o s c o p y  s tu d ie s  h a v e  s h o w n  th a t  S p  1 -b o u n d  d is ta l  
e le m e n t s  in  th e  e u k a r y o t ic  p r o m o te r  c a n  in te r a c t  d ir e c t ly  w ith  
th o s e  b o u n d  to  th e  p r o x im a l  e le m e n t  ( M a s t r a n g e lo  e t  a l . ,  1 9 9 1 ;  
S u e t a l . ,  1 9 9 1 ) .  U p o n  th e  b a s is  o f  th e  r e s u lt s  o f  th e  h y d r o x y l-  
r a d ic a l  c le a v a g e  a n d  c ir c u la r iz a t io n  e x p e r im e n t s  d e s c r ib e d  
h e r e , t o g e t h e r  w ith  t h e  a b i l i t y  o f  ( + ) - C C - 1 0 6 5  to  s t i l l  r e a c t  
w ith  D N A  in  th e  p r e s e n c e  o f  s a t u r a t in g  a m o u n ts  o f  S p l ,  w e  
p r o p o s e  th a t  th e  m u lt ip le  b in d in g  o f  S p l  to  t h e  2 1 -b p  r e p e a ts  
p r o d u c e s  a n  o v e r a ll  b e n d in g  o f  a b o u t  1 5 0 - 1 8 0 °  w ith in  th e  
2 1 -b p  r e p e a t  r e g io n  ( s ix  S p l  m o le c u le s ,  e a c h  c o n t r ib u t in g  
a b o u t  3 0 ° ;  s e e  1 in  F ig u r e  8 ) .  S in c e  th e  S p l  b in d in g  r e g io n  
t h a t  c o n s is t s  o f  th r e e  2 1 -b p  r e p e a t s  s p a n n in g  6 4  b p  is  l o c a t e d  
u p s tr e a m  a d j a c e n t  t o  t h e  T A T A  b o x  fo r  e a r ly  tr a n s c r ip t io n  
o f  S  V 4 0  a n d  d o w n s t r e a m  o f  th e  7 2 -b p  e n h a n c e r  r e g io n s  (D y n a n  
&  T j ia n ,  1 9 8 3 ; G id o n i  e t  a l . ,  1 9 8 4 ;  J a n s o n  &  P e t te r s s o n , 1 9 9 0 ) ,  
w e  p r o p o s e  t h a t  th e  s t a b i l i z a t io n  o f  a  1 8 0 °  b e n d  in  th e  2 1 -b p  
r e p e a t s  p r o d u c e d  b y  th e  c o o p e r a t iv e  b in d in g  o f  s ix  S p l  
m o le c u le s  to  t h e  s ix  G C  b o x e s  m ig h t  f a c i l i t a t e  th e  in te r a c t io n  
b e t w e e n  th e  t r a n s c r ip t io n a l  fa c t o r s  c o m p le x e d  w ith  t h e  7 2 - b p  
e n h a n c e r  r e g io n  a n d  b a s a l  tr a n s c r ip t io n a l  fa c to r s  ( e .g . ,  T F I I D ,  
R N A  p o ly m e r a s e )  to  e n h a n c e  th e  t r a n s c r ip t io n a l  r a te  a t  th e  
e a r ly  p r o m o te r  r e g io n . T h e  lo o p in g  m o d e l  p r o p o s e d  h e r e  a l s o  
e x p la in s  th e  a p p a r e n t  p a r a d o x , id e n t i f ie d  b y  G id o n i  a n d  c o ­
w o r k e r s  ( 1 9 8 4 ) ,  th a t  t h e  21 -b p  r e p e a t ,  w h ic h  is  a n  asymmetric 
s e q u e n c e ,  c a n  p r o d u c e  a sym m etrical e f f e c t ,  s in c e  u p o n  
in v e r s io n  o f  th e  r e p e a t s  th e  p r o m o te r  r e m a in s  c o m p e t e n t .  T h e  
S p l - i n d u c e d  c u r v a tu r e  o f  th e  2 1 -b p  r e p e a t  r e g io n  w o u ld ,  o f  
c o u r s e ,  b e  in s e n s i t iv e  to  in v e r s io n .
O u r  p r e s e n t  c o n c lu s io n ,  b a s e d  o n  th e  r e s u lt s  o f  h y d r o x y l-  
r a d ic a l  c le a v a g e  a n d  t h e  c ir c u la r iz a t io n  e x p e r im e n t s ,  t h a t  th e  
2 1 -b p  r e p e a t  r e g io n  h a s  a n  in h e r e n t  p r o p e n s ity  to  fo r m  a  
lo o p in g  D N A  s t r u c tu r e  ( s e e  2  in  F ig u r e  8 )  in  t h e  a b s e n c e  o f  
S p l ,  p r o v id e s  a n  e x p la n a t io n  fo r  th e  o b s e r v e d  d e g r e e  o f  b a s a l  
r e p r e s s io n  p r o d u c e d  b y  t r ip le - h e l ix  c o m p le x a t io n  ( M a h e r  e t  
a l . ,  1 9 9 2 ) ,  e v e n  in  th e  absence o f  S p l .  T h e  p r o p o s a l  th a t  
t r ip le - h e l ix - in d u c e d  r e p r e s s io n  in v o lv e s  c h a n g e s  in  D N A  
f l e x ib i l i t y  is  in  a c c o r d  w ith  th e  id e a s  p r e s e n te d  h e r e ,  n a m e ly ,  
th a t  D N A  f l e x ib i l i t y  a n d  b e n d in g  a r e  im p o r t a n t  c o m p o n e n t s  
o f  th e  t r a n s c r ip t io n a l  r e g u la t io n  in  th e  e a r ly  p r o m o te r  r e g io n  
o f  S V 4 0  D N A .  L a s t ,  th e  m o d e l  p r o p o s e d  h e r e  h a s  p r o b a b le  
im p l ic a t io n s  fo r  o th e r  m u lt i - z in c - f in g e r  b in d in g  p r o te in s ,  su c h  
a s  T F I I I A  ( C h u r c h il l  e t  a l . ,  1 9 9 0 ) ,  in  th e ir  p r o t e i n - D N A  
c o m p le x e s .
Structural and Biological Implications o f  the Modification 
o f  the 21-bp Repeat Region by (+ )-C C -1065. D N A  
m o le c u le s  h a v e  lo n g  b e e n  c o n s id e r e d  to  b e  th e  m o le c u la r  ta r g e t  
fo r  th e  s e le c t iv e  a c t io n  o f  a  n u m b e r  o f  a n t iv ir a l  a n d  a n t itu m o r  
c o m p o u n d s  ( S h e a  &  M il l ig a n ,  1 9 9 2 ) .  A s  a  r e f in e m e n t  o f  th is  
p o s tu la t e ,  w e  h a v e  p r o p o se d  th a t  i t  is  m o r e  a c c u r a t e  t o  c o n s id e r  
th e  r e a l  d r u g  r e c e p to r  a s  th e  D N A  c o m p le x e d  w it h  D N A  
b in d in g  p r o te in s  r a th e r  th a n  th e  n a k e d  D N A  s in c e ,  in vivo, 
m o s t  D N A  m o le c u le s  a r e  c o a t e d  w ith  D N A  b in d in g  p r o te in s ,  
s u c h  a s  tr a n s c r ip t io n a l  fa c to r s  a n d  h is to n e  m o le c u le s  ( H u r le y ,  
1 9 8 9 ) .  In m o s t  c a s e s ,  it  is  to  b e  e x p e c t e d  t h a t  t h e  fo r m a t io n  
o f  d r u g - D N  A  c o m p le x e s  w ill  b e  s ig n i f i c a n t ly  in h ib i t e d  b y  th e  
a d d it io n  o f  in c r e a s in g  a m o u n ts  o f  p r o te in s  p r io r  to  t h e  a d d it io n  
o f  d r u g  m o le c u le s  (B r o g g in i  e t  a l . ,  1 9 8 9 ;  R e e v e s  &  N i s s e n ,  
1 9 9 0 ;  D o r n  e t  a l . ,  1 9 9 2 ) .  H o w e v e r ,  in  th e  c a s e  o f  ( + ) - C C -  
1 0 6 5  a n d  r e la te d  a n a lo g o u s  c o m p o u n d s ,  p r e b in d in g  o f  2 1 -b p  
r e p e a t s  w ith  S p l  m o le c u le s  did  not in h ib it  th e  b in d in g  o f  
( + ) - C C - 1 0 6 5  t o  th e  s e q u e n c e  5 ' - A G T T A *  ( s e e  F ig u r e  3 ) ,  
w h i le  in  c o n tr o l  e x p e r im e n t s  S p l  c o m p le t e ly  in h ib i t e d  th e  
b in d in g  o f  p lu r a m y c in  to  t h e  s e q u e n c e  5 ' - A G * T T A G *  (*  
in d ic a t e s  th e  p lu r a m y c in  b in d in g  s i t e s ) .  T h e  p r e v io u s  a r g u ­
m e n t s  p u t  fo r th  in  th is  p a p e r  r a t io n a l iz e  th e  h ig h  r e a c t iv ity  
o f  ( + ) - C C - 1 0 6 5  w ith  th e  2 1 -b p  r e p e a t s ,  e v e n  in  th e  p r e s e n c e  
o f  S p l .
In  a p a r a lle l  s tu d y  ( S u n  &  H u r le y ,  1 9 9 4 ) ,  w e  h a v e  
d e t e r m in e d  th e  e f f e c t  o f  ( + ) - C C - 1 0 6 5  o n  t h e  b in d in g  o f  S p l  
t o  th e  2 1 -b p  r e p e a t s  o f  S V 4 0  D N A .  A s  a  c o n s e q u e n c e  o f  
a lk y la t io n  o f  th e  tw o  5 ' - A G T T A *  s e q u e n c e s ,  w h ic h  r e s id e  
b e t w e e n  G C  b o x e s  I I I  a n d  IV  a n d  b o x e s  V  a n d  V I ,  p r o te in  
b in d in g  to  th e  3' s i t e s  is  c o m p le t e ly  a b o l i s h e d ,  a n d  th e r e  is a  
s ig n i f i c a n t  d e c r e a s e  in  S p l  b in d in g  to  t h e  o t h e r  r e g io n s .  T h e  
e f f e c t  o f  s u b s t i t u t in g  A 5-tr a c t s  fo r  t h e  ( + ) - C C - 1 0 6 5  b o n d in g  
s e q u e n c e  w a s  in t e r m e d ia t e  b e tw e e n  th e  u n m o d if ie d  5 '-  
A G T T A *  a n d  th e  d r u g - m o d if ie d  s e q u e n c e s .  I t  is  p r o p o s e d  
t h a t  a  s t r u c tu r a l  d is to r t io n  o f  D N A  a s s o c ia t e d  w i t h  s t i f f e n in g  
o f  th e  h e l ix  in d u c e d  b y  th e  d r u g  a d d u c t  fo r m a t io n  is  p r im a r i ly  
r e s p o n s ib le  fo r  t h e  in h ib it io n  o f  b in d in g  o f  S p l  m o le c u le s  to  
2 1 -b p  r e p e a ts ,  r a th e r  th a n  s t e r ic  h in d r a n c e  d u e  to  th e  
o c c u p a n c y  b y  d r u g  m o le c u le s  o f  th e  m in o r  g r o o v e  w it h in  th a t  
r e g io n .
A C K N O W L E D G M E N T
W e  th a n k  P r o f .  T h o m a s  K o d a d e k  fo r  c r i t ic a l  r e a d in g  o f  
t h is  m a n u s c r ip t  a n d  u s e fu l  d i s c u s s io n s ,  P r o f .  D o n a ld  C r o th e r s  
fo r  c r i t ic a l  a p p r a is a l  o f  th e  b e n d in g  e x p e r im e n t s ,  P r o f .  P e te r  
D e r v a n  fo r  r e m in d in g  u s  o f  th e  t r ip le - h e l ix  e x p e r im e n t s ,  a n d  
M r . D a v id  B is h o p  fo r  p r e p a r in g , p r o o fr e a d in g ,  a n d  e d it in g  
t h e  m a n u s c r ip t .  L a s t ,  w e  a p p r e c ia t e  th e  c r i t ic a l  a n d  c o n ­
s t r u c t iv e  c o m m e n t s  o f  th e  r e v ie w e r s .
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T B P  b i n d i n g  t o  t h e  T A T A  b o x  i n d u c e s  a  s p e c i f i c  d o w n s t r e a m  
u n w i n d i n g  s i t e  t h a t  i s  t a r g e t e d  b y  p l u r a m y c i n
Daekyu Sun* and Laurence H Hurley*
Drug Dynamics Institute, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712-1074, USA
B ackground: The TATA-binding protein (TBP) is one of 
the major components of the human TFIID multiprotein 
complex. It is important in directing the initiation of 
RNA transcription at a site immediately downstream of 
the TATA sequence (TATA box) found in many eukar­
yotic promoters. The crystal structure of TBP complexed 
with an oligonucleotide containing the TATA box 
revealed a protein with an approximate two-fold sym­
metry which apparendy has symmetrical interactions with 
DNA. It is not known how an asymmetric effect involv­
ing downstream activation can be produced by an appar­
ent symmetric complex. We set out to examine the state 
of DNA in the TBP—DNA complex using pluramycin, a 
small molecular weight probe of DNA accessibility. 
R esults: Binding of TBP to the TATA box facilitates 
intercalation of pluramycin at a defined site immediately
downstream of the TATA sequence through an apparent 
transient unwinding of the DNA. Pluramycin adducts are 
detected by the production of DNA strand breakage prod­
ucts upon heating. Incubation of pluramycin with the 
TBP—DNA complex facilitates the trapping of the specific 
complex by intercalation. Gel mobility shift and circular­
ization assays reveal that the binding of pluramycin on the 
3'-side of the TATA box region considerably stabilizes the 
TBP—DNA complex.
C onclusions: We propose that the TBP—DNA—pluramycin 
ternary complex is a ‘specific’ binding mode in which TBP 
and pluramycin make compensatory alterations in DNA, 
accounting for the improved stability of the ternary 
complex. We also propose a model of the ternary complex 
that explains the observed asymmetric effect of TBP 
binding to the TATA box.
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In tro d u c tio n
T A T A - b in d in g  p r o t e in  (T B P ) is  a m a jo r  c o m p o n e n t  o f  
t h e  tr a n s c r ip t io n  fa c to r  I I D  (T F I I D )  f o u n d  in  a ll m a m ­
m a lia n  c e l ls  [ 1 ,2 ] .  T h e  a s s o c ia t io n  o f  T F I I D  w i t h  th e  
T A T A  b o x  is th e  first s te p  in  th e  fo r m a t io n  o f  a tr a n sc r ip ­
t i o n  c o m p l e x  th a t  c a n  in it ia te  th e  s y n th e s is  o f  m R N A  
[3 —7 ] .  R e c e n t  s tu d ie s  s u g g e s t  th a t  r e c r u i tm e n t  o f  T B P  t o  
t h e  p r o m o t e r  c a n  b e  a r a te - l im it in g  s te p  fo r  t r a n s c r ip t io n  
in vivo a n d  th a t  in te r a c t io n  o f  T B P  w i t h  t h e  a c t iv a t io n  
d o m a in s  o f  o t h e r  tr a n s c r ip t io n  fa c to r s  m a y  s ta b iliz e  th e  
b in d in g  o f  T B P  to  t h e  p r o m o te r  [8 ,9 ] , T B P  is h ig h ly  c o n ­
s e r v e d  i n  e u k a r y o t ic  o r g a n ism s  a n d  is o n e  o f  th e  m o s t  
in t e n s iv e ly  s tu d ie d  p r o te in s  in v o lv e d  in  tr a n s c r ip t io n . T h e  
sh a p e  o f  th e  c a r b o x y - t e r m in a l  p o r t io n  o f T B P  r e se m b le s  a 
s a d d le  c o n s is t in g  o f  t w o  r o u g h ly  s y m m e tr ic  h a lv e s  [1 0 ] .  
T h e  in n e r  s u r fa c e  o f  t h e  sa d d le  in te r a c ts  w i t h  th e  m in o r  
g r o o v e  o f  th e  T A T A  s e q u e n c e ,  c a u s in g  s tr ik in g  d is to r t io n s  
in  D N A  [1 1 —1 3 ] .  T h e  m in o r  g r o o v e  o f  t h e  T A T A  b o x  is  
w i d e n e d  a n d  f la t t e n e d  a n d  in te r a c ts  w i t h  t h e  w h o l e  
c o n c a v e  u n d e r s id e  o f  th e  m o le c u la r  sa d d le  th r o u g h  a 
v a r ie ty  o f  h y d r o p h i l ic  a n d  h y d r o p h o b ic  c o n ta c t s  [ 2 ,1 0 ] ,  
A s  a c o n s e q u e n c e  o f  th is  u n p r e c e d e n te d  m o d e  o f  in te r a c ­
t i o n  b e t w e e n  a D N A - b i n d i n g  p r o te in  a n d  D N A ,  th e  
e n t ir e  T A T A  b o x  is  s e v e r e ly  b e n t  t h r o u g h  a n  a n g le  o f  
a b o u t  8 0 °  to w a r d  t h e  m a jo r  g r o o v e ,  w i t h  a n  a s s o c ia te d  
u n w i n d in g  o f  t h e  T A T A  b o x  o f  a b o u t  1 0 0 °  [1 1 —1 3 ].
D e s p i t e  th e  d e t a i le d  s tr u c tu r a l a n a ly sis  o f T B P  a n d  th e  
T B P - T A T A  b o x  c o m p le x ,  sev er a l im p o r ta n t  fe a tu r e s
r e m a in  t o  b e  e x a m in e d .  A m o n g  t h e s e  are t h e  q u e s t io n  o f  
h o w  T B P  b in d in g  a ffe c ts  t h e  s tr u c tu r e  o f  th e  r e g io n s  th a t  
f la n k  t h e  T A T A  b o x  a n d  t h e  s tr u c tu r a l o r ig in  o f  th e  
a s y m m e tr y  th a t  f o l lo w s  in i t ia t io n  o f  t r a n s c r ip t io n  at th e  
3 ' - s id e  o f  th e  T A T A  b o x ,  as a r e su lt  o f  b in d in g  o f  a n  
a lm o s t  s y m m e t r ic  p r o te in .  W e  w is h e d  to  e x p lo r e  th e  p o s ­
s ib i l i ty  th a t  t h e  a s y m m e tr ic  e f f e c t  o f T B P  b in d in g  t o  th e  
T A T A  s e q u e n c e  m i g h t  b e  d u e  t o  a tr a n s ie n t  u n w i n d in g  
o c c u r r i n g  p r e fe r e n t ia lly  t o  t h e  d o w n s t r e a m  s id e  o f  th e  
T A T A  b o x .  W e  th e r e fo r e  d e s ig n e d  e x p e r im e n t s  w i t h  
p lu r a m y c in ,  w h i c h  s h o u ld  p r e fe r e n t ia lly  in te r c a la te  i n  
u n w o u n d  D N A  s ite s . T h u s ,  d y n a m ic  e f fe c ts  p r o p a g a te d  
p r e fe r e n t ia lly  t o  o n e  s id e  o r  th e  o th e r  o f  th e  T A T A  b o x  as 
a c o n s e q u e n c e  o f  th e  T B P - i n d u c e d  u n w i n d in g  o f  th e  
T A T A  s ite  c a n  b e  m o n it o r e d .  P lu r a m y c in  (F ig . l a )  is  a 
m e m b e r  o f  t h e  fa m ily  o f  a n t h r a q u in o n e - d e r iv e d  a n t i­
t u m o r  a n t ib io t ic s ,  w h i c h  are  b r o a d ly  c h a r a c te r iz e d  as 
D N A - t h r e a d i n g  in te r c a la t io n  a g e n ts  (F ig . l b )  [14—1 8 ] . In  
a d d i t io n  t o  th e ir  in te r c a la t io n  p r o p e r t ie s ,  th e s e  d r u g s  a lso  
f o r m  c o v a le n t  a d d u c ts  w i t h  N 7  o f  g u a n in e ,  w h i c h  u p o n  
h e a t  tr e a tm e n t  g iv e  r ise  to  D N A  stra n d  b r e a k a g e  p r o d u c ts  
[1 5 ] ,  th u s  r e v e a lin g  th e ir  s ite  o f  in te r c a la t io n  (F ig . l c ) .
R esults
Specific and  nonspecific binding of hTBP to DNA containing 
a  TATA box
A  D N a s e  I p r o t e c t io n  assay w a s  c a r r ie d  o u t  in it ia l ly  t o  
m o n it o r  t h e  k in e t ic s  o f  fo r m a t io n  o f  th e  h u m a n  T B P  
( h T B P ) - T A T A  b o x  c o m p l e x  u s in g  a 6 4 -b a s e -p a ir  (b p ),
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©  C u r r e n t  Biology Ltd ISSN 1 0 7 4 - 5 5 2 1 4 5 7
C h e m i s t r y  &  B i o l o g y  1 9 9 5 ,  V o l  2  N o  7
double-stranded oligonucleotide (64M) (see Fig. 2) con­
taining the muscle-specific p rom oter o f  the hum an m yo­
globin gene [19,20]. As illustrated in Figure 3a (lanes 2 and
10), the TATA box (5-TATAAAAA) was com pletely pro­
tected  from D N ase I digestion in the absence o f  com peti­
to r D N A , and a region exterior to the TATA box was also 
weakly protected by hT B P (see brackets to the right o f  
lane 10 in Figure 3a, denoting specific and nonspecific 
hT B P  binding).To quantitate the affinity o f  hT B P for the 
flanking region o f  the TATA box (nonspecific binding) 
and for the TATA box region (specific binding), unlabeled 
tem plate D N A  (40 m olar excess) was added to each reac­
tion, and the dissociation o f  the hTB P—D N A  com plex was 
analyzed by D N ase I footprin ting  after various intervals. 
T h e  autoradiogram  in Figure 3a was scanned by an LBK 
laser scanner, and the fraction o f  the specific and nonspeci­
fic h T B P -D N A  com plexes was calculated to determ ine 
the dissociation rates o f  the h T B P -D N A  complexes in 
solution. By plotting  the natural log o f  the fraction o f
Fig. 1 . Pluramycin as a p robe  of DNA 
accessibility, (a) Structure of plura­
mycin. (b) Solution conformation  of 
the p luram ycin-(N 7-guanine) DNA 
adduct showing the intercalated 
moiety side chain at C2 (white), which 
undergoes reaction with N7 of guanine 
(cyan), and  the sugars at C8 and CIO 
(yellow), which interact within the 
minor groove of DNA [18]. (c)
M echanisms for the covalent reaction 
of pluramycin with DNA and the heat- 
induced strand breakage of the plura- 
mycin-(N7-guanine) DNA adduct [15]. 
The multiplicity of bands  in Figs 3, 4, 
and 6 for each alkylation site are due 
to incom plete  chem ical degradation, 
which gives rise to both species A and
B. Species A can be  converted to 
species B with piperidine treatment.
probe D N A  bound versus time, the first-order dissociation 
rate constants were calculated (Fig. 3b). As expected, the 
nonspecific com plex betw een hT B P and the flanking 
regions o f  the TATA box was m uch less stable, w ith  a half- 
life o f  10 m in, w hile the specific com plex betw een  hTB P 
and the TATA box region was m uch m ore stable, w ith  a 
half-life o f  120 m in. The dissociation rate constants for the 
specific and nonspecific h T B P -D N A  complexes in solu­
tion were calculated to be 8.9 x 10-5  s-1 and 2 .6 x 10-3 
s-1 , respectively. T h e  ~30-fold difference in dissociation 
rates for the tw o types o f  hT B P binding sites provides evi­
dence for bo th  a class o f  weak, nonspecific b ind ing  sites 
betw een hT B P and the TATA binding region and a class 
o f  stronger, specific binding sites that have also been found 
w ith  yeast T B P  (yTBP) [21]. A similar pattern  o f  protec­
tion was also observed w ith yT B P (unpublished results), 
bu t in this case, a region ex terior to the TATA box was 
m ore weakly protected  by yT B P com pared to  hTBP. 
Furtherm ore, the nonspecific com plex betw een yT B P and
Sjvcics 11
Pluram ycin
(N 7 -(u ia n in e )
adduct
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Fig. 2. Sequences of oligonucleotides 
used in these studies. 64M is the 
sequence of the muscle-specific pro­
moter of the human myoglobin gene. In 
oligonucleotide 64MI, the highlighted 
nucleotides flanking the TATA box are 









the flanking regions o f the TATA box was much less stable 
than the nonspecific complex formed by hTBP, in agree­
m ent with the observations made by Hawley and col­
leagues [21]. We speculate that the amino terminus o f 
hTBP may be im portant in modulation o f  nonspecific 
complex formation, since the carboxyl terminus is highly 
conserved between yTBP and hTBP [10-13], while the 
amino-terminal region varies considerably in length and in 
primary structure in different species [22 ],To eliminate the 
nonspecific binding complex between hTBP and D N A  
in subsequent experiments, an excess o f unlabeled com ­
petitor D NA was added to the preformed hT B P -D N A  
complex, and the reactions were incubated for 10 min 
before further experimentation.
Effect of specific binding of hTBP to the myoglobin TATA box 
on pluramycin modification of 64M
Pluramycin was used as a probe to identify possible 
unwinding sites generated by hTBP binding to the TATA
box. T he effect o f  hTBP binding to the TATA box on 
both the DNase I cleavage and pluramycin modification 
patterns is shown in Figure 4. In the absence o f  hTB P 
binding to the TATA box, pluramycin produces highly 
reactive bonding sites on both sides o f  the TATA box (see 
lanes 4 and 5 in Fig. 4a and arrows, w hich correspond to 
alkylated guanines). However, in the presence o f  hTBP, 
the pluramycin alkylation site immediately downstream o f 
the TATA box shows enhanced cleavage, while alkylation 
o f  sites adjacent to the 5'-side o f the TATA box is severely 
inhibited (compare lanes 4 and 6 and lanes 5 and 7 in Fig. 
4a).T he pluramycin modification pattern in the absence 
and presence o f hTB P on the o ther strand is shown in 
Figure 4b (lanes 4 and 5, respectively). In contrast to the 
top strand, significantly enhanced pluramycin alkylation 
sites are not evident, and alkylation o f  the guanine im m e­
diately adjacent to the downstream site o f  the TATA box 
is not significantly inhibited. The unique reactivity o f  this 
downstream site is clearly related to the binding ofT B P to
5 5 5 7 10 20  30  4 0  50  5 0  (m in )
(a) -  +  +  +  +  + +  +  +  +  t b p
- -  +  +  +  +  +  +  +  -  C o m p e t i t o r
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Fig. 3. Formation of specific and nonspecific complexes of hTBP with 64M. (a) DNase I footprinting. hTBP-DNA complexes were 
formed as described in Materials and methods and incubated for various periods of time (shown in the figure heading) in the absence 
(lanes 2 and 10) or presence (lanes 3-9) of unlabeled competitor DNA. For the footprinting analysis, 20 |xl of the sample was removed, 
added to DNase I, and incubated an additional one min at 37 °C. The DNase I reactions were quenched with alkaline dye and 
processed for analysis on a sequencing gel. Brackets on the right-hand side of the gel show regions of specific and nonspecific hTBP 
binding, (b) Dissociation rates of the specific (-A-) and nonspecific (—□ —) complexes in solution. The natural log (In) of the fraction of 
the DNA bound to hTBP is plotted against time (min). The first-order dissociation rate constants, calculated as the negative of the 
slopes, were determined to be 8.9 x 10-5 s_1 and 2.6 x 10-3 s-1 for the specific and nonspecific complexes, respectively.
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Fig. 4. Effect of specific HTBP binding 
to the TATA box on the pattern of plura­
mycin modification of 64M on the (+) 
and (-) strands. The specific hTBP-DNA 
complex was formed as described in 
Materials and methods and modified 
with pluramycin for 5 min. Drug m odi­
fication was terminated by adding 
100 |jlI of double-distil led water (DDW) 
containing 1 0 (jug of calf thymus DNA 
followed by heating the reactions at 
95 °C for 15 min to induce DNA strand 
breakage at the drug modification sites 
[15]. Lanes 1 and 2 of (a) [(+) strand] 
and (b) [(-) strand] are DNase I foot­
printing without and with hTBP, respec-:' 
tively. For (a), lanes 4 and 6 contained 
100 nM of pluramycin (final concentra­
tion) and lanes 5 and 7 conta ined  400 
nM of pluramycin. Drug modification 
was carried out for a period of 5 min. 
For (b), lanes 4 and 5 contained 
400 nM of pluramycin.
the TATA box, as is the dam pened reactivity o f  the other 
sites on both  sides o f  the TATA box. To determ ine if 
sequence context could change the pattern  o f  enhanced 
and dim inished reactivity, a second sequence (64MI), in 
w hich  the flanking sequences to the TATA box were 
different, was also tested for this asym m etric p a t te r n  o f 
pluramycin m odification in the presence o f  hTBP.
Effect of multiple  p luramycin  in terca la tion  sites on both 
sides o f  the  TATA box
A lthough the natural m yoglobin muscle prom oter TATA 
sequence was useful in that it provided a result sugges­
tive o f  a dow nstream  side-specific effect o fT B P  binding 
on  pluram ycin in tercalation, it suffered from three 
po ten tia l drawbacks. First, a previous study on the 
sequence selectivity o f  pluram ycin [16] has revealed that 
p luram ycin prefers the 5 '-C G *  sequence to the 5'-AG*, 
5 -T G * , and 5 '-G G *  sequences (* indicates the plura­
m ycin m odification  site). T herefore, we could not 
exclude the possibility that the absence o f  5 '-C G *  
sequences on  the upstream  side o f  the TATA box m ight 
affect the overall efficiency o f  p luram ycin m odification 
in that region. Second, the enhanced pluram ycin reactiv­
ity site m ight be a function  o f  a special sequence context 
in proxim ity  to the b ind ing  o f  hT B P  to  the TATA box. 
T h ird , this natural sequence did n o t reveal w hether the 
effect was also specific for a site at a p redeterm ined  dis­
tance from  the TATA box, in addition  to  being selective 
for the  dow nstream  side. T herefore, a new  D N A  tem ­
plate was designed in w hich  repetitive 5 '-C G *  sequences 
w ere included on  bo th  strands o f  the  upstream  and 
dow nstream  sides o f  the TATA box in order to map pre­
cisely the h T B P -in d u ced  intercalative high-reactivity  
sites for pluram ycin (see 64M I in Fig. 5d). Figure 5a,b 
shows an experim en t sim ilar to that show n in Figure 4
using the new  D N A  tem plate. P luram ycin show ed 
enhanced in terca la tion /alky la tion  reactivity w ith  only a 
single site (c* in Fig. 5c), w hich is located on the down-1 
stream  side o f  the TATA box. O th e r  sites (d, e, f, i, j  a n d 1 
k) on the dow nstream  side showed dim inished reactivity 
or, in one case (h), similar reactivity. Significantly, site ‘h ’ 
is located on the o th e r side o f  the pluram ycin intercala­
tion  site, w h ich  shows enhanced reactivity on  the o ther 
strand (site c, Fig. 5c). Sites on  the upstream  side (a, b, 
and g) all show ed reduced  reactivity (see Fig. 5c). 
T herefore, the results using the  natural m yoglobin 
m uscle enhancer sequence (Fig. 4) and those using the 
artificial sequence contain ing  m ultip le C G * sites for 
pluram ycin m odification  are entirely  consistent and 
reveal that b ind ing  o f  h T B P  to the TATA box results in 
enhancem ent o f  pluram ycin in tercalation /reactiv ity  that 
is specific for the dow nstream  side o f  the TATA box and 
for a site im m ediately  to  the 3 -s id e  o f  the TATA box 
(both results are sum m arized in Fig. 5d). In addition, a 
com m on site on  the opposite strand, w hich  is located on  
the o ther side o f  the pluram ycin intercalation site in 
bo th  64M  and 64M I, shows negligible changes in alkyla­
tion  reactivity. T herefore, these results suggest that it is 
unlikely that these com m on  sites o f  enhanced or similar 
pluram ycin reactivity in 64M  and 64M I are due to 
e ither a structural consequence o f  a specific sequence 
con tex t o r the in h eren t sequence selectivity o f  p lura­
m ycin, bu t they are in accord w ith  a com m on u n w in d ­
ing site at this 5 '-C G  sequence, resulting from  T B P 
binding to the adjacent sequence.
Effect of p luram ycin  modification  on convers ion  of 
nonspecific to  specific hTBP-TATA-box complexes
Since hTB P binding to the TATA box creates a high reac­
tivity intercalation site for pluramycin, it was im portant to
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determ ine how pluramycin would affect conversion o f 
nonspecific to specific hT B P -D N A  complexes. A gel 
mobility shilt assay was used to m onitor the conversion o f 
nonspecific to specific hTBP complexes at 37 °C by adding 
a 40-m olar excess o f unlabeled com petitor D N A  and 
drawing aliquots at various times, which were then im m e­
diately loaded onto a native gel at 4 °C. Three parallel incu­
bations were carried out w ithout drug (control) or with 
pluramycin or (+)-C C -1065 (a minor-groove adenine N 3
alkylating agent) added at the same time as com petitor 
D N A . The results in Figure 6a (graphically represented in 
Fig. 6b), show that in the presence o f  pluramycin the 
am ount o f  conversion o f the nonspecific to the specific 
complex was significantly increased compared to a control 
experim ent w ithout pluramycin (compare left and middle 
panels).This is in sharp contrast to an experiment in which 
the conversion to the specific com plex was almost com ­
pletely inhibited in the presence o f (+)-C C -1065 [23],
(a ) -  -  -  +  +  P l u r a m y c i n
-  +  -  -  +  TBP
A  +  +  -  -  -  D N a s e  I
(b) -  -  -  +  +  P l u r a m y c i n  ( c )
-  +  -  -  +  TBP
A  +  +  -  -  -  D N a s e  I
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GCGCGCGGGACCAG-3 
CGCGCGCCCTGGTC-5
Fig. 5 . Effect of specific hTBP binding to the TATA box on the pattern of pluramycin modification of the 64MI DNA template on the 
(+) and (-) strands. The specific hTBP-DNA complex was formed as described in Materials and methods, and 200 nM of pluramycin 
(final concentration) was incubated with the reaction mixture for 5 min. Pluramycin modification was stopped by adding 100 |xl of 
DDW containing 10 |xg of calf thymus DNA followed by phenol/chloroform extraction and ethanol precipitation. DNA pellets were 
dissolved in 20 |jlI of 1M piperidine solution, and samples were heated at 95 °C for 15 min to induce strand breakage at drug modifi­
cation sites, as described in Materials and methods. The pattern of pluramycin protection on the (+) strand (a) and (-) strand (b) of 
oligomer DNA 64MI. The sequences to the left and right of (a) and (b) show the sequence of the TATA element and pluramycin alkyla­
tion sites on both sides of the TATA box, respectively, (c) Pairs of densitometer scans of lanes 4 and 5 from (a) and (b) of this figure. 
Inside scans are in the absence (-) and outside scans are in the presence (+) ofTBP. Sites 'a' through 1 k1 are pluramycin alkylation 
sites (the asterisk shows the pluramycin-enhanced site). The TATA box is enclosed in a rectangle, ( d )  Schematic representation of 
pluramycin enhancement, no change, and protection sites on a portion of oligomer DNAs 64M and 64MI. The yellow dots indicate 
sites of inhibition, solid red arrows indicate sites of enhancement, dotted red arrows indicate no change, and the blue arrows indicate 
sites of phenylalanine insertion. The dinucleotide numbering system used later in the paper is noted above the sequence.
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presumably due to the selective m odification o f  the m inor 
groove o f  the TATA box by (+ )-C C -1065 (see right panel; 
our unpublished data).
Subsequently D N A  was isolated from  bo th  the unbound 
and the h T B P -b o u n d  samples (I and II in Fig. 7a), and 
the  therm al strand-breakage assay was then used to 
de te rm in e  the ex ten t and the site selectivity o f  p lura­
m ycin m odification  in b o th  samples o f  D N A  on the (+) 
and (—) strands (Fig. 7b). In accord w ith  previous experi­
m ents, this assay reveals that pluram ycin  m odification is 
specifically en riched  at the tw o adjacent guanines on 
opposite  strands im m ediately  to the dow nstream  side o f  
the TATA box in the specific h T B P -b o u n d  D N A  
(com pare lanes B and F in Figure 7b for bo th  the (+) 
and (—) strands).
To obtain  fu rth er evidence for the increased conversion 
o f  nonspecific  to specific com plexes in the presence o f  
p luram ycin , the  effect o f  increasing quantities o f  drug 
in  the incub a tio n  m ix tu re  on  the  am o u n t o f  the spe­
cific h T B P -D N A  com plexes was analyzed by the gel 
m ob ility  shift assay. T h e  results show n in Figure 8 ind i­
cate tha t as the  c o n cen tra tio n  o f  pluram ycin is 
increased, the am ount o f  the h T B P -D N A  com plex also 
increases. In  a parallel ex p erim en t, the  p luram ycin- 
m od ified  D N A  was recovered from  the  h T B P -D N A
com plexes, and the  therm al strand-breakage assay was 
then  used to  m o n ito r the ex ten t o f  p luram ycin  m odifi­
cation. T his result also shows a positive co rre la tion  
betw een  the  ex ten t o f  pluram ycin  m odifica tion  at the 
dow nstream  sites and the am o u n t o f  conversion  o f  
nonspecific to  specific h T B P -D N A  com plexes (data 
n o t shown).
Pluramycin m odification  of dow nstream  sites increases the  
stability of th e  hTBP-DNA com plex
A direct com parison o f  the stability o f  the h T B P -D N A  
com plex in the absence and presence o f  pluram ycin 
specifically b o u n d  at the dow nstream  en hancem en t sites 
was m ade by determ in ing  the dissociation rate o f  the 
respective specific h T B P -D N A  complexes (left and right 
panels o f  Fig. 9, respectively); bo th  experim ents were 
carried  o u t in the presence o f  excess nonlabeled  com ­
petito r D N A .T h e  results in the righ t panel show that in 
the presence o f  pluram ycin the specific hT B P -T A T A  
box com plex is quite stable, at least up to 120 m in. In 
contrast, about a 50 % dissociation o f  the com plex 
occurred  in the absence o f  pluram ycin du ring  the same 
period  o f  tim e, based upon the densitom etric  m easure­
m ents o f  the specific com plex (unpublished results). 
Therefore, intercalation o f  pluram ycin in to  the region 
im m ediately dow nstream  o f  the TATA box considerably 
stabilizes the specific h T B P -D N A  com plex.
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Fig. 6. Effect of pluramycin and (+)-CC- 
1065 modification of 64M on the conver­
sion of the nonspecific to the specific 
binding complex between hTBP and the 
TATA box. The hTBP-DNA complexes 
were formed at 37 °C in a final volume of 
100 p.1, as described in Materials and 
methods, (a) A 20-fold excess of cold- 
template DNA was added to reactions 
without (left panel) or together with 
400 nM of pluramycin (center panel) or 
200 nM of (+)-CC-1065 (right panel). At 
the indicated times (min), the extent of 
hTBP-DNA complex formation was 
determined by a band shift analysis. A 
sample (5 ijlI) of the reaction was loaded 
onto the gel and separated by elec­
trophoresis at 4 °C. Lane 1 shows a 
control reaction without hTBP, lane 2 
shows an hTBP-DNA complex in the 
absence of competitor DNA, and lanes 
3 -7  are incubation with cold-template 
DNA for the indicated times before 
loading on the gel. (b) The left and center 
autoradiograms shown in (a) were 
scanned with a densitometer and the per­
centage of specific complex formed was 
plotted against time ( - • - ,  control; -CD- 
incubated with pluramycin).
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Fig. 7. Determination of the extent and sites of pluramycin modification in unbound and TBP-bound oligonucleotides, (a) Gel elec­
trophoretic isolation of the pluramycin-modified specific hTBP-64M complex after modification with pluramycin. The specific 
hTBP-DNA complex was formed as described in Materials and methods. After addition of 20 molar excess of unlabeled competitor 
DNA, the reaction was incubated for a further 10 min, modified with 200 nM of pluramycin for 5 min, and loaded onto a 5 % 
polyacrylamide gel to separate the hTBP-64M complex from the free 64M. Lanes 1 and 3 correspond to (+) strand-labeled template 
DNA and lanes 2 and 4 correspond to (-) strand-labeled template DNA (I and II refer to the free 64M and hTBP-64M complexes, respec­
tively). (b) Determination of the site of pluramycin modification on the (+) and (-) strands of 64M recovered from the specific hTBP-DNA 
complex. DNA molecules corresponding to bands I and II in (a) from the (+) and (-) strands were recovered from the gel (see Materials 
and methods) and subjected to the thermal strand-breakage assay [15]. Lane headings 'F' and 'B' refer to the free 64M and hTBP-64M 
complexes, respectively, obtained from lanes 3 [(+) strand] and 4 [(-) strand]. The sequence to the right of the (+) and (-) strands shows 
the pluramycin alkylation sites (denoted with an asterisk) on the downstream side.
Pluramycin modification stabilizes the  hTBP-induced 
bending and  unwinding of DNA
In previous studies, the ability o fT B P  to bend D N A  has 
been dem onstrated by means o f  a gel m obility shift assay 
and crystallographic observation [11—13,24]. In this 
study, the stability o f  the hT B P -induced  D N A  bending  
and unw inding was exam ined by studying the efficiency 
o f  cyclization o f  m ultim ers o f  a 53-bp oligom er D N A  
fragm ent contain ing the TATA box, carried ou t in the 
presence o fT 4  D N A  ligase. Significantly, no net change 
in the linking num ber occurs because the unw ind ing  is 
offset by changes in w rith ing  [25]. As shown in Figure 
10a, in the presence o fT 4  D N A  ligase, the 53-bp D N A  
fragm ent form ed a set o f  linear dimers, trim ers, and 
tetram ers (L2, L3 and L4) and closed circular trim ers 
(C3) but was no t converted into covalently closed cir­
cular dimers (C2). However, upon the addition o f  hTB P 
at a protein to D N A  ratio o f  3 to 1, circular dimers (106 
bp) appeared am ong the ligation products. In subse­
quent experim ents, the effect o f  pluram ycin m odifica­
tion  on the efficiency o f  the form ation o f  circular 
dimers was examined. Pluramycin m odification o f  D N A  
(Fig. 10c, lanes 5 and 6 ) increased the num ber o f  circu­
lar dimers; only one third o f  the am ount o f  hT B P was
required to produce the same am ount o f  C2. These 
results support the idea that pluram ycin m odification o f 
guanine residues at the 3'-side o f  the TATA box stabil­
izes a specific binding m ode o f  hT B P to D N A  by 
form ing  a stably unw ound  form  o f  D N A  adjacent to 
the hT B P binding site. This result also suggests that the 
specific b ind ing  m ode o f  the hT B P—TATA box 
com plex that is stabilized by pluram ycin has no net 
change in bending unless additional w rith ing  occurs to 
com pensate for this.
D i s c u s s i o n
T he main purpose o f this study was to use pluramycin as 
a m olecular probe to determ ine the effects o f  hTBP 
binding on local D N A  structure and the dynamics o f  the 
event in the vicinity o f  the TATA box. Pluramycin 
belongs to the anthraquinone-derived antitum or anti­
biotic family, w hich also includes the altromycins, 
hedam ycin, and rubiflavin (for review, see [14]). In a 
recent study, Beerm an and colleagues [26] used 
hedam ycin as a D N A  interactive agent to examine how 
drug m odification o f D N A  affects TBP binding. T heir 
study shows inhibition o fT B P  binding to the adenovirus 
m ajor late prom oter. This finding is not in conflict w ith
4 6 3
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Fig. 8. Determination of the effect of increasing concentrations 
of pluramycin on the formation of the specific hTBP-DNA 
com plexes using a gel shift assay, (a) hTBP-DNA complexes 
were formed as described in Materials and methods, and a pre­
determ ined  a m o un t of pluramycin was ad ded  to each of the 
incubations. After incubation for 30  min, the  am ounts  of the 
specific hTBP-DNA complexes were determined by densitome­
ter scans of individual lanes. Lane C, control (in the absence of 
hTBP). Lanes 1 -9  conta ined  hTBP plus 0, 0.2, 0.3, 0.4, 0.5, 
0.6, 0.8, 1.0 and  1.2 mM, respectively, of pluramycin. (b) 
Histogram of the percentage of the specific complex plotted 
against the concentration of pluramycin determined from (a).
the results reported  here, because b inding  o f  hedam ycin 
to the guanine (G*) adjacent to the 3'-side o f  the TATA 
box in this p rom oter (5'-TATAAAAG*GG) blocks the 
insertion  o f  the am ino-term inal pair o f  phenylalanine 
residues into the ApG dinucleotide, presum ably resulting 
in the prevention o f  TB P—D N A  com plex form ation.
We have recently  show n that these antibiotics in teract 
w ith  D N A  in a th reading  in tercalating  m ode, bu t they 
also alkylate N 7  o f  guanine w ith  a sequence specificity 
that lies to  the 5 '-side o f  the covalently m odified 
guanine [14—18]. As a requ irem en t for pluram ycin reac­
tion  w ith  D N A , the helix  m ust be u n w ound  and the 
m inor groove m ust be accessible to the sugar m oieties o f  
pluram ycin  (see Fig. lb ) . P luram ycin has a critical 
advantage over o ther, b e tte r k now n  unw ind ing  probes 
such as M P E F e(II) o r C u —phenan th ro line  as a m olecu­
lar p robe for p ro te in -in d u ced  u n w ind ing  o f  D N A , 
because it form s a stable covalent a ttachm ent at the 
in tercalation  site. T h e  o th e r agents h it and run , leaving
C o n t r o l  P l u r a m y c i n




Fig. 9. Dissociation kinetics of the specific hTBP-DNA complex 
in the presence (right panel) or absence  (left panel) of plura­
mycin, determined by a gel mobility shift assay. Using the plura- 
mycin-modified DNA (right) or unmodified DNA (left), 
hTBP-DNA complexes were formed as described in Materials 
and methods. To determine the dissociation rate of the 
hTBP-DNA complex, a 40-molar excess of unlabeled competitor 
DNA was added to the reactions, which was then incubated for 
the indicated periods of time shown in the lane headings. The 
residual amount of the specific hTBP-DNA complex at various 
time intervals was analyzed by gel mobility shift assay (see text).
strand breaks at the intercalation site. A lthough in previ­
ous studies using D N ase I, M PE Fe(II) and C u —phenan­
throline, the area pro tec ted  by T B P  ex tended  beyond 
the base pairs norm ally  considered part o f  the TATA 
box consensus sequence [27—29], these fo o tp rin tin g  
m ethods generally did not reveal the relative im portance 
o f  individual bases in the in teraction  w ith  the protein or 
altered D N A  structure  upon  T B P  b ind ing  to  the  TATA 
box. M oreover, the dem onstrated com patibility  o f  plura­
m ycin in tercalation  w ith  hT B P  b ind ing  to  the TATA 
box and the increased stability o f  the te rnary  com plex 
could  no t have been  de te rm in ed  w ith  these strand 
breakage reagents.
In this study we dem onstrate that hT B P  b ind ing  to the 
TATA box creates an enhanced pluram ycin intercalation 
site im m ediately dow nstream  o f  the TATA sequence. 
This results in increased covalent reactivity w ith  one o f  
the guanines flanking this intercalation site (see Figs 4, 
5d).This result is surprising, since in the crystal structures 
o fT B P  bound  to D N A  solved by bo th  Burley and col­
leagues [12] and Sigler and colleagues [11], there is no 
indication o f  a deform ation  o f  D N A  at, o r adjacent to, 
the enhanced pluram ycin reactiv ity /in tercalation  site. In 
fact, at the 8—9 and 9 -1 0  dinucleotides (pluram ycin 
intercalates betw een base pairs 9 and 10, num bered  w ith 
the first T  o f  TATA as nucleotide 1; see Fig. 5d), the co­
crystals show B -fo rm  D N A . T herefore, we propose that 
pluram ycin is detecting  a transient unw ind ing  effect
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Fig. 10. (a) Effect of incubation with 
hTBP on the T4 ligase-catalyzed con­
version of a 53-bp oligonucleotide to 
dimer 106-bp circles. L1-L5 indicate 
linear monomer to linear pentamer, and 
C2 and C3 indicate circular dimer and 
circular trimer DNA. Lanes C and P 
represent the ligation products without 
and with three molar excess of hTBP in 
the reaction, (b) Denaturing gel analy­
sis of the DNA species (L1-L5 and 
C2-C3) isolated from the gel shown in 
(a). For DNA molecules designated as 
C2 and C3, bands a, b and c represent 
linear, circular single-stranded and 
undenatured DNA species, respectively 
[36]. (c) Effect of pluramycin modifica­
tion on the efficiency of hTBP-induced 
cyclization. Lanes 1 and 3 show control 
reactions without hTBP and lanes 2 and 
4 represent ligation with three- and 
one-molar excesses of hTBP, respec­
tively. Lanes 5 and 6 contain 2 and 5 ng 
of pluramycin, respectively, in addition 
to hTBP at a one-molar excess, (d) 
Sequence of the 53-bp oligonucleotide 
used in the cyclization experiments. 
The bar indicates the TATA box consen­
sus sequence, and the flanking A5 
tracts are underlined.
rather than a stable structural change in this region, and 
this is associated w ith hTB P binding to the adjacent 
TATA box. It is im portan t to differentiate between the 
possibility that enhanced reactivity o f  pluramycin at this 
site is a direct effect o f  a stable change in m inor groove 
geom etry at the upstream base pair, providing an 
increased proximity effect at the alkylation site, and the 
possibility that the indirect unw inding effect is transient 
and related to the adjacent binding o f  hTBP to D N A . 
We believe the form er explanation, involving a favorable 
m inor-groove geom etry change, is unlikely because this 
would be revealed in the X-ray studies. It would also be 
sequence dependent, and therefore should result in sites 
o f enhancem ent that w ould vary w ith the different 
flanking sequences (such as in 64M  and 64M I).T his is 
clearly not the case, since the site o f  pluram ycin- 
enhanced reactivity occurs at just one defined position 
relative to the TATA box, irrespective o f  sequence 
context. O n  the contrary, this observation argues for a 
source that is com m on to both  the 64M and 64MI 
sequences (that is, the TB P—5 -TATAAAAA sequence 
complex) and is independent o f sequence context.
We propose that the enhanced pluramycin reactivity is 
due to a transient unw inding effect occurring specifically 
at the 9-10 dinucleotide step that stabilizes pluramycin 
intercalation at this site. This proposal is consistent w ith 
the enhanced reactivity at site ‘c’ and no change in reac­
tivity at site ‘h ’ (Fig. 5c) and the corresponding plura­
mycin reactivities shown in Figure 4. Furtherm ore, 
pluramycin intercalation adjacent to the hTBP—TATA- 
box com plex appears to be associated w ith a ‘specific’ 
binding m ode that stabilizes a ternary complex in which
compensatory alterations occur in D N A  induced by both 
ligands.This conclusion is further supported by com peti­
tion experiments showing the enrichm ent o f  D N A  
specifically modified by pluramycin at the enhancem ent 
site in specific hTBP—TATA box complexes and by the 
increased efficiency o f circularization o f the C2 species in 
the presence o f pluramycin demonstrated in the ligation 
experiments. Last, in order to determ ine directly the 
effect o f flexibility o f  adjacent base pairs to pluramycin 
alkylation, we have determ ined the relative reactivity o f a 
site having a one-base bulge to the 5'-side o f  the interca­
lation/guanine alkylation site for pluramycin. Such one- 
base bulges dramatically increase the covalent reactivity o f 
the adjacent guanine to pluramycin (10 to 100 times 
greater reactivity) (S.-J. Lee, M. Flansen and L.FLH., 
unpublished results).This is consistent with the proposal 
presented here that the adjacent binding o f hTBP pro­
duces an unw inding o f  the C G  dinucleotide and, thus, 
enhanced reactivity o f pluramycin.
The dynamic effects o f pluramycin m odification o f the 
region immediately downstream o f  the TATA box on the 
h T B P -D N A  com plex are also very informative. 
Pluramycin binding to this downstream region causes an 
increased conversion o f nonspecific to specific complexes 
and a pronounced stabilization o f  the specific 
hT B P -D N A  complex (in the absence o f pluramycin, the 
half-life is 120 min, whereas in the presence o f  plura­
mycin, no significant dissociation was found during the 
same time period; see Fig. 9). M ost likely, the enhanced 
stabilization (and circularization efficiency) o f  the 
h T B P -D N A  complex by pluramycin intercalative 
binding is due to stabilization o f  a ‘specific’ binding
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m o d e ,  r e s u l t in g  i n  c o m p e n s a t o r y  a lte r a t io n s  in  D N A  
s tr u c tu r e  p r o d u c e d  b y  b o t h  l ig a n d s .
Structure of the pluramycin-TBP-TATA-box
B a s e d  u p o n  t h e  X - r a y  s t r u c tu r e  o f  t h e  T B P - T A T A  b o x  
c o m p l e x  [ 1 1 —1 3 ] ,  t h e  N M R  s o l u t i o n  s tr u c tu r e  o f  th e  
p l u r a m y c i n - D N A  c o m p l e x  [ 1 8 ] ,  a n d  t h e  e n h a n c e d  
c o v a l e n t  r e a c t i v i t y  s it e  f o r  p lu r a m y c in  in  th e  
h T B P - D N A  c o m p l e x  s h o w n  h e r e ,  a m o le c u la r  
m o d e l  fo r  t h e  t e r n a r y  s t r u c tu r e  o f  t h e  p lu r a -  
m y c i n - h T B P —D N A  c o m p l e x  w a s  c o n s t r u c t e d  (F ig .
1 1 ) .  D o c k i n g  o f  t h e  c o v a le n t ly  b o u n d  p lu r a m y c in  in  a n  
u n w o u n d  s i t e  a t t h e  9 —1 0  p o s i t i o n ,  s o  th a t  a lk y la t io n  
o c c u r s  a t s it e  ‘c (F ig .  5 c ) ,  d id  n o t  p r o d u c e  a n y  s te r ic  
c la s h e s  b e t w e e n  p l u r a m y c in  a n d  T B P . A f te r  m i n i m i z i n g  
in vacuo, L y s 9 7  f o r m s  a n  H - b o n d  w i t h  a p h o s p h a t e  
f la n k in g  t h e  p lu r a m y c in  b i n d in g  s it e  o n  t h e  m i n o r -  
g r o o v e  s id e  a n d  t h e  O - a c e t y l  g r o u p  o f  p lu r a m y c in ,  b u t  
th is  m a y  b e  a n  a r t if a c t  o f  t h e  in vacuo m in i m i z a t i o n  
(F ig . 1 1 a ) .  I t  is  i n t r i g u i n g  th a t  t h e  m a j o r - g r o o v e  s id e  o f  
t h e  p lu r a m y c in  in t e r c a la t io n  s it e  is  w i d e  o p e n  fo r  in t e r ­
a c t io n  w i t h  o t h e r  c o m p o n e n t s  o f  t h e  t r a n s c r ip t io n a l  
a c t iv a t io n  s y s t e m ,  a n d  i f  t h e  9 - 1 0  d i n u c l e o t id e  w a s  
u n w o u n d ,  i t  c o u l d  b e  c a p tu r e d  b y  a n  a p p r o p r ia te ly  
p o s i t i o n e d  a r o m a t ic  m o i e t y  (F ig . l i b ) .
Implications of hTBP-induced pluramycin intercalation for 
nudeation of unwinding by hTBP
A n  i m p o r t a n t  u n a n s w e r e d  q u e s t io n  r e la te d  t o  t h e  
b i n d in g  o f T B P  t o  t h e  T A T A  b o x  is  h o w  n u c le a t io n  o f  
u n w i n d i n g  is  a c h ie v e d  i n  a n  a s y m m e t r ic  manner [30]. 
T h e  T B P  m o l e c u l e  h a s  a n  a p p r o x im a te  t w o - f o l d  s y m ­
m e t r y  a x is , a n d  f u r t h e r m o r e ,  it s  in t e r a c t io n s  w i t h  t h e  
T A T A  b o x  a r e  a ll m a t c h e d  i n  t h e  t w o  p r o t e in  s u b d o ­
m a in s  [1 1 —1 3 ] .  In  c o n tr a s t ,  t h e  T A T A  b i n d in g  s e q u e n c e  
is  a s y m m e t r ic  b y  v i r t u e  o f  in d ir e c t  r e a d o u t  o f  s e q u e n c e  
i n f o r m a t io n ,  w i t h  t h e  5' h a l f  b e in g  m o r e  f le x ib le ,  d u e  to  
t h e  a l t e r n a t in g  A s  a n d  T  s, w h e r e a s  t h e  3 ' h a lf , c o n s is t in g  
o f  a n  A 4  tr a c t , is  m u c h  m o r e  r ig id .  A s  h a s b e e n  p r o p o s e d  
b y  S ig le r  a n d  c o l l e a g u e s  [ 1 1 ] ,  th is  w o u l d  r e su lt  in  a n  
in c r e a s e d  a m o u n t  o f  e n e r g y  r e q u ir e d  fo r  d e f o r m a t io n  o f  
t h e  3' r u n  o f  A ’s r e la t iv e  t o  th a t  r e q u ir e d  fo r  d e f o r m a t io n  
o f  t h e  T A T A  r e g i o n .  A n  a p p a r e n t  c o n s e q u e n c e  o f  th is  
s e q u e n c e  a s y m m e t r y  i n  t h e  T A T A  r e g i o n  is  t h e  i n d u c ­
t i o n  o f  h ig h - r e a c t iv i t y  p lu r a m y c in  a lk y la t io n  s ite s  s p e c i f ­
i c a l ly  a t a  s it e  o n  t h e  d o w n s t r e a m  s id e  o f  th e  T A T A  b o x  
u p o n  b i n d in g  o f T B P .
H o w  th is  i n d u c t i o n  o f  a s y m m e t r y  fr o m  th e  T A T A  
s e q u e n c e  t o  t h e  d o w n s t r e a m  s it e  i d e n t i f i e d  b y  p lu r a ­
m y c in  is t r a n s m it te d  b y  T B P  b i n d in g  is s till  n o t  c lear. T h e  
r esu lts  f r o m  th is  s tu d y  s u g g e s t  th a t  a tr a n s ie n t  u n w in d in g  
e f f e c t ,  r a th e r  th a n  a d ir e c t  s e q u e n c e  r e c o g n i t io n  m e d i ­
a te d  b y  a c h a n g e d  g r o o v e  g e o m e tr y ,  is  r e s p o n s ib le  fo r  th e  
in c r e a s e d  a lk y la t io n  r e a c t iv ity . C o n c e iv a b ly ,  th is  tr a n s ie n t  
u n w i n d in g  is  d u e  t o  a r e d i s t r ib u t io n  o f  to r q u e  e n e r g y  
in i t ia l ly  tr a p p e d  b y  T B P  b i n d in g  t o  t h e  u n w o u n d  T A T A  
b o x .  U n w i n d i n g  o f  t h e  T A T A  b o x  as a r e su lt  o f T B P  
b i n d in g  m i g h t  ta k e  p la c e  i n  a t w o - s t e p  p r o c e s s  (th a t is , 
f ir s t  t h e  5 - T A T A  s id e , t h e n  t h e  3 ' - s id e  A -tr a c t)  a n d
d u r in g  d is s o c ia t io n  is  t h e n  r e le a s e d  s t e p w is e  i n  t h e  
r ev e rse  t w o - s t e p  m o d e .  I f  th is  p r o p o s a l  is  t r u e , t h e n  a t a n  
in t e r m e d ia te  s te p  in  th e  T B P  d i s s o c ia t io n  p r o c e s s  a 
fa v o r a b le  tr a n s it io n  o f  to r q u e  e n e r g y  a n d  a s s o c ia te d  
u n w i n d in g  m ig h t  b e  r e le a s e d  s p e c i f ic a l ly  t o  t h e  d o w n ­
s tr e a m  s id e . T h is  w o u l d  c r e a te  t h e  u n w o u n d  s it e  in t e r ­
c e p t e d  b y  p lu r a m y c in  in te r c a la t io n .  T h a t  th is  tr a n s ie n t  
u n w o u n d  sta te  o f  th e  T B P - T A T A - b o x  c o m p l e x  is  a s p e ­
c if ic  b in d in g  m o d e  is s u g g e s te d  b y  t h e  s ta b ili ty  s tu d ie s  o n  
th e  te r n a r y  c o m p l e x  a n d  th e  c ir c u la r iz a t io n  e f f ic ie n c y  
e x p e r im e n t s .  B a s e d  u p o n  th e s e  o b s e r v a t io n s  a n d  t h e  
m o d e l  o f  th e  p lu r a m y c in —T B P —T A T A - b o x  c o m p l e x  
(F ig . 1 1 ) ,  i n  w h i c h  th e  u n w o u n d  s it e  is  a c c e s s ib le  v ia  t h e  
m a jo r  g r o o v e  t o  o t h e r  p r o te in s  in v o l v e d  i n  t r a n s c r ip ­
t io n a l  a c t iv a t io n ,  i t  is  t e m p t in g  t o  s u g g e s t  th a t  t h e  in t e r ­
c a la t io n  s ite  tr a p p e d  b y  p lu r a m y c in  m i g h t  a lso  b e  th e  
n u c le a t io n  s ite  fo r  th e  tr a n s c r ip t io n a l  s ta r t, w h i c h  m i g h t  
b e  r e c o g n iz e d  b y  a p la n a r  a r o m a t ic  m o i e t y  o f  a p r o t e in  
b in d in g  t o  th is  r e g io n .
A  n u m b e r  o f  p r e c e d e n t s  e x is t  f o r  p r o t e i n - i n d u c e d  d is ­
t o r t io n  i n v o lv in g  u n d e r w o u n d  r e g i o n s  o f  t h e  h e l i x .  T h e  
c a se  m o s t  r e le v a n t  t o  t h e  e x a m p le  d e s c r ib e d  h e r e  is  t h e  
tr a n s c r ip t io n a l  a c t iv a t io n  b y  t h e  m e t a l - r e s p o n s iv e  g e n e -  
r e g u la to r y  p r o t e in  ( M e r R )  i n  t h e  p r e s e n c e  o f  n a n o ­
m o la r  c o n c e n t r a t io n s  o f  m e r c u r ic  i o n s  [ 3 1 ] . T h e  r e s u lt  
o f  t h e  a d d i t io n  o f  H g  is  t h e  c o n v e r s i o n  o f  t h e  R N A  
p o ly m e r a s e  c o m p l e x  f r o m  t h e  c l o s e d  c o n f o r m a t i o n  t o  
t h e  s t r a n d -s e p a r a te d , t r a n s c r ip t io n a l ly  c o m p e t e n t  o p e n  
c o m p l e x .  In  p a r a lle l  w i t h  t h e  o b s e r v a t io n s  d e s c r ib e d  
h e r e ,  a n  H g - M e r R - i n d u c e d  s t r u c tu r a l  a l t e r a t io n  i n  t h e  
p r o m o t e r  h a s b e e n  d e t e c t e d  b y  t h e  i n t e r c a la t io n - s e n s i ­
t iv e  r e a g e n ts  M P E  a n d  C u - p h e n a n t h r o l i n e  [ 3 1 ] .  In  th is  
c a se , th e  o r ig in  o f  t h e  a s y m m e t r y  d o e s  n o t  a p p e a r  t o  b e  
th e  M e r R  b i n d in g  s it e ,  s in c e  th is  is  p a l in d r o m ic ,  b u t  
m a y  b e  i n d u c e d  b y  t h e  a s y m m e t r ic  i n t e r a c t io n  o f  H g  
w i t h  th e  M e r R .
W e  w o u l d  lik e  t o  c o n s id e r  t h e  b i o lo g i c a l  im p l ic a t io n s  o f  
th e  i m m o b i l i z a t i o n  o f  a n  in t e r c a la t io n  a g e n t  l ik e  p lu r a ­
m y c in  a t a s it e  o f  p r o t e i n - i n d u c e d  d i s t o r t io n  o f  D N A .  
O n e  o f  u s  h as p r e v io u s ly  p r o p o s e d  th a t  t h e  b i o lo g i c a l ly  
im p o r t a n t  le s io n s  fo r  D N A - r e a c t i v e  d r u g s  l ik e  t h e  
p lu r a m y c in s  a n d  C C - 1 0 6 5  r e s u lt  f r o m  s p e c ia l  n ic h e s  
p r o d u c e d  o n  D N A  as a c o n s e q u e n c e  o f  p r o t e i n -  
i n d u c e d  d i s t o r t io n  o f  D N A  [ 3 2 ,3 3 ] .  W e  h a v e  n o w  
d o c u m e n t e d  t w o  s u c h  e x a m p le s ,  t h e  o n e  d e s c r ib e d  h e r e  
a n d  th e  S p l - i n d u c e d  b e n d in g  s it e s  th a t  o c c u r  in  th e  2 1 -  
b p  r e p e a t  r e g io n  o f  S V 4 0  D N A ,  w h i c h  m a in t a in s  h i g h -  
r e a c t iv ity  s ite s  f o r  C C - 1 0 6 5  b e t w e e n  G C  b o x e s  III a n d  
IV  a n d V  a n d V I  [ 3 4 ] .  In  t h e  c a s e  d e s c r ib e d  h e r e , w h e r e  
h T B P  b i n d in g  t o  t h e  T A T A  b o x  r e s u lts  i n  a n  e n h a n c e d  
r e a c t iv ity  o f  p lu r a m y c in  a t a s p e c i f ic  s it e  d o w n s t r e a m  o f  
th e  T A T A  b o x ,  w h i c h  t h e n  i m m o b i l i z e s  h T B P  o n  
D N A ,  o n e  c a n  p r o p o s e  a t le a s t  t w o  d i f f e r e n t  b i o lo g i c a l  
c o n s e q u e n c e s .  F ir s t , th e  i m m o b i l i z a t i o n  w o u l d  le a d  t o  
tr a p p in g  o f T B P  a n d  a s s o c ia te d  tr a n s c r ip t io n a l  fa c to r s  at 
t r a n s c r ip t io n  s ta r t  s it e s  w h e r e  p lu r a m y c in  is  c o v a le n t ly  
b o u n d .  T h e s e  s it e s  w o u l d  p r e s u m a b ly  b e  u n p r o d u c t iv e  
tr a n s c r ip t io n a l  r e g io n s ,  l e a d i n g  t o  d o w n  r e g u la t io n  o f
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Fig. 11. Molecular models of the plura- 
mycin-TBP-TATA-box complex. The 
structures were formed as described in 
Materials and methods. The ternary 
complex contains the following duplex 
DNA sequence:
v  v  .
5 ' - C G A G A A G G T A T A T A A A C IG * C C C T T G
g g t c t t c c a t a t a t t t g I C  G G G A A C - 5 '
A A
where the arrows show phenylalanine 
insertions, the vertical line is the plura­
mycin intercalation site, and G* shows 
the alkylated guanine, (a) The minor- 
groove side of the pluramycin modifica­
tion site on DNA. The sugar moieties of 
pluramycin (see Fig. 1) interact in the 
minor groove, and the vinyl epoxide 
flanks the left-hand side of the helix 
(pluramycin is shown in yellow). TBP is 
shown as a ribbon diagram (blue), 
except for Lys97 (green), which after 
minimization H-bonds with a phos­
phate and the O-acetyl group of plura­
mycin. The N7-alkylated guanine is 
shown in cyan. The DNA helix is shown 
in purple (bases), magenta (deoxyri- 
boses), and gray (phosphates), (b) The 
major-groove side of the pluramycin 
modification guanine nucleotide 10 
showing the clear accessibility of the 
pluramycin-trapped intercalation site 
from this side. Colors as for (a).
specific gene transcription and perhaps even general 
transcription because o f  the resulting depletion o f 
transcriptional factors. Second, the ‘fixation’ o f  
p ro te in -D N A  complexes is well know n to have po ten t 
biological consequences, as, for example, in the case o f  
the form ation o f  cleavable com plexes w ith  topoisom - 
erase I and II and certain an ticancer drugs, such as 
cam ptothecin and VP 16 [35].
S i g n i f i c a n c e
T h e  r e s u l t s  o f  t h i s  s t u d y  d e m o n s t r a t e  t h a t  t h e  s p e ­
c i f i c  b i n d i n g  o f  h T B P  t o  t h e  T A T A  b o x  c r e a t e s  a  
u n i q u e  u n w i n d i n g  s i t e  i m m e d i a t e l y  d o w n s t r e a m  
o f  t h e  T A T A  b o x  t h a t  i s  t r a p p e d  b y  t h e  i n t e r c a l a -  
t i v e  d r u g  p l u r a m y c i n ,  w h i c h  a l k y l a t e s  N 7  o f  
g u a n i n e  a t  t h e  f l a n k i n g  s i t e .  T h e s e  r e s u l t s  d e m o n ­
s t r a t e  t h e  u t i l i t y  o f  p l u r a m y c i n  a s  a  s p e c i f i c  p r o b e  
f o r  p r o t e i n - i n d u c e d  u n w i n d i n g  s i t e s  w h e r e  i n t e r ­
c a l a t i o n  m a y  s t a b i l i z e  a  s p e c i f i c  b i n d i n g  m o d e  o f  
t h e  p r o t e i n - D N A  c o m p l e x .  B a s e d  u p o n  t h e  c o m ­
p a t i b i l i t y  o f  i n t e r c a l a t i o n  b y  p l u r a m y c i n  w i t h
h T B P  b i n d i n g  t o  t h e  T A T A  b o x  a n d  t h e  p r o p o s e d  
s t r u c t u r e  o f  t h e  t e r n a r y  c o m p l e x ,  w h i c h  s h o w s  
c l e a r  a c c e s s i b i l i t y  v i a  t h e  m a j o r - g r o o v e  s i d e  t o  a n  
u n w o u n d  s i t e  d o w n s t r e a m  o f  t h e  T A T A  b o x ,  w e  
p r o p o s e  t h a t  t h i s  s i t e  m a y  b e  a  n u c l e a t i o n  s i t e  f o r  
u n w i n d i n g  o f  D N A  r e c o g n i z e d  b y  a  t r a n s c r i p t i o n  
f a c t o r .  A  m e c h a n i s m  i n v o l v i n g  a n  a s y m m e t r i c  
s p r i n g  l o a d i n g  a n d  t h e  r e l e a s e  o f  t o r q u e  a s s o c i a t e d  
w i t h  b i n d i n g  a n d  d i s s o c i a t i o n  o f  T B P  f r o m  t h e  
T A T A  b o x  i s  u s e d  t o  r a t i o n a l i z e  t h e  a s y m m e t r i c  
d i s t r i b u t i o n  o f  p l u r a m y c i n  i n t e r c a l a t i o n  s i t e s .  T h e  
c o n s e q u e n c e s  o f  t h e  i m m o b i l i z a t i o n  o f  T B P  a t  
T A T A  b o x e s  b y  p l u r a m y c i n  m o d i f i c a t i o n  o f  a  
d o w n s t r e a m  s i t e  m a y  h a v e  p o t e n t  e f f e c t s  o n  t r a n s ­
c r i p t i o n a l  c o n t r o l  a n d  l e a d  t o  d r a m a t i c  e f f e c t s  o n  
c e l l  s u r v i v a l .
M a t e r i a l s  a n d  m e t h o d s
Materials
H um an T B P  and D N ase I were obtained from Prom ega, and 
T 4 D N A  ligase and T 4  polynucleotide kinase were from
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U nited  States Biochemical. Pluramycin was kindly provided by 
A bbott Laboratories (Chicago, IL) and used in this study 
w ithou t further purification. A stock solution was prepared by 
dissolving pluramycin (1 mg) in  1 ml o f  m ethanol and diluting 
it w ith  double-distilled w ater (DDW ) ju s t before carrying out 
each experim ent. T he oligonucleotides (64M  and 64M I in Fig. 
2) were synthesized on an A pplied Biosystems M odel 380A 
oligonucleotide synthesizer and purified by polyacrylamide gel 
electrophoresis, as described before [15].
DNase I footprinting assay
To form  h T B P -D N A  complexes, 5 ng o f  the 5' end-labeled, 
64-bp double-stranded oligonucleotide was added to hT B P 
(final concentration 20 nM) in 20 fil o f  a solution containing 
25 m M  Tris-H Cl (pH 7.8), 50 m M  KC1, 6.25 m M  M gC l2, 
0.5 m M  ethylenediam inetetraacetic acid (EDTA), 0.5 m M  
dithiothreitol (D TT), 0.01 % N P -40 , and 5 % glycerol. After a 
30-m in incubation at 37 °C, 100 ng o f  unlabeled 64-bp 
oligonucleotide was added, and the reaction was incubated for a 
further 10 m in. Following treatm ent for 1 m in w ith  0.2 U  o f  
D N ase I, the reaction was term inated  by the addition o f  40 |jl1 
o f  alkaline dye (80 % formamide, 10 m M  N aO H ) and then 
heated at 95 °C for 10 min. For m easuring dissociation kinetics 
o f  the h T B P -D N A  complex, 50 m g o f  D N A  tem plate was 
added to hT B P (final concentration 20 nM ) in 200 fxl o f  the 
same solution. After incubation for 30 m in at 37 °C, 160 |xl 
portions o f  the reaction were rem oved and added to 2 |xg o f  
the unlabeled tem plate D N A . A t the indicated times, 20 |xl o f  
the reaction were w ithdraw n, and the extent o f  h T B P -D N A  
com plex form ation was analyzed by D N ase I footprinting. In 
all cases, kinetic experim ents were repeated at least tw ice to 
ensure reproducibility.
Pluramycin protection experiments
T he hT B P—TATA-box com plex was form ed in  20 |xl o f  solu­
tion  by incubating the reactions for 30 m in at 37 °C, as 
described for the D N ase I foo tprin ting  experim ent. A fter the 
addition o f  100 ng o f  unlabeled D N A , the reaction was incu­
bated for a further 10 m in, and the indicated amounts o f  plura­
mycin w ere added to the reactions. R eac tion  w ith  d rug was 
continued  for 5 m in and stopped by adding 100 |xl o f  D D W  
containing 10 |JLg o f calf thymus D N A , followed by heating the 
reactions at 95 °C for 15 m in to induce D N A  strand breakage 
at the d rug  m odification sites [15]. In som e experim ents, free 
drug m olecules were rem oved by pheno l/ch lo ro fo rm  extrac­
tion  followed by ethanol precipitation. D N A  pellets were dis­
solved in 20 |xl o f  1 M  piperidine solution, and samples were 
heated at 95 °C for 15 m in to induce strand breakage at d rug 
m odification sites. Samples w ere lyophilized, redissolved in  20 
|xl o f  alkaline dye (80 % form am ide and 10 m M  N aO H ), and 
then  separated by electrophoresis on  a 10 % sequencing gel at 
room  tem perature at 1400 V for 2 h.
Formation ofTBP-DNA com plexes and the 
gel m obility shift assay
T he gel m obility  shift assay was perform ed by b inding hT B P 
to 64M  in  a buffer containing 25 m M  Tris-H Cl (pH 7.8), 
50 m M  KC1, 6.25 m M  M gC l2, 0.5 m M  EDTA , 0.5 m M  D TT, 
0.01 % N P -40 , and 5 % glycerol. After incubation at 37 °C for 
30 m in, a 20-m olar excess o f  unlabeled 64M  was added to the 
reaction, and the reactions w ere fu rther incubated for the 
indicated period  o f  tim e. Free and h T B P -bound  D N A  w ere 
separated on a 5 % polyacrylam ide gel (39:1 acrylam ide/bis- 
acrylamide) in  T ris-borate-M gC l2 (TBM ) (50 m M  Tris base, 
40 m M  boric  acid, 5 m M  M gC l2) supplem ented w ith  5 %
glycerol. Gel electrophoresis was perform ed in T B M  buffer at 
4 °C for 4 h  at 250 V.
Determination o f  the dissociation kinetics o f the 
TBP-DNA com plex
To prepare the 64-bp  o ligonucleo tide m odified  w ith  p lu ra ­
m ycin at the  3 '-side o f  the TATA box, 50 ng  o f  64M  was 
incubated  w ith  hT B P  (final 20 nM ) in 200 |xl o f  b ind ing  
buffer at 37 °C for 30 m in, and D N A  was m odified  w ith  
pluram ycin  (400 nM ) for 5 m in  in  the  presence o f  hTBP. 
D N A  was re-iso lated  by p h en o l/ch lo ro fo rm  ex trac tion  fo l­
low ed by ethanol precipitation. h T B P -D N A  complexes were 
reform ed using this p luram ycin-m odified  D N A  by the in cu ­
bation  o f  the  reaction  m ixture at 37 °C for 10 m in  follow ed 
by fu rth e r incubation  for 120 m in. D u rin g  the  incubation , a 
40 m olar excess o f  unlabeled D N A  was added to the reac­
tion  fo r the  indicated  p e rio d  o f  tim e, and the am oun t o f  the 
specific h T B P -D N A  com plex was analyzed using a gel 
m obility  shift assay.
Cyclization experiments
A 53-bp double-stranded oligonucleotide contain ing the 
TATA box sequence was used as a D N A  substrate for the 
cyclization experim ent. This oligonucleotide was also designed 
to contain tw o A ttr a c ts  that are 16 bp away from  the center 
o f  the TA TA -box sequence to im prove overall efficiency o f  
cyclization (see Fig. lOd). T he oligonucleotide (2 ng) was 
labeled w ith  [y -32P]ATP and was incubated  for 30 m in at 
37 °C w ith  indicated am ounts o f  hT B P  in  20 pd o f  a ligase 
buffer.T he ligation reaction was in itiated  by the addition o f  
200 U  o fT 4  D N A  ligase and incubated for 30 min. T he effect 
o f  pluram ycin modification on the efficiency o f  the form ation 
o f  circular dim ers was exam ined by adding pluram ycin to the 
preform ed h T B P -D N A  complex p rio r to initiation o f the lig­
ation reaction. A fter ligation was com plete, hT B P  was 
rem oved from  the D N A  substrate by adding sodium  dodecyl- 
sulfate to  a 0.5 % concentration  and heating  at 65 °C for 
15 m in. Ligated reaction products were separated by elec­
trophoresis in  a 6 % polyacrylam ide gel. Each band was then  
extracted from  the gel, purified, and loaded o n to  a 4 % dena­
tu ring  polyacrylam ide gel to determ ine the size o f  the D N A , 
according to the m ethod  described previously [36].
Generation o f molecular models
M olecular models were created by modifying the crystal struc­
ture o f  the T B P -D N A  complex. Flanking sequences were 
mutated and elongated to closely match sequences used in the gel 
studies, and pluramycin A was docked on the molecule using the 
program MIDAS [37].T he molecular model was then minimized 
in vacuo using the molecular modeling package A M B ER  [38].
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VIII. Quinobenzoxazines: Structure of an Mg2+-Drug-DN A Complex
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a Quinobenzoxazine-M g2+ Complex on DNA: A New  Paradigm for the 
Structure of a Drug-DNA Complex and Implications for the Structure of 
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The quinobenzoxazine compounds A-62176 and A-85226 belong to a novel class of antineoplastic 
agents that are catalytic inhibitors of topoisomerase II and also structural analogs of the 
antibacterial DNA gyrase inhibitor Norfloxacin. In vitro  studies have shown that their 
antineoplastic activity is dependent upon the presence of divalent m etal ions such as Mg2+ 
and Mn2+, although the precise role of these ions in the mechanism of action is unknown. In 
this study we have investigated the structures of the binary complex between the quinoben- 
zoxazines and Mg2+ and the ternary complex between quinobenzoxazine—Mg2+ and DNA. The 
stoichiometry of the binary and ternary complexes and the biophysical studies suggest that a 
2:2 drug:Mg2+ complex forms a “heterodimer complex” with respect to DNA in which one drug 
molecule is intercalated into DNA and the second drug molecule is externally bound, held to 
the first molecule by two Mg2+ bridges, which them selves are chelated to phosphates on DNA.
There is a cooperativity in binding of the quinobenzoxazines to DNA, and a 4:4 drug:Mg2+ 
complex is proposed in which the two externally bound molecules from two different 2:2 dimers 
interact via it—n  interactions. The externally bound quinobenzoxazine molecules can be 
replaced by the quinolone antibacterial compound Norfloxacin to form mixed-structure dimers 
on DNA. Based upon the proposed model for the 2:2 quinobenzoxazine:Mg2+ complex on DNA, 
a parallel model for the antibacterial quinolone—Mg2+—DNA gyrase complex is proposed that 
relies upon the ATP-fueled unwinding of DNA by gyrase downstream of the cleavable complex 
site. These models, which have analogies to leucine zippers, represent a new paradigm for 
the structure of drug—DNA complexes. In addition, these models have important implications 
for the design of new gyrase and topoisomerase II inhibitors, in that optimization for structure— 
activity relationships should be carried out on two different quinolone molecules rather than  
a single molecule.
Introduction
Research at Abbott Laboratories with the objective 
to discover novel anticancer drugs has resulted in the 
identification of a number of synthetic quinolone analogs 
with excellent in vivo antineoplastic activity.1,2 This 
biological activity differs from that of the parent qui- 
nolones, typified by Norfloxacin, which show antibacte­
rial activity but are devoid of antineoplastic activity. The 
quinobenzoxazine compounds A-62176 (l-(3-aminopyr- 
rolidin-1 -yl)-2-fluoro-4-oxo-4ff-quino[2,3,4-y ][ 1,4]benz- 
oxazine-5-carboxylic acid) and A-85226 (3-amino-l-(3- 
aminopyrrolidin-l-yl)-2-fluoro-4-oxo-4H-quino[2,3,4- 
y][l,4]benzoxazine-&-carboxylic acid) (Figure 1) are two 
examples of these agents and have been identified as 
part of a novel class of synthetic antineoplastic agents.2 
While the quinobenzoxazines are structurally related 
to the quinolone bacterial gyrase inhibitor Norfloxacin, 
they possess a planar tetracyclic ring structure in place 
of the fused bicyclic ring system of Norfloxacin (Figure 
1). Recent studies at Abbott Laboratories demonstrate 
that the quinobenzoxazine compounds are active against 
a wide range of human and murine cell lines in vitro, 
have curative activity against systemic tumors in mice, 
and have reproducible cytotoxic activity in a number of 
solid tumor models (Shen, unpublished results).2 The 
molecular basis for the anticancer activity of the
* Address correspondence to either of these authors. Telephone: 
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Quinobenzoxazines 
A-62176, R = H 
A-85226, R = NH2
O
COOH
N o r f lo x a c in
Figu re 1. Structures of the quinobenzoxazine (A-62176 and 
A-85226) and quinolone (Norfloxacin) compounds used in this 
study. In the case of the quinobenzoxazines, the S  enanti- 
omers were used.
quinobenzoxazines is not understood but is believed to 
be mediated by their interaction with topoisomerase II. 
Recently, Permana and co-workers have shown that the 
quinobenzoxazines are potent mammalian DNA topo­
isomerase II inhibitors but do not cause topoisomerase 
Il-mediated strand breaks.3 Thus, it has been proposed 
that these compounds inhibit the DNA topoisomerase 
II reaction at a step prior to the formation of the 
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Self-Assembly of Quinobenzoxazine—Mg2+ Complex on DNA
affinity of various quinobenzoxazines to DNA parallels 
their cytotoxic potency.4 However, the mode of interac­
tion (e.g., intercalation vs groove binding) of the 
quinobenzoxazines with DNA was undefined. While 
many studies on the mechanism of action of the parent 
quinolones have been reported, there are conflicting 
reports, particularly in regard to the role played by DNA 
in the mechanism of action of the quinolones.5-8 A large 
amount of biological data has suggested that DNA 
gyrase is the intracellular target for quinolones.6 7’9-12 
However, several recent reports have shown that the 
quinolones do not bind to DNA gyrase but instead bind 
to DNA.813-16 The Abbott investigators have proposed 
a novel cooperative quinolone—DNA binding model and 
suggested that self-associated Norfloxacin molecules 
bind via hydrogen bonds to transient single-stranded  
regions in DNA that are produced by gyrase during the 
intermediate gate-opening step of the duplex DNA 
supercoiling process.15 Significantly, Norfloxacin is also 
able to unwind DNA but only in the presence of Mg2+ 
ions.1718 Drug-induced DNA unwinding, which is mea­
sured in an assay using closed circular DNA, has been 
considered in many cases as indicative of intercalative 
binding by drugs to DNA. However, the DNA unwind­
ing efficiency of Norfloxacin is far less than that for 
adriamycin and daunomycin, which are known to 
intercalate into duplex DNA.17 In fact, the putative 
unwinding angle for Norfloxacin is less than 11°, which 
is the minimum possible unwinding angle consistent 
with intercalation.19 Also, the instability to electro­
phoresis of the DNA—Norfloxacin complex is only 
consistent with either weak intercalative binding by 
Norfloxacin in native duplex DNA or dissociative release 
of the ligand during the assay.1718
Like Norfloxacin, preliminary mechanism of action 
studies have shown that DNA binding of the quinobenz­
oxazines is dependent upon the presence of divalent 
metal ions (Shen, unpublished results). However, the 
role of these divalent ions in the binding of the quinobenz­
oxazines to DNA is unknown. To account for the Mg2+ 
dependency of Norfloxacin binding to DNA, the lack of 
evidence for intercalation, and the preference for bind­
ing to single-stranded DNA, Palumbo and co-workers 
have proposed a new model for DNA binding in which 
Mg2+ acts as a bridge between the phosphate groups of 
the nucleic acid and the carbonyl and carboxyl groups 
of Norfloxacin, although direct experimental evidence 
is lacking.518 Stacking interactions between the Nor­
floxacin aromatic rings and the DNA bases in single­
stranded regions have been proposed to further stabilize 
the ternary (Norfloxacin-Mg2+—DNA) complex.5’18 The 
present study of the quinobenzoxazines demonstrates 
that for these analogs of the antibacterial quinolones 
both  duplex DNA unwinding and a noncovalent binding 
mode to DNA are Mg2+ dependent. However, moderate 
structural differences between quinolone and quinobenz­
oxazine compounds result in large differences in their 
biological activities, as the former are antibacterial 
agents and the latter are antineoplastic agents. Our 
results with the quinobenzoxazine antineoplastics pro­
vide firm experimental evidence for the proposed bind­
ing role of Mg2+ in the complex with DNA5 and suggest 
an alternative mechanism for interaction of the anti­
bacterial compounds with the partially unwound duplex  
DNA produced by the interaction with topoisomerase.
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C  M g 2 +  M n 2 +  K +
Figure 2. F lu o r e s c e n c e - d e te c te d  g e l e l e c t r o p h o r e s i s  o f  A -6 2 1 7 6  
i n  t h e  a b s e n c e  (C ) a n d  p r e s e n c e  o f  M g 2+, M n 2+, o r  K + io n . E a c h  
l a n e  c o n t a i n s  2  pL  o f  a  1 0  m M  s o l u t i o n  o f  A - 6 2 1 7 6  c o n t a i n i n g  
M g 2+, M n 2+, a n d  K + , r e s p e c t i v e l y ,  a t  a  d r u g : m e t a l  io n  r a t i o  o f  
1 :5 0 . T h e  a r r o w  p o i n t s  to  t h e  A - 6 2 1 7 6 - M g 2+ o r  A - 6 2 1 7 6 — 
M n 2+ c o m p le x .
In this article, the binary complex between the 
quinobenzoxazines and Mg2+ and the ternary complex 
between quinobenzoxazine, Mg2+, and DNA have been 
investigated using a variety of experimental methods, 
including 1H- and 31P-NMR, FT-IR, U V -v is  spectros­
copy, viscometry, and gel electrophoresis, in an attempt 
to gain insight into the binding specificity, ligand- 
induced conformational transitions in DNA, coopera­
tivity in binding, and drug binding modes to DNA. 
A-85226, an amino analog of A-62176 (Figure 1), was 
used in the FT-IR, NMR, and viscometry studies 
because it has greater solubility than A-62176 in water. 
Last, the combined interactions of a quinobenzoxazine, 
ethidium bromide, or echinomycin together with Nor­
floxacin and DNA in the presence of Mg2+ have been 
studied to attempt to explain the different biological 
activities of the quinolone and quinobenzoxazine com­
pounds. Some of this work has been published in 
preliminary form.4’20 21
R esu lts
1. T he S tru ctu re  an d  S to ich io m etr y  o f  th e  
C oordination  C om plex Form ed b etw een  th e Q uino­
b en zo x a z in es  an d  D iv a len t M eta l Ion s. F lu o res­
c e n c e  D e tec tio n  o f  Q u in o b e n z o x a z in e -M e ta l Ion  
C om plexes T hat M igrate d u r in g  A garose G el E lec­
tro p h o res is . The ability of A-62176 to form cationic 
complexes with divalent metal ions was probed using 
agarose gel electrophoresis (Figure 2). Aliquots (2 pL) 
of a 4 mM aqueous solution of A-62176, containing 
either Mg2+, Mn2+, or K+ (all at a 1:50 drug:metal ion 
ratio), were loaded onto a 2.5% agarose gel and sub­
jected to electrophoresis at pH 8.0. The intrinsic 
fluorescence of A-62176, upon irradiation with UV light, 
was exploited to detect the location of A-62176 and its 
complexes in the gel. The lanes having a combination 
of A-62176 with Mg2+ or Mn2+ show formation of a 
stable complex (see arrow in Figure 2), which migrates 
into the gel toward the cathode. In contrast, the sample 
of A-62176 in the presence of K+ or in the absence of 
metal ions did not migrate into the gel. In the absence 
of metal ions, A-62176 is zwitterionic at pH 8; therefore, 
it does not migrate to the cathode. In the presence of 
Mg2+ and Mn2+, the migration of the drug complex 
indicates that a positively charged complex is formed. 
The fact that the drug does not migrate in the presence
410 Journal o f Medicinal Chemistry, 1995, Vol. 38, No. 3 Fan et al.
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of K+ indicates there is no complex formation with 
univalent metal ions.
In a second experiment, aliquots of the A-62176—Mg2+ 
mixture within a range of drug:Mg2+ ratios (1:0.5—1: 
100) were applied to a 2.5% agarose gel (data not 
shown). Very little of the A -62176-M g2+ complex 
migrated into the gel in mixtures having drug:Mg2+ 
ratios of less than 1:50. Since complex formation is only 
seen when the ratio of A-62176:Mg2+ is at least 1:50, 
this suggests that the complex is relatively unstable and 
that a large excess of Mg2+ is needed in order to drive 
the complex formation between drug and Mg2+ to 
completion.
C h a ra c ter iza tio n  o f  th e  Q u in o b e n z o x a z in e -  
M g2+ C om plex  b y  IR. Infrared spectral analysis has 
been used previously to study the complexes formed 
between quinolones and magnesium, as well as other 
divalent metal ions.22 We sought to extend these 
studies to the quinobenzoxazine—Mg2+ complexes. For 
these experiments, we employed the quinobenzoxazine 
A-85226 because of its relatively higher solubility.
The IR spectra of the A -85226—Mg2+ and the 
A-85226—Mg2+ complexes in KBr disks are shown in 
Figure 3. In the lower spectrum, the ketonic group for 
free A-85226 has a strong IR band at 1640 cm-1, typical 
of the ketonic group in l,4-dihydro-4-oxoquinolines.23 
The carbonyl of the carboxylic acid of the free drug has 
a weaker band at 1700 cm-1. In the A -85226-M g2+ 
complex, the corresponding IR bands are weaker (upper 
spectrum, Figure 3). The band for the carboxylate 
carbonyl clearly shifts to a lower frequency (1685 cm-1). 
However, due to interference by other bands in the same 
region, it is not clear that the ketonic band also shifts. 
A typical Mg2+- 0  asymmetrical stretching frequency24 
at 426 cm-1 is also seen for the complex. A parallel 
experiment for the Norfloxacin—Mg2+ complex also
shows the same change for the carboxylate carbonyl/ 
ketonic bands and the formation of a new Mg2+—O 
stretching frequency at 423 cm-1 (data not shown).
J o b  T itra tio n  A n a ly sis  o f  th e  A -6 2 1 7 6 -M n 2f 
C om plex. Job titration analysis25,26 was used to de­
termine the stoichiometry of m etal-ligand  complexes. 
Our agarose gel electrophoresis experiments indicated 
that A-62176 forms complexes with both magnesium  
and manganese but that the relative instability of the 
magnesium complex dictates the use of excess magne­
sium to drive complex formation to completion. There­
fore, we used Mn2+ in this experiment. Absorbance 
titration of A-62176 by MnC^ was performed in MeOH. 
Upon addition of MnCl2, the intensity of both absorption 
bands at 320 and 395 nm increased, but both bands 
shifted in opposite directions (Figure 4A); i.e., while the 
320 nm band shifted to the blue, the 395 nm band 
shifted to the red. Up to a 1:1 ratio of A-62176:Mn2+, 
there were two isobestic points at 326 and 370 nm, 
indicative of complex formation. However, further 
addition of Mn2+ caused the isobestic points to shift. We 
interpret this to mean that a new type of m etal—drug 
complex is forming. The Job titration analysis for 
A-62176 with Mn2+ was performed at 320 nm in MeOH 
at room temperature. The mole fraction of Mn2+ was 
varied between 0 and 1. The normalized plot in Figure 
4B shows a distinctive maximum at Xdrug =  0.50 (mole 
fraction of drug), indicating that the stoichiometry of 
the drug—Mn2+ complex is 1:1, 2:2, etc.
2. T he Q u in o b en zo x a zin es B ind  to  DNA, and  
th e  B in d in g  to  DNA  Is D ep en d en t u p on  D iv a len t  
C ation s. D N ase I F o o tp r in tin g  A n alysis. A typical 
DNase I digestion pattern for the 63-bp oligomer (oli­
gomer 1 in the Experimental Section) complexed with 
various concentrations of A-62176 in the presence of 
MgCl2 (2 mM) is shown in Figure 5, left. The densito-
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Figure 4. (A ) U V - v i s  t i t r a t i o n  o f  a  3 0  ,wM m e t h a n o l i c  s o lu t io n  
o f  A - 6 2 1 7 6  w i t h  M n 2+ a t  ro o m  t e m p e r a t u r e .  P lo t s  f r o m  b o t to m  
t o  t o p  in  r e s p e c t  t o  t h e  a b s o r p t i o n  a t  3 2 0  n m  a r e  m o l a r  r a t i o s  
o f  [ M n 2+] / [A -6 2 1 7 6 ]  =  0 , 0 .2 ,  0 .4 ,  0 .6 ,  a n d  0 .9 .  T h e  a r r o w  o n  
t h e  y a x i s  i n d i c a t e s  t h e  s p e c t r u m  o f  t h e  d r u g  i n  t h e  a b s e n c e  o f  
M n 2+. (B )  J o b  t i t r a t i o n  p l o t 25 f o r  t h e  A - 6 2 1 7 6 - M n 2+ c o m p le x  
in  m e t h a n o l  a t  r o o m  t e m p e r a t u r e .  T h e  t o t a l  c o n c e n t r a t i o n  o f  
d r u g  a n d  M n 2+ i s  1 0 0  pM.
metric scans in Figure 5, right, correspond to lanes 1 -4  
of the left panel. At the lowest concentration of A-62176 
(lane 2), it is clear that A-62176 first interacts with the 
GC-rich region of oligomer 1 (brackets A—D in the left 
panel and scans corresponding to lanes 1 and 2 in the 
right panel). However, at the two lowest concentrations 
of A-62176 (lanes 2 and 3), the central region of the 63- 
bp oligomer (bracket E) that contains the Tytract shows 
enhanced  DN ase I cleavage in the presence of A-62176. 
One interpretation of this observation is that the 
presumed local unwinding of the T-tract due to the 
binding of A-62176 to the adjacent GC-rich region then  
renders this normally insensitive AT region susceptible 
to DNase I cleavage. In the presence of increasing drug 
concentrations (lanes 3 -5 ) , all regions of the DNA  
oligomer show diminished cleavage, except for the 
T-tract region, which only shows diminished cleavage 
in the presence of the highest concentration of A-62176. 
These results suggest that the interaction between  
A-62176 and DNA may involve a cooperative binding 
mechanism in which the binding of A-62176 to the GC- 
rich regions of the oligomer facilitates the subsequent 
binding of A-62176 at adjacent AT-rich regions.
The ability of A-62176 to bind to DNA is dependent 
upon the concentration of Mg2+, as shown in Figure 6. 
Inspection of the autoradiograph (Figure 6) reveals that 
the DNase I cleavage pattern of the drug-DN A complex 
in the absence of Mg2+ (lane 2) is only slightly different 
from the cleavage pattern in the absence of any ligand 
(lane 1). However, increasing the Mg2+ concentration
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in the presence of a constant amount of A-62176 results 
in increased protection from DNase I cleavage (see 
brackets A—C). The DNA binding sites do not become 
saturated until the concentration of Mg2+ reaches 1 mM. 
Therefore, this DNase I footprinting result shows that 
the cooperative binding of A-62176 to DNA, which 
results in inhibition of DNase I cleavage, is dependent 
upon Mg2+ concentration.
S p e c tr o p h o to m e tr ic  A n a ly s is . The binding of 
A-62176 to calf thymus DNA in the absence and 
presence of Mg2+ was also measured spectrophotomet- 
rically, and the results are shown in Figure 7. The free 
quinobenzoxazines show absorption peaks at 320 and 
380 nm. Incremental addition of calf thymus DNA to 
drug solution in the absence of Mg2+ causes a slight blue 
shift and a decrease in absorbance only at the 320 nm 
peak of A-62176 (Figure 7A). In contrast, a red shift 
and reduction in absorption in both the 320 and 380 nm 
peaks, as well as three clear isobestic points (at 328, 
345, and 414 nm), are observed when a solution of 
A-62176 containing 10 mM MgCl2 is titrated with the 
DNA stock solution. Figure 7C shows the absorption 
change of A-62176 at 380 nm upon addition of DNA in 
the presence and absence of Mg2+. While very little 
change in the absorption is observed in the absence of 
Mg2+, a significant decrease in absorption is observed 
in the presence of Mg2+. Since A-85226 behaves in a 
similar manner, the 380 nm absorption peak of the 
quinobenzoxazines can be used to monitor the divalent 
metal ion-specific binding of these drugs to DNA.
3. T he Q u in o b en zo x a zin e  A n tin eo p la stic  A gents  
F orm  T ern ary  C o m p lex es w ith  DNA in  w h ich  
M g2+ B rid g es  b e tw e e n  th e  In ter ca la ted  D ru g  and  
a P h o sp h a te  O xygen  in  D N A  T h e Q u in o b en zo x ­
a z in es  F orm  In te r c a la tio n  C o m p lex es w ith  DNA  
in  th e  P r e se n c e  o f  M g2+ Ion s, (i) T o p o iso m era se  
R ela x a tio n  A ssay . The topoisomerase I-induced re­
laxation assay was carried out using supercoiled DNA, 
as described previously,27 to test the helix unwinding 
ability of A-62176. Supercoiled DNA was incubated in 
the presence of magnesium and increasing concentra­
tions of A-62176, then the DNA—drug complexes were 
incubated with topoisomerase I, and the resulting DNA 
topoisomers were separated by agarose gel electro­
phoresis. In the absence of added drug, a single band 
corresponding to relaxed circular DNA is produced; 
however, in the presence of increasing concentrations 
of A-62176, well-defined bands representing different 
topological forms, which migrate faster than the relaxed 
form, are produced (Sun and Hurley, data not shown). 
This result provides excellent evidence for an intercala­
tion mechanism for A-62176 binding to DNA but in itself 
does not rule out minor groove binding with concomitant 
unwinding.
(ii) V isco m etry  M ea su rem en ts . Viscometry mea­
surements were used to further explore the binding 
mechanism of the quinobenzoxazines to DNA. In these 
experiments, the effect of A-85226, either in the pres­
ence or absence of Mg2+, on the viscosity of sonicated 
calf thymus DNA was examined (Figure 8). For com­
parison, the viscometric titration profile of the contour 
length ratio of DNA (L/Lo) against moles of drug added 
per mole of DNA base pair (v) for ethidium bromide, a 
classic intercalator, is also shown in Figure 8.
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F i g u r e  5 . ( L e f t )  D N a s e  I f o o t p r i n t i n g  o f  o l i g o m e r  1 ( f o r  s e q u e n c e ,  s e e  E x p e r i m e n t a l  S e c t io n )  i n  t h e  a b s e n c e  ( l a n e  1 ) o r  p r e s e n c e  
( l a n e s  2 —5 ) o f  A - 6 2 1 7 6 . A G  a n d  T C  r e p r e s e n t  t h e  p u r i n e -  a n d  p y r im id in e - s p e c i f i c  c h e m ic a l  c l e a v a g e  r e a c t i o n s .  L a n e s  2 —5 c o n t a in  
1 , 2, 4 , a n d  8  /vM  A - 6 2 1 7 6 ,  r e s p e c t i v e l y ,  w i t h  1 0  n g  o f  D N A  a n d  2  m M  M g C L . B r a c k e t s  A - D  c o r r e s p o n d  to  r e g io n s  o f  d i m i n i s h e d  
c l e a v a g e  w i t h  D N a s e  I , w h e r e a s  b r a c k e t  E  s h o w s  i n i t i a l l y  e n h a n c e d  c le a v a g e .  ( R i g h t )  D e n s i t o m e t r i c  s c a n s  o f  l a n e s  1 - 4  o f  t h e  
l e f t  p a n e l .  T h e  D N A  s e q u e n c e  o f  t h e  lo w e r  s t r a n d  o f  o l ig o m e r  1 is  s h o w n  in  l a n e  1, a n d  D N a s e  I i n h i b i t i o n  ( A - D )  a n d  e n h a n c e m e n t  
(E )  z o n e s  a r e  s h o w n  in  l a n e  2 .
As anticipated, for ethidium bromide and A-85226 in 
the presence of Mg2+, the DNA contour length ratio 
increases with increasing ratio of ligand to DNA but 
reaches a plateau value when saturation binding is 
attained. For ethidium bromide, the saturation point 
is at a ratio of 0.45 drug molecules per DNA base pair, 
while for A-85226, saturation binding occurs at a ratio 
of 0.80 drug molecules per DNA base pair. The contour 
length ratio of DNA reaches a plateau value of 1.09 at 
a drug:DNA base pair ratio of 0.45 for a classical 
intercalator like ethidium bromide. Significantly, a 
similar value is obtained for A-85226 in the presence of 
Mg2+ (25 mM) at the same drug:DNA ratio (point at 
which the lines cross in Figure 8). In the absence of 
Mg2+, addition of A-85226 to calf thymus DNA initially 
causes a decrease in contour length, and this is followed 
by a slow increase in contour length as more drug is 
added.
The viscometric results provide excellent evidence 
that the quinobenzoxazine-M g2+ complex is an inter­
calator and that it increases the contour length of DNA 
in a similar way to ethidium bromide, although the final 
stoichiometry (drug:DNA base pair) is apparently dif­
ferent. However, in the absence of Mg2+, the contour 
length of DNA is not affected by addition of drug, 
indicating that drug binding involves an alternative
mechanism, such as minor groove or an external binding 
mode.
(iii) NMR E xperim en ts. The effects on the low-field 
^-N M R  spectra of DNA upon addition of DNA ligands 
are a diagnostic tool for deducing ligand binding modes. 
For intercalators, upfield shifts of imino protons are 
often observed, which are accompanied by some broad­
ening of the resonance envelopes. In contrast, downfield 
shifts of imino resonances are characteristic of groove 
binders.28
Figure 9 (panel A) shows the low-field NMR spectra 
of a magnesium-containing solution of [dlG-Cfsh as a 
function of increasing amounts of A-85226. The pres­
ence of resonances due to the H-bonded imino protons 
of the G residues of [dlG-Osh in H2O demonstrates that 
the oligomers are in the duplex form.29 As drug is added 
to a solution of [dlG-Osk, a new peak appears at 12.62 
ppm, and the resonances at 13.00 and 13.15 ppm 
decrease in intensity (scans a—e). At relatively high 
drug levels (scan e, ratio of DNA to drug is 1:2), even 
the originally most downfield resonance signal shifts 
slightly upfield. These spectral effects are indicative of 
an intercalative binding mode.
In contrast, a quite different result is obtained for the 
[d(A-T)s]2 titration experiment with A-85226 in the 
presence of Mg2+ (Figure 9, panel B). As A-85226 is
ra n  et al
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F i g u r e  6 .  E f f e c t  o f  i n c r e a s i n g  c o n c e n t r a t i o n s  o f  M g 2+ o n  t h e  
D N a s e  I f o o t p r i n t i n g  o f  o l ig o m e r  2  ( f o r  s e q u e n c e ,  s e e  E x p e r i ­
m e n t a l  S e c t io n )  i n  t h e  p r e s e n c e  o f  2  ,«M  A - 6 2 1 7 6 .  L a n e s  1 —6 
c o n t a i n  5 , 0 , 0 .2 ,  0 .5 ,  1, a n d  5  m M  M g C L , r e s p e c t i v e l y .  L a n e  
1 c o n t a i n s  7  n g  o f  D N A  b u t  w i t h o u t  A - 6 2 1 7 6 .  L a n e s  2 —6 
c o n t a i n  7 n g  o f  D N A  w i t h  2  pM  A - 6 2 1 7 6  in  2 0  uh  o f  a  s o l u t i o n  
c o n t a i n i n g  1 0  m M  T r i s - H C l  ( p H  7 .6 )  a n d  1 0  m M  N a C l .  
B r a c k e t s  A - C  c o r r e s p o n d  to  t h r e e  s i t e s  o f  i n h i b i t i o n  o f  D N a s e  
I c l e a v a g e  (5 '-C G A , 5 '- T T G C T , a n d  5 '-A A A G C , r e s p e c t i v e l y ) .
added to a magnesium-containing solution of [d(A-T)s]2, 
new resonance signals do not appear. The imino proton 
signals broaden but shift less than 0.1 ppm (compare 
scans a and d). By UV spectrophotometry, A-85226 has 
been shown to bind to [d(A-T)5l2 in the presence of 
magnesium, since the UV spectrum shows a red shift 
and clear isobestic points during the titration of A-85226 
by DNA (data not shown). Therefore, the peak broad­
ening observed in the NMR titration experiment (panel
B) suggests that A-85226 binds to the outside of [d(A- 
T)sl2 in a nonspecific manner, possibly by electrostatic 
interactions with the phosphate backbone.28 30
The spectral changes of the ternary [d ^ G C T ^ k — 
Mg2+— A-85226 complexes as a function of increasing 
drug:DNA ratio are shown in Figure 9 (panel C). Initial 
additions of drug up to a drug:DNA ratio of 1:1 produce 
upfield shifts for GC imino proton resonances from 12.8 
to 12.5 ppm, while the chemical shifts of the A-tract 
imino proton resonances remain unchanged (compare 
scans a and c). When excess drug is added (DNA:drug 
ratio of 1:2), the A-tract imino proton peaks broaden and 
move upfield, while the GC imino proton resonances 
shift further upfield to 12.4 ppm (scan d). This result 

















F i g u r e  7 . E f f e c t  o f  i n c r e a s i n g  D N A  c o n c e n t r a t i o n s  o n  t h e  U V  
a b s o r p t i o n  ( a r b i t r a r y  u n i t )  o f  A - 6 2 1 7 6  i n  t h e  a b s e n c e  ( p a n e l  
A ) a n d  p r e s e n c e  ( p a n e l  B ) o f  10  m M  M g 2+ a t  r o o m  t e m p e r a t u r e .  
T h e  a b s o r b a n c e  c h a n g e s  a t  3 8 0  n m  a s  a  f u n c t i o n  o f  i n c r e a s i n g  
c o n c e n t r a t i o n s  o f  D N A  i n  t h e  p r e s e n c e  a n d  a b s e n c e  o f  M g 2+ 
a r e  s h o w n  i n  p a n e l  C . T h e  a r r o w s  o n  t h e  y  a x i s  o f  p a n e l s  A  
a n d  B  i n d i c a t e  t h e  s p e c t r u m  o f  t h e  d r u g  i n  t h e  a b s e n c e  o f  D N A .
intercalate in the GC region. However, once intercala­
tion of GC base pairs occurs, further drug intercalation  
in the A-tract region follows.
Mg2+ B rid ges th e  Q u in ob en zoxazin e M olecu le to  
th e  P h o sp h a te  B a ck b o n e o f  DNA. Palumbo and co- 
workers518 have suggested that the quinolone antibiot­
ics may interact with the phosphate of single-stranded  
DNA via a bridging Mg2+ ion. To explore whether the 
quinobenzoxazine antineoplastics are bridged via an 
Mg2+ ion to the DNA phosphate backbone, the 31P-NMR 
spectral changes of [d(G-C)5l2 in the presence of A-85226 
and Mg2+ were studied.
Figure 10 shows the 31P-NMR spectra of [d(G-C)sk 
in the presence and absence of A-85226 in NMR buffer 
(10 mM NaH2P04 and 100 mM NaCl) containing 100 
mM MgCU. A single resonance signal at —0.88 ppm for 
all the phosphate groups is observed for [d(G-C)5k









F igu re 8. V is c o m e t r ic  t i t r a t i o n  o f  s o n i c a t e d  c a l f  t h y m u s  D N A  
w i t h  e t h i d i u m  b r o m i d e  a n d  A - 8 5 2 2 6  i n  t h e  p r e s e n c e  a n d  
a b s e n c e  o f  M g 2+ (2 5  m M ) a t  2 2  °C  i n  0 .0 1  M  T r i s  b u f f e r .  T h e  
r a t i o  o f  t h e  c o n t o u r  l e n g t h  o f  D N A , L /L o , i s  p l o t te d  a s  a  f u n c t io n  
o f  m o le s  o f  d r u g  a d d e d  p e r  m o le  o f  D N A  b a s e  p a i r s ,  v. T h e  
v e r t i c a l  d o t t e d  l i n e s  s h o w  t h e  i n t e r c e p t s  o n  t h e  x a x i s  w h e r e  
t h e  e t h i d i u m  b r o m i d e  a n d  A - 8 5 2 2 6  (M g 2+) p l o t s  i n t e r s e c t .  
( - A - )  =  A - 8 5 2 2 6  +  M g 2+; ( - O - )  =  A - 8 5 2 2 6 ;  a n d  ( - □ - )  =  
e t h i d i u m  b r o m id e .
/  'S> k/\
12.0 ppm  14.0 12.0 ppm 14.0 12.0ppm  14.0
F ig u re  9. L o w - f ie ld  'H - N M R  s p e c t r a  s h o w i n g  t h e  e f f e c t  o f  
a d d i t i o n  o f  A - 8 5 2 2 6  o n  t h e  im in o  p r o t o n  s i g n a l s  o f  t h r e e  
s y n t h e t i c  D N A  o l ig o m e r s .  T h e  D N A  c o n c e n t r a t i o n  is  1 m M  
in  1 0  m M  N a F D P C h , 1 0 0  m M  N a C l ,  1 0 0  m M  M g C l2 in  9 :1  H 2O : 
D 20 .  (A ) [d ( G -C )5]2:A -8 6 2 2 6  r a t i o s  o f  ( a )  1 :0 , (b )  1 :0 .5 ,  (c ) 1 :1 , 
(d )  1 :1 .5 , a n d  (e )  1 :2  a r e  s h o w n .  (B )  [d (A -T )5]2:A -8 6 2 2 6  r a t i o s  
o f  ( a )  1 :0 , (b )  1 :0 .5 , (c ) 1 :1 , a n d  (d )  1 :2  a r e  s h o w n .  (C )  [ d ( A r  
G C T 4 )]2:A -8 6 2 2 6  r a t i o s  o f  ( a )  1 :0 , (b )  1 :0 .5 ,  (c ) 1 :1 , a n d  (d )  1 :2  
a r e  s h o w n .
(Figure 10A). However, upon addition of A-85226 to the 
[d(G-C)5]2 solution, two new resonance signals in the 
downfield region between —0.72 and —0.10 ppm appear 
(Figure 10C). For comparison, the intercalator ethidium  
bromide was also used in this study. Upon addition of 
ethidium bromide to the [dlG -O sk oligomer, just one 
new resonance signal at —0.68 ppm is observed, pre­
sumably due to conformational changes on the DNA 
phosphate backbone induced by intercalation of ethid­
ium bromide into DNA (Figure 10B). This appearance 
of a new signal slightly downfield from the DNA 
backbone 31P resonance has been observed in previous 
studies of DNA—intercalator complexes31-33 and reflects 
the local distortion of the backbone that occurs due to 
formation of the intercalating complex. Significantly, 
for both ethidium bromide and A-85226, distinct signals
0 -1 -2 p p m
F igu re  10. 31P - N M R  s p e c t r a  o f  |d ( G - C ) 5]2 (A ) a n d  ld (G - C ) s ]2 
i n  t h e  p r e s e n c e  o f  e t h i d i u m  b r o m i d e  (B ) a n d  A - 8 5 2 2 6  (C ) . F o r  
B  a n d  C , t h e  m o le  r a t i o s  o f  o l i g o m e r  to  d r u g  w e r e  1 :2 . T h e  
o l ig o m e r  ( d r u g )  c o m p le x e s  w e r e  d i s s o lv e d  i n  N M R  b u f f e r  (1 0  
m M  N a H 2P O ., a n d  1 0 0  m M  N a C l )  a n d  1 0 0  m M  M g C l2 a t  2 7  
°C  in  1 0 0 %  D 20 .
are seen for both unperturbed and unwound phosphate 
backbone 31P resonances, indicating that the exchange 
between intercalated and free DNA sites is slow on the 
31P-NMR time scale for these ligands. Since in the 
present study the quinobenzoxazine—Mg2+ complexes 
have been confirmed as intercalators, the new downfield 
signal at —0.72 ppm in Figure 10B can be attributed to 
intercalation. However, the additional 31P-NMR reso­
nance signal at —0.10 ppm, which is unique to the 
A-85226-M g2+-[d(G-C)5l2 complex, cannot be explained 
by either purely intercalation or groove binding. The 
resonance signal at -0 .1 0  ppm must be due to a 
different effect and is consistent with a distortion of the 
deoxyribose phosphate backbone due to formation of an 
A-62176—Mg2+—(oxygen)phosphate coordination com­
plex.
A-62176 H as GC B a se  P a ir  P re fer en ce  at S u b ­
s t itu tio n  L ev els  o f  D ru g  an d  In tera c ts  in  a C oop­
era tiv e  M anner w ith  DNA. The previously described 
DNase I footprinting experiments (Figures 5 and 6) and 
the ^ -N M R  results (Figure 9) demonstrate the GC base 
pair binding preference of the quinobenzoxazines. In 
order to quantify this preference, association constants 
for binding of A-62176 to various DNA oligomers were 
measured spectrophotometrically. The Scatchard plots 
for A-62176 bound to poly[d(G-C)2l and poly[d(A-T)2] in 
the presence of 10 mM MgCU are shown in Figure 11. 
The solid lines drawn through the data represent the 
best fit using the Scatchard equation.34 Under identical 
conditions, A-62176 binds more strongly to poly[d(G- 
O 2] than it does to poly[d(A-T)2l, and the association 
constants for the drug binding to poly[d(G-C)2] and poly- 
[d(A-T)2] are 6.1 x 105 and 3.8 x 105 M-1, respectively. 
These results confirm that the A -62176-M g2+ complex 
binds preferentially to GC-rich regions in double-
+ A-85226  
+  M g 2+
D r u g " I n t e r c a l a t i o n N o n - c o m p l e x e d
[d (G -C )5l2
+ E th id iu m  B rom ide
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F ig u re  11. S c a t c h a r d  p l o t  o f  A - 6 2 1 7 6  b i n d i n g  t o  p o ly [d (G -  
O 2] ( —□ —) a n d  p o ly [d (A -T )2] ( —O —) i n  t h e  p r e s e n c e  o f  M g C l2 
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F ig u re  12. S c a t c h a r d  p lo t  o f  c o m b in e d  d a t a  f r o m  e q u i l i b r i u m  
d i a l y s i s  f l u o r e s c e n c e  e m i s s i o n  a t  5 0 0  n m  ( o p e n  c i r c l e s )  a n d  
s p e c t r o p h o t o m e t r i c  t i t r a t i o n  a b s o r p t i o n  a t  3 8 0  n m  ( c lo s e d  
c i r c l e s )  f o r  A - 6 2 1 7 6  b i n d i n g  t o  c a l f  t h y m u s  D N A .
stranded DNA, as would be expected for a typical 
intercalator.
As shown in Figure 11, spectrophotometric titration  
failed to produce data for v < 0.2. In this low-binding 
region, addition of more DNA causes only very small 
changes in absorbance (Figure 7) and therefore is not 
suitable for calculating the bound and free drug con­
centrations. Equilibrium dialysis can overcome this 
problem by separating the free drug and the drug—DNA 
complex into two compartments. Free drug concentra­
tion can be measured by the intrinsic fluorescence of 
the drug. However, at high-binding ratios (v > 0.3), free 
drug becomes more concentrated, and the prolonged 
time periods needed for reaching equilibrium cause the 
drug to precipitate. Therefore, the two methods were 
combined to obtain a complete Scatchard plot.
A Scatchard plot obtained by combining data from 
both sources for A-62176 binding to calf thymus DNA 
generates a smooth isotherm with a maximum near v 
=  0.2 (Figure 12). Fitting the combined data to the 
McGhee and von Hippel model35 gives an association  
constant (&) of 3.5 ±  0.4 x 105 M~1 with a cooperativity 
parameter (w) of 3.2 ±  0.6 and a binding site size (n ) of 
1.27 ±  0.06. A value for w  of >1 is associated with  
positive cooperativity, and the binding site size fits well 
with the viscometry measurements (see Figure 8). Not 
unexpectedly, there was also a systematic deviation of
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data from the best fit. In the model proposed (see later) 
for the quinobenzoxazine—Mg2+—DNA complex involv­
ing multiple interactions between drug molecules in 
different environments, it is not surprising that the 
model does not adequately describe the experimental 
system. Therefore, the McGhee and von Hippel model 
is only used to qualita tive ly  show the positive cooper­
ativity effect. This result confirms our expectations 
from the DNase I footprinting experiments (see Figure 
5) that binding of a first drug molecule creates better 
binding sites for other drug molecules.
4. N orfloxacin  E n h a n ces  th e  D N ase I F o o tp rin t  
G en erated  by A-62176 in  th e  P re sen ce  o f  M g2 f and  
P ro d u ces a G reater DNA L en g th en in g  E ffect w ith  
A-62176 as D e term in ed  b y  V iscom etry . Since both 
Norfloxacin and the quinobenzoxazine antitumor agents 
require Mg2f for interaction with DNA, but only the 
quinobenzoxazines can form a stable intercalation com­
plex with duplex DNA, the possibility of a cooperative 
binding to DNA by the two compounds was evaluated. 
The DNase I footprinting patterns of A-62176 alone 
(lanes 2—5), Norfloxacin alone (lane 7), and the two 
combined drugs (lanes 8 —11) are shown in Figure 13, 
top. As anticipated, Norfloxacin alone is invisible to 
DNase I footprinting (compares lanes 6 and 7), while 
increasing concentrations of A-62176 initially inhibit 
DNase I cleavage of GC-rich regions with associated 
unwinding and enhanced cleavage of the AT-rich re­
gions (lanes 2—4). These AT regions are them selves 
inhibited from DNase I cleavage at the highest drug 
concentration (lane 5). The effect of a constant amount 
of Norfloxacin (15 /*M) on the DNase I footprinting 
pattern of A-62176 is shown in lanes 8 —11. While this 
concentration of Norfloxacin alone does not inhibit the 
DNase I cleavage pattern, in combination with A-62176 
there is enhancement of the footprinting strength of the 
quinobenzoxazine antineoplastic agent A-62176. This 
is most clearly shown by comparing the densitometric 
scans of lanes 4 and 10 (scans A and C in Figure 13, 
bottom) with those of lanes 5 and 11 (scans B and D in 
the bottom panel), respectively. Addition of 15 //M 
Norfloxacin to 2 ^M A-62176 (lane 10 in the top panel 
and scan C in the bottom panel) results in a DNase I 
footprinting pattern that is almost equivalent to that 
obtained with 4 /iM A-62176 (lane 5 in the top panel 
and scan B in the bottom panel). The results of these 
experiments suggest that, although less potent than 
A-62176, Norfloxacin can interact cooperatively with 
A-62176.
If Norfloxacin and A-62176 can cooperatively interact 
with DNA in the presence of Mg2+, as suggested by the 
DNase I footprinting experiments, then together they 
should have an additive effect on lengthening of the 
DNA helix. To test this postulate, viscometric titration 
profiles of the contour length ratio of DNA (L/Lo) against 
moles of drug adduct per mole of DNA base pair were 
carried out for A-85226 alone, Norfloxacin alone, and a 
1:1 mixture of both in the presence of Mg2+. The results 
shown in Figure 14 demonstrate that while Norfloxacin 
alone shows no lengthening effect on DNA the 1:1 
mixture of Norfloxacin and A-85226 shows an additive 
lengthening effect that parallels the effect of pure 
A-85226 at twice the concentration of quinobenzoxzine 
present in the 1:1 Norfloxacin:A-85226 mixture. Inter­
estingly, the 1:1 mixture of Norfloxacin and A-85226
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F ig u re  13. (T o p )  E f f e c t  o f  N o r f l o x a c i n  o n  t h e  D N a s e  I 
f o o t p r i n t i n g  o f  A - 6 2 1 7 6  w i t h  o l ig o m e r  1 ( f o r  s e q u e n c e ,  s e e  
E x p e r i m e n t a l  S e c t io n ) .  L a n e s  1 —5 c o n t a i n  0 , 0 .5 ,  1 , 2 ,  a n d  4  
/ /M  A - 6 2 1 7 6 ,  r e s p e c t i v e l y ,  w i t h  2 0  n g  o f  D N A  i n  2 0  / iL  o f  
s o l u t i o n  c o n t a i n i n g  1 0  m M  T r i s - H C l  ( p H  7 .6 ) , 2  m M  M g C k ,  
a n d  1 0  m M  N a C l .  F o r  l a n e s  7 —1 1 , 1 5  ^ M  N o r f l o x a c i n  w a s  
p r e i n c u b a t e d  w i t h  0 , 0 . 5 , 1 ,  2 , a n d  4  / /M  A -6 2 1 7 6 ,  r e s p e c t i v e l y ,  
i n  t h e  s a m e  b u f f e r  s o l u t i o n  fo r  1 0  m i n ,  a n d  2 0  n g  o f  D N A  
( o l ig o m e r  1) w a s  t h e n  a d d e d  to  t h e  r e a c t i o n  m i x t u r e s .  L a n e  6  
i s  i d e n t i c a l  w i t h  l a n e  1. A G  a n d  T C  r e p r e s e n t  t h e  p u r i n e -  a n d  
p y r im id in e - s p e c i f i c  c h e m ic a l  c l e a v a g e  r e a c t i o n s .  T h e  s e q u e n c e  
o f  t h e  D N a s e - e n h a n c e d  r e g io n  i s  s h o w n  to  t h e  r i g h t .  ( B o t to m )  
D e n s i t o m e t r i c  s c a n s  o f  l a n e s  3 , 4 , 9 , a n d  1 0  o f  t h e  t o p  p a n e l  










F ig u re  14. V i s c o m e t r ic  t i t r a t i o n  o f  s o n i c a t e d  c a l f  t h y m u s  
D N A  w i t h  A - 8 5 2 2 6 ,  N o r f lo x a c in ,  a n d  a  1 :1  m i x t u r e  o f  A - 8 5 2 2 6  
a n d  N o r f lo x a c in  i n  t h e  p r e s e n c e  o f  M g 2+ (2 5  m M ) a t  2 2  °C  i n  
0 .0 1  M  T r i s  b u f f e r .  T h e  r a t i o  o f  t h e  c o n t o u r  l e n g t h  o f  D N A , 
L /L o , i s  p l o t t e d  a s  a  f u n c t i o n  o f  m o le s  o f  d r u g  a d d e d  p e r  m o le s  
o f  D N A  b a s e  p a i r s ,  v. T h e  v e r t i c a l  d o t t e d  l i n e s  s h o w  t h e  
i n t e r c e p t s  ( 0 .8 0  a n d  0 .9 6 )  o n  t h e  x  a x i s  f o r  w h e r e  s a t u r a t i o n  
b i n d i n g  o f  A - 8 5 2 2 6  (M g 2+) a n d  A - 8 5 2 2 6  a n d  N o r f l o x a c i n  i s  
a t t a i n e d ,  r e s p e c t i v e l y .  ( —A —) =  A - 8 5 2 2 6  +  N o r f l o x a c i n  (1 :1 ) ;  
( —□ —) =  A - 8 5 2 2 6 ;  a n d  ( —O —) =  N o r f lo x a c in .
produces an even greater lengthening effect than A-85226 
alone (i.e., a final drug to DNA ratio (v) of almost 1 vs 
0.8 for A-85226 alone). This result, when taken in 
conjunction with the DNase I footprinting experiment 
(Figure 13), demonstrates that Norfloxacin and the 
quinobenzoxazines bind to DNA in a cooperative man­
ner.36
5. T he In ter ca la tiv e  B in d in g  D rugs E th id iu m  
B rom id e an d  E ch in o m y c in  C an n ot S u b stitu te  for  
A-62176 in  th e  C o o p era tiv e  In tera c tio n  o f  N or­
flo x a c in  w ith  DNA in  th e  P re sen ce  o f  M g2+. Based 
upon the data described above, two alternative models 
for the A-62176-Norfloxacin complex with DNA in the 
presence of Mg2+ ions can be proposed. In the first 
model, A-62176 and Norfloxacin play s im ilar  structural  
roles in the interaction with DNA. However, the ability 
of Norfloxacin to interact with DNA is dependent upon 
initial intercalative binding by A-62176, which results 
in local unwinding of DNA, thereby providing a desta­
bilized adjacent site for stable intercalative binding by 
Norfloxacin. In the second case, A-62176 and Norfloxa­
cin play d iss im ila r  structural  roles in the interaction 
with DNA. In this case, A-62176 is uniquely responsible 
for the intercalative role and Norfloxacin plays a non- 
intercalative role in the complex but is still structurally 
dependent upon A-62176 and Mg2+ for interaction with 
DNA. The two models can be differentiated by testing  
the general role of intercalation in creating binding sites 
on DNA for Norfloxacin. If the sole purpose of A-62176 
is to provide destabilized intercalation sites for Nor­
floxacin through intercalation, then structurally unre­
lated intercalating agents such as ethidium bromide or 
echinomycin should be able to substitute for A-62176. 
Conversely, if Norfloxacin does not itself intercalate but 
rather interacts with DNA in a manner that is depend­
ent upon both Mg2+ and A-62176, then simple intercala­
tion per se will be insufficient to provide a cooperative 
interaction with Norfloxacin. Parallel experiments to 
those described before (using DNase I footprinting and 
viscometry) but using echinomycin and ethidium bro­
mide, respectively, in place of A-62176 were carred out
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F igu re 15. E f f e c t  o f  N o r f lo x a c in  o n  t h e  D N a s e  I f o o t p r i n t i n g  
p a t t e r n  o f  e c h in o m y c in .  L a n e s  1 - 6  a n d  2 - 7  in  t h e  l e f t  a n d  
r i g h t  p a n e l s ,  r e s p e c t iv e ly ,  a r e  t h e  s a m e  i n c r e m e n t a l  i n c r e a s i n g  
c o n c e n t r a t i o n s  o f  e c h in o m y c in ,  a n d  in  t h e  r i g h t  p a n e l  o n ly ,  
l a n e s  2 —7 c o n t a i n  N o r f lo x a c in  (1 5  / /M ) . A G  a n d  T C  r e p r e s e n t  
t h e  p u r i n e -  a n d  p y r i m i d in e - s p e c i f i c  c h e m ic a l  c l e a v a g e  r e a c ­
t i o n s .  T h e  s e q u e n c e  to  t h e  r i g h t  o f  l a n e  7 c o r r e s p o n d s  t o  t h e  
e c h in o m y c in  D N a s e  I f o o t p r i n t .
with Norfloxacin. The results of the DNase I footprint­
ing experiments (see Figure 15) show that echinomycin 
is unable to provide an additive effect on inhibition of 
DNase I footprinting, despite the documented ability of 
similar bis-intercalators37 to produce local unwinding 
of DNA (compare lanes 1—6 in the left panel with lanes 
3 - 7  in the right panel in Figure 15, which have the 
same concentrations of echinomycin but in the presence 
or absence of Norfloxacin). The viscometry experiments 
also show that Norfloxacin was unable to provide an 
additive lengthening effect on DNA in the presence of 
ethidium bromide (data not shown). Therefore, both 
sets of results show that mere intercalative binding by 
echinomycin and ethidium bromide, and thus local 
unwinding of DNA, is insufficient to provide a local DNA 
environment suitable for cooperative interactions with 
Norfloxacin. This argues strongly against the first 
model, in which Norfloxacin and the intercalators would 
play interchangeable roles. Rather, this data is consis­
tent with a second model, in which A-62176 exclusively 
provides the intercalative binding moiety and also plays 
an additional structural role in interacting with Mg2+ 
and Norfloxacin. In a subsequent experiment, in which 
the descarboxyl A-62176 was used in conjunction with 
Norfloxacin, no cooperative effect was observed, even 
though the descarboxyl compound is able to weakly 
intercalate with DNA (data not shown). This provides 
additional evidence for the importance of the /Lketo acid 
in providing stabilization of the drug:Mg2+ complex in 
the cooperative intercalation with Norfloxacin.
D iscu ss io n
The quinobenzoxazine antineoplastic agents bear 
strong structural similarities to the quinolone antibiot­
ics typified by Norfloxacin (see Figure 1). Indeed, the 
design of these compounds was inspired by the structure 
of Norfloxacin-type compounds that are clinically useful 
antibacterial compounds. Surprisingly, while the quino­
benzoxazine compounds lacked significant antibacterial 
activity, they did have antineoplastic activity that was 
dependent upon the presence of divalent cations, such 
as Mg2+ and Mn2+.2 This latter observation was sig­
nificant because although the biological activities were 
different, both the quinobenzoxazines (data shown here) 
and the quinolones18 exhibit a requirement for Mg2+. 
The subsequent observation reported here that, while 
the quinolones do not appear to form stable complexes 
with duplex DNA, the quinobenzoxazines were able to 
do so in the presence of Mg2+ suggested that stable com- 
plexation with duplex  DNA might be the basis for 
departure from antibacterial to antineoplastic activity. 
These preliminary observations inspire two related 
questions: (1) what is the structure of the quinobenz- 
oxazine-M g2+ complex with duplex DNA that is pre­
sumably responsible for the catalytic inhibition of 
topoisomerase II activity and antineoplastic activity and 
(2) what is the structural relationship between the ter­
nary quinobenzoxazine—Mg2+-D N A  complex and the 
quaternary quinolone—Mg2+—DNA—gyrase complex? 
The results reported here, together with the recently 
proposed Palumbo model for the quinolone—Mg2+— 
phosphate chelation complex,5 provide the basis for a 
revised model for the quinolone-M g2+—D N A -gyrase  
complex and important insights into the design of new 
quinolone antibacterial agents, as well as a proposed 
structure for the quinobenzoxazine-M g2+—DNA com­
plex.
D e term in a tio n  o f  th e  S tru ctu re  o f  th e  Q u in o­
b e n z o x a z in e -M g 2 "/Mn2t C om plex. The well-estab­
lished ability of the antibacterial quinolones to bind to 
di- and trivalent metal ions has led us to investigate 
the ability of the related quinobenzoxazines to bind 
manganese and magnesium ions. The formation and 
structure of the quinobenzoxazine—metal ion complexes 
were characterized by FT-IR and agarose gel electro­
phoresis experiments. The FT-IR results clearly impli­
cate the 5-carboxylate moiety of the quinobenzoxazines 
in magnesium complexation, although definitive proof 
is still lacking. Although we have no unequivocal 
evidence for the role of the 4-keto group in complexation, 
we favor a model in which the 4-keto group of the 
quinobenzoxazines participates, in combination with the 
5-carboxylate group, in chelation of the divalent metal 
ion. This model is consistent with the invariant nature 
of the 4-keto group in the closely related antibacterial 
quinolones. Mendoza-Diaz and co-workers38 have shown 
by X-ray crystallography that the 4-keto group of 
nalidixic acid is involved in the complexation of this 
quinolone with Cu2+-phenanthroline.39 We note that 
there are other, unassigned bands unique to the IR 
spectrum of the quinobenzoxazine—Mg2+ complex (~1000 
cm-1, Figure 3, upper spectrum) that may indicate that 
additional functional groups of the drug are involved 
in complexation with magnesium. Potential sites for 
complexation include the amino substituent of the C-l 
pyrrolidine moiety.





F ig u re  16. P r o p o s e d  s t r u c t u r e s  o f  t h e  1 :1  ( to p )  a n d  2 :2  ( b o t t o m )  A - 6 2 1 7 6 :M g 2 f c o m p le x e s .  I n  t h e  2 :2  c o m p le x ,  s t e r e o d i a g r a m s  
o f  t h e  h e a d - t o - t a i l  c o m p le x e s  a r e  s h o w n .
Both the quinobenzoxazine—Mn2+ and quinobenzox­
azine—Mg2+ complexes migrate during gel electrophore­
sis (Figure 2). The Mg2+ and Mn2+ ions have similar 
ionic radii (0.065 and 0.080 nm, respectively)40 and, 
excluding redox reactions, are chemically similar. Evi­
dence from FT-IR with supportive data from 1H- and 
13C-NMR spectra (unpublished results) suggests that 
both metal ions bind to the ketonic carbonyl and 
carboxyl moieties of the quinobenzoxazine compounds, 
as shown in Figure 16. We therefore have used the 
more tightly binding manganese ion in a Job titration 
to determine the stoichiometry of the quinobenzox­
azine—metal complex. The Job titration confirms that 
the quinobenzoxazine-M n2+ complex forms in an 
equimolar ratio, e.g., 1:1, 2:2, etc. By extension, the 
quinobenzoxazine—Mg2+ complex also forms a similar 
positively charged complex.
The combined results of the gel electrophoresis, FT- 
IR, and Job titration experiments suggest that a 
quinobenzoxazine—Mg2+ complex forms in equimolar 
proportions between the drug and divalent cation. The 
simplest complexation would involve a 1:1 ratio of drug 
to Mg2+ (Figure 16, top), but for reasons discussed later, 
we favor the alternative 2:2 complex of drug to Mg2+, 
in which two drug molecules form a head-to-tail com­
plexation with two Mg2+ ions. In such a 2:2 quinobenz­
oxazine—Mg2+ complex, each drug molecule could par­
ticipate in Mg2+ complexation, with the /3-keto acid and 
the amino group of two different drug molecules serving 
as ligands for each of the two magnesium ions (see 
Figure 16, bottom). Such a 2:2 complex has previously 
been proposed, on the basis of spectrofluorimetric stud­
ies, for the interaction between the antibacterial fluo­
roquinolones and magnesium ions.41
M agn esiu m  Ion s P la y  an  Im p ortan t R ole  in  th e  
In tera c tio n  o f  th e  Q u in o b en zo x a z in es  w ith  DNA.
To investigate the role of Mg2+ in the interaction of the 
quinobenzoxazines with DNA, we employed UV—vis 
spectroscopy to study the interaction of quinobenzox­
azines with calf thymus DNA in the presence and 
absence of magnesium. In the absence of magnesium, 
the quinobenzoxazines appear to interact with DNA in 
a relatively weak, nonselective fashion. There are 
modest changes in the UV region of the absorption 
spectrum of A-62176 with added DNA in the absence 
of magnesium, but the lack of a clear isobestic point 
indicates a multitude of binding modes. In contrast, in 
the presence of magnesium, a number of marked 
changes occur in the absorption spectra of A-62176 upon 
addition of DNA. There are bathochromic shifts in both 
the UV and visible regions of the spectrum of the drug 
and clear isobestic points (compare panels A and B in 
Figure 7). Upon the basis of these observations, the 
quinobenzoxazines appear to interact with DNA in quite 
different ways in the presence and absence of Mg2+ ions. 
A topoisomerase relaxation assay, viscometric titrations, 
and NMR evidence clearly indicate that the magnesium- 
dependent DNA binding of the quinobenzoxazines in­
volves intercalation; we assume that the magnesium- 
independent binding involves interaction with the grooves 
or exterior of the DNA double helix. The association 
constant of A-62176 binding to poly[d(G-C)2l in the 
presence of 10 mM Mg2+ was determined to be 6.1 x 
105 M-1. This magnesium-dependent interaction of 
quinobenzoxazines with linear double-stranded DNA is 
to be contrasted to the antibacterial quinolones, which 
only bind to supercoiled circular DNA, not linear double­
stranded DNA, in the presence of magnesium. Fur­
thermore, the association constant for the magnesium-
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dependent binding of A-62176 to calf thymus DNA that 
we report is an order of magnitude higher than the 
association constant previously reported for Norfloxacin 
binding to supercoiled DNA in the presence of magne­
sium (4.2 x 104 M -1).18
Determ ination o f the Structure o f the Quino­
benzoxazine—Mg2+ Complex w ith DNA. Spectro­
scopic (UV, CD, NMR) and other experimental methods 
(viscometry, gel electrophoresis) were used to explore 
the nature of the ternary complex between the quino­
benzoxazines, Mg2+, and DNA. The results of these 
studies provide insights into the sequence specificity of 
the drug—DNA binding reactions and a detailed char­
acterization of the quinobenzoxazine—Mg2+—DNA com­
plex, ligand-induced conformational transitions in DNA, 
the stoichiometry of the drug—Mg2+—DNA complex, and 
cooperativity in drug binding.
Previous studies have shown that when the concen­
tration of Mg2+ in the solution is greater than 0.7 M, or 
the concentration of Na+ is greater than 2 M, the 
conformation of DNA is changed from B- to Z-form.42 
Thus, reaction conditions throughout this study are 
carefully selected in order to avoid conformational 
changes in DNA induced by high salt concentration. The 
CD spectral changes (unpublished results) observed 
upon addition of the quinobenzoxazines to poly[d(G-C)2] 
confirm the importance of Mg2+ in facilitating the 
interaction of A-85226 with DNA and also show that 
the DNA remains in B-form DNA throughout the 
titration process in both the presence and absence of 
10 mM MgCl2.
There is clear evidence that in the presence of 
magnesium the quinobenzoxazines intercalate into 
double-stranded DNA: quinobenzoxazine binding is 
accompanied by unwinding of closed circular DNA, as 
determined in the topoisomerase assay, by lengthening 
and stiffening of linear double-stranded DNA, as deter­
mined by viscometric studies, and by downfield shifts 
of the phosphorus signals and upfield shift of the imino 
proton signals in the NMR. Additional information 
concerning the nature of the intercalation complex 
formed between quinobenzoxazine, Mg2+, and DNA was 
also obtained from these studies.
In contrast to the quinolone gyrase inhibitors, the 
quinobenzoxazines form a stable complex with duplex 
DNA. Therefore, we were able to probe directly the 
interaction of the quinobenzoxazines with DNA, using 
31P-NMR to address the possibility of a drug—phosphate 
bridging role for Mg2+. The results show that at 
subsaturating levels of drug three 31P-NMR signals are 
present. The most upfield (—0.88 ppm in Figure 10C) 
is assigned to those phosphates in the backbone at 
which drug modification has not occurred. The down­
field chemical shift of the middle 31P-NMR signal (—0.72 
ppm) is typical for phosphates at which intercalation 
has occurred. The remaining most downfield 31P-NMR 
signal (—0.10 ppm) is unique to the intercalating 
quinobenzoxazines, which require Mg2+ for their binding 
to DNA. We propose that this downfield-shifted signal 
is due to the Mg2+-chelated phosphate in which the 
chelation produces an additional distortive effect on the 
deoxyribose phosphate backbone.
Several lines of evidence point toward a GC prefer­
ence for the initial intercalative binding complex of the 
quinobenzoxazine—Mg2+ complex. First, the Scatchard
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plots show that the association constants for drug 
binding to poly[d(G-C)2 ] and poly[d(A-T)2 l are 6.1 x 105 
and 3.8 x 105 M-1, respectively. The initial DNase I 
footprints of A-62176 reveal a clear GC preference. 
Proton NMR studies of the magnesium-dependent in­
teraction of the quinobenzoxazines with various double­
stranded DNA oligomers have proved to be especially 
insightful. The interaction of A-85226 with [d(G-C)s]2  
clearly demonstrates intercalation, as evidenced by 
upfield shifts in the imino proton signals. In contrast, 
with [d(A-T)5]2 , there is no indication of intercalation 
under similar conditions. Remarkably, with the oligo­
mer [d(AiGCT4)]2 , initial intercalation at the GC step 
is followed by intercalation at the AT base pairs. Thus, 
while isolated AT base pairs cannot serve as intercala­
tion sites for A-85226, AT base pairs flanking a favored 
CG site can serve as intercalation sites, clearly demon­
strating the cooperativity in the DNA binding by 
quinobenzoxazines. A parallel result is evident in the 
DNase I footprinting experiments, where the initial 
footprint occurs at GC-rich regions, and only sifter drug 
binding has occurred at these regions does the adjacent 
A-tract become receptive to drug binding (Figure 5). We 
note that there is additional information in the DNase 
I footprinting experiments that indicates some distortion 
of A-tract regions flanked by quinobenzoxazine-inter- 
calated GC-rich regions (regions B and E in Figure 5). 
As expected, the GC-rich regions are cleaved more 
readily by the DNase I than the A-tract, where little 
cleavage occurs. However, once intercalation by the 
quinobenzoxazine has occurred in the GC-rich region, 
the A-tract becomes susceptible to DNase I cleavage, 
presumably as a consequence of local unwinding due to 
intercalation at the adjacent site. Only then, at higher 
drug concentrations, does this region of drug-induced 
DNase I cleavage become receptive to intercalation by 
A-62176. A parallel sequence of events presumably 
results in the consecutive GC and then AT imino upfield 
1H-NMR shifts in the [d(AiGCT4 ) ] 2  duplex during titra­
tion with A-62176.
A Scatchard plot (Figure 12) shows that A-62176 
binds to DNA with a positive cooperativity. The positive 
binding cooperativity reveals that intercalation of the 
first drug creates other intercalative sites. The coop­
erativity can come from two sources: (1) as already 
mentioned, intercalation in the GC region by A-62176 
locally unwinds the adjacent DNA double helix, and this 
may create better intercalation sites, even within A- 
tracts, and (2) the aromatic stacking of the externally 
bounded drug molecule with other drug molecule(s) may 
initiate and stabilize the intercalation at adjacent sites 
(see later).
The viscometric titrations demonstrate that the maxi­
mal increase in viscosity corresponds to a drug-DNA  
base pair ratio of ~1:1. This surprising result requires 
that, at saturation, every base pair step be occupied by 
an intercalated quinobenzoxazine molecule—in violation 
of the well-established neighbor exclusion rule.43 How­
ever, if the quinobenzoxazines exist, in the presence of 
magnesium, as a 2:2 drug-M g2+ complex, and further, 
if  in such a 2:2 complex, only one of the two drug 
chromophores serves as an intercalator, then there is 
no violation of the neighbor exclusion rule: at saturation 
only one 2:2 quinobenzoxazine—Mg2+ dimer is interca­
lated between two base pairs. Minor or major groove
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F i g u r e  1 7 . M o le c u la r  m o d e ls  o f  t h e  4 :4  q u in o b e n z o x a z in e :M g 2+ (to p ) a n d  t h e  2  +  2 :4  m ix e d  q u in o b e n z o x a z in e /q u in o lo n e —M g 2+-  
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m o le c u le s  a r e  s h o w n  in  y e l lo w , th e  p h o s p h a t e s  in v o lv e d  in  t h e  c o o r d in a t io n  a r e  b lu e , a n d  t h e  M g 2+ io n s  a r e  g r a y . T h e  e x t e r n a l ly  
b o u n d  m o le c u le s  (A -6 2 1 7 6  fo r  th e  to p  a n d  N o r f lo x a c in  for  th e  b o t to m ) a r e  c o lo r e d  g r e e n .
binding can be eliminated for the second drug molecule 
of the 2:2 complex, since only upfield ^ -N M R  shifts of 
imino protons occur upon formation of the quinobenz­
oxazine—Mg2+—DNA complex. In order to maximize the 
quinobenzoxazine stacking interactions in the nonin­
tercalated members of the 2:2 complex, two separate 2:2 
complexes may arrange them selves so that the exter­
nally bound drug molecules are at adjacent positions, 
but the intercalated moieties are still separated by two 
base pairs (see Figure 17, top).
Let us examine the data that would support the 
proposed 2:2 quinobenzoxazine-M g2+ model for the 
active species involved in intercalation into DNA. Our 
studies of the A-62176-M n2+ complexation clearly show 
that a single complex forms with equal molar ratios of 
metal ion and drug. Previous investigators have pro­
posed a 2:2 drug-M g2+ complex for the closely related 
antibacterial fluoroquinolones.41 Thus, our model is
consistent with our data on the quinobenzoxazines as 
well as previously published data on the structurally 
similar fluoroquinolones. The cooperative nature of the 
intercalation of quinobenzoxazines can at least be 
partially attributed to the presence of the “exterior,” 
nonintercalating quinobenzoxazine member of the 2:2 
drug-M g2+ complex. The importance of drug—drug 
interactions in the structure-activity relationship of the 
antibacterial quinolones has previously been proposed 
and is supported by a number of X-ray crystal structures 
of antibacterial quinolones, which show close interac­
tions between neighboring molecules in the crystal 
lattice.38 These interactions involve a combination of 
j i - n  stacking and van der Waals contacts between  
substituents at N -l. We invoke these same interactions, 
particularly ji- ji stacking, to explain how the presence 
of one intercalated 2:2 complex, with its associated  
exterior quinobenzoxazine, can facilitate the nearby
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intercalation of another 2:2 complex. Drug—drug as­
sociation between the exterior chromophore of the 
intercalated 2:2 complex and one of the chromophores 
of the incoming 2:2 complex will stabilize the intercala­
tion of the incoming 2:2 complex at an intercalation site 
that might not otherwise be favored. An extension of 
this rationale dictates that the exterior chromophore of 
the intercalated 2:2 complex need not be optimized for 
intercalation but rather must serve only to coordinate 
the shared magnesium ions in the 2:2 complex and 
facilitate drug—drug interactions on the exterior of the 
DNA, We reasoned that the antibacterial quinolones 
should serve these two functions. Thus, the coopera­
tivity that we observe between the intercalation of the 
quinobenzoxazines and Norfloxacin is a strong indica­
tion that our model is fundamentally correct. Finally, 
we acknowledge that the principle of self-assembly in 
designing cytotoxic agents was described some years ago 
by Rideout.44 Fortuitously, the self-assembly of the 4:4 
drug:Mg2+ complex described here on a DNA double 
helix seems to fulfill the principles proposed in this 
elegant and clever proposal.
Both the Shen and Palumbo models for the quin­
olone—DNA interactions have similarities to the 2:1 
chromomycin—Mg2+ complexes.45 46 In one case,14 a self­
associated quinolone complex is proposed, and in the 
other,5’18 a drug—Mg2+ complex is proposed. Conceptu­
ally, our thinking about the structure of the quinobenz­
oxazine—Mg2+—DNA complex was influenced by the 
existing models for the quinolone—DNA complexes 
proposed by the Italian group5 and the U.S. group.15 
Unexpectedly, the cooperative role of A-62176 and 
Norfloxacin and, conversely, the noncooperative effect 
of general intercalators such as ethidium bromide were 
also important observations. Last, the recently reported 
comparison of the hydroxyl radical footprinting patterns 
of DNA with the bacterial gyrase, and then after 
formation of the cleavable complex trapped with a 
nonhydrolyzable ATP analog or quinolone antibiotic, 
provided additional crucial insight.46
Stereomodels for the proposed 4:4 A-62176—Mg2+— 
DNA ( P O 4 )  chelation complex are shown in Figure 17, 
top. This 4:4 complex consists of a pair of 2:2 A-62176— 
Mg2+ dimers. In each 2:2 dimer, the quinobenzoxazine 
ring D (Figure 1) of one A-62176 molecule is intercalated 
between the adjacent base pairs and the pyrrolidine ring 
of this molecule lies in the minor groove, with the amino 
group coordinating an Mg2+ ion that is in proximity to 
the negatively charged phosphate backbone. Mg2+ 
coordination serves to bridge the amino group of this 
A-62176 molecule with the carbonyl and carboxyl groups 
of an adjacent, nonintercalated A-62176 molecule. In 
a similar way, the carbonyl and carboxyl groups of the 
intercalated A-62176 molecule coordinate a second Mg2+ 
molecule that is also bound by the amino group of the 
exterior, nonintercalated A-62176 molecule. Both Mg2+ 
ions of the 2:2 Mg2+:A-62176 complex are also coordi­
nated by the oxygen of the DNA phosphate backbone. 
The additional coordination sphere about these Mg2+ 
ions is filled with water molecules. Because of steric 
constraints, it was not possible to form a similar drug— 
Mg2+—P O 4  complex in the major groove of DNA. Two 
such 2:2 dimers are then arranged on DNA such that 
the two externally bound quinobenzoxazines interact 
through 7i—7i stacking forces and the two intercalated
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molecules are separated by two base pairs. Stereomod­
els of an analogous 4:4 mixed A-62176:Norfloxacin 
dimer Mg2+ complex are shown in Figure 17, bottom. 
In this model, consistent with the results of the coop­
erativity experiments, the two Norfloxacin molecules are 
externally bound and the A-62176 molecules are inter­
calated.
Relationship betw een the Structure o f the 2:2 
Q uinobenzoxazine-M g2+ Complex w ith DNA and 
the Norfloxacin Interaction w ith the Bacterial 
Gyrase—DNA Complex. While there are certain 
similarities between the quinobenzoxazipe-DNA and 
quinolone—gyrase-DNA interactions, there are also 
critical differences. There is ample evidence that both 
drugs require Mg2+ for their interaction with DNA,18 
and an Mg2+ bridged phosphate is implicated. On the 
other hand, only the quinobenzoxazines are able to form 
a stable intercalated complex with DNA. Although 
A-62176 and Norfloxacin are able to form a heteroge­
neous 2:2 Mg2+ complex on DNA (Figure 17, bottom), 
direct evidence for an intercalative role for Norfloxacin 
is lacking. The DNA unwinding role of echinomycin at 
adjacent sites is insufficient to create stable intercala­
tion sites for Norfloxacin, even in the presence of Mg2+. 
Both the Shen and Palumbo models515 propose that a 
transient step in the gyrase manipulation of DNA 
produces a DNA substrate that provides a special niche 
for the quinolone antibiotics. The two models differ 
considerably in the precise structure of the substrate 
binding site and the quinolone complexation species. 
Upon the basis of the analogies to the 2:2 quinobenzox­
azine—Mg2+—DNA complex, we propose a quinolone— 
Mg2+—phosphate bridge parallel to the Palumbo model5 
but suggest that gyrase-mediated unwinding of duplex 
DNA  rather than single-stranded DNA is the more 
likely target.
Recently, the Maxwell laboratory has determined the 
hydroxyl radical footprint of DNA in the presence of 
bacterial gyrase and the quinolones.47 A comparison of 
the hydroxyl radical footprinting patterns of DNA with 
gyrase alone and then after formation of the cleavage 
complex trapped with a quinolone (CFX) or a nonhy­
drolyzable ATP analog (ADPNP) shows that the major 
changes are a shift in the phasing of the cleavage 
maxima upstream of the cleavage site (i.e., 5' to the 
cleavage site on the top strand) and an additional 
cleavage peak adjacent to the cleavage site (Figure 18). 
This is common to the footprints found with both the 
quinolone and nonhydrolyzable ATP analog. We pro­
pose that this enhanced cleavage site downstream on 
both strands is due to transient unwinding of the helix, 
which is then trapped by intercalation of a Mg2+- 
stabilized dimer (2:2 model) or pair of dimers (4:4 model) 
of the quinolones. It is important to recognize that we 
do not propose the quinolones induce this unwinding 
but rather that they simply trap the kinetically acces­
sible unwound DNA, since this same enhanced hydroxyl 
radical cleavage is found in the case of the nonhydro­
lyzable ATP analog.
Im plications for Drug Development. Our model 
for the structure of the quinobenzoxazine-Mg2+-D N A  
complex (Figure 17) proposes what is effectively a 
heterodimer of the 2:2 drug—Mg2+ complex with respect 
to the receptor, since while one drug molecule is 
intercalated the other is externally bound to DNA. In
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Figure 18. Plots of relative hydroxyl radical cleavage fre­
quency at each nucleotide of duplex DNA in the presence of 
bacterial gyrase alone (—• —); with ADPNP (5'-adenylyl-y3,y- 
iminodiphosphate), a nonhydrolyzable ATP analog (—O—); and 
with CFX (ciprofloxacin), a quinolone antibacterial (—□ —) 
(adapted from Figure 3C in ref 47, with permission). Arrows 
between the duplex sequences indicate gyrase-induced DNA 
cleavage sites. The brackets indicate the quinolone antibacte­
rial—Mg2+ complex intercalation/external binding site, as 
proposed by us.
the presumed intracellular target (topoisomerase II for 
the quinobenzoxazines and bacterial gyrase for the 
quinolones), this represents two distinct targets for the 
drug molecules. While the intercalated molecule inter­
acts exclusively with DNA, the second externally bound 
molecule interacts with the protein (topoisomerase II 
or gyrase). The important implication from this model 
is that two different quinobenzoxazines or quinolones 
should be optimized for SAR rather than just a single 
molecule! In this way the two quinobenzoxazine (or 
quinolone) molecules interacting with DNA and the 
protein can each be independently fine-tuned for binding 
interactions.
Conclusions
The structure of a novel 4:4 quinobenzoxazine:Mg2+ 
complex assembled on DNA is proposed. In this com­
plex the quinobenzoxazine—Mg2+ complex forms a “het­
erodimer” in respect to DNA in which one molecule is 
intercalated into DNA and the second molecule is bound 
externally, held to the first molecule by two Mg2+ 
bridges. The assembly of two such heterodimers forms 
a 4:4 complex in which the two externally bound 
molecules interact via n—n  interactions (Figure 17, top). 
This proposed structure for a drug—DNA complex is a 
new paradigm for how drugs may interact with DNA 
and has structural features that mimic “leucine zippers”,
Fan et al.
which dimerize on DNA through external hydrophobic 
interactions.48
Based upon cooperativity experiments with Norfloxa­
cin, the structure of a mixed 4:4 quinobenzoxazine/ 
Norfloxacin:Mg2+ complex is also proposed in which two 
Norfloxacin molecules replace the two externally bound 
quinobenzoxazines in the previous complex (Figure 17, 
bottom). The proposed structures (Figure 17) have 
important implications for the design of new topo­
isomerase II and bacterial gyrase inhibitors.
Experim ental Section
M aterials. Quinolone and quinobenzoxazine compounds 
were provided by Abbott Laboratories and used without ;j 
further purification. Double-stranded calf thymus DNA, plas- ;j 
mid DNA pU19, poly[d(G-C)2], and poly[d(A-T)2l were pur- | 
chased from Sigma. Synthetic oligodeoxynucleotides for the 1 
NMR experiments were purchased from Midland. Electro- I 
phoretic reagents (acrylamide, bisacrylamide, ammonium per- |  
sulfate, and N,N,N',N'-tetramethylethylenediamine) were pur- I 
chased from BioRad. T4 polynucleotide kinase was from 1 
United States Biochemical Co., and DNase I was from Prome- | 
ga. The concentration of nucleic acids was determined spec- 1 
trophotometrically. Molar absorptivities at 260 nm are re- f 
ported as 6600 M-1 cm-1 for calf thymus DNA,49 7100 M_1 cm-1 I 
for poly[d(G-C)2l, and 6600 M_1 cm-1 for poly[d(A-T)2].50
DNA sequences of oligomers 1 and 2 used in the DNase I 
footprinting experiments are shown below:
Oligomer 1
5 '-CGATCTTCGTCAAGCATCCCAGAAGGAAAAAATCGCCCTCGGACCAGGCAGCCTCAAACCCT-3 '3 ' -GCTAGAAGCAGTTCGTAGGGTCTTCCTTTTTTAGCGGGAGCCTGGTCCGTCGGAGTTTGGGA- 5 '
Oligomer 2
5 ' -GTCGCGTAAGTTGGCATTATAAAAAGCATTGCTTATCAATTTGTTGCAACGAACAGGTCACTGAATGCGCTGA- 3 '3 ' -CAGCGCATTCAACCGTAATATTTTTCGTAACGAATAGTTAAACAACGTTGCTTGTCCAGTGACTTACGCGACT-5 '
*
A garose G el E lectroph oresis. Electrophoresis was car­
ried out on a 2.5% agarose gel (10 x 8 x 0.5 cm) in TA buffer 
(0.04 M Tris-acetate), pH 8.0, at room temperature. Mixtures 
of A-62176 (1 fiL, 10 mM) and salt stock solutions (1 juL, 0.5 
M) were treated with a gel-loading buffer (0.5 fiL) and 
electrophoresed at 100 V (~5.4 V/cm) for 1.5 h. The gels were 
photographed under UV light with a red filter.
P reparation  o f  O ligom er DNA for D N ase I F ootp rin t­
ing. The oligonucleotides (oligomers 1 and 2) used in this 
study were synthesized on an Applied Biosystems 381A DNA §
synthesizer using the phosphoramidite method. The crude 1
oligomers were purified by preparative polyacrylamide gel |
electrophoresis. Purified oligomer was labeled with [y-32P]ATP |
using standard methods and annealed with the complemen- I
tary strand to generate duplexes. Annealed duplexes were I
further purified using previously described methods.27 1
D N ase I F ootp rin tin g . The 5' 32P-labeled oligomer DNA jj
(5 ng) was mixed with a desired amount of A-62176 for 10 min if
at room temperature in 20 /uL of a solution containing 10 mM |
Tris-HCl (pH 7.6), 10 mM NaCl, and 2 mM MgCl2, unless j
otherwise indicated. Reaction mixtures were digested with 0.1 1
U o f DNase I for 1 min. The DNase I reaction was stopped by |
the addition of 20 fih of sequence dye (80% formamide in 10 
mM NaOH), and samples were loaded on a 10% denaturing 
sequence gel.
NMR S pectroscopy. All NMR spectra were recorded on 
a Bruker MSL-500 spectrometer at 27 °C. A-85226, an amino 
analog of A-62176, was chosen in the NMR study because it 
has greater solubility in water. 1H-NMR experiments were 
carried out by adding aliquots of a concentrated drug solution 
to solutions of[d(G-C)5]2, [d(A4GCT4)]2, and [d(A-T)s]2 in NMR 
buffer (10 mM NaH2P 0 4 and 100 mM NaCl, pH 7.0) in the 
presence of 100 mM MgCL in 90% H2O/1 0 % D2O. The total 
DNA concentration was 1 mM. 31P-NMR experiments were 
carried out by adding A-85226 or ethidium bromide to [d(G-
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C)5]2 solutions (1 mM) in NMR buffer in the presence of 100 
mM MgCL in D2O. H3PO4 was used as an external reference 
(0 . 0  ppm).
FT-IR Spectroscopy. The FT-IR spectra were obtained 
with a Nicolet 550 IR spectrometer operating between 4000 
and 400 cm- 1  in KBr phase. Typically, 64 scans at a resolution 
of 4.0 cm - 1  were averaged. The A-85226—Mg2+ complex was 
prepared by mixing A-85226 and excess MgCl2 in H2O and 
incubating at room temperature for 24 h. The mixture was 
then cooled in ice, and an orange suspension was obtained. 
The suspension was filtered, washed with ethanol, and dried 
in vacuum.
U V -V is Spectrophotom etric T itration. Absorbance 
spectra were recorded by a Perkin-Elmer 553 diode array UV -  
vis spectrophotometer. Aliquots (1—5 pL) of a 3 mM MnCl2 
solution containing drug at a concentration of 30 pM in MeOH 
were added to a 30 pM drug solution in MeOH. After addition 
of each aliquot, the absorption spectrum (290—500 nm) was 
recorded. Similar experiments were carried out for the drug- 
DNA interaction study. Sequential aliquots of a concentrated 
solution (5 mM base pair, ~1  pL) of nucleic acid containing 
drug at a concentration of 10 pM were added to a 10 pM drug 
solution containing 0.01 M Tris-HCl buffer with or without 
10 mM MgCl2 (pH 7.0) in a 1 cm cuvette. The total drug 
concentration was thus maintained at a constant value. After 
addition of each aliquot, the absorption spectrum (290-500  
nm) was recorded. Addition of aliquots continued until either 
the absorbance became constant or the increasing concentra­
tion of nucleic acid itself caused a slight increase in absorbance.
Job  T itrations. Separate stock solutions of metal ion and 
A-62176 at a concentration of 5 mM were prepared. A suitable 
amount of the metal ion and drug stock solutions was added 
to 1 mL of MeOH in a cuvette, resulting in 14 different [drug]/ 
[Mn2+] ratios between 0 and 1. The total concentration of 
(drug +  Mn2+) was kept constant at 100 pM. The absorbance 
(A) at 320 nm, which shows maximal change due to complex 
formation (Figure 4B), was measured. Subtraction of the 
absorbance (Ao) for the same drug concentration without Mn2+ 
from A yielded the absorbance change (A — Ao) due to complex 
formation. The A — Ao values were normalized to the 
theoretical maximum absorbance change (Amax), which was' 
obtained as described by Likussar and Boltz. 25 The normalized 
value, y =  (A — Ao)/Amax, was then plotted against the mole 
fraction of drug Gtdrug) to obtain the continuous variations plot 
or the Job plot.
V iscom etric T itrations. Successive aliquots of 10 mM 
drug stock aqueous solution were added to a 5 mL sonicated 
calf thymus DNA (molecular weight ~  2 x 105) solution (0.25 
mM in 0.01 M Tris-HCl buffer, pH 7.0) in the reservoir of a 
Cannon-Ubbelohde semimicroviscometer (Cannon Instrument 
Co., series no. 50). The Mg2+ concentration was 25 mM. 
Under these conditions, the native double-helical structure of 
the DNA was not affected.51 After each addition the flow time, 
t, was measured.
The specific viscosity was calculated by rjsp = t/to — 1. 
Reduced viscosities (rjsp/Cn) were evaluated at one concentra­
tion only (for each value of v), and intrinsic viscosities, \rf\, 
were calculated using a value of 0.53 for Huggins’ coefficient 
k in eq l :52
=  f o l d  +  ^ M C n ) (1 )
The concentration Cn refers to mol of nucleotide/L, irrespective 
of the amount of drug bound. Since the volume change was 
<1.5% during the titration, Cn was not corrected. Therefore, 
[?/], which is the intrinsic viscosity for the drug—DNA complex, 
is calculated by substituting rjsp = t/to ~ 1 into eq 1. The value 
of [?7]o is the intrinsic viscosity for the DNA solution alone.
Cohen and Eisenberg52 have shown that the ratios of the 
intrinsic viscosities depend upon the relative ratios of the 
contour length of DNA, L/Lo (L and Lo represent contour 
lengths in the presence and absence of drug) (eq 2 ).
L/L0 *  (2)
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Equilibrium  D ialysis. Since spectrophotometric titration 
is not sufficiently sensitive at low drug binding ratios (v < 
0.15), equilibrium dialysis was used to obtain binding data for 
this region. A 5 mL, 10 pM drug solution in a sealed dialysis 
tube (Spectro/Por, MWCO 6000—8000) as the first compart­
ment was placed in a glass tube containing 8  mL of a calf 
thymus DNA (Sigma) solution at various concentrations (10 
juM to 1 mM base pairs) as the second compartment. The 
whole assembly was placed in a shaker for 60 h at 20 °C in 
the dark. The calf thymus DNA used was predialyzed to 
eliminate short DNA strands. All solutions contained 5 mM 
MgCL and were buffered by 20 mM phosphate at pH 7.0.
The intrinsic fluorescence of the drug was used to determine 
the free (Cf) and bound (Cb) drug concentrations. Fluorescence 
spectra were recorded on a Hitachi F-2000 fluorometer with 
an excitation wavelength at 380 nm. A-62176 has a weak 
fluorescence emission at ~500 nm in pH 7.0 buffer. Addition 
of DNA and Mg2+ increases the fluorescence intensity but 
produces very little spectral shift (data not shown). The 
fluorescence intensity (/) at 500 nm in the drug compartment 
was used to calculate drug concentrations (mM) in both 
compartments:
Cf =  (7//0) x 10 (3)
Cb =  [(5 x 10) -  (13 x Cf)]/8 (4)
where Io is the fluorescence intensity for 1 0  ^M drug in the 
same buffer. The bound drug concentrations calculated in this 
way agree to within 5% with those calculated by fluorescence 
measurements of the solution outside the dialysis bag. The 
binding ratio (v) can thus be calculated by
v = Cb/[DNA] (5)
where DNA concentration is in base pairs.
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D N A  a s  a  t a r g e t  f o r  d r u g  a c t i o n
L a u r e n c e  H .  H u r l e y  a n d  F .  L e s l i e  B o y d
DNA is the presumed target for a number of clinically useful anticancer drugs. 
In this review, Laurence Hurley and Leslie Boyd discuss the appropriateness 
of the term 'receptor' for DNA and outline the forseeable problems in designing 
drugs that will produce a defined pharmacological response through interaction 
with DNA. They describe the structural features which present DNA as an 
attractive target for drug design, and the possible characteristics of drugs that 
react with DNA to produce a predetermined biochemical response. Finally, they 
outline modern approaches to elucidating the structural and biological 
consequences of drug modification.
DNA is the presumed intracellular 
target of some of the more clinic­
ally important antitumor agents, 
including bleomycin, doxorubicin 
(adriamycin), cisplatin, actinomy- 
cin D, mitomycin and cyclophos­
phamide (Fig. 1). In spite of the
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well accepted premise that DNA is 
the receptor for these drugs, 
definitive data that pin-point the 
exact mechanism of action for any 
DNA-reactive drug are as yet 
unavailable1.
However, recent advances in 
high-field NMR, computer-assisted 
drug design and molecular biology 
now provide improved oppor­
tunities to elucidate the molecular 
basis for drug action, and design  
new DNA-reactive drugs with  
perhaps more selective biochem i­
cal and pharmacological effects. 
For example, because DNA is 
a structurally well characterized 
molecule, excellent opportunities 
exist to use computational chem­
istry to assist in the design of drugs 
that bind in predetermined ways 
to DNA2. Likewise, sufficient 
amounts of defined-sequence 
DNA molecules can be prepared 
by automated synthesis methods 
for physical characterization by X- 
ray diffraction and/or high-field  
NMR3. Finally, recombinant DNA  
technology provides the methods 
and materials to test both new and 
old concepts as to how DNA- 
reactive compounds may exert 
their potent biological effects.
Although DNA is a well char­
acterized target, its large size 
and repetitive nature make it an 
elusive target for selective drug 
action. Two observations increase 
the hope for designing drugs that 
will exhibit therapeutically useful 
selectivity by reaction with DNA. 
Firstly, some DNA binding pro­
teins (e.g. transcriptional factors) 
have evolved to achieve a DNA
© 1988, Elsevier Science Publishers Ltd. (UK) 0165 -  6147/88/S02.00
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sequence selectivity which per­
mits their participation in precise 
control of gene expression and 
other genetic events. Secondly, 
one can argue that the existence 
•of clinically effective anticancer 
s drugs such as cyclophosphamide 
; and cisplatin, whose primary basis 
(for chemotherapeutic efficacy is 
| reaction with DNA, proves that 
selective toxicity toward cancer 
cells is possible.
In this review, the cognitive and 
response features of DNA in its 
receptor role are discussed, and we 
consider the appropriate proper­
ties of DNA-reactive drugs that 
will produce predetermined bio­
chemical and pharmacological res­
ponses.
DNA as a receptor
For DNA to be a receptor in the 
strict pharmacological sense it 
must possess both cognitive and 
response characteristics4. In spite 
of its seemingly repetitive nature, 
structural biologists have demon­
strated that DNA binding proteins 
such as repressors and endo­
nucleases can recognize DNA with  
amazing sequence specificity. The 
sequence-specific recognition of 
I DNA by proteins involved in 
I transcriptional control leads to 
I tight control of gene expression by 
processes yet to be fully character­
iz e d 5. Thus it is clear that DNA  
I fulfills the definition of a receptor, 
; as described above, through these 
protein-DNA interactions.
In addition to proteins, oligo- 
i meric single-stranded RNA and 
j DNA molecules and low molecular 
weight ligands such as drugs and
carcinogens bind to DNA with  
varying degrees of sequence selec­
tivity. Binding of low  molecular 
weight ligands to DNA can cause a 
w ide variety of potent biological 
responses including inhibition of 
transcription and replication, as 
well as mutagenic and oncogenic 
effects. We do not consider 
changes in genetic make-up caused 
by mutation and other genetic 
events to be typical receptor 
responses, although genetic toxi­
cologists might consider these 
receptors in a toxicological sense. It 
is likely that the interaction of the 
vast majority of sites on DNA that 
are recognized by low  molecular 
weight ligands such as drugs do 
not lead to a measurable pharma­
cological response. According to 
receptor terminology4, these are 
acceptor sites (i.e. cognition but 
no response). Conversely, those 
recognition sites on DNA that are 
linked to a response are receptor 
sites.
Since we seek to establish  
whether or not DNA should be 
called a bona fide receptor in the 
strict pharmacological sense it is 
useful to compare DNA with other 
more traditional and established  
receptors such as proteins. As 
w e have discussed already, only 
certain sequences on DNA are 
linked to a productive pharmaco­
logical response. The number of 
recognition sites on DNA de­
creases with increasing specified  
sequence length; for example, 
DNA target sites 10,11 and 12 base 
pairs in length would be expected 
to occur approximately 2080, 1024 
and 528 times in the human
genome, respectively. However, a 
longer target sequence (15 or 16 
base pairs) may only occur a few  
times or just once, and conse­
quently a single 'hit' may seriously 
impair the ability of a cell to 
survive if this is a critical sequence.
Drug reaction sites on DNA are 
subject to allosteric effects at 
adjacent or distant sites on the 
same molecule6. These effects may 
be transmitted by the dynamic 
properties of DNA which are 
coupled by enzymatically induced  
superhelical stress, i.e. the DNA  
may be over- or under-wound. 
Potential receptor sites on DNA  
may be protected by histone 
molecules which are involved in  
higher orders of DNA structure7, 
or proteins involved in control and 
expression of DNA functions such 
as transcription and replication.
These features are all properties 
of DNA which have parallels in  
more traditional receptor research. 
However, there are features of 
DNA as a 'receptor' that are 
departures from concepts associ­
ated with proteinaceous receptors. 
For example, cells may overexpress 
an enzyme in response to drug- 
induced inactivation of target 
protein. However, when DNA is 
modified by a low molecular 
weight ligand it potentially be­
comes a substrate for DNA repair 
processes8. Furthermore, replica­
tion may be inhibited until the 
lesion on DNA is removed and re­
pair is completed9. Poly(ADP)ribo- 
sylation may play a critical role 
in this delay of replication10. 
Irrespective of the existence of an 
alarm system such as poly(ADP)-
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Fig. 1. Structural formulae of drugs used for the treatment of cancer that are believed to exert their antitumor effects by reaction with DNA. 
Bleomycin causes DNA strand breakage, actinomycin and adriamycin form intercalation complexes, mitomycin and cyclophosphamide 
form DNA-DNA interstrand cross-links and cisplatin forms DNA-DNA intrastrand cross-links1.
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Fig. 2. Structural features of 
DNA. Right: dinucleotide 
base pairs of A T (upper) 
and G C (lower). Recog­
nition determinants are 
found on the major (M) and 
minor (m) groove edges.
Below: diagrammatic (left) 
and space-filling (right) 
models of the DNA double 
helix (B-form). (Repro­


















diagram of nucleosome 
core particle. The DNA 
molecule is wound 13A 
turns around a histone 
octamer (two molecules 
each of histones H2A, H2B, 
H3 and H4). Histone HI 
(not shown) is bound to the 
linker DNA. Note that the 
two linker units point in the 
same direction.
ribosylation, the stage in the cell 
cycle at which DNA damage occurs 
is probably a factor that can 
influence the ultimate outcome of 
ligand-induced DNA damage. The 
shorter the time period before 
entry into the S phase, the less time 
available for repair and recovery. 
This may be particularly important 
where massive genomic damage 
occurs.
Accepting the fact that DNA  
may contain bona fide receptors, 
we wish to emphasize what w e  
believe is an appropriate 'receptor 
model' to use when considering 
how DNA-reactive drugs may 
exert their potent biological ef­
fects. DNA is an acceptor or 
receptor for a w ide variety of 
DNA binding proteins that be­
come associated with DNA in a 
sequence-neutral or -dependent 
manner. After drugs interact with  
DNA, the drug-modified DNA  
becomes the receptor for protein 
recognition and processing. It is 
possible that many biologically 
potent DNA ligands exert their 
biological effects through inter­
ference with the recognition and 
function of DNA binding proteins. 
This may be the case for the 
intercalation drug doxorubicin, 
since topoisomerase II (a DNA  
untwisting enzyme) has been  
implicated in the mechanism of 
action of this compound11. There­
fore, if a DNA binding protein is 
required to mediate the biological 
effects of a DNA-reactive drug, 
it is critical to identify the appro­
priate ternary complex (drug- 
DNA-protein) if we are to move 
nearer to understanding how these 
compounds exert their biological 
effects.
Structural features of DNA  
important in drug design
DNA is a far more complex 
target for drug design than first 
implied by the now familiar 
Watson and Crick double helix. In 
its simplest form DNA is a 
repeating unit of a base-paired A T 
or G C dinucleotide. A T  or G C 
base pairs offer two long edges, 
each having characteristic features 
for molecular recognition (Fig. 2). 
Because DNA is a duplex target in 
the cell nucleus, except when  
undergoing transcription or repli­
cation, the Watson and Crick base- 
paired hydrogen bonding patterns 
have severe limitations as mol­
ecular recognition targets. H ow ­
ever, if denaturation and d is­
placement of one of the duplex 
strands by a synthetic oligodeoxy- 
nucleotide can be achieved then 
long recognition sequences may 
be targeted. Efforts along these 
lines are being pursued using 
oligodeoxynucleotides that con­
tain modified phosphates which  
are uncharged and enzymatically 
stable12, or possess a-anomeric 
sugars13. Intercalation agents co­
valently linked to the oligodeoxy- 
nucleotide have been used to 
further stabilize the new duplex 
which is formed after displace­
ment of one of the natural strands12. 
In special sequence cases, strand
separation in duplex DNA may not 
be required to bind an external 
single-stranded template because 
triple helices can be formed14; e.g. 
poly(dAdT) duplexes can form 
triple helices with poly(dT). This 
may be an important feature fof  
recognition of certain types of 
sequence.
The major and minor grooves of 
DNA are revealed when the base- 
paired dinucleotides are linked via 
phosphodiester bonds (Fig. 2). 
These are the predominant fea­
tures recognized by sequence- 
specific DNA binding proteins 
and also by drugs that show!
'IPS -  November 1988 [Vol. 9]
equence selectivity15,16. Discrimi- 
lation between cognate and non- 
ognate sequences is based upon  
he sequence-dependent varia- 
)ility in  D N A  conformation mani- 
ested in the recognition patterns 
n the grooves of DNA16. The two 
xtremes are B and Z families of 
)N A  w hich exist in right- and left- 
landed helical forms respectively.
Postreplication events such as 
hemical modifications of DNA by 
aethylation of cytosine17 and 
Introduction of free energy into 
he helix bv the action of topo- 
jsomerases must have a signifi­
cant effect on DNA conformation 
|nd dynamics, and presumably 
n̂ sequence-specific recognition 
jf DNA by proteins and low  
nolecular weight molecules. In 
Jnammalian cells nuclear DNA  
issociates w ith histone molecules 
po form a nucleosomal structure7, 
phis higher order of structure 
:an affect drug accessibility to 
j)NA19 as well as its conforma- 
ional and dynamic characteristics, 
transcriptionally active DNA is 
jiucleosome free and would conse­
quently be expected to present a 
nore favored target for ligands 
jvith affinity for DNA19. Even 
jvhen DNA is nucleosome free 
it can be partially coated with  
j>ther DNA binding proteins such 
p  those involved in replication, 
transcription and recombination. 
Drug interaction with DNA may 
pe altered by the presence of these 
proteins or, alternatively, drug 
unding may affect recognition or
processing of DNA by these 
proteins20.
The final extent and distribution  
of damage on the human genom e 
is not only influenced by its 
transcriptional state and the stage 
of the cell cycle, but may also 
be affected by prior genetic 
events such as gene amplification, 
chromosomal rearrangement and 
oncogenesis. Cells that are de­
fective in DNA repair (e.g. certain 
virally transformed cells) may be 
more adversely affected by DNA  
damaging agents than DNA repair- 
competent cells21. In conclusion  
DNA should certainly not be 
considered to be an inert target 
for drug design. Moreover its * 
structural diversity and com­
plexity would seem to be a 
blessing in disguise since target­
ing of unique sequences may be 
achievable in what was initially 
thought to be a highly redundant 
and even unexciting target.
Desirable characteristics of 
drugs that react w ith DNA
If w e take the layered complexity 
of the DNA target as a positive 
reason for thinking that DNA  
may present an opportunity for 
selective drug action, it is also 
important to consider the ideal 
characteristics of the DNA-reactive 
drug molecule. If high sequence 
selectivity is required, then the 
drug molecule must be capable of 
searching the genome for its 
cognate sequence and discrimi­
nate against the vast excess of non­
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cognate sequences, many of which  
may differ only in minor ways (e.g. 
absence of a hydrogen bond  
acceptor or donor) from the cog­
nate or target sequence. Many 
drugs that react with DNA may do 
so through non-covalent (binding) 
and/or covalent (bonding) re­
actions. DNA binding proteins are 
similar in this respect. Most drugs 
that react via covalent bonding  
reactions are mediated by strong 
electrophiles which seriously re­
duce their sequence selectivity, 
although there are some important 
exceptions to this rule22. For 
example, the potent antitumor anti­
biotic CC-1065 (Fig. 3) binds 
covalently through N-3 of adenine 
and is unusual in that it achieves 
its sequence selectivity through 
the bonding reaction23.
Non-covalent binding reactions 
of drugs that lead to sequence 
selectivity have been more ex­
tensively studied than drugs that 
react w ith DNA through bonding  
reactions24. Some drugs have been  
isolated that read minor rather 
than major groove recognition 
determinants [e.g. stallimycin 
(distamycin A) and netropsin] and 
show limited selectivity for A T  
and G C pairs based primarily 
upon close van der Waal's contacts 
and electrostatic interactions25. 
There are, however, limitations to 
minor groove recognition probes 
since this groove is information 
poor compared w ith the major 
groove, which appears to be the 
groove of choice for DNA binding
Approaches towards elucidation of the molecular basis of DNA-reactive 
drug action
A key step in  approaches towards determining the 
molecular basis of drug action is to prepare site-directed  
DNA adducts in  short (6-12 base pairs) or long (>30 base 
pairs) duplex DNA molecules. A prerequisite for this is 
the determination of the optimum binding sequences 
and methods to prepare unique complexes or adducts 
(see panels).
The structure of short drug-oligomer duplexes can 
then be studied by high-field NMR or possibly by X-ray










Strategies for determ ination of D N A  sequence specificity. Site of 
D N A  backbone cleavage. (See Ref. 27.)
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Construction of site-directed D N A  adducts. (See Ref. 29.)
crystallography. Longer DNA sequences containing 
unique drug adducts can be examined for their ability to 
carry out normal template function such as transcription 
or replication in  in-vitro system s27. In more defined 
systems, purified proteins such as those involved in 
DNA repair or transcription can be used to construct 
ternary system s.
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proteins designed  to achieve se ­
quence specificity26.
D esign  of agents that recognize 
D N A  through intercalation has 
severe lim itations im posed by the 
site exclusion rule; design  of 
agents that recognize D N A  by 
W atson-Crick hydrogen bonding  
patterns has lim itations im posed  
by the predom inant duplex state of 
DNA . Even more lim iting w ould  
be the use of a com bination of 
these processes, as has been  
suggested  by som e proponents of 
h ost-gu est chem istry (molecular- 
recognition studies using small 
synthetic m olecules).
Unfortunately the design  and 
synthesis of low  molecular w eight 
m olecules capable of attaining  
sufficient sequence specificity to 
bind selectively to the desired  
cognate sequences is only part of 
the overall problem. Two equally  
important questions related to 
D N A  as a receptor still remain  
to be answered: what are appro­
priate target sequences (receptor) 
to attain the required biological 
response; and what type of D N A  
m odification is desirable?
Answ ers to the first question  
will presum ably em erge from an 
understanding of the intricacies 
involved in the control of gene  
expression and other molecular 
events that are orchestrated on the 
D N A  template (e.g. an origin of 
replication or an enhancer se ­
quence m ight be the desired target 
receptor). The second question  
concerns the physical or chem ical 
consequences of drug interaction  
at the target receptor. If inh ib ition  
of repressor or transcriptional 
factor b ind ing to specific se ­
quences of D N A  is desired, then  
steric blockage or, perhaps more 
subtly, prevention of conforma­
tional changes required for protein  
bind ing may be sufficient. If on the 
other hand deletions or insertions 
at predeterm ined sequences are 
desired, then perhaps the chem ical 
cleavage of the phosphodiester  
backbone or the creation of nodes 
for denaturation of duplex D N A  
may be desirable. This s ign ifi­
cantly increases the com plexity of 
the drug design  problem because  
n ow  the desired drug should  
have both a recognition m otif 
and a DN A -reactive com ponent. 
Furthermore, these recognition  
and reactive features must act 
sequentially and in the correct 
order.
A gainst this background of prob­
lem s in molecular recognition and  
chemical processing remains the 
ever-present problem of the in ­
herent ability of cells to identify  
and very efficiently remove chem i­
cal damage to D N A 8. Thus q u es­
tions relating to D N A  damage 
recognition and how  to avoid  
repair w ill becom e of increased  
significance in drug design.
Approaches towards design  o f  
DN A -interactive drugs
If one believes that D N A  con­
tains viable receptor sites for 
drug action and one is not too 
discouraged by the apparent com ­
plexity of the system , where is 
a good place to start? Clearly 
an interdisciplinary approach is 
essential. The tools for exam ining  
the molecular basis for sequence- 
specific recognition are available. 
The de-novo  design  of a sequence- 
specific probe for D N A  is a form id­
able task probably equivalent to 
that of design  of non-peptide  
m im ics. W ith the present state 
of know ledge, a more realistic 
approach is an in-depth  study of 
the molecular basis for the existing  
sequence specificity of proteins 
and low  molecular w eight ligands 
and m easured steps to m im ic 
the proteins or im prove upon  
the versatility and specificity of 
existing low  molecular w eight 
ligands27.
Routine m ethods are available to 
synthesize oligodeoxynucleotides  
and biophysical techniques are 
sufficiently advanced to probe the 
fine structure of the drug-oligom er  
com plexes3. Therefore stud ies of 
drug-receptor com plexes at the
Fig. 3. Structure of CC-1065.
TIPS -N o v e m b e r  1988 [Vol. 91
duplex oligodeoxynucleotide level 
are possib le and strongly en­
couraged compared with studiesat 
less com plex and relevant levels. 
Since studies of this type require 
defined drug-D N A  complexes or 
adducts, it is first necessary to i 
determ ine optimum sequences for 
drug reaction with DNA. This can 
be achieved in a variety of ways- 
using, for example, chemical or 
enzym atic foot-printing of labeled 
restriction enzyme fragments27. In­
formation on optimum binding se­
quences can then be used to predict j 
short oligom er sequences (6-12 i 
base pairs in length) which will 
bind the drugs in unambiguous 
ways. Physical methods such as 
X-ray crystallography or one- 
and two-dimensional high-field 
NMR in combination with com­
putational chemistry can be 
used to generate realistic three- 
dim ensional structures of the 
drug-D N A  complexes28. If co­
valent adducts are formed, then 
site-directed adducts in larger 
DN A  restriction enzyme frag­
m ents or even plasmids can be 
prepared29. The preparation of 
site-directed adducts in larger 
fragments provides unique oppor­
tunities to evaluate both longer 
range effects of drug binding, and 
to use enzymatic probes (e.g. 
D N ase I) which provide informa­
tion complementary to that ob­
tained by physical methods on 
short oligomers.
There is increasing evidence 
that it may not be sufficient to 
exam ine drug-DNA complexes or 
adducts in isolation if we are to 
understand fully the biochemical 
and biological effects of drug 
binding, since it is really a drug- 
m odified DNA which is now the 
receptor for protein binding. If 
D N A  binding proteins such as 
topoisom erases and transcrip­
tional factors are important in 
m ediating the potent biological 
effects of these drugs, then defined 
system s using isolated proteins 
in combination with site-directed 
D N A  adducts are urgently re 
quired. Consequently, it is im­
portant to devise methods to 
identify DNA binding proteins 
that are involved in mediating the 
biological effects of DNA-reactive 
drugs.
□  □  □
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1 It is difficult to predict just how  
important chemical m odification  
of DNA using low  molecular 
weight ligands w ill be in treatment 
of diseases such as cancer ten years 
from now. Several major problems 
will have to be solved before it 
is feasible to achieve selective  
pharmacological action w ithout 
serious side-effects, using drugs 
that react w ith DNA. These in ­
dude learning the rules for DNA  
sequence selectivity16, identifying  
appropriate sequence receptors 
tor drug action, selecting the 
type of DNA  m odification to use 
e.g. non-covalent b inding, DNA  
strand breakage, covalent adduct 
formation) and last but not least 
achieving selective cellular uptake. 
These are formidable problem s, 
but the technology is either al­
ready available or is fast becom ing  
available to address these issues 
realistically.
Many molecular im m unologists 
feel that the chemical approach 
has too many problems and lim ita­
tions to be worth the investm ent of 
effort, and that im m unology and 
the host defence system s hold the 
true promise for real progress in  
treatment of cancer and virally 
mediated d iseases. We feel it is 
premature to make a clear choice 
between these approaches and 
sufficient financial support should  
be provided to test both options, 
life should not forget that som e 
DNA-reactive drugs have already 
proven to be highly effective in 
treating certain hum an cancers -  
in sharp contrast to the new er
i m m u n o l o g i c a l  a p p r o a c h e s 30 . I r ­
r e s p e c t i v e  o f  t h e  f i n a l  r e l a t i v e  
t h e r a p e u t i c  v a l u e s  o f  t h e  c h e m i c a l  
v e r s u s  i m m u n o l o g i c a l  a p p r o a c h e s ,  
s t u d i e s  w i t h  l o w  m o l e c u l a r  w e i g h t  
l i g a n d s  w i l l  d o u b t l e s s  c o n t r i b u t e  
s i g n i f i c a n t l y  t o  o u r  u n d e r s t a n d i n g  
o f  p r o t e i n - D N A  i n t e r a c t i o n s  a n d  
b e  u s e f u l  i n  d e c i p h e r i n g  t h e  
m o l e c u l a r  m e c h a n i s m s  t h a t  c o n t r o l  
p r o c e s s e s  a t  t h e  D N A  l e v e l .
A cknow ledgem ents
T h e  r e s e a r c h  i n  t h e  a u t h o r ' s  
l a b o r a t o r y  i s  s u p p o r t e d  b y  g r a n t s  
f r o m  t h e  D e p a r t m e n t  o f  H e a l t h ,  
E d u c a t i o n  a n d  W e l f a r e  ( C A - 3 0 3 4 9  
a n d  C A - 3 5 3 1 8 ) ,  t h e  T e x a s  B o a r d  o f  
H i g h e r  E d u c a t i o n  a n d  t h e  W e l c h  
F o u n d a t i o n .  W e  g r a t e f u l l y  a c k ­
n o w l e d g e  D o n n a  J a c o b s e n  a n d  
M e l i s s a  W i n s t e a d  f o r  c a r e f u l  p r e p ­
a r a t i o n  o f  t h i s  m a n u s c r i p t .
References
1  G a l e ,  E .  F . ,  C u n d l i f f e ,  E . ,  R e y n o l d s ,  P .  E . ,  
R i c h m o n d ,  M .  H .  a n d  W a r i n g ,  M .  J .  
( 1 9 8 1 )  The Molecular Basis of Antibiotic  
Action  ( 2 n d  e d n ) ,  J o h n  W i l e y  &  S o n s
2  H o p f i n g e r ,  A .  J .  ( 1 9 8 5 )  J. Med. Chem.  2 8 ,  
1 1 3 3 - 1 1 3 9
3  P a t e l ,  D .  J .  a n d  S h a p i r o ,  L. ( 1 9 8 7 )  Annu.  
Rev. Biophys. Biophys. Chem.  1 6 ,  4 2 3 - 4 5 4
4  G r e e n ,  J .  P .  ( 1 9 8 7 )  Trends Pharmacol.  Sci. 
8 ,  9 0 - 9 4
5  P t a s h n e ,  M .  ( 1 9 8 6 )  A  Genetic Switch,  
C e l l  P r e s s  a n d  B l a c k w e l l  S c i e n t i f i c  
P u b l i c a t i o n s
6  W a n g ,  J .  C . a n d  G i a e v e r ,  G .  N . ( 1 9 8 8 )  
Science  2 4 0 ,  3 0 0 - 3 0 4
7  F e l s e n f e l d ,  G .  a n d  M c G h e e ,  J .  D .  ( 1 9 8 6 )  
Cell  4 4 ,  3 7 5 - 3 7 7
8  F r i e d b e r g ,  E .  C .  ( 1 9 8 4 )  D N A  Repair,  
W .  H .  F r e e m a n
9  P a i n t e r ,  R .  B .  ( 1 9 7 8 )  Cancer Res.  3 8 , 4 4 4 5 -  
4 4 4 9
1 0  U e d a ,  K .  a n d  H a y a i s h i ,  O .  ( 1 9 8 5 )  Annu.  
Rev. Biochem.  5 4 ,  7 3 - 1 0 0
1 1  D o l i c a ,  K .  a n d  F r a n c o ,  R .  J .  ( 1 9 8 8 )  
Biochemistry  27,  2 2 5 3 - 2 2 5 9
1 2  S t e i n ,  C. A .  a n d  C o h e n ,  J .  S .  ( 1 9 8 8 )  
Cancer Res.  4 8 ,  2 6 5 9 - 2 6 6 8
1 3  T h u o n g ,  N .  T . ,  A s s e l i n e ,  U . ,  R o i g ,  V . ,  
T a k a s u g i ,  M .  a n d  H e l e n e ,  C .  ( 1 9 8 7 )  Proc.  
N atl  Acad. Sci. USA  8 4 ,  5 1 2 9 - 5 1 3 3
1 4  C o o n e y ,  M . ,  C z e r n u s z e w i c z ,  G . ,  P o s t e l ,  
E .  H . ,  F l i n t ,  S .  J .  a n d  H o g a n ,  M .  E .  ( 1 9 8 8 )  
Science  2 4 1 ,  4 5 6 - 4 5 9
1 5  D e r v a n ,  P .  B .  ( 1 9 8 6 )  Science  2 3 2 ,  4 6 4 - 4 7 1
1 6  O l l i s ,  D .  L .  a n d  W h i t e ,  S .  W .  ( 1 9 8 2 )  Chem.  
Rev.  8 7 ,  9 8 1 - 9 9 5
1 7  H e r t z b e r g ,  R .  P., C a r a n f a ,  M .  J .  a n d  
H e c h t ,  S .  M .  ( 1 9 8 5 )  Biochemistry  2 4 ,  
5 2 8 5 - 5 2 8 9
1 8  W a n g ,  J .  C .  ( 1 9 8 5 )  Annu. Rev.  Biochem.  
5 4 ,  7 3 - 1 0 0
1 9  H a n a w a l t ,  P .  C . ,  C o o p e r ,  P .  K . ,  G e n e s a n ,  
A .  K .  a n d  S m i t h ,  C .  A .  ( 1 9 7 9 )  Annu. Rev.  
Biochem.  4 8 ,  7 8 3 - 8 3 6
2 0  L o w ,  C .  W .  L . ,  D r e w ,  H .  R .  a n d  W a r i n g ,  
M .  J .  ( 1 9 8 6 )  Nucleic Acids Res. 1 4 ,  6 7 8 5 -  
6 8 0 1
2 1  E r i c k s o n ,  L .  C . ,  L a u r e n t ,  G . ,  S h a r k e y ,  
N . A .  a n d  K o h n ,  K .  W .  ( 1 9 8 0 )  Nature  2 8 8 ,  
7 2 7 - 7 2 9
2 2  W a r p e h o s k i ,  M .  a n d  H u r l e y ,  L .  H .  Chem.  
Res. Toxicol,  ( i n  p r e s s )
2 3  H u r l e y ,  L .  H .  et al. ( 1 9 8 8 )  Biochemistry  2 7 ,  
3 8 8 6 - 3 8 9 2
2 4  D a b r o w i a k ,  J .  C .  ( 1 9 8 3 )  Life Sci. 3 2 ,  2 9 1 5 — 
2 9 3 1
2 5  K o p k a ,  M .  L . ,  Y o o n ,  C . ,  G o o d s e l l ,  D . ,  
P j u r a ,  P .  a n d  D i c k e r s o n ,  R .  E .  ( 1 9 8 5 )  
Proc. N a tl  Acad. Sci. U SA  8 2 ,  1 3 7 6 - 1 3 8 0
2 6  S a e n g e r ,  W .  ( 1 9 8 3 )  i n  Principles of  
Nucleic Ac id  Structure  ( C a n t o r ,  R . ,  e d . ) ,  p .  
3 9 1 ,  S p r i n g e r - V e r l a g
2 7  H u r l e y ,  L .  H .  a n d  B o y d ,  F .  L .  ( 1 9 8 7 )  
Annu. Rep. Med. Chem. 22,  2 5 9 - 2 6 8
2 8  H a r r i s ,  T .  M . ,  S t o n e ,  M .  P .  a n d  H a r r i s ,  
C .  M .  ( 1 9 8 8 )  Chem. Res. Toxicol. 1, 7 9 - 9 6
2 9  B a s u ,  A .  K .  a n d  E s s i g m a n n ,  J .  M .  ( 1 9 8 8 )  
Chem. Res. Toxicol.  1 ,  1 - 1 8
3 0  H a w k i n s ,  M .  J . ,  H o t h ,  D .  F .  a n d  W i t t e s ,  R .
E .  ( 1 9 8 6 )  Semin. Oncol.  1 3 ,  1 3 2 - 1 4 0
3 1  K o r n b e r g ,  A .  ( 1 9 8 0 )  D N A  Replication  
p .  1 1 ,  W .  H .  F r e e m a n
I
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Hoechst-Roussel Pharmaceuticals Inc., Somerville, New Jersey
Chapter 26. Approaches Toward the Design of Sequence-Specific Drugs for DNA
Laurence H. Hurley and F. Leslie Boyd, Division of Medicinal and Natural Products 
Chemistry, College o f Pharmacy, The University o f Texas at Austin, Austin, Texas 
78712
Introduction - DNA is perhaps the best defined o f all cellular targets for drug design, 
but because of its large size and partially redundant nature, discrimination between 
competing binding sites is a major problem. Nevertheless, many proteins are able to 
bind to DNA with sufficient sequence selectivity to very precisely "turn up" or "turn 
down" transcription of particular genes. The problem at hand for the medicinal chemist 
is how to design non-protein small molecular weight molecules that will bind to any 
sequence and site size o f DNA. Design of sequence-specific DNA-binding molecules 
has been recently addressed by Dervan (1) and consequently we will concentrate on 
aspects that are o f prime concern to the medicinal chemist. A report on the interaction 
of intercalating agents with DNA has previously appeared in this series (2).
As a consequence of the toxic nature o f DNA reactive compounds, therapies 
utilizing these agents are usually reserved for life-threatening diseases such as cancer. 
Cancer chemotherapeutic agents react with DNA in a variety o f ways including 
intercalation (Adriamycin, actinomycin D), and alkylation (mitomycin C, 
cyclophosphamide and cis-platinunU or cause extensive degradation o f DNA  
(bleomycin) (3). Although some o f these agents may exhibit some very limited 
sequence preference, this is not generally believed to be o f sufficient magnitude to 
account for their selectivity against cancer vs. normal cells (4-6). If classes of agents 
could be designed that exhibit sufficient sequence specificity, then opportunities would 
be available to treat diseases which result from over-or under-expression of key genes 
or even genetic disorders in which genes are misplaced.
Within the last two to three years it has become a popular topic o f debate 
whether it may be within the capabilities of medicinal chemists to evolve a strategy for 
design of a synthetic non-protein molecule, which through its interaction with a specific 
sequence in DNA will mediate a desirable biological response. Not surprisingly, this is 
a complex problem which will require a team of researchers spanning disciplines such 
as computational and biophysical chemistry, molecular pharmacology and biology and 
medicinal and bio-organic chemistry. The overall problem o f design of non-protein 
DNA-effector molecules can be broken down into learning the rules o f DNA sequence 
specific recognition; identification of key sequences to target for modulation of gene 
expression, amplification or recombination; design and synthesis o f appropriate 
compounds and development o f cell-specific delivery systems. This report will 
concentrate on the first three topics since the last topic is outside the scope of this 
article, even though its importance is recognized by the authors.
DNA as a Specific Receptor - If DNA sequence-specific binding is to be the basis 
for the selective effects of drugs, then agents must be designed which can effectively
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bonding between reactive sites o f netropsin and adenine N3 and thymine 02 atoms in the 
floor o f the central AATT region of the dodecamer. Importantly, the X-ray structure 
analysis shows that although these hydrogen bonding interactions may provide 
stabilization o f the complex, the dA*dT base pair specificity originates from close van der 
Waals contacts between adenine H2  hydrogens and the CH groups o f the pyrrole rings of 
netropsin (24) (see figure IB). Attempts to convert AT to GC specificity have been made 
and these will be discussed later (30).
Methods for Evaluation o f Sequence Specificity - Several techniques have been developed 
to evaluate the ability of agents to discriminate between binding to target vs. non-target 
sequences. All depend upon single 3'-or 5'-32P-end-labeled DNA molecules which are 
available through routine enzymatic procedures common in molecular biology (31). 
Typically, DNA fragments 100 to 300 base pairs in length are obtained single-32P-end- 
labelled, and these are subjected to drug modification. Depending upon the particular 
drug to be tested for sequence specificity, the type o f information required, and the 
expertise of the particular laboratory involved, footprinting with methidiumpropyl-EDTA* 
Fe(II) [MPE'Fe(II)] (32) or DNase I (33), affinity cleavage (34), exonuclease III 
digestions (35), or direct strand breakage (36) can be used.
(i) Footprinting Techniques (a) MPE*Fe(II) - This low molecular weight DNA-cleaving 
molecule is used widely for footprinting of DNA reactive drugs. Its design is based upon 
attaching an intercalator (methidium) via a linker to a metal chelator (EDTA), which in the 
presence of ferrous ion and reducing agents such as dithiothreitol and dioxygen, produces 
single strand breaks at 25° in double-helical DNA (37-38). MPE*Fe(II) cleaves DNA in a 
fairly random manner, but in the presence o f DNA binding ligands it leaves protected 
sites (footprints) which provide direct information on binding locations and site size. 
Asymmetric cleavage protection to the 3' side of each binding site is a consequence o f the 
generation o f a diffusible reactive species in the minor groove o f right-handed DNA (32). 
This reagent has been used to footprint a variety of natural products such as actinomycin 
D, distamycin, chromomycin, and echinomycin on DNA (39-41).
(b) DNase I - DNase I is a DNA cleaving enzyme whose structure with a cognate 
oligodeoxynucleotide sequence has recently been revealed by X-ray structure analysis 
(42). Based on the known interactions between the protein and DNA, a firm basis for the 
interpretation o f DNase I drug footprinting results is possible. While MPE*Fe(II) 
provides exact site sizes for ligands, DNase I produces larger footprints and generally 
reveals more about drug-induced conformational changes in DNA (43-44). Therefore, 
when used side-by-side, DNase I and MPE*Fe(II) provide complementary information.
(ii) Affinity Cleavage - A natural extension o f MPE*Fe(II) footprinting is the attachment 
of EDTA*Fe(II) to a DNA binding molecule such as distamycin to convert a sequence- 
specific DNA-binding agent to a sequence-specific DNA-cleaving molecule (34). This 
results in a positive image visualized on an autoradiogram rather than the negative image 
produced by footprinting. In addition, the orientation o f the drug (31 or 5') in the minor 
groove is revealed by affinity cleavage to which footprinting is generally blind.
(iii) Direct DNA Strand Breakage - Under appropriate conditions, such as reduction in the 
presence o f metals, alkali or thermal treatment, some DNA reactive compounds [e.g., 
bleomycin (36), aflatoxins (45), neocarzinostatin (46) , and CC-1065 (47)] produce 
breakage of the phosphodiester backbone. The sites of DNA breakage, and therefore the 
sites of DNA modification, can be determined by comparison o f the electrophoretic 
mobility of the cleavage products created by treatment of the same non-drug modified 
DNA fragment with the products of the standard Maxam & Gilbert DNA sequencing 
reactions. While this method negates the need for the use o f external reagents such as 
MPE*Fe(H) and DNase I, some caution is needed in the interpretation of the results, since 
the chemistry o f DNA strand breakage can affect the gel electrophoretic mobility o f the 
cleavage product, and in addition, not all drug binding sites may be revealed by this 
method (36,51).
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dG*dC specificity when intercalators are mixed with groove binding molecules, the 
linkers may be a critical design feature for which we still lack definite information.
Strategies for D eterm ining the Structural. B iochem ical and Biological 
Consequences o f Sequence-Specific M odification o f DNA - In addition to the 
design of sequence specific probes for DNA, a parallel effort to determine the structural 
and biological consequences o f  DNA modification is urgently required to identify 
appropriate types o f DNA modification and sequences to be targeted. In this section we 
will first describe the strategy for preparation of suitable site-directed modifications of 
DNA for studies with oligomers, DNA restriction enzyme fragments, and plasmids. Our 
second objective will be to describe how these preparations can be used to probe 
structural, biochemical and biological consequences of DNA damage. Except for small 
oligomers, the use o f site-directed modified DNA molecules is restricted to irreversible 
covalent adduct formation.
Construction o f Site-Directed Duplex Complexes and Adducts - Where short duplex 
molecules of up to about 1 2 - 1 4  base pairs are used, it is often only necessary to choose 
the appropriate sequence to obtain an unambiguous complex or adduct. For example the 
Dickerson dodecamer 5’CGCGAATTCGCG duplex forms a 1:1 distamycinrduplex 
complex that has been examined by ^H-NMR (29) and a single crystal X-ray structure 
has been solved (24). Likewise, triostin A forms a 1:1 drug:duplex adduct with the 
double-helical fragment having the sequence 5'CGTACG, the structure which has been 
solved by X-ray crystallography (53). However, in some cases even for small oligomers 
a combination of synthesis of a ligand-nucleotide adduct followed by incorporation into 
an oligomer by oligodeoxynucleotide synthesis is sometimes necessary (54).
The construction of longer oligodeoxynucleotide duplex adducts requires a strategy 
which combines procedures from organic synthesis and molecular biology, unless a 
duplex dependent construction strategy can be used. Essigmann has recently prepared a 
platinated DNA using a strategy which appears to be generally applicable for building 
other modified oligonucleotides into specific sites in DNA (55). In this experiment a 
chemically synthesized dodecanucleotide containing a unique site for cis-Pt modification 
was reacted with drug and then the modified oligodeoxynucleotide was ligated into a 
separately constructed gapped heteroduplex DNA molecule. In a different approach 
relying upon the known sequence specificity of CC-1065 and its selectivity to bind only 
duplex DNA, a 117 base pair duplex adduct with a single site of drug modification was 
prepared. (56).
Structural Characterization of Site-Specific Drug-Oligomer Complexes and Adducts - A 
wide array of physical methods can be used to probe the structures o f oligomers that are 
drug modified including UV absorption, CD, ORD, IR, Raman spectroscopy, viscosity, 
electric dichromism, thermal melting, NMR and X-ray crystallography (21). Of these 
methods, NMR and X-ray crystallography are the most powerful and a few examples will 
be described here.
Modem methods in oligodeoxynucleotide synthesis (57) permit multimilligram 
amounts of short oligomers (up to about 15-mer size) to be prepared and purified by 
HPLC (58). These are suitable for NMR and X-ray crystallographic studies. One- and 
two-dimensional NMR experiments, principally the COSY and NOESY techniques, can 
be used to unambiguously assign many o f the aromatic base and sugar protons in 
oligomer duplex drug complexes or adducts (59). Distance measurements between intra- 
or inter-nucleotide protons and between drug and nucleotide protons are made which 
provide information on the effect o f drug binding on DNA conformation and drug 
positioning in the oligomer complex or adduct (59). Using these methods, the structure 
of oligomers modified with nonintercalating drugs such as distamycin (29), SN6999 
(60), and anthramycin (61) have been probed. In a few cases, single crystal X-ray 
structures of drug modified oligomers have been obtained. These results have revealed a 
few surprises, such as the presence o f a Hoogsteen base pair at the A*T base pair flanking 
the quinoxaline intercalating moiety in the triostin A-hexamer duplex complex (53) and 
the importance o f van der Waals contacts for base sequence recognition by netropsin
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In tro d u c tio n
DNA sequence selectivity is achieved by both proteins 
(1, 2) and small molecular weight ligands (3, 4). DNA- 
binding proteins have evolved to recognize sequence-de­
pendent features of DNA in order to  participate in a va­
riety of genetic events such as control of gene expression 
and replication of DNA (5). S tructural biologists are 
currently unmasking the recognition motifs that allow the 
sequence-specific recognition of DNA by binding proteins 
such as endonucleases (6) and repressors (7-12). The 
central function of any sequence-specific protein is its 
ability to discriminate its cognate sequence from the vast 
excess of noncognate DNA sequences in which it is em­
bedded. This is achieved by a number of different mo­
lecular mechanisms including specific hydrogen bonding
(2) and hydrophobic interactions (13) which occur pri­
marily between amino acid residues in the protein and 
major or minor groove substituents on DNA Electrostatic 
interactions (6), and in some cases DNA flexibility or 
elasticity (14), may also contribute to the overall sequence 
selectivity- In the case of EcoRI endonuclease covalent 
modification of DNA permits a higher degree of sequence 
specificity than simple protein binding (4, 6).
While their overall sequence selectivity is generally 
lower, small molecular weight ligands such as DNA-re­
active drugs and carcinogens may also exhibit DNA se­
quence recognition (3, 4). These drugs and carcinogens 
may share common DNA recognition motifs with proteins, 
and because of their relatively small molecular weight and 
corresponding reduced structural complexity may serve 
as useful models for the more complex protein-DNA 
recognition mechanisms. Like DNA-binding proteins, 
drugs and carcinogens may possess one or more different 
molecular mechanisms for DNA sequence recognition (4). 
A practical way of classifying these molecular mechanisms 
is to divide them into noncovalent and covalent recognition 
processes. In the drug-DNA interaction literature, the 
term “DNA binding” frequently has loosely encompassed 
both covalent and noncovalent interactions. However, in 
recent years experiments studying those interactions have 
become increasingly sophisticated and generally can dis­
tinguish quite clearly the manifestations of covalency vs 
those of physical interactions. Since we wish to understand 
the relative importance of covalent and noncovalent in­
teractions in the drug-DNA interaction area, we will use 
the terms “binding” and “bonding” to differentiate between 
noncovalent and covalent intermolecular interactions, re­
spectively. (These are the commonly accepted usages of
1 The Upjohn Co.
* The University of Texas.
these terms in chemistry, notwithstanding the somewhat 
misleading term “hydrogen bond”. The energy of this 
noncovalent “bond” is typically 3-7 kcal/mol, in contrast 
to covalent bond energies which are on the order of 100 
kcal/mol.)
Considerable effort has been invested into both eluci­
dating the sequence recognition mechanisms for nonco­
valent binding (15-20) and designing noncovalent se­
quence-specific probes for duplex DNA (21-24). While the 
information content or “readout” in the minor groove of 
DNA is poorer than in the major groove (25), to date the 
most successful nonprotein DNA sequence specific probes 
for duplex DNA are minor groove binders (4). This situ­
ation may change as the more complex protein recognition 
motifs for major groove specificity are elucidated and can 
then be mimicked by small molecular weight ligands. In 
contrast, covalent bonding as a molecular mechanism for 
sequence recognition has so far received much less atten­
tion, even though many of the most potent DNA inter­
active agents like CC-1065 and the anthramycins, or 
metabolically activated carcinogens, and many clinically 
useful antitumor agents, react covalently with DNA.
In principle, ligands such as drugs or carcinogens which 
become covalently bonded to DNA in a sequence-selective 
fashion may recognize the sequence by either noncovalent 
(binding) or covalent (bonding) mechanisms, or perhaps 
more likely by a combination of these mechanisms. In 
terms of a generalized kinetic scheme (eq 1) the binding
Kb kr
drug + DNA v —-  (dmg-DNA) --------  (drug-DNA)^
(1)
step is sequence selective if different sequences have dif­
ferent binding affinities for the drug (a situation with 
ample precedent among noncovalently binding drugs). 
The bonding step is sequence selective if the rate constant 
(kT) for covalent bond formation is different for different 
sequences, i.e., if the free energy of activation to the 
transition state leading to the covalent adduct depends 
upon the nucleotide sequence around it. While the com­
mon perception is that covalent or bonding mechanisms 
can only give rise to low sequence discrimination, we il­
lustrate here that with certain drugs, such as CC-1065 
analogues, relatively marked sequence selectivity can be 
achieved predominantly by a bonding mechanism.
This perspective weighs the relative importance of the 
noncovalent and covalent mechanisms in DNA sequence 
selection by certain small molecular weight molecules 
which become covalently bonded to DNA. We begin by 
consideration of the experimental approaches that have 
been used to reveal sequence selectivity of such agents, 
since experimental conditions may have a significant effect
0893-228x/88/2701-0315S01.50/0 © 19S8 American Chemical Society
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on th e  “selectiv ity” described. N ex t we sum m arize the 
pertinen t results reported for a num ber of im portan t drugs 
and  carcinogens, along with th e  in te rp re ta tio n s  of the 
sources of observed selectivities as p resen ted  by the  in­
vestigators. T he extensive recent work on DNA sequence 
selectiv ity  o f CC-1065 and  its analogues is described in 
detail, since this example has given us considerable insight 
into the  molecular basis of its sequence-selective reaction 
w ith DNA. From  this survey, we a tte m p t to  ex tract some 
general principles regarding th e  in te rp lay  of noncovalent 
and  covalent m echanism s in d eterm in ing  th e  sequence 
d iscrim ination  observed for drugs an d  carcinogens th a t 
reac t covalently w ith DNA.
T o th e  ex ten t th a t th is  selectiv ity  im pinges upon bio­
logical action, we propose th a t th is analysis has an obvious 
bearing on drug design. We also com m ent on the  possible 
relevance of the bonding reaction between small molecular 
w eight ligands and DNA, to  p ro te in -D N A  interactions. 
Finally, we propose th a t covalent m echanism s which result 
in selection of a base (e.g., adenine) in a particular sequence 
m ay have biological relevance to  th e  m echanism  of action 
of certa in  D N A -reactive drugs.
Experimental M easurem ents of Sequence 
Selectivity
Over th e  last decade th e  availab ility  of defined DNA 
restric tion  fragm ents and  of m ethods to  determ ine  the ir 
nucleotide sequences has enabled investigators to  examine 
the sequence selectivity of a large num ber of D NA-inter- 
active compounds. T he experim ents th a t provide sequence 
selectivity inform ation are quite in tricate, and  statem ents 
abou t “selectiv ity” m ust be qualified  by describing some 
experim en ta l param eters . I t is in stru c tiv e  to  begin the 
discussion of these p aram eters by describ ing the  widely 
used M axam  and G ilbert sequencing m ethod , which pro­
vides th e  “sequence lad d er” of DNA for v irtually  all of 
these sequence selectivity stud ies (26). In  th is m ethod a 
single- or double-stranded DNA restriction  fragm ent with 
a single end label (32P) is subjected  to  four d ifferen t sets 
of chem ical reactions, each se t resu lting  in cleavage of a 
fraction of the DNA m olecules a t  a p a rticu la r base (G or 
C) or pairs of bases (G+A or C +T). T he cleaved fragments 
are sep ara ted  according to size by high-resolution  poly­
acrylam ide gel electrophoresis and  visualized by au to ra ­
diography. T he nucleotide sequence is read by ordering 
each successive cleavage fragm ent according to  the  base- 
specific reaction set th a t  p roduced it.
For exem plary purposes we consider in de ta il the  gua­
nine-specific set of reactions. F irst, th e  single end-labeled 
DNA restriction fragm ent is reacted to  a small extent (only 
a few percen t of the  DNA m olecules are m odified) with 
the electrophilic reagent dim ethyl sulfate, which alkylates 
the nucleophilic N-7 position of guanine bases. T he par­
tially m odified DNA is th en  tre a te d  w ith  h o t aqueous
• 0
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piperid ine, during  which th e  series of transfo rm ations 
depicted in Scheme I takes place (26, 27), which ultim ately 
leads to  s tran d  cleavage. T h a t  segm ent of th e  original 
DNA restriction fragm ent extending from the radioactively 
labeled end (e.g., 5' in Schem e I) up  to  th e  m odified gua­
nine will appear as a d iscrete band  in th e  guanine-specific 
lane of the  sequence ladder (as well as in th e  guanine + 
adenine lane resulting from  ano ther se t of reactions) after 
e lectrophoresis and  au to rad io g rap h y . Several points 
concerning th e  procedure w arran t ad d itio n a l com m ents 
for th e  purposes of th is  article.
(1) I t  is th e  consequence of th e  en tire  se t of chem ical 
reac tions lead ing  to  s tra n d  cleavage, u n d er carefully  
specified reaction conditions, th a t  resu lts  in base specif­
icity. For instance, in addition to  N-7 of guanine, dimethyl 
su lfa te  also alky lates N-3 o f aden ine  to  som e ex ten t, b u t 
these m odified adenines are  n o t converted  to backbone 
stran d  breaks during  th e  p iperid ine reaction and  thus do 
not give rise to  fragm ents in th e  guanine-specific lane. In 
other words, dim ethyl sulfate itself is n o t “specific” for N-7 
of guanine in a purely  chem ical sense.
(2) I t  has been estab lished  for th e  M axam -G ilbert 
p rocedures th a t  th e  in ten s ity  of th e  observed band  (i.e., 
the  am o u n t of rad ioactiv ity  in each fragm ent) is p ropor­
tional to  the  frequency  of m odification  (rate  of covalent 
reaction) a t the  base involved. T h a t is, once the N-7 atom  
of th e  guanine is alkylated , th e  chem ical transform ations 
(Schem e I) leading to  s tra n d  breakage are q u an tita tive ; 
further, those transform ations cannot occur when the N-7 
of guanine is n o t a lky la ted  (26).
(3) In  determ in ing  th e  nucleo tide sequence of a given 
region of DNA, th e  goal is to  visualize each possible sub­
fragm ent resulting from specific cleavage a t each base. If 
a given labeled DNA m olecule were to  be m ethy la ted  by 
dim ethyl sulfate a t two of its guanine nucleotides, only the 
fragm ent corresponding to cleavage a t  th e  guanine nearest 
the  labeled end  would be de tec ted . T hus, the  m ore ex­
tensively the DNA is alkylated, the less likely it is th a t the 
more d istan t bases from the  labeled end will be visualized; 
experim entally  a “fade-ou t” tow ard th e  high m olecular 
w eight end of th e  au to rad iog ram  would appear, and  the 
in ten sity  of a band  would no longer reflec t th e  tru e  fre­
quency of a lky lation  a t  th e  site  re la tive  to o ther bases. 
W hen very lim ited  reaction  is allow ed, w ith m ost of the 
DNA rem aining unreacted there  is greater probability th a t 
each DNA m olecule th a t  reac ts  does so a t  only one of its 
po ten tia l sites.
T h e  highly reactive d im ethyl su lfate  ensures th a t there 
is sufficient probability  th a t each guanine in the DNA will 
reac t in enough of th e  m olecules to  allow detection . Al­
though conditions are chosen such th a t  all of the guanines 
can be detec ted , in fac t n o t all of th e  bands observed in 
a dim ethyl sulfate guanine sequencing lane may be equally 
intense, indicating th a t alkylation and consequent cleavage 
occur m ore frequen tly  a t  som e guan ines th an  a t  others.
Perspective
Hartley e t al. have observed slight enhancement of 
cleavage a t  runs of guanines in double-stranded DNA, 
suggesting some degree of sequence selectivity for the 
alkylation reaction (28). In an alternative sequencing 
method, guanines are photooxidized in the presence of 
methylene blue or rose bengal to products that lead to 
strand scission upon treatment with piperidine (29). This 
guanine-specific set of reactions is reported to give some­
what more uniform bands on sequencing gels than does 
dimethyl sulfate, indicating that singlet oxygen is an even 
less DNA sequence selective reagent than dimethyl sulfate.
Most of the studies on sequence selectivity of agents that 
covalently modify DNA have been more or less modeled 
after Maxam-Gilbert type methodology. DNA alkylation 
leads to strand cleavage (or inhibition of cleavage, as in 
footprinting; vide infra) which is then located and quan­
tified. The three same points discussed above must be 
considered when evaluating and integrating these studies.
For example, a number of drugs and carcinogens react 
a t more than one heteroatom or more than one base. The 
sequence selectivity for one type of reaction may be dif­
ferent than  th a t for another (this appears to be the case 
for benzpyrenediol epoxide, as will be discussed below). 
Postalkylation reaction steps leading to strand breakage 
may visualize only one type of alkylation chemistry, al­
though in some cases, such as methods using exonuclease 
cleavage or DNA footprinting, this adduct selectivity 
cannot be assumed. Thus the chemical and enzymatic 
procedures used in determining a given “sequence 
selectivity” are an im portant part of its description and 
of the evaluation of its possible biological significance.
Likewise, it is important to establish that the sequence 
selectivity observed is due to the initial covalent modifi­
cation event, and not to sequence effects on subsequent 
transform ations which lead to the observed strand 
breakage. For a given level of covalent reaction it should 
be shown experimentally that the follow-up reactions are 
quantitative for all sequences under the conditions chosen 
(27).
Finally, “sequence selectivity” as presently understood 
refers not only to which bases in which sequence contexts 
can be made to react with a given drug or carcinogen at 
high ligand concentration, but also to how readily a base 
in a particular sequence reacts relative to the same base 
in another sequence, i.e., to what extent is one sequence 
preferred to other sequences? Ideally this means that, in 
addition to quantitative cleavage as discussed in (2), 
“single-hit statistics” are followed, i.e., that most fragments 
represent DNA molecules experiencing only one covalent 
reaction. Thus, conditions should be chosen such that only 
a small percentage of the DNA has reacted at all.
Only a  few years ago a review on DNA sequence selective 
drugs dismissed covalently modifying agents and in par­
ticular nitrogen mustards and aflatoxin as being poorly 
sequence selective (17). These agents primarily alkylate 
the guanine N-7 position (30, 31) and thus can be made 
to give strand  breaks that can reveal the alkylation site, 
in the same way th a t 7-methylguanine is detected in 
M axam -G ilbert sequencing. However, the early se­
quencing studies, to which the reviewer referred, were 
primarily concerned with establishing the base specificity 
of these agents and used relatively high drug concentra­
tions which would perm it detection of all reasonably at­
tainable covalent products (32,33). Consequently, it was 
little wonder that all guanines were susceptible to alkyl­
ation under such conditions and that this aspect of the 
experimental results was emphasized. Later studies fo­
cused in  on the markedly different intensities of some of
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the bands observed with these agents, and experiments 
were designed to maximize sequence selectivity informa­
tion.
Sequence Selectivity of DNA-Reactive Agents
A flatoxin . Aflatoxin B L is a highly mutagenic and 
carcinogenic mycotoxin which creates a significant problem 
in many parts of the world as a food chain contaminant 
(34). The possibility th a t inherent selectivity for reaction 
a t certain sequences in DNA might contribute to the ex­
traordinary genotoxic potency of this natural product 
prompted detailed investigations of its sequence selectivity. 
Humayun explored the “sequence contexts” of aflatoxin 
Bx which was oxidized in situ to its epoxide (Figure la), 
the putative reactive species. Its reaction a t guanine N-7 
with several single- and double-stranded DNA restriction 
fragments, under conditions of minimal DNA cleavage, was 
determined (35, 36). He found up to 10-fold increases in 
the rate of alkylation of certain guanines relative to others 
in double-stranded DNA, but not in single-stranded DNA 
The sequence patterns were remarkably consistent, al­
lowing the formulation of a set of rules for the sequences 
immediately flanking the reacted guanine. Single-stranded 
DNA reacted sluggishly with activated aflatoxin, with all 
guanines equally susceptible to the slow reaction. Hu­
mayun presented two dichotomous interpretations: (1) 
aflatoxin oxide diffuses freely, and the observed selectivity 
is due to sequence-dependent conformational features of 
DNA favoring reaction with the drug [in essence, rate 
constant (kt in eq 1) differences among guanines], or (2) 
all guanine residues are equally reactive, irrespective of 
sequence, but the relative frequency of alkylation is due 
to variations in local drug concentration (mass action ef­
fect). This variation would be a result of noncovalent 
binding of aflatoxin oxide, which would thus be the se­
quence-dependent factor (i.e., Kb in eq 1). Humayun fa­
vored the latter interpretation, both because of the greater 
activity of double-stranded DNA and because of partial 
inhibition of the alkylation by nonreactive structural 
analogues of aflatoxin Bx (36).
Recently, B enasutti e t al. described extensive and 
carefully executed experiments revealing the sequence 
selectivity of activated aflatoxin Bx reaction with DNA, 
examining 190 guanine residues (37). Statistical treatment 
of the data gave trinucleotide priority to 5'GG*G, followed 
closely by 5'GG*T and 5'CG*G. The most reactive se­
quence was about 20-fold more frequently alkylated than 
was the least reactive sequence. Like Humayun, these 
investigators invoked a sequence-dependent noncovalent 
(precovalent) binding site for aflatoxin oxide in the DNA 
major groove. The importance of binding interactions was 
also supported by other lines of evidence which these au­
thors listed (37). However, the role of binding was not 
merely postulated to favor mass action, but also to “orient 
(the drug) for covalent reaction”. Thus, “significant en­
hancement of reaction would be expected with nucleophilic 
centers in DNA compared to reaction with simple nu­
cleophiles of similar basicity” (37). The precovalent 
binding is postulated to enhance not only the effective 
concentration of the carcinogen but also the rate constant 
for covalent reaction, in keeping with current under­
standing of the sources of reactivity of bound complexes 
(38).
A lkylating  A gents. Nitrogen mustards and alkyl- 
nitrosoureas are highly efficacious antitumor agents in 
animal tumor systems, and some have become important 
clinically used drugs (39). Nitrogen mustards are bi­
functional agents th a t are postulated to react as aziridi-
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F igure  1 .  S t r u c t u r a l  f o r m u l a s  o f  s o m e  D N A  c o v a l e n t l y  m o d i f y i n g  a g e n t s  ( a - i )  o r  r e a c t i v e  i n t e r m e d i a t e s  d e s c r i b e d  i n  t h e  t e x t .
nium  cation  in term ed ia tes (Figure lb ) w ith, principally, 
th e  nucleophilic N-7 atom s of guanines (30). N itrosoureas 
are known to  decom pose in w ater, a t  neu tral pH , via 
electrophilic alkyldiazohydroxide species (Figure lb ') , and 
these  have been proposed as in term edia tes in DNA al­
kylation  (28),  a lthough th is is still an area  of deba te  (40, 
41).
K ohn has m ade a careful s tudy  of th e  sequence selec­
tivity of guanine N-7 alkylation of a wide range of nitrogen 
m ustards, using experim en tal conditions th a t  allow an 
accurate assessm ent of relative reaction rates of guanines 
in d iffe ren t sequence contex ts (42, 43).  T he recurring 
find ing  was an  increased reaction frequency a t  guanines 
w ithin guanine clusters. Typically, these reaction in ten ­
sities varied by a factor of 2, b u t in runs of three guanines 
each was, on average, th ree to  four tim es as reactive as an 
iso lated guanine. T h e  fact th a t  m any agents differing 
significantly in their nonalkylating structure show the same 
sequence p reference argues against a role for specific 
b ind ing  in terac tions of th e  nonalkylating m oieties in in­
fluencing th is  selectivity . In tra s tra n d  cross-linking does 
n o t ap p ear to  be a causal factor in the  enhanced reaction 
a t ad jacen t guanines. A cross-link would be visualized as 
a break  nea rest th e  labeled end. Analysis of the  sam e 
fragm en t labeled a t  e ither th e  3' or th e  5' end showed no 
such p a tte rn  of weak and  strong  bands (42).
Theoretical calculations by Pullm an and Pullm an on the 
electrostatic  po ten tia l of DNA indicate th a t this potential
is sequence d ep en d en t (44). In p articu lar, guanines su r­
rounded  by o th e r guan ines are  associated  w ith a consid­
erably more negative p o ten tia l a t  N-7 th an  are isolated 
guanines. Using th e  m olecular e lec trosta tic  po ten tia l 
(M EP) calculated for various XG*Y sequences, K ohn ob­
served a rem arkable correlation of negative M EP with the 
reaction in tensity  of m ost n itrogen  m ustards a t these se­
quences (43, 44). T h e  m olecular ra tionale  advanced for 
th is phenom enon was th a t  th e  “positively charged aziri- 
din ium  group ... w ould be d raw n selectively tow ards the 
more electronegative regions” (43). (N ote th a t in K ohn’s 
paper the term  “electronegative” was used to mean “having 
a m ore negative M E P ”, ra th e r  th a n  P au ling ’s defin ition  
of “the power of an  atom  in a molecule to a ttrac t electrons 
to  itself”. T h e  im plica tion  is th a t  th e  electrostatic  a t­
traction  betw een negative regions on DNA and positively 
charged reactive in term ed ia tes serves a “collection” func­
tion, i.e., increases the  ra te  by increasing the effective local 
concen tra tion  of ca tion ic  in term ed ia tes. A sim ilar se­
quence selectiv ity  for c lusters o f guanines was found for 
(ch loroethyl)n itrosourea and  led to  th e  suggestion th a t  a 
“partia l ch loronium ” ion in te rm ed ia te  (Figure lb " ) , with 
a partia l positive charge, was involved (28). T hese in ­
vestigators had  rep o rted  a  lack of sim ilar guanine N-7 
sequence se lectiv ity  for e th y ln itro so u rea  and  (chloro- 
ethyl)m ethanesulfonate and  felt th is to be consistent with 
the inability of these agents to form  an  analogous partially 
charged in term ed ia te .
■OCONHj
Perspective
Very recently, the guanine N-7 sequence selectivity of 
methylnitrosourea (MNU) has been reported (40) and 
found to resemble the same selectivity for oligo(dG) se­
quences shown by the nitrogen mustards and (chloro- 
ethyl)nitrosourea. The inhibition of guanine alkylation 
by salt or by the cationic DNA binders spermine, dista- 
mycin, and ethidium bromide, which weaken the negative 
M EP (45), was interpreted as consistent with “a strong 
electrostatic attraction (at low salt) between the polyan­
ionic DNA backbone and a positively charged alkylating 
intermediate” (from hydrolysis of MNU).
These data appear to fan a controversy since a number 
of kinetic, product structure, and isotope exchange ex­
periments argue against carbocationic hydrolysis products 
of nitrosoureas as intermediates in DNA alkylation by 
these agents (41). Indeed, an intriguing mechanism for 
DNA alkylation was postulated by Buckley, whereby a 5' 
guanine, in lieu of the hydroxide ion (involved in the hy­
drolysis mechanism), attacked an imido form of the al- 
kylnitrosourea, allowing subsequent regioselective attack 
on the electrophilic carbon by the 3' guanine, without the 
intermediacy of a carbocation. In effect, this GG sequence 
would catalyze its own alkylation. Either N-7 or 0-6 of 
the 3' guanine was proposed as likely nucleophiles. How­
ever, as pointed out by Wurdeman and Gold (40), the 
observed sequence preference for guanine N-7 alkylation 
is not consistent with this mechanism, since the guanine 
nearest the 3' end of a run of guanines is least likely to be 
alkylated. The sequence selectivity of 0-6 guanine al­
kylation, which is probably the more critical lesion for 
mutagenesis and carcinogenesis (46), cannot be determined 
by this Maxam-Gilbert type experiment and thus is still 
a matter of speculation. Experiments quantifying N-7- and 
0-6-methylguanine, and other modified bases, from reac­
tion of MNU with various synthetic polydeoxynucleotides 
show clear sequence dependence of alkylation product 
ratios, consistent with unique sequence preferences for 
each type of adduct (47). In support of his mechanism, 
Buckley stated th a t certain mutational studies show 
“sequence-specific alkylation of 06-dG2 in a 5'-dGdGdN-3' 
DNA codon” (41). However, it should be clarified that 
these data refer to sequence-specific mutational events and 
not sequence-specific alkylation per se. Mutational se­
lectivity could be introduced in sequence-dependent repair 
and mispairing capabilities as well as in the alkylation step
(48).
While the above examples imply a great deal of simi­
larity in the sequence preferences of a number of alkylating 
agents, in reactions with N-7 of guanine, several exceptions 
m erit a more detailed description. Of the rather broad 
structural range of nitrogen mustards studied, two pres­
ented unique sequence specificities which must be attrib­
uted to their nonalkylating moieties (42, 43). In an im­
pressive piece of detective work, Kohn showed that uracil 
mustard had enhanced reactivity with 5TyG*C sequences. 
For most mustards, however, a 3'C greatly reduced guanine 
N-7 reaction, presumably because the cytosine amino 
group nearly overlies the guanine N-7, exerting, with its 
dipole, a positive electrostatic field. Modeling the uracil 
mustard interaction with the perferred nucleotide sequence 
indicated that the uracil 0-4 atom could interact with and 
counter the suppressive effects of the 3' cytosine amino 
group and, further, that such interaction would be facili­
ta ted  by “a displacement of the reacting guanine towards 
the sugar-phosphate backbone”—a process in turn favored 
by the flanking pyrimidines (43). Thus this special se­
quence selectivity is attributed to a specific hydrogen bond 
(uracil 0-4 to cytosine NH2) which enhances the negative
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electrostatic potential of the target guanine, and to se­
quence-dependent DNA flexibility in a “sliding” mode.
The other anomalous nitrogen mustard, quinacrine 
mustard, showed an even greater degree of sequence dis­
crimination (43). Here the reacting guanine must be 
flanked on the 3' side by either guanine or thymine, and 
then by a purine, in order to show maximum reactivity. 
Kohn’s model invokes rapid, noncovalent intercalation of 
the quinacrine ring between the second and third bases 
to the 3' side of the guanine target The covalently reactive 
portion of the drug must then successfully reach over the 
edge of the middle base in the major groove to approach 
the guanine N-7. Evidently the amino groups of adenine 
or cytosine which would occupy this edge in 5'G*APu or 
5'G*CPu sequences interfere with this required confor­
mation of the linking hydrocarbon chain, while the oxygens 
of guanine or thymine occupying this edge do n o t Again, 
although precovalent binding is indicated, the sequence 
selectivity is not simply dictated by the preferred sites of 
intercalation, since intercalation of the quinacrine ring may 
be occurring a t many other sites with equal or greater 
affinity. Rather, in this model, the selectivity (for a central 
guanine or thymine) is dictated by the conformational 
needs of the intercalated drug in approaching the correct 
trajectory for the covalent reaction.
B enzpyrened io l Epoxide. Benzo[a]pyrene is one of 
a number of environmentally prevalent polycyclic aromatic 
hydrocarbons implicated in human cancer (49). I t is me­
tabolized to the highly tumorigenic (+)-diol epoxide 
(BPDE, Figure lc), which reacts covalently with DNA, 
predominantly a t the exocyclic 2-NH2 gro.up of guanine
(49).
Sequence selectivity studies with this potent carcinogen 
present an instance where different sequence preferences 
are shown for the covalent reaction of the same electrophile 
a t two different atoms, N-7 or N-2, of guanine. Boles and 
Hogan (50) exploited the long-wavelength UV photolability 
of the covalent BPDE-DNA adduct to produce single- 
strand cuts (independent of diffusible oxygen species) lo­
cating the reaction site. Unlike the usual sequencing 
studies, in this case the carcinogen was reacted with the 
entire supercoiled plasmid, which was then cleaved with 
restriction enzymes, end labeled, laser photolyzed, and 
analyzed on a denaturing electrophoresis gel. Since the 
N-2 guanine adduct is the major one (80-90%) formed in 
DNA by BPDE (51), it is presumed to be the major origin 
of the observed photolytic cuts, although low levels of 
cutting at adenine and cytosine suggest that the photolysis 
can operate on a variety of adduct structures. The most 
pronounced sequence preference was for adjacent guanines, 
such that strings of three to five guanines, and one se­
quence of 16 guanines, were cleaved three to four times 
as readily as isolated guanines. These investigators pro­
posed that this sequence preference reflected favored in­
tercalation binding sites for BPDE. Alternatively, they 
suggested th a t the sequence selectivity could reflect a 
tendency for A-like helix geometry in tracts of poly- 
(dG)*poly(dC) (52), which would expose guanine N-2, 
making it more accessible to attack (50).
A very different preferred sequence context for BPDE 
reaction a t guanine N-7 with DNA restriction fragments 
was determined by Lobenenkov et al. (53). These workers 
analyzed the strand breaks produced by piperidine and 
heat treatment of the covalently modified DNA, and hence 
they presumably detected only guanine N-7 adducts, which 
are expected to be formed in much lesser amounts than 
guanine N-2 adducts (51). Preferred cleavages occurred 
a t the central guanines of 5TyGN sequences. While
320 Chem. Res. Toxicol., Vol. 1, No. 6, 1988
densitometric scans were not run to show relative intensity 
of the various sites, the absence of cleavage a t the 3' 
guanine of 5'GG sequences was marked, and longer strings 
of guanines were likewise devoid of evidence of cleavage- 
inducing alkylation, in sharp contrast to the outcome of 
Boles and Hogan’s results for guanine N-2 alkylation (50). 
Interestingly, these investigators also attributed this very 
different sequence selectivity to preferred intercalation 
sites for BPDE (53)!
Physical studies offer some insights into the reaction of 
BPDE with DNA, which may have an important bearing 
on the sequence determinants of covalent reaction. In spite 
of apparently reasonable, if conflicting, speculations about 
preferred intercalation of BPDE described above, Harvey 
and Geacintov have shown that BPDE intercalation is 
actually favored a t dA-dT sequences (49). The location 
of the intercalated complex does not seem to be critical 
except to protect the very reactive electrophile from non­
productive chemical reactions with other cellular nucleo­
philes. The BPDE may in fact “diffuse” from one binding 
site to another along the helix (49). Only when it reaches 
an appropriately reactive guanine will covalent reaction 
occur, i.e., when the “requirements for proper orientation 
and sufficiently close approach of the reacting electrophile 
(i.e., a triol carbonium intermediate) to an appropriate base 
site on DNA” (49) are met.
Some insight into what might be the “requirements” for 
covalent reaction between DNA and BPDE might be 
gained from studying another reaction between DNA and 
BPDE, namely, DNA-catalyzed hydrolysis of the diol ep­
oxide (54,55). Spectroscopic evidence shows initial rapid 
noncovalent binding to DNA, and while a small fraction 
of the carcinogen then reacts covalently with DNA, most 
of it undergoes hydrolytic ring opening of the epoxide at 
a rate much faster than hydrolysis in the absence of DNA. 
This DNA-catalyzed hydrolysis is hydronium ion de­
pendent, either through protonation of the epoxide or the 
kinetically equivalent general-acid catalysis. I t  is also 
extremely sensitive to salt concentration. Thus even at 
physiological ranges of ionic strength, the ability of DNA 
to catalyze BPDE hydrolysis is significantly impeded. This 
has been interpreted to reflect electrostatic stabilization 
by the polyelectrolytic DNA of the transition state in the 
rate-determining step of BPDE hydrolysis and “suggests 
th a t such an interaction may provide a large part of the 
driving force for the observed catalysis by DNA” (54). 
Michaud e t al. compared the rate constants for acid-cat­
alyzed hydrolysis by calf thymus DNA and by poly(dA), 
concluding that the reaction was not highly dependent on 
DNA secondary structure or sequence. They proposed 
general-acid catalysis by a protonated phosphodiester 
group of DNA as one possible mechanism (54). MacLeod 
et al. reported an increasing ability of various natural and 
synthetic DNAs to catalyze BPDE hydrolysis with in­
creasing GC content, which did not correlate with nonco­
valent association constants. They postulated that gene­
ral-acid catalysis of BPDE hydrolysis might be provided 
by small concentrations of protonated exocyclic NH2 
groups of guanines (55). They reported a similar depen­
dence of the extent of covalent adduct formation (with 
titrated BPDE) on the base composition of the DNA (55). 
Thus, in addition to the suggested sequence-dependent 
binding of the drug, there may be sequence-dependent 
electrostatic stabilization of the transition state for adduct 
formation and sequence-dependent general-acid catalysis 
of the covalent reaction.
M itom ycin C. Mitomycin C is a potent antitumor an­
tibiotic which reacts covalently with DNA following ac­
Warpehoski and Hurley
tivation by chemical or enzymatic reduction, or by pro­
tonation. Recently Tomasz has investigated the regio- 
chemistry of the guanine adduct with mitomycin C, formed 
under either reductive or acidic activation (56). The 
heteroatom selectivity is quite high for the covalent re­
action with the dinucleotide dGpC: acid activation gives 
95:5 guanine N-7:N-2 alkylation, while reductive activation 
leads to 15:85 guanine N-7:N-2 derived products. This has 
been explained according to the electronic character of the 
reactive mitomycin species believed to be formed under 
each set of conditions (56). Acid activation produces a 
species (Figure Id') with relatively localized carbocationic 
character and is thus a “hard” alkylating agent, which is 
expected to react a t guanine N-7, the site of greatest 
electron density. Reductive activation forms a quinone 
methide (Figure Id") with highly delocalized electropo­
sitive character, i.e., a “soft” alkylator. Delocalized elec- 
trophiles are known to react preferentially at guanine N-2 
(57).
However, in double-stranded DNA, guanine N-2 alkyl­
ation is enhanced relative to guanine N-7 alkylation, re­
gardless of the activation mode. Thus, in the acidic re­
action, only half of the guanine adducts from calf thymus 
DNA derive from N-7 alkylation, while reductive activation 
leads exclusively to guanine N-2 adducts (56, 58). The 
rationale suggested for this striking influence of double­
helical DNA structure on the chemical nature of the co­
valent reaction was the possible steric hindrance of attack 
on the guanine N-7 atom in the major groove (56).
Differences in sequence selectivity for formation of 
guanine N-2 (50) and guanine N-7 (53) adducts of BPDE 
suggest th a t such differences may also be found for mi­
tomycin and might aid in evaluating the significance of 
acid activation of mitomycin C in vivo.
The sequence selectivity studies published on mitomycin 
C (59, 60) leave a number of unanswered questions. In 
these studies strand breaks were created, mostly a t gua­
nines, but also to a significant extent a t adenines, by in­
cubation of DNA fragments with mitomycin C and sodium 
borohydride, the chemical reducing agent, under aerobic 
conditions, and then briefly heating (90 °C, 5 min) the 
isolated, modified DNA. When the heating was extended 
to 30 min and done in the presence of piperidine, strand 
cleavage was much more extensive, although the pattern 
of fragments was judged to be the same. Ueda et al. (59) 
noted that under reductive conditions the known products 
of mitomycin-DNA covalent reaction (N-2 guanine ad­
ducts) are not heat labile. Guanine N-7 alkylated products, 
which might give such cleavage, are presumed not to be 
formed under reductive conditions (58). However, they 
also pointed out that the heat-labile sites which they ob­
served are evidently not generated under anaerobic re­
ducing conditions (59). Oxygen radical and singlet oxygen 
scavengers, and metal chelating agents, inhibited this 
heat-labile site induction. A specific chemical rationale 
uniting all of these observations was not formulated, al­
though the suggestion was made that intercalation of the 
mitomycin semiquinone was the basis of the observed 
sequence selectivity (60). These selectivities were very 
modest. Almost all guanines and many adenines reacted 
to some extent, with central guanines in some (but not all) 
5'GGT sequences appearing to react three to four times 
as readily as others (59). In view of Tomasz’ more recent 
characterization of chemical adduct differences depending 
on mitomycin activation conditions (56), the need for 
further work in evaluating the sequence selectivity of 
mitomycin C is clear.
Perspective
A nthram ycin . Anthramycin (Figure le) is a carbinol- 
amine-containing antitumor antibiotic th a t bonds cova­
lently to guanine N-2, with the resulting adduct fitting 
snuggly in the minor groove (61, 62). The sequence se­
lectivity of this and related pyrrolo [ 1,4] benzodiazepines 
[P(l,4)B’s] has been examined by methidium-EDTA-Fe 
(MPE-Fe) footprinting (63). In this technique, in principle 
applicable to either covalent or noncovalent complexes, the 
DNA fragment is incubated with the drug of interest and 
then exposed to the non-sequence-selective intercalator, 
methidium, which in turn is linked to  EDTA-Fe. Under 
the appropriate redox conditions the MPE-Fe reagent 
generates diffusible reactive oxygen species which cause 
strand cleavage (ideally, one cleavage per DNA molecule) 
a t every possible nucleotide except those protected by the 
presence of the drug complex (64). This technique is a t­
tractive in th a t it can reveal sequence selectivity for the 
formation of adducts (such as those of N-2 guanine) which 
are not readily susceptible to direct chemical cleavage. 
More recently, an exonuclease III stop assay has been used 
to examine the sequence selectivity of a variety of natural 
and synthetic P(l,4)B’s (65). Similar results to that pre­
viously revealed by MPE-Fe footprinting were found. The 
P(1,4)B drugs preferentially protected 5TuGPu sequences 
(bonding to the middle guanine) and enhanced MPE-Fe 
cleavage in regions between footprints (63). The close van 
der Waals contacts between the twisted drug adducts and 
the floor and sides of the minor groove indicated by CPK 
models were considered as possibly of key importance in 
sequence recognition (63). Theoretical calculations, how­
ever, indicated that the actual residual binding energies 
of the covalent adducts in various sequences were quite 
similar but that there were pronounced differences in the 
requisite distortion energies of the different sequences, 
with 5'PuGPu sequences showing the lowest deformation 
energy costs on binding of the already bonded anthramycin 
(66). The nature of this proposed requisite deformation 
resembled the parameters of A-DNA, in which the minor 
groove is wider and shallower than in B-DNA (67). I t  is 
interesting that Boles and Hogan had also remarked on 
the possibility that the contiguous guanine preference or 
BPDE (with respect to guanine N-2 adducts) might be 
promoted by the A-like helical tendencies of poly(dG)- 
poly(dC) tracts (50). The hypothesis implied here, in any 
event, is that the inherent dynamic conformational prop­
erties of a given sequence of nucleotides, i.e., flexibility of 
deformability along certain coordinates, may be important 
in affecting the rate of a covalent reaction at that sequence 
(66). W hether it does so by creating a favorable nonco­
valent binding site for the drug, increasing its effective local 
concentration, or whether the deformability is necessary 
to bring the reactive atoms of the drug and the target 
nucleotide into bonding distance (i.e., binding of the 
transition state) is a question potentially answerable by 
analogue studies. The distortion indirectly observed or 
calculated for a final covalent adduct must be interpreted 
with some caution, until direct structural data are avail­
able.
T ransition  M etal Complexes. Transition metal com­
plexes can readily coordinate with “soft” endocyclic ni­
trogen lone pair electrons on DNA bases, forming or- 
ganometallic covalent bonds (68). The clinically important 
an titum or agent cis-diam m inedichloroplatinum (II) 
(cisDDP) (Figure If) has been shown to form a coordina­
tion complex with two adjacent guanines through their N-7 
atoms, in effect creating a single atom (Pt) cross-link (69). 
Early sequencing studies using exonuclease III inhibition 
to locate cisDDP on DNA fragments reported inhibition
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by both cisDDP and transDDP at every guanine, which 
was attributed to monoguanine-platinum coordination 
(70). In addition, the exonuclease was inhibited one (70) 
or three (71) nucleotides preceding runs of two or more 
guanines, and this phenomenon, which was shown only by 
the biologically active cisDDP, and not by the inactive 
trans isomer, was attributed to the locally distorting bi- 
functionally coordinated complex. Again, rather large drug 
loading was used (8-16 P t atoms per 165 base pair frag­
m ent in reference 71), with the object of detecting all 
possible sites rather than discerning the most reactive sites. 
Hence, other possible sequence effects on relative reaction 
rates a t different guanines have not yet been explored.
Although not yet subjected to specific sequence analyses, 
the chiral transition metal complexes studied by Barton 
provide some interesting insight into covalent DNA 
modification as a recognition mechanism (68). The left- 
and right-handed tris(phenanthroline) complexes of ru- 
thenium(II) (structures g/ and g" of Figure 1), which bind 
noncovalently to DNA by intercalation of one of the 
phenanthroline rings, with the other ligands lying along 
the DNA groove, show a modest degree of difference in 
their affinity for B-DNA. Dialysis of calf thymus DNA 
against the racemic mixture produced enrichment of the 
left-handed isomer in the dialysate, consistent with pref­
erential intercalative binding of the right-handed isomer 
(72). The left-handed isomer appears to interact with 
B-DNA in a more loosely held hydrophobic groove binding 
mode (73). Replacement of a phenanthroline ligand 
(Figure lh ', h") with two chlorine ligands, on the other 
hand, gives complexes th a t can now covalently bond to 
guanine N-7 atoms, forming cross-links in much the same 
manner as cisDDP, except that they are octahedral and 
chiral (68, 74). When racemic bis(phenanthroline)di- 
chlororuthenium(II) was incubated with calf thymus DNA, 
and the DNA-bonded ruthenium complexes were sepa­
rated out, the supernatant solution was enriched in the 
right-handed isomer, indicating th a t DNA covalent 
bonding to the left-handed isomer was more efficient Not 
only was the enrichment of recovered metal complex in 
solution opposite to that found with the complexes which 
were merely intercalated, but the magnitude of the en­
richment was 5-fold greater (74). Thus the covalent in­
teraction is a much more enantiospecific one. Furthermore 
the degree of stereoselectivity with synthetic polymers 
depended on DNA sequence, being highest for poly- 
(dG)-poly(dC) (68). Modeling of this left-handed isomer 
showed that selective covalent reaction with adjacent 
guanines in the major groove is reminiscent of the groove 
binding interactions of the left-handed tris(phenanthro- 
line)ruthenium(II) noncovalent complex (68). The broad 
picture emerging from this and related work, as Barton 
insightfully pointed out (68), is th a t this class of simple 
coordination complexes recognizes specific regions of DNA 
by “matching of shapes and symmetries”. Such recognition 
can be “site selective”, i.e., for Z-DNA, but is not neces- 
-sarily sequence selective. However, metal coordination 
(covalent bonding) provides a mechanism for sequence 
selectivity, since it involves specific reactions with bases 
while still maintaining, in the optimum situation, the shape 
and symmetry complementarity.
N-(Brom oacetyl)distam ycin. In order to separate the 
contributions of noncovalent “physical” binding and those 
of covalent bonding to the sequence selectivity of agents 
th a t are capable of both interactions (as are most of the 
compounds discussed above), one would ideally want to 
compare the sequence selectivity of the noncovalent 
binding forces independently of the covalent bonding re-
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Figure 2. Reaction of CC-1065 with acetic acid or DNA to give 
rise to the cyclopropane ring opened products (a) and (b), re­
spectively (81,82). For production of the CC-1065-(N3-adenine) 
product (b) subsequent thermal treatment is required (Figure 3).
action . D ervan has achieved th is  by a k inetic  separation 
of b ind ing  and bonding. T he trip ep tid e  tris-(7V-methyl- 
pyrrolecarboxam ide) un it of th e  n a tu ra l p roduct dista- 
m ycin was shown to bind (noncovalently) four A-T sites, 
each covering five base pairs, on a 167 base pair DNA 
re s tr ic tio n  fragm ent, by fo o tp rin tin g  and  by affin ity  
cleavage m ethods (75). Inco rpo ra ting  a  brom oacetyl 
m oiety  on th e  am ino end  of th is  trip ep tid e  gave a com­
po u n d  (Figure li)  which, a fte r sh o rt (0.5-h) in teraction  
tim es w ith  th e  sam e DNA fragm ent, gave identical foot­
prin ts . B u t after longer (10-h) incubation  tim es, N -(bro- 
m oacety l)d istam ycin  (BD) produced a single cleavage 
following heat and piperidine trea tm en t a t one adenine of 
one of th e  four b inding sites (76). P resum ably  BD al­
kylated th e  adenine N-3, as does CC-1065 (see below). An 
a-b rom oacety l am ide is no t an  extrem ely  reactive elec­
troph ile , unlike th e  un iso latab le  reactive in term ediates 
described  in th e  foregoing discussion. T h e  covalent re­
ac tion  o f BD w ith DNA is slow relative to  those agents, 
bu t this serves to amplify the rate differences th a t underlie 
th e  phenom enon of sequence selectivity . Only one n u ­
cleotide in 334, and  only one of a m inim um  of seven ad ­
en ines n ear th e  noncovalently  (and also sequence-selec- 
tively) bound drug, underwent detectable covalent reaction 
in 10 h. A t longer tim es, a second covalent site  began to 
appear a t  ano ther foo tprin ted  b inding site (76). Clearly, 
noncovalen t in terac tions of th is  m olecule are qu ite  se­
quence selective and m ost likely resem ble those described 
in th e  crystal s truc tu re  of netropsin-oligonucleotide com­
plex (16). T hey localize the drug a t the  four binding sites. 
B u t even fu rth er selectivity is im parted  a t th e  covalent 
reaction stage, where th e  sequence-dependent differences 
o f local D N A  stru c tu re  m ust m eet th e  “stereoelectronic 
req u irem en t in th e  tran sitio n  s ta te  for th e  backside nu- 
cleophilic d isplacem ent reaction” (76). D ervan suggested 
th a t  BD m ay be a m echanistic  m im ic of th e  an titu m o r 
antibiotic CC-1065, which alkylates adenine N-3 in AT-rich 
regions o f DNA. In the remaining discussion we shall focus 
on this extraordinary DNA-interactive natural product and 
som e of its  syn thetic  analogues.
CC-1065. CC-1065, one of th e  m ost p o ten t an titum or 
antib io tics known (77), interacts w ith double-helical DNA 
both covalently and through unusually strong noncovalent 
bind ing  in  th e  m inor groove a t  A T-rich regions (78-80).  
Am ong D N A -in teractive n a tu ra l p roducts, CC-1065 ap ­
pears to  be exceptionally  selective, bo th  w ith respect to 
th e  covalent adduc t th a t  it form s and  w ith respect to the 
sequences in which th a t  ad d u c t occurs.
(A ) S t r u c t u r e  o f  th e  C C -1065-D N A  A d d u c t. Defi­
nitive evidence for a covalent adduct between CC-1065 and 
D N A  was ob tained  from  a 1H  and 13C N M R  analysis of 












Reaction of CC-1065 with DNA to form the CC-
1065-(N3-adenine)-DNA adduct and products of thermally in­
duced strand breakage (81, 84). The structure of the modified 
deoxyribose on the 3' side of the strand break is not definitely 
known.
chrom ophore) ob ta ined  a fte r  therm al tre a tm e n t of calf 
th y m u s DNA previously incubated  w ith  CC-1065 (81). 
T h e stru c tu re  of th e  CC-1065-base ad d u c t was analogous 
to  th e  acetic acid add itio n  p ro d u c t (Figure 2a) (82). In 
place o f an acetoxy group, adenine was now covalently 
a tta c h e d  a t  C-4 via its N-3 position, i.e., s tru c tu re  b in 
F igure 2; and for reaction  of CC-1065 to  form  th e  CC- 
1065-(N 3-adenine)-D N A  ad d u c t see F igure 3. R adio­
labeling experim ents showed adenine to  be the only base 
d e tec tab ly  a lky lated  (81). S ince N-3 of deoxyadenosine 
is located  in the  m inor groove of DNA, th is  im plied th a t 
on D N A  th e  d rug  m olecule is cradled w ith in  th is groove 
following th e  righ t-handed  tw ist of B -type DNA (81) 
(F igure 4) and  corrobora ted  earlier evidence of m inor 
groove in terac tion  (79). M ore recently , tw o-dim ensional 
N M R  studies on CC-1065-oIigom er duplex adducts 
have confirm ed m inor groove occupancy through d ru g - 
nucleotide in terp ro ton  nuclear O verhauser effect connec­
tiv ities (83). In early  1985 th e  abso lu te stereochem istry  
of th e  cyclopropyl ring of CC-1065 was still unknown; 
however, th is was ten ta tive ly  assigned on th e  basis of the 
d irectionality  of the  DNA sequence specificity in relation 
to th e  covalent binding site (84). We assum ed on the basis 
of availab le evidence th a t  th e  DNA sequence specificity 
was en tire ly  a consequence of the  b ind ing  in teractions 
(close van der W aals con tac ts betw een th e  inside edge of 
th e  d rug  molecule and  th e  floor of th e  m inor groove of 
DNA), and therefore directionality  of sequence specificity 
w ould be akin to  d irec tional o rien ta tion  in the  m inor 
groove. As luck would have it, our stereochem ical p re ­
d ic tion  was la te r de te rm in ed  to  be co rrect (85), b u t our 
argum ent was partially flawed, since more recent data have 
show n th a t  th e  m olecular basis for DNA sequence selec­
tiv ity  of CC-1065 is prim arily due to th e  bonding reaction  
(see la ter) and is consequently  independen t of the  drug’s 
d irec tional o rien ta tion  in th e  m inor groove of DNA.
(B ) D N A  S eq u en ce  S e le c tiv ity  o f  CC-1065. Therm al 
tre a tm e n t (e.g., 100 °C for 30 min) of CC-1065-DNA ad-
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Figure 4. Stereo diagram of a CC-1065-DNA adduct. The computer graphic representation of a CC-1065-DNA adduct using the 
X-ray crystal coordinates for ring-opened CC-1065 (78) and B-form DNA generated by the m i d a s  graphics program. The sequence 
used is that of the center of a 14 base pair oligodeoxy duplex shown to covalently bond a single CC-1065 molecule, a bonds around 
amide linkages between the drug subunits (see Figure 5) were rotated to reduce close drug-DNA contacts upon docking. CC-1065 
A, B, and C subunits are labeled.
d u c ts  p roduces cleavage of th e  N-glycosidic bond th a t 
connects th e  CC-1065-modified adenine to its deoxyribose 
(84). T h e  resu lting  apu rin ic  site  th en  presum ably  u n ­
dergoes a /3-elim ination to  give rise to  a DNA backbone 
s tra n d  breakage, leaving a 5 '-p h o sp h a te  on th e  3 ' side of 
the  strand  break and a modified deoxyribose on the  5' side 
(Figure 3). T h is therm al s tran d  breakage assay has been 
used to  de te rm in e  th e  consensus bonding sequences for 
CC-1065 (84). In all, over 1000 base pairs from  SV40 and 
T 7 DNA restric tion  fragm ents w ere used in th e  analysis. 
A wide range (7 o rders of m agn itude) of d rug  concentra­
tions were exam ined to  give some indication of the relative 
reactiv ities of d iffe ren t sequences. A t th e  lowest drug 
levels a t  which any  a lky la tion -m ed ia ted  s tran d  cleavage 
could be detec ted  (0.14 p m o l/m L ), only th e  3' adenine of 
th e  5 'A G TTA  sequences in the  21 base pair repeats of the 
SV40 early prom oter region was alkylated. A t 10-100-fold 
higher d rug  concen tra tions (1.4-14 p m o l/m L ), 32 ad d i­
tional alky lation  sites in th e  various fragm ents could be 
d e tec ted  under th e  sam e incubation  conditions. A t these 
concen tra tions, m ost of th e  DNA rem ained  as high mo­
lecular w eight m ateria l on th e  gels, ind icating  a high 
likelihood th a t  each s tran d  break observed represen ted  a 
single “h it” on th e  D NA m olecule. R em arkably , in 18 of 
these  sites th e  aden ine  was flanked  on th e  5' side by 
thym ine, and  14 of these  had  a second 5' thym ine. T he 
o th e r a lky la ted  aden ines were flanked  by two m ore ade­
nines (in 13 o u t of 14 instances). A t a 10-fold higher 
concentration the  11 additional sites still m aintained a two 
base p a ir specificity  (AA* or TA*). S till h igher concen­
tra tio n s  of CC-1065 led to  m ore extensive DNA reaction, 
presum ably resulting in m ultip le h its and  w ith less regard 
for th e ir in trinsic reactiv ity . F rom  th e  sequence d a ta  ob­
ta ined  a t  the  lower drug  concentrations (140 pm ol/m L  or 
less), two subsets of sequences were identified, 5'AAAAA* 
and  5 'P u N T T A * , w here A* rep resen ts  th e  covalently 
m odified  aden ine, an d  th e  m ost s tr in g en t sequence spe­
cificity lies to th e  3' end of the  sequences, (i.e., AAA* and 
TTA *).
I t  is im portan t to  recognize th a t these are the consensus 
sequences for th e  co v a le n t  b on d in g  reaction , since this 
assay depends upon therm al labilization of the N-glycosidic 
bond as a  consequence of N-3 alkylation. A t the  tim e we
determ ined these consensus sequences for the  covalent 
reaction, we assum ed, because of th e  d rug  overlap w ith 
these sequences, th a t  th e  noncovalen t in terac tions were 
selecting the adenines th a t  underw ent alkylation, i.e., th a t 
the binding in teractions d irec ted  th e  bonding selectivity. 
Specifically, we proposed a m odel in which close van der 
W aals contacts betw een th e  inside edge of th e  drug mol­
ecule and the  floor of th e  m inor groove o f DNA precisely 
aligned the  drug m olecule in th e  m inor groove, and as a 
consequence of this p referred  physical alignm ent a subset 
of CC-1065 noncovalent b ind ing  sites were selected for 
covalent bonding by a proxim ity  to  an adenine N-3 atom. 
Indeed, we referred to  th e  m ost reactive sites as “highest 
affinity binding s ite s” on th e  basis o f th is  assum ption.
Subsequent a ttem pts to  detect noncovalent binding sites 
of CC-1065 on a DNA restric tio n  enzym e fragm ent by 
“chemical footprinting” with M PE-Fe (64) revealed no new 
sites other than the covalent reaction sites (Figure 5) (86). 
A ttem pts to  d e tec t fo o tp rin ts  w ith  th e  nonalkylating  
species des-ABC (Figure 6) proved unsuccessful p resum ­
ably because the  s tab ility  of its b ind ing  to  DNA was in­
sufficient to  allow detec tio n  by th is  technique (86). 
However, spectroscopic m ethods can be used to distinguish 
noncovalent binding from covalent bonding modes. I t  has 
been shown th a t synthetic polydeoxynucleotides th a t bind 
CC-1065 reversibly (noncovalen tly ) exh ib it a longer 
wavelength m axim um  induced  c ircu lar dichroism  (CD) 
than those polym ers th a t  undergo irreversible (covalent) 
reaction with CC-1065 (390 vs 370 nm), due to the different 
chromophores of in tact and ring-opened drug (87-89). The 
covalent reaction could be followed by slow conversion of 
the 390-nm CD band to a 370-nm band, for some polymers.
T he observation of CC-1065 sequence selectivity  with 
DNA restriction fragm ents (84) p ro m p ted  T h eriau lt and 
Krueger to exploit these spectroscopic tags of th e  bonded 
and unbonded (bu t physically  bound) drug in an elegant 
and powerfully precise m anner, w ith  a series of defined 
oligonucleotides (90). Unlike the  modified M axam -G ilbert 
sequencing technique, th is s tu d y  allowed exam ination of 
sequence effects both  on covalent bonding and on nonco­
valent binding. [W hile chem ical foo tprin ting  had shown 
no additional CC-1065 sites o th e r th a n  th e  adenine N-3 
alkylation sites, it  is possible th a t  noncovalently  bound
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Table I. Biological Activities of CC-1065 and Its Analogues
( 8 6 )




nM CC-1065 % ILS day)
(+)-CC-1065 0.03 1 67 100
(+)-AB'C' 0.05 2 77 100
des-ABC 160 5300 0 6000d
(+)-ABC 0.004 1/7 (4/6)' 25
(+)-AB 0.1 3 100 250
(+)-A 12 400 45c 3000'
“ Drug concentration causing 50% inhibition of celi growth with 
3-day drug incubation. 6I.p.-implanted P388 leukemia with i.p.- 
drug treatment on days 1,5,9- %ILS = percent increase in life 
span of treated compared to control mice. O.D. = optimum dose. 
c Tested as racemic mixture of (+)-A and (-)-A. d Highest dose 
tested. 'Ratio of the number of day 30 survivors/total number 
mice in test group.
tran s itio n  (i.e., th e  ra te  of th e  covalent reaction). T hese 
experim en ts suggest th a t  i t  is the  ra te  constan t for the  
covalen t reaction  itse lf which is so d iffe ren t for, say, 
5'TTA A  and  5'A A TT. The stereoelectronic requirem ents 
for covalen t reac tion  w ith CC-1065 reflected in th a t ra te  
c o n s ta n t are s im p ly  no t energetically  accessible for 
5'AATT, even though a very strong and sequence-selective 
(90)  noncovalen t com plex forms.
I t  is in te re s t in g  to  no te  th a t  th e  dodecam er 
5 'C G C G A A TTC G C G , which binds CC-1065 so well, b u t 
only noncovalently , is th e  sam e one used in the  crystal 
structure  of a netropsin-D N A  binding site (16). From th a t 
crysta l s tru c tu re , p rim ary  sequence recognition for th is 
cationic, noncovalent m inor groove binding molecule was 
a ttr ib u te d  to  favorab le  van der W aals contacts between 
p ro tons on adenine and  the inside edge of th e  drug. T he 
A -T binding preference of netropsin and similarly shaped 
m inor groove b ind ing  drugs, including CC-1065, has for 
som e tim e been considered to reflect th e  steric inhibition 
to  such close b inding  presen ted  by exocyclic N H 2 groups 
of guanines protruding into the minor groove (84,91). The 
strong noncovalent binding of CC-1065 to  this dodecamer 
could su p p o rt th e  com m onality  of these factors in non­
covalen t groove in teraction . On the  o th e r hand, a com ­
parison  of d istam y cin  M PE  fo o tp rin ts  w ith those of 
CC-1065 (which also correspond to covalent bonding sites) 
on a  117 base pair restriction fragment for M l3 m p l (Figure
5) shows significant differences in both th e  positions and 
relative p ro tec tion  of these sites; e.g., th e  best  CC-1065 
bonding  site  in F igure  5 is located in proxim ity to the  
po o re s t  d istam ycin  binding site (86). T h u s the in troduc­
tion  of covalen t bond  form ation in the  case of CC-1065 
strong ly  m odifies th e  effect of w hat m igh t possibly be 
sim ilar noncovalent recognition processes for these agents.
A com plem en tary  approach  to  th a t  of T h eriau lt and 
K rueger, who analyzed the  complex reaction com ponents 
by sim plifying th e  DNA, is to  sim plify th e  CC-1065 mol­
ecule, in o rder to  separa te ly  evaluate its binding and 
bond ing  co n trib u tio n s  to  sequence selectivity . T he 
availability  of syn thetic  analogues of (+)-CC-1065 (Figure
6) allow ed us to  d issec t the  stru c tu ra l requ irem ents for 
bo th  D N A  sequence selectivity  and biological potency. 
T h e  analogues (+)-A , (-f)-AB, and  (+)-A BC (Figure 6) 
exemplify three m ain groups of a large num ber of synthetic 
cyclopropylpyrroloindole (CPI) analogues (92-95). Com­
po unds like (+)-A  do n o t show evidence of significant 
noncovalen t D NA binding  by CD or th e rm al m elting 
m easu rem en ts  (92, 96). These com pounds, although ef­
ficacious as an titu m o r agents in vivo, have relatively low
•  •  •
*  *
F igure 7. Concentration dependency of alkylation by (+)-A, 
(+)-AB, and (+)-ABC of the S'-^P-labeled (+) strand in the 117- 
bp A/spI-BstNI fragment of M13mpl DNA (86). Aliquots of 
single 5'-32P-labeled 117-bp DNA fragments were modified with 
1 x  10" (n = +1 through -7) dilutions (labeled +1 through -7) 
of 280 nM stock of (-t-)-A, (+)-AB, or (+)-ABC solution. Modified 
DNA was heated at 90 °C for 30 min in DSC buffer and elec- 
trophoresed adjacent to Maxam-Gilbert purine- and pyrimi­
dine-specific DNA cleavage reactions. The drug alkylation se­
quences are shown, and arrows indicate adenines modified by 
(+)-A, (+)-AB, and (+)-ABC.
potency in vivo or in vitro  (Table I). A t the other extreme 
are com pounds resem bling (+)-ABC, which show intense 
induced  CD bands w ith  DNA and  cause large m elting 
tem perature increases, indicative of strong physical binding 
in terac tions. T hese  com pounds rival or exceed CC-1065 
itse lf in biological potency. F inally, com pounds of in te r­
m edia te  leng th , like (+)-A B , ten d  to  show in term edia te  
b ind ing  pa ram ete rs  and  potencies (T able I).
In view of our early  assum ptions th a t  strong, specific 
noncovalent b inding in terac tions d ic ta ted  the  location of 
the  u ltim ate alkylation sites, we expected a progressive loss 
of site d iscrim ination  w ith  analogues of progressively less 
DNA b inding  ab ility  [i.e., proceeding from  (+)-ABC to 
(+)-A B to  (+)-AJ. S urely  th e  surrounding  sequence con­
tex t could m atter very little to  a molecule as small as (+)-A. 
T o  our g rea t su rp rise , (+)-A , (+)-A B, and  (+)-ABC, so 
d iffe ren t in th e  degree o f th e ir  physical binding in te rac­
tions w ith DNA, show ed v irtually  th e  sam e sequence 
specificity  (F igure 7)!! W hile th e  abso lu te  ra tes of a l­
ky lation  were q u ite  d iffe ren t, judged by th e  102 and  104 
higher m olar concentrations of (+)-AB and (+)-A required 
to  achieve th e  eq u iv a len t in ten sity  of s tran d  breakage 
shown by (+)-ABC (Figure 7), the relative rates among the 
various p o ten tia l a lky la tion  sites rem ained  basically the 
sam e, i.e., (+)-A  “p re fe rred ” th e  sam e sequences th a t 
(+)-A B C  did. T h is  im plies th a t  th e  DNA sequence se­
lectiv ity  of (-t-)-ABC, an d  presum ably  of (+)-CC-1065, is 
prim arily  m ediated no t by its strong, noncovalent binding 
in teractions, b u t by th e  bonding reaction, which it shares
| (+)~A (+)-AB (+)-ABC
C Pu Py +1 0 -1 - 2  - 3  (5 -1 - 2  -3  - 4  -3  -4  -5  -6  - i
32ti Ctiern.  t ies .  l o x i c o l . ,  Vol. I, l \ o .  6, Warpetioski ana Hurley
( + ) - a b 'c '(+ >-A (+)-C C -1065 (+)-ABC
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Figure 8. Temperature dependency of alkylation by (+)-CC-1065, 
(+)-ABC, and (+)-AB'C' of the 118-bp M bol-H infl fragment of 
SV40 DNA (86). Aliquots of single 5'-*T-labeled 118-bp fragments 
were incubated with 2.8 mM (+)-A or 28 mM (+)-CC-1065, 
(+)-ABC, and (-f)-AB'C' and incubated at 4, 25, or 37 °C for 2 
h. Drug-modified DNA was heated at 90 °C for 30 min in DSC 
buffer and electrophoresed adjacent to Maxam-Gilbert purine- 
and pyrimidine-specific DNA cleavage reactions. The drug 
bonding sequences are shown, and arrows indicate adenines 
modified by either (+)-A, (+)-CC-1065, (+)-ABC, or (+)-AB'C'.
in com m on w ith (+)-A  and  (+)-AB. G ratifyingly, th e  
corresponding higher levels of (+)-AB and  (+)-A th a t were 
requ ired  to produce equivalen t DNA bonding  also p ro ­
duced sim ilar levels of cytotoxic po tency  (T able I). T h is  
suggests th a t the therm ally induced DNA strand  breakage 
assay, a gauge of th e  covalent bonding reaction, is a good 
ind ica to r of biological potency.
W hile the  (+)-A su b u n it of (+)-A B C  is s tru c tu ra lly  
suffic ien t to  m ediate  th e  p rim ary  basis for th e  sequence 
selectivity of the en tire  molecule, we noted  th a t  d ifferen t 
“B ” and  “C” subun its  m odulate  or fine-tune  th e  precise 
sequences to  which CC-1065 analogues covalently  bond 
(Figure 8). Thus there are a few sequences which (+)-ABC 
and  (+)-CC-1065, for exam ple, do n o t share  in com m on 
[although (+)-A  a t  sufficiently  high concen tra tions a l­
kylates both sets of po ten tia l bonding sites]. P resum ably  
steric  inhibition  to  b inding of CC-1065 can effectively 
exclude some sites available to  (+)-A BC; alternative ly , 
specific favorable b ind ing  in te rac tio n s o f CC-1065 could 
prom ote reaction a t  some sties th a t  m igh t a lky late  (+)- 
ABC too slowly. An analogue of in te rm ed ia te  s tru c tu ra l 
com plexity  to  (+)-A BC and  (+)-CC-1065, nam ely, (+)- 
AB'C ', which shows physical binding param eters (induced 
CD, A Tm) closely resem bling those o f (+)-A B C  (95, 97),  
nevertheless closely m atches CC-1065 in sequence spe­
cificity. Thus, changing the  inside edge substituen ts of the 
B and  C subun its  [i.e., (+)-CC-1065 or (-O -A B 'C ' to  
(+)-A BC] is suffic ien t to m odulate  th e  DNA sequence 
selectivity of the  p a ren t drug molecule. T he outside-edge 
hydrophilic substitu en ts  of (+)-CC-1065 ap p aren tly  have 
little  effect in th is regard. T h u s  we conclude th a t  while
th e  bonding  reac tion  is th e  m ain  d e te rm in an t of DNA 
sequence specificity of (+)-CC-1065, certa in  b in d in g  in ­
teractions  (close van der W aals contacts between the inside 
edge of the drug molecule and the  floor of the minor groove 
of DNA) can m odulate  or fine-tune  th is  sequence selec­
tivity . T he “fine tu n in g ” in th is  instance assum es added 
significance from  th e  observation  th a t  (+ )-A B 'C ' also 
shares with (+)-CC-1065 th e  unusual and p o ten t biological 
action  of causing delayed d ea th  in roden ts (95).
M o lecu la r  B a s is  fo r th e  DNA S e q u e n c e  
S e le c tiv ity  of DNA C o v a le n t  M od ifica tio n
T he recent literature on the sequence selectivity of drugs 
and carcinogens th a t  bond covalently to  DNA establishes 
a strong  case for th e  existence o f such selectivity. T h a t 
is, th e  ra te  of covalent reaction  of a given d rug  w ith  a 
nucleotide base in one sequence m ay be m uch faster than  
th a t  w ith th e  sam e base in a d iffe ren t sequence. W hile 
some drugs (e.g., CC-1065) are m uch m ore sequence d is­
criminating than others (e.g., B PD E  or nitrogen m ustards), 
very few appear to  be non sequence selective.
E xam ination of m ost of th e  published lite ra tu re  would 
seem to suggest, however, th a t these observed selectivities 
for reaction a t  ce rta in  sequences are th e  consequence of 
sequence-specific binding, preceding the  bonding reaction 
(35, 50, 53, 59, 63, 84). In  te rm s o f eq 1, th e  sequence
drug +  DNA (drug-D N A )noncov —^  (d ru g -D N A )^
(1)
inform ation is generally  presum ed to  be im p o rtan t only 
in th e  requisite  in itia l b ind ing  step . A priori, th is  is a 
reasonable notion in ligh t of th e  extensive lite ra tu re  es­
tablishing the ab ility  of noncovalently  binding molecules 
to discrim inate am ong DNA sequences (15-20). T hus the 
faster ra tes of covalen t reaction  a t  certa in  sequences are 
presum ed to  reflect h igher concen tra tions of th e  nonco­
valently  held com plex a t  those sequences.
In principle, however, th e  bonding step  m ight also be 
sequence selective; th a t is, certain sequences may be better 
th an  others a t stabilizing th e  transition  sta te  for covalent 
reaction. Some of th e  ways th a t  th is  bonding sequence 
selectivity  m ight be b rough t ab o u t have already  been 
m entioned in one con tex t or ano ther: e lec trosta tic  s ta ­
bilization of charge developm ent in the transition sta te  [as 
in D N A -catalyzed B P D E  hydrolysis (55)], DNA confor­
m ational flexibility [proposed for an th ram ycin  (66) and 
uracil m ustard  (43)], o rien ta tio n -d ep en d en t m u ltifunc­
tional catalysis [proposed for M N U  (41) and m odeled by 
nucleotide-catalyzed B P D E  hydrolysis as discussed below 
(98)], and  steric  accessibility  [proposed for qu inacrine 
m ustard  (43)]. In m ost cases th e  experim ental work re­
quired to distinguish am ong these possibilities has no t yet 
been undertaken . N evertheless, we believe it is possible 
to form some useful, if tentative, generalizations about the 
origins of selectivity  in some of these  instances.
It m ight be supposed th a t sources of bonding selectivity 
could be m ost easily d iscerned w hen binding selectivity  
is likely to be weak or nonspecific. Small molecular weight 
a lkylating agents in general have few noncovalent DNA 
binding capabilities except for charge a ttrac tio n . T he 
observed M E P -d ep en d en t sequence selectiv ity  of m ost 
n itrogen m ustards was a ttr ib u te d  to  selective a ttrac tio n  
of aziridinium cations to negative potential regions of DNA 
(43). However, the  detailed  s tu d y  of sa lt effects on DNA 
alkylation by the m ustards (43) suggested th a t electrostatic 
po ten tia l m ight be perform ing m ore th a n  th is collecting 
function. Negatively charged m ustards (with therefore net 
neu tral aziridinium  interm ediates) still showed selectivity
for guanine clusters, even though they were not inhibited 
by salts as were other mustards. In general, salts reduced 
the magnitude but not the order of selectivity (i.e., rate 
differences) for different sequences. Thus bonding se­
lectivity remained even under ionic strength conditions 
which made ionic binding interactions extremely weak (43). 
Similarly, inhibition of MNU guanine N-7 alkylation by 
salt of DNA binding cations still retained relative selec­
tivity for certain guanine sequences (40). Kohn had sug­
gested (42) th a t the observed selectivity for runs of gua­
nines shown by aflatoxin (35-37) might be due to the more 
negative electrostatic potential a t these sequences, even 
though a discrete cation of sufficient lifetime to allow 
equilibrium binding seems unlikely, since the aflatoxin 
epoxide itself cannot be isolated.
These observations suggest that a sequence-dependent 
molecular electrostatic potential may operate on the 
bonding step, perhaps by stabilizing an incipient positive 
charge on the electrophilic substrate in the transition state. 
This has precedent in the DNA-catalyzed hydrolysis re­
action of BPDE (55) discussed above. It implies some 
degree of catalysis of the alkylation by the electronegative 
DNA sequence. I t  has been noted th a t guanine N-7 in 
double-stranded DNA reacts with aflatoxin oxide much 
more rapidly than does guanosine (37). Similarly, N 1- 
methyl-N-nitro-A^-nitrosoguanidine (MNNG) does not 
alkylate guanosine but readily alkylates DNA (99). The 
rate constant for hydrolysis of n-propylnitrosourea (PNU) 
is 3-fold lower than th a t for its alkylation of calf thymus 
DNA (41). Numerous other instances of alkylation rate 
acceleration by DNA have been enumerated by the 
Pullmans and tentatively ascribed to M EP effects (44). 
These instances suggest that in some way DNA is acting 
to catalyze its own alkylation by these reagents. While 
the interesting sequence-dependent catalytic mechanism 
proposed by Buckley (41) for MNU alkylation of DNA is 
inconsistent with the observed sequence selectivity, at least 
for guanine N-7 alkylation (40), an alternative electrostatic 
stabilization of a cationic transition state could perhaps 
reconcile the sequence selectivity (40), salt effects (40), and 
kinetic and product studies (41) on alkylnitrosourea re­
actions with DNA.
The concept of electrostatic stabilization of a cationic 
transition state by a sequence of negative electrostatic 
potential, as opposed to that of rate acceleration simply 
by virtue of the local concentration of discrete cations near 
such a sequence, helps to explain the interesting behavior 
of uracil mustard. It was proposed that a specific hydrogen 
bond (uracil 0-4 and 3' cytosine NH2) facilitated reaction 
at the 5' guanine by in essence unmasking its potentially 
electron-rich N-7 (43). The drug must already be present 
at this site in order for this N-7 activation to occur, so the 
guanine electrostatic potential is not serving to collect the 
drug. Rather, this model appears to present an intriguing 
picture of sequence-dependent bifunctional catalysis of 
DNA alkylation with one part of the substrate (uracil) 
interacting with a “suppressor” (the amino group of the 
3' cytosine) to allow “activation” of the adjacent guanine 
N-7, which can then stabilize positive charge formation in 
the alkylating portion of the substrate.
A clear case for DNA catalysis of DNA alkylation by 
these agents is difficult to demonstrate, because they are 
such highly reactive molecules to begin with. It would 
seem that such high reactivity (high kT in eq 1) is necessary 
to offset the lack of strong, specific DNA binding capa­
bilities (low Kb) in these small molecules, and still retain 
biological impact. Quinacrine mustard provides a fasci­
nating example of what can happen to sequence discrim­
ination when a significant DNA binding (in this case, by 
intercalation) component is present in the alkylating drug 
(43). First, this drug efficiently alkylates DNA at a much 
lower concentration than th a t required for the other 
mustards (42), reflecting the collection of drug from bulk 
solution by its binding to DNA. Second, the degree of 
discrimination among sequences is larger, and finally, the 
preferred sequences are quite different from those of other 
mustards and do not show a straightforward correlation 
with sequence M EP (43). However, the model presented 
to rationalize the sequence selectivity observed is not a 
simple case of preferred binding a t those sequences 
(magnitude of K b) but rather represents a compromise 
between binding and bonding interactions. The strong 
requirement for a G or T  3' to the reacting guanine is 
postulated to be due to unfavorable stereoelectronic in­
teractions between the base and the alkyl chain of the drug 
when A or C occurs in that position, i.e., the transition state 
for alkylation of the intercalated drug would be of con­
siderably higher energy in these sequences, and hence 
alkylation is less favored. Intercalation at those sequences 
may be as favorable or even more favorable, but the final 
discriminant is the relative free energy of activation of the 
bonding reaction of the (noncovalently) bound drug. Thus, 
binding (Kb) in this case does not dictate sequence spe­
cificity, but it does constrain the selectivity of the purely 
bonding reaction shown by other nitrogen mustards and 
introduces additional requirements.
Quinacrine m ustard may be a good model of the de­
term inants of sequence selectivity for many natural 
products and metabolites such as aflatoxin oxide and 
BPDE, which are highly reactive alkylators th a t are ca­
pable of significant noncovalent binding to DNA. Thus 
the AT intercalation preference reported for BPDE (49), 
for example, is not inconsistent with the observed pref­
erence for guanine N-2 alkylation on G-rich regions if it 
is allowed th a t less favored binding sites (lower might 
nevertheless provide a much better stereoelectronic en­
vironment for covalent reaction (higher kT). The interac­
tion of ruthenium complexes with DNA (68) may represent 
a case in which bonding ultimately selects sites with lower 
affinity binding. Thus while DNA preferentially binds 
(noncovalently) the right-handed isomer tris(phenan- 
throline) ruthenium  complexes, with a lower affinity 
binding mode for the left-handed isomer (72, 73), it is the 
left-handed isomer of the bis(phenanthroline)dichloro- 
ruthenium  complex th a t undergoes faster alkylation. 
While DNA binding affinity is likely to increase potency 
in general by mass action, its effect on sequence selectivity 
might be quite indirect and dependent on the covalent 
bonding ability of the noncovalent complex.
One might expect binding affinity to exert a predomi­
nant effect on sequence selectivity for those agents in­
herently capable of strong, sequence-selective noncovalent 
interactions with DNA, such as the minor groove binders. 
Dervan has engineered molecules in which a highly se­
quence selective binder, distamycin, is tethered to EDTA. 
In the presence of Fe(II), oxygen, and a reducing agent, 
this produces a sequence-selective DNA cleaving molecule, 
whose sequence selectivity is determined totally by non­
covalent binding. The “covalent” component, in this case 
a diffusible oxygen radical induced cleavage rather than 
base alkylation, is totally sequence nonspecific (64). 
(Bromoacetyl)distamycin (BD), in contrast, contains the 
same selective binding moiety, but in this case tethered 
to a relatively unreactive a-bromoacetyl alkylating moiety. 
Covalent reaction with N-3 of adenine occurs at only one 
of the four binding sites examined, and that only after a
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5-10-h incubation. The covalent reaction, by as yet un­
described mechanisms, adds another set of requirements 
to further discriminate among the sets of sequences per­
mitted by binding.
The alkylation of DNA by BD is extremely slow (very 
low k t), and thus it  becomes experimentally feasible to 
distinguish between sequences having relatively small 
differences in kr  The second alkylation site of BD, which 
becomes detectable after 10 h, may not be significantly less 
reactive than the first site, even though each alkylation 
event may be experimentally easy to isolate. Thus the 
sequence selectivity attributable to the alkylation step may 
not be very high. To the extent th a t such bonding selec­
tivity is present, i t  would seem most likely to reflect steric 
constraints imposed by binding. Indeed, it would not be 
surprising if a similar electrophile devoid of the strong 
DNA binding component, for instance a simple a-bromo- 
acetyl amide, failed to alkylate adenine N-3 of DNA under 
conditions resembling those used for BD. In this regard, 
the BD model differs fundamentally from the quinacrine 
mustard model, in which the alkylating moiety has suf­
ficient intrinsic reactivity to alkylate DNA. While in the 
quinacrine mustard model, binding facilitates potency and 
constrains the covalent reaction to certain sequences, in 
the example of BD, strong specific binding may be es­
sential for covalent reaction to occur a t all. If this is the 
case, then the concept championed by Boger, originally to 
describe CC-1065, namely, “accessible hydrophobic binding 
driven binding” (100), would seem particularly suitable to 
describe DNA alkylation by BD. According to this con­
cept, as we understand it, an energetically unfavorable 
covalent process cam be “promoted and rendered irre­
versible (bonding) by the strong, stabilizing noncovalent 
association” (101) of the drug with DNA.
CC-1065 also exhibits strong noncovalent binding se­
lective for AT-rich regions of the minor groove of DNA. 
Like BD, it contains a potential alkylating moiety. For 
quite some time we, like Boger, regarded CC-1065 as a 
molecule possessing a reactive alkylating moiety 
“superimposed” (101) on the sequence-selective DNA 
binding structure and, as discussed earlier, interpreted the 
initial sequence selectivity studies as revealing “high-af- 
finity binding sites” (84).
However, further experimentation has forced us to 
reinterpret the sequence selectivity observed for CC-1065. 
The oligomer studies have shown that very high affinity 
binding is not a sufficient condition for bonding. Spe­
cifically, both 5'AGTTA- and 5'GAATT-containing oli­
gomers exhibit strong binding td CC-1065 (high K b), yet 
the former is alkylated readily while the latter is not al­
kylated a t all (90). Clearly, kr is very different for those 
two noncovalent complexes. The nearly identical sequence 
selectivity of small CPI analogues such as (+)-A, which can 
contribute very little to the hydrophobic and van der 
Waals noncovalent interactions shown by (+)-ABC or by 
CC-1065, clearly dem onstrates th a t such A-T-selective 
noncovalent interaction is not essential for the observed 
sequence selectivity of the covalent reaction of DNA with 
the alkylating segment. While this binding equilibrium 
does appear to have an important effect on the overall rate 
of the covalent reaction, in that strongly binding analogues 
detectably react a t much lower concentrations than non­
binding analogues (86), as might be expected from a mass 
action effect of binding, it is not the important determinant 
of the sequence selectivity of the CPI agents. Therefore, 
the phrase “accessible hydrophobic binding driven 
bonding” (100) is inappropriate to generally describe the 
reaction of (+)-CC-1065 and analogues with DNA, since
it implies th a t the hydrophobic binding provided by the 
concave surface of these agents is both necessary and 
sufficient for the bonding reaction to take place, which is 
contrary to the experimental results (86,90). While non­
covalent binding in the minor groove of DNA must take 
place as a prelude to reaction, this binding might, as in the 
case of (+)-A, be very weak, and need not be sequence 
selective. When noncovalent binding is stronger and can 
exert sequence selectivity [e.g., (+)-CC-1065 or (+)-AB'C'], 
it may modulate reaction a t those sequences where kr is 
not prohibitively small.
If sequence-dependent binding interactions do not solely 
determine the preferred sequences alkylated by CC-1065 
and its CPI analogues, this selectivity m ust originate in 
the bonding reaction. Several models can be proposed 
that, together or separately, can rationalize sequence 
discrimination in the covalent bonding reaction of CC-1065 
with DNA.
One mechanism by which the bonding reaction can exert 
sequence selectivity is through a required alteration in 
conformation of the local region of DNA in the transition 
state for alkylation. The energetics of DNA helix distor­
tions are highly sequence dependent. Reactive sequences 
would be those capable, a t  the least cost of distortion 
energy, of adopting an “active conformation" required for 
covalent reaction. In the most obvious situation the con­
formational change would bring the nucleophilic atom 
within bonding distance of the electrophilic center. Studies 
of a site-directed (+)-CC-1065-DNA adduct (102, 103) 
provided evidence for an asymmetric effect on DNA 
structure, based on cleavage patterns of DNase I and Alul 
restriction enzymes. In the case of Alul, strand scission 
was selectively inhibited on the noncovalently modified 
strand 14 bases away from the (+)-CC-1065 covalent 
bonding site on the 5' side of the adduct. Likewise, DNase 
I cleavage was selectively inhibited on the noncovalently 
modified strand and also on the 5' side of the adduct. On 
the basis of the X-ray structure of DNase I (104) we in­
terpreted this to mean th a t the deoxyribose-phosphate 
backbone conformation of DNA was changed to the 5' side 
of the covalent binding site (86). A more recent structure 
of a DNase I-oIigomer complex (105) offers a second 
possibility for interpretation of our results. In this case, 
reduced DNA flexibility induced by (+)-CC-1065 bonding 
in the vicinity of the CC-1065-DNA adduct could inhibit 
DNase I cleavage. Experimental data which differentiate 
between these possibilities are as yet unavailable. If DNA 
flexibility is im portant for (+)-CC-1065 and protein re­
action with DNA; one might speculate th a t the reason 
(+)-CC-1065 and (+)-A alkylate only certain adenines is 
that these are embedded in flexible regions of DNA, and 
once alkylation by (+)-CC-1065 occurs DNA flexibility is 
lost and enzymatic cleavage by DNase I and Alul is se­
lectively inhibited in the vicinity of the adduct. An im­
portant prediction from this speculation is that the (+)-A 
subunit should show the same pattern of DNase I inhib­
ition as (+)-CC-1065. We have shown this to be true (86). 
We suggested th a t this altered DNA structure might rep­
resent a “trapped” reactive conformation of DNA, a con­
formation that certain sequences could presumably adopt 
more readily than others and th a t could thus be a basis 
for sequence selectivity (86).
DNA conformational mobility has also been suggested 
for the sequence selectivity of anthramycin (66), and as 
a component in the selectivity of uracil mustard (43). 
Examining the features, experimentally or theoretically, 
of a postalkylation adduct does not necessarily give in­
formation on the transition state for the alkylation step.
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Table II. Influence of Binding ( K b) on Sequence 
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Figure S. Proposed mechanism for general-acid-catalyzed suicide 
inactivation of DNA by CC-1065.
However, the finding of similar alterations in DNA by the 
tru n ca ted  (+)-A  segm ent and  by (+)-CC-1065 argues 
against a role for th e  noncovalent binding in teractions in 
causing these conform ational changes in DNA since these 
would be expected to  be q u ite  d ifferen t for (+)-A  and 
(+)-CC-1065.
T h e  sequence-dependen t catalysis of th e  alkylation  is 
a second m echanism  th rough  which sequence selectivity 
can be expressed by a covalent reaction. T h is type of 
m echanism  was recently  proposed, bu t w ithout d irect ex­
perim enta l support, for M N U  alkylation (41). CC-1065 
and its analogues are, because of their chemical properties, 
also attractive candidates for sequence-dependent catalysis. 
Unlike th e  m ustards, nitrosoureas, and reactive epoxides 
already discussed, CC-1065 and its CPI analogues are quite 
stable, when appropria tely  solubilized in neu tra l aqueous 
solutions (92,106).  T hey  do not undergo cyclopropyl ring 
opening reactions under these conditions, even with fairly 
good nucleophiles. Yet, in th e  presence of DNA, covalent 
reaction occurs rapidly (80, 107). In th is regard they also 
d iffer from  the  poorly reactive alkylating m oiety of BD. 
CC-1065 and the CPI analogues do undergo ready opening 
of th e  cyclopropane ring by nucleophiles (even such weak 
nucleophiles as acetic acid or w ater) in th e  presence of 
acids (82), or in aqueous solutions a t low pH  (92). I t  is 
possible th a t certain  sequences of DNA m ay catalyze the 
irreversible ring-opening reaction of CPI, by providing the 
prerequ isite  activation  sim ultaneously  w ith nucleophilic 
a ttack .
T he recently described nucleotide-catalyzed hydrolysis 
of B P D E  (98) provides an elegant m odel of how m ulti­
functional catalysis can express an electronic and  spatial 
“recognition” event in a very sim ple system . W hile the 
acidic phosphate  group of th e  nucleotide provides gene­
ral-acid catalysis for B PD E  hydrolysis, large additional rate 
enhancem ents occur when sim ultaneous stacking in te r­
actions with the nucleotide base can occur. T he magnitude 
of th e  ra te  enhancem en t depends on th e  base. T he elec­
tron-donating  ab ility  of the  base appears to  stabilize the 
tran sitio n  sta te  for hydrolysis of B PD E, while th e  phos­
phate , when located in certa in  positions on th e  sugar, 
provides acidic activation .
For C P I analogues an d  CC-1065, we m ight p ic tu re  an 
“active s ite ”, consisting of the  m inor groove along 5 'AAA 
or 5 'T T A  duplex nucleo tide sequences, which, when oc­
cupied by CPI, would position th e  N-3 of adenine w ithin 
bonding distance of the cyclopropyl methylene carbon and, 
a t  th e  sam e tim e (or slightly  before), would position a 
p ro ton , perhaps from  a phosphate  group, or an electron-
exclusive (nonselective kr) 
predominant (selectivity 
parallels K h) 
constraining (binding imposes 
limitations on bonding sites)












most nitrogen mustards 
methylnitrosourea 
(+)-A (nonbinding CPI’s)
a ttrac tin g  ion such  as M g2+ close to  th e  carbonyl oxygen 
atom  which becom es a phenolic group in the final adduct 
(F igure 9). W hile only m inu te  am oun ts of p ro tonated  
phosphates are present on DNA a t neutral pH , it is a t least 
conceivable th a t  th e ir  strong  acid ity  m ight allow them  to 
be kinetically  relevant. T h u s catalysis for th e  hydrolysis 
of certa in  carcinogenic epoxides by phosphoric acid, a t 
pH ’s th a t are 4 orders of m agnitude above its pK a, has been 
reported  (108). Such bifunctional catalysis m ight account 
for th e  observed rap id  nucleophilic  ring opening of C PI 
u n d er neu tra l conditions. T h is  process also resem bles 
suicide enzym e inactiva tion , in w hich th e  in h ib ito r is a 
relatively  unreactive m olecule u n til it becomes activated  
a t  th e  enzym e’s ca ta ly tic  site  (109).
I t  would be necessary to  postu la te  th a t  th is orientation 
of functionalities was sequence dependent. In this regard, 
it is in teresting  to  note th a t, in m olecular diagram s based 
on theo re tica l calcu lations of CC-1065, covalent adducts 
w ith  several o ligonucleotides show ed a “stabilizing” hy­
drogen bond betw een th e  new phenolic group and  an 
anionic oxygen of the  phosphate on the unmodified strand, 
d is tan t by two base pairs from the covalent site, “in all the 
o p tim al com plexes (5'AAA, 5 'T T A ) ob ta in ed ” (110). In 
such a  m odel for sequence selectivity , binding would be 
necessary only to  perm it approach and  desolvation of the 
“active site” and m ight be very weak, while still perm itting 
the  sequence selection of the  bonding step, accounting for 
th e  behavior o f (+)-A .
T h u s , the  m ain  d e te rm in a n t of which sequences of all 
th e  possible binding regions will becom e covalently m od­
ified by (+)-CC-1065 is n o t th e  affin ity  of th e  various 
b inding sites ( K b), b u t ra th e r the  energetic requirem ents 
of th e  bonding reaction  (kr). Existing  evidence on CC- 
1065-DNA adduct local s truc tu re  points to a possible role 
for s e q u e n c e - d e p e n d e n t  con form ation a l  f le x ib i l i ty  of 
DNA, and  the  observed acceleration  of C PI ring opening 
by DNA also suggests a possible role for seq u e n c e -d e ­
p e n d e n t  c a ta ly t ic  a c t iv a t io n  of th e  drug.
These examples illustrate the m any possible mechanisms 
for sequence selectivity available to  agents th a t covalently 
m odify DNA. T ab le  II is a ten ta tiv e  “classification” of 
some of these examples according to the degree of influence 
exerted  by b inding  in te rac tions ( K h) vs bonding in terac­
tions (kT) on the overall sequence selectivity of the covalent 
reaction.
T h e  only clear instance  of exclusive selectivity  control 
by noncovalent binding in teractions is distam ycin-ED TA , 
which is no t an  alky lating  agen t b u t ra th e r m ediates 
non-sequence-specific DNA cleavage by diffusible oxygen 
radical species. Such a  process m ay generally operate for 
agents, like bleomycin, th a t cleave DNA through this type 
of m echanism . I t ap p ears  th a t  any  alkylation reaction
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[recall even the reaction of guanine N-7 with dimethyl 
sulfate (27)] exerts some degree of sequence discrimination. 
While there may be agents for which the relative rate of 
alkylation a t various sites may parallel the binding affinity 
a t these sites (BD may be an example), and hence which 
fit the term “binding driven bonding” (100), most agents, 
including many natural products, fall into the more com­
plex category in which both finding forces and bonding 
requirements play an essential role in sequence discrimi­
nation. Unraveling the molecular details of these processes 
promises to be a fascinating exploration into chemical 
evolution [e.g., CC-1065 (86), aflatoxin (37)] and into drug 
design [e.g., quinacrine mustard (43)].
W h at I s  th e  S tru c tu ra l, B io ch em ica l, a n d  
B io log ical S ig n if ican ce  of S e q u e n c e -S p e c if ic  
C o v a le n t M odification of DNA?
The major impetus behind investigations of the sequence 
specificity of DNA-reactive drugs and carcinogens is the 
search for clues to  their biological mechanisms of action. 
Certainly, the potential for nucleotide sequence selective 
recognition exists a t various stages of the biochemical 
processes linking the chemical reaction to the biological 
expression. Topoisomerase II inhibitors of the 9-amino- 
acridine class, for example, cleave DNA at sequences that 
appear to be selected by the topoisomerase enzyme, rather 
than by the drugs themselves (111). The lack of correlation 
of mutational “hot spots” on DNA with sites of guanine 
C-8 reaction with N-acetoxy-N-acetyl-2-aminofluorene has 
been interpreted as indicating that mutation specificity 
depends on protein recognition of covalently modified 
mutation-prone sequences (112). In addition to the many 
levels of protein intervention in drug action, the correlation 
of DNA-drug complexes or adducts with biological con­
sequences is further complicated, in most cases, by the 
multiplicity of complexes and adducts formed.
An observation th a t may be of general significance is 
that drugs and carcinogens which bond covalently to DNA 
are typically far more biologically potent than related 
structures devoid of alkylating ability; e.g., des-ABC is 4 
X 104 less potent than (+)-ABC (Table I). The synthetic 
elaboration of doxorubicin to the electrophilic (cyano- 
morpholinyl)doxorubicin changes a moderately potent 
cytotoxic anthracycline into a potentially covalently 
bonding drug which is one thousand times more potent 
than the noncovalently binding drug (113). Potentially 
covalently bonding bromo derivatives of the distamycins 
have been synthesized that are one to two hundred times 
more potent than the nonbonding parent molecule (114). 
Metabolic activation is already a well-established concept 
in chemical carcinogenesis since the Millers in their pio­
neering work (115) demonstrated that metabolic activation 
of aromatic compounds to electrophilic species can occur, 
the products of which can then react covalently with DNA. 
BPDE discussed above is one example of oxidative acti­
vation of a precarcinogen benzpyrene to an alkylating 
species (49,54). The antitumor drug mitomycin C is, on 
the other hand, the prototype of “bioreductive alkylating 
agents” (116), which are metabolically reduced to give 
alkylating species. These examples serve to illustrate the 
importance of metabolic activation in bioconversion of 
DNA binding ligands to DNA bonding agents. I t is in­
teresting to  speculate th a t some of the biological effects 
normally attributed to DNA binding mechanisms may be 
due to very minor amounts of DNA bonding species pro­
duced by metabolic activation.
However, even when the discussion is restricted to co­
valent DNA adducts, the variety of alkylation products
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usually formed complicates any attem pted correlation. 
The most abundant adducts may not be the most biolog­
ically significant. From a purely experimental viewpoint, 
the problem is enormous.
If N ature has given us any assistance in this matter, 
surely the extraordinarily potent, highly sequence selective 
CC-1065 molecule is a part of it. Designed by evolution, 
it is among the most highly efficient toxins known. The 
selectivity of its chemical reaction with DNA allows us to 
ask several questions that have important implications for 
mechanistic understanding as well as for drug design. 
First, is this sequence-dependent reactivity of select ade­
nines for bonding to CC-1065, which apparently depends 
a t least partially upon DNA flexibility, also a general as­
pect of sequence recognition by DNA binding proteins? 
In this regard Hogan and Austin have proposed (14) that 
certain DNA sequences do have increased flexibility, and 
this may be im portant in sequence recognition by DNA 
binding proteins. It will be im portant to determine 
whether CC-1065 bonding sequences are also protein 
recognition sequences; i.e., does (+)-CC-1065 have a “fine 
nose” for regions of increased DNA flexibility and is it 
consequently a sensitive probe (exogenous substrate?) for 
DNA sequences recognized by certain DNA binding pro­
teins? Intriguingly, we have previously noted that the 
hierarchy of S p l binding sites in the 21 base pair repeats 
of SV40 DNA is predicted by the sequence selectivity of 
CC-1065 in this region of SV40 DNA (83,85). Second, if 
a conformational variant of DNA is entrapped by the co­
valent bonding of CC-1065, how does this affect DNA 
recognition by DNA binding proteins such as those in­
volved in DNA repair or transcriptional control? In this 
regard, the CC-1065-DNA adduct is poorly recognized by 
the UVRABC nuclease (117), although more recent work 
suggests that the particular sequence alkylated by CC-1065 
may be an additional factor (118). For the particular 
sequence examined in this study (117) nuclease scission 
occurs predominately on the 5' side of the CC-1065-DNA 
adduct rather than on both sides as is common with other 
DNA adducts. A possible reason for the predominantly 
unilateral scission is th a t the proposed entrapped con­
formational change is also preferentially on this side of the 
covalently bonded site (103). Last, can the sequence- 
specific modification of DNA by CC-1065 and its analogues 
be related to biological end points such as antitumor ef­
ficacy and the delayed death effects of select CC-1065 
analogues (95)7 In this regard, the biological properties 
of CC-1065 analogues vary quite widely. Is it possible that 
the precise tuning of DNA sequence specificity which is 
mediated by variation in the structure of the nonalkylating 
subunits (86) can account for these variations in biological 
effects? While such questions are not easily answered, they 
are of considerable current interest to us.
The recent advances in high-field NMR, computational 
chemistry, and molecular biology provide excellent op­
portunities to study both the structural and biochemical 
consequences of ligand binding and bonding to DNA. For 
example, sufficient amounts of defined DNA sequence 
molecules can be prepared by automated synthesis meth­
ods and then characterized by X-ray crystallography and 
high-field NMR. The application of high-field NMR to 
elucidation of the three-dimensional structure of carcino- 
gen-DNA adducts has been recently reviewed by Harris 
et al (119). Recombinant DNA technology provides both 
the methods and materials to test both old and new con­
cepts on how DNA-reactive ligands may exert their potent 
biological effects. The construction of site-directed adducts 
in DNA to examine structural, biochemical, and biological
Perspective Chem. Res. Toxicol., Vol. 1, No. 6, 1988 331
effects such as mutagenicity is a very important aspect of 
molecular toxicology and pharmacology. This has recently 
been insightfully reviewed by Essigmann (120). This latter 
technology permits the study of ternary complexes 
(drug-DNA-protein), a procedure that we believe will be 
a  major contributor in the future to the elucidation of the 
molecular basis of carcinogen or drug action.
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It is over 60 years since the first nitrogen mustards were 
used in cancer chemotherapy. Since then a structurally 
diverse group of DNA-reactive drugs has been discovered 
largely through cytotoxic screens. In virtually every case 
the molecular target was only tentatively identified as 
DNA after antitumor activity in animal model systems was 
demonstrated. On the basis of what is known concerning 
the molecular interactions of these compounds with DNA, 
three major groups of clinically im portant DNA reactive 
agents have been identified.1 The three groups are the 
alkylating agents exemplified by Cytoxan, Cisplatin, and 
mitomycin C, the DNA strand breakage compounds such 
as bleomycin, and the intercalating agents typified by 
Adriamycin and actinomycin D. A fourth group typified 
by chromomycin, anthramycin, and CC-1065 are drugs that 
modify DNA in the minor groove of DNA. However, these 
compounds have yet to be proven to have clinical utility. 
Some of the discoveries th a t could be considered to be 
seminal in our present understanding of the molecular 
basis for antitumor activity of DNA-reactive compounds 
are the DNA intercalation model for acridine proposed by 
Lermari,2 the in vitro inhibition of RNA polymerase pro­
duced by complexation of actinomycin D with DNA dem­
onstrated by Goldberg,3 and the demonstration of in­
terstrand DNA-DNA cross-linking by mitomycin C due 
to Szybalski.4 More recent landmark discoveries are the 
identification by Liu5 and Kohn6 of the importance of 
topoisomerase II in mediating the antitum or activity of 
compounds such as adriamycin, and the contributions by 
various groups to understanding the molecular basis for 
the DNA sequence specificity of DNA-reactive drugs.7-10
tThis article is not meant to be a comprehensive review of the 
drug-DNA interaction area. Nor does this Perspective consider 
how therapeutic selectivity can be achieved through pharma­
cokinetic and pharmacodynamic parameters. The brevity of 
discussion is imposed by space constraints.
What is clear as we approach the end of the 20th century 
is th a t structural tools such as X-ray crystallography, 
high-field NMR, and computational chemistry, alongside 
techniques from molecular biology such as DNA se­
quencing, DNA construction strategies, and gene cloning, 
have ushered in a new era in conception and design of new 
drugs. The availability of these tools together with the 
recently uncovered structural heterogeneity in DNA and 
restricted access of domains in eukaryotic genomes makes 
the human genome an attractive target for drug design. 
In this Perspective I will address four important issues that 
relate to strategies for improving the therapeutic selectivity 
of existing groups of agents and discovery of new groups 
of important drugs that either interact directly with DNA 
or an associated target. These are (1) identification and 
characterization of the biologically im portant lesions on 
DNA produced by clinically im portant DNA-reactive 
drugs, (2) molecular strategies to improve the sequence 
selectivity of existing groups of DNA-reactive drugs, (3) 
the design of mechanism-based pharmacological screens 
to identify new classes of drugs th a t react with DNA and
(1) Gale, E. F.; Cundliffe, E.; Reynolds, P. E.; Richmond, M. H.; 
Waring, M. J. The Molecular Basis of Antibiotic Action, 2nd 
ed.; John Wiley & Sons: New York, 1981; pp 258-401.
(2) Lerman, L. S. J. Mol. Biol. 1961, 3, 18.
(3) Goldberg, I. H.; Rabinowitz, M. Science 1962, 136, 315.
(4) Iyer, V. N.; Szybalski, W. Proc. Natl. Acad. Sci. U.S.A. 1963, 
50, 355.
(5) Nelson, E. M.; Tewey, K. M.; Liu, L. F. Proc. Natl. Acad. Sci. 
U.S.A. 1984, 81, 1361.
(6) Ross, W. E.; Glaubiger, D. L.; Kohn, K. W. Biochem. Biophys. 
Acta 1978, 519, 23.
(7) Dervan, P. B. Science 1986, 232, 464.
(8) Kohn, K. W.; Hartley, J. A.; Mattes, W. B. Nucleic Acids Res. 
1987, 15, 10531.
(9) Kopka, M. L.; Yoon, C.; Goodsell, D.; Pjura, P.; Dickerson, R.
E. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 1876.
(10) Warpehoski, M. A.; Hurley, L. H. Chem. Res. Toxicol. 1988,
1, 315 and references therein.
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associated targets, and (4) the design of new drug classes 
based upon the identification of pharmacologically selec­
tive receptors on, or associated with, DNA.
If we are successful in the design of new therapeutic 
classes that have improved selectivity for defined cellular 
receptors, these agents will have applications beyond 
treatment of cancer. For example, they may be useful in 
treating infectious diseases or genetic disorders that result 
from aberrant expression of cellular proteins.
I. Identification and Characterization of the 
Biologically Important Lesions Produced on DNA 
by Important DNA-Reactive Drugs
Identification and characterization of the types of DNA 
modification produced by DNA-interactive drugs is a 
prerequisite for understanding the biochemical and bio­
logical responses induced by these agents. Since the ma­
jority of DNA-reactive drugs produce a variety of lesions 
on DNA, it is an important objective to  determine which 
lesions are biologically important. In recent years studies 
aimed toward these goals have used both short (6-12 base 
pairs), intermediate (100-300 base pairs), and circular 
DNA fragments obtained through oligodeoxynucleotide 
synthesis, restriction enzyme digestions, and plasmid 
constructions, respectively. While this represents progress 
from studies with individual bases or nucleotides, it still 
stops short of the desired goal of using human chromatin 
as the target structure. The formidable analytical prob­
lems associated with analyzing whole human genomic DNA 
because of the large size of the molecular target argue 
strongly for designing plasmid systems th a t can be con­
structed in vitro and th a t then use the replication and 
transcriptional machinery of eukaryotic cells. In systems 
such as SV40 DNA the nucleosomal structure is retained 
and the circular DNA can be isolated free of nuclear DNA 
for subsequent analytical manipulation.11 Using a com­
bination of short oligomers for structural work,12-14 re­
striction enzyme fragments for studies on DNA sequence 
specificity,15-17 and plasmid systems18 for in vivo experi­
ments, considerable information relevant to the manner 
in which drugs may interact and modify DNA structure 
and function in human genomic DNA can be obtained. 
Thus it is now possible to gain structural and mechanistic 
data that allow the investigator to gain considerable insight 
into which are the biologically im portant lesions on DNA 
and how these cause the observed potent biological effects. 
Some examples of these approaches for DNA-reactive 
drugs that produce DNA strand breakage, intercalate into 
DNA, or alkylate DNA are given below.
The oxidative mechanisms leading to DNA strand 
breakage by such drugs as bleomycin19,20 and neo- 
carzinostatin21 are quite complex and some of the finer 
points for bleomycin remain controversial. However, the
(11) Hirt, B. J. Mol. Biol. 1967, 26, 365.
(12) Patel, D. J.; Shapiro, L. Annu. Rev. Biophys. Biophys. Chem. 
1987,16, 423.
(13) Harris, T. M.; Stone, M. V.; Harris, C. M. Chem. Res. Toxicol. 
1988,1, 79.
(14) Neidle, S. Topics in Nucleic Acid Structure; Neidle, S., Ed.; 
Halsted Press: New York, 1981; pp 177-198.
(15) Hurley, L. H.; Boyd, F. L. Annu. Rep. Med. Chem. 1987, 22, 
259.
(16) Dabrowiak, J. C. Life Sci. 1983, 32, 2915.
(17) Wilkins, R. J. Mol. Cell. Biochem. 1984, 64, 111.
(18) Basu, A. K.; Essigmann, J. M. Chem. Res. Toxicol. 1988,1,1  
and references therein.
(19) Stubbe, J.; Kozarich, J. W. Chem. Rev. 1987, 87, 1107.
(20) Hecht, S. M. Acc. Chem. Res. 1986, 19, 383.
(21) Chin, D-H.; Zeng, C-h.; Costello, C. F.; Goldberg, I. H. Bio­
chemistry 1988, 27, 8106.
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chemical products of such reactions are well described. 
Hecht and co-workers designed a dodecamer with which 
they characterized the reaction of bleomycin with DNA.22 
The products of bleomycin-induced chemistry under a 
variety of conditions were determined by comparison with 
authentic standards. Longer DNA fragments have been 
used to determine other aspects of bleomycin reaction with 
DNA, such as the strand specificity of DNA breakage23 and 
the effect of DNA methylation on sequence specificity.24 
The sequence specificity of bleomycin cleavage in SV40 
DNA has also been compared in purified and intracellular 
systems.25 Using a pLTL-1 plasmid containing a herpes 
simplex virus thymidine kinase gene grown in mouse 
mammary tumor cells, bleomycin and neocarzinostatin 
have both been demonstrated to cleave preferentially 
within regions of DNA th a t are actively transcribed fol­
lowing glucocorticoid induction.26 While these experi­
ments do not provide definitive answers to the mechanism 
of bleomycin cytotoxicity they provide a background for 
the design of even more exacting studies. Goldberg and 
co-workers have demonstrated for neocarzinostatin th a t 
mutational events can be directly related to the spectrum 
of damage produced on DNA.27 This is an im portant 
example of how in vitro and in vivo data can be correlated.
The DNA-intercalation model proposed by Lerman2 and 
confirmed by X-ray structure analysis for drugs such as 
Adriamycin28 and actinomycin D29 has long been accepted 
as a biologically im portant event in the cytotoxicity and 
antitumor activity of these compounds. However, it has 
always been disconcerting th a t the structure-activity re­
lationships for anthracyclines and other intercalators have 
never strongly supported this claim.30 For some com­
pounds, such as the anthracyclines, this has been ration­
alized by involving non-DNA related targets such as 
membranes and oxidative DNA damage mechanisms.31 In 
reality, the truth may be somewhere in between. DNA per 
se may not be the ultimate target, bu t intercalation may 
serve as a mechanism for holding the drug “on location” 
until a critical event, such as a change in supercoiling 
catalyzed by a DNA topoisomerase, occurs. The interca­
lating agent th a t is intimately associated with the DNA 
molecule then interferes with this process a t a critical step, 
resulting in protein-associated strand breaks in DNA.6 
Exactly how intercalating agents such as Adriamycin and 
m-AMSA interfere with topological processing is still un­
known, but it is quite possible that topoisomerase II or the 
enzyme-DNA complex are the actual targets.32 This ob­
servation may behoove medicinal chemists to examine
(22) Sugiyama, M.; Kilknskie, R. F.; Hecht, S. M.; van der Marcel, 
G. A.; van Boom, J. M. J. Am. Chem. Soc. 1985, 107, 7765.
(23) Krishramoothy, C. R.; Vanderwall, D. E.; Kozarich, J. W.; 
Stubbe, J. J. Am. Chem. Soc. 1988,110, 2008.
(24) Hertzberg, R. P.; Caranfa, M. J.; Hecht, S. M. Biochemistry 
1985, 24, 5285.
(25) Grimwade, J. E.; Cason, E. B.; Beerman, T. A. Nucleic Acids 
Res. 1987, 15, 6315.
(26) Beckmann, R. P.; Agostino, M. J.; McHugh, M. M.; Sigmund, 
R. D.; Beerman, T. A. Biochemistry 1987, 26, 5409.
(27) Povirk, L. F.; Goldberg, I. H. Proc. Natl. Acad. Sci. U.S.A. 
1985, 82, 3182.
(28) Quigley, G. L.; Wang, A. M. J.; Ughetto, G.; van der Marel, G.; 
van Boom, J. H.; Rich, A. Proc. Natl. Acad. Sci. U.S.A. 1980, 
77, 7204.
(29) Takusagawo, F.; Dabrow, M.; Neidle, S.; Beerman, H. M. Na­
ture 1982, 296, 466.
(30) DiMarco, A. Cancer Chemother. Rep. 1975, 6, 91.
(31) Schwartz, H. S. In Molecular Aspects of Anti-cancer Drug 
Action-, Neidle, S., Waring, M. J., Eds.; Macmillan Press Ltd.: 
London, 1983; pp 93-126.
(32) Lock, R. B.; Ross, W. E. Anticancer Drug Des. 1987, 2, 151.
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other ternary systems (drug-DNA-protein) in order to 
understand more completely the biochemical and biological 
effects of drug-DNA interactions.
In some respects alkylation of DNA is the most chal­
lenging area in which to make correlations between DNA 
damage and its biochemical and biological consequences.33 
The complexity of these systems can a t first appear to be 
overwhelming. Many alkylating agents produce a variety 
of lesions on DNA, some of which are chemically unstable 
and thus difficult to characterize.34 Virtually all covalently 
bonding drugs show some degree of DNA sequence se­
lectivity that can be attributed to either the noncovalent 
(binding) interaction, the covalent (bonding) reaction, or 
a combination of these processes.10 DNA repair recognition 
and subsequent repair of lesions can be variable, depending 
upon the adduct characteristics,35 tissue type,36 and tran­
scriptional state of the damaged area.37 Nevertheless 
progress is being made in unraveling these complexities 
by making “site-directed adducts” in plasmids.18 Different 
types of adducts are engineered into predetermined sites 
in the genome and chemically and enzymatically charac­
terized. DNA repair recognition, DNA replication, tran­
scriptional activity, phage survival, or mutagenesis can 
then each be examined separately. Although this may 
seem to be a considerable effort, it is probably the only 
viable way of unraveling the complexity of an otherwise 
intractable system. In this regard Essigmann and Lippard 
have provided im portant data on the construction and 
characterization of a Cisplatin adduct on DNA.38,39 This 
area has been recently reviewed by Essigmann.18
There is still a large gap in our knowledge about the 
structure of the drug-DNA complex or adduct and its 
relationship to  the biological response, e.g., cell death, 
mutagenicity. Considerably headway has been made a t 
the structural end of the problem, but only in rare cases27 
has this provided insight into rationalizing the biological 
effects. There is an urgent need to develop biochemical 
systems that will extend our knowledge beyond DNA as 
the target for drug action. For example, are DNA-binding 
proteins such as those involved in regulation of tran ­
scription, replication, or repair necessary to  express the 
biological potency of some DNA-reactive drugs? I will 
return to some of these questions later in this Perspective.
II. Molecular Strategies To Improve the 
Sequence Selectivity of Existing Groups of 
DNA-Reactive Drugs
Cellular and molecular selectivity are key aspects of drug 
action. For cytotoxic drugs such as DNA-reactive com­
pounds selective uptake a t the cellular level would appear 
to be crucial unless unique intracellular targets can be 
identified in, for example, cancer cells. Strategies for se­
lective cellular retention are outside the scope of this article 
bu t include such mechanisms as targeting using mono­
clonal antibodies to tumor antigens.40 At the intracellular 
level the ultimate selectivity of a DNA-reactive drug should 
be at the sequence level. In mammalian cells the DNA
(33) See for example: Singer, B.; Grunberger, D. In Molecular 
Biology of Mutagens and Carcinogens; Plenum Press: New 
York, 1983 and references therein.
(34) Reference 33, pp 45-94 and 143-190.
(35) Reference 33, pp 199-216.
(36) Reference 33, pp 221-245.
(37) Irvine, R.; Wogen, G. Proc. Natl. Acad. Sci. U.S.A. 1983, 81, 
664.
(38) Pinto, A. L.; Naser, L. J.; Essigmann, J. M.; Lippard, S. J. J. 
Am. Chem. Soc. 1986, 108, 7405.
(39) Naser, L. J.; Pinto, A. L.; Lippard, S. J.; Essigmann, J. M. 
Biochemistry, in press.
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receptor is an elusive target.41 Besides its large size (2.9 
X 109 base pairs), human nuclear DNA is largely covered 
with proteins42 and the accessibility of potential drug 
binding regions may be dependent upon DNA processing 
events such as replication and transcription. The reactivity 
of open regions undergoing processing to DNA-binding 
proteins43 and DNA-reactive drugs44 may also be modu­
lated by superhelical stress. These are certainly compli­
cating factors in the design of more selective DNA-reactive 
drugs. However, this increased complexity could be an 
advantage since such factors may allow greater sequence 
selectivity to be achieved. In this section I will provide 
examples of how processes, such as transcription activity 
and DNA repair may lead to greater selectivity for drug 
action. The main focus will, however, be on the design of 
DNA-reactive drugs with increased sequence selectivity.
While nuclear DNA is generally cited as the target for 
all three classes of DNA-reactive drugs (intercalating 
agents, DNA-degradative drugs, or alkylating agents), 
competing targets such as mitochondrial DNA and cellular 
RNA may also be significant targets. For drugs th a t are 
A-T selective or whose binding to  DNA is restricted by 
nucleosomal structure, mitochondrial DNA (which is A-T 
rich and relatively “naked”) may be the preferred target. 
Mitochondrial DNA may also be the preferred target for 
drugs which are selectively traken up through the mito­
chondria membrane rather than nuclear membrane. Also 
the absence of DNA repair in mitochondria may predispose 
mitochondrial DNA to selective toxicity of DNA reactive 
compounds.45,46
Actively transcribed regions of DNA are the preferred 
target for a number of DNA-reactive molecules. The po­
tent carcinogenic fungal toxin aflatoxin Bx selectively reacts 
with such regions37 and the DNA strand cleavage agents, 
bleomycin and neocarzinostatin, selectively cut within 
transcriptionally active regions.26 Drugs or carcinogens 
that react selectively with single-stranded DNA would also 
be expected to  have increased reactivity with actively 
transcribed or replicated regions of DNA.47 Since actively 
transcribed regions of DNA are preferred targets for some 
DNA-reactive drugs, then agents such as steroids that can 
selectively induce transcription48 may increase the selec­
tivity of DNA-reactive drugs for these regions. This may 
provide a rationale for the combined use of steroids and 
cytotoxic agents such as DNA-reactive drugs in hor­
mone-responsive cancers. Where enzymes such as topo­
isomerase II are involved in modulating the superhelical 
density of transcriptionally active regions and are also a 
requirement for drug action, then this may significantly 
increase the selectivity of such agents.49 Finally there is 
evidence from experiments with certain DNA-reactive 
drugs th a t nucleosomal structure50 and superhelical den­
(40) See for example: In Immunoconjugates: Antibody Conju­
gates in Radioimaging and Therapy of Cancer; Vogel, C.-W., 
Ed.; Oxford University Press: New York, 1987.
(41) Hurley, L. H.; Boyd, F. L. Trends Pharmacol. Sci. 1988,9 ,402.
(42) Felsenfeld, G.; McGhee, J. D. Cell 1986, 44, 375.
(43) Gellert, M.; Monzel, R. In New Frontiers in the Study of Gene 
Functions; Poste, G., Crooke, S. T., Eds.; Plenum Press: New 
York, 1987; pp 51-59.
(44) Boles, T. C.; Hogan, M. E. Biochemistry 1986, 25, 3039.
(45) Clayton, D. A.; Doda, J. N.; Friedberg, E. C. Proc. Natl. Acad. 
Sci. U.S.A. 1974, 71, 2777.
(46) Segal-Bendirdjian, E.; Couland, D.; Roques, B. P.; LePecq, J-B. 
Cancer Res. 1988, 48, 4982.
(47) Muench, K. F.; Misra, R. P.; Humayun, M. Z. Proc. Natl. 
Acad. Sci. U.S.A. 1983, 80, 6.
(48) Yamamoto, K. R. Annu. Rev. Genetics 1985, 19, 209.
(49) Wang, J. C. Annu. Rev. Biochem. 1985, 54, 73.
2030 Journal of Medicinal Chemistry, 1989, Vol. 32, No. 9
sity44,51 may influence sequence selectivity. Consequently 
sequence selectivity data obtained on linear DNA mole­
cules may not always be directly applicable to nuclear 
DNA.
When a defined sequence in DNA is considered as a 
possible drug receptor (see later), it has some properties 
(th a t are in sharp contrast to the more conventional pro- 
teinaceous receptor molecules. For example, when cova- 
j lently modified by a drug, DNA may be restored by very 
efficient repair processes,52 whereas proteinaceous recep­
tors must be resynthesized. It follows that cells deficient 
in DNA-repair processes may be particularly sensitive to 
DNA-reactive drugs. Indeed there is evidence th a t some 
cancer cells defective in DNA repair are more susceptible 
to cross-linking agents such as nitrosoureas than repair- 
proficient cells.53 Even within the cell nucleus selective 
repair may take place in certain regions.64 In repair- 
proficient cells it is possible to potentiate the cytotoxic 
effects of DNA-reactive drugs by combining alkylating 
agents with inhibitors of DNA repair.55 In this case, 
selectivity of the cytotoxic effect for tumor cells may not 
necessarily be achieved. Poly(ADP)ribosylation of histone 
molecules is associated with DNA damage by agents that 
cause DNA strand breaks directly or as a consequence of 
repair.66 Poly(ADP)ribosylation is believed to be im­
portant for the survival of cells with damaged DNA, al­
though the exact role is not clear. The discovery th a t 
benzamide derivatives are selective inhibitors of poly- 
(ADP)ribosylation provided a rationale for laboratory 
, experiments to potentiate the effect of alkylating agents, 
and a t least in vitro significant increases in the cytotoxic 
potency of nitrosoureas have been achieved.57 However, 
the in vivo effectiveness of this strategy has yet to be 
demonstrated. The multifunctional aspects of poly- 
(ADP)ribosylation in cellular processes and nonselective 
inhibition by benzamide derivatives such as 3-amino- 
, benzamide at the high dosage levels used may complicate 
the picture for rational combination therapy.58 Never­
theless the dem onstration of potentiation of cytotoxic 
potency by DNA-repair-associated inhibitors argues for the 
search for other inhibitors th a t may be useful in combi­
n a tio n  chemotherapy with DNA-reactive drugs.
! The site-size DNA sequence specificity is a critical 
feature of drugs that exert their selectivity by reaction with 
target sequences. Virtually all DNA-reactive drugs exert 
some degree of sequence selectivity, although in the case 
of highly reactive alkylating agents such as the nitrogen 
mustards, this may be very modest.10 Other drugs such 
as CC-1065 show a surprising degree of sequence selec­
tivity.89 Sufficient DNA sequence specificity is achieved 
by proteins to perm it their participation in the precise
(50) Low, C. W. L.; Drew, H. R.; Waring, M. J. Nucleic Acids Res.
1986, 14, 6785.
(51) Mirabelli, C. K.; Huang, C. H.; Crooke, S. T. Biochemistry 
1983, 22, 300.
(52) Friedberg, E. C. In DNA Repair, W. H. Freeman: San Fran­
cisco, 1984.
(53) Erickson, L. C.; Laurent, G.; Sharkey, N. A.; Kohn, K. W. 
Nature 1980, 288, 727.
(54) Hanawalt, P. Cell 1989, 40, 359.
(55) Collins, A. R. S.; Squires, S.; Johnson, R  T. Nucleic Acids Res. 
1982, 4, 1203.
(56) Ueda, K.; Hayaishi, O. Annu. Rev. Biochem. 1985, 54, 73.
(57) Berger, N. A.; Berger, S. J.; Gerson, S. L. Anticancer Drug Des.
1987, 2, 203.
(58) Rankin, P. W.; Jacobson, E. L.; Benjamin, R. C.; Moss, J.; 
Jacobson, M. K. J. Biol. Chem., in press.
(59) Hurley, L. H.; Lee, C.-S.; McGovren, J. P.; Mitchell, M.;
Warpehoski, M. A.; Kelly, R. C.; Aristoff, P. A. Biochemistry
1988, 27, 3886.
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control of gene expression and other genetic events.60 
Therefore the ability to design and synthesize a nonpeptide 
small molecular weight molecule th a t would bind to  a 
desired DNA sequence of reasonable site size (up to about 
15-16 base pairs) would be a significant achievement in 
medicinal chemistry.
Before discussing the design of drugs that have improved 
chemotherapeutic selectivity by virtue of increased se­
quence specificity, it is instructive to examine how natural 
biological molecules such as proteins and oligonucleotides 
achieve sequence specificity for duplex DNA. The most 
familiar DNA recognition motif for proteins th a t bind 
selectively to defined duplex DNA sequences is the 
“helix-tum-helix”.61 In this case, one-a-helix of the protein 
is held in the major groove of DNA by the second a-helix 
th a t lies across the back side of the first. Direct readout 
of major groove information such as hydrogen-bonding 
patterns and van der Waals contacts can be achieved by 
a complementary reading frame in the amino acid residues 
of the protein.62 In some cases a sequence-dependent 
conformational change is required before the reading 
frames of the DNA and protein are brought into sync.63 
This has been termed “indirect readout” and in the case 
of the trp  repressor results in specific hydrogen-bonding 
recognition of the phosphate backbone of DNA. As far 
as I am aware the design and synthesis of nonprotein 
mimics of this form of sequence-specific recognition (i.e. 
taking place in the major groove or on the phosphate 
backbone) have not yet been achieved. Oligonucleotides 
can also bind to duplex DNA in a sequence-selective 
fashion. Pyrimidine oligonucleotides bind to duplex DNA 
sequence specifically a t homopurine sites to form a “triple 
helix” structure,64 and RNA oligonucleotides can form a 
similar structure with a G-rich polypurine sequence.65 
Charge and stability problems of the oligonucleotides re­
main to be solved before these latter molecules can be used 
as drugs to attain selective pharmacological action in living 
cells. However, these are attractive ideas for cases in which 
high selectivity will be required (e.g. oncogene inactivation; 
see below).
Nonpeptide or nonoligomeric molecules th a t bind to 
DNA with sequence selectivity generally do so either by 
intercalation or by minor groove binding. While polyin- 
tercalators (i.e. molecules possessing two or more planar 
ring systems spaced by linkers to insert every two or more 
base pairs into DNA) can achieve a modest degree of se­
quence selectivity,66 their inherently poor discrimination 
between A-T and G-C base pairs and the “site exclusion 
rule” prohibit their practical application as sequence- 
specific probes. Nonintercalating minor groove binding 
agents use planar recognition words for sequence recog­
nition within the minor groove of DNA.67 In contrast to 
the direct sequence-specific complementarity of protein
(60) Ptashne, M. A Genetic Switch; Cell Press and Blackwell Sci­
entific Publications, Cambridge, MA, 1986.
(61) Ohlendorf, D. H.; Anderson, W. F.; Lewis, M.; Pabo, C. O.; 
Matthews, B. W. J. Mol. Biol. 1983,169, 757.
(62) McClarin, J. A.; Frederick, C. A.; Wang, B.-C.; Geene, P.; 
Boyes, H. W.; Grable, J.; Rosenberg, J. M. Science 1986,234, 
1526.
(63) Otwinowski, Z.; Schevitz, R. W.; Zhang, R.-G.; Lawson, C. L.; 
Joachimiak, A.; Marmorstein, R. Q.; Luisi, B. F.; Sigler, P. B. 
Nature 1988, 335, 321.
(64) Moser, H. E.; Dervan, P. B. Science 1987, 238, 645.
(65) Cooney, M.; Czernuszewicz, G.; Postel, E. H.; Flint, S. J.; Ho­
gan, M. E. Science 1988, 241, 456.
(66) Wakelin, L. P. G. Med. Res. Rev. 1986, 6, 275.
(67) Zimmer, C.; Wahnert, U. Prog. Biophys. Mol. Biol. 1986, 47,
31.
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recognition of DNA, nonintercalating minor groove-binding 
agents generally “read” DNA sequence by indirect mech­
anisms such as groove geometry, secondary structure, and 
electrostatic interactions.67 These processes inherently give 
rise to a lower sequence specificity, or more aptly termed, 
sequence selectivity, than direct hydrogen bonding or van 
der Waals interactions. Nevertheless A-T and G-C se­
lective “words” do exist th a t discriminate based upon 
recognition features in the minor groove of DNA.15,67 A 
variety of natural and synthetic products including net- 
ropsin, Hoechst 33258, SN6999, and CC-1065 exemplify 
the utilizing of planar, sometimes fused aromatic rings that 
can be sandwiched within the minor groove of DNA.67 The 
compounds listed above are all A-T “words” and heroic 
efforts have been made to convert A-T words into G-C 
words by Lown and co-workers.68 While some degree of 
success has been achieved, the converted A-T word does 
not have a high selectivity for G-C base pairs. Some 
natural minor groove G-C words also exist, i.e., chromo- 
mycin and the anthramycins. Chromomycin has a complex 
recognition motif for G-C base pairs involving a dimer of 
antibiotic molecules and magnesium ion.69 Anthramycin 
covalently bonds to the exocyclic 2-amino group of guanine 
in a  nondistortive but helix-stabilizing manner.70 Con­
sequently in either case the use of these recognition words 
is complicated by those features. For this problem to be 
addressed successfully we will have to await the discovery 
or design of a simple G-C word th a t is chemically com­
patible with the existing A-T words. “Sentences” can then 
be constructed of suitable phased A-T and G-C words to 
read any chosen sequence. Even with the availability of 
suitable A-T and G-C words, it remains to be seen whether 
the minor groove of DNA inherently has sufficient se­
quence specificity information to give rise to the level of 
selectivity required to  successfully read DNA. The lesson 
from Nature (Le., protein-DNA interactions) would suggest 
the  major groove is a better target.
At this time, any increase in selectivity of existing agents 
th a t  react with DNA appears to depend upon either 
modulating the relative efficiency a t which a target se­
quence is hit, or preferential inhibition of DNA repair in 
select cells, e.g. cancer cells. The relative efficiency of 
targeting a chosen cognate sequence vs other noncognate 
sequences is dependent upon the extent of sequence se­
lectivity of the DNA-reactive drug and the relative fre­
quency of occurrence of the chosen sequence in target cells 
and  its accessibility to drug modification. These variables 
are attractive features for drug development. If the ge­
nomic target for drug reaction can be limited to functional 
domains such as transcriptionally or replicationally active 
regions, then the overall size of the target can be dra­
matically reduced. An alternative to the preferential in­
hibition of DNA repair in target cells as an approach to 
obtain improved selectivity is the design of less well rec­
ognized and consequently excised lesions on DNA. Efforts 
will surely be made in these directions, but it is difficult 
to  predict the possibilities for improvement a t the thera­
peutic level. In the next two sections I will focus on 
strategies for the discovery and design of new therapeutic 
entities.
III. The Design of Mechanism-Based Screens To 
Identify New Classes of Drugs That React with 
DNA and Associated Targets
DNA-reactive compounds such as the bleomycins,
(68) Lee, M.; Krowicki, K.; Hartley, J. A.; Pon, R. T.; Lown, J. W. 
J. Am. Chem. Soc. 1988, 110, 3641 and references therein.
(69) Gao, Z.; Patel, D. J. Biochemistry 1989, 28, 751.
(70) Hurley, L. H.; Needham-VanDevanter, D. R. Acc. Chem. Res.
IflS fi 19 530.
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Adriamycin, and actinomycin D were originally identified 
through in vitro cytotoxic screens using for example L-1210 
leukemia cells. These drugs are representatives of just a 
handful of clinically useful drugs th a t were selected by 
cytotoxic screens and show in vivo antitumor activity. 
Most cytotoxic agents identified by these screens show 
little selective activity in in vivo systems. The poor cor­
relation between in vitro and in vivo activity has forced 
the drug discovery community to explore alternatives to 
cytotoxic screens. Two major screening strategies have 
evolved; the disease-oriented screen and mechanism-based 
screen. The NCI has recently adopted a disease-oriented 
approach to attem pt to identify more selective antitumor 
agents.71 In this screening program compounds are tested 
against a large panel of human tumor cell lines derived 
from a broad spectrum of solid tumors. Compounds that 
only show activity in vitro in select tumor lines are then 
earmarked for in vivo screening. I t  is still too early to 
evaluate how effective this new strategy will be in iden­
tifying new classes of clinically useful antitumor agents. 
In principle, mechanism-based strategies can use DNA or 
a DNA-mediated process as the screening event. I will 
describe these strategies in more detail.
The mechanism-based screen identifies a specific target 
or process th a t when modulated is likely to produce a 
desired pharmacological response, e.g., antiviral or anti­
tumor activity. A review of mechanism-based screens for 
the discovery of new DNA-reactive drugs has been pub­
lished by Johnson et al.72 A broad screen that is sensitive 
to virtually all of the known DNA-reactive drugs is the 
biochemical induction assay (BIA).73 The BIA is a mod­
ification of the lysogenic phage induction assay in which 
X phage repressor regulates expression of /S-galactosidase 
from a lambda promotor fused to a lac Z gene in Es­
cherichia coli.74 As a consequence of exposure to DNA- 
damaging agents the SOS response (DNA-repair pathway) 
is triggered, which leads to induction of expression of /3- 
galactosidase. Bartus et aL73 have increased the sensitivity 
of this screen by construction of a subclone with an in­
creased copy number of the /8-galactosidase transcriptional 
unit. This has been shown to be a very effective prescreen 
for active cultures th a t can then be further examined by 
more specific mechanism-based screens.
Many potent DNA-reactive drugs can produce single or 
double strand breaks in DNA. These reactions are gen­
erally oxygen dependent and may also depend on the 
presence of metal ions such as magnesium or copper. 
Other DNA-reactive compounds cause changes in the to­
pological conformation of DNA by, for example, interca­
lation. By use of agrose gel electrophoresis of covalently 
closed circular DNA (cccDNA), these DNA strand breaks 
and topological changes can be sensitively detected 75,76 e.g., 
conversion of cccDNA to nicked, circular, or linear forms 
th a t can be resolved by electrophoresis. DNA-reactive 
drugs th a t do not produce strand breaks or topological
(71) Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; 
Czerwinski, M. J.; Fine, D. L.; Abbot, B. J.; Mayo, J. G.; 
Shoemaker, R. M.; Boyd, M. R. Cancer Res. 1988, 48, 589.
(72) Johnson, R. K.; Bartus, H. F.; Hofmann, G. T.; O’Leary Bar­
tus, J.; Mong, S.-M.; Faucette, L. F.; McCabe, F. L.; Chan, J. 
A.; Mirabelli, C. K. In In Vitro and In Vivo Models for De­
tection of New Antitumor Drugs, Proceedings of the 14th In­
ternational Congress of Chemotherapy, Kyoto, 1985, pp 15-26.
(73) Bartus, H. F.; Mirabelli, C. K.; Auerbach, J. I.; Shatzman, A. 
R.; Taylor, D. T.; Roseberg, M.; Crooke, S. T. Antimicrob. 
Agents Chemother. 1984, 25, 622.
(74) Elespuru, R. K.; White, R. J. Cancer Res. 1983, 43, 2819.
(75) Mong, S.; Strong, J. E.; Busch, J. A.; Crooke, S. T. Antimicrob. 
Agents Chemother. 1979, 16, 398.
(76) Scannell, R. T.; Barr, J. R.; Murty, V. S.; Reddy, K. S.; Hecht,
S. M. J. Am. Chem. Soc. 1988, 110, 3650.
2032 Journal of Medicinal Chemistry, 1989, Vol. 32, No. 9
changes in DNA either spontaneously or in the presence 
of metals may still be detected by using thermal treatment 
(e.g., CC-1065).77 By use of a combination of these 
chemical, physical, or enzymatic treatments, it is possible 
to detect and categorize most of the known DNA-reactive 
drugs. Rapid differentiation of potentially new activities 
from already existing compounds can be made a t this 
stage.
Mechanism-based screens th a t depend upon yeast mu­
tants that have decreased or increased activity of key 
proteins involved in DNA processes such as repair are very 
useful in identifying both new compounds as well as 
classifying activities.78 Because yeasts are eukaryotic 
organisms they are genetically and biochemically nearer 
to mammalian cells than bacterial cells. However, they 
retain the advantages of short generation times and genetic 
manipulability of prokaryotic organisms. The array of 
DNA-repair mutants available th a t have been character­
ized biochemically provide excellent opportunities to de­
sign mechanism-based screens to  select compounds th a t 
interact with DNA to produce defined lesions on DNA 
such as double strand breaks. Johnston et al.72 have used 
a battery of DNA-repair-deficient m utants of Saccharo- 
myces cerevisia to discriminate between various classes 
of DNA-reactive drugs.
More recently yeast mutants have been isolated that are 
defective in the expression of topoisomerase I.79-80 These 
mutants are either resistant to camptothecin80 or when 
carrying a plasmid that overproduces topoisomerase I79 are 
hypersensitive to camptothecin. These m utants have 
obvious roles in mechanism-based screens to discover other 
topoisomerase I  inhibitors. W ith this principle in mind 
it should be possible to design other mechanism-based 
screens, providing the absence of enzyme does not prevent 
growth of the mutant. However, where the activity (e.g., 
topoisomerase I) is necessary to express the potent bio­
logical effects, it is overproduction rather than underpro­
duction of the protein th a t will give rise to increased 
sensitivity to the agent.79 While there are a variety of 
topoisomerase II inhibitors, camptothecin is unique as a 
topoisomerase I inhibitor. Cytotoxic screens apparently 
do not select well for topoisomerase I inhibitors; therefore, 
the mechanism-based approach described here may be a 
more effective screen.
Compounds th a t modulate gene expression either in a 
positive or negative way would seem to have potential 
therapeutic utility for treatm ent of diseases where either 
the absence or overexpression of proteins results in de­
leterious effects. Molecular biologists have cloned euka­
ryotic transcriptional regulatory systems into plasmids that 
can be conveniently manipulated to determine the se­
quences that are involved in activation of the system.81 
The glucocorticoid-inducible LTL gene82 has been used as 
a model target to evaluate preferential drug effects on gene 
expression.83 With this system the possibility th a t bleo­
mycin, neocarzinostatin, and actinomycin D would induce 
alterations in either transcription or posttranscriptional
(77) Reynolds, V. L.; Molineux, I. J.; Kaplan, D.; Swenson, D. H.; 
Hurley, L. H. Biochemistry 1985, 24, 6228.
(78) Mirabelli, C. K.; Bartus, H.; Bartus, J. O. L.; Johnson, R. K.; 
Mong, S. M.; Sung, C. P.; Crooke, S. T. J. Antibiot. 1985, 38, 
758.
(79) Eng, W. K.; Faucette, L.; Johnson, R. K.; Sternglanz, R. Mol. 
Pharm., in press.
(80) Nitiss, J.; Wang, J. C. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 
7501.
(81) Brown, D. Science 1981, 211, 667.
(82) Zaret, K. S.; Yamamoto, K. R. Cell 1984, 38, 29.
(83) Beckmann, R. P.; Beerman, T. A. Mol. Pharm., in press.
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gene expression was assessed. Although no preferential 
effects were observed for these particular drugs, this would 
seem to be a useful model system. In a more sophisticated 
system, m utants in the transcriptional activation system 
might be used as a mechanism-based screen to select for 
DNA-reactive drugs th a t would affect DNA structure or 
conformation and annul the effect of the m utation on 
transcriptional activity. Similarly, compounds that in­
crease recombinational events might be detected in a 
mechanism-based screen. Clearly the application of mo­
lecular biology holds many attractive possibilities for de­
tection of compounds with interesting biological properties.
IV. The Design of New Drug Classes Based upon 
the Identification of P h a r m a c o l o g i c a l l y  Selective 
Receptors on, or Associated with, DNA
The ultim ate objective in any drug design program is 
the synthesis of a specific drug entity  th a t binds with 
sufficient selectivity to a receptor resulting in a defined 
pharmacological response without adverse side effects. For 
the initiation of pharmacological events th a t originate on 
DNA, the receptor molecule m ight be DNA itself, a 
DNA-binding protein, or a protein-D NA complex.
A receptor in the strict pharmacological sense must have 
both cognitive and response features.84 The majority of 
sequences on DNA are acceptors rather than  true recep­
tors, since they lack response characteristics41 (except in 
a toxicological sense, e.g., m utation, deletion, etc.). Re­
ceptor sequences may, for example, be part of regulatory 
regions of DNA th a t are normal DNA-binding regions for 
proteins or even short oligonucleotides such as RNA. For 
example, the transcriptional factor Spl binds to GC boxes 
in the 21 base pair repeat region of DNA in the tran­
scriptional regulatory regions of various genes.85 Many 
other proximal and distal signal regions have been iden­
tified in cis-acting regulatory and transcriptional control 
regions.86 Such sequences are potential receptor sequences 
for drugs th a t might modulate gene expression.
While the sequence-dependent microheterogeneity of 
DNA gives rise to a vast array of recognition features for 
sequence specific binding of proteins,87 there are also a 
variety of unusual DNA structures th a t can form within 
AT- or GC-rich regions of DNA For example, guanine-rich 
DNA sequences can form “four-stranded” complexes in 
which the strands run in a parallel fashion.88 Homo- 
purine-homopyrimidine sequences [d(C-T)„-d(A-G)n] are 
proposed to form a “triple-helical” structure (CiGiT).89 
G-rich strands occur a t chromosome ends and form novel 
intramolecular structures.90 I t  is believed th a t these un­
usual DNA structures are involved in such processes as 
meiosis (four-stranded complex)88 transcriptional control 
(three-stranded complexes)89 and chromosomal mainte­
nance (G-rich strands).90 These structures are also 
therefore potential receptors for selective drug action.
The chemical modification of DNA sequences th a t are 
specific DNA-protein binding sites could, in principle, lead
(84) Green, J. P. Trends Pharmacol. Sci. 1987, 8, 90.
(85) Kadonaga, J. T.; Briggs, M. R.; Tjian, R. In New Frontiers in 
the Study of Gene Function; Poste, G., Crook, S. T., Eds.; 
Plenum Press: New York, 1987; pp 87-98.
(86) Freifelder, D. In Molecular Biology, 2nd ed.; Jones & Bartlett 
Publ. Inc.: Boston, 1987; pp 501-550.
(87) von Hippel, P. H.; Berg, O. G. Proc. Natl. Acad. Sci. U.S.A. 
1986, 83, 1608.
(88) Sen, D.; Gilbert, W. Nature 1988, 334, 364.
(89) Johnston, B. H. Science 1988, 241, 1800.
(90) Moyzis, R. K.; Buckingham, J. M.; Cram, L. S.; Dani, M.; 
Deaven, L. L.; Jones, M. D.; Meyne, J.; Ratliff, R. L.; Wu, J.-R. 
Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 6622.
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to an increase or decrease in protein binding. It has been 
elegantly dem onstrated that distamycin A or netropsin 
binding to a specific nonalternating AT sequence in the 
promotor region of the phage I leads to  activation of 
transcription initiation.91 This is because distamycin 
binding to DNA leads to an increase in RNA polymerase 
binding to the promotor region to form the “open” or active 
complex. This can be rationalized since distamycin pro­
duces a bending of the DNA helix in the spacer region (a 
region not contacted by the enzyme) th a t is also a re­
quirement for formation of the RNA polymerase-promoter 
open complex. Consequently other sequence-specific 
DNA-binding drugs th a t modulate the structural or con­
formational forms of DNA binding protein regions might 
also be expected to  increase or decrease protein binding 
and presumably the processes they control.
Altered forms of cellular proto-oncogenes have been 
implicated in the development of human cancer.92 These 
transforming genes (oncogenes) are often found in solid 
tumors and leukemias. The ras oncogene is frequently 
associated with myeloid leukemias and various carcino­
mas.93 This ras gene family encodes for 21kDa proteins 
that bind GTP (G-proteins).94 Because the positions of 
oncogenic m utation are known for a number of ras genes, 
these seem possible selective targets for drug design. 
However, the single base substitutions th a t differentiate 
the normal cellular proto-oncogenes from their oncogenic 
counterparts make selective targeting a formidable task. 
Conceivably the triple-strand approach (see above) may 
be useful if this principle can be broadened to accommo­
date mixed A-T and G-C sequences. Even so, the previ­
ously mentioned problems with using oligonucleotides as 
therapeutic agents still remain.
As an  alternative to targeting isolated unique DNA se­
quences, it may be possible to gain increased selectivity 
by targeting DNA structures and conformations which are 
the consequence of protein-DNA interactions. For ex­
ample, the binding of RNA polymerase to DNA has been 
proposed to produce a /9-kinked structure95 th a t may be 
an optimal target for intercalators. The binding of topo- 
i&omerase II to  DNA may create special receptor binding 
sites on DNA for intercalation agents such as m-AMSA.32 
Since these binding sites are only created as a consequence 
of protein binding to DNA, increased receptor selectivity 
may result.
While not directly a DNA target, the binding of drugs 
to  the DNA recognition motifs of DNA-binding proteins 
such as zinc-fingers96 or helix-tum-helix61 motifs would be 
expected to modulate processes such as transcriptional
(91) Bruzik, J. P.; Auble, D. T.; deHaseth, P. L. Biochemistry 1987, 
26, 950.
(92) Cairns, J. Nature 1981, 289, 352.
(93) Barbacid, M. Carcinogenesis 1986, 7, 1037.
(94) Gibbs, J. B.; Sigal, I. S.; Scolnick, E. M. Trends Biochemical 
Sci. 1985, 10, 350.
(95) Sobell, H. M. In Molecular Actions and Targets for Cancer 
Chemotherapeutic Agents; Sartorelli, A. C., Lazo, J. S., Ber- 
tino, J. R., Eds.; Academic Press: New York, 1981; pp 119-135.
(96) Rhodes, D.; Klug, A. In Nucleic Acids and Molecular Biology,
Vol. 2; Eckstein, F., Lilley, D. M. J., Eds.; Springer-Verlag:
West Berlin, 1988; pp 149-166.
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control. Since a defined sequence duplex DNA molecule 
is the specific binding molecule for these proteins, it is an 
interesting, and as far as I am aware, untested idea to 
design surrogate duplex molecules that would compete for 
these sequence specific proteins. There are, of course, 
inherent problems in this approach such as duplex stability 
and cellular uptake. These however, are being addressed 
in the anti-sense area.97,98 In a more complex case it might 
be possible to synthesize mechanism-based inhibitors of 
DNA-cleavage enzymes such as topoisomerases by de­
signing modified duplex DNA molecules. This is partic­
ularly attractive where both the topoisomerase consensus 
sequence and the DNA-cleavage site within the region is 
also known.99
C onclusions
In this Perspective I have attempted to summarize some 
of the opportunities available to  medicinal chemists 
through DNA and its associated drug targets. Modern 
techniques in structural chemistry (high-field NMR, X-ray 
crystallography, molecular modeling) and techniques and 
concepts from molecular biology provide new opportunities 
to  reexamine the mechanism of action of existing com­
pounds that are thought to interact with DNA, as well as 
select and design new drug classes. Many of the recent 
discoveries in molecular biology have yet to be applied to 
drug discovery. Although there are still tremendous voids 
in our understanding of how existing drugs th a t are 
thought to interact with DNA really do work, experiments 
can now be designed th a t can potentially narrow this gap. 
The therapeutic opportunities offered through DNA and 
associated targets are not limited to anticancer and anti­
viral diseases, but also include genetic disorders that result 
in over- or underexpression of gene products, gene therapy, 
and autoimmune diseases. Because DNA-reactive ligands 
can be carcinogens as well as chemotherapeutic agents, 
separation of these activities will be an important objective. 
Even in cases where a therapeutic product may not ulti­
mately be forthcoming, the receptor-selective ligands de­
signed and developed by medicinal chemists will likely be 
very useful as biochemical tools to unravel the complexities 
of processes such as transcriptional control in eukaryotic 
cells.
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Molecular struggle for transcriptional control
What DNA interactive ligands, such as antitumour agents and carcinogens, can do 
is well known, but exactly how they do it has been a mystery until now.
DNA has long been recognized as a target 
for carcinogens and antitumour agents. 
What is still largely unclear is how the 
structural modification of DNA by these 
compounds leads to the very potent 
biological consequences'. Our abilities to 
relate the biochemical and biological 
sequellae to the structural consequences of 
modification of DNA have been limited by 
the degree of complexity of the in vitro 
systems that can be assembled.
In the earliest such systems, single bases 
and nucleosides combined with carcino­
genic compounds were used to character­
ize both the selectivity and reactivity of 
electrophilic reagents such as polycyclic 
aromatic hydrocarbons. Subsequently, it 
was discovered that these systems, though 
useful for establishing analytical proce­
dures, were often inadequate models for 
macromolecular systems. With the advent 
of automated DNA synthesis and DNA se­
quencing technology, duplex DNA mole­
cules could be used as substrates, and the 
reactive site (for example, N7 of guanine) 
and DNA sequence selectivity (for exam­
ple, 5'-AGTTA) could be determined. A 
combination of synthetic methodology 
and DNA construction experiments then 
made possible the preparation of site-di­
rected adducts for in vitro and in vivo ex­
perimentation2. For the first time, the bio­
chemical and biological effects of specific 
modifications of DNA could be evaluated.
Biophysical techniques, especially high- 
field nuclear magnetic resonance (NMR), 
now permit the determination of the 
precise three-dimensional structures of 
cardnogen-DNA and drug-DNA com­
plexes and adducts, leading to the realiza­
tion that the degree of distortion of the 
DNA has important consequences for 
functional interactions with polymerases, 
transcription factors, and DNA repair pro­
teins. Every week new transcription factors 
and/or binding sites are characterized, ex­
panding the range of potential targets for 
carcinogens and DNA-reactive drugs. Gel 
mobility shift assays and DNA footprinting 
techniques allow a convenient method for 
isolating and studying ternary complexes 
between ligand, DNA, and protein.
The most recent evidence indicates that 
several different mechanisms may be in­
volved in the targeting of transcriptional
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control by carcinogens and DNA-reactive 
drugs. Thus far, various DNA-reactive mol­
ecules and their DNA adducts and com­
plexes have been shown to (1) hijack tran­
scriptional factor proteins, (2) act as 
surrogate proteins, (3) act as specific antag­
onists and (4) cause mechanism-based in­
teractions that alter protein function. 
Most of these interactions involve drug-in­
duced architectural changes in the DNA 
that can potentially after transcription.
A paper by M. MacLeod and co-workers 
in a recent issue of Carcinogenesis presents 
a dramatic example of a small DNA-reac­
tive molecule that hijacks a transcription 
factor protein, apparently by changing the 
architecture of the DNA3. The small 
reactive molecule is the carcinogen 
benzo[a]pyrene diol epoxide (BPDE), a 
polycyclic aromatic hydrocarbon that 
modifies dG residues in DNA, and the pro­
tein being hijacked is Spl, a transcrip­
tional activator that binds to GC-rich re­
gions of DNA called GC boxes. The 
promoters and upstream regulatory re­
gions of many housekeeping genes, in­
cluding human oncogenes and cell-cyde 
genes, contain GC boxes. In their paper, 
the researchers report using BPDE to mod­
ify a DNA fragment containing a promoter 
that has two GC boxes. They then per­
formed mobility shift, competition, and 
footprinting assays to monitor the Spl 
binding affinity for the DNA. Spl was 
found to bind with greater affinity to the 
BPDE-modified fragment containing GC 
boxes than to the unmodified fragment. 
Initially, the results indicated that perhaps 
the increased affinity of Spl for the modi­
fied DNA was due to tighter Spl binding 
to the BPDE-modified GC boxes. The au­
thors subsequently learned, however, that 
a BPDE-modified fragment without GC 
boxes effectively competed for Spl against 
the unmodified sequence with GC boxes. 
Moreover, the footprinting analyses in­
volving BPDE-modified DNA with GC 
boxes suggested that numerous 
BPDE-DNA adducts were interacting with 
Spl. Thus, BPDE seemed to be creating 
new Spl binding sites, and the new sites
apparently bound Spl with comparable 
affinity to that of GC boxes.
How did BPDE modification of DNA cre­
ate new Spl binding sites? The authors rea­
soned, on the basis of previously reported 
work by Li and co-workers4, that BPDE 
modification induces a static bend or pos­
sibly increases the flexibility of the DNA. 
Such an architectural change might reduce 
the free energy required for Spl binding to 
the site by the amount of energy required 
to bend the DNA. The creation of numer­
ous artificial Spl binding sites in chromo­
somes may lead to the hijacking of Spl 
from normal binding sites, decreasing the 
level of transcription from Spl-regulated 
genes or, in rare cases, increasing transcrip­
tion for genes not activated by Spl, includ­
ing certain human oncogenes.
Although these results are dramatic, this 
is not the first time a DNA-reactive com­
pound has been implicated in protein hi­
jacking. Recent work by D. Treiber and co­
workers with cisplatin, a drug used to treat 
testicular and ovarian cancer, indicates 
that cisplatin-induced DNA modification 
creates binding sites for human upstream 
binding factor (hUBF), an activator of ribo- 
somal RNA transcription5. hUBF belongs to 
a family of proteins that includes the high 
mobility group (HMG) proteins, many of 
which exhibit a high affinity for bent DNA 
structures, particularly DNA containing 
sharply angled bends. Cisplatin produces 
l,2-d(GpG) intrastrand crosslinks that 
mimic this architectural feature, which 
may increase the affinity of hUBF for the 
drug-modified sequence. Earlier work by S. 
Brown and co-workers6 suggested that the 
binding of hUBF to cisplatin-modified 
DNA protects the adduct from DNA repair 
enzymes, presumably increasing its life­
time. Thus, cisplatin, and possibly BPDE, 
may not only hijack proteins but also use 
them as shields against repair enzymes, ex­
tending the life of the carcinogen-DNA or 
drug-DNA adduct.
Another way in which DNA-reactive 
molecules may influence transcription is 
by acting as surrogate transcription activa­
tor proteins. (+)-CC-1065, the lead com­
pound for a series of drugs currently in 
clinical trials for several forms of cancer, 
may act in this manner. The drug targets 
the minor groove and alkylates the DNA in
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general transcription factors th a t result in transcriptional 
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are critical in m aintain ing the topological equilibrium  state during  
transcription. These pro te in -D N A  complexes are targeted by 
m echansim -based inhibitors such as the quinolones and 
cam ptothecin , a process th a t result in the form ation of 
im m obilized to po l-D N A  and to p o  ll-D N A  complexes.
a sequence-specific fashion, favoring re­
gions of DNA with inherent bends. D. Sun 
and L. Hurley have identified two consen­
sus (+)-CC-1065 modification sites be­
tween GC boxes in the SV40 tumour virus 
early promoter region and have shown 
that these flexible regions serve as a locus 
of bending for Spl binding to GC boxes, 
permitting the DNA to form a loop7. This 
DNA loop is believed to bring DNA-bound 
transcriptional proteins closer together, al­
lowing protein-protein interactions that 
increase transcription. (+)-CC-1065 modi­
fication of the DNA between the GC boxes 
entraps and intensifies the bending in this 
region. Although yet to be verified, the 
(+)-CC-1065-DNA interaction could trap 
the DNA in a transcriptionally active state 
that mimics the transcriptional activation 
of Spl. The (+)-CC-1065 surrogate Spl 
function differs in a fundamental way 
from the BPDE hijacking role, since in one 
case ((+)-CC-1065) the drug may replace 
the protein function, while in the other 
(BPDE), the carcinogen-modified DNA 
traps Spl at previously unrecognized sites.
In certain cases architectural changes in­
duced by drugs alter the DNA so that a pro­
tein loses affinity for its binding site. An­
tagonism of this form may occur when the 
glycoside of the DNA sequence-specific an­
ticancer agent calicheamicin (CLM-MG) 
interacts with DNA8. CLM-MG inhibits the 
formation of various DNA-transcriptional 
activator complexes, such as the complex 
between the transcription factor NFAT and 
its binding site, in a sequence-specific 
manner. The CLM-MG-DNA interaction 
also reduces in vivo transcription with simi­
lar sequence specificity. The antagonism is 
thought to result from distortions in the 
DNA that alter the architecture of the tran­
scription factor binding site, as indicated 
by NMR structural work by Walker and co­
workers’. While the effect on in vitro tran­
scription has not been determined, other 
minor groove binding drugs have also been 
shown to inhibit binding of transcription 
factors (homeodomain) and TATA binding 
protein (TBP) to their cognate sequences10 ".
A number of therapeutically important 
drugs used to treat bacterial infections and 
cancer target protein-DNA complexes. 
However, unlike the static targets pre­
sented by transcriptional factor-DNA com­
plexes, these drug targets are only present 
as intermediates in catalytic processes car­
ried out by topoisomerases. We categorize 
these targets as 'mechanism-based inter­
mediates', by analogy to mechanism-based 
enzyme inhibitors such as 5-fluorouracil. 
Topoisomerases control DNA topology 
and relieve the tension created when the 
transcription complex travels through a 
constrained DNA duplex. These proteins 
bind to under- or over-wound DNA, cleave 
one (topoisomerase I) or both (topoiso­
merase II) DNA strands and allow DNA 
passage before the DNA is resealed in a 
fashion that relieves torsional stress. Dur­
ing the cleavage cycle, specific high-affin- 
ity sites for topoisomerase inhibitors such 
as quinolones12 and camptothecins13 are 
produced in the protein-DNA complex. 
The drugs permanently trap the topoiso- 
merase-DNA complex in the cleavage 
state, the so-called cleavable complex, an 
action that interferes with replication and 
transcription and ultimately leads to the 
death of the cell.
Although the antibacterial quinolones 
are proposed to target the interface 
between the gyrase and the DNA and in­
teract with both components of the com­
plex", in the case of the TBP-TATA bind­
ing complex, the site for enhanced 
reactivity of the DNA-reactive drug 
pluramycin is exclusively associated with
the DNA1S. When TBP binds to the TATA 
box, the DNA immediately downstream 
becomes transiently unwound. The un­
wound region of DNA is proposed to serve 
as a nucleation site for the open complex 
formation required for initiation of tran­
scription. Pluramycin intercalates into the 
DNA at the unwound site in the human 
myoglobin promoter and modifies the 
guanine directly adjacent to the down­
stream side of the TATA box, trapping the 
DNA into a conformation that stabilizes j  
the binding of TBP to the TATA box. Al­
though not yet proven, this form of 
drug-protein-DNA interaction could lead 
to increased levels of transcription from 
various TATA-containing promoters.
The concept that small DNA-reactive 
ligands may mediate some of their potent 
biological effects through interactions 
with nucleoprotein complexes involved in 
transcription is not without indirect sup­
port. Indeed, agents such as (+)-CC-1065 
are known to produce unbalanced growth 
in cells where excessive amounts of RNA 
and protein are produced16. Pointing to 
transcriptional factor-DNA complexes as 
important targets for carcinogen and drug 
action may be useful in explaining the 
specificity of the biological effects; how­
ever, this does not immediately identify 
the most critical complexes that are tar­
geted. For studies where this is a prime ob­
jective, ligand-modified duplex DNA may 
be a useful lure for snagging proteins that 
bind to specific binary complexes. Mean­
while, the assembly of ternary complexes 
using well-defined ligand-DNA complexes 
and DNA binding proteins for structural 
and in vitro biochemical studies is now an 
attractive and feasible objective.
Finally, these very specific DNA ligands 
may also be useful probes for unraveling 
the complexities of transcriptional con­
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trol. For example, the use of pluramycin to 
freeze TBP-TATA binding complexes ap­
pears to offer significant possibilities for 
examining the assembly of transcriptional 
complexes. Just as antibiotics were invalu­
able tools in elucidating the steps in pro­
tein synthesis, specific DNA-reactive com­
pounds may be useful probes for 
unraveling the complexities of transcrip­
tional control.
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Multidrug resistance: Locked in the vault?
The discovery that multidrug resistance 
could be explained by transmembrane 
transporter molecules (MRP and PgP) act­
ing as pumps to remove toxic drugs was 
soon followed by the realization that some 
tumours resisted chemotherapy by an alter­
nate mechanism. The article by Scheffer et 
al. in this issue of Nature Medicine1 sheds 
new light on this important problem. This 
group has for some time been focusing on a 
protein, LRP, found to be overexpressed in 
non-PgP multidrug resistant tumour cell 
lines. In addition to its presence in drug-re­
sistant lines, LRP expression was shown to 
decrease in at least one line that lost the re­
sistant phenotype. It also appears to have a 
high predictive value for resistance to 
chemotherapy in acute myeloid leukemia 
and ovarian carcinoma.The present article, 
describes the isolation and sequencing of a 
full-length cDNA encoding LRP; surpris­
ingly it turns out to be the human homo- 
logue of the major vault protein. This pro­
tein of which the cDNA was previously 
cloned and sequenced from rat and Dic- 
tyostelium, is the major structural protein of 
the vault, a large abundant cytoplasmic ri- 
bonucleoprotein particle which has been 
highly conserved from slime mold to man.
Since vaults were first described nearly 
ten years ago2, we have been searching for 
the function of these organelles. Structural 
studies reveal the vault to be a large (12.9 
megadaltons), ovoid barrel-like particle 
j with dimensions of approximately 35 x 60 
nm. A single vault is composed of two 
eightfold symmetric halves and each half
L e o n a r d  H. R o m e
can be shown to open into a delicate eight- 
petaled flower (see figure, reviewed in 3). 
This unusual structure led us to examine 
vaults as possible components of the eight­
fold symmetric nuclear pore complex 
(NPC). They are most similar to the central 
plug of the NPC, which has dimensions, 
mass and geometry nearly identical to the 
vault particle. This relationship has been 
supported by immunolocalization studies 
which demonstrate that vaults can associate 
with nuclear membranes and NPCs\ If 
vaults are NPC plugs, their abundance and 
cellular distribution suggests that they may 
function in nucleo-cytoplasmic transport. 
Vaults contain multiple copies of a single 
small RNA (vRNA) with a conserved sec­
ondary structure5, making it tempting to 
speculate that the transport cargo of vaults
is cellular RNA, which associates with vaults 
via an interaction with the vRNA.
The evidence linking vaults and the mul­
tidrug resistance phenotype is still circum­
stantial. Resistance does not appear to be 
due solely to over expression of the major 
vault protein and may require the intact 
vault particle. A definitive role for vaults in 
multidrug resistance will require a direct 
demonstration that vault expression can 
confer resistance on cells and that specific 
interference with vaults in non-PgP mul­
tidrug resistant cell lines restores drug sensi­
tivity. For now, however, the prospect that 
vaults could play a role in mediating mul­
tidrug resistance opens new avenues for 
functional studies, and the exciting possi­
bility that anti-vault therapeutic reagents 
could be designed to lower the resistance of 
tumours to drug treatment.
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